Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions, 66222-66578 [07-5506]
Download as PDF
66222
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Parts 409, 410, 411, 413, 414,
415, 418, 423, 424, 482, 484, and 485
[CMS–1385–FC]
RIN 0938–AO65
Medicare Program; Revisions to
Payment Policies Under the Physician
Fee Schedule, and Other Part B
Payment Policies for CY 2008;
Revisions to the Payment Policies of
Ambulance Services Under the
Ambulance Fee Schedule for CY 2008;
and the Amendment of the
E-Prescribing Exemption for Computer
Generated Facsimile Transmissions
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Final rule with comment period.
cprice-sewell on PROD1PC72 with RULES
AGENCY:
SUMMARY: This final rule with comment
period addresses certain provisions of
the Tax Relief and Health Care Act of
2006, as well as making other proposed
changes to Medicare Part B payment
policy. We are making these changes to
ensure that our payment systems are
updated to reflect changes in medical
practice and the relative value of
services. This final rule with comment
period also discusses refinements to
resource-based practice expense (PE)
relative value units (RVUs); geographic
practice cost indices (GPCI) changes;
malpractice RVUs; requests for
additions to the list of telehealth
services; several coding issues including
additional codes from the 5-Year
Review; payment for covered outpatient
drugs and biologicals; the competitive
acquisition program (CAP); clinical lab
fee schedule issues; payment for renal
dialysis services; performance standards
for independent diagnostic testing
facilities; expiration of the physician
scarcity area (PSA) bonus payment;
conforming and clarifying changes for
comprehensive outpatient rehabilitation
facilities (CORFs); a process for
updating the drug compendia; physician
self referral issues; beneficiary signature
for ambulance transport services;
durable medical equipment (DME)
update; the chiropractic services
demonstration; a Medicare economic
index (MEI) data change; technical
corrections; standards and requirements
related to therapy services under
Medicare Parts A and B; revisions to the
ambulance fee schedule; the ambulance
inflation factor for CY 2008; and
amending the e-prescribing exemption
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
for computer-generated facsimile
transmissions. We are also finalizing the
calendar year (CY) 2007 interim RVUs
and are issuing interim RVUs for new
and revised procedure codes for CY
2008.
As required by the statute, we are
announcing that the physician fee
schedule update for CY 2008 is ¥10.1
percent, the initial estimate for the
sustainable growth rate for CY 2008 is
¥0.1 percent, and the conversion factor
(CF) for CY 2008 is $34.0682.
DATES: Effective Date: The provisions of
this final rule with comment period are
effective January 1, 2008, except for the
amendments to § 409.17 and § 409.23
which are effective July 1, 2008, and the
amendments to § 423.160 which is
effective January 1, 2009.
Comment Date: Comments will be
considered if we receive them at one of
the addresses provided below, no later
than 5 p.m. e.s.t. on December 31, 2007.
ADDRESSES: In commenting, please refer
to file code CMS–1385–FC. Because of
staff and resource limitations, we cannot
accept comments by facsimile (FAX)
transmission.
You may submit comments in one of
three ways (no duplicates, please):
1. Electronically. You may submit
electronic comments on specific issues
in this regulation to https://
www.cms.hhs.gov/eRulemaking. Click
on the link ‘‘Submit electronic
comments on CMS regulations with an
open comment period.’’ (Attachments
should be in Microsoft Word,
WordPerfect, or Excel; however, we
prefer Microsoft Word.)
2. By mail. You may mail written
comments (one original and two copies)
to the following address ONLY: Centers
for Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–1385–FC, P.O.
Box 8020, Baltimore, MD 21244–8020.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments (one
original and two copies) to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–1385–FC, Mail Stop C4–26–05,
7500 Security Boulevard, Baltimore, MD
21244–1850.
4. By hand or courier. If you prefer,
you may deliver (by hand or courier)
your written comments (one original
and two copies) before the close of the
comment period to one of the following
addresses. If you intend to deliver your
comments to the Baltimore address,
please call telephone number (410) 786–
PO 00000
Frm 00002
Fmt 4701
Sfmt 4700
7197 in advance to schedule your
arrival with one of our staff members.
Room 445–G, Hubert H. Humphrey
(HHH) Building, 200 Independence
Avenue, SW., Washington, DC 20201; or
7500 Security Boulevard, Baltimore, MD
21244–1850.
(Because access to the interior of the
HHH Building is not readily available to
persons without Federal Government
identification, commenters are
encouraged to leave their comments in
the CMS drop slots located in the main
lobby of the building. A stamp-in clock
is available for persons wishing to retain
a proof of filing by stamping in and
retaining an extra copy of the comments
being filed.)
Comments mailed to the addresses
indicated as appropriate for hand or
courier delivery may be delayed and
received after the comment period.
Submission of comments on
paperwork requirements. You may
submit comments on this document’s
paperwork requirements by mailing
your comments to the addresses
provided at the end of the ‘‘Collection
of Information Requirements’’ section in
this document.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Pam West, (410) 786–2302 for issues
related to practice expense and
comprehensive outpatient rehabilitation
facilities.
Rick Ensor, (410) 786–5617 for issues
related to practice expense
methodology.
Stephanie Monroe, (410) 786–6864 for
issues related to the geographic practice
cost index and malpractice RVUs.
Craig Dobyski, (410) 786–4584 for
issues related to list of telehealth
services.
Ken Marsalek, (410) 786–4502 for
issues related to the DRA imaging cap.
Catherine Jansto, (410) 786–7762 for
issues related to payment for covered
outpatient drugs and biologicals.
Edmund Kasaitis (410) 786–0477 for
issues related to the Competitive
Acquisition Program (CAP) for part B
drugs.
Anita Greenberg (410) 786–4601 for
issues related to the clinical laboratory
fee schedule.
Henry Richter, (410) 786–4562 for
issues related to payments for end-stage
renal disease facilities.
August Nemec (410) 786–0612 for
issues related to independent diagnostic
testing facilities.
Kate Tillman (410) 786–9252 or Brijit
Burton (410) 786–7364 for issues related
to the drug compendia.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
David Walczak (410) 786–4475 for
issues related to reassignment and
physician self-referral rules for
diagnostic tests and beneficiary
signature for ambulance transport.
Lisa Ohrin (410) 786–4565 or Joanne
Sinsheimer (410) 786–4620 for issues
related to physician self-referral rules.
Bob Kuhl (410) 786–4597 for issues
related to the DME update.
Rachel Nelson (410) 786–1175 for
issues related to the physician quality
reporting system for CY 2008.
Maria Ciccanti (410) 786–3107 for
issues related to the reporting of anemia
quality indicators.
James Menas (410) 786–4507 for
issues related to payment for physician
pathology services.
Dorothy Shannon, (410) 786–3396 for
issues related to the outpatient therapy
caps.
Drew Morgan, (410) 786–2543 for
issues related to the E-Prescribing
Exemption for Computer Generated
Facsimile Transmissions.
Roechel Kujawa (410) 786–9111 or
Anne Tayloe (410) 786–4546 for issues
related to the ambulance fee schedule.
Diane Milstead, (410) 786–3355 or
Gaysha Brooks (410) 786–9649 for all
other issues.
SUPPLEMENTARY INFORMATION:
Submitting Comments: We welcome
comments from the public on the
following issues: Interim Relative Value
Units (RVUs) for selected codes
identified in Addendum C and the
physician self-referral designated health
services (DHS) procedures listed in
Addendum I. You can assist us by
referencing the file code [CMS–1385–
FC] and the specific ‘‘issue identifier’’
that precedes the section on which you
choose to comment.
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following Web
site as soon as possible after they have
been received: https://www.cms.hhs.gov/
eRulemaking. Click on the link
‘‘Electronic Comments on CMS
Regulations’’ on that Web site to view
public comments.
Comments received timely will also
be available for public inspection as
they are received, generally beginning
approximately 3 weeks after publication
of a document, at the headquarters of
the Centers for Medicare & Medicaid
Services, 7500 Security Boulevard,
Baltimore, Maryland 21244, Monday
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an
appointment to view public comments,
phone 1–800–743–3951.
This Federal Register document is
also available from the Federal Register
online database through Government
Printing Office Access a service of the
U.S. Government Printing Office. The
Web site address is: https://
www.access.gpo.gov/nara/.
Information on the physician fee
schedule can also be found on the CMS
homepage. You can access this data by
using the following directions:
1. Go to the following Web site:
https://www.cms.hhs.gov/Physician
FeeSched/.
2. Select ‘‘PFS Federal Regulation
Notices.’’
To assist readers in referencing
sections contained in this preamble, we
are providing the following table of
contents. Some of the issues discussed
in this preamble affect the payment
policies, but do not require changes to
the regulations in the Code of Federal
Regulations. Information on the
regulation’s impact appears throughout
the preamble and is not exclusively in
section VI.
Table of Contents
I. Background
A. Development of the Relative Value
System
B. Components of the Fee Schedule
Payment Amounts
C. Most Recent Changes to Fee Schedule
II. Provisions of the Final Rule Related to the
Physician Fee Schedule
A. Resource Based Practice Expense (PE)
Relative Value Units (RVUs)
1. Current Methodology
2. PE Proposals for CY 2008
B. Geographic Practice Cost Indices (GPCIs)
1. GPCI Update
2. Payment Localities
C. Malpractice (MP) RVUs (TC/PC issue)
D. Medicare Telehealth Services
E. Specific Coding Issues Related to PFS
1. Reduction in the Technical Component
(TC) Payment for Imaging Services
Under the PFS to the Outpatient
Department (OPD) Payment Amount
2. Application of Multiple Procedure
Payment Reduction for Mohs
Micrographic Surgery (CPT Codes 17311
Through 17315)
3. Payment for Intravenous Immune
Globulin (IVIG) Add On Code for
Preadmission Related Services
4. Reporting of Cardiac Rehabilitation
Services
F. Part B Drug Payment
1. Average Sales Price (ASP) Issues
2. Competitive Acquisition Program (CAP)
Issues
G. Issues Related to the Clinical Lab Fee
Schedule
1. Date of Service for the Technical
Component (TC) of Physician Pathology
Services (§ 414.510)
PO 00000
Frm 00003
Fmt 4701
Sfmt 4700
66223
2. New Clinical Diagnostic Laboratory Test
(§ 414.508)
H. Revisions Related to Payment for Renal
Dialysis Services Furnished by EndStage Renal Disease (ESRD) Facilities
1. Growth Update to the Drug Add-On
Adjustment to the Composite Rates
2. Update to the Geographic Adjustment to
the Composite Rates
I. Independent Diagnostic Testing Facility
(IDTF) Issues
1. Revisions of Existing IDTF Performance
Standards
2. New IDTF Standards
J. Expiration of MMA Section 413
Provisions for Physician Scarcity Area
(PSA)
K. Comprehensive Outpatient
Rehabilitation Facility (CORF) Issues
1. Requirements for Coverage of CORF
Services Plan of Treatment (§ 410.105(c))
2. Included Services (§ 410.100)
3. Physician Services (§ 410.100(a))
4. Clarifications of CORF Respiratory
Therapy Services
5. Social and Psychological Services
6. Nursing Care Services
7. Drugs and Biologicals
8. Supplies and DME
9. Clarifications and Payment Updates for
Other CORF Services
10. Cost Based Payment (§ 413.1)
11. Payment for Comprehensive Outpatient
Rehabilitation Facility (CORF) Services
12. Vaccines
L. Compendia for Determination of
Medically Accepted Indications for Off
Label Uses of Drugs and Biologicals in an
Anti-Cancer Chemotherapeutic Regimen
(§ 414.930)
1. Background
2. Process for Determining Changes to the
Compendia List
M. Physician Self Referral Issues
1. General
2. Changes to Reassignment and Physician
Self Referral Rules Relating to Diagnostic
Tests (Anti Markup Provision)
N. Beneficiary Signature for Ambulance
Transport Services
O. Update to Fee Schedules for Class III
DME for CYs 2007 and 2008
1. Background
2. Update to Fee Schedule
P. Discussion of Chiropractic Services
Demonstration
Q. Technical Corrections
1. Particular Services Excluded From
Coverage (§ 411.15(a))
2. Medical Nutrition Therapy (§ 410.132(a))
3. Payment Exception: Pediatric Patient
Mix (§ 413.184)
4. Diagnostic X ray Tests, Diagnostic
Laboratory Tests, and Other Diagnostic
Tests: Conditions (§ 410.32(a)(1))
R. Other Issues
1. Recalls and Replacement Devices
2. Therapy Standards and Requirements
3. Amendment to the Exemption for
Computer Generated Facsimile
Transmission from the National Council
for Prescription Drug Programs (NCPDP)
SCRIPT Standard for Transmitting
Prescription and Certain Prescription
Related Information for Part D Eligible
Individuals
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66224
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
S. Division B of the Tax Relief and Health
Care Act of 2006—Medicare
Improvements and Extension Act of 2006
(Pub. L. 109–432) (MIEA–TRHCA)
1. Section 101(b)—Physician Quality
Reporting Initiative (PQRI)
2. Section 110—Reporting of Hemoglobin
or Hematocrit for Part B Cancer AntiAnemia Drugs (§ 414.707(b))
3. Section 104—Extension of Treatment of
Certain Physician Pathology Services
Under Medicare
4. Section 201—Extension of Therapy Cap
Exception Process
5. Section 101(d)—Physician Assistance
and Quality Initiative (PAQI) Fund
III. Revisions to the Payment Policies of
Ambulance Services Under the Fee
Schedule for Ambulance Services;
Ambulatory Inflation Factor Update for
CY 2007
A. History of Medicare Ambulance
Services
1. Statutory Coverage of Ambulance
Services
2. Medicare Regulations for Ambulance
Services
3. Transition to National Fee Schedule
B. Ambulance Inflation Factor (AIF) During
the Transition Period
C. Ambulance Inflation Factor (AIF) for CY
2008
D. Revisions to the Publication of the
Ambulance Fee Schedule (§ 414.620)
IV. Refinement of Relative Value Units for
Calendar Year 2008 and Response to
Public Comments on Interim Relative
Value Units for 2007
A. Summary of Issues Discussed Related to
the Adjustment of Relative Value Units
B. Process for Establishing Work Relative
Value Units for the Physician Fee
Schedule
C. 5 Year Review of Work RVUs
1. Additional Codes from the 5-Year
Review of Work RVUs
2. Anesthesia Coding (Part of 5-Year
Review)
3. Budget Neutrality Adjustment
D. Work Relative Value Unit Refinements
of Interim Relative Value Units (Interim
2007 Codes)
E. Establishment of Interim Work Relative
Value Units for New and Revised
Physician’s Current Procedural
Terminology (CPT) Codes and New
Healthcare Common Procedure Coding
System Codes (HCPCS) for 2008
(Includes Table Titled ‘‘American
Medical Association Specialty Relative
Value Update Committee and Health
Care Professionals Advisory Committee
Recommendations and CMS’s Decisions
for New and Revised 2008 CPT Codes’’)
F. Discussion of Codes and RUC/HCPAC
Recommendations
G. Additional Coding Issues
H. Establishment of Interim PE RVUs for
New and Revised Physician’s Current
Procedural Terminology (CPT) Codes
and New Healthcare Common Procedure
Coding System (HCPCS) Codes for 2008
V. Physician Self-Referral Prohibition:
Annual Update to the List of CPT/
HCPCS Codes
VI. Physician Fee Schedule Update for CY
2008
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
A. Physician Fee Schedule Update
B. The Percentage Change in the Medicare
Economic Index (MEI)
C. The Update Adjustment Factor (UAF)
VII. Allowed Expenditures for Physicians’
Services and the Sustainable Growth
Rate
A. Medicare Sustainable Growth Rate
B. Physicians’ Services
C. Preliminary Estimate of the SGR for
2008
D. Revised Sustainable Growth Rate for
2007
E. Final Sustainable Growth Rate for 2006
F. Calculation of 2008, 2007, and 2006
Sustainable Growth Rates
VIII. Anesthesia and Physician Fee Schedule
Conversion Factors for CY 2008
A. Physician Fee Schedule Conversion
Factor
B. Anesthesia Fee Schedule Conversion
Factor
IX. Telehealth Originating Site Facility Fee
Payment Amount Update
X. Provisions of the Final Rule
XI. Waiver of Proposed Rulemaking and
Delay in Effective Date
XII. Collection of Information Requirements
XIII. Response to Comments
XIV. Regulatory Impact Analysis
Regulation Text
Addendum A—Explanation and Use of
Addendum B
Addendum B—2008 Relative Value Units
and Related Information Used in
Determining Medicare Payments for
2007
Addendum C—Codes With Interim RVUS
Addendum D—2008 Geographic Adjustment
Factors (GAFs)
Addendum E—2008 Geographic Practice
Cost Indices (GPCIs) by State and
Medicare Locality
Addendum F—CPT/HCPCS Imaging Codes
Defined by Section 5102(b) of the DRA
Addendum G—FY 2008 Wage Index for
Urban Areas Based on CBSA Labor
Market Areas
Addendum H—FY 2008 Wage Index Based
on CBSA Labor Market Areas for Rural
Areas
Addendum I—Updated List of CPT/HCPCS
Codes Used To Describe Certain
Designated Health Services Under the
Physician Self-Referral Provision
Acronyms
In addition, because of the many
organizations and terms to which we
refer by acronym in this final rule with
comment period, we are listing these
acronyms and their corresponding terms
in alphabetical order below:
AAA Abdominal aortic aneurysm
AAP Average acquisition price
ACOTE Accreditation Council for
Occupational Therapy Education
ACR American College of Radiology
AFROC Association of Freestanding
Radiation Oncology Centers
AHFS–DI American Hospital Formulary
Service—Drug Information
AHRQ Agency for Healthcare Research and
Quality (HHS)
AIF Ambulance inflation factor
PO 00000
Frm 00004
Fmt 4701
Sfmt 4700
AMA American Medical Association
AMA–DE American Medical Association
Drug Evaluations
AMP Average manufacturer price
AOTA American Occupational Therapy
Association
APC Ambulatory payment classification
APTA American Physical Therapy
Association
ASA American Society of Anesthesiologists
ASC Ambulatory surgical center
ASP Average sales price
ASTRO American Society for Therapeutic
Radiology and Oncology
ATA American Telemedicine Association
AWP Average wholesale price
BBA Balanced Budget Act of 1997 (Pub. L.
105–33)
BBRA [Medicare, Medicaid and State Child
Health Insurance Program] Balanced
Budget Refinement Act of 1999 (Pub. L.
106–113)
BIPA Medicare, Medicaid, and SCHIP
Benefits Improvement Protection Act of
2000
BLS Bureau of Labor Statistics
BMD Bone mineral density
BMI Body mass index
BMM Bone mass measurement
BN Budget neutrality
BSA Body surface area
CAD Computer aided detection
CAH Critical access hospital
CAP Competitive acquisition program
CBSA Core-Based Statistical Area
CEM Cardiac event monitoring
CF Conversion factor
CFR Code of Federal Regulations
CMA California Medical Association
CMS Centers for Medicare & Medicaid
Services
CNS Clinical nurse specialist
CORF Comprehensive Outpatient
Rehabilitation Facility
COTA Certified Occupational Therapy
Assistant
CPEP Clinical Practice Expert Panel
CPI Consumer Price Index
CPI–U Consumer price index for urban
customers
CPT (Physicians’) Current Procedural
Terminology (4th Edition, 2002,
copyrighted by the American Medical
Association)
CRT–D Cardiac resynchronization therapy
defibrillator
CT Computed tomography
CTA Computed tomographic angiography
CY Calendar year
DEXA Dual energy x-ray absorptiometry
DHS Designated health services
DME Durable medical equipment
DMEPOS Durable medical equipment,
prosthetics, orthotics, and supplies
DO Doctor of Osteopathy
DRA Deficit Reduction Act of 2005 (Pub. L.
109–432)
E/M Evaluation and management
ECI Employment cost index
EHR Electronic health record
EPC [Duke] Evidence-based Practice
Centers
EPO Erythopoeitin
ESRD End stage renal disease
F&C Facts and Comparisons
FAW Furnish as written
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
FAX Facsimile
FDA Food and Drug Administration (HHS)
FMR Fair market rents
FQHC Federally qualified health center
FR Federal Register
GAF Geographic adjustment factor
GAO General Accounting Office
GII Global Insight, Inc.
GPO Group purchasing organization
GPCI Geographic practice cost index
HCPAC Health Care Professional Advisory
Committee
HCPCS Healthcare Common Procedure
Coding System
HCRIS Healthcare Cost Report Information
System
HIPAA Health Insurance Portability and
Accountability Act of 1996 (Pub. L. 104–
191)
HHA Home health agency
HHS [Department of] Health and Human
Services
HIT Health information technology
HMO Health maintenance organization
HPSA Health Professional Shortage Area
HRSA Health Resources Services
Administration (HHS)
HUD [Department of] Housing and Urban
Development
ICD Implantable cardioverter-defibrillator
ICF Intermediate care facilities
IDTF Independent diagnostic testing facility
IFC Interim final rule with comment period
IOTED International Occupational Therapy
Eligibility Determination
IPPE Initial preventive physical
examination
IPPS Inpatient prospective payment system
IV Intravenous
IVIG Intravenous immune globulin
IWPUT Intra-service work per unit of time
JCAAI Joint Council of Allergy, Asthma,
and Immunology
LPN Licensed practical nurse
MA Medicare Advantage
MA–PD Medicare Advantage Prescription
Drug Plans
MD Medical doctor
MedCAC Medicare Evidence Development
and Coverage Advisory Committee
(formerly the Medicare Coverage Advisory
Committee (MCAC))
MedPAC Medicare Payment Advisory
Commission
MEI Medicare Economic Index
MIEA–TRHCA Medicare Improvements and
Extension Act of 2006 (That is, Division B
of the Tax Relief and Health Care Act of
2006 (TRHCA)
MMA Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (Pub. L. 108–173)
MNT Medical nutrition therapy
MP Malpractice
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
MSP Medicare Secondary Payer
MSVP Multi-specialty visit package
NBCOT National Board for Certification in
Occupational Therapy, Inc.
NCCN National Comprehensive Cancer
Network
NCPDP National Council for Prescription
Drug Programs
NCQDIS National Coalition of Quality
Diagnostic Imaging Services
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
NDC National drug code
NEMC New England Medical Center
NISTA National Institute of Standards and
Technology Act
NLA National limitation amount
NP Nurse practitioner
NPP Nonphysician practitioners
NQF National Quality Forum
NTTAA National Technology Transfer and
Advancement Act of 1995 (Pub. L. 104–
113)
OACT [CMS’] Office of the Actuary
OBRA Omnibus Budget Reconciliation Act
OIG Office of Inspector General
OMB Office of Management and Budget
OPD Outpatient Department
OPPS Outpatient prospective payment
system
OPT Outpatient physical therapy
OSCAR Online Survey and Certification
and Reporting
PA Physician assistant
PC Professional component
PCF Patient compensation fund
PDP Prescription Drug Plan
PE Practice Expense
PE/HR Practice expense per hour
PEAC Practice Expense Advisory
Committee
PECOS Provider Enrollment, Chain, and
Ownership System
PERC Practice Expense Review Committee
PET Positron emission tomography
PFS Physician Fee Schedule
PLI Professional liability insurance
PPI Producer price index
PPS Prospective payment system
PQRI Physician Quality Reporting Initiative
PRA Paperwork Reduction Act
PSA Physician scarcity areas
PT Physical therapy
PT/INR Prothrombin time, international
normalized ratio
RFA Regulatory Flexibility Act
RHC Rural health clinic
RIA Regulatory impact analysis
RN Registered nurse
RT Respiratory therapist
RUC [AMA’s Specialty Society] Relative
(Value) Update Committee
RVU Relative value unit
SBA Small Business Administration
SGR Sustainable growth rate
SLP Speech—language pathology
SLPs Speech—language pathologists
SMS [AMA’s] Socioeconomic Monitoring
System
SNF Skilled nursing facility
STS Society of Thoracic Surgeons
TA Technology Assessment
TC Technical Component
TENS Transcutaneous electric nerve
stimulator
TRHCA Tax Relief and Health Care Act of
2006 (Pub. L. 109–432)
USP–DI United States Pharmacopoeia-Drug
Information
WAC Wholesale acquisition cost
WAMP Widely available market price
Wet AMD Exudative age-related macular
degeneration
WFOT World Federation of Occupational
Therapists
I. Background
Since January 1, 1992, Medicare has
paid for physicians’ services under
PO 00000
Frm 00005
Fmt 4701
Sfmt 4700
66225
section 1848 of the Social Security Act
(the Act), ‘‘Payment for Physicians’
Services.’’ The Act requires that
payments under the physician fee
schedule (PFS) be based on national
uniform relative value units (RVUs)
based on the resources used in
furnishing a service. Section 1848(c) of
the Act requires that national RVUs be
established for physician work, practice
expense (PE), and malpractice expense.
Before the establishment of the
resource-based relative value system,
Medicare payment for physicians’
services was based on reasonable
charges.
A. Development of the Relative Value
System
1. Work RVUs
The concepts and methodology
underlying the PFS were enacted as part
of the Omnibus Budget Reconciliation
Act (OBRA) of 1989, Pub. L. 101–239,
and OBRA 1990, (Pub. L. 101–508). The
final rule, published November 25, 1991
(56 FR 59502), set forth the fee schedule
for payment for physicians’ services
beginning January 1, 1992. Initially,
only the physician work RVUs were
resource-based, and the PE and
malpractice RVUs were based on
average allowable charges.
The physician work RVUs established
for the implementation of the fee
schedule in January 1992 were
developed with extensive input from
the physician community. A research
team at the Harvard School of Public
Health developed the original physician
work RVUs for most codes in a
cooperative agreement with the
Department of Health and Human
Services (HHS). In constructing the
code-specific vignettes for the original
physician work RVUs, Harvard worked
with panels of experts, both inside and
outside the Federal government, and
obtained input from numerous
physician specialty groups.
Section 1848(b)(2)(B) of the Act
specifies that the RVUs for anesthesia
services are based on RVUs from a
uniform relative value guide. We
established a separate conversion factor
(CF) for anesthesia services, and we
continue to utilize time units as a factor
in determining payment for these
services. As a result, there is a separate
formula used to calculate payment for
anesthesia services.
We establish physician work RVUs for
new and revised codes based on
recommendations received from the
American Medical Association’s (AMA)
Specialty Society Relative Value Update
Committee (RUC).
E:\FR\FM\27NOR2.SGM
27NOR2
66226
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
2. Practice Expense Relative Value Units
(PE RVUs)
Section 121 of the Social Security Act
Amendments of 1994 (Pub. L. 103–32),
enacted on October 31, 1994, amended
section 1848(c)(2)(C)(ii) of the Act and
required us to develop resource-based
PE RVUs for each physician’s service
beginning in 1998. We were to consider
general categories of expenses (such as
office rent and wages of personnel, but
excluding malpractice expenses)
comprising PEs.
Section 4505(a) of the Balanced
Budget Act of 1997 (BBA) (Pub. L. 105
33), amended section 1848(c)(2)(C)(ii) of
the Act to delay implementation of the
resource based PE RVU system until
January 1, 1999. In addition, section
4505(b) of the BBA provided for a 4-year
transition period from charge based PE
RVUs to resource-based RVUs.
We established the resource based PE
RVUs for each physician’s service in a
final rule, published November 2, 1998
(63 FR 58814), effective for services
furnished in 1999. Based on the
requirement to transition to a resource
based system for PE over a 4-year
period, resource-based PE RVUs did not
become fully effective until 2002.
This resource-based system was based
on two significant sources of actual PE
data: The Clinical Practice Expert Panel
(CPEP) data and the AMA’s
Socioeconomic Monitoring System
(SMS) data. The CPEP data were
collected from panels of physicians,
practice administrators, and
nonphysicians (for example, registered
nurses (RNs)) nominated by physician
specialty societies and other groups.
The CPEP panels identified the direct
inputs required for each physician’s
service in both the office setting and
out-of-office setting. We have since
refined and revised these inputs based
on recommendations from the RUC. The
AMA’s SMS data provided aggregate
specialty-specific information on hours
worked and PEs.
Separate PE RVUs are established for
procedures that can be performed in
both a nonfacility setting, such as a
physician’s office, and a facility setting,
such as a hospital outpatient
department. The difference between the
facility and nonfacility RVUs reflects
the fact that a facility typically receives
separate payment from Medicare for its
costs of providing the service, apart
from payment under the PFS. The
nonfacility RVUs reflect all of the direct
and indirect PEs of providing a
particular service.
Section 212 of the Balanced Budget
Refinement Act of 1999 (BBRA) (Pub. L.
106–113) directed the Secretary of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Health and Human Services (the
Secretary) to establish a process under
which we accept and use, to the
maximum extent practicable and
consistent with sound data practices,
data collected or developed by entities
and organizations to supplement the
data we normally collect in determining
the PE component. On May 3, 2000, we
published the interim final rule (65 FR
25664) that set forth the criteria for the
submission of these supplemental PE
survey data. The criteria were modified
in response to comments received, and
published in the Federal Register (65
FR 65376) as part of a November 1, 2000
final rule. The PFS final rules published
in 2001 and 2003, respectively, (66 FR
55246 and 68 FR 63196) extended the
period during which we would accept
these supplemental data through March
1, 2005.
In the CY 2007 PFS final rule with
comment period (71 FR 69624), we
revised the methodology for calculating
PE RVUs beginning in CY 2007 and
provided for a 4-year transition for the
new PE RVUs under this new
methodology. We will continue to
reexamine this policy and proposed
necessary revisions through future
rulemaking.
3. Resource-Based Malpractice (MP)
RVUs
Section 4505(f) of the BBA amended
section 1848(c) of the Act to require us
to implement resource-based
malpractice (MP) RVUs for services
furnished on or after 2000. The
resource-based MP RVUs were
implemented in the PFS final rule
published November 2, 1999 (64 FR
59380). The MP RVUs were based on
malpractice insurance premium data
collected from commercial and
physician-owned insurers from all the
States, the District of Columbia, and
Puerto Rico.
4. Refinements to the RVUs
Section 1848(c)(2)(B)(i) of the Act
requires that we review RVUs no less
often than every 5 years. The first 5-Year
Review of the physician work RVUs was
effective in 1997, published on
November 22, 1996 (61 FR 59489). The
second 5-Year Review went into effect
in 2002, published in the CY 2002 PFS
final rule (66 FR 55246). The third 5Year Review of physician work RVUs
went into effect on January 1, 2007 and
was published in the CY 2007 PFS final
rule with comment period (71 FR
69624) (although we note that certain
additional proposals relating to the third
5-Year Review are addressed in the CY
2008 PFS proposed rule and in this final
rule with comment period).
PO 00000
Frm 00006
Fmt 4701
Sfmt 4700
In 1999, the AMA’s RUC established
the Practice Expense Advisory
Committee (PEAC) for the purpose of
refining the direct PE inputs. Through
March 2004, the PEAC provided
recommendations to CMS for over 7,600
codes (all but a few hundred of the
codes currently listed in the AMA’s
Current Procedural Terminology (CPT)
codes). As part of the CY 2007 PFS final
rule with comment period (71 FR
69624), we implemented a new
methodology for determining resourcebased PE RVUs and are transitioning
this over a 4-year period.
In the CY 2005 PFS final rule with
comment period (69 FR 66236), we
implemented the first 5-Year Review of
the malpractice RVUs (69 FR 66263).
5. Adjustments to RVUs are Budget
Neutral
Section 1848(c)(2)(B)(ii)(II) of the Act
provides that adjustments in RVUs for a
year may not cause total PFS payments
to differ by more than $20 million from
what they would have been if the
adjustments were not made. In
accordance with section
1848(c)(2)(B)(ii)(II) of the Act, if
adjustments to RVUs cause
expenditures to change by more than
$20 million, we make adjustments to
ensure that expenditures do not increase
or decrease by more than $20 million.
As explained in the CY 2007 PFS final
rule with comment period (71 FR
69624), due to the increase in work
RVUs resulting from the third 5-Year
Review of physician work RVUs, we are
applying a separate budget neutrality
(BN) adjustor to the work RVUs for
services furnished during 2007. This
approach is consistent with the method
we use to make BN adjustments to the
PE RVUs to reflect the changes in these
PE RVUs.
B. Components of the Fee Schedule
Payment Amounts
To calculate the payment for every
physician service, the components of
the fee schedule (physician work, PE,
and MP RVUs) are adjusted by a
geographic practice cost index (GPCI).
The GPCIs reflect the relative costs of
physician work, PE, and malpractice
insurance in an area compared to the
national average costs for each
component.
Payments are converted to dollar
amounts through the application of a
CF, which is calculated by the Office of
the Actuary (OACT) and is updated
annually for inflation.
The formula for calculating the
Medicare fee schedule amount for a
given service and fee schedule area can
be expressed as:
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
Payment = [(RVU work × budget
neutrality adjuster × work GPCI) + (RVU
PE × PE GPCI) + (MP RVU × MP GPCI)]
× CF.
C. Most Recent Changes to the Fee
Schedule
The CY 2007 PFS final rule with
comment period (71 FR 69624)
addressed certain provisions of the
Deficit Reduction Act of 2005 (Pub. L.
109–432) (DRA) and made other
changes to Medicare Part B payment
policy to ensure that our payment
systems are updated to reflect changes
in medical practice and the relative
value of services. This final rule with
comment period also discussed GPCI
changes; requests for additions to the
list of telehealth services; payment for
covered outpatient drugs and
biologicals; payment for renal dialysis
services; policies related to private
contracts and opt-out; policies related to
bone mass measurement (BMM)
services, independent diagnostic testing
facilities (IDTFs), the physician selfreferral prohibition; laboratory billing
for the technical component (TC) of
physician pathology services; the
clinical laboratory fee schedule;
certification of advanced practice
nurses; health information technology,
the health care information
transparency initiative; updated the list
of certain services subject to the
physician self-referral prohibitions,
finalized ASP reporting requirements,
and codified Medicare’s longstanding
policy that payment of bad debts
associated with services paid under a
fee schedule/charge-based system is not
allowable.
We also finalized the CY 2006 interim
RVUs and issued interim RVUs for new
and revised procedure codes for CY
2007.
In addition, the CY 2007 PFS final
rule with comment period included
revisions to payment policies under the
fee schedule for ambulance services and
announced the ambulance inflation
factor (AIF) update for CY 2007.
In accordance with section
1848(d)(1)(E)(i) of the Act, we also
announced that the PFS update for CY
2007 is ¥5.0 percent, the initial
estimate for the sustainable growth rate
(SGR) for CY 2007 is 1.8 percent and the
CF for CY 2007 is $35.9848. However,
subsequent to publication of the CY
2007 PFS final rule with comment
period, section 101(a) of Division B,
Title I of the Tax Relief and Health Care
Act of 2006 (Pub. L. 109–432) (MIEA–
TRHCA), which was enacted on
December 20, 2006, amended section
1848(d) of the Act. [Division B of the
Tax Relief and Health Care Act of 2006
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
is entitled Medicare and Other Health
Provisions and its short title is the
Medicare Improvements and Extension
Act of 2006. Therefore, the law is
hereinafter referred to as ‘‘MIEA–
TRHCA’’.] As a result of this statutory
change, the CF of $37.8975 was
maintained for CY 2007.
II. Provisions of the Final Rule Related
to the Physician Fee Schedule
In response to the CY 2008 PFS
proposed rule (72 FR 38122), we
received approximately 27,000
comments. We received comments from
individual physicians, health care
workers, professional associations and
societies, and beneficiaries. The
majority of the comments addressed the
proposals related to anesthesia coding
and the 5-Year Review, the physician
self-referral provisions and the technical
correction to § 410.32(a)(1) concerning
an exception to the requirement that
diagnostic services (including x-rays)
must be ordered by the treating
physician. To the extent that comments
were outside the scope of the proposed
rule, they are not addressed in this final
rule with comment period.
RVU changes implemented through
this final rule with comment are subject
to the $20 million limitation on annual
adjustments contained in section
1848(c)(2)(B)(ii)(II) of the Act. After
reviewing the comments and
determining the policies we would
implement, we have estimated the costs
and savings of these policies and
discuss in detail the effects of these
changes in the Regulatory Impact
Analysis in section XIV. For the
convenience of the reader, the headings
for the policy issues correspond to the
headings used in the CY 2008 PFS
proposed rule (72 FR 38122). More
detailed background information for
each issue can be found in the CY 2008
PFS proposed rule.
A. Resource Based Practice Expense
(PE) Relative Value Units (RVUs)
Practice expense (PE) is the portion of
the resources used in furnishing the
service that reflects the general
categories of physician and practitioner
expenses, such as office rent and
personnel wages but excluding
malpractice expenses, as specified in
section 1848(c)(1)(B) of the Act.
Section 121 of the Social Security
Amendments of 1994 (Pub. L. 103–432),
enacted on October 31, 1994, required
CMS to develop a methodology for a
resource-based system for determining
PE RVUs for each physician’s service.
Until that time, PE RVUs were based on
historical allowed charges. This
legislation required that the revised PE
PO 00000
Frm 00007
Fmt 4701
Sfmt 4700
66227
methodology must consider the staff,
equipment, and supplies used in the
provision of various medical and
surgical services in various settings
beginning in 1998. The Secretary has
interpreted this to mean that Medicare
payments for each service would be
based on the relative PE resources
typically involved with furnishing the
service.
The initial implementation of
resource-based PE RVUs was delayed
from January 1, 1998, until January 1,
1999, by section 4505(a) of the BBA. In
addition, section 4505(b) of the BBA
required that the new payment
methodology be phased in over 4 years,
effective for services furnished in CY
1999, and fully effective in CY 2002.
The first step toward implementation of
the statute was to adjust the PE values
for certain services for CY 1998. Section
4505(d) of the BBA required that, in
developing the resource-based PE RVUs,
the Secretary must:
• Use, to the maximum extent
possible, generally-accepted cost
accounting principles that recognize all
staff, equipment, supplies, and
expenses, not solely those that can be
linked to specific procedures and actual
data on equipment utilization.
• Develop a refinement method to be
used during the transition.
• Consider, in the course of notice
and comment rulemaking, impact
projections that compare new proposed
payment amounts to data on actual
physician PE.
In CY 1999, we began the 4-year
transition to resource-based PE RVUs
utilizing a ‘‘top-down’’ methodology
whereby we allocated aggregate
specialty-specific practice costs to
individual procedures. The specialtyspecific PEs were derived from the
American Medical Association’s
(AMA’s) Socioeconomic Monitoring
Survey (SMS). In addition, under
section 212 of the BBRA, we established
a process extending through March 2005
to supplement the SMS data with data
submitted by a specialty. The aggregate
PEs for a given specialty were then
allocated to the services furnished by
that specialty on the basis of the direct
input data (that is, the staff time,
equipment, and supplies) and work
RVUs assigned to each CPT code.
For CY 2007, we implemented a new
methodology for calculating PE RVUs.
Under this new methodology, we use
the same data sources for calculating PE,
but instead of using the ‘‘top-down’’
approach to calculate the direct PE
RVUs, under which the aggregate direct
and indirect costs for each specialty are
allocated to each individual service, we
now utilize a ‘‘bottom-up’’ approach to
E:\FR\FM\27NOR2.SGM
27NOR2
66228
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
calculate the direct costs. Under the
‘‘bottom-up’’ approach, we determine
the direct PE by adding the costs of the
resources (that is, the clinical staff,
equipment, and supplies) typically
required to furnish each service. The
costs of the resources are calculated
using the refined direct PE inputs
assigned to each CPT code in our PE
database, which are based on our review
of recommendations received from the
AMA’s Relative Value Update
Committee (RUC). For a more detailed
explanation of the PE methodology see
the Five-Year Review of Work RVUs
Under the PFS and Proposed Changes to
the PE Methodology proposed notice (71
FR 37242) and the CY 2007 PFS final
rule with comment period (71 FR
69629).
1. Current Methodology
cprice-sewell on PROD1PC72 with RULES
a. Data Sources for Calculating Practice
Expense
The AMA’s SMS survey data and
supplemental survey data from the
specialties of cardio-thoracic surgery,
vascular surgery, physical and
occupational therapy, independent
laboratories, allergy/immunology,
cardiology, dermatology,
gastroenterology, radiology,
independent diagnostic testing facilities
(IDTFs), radiation oncology, and urology
are used to develop the PE per hour (PE/
HR) for each specialty. For those
specialties for which we do not have
PE/HR, the appropriate PE/HR is
obtained from a crosswalk to a similar
specialty.
The AMA developed the SMS survey
in 1981 and discontinued it in 1999.
Beginning in 2002, we incorporated the
1999 SMS survey data into our
calculation of the PE RVUs, using a 5year average of SMS survey data. (See
the Revisions to Payment Policies and
Five-Year Review of and Adjustments to
the Relative Value Units Under the
Physician Fee Schedule for CY 2002
final rule (66 FR 55246, November 1,
2002) (hereinafter referred to as CY 2002
PFS final rule).) The SMS PE survey
data are adjusted to a common year,
2005. The SMS data provide the
following six categories of PE costs:
• Clinical payroll expenses, which
are payroll expenses (including fringe
benefits) for nonphysician clinical
personnel.
• Administrative payroll expenses,
which are payroll expenses (including
fringe benefits) for nonphysician
personnel involved in administrative,
secretarial or clerical activities.
• Office expenses, which include
expenses for rent, mortgage interest,
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
depreciation on medical buildings,
utilities and telephones.
• Medical material and supply
expenses, which include expenses for
drugs, x-ray films, and disposable
medical products.
• Medical equipment expenses,
which include expenses depreciation,
leases, and rent of medical equipment
used in the diagnosis or treatment of
patients.
• All other expenses, which include
expenses for legal services, accounting,
office management, professional
association memberships, and any
professional expenses not previously
mentioned in this section.
In accordance with section 212 of the
BBRA, we established a process to
supplement the SMS data for a specialty
with data collected by entities and
organizations other than the AMA (that
is, the specialty itself). (See the Criteria
for Submitting Supplemental Practice
Expense Survey Data interim final rule
with comment period, (65 FR 25664,
May 3, 2000).) Originally, the deadline
to submit supplementary survey data
was through August 1, 2001. In the CY
2002 PFS final rule (66 FR 55246), the
deadline was extended through August
1, 2003. To ensure maximum
opportunity for specialties to submit
supplementary survey data, we
extended the deadline to submit surveys
until March 1, 2005 in the Revisions to
Payment Policies Under the Physician
Fee Schedule for CY 2004 final rule,
(November 7, 2003; 68 FR 63196)
(hereinafter referred to as CY 2004 PFS
final rule).
The direct cost data for individual
services were originally developed by
the Clinical Practice Expert Panels
(CPEP). The CPEP data include the
supplies, equipment, and staff times
specific to each procedure. The CPEPs
consisted of panels of physicians,
practice administrators, and
nonphysicians (for example, RNs) who
were nominated by physician specialty
societies and other groups. There were
15 CPEPs consisting of 180 members
from more than 61 specialties and
subspecialties. Approximately 50
percent of the panelists were
physicians.
The CPEPs identified specific inputs
involved in each physician’s service
provided in an office or facility setting.
The inputs identified were the quantity
and type of nonphysician labor, medical
supplies, and medical equipment.
In 1999, the AMA’s RUC established
the Practice Expense Advisory
Committee (PEAC). From 1999 to March
2004, the PEAC, a multi-specialty
committee, reviewed the original CPEP
inputs and provided us with
PO 00000
Frm 00008
Fmt 4701
Sfmt 4700
recommendations for refining these
direct PE inputs for existing CPT codes.
Through its last meeting in March 2004,
the PEAC provided recommendations
for over 7,600 codes which we have
reviewed and accepted. As a result, the
current PE inputs differ markedly from
those originally recommended by the
CPEPs. The PEAC has now been
replaced by the Practice Expense
Review Committee (PERC), which acts
to assist the RUC in recommending PE
inputs.
b. Allocation of PE to Services
The aggregate level specialty-specific
PEs are derived from the AMA’s SMS
survey and supplementary survey data.
To establish PE RVUs for specific
services, it is necessary to establish the
direct and indirect PE associated with
each service.
(i) Direct costs. The direct costs are
determined by adding the costs of the
resources (that is, the clinical staff,
equipment, and supplies) typically
required to provide the service. The
costs of these resources are calculated
from the refined direct PE inputs in our
PE database. These direct inputs are
then scaled to the current aggregate pool
of direct PE RVUs. The aggregate pool
of direct PE RVUs can be derived using
the following formula: (PE RVUs *
physician CF) * (average direct
percentage from SMS/(Supplemental
PE/HR data)).
(ii) Indirect costs. The SMS and
supplementary survey data are the
source for the specialty-specific
aggregate indirect costs used in our PE
calculations. We then allocate the
indirect costs to the code level on the
basis of the direct costs specifically
associated with a code and the
maximum of either the clinical labor
costs or the physician work RVUs. For
calculation of the 2008 PE RVUs, we are
using the 2006 procedure-specific
utilization data crosswalked to 2007
services. To arrive at the indirect PE
costs:
• We apply a specialty-specific
indirect percentage factor to the direct
expenses to recognize the varying
proportion that indirect costs represent
of total costs by specialty. For a given
service, the specific indirect percentage
factor to apply to the direct costs for the
purpose of the indirect allocation is
calculated as the weighted average of
the ratio of the indirect to direct costs
(based on the survey data) for the
specialties that furnish the service. For
example, if a service is furnished by a
single specialty with indirect PEs that
were 75 percent of total PEs, the indirect
percentage factor to apply to the direct
costs for the purposes of the indirect
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
allocation would be (0.75/0.25) = 3.0.
The indirect percentage factor is then
applied to the service level adjusted
indirect PE allocators.
• We use the specialty-specific PE/HR
from the SMS survey data, as well as the
supplemental surveys for cardiothoracic surgery, vascular surgery,
physical and occupational therapy,
independent laboratories, allergy/
immunology, cardiology, dermatology,
radiology, gastroenterology, IDTFs,
radiation oncology and urology. (Note:
For radiation oncology, the data
represent the combined survey data
from the American Society for
Therapeutic Radiology and Oncology
(ASTRO) and the Association of
Freestanding Radiation Oncology
Centers (AFROC).) We incorporate this
PE/HR into the calculation of indirect
costs using an index which reflects the
relationship between each specialty’s
indirect scaling factor and the overall
indirect scaling factor for the entire PFS.
For example, if a specialty had an
indirect practice cost index of 2.00, this
specialty would have an indirect scaling
factor that was twice the overall average
indirect scaling factor. If a specialty had
an indirect practice cost index of 0.50,
this specialty would have an indirect
scaling factor that was half the overall
average indirect scaling factor.
• When the clinical labor portion of
the direct PE RVU is greater than the
physician work RVU for a particular
service, the indirect costs are allocated
based upon the direct costs and the
clinical labor costs. For example, if a
service has no physician work and 1.10
direct PE RVUs, and the clinical labor
portion of the direct PE RVUs is 0.65
RVUs, we would use the 1.10 direct PE
RVUs and the 0.65 clinical labor
portions of the direct PE RVUs to
allocate the indirect PE for that service.
cprice-sewell on PROD1PC72 with RULES
c. Facility/Nonfacility Costs
Procedures that can be furnished in a
physician’s office, as well as in a
hospital or facility setting, have two PE
RVUs: facility and nonfacility. The
nonfacility setting includes physicians’
offices, patients’ homes, freestanding
imaging centers, and independent
pathology labs. Facility settings include
hospitals, ambulatory surgical centers
(ASCs), and skilled nursing facilities
(SNFs). The methodology for calculating
PE RVUs is the same for both, facility
and nonfacility RVUs, but is applied
independently to yield two separate PE
RVUs. Because the PEs for services
provided in a facility setting are
generally included in the payment to
the facility (rather than the payment to
the physician under the PFS), the PE
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
RVUs are generally lower for services
provided in the facility setting.
d. Services With Technical Components
(TCs) and Professional Components
(PCs)
Diagnostic services are generally
comprised of two components; a
professional component (PC) and a
technical component (TC), which may
be furnished independently or by
different providers. When services have
TC, PC, and global components that can
be billed separately, the payment for the
global component equals the sum of the
payment for the TC and PCs. This is a
result of using a weighted average of the
ratio of indirect to direct costs across all
the specialties that furnish the global
components, TCs, and PCs; that is, we
apply the same weighted average
indirect percentage factor to allocate
indirect expenses to the global
components, PC, and TCs for a service.
(The direct PE RVUs for the TC and PCs
sum to the global under the bottom-up
methodology.)
e. Transition Period
As discussed in the CY 2007 PFS final
rule with comment period (71 FR
69674), we are implementing the change
in the methodology for calculating PE
RVUs over a 4-year period. During this
transition period, the PE RVUs will be
calculated on the basis of a blend of
RVUs calculated using our methodology
described previously in this section
(weighted by 25 percent during CY
2007, 50 percent during CY 2008, 75
percent during CY 2009, and 100
percent thereinafter), and the CY 2006
PE RVUs for each existing code. PE
RVUs for codes that are new during this
period will be calculated using only the
current PE methodology, and will be
paid at the fully transitioned rate.
f. PE RVU Methodology
The following is a description of the
PE RVU methodology.
(i) Setup File
First, we create a setup file for the PE
methodology. The setup file contains
the direct cost inputs, the utilization for
each procedure code at the specialty
and facility/nonfacility place of service
level, and the specialty-specific survey
PE per physician hour data.
(ii) Calculate the Direct Cost PE RVUs
Sum the Costs of Each Direct Input
Step 1: Sum the direct costs of the
inputs for each service. The direct costs
consist of the costs of the direct inputs
for clinical labor, medical supplies, and
medical equipment. The clinical labor
cost is the sum of the cost of all the staff
PO 00000
Frm 00009
Fmt 4701
Sfmt 4700
66229
types associated with the service; it is
the product of the time for each staff
type and the wage rate for that staff
type. The medical supplies cost is the
sum of the supplies associated with the
service; it is the product of the quantity
of each supply and the cost of the
supply. The medical equipment cost is
the sum of the cost of the equipment
associated with the service; it is the
product of the number of minutes each
piece of equipment is used in the
service and the equipment cost per
minute. The equipment cost per minute
is calculated as described at the end of
this section.
Apply a BN Adjustment to the Direct
Inputs
Step 2: Calculate the current aggregate
pool of direct PE costs. To do this,
multiply the current aggregate pool of
total direct and indirect PE costs (that is,
the current aggregate PE RVUs
multiplied by the CF) by the average
direct PE percentage from the SMS and
supplementary specialty survey data.
Step 3: Calculate the aggregate pool of
direct costs. To do this, for all PFS
services, sum the product of the direct
costs for each service from Step 1 and
the utilization data for that service.
Step 4: Using the results of Step 2 and
Step 3 calculate a direct PE BN
adjustment so that the proposed
aggregate direct cost pool does not
exceed the current aggregate direct cost
pool and apply it to the direct costs
from Step 1 for each service.
Step 5: Convert the results of Step 4
to an RVU scale for each service. To do
this, divide the results of Step 4 by the
Medicare PFS CF.
(iii) Create the Indirect PE RVUs
Create Indirect Allocators
Step 6: Based on the SMS and
supplementary specialty survey data,
calculate direct and indirect PE
percentages for each physician
specialty.
Step 7: Calculate direct and indirect
PE percentages at the service level by
taking a weighted average of the results
of Step 6 for the specialties that furnish
the service. Note that for services with
a TC and PCs we are calculating the
direct and indirect percentages across
the global components, PCs and TCs.
That is, the direct and indirect
percentages for a given service (for
example, echocardiogram) do not vary
by the PC, TC and global component.
Step 8: Calculate the service level
allocators for the indirect PEs based on
the percentages calculated in Step 7.
The indirect PEs are allocated based on
the three components: the direct PE
E:\FR\FM\27NOR2.SGM
27NOR2
66230
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
RVU, the clinical PE RVU and the work
RVU.
For most services the indirect
allocator is: indirect percentage * (direct
PE RVU/direct percentage) + work RVU.
There are two situations where this
formula is modified:
• If the service is a global service (that
is, a service with global, professional
and technical components), then the
indirect allocator is: indirect percentage
* (direct PERVU/direct percentage) +
clinical PE RVU + work RVU.
• If the clinical labor PE RVU exceeds
the work RVU (and the service is not a
global service), then the indirect
allocator is: indirect percentage * (direct
PERVU/direct percentage) + clinical PE
RVU.
(Note that for global services the
indirect allocator is based on both the
work RVU and the clinical labor PE
RVU. We do this to recognize that, for
the professional service, indirect PEs
will be allocated using the work RVUs,
and for the TC service, indirect PEs will
be allocated using the direct PE RVU
and the clinical labor PE RVU. This also
allows the global component RVUs to
equal the sum of the PC and TC RVUs.)
For presentation purposes in the
examples in Table 1, the formulas were
divided into two parts for each service.
The first part does not vary by service
and is the indirect percentage * (direct
PE RVU/direct percentage). The second
part is either the work RVU, clinical PE
RVU, or both depending on whether the
service is a global service and whether
the clinical PE RVU exceeds the work
RVU (as described earlier in this step.)
Apply a BN Adjustment to the Indirect
Allocators
Step 9: Calculate the current aggregate
pool of indirect PE RVUs by multiplying
the current aggregate pool of PE RVUs
by the average indirect PE percentage
from the physician specialty survey
data. This is similar to the Step 2
calculation for the direct PE RVUs.
Step 10: Calculate an aggregate pool of
proposed indirect PE RVUs for all PFS
services by adding the product of the
indirect PE allocators for a service from
Step 8 and the utilization data for that
service. This is similar to the Step 3
calculation for the direct PE RVUs.
Step 11: Using the results of Step 9
and Step 10, calculate an indirect PE
adjustment so that the aggregate indirect
allocation does not exceed the available
aggregate indirect PE RVUs and apply it
to indirect allocators calculated in Step
8. This is similar to the Step 4
calculation for the direct PE RVUs.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Calculate the Indirect Practice Cost
Index
Step 12: Using the results of Step 11,
calculate aggregate pools of specialtyspecific adjusted indirect PE allocators
for all PFS services for a specialty by
adding the product of the adjusted
indirect PE allocator for each service
and the utilization data for that service.
Step 13: Using the specialty-specific
indirect PE/HR data, calculate specialtyspecific aggregate pools of indirect PE
for all PFS services for that specialty by
adding the product of the indirect PE/
HR for the specialty, the physician time
for the service, and the specialty’s
utilization for the service.
Step 14: Using the results of Step 12
and Step 13, calculate the specialtyspecific indirect PE scaling factors as
under the current methodology.
Step 15: Using the results of Step 14,
calculate an indirect practice cost index
at the specialty level by dividing each
specialty-specific indirect scaling factor
by the average indirect scaling factor for
the entire PFS.
Step 16: Calculate the indirect
practice cost index at the service level
to ensure the capture of all indirect
costs. Calculate a weighted average of
the practice cost index values for the
specialties that furnish the service.
Note: For services with TC and PCs, we
calculate the indirect practice cost index
across the global components, PCs and
TCs. Under this method, the indirect
practice cost index for a given service
(for example, echocardiogram) does not
vary by the PC, TC and global
components.
Step 17: Apply the service level
indirect practice cost index calculated
in Step 16 to the service level adjusted
indirect allocators calculated in Step 11
to get the indirect PE RVU.
(iv) Calculate the Final PE RVUs
Step 18: Add the direct PE RVUs from
Step 6 to the indirect PE RVUs from
Step 17.
Step 19: Calculate and apply the final
PE BN adjustment by comparing the
results of Step 18 to the current pool of
PE RVUs. This final BN adjustment is
required primarily because certain
specialties are excluded from the PE
RVU calculation for rate-setting
purposes, but all specialties are
included for purposes of calculating the
final BN adjustment. (See ‘‘Specialties
excluded from rate-setting calculation’’
below in this section.)
PO 00000
Frm 00010
Fmt 4701
Sfmt 4700
(v) Setup File Information
• Specialties excluded from ratesetting calculation: For the purposes of
calculating the PE RVUs, we exclude
certain specialties such as midlevel
practitioners paid at a percentage of the
PFS, audiology, and low volume
specialties from the calculation. These
specialties are included for the purposes
of calculating the BN adjustment.
• Crosswalk certain low volume
physician specialties: Crosswalk the
utilization of certain specialties with
relatively low PFS utilization to the
associated specialties.
• Physical therapy utilization:
Crosswalk the utilization associated
with all physical therapy services to the
specialty of physical therapy.
• Identify professional and technical
services not identified under the usual
TC and 26 modifier: Flag the services
that are PC and TC services, but do not
use TC and 26 modifiers (for example,
electrocardiograms). This flag associates
the PC and TC with the associated
global code for use in creating the
indirect PE RVU. For example, the
professional service code 93010 is
associated with the global code 93000.
• Payment modifiers: Payment
modifiers are accounted for in the
creation of the file. For example,
services billed with the assistant at
surgery modifier are paid 16 percent of
the PFS amount for that service;
therefore, the utilization file is modified
to only account for 16 percent of any
service that contains the assistant at
surgery modifier.
• Work RVUs: The setup file contains
the work RVUs from this final rule with
comment period.
(vi) Equipment Cost Per Minute =
The equipment cost per minute is
calculated as:
(1/(minutes per year * usage)) * price
* ((interest rate/(1¥(1/((1 + interest rate)
* life of equipment)))) + maintenance)
Where:
minutes per year = maximum minutes
per year if usage were continuous
(that is, usage = 1); 150,000
minutes.
usage = equipment utilization
assumption; 0.5.
price = price of the particular piece of
equipment.
interest rate = 0.11.
life of equipment = useful life of the
particular piece of equipment.
maintenance = factor for maintenance;
0.05.
E:\FR\FM\27NOR2.SGM
27NOR2
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00011
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
2 The
1 The
AMA ...............................
AMA ...............................
AMA ...............................
........................................
See footnote 1 ................
Source
=(Sup * Dir Adj)/CF ........
Step 5 ............................
Step 5 ............................
=(Eqp * Dir Adj)/CF ........
=(Lab * Dir Adj)/CF .........
Steps 2–4 ......................
Steps 2–4 ......................
Steps 2–4 ......................
Steps 2–4 ......................
Step 5 ............................
See footnote 2 ................
=Ind Alloc * Ind Adj ........
See Steps 12–16 ...........
Steps 9–11 ....................
Steps 9–11 ....................
Steps 12–16 ..................
= Adj. Ind Alloc * PCI .....
=(Adj Dir+Adj Ind) * budn
........................................
........................................
........................................
Step 8 ............................
Step 8 ............................
Step 17 ..........................
Steps 18–19 ..................
See (20) .........................
=(19)+(21) ......................
........................................
See Step 8 ....................
Step 8 ............................
Step 8 ............................
=(24) * (25) .....................
=((14)+(26)) * budn ........
........................................
........................................
See (18) .........................
........................................
........................................
........................................
........................................
Surveys ..........................
Surveys ..........................
See Step 8 ....................
Steps 6, 7 ......................
Steps 6, 7 ......................
Step 8 ............................
0.8806 ............................
=(11)+(12)+(13) .............
MFS ...............................
Step 5 ............................
=(8)/(10) .........................
=(7)/(10) .........................
=(6)/(10) .........................
=(1) * (5) .........................
=(2) * (5) .........................
=(3) * (5) .........................
=(6)+(7)+(8) ...................
........................................
........................................
........................................
........................................
=(1)+(2)+(3) ...................
........................................
Formula
Setup File ......................
........................................
Step 5 ............................
=Lab * Dir Adj ................
=Sup * Dir Adj .................
=Eqp *Dir Adj .................
........................................
MFS ...............................
Step 1 ............................
Step 1 ............................
Step 1 ............................
Step 1 ............................
Steps 2–4 ......................
Step
0.48
0.77
0.968
0.50
0.362
0.81
1.37
33.8%
66.2%
((14)/
(16)) * (17)
0.56
(15)
0.81
0.29
0.00
0.05
0.23
$7.89
$1.77
$0.12
$9.77
$34.0682
$13.32
$2.98
$0.19
$16.50
0.592
Office visit,
est nonfacility
99213
11.15
12.64
0.942
11.84
0.362
29.62
32.70
32.6%
67.4%
((14)/
(16)) * (17)
3.07
(15)
29.62
1.49
0.01
0.13
1.35
$45.89
$4.35
$0.39
$50.62
$34.0682
$77.52
$7.34
$0.65
$85.51
0.592
CABG, arterial, single facility
33533
0.28
0.58
1.054
0.26
0.362
0.29
0.73
40.7%
59.3%
((14)/
(16)) * (17)
0.44
(15)+(11)
0.19
0.30
0.14
0.06
0.10
$3.40
$2.01
$4.84
$10.25
$34.0682
$5.74
$3.39
$8.17
$17.31
0.592
Chest xray nonfacility
71020
0.21
0.51
1.054
0.19
0.362
0.10
0.54
40.7%
59.3%
((14)/
(16)) * (17)
0.44
(11)
0.00¥
0.30
0.14
0.06
0.10
$3.40
$2.01
$4.84
$10.25
$34.0682
$5.74
$3.39
$8.17
$17.31
0.592
Chest xray nonfacility
71020TC
0.592
0.07
0.07
1.054
0.07
0.362
0.19
0.19
40.7%
59.3%
((14)/
(16)) * (17)
..................
(15)
0.19
..................
..................
..................
..................
$
$
$
$
$34.0682
$
$
$
$
Chest xray nonfacility
7102026
TABLE 1.—CALCULATION OF PE RVUS UNDER METHODOLOGY FOR SELECTED CODES
direct adj = [current pe rvus * CF * avg dir pct] / [sum direct inputs] = [Step 2] / [Step 3].
indirect adj = [current pe rvus * avg ind pct] / [sum of ind allocators] = [Step 9] / [Step 10.
(1) Labor cost (Lab) ........
(2) Supply cost (Sup) .....
(3) Equipment cost (Eqp)
(4) Direct cost (Dir) .........
(5) Direct adjustment (Dir
Adj).
(6) Adjusted labor ...........
(7) Adjusted supplies ......
(8) Adjusted equipment ..
(9) Adjusted direct ..........
(10) Conversion Factor
(CF).
(11) Adj. labor cost converted.
(12) Adj. supply cost converted.
(13) Adj. equip cost converted.
(14) Adj. direct cost converted.
(15) Wrk RVU * Wrk
Scaler.
(16) Dir_pct .....................
(17) Ind_pct .....................
(18) Ind. Alloc. formula
(1st part).
(19) Ind. Alloc. (1st part)
(20) Ind. Alloc. formulas
(2nd part).
(21) Ind. Alloc. (2nd part)
(22) Indirect Allocator
(1st+2nd).
(23) Indirect Adjustment
(Ind Adj).
(24) Adjusted Indirect Allocator.
(25) Ind. Practice Cost
Index (PCI).
(26) Adjusted Indirect .....
(27) PE RVU ...................
cprice-sewell on PROD1PC72 with RULES
93000
0.22
0.35
1.280
0.17
0.362
0.26
0.47
37.7%
62.3%
((14)/
(16)) * (17)
0.21
(15)+(11)
0.15
0.13
0.00
0.02
0.11
$3.62
$0.71
$0.07
$4.40
$34.0682
$6.12
$1.19
$0.12
$7.43
0.592
ECG, complete nonfacility
93005
0.15
0.28
1.280
0.12
0.362
0.11
0.32
37.7%
62.3%
((14)/
(16)) * (17)
0.21
(11)
0.00
0.13
0.00
0.02
0.11
$3.62
$0.71
$0.07
$4.40
$34.0682
$6.12
$1.19
$0.12
$7.60
0.592
ECG, tracing nonfacility
93010
0.592
0.07
0.07
1.280
0.05
0.362
0.15
0.15
37.7%
62.3%
((14)/
(16)) * (17)
..................
(15)
0.15
..................
..................
..................
..................
$
$
$
$
$34.0682
$
$
$
$
ECG, report nonfacility
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66231
66232
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
Comments Related to PE Methodology
Comment: Several commenters
recommend that the unadjusted work
RVUs be used in the allocation of the
indirect PE RVUs.
Response: The decision to use the
budget neutralized work RVUs in the
calculation of indirect PEs appropriately
maintains the current relationships
between the work, PE, and professional
liability payments. We also believe it is
important to apply the revised, budget
neutralized work RVUs consistently
within the PFS framework. It would not
be consistent to apply one set of work
RVUs for work payments, but a different
set for purposes of calculating indirect
PEs. Therefore, we will base the
calculation of both the work payments
and the indirect PE payments on the
adjusted work RVUs, and maintain the
current overall relationships between
work, PE, and professional liability. The
PE RVUs in Addendum B and
throughout the rest of this rule reflect
this policy.
Comment: Several commenters
commended CMS on the bottom up
approach to calculating resource based
PE RVUs. Commenters expressed
gratitude for the transparency and
straight forward nature of the revised
methodology.
Response: We appreciate the support
for the revised bottom up practice
methodology and agree that the bottom
up methodology is a more straight
forward methodology then its
predecessor.
Comment: Some commenters contend
that the approach of basing PE
calculations on the weighted average of
all specialties furnishing a service is
flawed and should be replaced with an
approach that bases the specialty
weighted factors upon specialties that
represent 95 percent of the total
utilization of each respective service.
Response: This issue was fully
addressed in the comment and response
section of the CY 2007 PFS final rule
with comment period (71 FR 69641),
and we did not make any further
proposals relating to this policy in the
CY 2008 PFS proposed rule. Thus, these
comments are outside the scope of the
CY 2008 PFS proposed rule.
Comment: One commenter stated that
the use of direct PEs in the allocation of
indirect PEs unfairly penalizes PC only
billers that do not have any direct costs.
Additionally, this commenter contends
that the use of only the work RVU in the
allocation of indirect PEs for this
situation underestimates the indirect
PEs for PC only billers.
Response: The resource-based PE
methodology uses both the work RVU
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
and the direct cost PE RVU in the
allocation of indirect PEs. For PC only
billers, which do not have any direct
costs, indirect costs will only be
allocated based upon the work RVUs.
There is no provision within the current
methodology to allocate the indirect PEs
differently, and we made no proposals
in the CY 2008 PFS proposed rule
regarding this allocation. Additionally,
we note that a review of comments on
past regulations confirms that the
physician community believes that the
work RVUs ‘‘over allocate’’ the indirect
PEs. Thus, there appear to be differing
views regarding the effect of this
allocation. We will continue to allocate
the indirect PEs of PC only services on
the work RVUs.
Comment: One commenter
recommended that, for procedures that
have supply costs in excess of 40 to 50
percent of total direct costs, all supply
costs be passed through and exempt
from the direct adjustment factor.
Response: The resource-based PE
methodology converts the direct costs
for a service, obtained from the direct
cost database, into PE RVUs by
comparing the service specific aggregate
costs to the aggregate pool of costs
available for expenditure on direct
costs. Because the aggregate direct costs
for all services contained in the direct
cost database exceed the aggregate pool
of available direct dollars, a direct cost
adjustment must be applied to scale the
database to the pool. Irrespective of the
percentage of total direct costs for a
specific service represented by supplies,
this adjustment will still be applied. If
this adjustment were not applied to
certain services, the system would
either not be budget neutral or RVUs for
all other services would have to be
reduced to offset these exemptions. We
did not make any proposals relating to
this adjustment. Moreover, we see no
methodological reason to exempt any
services regardless of the percentage of
their direct costs represented by
supplies from the adjustments that
apply to all direct costs.
g. Discussion of Equipment Usage
Percentage
In the CY 2008 PFS proposed rule (72
FR 38132), we included a discussion
about our use of the equipment usage
assumption of 50 percent, and stated
that we continue to receive requests that
we refine this usage percentage. Some
groups and individuals state that this
usage percentage should be in the range
of 70 to 80 percent while others contend
that the current utilization rate is too
high at 50 percent and should be refined
downward to a lower usage percentage.
PO 00000
Frm 00012
Fmt 4701
Sfmt 4700
If the equipment usage percentage is
set too high, the result would be
insufficient allowance at the service
level for the practice costs associated
with equipment. If the equipment usage
percentage is set too low, the result
would be an excessive allowance for the
PE costs of equipment at the service
level. Although we acknowledged the
50 percent across the board usage rate
that we currently apply for all
equipment does not capture the actual
usage rates for all equipment, we
indicated we do not believe that we
have sufficient empirical evidence to
justify an alternative proposal on this
issue. Therefore, we requested that
commenters submit information relating
to alternative percentages and
approaches that differentially classify
equipment into mutually exclusive
categories with category specific usage
rate assumptions. In addition, we
requested any empirical data that would
assist us in these efforts.
h. Equipment Interest Rate
As part of our calculation of the PE
equipment costs, we consider several
factors, for example, the useful life of
each piece of equipment and the typical
interest that would be incurred in the
purchase of the equipment. We updated
the assigned useful life for all the
equipment in our PE input database in
the CY 2005 PFS final rule with
comment period. However, we have
used the same interest rate of 11 percent
since the inception of the resource
based PE methodology in 1999. There
has been much discussion regarding
whether this is still the appropriate
interest rate to utilize in the calculation
of the equipment costs. The majority of
comments on the CY 2007 PFS final rule
with comment period requested an
interest rate of prime plus 2 percent
while a small number of commenters
requested an interest rate significantly
lower than prime plus 2 percent.
In the CY 2008 PFS proposed rule (72
FR 38132), we discussed the basis for
the current interest rate of 11 percent
and indicated that, based on our
analysis of the revised SBA interest rate
data, we believe 11 percent continues to
be an appropriate assumption; therefore,
we stated would retain the interest rate
used in the calculation of equipment
costs at 11 percent.
Comments Concerning Equipment
Usage and Interest Rate
Comment: Several commenters,
including several specialty societies,
MedPAC, and the AMA RUC offered
recommendations regarding the 11
percent interest rate and the 50 percent
utilization rate used to calculate the
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
price per minute for each piece of
equipment. The recommendations
received regarding the proposed 11
percent interest rate were generally
favorable with the majority of
commenters recommending that we
monitor the interest rate annually to
ensure that the appropriate percentage
is utilized in the calculation of the
equipment costs.
The commenters’ recommendations
about making adjustments to the 50
percent utilization rate varied. Certain
commenters recommended we do
nothing until stronger empirical
evidence is available, while other
commenters recommended a decrease in
the utilization assumptions, and some
commenters recommended an increase
in the utilization assumption. The
particular changes recommended in the
utilization assumptions were, in most
cases, directly related to a specific code.
Virtually all comments received support
an on going process of obtaining reliable
empirical data to utilize in the
calculation of equipment costs in the
future.
Response: As discussed in detail in
the CY 2007 PFS final rule with
comment period (71 FR 69650), we
agree with commenters that both the
equipment interest rate and the
equipment utilization rate should
continue to be examined for accuracy.
We are committed to working with all
interested parties to define the most
accurate utilization and interest rate
information for equipment used in the
provision of physicians’ services. Since
we did not propose a specific change,
we will maintain the assumptions of a
50-percent equipment utilization rate
and an 11-percent equipment interest
rate in the calculation of the PE RVUs
published in Addendum B of this final
rule with comment period. We will
continue to monitor the appropriateness
of these assumptions, and evaluate
whether changes should be proposed in
light of the data available.
Comment: A few commenters
recommended that the equipment
utilization rate associated with
preventive services be reduced since
much of the equipment associated with
preventive services is procedure specific
and thus not utilized at as high a rate
as other medical equipment.
Response: Similar to our response
regarding the equipment utilization rate
associated with the entire universe of
medical equipment, we do not believe
that we have any strong empirical
evidence to suggest a change in the
current equipment utilization rate
associated with preventive services. We
are committed to continue working with
all interested parties to identify the most
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
accurate utilization rate information for
equipment used in the provision of
physicians’ services.
2. PE Proposals for CY 2008
a. Radiology Practice Expense Per Hour
The American College of Radiology
(ACR) presented CMS with information
regarding the PE/HR that was used in
the PE methodology for radiology in the
CY 2007 PFS final rule with comment
period. ACR suggested that we change
our methodology in a way that would
weight the survey data to provide an
alternative method of representing large
and small practices. We agreed to take
their approach to our contractor, the
Lewin Group, for further analysis. (We
note that the Lewin Group, in its initial
analysis of the ACR survey data, had
also raised concerns about the
representation of small high cost entities
in the ACR survey data.) The Lewin
Group reviewed ACR’s approach and
concluded that weighting the ACR
survey by practice size more
appropriately accounts for the small
high cost entities in the final PE/HR.
After reviewing both the ACR inquiry
and the Lewin response, we also agreed
that ACR’s approach more appropriately
identifies the PE/HR for radiology.
For these reasons, we proposed to
revise the PE/HR associated with
radiology using the survey data
weighted by practice size and included
this revised PE/HR in Table 2 of the CY
2008 PFS proposed rule which
identified the PE/HR for all specialties.
Comment: Several commenters,
including the AMA’s RUC, expressed
concern over the proposed increase in
the PE/HR for radiology whereby the
PE/HR associated with this specialty
would be developed based upon a
revised practice size weighting
methodology. Commenters believed that
it is inappropriate to refine the current
weighting methodology because: (1)
This weighting methodology was not
done for all specialties; and (2) some
specialties requested to survey their
memberships after the deadline to
submit supplemental survey data and
were denied this opportunity by CMS.
Several other commenters commended
CMS on their ability to review this
potential problem and offer a timely
resolution to the affected specialty.
Response: The American College of
Radiology approached CMS with
questions regarding the weighting
methodology that were used in the
development of their PE/HR.
Specifically, ACR believed that small
high cost practices that primarily
furnish professional only services were
severely underrepresented in the
PO 00000
Frm 00013
Fmt 4701
Sfmt 4700
66233
published PE/HR. Therefore, we
forwarded ACR’s concerns to our
contractor for further review. Upon
review of ACR’s concerns, our
contractor concluded that their initial
PE/HR recommendation to CMS was not
fully representative of these smaller
high cost practices. For this reason, our
contractor recommended a revised
weighting approach that would fairly
represent these small high cost
practices. We agree with both the ACR
and our contractor and will finalize our
proposal to use the revised PE/HR for
radiology.
Additionally, we do not believe that
these revisions to the PE/HR for
radiology constitute a submission of
data after the deadline. No new data
were submitted. Rather, we view this as
a revision to the weighting methodology
in order to address a unique situation.
Comment: Several commenters
recommended that all pain management
services be crosswalked to the
interventional pain management
specialty as opposed to using the actual
data which currently report the
anesthesiology specialty furnishing a
significant portion of the pain
management services. According to the
comments received, anesthesiology is
listed as the primary specialty on many
pain management services and since the
PE/HR associated with anesthesiology is
lower than interventional pain
management, pain management services
are being inappropriately valued.
Response: Physicians self-designate
their respective specialty for purposes of
Medicare enrollment. If commenters
believe that physicians are incorrectly
self-designating their specialty as
anesthesiology when it would be more
appropriate for them to designate
interventional pain management,
commenters should work with their
respective specialty organizations to
ensure physicians appropriately
designate the correct specialty. If the
specialty of a certain percentage of the
physicians furnishing the pain
management service is actually
anesthesiology, we believe that
weighting the various
PE/HR for all specialties that furnish
these services, as we currently do, is the
appropriate methodology to establish
the final PE/HR for pain management
services.
Comment: One commenter
recommends that only the PE/HR
associated with ophthalmology be used
in the establishment of RVUs for CPT
code 66984, Extracapsular cataract
removal with insertion of intraocular
lens prosthesis (one stage procedure),
manual or mechanical technique (e.g.,
irrigation and aspiration or
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66234
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
phacoemulsification). The commenter
contends that the 14 percent of the
utilization that is associated with
optometry is in error as optometrist
would only be involved in the postoperative care of these patients and not
the surgical procedure.
Response: Although we did not make
any proposals in the CY 2008 PFS
proposed rule regarding this issue, we
agree that, generally, optometrists will
not be involved in the surgical
procedure. As stated by the commenter,
and supported by the utilization data,
there are a significant number of
services for which optometrists are
involved in the post-operative care of
CPT code 66984. The resource-based PE
methodology appropriately adjusts for
those services identified with modifier
55 (post-operative care only). Since
there are PEs associated with the postoperative care of CPT code 66984, and
since we adjust the utilization for those
services that are identified as the postoperative care only of CPT code 66984,
we believe the current methodology
appropriately reflects the correct
weighted specialty mix associated with
this service.
Comment: One commenter
recommended that the PE/HR for CPT
codes 22862, Revision including
replacement of total disc arthroplasty
(artificial disc) anterior approach,
lumbar, single interspace, and 22865,
Removal of total disc arthroplasty
(artificial disc) anterior approach,
lumbar, single interspace, be
crosswalked to orthopedic surgery as
opposed to the all physician PE/HR. The
commenter contended this is similar to
the crosswalk change from all
physicians to orthopedic surgery that
was reflected in the PE methodology in
the proposed rule for CPT code 22857,
Total disc arthroplasty (artificial disc),
anterior approach, including
discectomy to prepare interspace (other
than for decompression), lumbar, single
interspace.
Response: CPT codes 22862 and
22865 were new for CY 2007 and absent
specific information with respect to the
specialty performing the services, we
had crosswalked these codes to the all
physician PE/HR. We agree with the
commenter that these codes are of a
similar nature to CPT code 22857. They
are part of the same orthopedic family
of codes and should be treated
consistently when applying the PE
methodology. Therefore, we will assign
the orthopedic surgery PE/HR to CPT
codes 22862 and 22865 as opposed to
the all physician PE/HR.
Comment: Several commenters
conveyed support for the Physician
Practice Information Survey which is
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
currently being administered
throughout the nation and encouraged
CMS to use this practice cost
information to update the current
PE/HR data that is being utilized in the
development of resourced-based PE
RVUs.
Response: The Physician Practice
Information Survey is a practice cost
survey that is being conducted by the
AMA with support from various
specialty societies and CMS. We look
forward to analyzing the results of the
AMA data collection efforts for possible
inclusion in the resource-based PE
methodology in future rulemaking
cycles.
b. RUC Recommendations for Direct PE
Inputs and Other PE Input Issues
In the CY 2008 PFS proposed rule (72
FR 38133), we proposed the following
concerning direct PE inputs.
(i) RUC Recommendations
In 2004, the AMA’s Relative Value
Update Committee (RUC) established a
new committee, the Practice Expense
Review Committee (PERC), to assist the
RUC in recommending direct PE inputs
(clinical staff, supplies, and equipment)
for new and existing CPT codes, a
process that was previously
accomplished by the Practice Expense
Advisory Committee (PEAC).
The PERC reviewed the PE inputs for
nearly 300 existing codes at its meetings
held in February 2007 and April 2007.
(A list of these reviewed codes can be
found in Addendum C of the CY 2008
PFS proposed rule.)
In the CY 2007 PFS final rule with
comment period, we addressed several
issues concerning direct PE inputs and
encouraged specialty societies to pursue
further review of these inputs through
the RUC/PERC process. The following
discussions summarize the PERC
recommendations regarding these
issues:
Cardiac Catheterization Procedures
As discussed in the CY 2008 PFS
proposed rule, the PERC considered
recommendations for new or updated
PE inputs for the family of CPT codes
93501 through 93556 for cardiac
catheterization. The American College
of Cardiology (ACC), in cooperation
with the Society of Cardiac Angiography
and Interventions (SCA&I) and the
Cardiovascular Outpatient Center
Alliance (COCA), developed PE inputs
for the nonfacility setting for 13 of the
28 CPT codes in this family.
We proposed to accept the PERC
recommendations for the direct PE
inputs for the nonfacility setting for the
CPT codes 93501, 93505, 93508, 93510,
PO 00000
Frm 00014
Fmt 4701
Sfmt 4700
93526, 93539, 93540, 93542, 93543,
93544, 93545, 93555, and 93556.
In addition, we proposed that the PE
for the following CPT codes will not be
valued or applicable to the nonfacility
setting: 93503, 93511, 93514, 93524,
93527, 93528, 93529, 93530, 93531,
93532, 93533, 93561, 93562, 93571, and
93572.
Comment: We received comments
from the ACC and the SCA&I thanking
us for our consideration of the PERC
recommendations for 13 CPT codes for
cardiac catheterization procedures
performed in the nonfacility setting and
for accepting their request not to
establish nonfacility PE RVUs for the
remaining 15 procedures in the cardiac
catheterization family.
Response: We appreciate the
commenters’ support and have accepted
the PERC recommendations for the 13
cardiac catheterization procedures and
have changed our PE database to reflect
the PE inputs. For the 15 remaining
codes, we will finalize the proposal and
attach the ‘‘NA’’ indicator to them.
Comment: We received comments
from COCA, a national organization
representing nonfacility medical
cardiology practices that conducted a
‘‘Direct Cost Study’’ purporting to
demonstrate that the major problem
with the 2006 RUC estimates of direct
PE costs for nonfacility outpatient
cardiac catheterization was an
inadequate list of direct patient care
activities. In addition, COCA contends
that the total RUC estimates of clinical
labor time were so low as to lack
credibility. The commenter contends
that a significant amount of the data
from its Direct Cost Study were not
incorporated into the PE
recommendations that were jointly
prepared and presented at the April
2007 RUC meeting with ACC and SCA&I
for the cardiac catheterization
procedures. In addition to the
inadequate clinical labor inputs, the
commenter believes that the RUC
process does not allow for the inclusion
of safety devices, such as crash carts, as
direct PE inputs because these are not
used in the typical case; rather, these are
considered indirect PE. COCA has
requested that we review the data from
the Direct Cost Study and revise the
current proposed PE RVUs for these
procedures to values that reflect more
appropriately the direct and indirect
costs of providing these services. As an
alternative solution, COCA asks that we
tie reimbursement for these services to
a reasonable percentage of the hospital
APC.
We also heard from many cardiology
practices that provide cardiac
catheterizations in the nonfacility
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
setting. They had similar comments and
indicated their support for COCA’s
request that we review the cost study
data and revise the PE RVUs to more
appropriately value the cardiac
catheterization procedures when
performed in the nonfacility setting.
Response: While we understand
COCA’s and the other commenters’
concerns about the decrease in the PE
RVUs for the cardiac catheterization
procedures, we want to clarify that the
PE inputs for these procedures were
fully considered by the RUC process.
The RUC has identified standard
descriptions of clinical staff activities
that the specialty societies follow as
they prepare their recommendations for
direct PE inputs believed to be typical
to a service and the RUC has established
standard values for some of these
clinical activities. The RUC does not
deviate from accepted standard unless
the specialty society presents
compelling evidence to substantiate that
the variance is typical to the practice for
each procedure. In the past, the RUC has
recommended, and we agreed, that the
crash cart would be included as
equipment necessary to perform the
services of cardiopulmonary
resuscitation, CPT 92950, but is not
necessary to perform other services,
even though many physicians have
purchased and maintain crash carts as
part of their medical practices. Since the
crash cart is only specified as required
for use in CPT 92950, it is considered
as indirect PE for all other procedures.
We note that COCA’s request in the
alternative to make payment for these
procedures based on a percentage of the
OPPS APC is not feasible. The PFS and
the OPPS APC payment amounts are
determined by different payment
methodologies that are specified in the
statute. We rely on the RUC process to
assist us in establishing the typical PE
inputs that are necessary to provide
physician services. This is because the
specialty-developed PE
recommendations that are presented to
the RUC are all subject to the same
multi-specialty scrutiny. We agree with
the PERC’s direct PE recommendations
for the 13 cardiac catheterization codes
in the nonfacility setting and we will
accept the RUC PE recommendations for
these 13 procedures. However, we are
sympathetic to the concerns raised by
COCA and echoed by other commenters
about the extent to which the data from
the Direct Cost Study were considered
in the RUC process and we ask that the
RUC provide another opportunity for
the review of the direct PE inputs for
these cardiac catheterization procedures
to ensure that the data from the COCA
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Direct Cost Study is afforded
appropriate and adequate consideration.
Obstetric/Gynecologic PE
As discussed in the CY 2008 PFS
proposed rule, we agreed with the PERC
recommendation to add a non-sterile
sheet (drape) 40 in by 60 in (supply
code SB006) priced at $0.222 to the
pelvic exam pack resulting in the new
price of $1.172. This change affected
236 CPT codes for obstetric/gynecologic
services containing the pelvic exam
pack. We also proposed to accept the
PERC recommendations to standardize
the equipment used in post-operative
visits to include both a power table and
fiberoptic light in the PE database for 70
obstetric/gynecologic codes.
Comment: We received a comment
from the society representing
gynecologic oncologists commending us
for making the above changes to the
pelvic exam pack and for standardizing
the equipment used in follow-up visits.
The society believes these changes
enable gynecologic oncologists to
account for the additional costs incurred
in their practice specialty.
Response: We appreciate the specialty
society’s comments and we will adopt
the PERC recommended inputs as
proposed.
Dual Energy X-Ray Absorptiometry
(DEXA)
The PERC recommended revisions to
the direct PE inputs for CPT codes
77080, 77081, and 77082 to comply
with established PERC standards, and
more appropriately reflect the resources
used to furnish these services. We
agreed with these PERC
recommendations.
Comment: We received several
comments thanking us for accepting the
RUC’s PE recommendations for the
DEXA codes. We also received
comments from several device
manufacturers and specialty societies
representing gynecologists,
endocrinologists, rheumatologists, and
radiologists informing us that the PE
recommendations passed by the RUC,
which we had proposed to accept in the
proposed rule, contained a mistake as to
the correct DEXA equipment that is
typically used to perform the procedure
represented by CPT code 77080. The
RUC’s PE recommendations listed the
DEXA equipment as that using a ‘‘pencil
beam’’ technology, priced at $41,000.
However, the correct DEXA equipment
used for CPT 77080 uses the ‘‘fan-beam’’
technology and is priced at $85,000.
Response: We were sympathetic to the
concerns expressed by the commenters
about the listing of the incorrect DEXA
equipment, and we worked with the
PO 00000
Frm 00015
Fmt 4701
Sfmt 4700
66235
RUC staff to arrange for this equipment
error to be reconsidered by the RUC at
its September 2007 meeting. The RUC
agreed to the specialty society’s
recommended change in the DXA
equipment for CPT 77080. We agree
with the recommendations from the
specialty societies and the RUC and we
have corrected our PE database to reflect
that the fan-beam DEXA equipment is
typically used for CPT 77080. In
addition, a price of $3,000, with
documentation, was presented for the
spinal phantom used in this procedure.
We have also accepted this price and
have changed the PE database
accordingly.
Comment: We received many
comments expressing concerns about
the cuts to the PE RVUs for these DEXA
services. These commenters believe the
cuts are a result of the new PE
methodology and may result in access
problems for patients because
physicians will no longer be able to
afford to provide these services in the
office setting. One commenter asked us
to identify and make available to the
public the inputs used to derive the
indirect PE RVUs.
Response: We are aware that the PE
RVUs for these DEXA services were
negatively impacted by the change in
the PE methodology, as were those for
many other services in which the
previous PE RVUs were not based on
the PE resources used to furnish the
service. Because the new PE
methodology now utilizes these
resources, it is important to make
certain that the PE direct inputs actually
reflect the typical resources that are
used to provide each service. The
methodology for determining the
indirect PE RVUs, including a
description of each step in the
calculation, is detailed earlier in this
section. We share the commenters
concerns about beneficiary access to
DEXA services and will continue to
monitor this issue.
Computer-Aided Detection (CAD) Codes
The specialty society for radiological
services reviewed the direct inputs for
CPT codes 77051 and 77052 and
recommended that no changes to the PE
inputs were needed. The PERC
concurred with this decision and we are
in agreement.
Comment: We received a comment
from the society representing
radiologists conveying their
appreciation for accepting the
unchanged direct PE inputs for CAD
services.
Response: We appreciate the
commenter’s support and will maintain
the PE inputs as proposed.
E:\FR\FM\27NOR2.SGM
27NOR2
66236
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Nuclear Medicine Services
The specialty society representing
nuclear medicine and the PERC
recommended that the direct PE inputs
for 2 CPT codes contained CPEP inputs
and needed to be updated to agree with
2004 PEAC-approved inputs. However,
in reviewing the PE database, we
discovered that there were 4 other
related codes which also had CPEP
inputs which should be updated. We
made the appropriate adjustments to
substitute the PEAC inputs for the CPEP
for CPT codes 78600, 78607, 78206,
78647, 78803 and 78807.
The specialty society also noted that
for 7 CPT codes, revision of x-ray
related supplies was required, including
the number of x-ray films, developer
solution, and film jackets. The PERC
forwarded these recommendations and
we made the appropriate changes to the
PE database for the following CPT
codes: 78600, 78601, 78605, 78606,
78607, 78610 and 78615.
Comment: The specialty society
representing nuclear medicine
expressed appreciation for acceptance of
their recommended inputs and
indicated it will continue to monitor the
nuclear medicine codes and provide
inputs and refinements as necessary and
appropriate.
Response: We appreciate the specialty
society’s comments and we will adopt
the PERC recommended inputs as
proposed.
cprice-sewell on PROD1PC72 with RULES
Transcatheter Placement of Stent(s)
At the request of the specialty
societies representing radiology and
interventional radiology, the PERC
considered and approved direct PE
inputs for the nonfacility setting for 3
CPT codes, 37205, 37206, and 75960, for
transcatheter placement of stent(s).
Among the supplies, a ‘‘vascular stent
deployment system’’, valued at $1,645,
was noted by the society as the typical
stent used for CPT codes 37205 and
37206 requiring 2 such stents for the
placement in the initial vessel and 1
stent for each subsequent vessel,
respectively. We reviewed a published
clinical research study that was
forwarded by the specialty society. The
study indicated that 1 stent was typical
for the procedure of CPT code 37205. As
discussed in the CY 2008 PFS proposed
rule (72 FR 38134), absent any further
verification from the specialty, we
included only 1 stent in the PE database
for this code.
Comment: Commenters, representing
specialty societies for radiology,
interventional radiology and vascular
surgery appreciated the proposal
assigning direct PE inputs for the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
nonfacility setting for these three CPT
codes. However, these commenters
expressed concern that the number of
stents had been reduced. One
commenter agreed that two stents may
not be typical but requested guidance on
how the cost of the additional stent
could be billed; another of the
commenters asked that we reconsider
this decision or at a minimum include
the ‘‘average’’ of 1.5 stents. One of the
commenters also noted that several
studies clearly establish that these
peripheral stent services are safely
performed in the nonfacility
environment, with nearly all of the
procedures in the studies resulting in
short observation stays, typically of less
than 4 hours.
Response: Based on a review of the
literature and other information
provided by the commenters we will
revise the PE database for CPT code
37205 to reflect 1.5 stents.
Comment: Two commenters,
representing manufacturers, expressly
urged us to consider the safety issues
surrounding the proposal to value these
procedures in the nonfacility setting and
believe that this conflicts with the
decision to exclude these procedures
from the ambulatory surgical center
(ASC) list. One of these commenters
acknowledged that, while we have no
specific policy to identify which
procedures can be safely performed in a
physician’s office, we do have some
safety standards for ASCs. The
commenter requested that the ASC
standards be extended to the physician
office. This commenter also referenced
studies that demonstrate complications
can be associated with these procedures,
and suggested that these risks need to be
addressed by appropriate safety or
quality standards.
Response: We appreciate the
commenters’ viewpoint. However, as
the commenters acknowledged, we have
no established policy to designate
procedures that can be ‘‘safely’’
performed in the physician office
setting. The purpose of the PFS is to
establish proper payment for procedures
furnished by physicians and other
health professionals. Several medical
specialty societies recommended the
valuation of these services in the
nonfacility setting, which suggests to us
that these procedures are being
furnished in nonfacility settings on a
regular basis. These societies provided
the recommended PE inputs involved in
furnishing the typical service in a
nonfacility setting, and these inputs
were reviewed, accepted and
recommended by the RUC. We also note
that, as indicated in the previous
comment, one commenter provided
PO 00000
Frm 00016
Fmt 4701
Sfmt 4700
literature from studies to support that
these services are safely performed in
the nonfacility environment. Because it
appears these procedures are being
furnished regularly in nonfacility
settings, we believe it is appropriate to
value them for payment in those
settings. Therefore, we will value these
procedures in the nonfacility setting as
proposed.
Comment: One commenter noted that
payment for CPT code 75960, the
supervision and interpretation service
associated with the 2 CPT codes
discussed above for the transcatheter
placement of stent(s), is still shown as
carrier-priced in the Addendum of the
proposed rule.
Response: We regret the error. The
Addendum and PFS database have been
corrected to reflect the appropriate
RVUs.
(ii) Remote Cardiac Event Monitoring
In the CY 2007 PFS final rule with
comment period, direct PE inputs for
remote cardiac event monitoring (CEM)
services represented by CPT codes
93012, 93225, 93226, 93231, 93232,
93270, 93271, 93733, and 93736 were
revised on an interim basis to reflect the
unique circumstances surrounding the
provision of these services. Unlike most
physicians’ services, CEM services are
furnished primarily by specialized
IDTFs that, due to the nature of CEM
services, must operate on a 24/7 basis.
The specialty group representing
suppliers that furnish CEM services
believes that these services require
additional direct PE inputs, such as
telephone line charges associated with
trans-telephonic transmissions and fees
associated with providing Web access
for storage and transmission of clinical
information to the patient’s physician.
We continue to work with the specialty
group regarding the specific direct PE
inputs, as well as the components for
the indirect PE allocation, based on
surveys conducted by the specialty
group. To clarify and further the results
of our discussions with and information
provided by, the specialty group, we
requested comments in the CY 2008 PFS
proposed rule on the appropriateness of
the above-mentioned direct PE inputs.
In addition, we invited comments on
any additional direct inputs and
components of the indirect PE
allocations which would be appropriate
for these services, along with supporting
documentation to justify their inclusion
for PE purposes.
Comment: We received comments
from medical societies, provider
organizations and a device manufacturer
thanking us for working with these
organizations to develop direct PE for
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
these services that do not fit the typical
physician service model. Several
comments supported the specific PE
proposals supplied by the specialty
group representing providers that
furnish CEM services, and urged us to
adopt them. A medical society
representing cardiologists requested to
work with us and the remote CEM
provider groups to gather and review
any additional necessary data prior to
adoption of additional direct PE inputs.
The CEM provider group specifically
proposed that we add telephone
transmission costs to the direct PE
inputs for CPT codes for CEM, 93012
and 93271 and the CPT codes for
pacemaker monitoring, 93733, and
93736. The group also identified
expenses for Web-based storage,
maintenance and access to clinical
information to be allocated to the CEM
and pacemaker monitoring CPT codes,
as well as the holter monitoring CPT
codes 93226 and 93232. In addition to
these supply PE recommendations, the
CEM provider group proposed
equipment time-in-use increases for the
holter monitors, cardiac event monitors
and for INR monitors (which are
discussed later in this section).
Response: We carefully reviewed the
information supplied by all of the
commenters and believe that it would
be valuable for the commenters to work
together, including the cardiology
specialty society, before we establish
further direct PE inputs for these cardiac
monitoring services. In addition, we
would like to make the CEM providers
aware that it appears the assignment we
made in CY 2007 of 43,200 time-in-use
minutes for the looping CEM monitor
used in CPT code 93271 (typically used
for a 30-day period) pays back the cost
of this CEM monitor, that is valued at
$995, in less than 5 months, even
though the CEM monitor has an
established 4-year useful life. As we
discuss later in the Prothrombin Time,
International Normalized Ratio (PT/INR)
section, we believe that the time-in-use
assigned to any one device should not
exceed its useful life. We will review
this time-in-use assignment for CEM
monitors during our CY 2009
rulemaking.
(iii) Prothrombin Time, International
Normalized Ratio (PTI/NR)
As discussed in the CY 2008 PFS
proposed rule, based on comments
received and subsequent discussions
with entities that furnish these PT/INR
services, we adjusted the time in use for
the home monitor equipment for G0249
Provision of test materials and
equipment for home INR monitoring to
patient with mechanical heart valve(s)
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
who meets Medicare coverage criteria;
includes provision of materials for use
in the home and reporting pwiof
[prothrombin] test results to physician;
per four tests to 1440 minutes to reflect
that the monitor is dedicated for use 24
hours a day and unavailable for others
receiving this service. We invited
comments on this change, as well as
comments on any additional direct
inputs which would be appropriate to
this service, along with supporting
documentation to justify their inclusion
for PE purposes.
Comment: We received comments
from specialty societies, provider
groups, and individuals expressing their
appreciation of our attempt to correct
the problem concerning the application
of PE methodology for the PT/INR
service, but noted their concern that
changing the INR home monitor time-inuse minutes from 32 to 1440 does not
have a rational basis nor does it provide
for an adequate recoupment of the cost
of the device. These commenters
requested that we assign a more realistic
figure to capture the 28-day period that
the patient is required to use the
monitor. One commenter noted that
using the current 1440 minutes, it
would take 11.7 years to recoup the
$2000 price of the equipment which has
an assigned life of 4 years. The
commenters suggested several
alternative methodologies to calculate
the time-in-use for the INR monitor. One
method suggests multiplying the 1-day
time, 1440 minutes, by 4, which
represents the number of tests
conducted in the 28-day period, to equal
5,760 minutes. This method would take
3 years to get back the $2000 value of
the INR monitor. Another proposal
suggests multiplying the 1-day 1440
minutes by 28 days which is the actual
time the patient has the equipment. This
method yields 40,300 minutes and the
commenter admittedly states this
method greatly overestimates the value
of the INR monitor because it would
take just 5 months to recoup the $2000
price. One commenter suggested that we
simply amortize the price of the
equipment, $2,000, over the useful life
of 4 years. Another commenter’s
suggestion uses the annual minutes
figure of 150,000 that we use in our
formula for deriving per minute
equipment costs, and divides it by 28
(days) to arrive at 5,753 minutes. This
method recoups the INR monitor price
in 3 years.
Other commenters voiced concerns
about the valuation of the INR home
monitor and offered alternatives to
capture the cost of the device. One
commenter suggested that we treat the
cost of the INR home monitor as a one-
PO 00000
Frm 00017
Fmt 4701
Sfmt 4700
66237
time upfront cost and include this price
in HCPCS code G0248 that is used to
report the demonstration of the INR
monitor to the patient, at the initial use.
Another commenter recommended that
the INR home monitor be removed from
the PE for both G0248 and G0249 and
be considered under the DME benefit.
Response: We understand the
concerns expressed by the commenters
and appreciate their suggested
alternatives that we could use to more
appropriately cover the costs of the INR
home monitor. Further, we agree that
the 1440 minutes we assigned for CY
2007 seems too low considering that the
patient uses the INR home monitor for
28 days, not just one. After reviewing all
of the suggested alternatives, we
eliminated the two proposals asking us
to change the mechanism of payment for
the INR home monitor. We, therefore,
considered the various suggestions for
establishing a more appropriate time-inuse value for the INR home monitor. We
believe the proposal that best reflects
the policy we use to determine the timein-use for equipment items where the
actual minutes-in-use exceed the
assigned useful life is the commenter’s
suggestion to amortize the $2000 INR
monitor over its 4-year life. Using this
method, 4,315 minutes is the necessary
time-in-use figure to recover the
purchase price of the equipment in 4
years. We will replace the 1440 minutes
assigned for CY 2007 with 4,315
minutes as the time-in-use for the INR
home monitor and will change the PE
database accordingly.
(iv) Positron Emission Tomography
(PET) Codes Clinical Labor Time
We received comments from the
specialty society representing nuclear
medicine regarding a discrepancy in the
clinical labor time for CPT codes 78811,
78812, and 78813 which are PET codes
for tumor imaging. The specialty noted
that the clinical labor time indicated in
the PE database differs by 7 minutes
from the time that was previously
recommended by the PERC in April
2004. We agreed with the specialty
society that the PE database labor inputs
for these 3 PET codes are incorrect and
we made the appropriate adjustments to
the PE database.
Comment: The specialty society
representing nuclear medicine
expressed appreciation for acceptance of
its recommended inputs and indicated
it will continue to monitor the nuclear
medicine codes and provide inputs and
refinements as necessary and
appropriate.
Response: We thank the specialty
society for reviewing the direct inputs
for their related procedures in the PE
E:\FR\FM\27NOR2.SGM
27NOR2
66238
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
database that we post as a download
with each proposed and final rule on
our Web site (www.cms.hhs.gov/
PhysicianFeeSchedule/PFSFRN). We
will adopt the recommended inputs as
proposed.
cprice-sewell on PROD1PC72 with RULES
(v) Nuclear Medicine PE Supplies
The specialty society representing
nuclear medicine commented that the
PE database currently contains supply
items that are inappropriate for certain
procedures and provided the
information to make the corrections. For
respiratory imaging procedures
represented by CPT codes 78587, 78591,
78593, 78594, 78630, 78660, 78291, and
78195, the specialty society noted
specific IV supply items to be deleted
from procedures where they are not
required. For a thyroid imaging
procedure represented by CPT code
78020, x-ray supply items were
recommended for deletion. In addition,
the society recommended adding supply
items for respiratory imaging
procedures, including nose clips, masks,
and nebulizer kits, as appropriate, to
CPT codes 78584, 78585, 78591, 78593,
78594, 78586, 78587, 78588, and 78596.
For a kidney function study represented
by CPT code 78725, injection supply
items were noted as missing and the
specialty society requested that these be
added. We proposed to accept these
direct PE input corrections and revised
our PE database accordingly.
Comment: The specialty society
voiced its gratitude for the acceptance of
their recommended inputs.
Response: We thank the specialty
society for its interest in assuring the
accuracy of the PE inputs in the
procedures provided by their members.
We will adopt the PERC recommended
inputs as proposed.
(vi) Arthroscopic Procedure Nonfacility
Inputs
In the CY 2008 PFS proposed rule (72
FR 38135), we included a discussion
about the establishment of nonfacility
direct PE inputs for the arthroscopic
procedures represented by CPT codes
29805, 29830, 29840, 29870, and 29900.
Absent specific recommendations from
the RUC and because some physicians
are already performing these procedures
in the office setting, we specifically
requested comments regarding the
appropriateness of establishing
nonfacility PE inputs for these
arthroscopic procedures when they are
provided in the office setting. We also
invited comments as to the specific
direct PE inputs, following the RUC
approved standardized format, that are
typical in the provision of each above
listed arthroscopic procedure furnished
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
in the physician’s office. We indicated
we will review these comments to
determine whether or not it is
appropriate to propose on an interim
basis PE inputs for these codes in the
nonfacility setting in our final rule.
Comment: We received comments
from the specialty society representing
orthopedic surgeons in opposition to the
establishment of nonfacility PE for the
arthroscopic procedures because they
believe these procedures are not safely
performed in the office setting. The
specialty society indicated that one of
these codes, CPT 29900, Arthroscopy,
metacarpophalangeal joint, diagnostic,
includes synovial biopsy, was surveyed
by the RUC in April 2001 and, at that
time, the RUC recommended this
service only as a facility-based
procedure. The RUC supported the
AAOS concerns and recommended that
the PE RVUs for the nonfacility setting
remain designated as ‘‘NA.’’ The
specialty society believes that if the
arthroscopic procedures were valued in
the nonfacility setting, untrained
physicians may begin to perform them
and, as a result, patients will face
significant risks. The specialty society
believes that only credentialed
physicians should perform these
procedures and that this process can
only be ensured in the facility-based
setting. The specialty society also
asserts the facility-based setting is the
safest setting for these procedures
because it affords the physician more
clinical options for dealing with any
complications that may arise. In
addition, if the procedure is furnished
in the nonfacility setting, there would
be no way to address any treatable
lesion that is found and a patient would
need to be seen in the facility setting to
undergo a second procedure.
Because the specialty society’s
position was established by an expert
panel, the society states that it will
reconsider its position if evidence is
presented establishing the safety and
efficacy of these procedures in the office
setting and if a method is established to
ensure that only qualified physicians
perform these procedures in the office
setting.
We also received comments from
orthopedic practices and individual
physicians—the majority of which
indicated they are members of the
orthopedic specialty society—all stating
that they are currently performing these
procedures in the nonfacility setting.
These comments requested that we
establish PE inputs for the arthroscopic
procedures because this would allow
patients greater access to these services
in more convenient settings and,
because it would establish payment that
PO 00000
Frm 00018
Fmt 4701
Sfmt 4700
would more fairly compensate them for
the resources they use to provide these
services in the office location. A product
manufacturer supported the views of the
physicians who requested the
establishment of nonfacility PE for the
nonfacility setting.
These physicians note that the safety
of the in-office procedures is well
documented in the literature, and
provided us with citations of articles
going back to the mid-1990s. We also
received suggested PE inputs including
clinical labor, supplies and equipment
that are typically used when these
procedures are provided in the
nonfacility setting.
Response: We appreciate the concern
expressed by the commenters opposing
the establishment of PE for the office
setting and are sympathetic to those
supporting the assignment of PE for
these codes. We are also dismayed that
the parties involved on each side of this
issue have not been able to resolve these
issues to date. We have decided that the
most prudent course of action is to defer
proposing nonfacility inputs for these
arthroscopic procedures in this final
rule. We are hopeful that the specialty
society and its physician colleagues
who provide these services in the
nonfacility setting will be able to
discuss the issues of mutual concern
regarding the safety of performing these
procedures in the office setting. We are
hopeful that this issue can be resolved
and that the physicians performing
these services in the nonfacility setting
will be given the opportunity to have a
multi-specialty review by the RUC. We
are aware that this decision to refer this
issue back to the specialty society and
the RUC postpones the establishment of
nonfacility PE values for these
procedures until CY 2009, at the
soonest, and that a review by the RUC
process is not guaranteed. However,
given the apparent level of dissension
within the specialty, we believe that the
specialty society, its physician
colleagues, and the RUC should first be
given an opportunity to resolve these
important issues.
(vii) Nonfacility Inputs for CPT Code
52327
As discussed in the CY 2008 PFS
proposed rule we indicated that the
society representing urologists
requested that we remove all of the
nonfacility PE inputs for CPT code
52327, Cystourethroscopy (including
ureteral catheterization); with
subureteric injection of implant
material. The specialty society reasoned
that the nonfacility PE value is
inappropriate since the procedure is
never performed in the physician office;
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
it is specific to the pediatric population;
and, as such, is always performed with
general anesthesia. We agreed with the
specialty society that this procedure is
incorrectly valued for the nonfacility
setting and proposed to accept its
recommendation to remove the
nonfacility direct PE inputs, revising the
PE database accordingly.
Comment: The specialty society
thanked us for accepting its
recommendation to remove the
nonfacility PE for this procedure.
However, the society indicated that a
review of the PE database on our Web
site indicated that these inputs were
still included and suggested that they be
deleted.
Response: We appreciate the
commenter’s attention to detail and
have removed the PE inputs from the PE
database.
(viii) Maxillofacial Prosthetics
We have been working with the
society representing maxillofacial
prosthetists since 2005 to establish
nonfacility direct inputs for the
prosthetic services represented by the
CPT code series, 21076 through 21087.
The current PE database reflects the
labor, supplies, and equipment needed
to perform each procedure. However,
we do not have pricing information and
documentation for many supply items.
The society provided information and
documentation for equipment prices,
but because specific time-in-use
information was not provided, we
developed time in use in 2006 for each
equipment item in each procedure. For
CY 2007, these equipment inputs were
utilized under the new PE methodology
to calculate the nonfacility PE RVUs for
these procedures. Although we have
asked the specialty society to provide
the supply pricing information and time
in use data for each equipment item for
each procedure, we have not received
the requested information to date.
Consequently, unless such information
is provided, the PE database will
continue to have no prices associated
with these supplies. Therefore, in the
CY 2008 PFS proposed rule, we
proposed to cap the time in use for each
equipment item at 25 minutes until
specific information is received
regarding the actual time in use. Tables
listing the needed information for were
included in the proposed rule.
Comment: The specialty society
representing the maxillofacial
prosthetists supplied us with some of
the requested information. The society
provided us with the time-in-use data
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
for every piece of equipment for each of
the procedures in the CPT code series
21076 through 21087. The specialty also
provided prices for the supply items
used in this code series; however, it did
not provide any documentation to
support these prices.
Response: We appreciate the
information provided by the specialty,
especially that in relation to the
equipment time-in-use. The
recommended equipment times were
compared with the total clinical labor
time for each procedure and times that
were greater were reduced to equal the
labor time, in accordance with our usual
allocation policy. Capping the
equipment time-in-use to match the
labor time affected 4 pieces of
equipment in every procedure
including: the dental chair, ceiling light,
air compressor, and delivery unit. For 3
of these codes, the time-in-use for a 5th
piece of equipment, the washout and
curing unit, was also capped. We will
accept the specialty’s equipment timein-use information, with the
aforementioned variances, and have
changed the PE database accordingly.
We regret that documentation for the
supply prices was not forwarded. We
did, however, receive a catalog
documented pricing for articulating
paper/ribbon that was submitted by a
different specialty in reference to
another CPT code, and have entered this
price in the PE database for 8 of the 10
codes in this family, as appropriate. The
specialty is reminded that our policy for
accepting prices for supplies or
equipment in the PE database requires
the submission of acceptable
documentation, the definition of which
is specified below the table that
appeared in the proposed rule listing
the outstanding prices for supply items
needing documentation. We will
continue to work with the specialty as
it collects and forwards this important
information.
(ix) Requests for Increases in Supply
Prices
We received a request from the
specialty society for obstetrics and
gynecology to increase the price of
supply item (kit, hysteroscopic tubal
implant for sterilization) for CPT code
58565, Hysteroscopy, surgical; with
bilateral fallopian tube cannulation to
induce occlusion by placement of
permanent implants for this code which
was created for CY 2005. This
hysteroscopic implant kit is priced at
$980 and the specialty is now
PO 00000
Frm 00019
Fmt 4701
Sfmt 4700
66239
requesting a price of $1,245, providing
an invoice for documentation. The
specialty reports that the higher price is
attributed to a manufacturer change in
design and materials, and submitted the
manufacturer’s documents supporting
these changes that were used to secure
FDA approval. Therefore, we proposed
to accept the new price of $1,245 for the
hysteroscopic implant kit due to the
changes made in the modified model.
Comment: We did not receive
comments on this proposal.
Response: We will finalize our
proposed price of $1,245 for the
hysteroscopic implant kit and will
amend our PE database, as appropriate.
(x) Supply and Equipment Items
Needing Specialty Input
We have identified certain supply and
equipment items for which we were
unable to verify the pricing information
(see Table 2: Supply Items Needing
Specialty Input for Pricing and Table 3:
Equipment Items Needing Specialty
Input for Pricing). In our CY 2008 PFS
proposed rule, we listed both supply
and equipment items for which pricing
documentation was needed from the
medical specialty societies and, for
many of these items, we received
sufficient documentation containing
specific descriptors and pricing
information in the form of catalog
listings, vendor Web pages, invoices,
and manufacturer quotes. We have
accepted the documented prices for
many of these items and these prices are
reflected in the PE RVUs in Addendum
B of this final rule with comment
period. For the items listed in Tables 2
and 3, we are requesting that
commenters provide pricing
information on items in these tables
along with acceptable documentation,
as noted in the footnote to each table, to
support recommended prices. For
supplies or equipment that have
previously appeared on this list, and for
which we received no or inadequate
documentation, we proposed to delete
these items unless we receive adequate
information to support current pricing
by the conclusion of the comment
period for this proposed rule.
In Tables 4 and 5, we have listed new
supplies and equipment from the new
CPT codes for CY 2008 that are
discussed elsewhere in this final rule
with comment period. These items have
been added to the PE database and,
where priced, are reflected in the PE
RVUs in Addendum B.
E:\FR\FM\27NOR2.SGM
27NOR2
66240
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 2.—SUPPLY ITEMS NEEDING SPECIALTY INPUT FOR PRICING
2008
item
status
refer to
note(s)
Associated
*CPT code(s)
Prior item
status on
table
Commenter response
and CMS action
C
Code
2006/7 Description
Unit
Unit price
Primary associated
specialties
SC088 ..
Fistula needle, dialysis, 17g.
Item ...
................
Dermatology ..............
36522 ............
Yes ..........
Gas, argon,
cryoablation.
............
................
50395 ............
No ............
Gas, helium,
cryoablation.
............
................
50395 ............
No ............
New Item ...................
A, E
SD140 ..
Pressure bag .............
item ....
8.925
Urology, Radiology,
Interventional Radiology.
Urology, Radiology,
Interventional Radiology.
Cardiology .................
Documentation received. Revised description per specialty’s comments.
Price accepted at
$1.62.
New Item ...................
Yes ..........
Sealant spray ............
oz .......
................
Radiation Oncology ...
SD213 ..
Tubing, sterile, nonvented (fluid administration).
Stent, vascular, deployment system.
item ....
1.99
Cardiology .................
Yes ..........
Kit ......
$1,645
Radiology, Interventional Radiology.
93501, 93508,
93510,
93526.
37205, 37206
Catheter, Kumpe .......
Item ...
................
50385, 50386
No ............
Disposable aspirating
syringe.
Guidewire, angle tip
(Terumo), 180 cm1.
Snare, Nitinol
(Amplatz).
............
................
21073 ............
No ............
New item ...................
A, E
............
................
50385, 50386
No ............
New item ...................
A, E
Item ...
................
Radiology, Interventional Radiology.
Oral and Maxillofacial
Surgery.
Radiology, Interventional Radiology.
Radiology, Interventional Radiology.
Documentation received. Price accepted at $19.00.
No comments received.
Documentation received. Price accepted at $0.949.
Documentation received. Price retained at $1,645.
New item ...................
C
SL119 ..
93501, 93508,
93510,
93526.
77333 ............
50385, 50386
No ............
New item ...................
A, E
Yes ..........
Yes ..........
A, E
B
C
C
A, E
* CPT
codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
Note: Acceptable documentation includes—Detailed description (including system components), source, and current pricing information, such
as copies of catalog pages, hard copy from specific Web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes—phone numbers and addresses of manufacturer, vendors or distributors, Web site links without pricing information, etc.
Note A: Additional documentation required. Need detailed description (including kit contents), source, and current pricing information (including
pricing per specified unit of measure in database). Accept copies of catalog pages or hard copy from specific Web pages. Phone numbers or addresses of manufacturer, vendors or distributors are not acceptable documentation.
Note B: No/Insufficient received. Retained price in database on an interim basis. Forward acceptable documentation promptly.
Note C: Submitted price accepted.
Note D: Deleted per comment or CMS.
Note E: 2007/8 price retained on an interim basis. Forward acceptable documentation promptly.
TABLE 3.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS
Code
Primary specialties associated with item
*CPT code(s)
associated
with item
Prior status on
table
Commenter response
and CMS action
Documentation provided. Price accepted is $1525 (Did not
accept $395 warranty cost.).
Specialty to submit,
asap.
Specialty to submit,
asap.
Documentation provided. Price accepted at $4500.
Documentation provided. Price accepted at $650 ( average of the cost of
the two items provided).
Ambulatory blood
pressure monitor.
3000
Cardiology ..................
93784, 93786,
93788.
Yes ..........
Camera mount—floor
2300
Dermatology ...............
96904 .............
Yes ..........
Cross slide attachment.
Dermal imaging software.
cprice-sewell on PROD1PC72 with RULES
EQ269 ...
2007/8
Price
2006/7 Description
500
Dermatology ...............
96904 .............
Yes ..........
4500
Dermatology ...............
96904 .............
Yes ..........
Dermoscopy attachments.
650
Dermatology ...............
96904 .............
Yes ..........
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00020
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
2008 Item
status refer
to note(s)
C
A, E
A, E
C
C
66241
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 3.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS—Continued
Primary specialties associated with item
*CPT code(s)
associated
with item
Prior status on
table
Commenter response
and CMS action
8,250
Cardiology, IM ............
93278 .............
Yes ..........
A, E
..................
Pathology ...................
88380 .............
No ............
Documentation provided. Revised description to better
describe system.
Price accepted at
17,900.
New Item ....................
..................
Dermatology ...............
96904 .............
Yes ..........
D
Radiology, Dermatology.
36481, G0341
Yes ..........
Deleted item as price
is less than $500
per documentation
received.
Revised description
based on comments
received that light
source was not part
of item. Documentation requested.
Specialty to submit,
asap.
Documentation provided. Price accepted at $489,940 ( average of the cost of
the two items provided).
Documentation requested.
New item ....................
2007/8
Price
Code
2006/7 Description
EQ008 ...
ECG signal averaging
system w-P waves
and late potentials
software.
Instrument, microdissection.
Lens, macro, 35–
70mm.
Plasma pheresis machine.
ED039 ...
37,900
..................
Psychology .................
96101, 96102
Yes ..........
377,319
Radiation oncology ....
77421 .............
Yes ..........
Strobe, 400 watts
(Studio) (2).
Cryosurgery system
(for tumor ablation)1.
ER070 ...
Psychology Testing
Equipment.
Portal imaging system
(w/PC work station
and software).
1500
Dermatology ...............
96904 .............
Yes ..........
Urology, Radiology,
Interventional Radiology.
50593 .............
No ............
..................
2008 Item
status refer
to note(s)
A, E
B
B
C
B
A, E
* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
Note: Acceptable documentation includes—Detailed description (including system components), source, and current pricing information, such
as copies of catalog pages, hard copy from specific Web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes—phone numbers and addresses of manufacturer, vendors or distributors, Web site links without pricing information, etc.
Note A: Additional documentation required. Need detailed description (including kit contents), source, and current pricing information (including
pricing per specified unit of measure in database). Accept copies of catalog pages or hard copy from specific Web pages. Phone numbers or addresses of manufacturer, vendors or distributors are not acceptable documentation.
Note B: No/Insufficient received. Retained price in database on an interim basis. Forward acceptable documentation promptly.
Note C: Submitted price accepted.
Note D: Deleted per comment or CMS.
Note E: 2007/8 price, where specified, retained on an interim basis. Forward acceptable documentation promptly.
TABLE 4.—PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR CY 2008
Equip
code
cprice-sewell on PROD1PC72 with RULES
NA
NA
NA
NA
NA
NA
NA
NA
NA
........
........
........
........
........
........
........
........
........
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
........
........
........
........
........
........
........
........
........
........
........
Supply description
Unit
Unit price
*CPT code(s) associated with item
Supply category
Blade, sharp pointed surgical .................................................
Buffer, lysis ..............................................................................
Caps, Capsure Macro LCM ....................................................
Catheter, balloon, lacrimal ......................................................
Catheter, Kumpe 1 ...................................................................
Disposable aspirating syringe 1 ...............................................
Ethanol, 95% ...........................................................................
Fee, image analysis ................................................................
Gas, argon, cryoablation .........................................................
Gas, helium, cryoablation .......................................................
Gastrostomy. Low profile replacement button (Mic-Key) .......
Gastrostomy. Stoma measuring device (Mic-Key) .................
Glycerol, 3% ............................................................................
Guidewire, angle tip (Terumo), 180 cm 1 ................................
IV infusion set, Sof-set (Minimed) ...........................................
Methylene blue stain ...............................................................
Probe, cryoablation, renal .......................................................
Rnase-free water .....................................................................
Slide, microscope, sterile ........................................................
Snare, Nitinol (Amplatz) 1 ........................................................
Swab, patient prep, 1.5 ml (chloraprep) .................................
item ......
ml .........
ml .........
item ......
item ......
..............
ml .........
item ......
..............
..............
item ......
item ......
ml .........
item ......
item ......
ml .........
item ......
ml .........
item ......
item ......
item ......
0.73
0.46
4.54
306
......................
......................
0.0033
18
......................
......................
5
10
0.001
......................
11.50
0.178
1175
0.85
1
......................
1.04
88381 ......................
88381 ......................
88380 ......................
68816 ......................
50385, 50386 ..........
21073 ......................
88380, 88381 ..........
99174 ......................
50593 ......................
50593 ......................
43760 ......................
43760 ......................
88380, 88381 ..........
50385, 50386 ..........
90769, 90771 ..........
88380 ......................
50593 ......................
88381 ......................
88380, 88381 ..........
50385, 50386 ..........
36592 ......................
Cutters, closures.
Lab.
Lab.
Accessory.
Accessory.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00021
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
Lab.
Office supply.
Accessory.
Accessory.
Accessory.
Accessory.
Lab.
Accessory.
Hypodermic, IV.
Lab.
Accessory.
Lab.
Lab.
Accessory.
Pharmacy, NonRx.
66242
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 4.—PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR CY 2008—Continued
Equip
code
Supply description
Unit
Unit price
*CPT code(s) associated with item
NA ........
Tube, jejunsostomy .................................................................
item ......
195
49441, 49446,
49451 and 49452.
Supply category
Accessory.
* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
1 Price verification needed. Item(s) added to table of supplies requiring specialty input.
TABLE 5.—PRACTICE EXPENSE EQUIPMENT ITEM ADDITIONS FOR CY 2008
Equip
code
Equipment description
NA .........
NA .........
Cryosurgery system (for tumor ablation) 1 ...........................
Cardiac coil, 1.5T 8-channel (MR) .......................................
NA .........
NA .........
Instrument, Microdissection ..................................................
Pressure sensor, wireless (for implanted AAA sac sensor)
Camera, ocular photoscreening, w-laptop and software .....
Unit price
*CPT code(s) associated with item
10
5
....................
35400
7
5
5
....................
25000
7000
50593 .....................
7557, 7558 and
75559.
88381 .....................
93982 .....................
99174 .....................
Life
Equipment
category
Other Equipment.
Imaging Equipment.
Laboratory.
Documentation.
Documentation.
* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
1 Price verification needed. Item(s) added to table of equipment requiring specialty input.
cprice-sewell on PROD1PC72 with RULES
(xi) Additional PE Issues Raised By
Commenters
Comment: One commenter
recommends that the direct inputs
associated with all fee schedule services
be made available to the public.
Response: Since the inception of
resource based PEs, all direct input data
has been made available to the public
on the CMS Web page. The direct inputs
associated with this final rule with
comment period are also available to the
public at the following Web site under
CMS–1385–IFC: https://
www.cms.hhs.gov/PhysicianFeeSched/
PFSFRN/list.asp#TopOfPage.
Comment: Several commenters
recommend that we reprice supply
items over $200 in the PE direct input
database annually. Additionally,
commenters also requested that we
establish individual J codes for these
high cost supplies. Alternatively,
several other commenters expressed
concerns over this recommendation
stating that utilization guidelines must
be set up that would trigger repricing or
an undue burden would be placed upon
those specialties using these high cost
supplies.
Response: Using an individual HCPCS
code for each of these supplies would be
difficult as there are multiple
manufacturers, with multiple prices,
associated with the majority of these
codes. Having multiple manufacturers,
and thus multiple prices, also makes it
difficult to reprice these supplies within
the PE methodology, which is why we
continue to work with the AMA RUC to
establish direct cost input data.
Additionally, all direct inputs need to
be budget neutralized within the PE
methodology. Removing these high cost
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
supplies from the standard PE
methodology would unfairly advantage
procedures that contain these supplies
as they would not be subject to the same
budget neutrality adjustments as would
other supplies. Finally, we agree with
those commenters that state that any
annual repricing of these supplies
would place undue burden on specific
physician groups. For these reasons, we
will continue to price these high cost
supplies within the standard PE
methodology.
Comment: A few comments were
received that recommended that
desktop computers be included as a
direct PE cost.
Response: The direct PE database
includes desktop computers with
monitor when this computer is
identified as being dedicated to a
specific procedure. The costs associated
with computers that are used for nonclinical purposes assigned to a specific
procedure, for example, used for
administrative procedures, are more
appropriately captured in the indirect
cost category.
Comment: One commenter
representing home care physicians
requested that travel time and other
inherent costs related to mobile medical
services such as vehicle operation and
mobile communication should be
accounted for in the PE calculation.
Response: To the extent that travel
time is necessary to furnish physician
services outside of the office setting,
these expenses are not considered direct
costs under the PE methodology.
Although the mobile communication
devices are not specifically included as
direct PE inputs, 12 minutes of clinical
labor time is assigned for each of the
home visit E/M services, 6 minutes in
PO 00000
Frm 00022
Fmt 4701
Sfmt 4700
the pre-time period and 6 minutes in the
post time period. Phone calls are
standardized at 3 minutes each for
purposes of the direct PE inputs and
would be included as part of this
clinical labor time.
Comment: One commenter stated that
adjustments need to be made to the PE
database for certain dialysis codes and
requested that for G0393 and G0392 an
angioplasty balloon be added to the PE
database and that for CPT code 36870
the PE database should be revised to
include an angiographic room and a
power table.
Response: The balloon catheters are
reflected in the PE database, as supply
number SD152, and the angiographic
room and an exam table are included in
the equipment for CPT code 36870.
Comment: Commenters expressed
concern about the level of
reimbursement for intrathecal pump
management services for chronic pain
patients and believe that the refill kit is
not accounted for in the PE. In addition,
commenters expressed concern that
reimbursement did not cover the leasing
costs for the equipment.
Response: We reviewed the PE
database and have verified that a refill
kit, priced at $28, is included as a
supply in CPT codes 95990 and 95991.
In our PE database, equipment costs are
assigned based on the purchase price for
each piece of equipment, regardless of
whether the equipment is owned, rented
or leased.
Comment: A manufacturer expressed
concern that the PE RVUs for intranasal
administration of vaccines (CPT codes
90467/8 and 90473/4) are
inappropriately low and should be
equalized to the injectable
immunization administration PE RVUs.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
The commenter stated that when the
codes were reevaluated in 2004 there
was not enough experience in the office
to fully understand the time associated
with providing an intranasal vaccine.
The commenter stated that specialty
organizations have indicated that this
issue is worth reexamining and
indicated that they had been encouraged
to communicate with the RUC in
support of equalizing payment for the
codes.
Response: We appreciate the
commenter’s concerns about the
disparity in the PE RVUs for the
intranasal and injectable immunization
administration procedures. To the
extent that these concerns relate to the
direct PE inputs, we would encourage
the commenter to work with the
specialty organizations to determine if it
is appropriate to bring these codes
forward for further RUC review.
Comment: One commenter requested
that we publish the RUC approved
RVUs for all noncovered and carrier
priced services, particularly for the
positron emission tomography (PET)
and PET/CT procedures.
Response: We have made it our policy
to publish work and PE RVUs for
services in instances where the
information has been forwarded to us,
with a few exceptions. One exception to
this policy is for carrier priced codes.
Our rationale for this policy is simply
that any published values for carrierpriced codes would be in direct
contradiction of our intentions with
respect to this designation. As we state
in Addendum A, a ‘‘C’’ status indicator
means that carriers price this code
establishing RVUs and payment
amounts without direct guidance from
CMS. Because the commenter did not
provide us with information about
specific noncovered services that do not
have published RVUs, we are not able
to address this particular aspect of the
comment.
Comment: Commenters representing
radiation oncologists expressed concern
about the significant PE reductions in
CPT code 77336 for continuing medical
physics consults. The commenters
noted this code was last reviewed by the
PEAC in 2002 and the practice standard
has changed significantly. Commenters
recommended that the direct PE inputs
for this code be reviewed and refined so
that accurate PE data is reflected for this
code.
Response: While we appreciate that
the commenters expressed their
concerns to us regarding a change in the
practice standards for the services of
CPT code 77336 which they believe
results in the need to change the direct
PE inputs, we believe that the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
appropriate course of action for the
commenters is to work together with the
RUC affiliated specialty society in order
to determine if these concerns can be
appropriately addressed by the RUC.
Comment: We received comments
from individuals and associations with
concerns about the new bottom-up PE
methodology and the resulting effect of
decreases in the PE RVUs for various
services including, but not limited to
the following: chemotherapy
administration, endovenous ablation
procedures, brachytherapy treatments,
3-D imaging services, and procedures
for photopheresis and plasma pheresis.
Response: As we noted earlier in this
section, we are aware that the PE RVUs
for some services were negatively
impacted by the change in our PE
methodology. However, we will
reiterate here that it is our policy to
make certain, to the maximum extent
possible, that the direct PE inputs used
in the PE RVU calculation actually
reflect the typical resources used to
provide each service. To the extent that
the current PE RVUs are lower than
those determined under our previous
methodology, the difference is likely
attributable to a previous PE RVU that
was based on charges that overvalued
the service. Because the current
methodology uses the direct PE inputs
that are inherent and typical to each
procedure, the resulting PE RVUs more
accurately reflect the resources that are
used to provide the service.
Comment: One commenter explained
that, in the CY 2004 PFS final rule, we
decided to set the values for the
monthly ESRD-related services for home
dialysis patients (for example, G0323) at
the same rate as the monthly ESRD
related services with 2 or 3 visits per
month (for example, HCPCS code
G0318) to provide an incentive for the
increase use of home dialysis (as
authorized under 1881(b)(3)(B) of the
Act). The commenter notes that the
current payment rate for ESRD related
services, with 2 or 3 face-to-face visits
per month is higher than ESRD related
services for home dialysis patients, (due
to a difference in PE). As such, the
commenter is concerned that the
differential in payment rates mitigates
the incentives that we previously
attempted to establish. The commenter
suggested that incentives for using home
dialysis should be strengthened by
using a consistent PE value for MCP
codes G0323 and G0318. However, the
commenter prefers that we establish a
new payment rate for the monthly
management of home dialysis patients
based on the weighted average of the
MCP for patients who dialyze in a
PO 00000
Frm 00023
Fmt 4701
Sfmt 4700
66243
dialysis center or other outpatient
facility.
Response: We appreciate the
suggestions regarding our payment
policy for the monthly management of
home dialysis patients. We intend to
consider the commenters suggestions as
we continue to evaluate payment rates
for the monthly management of patients
on home dialysis.
Note: We received comments regarding
certain items and services that are not
germane to the PE RVUs or other components
of the PFS. These issues include comments
regarding: revisions to the definition of preservice work and time for certain global
services; inadequate pricing of HCPCS code
A4562 for pessaries, requests for payment
adjustments for certain services under PFS to
approximate payment amounts for these
services established under OPPS and ASCs,
inadequate payment for pharmacy costs and
nursing services for drug administration
codes, and concerns about the reduction of
PE RVUs in the nonfacility setting due to the
changes in the PE methodology along with
requests to freeze payment amounts at the
level of the CY 2006 transitional PE RVUs.
Because these comments are outside the
scope of the issues raised in the CY 2008 PFS
proposed rule, we will not respond to these
issues in this final rule with comment period.
B. Geographic Practice Cost Indices
(GPCIs)
We are required by section
1848(e)(1)(A) and (C) of the Act to
develop separate Geographic Practice
Cost Indices (GPCIs) to measure
resource cost differences among
localities; and to review and, if
necessary, adjust the GPCIs at least
every 3 years. In the CY 2008 PFS
proposed rule, we published the
proposed GPCIs for CY 2008 in
Addendum E, noting that the proposed
GPCIs do not reflect the 1.000 floor that
was in place during CY 2006 and CY
2007. This floor expires as of January 1,
2008 in accordance with section 102 of
the MIEA–TRHCA.
In developing a GPCI, section
1848(e)(1)(A)(i) and (ii) of the Act
require that the PE and malpractice
(MP) GPCIs reflect the full relative cost
difference while section
1848(e)(1)(A)(iii) of the Act requires that
the physician work GPCIs reflect only
one quarter of the relative cost
differences. Section 1848(e)(1)(C) of the
Act also specifies that if more than 1
year has elapsed since the last GPCI
revision, we must phase in the
adjustment over 2 years, applying only
one half of any adjustment in each year.
All GPCIs are developed through a
comparison to a national average for
each component, and the RVUs for
different services uniformly weight each
component.
E:\FR\FM\27NOR2.SGM
27NOR2
66244
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
1. GPCI Update
A detailed description of the
methodology used to develop and
update the GPCIs can be found in the
CY 2004 PFS proposed rule (68 FR
49039, August 15, 2003). There are three
components of the GPCIs (physician
work, PE, and MP) and each relies on its
own data source.
a. Physician Work
The physician work GPCI is
developed using the median hourly
earnings from the 2000 Census of
workers in six professional specialty
occupation categories which we use as
a proxy for physician wages and
calculate to reflect one quarter of the
relative cost differences. Physician
wages are not included in the
occupation categories because Medicare
payments are a key determinant of
physicians’ earnings; therefore,
including physician wages in the
physician work GPCI would, in effect,
make the index dependent upon
Medicare payments. The physician
work GPCI was updated in 2001, 2003,
and 2005 using data from the 2000
Census; the proposed CY 2008
physician work GPCI is also based on
the 2000 Census data. Because all
updates since 2001 have relied on the
2000 Census data, the changes observed
in the physician work GPCI in the
update years are due to minor changes
in utilization and budget neutrality
factors; for CY 2008, Addendum E
shows that there have been small
changes in the physician work GPCI.
Section 102 of the MIEA–TRHCA
required application of a 1.000 floor on
the work GPCI in payment localities
where the work GPCI was less than
1.000. This provision expires on
December 31, 2007. The CY 2008
proposed physician work GPCI reflects
the removal of this floor.
cprice-sewell on PROD1PC72 with RULES
b. Practice Expense
The PE GPCI is developed from three
data sources:
(i) Employee Wages: We use 2000
Census median hourly earnings of four
occupation categories. The physician
work GPCI was updated in 2001, 2003,
and 2005 using data from the 2000
Census.
(ii) Office Rents: We use residential
apartment rental data produced
annually by the Department of Housing
and Urban Development (HUD) as a
proxy for physician office rents. In 2001,
2003, and 2005, we used rents in the
HUD 40th percentile. For CY 2008, we
have calculated the GPCI using rents in
the 50th percentile for the physician
office rent proxy. We proposed to use
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the 50th percentile because although
HUD generally allows payment for
subsidized housing up to the 40th
percentile, in some areas it allows
payment up to the 50th percentile. We
made this change to reflect the trend
toward higher rents across the country.
Fair Market Rents (FMRs) are gross
rent estimates including rent and
utilities. HUD calculates the FMRs
annually using: (1) Decennial Census
data; (2) American Housing Surveys
conducted by the Census Bureau for
HUD to enable HUD to develop
revisions between Census years; and (3)
random digit dial surveys to enable
HUD to develop gross rent change
factors. The American Housing Surveys
cover 11 areas annually, rotating among
the 44 largest metropolitan areas. The
random digit dial component surveys 60
FMR areas annually.
The FMR is set as a percentile point
in the distribution of rents for standard
housing occupied by people who moved
within the previous 15 months. The
current FMR definition is the 40th
percentile rent (the amount below
which 40 percent of units are rented).
Each year, the 50th percentile rent is
also calculated by HUD and available
through the HUDUSER Web site.
In 2000, HUD changed its FMR policy
to increase access to housing for
families receiving Section 8 rent subsidy
vouchers (65 FR 58870). To do so, HUD
increased FMRs from the 40th
percentile to the 50th percentile in areas
where subsidized families were highly
concentrated in certain census tracts,
given evidence that affordable housing
was not well distributed. Only
metropolitan areas with more than 100
census tracts are considered for possible
increase to the 50th percentile rent.
FMRs can be moved from 40th to 50th
percentile or back from 50th to 40th
percentile.
In the case of the office rent index for
the PE GPCI, FMRs have been used to
capture geographic differences in rental
costs, in the absence of a consistent
commercial rent index that covers all
metropolitan and nonmetropolitan areas
in the U.S. It has been used as a measure
of the ‘‘average rent’’ in a market.
However, since 2000, the FMRs have
been a mixture of the 40th percentile
and 50th percentile rents. FMR areas
move between the two cutoffs. For
example, in California, 9 counties had
FMRs set at the 50th percentile in 2004.
In 2007, only 2 of these 9 counties were
still at the 50th percentile level for the
FMR, out of 4 total counties at the 50th
percentile level.
As described above in this section
(and as detailed in 65 FR 58870), the
criteria for setting the FMR at the 40th
PO 00000
Frm 00024
Fmt 4701
Sfmt 4700
or 50th percentile are based on
concentrations of subsidized
households. There is no reason to
assume that commercial rents would
follow the same patterns.
Therefore, we believe the 50th
percentile, or median, rents calculated
by HUD will be a more consistent, fair
measure of geographic differences for
the purpose of proxying for commercial
rents.
Rent data produce the most
significant changes because they are
based on annual changes in HUD rents,
and therefore, are more volatile than the
wage (Census) data. While it has been
suggested that we explore sources of
commercial rental data for use in the
GPCI, we do not believe there is a
national data source better than the
HUD data.
(iii) Equipment and Supplies: We
assume that items such as medical
equipment and supplies have a national
market and that input prices do not vary
among geographic areas. As mentioned
in previous updates, some price
differences may exist, but we believe
these differences are more likely to be
based on volume discounts rather than
on geographic market differences.
Equipment and supplies are factored
into the GPCIs with a component index
of 1.000.
c. Malpractice
The MP GPCI is calculated based on
insurer rate filings of premium data for
a $1 million to $3 million mature
‘‘claims made’’ policy along with
premium or surcharge data for
mandatory patient compensation funds
(PCFs). The MP GPCI is the most
volatile of the GPCIs. This GPCI was
updated in 2001 and 2003 as scheduled
with the physician work and PE GPCIs;
but, there was an unscheduled update of
the MP GPCI in 2004 (68 FR 49043) to
reflect increases in MP premiums
nationwide. The proposed CY 2008 MP
update reflects the most recent premium
data available. The physician work and
PE GPCIs are being updated at the same
time.
We received the following comments
about our proposed GPCIs:
Comment: We received several
comments expressing the concern that
San Benito County in California was
placed in the wrong payment locality.
Response: In 2003, the U.S. Census
Bureau moved San Benito County from
the Rest of State Census category and
placed it in the San Jose MSA. Our data
and methodology do not accommodate
mid-decennial changes in Census data,
and therefore, our 2008 update reflects
that San Benito County remains in the
Rest of California payment locality.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Comment: We received several
comments about the PE GPCI for Santa
Clara County, California. In the
proposed rule, the PE GPCI was lower
for Santa Clara than it has been in
previous years and commenters were
concerned about why this happened.
Response: We recognize that there
was a decrease in the proposed Santa
Clara County PE GPCI. We have studied
this issue including examining both the
source data and the methodology for
obtaining the PE GPCI in case there was
a mistake in the proposed values.
However, a close examination of the
data showed that the GPCI is accurate
and reflects a decrease in the value of
HUD rentals in Santa Clara County.
Comment: One commenter suggested
that a GPCI adjustment should not be
applied to physician work, or that the
physician work GPCI should be 1.000
for all localities.
Response: We are required to apply a
GPCI adjustment to physician work in
accordance with section 1848(e) of the
Act. Therefore, we will continue to
apply the physician work GPCI.
Comment: We received several
comments suggesting that the PE GPCI
is inaccurate due to our continued use
of HUD rental data as a proxy for
medical office space.
Response: Because Medicare is a
national program, we believe it is
important to use the best data that is
available on a nationwide basis. We
believe the HUD rental data is the most
comprehensive and valid indicator of
the national real estate rental market
that is available. Additionally, as we
stated most recently in the CY 2007 PFS
final rule with comment period (71 FR
69656), we believe the HUD rental data
remains the best data source to fulfill
our requirements that the data be
available for all areas, be updated
annually, and retain consistency area-toarea and year-to-year. In the past, we
have had both the GAO and the
Research Triangle Institute examine
available data sources for use in the PE
GPCI, and both have found that
available commercial data sets either
have insufficient coverage nationally or
are developed by suspect methodology.
Therefore, we continue to believe the
HUD rental data is the best nationally
available data source to use as a proxy
for physician office rents.
Comment: We received several
comments suggesting that the GPCIs of
Hawaii/Guam and Alaska need to be
adjusted to accommodate the higher
costs of transportation of supplies and
equipment to these localities.
Response: The GPCIs are a proxy for
costs associated with providing services
to beneficiaries, not costs associated
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
with living in a particular place.
However, we will consider these
comments as we evaluate possible
changes to our methodology.
Comment: We received comments
from the Medicare Payment Advisory
Commission (MedPAC) suggesting an
alternative method for calculating the
PE GPCI. This alternative PE GPCI
method excludes cost measures for
equipment and supplies.
Response: We appreciate MedPAC
suggesting an alternative method. We
intend to evaluate the suggested change
to the PE GPCI methodology and will
propose any changes in future
rulemaking.
We will finalize the GPCIs shown in
Addendum E. The GPCI values shown
represent the first year of the two-year
GPCI update transition and have been
budget neutralized to ensure that
nationwide total RVUs are not impacted
by changes in locality GPCIs.
Specifically, this is done by applying a
weight that is derived from the
difference between payments using the
‘‘old’’ GPCIs and the ‘‘new’’ GPCIs to the
proposed GPCIs that insures that total
payments would not be different. As we
indicated above in this section, there is
no 1.000 floor on the physician work
GPCI in 2008. The GAFs are shown in
Addendum D.
2. Payment Localities
a. Background
The Medicare statute requires that
PFS payments be adjusted for certain
differences in the relative costs among
areas. The statute requires an
adjustment which reflects differences
among areas for the relative costs of the
mix of goods and services comprising
PEs (other than Malpractice expenses)
compared to the national average. The
statute also requires adjustment for the
relative costs of MP expenses among
areas compared to the national average.
Finally, the statute requires adjustment
for one quarter of the difference between
the relative value of physicians’ work
effort among areas and the national
average of such work effort.
The physician work component
represents 52.466 percent of the
national average fee schedule payment
amount. Thus, the statutory requirement
for geographic adjustment of only onequarter of the differences in the
physician work component means that,
on average, only 13.117 percentage
points of physician work are
geographically-adjusted, and, on average
39.349 percentage points of the
physician work component are not
adjusted and represent a national fee
schedule amount.
PO 00000
Frm 00025
Fmt 4701
Sfmt 4700
66245
In addition, the PE component
represents 43.669 percent of the
national average fee schedule payment
amount. PEs are comprised of
nonphysician employee compensation,
office expenses (including rent),
medical equipment, drugs and supplies,
and other expenses. As explained above
in this section, we do not make a
geographic adjustment relating to
medical equipment, drugs, and supplies
because there is a national market for
these items. Thus, only the categories of
nonphysician employee compensation
and rents are geographically adjusted.
These categories represent, on average,
30.862 percentage points of the total PE,
and 12.807 percentage points of PEs are
not geographically-adjusted.
In total, more than half (52.156
percent) of the average PFS amount is a
national payment that is the same in all
areas of the country; that is, 52.156
percent of the average fee is not
geographically-adjusted.
There are two additional points about
the geographic indices that are
important to note. First, as described
above in this section, the data used to
measure cost differences among
localities are proxies for physician
work, employee compensation and
office rents. That is, wage data for
various categories of employees are used
to proxy the actual wages of physician
employees. Second, the data used for
such proxies are based on actual Census
data only for a limited number of
counties. The geographic adjustment
factors (GAFs) for more than 90 percent
of counties are developed using proxies
based on larger geographic areas (for
example, data for all rural areas in a
State are combined and used to proxy
the values for each rural county in a
State). This aggregation is necessary for
areas where country level data are not
available. Thus, the underlying data are
proxies for actual costs, and the
resulting GPCIs do not measure
perfectly the cost differences among
localities.
Currently, there are 89 Medicare
physician payment localities to which
GPCIs are applied. The payment locality
structure under the PFS was established
in 1996 and took effect January 1, 1997.
The development of this structure is
described in detail in both the CY 1997
PFS proposed (61 FR 34615) and final
rules (61 FR 59494).
b. Revision of Payment Localities
Over time, changing demographics
and local economic conditions may lead
to increased variations in practice costs
within payment locality boundaries. We
are concerned about the potential
impact of these variations and have
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66246
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
been studying this issue and potential
alternatives for a number of years.
However, because changes to the GPCIs
must be applied in a budget neutral
manner (and under the current locality
system, budget neutrality results in
aggregate payments within each State
remaining the same), there are
significant redistributive effects to any
change. Therefore, we are also
concerned about the potential impact of
locality revisions.
For the past several years, we have
been involved in discussions with
California physicians and their
representatives about recent shifts in
relative demographics and economic
conditions among a number of counties
within the current California payment
locality structure.
The California Medical Association
(CMA) suggested that we use our
demonstration authority to adopt an
alternative locality configuration and
avoid certain redistributive effects, but
such an approach was not feasible (as
discussed in the CY 2005 PFS final rule
with comment period (70 FR 70151)). In
the CY 2006 PFS proposed rule (70 FR
45784), we proposed to remove two
counties from the ‘‘Rest of California’’
payment locality and create a new
payment locality for each county. These
two counties were the ones with the
largest difference between the county
and locality GAFs. However, there was
much more opposition than support for
this proposal, in large part because of its
negative effect on payments for the
counties that would have remained in
the ‘‘Rest of California’’ locality. For
example, the CMA commented on this
proposal stating, ‘‘a nationwide
legislative solution that would provide
additional funding * * * is the only
solution we are supporting at this time.’’
We did not finalize the proposal and
described our reasons in the CY 2006
PFS final rule with comment period (70
FR 70151).
As indicated previously, we recognize
that changing demographics and local
economic conditions may lead to
increased variations in practice costs
within payment locality boundaries. We
are concerned about the potential
impact of these variations.
In considering potential changes in
payment localities, we believe it is
important to evaluate both the potential
impact of intralocality practice cost
variations and the redistributive impacts
that would result from any revisions to
the localities. We also indicated that we
are concerned about the considerable
administrative issues in making locality
changes, particularly if such changes
involve a transition, and if they occur
when new GPCI data are being phased-
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
in. As we noted in the response to the
June 2007 General Accountability Office
report on localities (GAO–07–466),
changing localities requires
reprogramming systems and extensive
provider education, both of which are
expensive and burdensome
administrative activities that can last for
a significant period of time. We receive
claims for payment that cross calendar
years and carriers must maintain
payment files for the 2 different years.
In the proposed rule we solicited
comments on three possible locality
reconfigurations. We indicated that
because of the importance of striking an
appropriate balance between
intralocality variations and
redistributive impacts with any such
locality revisions, we wanted to be
cautious and evaluate the impacts in
California before considering applying
the policy more broadly in the future.
The three options from the proposed
rule are described as follows:
Option 1: Using the existing locality
structure, apply a rule whereby if a
county GAF is more than 5 percent
greater than the GAF for the locality in
which the county resides it would be
removed from the current locality. A
separate locality would be established
for each county that is removed. Based
on the new fully phased-in GPCI data
(that is, for CY 2009), application of this
approach in California would remove
three counties (Santa Cruz, Monterey,
and Sonoma) from the Rest of California
payment locality and Marin county from
the Marin/Napa/Solano payment
locality and create separate payment
localities for each of these four counties.
This approach focuses on counties for
which there is the biggest difference
between the county GAF and the
locality GAF.
This proposal is similar to the policy
we previously proposed in the CY 2006
PFS proposed rule (70 FR 45784) but
did not adopt to address the counties
with GAFs that are most different from
their current locality designation.
Implementation of this option would
lead to an increase in payment of 7.6
percent for Santa Cruz County (and
average increase of 5 percent for the
other counties involved) and a decrease
in payment of 4.3 percent for Napa and
Solano Counties.
Option 2: This approach is similar to
option 1, but the new localities would
be structured differently. We would use
the same 5 percent threshold
methodology but instead of creating four
new localities in which each county
becomes its own new locality, the three
counties that are removed from the Rest
of California locality would become one
new locality. Marin County would still
PO 00000
Frm 00026
Fmt 4701
Sfmt 4700
be removed from the Marin/Napa/
Solano locality to become its own
locality. Application of this approach
would remove three counties (Santa
Cruz, Sonoma, and Monterey) from the
Rest of California payment locality, and
Marin County from the existing Marin/
Napa/Solano payment locality. This
approach groups together counties from
the Rest of California locality that have
the greatest difference between the
county and locality GAF. (This option
would lead to an increase of 6 percent
for the new 3-county payment locality.)
These counties have similar cost
structures and grouping them together
into one new locality is consistent with
our goal of homogeneous resource costs
within a locality.
Option 3: Apply a methodology
similar to that used in the 1997 locality
revisions (61 FR 59495), but applied at
the county level rather than the
‘‘existing locality’’ level. That is, we
sorted the counties by descending GAFs
and compared the highest county to the
second highest. If the difference is less
than 5 percent, the counties were
included in the same locality. The third
highest is then compared to the highest
county GAF. This process continues
until a county has a GAF difference that
is more than 5 percent. When this
occurs, that county becomes the highest
county in a new payment locality and
the process is repeated for all counties
in the State. This approach would group
counties within a State into localities
based on similarity of GAFs even if the
counties were not geographically
contiguous.
This organizes payment localities
based on costs, which would reduce the
number of payment localities in
California from 9 to 6 localities. This
option alleviates the greatest variations
in cost between counties in California.
This proposal is unique in that the new
localities are not contiguous. Currently,
all localities encompass adjacent
geographic areas.
The impacts associated with this
option are significant. Depending on the
tier, changes could reflect increases of
as much as 7.6 percent or decreases of
as much as 7.3 percent.
We received numerous comments on
these options as discussed below:
We received similar comments from a
number of individuals, State and local
medical societies, and organizations,
including the California Medical
Association, on several significant
issues and are addressing these together:
Comment: Santa Cruz County should
be removed from the Rest of California
payment locality due to its higher costs.
Response: We recognize that Santa
Cruz County has higher costs than other
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
counties within the Rest of California
locality, and the methodologies we
presented in each of the options would
result in Santa Cruz County being
removed from the Rest of California
payment locality.
Comment: Many commenters were
concerned about the description of the
methodology used for Options 1 and 2.
Specifically, these comments directed
us to adopt a methodology suggested by
the California Medical Association. The
methodology compares the highest GAF
county to the weighted average (GAF) of
the remaining counties of the locality.
Response: To clarify, the methodology
we used identified counties where the
county GAF was at least 5 percent
higher than the GAF of the locality and
then we either left that county as a
payment locality itself or joined it with
other counties into a payment locality.
In Option 1, each of these counties
became a separate locality; in Option 2,
we combined several of these counties
into a single payment locality. This
approach is not the ‘‘iterative
methodology’’ that some commenters
suggested we should follow. We
recognize that there are alternative
methodologies that can be used to
consider reconfigurations to locality
structures. We will consider the
suggestions of the commenters in the
future.
Comment: There were concerns that
combining several counties into a single
payment locality in Option 2 was
arbitrary and led to lower payments for
these counties.
Response: As we stated in the
proposed rule, there are trade-offs
involved in making any changes to
localities, and we recognize the
importance of trying to achieve a
reasonable balance among competing
priorities. One of our goals was to keep
the number of payment localities
manageable. Although we recognize that
there are effects on each of the
individual counties, combining counties
with very similar costs was a reasonable
way to meet this goal.
Comment: Numerous commenters
from California recommended that we
implement Option 3 but suggested that
we erred in describing the methodology
used in the development of Table 9 of
the proposed rule and recommended
that if we implement it, we should use
their suggested methodology.
Commenters suggested that we really
meant to insert a hierarchical approach
and discussed how these are both
acceptable ways to accomplish the
restructuring of the counties. Other
State societies expressed interest in this
option as long as we use the alternative
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
methodology suggested by the California
commenters.
Response: In Option 3 in the proposed
rule, we ranked the counties by GAF
from highest to lowest. We then
combined into a new payment locality
the county with the highest GAF and
the other counties that have a GAF
within 5 percent of the highest GAF
county. Then, we found the county with
the highest GAF among the remaining
counties. We combined that county and
all the counties that have a GAF within
5 percent of the new highest GAF
county into a payment locality. We
continued this method until all counties
were included in a locality. As
previously mentioned, there are
multiple approaches to reconfiguring
the localities that result in similar
outcomes. We will further study the
suggestions provided by the
commenters.
Comment: We received a number of
comments requesting that we provide a
wide variety of data, at the county level,
from numerous sources covering the
years 1999 through 2006.
Response: We believe we provided
commenters sufficient information to
fairly evaluate our proposals. We note
that many of these requests involved
county level data. There is very little
county level data available nationwide.
Most of our data sources are collected at
the MSA or Consolidated MSA, or NonMetropolitan Area level, and our
methodology was designed to be used to
develop GPCIs within a payment
locality analysis, not a county level
analysis. We do our best to provide
requestors with sources for publicly
available data and to provide any other
data that is requested of CMS. However,
we often simply do not have data
available at other than the locality level.
Comment: Several commenters are
concerned that the data used to develop
the latest GPCI update are out of date or
inaccurate.
Response: We used the most up-todate data available for the GPCIs used in
the calculation of the proposed options.
Descriptions of the data sources we use
can be found in previous regulations (69
FR 66261) but we will reiterate them
here. For the physician work GPCI, we
use data files from the latest decennial
census (currently 2000) supplied to
CMS by the Census Bureau. These data
are available to any individual or group
interested in obtaining them from the
Census Bureau. Data for the rental
portion of the PE GPCI update come
from HUD rental files, and these data
are available online to anyone wishing
to obtain them. Wage data for the PE
GPCI come from the 2000 Census files
which are available from the Census
PO 00000
Frm 00027
Fmt 4701
Sfmt 4700
66247
Bureau. Data for the malpractice GPCI
come from premium data that are filed
by companies writing Professional
Liability Insurance in each state. These
filings are provided, upon request by
our contractor, to CMS by each State
Department of Insurance. Our latest
update covers premium data for 2004,
2005 and 2006.
Comment: We received comments
from certain physicians in Ohio
requesting that we examine Ohio for a
possible change in the current Statewide
payment locality.
Response: We are currently examining
alternatives to the current locality
structure. As a part of our study we will
revisit Statewide localities to determine
if revisions are appropriate.
Comment: We received a number of
comments from ambulance suppliers
throughout the mid-West requesting that
we make no changes that would have a
negative impact on the GPCIs in rural
areas. Other commenters expressed
similar concerns about the impact of
locality changes on rural physicians and
beneficiaries.
Response: The vulnerability of rural
areas to decreases in relative payments
as a result of locality revisions is an
issue that is of considerable concern to
us and something we take very
seriously. However, as previously noted
we must find an acceptable balance
between the multiple competing
concerns when making changes in
localities in order to best meet the needs
of the entire program and this generally
cannot be done without having any
impact on rural areas.
Comment: MedPAC provided
comments outlining two possible
mechanisms for developing changes in
the payment localities of the States.
These methods are similar but differ in
that one method begins at the locality
level and the other starts with MSA
level data. MedPAC also suggests that
we determine whether those States that
are currently single payment localities
wish to remain single payment
localities.
Response: As always, we value the
input of MedPAC and we intend to
analyze their suggested methods
carefully as we discuss possible national
policy changes.
Comment: Comments regarding
changes in the payment localities in
California were universally
accompanied with a belief that we
should implement these changes,
without decreasing payments to any
counties.
Response: We understand the desire
to avoid the negative impact
implementing any of these options
might have on certain areas. However,
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66248
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the statute requires that geographic
adjustments be established based upon
an index of costs that is tied to national
averages. As a result, when the average
increases in one locality because of the
addition of a higher cost county, the
average in the locality that previously
contained the higher cost county will
necessarily decrease. Any changes in
localities will necessarily produce
changes in the underlying GPCIs, and
we have no authority to assign or retain
GPCIs that do not represent the actual
values for a locality.
Comment: Many commenters
suggested that we consider a national
solution to payment locality structure
problems, not focus on a single state.
Response: Our proposals attempted to
address locality issues in an area of the
country where the incongruity of certain
GAFs within localities is particularly
evident. In addition, these issues have
been brought to our attention regularly
over the past several years, and the
California Medical Association has
demonstrated its desire and willingness
to work with us to develop ideas for
resolving them. We viewed these
proposals relating only to California as
a starting point and, as we indicated in
the proposed rule, we would consider
applying any changes to additional
States in the future.
Decision: We appreciate the
thoughtful comments we received in
response to the three options we
included in the proposed rule. As
mentioned above, we recognize that
changing the locality structure is a
complex undertaking and there are
competing concerns, including budget
neutrality that results in payments in
certain areas decreasing whenever
payments in other areas are increased,
that must be carefully balanced to
achieve the most appropriate results.
Historically, to help us find the best
balance in a particular state, we have
looked to State medical societies to
work with us to provide leadership and
support on preferred approaches to
locality reconfiguration in that
particular State.
The comments we received from
California physicians, including the
California Medical Association’s
indication that it does not support any
of the options, and interested parties
from other States have convinced us
that this issue requires further study and
analysis. Therefore, we will not be
finalizing any of the three proposed
options in this rule. Commenters have
suggested some other methodologies
that we find worthy of further
exploration, including the use of
Metropolitan Statistical Areas (MSAs).
We do not necessarily believe that the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
county is the appropriate geographic
unit on which we should be focusing for
locality revisions. Commenters also
made strong arguments for why any
locality reconfiguration should be done
on a nationwide basis and not just one
State at a time. Therefore, we intend to
conduct a thorough analysis of
approaches to reconfiguring localities
and will address this issue again in
future rulemaking.
C. Malpractice RVUs (TC/PC Issue)
In the CY 2008 PFS proposed rule (72
FR 38142), we included a discussion
about the radiology codes for which the
technical component malpractice RVUs
are higher than the professional
component malpractice RVUs. In the
past, several organizations have
requested that we examine these codes
and make changes to this assignment of
malpractice RVUs. We asked for
information about how we could
address this issue and obtain data on
malpractice costs associated with these
radiology codes.
We received the following comments
on this issue.
Comment: The Professional Liability
Insurance (PLI) workgroup of the AMA/
Specialty Society RVU update
committee (RUC) supported by several
other organizations recommended that
we reduce the PLI technical component
for these codes to zero. They suggest
that there are no identifiable separate
costs for professional liability for
technical components. They also
recommend that the PLI RVUs be
redistributed across all physicians’
services. The RUC is concerned that the
Deficit Reduction Act of 2005 (Pub. L.
109–171) (DRA) cap on the TC payment
for imaging services will remove an
estimated $200 million from the Part B
pool (as a result of the exemption of the
reduced expenditures from the budget
neutrality requirement at section
1848(c)(2)(B)(v)). The RUC believes that
making the recommended changes will
keep money that would be lost due to
the DRA cap in the Part B pool. The
RUC wants CMS to implement this
change immediately and consider other
changes to the PLI RVU assignment
later.
Response: In the CY 2008 PFS
proposed rule, we explained that these
codes had not been reviewed due to a
lack of suitable data on the cost of PLI
for technical staff or imaging centers.
The RUC believes that no such data are
available because there are no
identifiable separate costs. At this point
in time, we are not able to evaluate
whether sufficient data exists or to make
a judgment on the RUC’s assertion that
such data are not available because
PO 00000
Frm 00028
Fmt 4701
Sfmt 4700
there are no identifiable costs. We will
continue to explore possible sources of
information about these costs. We made
no proposal regarding malpractice RVU
assignment and we are still considering
possible changes. If we identify in the
future what we believe is a more
appropriate way to pay for these
services, we will propose changes
through notice and comment
rulemaking.
Comment: Some commenters stated
that the malpractice RVUs in the
technical component should not be
zero. These commenters suggested that
we either ‘‘flip’’ the malpractice RVU
assignment between the professional
and technical components or make them
equal.
Response: As we stated in the CY
2008 PFS proposed rule, we do not
believe it would be appropriate to ‘‘flip’’
the PC and TC RVU values because the
professional part of the MP RVUs has
undergone a resource based review, is
derived from actual data, and is
consistent with the resource based
methodology for PFS payments. Further,
we will not simply equalize the PC and
TC RVU values because at this time we
have no data to demonstrate that the
malpractice costs for the technical
portion of these services are the same as
the professional portion. We will
continue to study this issue and will
propose any changes in future
rulemaking.
Comment: We received several
comments recommending that we make
the PLI RVUs resource based for all
codes and that we should continue to
collect and analyze appropriate
malpractice premium data before
making changes to the RVU assignment.
Response: We will continue to solicit,
collect, and analyze appropriate data on
this subject. Once we have sufficient
information, we will be better able to
make a determination as to what, if any,
changes should be made, and we will
propose any changes in future
rulemaking.
D. Medicare Telehealth Services
1. Requests for Adding Services to the
List of Medicare Telehealth Services
As discussed in the CY 2008 PFS
proposed rule (72 FR 38143), section
1834(m)(4)(F) of the Act defines
telehealth services as professional
consultations, office visits, and office
psychiatry services, and any additional
service specified by the Secretary. In
addition, the statute required us to
establish a process for adding services to
or deleting services from the list of
telehealth services on an annual basis.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
In the CY 2003 PFS final rule with
comment period (67 FR 79988), we
established a process for adding services
to or deleting services from the list of
Medicare telehealth services. This
process provides the public an ongoing
opportunity to submit requests for
adding services. We assign any request
to make additions to the list of Medicare
telehealth services to one of the
following categories:
• Category #1: Services that are
similar to office and other outpatient
visits, consultation, and office
psychiatry services. In reviewing these
requests, we look for similarities
between the proposed and existing
telehealth services for the roles of, and
interactions among, the beneficiary, the
physician (or other practitioner) at the
distant site and, if necessary, the
telepresenter. We also look for
similarities in the telecommunications
system used to deliver the proposed
service, for example, the use of
interactive audio and video equipment.
• Category #2: Services that are not
similar to the current list of telehealth
services. Our review of these requests
includes an assessment of whether the
use of a telecommunications system to
deliver the service produces similar
diagnostic findings or therapeutic
interventions as compared with the
face-to-face ‘‘hands on’’ delivery of the
same service. Requestors should submit
evidence showing that the use of a
telecommunications system does not
affect the diagnosis or treatment plan as
compared to a face-to-face delivery of
the requested service.
Since establishing the process, we
have added the following to the list of
Medicare telehealth services:
psychiatric diagnostic interview
examination; ESRD services furnished
under the monthly capitation payment
(MCP) with two to three visits per
month and four or more visits per
month (although we require at least one
visit a month, in person ‘‘hands on’’, by
a physician, Certified Nurse Specialist,
NP, or PA to examine the vascular
access site); and individual medical
nutrition therapy.
Requests to add services to the list of
Medicare telehealth services must be
submitted and received no later than
December 31 of each calendar year to be
considered for the next rulemaking
cycle. For example, requests submitted
before the end of CY 2006 are
considered for the CY 2008 proposed
rule. For more information on
submitting a request for an addition to
the list of Medicare telehealth services,
visit our Web site at www.cms.hhs.gov/
telehealth/.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
We received the following requests for
additional approved services in CY
2006: (1) Subsequent hospital care (as
represented by HCPCS codes 99231
through 99233); (2) neurobehavioral
status exam (HCPCS code 96116); and
(3) neuropsychological testing (HCPCS
codes 96118 through 96120).
After reviewing the public requests,
we proposed to add neurobehavioral
status exam as described by HCPCS
code 96116 to the list of Medicare
telehealth services in the CY 2008 PFS
proposed rule. We also proposed to
revise § 410.78 and § 414.65 to include
neurobehavioral status exam as a
Medicare telehealth service. We did not
propose to add subsequent hospital care
or neuropsychological testing but
requested comments as to how we could
determine when subsequent hospital
care is actually a follow-up inpatient
consultation and specific information
on neuropsychological testing. For
further information on our proposals,
see the CY 2008 PFS proposed rule (72
FR 38143).
Subsequent Hospital Care
The following is a summary of the
comments we received regarding
subsequent hospital care.
Comment: We received two comments
regarding the conditions (or
requirements) we could apply to
subsequent hospital care so that
subsequent hospital care reflects a
follow-up inpatient consultation. One
commenter suggested that follow-up
inpatient consultation should be
approved as a telehealth service only if
the initial inpatient consultation was
performed via telehealth. The
commenter does not believe we should
approve a follow-up inpatient
consultation for telehealth if the initial
inpatient consultation was furnished inperson (because it might lead to a
reduction in follow-up consultations
furnished face-to-face). The commenter
also agreed with our proposal not to
approve subsequent hospital care for
telehealth. Another commenter noted
that follow-up inpatient consultation
was previously on the list of Medicare
telehealth services and asserts that the
AMA’s deletion of follow-up inpatient
consultation (as described by CPT codes
99261 through 99263) created the need
to approve the addition of subsequent
hospital care to the list of Medicare
telehealth services when used for
follow-up inpatient consultation care.
The commenter suggested that we create
a special modifier to report follow-up
inpatient consultation via telehealth.
Response: We appreciate the
comments on the conditions (or
requirements) we could apply to
PO 00000
Frm 00029
Fmt 4701
Sfmt 4700
66249
subsequent hospital care so that
subsequent hospital care reflects a
follow-up inpatient consultation. We
intend to consider the suggestions
raised by the commenters as we
continue to evaluate whether
subsequent hospital care should be
approved for telehealth when it is used
to furnish a follow-up inpatient
consultation. With regard to the
commenter who suggested the creation
of a special modifier, we will assess
whether it would be appropriate to use
a modifier(s) to identify when a
subsequent hospital care service is
actually a follow-up inpatient
consultation.
Comment: One commenter who
supports approving subsequent hospital
care for telehealth explained that
recruiting specialists to North and South
Dakota is difficult and that telehealth
has helped hospital inpatients in these
States to obtain access to various types
of specialty care including
pulmonology, endocrinology, pediatric
gastroenterology, pediatric cardiology,
and infectious disease specialties. The
commenter also mentioned that
inpatient consultations are frequently
provided by infectious disease
specialists for patients in the intensive
care unit (ICU) and explained that once
the patient has made progress and is
moved from the ICU, the infectious
disease specialist at the distant site
continues to ‘‘follow’’ the patient until
the patient is discharged from the
hospital. The commenter recognized
that access to on-going specialty care for
outpatients is important but believes
that obtaining access to specialty
subsequent inpatient ‘‘follow-up’’ care
is even more critical. Commenters
submitted a comparative study between
subsequent hospital care furnished as a
telehealth service and furnished inperson.
Response: As discussed in the CY
2008 PFS proposed rule, given the
potential acuity level of the patient in
the hospital setting, we believe that
many services furnished within the
scope of the subsequent hospital service
codes are not similar to the current
telehealth services. As such, we
indicated that subsequent hospital care
is a category 2 service (which requires
sufficient comparative analyses before
approving it for telehealth). The
commenters did submit one
comparative analysis between
subsequent hospital care furnished as a
telehealth service and subsequent
hospital care furnished in-person.
However, the study submitted involved
only continuing specialist care (for one
specialty), not continuing inpatient care
by the primary attending physician. In
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66250
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
addition, the sample size was extremely
small. Thus, the study findings are not
generalizable.
As such, we continue to have
concerns about using a
telecommunications system as a
substitute for the on-going, day-to-day
(in-person) evaluation and management
of a hospital inpatient and believe
further study is necessary. In the
absence of sufficient, well-designed
comparison studies showing that the
use of a telecommunications system is
an adequate substitute for the in-person
delivery of subsequent hospital care, we
are not adding subsequent hospital care
to the list of Medicare telehealth
services. As discussed above in this
response, we will work with the
industry organizations and groups to
learn more about hospital care as a
telehealth service when it is used for
follow-up inpatient consultations.
Comment: One commenter (who
submitted the request to approve
subsequent hospital care for telehealth)
stated that the original request to add
subsequent hospital care to the list of
Medicare telehealth services was a
request to ‘‘re-establish’’ subsequent
inpatient visits (as a Medicare telehealth
service). The commenter described two
scenarios in which subsequent hospital
care could be furnished as a telehealth
service. The first scenario would
involve a specialty physician who
furnishes an inpatient consultation as a
telehealth service (as requested by the
attending physician). The second
scenario involves an attending or
admitting physician who furnishes
initial hospital care in-person (not as
telehealth) and provides subsequent
hospital care as a telehealth service. The
commenter believes that access to
telehealth care is better than not having
access to any care and that studies have
shown that telehealth care provides
better clinical outcomes than no care at
all. Additionally, the commenter asserts
that tertiary care trauma surgeons,
neurologists (for initial and follow-up
stroke evaluation), psychiatrists (for
initial assessment and prescriptive
safety orders), infectious disease
physicians, and cardiologists can be
made available through telehealth when
these specialties are not available onsite. The commenter believes that not
approving subsequent hospital care for
telehealth will severely hinder access to
specialty care in the inpatient hospital
setting and will lead to grave
consequences for patients when no
specialists are available on-site (at the
hospital).
Response: We agree that telehealth
services may help provide greater access
to specialty care, and therefore, better
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
clinical outcomes where a shortage of
medical professionals exist (or in
situations when no care is available). As
discussed in the CY 2008 PFS proposed
rule, we are considering approving
subsequent hospital care for telehealth
when it is used for follow-up inpatient
consultation. We believe that permitting
follow-up inpatient consultations via
telehealth will help provide greater
access to specialty care in the inpatient
hospital setting.
Additionally, we note that, contrary to
the commenter’s assertion, subsequent
inpatient hospital visits were not
previously on the list of Medicare
telehealth services. As mentioned by a
previous commenter, the AMA deleted
the codes for follow-up inpatient
consultation (as described by CPT codes
99261 through 99263). Effective January
1, 2006, these CPT codes no longer exist
and were removed from the PFS, and a
conforming change was made to the list
of Medicare telehealth services. Prior to
January 1, 2006, the physician (or
practitioner) at the distant site could
have used these CPT codes to bill for
follow-up inpatient consultations as a
telehealth service. However, subsequent
inpatient hospital visits were not on the
list of Medicare telehealth services.
Comment: One commenter cited the
concerns we raised in the proposed rule
regarding the acuity level of a hospital
inpatient and the use of a
telecommunications system to furnish
on going evaluation and management
services in the inpatient hospital setting.
The commenter believes that patients in
the emergency department typically
have a higher acuity level, are in a more
precarious physical state (as compared
to a hospital inpatient) and may not
have a diagnosis. The commenter
explains that hospitalized patients have
already been seen and admitted by a
physician on site and have at least a
preliminary diagnosis. Despite the
higher acuity level of a patient in the
emergency department, the commenter
asserts that we reimburse for telehealth
care in the emergency department (but
not for inpatients).
Additionally, the commenter
discussed various scenarios involving
the examination of acute stroke patients
via telehealth in the emergency room
and ICU. For example, the commenter
provided a summary of a study that
tested whether the use of an audio and
video multimedia telecommunications
system is a feasible and reliable means
for delivering emergency stroke care
(using the National Institute of Health
Stroke Scale). This study concluded that
‘‘remote examination of acute stroke
patients with a computer based
telesupport system is feasible and
PO 00000
Frm 00030
Fmt 4701
Sfmt 4700
reliable when applied in the emergency
room’’. The commenter also explained
how telehealth is being used to provide
24 hour access to acute stroke care
expertise for a number of hospitals in
Massachusetts and that similar
programs are being established
throughout the United States, Canada,
the United Kingdom, Scandinavia, and
other parts of the world. The commenter
also provided a discussion of a study
that examined the fiscal impact of
providing telehealth consultation (for
acutely ill and injured children in the
ICU) on rural hospitals. The study found
that as a result of greater access to
pediatric consultations, savings are
realized from a reduction in patient
transfers (to larger hospitals) and
increased revenue for rural hospitals.
Response: We appreciate the
information the commenter has
submitted on the remote evaluation of
stroke patients and pediatric telehealth
consultations in the emergency
department or ICU. We intend to
consider this information as we evaluate
whether to approve subsequent hospital
care for telehealth when it is used for
follow up inpatient consultation. We
would also mention that the nature of
the comment indicates a misconception
that we pay for emergency department
services as a telehealth service. We note
that only outpatient consultations (not
visits) are approved as a Medicare
telehealth service for a patient in the
emergency department. If guidance or
advice is needed in the emergency
department (for example, for acute
stroke care), an outpatient consultation
may be requested from an appropriate
source and may be furnished as a
telehealth service. However, emergency
department services (as described by
CPT codes 99281 through 99285) are not
on the list of Medicare telehealth
services.
Comment: One commenter mentioned
that we previously approved the
psychiatric diagnostic interview
examination and subsequent ESRD
related visits furnished under the
monthly capitation payment (MCP) for
telehealth without comparative analyses
and data showing patient satisfaction
(which implies that subsequent hospital
care could be approved for telehealth on
the same basis). The commenter also
cited the proposed regulatory impact
analysis for telehealth stating that
previous additions to the list of
Medicare telehealth services have not
resulted in a significant increase in
Medicare program expenditures.
Response: In approving the
psychiatric diagnostic interview
examination for telehealth, we
considered this service to be comparable
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
to an initial office visit, or consultation
service, which are currently Medicare
telehealth services. Likewise, we
considered the outpatient dialysis visits
furnished under the MCP (except for
one visit to examine the vascular access
site) to be comparable to office and
other outpatient visits currently on the
list of Medicare telehealth services.
Therefore, we considered these services
to be category 1, and therefore, we were
able to review and approve them for
telehealth without reviewing additional
research studies to support their
approval. However, as discussed above
in this section, because of the potential
acuity of a hospital inpatient, we were
not able to conclude that the entire
scope of services described by the
subsequent hospital care codes is
similar to the existing list of telehealth
services (for example, an office visit,
office psychology service, or
consultation). Therefore, we considered
subsequent hospital care to be a
category 2 service (which requires
sufficient comparative analyses before
approving for telehealth).
For more information on the addition
of the psychiatric diagnostic interview
examination see the CY 2003 PFS
proposed rule (67 FR 43863). For more
information on the addition of ESRDrelated visits furnished under the MCP,
see the CY 2005 PFS proposed rule (69
FR 47511).
Neurobehavioral Status Exam
Comment: Several commenters
expressed support for our proposal to
add the neurobehavioral status exam to
the list of Medicare telehealth services.
Commenters agreed that because the
neurobehavioral status exam is
primarily a clinical interview (similar to
the psychiatric diagnostic interview
which is currently a Medicare telehealth
service), it is logical and consistent to
approve this service for telehealth.
Response: We agree with the
commenters. As discussed in the
proposed rule, the neurobehavioral
status exam is furnished by a physician
or psychologist and includes an initial
assessment and evaluation of mental
status for a psychiatric patient. In this
regard, we believe the neurobehavioral
status exam is similar to psychiatric
diagnostic interview examination
(which is currently approved as a
Medicare telehealth service).
Comment: One commenter who
supported our proposal to approve the
neurobehavioral status exam for
telehealth, stated that HCPCS code
96116 is a new code that replaced
HCPCS code 96115 (the predecessor to
HCPCS code 96116) in the 2006 CPT
compendia. The commenter believes
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
that neurobehavioral status exam (as
described by HCPCS code 96115) was
previously on the list of Medicare
telehealth services and considers our
proposal to add neurobehavioral status
exam (as described by CPT code 96116)
to be a restoration of the
neurobehavioral status exam as a
telehealth service.
Response: The commenter’s assertion
that our proposal to add the
neurobehavioral status exam to the list
of Medicare telehealth services is a
restoration of the neurobehavioral status
exam as a telehealth service is not
correct. The neurobehavioral status
exam (as previously described by CPT
code 96115) was not on the list of
Medicare telehealth services. The
proposed addition of neurobehavioral
status exam is a new proposal.
Comment: One commenter stated that
the neurobehavioral status exam
appears to require that the service be
provided face to face (in person).
Therefore, the commenter requested us
to clarify that face to face services may
qualify as telehealth services.
Response: As discussed in the CY
2005 PFS final rule with comment
period, only services that traditionally
require a face-to-face (in-person)
physician or practitioner encounter are
candidates for the list of Medicare
telehealth services. Services not
requiring a face-to-face encounter with
the patient that may be furnished
through the use of a
telecommunications system are already
covered under Medicare. For more
information see the CY 2005 PFS final
rule (69 FR 66278).
Neuropsychological Testing
Comment: We received conflicting
comments regarding neuropsychological
testing. For example, one commenter
agreed with the requestor that
neuropsychological testing furnished
via telehealth is not significantly
different from being furnished in-person
(especially when administered by a
computer). Additionally, the commenter
stated that existing telehealth services
for psychiatric patients include office
visits, consultation, and office
psychiatry. The commenter believes that
the patient-provider dynamics of these
services would not appear to be so
significantly different from those for
neuropsychological testing as to justify
not approving the services for
telehealth. The commenter also believes
that testing dynamics, such as the
patient being blindfolded or having
numbers assigned to his or her fingers,
could be easily reproduced with the
help of someone at the originating site.
PO 00000
Frm 00031
Fmt 4701
Sfmt 4700
66251
The same commenter also provided a
discussion of the importance of early
detection of dementia through
neuropsychological testing. The
commenter included a letter from the
Armed Forces Epidemiological Board
about brain injury in military service
members with recommendations on
handling these injuries. The commenter
stated that although the Epidemiological
Board addressed military patients, the
principles of its findings apply to
civilian assessment and treatment of
brain injuries; that is, appropriate
testing at earlier stages of brain injury or
disease is likely to elicit a more accurate
patient profile, leading to more targeted
interventions and better patient
outcomes.
In addition, the commenter stated that
the administration of neuropsychological testing may be more difficult for
some patients than others; however, this
is true in both the in-person and
telehealth setting. The commenter
believes that if the patient requires
immediate in-person assistance, a
telepresenter could be used to facilitate
the testing and that the determination of
patient suitability for testing should be
up to the physician or practitioner at the
distant site. Two commenters agreed
that a telepresenter could assist the
physician or psychologist at the distant
site with the testing and that the
physician or psychologist should
determine which patients (and tests) are
appropriate for telehealth.
Another commenter who provides
neuropsychological testing via
telehealth explained that many
standardized neuropsychological tests
are available (literally hundreds) to the
physician or psychologist (or
technician) and that tests vary widely in
terms of administrative procedure and
the level of interaction between the
patient and practitioner responsible for
administering the test. The commenter
believes that many tests could be
effectively administered via telehealth
and that it is not appropriate for us to
issue a ‘‘global denial’’ of
neuropsychological testing. For
example, the commenter believes that
neuropsychological testing administered
via a computer should be approved for
telehealth and that testing administered
by a physician, psychologist, or
qualified technician should be reevaluated. The commenter also
explained that an RN is often used as a
telepresenter to assist the
neuropsychologist or technician with
testing. When testing cannot be
administered in a ‘‘standardized
fashion’’ via telehealth, a qualified
technician could be present on-site with
the patient to assist a psychologist who
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66252
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
furnishes the test at the distant site.
However, the commenter believes that
some testing measures may not be
appropriate for telehealth. The
commenter estimated that ‘‘fewer than
35 percent of the hundreds of available
measures do not lend themselves to
standardized administration via
telehealth’’. The commenter also cited
the American Psychological
Association’s Ethical Principles of
Psychologists and Code of Conduct and
stated these guidelines would prohibit
administration of certain individual
tests via telehealth.
Other commenters believe that further
study is necessary. The commenters
urged us to seek additional information
concerning the provision of
neuropsychological testing before
making a determination about these
services for telehealth. One commenter
believes that neuropsychological testing
should be considered for telehealth
approval stating, ‘‘however it is unclear
whether the technology has advanced
far enough to allow all
neuropsychological testing to be
provided via telehealth without
compromising the quality of care’’.
Additionally, the commenter stated that
more time is needed to assess how
neuropsychological testing could be
provided via telehealth and listed the
following issues that need further
consideration:
• The variety of disorders and
diagnoses appropriate via telehealth;
• The physical assistance that
patients may need to complete tests; and
• The impact of face-to-face
interactions with a psychologist or
trained psychological technician during
testing on the interpretation of test
results.
Response: We appreciate the
comments regarding the use of an
interactive audio and video
telecommunications system in
furnishing neuropsychological testing
services. Based on the comments
received, we believe that further study
is necessary before making a
determination about neuropsychological
testing for telehealth. As discussed
above in this section, we received
conflicting comments as to whether the
administration of a neuropsychological
test could be furnished adequately when
the practitioner who is responsible for
administering the test is not physically
present with the patient.
For example, some commenters
believe that neuropsychological testing
furnished via telehealth is not
significantly different than when
furnished in-person and that a
telepresenter could be used to assist the
physician or psychologist at the distant
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
site if necessary. Other commenters
believed that further study is necessary
before approving neuropsychological
testing for telehealth. One commenter
believed that it is unclear whether the
use of a telecommunications system for
administering neuropsychological
testing would compromise quality of
care and listed specific issues that need
greater exploration. Even a commenter
who supports approving
neuropsychological testing for
telehealth indicated that many
neuropsychological testing measures
would not be appropriate for telehealth.
As such, we continue to have concerns
about using an interactive audio and
video telecommunications system as a
substitute for the face-to-face (in-person)
requirements of neuropsychological
testing.
Comment: Two commenters believe
that sufficient empirical evidence exists
to support the approval of
neuropsychological testing for
telehealth. The commenters submitted
summaries of two comparative analyses
between neuropsychological testing
furnished via an interactive audio and
video telecommunications system and
neuropsychological testing furnished inperson.
Response: As discussed above in this
section, we believe that further study is
necessary before approving
neuropsychological testing for
telehealth. Although the commenters
did submit comparative analyses, in one
of the studies cited, the same
psychologist furnished
neuropsychological testing in both
conditions (face-to-face and via
telehealth). In another study cited, study
participants without neuropsychological
or psychiatric disturbance were tested.
Additionally, the studies cited had
extremely small samples. As such, we
believe it would be difficult to
generalize any findings to a broader
population.
Comment: One commenter questioned
whether the regulatory impact analysis
for telehealth was intended to provide a
rationale to make reductions in
Medicare payment for telehealth
services in the future. The commenter
urged us to continue to fund a wide
variety of telehealth services.
Response: The regulatory impact
analysis was not intended to be used as
a rationale for making reductions in
Medicare payment for telehealth
services. The intent of the regulatory
impact analysis on telehealth was to
illustrate that the proposed addition of
neurobehavioral status exam to the list
of Medicare telehealth services should
not have a significant budgetary impact
on the Medicare program. For more
PO 00000
Frm 00032
Fmt 4701
Sfmt 4700
information on our regulatory impact
analysis for the proposed addition of
neurobehavioral status exam to the list
of Medicare telehealth services, see the
CY 2008 PFS proposed rule (72 FR
38216).
Comment: One commenter stated that
neuropsychological testing is ancillary
to a neurobehavioral status exam and
that neuropsychological testing would
have little additional budgetary impact
(beyond the impact of adding
neurobehavioral status exam). To
support this assertion, the commenter
cited our proposed regulatory impact
analysis on the addition of
neurobehavioral status exam (as
described by CPT code 96116).
Response: As discussed above in this
section, we believe that further study is
necessary before approving
neuropsychological testing for
telehealth.
Comment: A few commenters
requested that we approve additional
services for telehealth (for example,
standardized performance testing as
described by CPT code 96125).
Response: Requests for additions
(including any supporting data
analyses) should be submitted through
our process for adding services and
must be received by December 31 of
each calendar year to be considered for
the next proposed rule. For more
information on how to submit a request
for addition, please visit our Web site at
https://www.cms.hhs.gov/telehealth.
Results of Evaluation of Comments
We are adding the neurobehavioral
status exam as represented by HCPCS
code 96116 to the list of Medicare
telehealth services. Additionally, we are
revising § 410.78 and § 414.65 to
include neurobehavioral status exam as
a Medicare telehealth service.
As discussed above, only services that
traditionally require a face-to-face (in
person) physician or practitioner
encounter are candidates for the list of
Medicare telehealth services. Services
not requiring a face-to-face encounter
with the patient that may be furnished
through the use of a
telecommunications system are already
covered under Medicare. As discussed
in chapter 15, section 30 of the
Medicare Benefit Policy Manual,
payment may be made for physicians’
services delivered via a
telecommunications system for services
that do not require a face-to-face patient
encounter. The interpretation of an xray, electrocardiogram,
electroencephalogram and tissue
samples are listed as examples of these
services.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
After further review of the requested
services for addition,
neuropsychological testing administered
by a computer (as described by HCPCS
code 96120) is not a candidate for the
list of Medicare telehealth services.
Neuropsychological testing
administered by a computer (HCPCS
code 96120) does not require a face-toface (in person) encounter between the
patient and the physician or
psychologist (or qualified technician)
responsible for the administration and
interpretation of the test results (for
example, the patient is interfacing with
the computer, not a physician or
psychologist). As such, a
telecommunications system may be
used to facilitate neuropsychological
testing administered by a computer (as
described by HCPCS code 96120); for
example, Web-based computer
neuropsychological testing, and/or
transmission of neuropsychological test
results to an interpreting physician or
psychologist via telecommunications
system.
cprice-sewell on PROD1PC72 with RULES
E. Specific Coding Issues Related to the
PFS
1. Reduction in the Technical
Component (TC) for Imaging Services
Under the PFS to the Outpatient
Department (OPD)
Effective January 1, 2007, section
5102(b)(1) of the Deficit Reduction Act
of 2005 (Pub. L. 109–171) (DRA)
amended section 1848 of the Act to
require that, for imaging services, if—
‘‘(i) The technical component (including
the technical component portion of a
global fee) of the service established for
a year under the fee schedule* * *
without application of the geographic
adjustment factor * * *, exceeds (ii)
The Medicare OPD fee schedule amount
established under the prospective
payment system for hospital outpatient
department services* * * for such
service for such year, determined
without regard to geographic adjustment
* * *, the Secretary shall substitute the
amount described in clause (ii), adjusted
by the geographic adjustment factor
[under the PFS], for the fee schedule
amount for such technical component
for such year.’’
As required by the statute, for imaging
services (described in this section)
furnished on or after January 1, 2007,
we cap the TC of the PFS payment
amount for the year (prior to geographic
adjustment) by the Outpatient
Prospective Payment System (OPPS)
payment amount for the service (prior to
geographic adjustment). We then apply
the PFS geographic adjustment to the
capped payment amount.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Section 5102(b)(1) of the DRA defines
imaging services as ‘‘imaging and
computer-assisted imaging services,
including X-ray, ultrasound (including
echocardiography), nuclear medicine
(including PET), magnetic resonance
imaging (MRI),computed tomography
(CT), and fluoroscopy, but excluding
diagnostic and screening
mammography.’’
To apply section 5102(b) of the DRA,
we needed to determine the CPT and
alpha-numeric HCPCS codes that fall
within the scope of ‘‘imaging services’’
defined by the DRA provision. In the CY
2008 PFS proposed rule, we explain in
detail the process we used for
establishing the list of codes that fall
within the scope of this DRA provision.
We also stated that upon further review,
we have determined that certain
ophthalmologic procedures meet the
DRA definition of imaging procedures,
but were not included in the original list
of imaging services subject to the OPPS
cap. Therefore, we proposed to add the
following procedures to the list of
procedures subject to the OPPS cap,
effective January 1, 2008:
• 92135, Scanning computerized
ophthalmic diagnostic imaging (e.g.,
scanning laser) with interpretation and
report.
• 92235, Fluorscein angioscopy
(includes multiframe imaging) with
interpretation and report.
• 92240, Indocyanine-green
angiography (includes multiframe
imaging) with interpretation and report.
• 92250, Fundus photography with
interpretation and report.
• 92285, External ocular photography
with interpretation and report for
documentation of medical progress (e.g.,
close-up photography, slit lamp
photography, goniophotography, stereophotography).
• 92286, Special anterior segment
photography with interpretation and
report; with specular endothelial
microscopy and cell count.
A complete list of CPT codes that
identify imaging services as defined by
the DRA OPPS cap provision, amended
to include these ophthalmologic
procedures, was also published in
Addendum F of the CY 2008 PFS
proposed rule (72 FR 38369 through
38372). Payment for an individual
service on this list will only be capped
if the PFS TC payment amount exceeds
the OPPS payment amount.
Comment: Several commenters
indicated that none of the six
ophthalmologic CPT codes proposed for
addition to the list of procedures subject
to the OPPS cap meet the statutory
definition of imaging under the DRA,
that is, none of the procedures codes fall
PO 00000
Frm 00033
Fmt 4701
Sfmt 4700
66253
under the categories of x-rays,
ultrasound, MRI, PET, CT or
fluoroscopy. Specifically, they noted
that CPT code 92250 utilizes a wide
angle camera used primarily for
detecting retinopathy in diabetics.
Likewise, CPT codes 92235, 92240, and
92285 are all photos, using
photographic equipment, or an
angioscope. The commenters concluded
that the Congress did not intend for any
service that uses a camera or
microscope, takes photographs, and
produces negatives to be included in the
DRA definition of imaging services.
Another commenter indicated that
CPT codes 92250 and 92285 do not meet
our criterion for including a procedure
under the DRA provision, that is,
services that provide visual information
regarding areas of the body that are not
normally visible, thereby assisting in the
diagnosis or treatment of injury. The
commenter noted that the subject
procedures take traditional pictures of
parts of the eye that are normally
visualized with the naked eye. One
commenter noted that the six CPT codes
have not experienced dramatic increases
in utilization, but rather, utilization has
remained stable or decreased.
Response: The DRA provision
describes imaging services broadly as
‘‘imaging and computer-assisted
imaging services,’’ and does not provide
for the type of distinctions the
commenters suggested. While it
specifically includes certain imaging
modalities (x-ray, ultrasound, MRI, PET,
CT, and fluoroscopy), it does not
exclude other imaging modalities. In
fact, the DRA provision excludes only
one imaging service, that is, diagnostic
and screening mammography.
Concerning CPT codes 92250 and
92285, we believe the images generated
by these services may include
information that requires the use of
photographic or imaging equipment and
is not normally visible by the unaided
human eye. Finally, the description of
imaging services to which the DRA
provision applies is not limited to
procedures that have experienced
dramatic increases in utilization. We
believe the six procedures meet the DRA
definition of imagining services and are
similar to other procedures already
subject to the DRA provision. Therefore,
we will include these CPT codes on the
list of procedures subject to the OPPS
cap. (Note: This list of procedures is
published in Addendum F of this final
rule with comment period.)
Comment: Many comments requested
clarification of the application of the
OPPS cap when there is no OPPS
payment for comparison; where the
code is bundled under OPPS; or where
E:\FR\FM\27NOR2.SGM
27NOR2
66254
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
the OPPS payment includes items (for
example, contrast agents or
radiopharmaceuticals) that are paid
separately under the PFS.
Response: Where there is no OPPS
payment for a procedure or where the
OPPS for a procedure is bundled, there
is no OPPS amount for the comparison
with the PFS payment. Therefore, it is
infeasible to apply an OPPS cap. The
codes will remain on the list of codes
subject to the OPPS cap, but will not be
affected by the cap. Where the OPPS
payment includes packaged services or
items that are paid separately under the
PFS, we can and do apply an OPPS cap.
The physician can continue to bill
separately for such services or items
when furnished in a place of service, for
example, a physician’s office, where the
item is paid separately.
2. Application of Multiple Procedure
Reduction for Mohs Micrographic
Surgery (CPT Codes 17311 Through
17315)
Under the multiple procedure
payment reduction policy,
reimbursement for subsequent surgical
procedures performed during the same
operative session by the same physician
is reduced by 50 percent. The Mohs
surgery codes have been exempt from
the multiple procedure payment
reduction rules since the inception of
the PFS (56 FR 59602, November 25,
1991).
The CPT Editorial Panel reviewed all
of the codes on the list of codes exempt
from the multiple procedure payment
reduction (the ‘‘¥51 modifier exempt
list’’) to identify which codes should be
exempt from the multiple procedure
payment reduction rules. Based on the
revisions to the code descriptors and a
clearer understanding regarding the
technical elements of the procedure, in
CY 2007, the CPT Editorial Panel
removed the Mohs procedure from the
¥51 modifier exempt list. The codes for
Mohs surgery were revised to take into
account the different level of physician
work intensity involved based on
anatomic site. The RVUs associated
with the codes for each anatomic
location were recommended by the
RUC, as they are for other procedures,
after a thorough discussion by the RUC
of all aspects of the service. Work RVUs
were developed for each Mohs surgery
base code based on an assumption that
each code is performed separately.
Because the work RVUs for these
services do not take into account the
efficiencies that occur when multiple
procedures are performed in one
session, we do not believe that these
codes should continue to be exempt
from the multiple procedure payment
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
reduction. Therefore, we proposed to
eliminate the modifier 51 exemption
and apply the multiple procedure
payment reduction rules to these codes.
Comment: We received comments
supporting our proposal and expressing
the belief that our proposal is fair and
consistent with our multiple procedure
payment policies already affecting a
wide range of procedures with codes in
the Surgery/Integumentary System of
CPT. Many commenters opposed our
proposal to eliminate the modifier ¥51
exemption and apply the multiple
procedure payment reduction to these
codes. These commenters believed that
eliminating these codes from the
modifier ¥51 exempt list would
negatively impact Medicare
beneficiaries’’ access to timely and
quality care, and could lead to increases
in pathology charges and increase the
amount spent on multiple facility fees,
thereby raising the overall cost of
treating an individual with skin cancer.
In addition to these concerns, many of
the commenters do not believe we have
sufficient justification to make the
change, and suggest that this is an
arbitrary decision. Further, the
commenters asserted that the AMA–
RUC and CPT decisions were in error
and should not be followed.
Response: We verified with the CPT
Editorial Panel that the application of
the modifier ¥51 exempt status
indicator, and subsequently, the
inclusion of this series of codes (CPT
codes 17311 through 17315) in
Appendix E, Summary of CPT Codes
Exempt from Modifier ¥51, of the 2008
CPT codebook would not be carried
forward with the new series of codes
created in 2007. The CPT panel
confirmed with us that the exclusion of
these codes from Appendix E was not
an error. The AMA RUC reviewed and
valued the new and existing codes for
Mohs surgery. Upon completion of a
thorough review and discussion of the
Mohs codes, the RUC valued these
codes with the full understanding these
codes were removed from the modifier
¥51 exempt list and would be subject
to the multiple procedure payment
reduction as well.
We believe the CPT Editorial Panel
and the Mohs workgroup on the CPT
Editorial Panel gave considerable time,
effort and discussion in the creation of
the new and existing codes for Mohs
surgery. We also believe the AMA-RUC
carefully reviewed the rationale and
deliberations which lead to the creation
of new Mohs surgery codes. In addition,
we believe the specialty society had
ample time and opportunity to express
its point of view to both the CPT Panel
and the AMA-RUC. As a result of the
PO 00000
Frm 00034
Fmt 4701
Sfmt 4700
revisions to these codes and their
respective valuation, we do not believe
they should continue to be treated
differently from other codes in the
Surgery/Integumentary System section
of the CPT book and see no reason not
to accept the recommendations
provided by the CPT Panel and AMARUC. Therefore, we are finalizing our
proposal to eliminate the modifier –51
exemption and apply the multiple
surgery procedure payment reduction
rules to these codes.
3. Payment for Intravenous Immune
Globulin (IVIG) Add-On Code for
Preadmission Related Services
Intravenous immune globulin (IVIG)
is a unique product derived from blood
plasma. This drug is paid for under the
ASP methodology and the
administration of this drug is reported
using the first hour and second hour
infusion codes for therapeutic,
prophylactic and diagnostic services
under CPT.
We recognize the importance of IVIG
to patients who require it and are
concerned about reports of problems
with IVIG access and availability. We
have initiated several actions in
response to concerns about the supply
of IVIG.
In July 2007, we implemented new
codes for reporting IVIG for liquid nonlyophilized IVIG.
In CY 2006 and 2007, we established
payment, through the creation of a
special G-code, G0332, for
preadministration services furnished in
connection with the procurement of
IVIG in the physician’s office. This code
is designed to compensate physicians
for the extra resources required to be
expended due to market conditions to
locate and obtain the appropriate IVIG
products and to schedule patient
infusions.
Comment: We received several
comments regarding our proposal to
continue in CY 2008 the
preadministration payment under the
PFS for patients treated with IVIG in a
physician’s office.
The majority commenters supported
our proposal and recommended that it
be finalized, and recommended that this
policy be made permanent. Commenters
stated that if this code and payment are
not made permanent, we would need to
present a convincing evidence to
terminate this payment. Commenters
indicated that without continuation of
the add on payment, access problems
for Medicare beneficiaries in need of
IVIG would be more severe.
Many commenters indicated problems
with the ASP payment methodology for
IVIG stating that IVIG is a unique
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
product for which market conditions are
unlike all other drugs paid under ASP.
Other commenters remarked that the
addition of the four new billing codes
for liquid IVIG adopted in July 2007
should improve market conditions and
beneficiary access to IVIG. Some
commenters asked that we consider
making the liquid IVIG codes permanent
J-codes. A few commenters asked that
CMS consider establishing an add on
payment for IVIG similar to the add on
payment for clotting factor.
Two commenters indicated that
Addendum B did not include the Gcode for preadministration services and
recommended that the code be included
in Addendum B for the final rule.
Response: Comments regarding the
ASP pricing methodology for IVIG, the
adoption of new drug codes for liquid
IVIG in CY 2007, and the consideration
of an add-on payment for IVIG similar
to the add-on payment for blood clotting
factor are beyond the scope of our
proposal which focuses on payment for
a service under the PFS. We will
consider these comments in context of
any proposed policies for drug
payments made as part of the CY 2009
PFS proposed rule.
In terms of the preadministration
service for IVIG, we will continue the
CY 2007 payment policy for code G0332
through CY 2008. We will carefully
consider all relevant information
including the conditions of the IVIG
drug market during CY 2008 when we
address whether it would be appropriate
to continue the payment policy as part
of the CY 2009 PFS.
We appreciate the commenters
alerting us that G0332 was omitted from
Addendum B in the proposed rule and
we will ensure that this code is listed in
Addendum B of this final rule with
comment period.
Therefore, we are finalizing the
proposal to continue to recognize
payment for preadministration services
for IVIG furnished to patients in a
physician’s office in CY 2008. Payment
for this service will be made based on
the PE RVUs previously established for
this service in CY 2007. Payment for
preadminstration services for IVIG
furnished to hospital outpatients is paid
under the outpatient PPS (OPPS) and is
addressed as part of that final rule.
4. Reporting of Cardiac Rehabilitation
Services
For CY 2008, we proposed to assign
a status indicator of ‘‘I’’ (invalid for
Medicare purposes, Medicare recognizes
another code for the billing of this
service) to the current CPT codes for
cardiac rehabilitation services, CPT
codes 93797, Physician services for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
outpatient cardiac rehabilitation;
without continuous ECG monitoring (per
session), and 93798, Physician services
for outpatient cardiac rehabilitation;
with continuous ECG monitoring (per
session) and proposed to establish two
new Level II HCPCS codes that we
believe are more appropriate for
specifically reporting cardiac
rehabilitation services under the PFS.
The proposed HCPCS codes are:
GXXX1, Physician services for
outpatient cardiac rehabilitation;
without continuous ECG monitoring (per
hour), and GXXX2, Physician services
for outpatient cardiac rehabilitation;
with continuous ECG monitoring (per
hour). We also proposed to crosswalk
the current RVUs associated with CPT
codes 93797 and 93798 to HCPCS Codes
Gxxx1 and Gxxx1.
Comment: Many commenters,
including physicians and providers of
cardiac rehabilitation services, were
generally supportive of the proposal for
the specific G-codes. Commenters
believed that this proposed coding
change would allow for more
appropriate coding and payment for
cardiac rehabilitation services in those
cases where intensive programs provide
multiple sessions each day. In addition,
commenters requested that we explicitly
state that multiple sessions of cardiac
rehabilitation can be paid for the same
date of service when modifier 59 is
reported. They also requested that we
crosswalk the payments for both of the
proposed G-codes to the higher cost CPT
code 93798 to ensure that the full range
of modalities provided in certain
intensive cardiac rehabilitation
programs are available.
Several of these commenters also
requested that we provide additional
guidance related to reporting of the
cardiac rehabilitation G-codes, such as:
(1) Explaining that it is likely to be
reasonable and necessary to cover 72
cardiac rehab sessions when multiple
sessions are provided in one day; (2)
encouraging contractors to factor the
‘‘proven results’’ of a program into
coverage decisions and that 72 sessions
should be ‘‘presumptively covered’’
when they are furnished by a certain
intensive cardiac rehabilitation
program; and (3) providing further
clarification and expansion of
nutritional counseling by registered
dieticians, indicating that they could
independently bill for nutritional
counseling within cardiac rehabilitation
programs using the medical nutrition
therapy codes because the NCD does not
specifically mention these services.
Alternatively, a few commenters,
including physician specialty groups,
questioned the need for the proposed G-
PO 00000
Frm 00035
Fmt 4701
Sfmt 4700
66255
codes, indicating that no new data
would be gained by a coding shift that
changes a unit from a session to an
hour. Commenters also suggested that
we work with the AMA to address the
issue of whether it would be appropriate
to modify the CPT definition for this
code from a per session to per hour
basis.
Many commenters also expressed
concern that the use of the term
‘‘physician services’’ and ‘‘MD services’’
in the G-code descriptors could be
misinterpreted by Medicare contractors
as requiring a physician to directly
deliver the care or be in attendance
during each service episode and
requested that the code descriptor be
revised.
Response: We are aware of several
intensive cardiac rehabilitation
programs that provide multiple sessions
in a day, lasting several hours total. The
NCD for cardiac rehabilitation currently
states that cardiac rehabilitation
programs are covered for certain
categories of patients and that the
programs must be comprehensive. To be
comprehensive the programs must
include a medical evaluation, a program
to modify cardiac risk factors (for
example, nutritional counseling),
prescribed exercise, education, and
counseling. The NCD does not
distinguish between different
approaches to the delivery of cardiac
rehabilitation services, whether the
more common practice of two sessions
per week or the more intensive
programs of several sessions per day. In
order to allow for flexibility and
tailoring of cardiac rehabilitation
programs based on patient needs, we
have not been prescriptive regarding the
precise amount of time that must be
spent on each component of the
program. Regarding intensity, we expect
the intensity of cardiac rehabilitation
programs to vary by patient and by
program.
We believe it is important that our
payment policy provides appropriate
payment for cardiac rehabilitation
services. In order to minimize the
administrative burden to physicians and
providers, but permit accurate reporting
and payment for cardiac rehabilitation
programs that provide more than one
session per day, we believe that
continuing the use of CPT codes 93797
and 93798 and allowing physicians and
providers to bill more than one session
per day under some circumstances
would be the most appropriate course.
Therefore, based upon the comments
received and upon further review of this
issue, for CY 2008, we will allow
physicians and providers to report more
than one unit for a date of service if
E:\FR\FM\27NOR2.SGM
27NOR2
66256
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
more than one cardiac rehabilitation
session lasting at least 1 hour each is
provided on the same day.
With respect to commenters’ concerns
about the use of the term ‘‘physician
services’’ in the proposed G-code
descriptors, we note that the descriptors
for these codes were proposed to be
parallel to the descriptors of the CPT
codes for cardiac rehabilitation sessions
which contain the term ‘‘physician
services’’ in their descriptors. We are
not aware that physicians and providers
have problems with Medicare
contractors’’ interpretation of the CPT
code descriptors.
After consideration of all public
comments received, we are not
finalizing our proposal to establish two
new G-codes for reporting cardiac
rehabilitation services. Instead, we will
continue to use the CPT codes 93797
and 93798 to report cardiac
rehabilitation services under the CY
2008 PFS.
We will provide further guidance on
coding and payment instructions for the
cardiac rehabilitation services codes
through program instructions.
We will not provide the additional
coverage-related guidance requested by
some commenters, such as the
presumptive coverage and independent
billing for registered dieticians. These
recommendations effectively request
changes to the NCD, and therefore, are
outside of the scope of this final rule
with comment period.
cprice-sewell on PROD1PC72 with RULES
F. Part B Drug Payment
1. Average Sales Price (ASP) Issues
Medicare Part B covers a limited
number of prescription drugs and
biologicals. For the purposes of this
proposed rule, the term ‘‘drugs’’ will
hereafter refer to both drugs and
biologicals, unless otherwise specified.
Medicare Part B covered drugs not paid
on a cost or prospective payment basis
generally fall into the following three
categories:
• Drugs furnished incident to a
physician’s service.
• DME drugs.
• Drugs specifically covered by
statute (certain immunosuppressive
drugs, for example).
Beginning in CY 2005, the vast
majority of Medicare Part B drugs not
paid on a cost or prospective payment
basis are paid under the ASP
methodology. The ASP methodology is
based on data submitted to us quarterly
by manufacturers. In addition to the
payment for the drug, Medicare
currently pays a furnishing fee for blood
clotting factors, a dispensing fee for
inhalation drugs, and a supplying fee to
pharmacies for certain Part B drugs.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
In January 2006, the drug coverage
available to Medicare beneficiaries
expanded with the implementation of
Medicare Part D. The Medicare Part D
program does not change Medicare Part
B drug coverage.
In this section, we discuss changes
and issues related to the determination
of the payment amounts for covered Part
B drugs and furnishing blood clotting
factor. This section also discusses
changes to how manufacturers calculate
and report ASP data to us.
a. ASP Payment
Section 303(c) of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (Pub. L. 108–
173) (MMA) amended Title XVIII of the
Act by adding section 1847A. This
section revised the payment
methodology for the vast majority of
drugs and biologicals not paid on a cost
or prospective payment basis furnished
on or after January 1, 2005. The ASP
reporting requirements are set forth in
section 1927(b) of the Act.
Manufacturers must submit ASP data by
11-digit National Drug Code (NDC) to us
quarterly. The manufacturers’
submissions are due to us not later than
30 days after the last day of each
calendar quarter. The methodology for
developing Medicare drug payment
allowances based on the manufacturers’
submitted ASP data is specified in 42
CFR, part 414, subpart K. We update the
Part B drug payment amounts quarterly
based on the data we receive. In this
section of the preamble, we discuss
certain aspects of the calculation of
manufacturers’ ASP data, issues related
to bundled price concessions, and other
Part B drug payment issues.
Further information on
manufacturers’ submission of ASP data
for Medicare Part B drugs and
biologicals is contained in prior
rulemaking documents and other
guidance accessible on the CMS Web
page at (https://www.cms.hhs.gov/
McrPartBDrugAvgSalesPrice/).
Specifically refer to the April 6, 2004
ASP interim final rule with comment
period (IFC) (69 FR 17935) and the CY
2007 PFS final rule with comment
period (71 FR 69624), which finalized
the ASP calculation and reporting
requirements of the April 6, 2004 IFC,
and the Frequently Asked Questions
available on the CMS Web page.
b. Bundled Price Concessions
In the CY 2007 PFS proposed rule and
final rule with comment period, we
solicited and responded to comments
regarding the issue of how to allocate
price concessions across drugs that are
sold under bundling arrangements for
PO 00000
Frm 00036
Fmt 4701
Sfmt 4700
purposes of calculating the ASP. We did
not establish a specific methodology
that manufacturers must use for the
treatment of bundled price concessions
for purposes of the ASP calculation in
the CY 2007 PFS final rule with
comment period. In the absence of
specific guidance, we maintained
existing guidance that manufacturers
may make reasonable assumptions in
their calculation of ASP, consistent with
the general requirements and the intent
of the Act, Federal regulations, and their
customary business practices. We also
indicated that we would be closely
monitoring this issue and may provide
more specific guidance in the future if
we determine it is warranted.
As stated in the CY 2008 PFS
proposed rule (72 FR 38150), in its
January 2007 Report to Congress,
‘‘Impact of Changes in Medicare
Payments for Part B Drugs,’’ the
MedPAC discussed the issue of
allocation of bundled price concessions
for purposes of calculating the ASP,
noting that ‘‘some manufacturers offer
provider discounts for one of their
products contingent on purchases of one
or more other products.’’ This report
discusses two approaches for allocating
bundled price concessions.
According to MedPAC, one option
would be to require manufacturers to
allocate bundled discounts in
proportion to the sales of each drug sold
under the bundled arrangement. For
example, Drug A and Drug B are sold
under a bundled arrangement and have
a combined bundled discount equal to
$200,000 on total sales of $1 million. If
Drug A has sales of $600,000, the
manufacturer would allocate 60 percent
of the bundled discount to that drug
when calculating ASP. Forty percent of
the bundled discount would be
allocated to Drug B. MedPAC states that
this approach would parallel bundling
requirements under Medicaid and
would be simpler to administer.
However, MedPAC notes that this
method might not capture contingent
discounts.
The other approach discussed by
MedPAC would be to require
manufacturers to allocate bundled
discounts to reflect the contingencies in
the contract. That is, manufacturers
would allocate any additional (or
increased) discount to the sales of the
drug (or drugs) that the discount is
meant to increase. This approach would
result in an ASP that more accurately
reflects the transaction price of drugs
when a discount for one drug or drugs
is contingent in whole or in part on the
purchase of another drug. For example,
if a greater discount on the purchase
price of Drug A is contingent on the
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
purchase (or purchases) of Drug B, this
additional discount would be allocated
to sales of Drug B in the calculation of
ASP.
In its discussion of bundling,
MedPAC states that the goal should be
to ensure that ASP reflects the average
transaction price for drugs. To that end,
MedPAC recommends that the Secretary
clarify the ASP reporting requirements
for bundled products to ensure that ASP
calculations allocate discounts to reflect
the transaction price for each drug.
Further, MedPAC states that we should
ensure that the reporting requirements
for allocating discounts are clear and
that they can be implemented by
manufacturers in a timely fashion.
In the CY 2008 PFS proposed rule (71
FR 77176), we also discussed the
Medicaid Program: Prescription Drugs
proposed rule published in the
December 22, 2006 Federal Register
(hereinafter referred to as the December
22, 2006 proposed rule) concerning the
calculation of manufacturers’ average
manufacturer price (AMP). In the
December 22, 2006 proposed rule, we
proposed that discounts associated with
a bundled sale would be allocated
proportionately according to the dollar
value of the units of each drug sold
under the bundled arrangement. For
bundled sales where multiple drugs are
discounted, the aggregate value of all
the discounts would be proportionately
allocated across all of the drugs in the
bundle. For AMP purposes, a bundled
sale would mean an arrangement
regardless of physical packaging under
which the rebate, discount, or other
price concession is conditioned upon
the purchase of the same drug or drugs
of different types (that is, at the ninedigit NDC level) or some other
performance requirement (for example,
the achievement of market share,
inclusion or tier placement on a
formulary), or where the resulting
discounts or other price concessions are
greater than those which would have
been available had the bundled drugs
been purchased separately or outside of
the bundled arrangement. In the
December 22, 2006 proposed rule, we
further proposed that the AMP should
be adjusted for bundled sales by
determining the total value of all the
discounts on all drugs in the bundle and
allocating those discounts
proportionately to the respective AMP
calculations. The aggregate discount is
allocated proportionately to the dollar
value of the units of each drug sold
under the bundled arrangement. Where
discounts are offered on multiple
products in a bundle, the aggregated
value of all of the discounts should be
proportionately allocated across all of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the drugs in the bundle. We received
many comments on the many aspects of
the December 22, 2006 proposed rule.
However, the review of those comments
and development of the final AMP
calculation policies and rule were not
complete at the time the CY 2008 PFS
proposed rule was developed.
In light of MedPAC’s recommendation
that we clarify the ASP reporting
requirements for bundled products and
our discussion of bundled price
concessions in the CY 2007 PFS
rulemaking, we stated in the CY 2008
PFS proposed rule that we believe
specific guidance in the ASP context is
warranted to provide for greater
consistency in ASP reporting across
manufacturers and to enhance the
accuracy of the ASP payment system.
We stated that we found MedPAC’s
suggestion not to defer further guidance
in this area compelling with respect to
the potential that manufacturers may
make differing assumptions in the
absence of specific guidance on how to
allocate bundled price concessions in
the context of ASP. In addition, we
stated that we believe it is appropriate
at this time to establish a specified
method for treating bundled price
concessions in the calculation of ASP
that is consistent with the treatment of
such discounts for purposes of the AMP
calculation, and that appropriate
consistencies across the calculations of
ASP and AMP will result in a lower
potential for error and more accurate
calculations of both prices.
As we noted in the CY 2008 PFS
proposed rule, although ASP and AMP
serve similar, but not identical,
purposes, differences between these
calculations provide a rationale for, and
in some instances may require, minor
differences between the final policies
adopted in Medicaid and Medicare
regulations. We believe any differences
would be necessary to clarify certain
aspects of a consistent approach for
treatment of bundling, and would not
result in significant policy differences
on how bundling is addressed in the
context of AMP and in the context of
ASP.
Therefore, for purposes of calculating
the ASP (beginning with the reporting
period for the first calendar quarter of
2008 and thereafter), we proposed that
the manufacturer must allocate the total
value of all price concessions
proportionately according to the dollar
value of the units of each drug sold
under a bundled arrangement to ensure
that the ASP is adjusted for bundled
arrangements as defined at proposed
§ 414.802. For a bundled arrangement,
where multiple drugs are discounted,
the aggregate value of all the discounts
PO 00000
Frm 00037
Fmt 4701
Sfmt 4700
66257
would be proportionately allocated
across all of the drugs sold under the
bundled arrangement. We proposed that
a bundled arrangement, for ASP
purposes, would mean an arrangement,
regardless of physical packaging under
which the rebate, discount, or other
price concession is conditioned upon
the purchase of the same drug or
biological or other drugs or biologicals
or some other performance requirement
(for example, the achievement of market
share, inclusion or tier placement on a
formulary, purchasing patterns, prior
purchases), or where the resulting
discounts or other price concessions are
greater than those that would have been
available had the drugs or biologicals
sold under the bundled arrangement
been purchased separately or outside of
the bundled arrangement. We proposed
to specify at proposed
§ 414.804(a)(2)(iii) that all price
concessions on drugs sold under a
bundled arrangement must be allocated
proportionately to the dollar value of
the units of each drug sold under the
bundled arrangement.
In the CY 2008 PFS proposed rule, we
also stated our intention to remain
consistent, as appropriate, with the final
policy adopted in the Medicaid
Program: Prescription Drugs final rule
with comment period published in the
July 17, 2007 Federal Register (72 FR
39142) (hereinafter referred to as the
July 17, 2007 final rule with comment
period), which was still under
development at that time. We stated that
the Medicaid policies on bundled sales
may ultimately differ from our
discussion of the topic in the CY 2008
PFS proposed rule as a result of the final
policy adopted in the July 17, 2007 final
rule with comment period and that our
policies for ASP in this final rule with
comment period may reflect the final
Medicaid policy on bundled sales, but
only to the extent that it is appropriate
for ASP and the public has had the
opportunity to comment on how the
final Medicaid policy for bundled sales,
if appropriately adopted for ASP
purposes, would effect the calculation
of ASP. The final Medicaid policy on
bundled sales adopted in the July 17,
2007 final rule with comment period
was consistent with the discussion of
this issue in the December 22, 2006
proposed rule with certain
clarifications.
Comment: We received many
comments on this issue. Most of these
commenters noted that our proposal for
the treatment of bundled price
concessions in the ASP context was
similar to the language finalized in the
July 17, 2007 final rule with comment
period. In general, most of the
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66258
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
commenters supported an appropriately
consistent approach for the treatment of
bundled price concessions within both
the AMP and ASP calculations.
However, several commenters indicated
that they were still reviewing the July
17, 2007 final rule with comment period
and believe additional time may be
needed to better understand how the
proposed Medicare bundled
arrangement definition is to be applied.
Several commenters had questions
about how the proposed bundling
policies may apply to certain
contracting arrangements, and because
of these questions, recommended that
we cease or delay implementation of our
proposed method for treatment of
bundled price concessions for purposes
of ASP.
Response: Based on comments
recommending a delay and to better
understand the concerns stated by the
commenters, we are not finalizing the
regulatory language changes we
proposed in the CY 2008 PFS proposed
rule at this time. Although we are not
establishing a specific methodology that
manufacturers must use for the
treatment of bundled price concessions
for purposes of calculating ASP at this
time, we are clarifying that, in the
absence of specific guidance,
manufacturers may make reasonable
assumptions in their calculation of ASP,
consistent with the general
requirements and the intent of the Act,
Federal regulations, and their customary
business practices. In making reasonable
assumptions for purposes of calculating
ASP, one method manufacturers could
use is to reallocate price concessions
that are conditioned upon other
purchases or a performance requirement
(for example, the achievement of market
share, inclusion or tier placement on a
formulary) so that the total value of all
such price concessions are allocated
proportionately according to the dollar
value of the units of each drug sold.
However, manufacturers may have other
methods they could use to report
bundled price concessions, so long as
manufacturers apply reasonable
assumptions consistent with the general
requirements and the intent of the Act,
Federal regulations, and their customary
business practices. Manufacturers’
reasonable assumptions consistent with
our requirements, guidance and
manufacturer’s customary business
practices remain an important aspect of
ASP reporting. These assumptions
should be submitted along with the ASP
data and the signed certification form.
Recognizing that the treatment of
bundled price concessions in the ASP
calculation has implications for the
integrity of the ASP payment
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
methodology, we will continue to
monitor this issue, will consider the
comments on this issue, and may
provide more specific guidance in the
future through rulemaking or through
program instruction or other guidance
(consistent with our authority under
section 1847A(c)(5)(C) of the Act) if we
determine it is warranted. As we
continue to review these issues, we
want to be sure we are aware of
concerns from all stakeholders, and thus
we encourage the public to provide
additional information or concerns to us
on this issue as they may arise.
c. Clotting Factor Furnishing Fee
Section 303(e)(1) of the MMA added
section 1842(o)(5) of the Act which
requires the Secretary, beginning in CY
2005, to pay a furnishing fee in an
amount the Secretary determines to be
appropriate to hemophilia treatment
centers and homecare companies for the
items and services associated with the
furnishing of blood clotting factor.
Section 1842(o)(5)(C) of the Act
specifies that the furnishing fee for
clotting factor for CY 2006 and
subsequent years will be equal to the fee
for the previous year increased by the
percentage increase in the consumer
price index (CPI) for medical care for
the 12 month period ending with June
of the previous year.
The furnishing fee for CY 2007 is
$0.152 per unit clotting factor. The
percent increase in the CPI for medical
care for the 12-month period ending in
June 2007 is 4.0 percent. Consequently,
the furnishing fee will be $0.158 per
unit of clotting factor for CY 2008.
While the furnishing fee payment rate is
calculated at 3 digits, the actual amount
paid to providers and suppliers is
rounded to 2 digits.
In the CY 2008 PFS proposed rule, we
proposed to announce the annual
update of the blood clotting factor
furnishing fee, as specified in section
1842(o)(5)(C) of the Act, by issuing
program instructions and postings on
the CMS Web site in lieu of including
a discussion of this issue in PFS
rulemaking for CY 2009, and thereafter,
until such time as the update
methodology may be modified. We
made our proposal because the update
is statutorily determined, is based on an
index not affected by administrative
discretion or public comment, is based
on the percentage increase in the CPI for
medical care for the 12-month period
ending with June of the previous year,
and is not released by the Bureau of
Labor Statistics until after our proposed
rule is published.
As stated in the CY 2008 proposed
rule, we believe that including a
PO 00000
Frm 00038
Fmt 4701
Sfmt 4700
discussion of the furnishing fee update
in annual rulemaking does not provide
an advantage over other means of
announcing this information, so long as
the current statutory update
methodology continues in effect. We
believe that the public’s need for
information and adequate notice
regarding the updated furnishing fee can
be better met by issuing program
instructions which will eliminate the
discussion of the furnishing fee update
annually in rulemaking. In addition, by
communicating the updated furnishing
fee in program instruction, the actual
figure for the percent change in the
applicable CPI and the updated
furnishing fee calculated based on that
figure can be announced more timely
than when included as part of the PFS
final rulemaking process.
Comment: We received comments in
support of our proposal to announce the
update furnishing fee via program
instructions beginning in CY 2009, and
to continue updating the furnishing fee
according to the consumer price index
for medical care. Comments supported
the continued use of our proposed
approach until such time as the
methodology is changed.
Response: After consideration of the
public comments, beginning for CY
2009, we will announce the updated
blood clotting factor furnishing fee via
program instructions and via a Web
posting. In addition, we may include the
updated blood clotting factor furnishing
fee in the annual PFS final rules to
promote broader dissemination of the
announcement.
d. Widely Available Market Prices
(WAMP) and AMP Threshold
Section 1847A(d)(1) of the Act states
that ‘‘the Inspector General of HHS shall
conduct studies, which may include
surveys to determine the widely
available market prices (WAMP) of
drugs and biologicals to which this
section applies, as the Inspector
General, in consultation with the
Secretary, determines to be
appropriate.’’ Section 1847A(d)(2) of the
Act states that, ‘‘Based upon such
studies and other data for drugs and
biologicals, the Inspector General shall
compare the ASP under this section for
drugs and biologicals with—
• The widely available market price
(WAMP) for these drugs and biologicals
(if any); and
• The AMP (as determined under
section 1927(k)(1) of the Act for such
drugs and biologicals.’’
Section 1847A(d)(3)(A) of the Act
states that, ‘‘The Secretary may
disregard the ASP for a drug or
biological that exceeds the WAMP or
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the AMP for such drug or biological by
the applicable threshold percentage (as
defined in subparagraph (B)).’’ The
applicable threshold is specified in the
statute as 5 percent for CY 2005. For CY
2006 and subsequent years, section
1847A(d)(3)(B) of the Act establishes
that the applicable threshold is ‘‘the
percentage applied under this
subparagraph subject to such
adjustment as the Secretary may specify
for the WAMP or the AMP, or both.’’ In
CY 2006 and CY 2007, we specified an
applicable threshold percentage of 5
percent for both the WAMP and AMP.
We based this decision on the limited
data available to support a change in the
current threshold percentage.
For CY 2008, we proposed to specify
an applicable threshold percentage of 5
percent for the WAMP and the AMP. At
present, the OIG is continuing its
comparison of both the WAMP and the
AMP. Furthermore, information on how
recent changes to the calculation of the
AMP may affect the comparison of AMP
to ASP is not available at this time.
Since we do not have data that suggest
another level is more appropriate at this
time, we believe that continuing the 5
percent applicable threshold percentage
for both the WAMP and AMP is
appropriate for CY 2008.
As we noted in the CY 2007 PFS final
rule with comment period (71 FR
69680), we understand that there are
complicated operational issues
associated with potential payment
substitutions and will continue to
proceed cautiously in this area and
provide stakeholders, particularly
manufacturers of drugs impacted by
potential price substitutions, with
adequate notice of our intentions
regarding such, including the
opportunity to provide input with
regard to the processes for substituting
the WAMP or the AMP for the ASP. As
part of our approach, we intend to
develop a better understanding of the
issues that may be related to certain
drugs for which the WAMP and AMP
may be lower than the ASP over time.
Comment: We received several
comments regarding our proposal to
maintain the threshold at 5 percent.
Most commenters supported
maintaining this threshold. One
commenter suggested increasing the
threshold but did not specify a
percentage to which it should be
increased. Another commenter
suggested increasing the threshold for
AMP to 10 percent while maintaining
the 5 percent threshold for WAMP.
Response: We recognize the public’s
concern regarding the establishment of
an appropriate threshold for making
price substitutions. We disagree with
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the commenter who recommended
different thresholds for WAMP
comparisons and for AMP comparisons
because of current operational
difficulties associated with maintaining
and communicating different
thresholds. At the current time, we also
believe that maintaining two thresholds
lessens stakeholders’ ability to
accurately predict the potential risk for
price adjustments. After considering
public comments on this issue, and as
required by statute, we are finalizing our
proposal to establish the WAMP/AMP
threshold at 5 percent for CY 2008.
Comment: We received many
comments suggesting that caution be
exercised in the determination of price
substitutions and that we develop a
formal process and criteria to be used to
determine when substitutions are
necessary. Commenters also
recommended that we assure adequate
notice is provided prior to making a
price substitution. Several commenters
indicated recent policy changes made to
the Medicaid AMP calculation could
impact the accuracy of the comparisons
between AMP and ASP and stated that
these changes should be carefully
studied and considered before
implementing any pricing changes.
Additionally, several commenters
opposed any price substitutions for
certain classes of providers or for certain
specific drugs. The commenters noted
that certain classes of providers may be
subject to different cost structures
making wholesale substitution of prices
impractical. Some commenters asserted
that certain drugs experience unique
market forces that may be adversely
affected by pricing substitutions.
Response: We understand that
complex operational issues, both within
CMS and externally could impact
potential payment rate substitutions. We
acknowledge the recent changes to the
AMP regulations and are studying such
changes carefully. Furthermore, we
recognize the variety of providers and
the marketplace forces that impact drug
pricing decisions under ASP. Therefore,
we will proceed cautiously and provide
stakeholders, particularly manufacturers
of drugs impacted by potential price
substitutions, with adequate notice of
our intentions regarding such, including
the opportunity to provide input with
regard to the processes for substitution.
e. Other Issues
Comment: A few commenters noted
that we did not discuss the payment for
separately billable ESRD drugs in the
CY 2008 PFS proposed rule. These
commenters supported continuation of
the current policy of basing the payment
on the ASP+6 percent.
PO 00000
Frm 00039
Fmt 4701
Sfmt 4700
66259
Response: We did not propose any
policy changes to the approach that we
currently use to pay for separately billed
ESRD drugs. Therefore, for CY 2008
payment for separately billable drugs
furnished by ESRD facilities will
continue at ASP+6 percent in
accordance with section 1847A of the
Act.
Comment: Several commenters noted
that the billing and payment codes
recently established for liquid IVIG to
implement separate payment under
section 1847A(b)(4) of the Act should
improve beneficiary access to these
products.
Response: We thank the commenters
for communicating their support.
Comment: We received a few
comments expressing concern that,
because ASP based payment limit
updates lag time by at least 2 calendar
quarters, increases in market prices may
not be reflected in a drug’s payment
limit for at least 6 months after a pricing
adjustment. One commenter suggested
that current technology should enable
CMS to decrease the lag time from 6
months to 2 to 3 months.
Response: By statute, the ASP based
payment allowances are determined on
a quarterly basis and are based on ASPs
reported by manufacturers quarterly.
Manufacturers must report to us no later
than 30 days after the close of the
calendar quarter. There is a necessary
time frame after the close of a calendar
quarter for manufacturers to calculate
and submit the ASP data to CMS, for
CMS to prepare and issue the payment
rates, and for the claims processing
contractors to implement the updated
payment files. We implement these new
payment limits through program
instructions or otherwise at the first
opportunity after we received the data,
which is the calendar quarter after
receipt.
Comment: One commenter suggested
that we modify the formula we use to
calculate the payment amounts based on
manufacturers’ ASP data so that the
formula is volume weighted as
suggested by the OIG.
Response: We discussed our formula
for determining the payment amounts
based on manufacturers’ ASP data in the
CY 2006 PFS final rule (70 FR 70217).
As we stated in the CY 2006 PFS final
rule, in establishing the formula used to
calculate the payment amounts based on
manufacturers’ ASP data, we considered
various approaches, including the
alternative suggested by this
commenter. If appropriate, we may
consider revising the methodology in
the future. We did not propose to
change our current formula, and are not
E:\FR\FM\27NOR2.SGM
27NOR2
66260
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
implementing changes to our formula at
this time.
Comment: We received a few requests
to increase the pharmacy supplying fee
for immunosuppressive, oral anticancer,
and oral anti-emetic drugs for CY 2008
to reflect actual supplying costs. We
also received comments expressing
concerns that primarily because of the
labor intensive Medicare Part B claims
processing services provided by
specialty transplant pharmacies, the
current supplying fee payment for
immunosuppressive drugs is
substantially lower than reported actual
supplying costs. One commenter
requested that we eliminate the twotiered pharmacy supplying fee for
prescriptions filled within a 30-day
period.
Response: We are committed to
assuring that our claims systems process
claims as timely and accurately as
possible and that their payment
methodologies result in the
determination of accurate payment
amounts. We recognize the operational
complexities under which certain
providers operate and strive to develop
systems and processes to minimize such
complexities. We appreciate the
comments that were provided and may
consider the issue in future rulemaking
if appropriate. Since we did not propose
a change to these rates for CY 2008, they
will continue to be in effect in CY 2008.
We received several other comments on
the use and potential impacts of the
ASP payment methodology and other
issues related to Part B drugs that are
also outside the scope of this
rulemaking and will not be addressed in
this final rule with comment. These
topics include the following:
• Requests for billing codes for
specific products;
• Whether alternative payment
methodologies or exceptions to the ASP
based payment should be considered;
• Variation in local coverage and
payment policies, including use of least
costly alternative policies and invoice
pricing for compounded drugs;
• Excluding prompt pay discounts
from the calculation of ASP; and
• Whether coverage under Part B
should be expanded to include certain
vaccines.
2. Competitive Acquisition Program
(CAP) Issues
Section 303(d) of the MMA required
the implementation of a CAP for certain
Medicare Part B drugs and biologicals
not paid on a cost or PPS basis. The
provisions for acquiring and billing
drugs under the CAP were described in
the Competitive Acquisition of
Outpatient Drugs and Biologicals Under
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Part B proposed rule (published in the
March 4, 2005 Federal Register;
hereinafter referred to as the March 4,
2005 proposed rule) and interim final
rule with comment period (published in
the July 6, 2005 Federal Register;
hereinafter referred to as the July 6,
2005 IFC) (70 FR 10746 and 70 FR
39022, respectively). Certain provisions
were finalized in the CY 2006 PFS final
rule with comment period (70 FR
70116). We specified a single CAP drug
category to include a defined list of
drugs furnished incident to a
physician’s service.
In this final rule with comment
period, we discuss the impact of
provisions in section 108 of the MIEA–
TRHCA on administrative and
operational aspects of the CAP. Topics
include the implementation of a postpayment review process and the
corresponding changes to claims
processing procedures, and changes to
other operational aspects of the CAP.
This final rule with comment period
implements conforming changes to the
CAP regulations to reflect these
provisions that made changes to the
payment process of the CAP for Part B
Drugs.
When the CAP program began on July
1, 2006, physicians were given a choice
between obtaining these drugs from
vendors selected through a competitive
bidding process and approved by CMS,
or directly purchasing these drugs and
being paid under the ASP system. In
this final rule with comment period, we
discuss areas related to transporting
CAP drugs and the administrative
burden of the CAP submitted in
response to the July 6, 2005 IFC. In
addition, we are finalizing portions of
the July 6, 2005 IFC that were not
finalized in the CY 2006 PFS final rule
with comment period and responding to
the other timely comments we received
on the July 6, 2005 IFC that we have not
responded to previously.
a. MMA Operational Provisions
Prior to the enactment of the MIEA–
TRHCA, section 1847B(a)(3)(A) of the
Act set forth specific requirements that
have a direct impact on the
administrative and operational
parameters for instituting a CAP. This
section of the statute required the
following:
(1) Approved CAP vendors bill the
Medicare program for the drug or
biological supplied, and collect any
applicable deductibles and coinsurance
from the Medicare beneficiary. (For
purposes of the preamble, the term
‘‘approved CAP vendor’’ means the term
‘‘contractor’’ as referred to in the
statute.)
PO 00000
Frm 00040
Fmt 4701
Sfmt 4700
(2) Any applicable deductible and
coinsurance may not be collected unless
the drug was administered to the
beneficiary. (For purposes of the
preamble, the term ‘‘drug’’ refers to
drugs and biologicals furnished under
the CAP, unless the context specifies
otherwise.)
(3) Medicare can make payments only
to the approved CAP vendor, and these
payments are conditioned upon the
administration of the drug.
Section 108 of the MIEA–TRHCA
amended this third element.
b. MIEA–TRHCA
Section 108 of the MIEA–TRHCA
made changes to the CAP payment
methodology. Section 108(a)(1) of the
MIEA–TRHCA amended section
1847B(a)(3)(A)(iii) of the Act by adding
new language that requires that payment
for drugs and biologicals be made upon
receipt of a claim for a drug or biological
supplied for administration to a
beneficiary. This statutory change took
effect on April 1, 2007.
Section 108(a)(2) of the MIEA–
TRHCA requires the Secretary to
establish (by program instruction or
otherwise) a post-payment review
process (which may include the use of
statistical sampling) to assure that
payment is made for a drug or biological
only if the drug or biological has been
administered to a beneficiary. The
Secretary shall recoup, offset, or collect
any overpayments determined by the
Secretary under this process.
Section 108(b) of the MIEA–TRHCA
states that nothing in this section shall
be construed as requiring the conduct of
any additional competition under
section 1847B(b)(1) of the Act; or
requiring an additional physician
election process.
Section 108(c) of the MIEA–TRHCA
states that the amendments of this
section apply to payments for drugs and
biologicals supplied: (1) On or after
April 1, 2007; and (2) on or after July 1,
2006 and before April 1, 2007, for
claims that are unpaid as of April 1,
2007.
Comment: Some commenters
suggested that any changes to the CAP
be made only after the expiration of the
current vendor contract. The
commenters stated that implementation
of changes before the next vendor
contract would be unfair to bidders who
chose not to participate in the CAP
because of previously issued guidance.
The commenters cited the CAP statutory
reference about waiving the FAR in
order to promote competition. The
commenters believe that such changes
would inappropriately favor the single
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
existing vendor, and therefore, hurt
competition.
Response: We do not have the
authority to delay implementing the
claims processing changes required by
the MIEA–TRHCA, which were effective
April 1, 2007. Although some of our
changes were not expressly required by
the statute, we believe these conforming
changes are necessary to allow the
program to function in a manner that is
consistent with, and required by, the
statutory changes. Further, because the
CAP is a new payment program, change
that is consistent with operational
experience and improves efficiency for
participants is to be expected. Finally,
we disagree that the FAR affects our
ability to make changes in the program
while the current contract is in force.
Because these changes do not modify an
approved CAP vendor’s responsibilities
under its contract with us, we do not
believe the FAR is implicated.
Further, as we have discussed in prior
rulemaking, the CAP statute authorizes
the waiver of provisions of the FAR
(other than provisions relating to
confidentiality of information and such
other provisions as the Secretary
determines appropriate) as necessary for
the efficient implementation of Section
1847B of the Act, in order to promote
competition.
We have discussed our approach to
conforming to the confidentiality
provisions in the July 6, 2005 IFC (70 FR
39077), and we intend to comply with
this approach during future vendor
bidding periods. In implementing the
CAP, we have waived all of the FAR
except for the confidentiality and the
conflict of interest provisions to
promote competition and the efficient
implementation of the program. We
made the decision to waive the FAR
(other than the provisions on
confidentiality and conflict of interest)
in order to increase the pool of qualified
vendors available to participate in the
program. It is our understanding that
compliance with the FAR is not
normally required of the companies that
make up the pool of potential CAP
vendors. It is also not required of other
Medicare suppliers. We waived these
provisions in order to structure CAP
bidding in a manner consistent with
established vendor bidding practices.
The FAR’s confidentiality provisions,
as well as the conflict of interest
standards and requirements found in
FAR subsection 9.5, apply to approved
CAP vendors and applicants. All other
provisions of the FAR have been waived
for purposes of the CAP. However, we
have used certain provisions of the FAR
for guidance in implementing the CAP,
and we may from time to time used
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
other FAR provisions as a guide, even
though they have been waived. For
example, as we discussed in the July 6,
2005 IFC (70 FR 39063), we look to the
provisions of the FAR to guide our
assessment of bidder’s financial
solvency.
However, even if the FAR were
implicated, we believe these changes
promote competition because they make
the program a more attractive option for
physicians, which will provide
physicians who compete among one
another a more meaningful choice
between the CAP and the ASP
methodology. We further believe the
changes we are implementing here are
designed to improve the flexibility and
administrative ease of the CAP.
Therefore, we will proceed with
implementing the provisions we are
finalizing as indicated in this final rule
with comment period.
c. CAP Claims Processing
In the July 6, 2005 IFC (70 FR 39042),
we initially implemented a claims
processing system that enables selected
approved CAP vendors to bill the
Medicare program directly, and to bill
the Medicare beneficiary and his or her
third party payer after verification that
the physician has administered the
drug. When a participating CAP
physician elects to join the program, he
or she must agree to obtain all drugs on
the CAP drug list from the approved
CAP vendor, with only a few
exceptions. For example in furnish as
written (FAW) situations (that is, where
a beneficiary needs a particular
formulation of a drug not available from
the approved CAP vendor) the
participating CAP physician would be
allowed to obtain that drug outside of
the CAP. In the case of Medicare
Secondary Payer (MSP) (that is, where
a Medicare beneficiary may have
another payer primary to Medicare), the
participating CAP physicians must
obtain physician administered drugs
from entities approved by the primary
plan and bill the primary payer.
Detailed MSP instructions have been
issued by CMS that allow the physician
to bill under the ASP methodology for
the portion of the drug not covered by
the primary payer in this situation.
Prior to the MIEA–TRHCA, the claims
processing procedures for the approved
CAP vendor and the participating CAP
physician were as follows:
• Once a shipment is received from
the approved CAP vendor, the
participating CAP physician stores the
drug until the date of drug
administration.
• When the drug is administered to
the beneficiary, the participating CAP
PO 00000
Frm 00041
Fmt 4701
Sfmt 4700
66261
physician places the prescription order
number for each drug administered on
the claim form submitted to his or her
regular Part B carrier.
Similarly, when the approved CAP
vendor bills Medicare for the drug it
shipped to the participating CAP
physician, it places the relevant
prescription order number on the claim
form submitted to the designated
carrier. The use of the prescription order
number on both the participating CAP
physician’s claim and the approved
CAP vendor’s claim is intended to
indicate drug administration to the
beneficiary. The participating CAP
physician’s claim and the approved
CAP vendor’s claim are matched in the
Medicare claims processing system so
that drug administration can be verified
and payment to the approved CAP
vendor can be made.
d. Required Changes to CAP Claims
Processing
As originally implemented, the claims
matching process described above in
this section was completed before
payment was made. However, as of
April 1, 2007, section 108 of the MIEA–
TRHCA requires payment to be made to
the CAP vendor for claims upon receipt.
The statute also requires us to establish
a post-payment review process to assure
that payment is made for a drug only if
the drug has been administered to a
beneficiary. We are authorized under
the statute to recoup, offset, or collect
any overpayments by the Secretary. We
are also authorized to conduct postpayment review using statistical
sampling and to implement the postpayment review process by program
instruction or otherwise. We
implemented the necessary changes to
our claims processing system and
initiated the post-payment review
process on April 1, 2007 via instructions
to the CAP-designated claims processing
contractor and Questions and Answers
posted on the CMS competitive bidding
Web site at https://www.cms.hhs.gov/
CompetitiveAcquisforBios/
15_Approved_Vendor.asp#TopOfPage.
Under the post-payment review
process, the CAP-designated carrier will
use the CMS claims processing system
to look for a match between the CAP
prescription order number on the
participating CAP physician’s claim and
the same prescription order number on
the approved CAP vendor’s claim to
track drug administration on a dose by
dose basis. If the CAP-designated carrier
is able to find a match between the two
claims, the carrier makes a
determination that the beneficiary did
receive the drug being billed for by the
CAP physician. The participating CAP
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66262
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
physician claim may also contain
information on any determination of
medical necessity and coverage made by
the local carrier.
We will also use statistical sampling
under the post-payment review process
to determine whether drugs were
medically necessary. All Medicare
claims are subject to medical necessity
determinations; however, under the
changes required by the MIEA–TRHCA,
CAP claims may not all have a chance
to be reviewed for medical necessity
before they are paid. Therefore, the postpayment review includes both
verification of drug administration and
a medical necessity review of a
statistically valid sample of CAP claims.
In conducting the post-payment review,
we will continue to monitor for fraud,
waste, and abuse. All CAP claims will
remain eligible for review for medical
necessity and verification of drug
administration. We anticipate that the
post-payment review process will
provide us with additional
opportunities to monitor for the
appropriate payment of drugs furnished
under this program.
To conduct post-payment review of
claims, we may also ask for
documentation of administration from
the approved CAP vendor and for
medical records from the participating
CAP physician for any claim that is
identified for review. While it is
standard practice for CMS to require
Medicare providers to submit medical
records as part of claims review, we
reserve the right to also specifically
request any other records that verify the
administration of a CAP drug.
Furthermore, we want to make it very
clear to the participating CAP physician
that when electing to join the program
that the physician may be asked to
supply medical records for postpayment review. Therefore, in the CY
2008 PFS proposed rule (72 FR 38153),
we proposed to revise § 414.908(a)(3)(xi)
and the physician election agreement
form to clarify that medical records and
certain other information may be
requested from the CAP physician
during the post-payment review
process.
The procedures used to verify valid
claims and ensure proper payment for
drugs supplied under the CAP are based
on established post-payment review
processes used in other parts of the
Medicare program. The request for
medical records as part of the claims
payment process during CAP postpayment review is intended to work in
conjunction with Item 12 on the Health
Insurance Claim Form CMS–1500
which, when signed by a beneficiary,
authorizes the release of ‘‘any medical
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
information necessary to process a
claim.’’
When a claim is selected for review
we notify the approved CAP vendor and
request its records to verify
administration. We also notify the
approved CAP vendor that we will be
requesting medical records from the
participating CAP physician. If the
medical record is not received within 30
days, the claim is denied because we
will not have sufficient information to
verify drug administration and medical
necessity.
This review process is similar to those
used elsewhere in the Medicare program
such as clinical laboratory payment
review or payment of radiology services.
As we specified in the July 6, 2005
IFC (70 FR 39038), the local carrier’s
medical review policies and coverage
determinations will continue to apply in
the CAP. Under our previous claims
processing methodology, the local
carrier made the coverage determination
on the drug ordered by the participating
CAP physician and furnished by the
approved CAP vendor as part of the
claim matching process prior to
payment of the approved CAP vendor’s
claim. Under the new methodology, the
drug claim will be paid upon receipt
unless the local carrier has already
made a coverage or medical necessity
determination on the drug, and the
match has already occurred showing
that the drug claim should be denied.
As part of the post-payment review
process, the CAP-designated carrier
checks the CMS central claims
processing system to determine whether
the local carrier has made a coverage or
medical necessity determination on the
CAP drug indicated on the participating
CAP physician’s drug administration
claim. If a coverage determination has
been made, the CAP-designated carrier
reflects the local carrier’s decision in its
post-payment review of the claim. If the
local carrier has not reviewed the drug
administration portion of the
participating CAP physician’s claim as
of the date that the designated carrier
processes the approved CAP vendor’s
drug claim, the CAP-designated carrier
uses the local carrier’s coverage
determination policies when conducting
medical review of the claim.
Comment: One commenter stated that
we had exceeded the scope of the
statute because we were planning to
conduct a medical necessity review on
CAP drug claims that were selected for
review as part of the statistical sample.
Another commenter recommended
that we make detailed description of the
claims sampling process available for
public comment and asked that we
design the process consistent with the
PO 00000
Frm 00042
Fmt 4701
Sfmt 4700
Medicare Program Integrity Manual. The
commenter also asked for more detail on
the information necessary to include in
the medical record to ensure that the
participating CAP physician has
appropriately documented the medical
necessity of the drug administered.
One commenter questioned whether
we needed to obtain additional
information from the CAP participating
physician on claims selected for post
pay review based on the statistical
sample and stated that the information
contained on the claim form should be
sufficient to verify administration.
Another commenter questioned why
we were changing the CAP claims
processing methodology to pay most
claims upon receipt and to verify
administration on a post pay basis. The
commenter asked whether we would
allow for extenuating circumstances if
the medical record was not supplied by
the participating CAP physician within
the 30-day time period for situations
such as bankruptcy, litigation, or
closure of the practice.
Response: As stated in the CY 2008
PFS proposed rule (72 FR 38153), we
were required to make changes to the
CAP claims processing methodology
because section 108 of the MIEA–
TRHCA amended section
1847B(a)(3)(A)(iii) of the Act by adding
new language that requires the payment
for drugs and biologicals upon receipt of
a claim for a drug or biological supplied
for administration to a beneficiary. This
change in the law was effective on April
1, 2007. Section 108(a)(2) of the MIEA–
TRHCA requires the Secretary to
establish (by program instruction or
otherwise) a post-payment review
process (which may include the use of
statistical sampling) to assure that
payment is made for a drug or biological
only if the drug or biological has been
administered to a beneficiary. The
Secretary is required to recoup, offset, or
collect any overpayment determined by
the Secretary under this process. We
implemented the necessary changes to
our claims processing system and
initiated the post-payment review
process on April 1, 2007, via
instructions to the CAP-designated
claims processing contractor and
Questions and Answers posted the CMS
competitive bidding Web site at https://
www.cmsm.hhs.gov/
CompetitiveAcquisforBios/
15_Approved_Vendor.asp#TopOfPage.
In the CY 2008 PFS proposed rule, we
described the changes we had made to
our claims processing system and
proposed conforming changes to our
regulations for additional items not
covered by the MIEA–TRHCA. Because
the MIEA–TRHCA gave us authority to
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
implement its provisions by program
instructions or otherwise by April 1,
2007, the necessary changes have
already been made to our claims
processing system and the post-pay
review process had been implemented.
The post-payment review process
includes verification of drug
administration and a medical necessity
review of a statistically-valid sample of
CAP claims. This process was designed
in conformance with the Medicare
Program Integrity Manual and in
consultation with CMS statistical
sampling experts, consistent with our
authority to establish these procedures
by program instruction or otherwise. For
additional information on the
requirements of the Program Integrity
Manual see https://www.cms.hhs.gov/
manuals/downloads/pim83co2pdf.
All Medicare claims are subject to
medical necessity determinations;
however, under the changes required by
the MIEA–TRHCA, there may not be
sufficient time for all CAP claims to be
reviewed for medical necessity before
they are paid. Prior to paying the
approved CAP vendor’s claim, the
designated carrier will check the claims
processing system to determine whether
the participating CAP physician has
submitted the claim for the
administration of the drug. If the
physician has submitted the claim and
the local carrier has made a
determination that the drug is not
payable because of a coverage or
medical necessity denial, the drug claim
will be denied by the designated carrier.
However, if no determination has been
made on the physician’s claim, the
designated carrier will pay the approved
CAP vendor’s claims for the drug under
the MIEA–TRHCA, and the claim will
be subject to statistical sampling on a
post-pay basis. If the claim is selected
for review, verification of drug
administration and a medical necessity
review will be conducted. As part of
this process, the designated carrier will
check the system to see whether the
local carrier had denied the claim as not
medically necessary. If a denial has
been made, the designated carrier will
deny the approved CAP vendor’s claim
on medical necessity grounds. The
designated carrier will use the local
carrier’s policies when conducting the
review.
Medical necessity review is always
conducted based on medical records
obtained from the physician and will be
conducted in an effort to look behind
the information on the claim form. As
specified in chapter 3 of the Medicare
Program Integrity Manual, standard data
elements for post-pay medical review
include signature requirements,
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
diagnosis requirements, and
documentation of orders for testing. The
carrier may also specify additional
information it will review to document
that coverage and medical necessity
requirements have been met. Under the
current CAP post-pay review process,
the designated carrier requests that all
records be supplied by the physician
within 30 days but allows for a limited
amount of time beyond that period
before the service will be considered not
to have been administered. Participating
CAP physicians are encouraged to send
any information they can provide to the
designated carrier within the timeframes
provided. If the physician is unable to
provide all of the requested information
in a timely manner to the carrier, he or
she may contact the carrier to determine
if the contractor will grant an extension.
There is also a provision in the
Medicare Program Integrity Manual that
allows contractors to grant additional
time in the event of a natural disaster.
As we indicated in the CY 2008 PFS
proposed rule, it is standard practice for
Medicare providers to be required to
submit medical records to assist in
claims review. Therefore, we are
finalizing our proposal to revise
§ 414.908(a)(3)(xi) and the physician
election agreement to make it very clear
to the CAP participating physician that
they may be asked to provide medical
records for post-payment review in the
CAP.
e. Provisions for Collection of
Beneficiary Coinsurance
In the CY 2006 PFS final rule with
comment period, we specified at
§ 414.914(h)(1) that subsequent to
receipt of final payment by Medicare, or
the verification of drug administration
by the participating CAP physician, the
approved CAP vendor must bill any
applicable supplemental insurance
policies. If a balance remains after the
supplemental insurer pays its share of
the bill, or if there is no supplemental
insurance, the approved CAP vendor
may bill the beneficiary for the balance.
In prior practice, a match in the claims
system between the participating CAP
physician’s drug administration claim
and the approved CAP vendor’s drug
claim and the subsequent payment by
Medicare was used to indicate that the
beneficiary received the drug. We also
allowed voluntary information
exchanges between the approved CAP
vendor and the participating CAP
physician’s office to verify CAP drug
administration. Additionally, we note
that under the CAP regulations, the
participating CAP physician has a
responsibility to notify the approved
CAP vendor when a drug is not
PO 00000
Frm 00043
Fmt 4701
Sfmt 4700
66263
administered or a smaller amount was
administered than was originally
ordered.
Because section 108 of the MIEA–
TRHCA requires the payment of CAP
claims upon receipt, payment of a claim
by Medicare may occur before
administration of the drug has been
verified. However, section
1847B(a)(3)(A)(ii) of the Act, which
states that deductible and coinsurance
shall not be collected unless the drug or
biological is administered, remains
unchanged. Thus, because we have
interpreted this provision as requiring
verification of administration prior to
the collection of applicable cost sharing
amounts, the requirement for
verification of administration similarly
remains unchanged. However, because
of the statutory change of section
108(a)(1) of the MIEA–TRHCA and its
resulting impact on our claims
processing methodology, the claims
processing system no longer provides a
way for CMS to verify administration on
the approved CAP vendor’s behalf
before the approved CAP vendor
collects coinsurance from the
beneficiary or the supplemental insurer.
Verification of CAP drug administration
is also conducted in the post-payment
review process. The approved CAP
vendor is expected to make information
available to verify administration for
post-payment review as necessary.
We believe that an approved CAP
vendor can verify whether a CAP drug
was administered in a variety of ways.
For example, an approved CAP vendor
may enter into a voluntary agreement
with a participating CAP physician to
exchange such information as described
in the CY 2006 PFS final rule with
comment period (70 FR 70251).
However, if a participating CAP
physician is unwilling to enter into a
voluntary agreement to verify
administration, the approved CAP
vendor may verify that the drug was
administered by contacting the
participating CAP physician’s office to
request verbal confirmation. In such an
instance, the approved CAP vendor is
expected to document the verbal
confirmation of CAP drug
administration, the identities of
individuals who exchanged the
information, and the date and time that
the information was obtained. In
addition to verifying administration
through contact with the physician’s
office, we also suggest that the approved
CAP vendor place a statement on
beneficiaries’ bills informing the
individual of the statutory requirement
and suggesting that the beneficiary
contact the participating CAP physician
to verify that he or she received the dose
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66264
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
of the drug for which he or she are being
billed prior to paying any cost sharing
amount.
For the reasons described above in
this section, we believe that the
verification of CAP drug administration
remains a required element of the CAP;
therefore, in the CY 2008 PFS proposed
rule (72 FR 38155), we proposed to add
§ 414.906(a)(6) by specifying that all of
the following elements are required to
document the verification of CAP drug
administration:
• Beneficiary’s name.
• Health insurance number.
• Expected date of administration.
• Actual date of administration.
• Identity of the participating CAP
physician.
• Prescription order number.
• Identity of the individuals who
supply and receive the information.
• Dosage supplied.
• Dosage administered.
In the CY 2008 PFS proposed rule,
these data elements were actually
proposed in § 414.914 (72 FR 38226).
We believe that the drug administration
verification requirements best fit in
§ 414.914 since CAP vendors must
collect this information as part of their
terms of contract. Therefore, we are
finalizing § 414.914 to include these
provisions.
Also, as a result of changes mandated
by section 108(a)(1) of the MIEA–
TRHCA, we proposed to revise new
§ 414.914(i)(1) to remove the reference
to ‘‘final payment by Medicare’’ and
revise this language to state, ‘‘payment
by Medicare.’’ The original language
was written to indicate that an approved
CAP vendor could not bill a
beneficiary’s supplemental insurer for
applicable amounts of cost sharing until
the CAP drug claim had matched the
corresponding physician’s drug
administration claim. Under the postpayment review process, the final
payment would not occur until a
statistical review of the claims was
complete, a process that may take
several months. Removing the word
final from this section of the regulation
will clarify that the approved CAP
vendor may bill the supplemental
insurer immediately after the designated
CAP carrier makes the initial payment
on a CAP drug claim. Under our current
regulations, the approved CAP vendor
may also bill the beneficiary if drug
administration is verified by the
participating CAP physician. This
provision remains unchanged.
Under the revised CAP claims
payment process, the approved CAP
vendor will bill Medicare for the CAP
drug that has been provided. In most
cases Medicare will pay the claim upon
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
receipt. If the beneficiary has a
supplemental insurance policy, and the
supplemental insurer has a crossover
agreement with Medicare, the claim
automatically will cross over to the
supplemental insurer for payment. The
supplemental insurer will pay its share.
Upon receipt of payment from the
supplemental insurer, the approved
CAP vendor may bill the beneficiary for
any residual amount. For beneficiaries
who do not have a supplemental
insurance policy, the approved CAP
vendor may bill the beneficiary after
payment by Medicare.
However, in either case, the approved
CAP vendor may not collect any
coinsurance owed from the beneficiary
or his or her supplemental insurer
unless it has verified that the drug was
administered. If the approved CAP
vendor believes that the drug was
administered but later learns that it was
not, the approved CAP vendor must
refund any coinsurance collected to the
beneficiary and his or her supplemental
insurer, as applicable. In addition, in
§ 414.914(i)(2), we proposed that the
approved CAP vendor must promptly
refund any payment made by CMS if the
vendor has been paid for drugs that
were not administered. We also
proposed to interpret the word
‘‘promptly’’ to mean 2 weeks. Thus, the
approved CAP vendor would have 2
weeks from the date it was notified that
it had been paid for a drug that had not
been administered to refund to the
designated carrier any payment for the
claim and refund any cost sharing
collected to the beneficiary or his or her
supplemental insurer.
Comment: We received few comments
on our proposal for provisions for
collection of beneficiary coinsurance.
One commenter was concerned about
the administrative burden placed on the
participating CAP physician if the
approved CAP vendor calls the
physician’s office to verify that a drug
was administered. Another commenter
agreed with our proposal to require that
the approved CAP vendor refund any
cost sharing collected in error promptly
to the beneficiary and or his or her
supplemental insurance provider. The
commenter also suggested that we
require the approved CAP vendor to pay
a penalty above the amount owed if it
does not refund the cost sharing amount
within the 2 week time frame.
Response: Physicians and their staff
are the best source of information for
drug verification since they have direct
contact with the beneficiary. We have
structured the process for verification of
CAP drug administration in the least
burdensome way possible for the
participating CAP physician that would
PO 00000
Frm 00044
Fmt 4701
Sfmt 4700
still provide us with information to
comply with the statutory mandate to
assure that payment is made for a CAP
drug only if it has been administered to
a beneficiary.
Physicians have flexibility in how
verification for drug administration
occurs. The physician is free to enter
into a voluntary agreement with the
approved CAP vendor to verify drug
administration and to specify the
manner in which he or she would like
the verification to occur. Alternatively,
if the physician chooses not to enter
into such an agreement and does not
notify the vendor that a dose of a CAP
drug has been administered, the
approved CAP vendor will contact the
physician to verify administration
before collecting coinsurance from the
beneficiary.
We believe that the degree of
flexibility built into this procedure for
drug administration verification
minimizes the burden for participating
CAP physicians within the confines of
our statutory obligation to assure that
payment is made for a CAP drug only
if it has been administered to a
beneficiary. Therefore, we are finalizing
our proposal to add new § 414.914(h)(1)
as described above in this section.
We are also finalizing our proposal to
revise new § 414.914(i)(1) to remove the
reference to ‘‘final payment by
Medicare’’ and revise this language to
state, ‘‘payment by Medicare.’’ Under
the post-payment review process, the
final payment will not occur until a
statistical review of the claims was
complete, a process that may take
several months. Removing the word
final from this section of the regulation
will clarify that the approved CAP
vendor may bill the supplemental
insurer immediately after the designated
CAP carrier makes the initial payment
on a CAP drug claim. Under our current
regulations, the approved CAP vendor
may also bill the beneficiary if drug
administration is verified by the
participating CAP physician. This
provision remains unchanged.
Under the revised CAP claims
payment process, the approved CAP
vendor will bill Medicare for the CAP
drug that has been provided. In most
cases Medicare will pay the claim upon
receipt. If the beneficiary has a
supplemental insurance policy, and the
supplemental insurer has a crossover
agreement with Medicare, the claim
automatically will cross over to the
supplemental insurer for payment. The
supplemental insurer will pay its share.
Upon receipt of payment from the
supplemental insurer the approved CAP
vendor may bill the beneficiary for any
residual amount. For beneficiaries who
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
do not have a supplemental insurance
policy, the approved CAP vendor may
bill the beneficiary after payment by
Medicare.
However, in either case, the approved
CAP vendor may not collect any
coinsurance owed from the beneficiary
or his or her supplemental insurer
unless it has verified that the drug was
administered. If the approved CAP
vendor believes that the drug was
administered but later learns that it was
not, the approved CAP vendor must
refund any coinsurance collected to the
beneficiary and his or her supplemental
insurer, as applicable.
In addition, we are finalizing
§ 414.914(i)(2), so that the approved
CAP vendor must promptly refund any
payment made my CMS if the vendor
has been paid for drugs that were not
administered. We are implementing our
proposal to interpret the term
‘‘promptly’’ to mean 2 weeks so that the
approved CAP vendor would have 2
weeks from the date that they were
notified that they had been paid for a
drug that had not been administered to
the beneficiary to refund any payment
for the claim made to the designated
carrier and refund any cost sharing
collected to the beneficiary and his or
her supplemental insurer. We are not
implementing a penalty if the refund of
any cost sharing collected in error
exceeds the two week time frame
because section 1847B of the Act does
not provide for such a remedy.
f. Approved CAP Vendor Appeals for
Denied Drug Claims
In the March 4, 2005 proposed rule
(70 FR 10757 through 10758) and the
July 6, 2005 IFC (70 FR 39054 through
39057), we discussed the development
of the CAP dispute resolution process
and the limited applicability of the
traditional Medicare fee for service
appeals process to an approved CAP
vendor’s dispute of CAP drugs claims
that are denied by the CAP-designated
carrier. We stated that the approved
CAP vendor could file appeals as a
Medicare supplier consistent with the
rules at 42 CFR part 405, subpart I. For
the purposes of the appeals regulations
at Part 405, Subpart I, we indicated that
a local carrier’s initial determination of
the participating CAP physician’s drug
administration claim was an initial
determination regarding payment of the
approved CAP vendor’s drug claim.
Thus, the approved CAP vendor was to
be considered a party to any
redetermination of the drug
administration claim by the local
carrier. In addition, the approved CAP
vendor would be considered a party to
an initial determination on the claim for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
payment for the drug product that the
approved CAP vendor filed with the
CAP-designated carrier.
We also specified that appeals of
either initial determination would be
filed with the local carrier. We stated
that the local carrier, rather than the
designated carrier, possessed all
information necessary to adjudicate an
appeal in this situation. Such
information included local coverage
decisions, medical necessity
determinations, and information
regarding payment of drug
administration claims. A dispute
resolution process was set forth in
§ 414.916.
Under our initial implementation of
the provision that authorized CAP, this
alternative approach provided party
status to the approved CAP vendor on
the participating CAP physician’s drug
administration claim. This was
necessary because an approved CAP
vendor was not permitted to receive
payment for a CAP drug until the
corresponding drug administration
claim was submitted by a participating
CAP physician. Payment for the
approved CAP vendor’s claim was
authorized when the participating CAP
physician’s claim and the approved
CAP vendor’s claim were matched in
the system.
However, changes to the claims
processing requirements and the
addition of a post-payment review
process required by section 108(a)(2) of
the MIEA–TRHCA (discussed above in
this section) eliminate the approved
CAP vendor’s dependency on a
participating CAP physician’s filing of a
drug administration claim in order to
receive payment for a CAP drug.
Accordingly, the approved CAP vendor
no longer needs party status on the drug
administration claim submitted by the
participating CAP physician. Instead,
under the MIEA–TRHCA, the approved
CAP vendor’s drug claim may be paid
by the CAP-designated carrier once it is
received. This determination made on
the claim constitutes an initial
determination as defined in § 405.924.
The approved CAP vendor is considered
a party to this initial determination and
may request a redetermination and
subsequent appeals consistent with the
process established under 42 CFR part
405, subpart I.
The changes to CAP claims processing
in this final rule with comment period
that conform to the MIEA–TRHCA
result in two scenarios that create
appeals rights for the approved CAP
vendor with respect to their drug
product claim: (1) Prepayment denials
of the approved CAP vendor’s claim
made by the CAP-designated carrier
PO 00000
Frm 00045
Fmt 4701
Sfmt 4700
66265
(based on information from the local
carrier that the payment for the drug
should be denied as excluded or noncovered); and (2) post-payment denials
by the CAP-designated carrier based on
the post-payment review process
established under the MIEA–TRHCA.
Therefore, as proposed in the CY 2008
PFS proposed rule (72 FR 38156), we
are making the following clarifications
regarding the CAP appeals process for
an approved CAP vendor’s denied drug
claims:
• For prepayment denials, the
approved CAP vendor, as a supplier, has
a direct right to appeal the initial
determination made by the designated
carrier on its drug product claim. The
local carrier will conduct the
redetermination on prepayment denials.
It is the most appropriate entity to
review prepayment denials since it is
most familiar with the relevant coverage
policies for that jurisdiction. We
acknowledge that this process differs
from a traditional fee-for-service appeal
since the redetermination will not be
conducted by the contractor that issued
the initial determination.
• For the post-payment review
process, an initial determination will be
considered re-opened if the CAPdesignated carrier selects the drug claim
for review. If the CAP-designated carrier
cannot verify administration or cannot
determine that the drug is covered or
medically reasonable and necessary, the
CAP-designated carrier will issue a
revised determination to deny coverage
of the drug product claim. The CAPdesignated carrier will then determine
whether an overpayment exists, and if
so, will recover the overpayment. As a
supplier, the approved CAP vendor
would then have the right to request a
redetermination of the revised coverage
determination, and the overpayment
assessment. The CAP-designated carrier
will process the redetermination.
We received no comments on this
topic; therefore, we are finalizing the
proposed conforming changes to the
CAP appeals process as described
herein.
g. Definition of Exigent Circumstances
Sections 1847B(a)(1)(A)(ii) and
1847B(a)(5)(A)(ii) of the Act require that
each physician be given the opportunity
annually to elect to obtain drugs and
biologicals through the CAP and to
select an approved CAP vendor. Section
1847B(a)(5)(A)(i) of the Act allows for
selection of another approved CAP
vendor more frequently than annually
in exigent circumstances as defined by
CMS.
In the CY 2005 PFS final rule with
comment period (70 FR 70258), we
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66266
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
stated that participating CAP physicians
would have the option of changing
approved CAP vendors or opting out of
the CAP program on an annual basis.
We also provided the circumstances, as
specified in § 414.908(a)(2), under
which a participating CAP physician
may choose a different approved CAP
vendor mid-year or opt-out of the CAP.
These circumstances are: (1) If the
selected approved CAP vendor ceases to
participate in the CAP; (2) if the
participating CAP physician leaves the
group practice that had selected the
approved CAP vendor; (3) if the
participating CAP physician relocates to
another competitive acquisition area (if
multiple CAP competitive areas are
developed) or, (4) for other exigent
circumstances defined by CMS.
We also identified a separate exigent
circumstance relating to instances in
which an approved CAP vendor
declines to ship CAP drugs (when the
conditions of new § 414.914(i) are met)
in § 414.908(a)(5). We noted that in
these cases, a physician may opt-out of
his or her drug category, and because
there is currently only one drug category
for the CAP, then the participating CAP
physician would be allowed to opt-out
of the CAP altogether (70 FR 39081).
The CAP became operational on July
1, 2006. At that time, we believed that
most issues raised by participating CAP
physicians would relate to quality and
service, which could be resolved
through the approved CAP vendor’s
grievance process and the dispute
resolution process conducted by the
designated carrier. However, since then,
we have been contacted by a few
participating CAP physicians who have
requested termination of their election
agreement because they misunderstood
the CAP program or determined that it
was not a viable option for their
practice.
These instances demonstrate that a
practice might wish to leave the
program for other business reasons that
are unrelated to the approved CAP
vendor’s performance. However, we
continue to believe that opportunities
for leaving the CAP outside the annual
election process should be limited
because the CAP was designed as a
program in which physicians would
make an annual decision to participate,
as consistent with sections
1847B(a)(1)(A)(ii) and 1847B(a)(5)(A) of
the Act.
Therefore, in the CY 2008 PFS
proposed rule (72 FR 38156), we
proposed to define an additional exigent
circumstance for opting out of the CAP.
We proposed that within 30 days of the
effective date of the election agreement,
the participating CAP physician may
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
submit a written request to terminate his
or her participation in the CAP. The
request would be sent to the designated
carrier under the dispute resolution
process, and the designated carrier
would determine within 1 business day
whether the request was related to the
service provided by the approved CAP
vendor. If so, the designated carrier
would refer the participating CAP
physician to his or her approved CAP
vendor’s grievance process to further
determine whether any appropriate and
reasonable steps could be taken to
resolve the identified issue.
We proposed that the approved CAP
vendor would have 2 business days to
respond to the participating CAP
physician’s concern, consistent with
§ 414.914(f)(5). If the approved CAP
vendor is unable to identify a solution
for resolving the issue that is consistent
with the CAP statute, regulations,
contracts and guidance, and that is
acceptable to the physician, then the
participating CAP physician would be
referred back to the designated carrier
for assistance under the dispute
resolution process. We also proposed
that the participating CAP physician’s
request would be handled under the
dispute resolution process because
protocols and defined time frames have
already been developed for handling
participating CAP physician and
approved CAP vendor complaints in
this set of procedures.
We proposed that if the designated
carrier does not believe that the
participating CAP physician’s request is
related to an issue that could be
resolved by the approved CAP vendor,
then the designated carrier would
conduct an investigation and attempt to
resolve any issues identified in the
physician’s request to terminate his or
her CAP election agreement. If the
designated carrier is unable to resolve
the situation to the physician’s
satisfaction within 2 business days, then
it can either make a recommendation to
CMS that the physician be permitted to
terminate his or her CAP election
agreement, or request a 2-day extension
to continue examining the issue. We
stated that we believed that 4 business
days would be sufficient to conclude
this process because it would give the
designated carrier time to gather
information from other affected parties,
such as the participating CAP
physician’s local carrier, but still
prepare a speedy summary of the issues
involved in the physician’s request.
Under our proposal, after the 2-day or
4-day period, as applicable, the
designated carrier would forward its
recommendation and the physician’s
request to CMS. We would then review
PO 00000
Frm 00046
Fmt 4701
Sfmt 4700
the recommendation and make a final
decision within 2 business days from
the date that we received the request.
We proposed that if the participating
CAP physician demonstrated that
remaining in the CAP was a significant
burden, then we would allow that
physician to terminate his or her
participation in the program. We would
inform the designated carrier of our
decision, which the designated carrier
would then communicate to the
participating CAP physician in writing.
As part of this process, the physician’s
termination date for his or her CAP
election agreement would be
determined and communicated to all
parties involved, including the
physician’s local carrier.
Conversely, if we did not believe that
the physician demonstrated that CAP
participation constituted a significant
burden, then we would not allow the
physician to terminate his or her CAP
contract. Subsequently, we would
inform the physician of our decision in
writing via the designated carrier. We
would also include a recommendation
for corrective action.
In the CY 2008 PFS proposed rule, we
also proposed that, even if we agreed to
terminate the participating CAP
physician’s CAP election agreement, the
physician would still be required to
continue to cooperate in any postpayment review and appeal of claims
for drugs that the approved CAP vendor
had already provided and been paid for.
The physician would also have to make
arrangements with the approved CAP
vendor for the return of any unused
drugs that had not been administered to
the beneficiary prior to the effective date
of the physician’s termination from the
CAP. If the approved CAP vendor had
billed CMS for drugs that had not yet
been administered to a beneficiary, then
the vendor would be required to correct
the claim and return any overpayment.
Comment: We received several
comments that supported defining an
additional exigent circumstance for
leaving the CAP because of a burden on
the practice. Several commenters
addressed the timeframe for leaving the
CAP. Of these comments, all supported
a 30-day timeframe, though several
encouraged a longer window.
Commenters who encouraged a longer
time period believe that 30 days was
insufficient time to determine the
suitability of the CAP for their practice.
While most commenters agreed that a
demonstration of burden should be
required, one commenter stated that
allowing physicians to opt-out for any
reason would be desirable. One
commenter suggested that physicians
should be allowed to opt-out of the CAP
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
at any time for any reason. Several
commenters asked that the opt-out
process be simplified. Another
commenter requested that the process
for determining whether to grant a
physician’s request to leave the CAP be
outlined.
Response: Based on the comments, we
are revising our proposal to make it
more flexible. While we recognize the
concerns raised by commenters who
recommended that we allow physicians
to leave the CAP for any reason at any
time, we continue to believe that there
should be limits on a participating CAP
physician’s ability to leave the CAP. The
CAP statute contemplates an annual
election process. Our proposal to allow
a 30-day period for opting out because
of a burden is based on our authority to
specify ‘‘exigent circumstances,’’ and
we do not believe it would be
appropriate to allow physicians to optout under this process without some
exigency that makes termination of CAP
participation necessary. However, in
recognition of these comments, and
because we agree that participating CAP
physicians should have a sufficient
opportunity to assess the suitability of
the CAP for their practice, we are
making the following changes to the
opt-out process.
First, we note that we intend to take
a broad view of what would constitute
a burden to the practice resulting in an
‘‘exigent circumstance.’’ We believe that
a broad view is appropriate because
there may be many reasons why a
participating CAP physician may find
CAP participation more burdensome
than he or she expected, and we do not
wish at this time to place a limit on
what those reasons may be. As we gain
experience with this process, we may in
a future rulemaking specify a list of
‘‘exigent circumstances’’ or prescribe
more specific standards for what
constitutes an ‘‘exigent circumstance’’
for purposes of the opt-out process;
however, for now we will assess
requests on a case-by-case basis under
the process described in this preamble
and set forth in the regulations at
§ 414.908.
In response to comments seeking
greater flexibility in the process and a
longer window in which to assess the
CAP’s suitability for the physician’s
practice, we are implementing a twotiered process that would both expand
the initial time frame for requesting to
opt-out of the CAP and would allow for
requests to opt-out at any time based on
a change in circumstances that was not
previously known to the participating
CAP physician. We believe that such a
process, which we outline below, strikes
a balance between providing
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
participating CAP physicians with
flexibility to opt-out of the CAP when
participation is burdensome, while still
placing appropriate limits on a
physician’s ability to leave the CAP
outside the annual election process.
Thus, under the two-tiered process we
are finalizing in this rule, we are
changing to 60 days the initial period
during which a physician can request
termination of his or her CAP
participation agreement as a result of
exigent circumstances. We agree with
commenters that allowing physicians
more time to determine whether the
CAP is suitable for their practices is
advisable. We believe that an initial 60day period will allow the participating
CAP physician time to make a more
complete assessment of the CAP’s
suitability. Although certain burdens
will be likely to be apparent
immediately, the first 30 days may be a
period with a steep learning curve for
the practice as it adapts to the CAP drug
ordering process, and the first 30 days
may involve working out any ‘‘start up’’
issues within the practice or with the
approved CAP vendor. For this reason,
the first 30 days may not be a fully
representative time period during which
to assess ongoing CAP participation. We
believe an additional 30 days of CAP
participation would be sufficient to
identify, in the vast majority of cases,
whether participation will constitute a
burden to the practice.
Under this process, therefore, if a
participating CAP physician’s election
agreement was effective on January 1,
2008, then he or she would have until
March 1, 2008, to request to terminate
participation in the program if CAP
participation results in a burden to the
practice. In addition, based on the
concerns raised by commenters, we will
allow physicians to leave the CAP at
any time after the first 60 days if they
can show that a change in
circumstances that was not known to
the practice previously results in a
burden to the practice. As noted above,
we believe that in the vast majority of
cases participating CAP physicians will
be able to identify a burden, if any,
within the first 60 days. However, we
also recognize that issues may arise
during the course of the year that would
result in an ‘‘exigent circumstance,’’ but
that were not known to the participating
CAP physician during the first 60 days
of CAP participation. In such instances,
we agree with commenters that
physicians should have a longer
window to request an opt-out.
For purposes of the two-tiered
process, then, examples of burdens that
we would expect a practice could
identify within the first 60 days may
PO 00000
Frm 00047
Fmt 4701
Sfmt 4700
66267
include difficulties with CAP billing or
drug ordering requirements, or
documentation that the practice’s initial
understanding of these requirements
was based on inaccurate information
provided by a third party. Examples of
burdens that might arise after the initial
60 days could include a change in
practice personnel, patient population,
computer systems, or vendor behavior
that makes it harder to participate in the
program. Where an opt-out request is
submitted after the initial 60 days, we
will require the participating CAP
physician to demonstrate the request is
based on information that he or she did
not have within the first 60 days.
All requests to terminate
participation, whether within the first
60 days or thereafter, would be
submitted to the CAP-designated carrier
and processed under the dispute
resolution process. The request would
need to document the physician’s
burden. Upon completion of the process
outlined in proposed § 414.917, we
would make the decision about whether
the participating CAP physician’s
participation in the CAP will be
terminated.
If the physician has not demonstrated
that CAP participation represents a
burden for his or her practice—either
during the first 60 days or, if thereafter,
as a result of a change in circumstances
that was not known to the practice
previously, then we would not allow the
physician to terminate his or her
participation in CAP because, as noted
above, we continue to believe that a
participating CAP physician’s ability to
opt-out of the CAP under this process
should be limited to ‘‘exigent
circumstances,’’ as contemplated by the
statute and our regulations.
We would inform the physician of our
decision in writing via the designated
carrier. We would also include a
recommendation for corrective action, if
appropriate. For example, if the reason
that the CAP participating physician
wanted to leave the program was that
the approved CAP vendor was not
delivering drugs timely, the designated
carrier would investigate the situation.
If it found that the approved CAP
vendor was complying with our
regulations on drug delivery at
§ 414.914(f) and § 414.902 but that the
participating CAP physician was not
ordering drugs consistent with the
vendor’s procedures, then the CAPdesignated carrier could educate the
physician about the proper drug
ordering procedures and facilitate a
discussion between the approved CAP
vendor and the participating CAP
physician about how the physician
could order drugs in a way that met the
E:\FR\FM\27NOR2.SGM
27NOR2
66268
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
needs of his or her practice and the drug
ordering requirements of the CAP
vendor. The CAP-designated carrier
would document the result of that
discussion in writing. The participating
CAP physician would have the right to
request a reconsideration of our
decision as specified in § 414.916(c). We
are revising § 414.916(c) to clarify that
the physician reconsideration process
would apply to reconsiderations of our
decision on whether the participating
CAP physician may opt-out of the CAP.
Based on our experience with the
program, we continue to believe that
handling all requests to terminate CAP
election under the dispute resolution
process is reasonable and
straightforward. We further believe the
use of our pre-existing process will not
create unnecessary delays in processing
opt-out requests, particularly in light of
the short time frames we have specified
for responding to opt-out requests.
Moreover, we believe the dispute
resolution process is sufficiently
detailed that it provides an ample
description of how a physician’s request
to terminate CAP participation will be
assessed.
Physicians will still be required to
return unused CAP drugs and to
complete any required CAP claims
processing activities as described in
proposed § 414.917. The notification to
a physician will also include the end
date of CAP participation in order to
facilitate an orderly and efficient
changeover between the CAP and ASP
payment systems.
Therefore, we are finalizing § 414.908
and § 414.917 as proposed, subject to
the changes described in this section.
(We are making an additional technical
change to § 414.908 to consolidate the
‘‘additional opt-out’’ provision,
currently set forth at § 414.908(a)(5),
with the other opt-out provisions at
§ 414.908(a)(2). We believe this
nonsubstantive change will improve the
clarity of the regulations.) Finally, we
also are finalizing § 414.916(c) as
amended as described in this section.
h. Transporting CAP Drugs
Although section 1847B((b)(4)(E) of
the Act provides for the shipment of
CAP drugs to settings other than a
participating CAP physician’s office
under certain conditions, we did not
propose to implement the CAP in
alternative settings. In the July 6, 2005
IFC (70 FR 39047), we described both
comments that supported the idea of
allowing participating CAP physicians
to transport drugs to multiple office
locations, and comments that raised
concerns about the risk of damaging a
drug that has not been kept under
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
appropriate conditions while being
transported.
As stated in § 414.906(a)(4), we
implemented the CAP with a restriction
that CAP drugs be shipped directly to
the location where they will be
administered. However, we were aware
that physicians may desire to administer
drugs in alternative settings, especially
in a home. We sought comment on how
this could be accommodated under the
CAP in a way that addresses the
concerns about product integrity and
damage to the approved CAP vendors’
property expressed by the potential
vendors.
Several comments submitted in
response to the July 6, 2005 IFC
suggested either narrowing or removing
the restriction on transporting drugs to
other locations. Commenters believed
that physicians, particularly those who
specialize in oncology, and their staff
are knowledgeable about drug stability
and handling, and therefore, were
capable of assuming this responsibility.
Other commenters indicated that
transporting the drug to another office
location may allow for flexibility in
scheduling patient visits. It would allow
practices with satellite operations that
are not open every business day to
receive shipments of CAP drugs at
another practice location and then to
administer the drugs in the satellite
office.
We also received several comments
discussing the impact of CAP-delivery
times on rural clinics and offices with
satellite locations. Many of these
responses discussed how easing the
restriction on transporting CAP drugs
between locations would be welcome in
rural areas and for satellite offices with
limited hours.
These comments and our experience
with the CAP thus far have caused us to
consider revising our policy. Therefore,
in the CY 2008 PFS proposed rule (72
FR 38157), we requested comments on
the potential feasibility of narrowing the
restriction on transporting CAP drugs
where this is permitted by State law and
other applicable laws and regulations.
We asked commenters to consider how
such a policy could be constructed so
that the approved CAP vendor could
retain control over how the drugs that
it owns are handled. We also requested
comments on other issues that we
should take into account concerning
transportation of CAP drugs between
practice locations listed on a physician’s
CAP election agreement form.
Additionally, we also solicited
comments on the following areas that
we could use in the development of
future proposals:
PO 00000
Frm 00048
Fmt 4701
Sfmt 4700
• How to structure requirements so
that drugs are not subjected to
conditions that will jeopardize their
integrity, stability or sterility while
being transported and steps to keep
transportation activities consistent with
all applicable laws and regulations;
• Whether any agreement allowing
participating CAP physicians to
transport CAP drugs to alternate
practice locations should be voluntary.
This means that approved CAP vendors
would not be required to offer such an
agreement and physicians who
participate in the CAP would not be
required to accept such an offer; and
• Whether the agreement should be
documented in writing, and whether it
is necessary to create any restrictions on
which CAP drugs could be transported.
We stated that we were not making a
specific proposal at this time but that
we would use any information received
to structure a future proposal in the
event we made one.
Comment: Several commenters
supported the concept of easing the
restriction on transporting CAP drugs if
this could be done safely, and if changes
were consistent with applicable rules,
regulations, and within the limitations
of product stability and integrity. The
restriction on transporting CAP drugs
was perceived as a barrier to physician
participation in the program. One
commenter stated that elimination of
the restriction would result in the same
flexibility as the ASP (buy and bill)
method of acquiring drugs. Another
commenter expressed a strong desire to
implement these changes promptly.
A few commenters also cautioned us
to be certain that appropriate safeguards
would be in place if we chose to ease
the transportation restriction. One
commenter asked that the safeguards be
available for public scrutiny before they
are implemented. Conversely, other
commenters stated that a physician’s
certification or discretion were
satisfactory.
Response: We are sympathetic to the
concerns expressed by the commenters
and expect to issue a proposal in the CY
2009 PFS proposed rule that would
allow the transportation of CAP drugs
from one physician practice location in
certain circumstances. We further
expect that our proposal would propose
to permit transport of CAP subject to
voluntary agreements between the
approved CAP vendor and the
participating CAP physician that
complied with all applicable State and
Federal laws and regulations and
product liability requirements. We
welcome comments on how to structure
such a proposal.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
i. Alternatives to the CAP Prescription
Order Number
In the July 6, 2005 IFC (70 FR 39043
and 39049), we responded to several
comments regarding the administrative
burden that the CAP ordering and
claims payment process imposes upon
participating CAP physicians;
specifically, activities associated with
using and tracking the prescription
order number were mentioned. We
received additional comments on this
issue in response to the IFC as well.
After the close of the comment period,
we also received an inquiry from the
current approved CAP vendor about the
potential length of the CAP prescription
order number and whether it could
present a burden to participating CAP
physicians. A 30-byte field is currently
available on the electronic claim form
for prescription numbers; however, it is
not necessary for the prescription order
number to be 30 bytes long. Typically,
15 or fewer total characters have been
used by the approved CAP vendor.
The requirements for developing the
CAP prescription order number are as
follows: The first 9 characters are the
approved CAP vendor’s ID and the
HCPCS code of the drug that is being
billed; the approved CAP vendor sets
the remaining characters. The assigned
CAP prescription order number is
captured in Loop 2410, REF02
(REF01=XZ) of the ANSI 4010A1
electronic claims transaction. This
segment of the electronic claims
transaction is part of a specific data
format that Medicare claims must
adhere to in order to meet national
electronic standards for the automated
transfer of certain health care data as
mandated by the Health Insurance
Portability and Accountability Act of
1996 (Pub. L. 104–191) (HIPAA).
Each prescription order number is
unique to a dose of a CAP drug that is
being shipped for administration to a
particular beneficiary. The prescription
order number is generated by the
approved CAP vendor and, as stated in
the July 6, 2005 IFC (70 FR 39042), each
dose of a CAP drug is required to have
a separate prescription order number.
After the drug is administered, the
participating CAP physician’s drug
administration claim is submitted with
a no-pay line containing the
prescription order number. The
approved CAP vendor’s claim for the
CAP drug also contains the prescription
order number.
When the CAP was implemented, the
prescription order number was used in
the claims matching process to facilitate
accurate payment of the approved CAP
vendor. Prior to payment, this system
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
paired an approved CAP vendor’s drug
claim to a participating CAP physician’s
drug administration claim using the
prescription order number. A matching
prescription order number between
these two claims indicated that the drug
had been administered.
Since the CAP began, the claims
process has changed because of
statutory changes. Section 108(a)(2) of
the MIEA–TRHCA requires us to make
payment upon receipt of an approved
CAP vendor’s drug claim and then to
conduct a post-payment review of
claims. As stated in the MIEA–TRHCA,
the post-payment review process is
intended to ‘‘assure that payment is
made only for a drug or biological * * *
if the drug or biological has been
administered to a beneficiary.’’
Under this new process, the
prescription order number still plays a
pivotal role. Prior to the payment of the
approved CAP vendor’s drug claim, the
CAP-designated carrier uses the
prescription order number to check the
claims processing system to ascertain
whether the local carrier has
adjudicated the drug administration
claim. If the local carrier has done so,
then the CAP-designated carrier will
look to see whether the local carrier has
determined that the CAP drug
administered by the participating CAP
physician is covered and is medically
necessary. The local carrier’s decision
determines whether the CAP-designated
carrier will pay the approved CAP
vendor’s drug claim. If the participating
CAP physician’s local carrier has not
made a determination on the
physician’s claim and the CAP drug
claim, then the designated carrier will
pay the approved CAP vendor’s claim
upon receipt and use the CAP
prescription order number to help verify
drug administration on a post-payment
basis.
The prescription order number is also
still used in other CAP processes. Each
dose of a CAP drug that is shipped by
the approved CAP vendor is tracked
using the prescription order number.
Moreover, the prescription order
number is particularly useful in certain
situations such as those that involve
recurring cyclic drug treatment
regimens. In these cases, the
prescription order number minimizes
the possibility of confusion by serving
as a unique differentiating factor
between highly similar drug claims.
Also, the prescription order number is
valuable during instances in which the
anticipated day of service submitted by
the participating CAP physician differs
from the actual date of drug
administration. In these situations, the
prescription order number would clarify
PO 00000
Frm 00049
Fmt 4701
Sfmt 4700
66269
confusion stemming from discrepancies
in dates. Overall, we believe that the
prescription order number remains an
appropriate and necessary tool to track
the administration of a specific dose of
a drug and for the accurate execution of
the post-payment review process.
Although we believe that the use of
the prescription order number is
necessary to facilitate accurate review of
CAP claims, we are aware that it may be
considered an inconvenience by some
potential participating CAP physicians
and approved CAP vendors. Therefore,
in the CY 2008 PFS proposed rule (72
FR 38158), we requested comments on
alternative methods to accurately track
the administration of specific doses of
drugs in order to meet the requirements
stated in section 108(a)(2) of the MIEA–
TRHCA. These comments could then be
used in the development of a proposal
for future rulemaking.
Comment: We received a few
comments on this issue. One commenter
suggested that the CAP-designated
carrier should simply match vendor and
physician claims but did not provide
any details about how that could be
accomplished without the prescription
order number. Another commenter
stated that the CAP prescription order
number was no longer needed to verify
drug administration and should be
eliminated. Instead they recommended
that we should rely on the approved
e-CAP vendor’s verification of drug
administration and the physician’s
records of drug administrations.
Response: While the records of
participating CAP physicians and the
CAP vendor are currently used in the
post pay review process, the CAP
prescription order number plays an
important role in that it enables the
designated carrier to identify the exact
doses of a drug that was administered
and provides a link between the
approved CAP vendor’s claim and the
participating CAP physician’s claim that
is not available otherwise.
We do not believe the suggestions that
we have received thus far would allow
us to discontinue the use of the
prescription order number. The
prescription order number allows us to
better ‘‘assure that payment is made
only for a drug or biological * * * if the
drug or biological has been
administered to a beneficiary’’ since it
tracks the administration of a specific
dose of a drug, which allows CMS to
match the vendor and the physician
claim in the post pay review process.
However, we would appreciate
receiving other suggestions that would
allow drug administration verification
on a dose specific basis. Since we did
not make a specific proposal about this
E:\FR\FM\27NOR2.SGM
27NOR2
66270
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
issue, we will not make any changes at
this time to the requirement that the
CAP prescription order number be
supplied by the approved CAP vendor
and included on claims from both the
participating CAP physician and the
approved CAP vendor.
j. Prefilled Syringes
In the July 6, 2005 IFC (70 FR 39061),
we described public comments which
stated that participating CAP physicians
could not vouch for the quality of
products that were opened by an
approved CAP vendor for repackaging,
for mixing the drug with other drugs or
injectable fluids (admixture), or for
removing a part of the contents to
supply the exact dose for a beneficiary.
Several commenters recommended that
approved CAP vendors deliver their
products in the same form in which
they are received from the
manufacturer, without opening
packaging or containers, mixing or
reconstituting vials, or repackaging.
Specifically, the commenters were
concerned about the capabilities of
individuals who mix the drug, as well
as shipping conditions, storage, and
stability.
We responded by stating that the CAP
is not intended to require approved CAP
vendors to perform pharmacy admixture
services (for example, to furnish
reconstituted or otherwise mixed drugs
repackaged in IV bags, syringes, or other
containers that are ready to be
administered to a patient) when
furnishing CAP drugs. Admixture
services for injectable drugs require
specialized staff, training, and
equipment, and these services are
subject to standards such as United
States Pharmacopoeia Chapter 797,
Pharmaceutical Compounding—Sterile
Preparations. These requirements have
significant impact on drug shipping,
storage, and stability requirements, as
well as system cost and complexity. As
stated in § 414.906(a)(4), the approved
CAP vendor must deliver ‘‘CAP drugs
directly to the participating CAP
physician in unopened vials or other
original containers as supplied by the
manufacturer or from a distributor that
has acquired the products directly from
the manufacturer.’’
Since issuing the July 6, 2005 IFC, we
have become aware that bevacizumab
(Avastin) is being used for the
treatment of exudative age-related
macular degeneration (wet AMD) in
very small doses. Although this is an off
label use, it is gaining acceptance among
ophthalmologists who treat wet AMD,
and this use has been the subject of
several carriers’ local coverage
determinations. Bevacizumab is
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
considerably less expensive than certain
other drugs used in the treatment of wet
AMD.
The smallest commercially-available
package of bevacizumab is a 100mg
single use vial, while a dose used to
treat wet AMD is approximately 1mg.
Some local carriers who have issued
coverage instructions for the use of
bevacizumab in the treatment of wet
AMD allow physicians to obtain these
small doses of drug from a pharmacy
that is capable of preparing sterile
products. We expect to issue
instructions that will allow participating
CAP physicians to use the furnish as
written option, as appropriate, and to
obtain small doses of bevacizumab
outside of the CAP in prefilled syringes
if their local carrier’s coverage
determinations allow such a practice
and if it is consistent with applicable
laws and regulations. We believe that
this approach will minimize the waste
associated with using a 100mg single
use vial for the treatment of wet AMD
and will increase the flexibility for
participating CAP physicians by making
an alternative quantity of this drug
available to participating CAP
physicians whose carriers have
applicable policies.
However, this option is not available
in all areas. Therefore, we stated that we
are considering reassessing our policy
on the use of prefilled syringes to
determine whether it would be feasible
to make the option of using prefilled
syringes supplied by an approved CAP
vendor available to all physicians who
participate in the CAP, rather than
requiring physicians to go outside the
CAP in order to obtain CAP drugs in
prefilled syringes. In the CY 2008 PFS
proposed rule (72 FR 38159), we
requested comments on whether
allowing approved CAP vendors to
repackage CAP drugs in certain
situations may be beneficial to
beneficiaries, the program, and to the
physicians who participate in it.
In considering whether to propose a
change to our regulations in the future,
we also solicited comments on:
• Whether approved CAP vendors are
likely to be pharmacies or have access
to pharmacy services with trained
personnel and facilities for the small
scale preparation of sterile drug
products in response to a specific
prescription order for a specific patient;
• Whether an approved CAP vendor
should be given an opportunity to
supply bevacizumab under the CAP if it
is repackaged in a patient-specific dose
consistent with applicable state laws
and regulations upon request from a
participating CAP physician;
PO 00000
Frm 00050
Fmt 4701
Sfmt 4700
• Whether this sort of activity should
be restricted to bevacizumab, or
possibly phased-in for other CAP drugs.
If we were to apply this sort of policy
to other CAP drugs, we would also have
to determine how phasing-in might
occur, which drugs it should apply to
and whether the preparation of
admixtures (including the preparation
of sterile syringes, minibags, and mixing
of drugs and solutions intended for
intravenous administration) should be
allowed as well;
• How this sort of service could be
limited to participating CAP physicians
who voluntarily agree to use it, and
whether such an agreement should be
made in writing between the approved
CAP vendor and the participating CAP
physician;
• How such a program could be
structured so that the service and staff
engaged in providing the service would
be required to meet all applicable laws
(including Stark, Anti-kickback, and
State pharmacy laws), as well as
regulations for the preparation of sterile
products, (including standards for
product integrity and sterility);
• Whether the cost of preparing such
product would be included in the CAP
vendor’s bid price; and
• Whether any other important
elements should be evaluated if we
consider changing CAP policy on
prefilled syringes in the future.
Comment: We received several
comments on these issues. Overall,
responses were generally equally
divided among those who supported
prefilled syringes, those who advocated
a cautious approach, and those who
opposed the practice.
Those who opposed making prefilled
syringes available through the CAP cited
stability and sterility concerns. Those
commenters also raised concerns about
whether the CAP vendor’s preparation
of a particular drug product for an offlabel use by participating CAP
physicians would violate existing drug
law because of the potential scale of an
approved CAP vendor’s activities and
because the drug was being prepared for
use in a manner other than as described
in its FDA-approved labeling. Several
commenters urged that caution be used
in developing changes to the aspects of
the CAP that are discussed above in this
section, but many of these commenters
were not completely opposed to the
preparation of prefilled syringes by
approved CAP vendors.
Several commenters were quite
supportive of using prefilled syringes.
One commenter stated that pharmacy
preparation of prefilled syringes was
regarded as a ‘‘convenient and safe
practice’’ and would avoid both waste
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
and some of the risk associated with
transferring sterile products. Another
commenter also recommended that a
mechanism to pay for the preparation
and waste associated with the process
be established.
There was a general point of
agreement between commenters who
urged a cautious approach and those
who agreed with the concept of prefilled
syringes. These commenters agreed that
that additional flexibility or
enhancements to the CAP would be
welcome provided that they did not
affect beneficiary safety and were
consistent with applicable laws,
regulations, product stability, and
product integrity requirements.
Response: We appreciate the
comments on prefilled syringes and we
will consider whether to develop a
proposal that is consistent with
applicable laws, regulations, product
stability, and product integrity concerns
in future rulemaking. Because we did
not propose a change to our current
regulations on the use of prefilled
syringes in the CAP, they remain
unchanged for the present time. We may
make a proposal in the future.
cprice-sewell on PROD1PC72 with RULES
k. Contractual Provisions
Section 1847B of the Act is generally
silent on the subject of disputes
surrounding the delivery of drugs and
the denial of drug claims. However,
section 1847B(b)(2)(A)(ii)(II) of the Act
states that a grievance process is a
quality and service requirement
expected of approved CAP vendors. In
the July 6, 2005 IFC (70 FR 39055
through 39058), we described the
process for the resolution of approved
CAP vendors’ claims denials and the
resolution of participating CAP
physicians’ drug quality and service
complaints. We encouraged
participating CAP physicians,
beneficiaries, approved CAP vendors,
and the designated carrier to use
informal communication as a first step
to resolve service-related administration
issues. However, we recognized that
certain disputes would require a more
structured approach, and therefore, we
established processes under § 414.916
and § 414.917.
Suspension and termination from the
CAP were the only remedies described
under the CAP dispute resolution
processes. Having gained some
experience with the CAP, we believe
that having an intermediate level of
remedy for less serious but persistent
problems is desirable in order to bridge
the gap between taking no action and
suspension or termination of an
approved CAP vendor.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
We believe that additional contractual
obligations, such as additional reporting
requirements, could be useful,
particularly if they provide an
opportunity for the approved CAP
vendor to come into compliance using
objective goals and a set timeline.
Therefore, in the CY 2008 PFS proposed
rule (72 FR 38160), we requested
comments on what types of potential
contractual provisions could be used to
encourage approved CAP vendors to
comply with CAP requirements for less
serious violations, such as missing
reporting deadlines, or participation in
inappropriate promotional strategies.
We also requested comments on the
following:
• The type of contractual provisions
that would be suitable. For example,
requests for specific or targeted
reporting and monitoring activities in
response to specific violations.
• Whether an approved CAP vendor’s
code of conduct could be used to
address these types of less serious
situations and how that could be
accomplished; and
• Whether the CAP physician
election agreement should be revised to
include provisions to address
participating CAP physicians’
noncompliance with CAP rules or the
CAP election agreement.
Comment: One commenter agreed
with the use of contractual provisions,
including additional reporting
requirements, as an intermediate form of
remedy in response to a CAP vendor’s
noncompliance with CAP requirements.
The commenter also noted that a vendor
code of conduct would be useful.
Response: We plan to develop a
proposal for additional provisions that
could be added to the CAP contract.
These provisions would be used to
encourage approved CAP vendors to
comply with CAP requirements. We will
propose such provisions in a future
rulemaking period.
l. Finalizing Remaining Provisions of
the July 6, 2005 Interim Final Rule with
Comment Period
In this PFS final rule with comment,
we are finalizing the portions of the July
6, 2005 IFC that were not finalized in
previous rulemaking. We are also
responding to other timely comments
we received on the July 6, 2005 IFC that
we have not responded to previously.
Comments that we will be addressing
in this rule include the following:
• The use of e-prescribing in CAP.
• Updating CAP prices and data
reporting.
• The application of Comprehensive
Error Rate Testing (CERT) to CAP
claims.
PO 00000
Frm 00051
Fmt 4701
Sfmt 4700
66271
• The 14-day participating CAP
physician billing requirement.
• The impact of CAP participation on
clinical research.
• Licensure requirements for CAP
pharmacies and distributors.
• Community mental health centers
and participation in the CAP.
• Administrative and financial
burden of CAP participation for
physicians.
We have addressed drug
transportation previously in this section
of this final rule with comment period.
Basis and Scope (§ 414.900)
These provisions provide that the
regulations in this subpart implement
sections 1847A and 1847B of the Act.
We received no comments on these
provisions and we are finalizing the
corresponding regulatory text at
§ 414.900 in its entirety.
Definitions (§ 414.902)
Section 414.902 lists the definitions
used in 42 CFR Subpart K. We did not
receive any comments about the
revisions to this section that we made in
the July 6, 2005 IFC (70 FR 39093). At
this time, we are finalizing the
regulatory text at § 414.902 as it
currently reads.
Competitive Acquisition Program as the
Basis for Payment (§ 414.906)
Section 414.906 specifies how
payment for CAP drugs is determined,
including vendor responsibilities for
billing, shipment and delivery;
computation of the payment amount;
substitution of CAP drugs and resupply
of a participating CAP physician’s drug
inventory.
i. 2005 Comments
In the July 6, 2005 IFC (70 FR 39074),
we discussed the methodology used to
update CAP drug prices during the
bidding process. We responded to
comments that suggested that single
price updates for CAP drugs should be
tied to changes in ASP prices. We stated
that we did not believe that there had
been enough experience with the ASP
payment methodology to update the
bids based on growth in the ASP. We
also solicited comments on this method
of updating single drug prices to the
payment year in order to develop and
refine the CAP in the future.
(a) Updating CAP Prices and Data
Submission
Comment: We received comments
about updating CAP drug prices more
frequently than annually. One
commenter suggested that we should
consider quarterly data submissions and
E:\FR\FM\27NOR2.SGM
27NOR2
66272
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
pricing updates even during the phase
in period in order to produce greater
savings in instances where vendors’
overall costs for CAP drugs were
declining, while providing greater
protection for vendors in instances
where vendors were experiencing cost
increases. Another commenter
encouraged us to compare CAP prices to
ASP prices using the most recent data
available and to account for
manufacturer price adjustments in a
timely manner.
Response: In the July 6, 2005 IFC (70
FR 39076), we stated, ‘‘when the
administrative mechanisms of the CAP
are operational and vendors have more
experience under the program, we will
consider whether more frequent
reporting (of reasonable net acquisition
costs) would be appropriate.’’ Section
414.914 requires that the CAP contract
must provide for the disclosure of the
approved CAP vendor’s reasonable, net
acquisition costs for a specified period
of time, not to exceed quarterly and
provide for appropriate adjustments as
described in § 414.906(c)(1). This
section describes the computation of an
annual update to the payment amount
and allows updates more often than
annually but no more often than
quarterly in any of the following cases:
introduction of new drugs; expiration of
a drug patent or availability of a generic
drug; material shortages that result in a
significant price increase for the drug;
and withdrawal of a drug from the
market. Also, the CAP payment amount
is limited by the weighted payment
amount established under section
1847A of the Act across all drugs for
which a composite bid is required in the
category, and limited by the payment
amount established under section
1847A of the Act for each other drug for
which the approved CAP vendor
submits a bid. It is not clear how the
commenter is proposing that we account
for changes in manufacturer’s price
adjustments in a more timely manner.
Because the CAP has been operational
for 15 months, we are still gaining
experience with the reporting and
update mechanisms already in place. At
present, we believe these processes are
sufficient to address the needs of the
CAP; however, as the program grows,
we may consider other options,
including more frequent price updates.
(b) Impact of CAP on Clinical Research
Comment: Some commenters stated
that they were concerned that CAP
participation would conflict with the
Medicare National Coverage Decision
(NCD) on Clinical Trials. Since the NCD
enables Medicare to reimburse
physicians for the current standard of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
care drugs that are administered to
beneficiaries in the control group of
clinical trial protocols, commenters
were concerned that physicians would
not be able to enroll Medicare
beneficiaries in clinical trials if drugs
required in the protocol were not on the
CAP drug list. In addition, some
commenters expressed their concern
that there was a lack of built in
oversight in CAP to ensure that vendors
would buy drugs directly from a
manufacturer or wholesaler. The
commenters were concerned that this
could result in the acquisition of
counterfeit product, and that as a result,
such products could infiltrate clinical
trials and compromise the results of
cancer clinical research that a CAP
physician might be participating in.
Response: As a result of an executive
memorandum issued by the President of
the United States in June 2000, we
instituted the NCD in September 2000
as explained in our ‘‘September 2000
Program Memorandum’’ on clinical
trials available at https://
www.cms.hhs.gov/ClinicalTrialPolicies/.
The NCD stipulates that Medicare will
provide payment for routine costs
associated with qualifying clinical trials
and for items or services needed to treat
complications arising from participation
in such trials. The NCD was revised in
July 2007 as outlined in CAG–00071R,
the ‘‘Decision Memorandum for the
Clinical Trial Policy,’’ which may be
found at https://www.cms.hhs.gov/mcd.
More information about the National
Coverage Decision on Clinical Trials can
be found on the CMS Web site at
https://www.cms.hhs.gov/
ClinicalTrialPolicies/ and through a
Medicare Learning Network article at
https://www.cms.hhs.gov/
MLNMattersArticles/.
We are very aware of the importance
of clinical trial research in the treatment
of cancer, and we do not believe that
CAP participation has imposed any
undue hardships on participating CAP
physicians or their Medicare patients
who engage in such activities.
Participating CAP physicians do not
have to buy and bill for the medications
they receive from the approved CAP
vendor. The vendor is responsible for
billing the designated carrier and the
beneficiary. Thus, if the standard of care
drug needed for the control group of a
research protocol is on the CAP drug
list, the participating CAP physician
may order the medication from the
approved CAP vendor. This should not
affect the participating CAP physician’s
ability to enroll Medicare patients in
clinical trials. Moreover, participating
CAP physicians may still purchase and
bill for medications that are not on the
PO 00000
Frm 00052
Fmt 4701
Sfmt 4700
CAP drug list through the ASP system,
which would allow them to obtain the
non-CAP drugs required in a research
protocol. If a particular NDC for a drug
is not on the CAP drug list but is part
of the research protocol, a participating
CAP physician may buy the medication
on their own and bill for it via the
‘‘furnish as written’’ provision, which
allows the physician to bill for the drug
under the ASP methodology in that
instance, even though it is on the CAP
drug list.
Though we have had no reports that
CAP physicians have been prevented
from engaging in clinical trial research
because of their CAP participation, we
are mindful that this could be an issue
because of the way some studies are
structured. In the event that we receive
comments that demonstrate that this has
become a problem in the future, we will
address the issues accordingly and
possibly propose mechanisms to
facilitate participation in clinical trial
research and the CAP.
We would also like to reemphasize
that CAP is a voluntary program. If
physicians do not believe that the
‘‘furnish as written’’ option and the CAP
drug list are sufficient to meet their
clinical research needs, then they may
decline to join the CAP and continue to
purchase and bill for medication under
the ASP system.
We also are cognizant of the
importance of preserving drug quality
and integrity in the CAP and have
structured the program accordingly. The
importance of drug quality and
oversight are recognized in both the
vendor bidding process and in the CAP
dispute resolution process administered
by the designated carrier. We have
discussed our concern for maintaining
CAP drug quality in the program as a
whole on several occasions, most
recently in the CY 2006 PFS final rule
with comment period (70 FR 70244).
Section 1847B of the Act and
§ 414.908(b) delineate several
requirements that vendors must meet in
order to be selected to participate in the
CAP, including an ability to ensure
product integrity, at least 3 years
experience in furnishing Part B
Injectable drugs, and acquisition of all
CAP drugs directly from the
manufacturer or from the distributor
that has acquired the products directly
from the manufacturers. After an entity
has been awarded a contract, we work
closely with the CAP-designated carrier
and the approved CAP vendor to
monitor and respond to any concerns
that are raised by participating CAP
physicians under the dispute resolution
process.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
We have not received any complaints
regarding CAP drug quality and
integrity. If such an event were to occur,
it would be investigated and resolved
promptly so that patient health and
safety would not be jeopardized. In light
of all of these requirements and
protections, we do not believe that
research and CAP participation are
incompatible.
At this time, we are finalizing the
remaining provisions of this section.
Competitive Acquisition Program
(§ 414.908)
This section specifies the process for
a physician to select an approved CAP
vendor. It also details the
responsibilities of a participating CAP
physician, such as including the
specific information required on the
prescription order, notifying the CAP
vendor about changes in drug
administration, and adhering to the
timeframe for submission of claims.
Moreover, § 414.908 delineates the
process for selecting approved CAP
vendors. It also outlines additional
factors that are considered both during
and after the vendor selection process
such as exclusion of entities from
participation in Medicare or other
Federal health care programs under
section 1128 of the Act.
i. 2005 Comments
cprice-sewell on PROD1PC72 with RULES
(a) Physician Administrative and
Financial Burden
Comment: We received several
comments from individual physicians
and physician groups expressing their
concern that CAP could place a
significant burden on physicians. Some
commenters stated that the requirement
to maintain a separate inventory of CAP
drugs will increase physicians’
administrative burden and costs. Others
indicated that physicians would have
no incentive to participate in the CAP
unless these extra administrative costs
could be reimbursed. One commenter
indicated that the program was
impractical and economically
unfeasible.
Response: In the July 6, 2005 IFC (70
FR 39049), we discussed the issue of
administrative burden. Although we
agree that a physician may have to make
some adjustments in his or her practice
in order to comply with the
requirements of the CAP, we believe
that the relief from the financial burden
of purchasing drugs and billing
Medicare for them will be a substantial
benefit for many physicians. We do not
believe that the clerical and inventory
resources associated with participation
in the CAP exceed the clerical and
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
inventory resources associated with
buying and billing drugs under the ASP
system. A physician is free to design his
or her practice in a way that minimizes
the extent of changes necessary to
comply with the CAP requirements. For
example, an electronic inventory of CAP
drugs is required, but separate drug
storage is not; it is a suggested option if
such a procedure makes it easier on the
physician’s practice to track the CAP
drugs. We recognize that although a
physician’s staff or their software
vendor may need to make system
changes to bill using the CAP format
and to accommodate the CAP modifiers
and prescription numbers, these initial
changes would be a one-time
occurrence.
In the ASP system, the payment for
clerical and inventory resources
associated with buying and billing for
drugs is bundled into the drug
administration payment under the
physician fee schedule. We have
adopted this same logic in the CAP and
believe that the drug administration
payment is sufficient to cover any
associated expenses of participating in
the CAP.
If a physician perceives that CAP
participation would be more
burdensome than the ASP system, then
he or she is under no obligation to join
the CAP because it is a voluntary
program. Additionally, as described in
other parts of this rule, participating
CAP physicians may also petition to
terminate their CAP election due to
exigent circumstances through the
dispute resolution process in the event
that they find the participation in the
program becomes a burden.
Comment: One commenter expressed
disappointment that community mental
health centers (CMHCs) cannot elect to
participate in the CAP.
Response: As noted in the July 6, 2005
IFC (70 FR 39030), CMHCs can not elect
to participate in the CAP for provision
of Part B drugs. The CAP statute is clear
that only physicians may elect to have
section 1847B of the Act apply in lieu
of the ASP payment methodology.
(b) E-Prescribing
Comment: One commenter
recommended that CAP vendors should
be capable of accepting and submitting
e-prescribing transactions in accordance
with the final e-prescribing standards
issued for Medicare Part D. The
commenter reasoned that vendor
compliance would not be an undue
hardship because vendors already will
have a fairly rigorous technical
infrastructure in place.
Response: Section 101 of the MMA
amended title XVIII of the Act to
establish a voluntary prescription drug
PO 00000
Frm 00053
Fmt 4701
Sfmt 4700
66273
benefit program. The MMA electronic
prescription program provisions found
in section 1860D–4(e) of the Act apply
to the electronic transmission of
prescription and certain prescriptionrelated information for Medicare Part D
drugs for Part D eligible individuals.
The Part D e-prescribing requirements
do not apply to the electronic
transmission of prescriptions and
prescription related information for Part
B drugs unless those prescriptions are
written for Part D eligible persons and
the prescribed drug is a Part D drug.
Prescription Drug Plan (PDP) sponsors
Medicare Advantage (MA) organizations
offering Medicare AdvantagePrescription Drug Plans (MA–PD) are
required to establish electronic
prescription drug programs to provide
for electronic transmittal of certain
information to the prescribing provider
and dispensing pharmacy and
pharmacist. Prescribers and dispensers
of Part D drugs are not required to write
prescriptions electronically, but those
that do so would be required to comply
with any applicable final e-prescribing
standards that are in effect when they
conduct electronic prescription
transactions, or seek or transmit
prescription information or certain other
related information electronically.
We responded to a comment on
whether participating physicians would
be required to incorporate e-prescribing
technologies into the CAP in the July 6,
2005 IFC (70 FR 39039). At that time,
we stated that we would monitor the
development of the program to see if
some aspects of it could be adapted to
the CAP. Since publication of the IFC,
we have adopted three foundation
standards (70 FR 67568), recognized six
initial standards in a Request for
Applications (RFA) (Available through
https://www.grants.nih.gov/grants/guide/
rfa-files/FRA-HS-06-001.htm), and
conducted a pilot program in 2006 to
test the six initial standards and their
ability to interoperate with the
foundation standards. More information
about the MMA e-prescribing program
and the outcome of the pilots can be
found on the CMS Web site at https://
www.cms.hhs.gov/EPrescribing/. The
MMA requires the adoption of
additional standards by the Secretary by
April 1, 2008. We will continue to track
the development of the e-prescribing
program to see whether it would be
appropriate to incorporate some of the
program’s elements into the CAP at a
later date.
E:\FR\FM\27NOR2.SGM
27NOR2
66274
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(c) The Comprehensive Error Rate
Testing (CERT) Program and CAP
Claims
The purpose of the CERT program is
to monitor and report the accuracy of
Medicare fee for service payments. In
the July 6, 2005 IFC (70 FR 39038), we
discussed CERT and how it would
apply to CAP claims. While we
anticipated that CERT would apply to
CAP, the process had not been
determined at that point. We received
no additional comments on this issue
and have implemented CERT review of
CAP claims since publication of the July
6, 2005 IFC. CAP claims paid by the
designated carrier may be selected for
review in a manner consistent with
other claims the carrier processes.
cprice-sewell on PROD1PC72 with RULES
(d) 14-Day Billing Requirement
In the July 6, 2006 IFC (70 FR 39050),
we summarized and responded to
comments about the 14-day requirement
for physicians to file claims for CAP
drug administration. Although a number
of commenters considered the time
period to be too brief and were opposed
to it, we decided to implement the 14day requirement at § 414.908(a)(3)(x)
because the approved CAP vendor’s
payment for drugs furnished under the
CAP depended on a match between the
vendor’s drug claim and the physician’s
drug administration claim.
Implementation of the post-payment
review as mandated by section 108 of
the MIEA–TRHCA has superseded our
original implementation of CAP claims
processing procedures, which had
required a pre-payment claims matching
process for CAP drug claims, and the
14-day billing requirement was not
finalized in previous rules (70 FR
70260).
Comment: In 2006 several
commenters asked us to allow at least
30 days or more for physicians to
submit CAP drug administration claims.
During this comment period, we also
received several comments stating that
the 14-day requirement be withdrawn
because changes to the claims
processing system made it unnecessary
and such an action would encourage
physician participation in the CAP.
Response: Our 14-day standard was
based on a review of Medicare claims
that showed approximately 75 percent
of part B drug and drug administration
claims were submitted within 14 days of
the date of service. It was initially
implemented as a means of facilitating
the CAP claims matching process that
was in effect prior to the
implementation of the post-payment
review process as mandated by section
108 of the MIEA TRHCA. As the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
commenters indicated, a 14-day
requirement is less than is allowed
under claim submission requirements
used in other parts of the program.
We agree that the claims processing
changes required by Section 108 of
MIEA–TRHCA have altered the role of
the claims submission standard.
However, we do not believe that it has
eliminated the need for a claimsmatching process under the CAP. Under
the new payment process that resulted
from the MIEA–TRHCA, the CAPdesignated carrier also conducts a prepayment review in which it checks for
any local carrier decisions about
medical necessity prior to paying for
drug claims submitted by the approved
CAP vendor. Retaining a claims
submission requirement for
participating CAP physician drug
administration claims may prevent the
agency from paying for drugs that have
been denied on a medical necessity
basis by the local carrier because when
the local carrier reviews the physician’s
claim it makes a determination on
whether the CAP drug that was
administered was medically necessary.
We are not eliminating the requirement
for prompt billing altogether, as
requested by commenters, because it
will continue to facilitate a quicker
determination that the drug can be
administered.
However, we acknowledge that a
somewhat longer claims submission
standard would not adversely affect the
post-payment review process because it
still would allow for a relatively quick
match between the claim for a particular
dose of a CAP drug and the claim for its
administration. Also, separate analyses
of previous claims submission data and
CAP drug claims lead us to conclude
that the overwhelming majority of
participating CAP drug administration
claims are submitted within 30 days of
the date of service. We further believe
that, in light of the comments,
increasing the 14-day claims submission
requirement would make the CAP more
appealing to physicians and provide
them with greater claims submission
flexibility.
Therefore, we are increasing the
requirement for timely CAP drug
administration claim submission from
14 days to 30 days. We are finalizing the
requirements at § 414.908 to include
this revision.
ii. Regulatory Text
At this time, we are finalizing
§ 414.908 as amended to reflect the
changes discussed in this final rule with
comment period.
PO 00000
Frm 00054
Fmt 4701
Sfmt 4700
The Bidding Process (§ 414.910)
This section outlines the specific
criteria for the submission of a bidding
price for a CAP drug, and specifies what
costs should be included in the bid
price. We received no comments on this
provision and are now finalizing the
regulatory text for § 414.910.
Conflicts of Interest (§ 414.912)
Section 414.912 states conflict of
interest requirements and standards that
vendor applicants and approved CAP
vendors must meet in order to
participate in CAP. We received no
comments on this provision, and
therefore, are finalizing § 414.912.
Terms of Contract (§ 414.914)
Section 414.914 outlines the contract
provisions between CMS and the
approved CAP vendor such as contract
length and termination, and specific
requirements that the approved CAP
vendor must comply with.
i. 2005 Comments
(a) Licensure Requirements for Cap
Pharmacies and Distributors
Comment: Some commenters
requested clarification on the types of
licenses that are required of CAP
vendors. A few commenters also asked
us to specify whether a CAP vendor will
be operating as a pharmacy or as a
wholesale distributor since licensing
requirements and regulatory laws for
these two types of entities can vary by
state, and since pharmacies and
distributors are two different models.
Response: As specified in § 414.914,
approved CAP vendors and their
subcontractors must meet applicable
licensure requirements in each State in
which it supplies drugs under the CAP.
This includes appropriate licensure in
States that the CAP vendor ships drug
to even though the vendor does not
maintain a physical establishment in
these States. In the July 6, 2005 IFC (70
FR 39066), we stated that a vendor, its
subcontractor, or both must be licensed
appropriately by each State to conduct
its operations under the CAP. Therefore,
a vendor under the CAP would be
required to be licensed as a pharmacy,
as well as a distributor if a State requires
it. It is the CAP vendor’s responsibility
to determine which State and national
requirements it must adhere to. Based
on our experience with the CAP, we are
not persuaded by the comments that any
changes to this policy are necessary at
this time.
ii. Regulatory Text
We finalized portions of § 414.914 in
the CY 2006 PFS final rule with
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
comment period (70 FR 70333) and are
now finalizing the remainder of the
regulatory text.
Dispute Resolution for Vendors and
Beneficiaries (§ 414.916)
This section discusses the steps,
timeframes, and requirements of the
dispute resolution process that are
available to an approved CAP vendor
and beneficiaries to address the issue of
denied CAP drug claims. It also
describes the protocol that physicians
would utilize to appeal the suspension
of their CAP contract.
We did not receive any comment on
this comments on this provision in
response to the CY 2006 PFS proposed
rule. However, a revision to this section
will be made in light of the exigent
circumstance discussion in section (g) of
this section of the preamble. We are
revising § 414.916(c) to clarify that the
physician reconsideration process
would apply to reconsiderations of our
decision on whether the participating
CAP physician may opt out of the CAP.
We are finalizing § 414.916 at this time.
Dispute Resolution and Process for
Suspension or Termination of Approved
CAP Contract (§ 414.917)
This section discusses the steps and
timeframes of the process available to
participating CAP physicians for the
resolution of quality or service issues
concerning an approved CAP vendor.
We did not receive any comments on
this section during the comment period
for the July 6, 2005 IFC. Comments that
we received on this section during the
comment period for the CY 2008 PFS
proposed rule are discussed above in
this section. We are now finalizing the
regulatory text for this section as
described in this final rule with
comment period.
Assignment (§ 414.918)
Section 414.918 specifies that
payment for a competitively biddable
drug may be made only on an
assignment related basis. We received
no comments on this provision and are
now finalizing § 414.918.
Judicial Review (§ 414.920)
cprice-sewell on PROD1PC72 with RULES
Section 414.920 outlines the areas
under the CAP that are not subject to
administrative or judicial review. We
received no comments on this provision
and are now finalizing this section.
m. Brief Summary of Comments We Are
Not Addressing
In response to the FY 2007 IPPS final
rule with comment period (71 FR
47870), we received a comment related
to the payment rate for intravenous
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
immunoglobulin (IVIG) therapy in
Medicare. We will not be addressing
this comment since it is outside the
scope of both the CY 2008 PFS proposed
rule and the FY 2007 IPPS final rule
with comment period. In addition, in
response to the CY 2007 PFS proposed
rule, one commenter recommended that
we implement continuous open
enrollment in the CAP and eliminate the
requirement for annual physician
election, and specify who are the
appropriate people to sign the CAP
election form. We are not addressing
these comments because it is outside the
scope of the proposed rule.
G. Issues Related to the Clinical
Laboratory Fee Schedule
1. Date of Service for the Technical
Component of Physician Pathology
Services (§ 414.510)
In the CY 2007 PFS final rule with
comment period (72 FR 69787), we
added § 414.510 for the date of service
of a clinical diagnostic laboratory test
that uses a stored specimen.
When we added § 414.510, we
indicated the provision applies to
clinical diagnostic laboratory tests. For
outpatients, clinical diagnostic
laboratory tests are paid under the
Medicare Part B clinical laboratory fee
schedule. Upon further review, we
believe the provision should also apply
to the technical component (TC) of
physician pathology services. In
practice, the collection date for both
clinical laboratory services and the TC
of physician pathology services is
similar. Therefore, we believe § 414.510
should apply to both types of services.
This will improve claims processing
and adjudication in relation to the
clarity of dates of service, accuracy of
payment, and detection of duplicate
services. For outpatients, the TC of
physician pathology services can be
paid under the Physician Fee Schedule
(PFS) or the hospital Outpatient
prospective payment system (OPPS). As
a result, for § 414.510, in the CY 2008
PFS proposed rule (72 FR 38160), we
proposed to revise the section heading
and introductory sentence to specify
that the provision applies to both
clinical laboratory and pathology
specimens. We also proposed revising
§ 415.130(d) to include a reference to
§ 414.510.
Comment: Some commenters
supported our proposal to revise the
section heading and introductory
sentence for § 414.510 to specify that the
provision applies to both clinical
laboratory and pathology specimens.
(We also proposed revising § 415.130(d)
to include a reference to § 414.510.) One
PO 00000
Frm 00055
Fmt 4701
Sfmt 4700
66275
commenter asked that we clarify
whether the provision applies to
pathology tests where the technical
component and the professional
component (PC) are performed by the
same lab and billed globally.
Response: Concerning one line global
billing, we would like to point out that
the TC and the PC of a laboratory test
should be on separate line items on the
same claim when two different dates of
service are involved, even when both
services are performed by the same
independent laboratory. One line global
billing is not appropriate in this
instance. Program instructions on this
issue will be forthcoming.
Comment: One commenter requested
revisions to our regulations to specify
that if the clinical laboratory test
specimen is collected outside the
hospital by nonhospital personnel, the
beneficiary qualifies as a nonhospital
patient.
Response: We do recognize that the
determination of whether the
beneficiary qualifies as an inpatient,
outpatient, or nonpatient is important
for payment purposes. However, we do
not agree that the laboratory date of
service regulation should be amended to
address the employment arrangements
of the personnel performing the
specimen collection. Furthermore, this
comment is outside the scope of our
proposal to broaden the clinical
laboratory date of service rules we
adopted last year.
We continue to believe the date of
service should relate to clear calendar
dates for the specimen collection and
day of discharge from the hospital if the
specimen was collected while the
patient was undergoing a hospital
procedure.
We are implementing our proposed
regulation at § 414.510 on the date of
service of the TC of the physician
pathology service.
2. New Clinical Diagnostic Laboratory
Test (§ 414.508)
a. Background
In the CY 2007 PFS final rule with
comment period (71 FR 69701), we
adopted a new subpart G under part 414
that implemented section 942(b) of the
MMA requiring that we establish
procedures for determining the basis for,
and amount of payment for any clinical
diagnostic laboratory test for which a
new or substantially revised HCPCS
code is assigned on or after January 1,
2005 (‘‘new tests’’).
Under § 414.508, we use one of two
bases for payment to establish a
payment amount for a new test. Under
§ 414.508(a), the first basis, called
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66276
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
‘‘crosswalking,’’ is used if a new test is
determined to be comparable to an
existing test, multiple existing test
codes, or a portion of an existing test
code. If we use crosswalking, we assign
to the new test code the local fee
schedule amount and national
limitation amount (NLA) of the existing
test code or codes. If we crosswalk to
multiple existing test codes, we
determine the local fee schedule amount
and NLA based on a blend of payment
amounts for the existing test codes. The
second basis for payment is
‘‘gapfilling.’’ Under § 414.508(b), we use
gapfilling when no comparable existing
test is available. We instruct each
Medicare carrier or MAC to determine a
carrier-specific amount for use in the 1st
year that the new code is effective. The
sources of information that these
carriers or MACs examine in
determining carrier-specific amounts
include:
• Charges for the test and routine
discounts to charges;
• Resources required to perform the
test;
• Payment amounts determined by
other payers; and
• Charges, payment amounts, and
resources required for other tests that
may be comparable (although not
similar enough to justify crosswalking)
or otherwise relevant.
After the first year, the carrier-specific
amounts are used to calculate the NLA
for subsequent years. Under
§ 414.508(b)(2), the test code is paid at
the NLA, rather than the lesser of the
NLA and the carrier-specific amounts.
We instruct our carriers or MACs to
use the gapfill method through program
instruction, which lists the specific new
test code and the timeframes to establish
carrier-specific amounts. During the first
year a new test code is paid using the
gapfill method, contractors are required
to establish carrier-specific amounts on
or before March 31. Contractors may
revise their payment amounts, if
necessary, on or before September 1. In
this manner, a carrier or MAC may
revise its carrier-specific amount based
on additional information during the 1st
year.
In the CY 2007 PFS final rule with
comment period (71 FR 69702), we also
described the timeframes for
determining the amount of and basis for
payment for new tests. The codes to be
included in the upcoming year’s fee
schedule (effective January 1) are
available as early as May. We then list
the new clinical laboratory test codes on
our Web site, usually in June, along
with registration information for the
public meeting.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
The public meeting is held no sooner
than 30 days after we announce the
meeting in the Federal Register. The
public meeting is typically held in July.
In September, we post our proposed
determination of the basis for payment
for each new code and seek public
comment on these proposed
determinations of the basis for payment.
The updated clinical laboratory fee
schedule is prepared in October for
release to our contractors during the
first week in November so that the
updated clinical laboratory fee schedule
is ready to pay claims effective January
1 of the following calendar year.
We received comments in response to
the CY 2007 PFS proposed rule
concerning information to be presented
during the public meeting process. In
responding to these comments in the CY
2007 PFS final rule, we stated that we
did not believe that opportunities for
information gathering on new tests have
been fully utilized within the public
meeting process. Payment
recommendations from the public have
sometimes lacked charge, cost, and
clinically-detailed information for the
new clinical laboratory tests. We also
stated that when soliciting public input
for the meeting we would recommend
that all participants in the public
meeting consultation process strive for
transparency and try to provide as much
supporting information as possible to
assist us in evaluating their
recommendations.
In addition, in the CY 2007 PFS final
rule with comment period, in response
to comments suggesting that the method
used by contractors to determine their
price for gapfilled tests should be more
specific, we indicated that we would
engage in discussions with our carrier
contractors and laboratory industry
representatives to explore their
experiences with the gapfill process. We
also agreed to host a forum to listen to
suggestions from the public and said
that we expected to solicit comments on
a potential reconsideration process in a
future rulemaking.
As explained in the CY 2008 PFS
proposed rule, we discussed these
issues with our contractors. We also
solicited comments on the gapfill
process in the July 16, 2007 clinical
laboratory public meeting.
Discussions with our contractors and
other interested parties revealed that the
length of time we allow for a contractor
to establish a carrier-specific amount
may sometimes be insufficient for
obtaining additional sources and data
on a new test. However, our contractors
and other interested parties were also
concerned that if procedures and
determinations were permitted to
PO 00000
Frm 00056
Fmt 4701
Sfmt 4700
extend over too long a time frame, the
uncertainty of the final payment amount
would be detrimental for laboratories,
practitioners, and patients for
incorporating new technology tests and
improving patient care. In the CY 2008
PFS proposed rule, we also encouraged
the public to submit written comments
on gapfilling and said that we would
respond to them to the extent they
related to a proposal in the rule.
In the CY 2008 PFS proposed rule, we
proposed a reconsideration process for
determining the basis for and amount of
payment for any new test for which a
new or substantially revised HCPCS
code is assigned on or after January 1,
2008. This proposed change attempted
to balance additional opportunities for
public input against the necessity for
establishing final fees for new clinical
laboratory test codes.
Section 1833(h)(8)(A) of the Act
provides broad authority to develop
through regulation procedures for the
method for determining the basis for
and amount of payment for new tests.
We believe that we have authority under
section 1833(h)(8)(A) of the Act to
establish procedures under which we
may reconsider the basis for and amount
of payment for a new test. Furthermore,
under section 1833(h)(8)(D) of the Act,
the Secretary may convene such other
public meetings to receive public
comments on payment amounts for new
tests as the Secretary deems appropriate.
We note that, under both section
1833(h)(8)(B)(v) of the Act and
§ 414.506(d)(2), the Secretary must make
available to the public a list of ‘‘final
determinations.’’ We do not believe that
these provisions preclude us from
reconsidering our final determinations.
It is not unusual for us to provide for
discretionary reopening or
reconsideration of final agency action. It
is not unusual for us to provide for
discretionary reopening or
reconsideration of final agency action.
For example, under § 405.1885, we may
reopen a final agency determination
regarding payment to a provider of
services.
Comment: Commenters were
supportive of our proposal to add
§ 414.509 concerning a reconsideration
process for new lab test payment
determinations. Generally, commenters
believed that in contrast to several other
payment systems, which have been
significantly revised in the last several
years, the procedures for operating the
clinical laboratory fee schedule have
remained relatively static. They further
commented that the implementation of
a reconsideration process would be a
significant step in helping assure
reasonable pricing decisions for new
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
tests, and they commended us for our
actions in this regard.
Response: We appreciate the support
for our proposal for a reconsideration
process for new lab test payment
determinations. We believe this
additional opportunity to revisit
payment determinations for clinical
laboratory test codes will foster accurate
payment levels for new tests. We will
discuss specific suggestions for
revisions to § 414.509 below in this
section.
b. Basis for Payment
Under our existing procedures for
determining the basis for payment of a
new test, either to crosswalk or gapfill,
we receive comments on the appropriate
basis for payment for a new test both at
the public meeting in July and after we
announce our proposed determinations
in September. In November, we post our
determination on the basis for payment
for the new test on the CMS Web site.
This determination of the basis for
payment is final, except in the case of
a gapfilled test for which we later
determine that gapfilling is not
appropriate under § 414.508(b)(3).
In the CY 2008 PFS proposed rule, we
proposed to create a reconsideration
process for determinations of the basis,
either crosswalking or gapfilling, for
payment of a new clinical diagnostic
laboratory test. Consistent with our
existing process, we would make a
determination using the information
gathered from the public meeting
process and post a determination of the
basis for payment, either to crosswalk or
gapfill, on the CMS Web site, likely in
September. We would accept written
comments asking for a reconsideration
on this basis determination for 30 days
after we posted the determination on the
CMS Web site. If a commenter
recommended that we switch from
gapfilling to crosswalking for a new
code, the commenter would also have
the opportunity to recommend the code
or codes to which to crosswalk the new
test code. Under § 414.508, claims
would be paid using this basis to
calculate fees beginning January 1.
After considering the comments
received and the information from the
public meeting, we would post our
decision on our Web site as to whether
we elect to reconsider our determination
of the basis for payment. If we elect to
reconsider the basis for payment (that is,
whether to crosswalk or gapfill a test),
we would post our determination as to
whether we would change the basis for
payment on the CMS Web site. Our
decision regarding the basis for payment
would be final and not subject to further
reconsideration.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
If we change our prior determination
of the basis for payment, the new
determination would be effective on
January 1. We would not reopen or
otherwise reprocess claims with dates of
service prior to the effective date of the
revised determination.
We note that, under our proposed
reconsideration processes (for both the
basis for payment and amount of
payment) we would make two separate
decisions. First, we would decide
whether to reconsider our prior
determination. If we elect to reconsider
our prior determination, we would then
determine whether we should change
our prior determination.
Comment: One commenter suggested
that the agenda for the public meeting
should announce a list of requests
received by CMS to reconsider the basis
for and amount of payment for a new
clinical laboratory test, and the agenda
should invite comment, either written
or orally, on the requests. The
commenter stated that in this way, we
will receive views on the validity of the
requests for reconsideration. Another
commenter indicated that more than
one public meeting per year should be
hosted by CMS to discuss comments
under the reconsideration process, as
well as the payment determination
process.
Response: We are receptive to
suggestions on providing information
about the public meeting agenda. We do
not believe a revision to the regulatory
text at subpart of § 414.509(a) is
required in order to disseminate
information on our meetings. We
publish a public meeting notice in the
Federal Register to announce the
meeting. The notice includes many
details about the purpose and
registration process for the meeting and
also refers to additional Web site
information for the meeting. If we
receive a request to reconsider the basis
of payment for a new test within the 60day window after we post our basis of
payment on the CMS Web site, the
requestor could also request to present
his or her comment orally at the next
clinical laboratory public meeting. We
can include this information in the
meeting agenda that will be posted on
the CMS Web site. Members of the
public who are interested in addressing
a particular reconsideration request at
the laboratory public meeting can let us
know of their interest in doing so after
they review the reconsideration requests
that will be addressed at the laboratory
public meeting. In addition, we will
accept written comments on the
reconsideration request after the public
meeting. We will accept written
comments during the same time period
PO 00000
Frm 00057
Fmt 4701
Sfmt 4700
66277
we set for accepting other comments
after the clinical laboratory public
meeting—usually 2 weeks. We note that,
if the party that submitted the
reconsideration request does not choose
to present at the public meeting,
members of the public may not
comment on the reconsideration request
and we will not accept written
comments.
However, hosting more than one
public meeting per year is a timing issue
which is limited by the constraints of
the process. Currently, there is a limited
amount of time between the receipt of
the new test codes for the upcoming
year and the deadline to issue them via
CMS instruction; therefore, we cannot
accommodate two public meetings in a
year. As a result, we are finalizing
§ 414.509(a) with revisions to specify
that other commenters may speak about
reconsideration requests on the
laboratory public meeting agenda and
that we will accept written comments
on reconsideration requests addressed at
the public meeting.
c. Amount of Payment
i. Crosswalking
Under our existing procedures,
commenters recommend the code or
codes to which to crosswalk a new
clinical laboratory test both at the public
meeting in July and during the comment
period after we issue our proposed
determination in September. We
consider the appropriate basis for
payment and the amount of payment at
the same time. Therefore, commenters
that recommend crosswalking as the
basis for payment for a new test also
make recommendations concerning the
code or codes to which to crosswalk the
new test. In November, we post the code
or codes to which we will crosswalk the
test and the payment amount for the test
on the CMS Web site. This
determination is final.
In the CY 2008 PFS proposed rule (72
FR 38162), we proposed to create a
reconsideration process under which we
may reevaluate the code or codes and
their corresponding fees to which we
crosswalk a new test’s fees. We would
accept reconsideration requests and
written comments on the crosswalked
code or codes and the resulting amount
of payment for the new code for 60 days
after we posted the determination on the
CMS Web site, sometime in November.
In addition, we proposed that a
commenter who had submitted a
written comment within the 60-day
comment period would also be given
the opportunity to present its comment
at the public meeting. After considering
the comments received and the
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66278
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
information of the public meeting, we
would post our decision as to whether
we had elected to reconsider our
determination of the crosswalked code
or codes and the resulting amount of
payment on the CMS Web site. If we
elect to reconsider the amount of
payment and had determined that we
should revise the amount of payment,
we would post a new determination of
the code or codes to which we would
crosswalk the test on the CMS Web site.
We proposed that, after we posted our
determination of the code or codes to
which the test would be crosswalked on
the CMS Web site, we would pay claims
on the basis of this determination
beginning January 1. Our decision
regarding the amount of payment would
be final and not subject to further
reconsideration.
If we change our prior determination
of the amount of payment, the new
determination would be effective
January 1. We would not reopen or
otherwise reprocess claims with dates of
service prior to the effective date of the
revised determination.
As discussed in section II.G.2.b., we
may also change the basis for payment
for a new test as the result of
reconsideration. If we change the basis
for payment from gapfilling to
crosswalking, we would also determine
the code or codes to which we would
crosswalk the test. Because we believe
it is important to establish final
payment amounts within a reasonable
amount of time, we also proposed that
these determinations of crosswalked
payment amounts would not be subject
to reconsideration.
Comment: Some commenters
indicated that § 414.509(b)(1) should
establish payment amounts at the
national limitation amount (NLA) of the
tests to which the new tests are
crosswalked. The NLA should replace
carrier-specific amounts below the NLA
for new tests. The commenters believe
that if the amount of payment is lower
than the NLA in a carrier’s geographic
area, patient access to a new test will be
limited in the geographic area.
Response: In the CY 2008 PFS
proposed rule, we did not make policy
proposals regarding the level of
payment for crosswalked tests. Rather,
our policy proposals were limited to the
reconsideration process. Accordingly,
we believe that this comment is outside
of the scope of this rulemaking
Comment: One commenter suggested
that a similar reconsideration process
should also be available for existing
laboratory tests. The commenter pointed
out that the payment amounts
determined for certain laboratory tests
by one or another Medicare carrier or
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
MAC now differ from the payment
amounts determined for these same tests
by other Medicare contractors and from
the corresponding NLA.
Response: Section 1833(h)(1) of the
Act sets forth the calculation of the
payment amounts for test codes
included on the clinical laboratory fee
schedule to be the lower of the charge
submitted, the carrier-specific amount,
or the NLA. We believe changes to
payment amounts for tests that are not
‘‘new tests’’ under section 1833(h)(8)(A)
of the Act would require a statutory
change.
Comment: One commenter
recommended that CMS clarify how fee
schedule amounts below the NLA will
be adjusted as carriers are phased out
and their functions are moved to MACs.
Response: This comment is outside
the scope of our proposal. If necessary
we may address this comment in a
future program memorandum.
We are finalizing § 414.509(b)(1).
Consistent with the revisions we made
to § 414.509(a), we are revising
§ 414.509(b)(1) to provide that other
commenters may speak about
reconsideration requests on the lab
public meeting agenda and that we will
accept written comments on
reconsideration requests addressed at
the public meeting.
ii. Gapfilling
As discussed in this preamble and in
accordance with § 414.508(b), after we
determine that gapfilling will be the
basis for payment for a new clinical
diagnostic laboratory test, we instruct
our carriers or MACs to determine
carrier-specific gapfill amounts by April
1 and finalize carrier-specific amounts
by September 30. We include the
determinations of carrier-specific
amounts and the NLA for the new test
code in the clinical laboratory fee
schedule the following November when
we post our payment determinations on
the CMS Web site. Except in the case of
a gapfilled test for which we determine
that gapfilling was not appropriate
under § 414.508(b)(3), these
determinations are final.
We proposed to provide for a
reconsideration process for gapfilled
payment amounts. Under this process,
by April 30, we would post the carrierspecific amounts on the CMS Web site
at https://www.cms.hhs.gov/
ClinicalLabFeeSched/02_clinlab.asp.
Interested parties would submit
written comments to CMS (which we
would provide to the carriers for their
consideration) on the carrier-specific
amounts within 60 days from the date
of posting the carrier-specific amounts.
PO 00000
Frm 00058
Fmt 4701
Sfmt 4700
In the CY 2008 PFS proposed rule, we
stated that carriers or MACs would
finalize carrier-specific amounts by
September 30 and that we would set the
NLA at the median of the carrierspecific amounts, and we would post
the carrier-specific amounts and the
NLA on our Web site. In addition, we
stated that the public would have 60
days to submit a reconsideration
request.
We also proposed that if we elect to
act on the reconsideration request to
reconsider the carrier-specific amounts
and decide to revise our prior
determination, we would adjust the
NLA based on comments received. We
would post the revised NLA on the CMS
Web site and payment for the test would
be made at the NLA beginning January
1. This determination would be final
and not subject to further
reconsideration.
In addition we proposed that, if we
change the basis of payment from
crosswalking to gapfilling as the result
of a reconsideration, the new gapfilled
payment amount would be subject to
reconsideration under proposed
§ 414.509(b)(2). Unlike a crosswalked
test, the payment amount for a gapfilled
test is not established when we
determine the basis for payment because
it takes approximately 9 months for our
contractors to establish carrier-specific
amounts. Thus providing for
reconsideration of gapfilled payment
amounts would not lengthen the period
of time it would take to determine a
final payment amount.
We proposed to amend § 414.508(b)(3)
to provide that § 414.508(b)(3) applies to
new tests for which a new or
substantially revised HCPCS code
assigned on or before December 31,
2007. We proposed that the more
comprehensive reconsideration
procedures would apply to new or
substantially revised HCPCS codes
assigned after December 31, 2007.
Comment: One commenter suggested
that we should accept comments after
the carrier-specific amounts become
final, which is currently on September
30.
Response: We appreciate this
commenter’s input. We have decided to
revise the reconsideration process that
we proposed. Under the final policy we
are adopting in this final rule with
comment period, we will post interim
determinations of carrier-specific
amounts on the CMS Web site in April
and, for 60 days, we will accept written
comments that we will share with our
carriers and MACs. However, we will
not accept reconsideration requests on
the interim carrier-specific amounts. In
September, we will post final carrier-
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
specific amounts on the CMS Web site.
Interested parties may request
reconsideration of the final carrierspecific amounts within 30 days of
when we post the final carrier-specific
amounts on the CMS Web site. Based on
the written reconsideration requests
received, we would evaluate whether
we should reconsider the carrierspecific amounts and NLA.
If we elect to reconsider the carrierspecific amounts and the NLA, we will
process the request for reconsideration
between the end of the 30-day comment
period and the deadline for
dissemination of the information to the
Medicare carriers or MACs via CMS
instruction so that we can finalize our
determinations prior to January 1. A
request for reconsideration can be
denied or reconsidered for a different
payment amount.
If we elect not to reconsider the
carrier-specific amounts and the NLA,
we will post the carrier-specific
amounts and NLA on the CMS Web site
on or before January 1. These amounts
would be based on the carrier-specific
amounts and NLA we had posted in
September. Payment for the test would
be made at the NLA on January 1. This
determination would be final and not
subject to further reconsideration.
In addition, after the final test codes
and payment amounts are effective on
January 1, there is no reconsideration
process that occurs after that date.
Comment: One commenter suggested
that CMS provide a rationale for either
accepting or declining a reconsideration
after it is received and for deciding
whether to change a prior
determination.
Response: We do not plan to post a
rationale for our decision to accept or
decline a reconsideration request. This
is consistent with our policy in other
areas of the Medicare program when we
make a decision about whether to
reopen a previous decision.
Comment: One commenter suggested
that we should convene an expert
advisory committee, broadly
representative of the laboratory
industry, to advise CMS on pricing
along with standardizing the sources
and quality of charge and cost data.
Response: The purpose of the Clinical
Laboratory public meeting is to convene
industry experts and entertain
comments, both orally and in writing, as
well as any charge and cost data that is
available from the industry. In fact, we
specifically asked, via public notice,
those in the clinical laboratory industry
to provide charge and cost data related
to the agenda items at the annual public
meeting. We welcome any related
information that industry
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
representatives would like to provide
via the public meeting forum and during
the associated comment period.
Comment: There were specific
concerns raised by commenters
regarding varying payment amounts set
by carriers when the gapfilling basis is
utilized to determine payment amounts
for a new test code. These commenters
recommended that we establish formal
procedures for carriers or MACs to
apply when establishing payment
amounts, including a formal appeals
process. The commenters stated the
payment amounts should be calculated
using information on the following
factors, resources needed to perform the
test, staff expertise, time needed to
perform the test and the test’s potential
value. In addition, the commenters
suggested we should publish the gapfill
payment amounts determined by
carriers or MACs and an explanation of
the payment amounts.
Response: Although we appreciate the
comments on the establishment of
payment amounts for new clinical
laboratory test codes using the gapfill
basis and the suggested improvements
to the way we set rates, these comments
are outside the scope of this rulemaking.
In the CY 2008 PFS proposed rule, we
proposed policies and requested
comment regarding our proposed
reconsideration process. We made no
policy proposals with respect to the
methodology our contractors use to
establish gapfilled payment amounts.
However, in the interest of transparency
we will instruct carriers or MACs to
provide a rationale for their final carrierspecific amounts, which we will post on
our Web site.
Comment: One commenter suggested
that we should establish a temporary
NLA based on the carrier-specific
amounts posted on April 30 within the
first year of the gapfill process.
Response: We appreciate the
commenter’s suggestion; however, we
are concerned that establishing a
temporary NLA within a 3 month time
period is not possible due to our
substantial program requirements each
year. Currently, clinical laboratory fee
schedule payment rates are established
on a calendar year basis. During the year
preceding each January 1, an extensive
multi-step process is in place in order
to bring those payment rates to fruition.
Currently, that process does not allow
for additional ratesetting procedures.
d. Jurisdiction for Reconsideration
Decisions
In the CY 2008 PFS proposed rule (72
FR 38163), we proposed that
jurisdiction for reconsideration would
rest exclusively with the Secretary. A
PO 00000
Frm 00059
Fmt 4701
Sfmt 4700
66279
decision whether to reconsider a
determination would be committed to
the discretion of the Secretary.
Accordingly, a refusal to reconsider an
initial determination would not be
subject to administrative or judicial
review. We recognize that parties
dissatisfied with an initial
determination as to the amount of
payment for a particular claim for
laboratory services may appeal the
initial determination under part 405,
subpart I of our regulations. Under our
proposal, a party could challenge under
part 405, subpart I a determination
regarding the amount of payment for a
new test—regardless of whether the
amount of payment was established as
the result of a reconsideration—but a
party could not challenge a decision not
to reconsider.
Comment: One commenter stated that
comments should be allowed on the
final payment determination amounts.
Response: This comment appears to
request an extension of the
reconsideration process or a change in
the jurisdiction as proposed in
§ 414.509. The commenter did not
provide additional information on the
circumstances that would warrant an
extension of the reconsideration
process. Also, the comment did not
specify the length of time for an
extension or procedures for an
extension or change of jurisdiction. We
believe § 414.506 through § 414.509
permit adequate opportunities for
public participation in the process of
establishing a payment amount and
requesting a reconsideration. More than
2 years can elapse if all steps of these
reconsideration procedures are
necessary for the establishment of the
basis and payment for a new test code.
We do not agree that revisions to
§ 414.509(d) are warranted.
3. Technical Revisions
We also proposed technical revisions
to § 414.502, § 414.506, and § 414.508.
Under section 1833(h)(8)(A) of the Act,
the term ‘‘new tests’’ is defined as any
clinical diagnostic laboratory test for
which a new or substantially revised
HCPCS code is assigned on or after
January 1, 2005. However, our
regulations do not define the term ‘‘new
test.’’ Therefore, we proposed to define
the term ‘‘new test’’ under § 414.502
using the statutory definition. In
addition, under § 414.506 and § 414.508,
we proposed to replace references to
‘‘new clinical diagnostic laboratory test
that is assigned a new or substantially
revised code on or after January 1,
2005’’ with references to ‘‘new test.’’
Response: We received one
supportive comment on this subpart,
E:\FR\FM\27NOR2.SGM
27NOR2
66280
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
H. Revisions Related to Payment for
Renal Dialysis Services Furnished by
End-Stage Renal Disease (ESRD)
Facilities
In the CY 2008 PFS proposed rule (72
FR 38163), we outlined the proposed
updates to the case mix adjusted
composite rate payment system
established under section 1881(b)(12) of
the Act, added by section 623 of the
MMA. These included updates to the
drug add-on component of the
composite rate system, as well as the
wage index values used to adjust the
labor component of the composite rate.
Specifically, we proposed the
following provisions which are
described in more detail below in this
section.
• A growth update to the drug add-on
adjustment to the composite rates for
2008 required by section 1881(b)(12)(F)
of the Act.
• An update to the wage index
adjustments to reflect the latest hospital
wage data, including a reduction to the
wage index floor and a revised budget
neutrality adjustment to the wage index
for 2008.
We received approximately 7
comments on these proposed changes
which are discussed in detail below in
this section.
previous decision to pay for separately
billable ESRD drugs at ASP+6 percent.
In addition, section 1881(b)(12)(F) of
the Act requires that beginning in CY
2006, we establish an annual update to
the drug add-on to reflect the estimated
growth in expenditures for separately
billable drugs and biologicals furnished
by ESRD facilities. This growth update
applies only to the drug add-on portion
of the case-mix adjusted payment
system.
The CY 2007 drug add-on adjustment
to the composite rate is 14.9 percent.
The drug add-on adjustment for 2007
incorporates an inflation adjustment of
0.5 percent. This computation is
explained in detail in the CY 2007 PFS
final rule with comment period (71 FR
69682 through 69684). We note that the
drug add-on adjustment of 15.1 percent
that was published in the CY 2007 PFS
final rule with comment period did not
account for the 1.6 percent update to the
composite rate portion of the basic casemix adjustment payment system that
was subsequently enacted by the MIEA–
TRHCA, effective April 1, 2007. Since
we compute the drug add-on adjustment
as a percentage of the weighted average
base composite rate, the drug add-on
percentage was decreased to account for
the higher composite payment rate
resulting in a 14.9 percent add-on
adjustment beginning April 1, 2007.
This adjustment was necessary to
ensure that the total drug add-on dollars
remain constant.
1. Growth Update to the Drug Add-On
Adjustment to the Composite Rates
Section 623(d) of the MMA added
section 1881(b)(12)(B)(ii) of the Act
which required the establishment of an
add-on to the composite rate to account
for changes in the drug payment
methodology stemming from enactment
of the MMA. Section 1881(b)(12)(C) of
the Act provides that the drug add-on
must reflect the difference in aggregate
payments between the revised drug
payment methodology for separately
billable ESRD drugs and the AWP
payment methodology. In 2005, we
generally paid for ESRD drugs based on
average acquisition costs. Thus the
difference from AWP pricing was
calculated using acquisition costs.
However, in 2006 when we moved to
ASP pricing for ESRD drugs, we
recalculated the difference from AWP
pricing using ASP prices.
Comment: Two commenters
supported our continued use of ASP+6
percent to pay for separately billable
ESRD drugs.
Response: Although these comments
are outside the scope of the proposed
rule, we appreciate the support of our
(a) Estimating Growth in Expenditures
for Drugs and Biologicals for CY 2008
In the CY 2007 PFS final rule with
comment period (71 FR 69682), we
established a methodology for annually
estimating the growth in ESRD drugs
and biological expenditures that uses
the Producer Price Index (PPI) for
pharmaceuticals as a proxy for pricing
growth in conjunction with 2 years of
ESRD drug data to estimate per patient
utilization growth.
For CY 2008, we proposed to continue
using this methodology to update the
drug add-on adjustment, using
expenditure data from CY 2005 and CY
2006 to estimate the growth in per
patient utilization of drugs. However,
we also proposed using only drug
expenditure data from independent
ESRD facilities because we were unable
to determine utilization change in
hospital-based dialysis facilities due to
the changes in payment methodology
for these types of dialysis facilities from
CY 2005 to CY 2006. In 2005, payments
to hospital-based facilities were based
on cost (or a percentage of charges),
whereas payments to those facilities in
2006 were based on ASP pricing.
cprice-sewell on PROD1PC72 with RULES
and we appreciate the positive input
received on our technical revisions.
Therefore, we are finalizing the
technical revisions as proposed.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00060
Fmt 4701
Sfmt 4700
Because of the cost payment
methodology, the ‘‘drug unit’’ fields on
the 2005 hospital-based ESRD facility
bills were not used for payment
purposes, and therefore, the data may
not have been accurately reported on
those bills. As such, we were unable to
accurately isolate the per unit payment
differential for hospital-based ESRD
facility drug expenditures between 2005
(cost payments) and 2006 (ASP
payments) for purposes of estimating
the residual utilization change between
years. We proposed imputing the same
utilization growth for hospital-based
ESRD facilities as estimated for
independent ESRD facilities.
Comment: One comment urged us to
reevaluate the data and methodology
used to estimate utilization changes.
The comment was specifically
concerned about the timeliness of the
data and that the exclusion of hospitalbased drug data may significantly skew
the accuracy of the utilization growth
calculation. However, the comment did
not suggest an alternative methodology.
Response: The data from CY 2005 and
CY 2006 represent the most up to date
and latest full years of data available.
Contrary to the commenter’s suggestion,
as we indicated in the CY 2008 PFS
proposed rule, including hospital-based
data in the computation would have
resulted in a negative utilization growth.
Therefore, we opted to exclude those
data to avoid penalizing ESRD facilities
because of the problems with the
hospital-based ESRD facility drug data.
We believe our approach provides the
most reasonable result given the
available data.
Comment: One comment suggested
that we adopt an index that would
account for both price and utilization
such as the National Health
Expenditures (NHE) index. This would
avoid the data issues associated with
estimating utilization growth.
Response: We do not believe that the
NHE projections would be the best
proxy for growth in ESRD drug
expenditures. The NHE projections are
based on the economic, demographic
and Medicare spending projections
contained in the Medicare Trustees
Report as opposed to an independent
forecast of economic assumptions, such
as the Global Insights projections of the
PPI for prescription drugs that are used
in our Medicare market basket forecasts
to update many of our payment systems.
The NHE projection modeling approach
is at an aggregate level and does not
capture the nuances of both labor and
economic markets as accurately as does
the specific PPI forecast. We believe
that, despite some of the limitations in
the data, estimating utilization growth
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
from reported ESRD claims data
provides the most accurate measure of
actual ESRD facility drug utilization.
Comment: One comment suggested
that the PPI may not result in an
accurate assessment of prices for ESRD
drugs and that there are other available
indices that would provide more
accurate data on ESRD drugs. In
addition, they stated that should we
choose to move forward with the PPI,
the most up to date PPI forecast should
be used.
Response: We do not know of any
better price index than the PPI for
measuring price growth for ESRD drugs.
However, we welcome any suggestion
the industry may have on an alternative
price index suitable for measuring price
growth of ESRD drugs. Global Insight,
Inc. is a nationally recognized economic
and financial forecasting firm that
contracts with CMS to forecast the
components of our market baskets. The
current projection of the PPI for
prescription drugs is based on the 2007
second quarter forecast using historical
data through the first quarter of 2007,
the most current data available at this
time.
Comment: One comment
recommended that a mechanism be
established to provide for a forecasting
error adjustment of prior estimates.
Response: While we appreciate the
concern related to the accuracy of an
update based on proxy measures for
price and the proposed utilization
computations, the very nature of
estimating future expenditures under a
prospective payment system requires
that those estimates are based on the
best historical data available. As such,
we believe we have met our obligation
under the statute in estimating growth
in ESRD drug expenditures for CY 2008.
Moreover, forecast error adjustments are
rarely made in our prospective payment
systems.
(b) Estimating Growth in Per Patient
Drug Utilization
To isolate and project the growth in
per patient utilization of ESRD drugs for
CY 2008, we removed the enrollment
and price growth components from the
historical data and considered the
residual to be utilization growth. As
discussed previously, we proposed to
use independent ESRD facility drug
expenditure data from CY 2005 and CY
2006 to estimate per patient utilization
growth for CY 2008.
We first estimated total drug
expenditures. For the CY 2008 PFS
proposed rule (72 FR 38165), we used
the final CY 2005 ESRD facility claims
data and the latest available CY 2006
ESRD facility claims data, updated
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
through December 31, 2006. That is, for
CY 2006 we used claims that were
received, processed, paid, and passed to
the National Claims History File as of
December 31, 2006. For this final rule
with comment period, we are using
more updated CY 2006 claims with
dates of service for the same time
period. This updated CY 2006 data file
includes all claims that were received,
processed, paid, and passed to the
National Claims History File as of June
30, 2007 for CY 2006.
For the CY 2008 PFS proposed rule,
we adjusted the December 2006 file to
reflect our estimate of what total drug
expenditures would be using the final
June 30, 2007 bill file for CY 2006. The
net adjustment we applied to the CY
2006 claims data was an increase of 12
percent to the December 2006 claims
file. For this final rule with comment
period, we are using the CY 2006 claims
file as of June 30, 2007, which
represents the final claims file for that
year. To calculate the proposed per
patient utilization growth, we removed
the enrollment component by using the
growth in enrollment data between 2005
and 2006. This was approximately 3
percent. To remove the price effect, we
calculated the weighted difference
between 2005 average acquisition price
(AAP) and 2006 ASP pricing for the
original top ten drugs for which we had
average acquisition prices. We weighted
the differences by the 2006 independent
ESRD facility drug expenditure data.
This process led to an overall 3 percent
reduction in price between 2005 and
2006 (72 FR 38165 through 38166).
After removing the enrollment and
price effects from the expenditure data,
the residual growth would reflect the
per patient utilization growth. To do
this, we divided the product of the
enrollment growth of 3 percent (1.03)
and the price reduction of 3 percent
(1.00 ¥ 0.03 = 0.97) into the total drug
expenditure change between 2005 and
2006 of ¥0.2 percent (1.00 ¥0.00 =
1.00). The result is a proposed
utilization growth factor equal to 1.00
(1.00/1.03 * 0.97) = 1.00.
Since we observed no growth in per
patient utilization of drugs between
2005 and 2006, we proposed no
projected growth in per patient
utilization for all ESRD facilities for CY
2008.
c. Applying the Proposed Growth
Update to the Drug Add-On Adjustment
In the CY 2007 PFS final rule with
comment period (71 FR 69684), we
revised our update methodology by
applying the growth update to the per
treatment drug add-on amount. That is,
for CY 2007, we applied the growth
PO 00000
Frm 00061
Fmt 4701
Sfmt 4700
66281
update factor of 4.03 percent to the
$18.88 per treatment drug add-on
amount for an updated amount of
$19.64 per treatment.
For CY 2008, we proposed to update
the per treatment drug add-on amount
of $19.64 established in CY 2007 by
converting the update into an
adjustment factor as specified in section
1881(b)(12)(F) of the Act.
(i) Update to the Drug Add-On
Adjustment
In the CY 2008 PFS proposed rule (72
FR 38166), we estimated no growth in
per patient utilization of ESRD drugs for
CY 2008. Using the projected growth of
the CY 2008 PPI for prescription drugs
of 3.66 percent, we projected that the
combined growth in per patient
utilization and pricing for CY 2008
would result in an update equal to the
PPI growth, or 3.66 percent (1.0 * 1.0366
= 1.0366). This proposed update factor
was applied to the CY 2007 per
treatment drug add-on amount of $19.64
(reflecting a 14.9 percent adjustment in
CY 2007), resulting in a proposed
weighted average increase to the
composite rate of $0.72 for CY 2008 or
a 0.5 percent increase in the drug addon percentage. Thus, the total proposed
drug add-on adjustment to the
composite rate for CY 2008, including
the growth update was 15.5 percent
(1.149 * 1.005 = 1.155).
In addition, we proposed to continue
to use this method to estimate the
growth update to the drug add-on
component of the case mix adjusted
payment system until we have at least
3 years worth of ASP-based historical
drug expenditure data that could be
used to conduct a trend analysis to
estimate the growth in drug
expenditures. Given the time lag in the
availability of ASP drug expenditure
data, we expect that the earliest we
could consider using trend analysis to
update the drug add-on adjustment
would be 2010. We intend to reevaluate
our methodology for estimating the
growth update at that time.
Comment: One comment suggested
that we should work with the kidney
care community as we consider a CY
2010 transition to trend analysis using
ASP-based historical data. The comment
expressed concern that using actual
historical ESRD drug expenditure data
reflecting ASP pricing could adversely
affect ESRD facilities due to changes in
ASP pricing for EPO and Procrit.
Response: Once we begin using trend
analysis to update the drug add-on
adjustment, we will provide details of
that methodology in future rulemaking.
E:\FR\FM\27NOR2.SGM
27NOR2
66282
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(ii) Final Growth Update to the Drug
Add-On Adjustment for 2008
Similar to the proposed rule, we
estimated no growth in per patient
utilization of ESRD drugs for CY 2008.
To remove the price effect, we used
2006 weights for each of the top ten
ESRD drugs billed by independent
ESRD facilities. These weights are
shown in Table 6.
TABLE 6.—CY 2006 DRUG WEIGHTS
FOR INDEPENDENT FACILITIES
Independent drugs
2006
weights
(percent)
EPO ..........................................
Paricalcitol ................................
Sodium_ferric_glut ....................
Iron_sucrose .............................
Levocarnitine ............................
Doxercalciferol ..........................
Calcitriol ....................................
Iron_dextran ..............................
Vancomycin ..............................
Alteplase ...................................
75.2
11.6
2.9
5.7
0.3
3.1
0.1
0.0
0.1
0.9
cprice-sewell on PROD1PC72 with RULES
We removed the enrollment and price
effects from the independent ESRD
facility expenditure data to determine
the per patient utilization growth. To do
this we divided the product of the
enrollment growth of 3 percent (1.03)
and the price reduction of 3 percent
(1.00¥0.03 = 0.97) into the total drug
expenditure change between 2005 and
2006 of ¥0.1 percent (1.00¥0.00 =
1.00). The result is a utilization growth
factor equal to 1.00 (1.00/1.03 * 0.97) =
1.00.
Using the latest projected growth of
the CY 2008 PPI for prescription drugs
of 3.5 percent, we project that the
combined growth in per patient
utilization and pricing of ESRD drugs
for CY 2008 would result in an update
equal to the PPI growth or 3.5 percent
(1.00 * 1.035 = 1.035). This update
factor was applied to the CY 2007
average per treatment drug add-on
amount of $19.64 (reflecting a 14.9
percent adjustment for CY 2007),
resulting in a weighted average increase
to the composite rate of $0.69 for CY
2008 or a 0.5 percent increase in the
drug add-on percentage for CY 2008.
Thus, the total drug add-on adjustment
to the composite rate for CY 2008,
including the growth update is 15.5
percent (1.149 * 1.005 = 1.155).
2. Update to the Geographic Adjustment
to the Composite Rates
Section 1881(b)(12)(D) of the Act, as
added by section 623(d) of the MMA,
gives the Secretary the authority to
revise the wage indexes previously
applied to the ESRD composite rates.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
The wage index values are calculated
for each urban and rural area. The
purpose of the wage index is to adjust
the composite rates for differing wage
levels covering the areas in which ESRD
facilities are located.
(a) Updates to Core-Based Statistical
Area (CBSA) Definitions
In the CY 2008 PFS proposed rule (72
FR 38166), we clarified that this and all
subsequent ESRD rules and notices are
considered to incorporate the CBSA
changes published in the most recent
OMB bulletin that applies to the
hospital wage data used to determine
the current ESRD wage index. The OMB
bulletins may be accessed online at
https://www.whitehouse.gov/omb/
bulletins/.
(b) Updated Wage Index Values
In the CY 2006 PFS final rule with
comment period (70 FR 70167), we
described that methodology for
calculating the CY 2006 wage index
values and stated that we intend to
update the ESRD wage index values
annually. Current wage index values for
CY 2007 were developed from FY 2003
wage and employment data obtained
from the Medicare hospital cost reports.
The ESRD wage index values are
calculated without regard to geographic
reclassifications authorized under
sections 1886(d)(8) and (d)(10) of the
Act and utilize pre-floor hospital data
that is unadjusted for occupational mix.
We proposed to use the same
methodology for CY 2008 (72 FR 38167),
with the exception that FY 2004
hospital data will be used to develop the
CY 2008 ESRD wage index values. For
a detailed description of the
development of the CY 2008 wage index
values based on FY 2004 hospital data,
see the FY 2008 IPPS final rule entitled
‘‘Changes to the Hospital Inpatient
Prospective Payment Systems and Fiscal
Year 2008 Rates’’ (72 FR 47320). Section
G of the preamble to that final rule
describes the cost report schedules, line
items, data elements, adjustments, and
wage index computations. The wage
index data affecting ESRD composite
rates for each urban and rural locale
may also be accessed on the CMS Web
site at https://www.cms.hhs.gov/
AcuteInpatientPPS/WIFN/list.asp. The
wage data are located in the section
entitled ‘‘FY 2008 Final Rule
Occupational Mix Adjusted and
Unadjusted Average Hourly Wage and
Pre-Reclassified Wage Index by CBSA.’’
Comment: One commenter expressed
concern in regard to our use of acute
care hospital wage data in the
calculation of the wage index stating
that the cost for hospital based facilities
PO 00000
Frm 00062
Fmt 4701
Sfmt 4700
and ambulatory centers varies greatly.
The commenter urged us to locate an
alternative data source that reflects
information directly tied to ESRD
facilities.
Response: At the present time, data
that is specific to independent dialysis
facilities is not available upon which to
base the wage index. As described in the
CY 2007 PFS final rule with comment
period (71 FR 69685), given the
similarity of the labor market for
professional, technical, and nursing staff
between hospitals and ESRD facilities,
we believe our use of hospital wage and
employment data obtained from the
Medicare cost reports to develop the
ESRD wage index is appropriate. In
addition, several of our major
prospective payment systems (PPS)
utilize the same wage index (for
example, Skilled Nursing Home PPS,
Inpatient Psychiatric Facility PPS,
Inpatient Rehabilitation Facility PPS,
Home Health PPS, and Hospice PPS.)
(i) Third Year of the Transition
In the CY 2006 PFS final rule with
comment period (70 FR 70169), we
indicated that we would apply a 4-year
transition period to mitigate the impact
on composite rates resulting from our
adoption of CBSA-based geographic
designations. Beginning January 1, 2006,
during each year of the transition, an
ESRD facility’s wage-adjusted composite
rate (that is, without regard to any casemix adjustments) will be a blend of its
old MSA-based wage-adjusted payment
rate and its new CBSA-based wageadjusted payment rate for the transition
year involved. In addition, beginning in
CY 2006 we provided a gradual
reduction in the wage index floor. We
indicated that we would reassess the
need for a wage index floor for CY 2008.
In the CY 2008 PFS proposed rule (72
FR 38167), we proposed a further
reduction in the wage index floor. For
each transition year, the share of the
blended wage-adjusted base payment
rate that is derived from the MSA-based
and CBSA-based wage index values and
the applicable wage index floor is as
follows:
• In CY 2006, the first year of the
transition, we implemented a 75/25
blend. The wage index floor was
reduced from 0.9000 to 0.8500.
• In CY 2007, the second year of the
transition, we implemented a 50/50
blend. The wage index floor was
reduced from 0.8500 to 0.8000.
• For CY 2008, consistent with the
transition blends announced in the CY
2006 PFS final rule with comment
period (70 FR 70170), we are
implementing a 25/75 blend between an
ESRD facility’s MSA based composite
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
rate, and its CY 2008 CBSA-based rate
reflecting its revised wage index values.
In addition, we proposed to continue
the wage index floor, but to further
reduce it from 0.8000 to 0.7500.
An example of how the wage-adjusted
composite rates would be blended
during CY 2008 and the additional
subsequent transition year follows.
Example: An ESRD facility has a
wage-adjusted composite rate (without
regard to any case-mix adjustments) of
$135.00 per treatment in CY 2007. Using
CBSA-based geographic area
designations, the facility’s CY 2008
wage-adjusted composite rate, reflecting
its wage index value would be $145.00.
During the remaining 2 years of the 4year transition period to the new CBSAbased wage index values, this facility’s
blended rate through 2009 would be
calculated as follows:
CY 2008 = 0.25 × $135.00 + 0.75 ×
$145.00 = $142.50
CY 2009 = 0 × $135.00 + 1.0 × $145.00
= $145.00
We note that this hypothetical
example assumes that the calculated
wage-adjusted composite rate of $145.00
for CY 2008 does not change in CY
2009. In actuality, the wage-adjusted
composite rate for CY 2009 would
change because of annual revisions to
the wage index. However, the example
serves only to demonstrate the effect on
the composite rate of the CBSA-based
wage index values which will be phased
in during the remaining 2 years of the
transition period. As noted above in this
section, the 4-year transition period will
expire and in CY 2009 and forward, we
will be using CBSA-based wage index
values.
Comment: Several commenters
expressed concern in regard to our
proposal to decrease the wage index
floor from 0.80 to 0.75. In addition, one
commenter indicated that a defunct
licensing board in Puerto Rico has
inhibited licensing of dialysis
technicians for a long period of time. As
a result, registered nurses are the only
group of licensed professional qualified
to furnish dialysis within this area.
In addition, a commenter believes that
decreasing the floor will make it
difficult to recruit and retain qualified
personnel in areas affected by the
removal of the floor. The commenter
also identified the recent transition to
the ASP drug pricing methodology and
increases in operating expense as factors
that have compounded the impact of
any further drop in the wage index
floor.
Response: As described in the CY
2007 PFS final rule with comment
period (71 FR 69686 through 69687), the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
proposed wage index floor was
substantially higher than the actual
wage index values for urban locales in
Puerto Rico, without application of any
floor and prior to the application of the
BN adjustment. Specifically, the
proposed wage index floor was 0.80
whereas the actual wage index values
ranged from 0.3241 to 0.4893. Similarly,
the proposed wage index floor for CY
2008 is 0.75 whereas the actual wage
index values for urban locales in Puerto
Rico range from 0.3064 to 0.4729.
Therefore, we believe that the CY 2008
wage index floor of 0.75 compared to
actual wage levels is an appropriate
level and the new floor would not
impede the ability of ESRD facilities to
recruit and retain staff.
(ii) Wage Index Values for Areas With
No Hospital Data
In CY 2006, while adopting the CBSA
designations, we identified a small
number of ESRD facilities in both urban
and rural geographic areas where there
is no hospital wage data from which to
calculate ESRD wage index values. The
affected areas were rural Massachusetts,
rural Puerto Rico and the urban area of
Hinesville, GA (CBSA 25980). For both
CY 2006 and CY 2007, we calculated the
ESRD wage index values for those areas
as follows:
• For rural Massachusetts, because
we had not determined a reasonable
proxy for rural data in Massachusetts,
we used the FY 2005 wage index value
for rural Massachusetts.
• For rural Puerto Rico, the situation
is similar to rural Massachusetts.
However, since all geographic areas in
Puerto Rico were subject to the wage
index floor in CY 2006 and CY 2007, we
applied the ESRD wage index floor to
rural Puerto Rico as well.
• For the urban area of Hinesville,
GA, we calculated the CY 2006 and CY
2007 wage index value for Hinesville,
GA (CBSA 25980) based on the average
wage index value for all urban areas
within the State of Georgia.
In the CY 2008 PFS proposed rule (72
FR 38168), we proposed an alternative
methodology for establishing a wage
index value for rural Massachusetts.
Since we have used the same wage
index value for two years with no
updates, we believed it was appropriate
to establish a methodology that uses
reasonable proxy data for rural areas
(including rural Massachusetts) and also
permits annual updates to the wage
index value based on that proxy data.
Therefore, in cases where there is a rural
area without hospital wage data, we
proposed to use the average wage index
values from all contiguous CBSAs to
PO 00000
Frm 00063
Fmt 4701
Sfmt 4700
66283
represent a reasonable proxy for that
rural area.
In determining the imputed rural
wage index, we interpret the term
‘‘contiguous’’ to mean sharing a border.
In the case of Massachusetts, the entire
rural area consists of Dukes and
Nantucket Counties. We determined
that the borders of Dukes and Nantucket
counties are ‘‘contiguous’’ with
Barnstable and Bristol counties. Under
the proposed methodology, the wage
index values for the counties of
Barnstable (CBSA 12700, Barnstable
Town, MA—(1.2539)) and Bristol (CBSA
39300, Providence-New Bedford-Fall
River, RI-MA—(1.0783)) are averaged,
resulting in a proposed imputed wage
index value of 1.1665 for rural
Massachusetts for CY 2008.
For rural Puerto Rico, we proposed to
continue to apply the wage index floor
in CY 2008. Since all areas in Puerto
Rico that have a wage index are eligible
for the proposed CY 2008 ESRD wage
index floor of 0.7500, we proposed to
also apply the floor to ESRD facilities
located in rural Puerto Rico.
For Hinesville, GA (CBSA 25980)
which is an urban area without specific
hospital wage data, we proposed to
continue using the same methodology
used to impute a wage index value for
that area as we used in CY 2006 and CY
2007. Specifically, we used the average
wage index value for all urban areas
within the State of Georgia for purposes
of calculating the wage index value for
Hinesville. Therefore, for CY 2008 we
proposed that the wage index value for
urban CBSA (25980) Hinesville-Fort
Stewart, GA is calculated as the average
of the wage index values of all urban
areas in Georgia.
We solicited comments on these
proposed approaches to calculate the
wage index values for areas without
hospital wage data for CY 2008 and
subsequent years. We indicated that we
would continue to evaluate existing
hospital wage data and, possibly, wage
data from other sources, such as the
Bureau of Labor Statistics, to determine
if other methodologies of imputing a
wage index value for these areas may be
feasible. We received one comment on
this issue.
Comment: One commenter was
supportive of our methodology used in
calculating wage index values for areas
with no hospital wage data including
rural Massachusetts, Puerto Rico, and an
urban area in Georgia. However, the
commenter requested that we carefully
evaluate the extent to which these
methodologies would be appropriate in
other situations nationwide.
Response: We agree with the
commenter. As additional areas are
E:\FR\FM\27NOR2.SGM
27NOR2
66284
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
identified for which hospital wage data
does not exist, we will reevaluate the
extent to which the methodologies used
for Massachusetts, Puerto Rico, and
Georgia would be appropriate and
consider alternative methodologies on
an as needed basis.
We are finalizing the ESRD wage
index and associated policies as
proposed for CY 2008. In addition, we
note that we plan to evaluate any
policies adopted in the FY 2008 IPPS
final rule (72 FR 47130, 47337 through
47338) that affect the wage index,
including how we treat certain New
England hospitals under section 601(g)
of the Social Security Amendments of
1983 (Pub. L. 98–21).
(iii) Budget Neutrality (BN) Adjustment
Section 1881(b)(12)(E)(i) of the Act, as
added by section 623(d) of the MMA,
requires that any revisions to the ESRD
composite rate payment system as a
result of the MMA provision (including
the geographic adjustment) be made in
a budget neutral manner. This means
that aggregate payments to ESRD
facilities in CY 2007 should be the same
as aggregate payments that would have
been made if we had not made any
changes to the geographic adjusters. We
note that this BN adjustment only
addresses the impact of changes in the
geographic adjustments. A separate BN
adjustment was developed for the casemix adjustments, currently in effect.
Since we are not proposing any changes
to the case-mix measures for CY 2008,
the current case-mix budget neutrality
will remain in effect for CY 2008. For
CY 2008, we again proposed to apply
the BN adjustment directly to the ESRD
wage index values, as we did in CY
2007. As we explained in the CY 2007
PFS final rule with comment period (71
FR 69687 through 69688), we believe
this is the simplest approach because it
allows us to maintain our base
composite rates during the transition
from the current wage adjustments to
the revised wage adjustments described
previously in this section. Because the
ESRD wage index is only applied to the
labor related portion of the composite
rate, we computed the BN adjustment
based on that proportion (53.711
percent).
To compute the proposed CY 2008
wage index BN adjustment, we used the
proposed wage index values, 2006
outpatient claims (paid and processed
as of December 31, 2006), and
geographic location information for each
facility.
Using the treatment counts from the
2006 claims and facility-specific CY
2007 composite rates, we computed the
estimated total dollar amount each
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
ESRD provider would have received in
CY 2007 (the 2nd year of the 4-year
transition). The total of these payments
became the target amount of
expenditures for all ESRD facilities for
CY 2008. Next, we computed the
estimated dollar amount that would
have been paid to the same ESRD
facilities using the proposed ESRD wage
index for CY 2008 (the 3rd year of the
4-year transition). The total of these
payments became the third year amount
of wage-adjusted composite rate
expenditures for all ESRD facilities.
After comparing these two dollar
amounts (target amount divided by 3rd
year new amount), we calculated an
adjustment factor that, when multiplied
by the applicable CY 2008 ESRD
proposed wage index value would result
in payments to each facility that remain
within the target amount of composite
rate expenditures when totaled for all
ESRD facilities. The proposed BN
adjustment for the CY 2008 wage index
was 1.054955.
We also must apply the BN
adjustment to the proposed wage index
floor of 0.7500 which resulted in a
proposed adjusted wage index floor of
0.7912 (0.7500 × 1.054955) for CY 2008.
Comment: One commenter expressed
concern in regard to the calculation of
the BN adjustment for the geographic
wage index stating that the methodology
included in the proposed rule lacked
transparency. The commenter urged us
to provide the data and methodology
used in calculating the BN adjustment.
Response: The commenter did not
identify where transparency was lacking
or any missing elements that would
enable the community to assess the
impact of the proposed changes.
However, we received a similar request
for clarification during last year’s
rulemaking process and provided an
extensive description of the manner in
which budget neutrality is applied to
the wage index in the CY 2007 PFS final
rule with comment period (71 FR 69687
through 69688). While claims data have
been updated since publication of that
final rule with comment period, the
methodology has not changed.
During the CY 2008 PFS proposed
rule comment period, we made
available an ESRD Composite Rate
Payment System File. This file
contained select claims level data from
the 2006 ESRD facility outpatient
claims, updated through December 31,
2006. For more information on this file,
see the following page on the CMS Web
site at https://www.cms.hhs.gov/
LimitedDataSets/06.asp#TopOfPage.
After publication of this final rule
with comment period, we intend to
provide the updated version of the CY
PO 00000
Frm 00064
Fmt 4701
Sfmt 4700
2006 outpatient claims (paid and
processed as of June 30, 2007) that were
used to compute the BN adjustment.
To compute the final CY 2008 ESRD
wage index BN adjustment, we used FY
2004 pre-floor, pre-reclassified, nonoccupational mix-adjusted hospital
wage data to compute the wage index
values, 2006 outpatient claims (paid and
processed as of June 30, 2007), and
geographic location information for each
ESRD facility which may be found
through Dialysis Facility Compare. The
FY 2004 hospital wage index data for
each urban and rural locale by CBSA
may also be accessed on the CMS Web
site at: https://www.cms.hhs.gov/
AcuteInpatientPPS/WIFN/list.asp. The
wage index data are located in the
section entitled ‘‘FY 2008 Final Rule
Occupational Mix Adjusted and
Unadjusted Average Hourly Wage and
Pre-Reclassified Wage Index by CBSA.’’
Dialysis Facility Compare Information
can be found on the CMS Web site at
https://www.cms.hhs.gov/
DialysisFacilityCompare/.
Using treatment data from the latest
2006 claims file and facility-specific CY
2007 composite rates, we computed the
estimated total dollar amount each
ESRD provider would have received in
CY 2007 (the 2nd year of the 4-year
transition). The total of these payments
became the target amount of
expenditures for all ESRD facilities for
CY 2008. Next, we computed the
estimated dollar amount that would
have been paid to the same ESRD
facilities using the ESRD wage index for
CY 2008 (the 3rd year of the 4-year
transition). The total of these payments
became the 3rd year new amount of
wage adjusted composite rate
expenditures for all ESRD facilities.
After comparing these dollar amounts
(target amount divided by 3rd year new
amount), we calculated an adjustment
factor that when multiplied by the
applicable CY 2008 wage index value,
will result in aggregate payments to
ESRD facilities that will remain within
the target amount of composite rate
expenditures. When making this
calculation, the ESRD wage index floor
value of 0.7500 is used whenever
appropriate.
The final BN adjustment for the CY
2008 wage index is 1.055473.
To ensure budget neutrality, we also
must apply the BN adjustment to all
index values, including the wage index
floor of 0.7500, which results in an
adjusted wage index floor of 0.7916 for
CY 2008.
(iv) ESRD Wage Index Tables
The final CY 2008 wage index tables
applicable to ESRD facilities are located
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
in Addenda G and H of this final rule
with comment period.
I. Independent Diagnostic Testing
Facility (IDTF) Issues
In the CY 2008 PFS proposed rule (72
FR 38169 through 38171), we clarified
our interpretation of several of the
existing performance standards at
§ 410.33(b), and § 410.33(g), proposed a
new IDTF performance standard at
§ 410.33(g)(15), and a new proposed
IDTF provision at § 410.33(i).
We received numerous comments
concerning the revisions to existing
performance standards and new
provisions affecting IDTFs and have
revised our proposed changes, where
applicable, to reflect the issues brought
forth by the commenters. We are
adopting the provisions contained in the
proposed rule as final with the
following changes.
1. Revisions of Existing IDTF
Performance Standards
cprice-sewell on PROD1PC72 with RULES
a. § 410.33(g)(6)
In § 410.33(g)(6), we had proposed to
revise this existing performance
standard to include the requirement that
an IDTF must list our designated
contractor as a Certificate Holder on the
comprehensive liability insurance
policy by revising § 410.33(g)(6) to state,
‘‘Has a comprehensive liability
insurance policy in the amount of at
least $300,000 per location that covers
both the supplier’s place of business
and all customers and employees of the
supplier and ensures that this insurance
policy must remain in force at all times.
The policy must be carried by a
nonrelative owned company. Failure to
maintain required insurance at all times
will result in revocation of the IDTF’s
billing privileges retroactive to the date
the insurance lapsed. IDTF suppliers are
responsible for providing the contact
information for the issuing insurance
agent and the underwriter. In addition,
we proposed that the IDTF must: ensure
that the insurance policy must remain
in force at all times and provide
coverage of at least $300,000 per
incident; notify the CMS-designated
contractor in writing of any policy
changes or cancellations; and list the
CMS-designated contractor as a
Certificate Holder on the policy.’’
Comment: One commenter suggested
that we amend the § 410.33(g)(6)
provision on the comprehensive
liability insurance policy to state that
IDTFs should have a comprehensive
liability insurance policy of at least
$100,000 per incident, $300,000
aggregate and that CMS should require
the IDTF to list Medicare contractors as
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
certificate holders for notification
purposes only.
Response: After receiving numerous
comments supporting the proposed
figures, we are adopting the proposed
figure of $300,000 per incident.
Comment: Several commenters
recommended that we revise the
proposed performance standard found
at § 410.33(g)(6) to remove the
requirement that our designated
contractor be listed as a Certificate
Holder on the liability insurance policy.
One commenter supported the proposed
changes to the performance standard at
§ 410.33(g)(6), but expressed concerned
about whether underwriters were
willing to list the government as a
certificate holder on an insurance
policy.
Another commenter questioned
whether insurance underwriters will be
open to the idea of adding the
government as a certificate holder on an
insurance policy and suggested that
CMS survey several insurance carriers
which provide this type of coverage to
determine if this performance standard
is achievable. One commenter stated
that the comprehensive liability
insurance policy provision
(§ 410.33(g)(6)) which requires the IDTF
to list the Medicare contractor as the
certificate holder on the policy is too
burdensome and obtrusive on small
business entities. They recommended
using a comparable approach to the one
required by DMEPOS supplier, and have
the IDTF provide a copy of the annual
renewal of the insurance coverage for
the IDTF to the Medicare contractor (the
renewal package would include
information on the coverage levels, as
well as the premiums paid).
One commenter suggested removing
the contractor as the certificate holder
for the comprehensive liability
insurance policy, but if they are named
as a certificate holder for the
comprehensive liability insurance
policy that it be only for notification
purposes.
Response: Given the concerns raised
about the increased administrative
burden, we agree that our designated
contractor should not be included as a
Certificate Holder on the IDTF’s
comprehensive liability insurance
policy. We have revised the
performance standard found at
§ 410.33(g)(6) to remove the requirement
that our designated contractor be listed
as a Certificate Holder on the IDTF’s
comprehensive liability insurance
policy. However, we believe that it is
essential that a Medicare fee for service
(FFS) contractor be allowed to verify
information contained in the
comprehensive liability insurance
PO 00000
Frm 00065
Fmt 4701
Sfmt 4700
66285
policy. We believe that a Medicare
contractor (that is, carrier or Part A/Part
B Medicare Administrator Contractor)
should be able to verify the issuance of
a comprehensive liability insurance
policy with an insurance agent or, as
necessary, an underwriter. This
approach will allow a Medicare FFS
contractor to review and verify that a
comprehensive liability insurance
policy has been issued and is in effect
at the time of enrollment and
throughout the enrollment period. We
have revised § 410.33(g)(6) to read, ‘‘Has
a comprehensive liability insurance
policy in the amount of at least
$300,000 per location that covers both
the supplier’s place of business and all
customers and employees of the IDTF.
The policy must be carried by a
nonrelative-owned company. Failure to
maintain required insurance at all times
will result in revocation of the IDTF’s
billing privileges retroactive to the date
the insurance lapsed. IDTF suppliers are
responsible for providing the contact
information for the issuing insurance
agent and the underwriter. In addition,
the IDTF must—
• Ensure that the insurance policy
must remain in force at all times and
provide coverage of at least $300,000
per incident; and
• Notify the CMS designated
contractor in writing of any policy
changes or cancellations.’’
b. § 410.33(g)(2)
In § 410.33(g)(2), we proposed to
establish a 30-day reporting period for
certain reportable events and a 90-day
reporting period for all other reportable
events.
Comment: One commenter asked that
we define the term ‘‘nonrelative owned’’
while another commenter asked that we
remove this term altogether because we
are not precluding self insurance.
Response: While we do not believe
that it is necessary to define the term
‘‘nonrelative owned’’ in this rulemaking
effort, a non-relative owned company
applies to insurance policies obtained
through a familial relationship, not a
related organization or business partner.
Therefore, we are not removing this
term from the performance standard.
Comment: Several commenters
supported our proposal to revise the
reporting requirements found in the
performance standard found at
§ 410.33(g)(2). One commenter
supported the CMS proposal to revise
the reporting requirements found in
performance standard at § 410.33(g)(2)
to establish separate reporting periods
for different reportable events. The
proposed changes will provide the
information desired by CMS in a timely
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66286
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
manner while minimizing the
administrative burdens on both IDTFs
and the Medicare contractors caused by
the current notification standard.
Response: We appreciate these
comments and agree that revising this
standard will reduce the administrative
burden on both IDTFs and our
contractors.
Comment: One commenter
recommended that we revise the CMS–
855B to list the specific changes that
must be reported within 30 calendar
days of the change. However, one
commenter stated that requiring the
reporting of changes depending on the
type change in 30 or 90 days puts an
unfair burden on IDTFs.
Response: We agree that the CMS–
855B should be revised and should list
the specific changes that must be
reported within 30 calendar days of the
change. Currently, IDTFs are required to
report all changes in 30 days. Our
proposal would limit the number of
reportable events that would need to be
reported within 30 days of the change.
We intend to revise the CMS–855B to
clarify which reportable events must be
reported within 30 and 90 days. We will
use the Paperwork Reduction Act
process to seek specific comments in
seeking revisions to the CMS–855B.
Comment: One commenter
recommended that we allow IDTFs to
make changes online.
Response: We are developing the
Provider Enrollment, Chain, and
Ownership System (PECOS) Web,
which will allow all providers and
suppliers, including IDTFs, to enroll or
report enrollment changes via the
Internet. We are hoping to implement
PECOS Web in most parts of the country
by March 2008.
Comment: One commenter suggested
that all changes should be reported to
CMS within 90 days or in the
alternative. This commenter also
recommended that IDTFs report any
changes that have occurred in the
preceding quarter on a quarterly basis.
Another commenter suggested that we
should allow at least 90 days for
reporting changes in contact
information with the contractor. This
commenter also suggested that we
further define what the policy and
coverage requirements for self insurance
and the term ‘‘independent
underwriter.’’
Response: Section 410.33(g)(2)
requires IDTFs to report all changes in
30 days. By adopting our proposal, we
limit the number of reportable events
that would need to be reported within
30 days of the change. As stated above,
we intend to revise the CMS–855B to
clarify what items must be reported
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
within 30 and 90 days. Since many
IDTFs operate on different schedules, it
would not be practical to implement a
quarterly reporting requirement.
As a result of the issues raised by the
commenters, we are revising
§ 410.33(g)(2) to read, ‘‘Provides
complete and accurate information on
its enrollment application. Changes in
ownership, changes of location, changes
in general supervision, and adverse
legal actions must be reported to the
Medicare FFS contractor on the
Medicare enrollment application within
30 calendar days of the change. All
other changes to the enrollment
application must be reported within 90
days.’’
c. § 410.33(g)(8)
We received the following comments
in response to our proposal at
§ 410.33(g)(8).
Comment: Several commenters
recommended that we consider limiting
the types of beneficiary complaints that
are subject to the performance standard
found in § 410.33(g)(8). Another
commenter recommended that the
standard found in § 410.33(g)(8) apply
only when a beneficiary formalizes their
complaint in writing. Other commenters
stated that the proposed change in
§ 410.33(g)(8) is unnecessary, not to
mention ambiguous and labor intensive
to implement.
One commenter recommended that
we model the IDTF documentation
requirement after standards established
by the Food and Drug Administration.
Specifically, this commenter
recommends that IDTFs maintain a
record for each serious complaint
received by the facility for at least 3
years from the date the complaint was
received.
Another commenter recommended
that we clarify that IDTFs are required
to monitor only those beneficiary
complaints that relate to the quality of
care the patient receives.
One commenter stated that the
standard at § 410.33(g)(8) be clarified to
eliminate the documentation of routine
billing questions so there is no
unnecessary burden on small business
entities.
One commenter suggested that
instead of adopting § 410.33(g)(8) as
written for documenting a beneficiary’s
questions or complaints, IDTFs should
be required to develop and adhere to a
complaint policy that includes
documentation of material medical or
billing complaints, and that if CMS
adopts the current provision, the word
questions should be changed to
complaints. The commenter also
maintains that IDTFs should be allowed
PO 00000
Frm 00066
Fmt 4701
Sfmt 4700
to keep documents that are older than
30 days at a site other than the IDTF’s
physical location and CMS should
clarify how long the IDTFs are required
to keep each complaint and whether an
IDTF will be required to record the
insurance claim number for each
complaint.
Other commenters recommended that
we clarify § 410.33(g)(8) to specifically
state that this standard relates to
complaints regarding the provision of
service, because as written, it will
impose a sweeping new recordkeeping
requirement that drastically affects
small business entities.
Response: Based upon the comments
received, we have revised this provision
to clarify and limit the amount of
documentation that is necessary when a
clinical complaint is received in
writing. We also are clarifying and
limiting the amount of documentation
that is necessary when a clinical
complaint is received in writing. We
believe that complaints should be
readily available for examination and
we will establish a time frame for
maintaining this documentation.
Therefore, we have revised
§ 410.33(g)(8) accordingly.
Comment: One commenter
recommended that we develop a
standardized complaint form and an
electronic Web-based platform for
submitting complaints regarding an
IDTF.
Response: We believe that an IDTF
can document any formal complaints it
receives in the most convenient way
possible for that IDTF.
After reviewing public comments
regarding our proposed change to
§ 410.33(g)(8), we are adopting this
proposed change with modifications. By
revising this language, we believe that
we are reducing the paperwork burden
on IDTFs to maintain and respond to
written clinical complaints, rather than
all questions and complaints it receives
from beneficiaries. Section 410.33(g)(8)
is revised to read, ‘‘Answer, document,
and maintain documentation of a
beneficiary’s written clinical complaint
at the physical site of the IDTF (for
mobile IDTFs, this documentation
would be stored at their home office.)
This includes, but is not limited to, the
following:
• The name, address, telephone
number, and health insurance claim
number of the beneficiary.
• The date the complaint was
received; the name of the person
receiving the complaint; and a summary
of actions taken to resolve the
complaint.
• If an investigation was not
conducted, the name of the person
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
making the decision and the reason for
the decision.’’
By making this change, we believe
that we are reducing the paperwork
burden on IDTFs by asking them to
maintain and respond to written clinical
complaints, rather than address all
questions and complaints it receives
from beneficiaries.
cprice-sewell on PROD1PC72 with RULES
d. § 410.33(b)(1)
We received the following comments
in response to our proposal at
§ 410.33(b)(1).
Comment: Several commenters agreed
with our proposal to delete the
requirement that the supervising
physician is responsible for the overall
operation and administration of an
IDTF.
Response: We appreciate these
comments and are adopting this change
in the final regulation.
Comment: One commenter
recommended that we delay the
implementation of our clarification that
a physician providing general
supervision can oversee a maximum of
three IDTF sites by noting that term,
‘‘sites’’ includes fixed, as well as mobile
sites.
Response: We believe that a physician
providing general supervision can
oversee a maximum of three IDTF sites
which includes fixed as well as mobile
sites.
Comment: One commenter
recommended that we clarify that the
three site limitation only relates to the
provision of general supervision. In
addition, one commenter recommended
that we clarify that while a physician
may only provide general supervision to
three IDTF sites, this provision does not
apply to the number of interpreting
physicians at an IDTF site.
Response: We agree with this
comment and will clarify that the
supervision limitation only applies to
general supervision.
Comment: One commenter stated that
our proposal to consider each mobile
IDTF unit as one IDTF site was
unreasonable.
Response: We disagree and we believe
that a physician providing general
supervision can oversee a maximum of
three IDTF sites. We maintain that fixed
and mobile IDTFs essentially are
furnishing the same services. We note
that the term, ‘‘sites’’ includes fixed as
well as mobile sites because there are
three concurrent locations where testing
may occur at a given time.
Comment: One commenter stated
individual locations should be counted
only if they have separate Medicare
PINs.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Response: With Medicare’s
implementation of the National Provider
Identifier (NPI) on or before May 23,
2008, Medicare contractors will no
longer issue billing numbers to the
public. Providers and suppliers will use
their assigned NPI to submit claims to
Medicare. As such, organizations may
obtain one or many NPIs. Accordingly,
we are not able to adopt this suggestion.
Comment: One commenter suggested
that it would be inappropriate to require
that a mobile IDTF have a different
supervising physician for every three
office locations that it visits, therefore
this provision should apply only to
those IDTFs in a fixed location.
Response: We believe that a physician
providing general supervision can
oversee a maximum of three IDTF sites
and note that the term, ‘‘sites’’ includes
fixed, as well as mobile sites, because
there are three concurrent locations
where testing may occur at a given time.
A mobile IDTF may visit multiple
locations and it would still be
considered one mobile unit. The
number of places a mobile IDTF visits
does not change the fact that this is a
single unit and up to three fixed base or
mobile units may be under the general
supervision of one physician.
Comment: One commenter stated that
the mobile unit described at
§ 410.33(b)(1) should be consistent with
the language used on the CMS-855B
enrollment application.
Response: We will consider revising
the CMS-855B to incorporate this
recommendation.
Comment: One commenter
recommended treating fixed base sites
and portable units on a comparable
basis in that a supervising physician not
be limited to supervising three portable
units, but also could supervise three
sites from which portable units are
dispatched.
Response: A mobile IDTF may visit
multiple locations, and it would still be
considered one mobile unit. The
number of places a mobile IDTF visits
does not change the fact that this is a
single unit and up to three fixed base or
mobile units may be under the general
supervision of one physician. Under the
commenter’s scenario, any number of
mobile units could be in use and a
physician would not be able to provide
general supervision to an infinite
number of mobile units.
Comment: One commenter
recommended that we revise § 410.33(b)
to move to a diagnostic equipment
threshold limit instead of an IDTF site
limit since, as proposed, the provision
allowing fixed based IDTFs to run
limitless testing procedures at the IDTF
is equated with a mobile unit running
PO 00000
Frm 00067
Fmt 4701
Sfmt 4700
66287
one test at a time. Therefore the number
of supervising physicians should be
determined through testing volume and
not location.
Another commenter recommended
that a maximum threshold of 15 units
per supervising physician would be
advisable and that is should be made
clear that this section applies to general
supervision and not direct or personal
supervision.
Response: Due to the varied and ever
changing equipment used by IDTFs, it
would be impractical to establish such
limits.
Comment: One commenter
recommended that we conduct
additional audits, monitoring, and
enforcement actions, where warranted,
to address existing compliance
problems.
Response: We agree with the
commenters that audits, monitoring,
and enforcement efforts are effective
ways to identify individual compliance
issues. We already require that Medicare
contractors conduct an onsite visit to
verify the performance standards found
in this section prior to initial
enrollment. We will consider adding
and/or redirecting existing resources to
ensure that an IDTF remains in
compliance with these standards.
Comment: One commenter requested
clarification to differentiate between
fixed and mobile IDTFs business models
and the differences by which IDTFs
using these models provide services.
Response: A fixed base IDTF performs
all of its diagnostic testing at the
practice location found on the Medicare
enrollment application (CMS–855),
whereas a mobile IDTF travels and
performs its diagnostic tests at locations
other than a single practice location.
Comment: One commenter requested
that we clarify the definition of ‘‘site’’
versus ‘‘testing locations’’ distinction.
Response: We consider sites and
testing locations to be a practice
location for both fixed base and mobile
IDTFs.
Comment: One commenter suggested
that the language at § 410.33(i)(3) is in
error and was meant to be a definition,
because it explains the first two parts of
the effective date provision. The
commenter stated that they believe that
the date which a signed enrollment
application is submitted should be
considered the date of filing and that
any time lag in contractor decisions
should be excluded when determining
the date of filing.
Response: We agree with the
commenter and are revising
§ 410.33(b)(1) accordingly.
After reviewing the public comments,
we are amending the provision to
E:\FR\FM\27NOR2.SGM
27NOR2
66288
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
remove the following sentence from
§ 410.33(b)(1), ‘‘The IDTF supervising
physician is responsible for the overall
operation and administration of the
IDTFs, including the employment of
personnel who are competent to
perform test procedures, record and
report test results promptly, accurately
and proficiently, and for assuring
compliance with the applicable
regulations’’.
We are adopting the provision at
§ 410.33(b)(1) which clarifies the
meaning of what constitutes three IDTF
sites to include both fixed sites and
mobile units. This includes moving
portable diagnostic equipment to
another location and used it to provide
IDTF services. Accordingly, we believe
that a physician providing general
supervision as defined in
§ 410.32(b)(3)(i) can oversee a maximum
of three sites (that is, fixed or mobile)
where concurrent operations can be
performed. In addition, we are clarifying
that that this provision applies only to
general supervision within an IDTF
setting. Section 410.33(b)(1) is revised to
read, ‘‘Each supervising physician must
be limited to providing general
supervision to no more than three IDTF
sites. This provision applies to both
fixed sites and mobile units where three
concurrent operations are capable of
performing tests.’’
2. New IDTF Standards
cprice-sewell on PROD1PC72 with RULES
a. § 410.33(i)
In § 410.33(i), we proposed to
establish an initial enrollment date for
IDTFs and to limit the retrospective
period for which an IDTF can obtain
payment for services after enrolling into
the Medicare program.
Comment: One commenter
recommended that we adopt an
accelerated rollout plan of the PECOS
Web to facilitate the enrollment process
for IDTFs.
Response: We expect to implement
PECOS Web in most parts of the country
by March 2008.
Comment: One commenter
recommended that we ensure that
Medicare contractors process
enrollment applications in a timely
manner so that beneficiaries will have
access to quality and convenient
healthcare delivery at an IDTF.
Response: We will continue to work
with all Medicare contractors to ensure
that applications are processed in a
timely and accurate manner. With the
implementation of PECOS Web, we
believe that many of the processing
delays that have occurred within the
last year will be corrected. Specifically,
PECOS Web will facilitate the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
submission of a complete application
and allow applicants to make any
necessary changes to their enrollment
application in a timely manner.
Comment: Several commenters
recommended that we revise our
proposals to allow an IDTF to begin
billing Medicare for claims with dates of
service on or after the day on which the
IDTF submits a ‘‘substantially correct’’
or ‘‘substantially complete’’ enrollment
application or the date the IDTF first
furnishes services at its location,
whichever is later.
Response: We disagree with the
recommendation to permit an IDTF to
submit claims with dates of service on
or after the day which the IDTF submits
a ‘‘substantially correct’’ enrollment
application or the date the IDTF first
furnishes services at its location,
whichever is later. We believe that it is
essential that all providers and
suppliers, including IDTFs, submit a
complete application at the time of
filing or perfect the submission of their
enrollment application in response to a
contractor’s request for information.
Accordingly, an applicant who submits
a complete application or responds in a
timely manner to a request for
additional information is not
disadvantaged by this proposal.
However, it is important to note that if
an application is rejected in accordance
with the provisions found at § 424.525,
the applicant will need to submit a new
application to enroll in the Medicare
program. In this case, the applicant only
will be able to seek payments for those
services furnished on or after the date of
filing or when the Medicare contractor
has approved the second application
request.
Comment: One commenter
recommended that retroactive billing
(once approval has been determined) be
allowed back to the time of the initial
application (even if the first submission
is rejected).
Response: As stated above in this
section, we disagree with this
recommendation. We believe that an
IDTF should be allowed to bill for
services furnished on or after the date of
filing or the date the practice location
became operational. However, we do
not believe that it is appropriate to
allow an IDTF to bill for services back
to the filing date of the initial
application if the initial application was
rejected due to the nonsubmission of
information or denied because the
applicant did not meet the program
requirements to enroll as an IDTF.
Comment: One commenter
recommended that a 60-day period be
allowed for retroactive billing before an
IDTF is enrolled.
PO 00000
Frm 00068
Fmt 4701
Sfmt 4700
Response: While we believe that an
IDTF should be allowed to bill for
services furnished on or after the date of
filing or the date the practice location
became operational, we do not believe
that it is appropriate to allow an IDTF
to bill for services prior to the filing date
associated with when the application
was submitted.
Comment: One commenter
recommended that Medicare contractors
follow a protocol that outlines the items
that will require a contractor to reject or
deny an enrollment application.
Response: Medicare contractors are
bound by applicable enrollment
regulations and CMS manual
instructions. Specifically, all Medicare
contractors are required to follow
regulations found at § 424.525 and
manual instructions found in
publication 100–8, Chapter 10 of the
Program Integrity Manual (PIM) when
rejecting an enrollment application for
insufficient information. In addition,
Medicare contractors are required to
follow regulations found at § 424.530
and manual instructions found in
publication 100–8, Chapter 10 of the
PIM when denying an enrollment
application.
Comment: One commenter
recommended that we not implement
our proposal to preclude an IDTF from
being allowed to bill Medicare
retroactively for services that are
rendered prior to the provider being
formally approved by the applicable
Medicare contractor to participate in the
Medicare program.
Response: Since our proposal
specifically allows an IDTF to receive
reimbursement for services furnished on
or after the filing or the date the IDTF
opened a new practice location,
whichever was later, we believe that we
are allowing IDTFs a limited amount for
retroactive billing. As stated in the
preamble to the proposed rule, the
purpose of this rulemaking effort is to
establish a date of enrollment for IDTFs
where we believe that the enrolling
IDTF meets all of the program
requirements to participate in the
Medicare program.
Comment: One commenter
recommended that we clarify that our
proposed change in billing be applied
only to new or initial enrollment
applications and would not affect
existing operations when changes or
additions are made to an enrollment
application, such as the addition of a
new physician or piece of equipment.
Response: In general, we agree with
this commenter in that the proposed
change only will apply to new or initial
enrollment applications. Since the
provision is designed to limit
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
retrospective billing prior to enrollment
in the Medicare program, we do not
believe this change will impact existing
IDTFs who are making a change to an
existing enrollment record for a fixed or
mobile practice location. However, it is
important to note that the limitations on
retroactive billing will apply to existing
IDTFs who are adding a new fixed or
mobile practice location to their existing
enrollment record. Moreover, a
limitation on retroactive billing may
apply when there is change of
ownership.
Comment: One commenter stated that
they had no issues with the effective
date of the billing privileges provision.
However, this commenter suggested that
this provision be tied to a requirement
that the CMS designated contractor
process the application in a timely
fashion.
Response: We are also concerned
about delays associated with the
enrollment process. However, we
recognize that many of the delays are
the result of IDTF suppliers not
submitting a complete application at the
time of filing or failing to submit
complete and timely responses to a
contractor’s request for information.
In addition, we believe that it is
appropriate to expect meaningful
Medicare contractor processing
timeliness standards. As necessary, the
agency can update or revise processing
standards through the manual
instructions and through contracts with
Medicare Administrative Contractors.
We fully expect that most enrollment
applications will be processed in
accordance with CMS processing
requirements found in Publication 100–
8, Chapter 10 of the PIM. The PIM
establishes processing standards for
initial applications, changes of
information, and reassignments that all
Medicare contractors must adhere to.
Specifically, we currently require
Medicare contractors to process 80
percent of initial applications within 60
days, 90 percent of initial applications
within 120 days, and 99 percent of
initial applications within 180 days. We
also require Medicare contractors to
process 80 percent of changes of
information and reassignments within
45 days, 90 percent of changes of
information and reassignments within
60 days, and 99 percent within 90 days.
With the implementation of PECOS
Web, an internet version of the
Medicare enrollment process, in FY
2008, we expect to establish more
stringent contractor processing
timeliness standards for applications
submitted via PECOS Web.
Comment: One commenter stated that
the effective date of the billing
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
privileges provision may economically
affect small and medium sized business
in that the IDTF must list the
credentialed employees on the
application itself in order for the
application to be processed, and that
these businesses cannot use or bill for
their services during the time periods
that they are not enrolled. Further, the
commenter states that it would be
impractical to hire these technicians if
they cannot use them to perform the
tests for the time it takes to get
approved.
Response: We disagree with the
commenter because all IDTFs should
have proper staffing, including
credentialed technicians, at the time the
IDTF practice location is applying to
participate in the Medicare program or
when the IDTF is operational.
Comment: One commenter suggested
that an IDTF that is enrolled and in
good standing in the Medicare program
at one location be able to enroll new
sites retroactively to the first date of
service at the new location.
Response: We disagree with this
recommendation because the approval
of one practice location does not
necessarily mean that a second practice
location meets the requirements for
approval.
Comment: One commenter
recommended that we require that
applicants be notified of their
enrollment status within 60 days of
submitting their applications.
Response: We believe that this
comment is outside the scope of this
final rule. However, given certain
resource limitations, contractors are
unable to respond to such status
inquiries. With the implementation of
PECOS Web, providers and suppliers,
except DMEPOS suppliers, will be able
to check the status of their applications
via the Internet.
After reviewing the public comments
we are finalizing the provision at
§ 410.33(i) to state that we will establish
an initial enrollment date for an IDTF
that would be the later of: (1) the date
of filing of a Medicare enrollment
application that was subsequently
approved by Medicare FFS contractor;
or (2) the date an IDTF first started
furnishing services at its new practice
location. We also adopted the ‘‘date of
filing’’ as the date that the Medicare FFS
contractor receives a signed provider
enrollment application that the
Medicare FFS contractor is able to
process for approval. If the Medicare
FFS contractor rejects or denies an
enrollment application that is not later
overturned during the appeals process,
the new date of filing would be
established when an IDTF submits a
PO 00000
Frm 00069
Fmt 4701
Sfmt 4700
66289
new enrollment application that the
contractor is able to process to approval.
With the implementation of an
Internet enrollment process referred to
as the PECOS Web in 2008, the date of
filing for applications submitted
through PECOS Web will be the date the
Medicare contractor receives all of the
following: (1) A signed Certification
Statement; (2) an electronic version of
the enrollment application; and (3) a
signature page that the Medicare
contractor processes to approval.
While this change limits the
retrospective payments that an IDTF
may obtain from the Medicare program,
we believe that this approach will
ensure that a Medicare contractor is able
to verify that an IDTF meets all program
requirements at the time of filing,
including the performance standards
outlined in § 410.33(g) before payment
for service occurs.
b. § 410.33(g)(3)
We received the following comments
regarding our proposal at § 410.33(g)(3)
to expressly preclude hotels and motels
from being considered an appropriate
site for an IDTF setting.
Comment: One commenter stated that
many IDTFs have contracts directly
with a hotel or motel where they rent
space for studies and that they disagreed
with the rules’ provision to ban such a
situation.
Response: We disagree with this
comment because we believe that space
located within a hotel or motel can
easily be transferred to other uses other
than providing sleep studies.
Comment: Several commenters stated
that a hotel or motel room is not
appropriate places for diagnostic testing
to take place.
Response: We agree with these
comments and have revised
§ 410.33(g)(3) accordingly.
Comment: One commenter suggested
that the provision at § 410.33(g)(3) be
changed to state that the requirements
for hand washing and patient privacy
only apply to IDTFs that see patients
and to clarify that being able to access
records electronically fulfills the
requirement of storing business and
medical records.
Response: We have amended
§ 410.33(g)(3) to state that the
requirements for hand washing and
patient privacy only apply to IDTFs that
see patients and to clarify that being
able to access records electronically
fulfills the requirement of storing
business and medical records.
We are adopting a revision to
§ 410.33(g)(3) to expressly preclude
hotels and motels from being considered
an appropriate site for an IDTF setting.
E:\FR\FM\27NOR2.SGM
27NOR2
66290
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Based on public comments, we believe
that a hotel or motel is not an
appropriate place for diagnostic testing
to take occur. Accordingly, we have
revised § 410.33(g)(3) to read, ‘‘Maintain
a physical facility on an appropriate
site. For the purposes of this standard,
a post office box, commercial mailbox,
motel, or hotel are not considered an
appropriate site. The physical facility,
including mobile units, must contain
space for equipment appropriate to the
services designated on the enrollment
application, facilities for hand washing,
adequate patient privacy
accommodations, and the storage of
both business records and current
medical records within the office setting
of the IDTF, or IDTF home office, not
within the actual mobile unit.’’
Additionally, we have added an
exception at § 410.33(g)(3)(ii), where
IDTFs that do not see beneficiaries at
their locations are exempt from
providing hand washing and patient
privacy accommodations.
cprice-sewell on PROD1PC72 with RULES
c. § 410.33(g)(15)
At § 410.33(g)(15), we proposed a new
performance standard which stated,
‘‘Does not share space, equipment, or
staff or sublease its operations to
another individual or organization.’’
Comment: One commenter stated that
they were concerned about the
emergence of arrangements in which a
physician practice leases a block of time
from an imaging provider (such as an
IDTF) or agrees to pay the provider a per
service fee to use its facility. The group
practice then refers its patients to the
imaging provider for imaging tests and
bills the insurer for the services, usually
profiting from the difference between
the insurer’s payment rates and the fees
the practice pays to the imaging
provider.
Response: We agree with the
commenter and reiterate that our
proposals are designed to prohibit such
practices.
Comment: Several commenters
supported our proposal to prohibit
IDTFs from sharing space, equipment,
or staff, or subleasing their operations to
another individual or organization.
Response: We appreciate these
comments and agree that there has been
a proliferation of share use agreements
between IDTFs and physicians and/or
other organizations that have allowed
the sharing of space and equipment.
Comment: One commenter stated that
they applauded our efforts to address an
alarming proliferation of referring
physicians entering into ‘‘lease’’ or
similar purchased test arrangements
with imaging centers for the primary
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
purpose of enabling physicians to profit
from their own referrals.
Response: We appreciate these
comments as our proposals are designed
to prohibit such practices.
Comment: Several commenters
recommended that CMS not finalize
§ 410.33(g)(15) because it severely
restricts the use of an IDTF’s property
and places unnecessary limitations on
the entity.
Response: We disagree with this
comment. With the revisions we are
making to § 410.33(g)(15), we believe
that an IDTF’s property is fully available
for use solely by the IDTF. The adopted
provision at § 410.33(g)(15) will allow
an IDTF to conduct all of its approved
diagnostic testing procedures.
Comment: One commenter stated that
the proposed rule would prohibit an
IDTF from participating in any type of
leasing arrangement.
Response: In this final rule with
comment period, we are prohibiting the
leasing or subleasing of an IDTF practice
location, as well as diagnostic
equipment that are used in taking the
initial diagnostic test. In addition, we
are prohibiting leasing and subleasing to
a third party.
Comment: One commenter requested
that we clarify whether the proposed
performance standard found at
§ 433.10(g)(15) would permit a multispecialty clinic and an IDTF to be
enrolled as a clinic and an IDTF, and for
portions of space and staff to be used for
both clinic and IDTF activities.
Response: While we understand the
commenter’s concern, we do not believe
that it is appropriate to co-locate a
multi-specialty clinic in the same
practice location as an IDTF.
Specifically, while we are not
prohibiting the sharing common of
hallways, parking, or common areas, we
believe that a multi-specialty clinic
cannot occupy or be co-located within
the same practice location. For example,
a multi-specialty clinic and an IDTF
could not enroll or remain enrolled
using the same suite number within the
same office building.
Comment: Some commenters
recommended that we define the term,
‘‘individual or organization’’ to exclude
hospitals and nonreferring radiologists,
because hospitals and nonreferring
radiologists are not in a position to selfrefer.
Response: We disagree that the terms
‘‘individual and organization’’ needs to
be defined. For the purposes of this rule,
an individual is a person, and an
organization is any entity other than an
individual.
Comment: One commenter
recommended that we permit an
PO 00000
Frm 00070
Fmt 4701
Sfmt 4700
adjoining physician practice or a
radiology group that is the owner of an
IDTF to share space, equipment, and
staff.
Response: While we agree that it is
common for IDTFs to share common
areas (that is, waiting rooms) with the
adjoining physician practice or
radiology group that is an owner of the
IDTF, we do not believe that it is
appropriate for IDTFs to share common
practice locations or diagnostic testing
equipment.
Comment: Several commenters
recommended that we not extend the
prohibition of sharing space, equipment,
and staff to the mobile IDTF setting.
Another commenter recommended
that the proposed restriction on sharing
space, equipment, and staff should not
apply to mobile IDTFs, as this would
add both physical and financial burdens
that mobile units simply could not
meet.
Response: We agree with these
commenters that requiring mobile IDTFs
to adhere to limitations regarding space,
equipment, and staffing may limit
beneficiary access to necessary mobile
services and increase the costs of
providing necessary diagnostic care.
Accordingly, we are excluding mobile
IDTFs from the provisions found at
§ 410.33(g)(15).
Comment: One commenter
recommended that we revise our
proposals to account for certain
practical implications concerning the
imaging industry, including common
and legitimate sharing practices
between multiple IDTFs, between IDTFs
and hospitals, and between IDTFs and
radiologist.
Response: While we agree that it
reasonable for IDTFs located within a
hospital to share practice locations and
diagnostic testing equipment, we
continue to have significant concerns
regarding the sharing of space by IDTFs
in a nonhospital setting.
Comment: One commenter
recommended that we revise the
performance standard found at
§ 410.33(g)(15) to state, ‘‘Does not share
space, equipment or staff or sublease its
operations to another individual,
organization, employee or contractor of
such organizations, that refers Medicare
patients to the IDTF for designated
health services.’’
Response: We have considered this
comment in revising the performance
standard at § 410.33(g)(15).
Comment: One commenter believed
that the performance standard found in
§ 410.33(g)(15) applies to hospitals.
Response: Upon review of the
comments, we have revised
§ 410.33(g)(15) to exclude hospitals.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Comment: Several commenters
recommended that we clarify that the
proposed performance standard found
in § 410.33(g)(15) would apply only to
newly enrolling IDTFs and not IDTFs
already enrolled in the Medicare
program. Specifically, these commenters
requested that we clarify that this new
standard would allow an IDTF to
continue to lease personnel and
equipment from third parties provided
that the IDTF uses the personnel, space,
and equipment exclusively throughout
the lease term.
Response: We maintain that the
provision found in § 410.33(g)(15)
applies to both newly enrolling IDTFs,
as well as those IDTFs currently
enrolled in the Medicare program. This
provision does not prohibit an IDTF
from leasing space or equipment that is
used solely by that IDTF-party, such as
a building management company or an
equipment manufacturer. This does not
preclude an IDTF from leasing any part
of its practice location or equipment
used in conducting the initial diagnostic
procedure to another Medicare-enrolled
individual or group to conduct
diagnostic testing activities.
Comment: One commenter
recommended that we clarify that
employees of affiliated employers under
the Fair Labor Standards Act are not
considered ‘‘shared staff’’ under this
new standard. In addition, several
commenters recommended that the
prohibition on sharing ‘‘staff’’ be limited
to sharing nonphysician personnel.
Response: The new sharing provision
has been modified to exclude the
prohibition on the sharing of staff.
Comment: One commenter
recommended that if we adopt the
proposed performance standard found
in § 410.33(g)(15) that the
implementation date be delayed for at
least 12 months to provide IDTFs and
physician practices with sufficient time
to find new office space, recruit
additional staff, notify their patients and
generally restructure their existing
relationships. Another commenter
recommended that we clarify our
proposed performance standard found
in § 410.33(g)(15).
Response: We agree with commenters
and we are adopting a 1-year delay in
implementation (effective January 1,
2009) of the space-sharing provision for
IDTFs that are currently occupying a
practice location with another
Medicare-enrolled individual or
organization that is found at
§ 410.33(g)(15)(i).
Comment: One commenter
recommended that we clarify whether
the proposed prohibition on sharing
space, equipment, and staff is intended
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
to apply when the IDTF leases or
subleases space from a hospital on a
full-time, exclusive basis. Other
commenters recommended that we
exclude mobile IDTFs from the
prohibition to share space because it is
impractical in complying with this
provision. One commenter stated that
the sharing of staff standard is
impractical to comply with and should
not be extended to mobile IDTFs,
because accredited and trained
contracted personnel are sometimes
necessary to contract with on a
temporary basis.
Another commenter suggested that we
not apply this provision to mobile
IDTFs and instead, permit an IDTF to
share space, equipment and staff with
an entity that is related to the IDTF,
such as through common control or
ownership. Also, this commenter
recommended that we should clarify in
what situation an IDTF could not share
staff, such as; supervising physician and
nonphysician personnel.
Response: This provision is not
intended to restrict an IDTF from
entering into a rental agreement for
space or equipment, excluding
hospitals, as long as that IDTF, or the
owner of the IDTF are exclusively using
that space or equipment. We are
excluding mobile IDTFs from the
prohibition on sharing space and staff.
Comment: One commenter stated that
the sharing of space provision should
not apply to a Medicare-certified IDTF
that leases or subleases space and/or
qualified technical staff from a hospital
on a full time, exclusive basis (they are
not ‘‘shared’’ with the hospital).
Response: We agree with the
comment and the standard has been
revised to reflect this concern.
Comment: One commenter wanted
clarification on whether we will permit
an IDTF to utilize a common area in a
building where an IDTF enters into a
lease or sublease with a hospital for the
full-time, exclusive use of the operation
of the IDTF.
Response: We will permit an IDTF to
utilize a common area in a building
where an IDTF enters into a lease or
sublease with a hospital for the full-time
exclusive use of the operation of the
IDTF. However, the IDTF must have its
own practice location that is only used
by that IDTF.
Comment: One commenter requested
clarification on whether we intend to
prohibit only new space, equipment, or
staff sharing arrangements from the
effective date of the rule or if it will
apply to existing arrangements. If it
applies to existing arrangements, then
the commenter requests that the
implementation be delayed by 1 year.
PO 00000
Frm 00071
Fmt 4701
Sfmt 4700
66291
Response: While we intend to
prohibit the sharing of space at a
practice location from the effective date
of the rule for newly-enrolling IDTFs
(including those with applications that
are still pending as of January 1, 2008),
we are adopting a 1-year delay in
implementation (effective January 1,
2009) of the space-sharing provision for
IDTFs that are currently occupying a
practice location with another
Medicare-enrolled individual or
organization that is found at
§ 410.33(g)(15)(i).
Comment: One commenter requested
clarification as to whether we will
permit an IDTF that leases or subleases
space and/or staff from a hospital to
purchase back-office services from the
hospital. (These types of service may
include, but are not limited to,
transcription, billing, collection,
recordkeeping, and computer access
services, based upon a flat fee or at cost
plus to the hospital).
Response: We will permit an IDTF to
lease or sublease space from a hospital
and to purchase services from the
hospital which may include, but are not
limited to, transcription, billing,
collection, recordkeeping, and computer
access services, based upon a flat fee or
at cost plus to the hospital.
Comment: One commenter
recommended that there should be an
exception made at § 410.33(g)(15) for
companies operating both an IDTF and
portable x ray supplier, since both are
surveyed and subject to multiple
standards under the Medicare program.
Response: While we understand this
concern, we believe that an IDTF must
have a practice location where only one
Medicare-enrolled IDTF is furnishing
services. If another Medicare-enrolled
entity is using the same practice
location space as an IDTF, especially for
shortened periods of time, our
designated contractor is not able to
determine which entity is responsible
for meeting performance standards at a
given time.
Comment: One commenter urged us
to address the sharing of space, staff,
and equipment provision by specifically
excluding radiologists and radiology
groups, who are not self-referring, from
the sharing arrangements in IDTFs due
to the increased costs and possible
detriment to the beneficiary (numerous
visits to different locations and
increased stress) that may occur in this
situation.
Response: We believe that the practice
location and equipment that an IDTF
uses for its initial diagnostic testing
cannot be used by another Medicare
provider or supplier, and therefore, we
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66292
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
are not excluding radiologists and
radiology groups.
Comment: One commenter agreed that
it would be inappropriate to commingle
the clinical staff listed on the CMS–855
enrollment application during the times
that the IDTF is open; however, the
commenter maintains that non-clinical
space and staff (such as waiting rooms,
receptionists, and schedulers) should be
shared with other entities.
Response: We agree with this
comment and have amended the
provision to reflect these concerns.
Comment: One commenter
recommends that the sharing of
nonclinical space, equipment and
personnel be allowed between an IDTF
and an adjacent facility, because it does
not offer the same potential for abuse as
situations where the clinical operations
of the IDTF would be commingled.
Response: We have amended the
provision found at § 410.33(g)(15) to
address these concerns.
Comment: One commenter
recommends that the sharing of space
between a group or a physician practice
and its own IDTF should not be
prohibited. Another commenter
recommends changing the proposed
§ 410.33(g)(15) because they believe it
would prohibit wholly-owned corporate
subsidiaries and affiliated under
common control from sharing space,
equipment, and staff in a cost efficient
manner.
Response: We disagree with this
recommendation since it is not feasible
to distinguish between two different
practices that are co-located at the same
practice location. Also, this provision
would not prohibit wholly-owned
corporate subsidiaries and affiliated
entities under common control from
sharing equipment, as long as the
change in equipment location is timely
reported. In addition, the IDTF’s
practice location must be separately
distinguishable and not commingled
with another Medicare provider or
supplier.
Comment: One commenter
recommends changing the proposed
§ 410.33(g)(15) to read as follows: ‘‘Does
not share space, equipment, or staff or
sublease it operations to another
individual or organization, except for a
subsidiary or affiliated IDTF that is
wholly owned by, and under the
complete control of, the IDTF.’’
Response: We understand the
commenter’s recommendation and we
have amended § 410.33(g)(15) to address
the commenter’s concern.
Comment: One commenter
recommends that CMS specifically
exempt IDTFs that have common
ownership and common control from
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the definition of ‘‘individual or
organization,’’ if CMS implements
§ 410.33(g)(15) as written.
Response: We disagree with the
commenter’s recommendation. While
IDTFs may have common ownership,
each practice location is enrolled
separately.
Comment: One commenter offered
support for our provision to prohibit
fixed site IDTFs from sharing space,
equipment, and staff or subleasing their
operations to another individual or
organization.
Response: We appreciate the
commenters support on the proposed
provisions.
Comment: One commenter suggested
excluding radiologist and radiology
groups from the definition of individual
or organization in the regulatory
language at § 410.33(g)(15) so that
imaging IDTFs can share space,
equipment, and staff with radiologists
and radiology groups.
Response: We disagree with this
recommendation because IDTFs enroll
each practice location separately.
Comment: One commenter suggested
that we clarify in the preamble that the
prohibition does not preclude affiliated
companies (which do not have any
referring nonradiologist physicians as
owners) that provide services integrally
related to the operations of an imaging
IDTF (such as interoperable information
system, centralized credentialing, staff
and billing) from sharing space,
equipment and staff.
Response: We modified
§ 410.33(g)(15) to reflect concerns about
the sharing of space and equipment.
Since Medicare enrolls each IDTF at a
separate location, we believe that it is
not necessary to address how affiliated
companies interact with an IDTF as long
as each IDTF is in compliance with the
provisions of this final rule with
comment period.
Comment: One commenter suggested
that CMS clarify that an ownership or
investment interest held by radiologists
and radiology groups in an imaging
IDTF does not constitute sharing under
§ 410.33(g)(15).
Response: We agree that an ownership
or investment interest held by
radiologists and radiology groups in an
imaging IDTF does not constitute
sharing under § 410.33(g)(15).
Comment: One commenter suggested
that we revise this provision to specify
that an IDTF cannot share its space,
equipment or staff with another
individual or organization that has
Medicare billing privileges, and that it
is okay for another non-Medicare
enrolled entity to use the IDTF’s space,
equipment, and staff.
PO 00000
Frm 00072
Fmt 4701
Sfmt 4700
Response: We agree with the
commenter. The IDTF may not share
clinical space or the diagnostic
equipment involved in the original
diagnostic test with a Medicare-enrolled
provider or supplier.
Based on public comments, we have
removed the sharing of staff aspect of
this provision, and we are revising
§ 410.33(g)(15) to read, ‘‘With the
exception of hospital-based and mobile
IDTFs, a fixed-base IDTF does not—
• Share a practice location with
another Medicare-enrolled individual or
organization;
• Lease or sublease its operations or
its practice location to another
Medicare-enrolled individual or
organization; or
• Share diagnostic testing equipment
used in the initial diagnostic test with
another Medicare-enrolled individual or
organization.’’
We believe that it is inappropriate for
a fixed-base (physical site) IDTF to
commingle its practice location or the
equipment used in conducting the
initial diagnostic test with another
individual or organization enrolled in
the Medicare program. By sharing space
and/or equipment, Medicare contractors
are not able to determine if an IDTF
meets all of enrollment requirements at
§ 424.500 through § 424.555 or whether
each IDTF meets and maintains all
performance standards and other
requirements under § 410.33 and other
applicable requirements.
After examining public comments, we
believe that it is appropriate to establish
two exceptions to the prohibition
associated with sharing space and
clinical equipment. These exceptions
apply to mobile IDTFs or IDTFs that are
co-located within a hospital.
A mobile IDTF, by its very nature,
may share space with other Medicareenrolled entities. As such, we believe
that it would be detrimental to the IDTF
industry to apply this new performance
standard to mobile IDTFs, because this
may limit beneficiary access to
necessary mobile IDTF services and
increase the costs of providing
necessary diagnostic care. In addition,
we believe that hospital-based IDTFs are
inherently located within a larger
facility type and based on the need of
the hospital, may appropriately share
space or clinical equipment to gain
operating efficiencies with little
additional risk to the Medicare program
or its beneficiaries.
Finally, while all IDTF provisions are
effective on the implementation date of
this final rule with comment period, we
believe that additional time may be
needed for some IDTFs to change their
business model if they are sharing a
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
practice location with another
Medicare-enrolled individual or
organization. Accordingly, we are
adopting a 1-year transition period for
IDTFs that are currently enrolled and
are sharing a practice location with
another Medicare individual or
organization. While this 1-year
transition period applies to the
provision found at § 410.33(g)(15)(i)
related to the sharing of space, it does
not apply to the provisions found at
§ 410.33(g)(15)(ii) or § 410.33(g)(15)(iii).
Accordingly, IDTFs are prohibited from
maintaining or establishing leasing or
subleasing agreements or the sharing of
diagnostic testing equipment used in
taking the initial diagnostic test, after
the effective date of this rule.
3. Additional Comments and
Responses
Comment: One commenter
recommended that our proposal to
prohibit the sharing of space,
equipment, and staff be applied
consistently in all imaging centers,
whether enrolled as an IDTF or as a
physician-directed clinic.
Another commenter recommended
that any policy initiative intended to
eliminate certain suspect leasing or
space sharing arrangements should be
applied to all imaging providers, not
just IDTF providers.
One commenter supported the
proposed prohibition on shared
equipment but urged us to apply this
prohibition to all entities (including
physician practices, mobile units, and
hospitals) that provide imaging services.
Some commenters believe an
exception should be made to include
cardiologists that are certified for the
interpretation of nuclear cardiology
studies in an IDTF as well as allow
interpretation of nuclear cardiology
studies for an IDTF.
One commenter stated that since selfinsurance is permitted, the requirement
that the insurance be purchased from a
‘‘non-relative owned company’’ should
be removed, or replaced with a
provision that permits an alternate
method of meeting the requirement by
maintaining insurance through a
relative-owned company that has been
approved by a state department of
insurance or comparable state agency or
that can be validated by a placing
broker.
Another commenter recommended
that CMS should end payments to
independent contractor physicians who
are not board-certified in Sleep
Disorders Medicine.
One commenter recommended that
CMS require interpreting physicians to
have board certification in Sleep
Medicine in metropolitan areas.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
One commenter recommended that
we edit the location of service language
at § 410.33(e)(2) to redefine the location
from which a service is billed.
Another commenter recommended
requiring a hospital licensed entity and
actual radiology group to be the owners
of entities that do not have to register as
IDTFs and allow related entities of the
hospital and radiology group to also
own the imaging center.
Response: We appreciate these
comments and we will consider these
recommendations in a future
rulemaking effort.
J. Expiration of MMA Section 413
Provisions for Physician Scarcity Area
(PSA)
Section 413(a) of the MMA added a
new section 1833(u) to the Act. That
section provided a 5 percent incentive
payment to physicians furnishing
services in physician scarcity areas
(PSAs) for physicians’ services
furnished on or after January 1, 2005,
and before January 1, 2008. Specifically,
section 1833(u) of the Act provided for
payment of an additional 5 percent of
the payment amount for services
furnished by primary care physicians in
a primary care scarcity area and by nonprimary care physicians in a specialist
care scarcity area.
Because the provisions of section
1833(u) of the Act do not apply to
services furnished after December 31,
2007, in the CY 2008 PFS proposed rule,
we provided notification that these 5
percent incentive payments will no
longer be made for services furnished on
or after January 1, 2008.
The list of zip codes for both primary
care and specialty PSAs can be found on
the CMS Web site at https://
www.cms.hhs.gov/
hpsapsaphysicianbonuses/
01_overview.asp.
Comment: We received comments
expressing concern over the expiration
of this provision. Commenters stated
that the expiration of this provision may
exacerbate the problems beneficiaries in
rural areas experience in accessing
medical services.
Response: We acknowledge the
commenters’ concerns regarding access
to care, especially in rural areas. We
provided notification of the pending
expiration of this provision in the CY
2008 PFS proposed rule. We note that
the Congress specifically established the
PSA incentive program to apply only to
claims for services furnished between
January 1, 2005, and January 1, 2008.
We do not have authority under the
current statute to extend PSA bonus
payments beyond this time frame.
PO 00000
Frm 00073
Fmt 4701
Sfmt 4700
66293
K. Comprehensive Outpatient
Rehabilitation Facility (CORF) Issues
In the CY 2008 PFS proposed rule (72
FR 38171), we discussed Medicare
payment for comprehensive outpatient
rehabilitation facility (CORF) services,
including nursing services delivered
within a CORF, which are defined by
HCPCS code (G0128) for such services.
We also explained that we use the
payment amount established by an
existing fee schedule other than the PFS
when the PFS does not establish a
payment amount for the CORF service.
Specifically, we use the existing fee
schedules for prosthetic and orthotic
devices, DME and supplies, and drugs
and biologicals for prosthetics and
orthotics devices, durable medical
equipment (DME) and supplies, and
drugs and biologicals, respectively,
provided by CORFs that are considered
CORF services. Covered DME, orthotic
and prosthetic devices, and supplies
provided by a CORF are paid under the
DMEPOS fee schedule.
Drugs and biologicals that are not
considered to be self-administered are
specified as CORF services at section
1861(cc)(1)(F) of the Act. However, as
discussed in the proposed rule, we
believe that drugs and biologicals
provided to CORF patients are not
appropriately provided as part of a
rehabilitation plan of treatment and, as
such, we proposed to remove drugs and
biologicals from the scope of CORF
services as defined at § 410.100. After
reviewing comments, we have decided
to retain within the definition of CORF
services drugs and biologicals that are
not self-administered, as discussed
below in section II.K.7. However, as we
are not aware of any non-selfadministered drugs and biologicals that
appropriately may be included as part of
a rehabilitation plan of treatment, we
intend to closely track the provision of
drugs and biologicals in the CORF
setting and do not expect CORFs to bill
for such drugs and biologicals. In
addition, because we believe it is
appropriate for pneumococcal,
influenza, and hepatitis B vaccines to be
administered to CORF patients in the
CORF setting, even though such
vaccines fall outside the scope of CORF
services, we also proposed to revise the
conditions of participation at § 485.51(a)
to permit CORFs to provide to their
patients pneumococcal, influenza, and
hepatitis B vaccines in addition to
CORF services.
Because the regulations under 42 CFR
parts 410 and 413 were never updated
to reflect the change in CORF payment
methodology from a ‘‘reasonable cost’’
basis to 80 percent of the lesser of a
E:\FR\FM\27NOR2.SGM
27NOR2
66294
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
payment amount under an existing fee
schedule or the CORF’s actual charge,
we proposed to add a new subpart M to
42 CFR part 414 to reflect the change in
CORF payment methodology.
In addition, we proposed revisions to
the definitions of certain CORF services
under § 410.100, in order to limit the
scope of such services and items to
those appropriately provided by
qualified CORF personnel and related to
the rehabilitation goals of the plan of
treatment established under
§ 410.105(c). Specifically, we proposed
to clarify the definition of physician
services; respiratory therapy services;
psychological and social services;
nursing services; drugs and biologicals;
supplies, appliances, and equipment;
and the home environment evaluation.
We also proposed to add clarifying
language to § 410.105(b)(3) to make clear
that physical therapy, occupational
therapy, and speech-language pathology
services can be provided offsite in the
patient’s home. In § 410.105(c), we
proposed to clarify that CORF services,
that are not skilled rehabilitation
services, must directly relate to the
physical therapy or other rehabilitation
plan of treatment and its associated
goals.
1. Requirements for Coverage of CORF
Services Plan of Treatment
(§ 410.105(c))
In accordance with section
1861(cc)(1) of the Act, requiring that
CORF services be furnished ‘‘under a
plan (for furnishing such items and
services to such individual) established
and periodically reviewed by a
physician,’’ § 410.105(c) provides that
CORF services as defined under
§ 410.100 are covered only if furnished
under a written plan of treatment.
Specifically, the plan of treatment must:
(1) Be established and signed by a
physician prior to the commencement of
treatment in the CORF setting; and (2)
indicate the diagnosis and anticipated
rehabilitation goals, and prescribe the
type, amount, frequency, and duration
of the services to be furnished. We
interpret these provisions as requiring
that the services furnished under the
rehabilitation plan of treatment must
relate directly to the rehabilitation of
injured, disabled, or sick patients.
Services provided in the CORF setting
that do not relate directly to such
rehabilitation goals and treatment plan
are not covered as CORF services.
Therefore, we proposed to revise
§ 410.105(c) to clarify our policy that
CORF services are covered only if they
relate directly to the rehabilitation of
injured, disabled, or sick patients. We
believe our policy is consistent with the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
statutory requirements under section
1861(cc) of the Act. Section 1861(cc)(1)
of the Act specifies that CORF services
must be furnished under a plan of
treatment. Section 1861(cc)(1)(H) of the
Act further states that ‘‘other items and
services’’ are considered CORF services
only if ‘‘medically necessary for the
rehabilitation of the patient.’’ We
believe the implication of this limitation
for ‘‘other items of services’’ is that all
other CORF services (that is, those listed
under sections 1861(cc)(1)(A) through
(G) of the Act) also must be necessary
for the rehabilitation of the patient. In
addition, we noted that section
1861(cc)(2)(A) of the Act specifies that
a CORF facility is a facility ‘‘primarily
engaged in providing * * * diagnostic,
therapeutic, and restorative services to
outpatients for the rehabilitation of
injured, disabled, or sick persons’’
(emphasis added). We believe this
requirement further signals the
Congress’s intent that the services
provided in a CORF setting be covered
as CORF services only if such services
relate directly to the rehabilitation of the
patient.
Comment: One commenter supported
the proposal to clarify that all services
provided in a CORF must be directly
related to the rehabilitation treatment
plan. The commenter noted that this
proposal is directly aligned with the
goals and purpose of physical therapy.
Response: We appreciate the
commenter’s support of this
clarification. Because the CORF is
defined as a facility that is primarily
engaged in providing diagnostic,
therapeutic and restorative services to
outpatients for the rehabilitation of
injured, disabled or sick persons, we
believe the intent of the statute is that
all services rendered in a CORF must
relate to the patient’s rehabilitation
needs which are stated in the patient’s
plan of treatment established by the
physician. Section 1861(cc)(1) of the Act
and § 410.100 clarify that physician
services, and services of other qualified
professionals, can be provided in a
CORF; but, a physician must first certify
that the patient requires skilled
rehabilitation services, including
physical therapy, occupational therapy,
speech-language pathology, and
respiratory therapy, and then establish
the CORF patient’s rehabilitation plan of
treatment.
Therefore, we are finalizing
§ 410.105(c) as proposed with the
exception that we have added language
to clarify our policy that the
rehabilitation plan of treatment, along
with its goals, is specific to the skilled
rehabilitation services for physical
therapy, occupational therapy, speech-
PO 00000
Frm 00074
Fmt 4701
Sfmt 4700
language pathology, or respiratory
therapy and that these services are
distinct from all other CORF services
which, when provided, must directly
relate to the goals of the rehabilitation
treatment plan.
2. Included Services (§ 410.100)
Section 410.100 establishes the
services that are covered under the
CORF services benefit, consistent with
section 1861(cc)(1) of the Act. Because
of the change in payment methodology
from that based on cost to payment
under the PFS and other existing fee
schedules beginning in CY 1999, this
section does not reflect our current
payment policies. Therefore, we
proposed to clarify our payment policy
in the introductory paragraph of this
section by including a cross reference to
proposed § 414.1101, which sets forth
the payment methodology for CORF
services, including identifying the
applicable fee schedule for each CORF
service. In addition, we proposed to
revise:
• The definition of physician services
to reflect the change in payment
methodology for CORF services;
• The definitions of physician
services, respiratory therapy services,
social and psychological services, and
nursing services to ensure that these
definitions include only those services
appropriately provided by qualified
nonphysician and physician personnel
and related to the rehabilitation plan of
treatment established under
§ 410.105(c); and
• The definition of supplies,
equipment, and appliances to conform
to the statutory provision at section
1861(cc)(1)(G) of the Act.
We also proposed to remove the
provision for drugs and biologicals.
Although vaccines are not included in
the definition of CORF services at
section 1861(cc)(1) and § 410.100, we
proposed to make revisions to the CORF
conditions of participation at § 485.51 to
reflect current coverage and payment
policy for vaccines provided in the
CORF setting.
3. Physician Services (§ 410.100(a))
Section 410.100(a) defines the
physician services included within the
scope of CORF services. Specifically,
those services of a CORF physician
described as administrative in nature
are considered CORF services, to the
exclusion of diagnostic and therapeutic
services, which are physician services
under section 1861(q) of the Act and
separately billable as physician services
under 42 CFR part 414, subpart B.
Section 1861(cc)(1) of the Act excludes
from the definition of CORF services
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
any item or service that, if furnished to
an inpatient of a hospital, would be
excluded under section 1861(b) of the
Act. Section 1861(b)(4) of the Act
excludes from the definition of
‘‘inpatient hospital services’’ the
‘‘medical or surgical services provided
by a physician,’’ which would include
the diagnostic and therapeutic services
of a physician. Consequently, diagnostic
and therapeutic services provided in the
CORF setting by a physician are not
considered CORF services. In contrast,
because those services of a CORF
physician that are of an administrative
nature are not ‘‘medical’’ services, such
services are included in the definition of
CORF services.
In accordance with section
1861(cc)(2)(B)(i) of the Act and
§ 485.70(a)(1), the CORF physician must
be either a medical doctor (MD) or a
Doctor of Osteopathy (DO). The
conditions of participation at
§ 485.70(a)(2) and (3) further require
that the physician have training or
experience in the medical management
of patients requiring rehabilitation
services. The conditions of participation
at § 485.58(a)(1)(i) also require the CORF
facility physician to provide, in
accordance with accepted principles of
medical practice, medical direction,
medical supervision, medical care
services and consultation. In the CY
2008 PFS proposed rule, we proposed to
revise § 410.100(a) to clarify that only
those physician services required and
provided by the CORF facility physician
that are administrative in nature are
considered CORF services, whereas
diagnostic and therapeutic services
provided by a physician to CORF
patients are considered physician
services under section 1861(q) of that
Act. Specifically, we proposed to define
CORF physician services as those
services provided by a CORF facility
physician that are administrative in
nature, such as consultation with and
medical supervision of nonphysician
staff, patient case review conferences,
utilization review, and the review of the
therapy plan of treatment, as
appropriate.
Services provided to a CORF patient
by the CORF facility physician or other
physician that are not administrative in
nature but that are diagnostic or
therapeutic services are considered
physician services under section
1861(q) of the Act. Where these services
are covered, they are separately payable
to the physician as physician services
under the PFS at the nonfacility
payment amount.
In addition, § 410.100(a) currently
provides that physician services
included within the definition of CORF
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
services are reimbursed on a reasonable
cost basis under part 413, and that
physician services to CORF patients not
included within the definition of CORF
services but billed as physician services
are paid by the carrier on a reasonable
charge basis subject to the provisions of
subpart E of part 405 of this chapter.
This description of the payment
methodology for physician services
provided in the CORF setting under
§ 410.100(a) is inconsistent with the
payment methodology set forth under
section 1834(k)(1) of the Act for CORF
services and section 1848 of the Act for
physician services, as well as the
preamble discussion in the CY 1999 PFS
final rule (63 FR 58860). In the CY 1999
PFS final rule, we stated that we would
base payment for diagnostic and
therapeutic physician services provided
to individuals in the CORF setting on
the PFS amount for the services.
Therefore, we proposed to revise
§ 410.100(a) to remove the reference to
reasonable cost based payments for
CORF physician services and the
reference to reasonable charge based
payments for non CORF physician
services. In place of these references, we
proposed to revise § 410.100(a) to add a
reference to 42 CFR part 414, subpart B,
setting forth the payment methodology
for non CORF physician services.
Comment: One commenter stated that
the nonfacility fee schedule amounts for
CORF services fail to fairly compensate
the CORF for services provided by a
CORF physician that are administrative
in nature. The commenter stated that
the PFS nonfacility amounts, containing
higher PE RVUs (than those for the
facility setting) for CORFs, are
inappropriately low to cover these costs
for the CORF setting. The commenter
believes that the required level of
physician activity in a CORF is greater
than that in a physician office. Since
there is no separate facility payment to
the CORF, the commenter requests that
we develop a new set of codes with
associated fees to pay for the required
CORF administrative physician services
in a manner similar to that we employed
to establish G0128 in the CY 1999 PFS
final rule to pay for CORF nursing
services.
Response: The 1997 BBA required
CMS to establish prospectively
determined payments for all outpatient
physical therapy, occupational therapy
and speech-language pathology services
regardless of the site-of-service and
additionally required that all other
CORF services also be based on existing
fee schedules. When we implemented
these BBA requirements during the CY
1999 rulemaking process, we
specifically addressed the issue of a site-
PO 00000
Frm 00075
Fmt 4701
Sfmt 4700
66295
of-service differential payment to
institutional providers of outpatient
therapy services, including CORFs. In
the CY 1999 PFS final rule, we reasoned
that a site-of-service differential
payment to a facility provider would
create payment incentives that favor one
setting over another. In addition, we
believe that the law intended the
creation of a ‘‘level playing field’’ for
these services and that we accomplished
this with the selection of the PFS
nonfacility rate to pay for all
rehabilitation and CORF services.
Therefore, we will continue to make
payment at the PFS nonfacility rate for
CORF services and will not change this
policy to allow a separate site-of-service
differential payment to the CORF.
Accordingly, we are finalizing
§ 410.100(a) as proposed.
4. Clarifications of CORF Respiratory
Therapy Services
Section 1861(cc)(1)(B) of the Act
states that CORF services include
respiratory therapy services along with
physical therapy, occupational therapy,
and speech-language pathology services.
Because respiratory therapists (RTs) are
not recognized as independent
practitioners in the Act or regulations,
and respiratory therapy services are not
specifically identified in a statutory
benefit category except as specified in
the CORF services benefit at section
1861(cc)(1)(B) of the Act, separate
payment, except that made to the CORF
provider, is not made for services
provided by RTs.
The description of CORF respiratory
therapy services currently includes
some services that we believe are more
appropriately provided by a physician
rather than a RT. As discussed above in
section II.K.3., diagnostic and other
medical services provided in the CORF
setting by a physician are not
considered CORF services, and therefore
may not be included in a respiratory
therapy plan of treatment. In addition,
the description of respiratory therapy
services under § 410.100(e) currently
includes services that in accordance
with § 410.105(c) must be performed by
a physician, and not a RT. For example,
only the physician may indicate the
clinical diagnosis and rehabilitation
goals, and prescribe the type, amount,
frequency, and duration of the services
to be furnished under the rehabilitation
plan of treatment.
Therefore, we proposed to amend
§ 410.100(e) to revise the definition of
respiratory therapy services to include
only those services that can be
appropriately provided to CORF
patients by RTs under a physicianestablished respiratory therapy plan of
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66296
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
treatment in accordance with current
medical and clinical standards and the
requirements of § 410.105(c).
Specifically, we proposed to remove
from the definition of CORF respiratory
therapy services at § 410.100(e)(1) the
terms ‘‘diagnostic evaluation’’,
‘‘management’’, and ‘‘assessment’’
because these services are performed by
the physician to establish the medical
and therapy-related diagnosis and the
respiratory therapy plan of treatment.
These services, referred to in the
proposed rule as ‘‘evaluation and
management (E/M)’’ services, may be
provided by either the CORF facility
physician, as CORF physician services
or as non-CORF physician services, or
by the patient’s referring physician, as
appropriate. We also proposed to
remove diagnostic tests and periodic
assessment at § 410.100(e)(2)(v) and (vi),
respectively, from the description of
CORF respiratory therapy services. As
discussed above, we believe that under
current medical standards, diagnostic
tests that are or become necessary for
patients receiving rehabilitation services
should be provided by physicians. In
addition, we believe that under current
medical standards, periodic assessment
of chronically ill patients in order to
determine their need for respiratory
services should be within the purview
of the physician. We note that these
services are covered under the
physician services benefit category at
section 1861(s)(2)(C) of the Act when
provided by the physician to a CORF
patient, and therefore, may be separately
billable by the physician under the PFS.
In addition to RTs, we noted that the
conditions of participation also
recognize respiratory therapy
technicians as CORF personnel;
however, during the CY 1999 PFS
rulemaking to recognize the 1997 BBA
payment requirements, we did not
include services performed by
respiratory therapy technicians because
we believed that current medical
standards for skilled respiratory therapy
services provided to patients in the
CORF setting required the educational
requirements possessed by RTs. This
determination to only recognize the
services of RTs, and not those provided
by respiratory therapy technicians in
carrying out the therapy plan of
treatment was further supported in the
CY 2002 and CY 2003 rulemaking (66
FR 55311 and 67 FR 79999), when we
developed and discussed G codes for
certain CORF respiratory therapy
services and specifically recognized the
RT as the appropriate level of personnel
to provide these CORF services. The
three HCPCS codes G0237, G0238, and
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
G0239 are specific to services provided
under the respiratory therapy treatment
plan and, as such, are not designated as
subject to the therapy caps. Therefore,
in the CY 2008 PFS proposed rule, we
proposed to revise the description of
respiratory therapy services to include
only those services that are
appropriately provided under a
respiratory therapy treatment plan. In so
doing, we sought to clarify those
services that we believe the physician
should provide, such as E/M services,
diagnostic tests, and establishing the
rehabilitation plan of treatment. In
addition, we stated that a condition of
coverage for the respiratory therapy
service is that it be provided by an
individual meeting the educational and
training level of the RT, rather than the
RT technician. For these reasons, we
indicated we would accept comments
on the service description at
§ 410.100(e), and the personnel
qualifications at § 485.70(j) and (k) for a
respiratory therapist and a respiratory
therapy technician, respectively.
Comment: One commenter opposed
the proposed revisions to the definition
of CORF respiratory therapy services
which removes diagnostic E/M services
from the list of services at
§ 410.100(e)(1) and diagnostic tests from
§ 410.100(e)(2)(v). The commenter
suggested that respiratory therapists, by
virtue of their training and competency
testing, can and do provide such
services as part of their scope of work
and asks us to add at § 410.100(e)(2)
certain tests, specifically ‘‘pulmonary
function tests, spirometry and blood gas
analyses’’, as well as services for
‘‘assessment, evaluation and monitoring
of the patient’s responses to the
respiratory treatment plan.’’ The
commenter also requested that we
reinsert the term ‘‘assessment’’ in the
definition of respiratory therapy
services at § 410.100(e)(1) in order to
bring consistency to the definitions of
all other CORF therapy services, such as
physical therapy, occupational therapy,
and speech-language pathology. Lastly,
the commenter objected to the CORF
requirement that the respiratory therapy
treatment plan be entirely established
by the physician.
Response: Section 1861(cc)(1) of the
Act states that respiratory therapy can
be provided in a CORF, by qualified
professional personnel, only under a
treatment plan established and reviewed
by a physician. In order to determine
the need for and to construct an
appropriate CORF respiratory therapy
plan of treatment, a physician provides
E/M services and often uses diagnostic
tests, such as pulmonary function and
spirometry tests, in order to establish
PO 00000
Frm 00076
Fmt 4701
Sfmt 4700
the patient’s medical and therapy
related diagnoses. These findings are
then detailed in the patient’s
rehabilitation treatment plan which, in
the CORF, the physician must wholly
establish.
The plan of treatment is described at
§ 410.105(c) and must include services
furnished under a written plan of
treatment that: (1) Is established and
signed by a physician before the
treatment is begun; (2) prescribes the
type, amount, frequency, and duration
of the services to be furnished, and
indicates the diagnosis and anticipated
rehabilitation goals. The respiratory
treatment plan must be reviewed at least
every 60 days by the physician who
must certify that the patient is making
reasonable progress in attaining the
treatment goals and that the treatment is
having no harmful effects. Therefore, we
believe that the E/M services and
diagnostic services associated with
establishing, periodically reviewing,
and overseeing the respiratory therapy
treatment plan are appropriately
furnished by the physician. As
discussed above, physician services,
including E/M services and diagnostic
services performed by the physician, are
separate Medicare benefits, defined at
sections 1861(q) and 1861(s)(3) of the
Act, respectively. These therapeutic and
diagnostic services are covered and
separately paid to the physician, not the
CORF, when they are furnished to a
CORF patient in the CORF setting by the
physician, as discussed previously in
this section at II.K.3.
We agree with the commenter’s
request to reinsert the word
‘‘assessment’’ in the definition of
respiratory therapy services at
§ 410.100(e)(1). Because assessments are
conducted as an integral part of any
service, we agree that revising the
definition more accurately describes the
services provided by RTs, as well as
other qualified and recognized CORF
personnel. As illustrated below,
assessments can be made by the RT
using the physiologic data gathered
from the monitoring services that are
inherent to CORF respiratory therapy
services.
Also, we would like to clarify the
term ‘‘monitoring’’ as used in
§ 410.100(e)(1) specifically as it relates
to the provision of CORF respiratory
therapy services. As we stated in the CY
2003 PFS final rule with comment
period (when we created 3 G-codes—
G0237, G0238, and G0239—to better
describe CORF respiratory therapy
activities), we incorporated the term
‘‘monitoring’’ in to each of the 3 G-code
descriptors. We further described this
‘‘monitoring’’ to include physiologic or
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
other data about the patient during the
period before, during, and after the
activities. It can represent, for example,
pulse oximetry readings,
electrocardiography data, pulmonary
testing measurements of strength or
endurance performed to assess the
status of the patient before, during and
after the activities. In order to further
illustrate and clarify our intention, we
provided an example in which pursed
lip breathing, used to create positive
pressure in the upper respiratory tract
and to improve respiratory muscle
action and described as G0237, was
identified as an included service in the
patient’s respiratory therapy treatment
plan.
Before providing this service, the RT
assesses the patient to determine the
appropriateness of providing this
pursed lip breathing activity and may
check the patient’s oxygen saturation
level (via pulse oximetry). If
appropriate, the RT then provides the
initial training and necessary retraining
in order to ensure that the patient can
accurately perform this activity. After
this session, the RT may again check the
patient’s oxygen saturation level, or
perform peak respiratory flow, or other
respiratory parameters. These services
are considered ‘‘monitoring’’ and are
bundled into the payment for G0237 (as
well as HCPCS codes G0238 and
G0239).
Another example of monitoring
includes the provision of a 6-minute
walk test that is typically conducted
before the start of the patient’s
respiratory therapy activities. When this
‘‘test’’ is conducted, the RT uses this
information to form an assessment of
the patient’s condition and uses it to
guide and monitor the activities that are
furnished as specified in the treatment
plan. This assessment, determined by
data from monitoring activities is
included as part of the activities
inherent to G0237. The time spent by
the RT, face-to-face and one-on-one,
with the patient to conduct these
respiratory measures is counted as part
of each of the respiratory therapy 15minute G-codes. When provided as part
of a CORF respiratory therapy treatment
plan, payment for these monitoring
activities is bundled into the payment
for other services provided by the RT,
including the three respiratory therapy
specific G-codes. The bundling of these
monitoring activities into each CORF
respiratory therapy service is to
acknowledge that these activities are
inherent to the services we envisioned
RTs would provide in the CORF setting.
Similarly, assessment, including the use
of monitoring data, is included as part
of services provided by other
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
rehabilitation therapists. The G-codes
were specifically created to better
describe the services provided as part of
a respiratory therapy plan of care under
the CORF benefit.
Comment: One commenter indicated
that the personnel qualifications in the
regulations for RTs and RT technicians
are out of date and that for over a
decade the term respiratory therapist
has been used to describe both
respiratory therapy care professional
categories currently defined in the
CORF regulations. Rather, the
commenter states that the certified
respiratory therapist (CRT) and the
registered respiratory therapist (RRT)
have replaced the older terms, RT techs
and RTs, respectively. The commenter
explained that the CRT designation is
awarded after successfully passing the
entry-level examination, while
qualifications to sit for the RRT
examination include graduation from
advanced levels of respiratory therapy
educational programs and obtaining the
CRT credential. Based on the newer
terminology for respiratory therapists,
along with information provided
regarding the CRT and RRT
credentialing processes, the commenter
requested that we change the CORF
conditions of participation to reflect the
newer qualifications. In addition, the
commenter requested that we change
the coverage provisions to recognize
both the CRT and RRT as qualified
personnel to provide CORF respiratory
therapy services.
Response: Based on the information
provided by the commenter, we will
work within CMS to develop and
update the personnel qualifications for
RTs and RT technicians at § 485.70(j)
and (k), respectively. This request
involves changes to longstanding
provisions for CORF personnel
qualifications, and we believe that other
organizations, individuals, and medical
specialties should have the opportunity
to comment on such changes. We will
propose updated qualifications for the
CRT and RRT in future rulemaking to
seek and review comments from other
interested parties, before finalizing any
changes to these personnel
qualifications. In that rulemaking, we
will revisit the issue of the respiratory
therapy professional(s) best qualified to
provide services under the CORF
respiratory therapy plan of treatment.
Until such time, we expect that the RT,
and not the RT technician, will provide
the services of the respiratory therapy
treatment plan as previously discussed
in CY 2002 and CY 2003 rulemaking
and, again, reinforced in this final rule.
We are finalizing our proposal to
revise § 410.100(e)(1), with the
PO 00000
Frm 00077
Fmt 4701
Sfmt 4700
66297
exception that we will not remove the
term ‘‘assessment’’ for the reasons
discussed above. We will also adopt the
revisions to § 410.100(e)(2), as proposed.
5. Social and Psychological Services
In accordance with section
1861(cc)(1)(D) of the Act, social and
psychological services are included
within the definition of CORF services
under § 410.100(h) and (i), respectively.
In addition, § 485.58 specifies that the
CORF must provide a coordinated
rehabilitation program that includes, at
a minimum, social or psychological
services, along with physical therapy
services and physician services, and
that these services must be consistent
with the therapy plan of treatment.
As discussed in the CY 2008 PFS
proposed rule, the current description of
social work services considered CORF
services under § 410.100(h) includes: (1)
Assessment of the social and emotional
factors related to the individual’s
illness, need for care, response to
treatment, and adjustment to care
furnished by the facility; (2) casework
services to assist in resolving social and
emotional problems that may have an
adverse effect on the beneficiary’s
ability to respond to treatment; and (3)
assessment of the relationship of the
individual’s medical and nursing
requirements to his or her home
situation, financial resources, and the
community resources available upon
discharge from facility care. The current
description of CORF psychological
services under § 410.100(h) includes:
(1) Assessment diagnosis and
treatment of an individual’s mental and
emotional functioning as it relates to the
individual’s rehabilitation; (2)
psychological evaluations of the
individual’s response to and rate of
progression under the treatment plan;
and (3) assessment of those aspects of an
individual’s family and home situation
that affect the individual’s rehabilitation
treatment. We believe these current
definitions of CORF social and
psychological services are too broad. As
discussed above in this section, we
proposed to revise § 410.105 to clarify
our policy that CORF services are
covered only if they are provided under
the rehabilitation plan of treatment and
relate directly to the rehabilitation of the
patient. As such, we are concerned that
the current descriptions of CORF social
and psychological services may be
misconstrued to include social and
psychological services for the treatment
of mental illness, which we believe is
outside the scope of coverage for CORF
social and psychological services
because these services do not relate
directly to a rehabilitation plan of
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66298
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
treatment and the associated
rehabilitation goals.
In addition, we believe it unnecessary
to distinguish between CORF social
services and CORF psychological
services given their similarities, and
therefore, we proposed to merge the two
definitions into a single definition of
CORF social and psychological services.
As noted at section 1861(cc)(2)(B) of the
Act, we believe that CORFs are required
to provide either social services or
psychological services, and not both
types of services. We believe that
merging the § 410.100(h) and (i) into a
single definition of CORF social and
psychological services is warranted to
clarify the similarities between them.
Therefore, we proposed to clarify the
description of social and psychological
services at § 410.100(h) to include only
those services that address the patient’s
response and adjustment to the
treatment plan; rate of improvement and
progress towards the rehabilitation
goals, or other services as they directly
relate to the physical therapy,
occupational therapy, speech-language
pathology, or respiratory therapy plan of
treatment. In addition, we proposed to
change the heading at § 410.100(h) from
‘‘social services’’ to ‘‘social and
psychological services,’’ and to
eliminate the separate definition for
psychological services under
§ 410.100(i).
Because we proposed to revise the
description of social and psychological
services in § 410.100(h), we also
solicited comments concerning the
CORF personnel qualifications in the
conditions of participation at § 485.70(g)
and (l) for psychologists and social
workers, respectively, and comments
relating to the appropriate CPT codes to
represent these CORF services.
Due to the specificity of the purpose
of CORF social and psychological
services requiring that these covered
services directly relate to the patient’s
rehabilitation treatment plan, we also
invited comments on which CPT codes
would be appropriate for CORF social
and psychological services. We believe
that the procedure codes for health and
behavior assessment and treatment,
represented by CPT codes 96150
through 96154, specific to the patient’s
physical health problems, best describe
the social and psychological services
required in the CORF setting.
Comment: A commenter suggested
that the proposed definition of social
and psychological services is too
restrictive. The commenter recommends
including social work, biopsychosocial
functioning, and discharge plans in the
new proposed definition of social and
psychological services.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
One commenter is concerned that
clarifying that CORFs are not intended
to be used to treat mental illness may
result in denial of the CORF benefit to
persons who need CORF services, but
who also suffer from a mental illness
(for example, patient with
schizophrenia suffers a stroke). A CORF
patient’s mental illness may need to be
accounted for in developing a
rehabilitation plan of treatment. The
commenter urges us to avoid causing a
‘‘chilling effect’’ on those individuals
providing social and psychological
services in CORFs at the expense of
allowing a patient to recover as fully as
possible.
A CORF provider cautioned that by
not treating social and psychological
services as a stand-alone CORF service
(like physical therapy or occupational
therapy) may have an adverse effect on
the patient’s ability to make progress
toward rehabilitation goals. They also
state that social and psychological
services may be needed even beyond the
conclusion of other CORF services.
Response: We believe that our
proposal to combine the descriptions of
social services and psychological
services into one definition best
describes the services that CORFs are
required to provide to their patients, as
an adjunct to the rehabilitation plan of
treatment. A broader definition of these
services could be interpreted to include
treatment of mental illness which the
CORF statute and regulations do not
permit, thereby causing Medicare to pay
for services that fall outside the clearly
defined scope of the CORF benefit.
We proposed to combine the
definitions of social services and
psychological services to clarify and
simplify the associated regulatory
provisions. We believe that our proposal
does not result in any actual change to
either the social or psychological
services, or the rehabilitation services,
provided to CORF patients that relate
directly to their rehabilitation plan of
treatment and the associated
rehabilitation goals.
Therefore, we will finalize our
proposal to combine the descriptions of
social services at § 410.100(h) and
psychological services at § 410.100(i)
into one definition for social and
psychological services at new
§ 410.100(h) to make clear that these
CORF services are the same, regardless
of whether provided by a qualified
social worker or a psychologist.
Comment: One commenter stated that
because there are several levels of social
work education and licensure for social
workers, a recommendation as to the
qualifications for CORF social workers
depends on whether we change our
PO 00000
Frm 00078
Fmt 4701
Sfmt 4700
proposal to include the treatment of
mental illness. As proposed, the
commenter supports the Bachelor of
Social Work (BSW) as the appropriate
qualification educational level.
However, if the scope of services is
expanded to include the treatment of
mental illnesses, then the commenter
believes that the educational level of the
Masters of Social Work (MSW) would be
the appropriate qualification.
A CORF provider stated that the
personnel qualifications to perform
CORF social and psychological services
should be either a licensed psychologist
at a Masters or PhD level, or a licensed
social worker.
A medical society representing
psychiatrists suggested we use an
existing set of qualifications for CORF
psychologists and social workers, such
as those established by the Office of
Personnel Management.
Response: We believe that the
appropriate qualification for individuals
providing social and psychological
services in the CORF setting is a BSW
for social workers and a Masters-level
degree for psychologists. In response to
the comment, the combination of social
and psychological services into one
definition was made for clarification
and simplification, and does not result
in any change to the scope of social and
psychological services provided to
CORF patients. Therefore, we believe it
is appropriate to maintain the existing
personnel qualifications for individuals
providing these unique services in the
CORF setting.
Comment: In terms of what CPT codes
might best describe the proposed CORF
social and psychological services, one
commenter suggested that CPT code
96155 should be added to the suggested
list of CPT codes 96150 through 96154
in order to allow CORFs to bill for social
and psychological services provided to
a patient’s family without the patient
presence.
Another commenter suggested that
limiting the services to those described
by CPT codes 96150 through 96154 is
potentially too restrictive because it may
not describe all of the services provided
by CORFs. The commenter believes that
this restriction would not permit CORFs
to code the social or psychological
services provided to the highest
specificity, although no specific CPT
codes were offered for consideration.
In addition, one commenter believes
that using a full range of CPT codes to
describe CORF social and psychological
services is inappropriate because these
codes were not intended to be used for
providing non-clinical CORF services.
This commenter specifically objects to
the use of CPT codes 96150 through
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
96154 because these services are
specifically used by PhD level
psychologists to provide clinical
services. The commenter notes that
other CPT codes are inappropriate to
CORF use, including the CPT code
range 90801 through 90899 that is used
to treat mental illnesses, and the E/M
CPT code series (CPT codes 99XXX),
because all of these CPT codes represent
clinical services. Rather, they believe
that the social and psychological
services provided in CORFs have
‘‘strong case management and patient
assessment components’’ as they relate
to the rehabilitation treatment plan.
Instead of using existing CPT code(s),
the commenter suggested we develop
HCPCS code(s) specifically for CORF
social and psychological services in
order to keep case management services
clearly distinguished from patient
treatment.
Response: In an effort to address the
coding issues, at this time we believe
that only CPT code 96152, Health and
behavior intervention, each 15 minutes,
face to-face; individual, best describes
these unique CORF social and
psychological services and should be
used to bill for all social and
psychological services provided in
CORFs.
We are sensitive to the concerns
expressed by the commenter that CPT
codes 96150 through 96154 do not
accurately represent the descriptions of
CORF social and psychological services,
and that there may be a need to develop
a HCPCS code designed specifically for
use in the CORF setting. However, in
this final rule, we do not believe it is
appropriate to create a HCPCS code to
reflect the nonclinical nature of the
CORF social and psychological services
when we did not propose doing so in
the proposed rule. However, we will
consider the commenter’s views in
making the determination regarding the
necessity to create a new HCPCS code
to describe CORF social and
psychological services in the future.
6. Nursing Care Services
Because the PFS does not contain a
CPT code for nursing services, we
established in the CY 1999 PFS final
rule a new HCPCS code (G0128) for
direct face to face skilled nursing
services delivered to a CORF patient by
an RN as part of a rehabilitation therapy
plan of treatment. In the CORF
conditions of participation at § 485.70(b)
and (h), qualified personnel for nursing
services include an LPN or vocational
nurse and an RN, respectively.
However, when the HCPCS code G0128
was created for CORF nursing services
we determined that a condition for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
coverage is that the nursing service be
provided by an individual meeting the
qualifications of an RN, rather than the
LPN, for CORF clinical nursing services
as they relate, or are part of, the therapy
plan of treatment. Because we
established coverage for CORF nursing
services only when provided by an RN,
in the CY 2008 PFS proposed rule, we
proposed to revise new § 410.100(i) (that
is, the current § 410.100(j) is
redesignated as § 410.100(i)) to
specifically reflect this coverage
decision. We also requested comments
on the appropriateness of the personnel
qualification standards at § 485.79(b)
and (h) for the LPN and for the RN,
respectively.
Comment: We received a comment
that opposed the proposed revisions
that would allow skilled nursing
services to be performed only by
registered nurses. The commenter
suggested that the CORF nursing
services provided by either a registered
nurse or the licensed practice nurse
should be determined by the legal scope
of practice as outlined in State law by
a State board of nursing.
Response: During the CY 1999 final
rule, we defined HCPCS code G0128 as
a face-to-face nursing service delivered
to a CORF patient that is directly related
to a rehabilitation plan of treatment. We
believe that the level of skill needed to
render clinical nursing services as they
relate to, or are supportive of the
rehabilitation plan of treatment is more
appropriately performed by registered
nurses.
Comment: One commenter asked us
to provide an example of nursing
services that would be appropriately
furnished and separately payable as
such in a CORF that also meets the
criteria of directly relating to the
rehabilitation treatment plan. This
commenter also requests clarification as
to whether an RN can provide services
as part of the respiratory therapy
treatment plan and if one of the HCPCS
G-codes for respiratory therapy services,
G0237, G0238, and G0239 can be used
to bill for these services.
Response: In the CY 1999 PFS final
rule, we established coverage for CORF
nursing services only when provided by
an RN. HCPCS code G0128 is used to
bill for services that are not included in
the work or PEs of other therapy or
physician services. Because of the
advances in medical science since the
inception of the CORF benefit in 1982,
the need for nursing services necessary
to be provided as an adjunct to the
rehabilitation treatment plan has
decreased significantly. In the CY 1999
PFS final rule, we used the example of
a RN who instructs a patient in the
PO 00000
Frm 00079
Fmt 4701
Sfmt 4700
66299
proper procedure of ‘‘in and out’’
urethral catheterization to illustrate one
such nursing service directly related to
the rehabilitation treatment plan. At that
time, nursing services might have been
provided to patients receiving
respiratory therapy services relating to
tracheostomy tube suctioning. Another
nursing service might be related to the
cleaning instructions for ileostomy or
colostomy bags for a patient receiving
physical therapy services where the care
is imminent to the start or completion
of a therapy session.
Comment: Another commenter noted
that CORFs are required to provide the
3 core services, including physician
services, physical therapy services, and
social or psychological services, and
asked that we clarify the amount that
these other non-core services—
specifically nursing services and
respiratory therapy services—can
comprise of the total CORF services.
The commenter cites examples of
CORFs where non-core services
comprise the majority of services,
sometimes as much as 90 percent or
more, including wound care services
where RNs are used to provide the
majority of these services and other
CORFs specializing predominantly in
respiratory therapy services.
Specifically, the commenter requested
that we unambiguously address our
intent as it relates to the provision of
non-core services.
Response: The CORF statutory
provision at section 1861(cc)(2)(B) of the
Act and § 485.58 require that the CORF,
as a minimum condition of
participation, provide three core
services— physician services, physical
therapy services, and social or
psychological services. When a CORF
provides only the three required core
services, we expect that physical
therapy services would comprise a clear
majority of the total CORF services,
since social and psychological services
are provided only as an adjunct to the
rehabilitation services and CORF
physician services are administrative in
nature and not easily identified.
However, when a CORF provides
physical therapy services and other
skilled rehabilitation services, we
expect that physical therapy services
will be the predominant rehabilitation
service provided. The case noted by the
commenter where CORFs specialize in
providing a preponderance of
respiratory therapy services is counter
to our expectations.
The example cited by the commenter
where the CORF is using RNs to provide
wound care services, which together
with other non-core services constitute
the majority of services provided to a
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66300
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
patient, exemplifies a situation in which
the CORF is providing nursing services
that are not in support of a
rehabilitation plan of treatment. In this
situation, the services provided by the
RNs do not conform to the requirement
that nursing services must directly
relate to or further a rehabilitation
treatment plan and its goals, and
therefore, are noncovered. As we
discussed previously in section II.K.6 of
this final rule with comment period, we
specifically define and require CORF
nursing services to relate to the
rehabilitation plan of treatment, with
such nursing services necessary for the
attainment of the rehabilitation goals of
the physical therapy, occupational
therapy, speech language pathology, or
respiratory therapy plan of treatment.
We believe only professional therapists/
pathologists, such as PTs, OTs, SLPs,
and RTs, may appropriately provide
these rehabilitation services and that it
is inappropriate for an RN to provide
these services. Nursing services may not
substitute for or supplant the services of
these therapists/pathologists, but
instead should lend support to or
further the services provided by
professional therapists/pathologists
under the rehabilitation plan of
treatment. Therefore, CORF nursing
services are covered as CORF services
only when provided by a RN and only
to the extent that they support or are an
adjunct to the rehabilitation services
provided by professional therapists/
pathologists under the rehabilitation
plan of treatment.
In addition to above clarification
regarding the coverage and provision of
the listed CORF services, we would also
like to clarify that CORFs cannot
provide services that are not included in
the definition of CORF services at
§ 410.100 (other than vaccines) and that
those services included in the definition
of CORF services are covered only to the
extent that they support or further the
rehabilitation plan of treatment. For
example, we believe that CORF services
do not include the provision of
hyperbaric oxygen services, infusion
therapy services, or diagnostic sleep
studies because they do not meet the
definition of CORF services at § 410.100
or they do not relate to the rehabilitation
plan of treatment. We believe that these
services and other services not
specifically listed as CORF services may
be covered under other categories of
Medicare benefits, such as physician
services and diagnostic services.
Comment: One commenter asked us
to clarify if a RN could perform
respiratory therapy services in a CORF.
Response: As we have discussed, we
believe only professional therapists/
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
pathologists, such as PTs, OTs, SLPs,
and RTs, may appropriately provide
rehabilitation services, such as
respiratory therapy services, and that it
is inappropriate for an RN to provide
these services. Therefore, respiratory
therapy services provided by an RN are
not considered CORF services under
§ 410.100. Services performed by an RN
may not substitute for or supplant the
services of these therapists, but instead
are covered as CORF services only to the
extent that they support or are an
adjunct to the rehabilitation services
provided by professional therapists/
pathologists under the rehabilitation
plan of treatment.
We would like to clarify that any
CORF nursing service must be provided
by a RN and coded as G0128 indicating
that CORF ‘‘nursing services’’ were
provided. Services provided by an RN
may only be billed as CORF nursing
services, provided they meet the
definition of CORF nursing services at
§ 410.100(i). We are aware that some
CORFs have billed RN services
inappropriately as E/M services, such as
CPT code 99211. In addition, we believe
some physicians have inappropriately
billed the services of CORF RNs as
incident to physician services. Because
CORF services are a distinct benefit
category, and because any therapeutic
and diagnostic services (as opposed to
administrative and supervisory services)
furnished by physicians are not CORF
services, any service furnished by CORF
personnel, including RNs, PTs, OTs,
SLPs, and RTs, are not considered to be
furnished incident to physicians’’
services, and thus cannot be billed as
services incident to physician services.
Therefore, the CORF nursing services of
RNs may only be billed using G0128,
provided that such services meet the
definition of CORF nursing services at
§ 410.100(i).
Therefore, we are finalizing
§ 410.100(i) as proposed.
7. Drugs and Biologicals
Section 410.100(k) currently provides
that drugs and biologicals included
within the definition of CORF services
includes drugs and biologicals that are
prescribed by a physician and
administered by a physician or a CORF
RN and not otherwise excluded from
Medicare Part B payment under § 410.29
(relating to self-administered drugs). In
addition, in accordance with
§ 410.105(c), drugs and biologicals
administered to a CORF patient will be
covered as CORF services only if
included as part of the rehabilitation
plan of treatment. However, we are
unable to identify any physician
prescribed drugs or biologicals that are
PO 00000
Frm 00080
Fmt 4701
Sfmt 4700
not self administered that would be
appropriately provided under a patient’s
rehabilitation plan of treatment. We also
expressed our concerns about the
potential for duplicative billing for
drugs and biologicals provided in the
CORF setting because they could be
billed by the CORF or the physician
furnishing such drugs and biologicals.
Therefore, we proposed to remove
§ 410.100(k) and invited comments on
this proposed revision, particularly on
the appropriateness of including drugs
and biologicals under a CORF patient’s
rehabilitation plan of treatment.
Comment: One commenter objected to
the proposed removal of the provision
for drugs and biologicals from the CORF
benefit and believes there is an inherent
risk that neither the CORF nor the
physician would be paid for drugs and
biologicals provided to CORF patients
when they are purchased by the CORF.
The commenter explained that, under
our proposal, the CORF would no longer
be permitted to submit claims for the
drugs and biologicals they purchase,
and further stated that, under this
scenario, the physician also could not
be compensated because the drug or
biological provided in this manner
would not satisfy the CMS incident to
rules. The commenter questioned our
concerns about the possibility of
duplicative billing permitted under the
current payment methodologies
although they believe that we might be
justified in our proposal should we have
proof that both the CORF and physician
are being paid for the same drug and
biological. Until such time, the
commenter requested we continue to
permit both the CORF and the physician
to submit claims for the drugs and
biologicals provided to CORF patients.
Another commenter also disagreed
with our proposal to remove drugs and
biologicals as a CORF service claiming
that when the Congress created the
CORF benefit, it ‘‘intended to create a
new type of facility that could provide
all of the services required by a patient
in a coordinated fashion.’’ They also
challenged our authority to remove this
provision and believe that duplicative
billing possibilities by the CORF and the
physician administering the drug or
biological is not cause for us to rewrite
the statute.
Response: The purpose of our
proposal was not intended to deny
patients access to or to avoid making
payment for medically necessary drugs
and biologicals. Because we proposed to
make payment directly to physicians for
the drugs and biologicals provided in
the CORF setting, CORFs opting to
continue purchasing these drugs and
biologicals would not also be paid.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Nevertheless, we are persuaded by the
commenter challenging our legal
authority to remove drugs and
biologicals from our regulatory
definition of CORF services § 410.100 in
light of their inclusion in the statutory
definition of CORF services under
section 1861(cc)(1) of the Act. As
explained in the legislative history of
the CORF statute, the intent of this
benefit was to simplify coordination of,
and access to, ‘‘a broad array of
rehabilitation services’’ (H.R. Rep. No.
96–1167, 96th Cong., 2nd Sess., at 375
(1980). Although as discussed in the
proposed rule, we have been unable to
identify among currently available drugs
or biologicals that are not selfadministered any such drugs or
biologicals that appropriately may be
included in as part of a rehabilitation
plan of treatment, we cannot rule out
the possibility that others will alert us
to such drugs or biologicals or that
future non self-administered drugs or
biologicals appropriately may be
included under a rehabilitation plan of
treatment. Therefore, in order to ensure
that, should we learn of any non selfadministered drugs or biologicals that
appropriately may be included in a
rehabilitation plan of treatment, we may
give effect to Congressional intent that
CORFs be able to provide any such
drugs or biologicals in coordination
with other CORF rehabilitation services,
we will not remove the reference to
drugs and biologicals from the
definition of CORF services under
§ 410.100 as proposed.
Instead, we will retain the existing
definition of CORF-covered drugs and
biologicals provided at new § 410.100(j)
(that is, the current § 410.100(k) is
redesignated as § 410.100(j)) with the
exception of adding the word ‘‘by’’ to
the new § 410.100(j)(1) to clarify our
policy that, in accordance with existing
professional standards, the
administration of the drug can by
provided by a RN but not by others
under the supervision of an RN. As we
are not aware of any non-selfadministered drugs and biologicals that
appropriately may be included in a
rehabilitation plan of treatment, we
intend to closely track the provision of
drugs in the CORF setting. If in the
future we learn that the administration
of drugs or biologicals in the CORF
setting is an appropriate service to
include in the rehabilitation treatment
plan, the regulatory framework will
allow for coverage of such drugs or
biologicals. In the mean time, we do not
expect to see CORFs submitting claims
for drugs and biologicals for the reasons
noted above.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
8. Supplies and DME
Payment for supplies and DME as part
of CORF services is specified at
§ 410.100(l) as ‘‘[s]upplies, appliances
and equipment’’ and includes
nonreusable supplies, medical
equipment and appliances, and DME as
defined in § 410.38 (except for renal
dialysis systems). These are CORF
covered services when provided for the
patient’s use outside the CORF whether
purchased or rented, and is paid under
the DMEPOS fee schedule. We believe
that the provision at § 410.100(l) is too
broad, out of date, and inconsistent with
current terminology used for covered
services or items. The CORF provision
at section 1861(cc)(1)(G) of the Act
applies only to supplies and DME, yet
the regulatory provision also
encompasses medical equipment and
appliances. Because we believe the
requirements of § 410.100(l) are
inconsistent with those of section
1861(cc)(1)(G) of the Act, we proposed
to revise both the title and description
at new § 410.100(k) (that is, the current
§ 410.100(l) is redesignated as
§ 410.100(k)) by deleting reference to
medical equipment and appliances to
reflect the CORF statutory provision by
including only the items specified
under section 1861(cc)(1)(G) of the Act.
[Note: The preamble discussion
incorrectly noted this new section as
§ 410.100(k) instead of § 410.100(j).
Section 410.100(k) is correct in this final
rule with comment period.] We also
noted that DME, as well as prosthetics,
orthotics, and supplies, provided in the
CORF setting requires the CORF’s
participation in the competitive bidding
process, where applicable, in
accordance with 42 CFR part 414
subpart F. In this final rule with
comment period, we have added
language at § 414.1105(c)(2) to clarify
that payment for DME, prosthetics,
orthotics, and supplies determined
under the DMEPOS competitive bidding
program is a single payment amount,
rather than an amount determined
under a fee schedule. While a payment
amount determined under a competitive
bidding program is not generally
thought of as a ‘‘fee schedule’’ for
purposes of section 1834(k)(3) of the Act
we believe the term refers to a single
payment amount determined through an
existing prospective payment system.
The Congress amended the Act to
replace reasonable cost-based payment
for CORF services with prospective
payments. Therefore, we believe the
reference to ‘‘fee schedule’’ at section
1834(k)(3) of the Act is meant to broadly
refer to existing prospective payment
systems for the CORF-covered services
PO 00000
Frm 00081
Fmt 4701
Sfmt 4700
66301
or items, including amounts determined
prospectively under a competitive
bidding program, and should not be
referring only to ‘‘fee schedules’’ in the
narrow sense. We did not receive
comments, in support of or in
opposition to, our proposal to specify
the new § 410.100(k) to include only
supplies and durable medical
equipment as specified at section
1861(cc)(G) of the Act in the CORF
benefit provision.
Therefore, we are finalizing
§ 410.100(k) as proposed with the
exception that we will add the revision,
discussed above, regarding the single
payment amount determined under the
DMEPOS competitive bidding program.
9. Clarifications and Payment Updates
for Other CORF Services
Section 4078 in the Omnibus Budget
Reconciliation Act of 1987 (Pub. L. 100203) (OBRA) amended section
1861(cc)(1) of the Act to provide that
there is no requirement that any item or
service furnished by a CORF in
connection with physical therapy,
occupational therapy, and speech
pathology services under the plan of
treatment be furnished at a single fixed
location; however, such items and
services are covered as CORF services
only if payment is not otherwise made
under Medicare. In the CY 2008 PFS
proposed rule, we noted that such items
and services may be covered under the
Medicare home health benefit
established under sections 1861(g), (m),
and (p) of the Act. Accordingly,
physical therapy, occupational therapy,
and speech-language pathology services
provided in the home are not covered as
CORF services if such services and
related items are covered under the
Medicare home health benefit. Because
the CORF regulations were not revised
to reflect these changes in coverage and
payment methodology, we proposed to
clarify the regulations at new
§ 410.100(l) (that is, the current
§ 410.100(m) which is redesignated as
§ 410.100(l)) and § 410.105(b)(3) to
reflect these requirements.
In § 410.105(b)(3), we proposed to
clarify that physical therapy,
occupational therapy, and speechlanguage pathology services can be
furnished in the patient’s home when
payment for these therapy services is
not otherwise made under the Medicare
home health benefit.
In addition, we proposed to revise
§ 410.100(l) to clarify that the patient
must be present during the home
environment evaluation that is
performed by the PT, OT or SLP, as
appropriate, because we believe that the
patient’s presence is necessary to fully
E:\FR\FM\27NOR2.SGM
27NOR2
66302
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
evaluate the potential impact of the
home situation on the patient’s
rehabilitation goals.
Comment: Some commenters
supported our proposal to clarify the
CORF therapy services that can be
provided in the home and who can
provide these services. One of these
commenters expressed concern about
the requirement that the patient be
present for the home environment
evaluation and requested that we further
clarify this proposal.
Response: Section 1861(cc)(1)(H) of
the Act states that there is no
requirement for physical therapy,
occupational therapy, or speechlanguage pathology services to be
provided at a fixed location such as at
the CORF’s physical location. This
provision was further clarified in
section 4078 of OBRA 1987 to clearly
permit that, so long as the physical
therapy, occupational therapy, or
speech language pathology services are
not otherwise covered under the
Medicare home health benefit, these
therapy services can be provided in the
patient’s home. Section 410.105(b)(3)
also provides that only physical
therapy, occupational therapy, or
speech-language pathology services can
be provided offsite, in the patient’s
home, and that all other CORF services
must be provided in the CORF facility.
We also proposed to clarify the
provision at the new § 410.100(l) (that
is, the current § 410.100(m) is
redesignated as § 410.100(l)) regarding
the provision of a single home
environment evaluation, to include the
presence of the patient, which can be
performed by a PT, OT, or SLP, as
appropriate. [Note: The preamble
discussion incorrectly noted this new
section as § 410.100(l) instead of section
§ 410.100(k). Section 410.100(l) is
correct in this final rule with comment
period.]
Therefore, we are finalizing the new
§ 410.100(l) (that is, the current
§ 410.100(m) is redesignated as
§ 410.100(l)), as proposed.
10. Cost Based Payment (§ 413.1)
Section 413.1(a)(2)(iv) currently
provides for cost-based payment for
CORF services, which reflects the
payment methodology provided for
under section 1833(a) of the Act,
requiring payment on the basis of the
lesser of the provider’s reasonable costs
or customary charges. As discussed
above, this payment methodology is
inconsistent with section 1834(k) of the
Act, requiring that the payment basis for
outpatient physical therapy services
(including outpatient speech-language
pathology services), outpatient
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
occupational therapy services, and all
other CORF services provided on or
after January 1, 1999 be 80 percent of
the lesser of: (1) The actual charge for
the services; or (2) the applicable fee
schedule amount. Therefore, we
proposed to remove § 413.1(a)(2)(iv) to
clarify that cost based payment is not
applicable to CORF services. We also
proposed to remove § 413.1(a)(2)(vi) for
OPTs or rehabilitation agencies as
referenced at section 1861(p) of the Act,
because these providers were also
affected by the same payment changes
required by the 1997 BBA for physical
therapy, occupational therapy, and
speech-language pathology services
effective for CY 1999.
We did not receive comments to these
technical corrections regarding the
change in payment methodology for
CORFs and OPTs that was effective CY
1999. Therefore, we are finalizing the
technical corrections to remove
references to cost-based payment for
CORFs and OPTs at § 413.1(a)(2)(iv) and
(vi).
11. Payment for Comprehensive
Outpatient Rehabilitation Facility
(CORF) Services
In the CY 2008 PFS proposed rule, we
proposed to establish a new regulatory
subpart M at 42 CFR part 414 to specify
the payment methodology for
comprehensive outpatient rehabilitation
services covered under Part B of Title
XVIII of the Act that are described at
section 1861(cc)(1) of the Act.
Specifically, this proposed subpart
would identify and describe how
payment is determined for services
included as CORF services under
§ 410.100.
Proposed § 414.1100 sets forth the
basis and scope for payment for CORF
services. Proposed § 414.1105 sets forth
the payment methodology for CORF
services, including identifying the
applicable fee schedule for each type of
CORF service identified in § 410.100.
Section 1834(k)(1)(B) of the Act
provides that the payment basis for
CORF services is 80 percent of the lesser
of: (1) the actual charge for the services;
or (2) the applicable fee schedule
amount. The term ‘‘applicable fee
schedule amount’’ is defined under
section 1834(k)(3) of the Act to mean,
for services furnished in a year, the
payment amount determined under the
PFS established under section 1848 of
the Act for such services for the year
‘‘or, if there is no such fee schedule
established for such services, the
amount determined under the fee
schedule established for such
comparable services as the Secretary
specifies.’’ Accordingly, we proposed at
PO 00000
Frm 00082
Fmt 4701
Sfmt 4700
new § 414.1105(a) to base payment for a
CORF service on 80 percent of the lesser
of the actual charge or the PFS amount
for the service when the PFS establishes
a payment amount for such service.
Payment for CORF services under the
PFS is made for physical therapy,
occupational therapy, speech-language
pathology, and respiratory therapy
services, as well as the related nursing
and social and psychological services.
In the CY 1999 PFS final rule (63 FR
58860), we explained that we interpret
section 1834(k)(3) of the Act, defining
the term ‘‘applicable fee schedule
amount,’’ as requiring us to use the
payment amount established by an
existing fee schedule other than the PFS
when the PFS does not establish a
payment amount for the CORF service.
Therefore, in the CY 2008 PFS proposed
rule we proposed at new § 414.1105(c)
that payment for covered DME, orthotic
and prosthetic devices and supplies
provided by a CORF be based on the
lesser of 80 percent of actual charges or
the payment amount established under
the DMEPOS fee schedule under
sections 1834 and 1847 of the Act and
in 42 CFR part 414, subparts D and F.
Finally, we proposed at new
§ 414.1105(d) that if there is no fee
schedule amount established for a CORF
service, payment shall be based on the
lesser of 80 percent of actual charges or
the amount determined under the fee
schedule established for a comparable
service, as specified by the Secretary.
As discussed in section II.K.3.,
physician services included within the
definition of CORF services under
§ 410.100(a) are limited to those services
of a CORF physician described as
administrative in nature, to the
exclusion of diagnostic and therapeutic
services which are considered
separately billable physician services.
Medicare generally does not permit
providers to separately bill for their
administrative costs; rather, such costs
typically are subsumed in the payment
amounts for covered medical services
and items furnished to Medicare
beneficiaries. Under the PFS these costs
are included in the payment amount as
part of the indirect PEs that are reflected
in the PE RVUs for each service and also
captured as part of the post-visit work
RVU component. Similarly, we believe
payment to CORFs for the
administrative duties of a CORF
physician, required as a condition of
participation at § 485.58(a), such as
participating in patient case review
conferences is subsumed within PFS
payments to CORFs for physical
therapy, occupational therapy, speechlanguage pathology, and respiratory
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
therapy services, and the related
nursing, and social and psychological
services. Generally, administrative costs
associated with the provision of such
services is incorporated into payment
amounts established under the PFS
through the PE RVUs representing the
resources necessary to perform each
service in the physician office or
nonfacility setting. Therefore, we
believe it unnecessary to separately
compensate CORFs for CORF physician
services given that such services are
administrative in nature, and proposed
at § 414.1105(b) not to separately pay
CORFs for CORF physician services.
To ensure that CORFs are not paid
twice for CORF services, we proposed at
new § 414.1105 to base payment for a
CORF service on the applicable fee
schedule amount only to the extent that
payment for such service is not
included in the payment amount for
other CORF services. Accordingly,
under proposed § 414.1105(c) a CORF
could not bill separately for supplies
included in the PE RVU component of
the payment amount established for a
service under the PFS. However, we
noted that CORFs could bill separately
for certain splint and cast supplies for
the application of casts and strapping
because these supplies have been
removed from the payment amounts
established under the PFS. We also
noted that Medicare makes separate
payment for surgical dressings, which
are also referenced at section 1861(s)(5)
of the Act, only when used by the
beneficiary in his or her home. No
separate payment is made when these
surgical dressings are used in the CORF
setting; rather the dressings’ costs are
bundled into the payment amount
established under the PFS for the
provided services.
For CORF services based on the
payment amount determined under the
PFS, we proposed at new
§ 414.1105(a)(2) to use the PFS amount
applicable to services furnished in a
nonfacility setting, with no separate
payment made for facility costs. We
proposed to use the PFS nonfacility
amount for CORF services in order to
offset any costs of providing such
services in the CORF setting. [Note: in
the proposed rule we incorrectly
referenced the codification of the
regulation text under proposed subpart
M as § 414.1001 or § 414.1101 rather
than § 414.1105. However, the proposed
regulation text was presented accurately
as § 414.1105 in the ‘‘List of Subjects’’
under the proposed subpart.]
Other than the objection discussed
above in section II.K.7 regarding the
proposed removal of the CORF
provision for drugs and biologicals, we
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
did not receive other comments about
our proposal to create a regulatory
provision to specify the payment
methodologies for the CORF services
identified at section 1861(cc)(1) of the
Act. Therefore, we are finalizing our
proposal to add a new regulatory
provision defining the payment
methodologies used to pay for CORF
services except that we also include a
section for payment of drugs and
biologicals included within the
definition of CORF services under the
new § 410.100(j), as explained in section
II.K.7. We will implement this proposal,
including the addition of the payment
provision for drugs and biologicals
included within the definition of CORF
services under the new § 410.100(j), and
revise, by adding a new subpart M to
part 414. The basis and scope for
payment for CORF services is set forth
at § 414.1100 and § 414.1105 sets forth
the payment methodology for CORF
services, including identifying the
applicable fee schedule for each type of
CORF service identified in § 410.100.
12. Vaccines
Section 485.51(a) defines a CORF as a
nonresidential facility that ‘‘is
established and operated exclusively for
the purpose of providing’’ rehabilitation
services by or under the supervision of
a physician. Because vaccines
administered in the CORF setting are
not rehabilitation services furnished
under a plan of treatment relating
directly to the rehabilitation of the
patient (or, presumably, even medically
necessary for the rehabilitation of the
patient), in accordance with § 485.51(a),
a CORF may not administer vaccines to
its patients. However, in the CY 2008
PFS proposed rule we noted that
nothing in the Medicare statute would
prohibit a CORF from providing
pneumococcal, influenza, and hepatitis
B vaccines to its patients provided the
facility is ‘‘primarily engaged in
providing * * * diagnostic, therapeutic,
and restorative services to outpatients
for the rehabilitation of injured,
disabled, or sick persons’’ (section
1861(cc)(2)(A) of the Act). Accordingly,
under the statute, such vaccines may be
covered separately from the CORF
services benefit under section
1861(s)(10) of the Act—defining the
term ‘‘medical and other health
services’’ to include the pneumococcal,
influenza, and hepatitis B vaccines—
provided the applicable conditions of
coverage under § 410.58 and § 410.63
are met. In order to include coverage
and payment for these vaccines when
provided to CORF patients in the CORF
setting, we proposed to amend the
CORF conditions of participation at
PO 00000
Frm 00083
Fmt 4701
Sfmt 4700
66303
§ 485.51 to permit CORFs to provide
vaccines to their patients in addition to
rehabilitation services. Such vaccines
would be covered in the CORF setting
provided the conditions of coverage
under § 410.58 and § 410.63 are met. In
accordance with sections 1833(a)(1) and
1842(o)(1) of the Act, payment for
covered pneumococcal, influenza, and
hepatitis B vaccines provided in the
CORF setting is based on 95 percent of
the average wholesale price (AWP).
Comment: We received a few
comments strongly supporting the
proposal to permit vaccines to be
provided in the CORF setting in
addition to the CORF services. These
commenters also strongly supported our
proposal to clarify our policy regarding
the administration of vaccines to CORF
patients by revising the CORF
conditions of participation to permit the
provision of vaccines, in addition to
CORF services. These commenters
believe that increasing the number and
types of providers where vaccinations
can be furnished will not only help to
ensure increased access to these
vaccinations but will result in improved
health outcomes and lower costs.
Response: We agree with the
commenters and will implement our
proposal to revise the CORF conditions
of participation, accordingly.
L. Compendia for Determination of
Medically-Accepted Indications for OffLabel Uses of Drugs and Biologicals in
an Anti-Cancer Chemotherapeutic
Regimen (§ 414.930)
1. Background
a. Statutory Requirements
Section 1861(t)(2)(B)(ii)(I) of the Act
lists three drug compendia that may be
used in determining the medicallyaccepted indications of drugs and
biologicals used in an anti-cancer
chemotherapeutic regimen. The three
drug compendia listed are:
• American Hospital Formulary
Service-Drug Information (AHFS– DI)
• American Medical Association Drug
Evaluations (AMA–DE)
• United States Pharmacopoeia Drug
Information (USP–DI)
Section 1861(t)(2) of the Act provides
the Secretary the authority to revise the
list of compendia for determining
medically-accepted indications for
drugs. Due to changes in the
pharmaceutical reference industry,
fewer of the statutorily named
compendia are available for our
reference. (That is, AMA–DE is no
longer in publication; USP–DI has been
purchased by Thomson Micromedex
and it is our understanding that the
E:\FR\FM\27NOR2.SGM
27NOR2
66304
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
name ‘‘USP–DI’’ may not be used after
2007.)
Section 6001(f)(1) of the Deficit
Reduction Act of 2005 (Pub. L. 109–171)
(DRA) amends both ‘‘sections
1927(g)(1)(B)(i)(II) and 1861(t)(2)(B)(ii)(I)
of the Act by inserting ‘‘(or its successor
publications)’’ after ‘United States
Pharmacopeia Drug Information’.’’ We
interpret this DRA provision as
explicitly authorizing the Secretary to
continue recognition of the
compendium currently known as USP–
DI after its name change if the Secretary
determines that it is in fact a successor
publication rather than a substitute
publication.
cprice-sewell on PROD1PC72 with RULES
b. Requests To Amend the Compendia
Listings
We received requests from the
stakeholder community for recognition
of additional compendia under the
following authorities:
• Section 1861(t)(2)(B) of the Act
which allows the Secretary to identify
additional authoritative compendia; and
• Section 1873 of the Act which
allows the Secretary to recognize a
successor publication if one of the
statutorily-named compendia changes
its name.
In contrast, others suggested that the
Secretary consider elimination of
certain listed compendia. However, as
we stated in the CY 2008 PFS proposed
rule (72 FR 38177), there was no
established regulatory process by which
we could accept and act definitively on
such requests. In addition, we saw the
need to increase transparency of
decision making criteria.
c. Technology Assessment of Drug
Compendia Used To Determine
Medically-Accepted Uses of Drugs and
Biologicals in an Anti-Cancer
Chemotherapeutic Regimen
We commissioned a technology
assessment (TA) from the Agency for
Healthcare Research and Quality
(AHRQ) on the currently listed
compendia (AHFS and USP–DI), as well
as other compendia (that is, National
Comprehensive Cancer Network
(NCCN), ClinPharm, DrugDex, Facts &
Comparisons (F&C)) which might
provide comparable information. AHRQ
contracted the TA to the New England
Medical Center (NEMC) and Duke
Evidence-based Practice Centers (EPCs)
and found little agreement in the
evidence cited among drug compendia.
In addition, the TA found little
agreement between the EPCs’
independent identification of evidence
on 14 example off-label indications and
evidence cited in the drug compendia.
The TA can be found at https://
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
www.cms.hhs.gov/ mcd/
viewtechassess.asp?
where=index&tid=46.
d. Medicare Evidence Development and
Coverage Advisory Committee
(MedCAC)
On March 30, 2006, the MedCAC
(formerly the Medicare Coverage
Advisory Committee (MCAC)) met in
public session to advise CMS on the
evidence about the desirable
characteristics of compendia to
determine medically-accepted
indications of drugs and biologicals in
anti-cancer therapy and the degree to
which the currently listed and other
available compendia display those
characteristics. All information on this
MedCAC meeting can be found on the
CMS Web site at https://
www.cms.hhs.gov/mcd/
viewmcac.asp?where=index&mid=33.
The agenda included a presentation of
the TA performed for AHRQ by staff of
the NEMC and Duke EPCs, scheduled
stakeholder presentations, as well as an
opportunity to hear testimony from
members of the audience. As is
customary, the MedCAC panelists
elicited additional information from the
presenters and discussed the evidence
in preparation for a formal vote.
The MedCAC identified the following
desirable characteristics:
• Extensive breadth of listings.
• Quick processing from application
for inclusion to listing.
• Detailed description of the evidence
reviewed for every individual listing.
• Use of pre specified published
criteria for weighing evidence.
• Use of prescribed published process
for making recommendations.
• Publicly transparent process for
evaluating therapies.
• Explicit ‘‘Not recommended’’ listing
when validated evidence is appropriate.
• Explicit listing and
recommendations regarding therapies,
including sequential use or combination
in relation to other therapies.
• Explicit ‘‘Equivocal’’ listing when
validated evidence is equivocal.
• Process for public identification
and notification of potential conflicts of
interest of the compendia’s parent and
sibling organizations, reviewers, and
committee members, with an
established procedure to manage
recognized conflicts.
The MedCAC concluded that none of
the compendia fully display the
desirable characteristics. The voting
results can be viewed at the same Web
site provided previously for the
MedCAC meeting. In addition the
MedCAC noted significant variability
among the compendia. There was no
PO 00000
Frm 00084
Fmt 4701
Sfmt 4700
agreement among the panel members
that any particular predetermined
number of compendia was desirable.
Participants in the meeting also
discussed the clinical usefulness of drug
compendia in the treatment of cancer. It
was reported that oncologists do not
rely on compendia when making
treatment decisions, relying instead on
published treatment guidelines, clinical
trial protocols, or consultation with
peers.
Prior to the CY 2008 PFS proposed
rule, we received, and reviewed,
unsolicited comments from professional
societies regarding additions and
deletions to the listing of compendia for
purposes of section 1861(t) of the Act.
We received 46 public comments
regarding these provisions on the CY
2008 PFS proposed rule.
2. Process for Determining Changes to
the Compendia List
A compendium for the purpose of this
section is defined as a comprehensive
listing of FDA-approved drugs and
biologicals or a comprehensive listing of
a specific subset of drugs and
biologicals in a specialty compendium,
for example, a compendium of anticancer treatment. A compendium: (1)
Includes a summary of the
pharmacologic characteristics of each
drug or biological and may include
information on dosage, as well as
recommended or endorsed uses in
specific diseases; (2) is indexed by drug
or biological; (3) differs from a disease
treatment guideline, which is indexed
by disease. We believe that the use of
compendia to determine medicallyaccepted indications of drugs and
biologicals in the manner specified in
section 1861(t)(2)(B)(ii)(I) of the Act is
more efficiently accomplished if the
information contained is organized by
the drug or biological and if the listings
are comprehensive.
We proposed an annual process,
incorporating public notice and
comment, to receive and make
determinations regarding requests for
changes to the list of compendia used to
determine medically-accepted
indications for drugs and biologicals
used in anti-cancer treatment as
described in section 1861(t)(2)(B)(ii)(I)
of the Act. The specific details of the
proposed process were outlined in PFS
CY 2008 proposed rule (72 FR 38118).
We received the following comments on
our proposed process.
Comment: Several commenters
remarked that we should correlate Part
B and Part D compendia for consistency
within the Medicare program.
Response: The Social Security Act
separately determines the Agency’s use
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
of authoritative compendia for specific
programs. The use of any compendium
for Part D or for Medicaid is beyond the
scope of this regulation.
Comment: Many commenters voiced
concerns about the time line proposed
by CMS to address requests for changes
to the list of compendia.
Response: We are striving to achieve
a more expedient and predictable time
line that will better serve the needs of
those who care for Medicare
beneficiaries. We have carefully
considered the comments and made the
following revisions:
(1) In order to shorten the proposed
timeline, CMS will not publish an
annual notice for formal requests.
(2) We expect to receive requests
annually during a 30-day window
starting January 15th.
(3) We expect to post these complete
requests received by March 15th for
public notice and comment on the CMS
Web site.
(4) We will accept public comments
for a 30 day period beginning on the day
that the request is posted by CMS on the
Web site.
Comment: Some commenters
suggested alternative review cycles
including changing the annual review
to: a rolling review process; an every 3year review process; or an every 5-year
review process.
Response: We appreciate the
commenters’ suggestions regarding
alternative review cycles; however, at
this time, we believe that an annual
review cycle is the best balance of these
suggestions to promote a publicly
responsive review process. Due to the
general stability of the compendium
publishing market, an annual review
process is sufficient. However, if we
determine that the public interest would
be served by an immediate compendia
review, we reserve the right to internally
generate a request at any time.
Comment: Several commenters
suggested specific additions to the list of
compendia.
Response: The addition or deletion of
specific compendia is beyond the scope
of this regulation. Formal requests for
additions and deletions may be
submitted during the annual open
request period established in this final
rule with comment period.
Comment: The comments received
from several associations and
manufacturers stated that the language
used for the individual desirable
characteristics was not clear and that we
did not give the appropriate
consideration to quality concerns and
the potential conflicts of interest.
Response: We appreciate the
commenters’ concerns and strive to
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
provide clarity on the MedCAC
desirable characteristics that we will
utilize in the compendia review process.
The characteristics presented here
represent an evidence-based consensus
from the MedCAC panel on the
desirability and priority of those
characteristics. We recognize that
different compendia might attempt to
achieve these characteristics in
individualized ways. CMS plans to use
the desirable characteristics as
framework and guidance in the review
process. However, we believe that the
public interest is best served by CMS
attention to the quality and the integrity
of each compendium’s evidence
evaluation process.
Comment: A few commenters made
the general suggestion for CMS to
prioritize the desirable characteristics
identified at the MedCAC meeting,
March 2006.
Response: We wish to clarify that the
desirable characteristics recommended
by the MedCAC will serve as guidance
and a framework which will aid in the
CMS review process. As stated in the
CY 2008 PFS proposed rule, we ‘‘may
consider additional reasonable factors in
making a determination’’ as deemed
appropriate. While we have decided not
to rank the MedCAC desirable
characteristics, we do consider the
characteristics referencing transparency
and conflict of interest to be of high
priority to preserve the integrity and
minimize bias during the review
process.
Comment: Some commenters stated
that a deletion from the list of
compendia could cause a beneficiary to
lose coverage of an off-label treatment
regimen already begun.
Response: We understand the concern
expressed by the commenters on a
beneficiary’s loss of coverage during the
continuance of off-label treatment in the
absence of compendium support;
however local contractors have
additional authority to make
determinations regarding medically
accepted indications. While we require
local contractors to use the compendia
as a reference in the determination of
‘‘medically-accepted’’ off-label
treatment regimens, the compendia are
not the sole reference for these
determinations. Section
1861(t)(2)(B)(ii)(II) of the Act provides
that local contractors use ‘‘supportive
clinical evidence in peer-reviewed
medical literature’’ to aid in making
determinations of ‘‘medically-accepted’’
off-label treatment regimens when
appropriate.
Comment: Commenters asked that we
recognize compendia indexed by
disease.
PO 00000
Frm 00085
Fmt 4701
Sfmt 4700
66305
Response: In order to meet our
criteria, a compendium should: (1)
Include a summary of the
pharmacologic characteristics of each
drug or biological and may include
information on dosage, as well as
recommended or endorsed uses in
specific diseases; (2) be indexed by drug
or biological; (3) differ from a disease
treatment guideline, which is indexed
by disease. We believe that the use of
compendia to determine medicallyaccepted indications of drugs and
biologicals in the manner specified in
section 1861(t)(2)(B)(ii)(I) of the Act is
more efficiently accomplished if the
information contained is organized by
the drug or biological and if the listings
are comprehensive.
Comment: Several commenters
suggested that we should regulate a time
frame for compendia to update their
recommendations.
Response: We believe that the public
interest is served if compendia generally
update their recommendations in a
timely manner when new evidence
regarding the use of drugs warrants an
update. We also believe that this is
consistent with spirit of the MedCAC’s
recommendations. However, medical
evidence on a particular use of a
specific drug may at times be complex
and inconsistent, and thus, merit a
prolonged rather than an expedited
analysis. We do not believe that we
should establish in regulation a specific
broad time line requirement at this time.
However, we will consider public input
regarding a compendium’s timely
updating of its recommendations as an
additional criterion in our compendium
review process.
Comment: We received comments
suggesting that a compendium’s use of
grades of evidence may add a confusing
factor in determining whether a
compendium citation supports a
particular drug use. Commenters stated
that it is desirable for a compendium to
clarify in a summary recommendation
whether it regards each drug use as
medically-accepted.
Response: We recognize and support
the desirability of an explicit summary
recommendation for each drug or
biological cited in each compendium.
This will facilitate the consistent
interpretation of off-label
recommendations by Medicare
contractors.
Comment: One commenter suggested
that a recognized compendium should
include and identify a well designed
clinical trial that is pending FDA
approval.
Response: We do not believe that we
can specify how a compendium
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66306
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
references materials regarding clinical
trials for a drug not yet FDA-approved.
Comment: Two commenters claimed
that section 1861(t)(2) of the Act
mandates separate processes for adding
and removing compendia.
Response: While we appreciate the
thoughtful interpretation of the
language, we do not agree separate
processes are required by the statute.
Comment: One commenter suggested
that the identity of the members of the
compendium’s advisory board and
scientific review committee should
become public record. The commenter
also requested that we to establish a
formal process to facilitate stakeholder/
compendia communication.
Response: Public identification of
members of the compendium’s advisory
board and the scientific review
committees and establishing a formal
process for stakeholders/compendia
communication is beyond our authority
and scope of this regulation.
Based on the public comments
received, we have made revisions to the
proposed compendia review process.
We appreciate the need for a more
expedient process to provide a useful
compendia list for Medicare providers
and have made the necessary changes.
Requests may be submitted in two
ways (no duplicates please). Electronic
submissions are encouraged to facilitate
administrative efficiency. We will
identify the electronic address to be
used for submissions. Hard copy
requests can be sent to the Centers for
Medicare & Medicaid Services, Coverage
and Analysis Group, Mailstop C1–09–
06, 7500 Security Boulevard, Baltimore,
MD, 21244. Please allow sufficient time
for hard copies to be received prior to
the close of the receipt period.
We may consider additional
reasonable factors in making a
determination. (For example, we may
consider factors that are likely to impact
the compendium’s suitability for this
use, such as but not restricted to a
change in ownership or affiliation,
suspension of publication, the standards
applicable to the evidence considered
by the compendium, and any relevant
conflicts of interest. We may consider
that broad accessibility by the general
public to the information contained in
the compendium may assist
beneficiaries, their treating physicians,
or both, in choosing among treatment
options.)
• We will also consider a
compendium’s grading of evidence used
in making recommendations regarding
off-label uses and the process by which
the compendium grades the evidence.
• We may, at our discretion, combine
and consider multiple requests that refer
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
to the same compendium, even if those
requests are for different actions. This
facilitates administrative efficiency in
our review of requests.
• We will notify the public of
additions or deletions to the list of
compendia on the CMS Web site.
• In keeping with our desire to
shorten the compendia review time line,
we will publish our decision no later
than 90 days following the close of the
public comment period.
M. Physician Self-Referral Issues
1. General
In the CY 2008 PFS proposed rule (72
FR 38122), we proposed several
revisions to the physician self-referral
regulations. We also solicited comments
regarding potential changes to or
limitations on the use of the in-office
ancillary services exception in
§ 411.355(b). We received
approximately 1100 pieces of timely
correspondence in response to these
proposals.
We received the following comments
regarding finalizing our proposals:
Comment: Many commenters were
concerned about the perceived
complexity and breadth of the physician
self-referral proposals. Several
commenters questioned our ability to
analyze sufficiently, and give adequate
consideration to, the public comments
due to the brief time period between
issuance of the CY 2008 PFS proposed
rule (72 FR 38122) and the statutory
deadline for publication of this final
rule with comment period. Some
commenters suggested that we not
finalize any of the proposals at this
time. Many of those commenters
asserted that we should further
contemplate the issues and propose
revised regulatory provisions in the CY
2009 PFS proposed rule if we continue
to believe that such revisions are
necessary.
Response: We are not inclined to
follow the commenters’ suggestion
regarding reproposal of the physician
self-referral provisions in the CY 2009
PFS proposed rule. However, given the
number of physician self-referral
proposals, the significance of the
provisions both individually and in
concert with each other, and the volume
of public comments, we do not believe
it is prudent to finalize any of the
proposals in this rule (except for the
proposal for anti-markup provisions for
diagnostic tests, as discussed below in
this section). Although we are not
finalizing the proposed revisions to the
other physician self-referral regulations
in this final rule with comment period,
we are confident that we have sufficient
PO 00000
Frm 00086
Fmt 4701
Sfmt 4700
information, both from the commenters
and our independent research, to
finalize revisions to the physician selfreferral regulations without the need for
new proposals and additional public
comment. We intend to publish a final
rule that addresses the following
proposals:
• Burden of proof;
• Obstetrical malpractice insurance
subsidies;
• Unit-of-service (per-click) payments
in lease arrangements;
• The period of disallowance for
noncompliant financial relationships;
• Ownership or investment interests
in retirement plans;
• ‘‘Set in advance’’ and percentagebased compensation arrangements;
• ‘‘Stand in the shoes’’ provisions;
• Alternative criteria for satisfying
certain exceptions; and
• Services furnished ‘‘under
arrangements.’’ Because we did not
make a specific proposal regarding the
in-office ancillary services exception,
but rather merely solicited comments
regarding its scope and application, any
revisions to the exception in
§ 411.355(b) will be accomplished
through a future notice of proposed
rulemaking with provisions for public
comment.
A measured, thoughtful approach to
the final physician self-referral rules is
critical. We believe that the future
rulemaking will address the public
comments and present a coordinated,
comprehensive approach to
accomplishing the goals described in
the proposed rule, namely, minimizing
the threat of program and patient abuse
while providing sufficient flexibility to
enable those who are parties to financial
arrangements to satisfy the requirements
of, and remain in compliance with, the
physician self-referral law and the
exceptions thereto.
2. Changes to Reassignment and
Physician Self-Referral Rules Relating to
Diagnostic Tests (Anti-Markup
Provisions)
Medicare regulations currently
prohibit the markup of the technical
component (TC) of certain diagnostic
tests that are performed by outside
suppliers and billed to Medicare by a
different individual or entity (§ 414.50).
In addition, Medicare program
instructions restrict who may bill for the
professional component (PC) (the
interpretation) of diagnostic tests
(Section 30.2.9.1 of the CMS InternetOnly Manual, Publication 100–04,
Medicare Claims Processing Manual,
Chapter 1, general billing requirements,
as amended or replaced from time to
time).
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
In the CY 2007 PFS proposed rule (71
FR 48982), we stated that recent changes
to our rules on reassignment concerning
the right to receive Medicare payment
may have led to some confusion as to
whether the anti-markup and purchased
interpretation requirements apply in
certain situations where a reassignment
has occurred pursuant to a contractual
arrangement. In addition, we expressed
concern about the existence of certain
arrangements that we believe are not
within the intended purpose of the
physician self-referral exception for inoffice ancillary services, which permits
physician group practices to bill for
certain services referred by group
physicians and furnished by a
contractor physician in a ‘‘centralized
building.’’ We also expressed concern
that allowing physician group practices
or other suppliers to purchase or
otherwise contract for the provision of
diagnostic testing services and to then
realize a profit when billing Medicare
may: (1) Lead to program and patient
abuse in the form of overutilization of
services; and (2) result in higher costs to
the Medicare program (71 FR 49054). In
the CY 2007 PFS proposed rule, we
proposed to amend § 424.80 to provide
that, if the TC of a diagnostic test (other
than a clinical diagnostic laboratory test
paid under section 1833(a)(2)(D) of the
Act, which is subject to the special rules
set forth in section 1833(h)(5)(A) of the
Act) is billed by a physician or medical
group (the ‘‘billing entity’’) under a
reassignment involving a contractual
arrangement with a physician or other
supplier who performs the service, the
amount billed to Medicare by the billing
entity would be limited. We also
proposed that, to bill for the TC, the
billing entity would be required to
perform the interpretation. In addition,
we considered imposing certain
conditions on when a physician or
medical group can bill for the
reassigned PC of a diagnostic test. For
our physician self-referral rules, we
proposed to modify the definition of
‘‘centralized building’’ at § 411.351.
Finally, we solicited comments on the
specific application of our proposals.
(See the CY 2007 and CY 2008 PFS
proposed rules for more information on
these proposals (71 FR 49054 through
49057 and 72 FR 38179 through 38180,
respectively).)
We received numerous comments on
the proposals in the CY 2007 PFS
proposed rule. Because we decided to
study the issues further, we did not
finalize our proposals in the CY 2007
PFS final rule with comment period.
Rather, based on the comments received
and other information that we
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
considered, in the CY 2008 PFS
proposed rule, we proposed to impose
an anti-markup limitation on the TC and
PC of diagnostic tests. We stated that we
would apply the anti-markup provision
irrespective of whether: (1) The billing
entity outright purchases the TC or the
PC; or (2) the physician or other
supplier performing the TC or PC
reassigns his or her right to bill the
Medicare program to the billing entity
(unless the performing supplier is a fulltime employee of the billing entity).
That is, we proposed to limit the
payment to the billing entity to the
lowest of: (1) The performing
physician’s or other supplier’s net
charge to the billing entity; (2) the
billing entity’s actual charge; or (3) the
fee schedule amount for the service that
would be allowed if the physician or
other supplier performing the service
billed directly. To prevent gaming,
whereby the performing physician’s or
other supplier’s net charge to the billing
entity is inflated to cover the cost of
equipment or space that is leased by the
billing entity to the performing
physician or other supplier, we stated
that we would define ‘‘net charge’’ as
exclusive of any amount that takes into
consideration such charges.
We also stated that we were
concerned that overutilization of
diagnostic tests could continue despite
our proposal to apply an anti-markup
provision to TCs that are reassigned to,
or outright purchased by, group
practices. That is, we intended to
address the situation in which the TC is
performed by a part-time or leased
employee of the group practice in a
‘‘centralized building,’’ and the group
neither receives a reassignment from the
employee technician (if the technician
is not able to bill for the TC in his or
her own right), nor purchases the TC
outright from the technician. Therefore,
we proposed to apply an anti-markup
provision to TCs that are performed in
a centralized building, and sought
comments on whether we should have
such a provision and, if so, how we
should effect such a provision (for
example, by amending the definition of
‘‘centralized building’’ or through some
other means). We stated that we would
except from the anti-markup provision
PCs performed by a physician pursuant
to an arrangement with an independent
laboratory as we do not believe that
such PCs ordered by an independent
laboratory pose a significant risk of
program abuse because the independent
laboratory does not order the diagnostic
test. We proposed revisions to § 424.80
(reassignments) and § 414.50 (purchased
diagnostic tests). (We did not propose
PO 00000
Frm 00087
Fmt 4701
Sfmt 4700
66307
regulatory text revisions for our
proposals to apply an anti-markup
provision to TCs that are performed in
a centralized building, and not apply
the anti-markup provision to PCs billed
by independent laboratories whose
personnel do not order the diagnostic
test.)
Many commenters supported our
proposals to prohibit the markup of the
TC and PC of diagnostic tests in order
to prevent physicians, physician group
practices, and medical groups from
profiting through the ordering of such
tests. Commenters that supported our
proposals often cited a concern about
overutilization. Many commenters were
opposed to our proposals. These
commenters stated that the Medicare
program and its beneficiaries are better
served by physicians who refer tests to
specialists (such as pathologists who
contract directly with group practices),
instead of physicians who use large
reference laboratories. These
commenters asserted that, because
physicians develop a working
relationship with particular
pathologists, and because the
pathologists ‘‘specialize’’ in a particular
type of biopsy (for example, prostate
biopsies), results are obtained more
quickly and quality is enhanced.
Finally, most commenters who
responded to our proposal to apply an
anti-markup to reassignments from parttime employees, irrespective of whether
they were in support generally of our
proposals, opposed this specific
proposal.
After careful consideration of all of
the comments, we are adopting our
proposals, with modification. We are
imposing an anti-markup provision on
TCs of diagnostic tests that are ordered
by the billing physician or other
supplier (or ordered by a party related
by common ownership or control to
such billing supplier), if the TC is
outright purchased or if the TC is
performed at a site other than the office
of the billing physician or other
supplier.1 (For purposes of the antimarkup provisions, the ‘‘office of the
billing physician or other supplier’’ has
its common meaning. The term is
defined at revised § 414.50(a)(2)(iii) as
space where the physician or other
supplier regularly furnishes patient
care. With respect to a billing physician
or other supplier that is a physician
1 We note that, in our proposals, we used the term
‘‘billing entity’’ to refer to a billing physician or
medical group. In this final rule with comment
period, the anti-markup provisions potentially
apply to TCs and PCs billed by any supplier;
therefore, we use the terms ‘‘billing physician or
other supplier’’ and ‘‘billing supplier.’’ These terms
are used interchangeably.
E:\FR\FM\27NOR2.SGM
27NOR2
66308
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
organization (as defined at § 411.351 of
this chapter), the ‘‘office of the billing
physician or other supplier’’ is space in
which the physician organization
provides substantially the full range of
patient care services that the physician
organization provides generally.) We are
also imposing an anti-markup provision
on PCs of diagnostic tests that are
ordered by the billing physician or other
supplier (or ordered by a party related
by common ownership or control to
such billing supplier), if the PC is
outright purchased or if the PC is not
performed in the office of the billing
physician or other supplier. Also, parttime employees are treated no
differently than full-time employees or
contractors who reassign benefits.
We are primarily revising § 414.50,
although we have also revised § 424.80
by adding (d)(3) to alert the reader that,
in the case of the reassignment of the TC
or PC of a diagnostic test, the reader
should consult § 414.50 to investigate
whether the anti-markup provisions
apply to the TC or PC. We are also
revising our definition of ‘‘entity’’ at
§ 411.351, which is relevant to our rules
on physician self-referral. Currently, the
definition of ‘‘entity’’ provides an
exception for a physician’s practice
when it bills Medicare for a diagnostic
test in accordance with § 414.50. We are
revising the definition of ‘‘entity’’ at
§ 411.351 to exclude a physician’s
practice when it bills Medicare for the
TC or PC of a diagnostic test in
accordance with § 414.50.
Examples of the application of the
final provisions to particular facts
appear immediately below, followed by
a discussion of the specific comments
we received on our proposals. We note
that the following examples are
intended only to illustrate the
application of the anti-markup
provisions of this final rule with
comment period; they are not intended
to address whether the physician selfreferral rules would prohibit payment
due to financial relationships that may
exist between the billing supplier and
any physician ordering a test or
performing the TC or PC of a test.
Example 1. A urology group practice
contracts with a leasing company that
supplies a technician and a pathologist to
perform testing on prostate samples. The
technician performs the tissue sampling and
the pathologist reads the slides. All work is
done outside of the office of the billing group
practice, and instead is performed in space
that is rented exclusively ‘‘24/7’’ by the
group practice (thus meeting the definition of
a ‘‘centralized building’’ at § 411.351) for the
sole purpose of providing pathology services
for the group’s patients. Because the
centralized building does not qualify as ‘‘the
office of the billing physician or other
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
supplier,’’ the anti-markup provisions apply
to both the TC and the PC, and the group may
bill Medicare the lowest of the following: (1)
The leasing company’s net charge to the
group; (2) the group’s actual charge; or (3) the
fee schedule amounts for the TC and
interpretation that would be allowed if the
leasing company were enrolled in and billed
Medicare directly.
Example 2. Same as Example 1, except that
the TC and PC are performed by the group
practice’s employee technician and a
pathologist who is an independent contractor
of the group practice, respectively. Here, the
anti-markup provisions again apply to both
the TC and the PC because the work was not
done in the ‘‘office of the billing physician
or other supplier’’ (that is, the office of the
group practice). It does not matter that the
technician is an employee and the
pathologist is an independent contractor
because the work was not performed in the
office of the billing group practice.
Example 3. A physician in a group practice
orders a diagnostic test and a technician who
is a part-time employee of the group performs
the test in the group’s office. A physician
who is an independent contractor of the
group performs the PC in the group’s office
and reassigns his or her right to payment to
the group. The anti-markup provisions do not
apply to the group’s billing of the TC or the
PC.
Example 4. Same as Example 3, except that
the independent contractor physician
performs the PC in his or her home and
reassigns his or her right to payment to the
group. The group’s billing of the TC is not
subject to the anti-markup provision, but the
group’s billing of the PC is subject to the antimarkup provision because the work was not
performed in the office of the billing
supplier.
Example 5. A group practice purchases
both a diagnostic test and its interpretation
from a laboratory and bills the TC and PC to
Medicare. The anti-markup provisions apply
to both the TC and the PC. Because the TC
and the PC were purchased, the location(s) at
which the TC and the PC were performed
does not matter.
Example 6. A group practice orders a
diagnostic test from an independent
laboratory. The laboratory performs the test
and contracts with a physician to perform the
PC. The laboratory bills Medicare for both the
TC and the PC. The laboratory is not subject
to the anti-markup provision for the PC,
because the laboratory did not order the test.
Example 7. Same as Example 6, except that
a physician orders a diagnostic test from an
independent diagnostic testing facility
(IDTF). The IDTF bills Medicare for both the
TC and the PC of the test. The anti-markup
provisions do not apply because the IDTF did
not order the test.
a. Authority
Comment: Several commenters
questioned whether we have the
authority pursuant to section 1842(n) of
the Act to impose an anti-markup
provision as described in the CY 2008
PFS proposed rule. The commenters
specifically noted that, in section
PO 00000
Frm 00088
Fmt 4701
Sfmt 4700
1842(n) of the Act, the Congress
directed the Secretary to impose an antimarkup on the TC of diagnostic tests,
yet our proposal applied to the TC and
the PC of diagnostic tests. Commenters
stated that the interpretation of a
diagnostic test is a physician service,
and that section 1848 of the Act
mandates that physician services be
paid the lesser of the billing physician’s
actual charge or the fee schedule
amount, and therefore, we have no
authority to extend the anti-markup rule
to physician services.
Response: We believe that several
provisions of the Medicare statute
provide us with the requisite authority
to impose anti-markup provisions on
the TC and PC of certain diagnostic
tests. Section 1842(n)(1)(A) of the Act,
which was enacted as part of the
Omnibus Budget Reconciliation Act of
1987, provides that, if the diagnostic test
was not performed or supervised by the
billing physician and also was not
performed or supervised by a physician
with whom the billing physician shares
a practice, the Medicare payment is the
lower of the costs (net of any discount)
charged by the performing supplier to
the billing physician, or the performing
supplier’s reasonable charge (or other
applicable limit). This is commonly
known as the anti-markup provision.
Although, to date, this statutory
provision has been implemented
through the regulation in § 414.50 that
imposes an anti-markup provision on
the TC only of a diagnostic test, nothing
in this section limits our authority to
apply this section to the PC of a
diagnostic test.
Moreover, we believe that we can
interpret the language ‘‘shares a
practice’’ as giving us the authority to
impose an anti-markup provision on the
TC of tests that are outright purchased
by a billing physician or group, as well
as on the TC of tests for which payment
is reassigned to the billing physician or
group. Although we previously
implemented this statutory provision
through regulation in § 414.50 by
enacting an anti-markup provision on
the TC of ‘‘purchased’’ diagnostic tests
from an outside supplier, the statutory
provision does not speak in terms of
‘‘purchased’’ tests. In the intervening
time since CMS promulgated the
regulation in § 414.50, other changes to
the Medicare program, in particular, the
changes made by section 952 of the
MMA to the reassignment exceptions
authority, have created incentives for
conduct that we believe increases the
risk of overutilization and abuse of the
Medicare program. We believe that the
language ‘‘shares a practice’’ in section
1842(n)(1) of the Act can cover not just
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
tests that are outright purchased, but
also tests for which payment is
reassigned to the billing supplier. We
are amending § 414.50 in this final rule
to provide that TCs and PCs that are not
performed in the office of the billing
physician or other supplier are subject
to the anti-markup provision. We
believe that, if the TC or PC is not
purchased and is performed in the office
of the billing supplier by an employee
(whether full-time or part-time) or an
independent contractor who reassigns
benefits, a sufficient nexus with the
practice of the billing supplier (that is,
the billing physician or group) is
established such that the employee or
independent contractor may be viewed
as ‘‘sharing a practice’’ with the billing
supplier for purposes of section
1842(n)(1) of the Act. In addition, we
believe that we have authority under
sections 1102(a) and 1871(a) of the Act
(our general rulemaking authority) to
impose anti-markup provisions on the
TC and PC of diagnostic tests in order
to fully effectuate the Congress’ intent in
enacting section 1842(n)(1) of the Act.
We find additional authority in
section 1842(b)(6) of the Act. This
section generally prohibits Medicare
payment to anyone other than the
Medicare beneficiary or the physician or
other person who furnished the item or
service to the beneficiary. We allow a
physician or other supplier to bill for
tests and test interpretations that are
purchased from an outside supplier
because we have deemed the test or
interpretation to be performed by the
billing supplier; however, we are not
required to deem the test or
interpretation as having been performed
by the billing supplier, nor are we
required to do so without placing limits
on the amount the purchasing supplier
may bill. Likewise, whereas section
1842(b)(6) of the Act also provides
exceptions (known as the reassignment
exceptions) to the general rule that
payment may be made only to the
beneficiary or the physician or other
person who furnished the item or
service, such exceptions allow us
(‘‘payment may be made’’), but do not
require us, to make payment to an
individual or an entity other than the
beneficiary or the physician or other
person who furnished the item or
service to the beneficiary. (We note that
the Congress specifically provided for
CMS to implement safeguards in the
context of reassignments pursuant to a
contractual arrangement. Section 952 of
the MMA permitted Medicare to pay a
physician or entity billing for an item or
service as a result of a reassignment
created pursuant to a contractual
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
arrangement, regardless of the site of
service. However, in section 952 of the
MMA, the Congress specifically
authorized the Secretary to subject such
arrangements to ‘‘such program integrity
and other safeguards as the Secretary
may determine to be appropriate.’’)
Therefore, we believe that we have
ample authority under section
1842(b)(6) of the Act to place
restrictions on the billing of tests and
interpretations when the tests or
interpretations were performed by
someone other than the billing supplier,
particularly with respect to situations in
which there is the potential for
overutilization.
We do not view the application of the
anti-markup provision to the PC of
diagnostic tests as representing a
conflict with section 1848 of the Act as
stated by the commenters. Although
section 1848 of the Act does outline
how physician services will be paid in
the typical situation, section 1848 of the
Act does not preclude us from setting
conditions on physician payment or
from deviating from the payment
methodology outlined in section 1848 of
the Act where a physician or other
supplier is seeking to take advantage of
a special situation made available to
physicians or other suppliers by CMS.
Payment pursuant to the terms of
section 1848 of the Act is available for
all the diagnostic tests in question.
Physicians and other suppliers are free
not to take advantage of the purchased
test option or the reassignment option,
and bill and receive payment only for
tests they have personally performed.
Where physicians and other suppliers
choose to take advantage of these
options, for purposes of convenience or
for other reasons, we have the authority
under our general rulemaking authority
in sections 1102(a) and 1871(a) of the
Act, as well as under our authority to set
conditions for the payment of purchased
and reassigned tests in section
1842(b)(6) of the Act, to promulgate
rules to ensure that these options do not
increase the likelihood of Medicare
program abuse.
b. Scope of Application of the AntiMarkup Provisions
Comment: One commenter offered
alternatives to our proposals. The
commenter stated that, at least initially,
the anti-markup provisions should
apply exclusively to gastroenterology,
dermatology, and urology physician
group practices because those
specialties order a significant number of
pathology tests. The commenter
suggested that we could subsequently
broaden application of the anti-markup
provisions to the extent that ‘‘new
PO 00000
Frm 00089
Fmt 4701
Sfmt 4700
66309
abusive’’ arrangements develop.
Alternatively, according to the
commenter, CMS could define the
specialties to which the anti-markup
provisions would apply on the basis of
objective criteria. For example, the antimarkup provisions could apply to group
practices billing for pathology services
where at least 75 percent of the
members are from a single nonpathology
specialty and where at least 75 percent
of the pathology services billed by the
group practice were ordered by
members of the group. The commenter
asserted that such a definition should
cover most of the abusive arrangements
that have developed in recent years. The
commenter urged us to impose a broad
prohibition on profiting from pathology
tests, which would apply without regard
to whether the histotechnologists are
full-time employees or independent
contractors of the group practice.
According to the commenter, a
prohibition on profiting could be
accomplished by prohibiting any
markup over the direct costs incurred by
the group practice in providing such
services, and direct costs should be
limited to the compensation paid to the
persons providing the services and the
cost of the equipment and supplies
utilized in performing the services.
Finally, the commenter suggested the
alternative of amending the
requirements for ‘‘group practices’’ in
§ 411.352 to prohibit gastroenterology,
dermatology and urology group
practices from profiting from Medicare
payments for pathology services
performed within the group practice.
Response: We decline to adopt any of
the approaches suggested by the
commenter. The anti-markup provisions
in this final rule with comment period
apply to group practices (as well as all
other suppliers) regardless of specialty.
We believe that making the rule
applicable to all suppliers ensures fair
and equitable treatment among types of
suppliers and also ensures that the
potential for overutilization is addressed
regardless of the particular type of
supplier involved. As we discuss in
greater detail below, we agree with the
commenter that it should not matter
whether the person performing the TC
is a full-time employee, part-time
employee or independent contractor. If
the TC (or PC) is purchased, or if it is
performed in a place other than the
office of the billing supplier, the antimarkup provision will apply,
irrespective of the employment status of
the person performing the TC (or PC).
We are not revising the requirements for
‘‘group practices’’ at § 411.352 at this
time. We did not propose to amend
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66310
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
these provisions and believe that such a
change would be outside the scope of
the proposed rulemaking.
Comment: A commenter suggested
that we consider an anti-markup
provision that would apply to any group
practice where at least 90 percent of the
practice is comprised of a single
specialty other than pathology that
orders the pathology tests billed by the
group. The anti-markup rule should
prohibit the markup of the direct costs
incurred by the group (such as
compensation paid to the
histotechnologists and pathologists, and
equipment and supplies utilized).
Response: We believe that the
commenter’s suggestion would be
cumbersome and difficult to administer,
and therefore, we are not persuaded to
adopt it. We believe that the antimarkup rules that we have finalized are
much more practical and will be an
effective deterrent to the ordering of
medically unnecessary tests.
Comment: One commenter stated that
the anti-markup provisions should
apply equally to all physicians,
including pathologists. The commenter
noted that, in some cases, a pathologist
performing the PC purchases the TC
from a hospital or another pathology
laboratory and bills globally. In
addition, the commenter asserted that it
is a myth to say that pathologists do not
order tests and, therefore, should be
exempt from the proposed anti-markup
provision applicable to the PC of a
diagnostic test. Another commenter
stated that there is no more likelihood
of abuse in specialty physician-owned
pathology laboratories than with
pathology groups ordering expensive
and unneeded special tests and stains
on specimens that they then interpret in
the pathology group-owned histology
laboratory.
Response: The revisions to § 414.50
and § 424.80 concerning the antimarkup requirements apply equally to
all physicians, including pathologists.
We recognize that, in some situations, a
pathologist may order additional tests to
be performed by an outside pathologist.
Where a pathologist orders and bills for
a test that he or she did not personally
perform, the anti-markup provisions
may apply to the TC or PC, or both
(depending on whether the TC or PC
was purchased or, if not, whether the
TC or PC was performed in the
pathologist’s office). If the pathologist
did not order the test, the anti-markup
rules do not apply.
Comment: One commenter requested
clarification that § 414.50 applies only
to physicians and medical groups, and
not to suppliers, such as medical
foundations, that, under State laws
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
governing the corporate practice of
medicine, are required to enroll in Part
B as a clinic or group practice. The
commenter asserted that, in States
prohibiting the corporate practice of
medicine, many suppliers enrolled as a
clinic or group practice are unable to
directly employ the radiologist or other
physician who performs a test
interpretation.
Response: In this final rule with
comment period, we are revising
§ 414.50 to apply to all suppliers.
However, the anti-markup provisions do
not apply to TCs and PCs that are not
purchased and that are performed in the
office of the billing physician or other
supplier. Therefore, in the commenter’s
example, if clinic personnel order, for
example, the TC and PC, and the TC and
PC are performed in the clinic’s office,
neither the TC nor the PC will be subject
to the anti-markup provisions.
Comment: Two commenters asserted
that IDTFs operate similarly to
independent laboratories in that the
tests are ordered by a financially
independent physician. The
commenters also said that the physician
performing the interpretation sees the
patient. Therefore, the commenters
recommended that we provide an
exception to the proposed anti-markup
rules for purchased interpretations for
imaging suppliers, such as IDTFs, if the
current purchased interpretation rules
are met.
Response: We are not persuaded to
provide an exception to the final antimarkup provisions for purchased
interpretations for imaging suppliers if
the current purchased interpretation
rules are met. We note that, if the
interpreting physician sees the patient,
the purchased interpretation rules are
not fully met. Therefore, the imaging
supplier is not satisfying all of the
purchased interpretation rules, and the
imaging supplier should only bill for the
TC portion of the test.
Comment: One commenter requested
clarification that the anti-markup
proposals do not apply to radiologists
who have contractual arrangements
with IDTFs. The commenter asserted
that radiologists and IDTFs are not in a
position to refer to each other or to
themselves because both are dependent
upon referrals from other physicians in
the community. Another commenter
asked us to clarify that the anti-markup
for the PC will not apply to an IDTF that
purchases the PC from the interpreting
physician, particularly in States in
which the corporate practice of
medicine doctrine applies. Another
commenter stated that the anti-markup
provision for the PC should not be
applied to physicians or group practices
PO 00000
Frm 00090
Fmt 4701
Sfmt 4700
that bill for the professional services
performed by an independent contractor
or part-time employee if those services
were performed pursuant to the order of
another practitioner who is independent
of the group, and thus would not profit
from his or her referral.
Response: As finalized, the antimarkup provisions are applicable to all
types of suppliers. However, in the
situation in which an IDTF, radiology
practice, or other supplier does not
order the diagnostic test, the anti
markup provisions do not apply.
Comment: A few commenters
questioned whether the proposed antimarkup provision, for the PC of
diagnostic tests, would apply to IDTFs
that purchase the PC from an
interpreting physician, particularly in
States where the corporate practice of
medicine prohibits an IDTF from hiring
the physician as an employee.
Response: The anti-markup rules will
not apply to entities that are enrolled as
an IDTF where the IDTF does not order
the test. If the IDTF orders the test, the
anti markup provisions will apply to the
same extent that they apply to other
suppliers.
Comment: A few commenters urged
us to clarify in § 424.80 that the antimarkup provisions apply to
reassignments under both the
contractual arrangement exception as
well as the employee reassignment
exception. The commenters also
suggested that § 424.80 and § 414.50
should state that the anti-markup
provisions are limited to claims
submitted by physicians and medical
groups and do not apply to claims
submitted by independent laboratories.
The commenters were concerned that
the preamble language on the
applicability of the anti-markup
provisions to independent laboratories
was not carried over and included in the
regulatory text in § 424.80 and § 414.50.
Response: We have determined to
revise § 414.50, with a cross reference in
new § 424.80(d)(3). As finalized, the
anti-markup provisions apply to
reassignments under both the employee
exception and the contractual
arrangements exception, to the extent
that the services for which payment is
reassigned are not performed in the
office of the billing physician or other
supplier. The anti-markup provisions
apply to a billing supplier only if the
billing supplier orders the TC.
Therefore, if an independent laboratory
does not order the TC, the anti-markup
provisions will not apply to the
laboratory billing of the TC or the PC.
Comment: Two commenters urged us
to create an exception for entities that
are located off-campus from a hospital
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
which are jointly owned by radiologists
and the hospital and which have an
exclusive contract for the provision of
professional interpretations to the
hospital. According to the commenters,
it is important to allow such joint
ventures to exist, because the profits
generated by the ventures give financial
stability to community hospitals that
otherwise would be financially
impaired as outpatient imaging
continues to migrate away from the
hospital. In States in which the
corporate practice of medicine doctrine
exists, the joint ventures do not directly
employ the physicians, but rather
typically contract with the professional
radiology practice to provide the PC.
The commenter stated that the
radiologists providing the professional
reads are neither full-time employees
nor exclusively employed by the joint
venture imaging center to which they
reassign their right to Medicare
payment.
Response: We do not believe that it is
necessary to create such an exception.
The comment is unclear as to which
entity, the joint venture imaging center
or the hospital, is billing for the service;
however, if the imaging center is billing
for the PC, the anti-markup provision
will not apply if the physician performs
the PC in the imaging center’s office. If
the imaging center, or an entity related
to it by common ownership or control,
orders the TC, and the physician does
not perform the PC in the imaging
center’s office, the anti-markup
provision will apply.
Comment: Some commenters believed
that the anti markup provisions should
not apply to imaging suppliers that meet
the purchased test rules in CMS
manuals.
Response: In the CY 2007 PFS
proposed rule, we stated that we were
considering placing restrictions on the
ordering of PCs that would be similar to
the purchased interpretation rules in
our manuals. After giving the matter
considerable thought, we believe that an
anti-markup billing provision is
necessary to guard against potential
overutilization and that it would not be
sufficient simply to require that billing
entities meet the purchased
interpretation rules in our manuals.
Comment: In the proposed rule, we
proposed to add new § 424.80(d)(3) to
require that, in order to bill for the TC,
the billing entity must directly perform
the PC of the service. Two commenters
asked that we clarify what we meant by
‘‘directly perform.’’ Other commenters
recommended that we clarify in
§ 424.80 the requirement to bill for the
TC of a diagnostic test, and clarify in
§ 414.50 the requirement that a billing
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
entity must directly perform the PC of
the service.
Response: We are not finalizing the
proposed change to § 424.80(d)(3). We
note that the requirement continues to
appear in our manuals at CMS InternetOnly Manual, Pub. 100–04, Chapter 1,
section 30.2.9. Currently, we are
considering whether to retain this
requirement in the manuals or to
withdraw it.
Comment: One commenter supported
generally the establishment of an antimarkup provision on purchased
interpretations, but voiced concerns that
our proposal to incorporate the billing
rules for purchased diagnostic testing
services to all reassigned services
(unless performed by a full-time
employee of the group) could adversely
affect the billing practices of
pathologists and pathology groups who
often depend upon the reassignment
rules to bill for services performed by
independent contractor and part-time
pathologists. Therefore, the commenter
requested an exception from our
proposed rules for independent
laboratories and single-specialty
pathology physician groups.
The commenter also asserted that
reassignment arrangements between
pathology groups do not raise the same
threat of abuse because the vast majority
of pathology services are initiated by a
request for a consultation from a
referring physician of another specialty,
and the pathologist is not in a position
to influence the referrals from ordering
physicians. The commenter further
stated that a broader exception for
single-specialty pathology physician
groups and independent laboratories
that covers both the TC and PC of a
pathology service is supported by the
existing physician self-referral law and
regulations. The commenter stated that,
the ‘‘Congress recognized that certain
physicians, specifically pathologists,
diagnostic radiologists and radiation
oncologists, who order certain services
pursuant to a consultation with another
physician do not have the same risk of
abuse and, consequently, will not be
treated as having made a restricted
referral to an entity with which they
have a financial interest.’’ The
commenter urged us, for this same
policy reason, to recognize an exception
for single-specialty pathology physician
groups and independent laboratories
that bill for pathology services
performed or supervised by another
pathologist, whether an independent
contractor or full-time or part-time
employee.
Response: In order to be fair and to
avoid the appearance of giving
preferential treatment to one physician
PO 00000
Frm 00091
Fmt 4701
Sfmt 4700
66311
specialty group over another, the antimarkup provisions on the TC and PC of
diagnostic tests are potentially
applicable to all physician specialty
groups that order tests and wish to bill
for the TC or PC, or both, performed by
another person or group and billed as a
purchased test or billed through a
reassignment. (Whether the anti-markup
provision for the TC or the anti-markup
provision for the PC will, in fact, apply
depends on whether the TC or the PC
was purchased, or, if not purchased,
whether the TC or the PC was
performed in the office of the billing
physician or other supplier.) Therefore,
we are not recognizing an exception for
single-specialty pathology physician
groups that bill for pathology services
performed or supervised by another
pathologist, unless the single-specialty
pathology physician group does not
order the test. If a pathologist in the
single-specialty pathology physician
group orders and bills for the test
performed by another supplier, the antimarkup rules apply. If the pathologist
does not order the test and wishes to bill
for the test, which is performed by
another supplier, the anti-markup rules
will not apply. Finally, we note that
clinical diagnostic laboratory tests
performed by independent laboratories
and paid under section 1833(a)(2)(D) of
the Act are not subject to the antimarkup provisions pertaining to
diagnostic tests.
c. Overutilization
Comment: Many commenters in favor
of the proposed rulemaking cited
overutilization as a concern in the
existing billing and payment
environment. Commenters opposed to
our proposals denied that contractual
arrangements for pathology services
lead to overutilization.
In support of their contention that
current arrangements facilitate
overutilization, some commenters cited
various studies for the proposition that
physician self-referral leads to increased
utilization. For example, one
commenter cited 1989 studies from the
OIG and GAO that found that
physicians who had an ownership or
investment interest in a laboratory
ordered more tests than those
physicians who did not have such an
interest. This commenter also noted that
an analysis by the Florida Cost
Containment Board in 1998 found that
physician-owned clinical laboratories,
diagnostic imaging centers, physical
therapy centers, and rehabilitation
centers performed more procedures on a
per-patient basis than those facilities
that were not physician-owned. The
commenter also cited the 2007 study by
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66312
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the McKinsey Global Institute that
found that the United States spends
more of its wealth on health care than
any other developed country, and that
one reason for the difference in
spending is due to profit incentives in
physician ownership of medical
facilities. Other commenters mentioned
the 2007 OIG studies of three urology
practices, which the commenters
described as finding that all three
practices substantially increased the
number of biopsies ordered per patient
after entering into an arrangement for
contracted pathology services, and that,
after entering into such an arrangement,
all three practices billed significantly
more biopsies than what their respective
carriers paid on average to other
suppliers. One commenter cited a study
by the Center for Health Policy Studies
that examined the effects of State
‘‘direct billing’’ laws. Under such laws,
the pathologist or entity performing the
ordered pathology services is required
to bill for the services. This study found
that laboratory charges per enrollee
under private health insurance
programs were 41 percent higher in
non-direct billing States than in direct
billing States. Another commenter
stated that a study in the American
Journal of Roentgenology in 2002
confirmed that physician self-referral
may be contributing to the uncontrolled
growth in imaging services. According
to the commenter, that study reported
that, when a managed care organization
prohibited certain non-radiologist
specialties from billing for imaging
services, total billings for imaging
declined 20 to 25 percent from the
amount of billings that were expected
based on the previous trend in imaging
growth.
One commenter stated that it is
unaware of any evidence of
overutilization by gastroenterologists
who have entered into contractual
arrangements for pathology services.
Another commenter stated that its
managed ‘‘pod labs’’ are vital to the
accurate detection and treatment of
prostate cancer and do not expose
Medicare to an undue risk of program
abuse. The commenter asserted that no
data supports the accusation that its
managed laboratories facilitate the
generation of medically unnecessary
biopsies, and in any event, clinical
indications for prostate biopsy are not
subject to manipulation.
Another commenter stated that
urological pathology volume is based
upon objectively demonstrated medical
necessity, and is not affected by profit
margin or who is billing for services.
This commenter suggested that specific
requirements could be placed on
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
contractual arrangements to address
overutilization concerns, while
preserving the benefits of these types of
arrangements. The commenter stated
that the best way to ensure that
contractual arrangements are
maximizing their potential for
improving care and outcomes, while
discouraging overutilization, is to
prohibit arrangements that are merely
passive investments of the treating
physicians. The commenter asserted
that physicians who own off-site
pathology laboratories should be
actively involved in their direction and
supervision, and responsible for the
services provided by the laboratory. The
commenter offered several specific
recommendations, including: (1) If a
group practice intends to bill for the TC,
it must also perform the PC; (2)
consistent with CLIA regulations, a
pathologist may not be the medical
director of more than five laboratories;
and (3) refined credentialing criteria for
pathologists. In its comments to the CY
2008 PFS proposed rule, MedPAC stated
that it agrees that allowing physicians to
purchase or contract for the provision of
diagnostic tests and to realize a profit
when billing Medicare could lead to
overuse of services and higher program
costs.
One commenter discussed available
types of diagnostic tests for prostate
cancer and stated that there does not
appear to be any added benefit to the
patient from receiving a 12-part biopsy
series instead of a smaller number.
According to the commenter, this
method of biopsy results only in
increased diagnosis of minimal prostate
disease or atypical small acinar
proliferations, which leads only to
further biopsies and increased medical
costs. The commenter stated that the
argument of urologists, that 12 biopsies
is the standard of care, is shown to be
fallacious by the fact that, when
members of a particular urology group
perform prostate biopsies in local
hospitals, they are doing only two-part
biopsies. However, another commenter
stated that he knows of more than one
urologist who routinely submitted two
core biopsies for review, but after
employing a pathologist, switched to 12
core biopsies. Another commenter
stated that patient care improves with
contractual arrangements because the
test results are timelier and are of higher
quality. Faster results, together with the
opportunity to collaborate with
pathologists, permit urologists to better
manage their patients’ care. According
to the commenter, the number of cores
taken for each prostate biopsy is a direct
result of the evolving understanding of
PO 00000
Frm 00092
Fmt 4701
Sfmt 4700
the nature of prostate cancer, rather
than, as some state, the formation of
urology specialty laboratory
arrangements between urologists and
pathologists. One commenter stated
that, whereas it understood our concern
of overutilization, the current
malpractice system creates far more
incentive to perform unnecessary tests.
Two commenters stated that the
incessant complaints of profits being
made at the expense of the Medicare
program do not serve any purpose. The
commenters claimed that, unless a
profit can be achieved, no one will
perform services needed by Medicare or
any other program. The commenters
suggested that, regardless of who
collects the fees for pathology and
laboratory services and makes a profit,
whether an individual pathologist, a
commercial laboratory, or a physician
specialty practice, this should not be a
focus of CMS. Rather, CMS should
review the standards of care and hold
suppliers to those standards. The
commenters pointed out that the
National Comprehensive Cancer
Network developed standards for a
patient with early prostate cancer. At
first, the standard was only two cores.
In the mid 1990s, the standard was
increased to six cores, then, with
additional research, the standard was
increased to ten cores, and, recently, the
recommendation was further increased
to 12 cores. The research has shown a
dramatic increase in prostate cancer
detection with increased core sampling.
The commenters stated that it is
hypocritical that pathologists are
claiming overutilization of services by
physician specialty groups, when these
same pathologists accepted 12 core
biopsies without a whisper of
discontent. These commenters asserted
that overutilization would cease to be an
issue if CMS actively pursued those
practitioners, including pathologists,
who do not follow the accepted and
published standards of care.
Response: It is difficult to determine
whether and the extent to which
overutilization is due to, or facilitated
by, arrangements that allow the referring
physician or group practice to bill for
the TC and the PC of diagnostic tests.
Our proposals were not predicated upon
a belief that there was a correlation
between the size of the group practice
and the volume of diagnostic tests and
the risk of program abuse. We
appreciate that, for a particular practice
specialty, an increase in biopsies
ordered may be due to a change in
business arrangements that produces
profits for the referring physician or
group practice, or it may be due to a
change in the standard protocols (or in
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
the referring physician’s or group’s
perception of the appropriate standard
of care). Nevertheless, studies have
shown that, in the aggregate, utilization
of diagnostic tests increases in the case
of physician self-referral. We believe it
is appropriate to guard against the
potential for overutilization through an
anti-markup provision on the TC and PC
of diagnostic tests. We decline to use a
specific number of prostate biopsies as
a trigger point for application of the
anti-markup provisions, as we believe
the appropriate number of biopsies is
largely patient-specific.
Comment: Several commenters stated
that contractual arrangements for
anatomic pathology testing pose no risk
of overutilization because Medicare
patients would not be subjected to
unnecessary testing due to the invasive
nature of test procedures such as colon
or prostate biopsies.
Response: We are skeptical that the
risk of overutilization for biopsies is
appreciably less than that of other types
of diagnostic tests. In any event, in
enacting the anti-markup provision in
section 1842(n)(1) of the Act, the
Congress made no exception for
biopsies or other minimally invasive
tests, and in order to effectuate
Congressional intent we are not
providing for such an exception.
d. Quality and Patient Access
Comment: Many commenters, both in
favor of and against the proposed
rulemaking, focused on the issue of the
quality of the diagnostic testing,
particularly pathology services.
Two commenters stated that the
financial incentive inherent in some
arrangements can result in physicians
selecting laboratories not on the basis of
quality but on the potential for profit
from these arrangements. One
commenter believes that ‘‘by reducing
pathologists to the status of indentured
servants of clinicians who ‘own’ the
patients and their biopsies, the
autonomy and quality of the pathology
services provided is fatally eroded.’’
According to one commenter, aspects of
pathology practice, such as the
adequacy of the biopsy, the sampling
procedure, the need for deeper or
additional sections, the severity of a
process, the adequacy of margins, the
need for re-excision, the
appropriateness of special studies, and
the need for outside expert consultation
despite increased expense, ultimately
are decided based on what provides the
maximum economic benefit to the
ordering and billing physician. The
other commenter stated that a
gastroenterology group practice that had
been sending its pathology work to his
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
pathology practice ended the
relationship because it entered into an
arrangement with another pathology
group under which the gastroenterology
group practice could bill for the TC. The
commenter stated that the
gastroenterology group said that there
was no dissatisfaction with quality or
the service of the commenter’s work, but
rather it was purely a business decision
that enabled the gastroenterology group
practice to capture additional revenue
in an environment of shrinking
reimbursement. Another commenter
stated that he received a biopsy for
review that was performed on a
urologist who routinely sent his (the
urologist’s) patients’ biopsies to his (the
urologist’s) employed pathologist. The
commenter stated that what was good
enough for the urologist’s patients was
not good enough for the urologist.
One commenter stated that captive
pathology arrangements are detrimental
to patient care. The commenter stated
that a local gastroenterology group was
able to locate a pathologist who was
desperate for work and who reads the
biopsies only once a week. The
commenter called the turn-around time
of once per week ‘‘atrocious.’’ The
commenter claimed that pathologists
who are not willing to work for less than
fair market value are being put out of
work by physicians who are ignorant of
the value of quality pathology services
and who hire anyone willing to read
slides for any price under any
condition. Another commenter asserted
that, although gastroenterologists claim
they get better service from pathologists
who allow the gastroenterologists to bill
for the pathology services, the ‘‘better
service’’ is, in reality, more money for
the gastroenterologists.
One commenter stated that surgeons
and surgical pathologists need to work
in close contact with each other, and
that the pathologist in a ‘‘pod lab’’ has
little or no interaction with surgeons
and other clinicians. Hospital-based
pathologists meet on a regular basis
with surgeons and other clinicians to
share insights and perspectives on
cases, sometimes with immeasurable
patient benefit. The ‘‘pod lab’’
arrangement impacts negatively upon
the ‘‘pod’’ pathologist’s professional
growth. Another commenter suggested
that we should be aware that the
‘‘current campaign’’ against so-called
‘‘pod labs’’ is led by a few self-interested
private pathologists, some in leadership
positions in their national organizations,
who wish to monopolize the outpatient
biopsy market. The commenter stated
that these pathologists are using scare
tactics to paint with the same brush any
nontraditional pathology arrangement,
PO 00000
Frm 00093
Fmt 4701
Sfmt 4700
66313
without regard to any real
demonstration of quality problems. The
commenter suggested that, instead of
focusing on the ‘‘straw man’’ of ‘‘pod
labs,’’ we should require all suppliers of
pathology services to demonstrate
quality of service and appropriateness of
utilization in order to end the ongoing
abusive pathology practices that are
occurring in traditional pathology
groups, independent laboratories and
academic medical centers.
One commenter asserted that the use
of contractual arrangements allows
specialization by pathologists that
otherwise would be seen only in the
largest medical centers or reference
laboratories. Moreover, the commenter
stated that pathologists who work
together in contractual arrangements
with various groups have the unique
opportunity to consult with each other
on a regular basis. An entity that
manages ‘‘pod labs’’ stated that internal
data generated by group practices that
refer to their own managed laboratories
show a higher positive incidence of
prostate cancer now than before they
contracted with the commenter. One
commenter contended that most
gastroenterologists who enter into
contractual arrangements with
pathology laboratories do so in order to
achieve a higher quality of patient care
through timely diagnoses and the use of
pathology personnel who are experts in
gastrointestinal and liver pathology. The
commenter expressed certainty that our
proposal would have an adverse effect
on practice efficiency and the quality of
patient care.
A commenter stated that large
corporate laboratories do not always
provide the highest level of care
available. According to the commenter,
large laboratories have an incentive to
hire the cheapest physician labor in
order to ‘‘churn out’’ a high volume of
services. The commenter argued that the
interaction between the urologists in a
group practice and a dedicated
pathologist in that practice will lead to
better outcomes. Another commenter
stated that some gastrointestinal group
practices have opened their own
pathology laboratories because they
believed that the pathology reports they
received from general laboratory
companies were in some ways lacking.
A commenter echoed that sentiment,
and added that the fact that the
pathologist was practicing in its office
meant that the group can easily discuss
the pathologist’s findings with him and
even review slides together.
One commenter contended that, based
on her experience gained from working
for large, national laboratories, sections
are poorly processed there and, often,
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66314
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
much of the tissue is lost. According to
the commenter, extra ribbons are not
collected at these laboratories and
immunostains often do not contain the
area suspicious for carcinoma. There is
no communication with the physician’s
office and usually no clinical
information is exchanged. She further
asserted that group practices that send
tissue samples to large laboratories run
the risk that an inexperienced
pathologist could be performing the
work. The commenter related a personal
experience in which biopsies were read
at a large national laboratory as showing
HGPIN, a precursor to adenocarcinoma.
The commenter stated that the slides
she reviewed on re-biopsy showed no
HGPIN, and, not only was the patient
made to worry unnecessarily, but the
mistaken biopsy review led to the
expense of a re-biopsy and another
reading. Another commenter stated that
its clients say that it provides better
quality services and in a timelier
manner than do the national
commercial laboratories. According to
the commenter, this is because
physician practices that send anatomic
pathology specimens to large
commercial laboratories do not choose
the pathologists who interpret the slides
and thus do not know the qualifications
of the pathologist.
Response: We believe that, everything
else being equal, there can be some
advantages to a physician or group
practice referring to the same
pathologist, if the referring physician or
group practice chooses the pathologist
on the basis of his or her qualifications
and experience, and the service that he
or she provides. However, we also
believe that, where there is a financial
reward for choosing a pathologist or
other diagnostic specialist based on
financial self-interest, there is the
potential to disregard, or at least
subordinate, quality considerations.
This final rule with comment period
eliminates the profit incentive in
choosing a pathologist or other
specialist while preserving the referring
physician or group practice’s right to
continue to use the pathologist or other
specialist of its choosing. That is, if a
billing group practice currently has a
contractual arrangement with a
particular histotechnologist and
particular pathologist because it
believes that the histotechnologist and
the pathologist provide superior quality
and service, it may continue to refer to
them; it only will be prevented from
marking up the TC and PC (unless the
TC and PC are not purchased and are
provided in the office of the group
practice).
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Comment: Many commenters asserted
that there would be no adverse effect on
patient access if the proposal was
adopted. Other commenters stated that
patient care would be significantly
disrupted if the proposal was adopted.
Specifically, commenters stated that the
proposed changes would limit access to
multiple urologic services in a local
area, namely, radiation therapy,
lithotripsy, and many in-office
procedures such as thermal ablative
procedures for prostate obstruction.
These commenters contended that many
in-office procedures are never
performed in hospitals, and that, if the
proposed changes to the reassignment
and purchased diagnostic test rules
become effective, it would be difficult,
if not impossible, to provide these
services to Medicare beneficiaries.
Response: We are skeptical that our
proposal would cause any patient access
problem. There appear to be adequate
choices throughout the country for
physicians and group practices to obtain
timely access to diagnostic testing. No
evidence was brought to our attention
that a patient access problem previously
existed and was somehow alleviated
when physicians and group practices
began entering into contractual
arrangements for the provision of
pathology and other diagnostic services.
In any event, as noted above, our
proposal as finalized does not prohibit
physicians and group practices from
continuing to use the same diagnostic
services that they have been using to
date.
e. Purchased Tests as They Relate to
Reassigned Tests
Comment: We received comments
stating that physician contractual
arrangements with pathologists
constitute an attempt to evade the
restrictions of the physician self-referral
law. Several commenters stated that
there is no practical distinction between
a purchased service and a reassigned
service. One commenter stated that the
proposal effectively eliminates the
reassignment rules. The commenter
argued that, although CMS states that,
under section 952 of the Act, it is
required to recognize contractual
reassignments only to the extent they
meet program integrity and other
standards determined by the Secretary,
the commenter asserts that the Congress
surely did not mean that this statutory
provision could be administratively
repealed by merging it into the already
existing purchased diagnostic test rules.
Another commenter stated that our
proposal appears to be mixing the
purchased diagnostic test policies with
contractual reassignments, which could
PO 00000
Frm 00094
Fmt 4701
Sfmt 4700
result in confusion for the imaging
industry.
Response: We are concerned that
some current arrangements are not in
accord with the spirit or the letter of the
anti-markup provision in section
1842(n)(1) of the Act. Section
1842(n)(1)(A) of the Act, which was
enacted as part of the Omnibus Budget
Reconciliation Act of 1987 (Pub. L. 100–
203), provides that, if a diagnostic test
described in section 1861(s)(3) of the
Act (other than a clinical diagnostic
laboratory test) was not performed or
supervised by the billing physician and
also was not performed or supervised by
a physician with whom the billing
physician ‘‘shares a practice,’’ Medicare
payment is the lower of the costs (net of
any discount) charged by the performing
supplier to the billing physician, or the
performing supplier’s reasonable charge
(or other applicable limit). We
implemented the anti-markup provision
of section 1842(n)(1) of the Act by
promulgating current § 414.50,
‘‘Physician billing for purchased
diagnostic tests.’’ The current version of
§ 414.50 applies to TCs performed by an
‘‘outside supplier,’’ but that term is
undefined. We acknowledge that some
have understood § 414.50 as applying
only to TCs that are outright purchased,
instead of reassigned, but as we
indicated in the CY 2007 PFS proposed
rule (71 FR 49056), and as some
commenters have noted, reassigned tests
are functionally the equivalent of
purchased tests. When section
1842(n)(1) of the Act was enacted, there
was perhaps more of a difference
between purchased tests and reassigned
tests, but subsequent events have
blurred the distinction between tests
that are outright purchased and tests for
which payment is reassigned.
At the time section 1842(n)(1) of the
Act was enacted, reassignments under
the contractual arrangement
reassignment exception in section
1842(b)(6)(A)(ii) of the Act were
permitted only to the extent the work
was performed on the premises of the
billing supplier. Therefore, at that time,
a physician reassigning benefits to
another physician was either an
employee of the billing supplier or a
contractor who was furnishing the
services on the premises of the billing
supplier. However, in our January 4,
2001 (Phase I) final rule with comment
period, we provided that, for purposes
of our rules on physician self-referral,
an independent contractor physician is
a ‘‘physician in the group practice,’’ as
defined at § 411.351, during the time the
physician is providing care to the group
practice’s patients ‘‘in the group
practice’s facilities’’ (66 FR 885 through
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
886, 955). Further, in that same
rulemaking, we provided that a group
practice’s facilities (again, for purposes
of our rules on physician self-referral)
can include a ‘‘centralized building’’ (66
FR 888 through 889). As defined at
§ 411.351, space qualifies as a group
practice’s ‘‘centralized building’’ if it is
leased ‘‘24/7’’ by the group practice,
irrespective of the amount of square
footage of the space and irrespective of
the proximity (or lack thereof) to the
group’s facilities. Following that
rulemaking, a group practice could, in
compliance with our rules on physician
self-referral, refer patients for designated
health services (DHS) (such as
diagnostic testing) to an independent
contractor physician, and such
physician could perform or supervise
the performance of diagnostic tests in a
centralized building, provided that all
requirements of an exception were
satisfied. Further, the independent
contractor physician arguably satisfied
the ‘‘on the premises’’ requirement of
section 1842(b)(6)(A)(ii) of the Act and,
thus, was permitted to reassign benefits
to the group practice for the work
performed in the centralized building,
because we considered a centralized
building to be the group practice’s
facilities. In any event, in section 952 of
the MMA of 2003, the Congress
amended section 1842(b)(6)(A)(ii) of the
Act to remove the requirement that the
services must be performed on the
premises of the billing supplier in order
to utilize the contractual arrangement
exception. Therefore, following the
MMA amendment, it is clear that
independent contractor physicians who
perform or supervise the performance of
diagnostic tests in a centralized building
may reassign payment for such tests to
the group practice that owns or leases
the centralized building.
Being mindful of the Congress’ intent
to impose an anti-markup on the TC of
diagnostic tests that are not performed
or supervised by a physician who
‘‘shares a practice’’ with the billing
physician, we are amending § 414.50 in
this final rule with comment period to
provide that TCs that are not performed
in the office of the billing physician or
other supplier are subject to the antimarkup provision. With respect to a
physician organization (such as a group
practice), we consider the ‘‘office of the
billing physician or other supplier’’ to
be medical office space in which the
physician organization provides
substantially the full range of patient
care services that the physician
organization provides generally.
Therefore, with respect to group
practices, we do not consider space to
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
be the ‘‘office of the physician or other
supplier’’ if that space does not meet the
requirement regarding patient care
services in revised § 414.50(a)(2)(iii) (for
example, space that is utilized as a
‘‘centralized building’’ for purposes of
the exceptions for physician services
and in-office ancillary services in
§ 411.355(a) and (b), respectively, but in
which the group practice provides
diagnostic testing services only).
We believe that, if the TC is
performed by an employee (full-time or
part-time), or by an independent
contractor who reassigns benefits, in the
office of the billing physician or other
supplier, a sufficient nexus with the
practice of the billing supplier is
established. (In this regard, we note that,
if the TC is performed by someone other
than an employee or a contractor who
reassigns benefits, that is, someone who
sells the test to the billing physician or
other supplier, the anti-markup
provision will apply regardless of where
the service is performed.) Further, we
see no reason to distinguish between the
TC and the PC of diagnostic tests for
purposes of the anti-markup provisions.
Although the Congress did not establish
an anti-markup provision in section
1842(n)(1) of the Act or elsewhere for
the PC of diagnostic tests, the omission
may have been inadvertent. That is, it is
not immediately clear why the
Congress, if it wished to prevent
overutilization of diagnostic testing,
would not have desired an anti-markup
on the PC, because without such a
provision, the incentive to order
unnecessary tests (and profit on the PC)
remains. We believe that, in order to
fully effectuate the Congress’ intent to
prevent or limit the ordering of
unnecessary diagnostic tests, it is
necessary to impose an anti-markup
provision on the PC of diagnostic tests.
Accordingly, our revisions to § 414.50
apply to PCs to the same extent as they
apply to TCs.
We see no reason to distinguish
between physicians and physician
group practices on the one hand, and
other types of suppliers on the other
hand, that bill for diagnostic tests. In the
proposed rule, we used the terminology
‘‘physician or medical group,’’ which
we borrowed from the existing manual
provisions on purchased tests and
purchased test interpretations. However,
the term ‘‘medical group’’ is not defined
and is not commonly used elsewhere.
We are amending § 414.50 so that it
applies to a billing ‘‘physician or other
supplier.’’ Any enrolled supplier that
bills for a diagnostic test or its
interpretation is potentially subject to
the anti-markup provisions in § 414.50.
PO 00000
Frm 00095
Fmt 4701
Sfmt 4700
66315
f. Definition of ‘‘Entity’’
Comment: One commenter stated that,
although we proposed to expand the
purchased diagnostic test rule in
§ 414.50 to apply also to the purchased
PC of a diagnostic test, it was not
entirely clear whether we proposed to
expand the scope of the exception in the
definition of ‘‘entity’’ at § 411.351 for
purposes of our rules on physician selfreferral. The commenter noted that the
definition of ‘‘entity’’ at § 411.351
provides that a physician’s practice is
not acting as an ‘‘entity’’ when it bills
Medicare for ‘‘a diagnostic test in
accordance with § 414.50.’’ The
commenter contended that the phrase
‘‘diagnostic test’’ is currently interpreted
to mean only the TC, in part because
§ 414.50 currently applies only to the
TC. The commenter also stated that if
the scope of § 414.50 is expanded to
cover both the TC and the PC, one could
interpret the phrase in § 411.351,
‘‘diagnostic test in accordance with
§ 414.50,’’ to mean that a physician
practice is not an entity when it bills
Medicare for either the TC or the PC in
accordance with § 414.50. The
commenter suggested that, if we finalize
our proposal to apply an anti-markup
provision to purchased TCs and PCs, we
should revise the definition of ‘‘entity’’
at § 411.351 to clarify that the exception
for purchased diagnostic tests applies to
both the TC and the PC. Another
commenter also supported changing the
definition of ‘‘entity’’ at § 411.351 to
except from that definition a supplier
that is billing for the PC in accordance
with the anti-markup provisions of
§ 414.50.
Response: Under our physician selfreferral rules in part 411, subpart J of
this chapter, a physician may not refer
a patient for certain designated health
services (DHS) to an entity with which
the physician (or an immediate family
member) has a financial relationship,
and the entity may not bill Medicare for
such DHS, unless an exception applies.
The definition of ‘‘entity’’ at § 411.351
‘‘does not include a physician’s practice
when it bills Medicare for a diagnostic
test in accordance with § 414.50.’’ The
rationale for excluding from the
definition of ‘‘entity,’’ and hence from
the application of our physician selfreferral rules, a physician practice that
is billing for a TC that is subject to the
anti-markup provision, is that there is
no risk of overutilization arising from a
financial relationship between the
referring physician and the physician’s
practice billing for the service. We
believe the same rationale should apply
to PCs made subject to an anti-markup
provision under this final rule with
E:\FR\FM\27NOR2.SGM
27NOR2
66316
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
comment period. We are amending
slightly the definition of ‘‘entity’’ at
§ 411.351 to make clear that the
exclusion applies to both TCs and PCs.
As amended, the pertinent language
reads ‘‘does not include a physician’s
practice when it bills Medicare for the
TC or the PC of a diagnostic test for
which the anti-markup provision is
applicable in accordance with
§ 414.50.’’
We note that, under our physician
self-referral rules, an independent
contractor physician is a ‘‘physician in
the group’’ for purposes of the physician
services exception in § 411.355(a) and
the in-office ancillary services exception
in § 411.355(b), only with respect to
services performed on the group’s
premises (including a ‘‘centralized
building’’ as defined at § 411.351).
Therefore, one practical effect of the
change in the definition of ‘‘entity’’ is
that a group practice that currently may
not bill for a PC performed by an
independent contractor physician,
because the independent contractor
physician is not performing the PC on
the group’s premises, will be able to do
so without running afoul of the
physician self-referral rules if the PC is
billed in accordance with the antimarkup provisions of this final rule
with comment period.
g. Employment Status
Comment: A commenter that
supported our proposed changes to the
reassignment rules pertaining to
diagnostic tests stated that it was
appropriate for CMS to focus on the
billing of diagnostic tests performed by
someone other than a full-time
employee. The vast majority of
commenters that addressed the
employment status issue, however,
opposed applying the anti-markup
provisions to part-time employees and
independent contractors based simply
on their employment status. Three
commenters asserted that the proposed
changes are unnecessary and would
negatively impact the way physicians
provide care to patients, possibly
resulting in the termination of part-time
physicians or a prohibition on part-time
physicians furnishing diagnostic tests.
Many commenters claimed that, if the
proposed changes to the purchased
diagnostic test rules are implemented,
physicians and group practices would
not be able to provide certain routine
medical procedures if limited to using
full-time employees. One commenter
requested that we exempt part-time
employees and independent contractors
from the anti-markup rules provided
that the billing supplier satisfies a
physician self-referral exception and the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
services are furnished in the billing
supplier’s office. A few commenters
proposed that CMS not apply the antimarkup requirements to technicians
who work on-site at the medical group
and who work at least half-time for that
specific group.
One commenter stated that limiting
reimbursement for the PC of diagnostic
tests performed by outside suppliers
would create an incentive to hire fulltime staff and then overutilize pathology
services in an attempt to recoup the
costs of such personnel. The commenter
urged us not to penalize physician
groups by having the anti-markup rules
apply when using part-time employees
or independent contractors who furnish
services on less than a full-time basis.
Two commenters considered our
proposal to be premised on the
unsupported belief that group practices
that perform a lower volume of
diagnostic tests and, therefore, need
only employ pathologists on a part-time
basis, present more risk of program
abuse. Another commenter stated that
forcing suppliers and their staff into
full-time relationships will impose
needless costs and will require forgoing
efficiencies that are available through
more flexible supplier-staff
relationships. Several commenters
believed that applying an anti-markup
provision based upon the employment
status of the technician or physician
would unfairly disadvantage
individuals who want to work only parttime (for example, mothers of young
children). One of these commenters
stated that we essentially placed a
hurdle in front of group practices that
wish to accommodate the professional
and personal needs of its employees,
and that, given the shortage of qualified
health professionals in many areas, we
should be making it easier, and not
more difficult, for professionals to
provide care.
Response: We agree that it is not
necessary or advisable to premise the
application of the anti-markup
provisions on the employment status of
the person performing the TC or PC. We
are revising the language in § 414.50 to
clarify that an outside supplier is
someone who is not an employee of the
billing physician or other supplier and
who does not furnish the test or
interpretation to the billing supplier
under a reassignment that meets the
requirements of § 424.80. Therefore,
diagnostic testing services furnished by
part-time employees and independent
contractors in the office of the billing
supplier will not be subject to the antimarkup rules, unless the services of the
independent contractor are billed as a
purchased diagnostic test.
PO 00000
Frm 00096
Fmt 4701
Sfmt 4700
Comment: One commenter stated that
the anti-markup provisions should
apply only when the diagnostic service
is provided in a centralized building
outside of the physician’s primary office
site where he or she provides his or her
professional services, and should not
apply based on the employment status
of the individual performing the TC.
Response: We agree generally and
have revised § 414.50 and § 424.80 to
specify that the anti-markup rules apply
to purchased tests and interpretations
(regardless of site of service) and to TCs
and PCs performed at a site other than
the office of the billing supplier. With
respect to physician group practices, the
group’s ‘‘office’’ is the medical office
space in which the physician
organization provides substantially the
full range of patient care services that
the physician organization provides
generally. The group’s office does not
include space utilized by the group as
a ‘‘centralized building’’ (or other space)
where only (or primarily) diagnostic
testing is performed by radiologists or
pathologists.
Comment: One commenter found the
proposed definition of an outside
supplier as someone other than a fulltime employee of the billing physician
or medical group to be confusing and
inconsistent with the definitions at
§ 411.351. Thus, the commenter
recommended replacing the term ‘‘fulltime employee of the billing physician
or medical group’’ with the defined term
‘‘member of the group or member of a
group practice.’’
Response: In the CY 2007 PFS
proposed rule (71 FR 49054), we
proposed that TCs and PCs that are
reassigned under the contractual
arrangements exception in section
1842(b)(6)(A)(ii) of the Act would be
subject to an anti-markup provision. We
received comments expressing concern
that our proposals would be ineffective
to the extent that contractors who
performed TCs and PCs for multiple
group practices would now become
part-time employees of the same group
practices. In response, in the CY 2008
PFS proposed rule, we proposed that
the anti-markup provisions would apply
to reassigned TCs and PCs that are not
performed by full-time employees.
However, we believe we can guard
adequately against potential
overutilization by imposing an antimarkup provision on purchased PCs
and TCs, and, with respect to nonpurchased TCs and PCs, imposing an
anti-markup provision on the TCs and
PCs that are performed outside of the
office of the billing physician or other
supplier, without regard to the
employment status of the person
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
performing the TC or PC, thus leaving
intact the part-time employment
arrangements that have traditionally
existed. Therefore, we believe it is
unnecessary and inadvisable to adopt
the commenter’s suggestion.
Comment: Several commenters
requested that we clarify what is meant
by a ‘‘full-time employee.’’ They urged
us to use the Department of Labor’s
Bureau of Labor Statistics standard,
which is 35 hours per week.
Response: For the reasons stated
above, we do not believe it is necessary
to define ‘‘full-time employee.’’
Comment: Several commenters
suggested that we exempt TCs and PCs
furnished by part-time employees of the
billing supplier from the anti-markup
provisions, provided that the employees
are working exclusively for one billing
supplier, such as a single health care
organization. Other commenters
suggested that, instead of providing that
the anti-markup provisions would apply
to the TCs and PCs performed by parttime employees, we apply an antimarkup provision to work performed by
employees who work for more than a
certain number of physician practices.
Response: We considered creating an
exception from the anti-markup
provisions for services provided by parttime employees who work exclusively
for one billing supplier. We also
considered restricting the application of
the anti-markup provision to work
performed by employees who work for
more than a certain number of
physicians’ practices. We rejected both
approaches as unnecessary given our
decision to base the application of the
anti-markup primarily on the site of
service, as well as because we believe
that each approach would add undue
complexity to the rule and would be
difficult for both billing suppliers and
for us to administer. We will monitor
the effectiveness of our site-of-service
approach in addressing our concerns
regarding potential overutilization. If
arrangements that currently are taking
place at a site other than the office of the
billing physician or other supplier
simply migrate to the ‘‘office of the
billing physician or other supplier’’ in
order to escape the application of the
anti-markup provisions, we may revisit
the idea of imposing an anti-markup
provision for services performed by a
technician or physician who works for
more than a certain number of physician
practices.
h. Deductibles and Coinsurance
Comment: Several commenters
observed that there appeared to be a
drafting error regarding the application
of deductibles and coinsurance to the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
anti-markup limits in proposed § 414.50
and § 424.80. In both sections, the
maximum payment is set as an amount
that is net of deductibles and
coinsurance, that is, ‘‘less the applicable
deductibles and coinsurance.’’ The
commenters noted that the price
limitation should represent the
Medicare allowable amount, which
should include any coinsurance or
deductibles to be paid by the Medicare
beneficiary. One of the commenters
stated that the current language could be
interpreted such that the combined
Medicare and beneficiary payment to
the physician could exceed the amount
that a physician paid an outside
supplier of a TC or PC by 20 percent, the
applicable coinsurance for PFS services.
The commenter recommended that the
language be revised to read ‘‘the
payment to the billing physician or
medical group, including applicable
deductibles and coinsurance, may not
exceed the lowest of the following
amounts.’’
Response: Proposed § 414.50 and
proposed § 424.80 stated that, payment
to the billing supplier, ‘‘less the
applicable deductibles and
coinsurance’’ may not exceed the lowest
of the following amounts: (1) The
supplier’s net charge to the physician;
(2) the physician’s actual charge; or (3)
the fee schedule amount for the test that
would be allowed if the supplier billed
directly. The quoted language
referenced above is identical to that in
current § 414.50 and is virtually
identical to that in section 1842(n)(1) of
the Act. We read the statute and
regulations as saying that the
contractor’s payment to the billing
supplier, in the situation in which the
anti-markup provision applies, is the
lowest of the performing supplier’s net
charge, or the billing supplier’s actual
charge, or the applicable fee schedule
amount, less any applicable deductible
and coinsurance amounts.
We agree with the commenters that
the total payment (that is, by the
contractor and the beneficiary or third
party payor on behalf of the beneficiary)
is limited to the lowest of the three
amounts specified above. This
interpretation represents historical
Medicare policy, and we believe that
this policy has been implemented
correctly by the carriers. However, we
are refining the language of the
regulation as suggested by the
commenter for greater clarity. We do not
consider this a substantive change. We
are revising § 414.50 to read ‘‘the
payment to the billing physician or
other supplier (including applicable
deductibles and coinsurance paid by the
beneficiary or on behalf of the
PO 00000
Frm 00097
Fmt 4701
Sfmt 4700
66317
beneficiary) for the technical or
professional component of the test may
not exceed the lowest of the following
amounts * * *’’
i. Net Charge
Comment: Several commenters
addressed the question of how to
determine the net charge for purposes of
applying the anti-markup provisions.
Commenters asserted that most
physicians are paid an aggregate
monthly or annual amount for their
services and therefore there is no
‘‘charge’’ to report on a claim. One
commenter stated that independent
contractors are frequently paid based on
time spent furnishing the services, as
opposed to a per-interpretation price.
Alternatively, payment may be made at
a fixed rate per month or year. Yet
another model is a per-service price
reflecting a blended rate of different
payor pricing, not just the Medicare
allowable amount. Employees,
including part-time employees, are often
salaried. Consequently, according to the
commenter, there is no cost or charge
per professional interpretation, and it
would be impossible for a group
practice to determine the unit price for
purposes of the anti-markup provision.
The commenter contended that all of
the various types of employment
relationships would have to be
restructured, at great cost and
administrative burden, to practices.
One commenter stated that it would
not be administratively feasible to
determine the net charge per test in
order to apply the anti-markup
provisions to part-time employees or
independent contractors who are paid
on an hourly basis or a per-diem rate.
Other commenters complained that the
proposed rules do not address how the
billing entity is supposed to determine
the net charge per service on the claim.
According to these commenters, it
causes confusion as well as the risk of
false claims liability to require
physician practices to include a charge
for all diagnostic test services. Another
commenter pointed to what it saw as
difficulties in allocating charges
between the TC and the PC when a
billing supplier purchases both the TC
and the PC.
A few commenters urged us to
provide guidance on how to determine
the ‘‘net charge’’ for a service. One
commenter requested that we clearly
state that the billing entity must
calculate its net unit price, which may
reflect payments divided by the number
of slides referred; for example, if the
billing entity pays a supplier a set
amount per month or per year to
prepare and read all the slides that were
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66318
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
referred. One commenter stated that it
agreed with the proposed approach of
not allowing the net charge to reflect the
cost incurred by the performing supplier
of leasing equipment or space from the
billing supplier. The commenter
expressed concern, however, that
participants in some joint venture
laboratories may inappropriately
attempt to inflate the acquisition cost of
the service, and suggested that we not
permit other related costs, such as
separately purchased or leased
equipment, supplies, insurance, etc., to
be included when determining the
amount charged by the person
performing the TC or PC. If these costs
were included, it would have the effect
of raising the net charge, and permit the
billing suppliers to charge Medicare a
higher price.
Response: We are leaving the
responsibility for determining the net
charge for a test with the billing
supplier. The anti-markup provision
imposed on the PC through this final
rule with comment period is similar to
the longstanding provision for
prohibiting a markup on the TC. Thus,
we do not believe most suppliers will
experience significant difficulty in
calculating the net charge, despite the
fact that some physicians are paid an
aggregate monthly or annual amount for
their services. Suppliers that incur
difficulty in calculating the net charge
may structure arrangements so that the
anti-markup provisions do not apply
(for example, by ensuring that tests and
interpretations are not purchased and
are performed in the office of the billing
physician or other supplier), may allow
the performing supplier to bill for the
TC or PC, or may use a payment method
(such as per-procedure) that yields an
easily ascertainable net charge.
Suppliers must calculate the net charge
in a reasonable manner. This final rule
with comment period does not prevent
suppliers from using any particular
method that yields an accurate net
charge. For example, in some situations,
it may be appropriate to divide a
technician’s weekly compensation by
the number of procedures performed to
arrive at the net charge for each
procedure performed during that week.
Because suppliers would have the
burden of establishing that the charge
billed was the net charge, suppliers
should retain contemporaneous
documentation of the methodology and
information used to calculate the net
charge.
We are not adopting at this time the
commenter’s suggestion that, to guard
against parties artificially inflating the
cost of the TC or PC, we specifically
prohibit the performing supplier to take
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
into account, when calculating its net
charge, the costs of equipment or
services (such as insurance), obtained
from the billing supplier. However, we
note that, to the extent that a billing
supplier would sell goods or services at
an inflated price so as to game the
application of the anti-markup
provisions, such excess compensation
may constitute a violation of our rules
on physician self-referral and may also
be a violation of the anti-kickback
statute (section 1128B(b) of the Act). We
will monitor financial relationships
between billing and performing
suppliers and, if it appears that parties
are attempting to evade application of
the anti-markup provisions through the
sale of goods and services, we may
modify the provisions.
Comment: One commenter expressed
concern about expanding the antimarkup provision to cover the PC,
noting that, because a per-interpretation
price is not the most efficient method of
compensation for purchased PCs,
practices would likely develop a system
of compensation that would pay the
reading physician differently depending
on the patient’s payor. For example,
practices might pay the reading
physician on a salary basis for reads for
patients of private and non-Medicare
payors and on a per-read basis for
Medicare patients. According to the
commenter, this could result in lower
costs associated with non-Medicare
patients than with Medicare patients,
depending on the way in which the
physician and the practice negotiate
payment for the different groups of
patients. The commenter questioned
whether it is appropriate to charge
Medicare more on a per-procedure basis
than other payors.
Response: Nothing in this final rule
with comment period requires practices
to pay for professional services for
Medicare patients on a per-procedure
basis or using any particular payment
method. What is important is that the
practice calculates an accurate net
charge for purposes of these regulations.
In reviewing the accuracy of the net
charges of a practice that pays
differently for professional services
based on the payor status of the
patients, we would look to see whether
the use of different payment structures
results in inappropriate shifting of costs
to Medicare (that is, by paying
physicians more for Medicare reads
than non-Medicare reads, the practice is
able to collect more reimbursement
under the anti-markup provisions).
Moreover, we note that section
1128(b)(6)(A) of the Act provides for the
permissive exclusion of providers or
suppliers that submit bills or requests
PO 00000
Frm 00098
Fmt 4701
Sfmt 4700
for payment based on charges or costs
to Medicare that are substantially in
excess of the party’s usual charges or
costs, absent a finding of good cause for
the differential. Responsibility for that
statute is delegated to the OIG.
Comment: One commenter questioned
whether the anti-markup provisions
would apply to diagnostic tests
performed through block lease
arrangements. This commenter (and
another commenter) also stated that it
would be difficult to calculate the pertest charge on tests performed in block
lease arrangements.
Response: The anti-markup rules do
apply to diagnostic tests performed
through block lease arrangements, and
the burden is on the billing entity to
determine how to calculate its net
charge per test.
Comment: Several commenters urged
us to ensure that the calculation of the
payment level under the anti-markup
rules will not impose new
administrative burdens on the billing
supplier. A few commenters stated that
the billing supplier should be able to
mark up the PC between 7 and 10
percent to cover the costs of billing. A
few commenters asserted that the
proposed anti-markup provisions will
adversely affect group practices that
wish to bill globally for interpretations
performed by teleradiologists located
outside of the billing group practice’s
office. The commenters were concerned
that billing physicians or other
suppliers would not be able to include
administrative expenses in the price
paid for the interpretation. One
commenter stated that, by limiting
reimbursement to a practice’s actual
acquisition cost, we are ignoring the role
of the RBRVS system to appropriately
establish a proper payment amount for
services.
Response: Where the anti-markup
provisions are applicable, the billing
supplier will be responsible for
calculating the net charge. Suppliers
that do not wish to contend with
calculating the net charge will have to
structure arrangements so that the antimarkup provisions do not apply (for
example, by requiring the suppliers
performing the TC and PC to bill for
them, or by ensuring that the TC and PC
are performed in the office of the billing
physician or other supplier), or utilize a
per-procedure method of payment or
other method that yields an easily
ascertainable net charge. Similarly,
suppliers that do not wish to incur the
cost of billing without being able to
mark up the TC or PC, should structure
arrangements so that the anti-markup
provisions do not apply.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Comment: One commenter contended
that, in a medical foundation context,
there is no way to determine the net
charge to the foundation for the services
of the interpreting physician. The
commenter stated that the anti-markup
proposal would result in the need to
generate artificial invoices, greatly
complicating and needlessly burdening
medical foundations.
Response: A medical foundation, or
any other medical group practice,
billing for the TC or PC of a diagnostic
test that it did not perform will need to
calculate its own net charge per test. We
perceive no need to generate artificial
invoices. The purpose of this
requirement is to address potential
program abuse where physicians and
other suppliers order tests and bill for
tests that they did not perform at a
markup from the price paid for the test.
Comment: Several commenters
inquired how we would be able to verify
the true cost of purchasing a TC or PC
of a diagnostic test. The commenters
questioned our rationale for this
proposal and asserted that the proposal
would be detrimental because it would
have the effect of precluding suppliers
from recouping overhead costs. The
commenters voiced concerns that we are
trying to eliminate purchased diagnostic
tests entirely.
Response: We can verify the true cost
of a purchased TC or PC by requesting
supporting documentation from the
provider or supplier. The burden of
proof in substantiating the validity of a
claim rests with the billing provider or
supplier. The anti-markup provisions
finalized in this rule are not designed to
prevent the billing supplier from
recovering overhead expenses or to
eliminate purchased diagnostic tests
entirely, but rather to minimize program
and patient abuse. Where the TC or PC
is performed in the office of the billing
physician or other supplier, the billing
supplier will be able to recoup some or
all of the overhead it incurs in the
performance of the TC or PC by billing
at the fee schedule amount (or at the
Medicare limiting charge amount). If,
however, the billing supplier has
incurred overhead expenses for a TC or
PC that was performed at a site other
than the office of the billing supplier
(such as in space leased by a billing
group practice and utilized by the group
practice as a ‘‘centralized building’’ that
does not meet the definition of ‘‘office
of the billing physician or other
supplier’’ at § 414.50(a)(2)(iii)), the
billing supplier will not be able to
recoup the overhead, but rather will be
limited to the lowest of the performing
supplier’s net charge, the billing
supplier’s actual charge, or the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
applicable fee schedule amount. (In the
unlikely event that the lowest of the
three amounts is either the billing
supplier’s actual charge or the
applicable fee schedule amount, the
billing supplier may be able to recoup
its overhead but nevertheless would be
receiving less payment than the
performing supplier’s net charge.) We
believe that this result is appropriate. If
billing suppliers were able to recoup
overhead incurred for TCs and PCs that
are performed at sites other than their
offices, the effectiveness of the antimarkup provisions would be
undermined, because there would be an
incentive to overutilize to recover the
overhead incurred for purchasing or
leasing space.
Comment: One commenter
recommended that we require, as a
condition for reassignment of a
purchased interpretation, that the
parties to the arrangement calculate a
net charge for the service. The
commenter stated that, if this condition
applied, per-diem or other time-based
arrangements, which are more
susceptible to markups, would not be
permitted.
Response: We realize that, in most
circumstances, a group practice would
not want to pay an independent
contractor more for a service than the
payment it receives from an insurer for
furnishing the service. However, we are
under the impression that some
physician group practices that have
exclusive contracts with hospitals under
which the group practice furnishes all
PCs of inpatient and outpatient
radiology services often hire
independent contractors to provide PCs
that are needed at night or on weekends.
We have been informed that, in some of
these cases, the group practice willingly
pays its independent contractors more
for their services than the group practice
receives in reimbursement so that the
group practice physicians do not have to
provide services late at night. There may
also be other reasons (for example, as an
improper inducement for referrals) why
parties could agree to an amount that
does not accurately reflect the true net
charge.
As explained above, we believe that a
group practice may pay an independent
contractor on a per-diem or hourly
basis, and also arrive at an appropriate
amount to bill Medicare for each service
based on the number and differing work
intensities of the services provided.
Comment: One commenter
recommended that we prohibit any
mark-up over the direct costs incurred
by the group practice in providing
diagnostic testing services. Direct costs
would be defined as limited to the
PO 00000
Frm 00099
Fmt 4701
Sfmt 4700
66319
compensation paid to the persons
providing the services and the cost of
equipment and supplies utilized in
performing the services. One commenter
asserted that the proposed restrictions
would not allow a billing practice to be
paid for its legitimate overhead costs.
Two commenters requested that we
permit employers to include in the
calculation of a supplier’s net charge the
lower of the following: (1) A reasonable
practice expense (PE) derived from its
own relative value cost; or (2) the actual
overhead costs attributable to the
supplier. The commenters suggested
that this would permit a group to utilize
part-time diagnostic physicians without
financially penalizing the employer, and
at the same time safeguard against
artificially inflated overhead costs.
Response: In effect, the commenters
requested that we adopt a ‘‘net charge
plus’’ approach. In order for the antimarkup provisions to have real effect, it
is necessary that payment by Medicare
be limited to the lowest of: (1) The
physician’s or other supplier’s net
charge to the billing supplier; (2) the
billing supplier’s actual charge; or (3)
the fee schedule amount for the service
that would be allowed if the physician
or other supplier billed directly. If we
were to allow billing suppliers to
include costs in addition to the
performing supplier’s net charge, we
would defeat the purpose of the antimarkup provisions.
Comment: A few commenters
requested that we ensure consistency in
the language in § 414.50 and § 424.80.
For example, proposed § 414.50(a)(3)(i)
states that net charge does not include
‘‘any charge that is intended to reflect
the cost of equipment or space leased to
the outside supplier,’’ whereas § 424.80
states that it does not include ‘‘any
charge that is intended to cover or
address the cost of this equipment.’’
Response: As noted above, we have
effectuated the anti-markup provisions
by revising § 414.50, and by placing a
cross reference to that section in new
§ 424.80(d)(3). The language of proposed
§ 414.50(a)(3)(i), ‘‘reflect the cost of
equipment or space leased’’ survives.
Comment: One commenter
recommended that we include in the net
charge the costs incurred by the
purchasing supplier to facilitate test
interpretations, specifically, the cost of
teleradiography to transmit images to
the interpreting physician and the cost
of producing a written report of the
interpretation.
Response: To the extent that costs
such as those noted by the commenter
are incurred by the billing supplier, as
opposed to the performing supplier, we
are not persuaded to permit the inflation
E:\FR\FM\27NOR2.SGM
27NOR2
66320
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
of the net charge to include such costs.
As discussed above with respect to the
recoupment of overhead costs, we
believe that allowing billing suppliers to
recoup the costs suggested by the
commenter would defeat the purpose of
the anti-markup provisions.
i. Miscellaneous
Comment: One commenter suggested
that, as an alternative to an anti-markup
provision, we prescribe a fixed dollar
amount (for example, based on a
percentage of what Medicare would pay
for the PC if billed directly), as a ceiling
for Medicare payment. The ceiling
would be adjusted for certain PEs such
as bona fide collection costs and bad
debt.
Response: We believe that setting a
fixed dollar amount for diagnostic tests
and interpretations performed under
particular circumstances is problematic.
There would be difficulties in
determining what the fixed dollar
amount should be, and what, if any, PEs
should be taken into consideration to
augment the fixed dollar amount. In
addition, we did not propose such an
approach, and believe it may be outside
the logical outgrowth test for issuing
final rules to adopt the commenter’s
approach in this final rule with
comment period. Moreover, even if we
were able to adopt such an approach
without first specifically proposing one,
it would take us considerable time to
study the feasibility of prescribing a
payment ceiling for TCs and PCs under
particular circumstances, and we
believe that it is important to issue a
final rulemaking on this subject without
further delay in order to address our
current concerns with potential
overutilization.
Comment: Two commenters stated
that, in addition to restrictions
contained in the proposed rule, we
should also require that: (1) A
pathologist not be allowed to work for
more than one physician group practice;
(2) a pathologist not be allowed to work
for, or have any arrangement with,
independent reference laboratories; and
(3) medical liability insurance for the
pathologist should be paid by the
physician group practice billing for the
pathologist’s services. (The commenters
explained that the purpose of the
second proposed requirement is to
eliminate the possibility that a reference
laboratory could provide a pathologist
to a physician group practice in return
for receiving the right to bill for the TC.)
One of the commenters was also
concerned that, if a single pathologist is
performing work for the billing
physician practice, appropriate or
optimal quality assurance will not take
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
place. The commenter stated that, in her
pathology group practice, all
malignancies are reviewed by at least
two pathologists.
Response: With respect to the
commenters’’ first suggested
requirement, we proposed that an antimarkup provision would apply to PCs
that are reassigned by someone who is
not a full-time employee of the supplier
billing for the PC, because we were
concerned with the potential for
overutilization where a single physician
performs interpretations for more than
one group practice in contiguous
centralized buildings (such as in ‘‘pod’’
or ‘‘condo’’ laboratories). Specifically,
we were concerned that a physician
who formerly reassigned benefits under
the contractual arrangements
reassignment exception could simply be
made a part-time employee of a number
of group practices. As noted above, in
response to public comments, we are
not imposing an anti-markup on the PC
of a diagnostic test simply because the
PC was performed by someone other
than a full-time employee of the billing
supplier. Rather, we are addressing our
concerns regarding potential
overutilization by imposing an antimarkup on the PC of a diagnostic test if
it is purchased or if it is not performed
in the office of the billing physician or
other supplier. We believe our decision
to impose an anti-markup provision on
PCs that are ordered by the billing
supplier and performed at a site other
than the office of the billing supplier
(for example, in space that the billing
supplier utilizes as a ‘‘centralized
building’’ but that does not meet the
definition of ‘‘office of the billing
physician or other supplier’’ in revised
§ 414.50(a)(2)(iii)), regardless of the
employment status of the physician,
will adequately address our concerns
with overutilization. As for the other
two proposed requirements and the
second commenter’s implied proposed
requirement, we do not believe it is
within the scope of this rule to attempt
to restrict a pathologist from working for
more than one supplier, or to require a
group practice to pay for a pathologist’s
malpractice premiums, or to impose
quality standards for pathologist
performed PCs.
Comment: A commenter
recommended that we revise the
definition of ‘‘centralized building’’ at
§ 411.351 to include the following
language: ‘‘In the case of a space used
for the performance of the [TC] of a
diagnostic test, which is billed by a
group practice, such space can qualify
as a centralized building only if the
group complies with the requirements
of § 414.50 or § 424.80(d)(3) when
PO 00000
Frm 00100
Fmt 4701
Sfmt 4700
billing for the [TC].’’ The commenter
also suggested that, by changing the
definition of ‘‘centralized building,’’ a
physician or medical group would be
prohibited from marking up what it paid
for the TC of a test that was performed
in a centralized building, unless it was
performed by a full-time employee.
Response: We are not revising the
definition of ‘‘centralized building’’ in
this rule. Because the anti-markup
provisions will apply to all TCs and PCs
that are both: (1) Ordered by a group
practice (or an entity related to the
group practice by common ownership or
control; see § 413.17 regarding
‘‘common ownership or control’’); and
(2) performed at a site other than the
office of the physician or other supplier,
it is not necessary at this time to narrow
the definition of a ‘‘centralized
building’’ in order to guard against
potential overutilization.
Comment: One commenter expressed
concern regarding physicians who have
invested heavily in in-office equipment
and have followed CMS guidelines
established for the in-office ancillary
services exception in § 411.355(b) for
purposes of the physician self-referral
rules. The commenter recommended
that we regulate the usage of ancillary
services through medical necessity
guidelines and by requiring that the
services be provided at fair market
value, rather than by the proposed
changes to the reassignment and
purchased test rules.
Response: As finalized, the antimarkup provisions do not apply to nonpurchased TCs and PCs performed in
the office of the billing physician or
other supplier. We note that in the CY
2008 PFS proposed rule, we sought
comments as to whether we should
narrow the in-office ancillary services
exception, including whether we should
exclude certain types of services from
the protection of the exception. We
received many comments on this issue,
and if we are inclined to make any
changes to the in-office ancillary
services exception we will first propose
such changes in a notice of proposed
rulemaking.
Comment: One commenter urged us
to require that imaging technology be
provided only by physicians trained in
modality-specific interpretation of
imaging procedures who follow the
guidelines of specialty organizations
such as the American College of
Cardiology and the American Society of
Echocardiography. In addition, the
commenter supported the accreditation
of facilities that provide such imaging
services, provided that we allow
adequate time for practices to become
accredited by relevant organizations that
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
are dedicated to improving the quality
of imaging services.
Response: The comment is outside the
scope of the proposed rule. Moreover,
currently we do not have the statutory
authority to restrict payment for these
procedures to physicians who possess
the training and accreditation
recommended by the commenter.
Comment: One commenter urged us
to enforce the anti-markup requirements
on purchased diagnostic tests by
auditing pathology practices and
laboratories. The commenter contended
that there is widespread ordering of
unnecessary tests by pathologists with
no regulatory oversight by CMS. The
commenter suggested that effective
enforcement and application of current
anti-markup rules to the pathology
community would obviate the need to
add new regulations that would limit
physician practices from providing
quality pathology services to their
Medicare patients. The commenter also
suggested that we adopt reasonable
protocols and standards for the review
of Pap smears, among other tests, which,
according to the commenter, would
significantly reduce unnecessary testing
by pathologists and result in
tremendous cost savings to the Medicare
program.
Response: Our contractors perform
pre-pay and post-pay reviews of
services, including reviews to determine
if the services were reasonable and
necessary. However, the extremely large
number of claims that contractors must
handle each year, as well as the
difficulty in sometimes knowing
whether services were reasonable and
necessary, underscores the need to
adopt rules to address the potential for
overutilization in other ways, rather
than relying solely on reviews for
medical necessity. The proposed antimarkup provisions would apply equally
to all physicians, including pathologists.
However, section 1842(n)(1) of the Act
does not authorize the anti-markup on
diagnostic tests to apply to clinical
laboratory tests, and we did not propose
to extend the anti-markup provisions to
such tests. We are concerned with
preventing the billing supplier from
ordering unnecessary tests for profit.
Laboratories typically do not order tests,
and therefore, there has not been a
concern about abuse by laboratories in
purchasing diagnostic tests. The
comment that we should adopt
protocols or standards for the review of
Pap smears and other tests is outside the
scope of the proposed rule.
Comment: One commenter urged us
to prohibit any markup of the TC of
surgical pathology specimens and let
each physician decide where the TC is
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
performed in addition to where the PC
is performed.
Response: Section 414.50 and section
30.2.9 of Pub. 100–04, Chapter 1, CMS
Internet-Only Manual, currently
prohibit markups of the TC of a
diagnostic test if the TC is performed by
an outside supplier. As finalized, our
revisions to § 414.50 will prohibit the
markup of a TC if the TC is ordered by
the billing supplier and is either
purchased or performed somewhere
other than the office of the billing
supplier. Physicians are permitted to
determine where the TC and PC are
performed, provided that the
arrangement is in compliance with the
purchased test rules and physician selfreferral rules.
Comment: One commenter stated that
the proposed anti-markup provisions
are unfair and would interfere with
existing business relationships. The
commenter asserted that medical
practices should have the freedom to
hire in-house professionals or contract
with other practices to perform services
without fear of financial penalty.
Response: We are not persuaded that
our anti-markup proposals, as finalized
in this final rule with comment, are
unfair. The proposals as finalized are
designed to reduce overutilization of
diagnostic tests, so that tests are ordered
because they are medically necessary
and are not ordered because a profit can
be made on each test. Practices can
maintain relationships with other
professionals on a part-time or
contractual basis. If the services are
furnished in the office of the billing
supplier, the anti-markup rules will not
apply, unless the services of an
independent contractor are billed as a
purchased test.
N. Beneficiary Signature for Ambulance
Transport Services
Section 424.36 requires that a
beneficiary’s signature must appear on
all claims submitted for Medicare
services, unless the beneficiary has
died, or another exception applies.
However, ambulance suppliers and
providers have stated that, in emergency
situations, it is often impossible or
impractical for ambulance providers or
suppliers to obtain a beneficiary’s or
other authorized person’s signature on a
claim to properly bill Medicare for
ambulance transport services because:
(1) Many beneficiaries are incapable of
signing claims due to their medical
condition at the time of transport; (2)
another person authorized to sign the
claim under § 424.36(b) is not available,
or is unwilling to sign the claim at the
time of transport; and (3) if an
individual listed in § 424.36(b) is not
PO 00000
Frm 00101
Fmt 4701
Sfmt 4700
66321
available or is unwilling to sign a claim
on behalf of the beneficiary at the time
of transport, it is impractical later to
locate the beneficiary (or the
beneficiary’s authorized representative)
to obtain a signature on the claim form
before submitting it to Medicare for
payment.
As stated in the CY 2008 PFS
proposed rule (72 FR 38187), we are
sympathetic to the concerns of
ambulance providers and suppliers
insofar as emergency transport services
are involved. Therefore, we proposed to
revise § 424.36 to provide that, for
emergency ambulance transport
services, where the ambulance provider
or supplier documents that the
beneficiary was physically or mentally
incapable of signing a claim form at the
time the service was provided and that
none of the individuals listed in
§ 424.36(b)(1) through (b)(5) 2 was
available or willing to sign a claim on
behalf of the beneficiary, the ambulance
provider or supplier could submit the
claim without a beneficiary signature.
Under our proposal, such claim
submission would be permitted only if:
(1) The beneficiary was physically or
mentally incapable of signing the claim
form at the time the service was
provided; (2) none of the individuals
listed in § 424.36(b)(1) through (b)(4)
was available or willing to sign the
claim form on behalf of the beneficiary
at the time the service was provided;
and (3) the ambulance provider or
supplier maintains in its files for a
period of at least 4 years from the date
of service certain documentation.
Required documentation would include:
(1) A signed contemporaneous
statement, made by an ambulance
employee present during the trip to the
receiving facility, that the beneficiary
was physically or mentally incapable of
signing a claim form and that none of
the individuals listed in § 424.36(b)(1)
through (b)(4) was available or willing
to sign the claim form on behalf of the
beneficiary at the time the service was
provided; (2) the date and time the
beneficiary was transported, and the
name and location of the facility where
the beneficiary was received; and (3) a
signed contemporaneous statement from
a representative of the facility that
received the beneficiary, which
documents the name of the beneficiary
and the time and date that the
beneficiary was received by that facility.
For non-emergency ambulance
transport services, the ambulance
2 We are making a technical change in the final
rule. The references in the proposed rule to
§ 424.36(b)(5) were in error, as individuals are
specified only in § 424.36(b)(1) through (b)(4).
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66322
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
provider or supplier would continue to
be required to obtain a beneficiary’s
signature on a claim form (or the
signature of someone who is authorized
to sign on behalf of the beneficiary
under § 424.36(b)(1) through (b)(4))
prior to submitting claims to Medicare.
We received comments from two
national associations that represent
providers and suppliers of ambulance
services and hospitals. The remainder of
the comments came from ambulance
owners and employees. The
commenters generally agreed that we
should eliminate the beneficiary
signature requirement entirely when a
beneficiary is mentally or physically
incapable of signing a claim and no
other person authorized to sign a claim
on behalf of the beneficiary is available
or willing to sign at the time of
transport. In addition, the commenters
argued that the proposed documentation
requirements would be costly and
burdensome to ambulance providers
and suppliers.
We are adopting our proposal, with
modification. Specifically, we are
allowing a secondary form of
verification to be used in lieu of the
proposed signed contemporaneous
statement from a representative of the
facility that received the beneficiary
(which remains an alternative). We are
also amending § 424.32(a) to clarify that
the beneficiary signature requirement is
satisfied if one of the exceptions in
§ 424.36 is satisfied. Finally, we are
making a technical change to our
proposal. In the proposed rule, we
stated that ambulance providers and
suppliers could utilize proposed
§ 424.36(b)(6) if none of the individuals
listed in § 424.36(b)(1) through (b)(5)
were available or willing to sign the
claim on behalf of the beneficiary at the
time the service was provided. The
references to § 424.36(b)(5) were in
error, as individuals are specified only
in § 424.36(b)(1) through (b)(4).
Comment: The majority of the
commenters opposed our proposed
changes to the beneficiary signature
requirements in § 424.36. The
commenters stated that the proposed
changes would have the unintended
effect of increasing the administrative
and compliance burden on providers
and suppliers of ambulance services and
on the hospitals.
Response: The proposal would not
have imposed any additional burdens
on providers and suppliers of
ambulance services. Rather, the
proposal, which we are adopting with
some modification, set forth an alternate
method of satisfying the beneficiary
signature requirement for claims
submitted for emergency ambulance
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
services. Those ambulance providers
and suppliers that believe that it is
burdensome to comply with new
§ 424.36(b)(6), may avail themselves of
the other means specified in § 424.36 for
satisfying the beneficiary signature
requirement.
Comment: Commenters asserted that
when a beneficiary is physically or
mentally incapable of signing a claim,
the ambulance industry has already
been signing claims on behalf of such
beneficiaries in accordance with the
requirements listed in the CMS InternetOnly Manual (IOM), Pub. 100–02,
Medicare Benefit Policy Manual,
Chapter 10, Section 20.1.2 and IOM,
Pub. 100–04, Medicare Claims
Processing Manual, Chapter 1, Section
50.1.6(A)(3)(c), without any objections
from CMS contractors. The commenters
stated that the ambulance industry has
also been relying on § 424.36(b)(5) as
further authority to sign claims on
behalf of beneficiaries when
beneficiaries are incapable of signing
and the requirements of § 424.36(b)(1)
through (b)(4) have not been met.
Response: Section 424.36(b)(5)
applies only if the beneficiary is
physically or mentally incapable of
signing the claim and none of the
persons listed in § 424.36(b)(1) through
(b)(4) is available to sign the claim. Note
that we interpret § 424.36(b), including
§ 424.36(b)(5), as meaning that neither
the beneficiary nor any of the persons
listed in § 424.36(b)(1) through (b)(4) is
available at all, not just that none of
them is available at the time the service
is performed. Thus, even assuming that
§ 424.36(b)(5) applies to ambulance
providers (and we believe that this
subparagraph was intended to apply
only to institutional providers such as a
hospital), an ambulance provider would
not be allowed to rely on § 424.36(b)(5)
to sign a claim for ambulance services
simply because the beneficiary was
incapable of signing the claim at the
time of delivery to the hospital or ESRD
facility and none of the persons listed in
§ 424.36(b)(1) through (b)(4) was
available and willing to sign the claim
for ambulance services at the time of
delivery. Instead, the provider would be
required, in advance of submitting the
claim, to make reasonable efforts to
locate and obtain a signature from the
beneficiary or, if the beneficiary is not
capable of signing, one of the alternative
individuals specified in § 424.36(b)(1)
through (b)(4). It would make little
sense to specify different categories of
individuals in § 424.36(b)(1) through
(b)(4) who could sign a claim on behalf
of a beneficiary who is unable to sign,
if a provider was allowed to file a claim
without making an effort to obtain a
PO 00000
Frm 00102
Fmt 4701
Sfmt 4700
signature from one of the other
authorized individuals. To the extent
that ambulance suppliers have been
relying on § 424.36(b)(5) under any
circumstances, such suppliers have
been failing to follow the regulations, as
this subparagraph does not pertain to
suppliers. We are clarifying
§ 424.36(b)(5) to provide that, before a
provider may avail itself of the
exception in § 424.36(b)(5), it must
make reasonable efforts (including over
a reasonable period of time) to have
either the beneficiary or one of the
individuals specified in § 424.36(b)(1)
through (b)(4) to sign the claim.
Similarly, the sections of the CMS IOM
cited by the commenters, Pub. 100–02,
Chapter 10, section 20.1.2 and Pub.
100–04, Chapter 1, section
50.1.6(A)(3)(c) imply that reasonable
efforts must be made to locate other
individuals prior to submitting the
claim. We plan to issue clarifying
instructions in the near future, to ensure
that our regulations and manual
instructions on the beneficiary signature
requirement are fully consistent with
each other.
In contrast, the proposal, as adopted
with modification, allows ambulance
providers and suppliers, in the case of
emergency transport, to sign the claim,
if certain documentation requirements
are met, where the beneficiary is not
capable of signing the claim at the time
of transport.
Comment: Most of the commenters
agreed that some of our proposed
documentation requirements are already
being followed by ambulance providers
and suppliers. However, they strongly
objected to proposed
§ 424.36(b)(6)(ii)(C), which would have
required a signed contemporaneous
statement from a representative of the
facility that received the beneficiary,
documenting the name of the
beneficiary, and the date and time the
beneficiary was received by that facility.
The commenters asserted that it is not
practical or feasible to obtain a signed
contemporaneous statement from a
representative of the receiving facility
documenting the name of the
beneficiary and the date and time the
beneficiary was received by that facility.
The commenters stated that hospital
personnel in emergency departments
often are either too busy or refuse to
sign any forms when receiving a patient.
In addition, the commenters contended
that attempting to obtain a signature
from a representative of the hospital
would decrease the amount of time
available for ambulances to serve their
respective communities. Therefore, the
commenters recommended that CMS
modify the proposed beneficiary
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
signature requirements for ambulance
services in § 424.36(b)(6) to include only
proposed subsection § 424.36(b)(6)(i).
One commenter stated that a signature
from hospital staff does not add any
more credibility to the ambulance
provider or supplier’s claim that the
patient was unable to sign the claim
than what is already present from the
EMT’s attestation that the patient was
unable to sign.
Response: We are not persuaded to
modify the proposed alternative to the
beneficiary signature requirement in
§ 424.36(b)(6) to include only
§ 424.36(b)(6)(i). The purpose of the
proposed requirement to secure a signed
contemporaneous statement from a
representative of the facility that
received the beneficiary, as a means of
satisfying the alternative, was to ensure
that someone other than an ambulance
employee verifies the transport and
receipt of the beneficiary; the purpose
was not to obtain verification that the
beneficiary was unable to sign the
claim. We continue to believe that in
many, if not most, cases the ambulance
transport personnel will have no
difficulty in securing a signature from
personnel at the hospital or other
facility that acknowledges receipt of the
patient. Indeed, it is our understanding
that, as protection from liability or for
other purposes, some ambulance
providers and suppliers routinely secure
a signature from the receiving facility in
order to document that the patient was
transported. We note that our proposal
would not have required the hospital or
other receiving facility to do anything
more than acknowledge receipt through
a signature. That is, the ambulance
provider or supplier could add a
signature block and an attestation
clause, acknowledging receipt, to its trip
ticket or other form that would already
contain the necessary patient
information (that is, the beneficiary’s
name and the date and time of delivery).
However, after further consideration, we
are revising § 424.36(b)(6)(ii)(C) to
provide an alternative to the
requirement under § 424.36(b)(6) that
ambulance providers or suppliers must
obtain a signed contemporaneous
statement from a representative of the
facility that received the beneficiary,
which documents the name of the
beneficiary and the date and time the
beneficiary was received by that facility.
The final rule allows the ambulance
provider or supplier to meet the
condition specified in § 424.36(b)(6) by
obtaining a secondary form of
verification, prior to submitting the
claim for payment. Secondary methods
of verification may include the patient
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
care or trip report, the patient medical
record, the hospital registration/
admissions sheet, the hospital log, or
other internal hospital or facility
records. Regardless of its specific form,
the documentation must be from the
receiving facility must indicate that the
beneficiary in question was transported
to the facility by the ambulance
provider or supplier that is submitting
the claim, and must be signed by a
representative of the facility.
Comment: One commenter stated that
the proposal was fair and correct, would
not create a heavy burden on the service
provider and can be accomplished in a
timely manner. A signed
contemporaneous statement used on a
limited basis and tightly controlled so
that it will not become a routine event
should help compliance in this area. A
clear and standardized format for the
contemporaneous statement should be
issued to allow for proper compliance
with the new rule.
Response: We understand the
commenter as supporting our proposal
and as saying that ambulance providers
and suppliers should not be entitled to
routinely rely on proposed
§ 424.36(b)(6), but rather should be able
to rely on this exception only when the
beneficiary is, in fact, unable to sign the
claim, and only when the proposed
documentation requirements have been
satisfied. We agree that in most cases an
ambulance provider or supplier should
not have difficulty in obtaining a
signature from the hospital or other
facility that acknowledges receipt of the
beneficiary; however, we are modifying
the proposal to provide for an alternate
method of documenting that the
beneficiary was transported to the
facility. We do not believe that it is
necessary to prescribe a specific form
for ambulance providers and suppliers
to use as a contemporaneous statement
to document the transport of the
beneficiary, but instead are allowing
ambulance providers and suppliers to
use existing forms of their own, or,
where necessary, to modify their forms
to comply with the requirements of the
new § 424.36(b)(6)(ii). We again
emphasize that ambulance providers
and suppliers that do not wish to take
advantage of the new exception in
§ 424.36(b)(6) to the beneficiary
signature requirement, may instead
obtain the beneficiary’s signature prior
to submitting the claim, satisfy one of
the exceptions in § 424.36(b)(1) through
(b)(5), or, where appropriate, bill the
beneficiary.
Comment: Several commenters
recommended that we eliminate the
beneficiary signature requirement
entirely. They believe that the
PO 00000
Frm 00103
Fmt 4701
Sfmt 4700
66323
requirement is not necessary because,
for every transport of a Medicare
beneficiary, the ambulance crew
completes a trip report that described
the condition of the beneficiary,
treatment, origin/destination, etc. Also,
the origin and destination facilities
complete their own records, which
document that the beneficiary was sent
or received. Commenters stated that if it
becomes necessary to audit claims, CMS
can obtain information from the
transporting and receiving facilities in
order to establish that the beneficiary
was, in fact, transported as claimed by
the ambulance provider or supplier.
Response: We proposed an
alternative, optional method of fulfilling
the beneficiary signature requirement
for claims for emergency transport
services. We did not propose to
eliminate the signature requirement and
are not prepared to do so at this time.
The beneficiary signature requirements
help ensure that services were in fact
rendered and were rendered as billed.
Although we agree that documentation
obtained from the transporting and
(particularly) from the receiving facility
may help to alleviate any concern
whether services were furnished or were
furnished as claimed, we do not believe
that it is our responsibility to attempt to
locate such documentation should
claims be called into question (and it is
also uncertain whether we would have
the right to compel the transporting or
receiving facility to provide us with
such documentation). Therefore, to the
extent that an ambulance provider or
supplier wishes to use third-party
documentation to demonstrate that a
beneficiary was transported as claimed,
instead of having the beneficiary sign
the claim or meeting one of the
exceptions in § 424.36(b)(1) through
(b)(4), it must follow the procedures in
new § 424.36(b)(6).
Comment: Most of the commenters
questioned the need for the beneficiary
signature, because they asserted that the
beneficiary signature is no longer
necessary given that it is not required
for the assignment of benefits or the
authorization of records release to CMS
or its contractors. In addition, the
commenters stated that almost every
covered ambulance transport is to or
from a facility (that is, a hospital or
skilled nursing facility) where a valid
signature is already on file. These
facilities typically obtain the
beneficiary’s signature at the time of
admission, authorizing the release of
medical records for their services, or
any related services. The commenters
believe that ambulance transport to a
facility, for purposes of receiving
treatment at that facility, constitutes a
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66324
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
‘‘related service,’’ because the
ambulance transports the patient to or
from that facility for treatment or
admission. Commenters also noted that,
with respect to beneficiaries who are
eligible both for Medicare and
Medicaid, a signature is already on file
with the State Medicaid office.
Therefore, they argued that duplicating
the requirement for a signature is costly
and burdensome on ambulance service
providers.
Response: The purpose of the
assignment of benefits signature is
different than the purpose of the
beneficiary signature to file a claim. As
stated above, the purpose of the
beneficiary signature to file a claim is to
ensure that services were furnished and
were furnished as billed. Although the
assignment of benefits signature is not
required for services billed on
mandatory assignment, the beneficiary
signature is still required for submitting
a claim to Medicare.
A beneficiary’s signature on file at a
hospital or a skilled nursing facility
does not indicate that an ambulance
provider or supplier was authorized to
submit a claim for transport services on
behalf of the beneficiary or that
transport services in fact were
furnished. Rather, the signature on file
at a facility is used for claims filed by
that facility for treatment the facility
furnished to the beneficiary. Similarly,
the fact that a beneficiary’s signature
may be on file with a State Medicaid
office (or elsewhere) does not in any
way speak to the issue of whether the
ambulance provider or supplier was
authorized to submit a claim for
transport services on behalf of the
beneficiary or that transport services in
fact were furnished.
Comment: A commenter stated that
when submitting claims electronically, a
provider or supplier must answer ‘‘Y’’
or ‘‘N’’ for the question of whether the
provider or supplier has obtained a
beneficiary signature. The commenter
suggested that we should add language
to the regulations to indicate that the
beneficiary signature requirement will
be met if one of the exceptions to the
requirement is met.
Response: We agree that it is proper
and accurate to answer ‘‘Y’’ (for yes) to
the question in the case where the
beneficiary has not signed the claim but
one of the alternatives in § 424.36(b)
through § 424.36(e) has been satisfied.
We are clarifying § 424.32(a)(3) (basic
requirements of all claims) accordingly.
Comment: Many commenters stated
that the proposal would encourage
ambulance providers and suppliers to
seek signatures from patients who are in
need of medical care and under mental
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
duress. They stated that beneficiaries
under duress should not be required to
sign anything.
Response: We agree that beneficiaries
under duress should not be required to
sign claims; in fact, we consider a
beneficiary signature obtained under
duress to be invalid. We do not agree,
however, that our proposal encouraged
ambulance providers and suppliers to
obtain beneficiary signatures under
duress. As stated above, the proposal
was intended to provide ambulance
providers and suppliers with another
alternative to obtaining the beneficiary’s
signature. It was not, and the final rule
is not, a narrowing of the available
alternatives to ambulance providers and
suppliers. Moreover, the commenters
appear to assume that if ambulance
providers and suppliers are to obtain a
beneficiary’s signature, they must do so
at the time of transport. However,
ambulance providers and suppliers have
always been able to obtain the
beneficiary’s signature (or the signature
of one of the persons specified in
§ 424.36(b)(1) through (b)(4)) at any time
prior to submitting the claim. In fact, as
noted above, before providers may avail
themselves of the exception in
§ 424.36(b)(5), they are required to make
reasonable efforts to have the
beneficiary or one of the persons
specified in § 424.36(b)(1) through (b)(4)
sign the claim. With this final rule,
ambulance providers and suppliers, in
the case of emergency transport
services, may submit the claim without
making such reasonable efforts if they
satisfy the documentation requirements
of new § 424.36(b)(6).
O. Update to Fee Schedules for Class III
Durable Medical Equipment (DME) for
CYs 2007 and 2008
1. Background
a. Durable Medical Equipment,
Prosthetics, Orthotics, and Supplies
(DMEPOS) Classifications
Under § 414.210, for Medicare
payment purposes, fee schedules are
determined for the following classes of
equipment and devices:
• Inexpensive or routinely purchased
items as specified in § 414.220.
• Items requiring frequent and
substantial servicing, as specified in
§ 414.222.
• Certain customized items, as
specified in § 414.224.
• Oxygen and oxygen equipment, as
specified in § 414.226.
• Prosthetic and orthotic devices, as
specified in § 414.228.
• Other DME (capped rental items), as
specified in § 414.229.
PO 00000
Frm 00104
Fmt 4701
Sfmt 4700
• Transcutaneous electric nerve
stimulators (TENS), as specified in
§ 414.232.
We designate the items in each class
of equipment or device through our
program instructions.
Under section 513 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
360c), the Food and Drug
Administration (FDA) must classify
devices into one of three regulatory
classes: Class I, class II, or class III. FDA
classification of a device is determined
by the amount of regulation necessary to
provide a reasonable assurance of safety
and effectiveness; class III devices
typically posing the greatest risk. See
the CY 2008 PFS proposed rule (72 FR
38188) for a specific explanation of the
three regulatory classifications of
devices.
b. DMEPOS Payment
Section 302(b)(1) of the MMA
amended section 1847 of the Act to
require the Secretary to establish and
implement competitive acquisition
programs for the furnishing under
Medicare Part B of certain types of
DMEPOS. Section 1847(a)(2)(A) of the
Act provides that devices determined by
the FDA to be class III devices under the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 301 et seq.) cannot be
included in the competitive acquisition
programs. As part of the transition to
competitive acquisition, the Congress
mandated in sections 1834(a)(14)(G)
through (I) of the Act that the fee
schedule amounts for DME, other than
class III devices, be frozen at 2003 levels
through 2008.
For class III devices, section
1834(a)(14)(G)(i) of the Act mandates
that an annual update factor based on
the percentage change in the consumer
price index for urban customers (CPI–U)
be applied to the fee schedule amounts
for CYs 2004 through 2006. Section
1834(a)(14)(H)(i) of the Act, as added by
section 302 of the MMA, gives the
Secretary discretion in determining the
appropriate fee schedule update
percentage for CY 2007 for DME which
are class III medical devices described
in section 513(a)(1)(C) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
360c(a)(1)(C)).3 Specifically, for 2007,
the 2006 fee schedule amounts for class
III devices are to be updated by the
percentage change determined to be
appropriate by the Secretary, taking into
account recommendations contained in
3 Section 513(a)(1)(C) of the Federal Food, Drug,
and Cosmetic Act has been codified as 21 U.S.C.
360c(a)(1)(C). Accordingly, we believe that the
references to 21 U.S.C. 360(c)(1)(C) in sections
1834(a)(14)(G)(i), (H)(i), and (I)(i) of the Act are
scrivener’s errors.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
a report of the Comptroller General of
the United States under section
302(c)(1)(B) of the MMA. Also
mandated by section 1834(a)(14)(I)(i) of
the Act, for 2008, the 2007 fee schedule
amounts for class III devices are to be
increased by an annual factor based on
the percentage change in the CPI–U, as
applied to the 2007 payment amount
determined after application of the
percentage change under section
1834(a)(14)(H)(i) of the Act.
As stated above in this section of this
final rule with comment period, section
1834(a)(14)(H)(i) of the Act mandated
that the Secretary take into account
recommendations by the Comptroller
General of the United States, who is the
head of the Government Accountability
Office (GAO), when determining the
appropriate update percentage for class
III devices for 2007. On March 1, 2006,
the GAO published a report, ‘‘Class III
Devices do not Warrant a Distinct
Annual Payment Update’’ (GAO–06–
62). The GAO concluded in that report,
‘‘because the initial payment rates for all
classes of devices on the Medicare DME
fee schedule are based on retail prices
or an equivalent measure, they account
for the costs of class III and similar class
II devices in a consistent manner.
Distinct updates for two different
classes of devices are unwarranted.’’
The GAO recommended that the
Secretary establish a uniform payment
update to the DME fee schedule for 2007
for class II and class III devices.
In the May 1, 2006 Federal Register,
we published the Competitive
Acquisition for Certain Durable Medical
Equipment, Prosthetics, Orthotics, and
Supplies (DMEPOS) and Other Issues
proposed rule (71 FR 25660). We
solicited comments on how to
determine the appropriate fee schedule
percentage change for class III devices
for 2007 and 2008. We stated that we
would consider the comments received
in conjunction with the
recommendations in the GAO report in
determining the appropriate update
percentage for these devices for 2007
and 2008.
A majority of the submitted public
comments indicated that the GAO
report was flawed since it did not
recommend a specific update factor or
take into account changes over time in
the costs of producing, supplying and
servicing class III devices. Several
commenters recommended that we
continue to use the CPI–U to adjust fee
schedule amounts for class III devices,
but offered no substantive information
that would otherwise support a distinct
update factor for class III devices.
Another commenter recommended that
the class III proposal be included in a
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
separate rulemaking procedure because
it is not related to competitive
acquisition.
2. Update to Fee Schedule
We believe that the GAO has done a
thorough job in reviewing Medicare
payment rules and methods and issues
associated with the costs of furnishing
class III devices. Accordingly, we agree
with the finding in the report that the
costs of furnishing class II and class III
DME devices have been factored into
the fee schedule amounts calculated for
these devices. We also agree with the
GAO recommendation that a uniform
payment update be established to the
DME fee schedule for 2007 for class II
and class III devices. For class II
devices, the MMA provided for a zero
percent payment update from 2004
through 2008. Accordingly, for 2007, in
the CY 2008 PFS proposed rule we
proposed a zero percent update for class
III devices (72 FR 38188 through 38189).
Also, in accordance with the MMA, we
proposed to use the percent change in
the CPI–U to update the class III device
2007 fee schedule amounts for 2008.
Comment: One commenter supported
an update based on the CPI–U but did
not provide any additional information.
A second commenter indicated that
class III devices are innovative,
beneficial, cost-effective devices and
supported a reasonable payment update
but did not recommend a specific
update and also did not provide any
information explaining why class III
devices should receive a different
update for 2007 than other DME.
Response: We do not believe that the
information submitted by the
commenters provides any information
that would indicate that class III devices
warrant a different update than other
DME. Accordingly, for 2007, we are
adopting the proposed update
methodology of applying a zero percent
update for class III devices. Also, in
accordance with the MMA, we are
adopting the proposed methodology of
applying the percent change in the CPI–
U to update the class III device 2007 fee
schedule amounts for 2008. The change
in the CPI–U for the 12-month period
ending with June 2007 was 2.7 percent.
Therefore, a 2.7 percent increase will be
applied to the 2007 fee schedule
amounts for class III DME to determine
the 2008 fee schedule amounts for these
items.
P. Discussion of Chiropractic Services
Demonstration
In the CY 2006 PFS final rule with
comment period (70 FR 70266) and the
CY 2007 PFS final rule with comment
period (71 FR 69707), we included a
PO 00000
Frm 00105
Fmt 4701
Sfmt 4700
66325
discussion of the 2-year chiropractic
services demonstration that ended on
March 31, 2007. This demonstration
was authorized by section 651 of the
MMA to evaluate the feasibility and
advisability of covering chiropractic
services under Medicare. These services
extended beyond the current coverage
for manipulation to care for
neuromusculoskeletal conditions
typical among eligible beneficiaries, and
covered diagnostic and other services
that a chiropractor was legally
authorized to perform by the State or
jurisdiction in which the treatment was
provided. The demonstration was
conducted in four sites, two rural and
two urban. The demonstration was
required to be budget neutral as the
statute requires the Secretary to ensure
that the aggregate payment made under
the Medicare program does not exceed
the amount which would be paid in the
absence of the demonstration.
Ensuring budget neutrality requires
that the Secretary develop a strategy for
recouping funds should the
demonstration result in costs higher
than those that would occur in the
absence of the demonstration. As we
stated in the CY 2006 and CY 2007 PFS
final rules with comment period, we
would make adjustments to the
chiropractor fees under the Medicare
PFS to recover aggregate payments
under the demonstration in excess of
the amount estimated to yield budget
neutrality. We will assess budget
neutrality by determining the change in
costs based on a pre- and postcomparison of aggregate payments and
the rate of change for specific diagnoses
that were treated by chiropractors and
physicians in the demonstration sites
and control sites. Because the aggregate
payments under the expanded
chiropractor services may have an
impact on other Medicare expenditures,
we will not limit our analysis to
reviewing only chiropractor claims.
Any needed reduction to chiropractor
fees under the PFS would be made in
the CY 2010 and CY 2011 physician fee
schedules as it will take approximately
2 years after the demonstration ends to
complete the claims analysis. If we
determine that the adjustment for BN is
greater than 2 percent of spending for
the chiropractor fee schedule codes
(comprised of the 3 currently covered
CPT codes 98940, 98941, and 98942),
we would implement the adjustment
over a 2-year period. However, if the
adjustment is less than 2 percent of
spending under the chiropractor fee
schedule codes, we would implement
the adjustment over a 1-year period. We
will include the detailed analysis of
budget neutrality and the proposed
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66326
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
offset during the CY 2009 PFS
rulemaking process.
Comment: We received a number of
comments on the methodology for
determining budget neutrality. One
commenter indicated that it continues
to oppose our methodology for assuring
budget neutrality under the
demonstration. Instead of the
application of an adjustment to the
national chiropractor fee schedule, the
commenter recommends that CMS make
an adjustment to the totality of services
payable under the Part B Trust Fund.
This would be consistent with the
requirements in section 651(f)(1)(A) of
the Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA).
Another commenter stated that CMS
should apply budget neutrality only to
the chiropractic codes used in the
demonstration project. Because the
demonstration did not require a
physician referral, physicians should
not be penalized for any utilization of
chiropractic services. The commenter
further noted that if budget neutrality is
not limited to the chiropractic codes,
CMS should incorporate estimates of the
impact on other services into its SGR
‘‘law and regulation’’ factor estimates.
Response: Section 651(f)(1)(B) of the
MMA requires that ‘‘* * * the Secretary
shall ensure that the aggregate payment
made by the Secretary under the
Medicare program do not exceed the
amount which the Secretary would have
paid under the Medicare program if the
demonstration projects under this
section were not implemented.’’ The
statute does not specify a specific
methodology for ensuring budget
neutrality. Our methodology meets the
statutory requirement for budget
neutrality and appropriately impacts the
chiropractic profession that is directly
affected by the demonstration. The
budget neutrality adjustment under the
PFS will be limited to adjusting
chiropractor fee schedule codes
(comprised of the 3 currently covered
CPT codes 98940, 98941, and 98942).
No other codes would be affected.
Comment: One commenter noted that
there are numerous dimensions to the
analysis of effectiveness of treatment. By
restricting our analysis only to Medicare
expenditure, CMS would miss the
important dimension of the effect of
care on the beneficiary. Combining
claims data with a measurement of
functional status would permit a more
useful examination of the impact of
expanding chiropractor services. The
commenter recommends that if CMS
undertakes any further examination of
the effectiveness of any intervention for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
neuromuscular conditions, functional
status be considered.
Response: The budget neutrality
analysis is only one part of a broader
evaluation of the chiropractic services
demonstration. A survey was conducted
of beneficiaries who received
chiropractic services under the
demonstration to determine the benefits
of treatment and satisfaction with the
chiropractic care provided under the
demonstration. These results will be
included in a Report to Congress on the
demonstration.
Q. Technical Corrections
1. Particular Services Excluded From
Coverage (§ 411.15)
Sections 612 and 613 of the MMA
added coverage under Part B for
cardiovascular disease screening tests
and diabetes screening tests, effective
for services furnished on or after
January 1, 2005, subject to certain
eligibility and other limitations. These
provisions were implemented in the CY
2005 PFS final rule with comment
period (69 FR 66236) and were codified
in § 410.17 and § 410.18, respectively.
However, at the time we neglected to
make additional conforming changes to
§ 411.15, which discusses particular
services excluded from coverage, to
reflect this expansion in coverage.
To conform the regulations to the
MMA provisions, we proposed a
technical correction to the provisions in
§ 411.15 by specifying additional
exceptions to provide payment for
cardiovascular disease screening tests
and diabetes screening tests that meet
the eligibility limitation and the
conditions for coverage that we
specified under § 410.17, Cardiovascular
Disease Screening Tests, and § 410.18,
Diabetes Screening Tests.
Comment: One commenter suggested
that the psychiatric screening
examination should be included in the
list of preventive health screenings and
examinations exceptions from services
that are excluded from Medicare
coverage under proposed § 411.15. The
commenter suggested the advantage for
having Medicare cover psychiatric
screening examination is that better
patient outcomes and decreased use of
services often occur as a result of early
identification of psychiatric disorders.
Response: The purpose of the
proposed technical correction in
§ 411.15 was to conform that provision
to the cardiovascular disease screening
test and the diabetes screening test
benefits that were established in
§ 410.17 and § 410.18, respectively.
These two part B screening benefits
were specifically authorized by sections
PO 00000
Frm 00106
Fmt 4701
Sfmt 4700
612 and 613 of the MMA. The proposed
rule did not address the possibility of
coverage of a psychiatric screening
examination under Medicare Part B.
There is no statutory provision that
authorizes a benefit for psychiatric
screening. Therefore, the commenter’s
suggestion in this regard falls outside
the scope of this final rule.
2. Medical Nutrition Therapy
(§ 410.132(a))
In the CY 2006 PFS final rule with
comment period (70 FR 70160), we
added individual medical nutrition
therapy, as represented by HCPCS/CPT
codes G0270, G0271, 97802, 97803, and
97804 to the list of telehealth services.
In the CY 2008 PFS proposed rule, we
proposed a technical correction to
§ 410.132(a) to conform the regulations
to include an exception for services
provided at § 410.78. This revised
paragraph reads as follows: ‘‘(a)
Conditions for coverage of MNT
services. Medicare Part B pays for MNT
services provided by a registered
dietitian or nutrition professional as
defined in § 410.134 when the
beneficiary is referred for the service by
the treating physician. Except as
provided at § 410.78, services covered
consist of face to face nutritional
assessments and interventions in
accordance with nationally accepted
dietary or nutritional protocols.’’
Comment: We received one comment
concurring with the proposed technical
correction.
Response: We are finalizing the
technical correction to § 410.132(a) as
proposed.
3. Payment Exception: Pediatric Patient
Mix (§ 413.184)
In the CY 2006 PFS final rule with
comment period (70 FR 70214), we
revised § 413.180 through § 413.192
regarding criteria and the application
procedures for requesting an exception
to the ESRD composite rate payment. As
part of the revisions we intended to
amend the section heading of § 413.184
to reflect that, as specified in the statute,
this exception only pertains to a
pediatric ESRD facility. However, this
change was not made. Therefore, we
proposed to revise the section heading
of § 413.184 to read as follows:
‘‘Payment exception: Pediatric patient
mix.’’
We did not receive any comments
regarding this proposal. Therefore, we
are finalizing this provision as
proposed.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
4. Diagnostic X-Ray Tests, Diagnostic
Laboratory Tests, and Other Diagnostic
Tests: Conditions (§ 410.32(a)(1))
Section 1861(r)(5) of the Act was
amended by section 4513(a) of the BBA
to allow Medicare payment for a
chiropractor’s manual manipulation of
the spine to correct subluxation,
without requiring the subluxation to be
demonstrated by an x-ray. The BBA
provision was effective for services
furnished on or after January 1, 2000.
Prior to this statutory change, the
subluxation was required to be
demonstrated by an x-ray. Because
chiropractors are limited by statute in
the services they can provide under
Medicare, it was necessary to create an
exception to the requirement that
diagnostic services (including x-rays)
must be ordered by the treating
physician as provided in § 410.32(a).
This exception, which permits a
physician who is not a treating
physician to order and receive payment
for an x-ray that is used by a
chiropractor, is specified in
§ 410.32(a)(1).
Because of the BBA change, which
removed the requirement that
subluxation must be demonstrated by an
x-ray, the so-called ‘‘chiropractic
exception’’ at § 410.32(a)(1) is no longer
warranted. We do not believe it is
necessary or appropriate to continue to
permit payment for an x-ray ordered by
a nontreating physician when a
chiropractor, not the ordering physician,
will use that x-ray. Therefore, we
proposed to revise § 410.32 by removing
paragraph (a)(1) and redesignating
paragraphs (a)(2) and (a)(3) as (a)(1) and
(a)(2), respectively.
Comment: We received several
comments on this proposal. Some
commenters noted that x-rays are not
necessary to identify spinal
subluxations, but stated that the ability
to obtain an x-ray for Medicare
beneficiaries is critical to providing
responsible, safe, and medically prudent
care. They stated that without this
ability they fear beneficiaries and the
chiropractic profession as a whole will
be at a higher risk for receiving and
providing the wrong type of care. The
majority of commenters expressed
concern that without the chiropractic
exception at § 410.32(a)(1), the
beneficiary may incur greater out of
pocket expenses to obtain a noncovered
x-ray when needed by the chiropractor.
Other commenters believed that the
overall costs for medical services may
increase because a beneficiary wanting
to seek chiropractic care directly may
elect to first seek care for their condition
from a medical doctor (MD) or doctor of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
osteopathy (DO) to obtain an order for
a covered chiropractic x-ray, resulting in
added costs for physician E/M services.
Finally, many chiropractors commented
that they are qualified to provide x-rays
and other services that Medicare does
not cover when furnished by a
chiropractor and they believe that x-rays
can be essential to rule out ‘‘red flags’’
and contraindications that may indicate
the need for further diagnostic imaging
or a referral to another health care
professional.
Response: We believe that retaining
the chiropractic exception would be
inconsistent with the statutory
provision at section 1861(r)(5) of the Act
which defines a chiropractor as a
physician only for the purposes of
sections 1861(s)(1) and 1861(s)(2)(A) of
the Act and only with respect to
treatment by means of manual
manipulation of the spine (that is, to
correct a subluxation). This statutory
provision does not include diagnostic
services at section 1861(s)(3) of the Act,
which is the benefit category under
which x-rays are covered under
Medicare. In addition, commenters
noted that x-rays are not required to
identify subluxations; rather,
commenters stated that they use the xrays to rule out other conditions where
manual manipulation of the spine
would be contraindicated or for which
further imaging studies are indicated.
While the use of x-rays for this purpose
is outside the scope of covered
chiropractic services, it is also not
addressed by the chiropractic exception
at § 410.32(a)(1). The chiropractic
exception only permits a non treating
physician to order an x-ray to identify
a subluxation. Therefore, we are
finalizing our proposal to revise
§ 410.32 by removing paragraph (a)(1)
and redesignating paragraphs (a)(2) and
(a)(3) as (a)(1) and (a)(2), respectively, so
that it is consistent and conforms to the
statutory revisions mandated by the
BBA.
R. Other Issues
1. Recalls and Replacement Devices
In the CY 2008 PFS proposed rule (72
FR 38191), we included a discussion
about recent recalls of implantable
cardioverter-defibrillator (ICDs) and
cardiac resynchronization therapy
defibrillators (CRT–Ds). These recalls, as
well as previous recalls of ICDs and
pacemakers in CY 2004 and CY 2005,
raise issues both with regard to the
additional costs of replacement devices
and with regard to the additional
physicians’ services and diagnostic tests
that beneficiaries who have these
devices often need.
PO 00000
Frm 00107
Fmt 4701
Sfmt 4700
66327
The impact of the costs of
replacement devices for Medicare
payment of inpatient and outpatient
hospital services is addressed in
separate rulemaking for the respective
inpatient and outpatient hospital
payment systems. However, in the CY
2008 PFS proposed rule, we also
acknowledged there are costs associated
with physician monitoring of patients
treated with recalled devices. This
could involve extra visits to physicians’
offices or hospital outpatient
departments, as well as additional
diagnostic tests which might be needed
to care for the beneficiaries who have
the recalled devices. Based on our
concern of the potential costs to both
Medicare and the beneficiary for these
unforeseen extra services, we solicited
comments on how to identify and
address additional health care costs and
Medicare expenditures associated with
device recall actions.
Comment: We received several
comments acknowledging the potential
for additional costs that may result from
recalled devices, particularly in light of
the increases in technology.
Commenters stated that such costs
should be the responsibility of device
manufacturers and not the Medicare
program, private payers, or the general
public. Some commenters expressed
concern that we would impose a
financial penalty on physicians who
deal with the consequences of product
recalls. Several of the commenters
suggested alternatives that could be
used to address this issue, such as
development of a modifier or a specific
‘‘recall code’’ that could be used to track
the additional time and work associated
with these recalls, and urged us to
ensure that these additional costs are
accounted for in the SGR target.
Commenters also stressed that any
proposal should be ‘‘vetted’’ through the
appropriate stakeholders.
Response: We appreciate the
suggestions that the commenters
provided. It is not our intention to
‘‘penalize’’ physicians who care for
patients affected by implantable device
recalls. Rather, it is our intention to
ensure that costs of the additional
physicians’ services and diagnostic tests
associated with recalled devices are
recognized and appropriately addressed.
We will consider the concerns and
suggestions provided by the
commenters as we develop a plan to
address this issue.
E:\FR\FM\27NOR2.SGM
27NOR2
66328
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
2. Therapy Standards and Requirements
cprice-sewell on PROD1PC72 with RULES
a. Revisions to Personnel Qualification
Standards for Therapy Services
In the CY 2005 PFS final rule with
comment period (69 FR 66354), we
amended § 410.59, § 410.60, and
§ 410.62 to refer to the qualifications for
physical therapists (PTs), occupational
therapists (OTs) and speech-language
pathologists (SLPs) at § 484.4, which
sets the personnel qualifications
required under the HHA Conditions of
Participation.
Section 484.4 contains requirements
for persons furnishing services in HHAs
that include physical therapists (PTs),
physical therapist assistants (PTAs),
occupational therapists (OTs),
occupational therapy assistants (OTAs)
and SLPs. The CY 2005 PFS final rule
with comment period clarified that the
personnel qualifications in § 484.4 are
applicable to all outpatient PT, OT, and
SLP services ‘‘in order to create
consistent requirements for therapists
and therapy assistants’’ (69 FR 66345).
In the CY 2008 PFS proposed rule (72
FR 38191), we proposed to update the
personnel qualifications in § 484.4 for
PTs, PTAs, OTs, and OTAs. We also
proposed to revise the qualifications for
SLPs to remove a reference to
audiologists in the definition for speechlanguage pathologists because a speechlanguage pathologist would not have a
Certificate of Clinical Competence in
audiology, as implied by the regulation,
unless that person was dually qualified
as an audiologist.
We proposed these changes for the
following reasons.
• The current regulations at § 484.4
contain outdated terminology relating to
several of the relevant professional
organizations.
• The standards that now exist in the
fields of physical therapy and
occupational therapy have changed
since a substantial portion of these
qualification requirements were
developed.
• Some of the current qualification
requirements do not address individuals
who have been trained outside of the
United States, or refer to outdated
requirements.
• These revisions would have the
benefit of establishing consistent
standards across provider/supplier
lines.
Although all States license PTs, some
States have no licensing provisions for
PTAs, OTs, OTAs, and SLPs. We
proposed to revise our requirements to
recognize as qualified PTs, OTs, PTAs,
or OTAs who meet their respective State
qualifications (or have received State
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
recognition as PTs, OTs, PTAs or OTAs)
before January 1, 2008.
We did not propose to allow those
who, before January 1, 2008, meet only
the State qualifications to practice
physical therapy, and not the education
requirements, to provide services under
the Home Health PPS or the Hospice
PPS. As we indicated in the CY 2008
PFS proposed rule, we did not expect
that there are therapists furnishing
services in a HHA or hospice that do not
meet either the current or proposed
revised qualifications.
Grandfathering Provision for Home
Health
Comment: Commenters were
concerned about the inconsistency in
standards between settings, stating that
there is no justification for the absence
of a grandfathering provision for
therapists and assistants practicing in
Home Health settings. Many also
indicated a concern that currently
licensed or regulated professionals
would not be allowed to continue to
practice in a HHA or hospice, and
recommended that sufficient time be
allowed before implementation of the
new standards for new professionals to
meet their training.
Response: The commenters make a
compelling case for the grandfathering
provisions to be applied uniformly
across payment systems. We agree that
it is important to apply consistent
standards and we will apply the
grandfathering provision in all settings
as specified in part 484 of our
regulations. Since all of part 484
describes personnel qualifications, we
refer to part 484 in this rule rather than
specifically to § 484.4. The crossreference has also been changed in the
regulation text from § 484.4 to part 484
in all applicable sections. Although we
proposed that these grandfathering
provisions would be included in
revisions to § 409.17, § 409.23, § 410.43,
§ 410.59, § 410.60, § 482.56, § 485.70,
§ 485.705, § 491.9, the application of the
grandfathering provisions to home
health in part 484 makes some sections
of proposed regulation text unnecessary
and necessitates changes in the language
of others. The changes proposed to
sections § 485.705 and § 491.9 have
been omitted, as they are no longer
necessary.
Delay in Implementation of New
Personnel Qualifications
Comment: Some commenters
requested that we delay implementation
of consistent therapy standards and
qualifications until we can apply them
consistently to SNF services, and
PO 00000
Frm 00108
Fmt 4701
Sfmt 4700
provide education to providers and
suppliers.
Response: We believe a 2-year delay
in implementation of personnel
qualifications will provide sufficient
time for new personnel to come into
compliance with the new standards.
Therapists and assistants who met the
qualifications of their State’s practice
act (in other words, who are licensed,
certified or otherwise regulated by the
State as a practitioner in the particular
discipline) prior to December 31, 2009,
will not be required to upgrade their
qualifications. However, in States that
have no regulations for practitioners in
a particular discipline and for services
furnished incident to the services of
physicians where licensure does not
apply, therapists and assistants must be
qualified by education and examination
as described in this final rule with
comment period. Those who currently
qualify to provide services without
licensure by meeting the Medicare
education or examination standards in
effect at the time of the CY 2008
proposed rule will continue to qualify
under those policies. On January 1,
2010, any individual who has not met
the earlier requirements must meet the
new requirements.
Consistent Policy Standards
Comment: Many commenters
indicated we have not provided a
justification for applying the personnel
and policy standards that we have
articulated for Part B services
consistently to Part A services. Most of
these comments came from commenters
who also support the right of States to
create Medicare standards, who
represent interest groups other than
Medicare beneficiary/therapy users, and
who believe we favor professional
organizations in setting policies.
Response: Under both Medicare Part
A and B, we must ensure that all
services are described within a statutory
benefit category. In order to do so, we
frequently establish qualifications for
health care professionals who furnish,
or are involved in furnishing, Medicare
services. In many Part A settings, we
have historically relied on Medicare
contractors to review facility records,
State laws and local policies to
determine that services have been
furnished by qualified therapists. As a
result of information provided by new
contractors, which has been confirmed
by numerous comments to the proposed
rule, we have concluded that therapy is
not always being furnished by
individuals trained as therapists—even
in some Part A settings. Therefore, we
believe it is critical that we establish in
regulations consistent standards for
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
qualified therapists in the Medicare
program.
Comment: Some commenters objected
to the use of the terms therapy and
rehabilitation to mean physical therapy
(PT), occupational therapy (OT), and
speech-language pathology (SLP)
services. The commenters
recommended allowing any State
licensed or authorized health
professional to provide rehabilitation
services if the provider’s medical staff
and State law would permit them to do
so. The commenters recommended
convening a work group to discuss the
creation of rational personnel
qualifications and scope of services.
Response: The terms ‘‘therapy’’ and
‘‘rehabilitation’’, as used in this section
of this final rule with comment period,
apply only to the Medicare benefit for
PT, OT, and SLP services and to the
qualified professionals who provide
them. The qualifications have been
established to assure that all of the
personnel who provide these services
are suitably trained in the discipline
they practice. We see no reason to
believe the skills and training required
to furnish therapy and rehabilitation in
Part A settings are less than those
required in Part B settings, and
therefore, qualifications for personnel in
the inpatient setting should not be less
stringent than in the outpatient setting.
Therefore, we will adopt the proposed
qualifications (with minor
modifications), and these qualifications
will be made applicable in Part A and
Part B settings.
Grandfathering Provision
Comment: Many commenters believe
that a grandfathering provision is not
necessary for physical therapists and
speech-language pathologists since the
changes to their qualifications are not
substantial.
Response: We agree and have
removed reference to physical therapists
and speech-language pathologists from
the relevant grandfather clauses in the
final rule with comment period.
Comment: Several commenters
believe that our proposal to require
those who were grandfathered to
continue to practice at least part time
without an interruption of more than 2
years is not necessary, and that the
language is confusing.
Response: We agree and have
removed the requirement for continued
practice from this final rule with
comment period.
Comment: We received many
comments concerning application of a
requirement for State licensure,
registration, certification or other
regulation to physical therapist
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
assistants. The commenters indicate
large numbers of PTAs in California and
other States are licensed but do not meet
the proposed education and
examination requirements. The
commenters report implementation of
the proposed qualifications would cause
severe access problems for beneficiaries
and operational disruption for facilities.
All commenters supported the adoption
of a grandfather clause to allow
currently practicing PTAs to continue
furnishing services to Medicare patients,
and many requested the grandfathering
be implemented when the rule is
finalized in November, rather than
January 1, 2008.
Response: We will recognize as
qualified to provide Medicare services
those therapists and assistants who are
licensed or otherwise regulated by their
States before December 31, 2009.
Individuals who are not licensed or
otherwise regulated as PTs, OTs, PTAs,
and OTAs in their States may furnish
services incident to a physician’s
service if they meet the education and
examination requirements in this final
rule with comment period. These
changes will be effective on the date this
final rule with comment period is
effective.
Personnel Qualifications—General
For therapists and assistants trained
outside the United States or trained by
the United States military, we proposed
standards we considered comparable to
those applied to therapists and
assistants trained in the United States.
However, we noted we would not
recognize as qualified therapists or
therapy assistants individuals trained in
other disciplines for purposes of
furnishing PT, OT, or SLP services to
Medicare beneficiaries.
Comment: APTA recommends the use
of the term ‘‘substantially equivalent’’ to
replace ‘‘comparable’’ to avoid
confusion in the language concerning
those trained outside the United States.
Response: We have modified the
language to substitute in regulations the
term ‘‘substantially equivalent’’ for
‘‘comparable’’.
Comment: Several commenters
believe that the qualifications for
military trained OTs/OTAs (when
applicable) and PTs/PTAs should be the
same as for all OTs/OTAs and PTs/
PTAs.
Response: We agree that separate
qualifications for U.S. military-trained
therapy personnel are not necessary for
PTs, OTs, and OTAs, since the training
programs available in the military
already meet the same standards as
other U.S.-trained OTs and PTs and
OTAs. For PTAs who may, in the future,
PO 00000
Frm 00109
Fmt 4701
Sfmt 4700
66329
be trained in the military, we will apply
the standard of substantial equivalency
consistent with those trained outside
the United States, or the same standards
as other United States trained PTAs, as
appropriate.
Comment: Some commenters
recommended that licensure be the only
qualification for PTs and OTs. The
commenters recommended we defer to
individual States or to the medical staff
of a hospital to determine the
qualifications for physical therapists
and occupational therapists.
Commenters agreed generally that we
should rely on State licensure in those
States where it exists and for those
settings where licensure is applicable.
The commenters note that there have
been attempts to deregulate health
professions in the name of regulatory
reform and they recommend inclusion
(for OT) and continuation (for PT) of
education and exam requirements to
assure there will be standards in place
when licensure does not apply.
Response: We believe it is
appropriate, as we proposed, to require
qualifications related to education and
examination to address those situations
where licensure does not apply. We
added language in regulations to
indicate that when licensure or other
regulation is not applicable for
therapists and assistants, the education
and examination requirements apply.
Comment: Several commenters
support applying the proposed
qualifications and therapy standards for
staff providing services incident to the
services of physicians. Some continue to
object to the implementation of section
1862(a)(20) of the Act.
Response: Section 1862(a)(20) of the
Act excludes from payment under
Medicare Parts A and B any expenses
for outpatient PT or OT services
furnished incident to the services of a
physician that do not meet the
standards and conditions that apply to
therapists, except ‘‘any licensing
requirement specified by the Secretary.’’
Therefore, as we described in the
proposed rule, we will not apply the
requirement that therapists and
assistants be licensed or otherwise
regulated by a State in the case of
services furnished incident to the
services of physicians. We will apply
education and examination
requirements.
In the proposed rule, we explained
that when we referred to persons who
are licensed, certified, and otherwise
regulated by a State, we interpreted
‘‘otherwise regulated’’ to mean that,
while a State may not regulate a
profession by granting a license or
certifying educational or training
E:\FR\FM\27NOR2.SGM
27NOR2
66330
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
credentials, it may nevertheless regulate
the practice of a profession by
application of certain other
requirements.
We received no comments on the use
of this term, and therefore, we intend to
use it as proposed. Because we believe
the term ‘‘certification’’ is redundant to
‘‘otherwise regulated’’, that term has
been omitted.
cprice-sewell on PROD1PC72 with RULES
Occupational Therapy
We proposed to require that OTs
beginning their practice after January 1,
2010, must be licensed, certified,
registered or otherwise regulated as an
OT, and have graduated from an
occupational therapist curriculum
accredited by the Accreditation Council
for Occupational Therapy Education
(ACOTE) of the American Occupational
Therapy Association (AOTA), and also
have successfully completed the
certification examination developed and
administered by the National Board for
Certification in Occupational Therapy
(NBCOT). We established that
‘‘successfully completed’’ means the
individual must perform sufficiently
well on the exam to receive (or be
eligible to receive) certification. For
services incident to a physician’s or
nonphysician practitioner’s service
where the licensure requirement does
not apply, we proposed the education
and examination requirements continue
to apply.
OT Comments
Comment: AOTA recommended
qualifications based on licensure or
education and examination.
Response: We require qualifications
based both on licensure and on
education and examination so that there
are appropriate qualifications that apply
where licensure is not applicable, for
example, to therapy services furnished
incident to the physician’s service.
Comment: The NBCOT recommended
that qualified OTs be credentialed by
their examination and be members in
good standing of their organization. The
AOTA recommended that AOTA
approve any new credentialing body
that might develop in the future.
Response: We recognize that currently
the ACOTE or the World Federation of
Occupational Therapists (WFOT)
credential education programs for OTs
and/or OTAs and the NBCOT
determines eligibility and furnishes
examinations. We have modified the
policy to approve those organizations
and added ‘‘or successor organizations’’
to allow for changes in the ACOTE title.
We do not agree membership in NBCOT
should be a requirement. Since NBCOT
is already approved by The American
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
National Standards Institute (ANSI), the
National Commission for Certifying
Agencies and the National Organization
for Competency Assurance, CMS does
not believe it is necessary to grant
AOTA’s request to permit it to approve
any future credentialing body.
International OT/OTA
We also proposed that OTs who are
educated outside the United States: (1)
Be graduates of an occupational therapy
curriculum accredited by the WFOT; (2)
have successfully completed the
NBCOT International Occupational
Therapy Eligibility Determination
(IOTED) review; and (3) have
successfully completed the certification
examination for Registered
Occupational Therapist. We proposed to
adopt similar standards for OTAs (but
with an OTA curriculum) and requested
comments on qualifications for
internationally educated occupational
therapy assistants.
Comment: The AOTA and NBCOT
support the proposal that the
internationally educated OT standards
should be comparable to United States
trained OTs and that the NBCOT
conduct the credentialing process for
these OTs. The AOTA requests that
there be a way to allow a professionally
recognized credentialing body other
than NBCOT to develop or administer
the examination.
NBCOT reports there are no
internationally trained OTAs and
recommends qualifications for such
OTAs be stricken from the rules.
Response: This final rule with
comment period recognizes the ACOTE,
NBCOT or WFOT to contribute to
credentialing internationally trained
OTs and OTAs. Although NBCOT may
not now recognize internationally
trained OTAs, such OTAs do exist. In
addition, we are adopting regulations in
anticipation of any international
programs that meet the qualifications in
the future.
Comment: AOTA commented that the
proposals for those who began practice
between December 31, 1977, and
January 1, 2008, are archaic and cannot
be directly applied to many
professionals qualified by their States.
Response: We agree that the current
language is not applicable and we have
updated this language for the new
qualifications in this final rule with
comment period, adding current
credentialing bodies for United States
trained and internationally trained OTs.
To assure that no one covered under the
existing qualifications is inadvertently
disqualified, the prior language
continues to apply for those who are not
PO 00000
Frm 00110
Fmt 4701
Sfmt 4700
licensed but were qualified under the
previous policy.
Comment: Commenters note that
many States allow graduate OTs and
OTAs to furnish services under a
temporary license or permit while
eligible for examination. The
commenters expressed concern that the
qualifications in the proposed rule
would limit new graduates from
entering the workforce.
Response: We agree that it is not
necessary to change the current
requirement of eligibility for the
examination for United States trained
OTs and OTAs when they are licensed
or otherwise regulated by their States.
However, we will require foreign
trained OTs and OTAs (when
applicable) to have passed the
examination, and not merely be eligible
for it. We believe this requirement is
appropriate in the case of foreign
trained individuals in order to ensure
that they have acquired sufficient
knowledge through their education
program to pass the examination and,
thus, are adequately prepared to begin
furnishing services to Medicare
beneficiaries.
Physical Therapy
For PTs, we proposed the therapist
must be licensed as a physical therapist
by the State in which practicing and
accredited by the CAPTE based on
APTA guidelines. When the licensure
requirement is not applicable (that is,
for services furnished incident to the
services of physicians and NPPs), we
proposed to require that PTs must be
accredited by the CAPTE. We requested
comments on qualifications for PTs
which include satisfactory completion
of a curriculum and a national
examination each approved by the
APTA.
Comment: APTA recommended that
we remove the requirement that a PT
pass a National Examination approved
by the APTA. Since all States require a
national licensing exam, APTA does not
believe it is necessary for APTA to
approve the exam. State Boards
supported State licensing requirements,
which include examination.
Response: In cases where the
licensing standards do not apply (for
therapy services incident to a
physician’s service or in the event a
State deregulates PT practice), we
believe it is important to have standards
in place to ensure that an individual is
qualified to furnish physical therapy
services. We will not finalize the
requirement for APTA to approve the
licensing exam. Instead, we will accept
a national licensing exam used by State
boards to qualify personnel who have
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
been trained in a physical therapy
curriculum.
We proposed that licensure or
certification, or other regulation by the
State in which services are furnished
would be required for PTAs under our
regulations. We also proposed that PTAs
be accredited by the CAPTE. We
requested comments on appropriate
qualifications for PTAs.
Comment: APTA believes it is critical
that we require approval by APTA for
foreign trained PTAs. The Commission
on Accreditation of Physical Therapist
Education (CAPTE) of the APTA has
been nationally recognized since 1977
as the only organization that approves
PT and PTA education programs; it has
no financial interest in the credentialing
bodies for PTs or PTAs.
Some commenters disagreed with our
proposal to allow the APTA to approve
the credentialing body that establishes
qualifications for foreign trained PTs
and/or PTAs. They suggest that the U.S.
Citizenship and Immigration Services
and the Department of Homeland
Security approve credentialing bodies
that set standards and credential
individuals and the States decide
whether to license that individual. The
commenters note there are currently no
approved foreign PTA programs.
Response: While commenters tell us
there are no foreign PTA programs that
meet their credentialing standards, there
may be PTA programs in foreign
countries that meet the standards in the
future. Therefore, this final rule with
comment period addresses this future
need. The CAPTE of the APTA is
approved by the U.S. Department of
Education (USDE) and the Council for
Higher Education Accreditation (CHEA).
We find no reason to doubt that CAPTE/
APTA will make fair determinations on
the appropriateness of educational
programs in the United States or
credentials evaluation organizations for
foreign trained PTs and PTAs. However,
in response to comments, we have
recognized both CAPTE and a
credentials evaluation organization
identified in 8 CFR 212.15(e) (the
Homeland Security Act) as it relates to
physical therapists and assistants to
determine an education program to be
substantially equivalent to PT and PTA
entry level education in the United
States. We believe the additional
requirement for passing a national
examination will mitigate any variations
in credentialing.
Comment: Several commenters stated
that adoption of the proposed
qualifications for PTs would usurp the
rights of State governments in licensing
and determining the scope of practice
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
for healthcare professionals, creating ‘‘a
monopoly for curriculum approval’’.
Response: As we indicated in the
proposed rule, we believe it is important
to establish consistent and meaningful
standards and conditions for the
provision of Medicare covered services.
Professional standards change
periodically and these are often
eventually adopted by State licensing
boards, each of which has different
language in its statutes. We believe the
standards we proposed would not usurp
or interfere with the adoption of
standards by States. Rather, in most
cases the standards incorporate the State
standards. However, we believe it is
necessary for CMS to address
circumstances where State licensing or
other regulation are not applicable. We
are not creating a monopoly for
curriculum approval by recognizing
CAPTE. While it is the only existing
credentialing body used by the States in
their licensing process, we assess other
credentialing qualifications if they are
developed. Therefore, we are finalizing
standards that include State standards
(licensing or other regulation), as well as
education and examination. We will
assess other credentialing qualifications
if they are developed.
66331
§ 484.4 should be made applicable in
other settings.
Consistent Personnel Qualification
Standards
Comment: Many commenters
supported consistent personnel
qualifications. Commenters indicated
beneficiaries deserve to be treated by
qualified professionals in both inpatient
and outpatient settings.
We also heard from commenters who
oppose the application of consistent
qualifications for therapists in Part A
settings. The commenters stated that if
only qualified physical therapists
provide physical therapy services in
Part A settings, it will prevent hospitals
from continuing to employ athletic
trainers to provide physical medicine
and rehabilitation services. The
commenters suggest the medical staff
should decide the qualifications for
therapists at a hospital.
Response: The policies outlined in the
proposed rule apply only to therapy
services. The State Operations Manual
Appendix A Survey Protocol,
Regulations and Interpretive Guidelines
for Hospitals (Rev. 1, 05–21–04)
§ 482.56 Condition of Participation:
Rehabilitation Services indicates that
therapy services, if provided, must be in
accordance with acceptable standards of
b. Application of Consistent Therapy
practice which include compliance with
Standards
any applicable Federal or State laws,
(1) Personnel Qualifications
regulations or guidelines, as well as
We believe therapy services should be standards and recommendations
provided according to the same
promoted by APTA, ASHA, and AOTA.
standards and policies in all settings, to In States where there are no personnel
the extent possible and consistent with
qualifications for therapists or
statute. Therefore, we proposed to revise assistants, hospitals should currently be
following the personnel qualification
our regulations to cross-reference the
personnel qualifications for therapists in standards set by those professional
organizations. Most States and all of the
§ 484.4 to the personnel requirements
professional organizations require
for PTs, OTs, PTAs, OTAs, and SLPs in
graduation from approved education
the following sections:
• § 409.10 and § 409.16 (Inpatient
programs and a passing grade on a
hospital services and inpatient critical
national examination. Therefore, we do
access hospital services).
not anticipate that adherence to the
• § 409.23 (Posthospital SNF care).
personnel qualifications in this final
• § 410.43 (Partial hospitalization
rule will cause any changes in hospital
services).
personnel.
At the same time, we recognize that
• § 410.59 (Outpatient occupational
there may be athletic trainers (AT),
therapy services).
lymphedema specialists, low vision
• § 410.60 (Outpatient physical
specialists, nurses, physicians, and
therapy services).
other staff employed in hospital settings
• § 410.62 (Outpatient SLP services).
who furnish other services for which
• § 418.92 (Hospice).
• § 482.56 (Optional hospital services, they are qualified, and for which
payment is included in the payment to
Rehabilitation services).
the facility. Those services should be
• § 485.70 (Specialized providers).
appropriately documented as, for
• § 485.705 (Clinics, Rehabilitation
example, athletic training or
agencies, Public health agencies).
lymphedema services. Where the
• § 491.9 (Rural health clinics and
services of health care professionals
Federally qualified health centers
who are not PTs, OTs, PTAs, OTAs, or
(FQHCs)).
SLPs are now being appropriately
We also solicited comments on
furnished, documented and reimbursed,
whether the personnel qualifications at
PO 00000
Frm 00111
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66332
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
we anticipate the application of
consistent personnel qualifications
relating to PT, OT and SLP services will
have no effect on the appropriate
provision of these other services. In
settings where therapy services are
separately billable, there will only be an
impact on current practice if services
that are being documented as PT, OT, or
SLP services are being furnished by
personnel who do not meet the
requirements to be considered qualified
therapists. Personnel who do not meet
the applicable professional standards to
be considered qualified therapists
cannot furnish or be paid for PT, OT,
and SLP services.
Comment: Several commenters
indicated that therapy services are not
covered in rural health clinics.
Response: Rural Health Clinics
(RHCs) provide a core set of primary
health care services as defined in
statute. RHC services include the
services that would commonly be
furnished in a physician’s office, (such
as PT, OT, and SLP services), but only
when directly provided by a Medicare
approved RHC provider, such as a
physician, nurse practitioner, or
physician assistant. A certified nurse
midwife, clinical psychologist, and or
clinical social worker may provide RHC
services, but not PT, OT, or SLP
services, because PT, OT, and SLP
services are not in their scope of
practice. A face-to-face encounter with
any other practitioner including, for
example, a PT, OT, or SLP, athletic
trainer, kinesiologist, or registered nurse
is not covered as an RHC encounter,
even if the service may be medically
necessary, because these are not
Medicare approved RHC providers (as
defined in statute). Since therapists are
not approved RHC providers, we will
remove the reference in § 491.9 to
personnel qualifications for therapists.
cprice-sewell on PROD1PC72 with RULES
Consistent Policies
(2) Application of Consistent Therapy
Standards
In tandem with cross-referencing Part
A and Part B therapy personnel
requirements in the regulations, we
proposed to clarify our policies to
improve consistency in the standards
and conditions for Part A and Part B
therapy services. Many, but not all, of
the policies described for therapy
services in Part B settings are also
appropriate to Part A settings.
Specifically, in § 409.17, we proposed
to clarify that hospital services include
physical therapy, occupational therapy,
and SLP. We also proposed to add
regulations for inpatient hospital
services to include a plan for therapy
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
services consistent with the plan
required for outpatient therapy services.
We invited comment on PT, OT, and
SLP plan of treatment policies that are
appropriately applied to all therapy
services, whether provided under
Medicare Part A or B.
While the concept of consistent
policies was strongly supported, many
commenters were concerned about the
application of specific Part B policies to
Part A settings.
Comment: Several commenters
indicated concern that application of
the Part B policies, especially plan and
documentation polices, to the inpatient
hospital setting would impact treatment
and increase the paperwork burden to
staff.
Response: We are aware that inpatient
stays are short. If clinically appropriate
documentation is now provided, the
new policies are unlikely to increase the
burden. We have not delineated which
of the Part B policies would apply in
Part A specifically to allow some
flexibility in the application of the
general treatment guidelines as
appropriate to the setting. We anticipate
addressing these issues in manual
instructions.
We note that we continue to believe
the general concept that therapy
services should be provided in a similar
manner by qualified personnel in all
settings is an appropriate one.
Comment: The AOTA requests that
any change to the therapy plan of care
be incorporated ‘‘as soon as possible’’
rather than ‘‘immediately.’’
Response: We recognize that the term
‘‘immediately’’ could be relative.
Therefore, we have substituted ‘‘as soon
as possible’’ to refer to changes in the
plan in § 424.24 and § 482.56.
Comment: Commenters indicated
concern that the outpatient plan of care
certification requirement would be
transferred to inpatient policy and that
an ordered service that is being
provided under the care of a hospital
physician would also require
certification for every change in the
provision of treatment.
Response: The policy at § 409.17 and
§ 482.56 is compatible with the concept
of the therapy plan as part of the overall
plan in a facility. Also, we defer to
hospital policies and procedures for
changes to the plan. Guidance will be
provided in manuals concerning
modifications in the provision of care
that do not constitute changes to the
plan. Requirements concerning orders
for establishment of a therapy plan
(development and implementation) in
the hospital are not changed by this
final rule with comment period. We
anticipate clarifying further in manual
PO 00000
Frm 00112
Fmt 4701
Sfmt 4700
instructions documentation
requirements that are consistent with
the care of inpatients and will take into
account comments received. We believe
that, in general, good practice would
call for documentation of significant
changes to the patient’s response to
treatment in all settings, even if the
Medicare program does not specifically
require it.
Comment: AOTA asserts that in the
inpatient setting, goal setting and
treatment planning may not fit the mold
of what is typically required by CMS in
outpatient settings, that is, functional
restoration. They indicate concern that
therapy will not be provided consistent
with their professional guidelines or
scope of practice.
Response: We recognize that some of
the services furnished by therapists in
the acute inpatient hospital setting may
not achieve functional changes expected
in other settings. We have noted in
§ 482.56 that the provision of care and
the personnel qualifications must be in
accordance with national acceptable
standards of practice. Although
documentation is not relevant to billing
in this setting, it is still critical that the
services furnished be accurately
documented. We anticipate issuing
further guidance regarding
documentation for therapy services in
hospital settings in Medicare manuals.
Comment: AOTA requests removal of
the reference to review of the plan prior
to certification in § 409.17(e). APTA
agrees that the review language is
unnecessary.
Response: We agree that it is
unnecessary in the regulation to remind
physicians or nonphysician
practitioners to read the plan before
they certify it and we have removed the
paragraph from § 410.61(e) and
§ 409.17(e), and § 482.56(e).
Comment: Several commenters agree
with the proposal that in the hospital
setting the physician’s review and
approval of a therapy plan should be
implied in the physician’s review and
approval of a facility plan that includes
therapy services. The commenters
believe the same rationale applies to
services furnished in skilled nursing
facilities and urge CMS to state that, in
the SNF Part A setting, review of the
therapy plan is implied by the
physician’s review of the facility plan.
Response: We agree with the
commenters regarding the implied
physician review and approval of the
therapy plan in the Part A SNF setting.
We have recognized this issue
previously in the preamble to the
Prospective Payment System and
Consolidated Billing for Skilled Nursing
Facilities; Update Notice (69 FR 45780),
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
where we stated that ‘‘ * * *. It is not
necessary for a SNF to obtain a separate
physician signature on the therapy
treatment plan itself prior to billing Part
A for therapy services * * * .’’
Delay in Implementing Policies
Comment: Many commenters
requested delays in the implementation
of the policies for Part A therapy
services, indicating they want time to
have input into the manual guidelines
and may need time to learn new
procedures.
Response: We will delay the
implementation of the policies pending
the issuance of manual guidance which
we anticipate that we will develop in
mid 2008.
cprice-sewell on PROD1PC72 with RULES
Students
Comment: Many commenters believe
that it is imperative that we not
inadvertently develop a policy that
prevents students from receiving
clinical training. APTA suggests we
consider conforming the policies for
students to the SNF policy for services
provided by aides and students. The
SNF policy allows services by aides and
students in the ‘‘line of sight’’ of the
therapist to count toward minutes
accrued on the Minimum Data Set.
Response: We will consider
conforming all policies for student
supervision to the SNF policy for line of
sight supervision, and will address this
issue in manual guidance.
c. Outpatient Therapy Certification
Requirements
In 1988, in an attempt to control the
expanding utilization of therapy
services, we added a 30-day
recertification requirement for
outpatient therapy services to our
regulation at § 424.24. This requires that
a physician certifies a plan of care for
30 days, regardless of the appropriate
length of treatment. To continue
treatment past 30 days, the physician is
required to recertify the plan. As
explained in the CY 2008 PFS proposed
rule, after many years of experience
with the current recertification
requirements, we now believe that
requiring recertification at 30-day
intervals may not always provide
sufficient flexibility to the physician to
order the appropriate amount of therapy
for the patient’s needs. Therefore, we
proposed to change the plan
recertification schedule in § 424.24 to an
episode length based on the patient’s
needs, not to exceed 90 days.
Comment: We received strong support
for changing the recertification schedule
to a date determined by the physician
(not to exceed 90 days) from the therapy
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
associations, medical societies,
facilities, and individuals. They
emphasized that physician approval of
a clinically appropriate length of
treatment at the initial certification will
improve the patients’ access to
treatment, reduce administrative burden
to physicians, therapists and office staff
and reduce unnecessary visits for
patients. Several indicated that a limit is
not necessary since the physician
should determine the episode length.
MedPAC indicated a concern about
reducing the number of physician
reviews of the services in the context of
the increasing utilization of therapy
services
Response: We agree that a physician
is qualified to certify the appropriate
length of care in the initial certification;
and that recertification should be
required as often as the individual’s
condition requires. However, we believe
a 90-day limit is a reasonable
modification of the policy at this time.
We will continue to review the
utilization of therapy services to assess
any changes in the relative utilization
patterns for beneficiaries or providers/
suppliers that may suggest changes in
practice related to this policy. As we
proposed, after 2 years, if we determine
that there are changes in relative
utilization patterns that suggest
inappropriate utilization of therapy
services based on the certification
timing, we will reconsider this policy.
Comment: One commenter stated that
a physician generally does not have
statistical data from which to make a
decision regarding the appropriateness
of initiation or continuation of therapy,
and, therefore, recertification of therapy
by physicians seems meaningless. The
commenter urges the use of riskadjusted data based on gains in
functional status relative to number of
visits to inform physician decision
making for appropriate utilization.
Response: We agree that collection of
data related to the patient’s functional
condition and relative utilization of
services may be useful in our ongoing
development of recommendations for
alternatives to therapy caps. On
September 6, 2007, we released a
Request for Task Order Proposals to the
pool of contractors under the CMS
MRAD (Master Research And
Development) contract vehicle. The goal
of this request for proposals is to
develop recommendations for
alternatives to therapy caps for CMS
covered Outpatient Therapy services.
Comment: There was very strong
support for extension of the 90 day
recertification policy to CORF settings,
consistent with the proposed policy for
all other settings. There were no
PO 00000
Frm 00113
Fmt 4701
Sfmt 4700
66333
comments opposed to consistent
recertification policy in the CORF.
Response: We will apply this policy
consistently across settings, including
the CORF reference in § 410.105(c)(ii)(2)
and 424.27(b).
Review of Plan
We proposed that review of the plan
as required in § 424.24 would continue
to be required at certification and
recertification. Since the plan may be
established by a nurse practitioner, a
clinical nurse specialist, or a physician
assistant (nonphysician practitioners),
as well as a physician, we proposed to
modify the language in § 410.61 to
include those professionals among those
who may review the plan. Since the
certification and recertification of the
plan for Part B services requires a
signature, we proposed to remove the
current redundant requirement at
§ 410.61(e) to date and sign a review at
the same time the plan is certified. In
addition, we proposed to revise § 424.24
to remove reference to a certification
‘‘statement.’’
Comment: We received one comment
supporting the changes to the review
language and no dissenting comments.
Response: We are finalizing the
proposed changes to the review of plan
language in this final rule with
comment period.
3. Amendment of the Exemption for
Computer-Generated Facsimile
Transmission From the National
Council for Prescription Drug Programs
(NCPDP) SCRIPT Standard for
Electronically Transmitting Prescription
and Certain Prescription-Related
Information for Part D Eligible
Individuals
a. Legislative History
Section 101 of the MMA amended
title XVIII of the Act to establish a
voluntary prescription drug benefit
program. Prescription Drug Plan (PDP)
sponsors and Medicare Advantage (MA)
organizations offering Medicare
Advantage—Prescription Drug Plans
(MA–PD) are required to establish
electronic prescription drug programs to
provide for electronic transmittal of
certain information to the prescribing
provider and dispensing pharmacy and
pharmacist. This would include
information about eligibility, benefits
(including drugs included in the
applicable formulary, any tiered
formulary structure and any
requirements for prior authorization),
the drug being prescribed or dispensed
and other drugs listed in the medication
history, as well as the availability of
lower cost, therapeutically appropriate
E:\FR\FM\27NOR2.SGM
27NOR2
66334
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
alternatives (if any) for the drug
prescribed. The MMA directed the
Secretary to issue uniform standards for
the electronic transmission of such data.
There is no requirement that
prescribers or dispensers implement eprescribing. However, prescribers and
dispensers who electronically transmit
prescription and certain other
prescription-related information for
covered drugs prescribed for Medicare
Part D eligible beneficiaries, directly or
through an intermediary, would be
required to comply with any applicable
final standards that are in effect.
b. Foundation Standards and Exemption
for Computer Generated Facsimiles
(Faxes)
In the E-Prescribing and the
Prescription Drug Program final rule (70
FR 67568, November 7, 2005), we
adopted the NCPDP SCRIPT standard,
Implementation Guide, Version 5,
Release 0 (Version 5.0), May 12, 2004,
excluding the Prescription Fill Status
Notification Transaction (and its three
business cases; Prescription Fill Status
Notification Transaction—Filled,
Prescription Fill Status Notification
Transaction—Not Filled, and
Prescription Fill Status Notification
Transaction—Partial Fill), hereafter
referred to as NCPDP SCRIPT 5.0, as the
standard for communicating
prescriptions and prescription-related
information between prescribers and
dispensers. Subsequently, on June 23,
2006 (71 FR 36020), HHS published an
interim final rule that maintained
NCPDP SCRIPT 5.0 as the adopted
standard, but allowed for the voluntary
use of a subsequent backward
compatible version of the standard,
NCPDP SCRIPT 8.1. As use of either of
these two named versions of the NCPDP
SCRIPT standard is permitted, for ease
of reference, we will simply refer to
‘‘NCPDP SCRIPT’’ in this rule.
The November 7, 2005 final rule also
established an exemption to the
requirement to utilize NCPDP SCRIPT
for entities that transmit prescriptions or
prescription-related information by
means of computer generated facsimiles
(faxes generated by one computer and
electronically transmitted to another
computer or fax machine which prints
out or displays a image of the
prescription or prescription-related
information). Providers and dispensers
who use this technology are not
compliant with NCPDP SCRIPT. The
exemption was intended to allow such
providers and dispensers time to
upgrade to software that utilizes the
NCPDP SCRIPT standard, rather than
forcing them to revert to paper
prescribing.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
c. Elimination of Exemption
In the CY 2008 PFS proposed rule (72
FR 38194), we proposed to revise
§ 423.160(a)(3)(i) to eliminate the
computer generated fax exemption to
the NCPDP SCRIPT Standard for the
communication of prescription or
certain prescription related information
between prescribers and dispensers for
the transactions listed at
§ 423.160(b)(1)(i) through (xii).
Since computer-generated faxing
retains some of the disadvantages of
paper prescribing (for example, the
administrative cost of keying the
prescription into the pharmacy system
and the related potential for data entry
errors that may impact patient safety),
we believed it was important to take
steps to encourage prescribers and
dispensers to move toward use of
NCPDP SCRIPT.
In our November 7, 2005 final rule
discussion of computer-generated
faxing, we distinguished between cases
where the prescriber’s or dispenser’s
software has the ability to generate
transactions utilizing the NCPDP
SCRIPT, but the prescriber has not
activated the feature on their software,
and other cases where software (such as
a word processing program) is used to
create a document that can be sent as a
fax that results in print out or displays
a image of a prescription or response at
the receiving end, but does not have
true e-prescribing (electronic data
interchange using NCPDP SCRIPT)
capabilities.
We believed the elimination of the
computer-generated fax exemption
would encourage prescribers and
dispensers using this computergenerated fax technology to, where
available, utilize true e-prescribing
capabilities.
It might also encourage those without
such capabilities to upgrade their
current software products, or, where
upgrades are not available, to switch to
new products that would enable true eprescribing.
Because the elimination of the
computer-generated facsimile exception
would encourage those prescribers that
are already using e-prescribing software
that is capable of true e-prescribing to
utilize those capabilities, we believed
that the elimination of the computergenerated fax exemption would increase
the number of NCPDP SCRIPT
transactions fairly significantly in a
relatively short time period, and that
this could, in turn, create a ‘‘tipping
point’’ that could create economic
incentives for independent pharmacies
to adopt NCPDP SCRIPT capable
software to begin to exchange true e-
PO 00000
Frm 00114
Fmt 4701
Sfmt 4700
prescribing transactions with their
prescriber partners.
We proposed to eliminate the
computer generated fax exemption
effective 1 year after the effective date
of the CY 2008 PFS final rule, on
January 1, 2009. We believed that this
would provide sufficient notice to
prescribers and dispensers who would
need to implement or upgrade eprescribing software to look for products
and upgrades that are capable of
generating and receiving transactions
that utilize NCPDP SCRIPT. It would
also afford current e-prescribers time to
work with their trading partners to
eventually eliminate computer-to-fax
transactions.
We believed the elimination of the
exemption for computer-generated
faxing would encourage e-prescribers
and dispensers to move as quickly as
possible to use of the NCPDP SCRIPT
standard with what we perceived to be
minimal impact.
We solicited comments on the impact
of the proposed elimination of this
exemption.
Comment: Several commenters
concurred with our proposal to
eliminate the exemption for computergenerated faxes. These commenters
indicated that lifting the exemption for
computer generated faxes would act as
an incentive to move prescribers and
dispensers toward true e-prescribing
(electronic data interchange using the
NCPDP SCRIPT standard) and that once
the benefits of true e-prescribing are
realized by a core group of prescribers
and dispensers, word of mouth would
help foster more extensive adoption.
Less than half of all commenters
disagreed with our proposal to eliminate
the exemptions for computer-generated
faxes, citing concerns about increased
hardware/software costs, transaction
fees, certification and other activation
costs. Some commenters agreed that
many prescribers who are already eprescribing likely already possess the
ability to generate NCPDP SCRIPT
compliant transactions using their
software or can comply by obtaining a
version upgrade under their
maintenance agreements. Some
commenters also questioned whether
lifting the exemption would move the
industry forward toward, or raise
barriers to, greater use of true eprescribing. We also received comments
from some individuals who erroneously
thought that we had proposed the
elimination of all faxes, including
paper-to-paper faxes.
Response: For new e-prescribers, the
cost of implementing a product that can
generate an NCPDP SCRIPT-compliant
transaction would not differ from a
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
product that could not, and we expect
that, over time, the market will move
toward the exclusive use of NCPDP
SCRIPT-compliant transactions.
Moreover, the adoption of the PQRI
structural measure discussed section
II.S.1. of this final rule with comment
period will provide an incentive to
providers to implement e-prescribing.
We recognize that pharmacies that are
not now conducting transactions that
utilize NCPDP SCRIPT will incur costs
to implement this capability, and that
pharmacies will likely experience an
increase in e-prescribing transaction
volumes and costs. However, those costs
would be balanced by administrative
savings. We refer to the November 7,
2005 final rule (70 FR 67568) for a
further discussion of potential costs
associated with e-prescribing.
As more prescribers and dispensers
embrace interoperable health
information technology in general, and
the use of e-prescribing standards in
particular, they will see real value and
realize costs savings. Dispenser data
entry time and transcription errors due
to data re-entry or illegible paper
prescriptions will be reduced.
Prescribers and dispensers will spend
less time on the phone requesting and
responding to refill requests. Improved
workflow will free up staff time for
patient counseling and other services.
Patient safety will improve as providers
are linked with medication history,
allergy information and/or drug
contraindications that will result in a
reduction of adverse drug events.
Comment: Many commenters agreed
that the proposed compliance date of
January 1, 2009 was a reasonable
timeframe for those who needed to
comply. Others urged us to extend the
compliance date to April 1, 2009, to
coincide with the projected effective
date of the next set of e-prescribing
standards, or to January 1, 2010, to give
prospective e-prescribers more time to
identify compliant products. Some
commenters recommended that the
requirement to use the adopted eprescribing standards should only apply
to those prescribers/dispensers who
have software or applications that have
the ability to generate transactions
utilizing NCPDP SCRIPT. Others
suggested that the use of computergenerated faxes continue to be permitted
for those prescribers and dispensers
who already have the functionality to
engage in transactions utilizing NCPDP
SCRIPT, and allow those who adopt
software that generates transactions
utilizing NCPDP SCRIPT after the
compliance date of January 1, 2009, an
additional 1 year to comply with the
NCPDP SCRIPT requirement.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Response: The 2006 CMS eprescribing pilot noted that the majority
of e-prescribing software currently being
used by prescribers is already able to
transmit information using NCPDP
SCRIPT. Moreover, commenters agreed
that most current e-prescribers could
become compliant by installing an
NCPDP SCRIPT-enabled version
upgrade. Therefore, we believe that the
January 1, 2009 compliance date
provides adequate time for current eprescribers in the industry to comply
with the NCPDP SCRIPT e-prescribing
standard provisions while encouraging
other prescribers and dispensers to
move closer toward true e-prescribing.
We do not see a purpose in affording
new e-prescribers an additional year to
comply, since it should not take more
time to implement an NCPDP SCRIPTcompliant product than a noncompliant
product.
Comment: Many commenters
suggested that we continue to allow for
the use of computer-generated faxes in
the case of transmission failure and
network outages.
Response: Computer-generated faxes
may be needed for prescriptions which
fail in electronic data interchange (EDI)
transmission. Allowing computergenerated faxes as a fall back measure
would allow the prescription to be
expedited to the pharmacy, ensuring
timely dispensing of the medication,
thus enhancing patient safety. We agree
that there should be a viable
contingency plan in the event that an
EDI-transmitted prescription fails due to
network transmission failures or similar,
temporary communication problems
that are episodic and non-repetitive in
nature. We find the use of computergenerated faxes, but only in instances of
the aforementioned transmission
failures or similar communication
problems of a temporary/transient
nature, to be an acceptable and viable
solution. We do not, however, consider
it to be a permanent substitute for
ongoing EDI transmission problems. As
we will continue to allow computergenerated faxes as a fallback in cases of
temporary/transient transmission
failures and communications problems,
we will not totally eliminate but instead
amend the exemption for computergenerated facsimile transmission from
the NCPDP SCRIPT Standard to account
for this contingency.
Comment: Approximately one-fourth
of commenters from all sectors of the
health care industry called for the delay
of the elimination of the exemption for
computer-generated faxes until such
time as the Drug Enforcement Agency
(DEA) changes its rules to allow the eprescribing of controlled substances.
PO 00000
Frm 00115
Fmt 4701
Sfmt 4700
66335
Commenters believe that the current
DEA position on disallowing eprescribing of controlled substances
creates a barrier to adoption, and the
proposed CMS compliance date of
January 2009 will only exacerbate the
issue.
Response: As we have no indication
as to when the Drug Enforcement
Agency will make a determination on
the e-prescribing of controlled
substances, it would be difficult for us
to predicate eliminating the exemption
for computer-generated faxes based
upon such an unknown timetable.
However, we concur with commenters
who stated that the inability to prescribe
these controlled substances
electronically hampers e-prescribing
adoption by providers. We continue to
work with the DEA to help facilitate a
solution that addresses both the
enforcement requirements of the DEA
with respect to prescribing of controlled
substances, and the needs of the
healthcare community for a solution
that is scalable and commercially viable.
Comment: One commenter suggested
that we exempt controlled substances
from this requirement.
Response: The November 7, 2005 Eprescribing final rule (70 FR 67568)
recognizes the DEA’s role in the
enforcement of the prescribing of
controlled substances. As controlled
substances cannot be legally eprescribed, an exemption from the
NCPDP SCRIPT standard for the eprescribing of controlled substances
would have no effect.
Comment: Some commenters were
confused as to whether the computer
generated fax exemption would affect
the exemption in the long term care
setting, and requested that we clarify
that prescribers and dispensers in the
long term care setting were exempt from
the requirement to use NCPDP SCRIPT
despite the amendment of the
exemption of the computer generated
faxes.
Response: Our amendment of the
exemption for computer generated faxes
does not apply at this time to the long
term care industry as defined under
Medicare Part D. At the time the CY
2008 PFS proposed rule (72 FR 38194)
was published in the Federal Register,
the long term care industry exemption
for using adopted standards in eprescribing (as contained in the
November 7, 2005 final rule (70 FR
67568)) was, and remains, in place.
Based on the comments we received, we
are finalizing an amendment of the
exemption for computer-generated
faxes.
E:\FR\FM\27NOR2.SGM
27NOR2
66336
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
S. Division B of the Tax Relief and
Health Care Act of 2006—Medicare
Improvements and Extension Act of
2006 (Pub. L. 109–432) (MIEA–TRHCA)
In addition to the provisions of the
MIEA–TRHCA discussed in sections
II.B. (GPCIs) and II.F. (CAP), additional
provisions of the MIEA–TRHCA are
discussed in this section of the final rule
with comment period.
1. Section 101(b)—Physician Quality
Reporting Initiative (PQRI)
cprice-sewell on PROD1PC72 with RULES
a. Background
(i) Program Background and Statutory
Basis
Section 101(b) of the MIEA–TRHCA
amended section 1848 of the Act by
adding subsection (k). Section
1848(k)(1) of the Act requires the
Secretary to implement a system for the
reporting by eligible professionals of
data on quality measures as described in
section 1848(k)(2) of the Act. Section
1848(k)(3)(B) of the Act specifies that for
the purpose of the quality reporting
system, eligible professionals include
physicians, other practitioners as
described in section 1842(b)(18)(C) of
the Act, physical and occupational
therapists, and qualified speechlanguage pathologists. Section 101(c) of
the MIEA–TRHCA authorizes
‘‘Transitional Bonus Incentive Payments
for Quality Reporting’’ in 2007,
specifically for satisfactory reporting of
quality data, as defined by section
101(c)(2) of the MIEA–TRHCA. We have
named this quality reporting system the
‘‘Physician Quality Reporting Initiative
(PQRI)’’ for ease of reference.
For 2007, section 1848(k)(2)(A)(i) of
the Act, as added by the MIEA–TRHCA,
provides that the quality measures for
the PQRI shall be the 66 physician
quality measures published as 2007
Physician Voluntary Reporting Program
(PVRP) quality measures on the CMS
web site as of the date of enactment of
this subsection, except for any changes
based on the results of a consensusbased process in January 2007. Based on
actions approved at the AQA Alliance
(formerly the Ambulatory Care Quality
Alliance) meeting on January 22, 2007,
8 measures were added to the 66
measures from the PVRP. Thus, the final
‘‘2007 PQRI Quality Measures’’
comprise 74 measures, which are
applicable to specific combinations of
patient conditions and Medicare
Physician Fee Schedule (PFS) covered
professional services. The measure
titles, descriptions, and specifications
are available for download from the
PQRI Measures/Codes page of the PQRI
section of the CMS Web site at https://
www.cms.hhs.gov/PQRI.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Section 1848(k)(2)(A)(ii) of the Act
does not allow for any further additions
to or deletions from the 2007 PQRI
Quality Measures after January 2007,
and does not allow modifications or
refinements (such as code additions,
corrections, or revisions) to the detailed
specifications for the 2007 PQRI quality
measures after the July 1, 2007,
beginning date of the reporting period.
The final 2007 specifications for the
2007 PQRI quality measures are
available as a download from the
Measures/Codes page of the PQRI
section of the CMS Web site at https://
www.cms.hhs.gov/pqri. Additional
information on the 2007 PQRI is also
available from this section of the CMS
Web site, including, but not limited to:
• Tools to help professionals select
measures;
• Tools to help professionals capture
data on 2007 PQRI quality measures;
• Explanations of the calculation of
eligibility for and amount of bonus
payment for satisfactory reporting; and
• A description of the methodology
that we will use to validate whether
professionals have satisfactorily
reported the MIEA–TRHCA required
minimum number of applicable
measures.
Section 1848(k)(2)(B) of the Act
further requires that the Secretary
publish in the Federal Register not later
than August 15, 2007, proposed quality
measures that would be appropriate for
eligible professionals to use to submit
data to the Secretary in 2008. The final
2008 PQRI quality measures must be
determined and published by November
15, 2007, as specified in section
1848(k)(2)(B) of the Act as amended by
the MIEA–TRHCA.
(ii) Overview of the PQRI Section in the
Final Rule With Comment Period
In the CY 2008 PFS proposed rule (72
FR 38196 through 38199), we provided
a slightly longer summary of the MIEA–
TRHCA requirements and the PQRI
program than is provided immediately
above in this section, and explained our
interpretation of applicable statutory
and government-wide policies relevant
to defining a consensus organization
and consensus-based measure
development process, and our policy for
determining which measures meet
requirements for inclusion in PQRI. In
satisfaction of the MIEA–TRHCA
requirement to publish proposed 2008
PQRI measures by August 15th, we
published 148 proposed 2008 PQRI
quality measures in the CY 2008 PFS
proposed rule (72 FR 38199 through
38202). We invited comments on the
implications of including or not
including any specific measure(s), and
PO 00000
Frm 00116
Fmt 4701
Sfmt 4700
on our plans to explore mechanisms for
submission of electronic clinical
performance measurement information
and/or summary measure results
information extracted from electronic
health records (EHRs) and/or clinical
data registries.
In this PQRI section of the final rule
with comment period, we first address
the general or overview public
comments.
(iii) General/Program Comments and
Responses
Comment: We received a number of
comments commending CMS and the
PQRI program for being responsive to
stakeholder concerns, focusing on
health care quality and performance
improvement, and consistently using
accurate and inclusive terminology (for
example, where appropriate, ‘‘eligible
professionals’’ rather than ‘‘physicians’’)
while implementing on an aggressive
timeline a functional program with an
extensive and well-received education
and outreach component. A number of
commenters also expressed a desire to
continue to work with us in a spirit of
partnership to advance and improve the
program and its utility to beneficiaries,
professionals, and the industry at large.
Response: We appreciate the
constructive input of the wide variety of
stakeholders who have provided
insights, information, and partnered
with us to disseminate informational
materials about PQRI to the eligible
professionals in the health care
community. We plan to continue
dialogue with stakeholder organizations
and will consider their and PQRI
participants’ input (including questions
and comments submitted via informal,
as well as formal, channels of inquiry)
as we continue working to provide 2007
PQRI participants with reporting rate
and clinical performance results
feedback reports and (for those
participants achieving satisfactory
reporting per MIEA–TRHCA
requirements) PQRI incentive payments
in mid-2008, and as we develop and
implement strategies for individualclinician-level and related quality
reporting and improvement initiatives
for 2008 and beyond.
Comment: We received numerous
comments identifying specific ways in
which commenters recommended we
enhance the PQRI in the future. One
theme was that, although defined per
MIEA–TRHCA as professionals eligible
to participate in PQRI, some clinicians
may be unable to participate due to lack
of PQRI measures applicable to their
practices. A closely related concern was
that some clinicians with otherwise
applicable PQRI measures may be
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
unable to participate due to data
submission relying on the Part B PFS
Fee-For-Service claims mechanism.
These limitations include that some
PQRI-eligible professionals (such as
physical and occupational therapists)
who cannot currently participate in
PQRI because reimbursement for the
MPFS covered professional services
they furnish is claimed in a format (X12
837–I electronic transaction or the UB04
form) that does not allow for attribution
of each service to the individual
professional who furnished it.
Several commenters suggested that
submission of electronic clinical
information (ECI) from registries and/or
electronic health records (EHRs) may
potentially address the limitations of
claims-based quality measures data
submission. Other commenters simply
urged us to find a mechanism,
potentially a claims-based mechanism,
to afford all eligible professionals the
opportunity to participate prior to
proceeding with PQRI subsequent to
2007.
Response: We agree with the goal of
offering the opportunity to participate in
PQRI to as many eligible professionals
as feasible and practical, consistent with
the MIEA–TRHCA statutory
requirements. In support of this goal,
especially where there are gaps in
available consensus measures for
specific practitioners, we have worked
to encourage and contract for the
development of quality measures and to
fund consensus projects. For 2008, we
have supported via contract with
Quality Insights of Pennsylvania (QIP)
the development of structural measures
and measures applicable to a broad
cross-section of PQRI eligible
professionals, including some
nonphysician practitioners (NPPs) who
had few or no measures available in
2007. We prioritized development of
these measures based on the existing
gaps in measures available or otherwise
in development and on a need to
address as broad a cross section of
eligible professions or specialties as
possible within the limited volume of
measures for which we could support
development in time for inclusion in the
2008 PQRI.
We plan to continue working to fill
gaps in available consensus-endorsed or
-adopted measures consistent with
available time and resources. However,
we largely depend on and encourage the
development of measures by
professional organizations and other
measure developers. We note that
MIEA–TRHCA includes a provision that
requires the Secretary to include
measures developed by specialty
societies. Ideally, in the future CMS
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
would not need to be closely involved
in the development of clinician-level
quality measures, but would select from
measures that meet the MIEA–TRHCA
requirements.
In regard to the potential use of
nonclaims mechanisms for submission
of electronic clinical information, we
agree with this goal; however it is not
feasible to implement for 2008. In regard
to claims-based alternatives to enable
participation by professionals for whose
covered professional services payment
is made under or based on the MPFS but
claimed via institutional formats (X12
837–I electronic transaction or UB04
form), we have analyzed the
possibilities and determined that the
MIEA–TRHCA requirement that
satisfactory reporting and amount of any
incentive payment be determined at the
individual-professional level cannot be
satisfied without extensive
modifications to the claims processing
systems of CMS and providers, which
would represent a material
administrative burden to us and
providers, and/or modifications to the
industry standard claims formats, which
would require substantial time to effect
via established processes and structures
that we do not maintain or control.
Comment: Although most
commenters acknowledged that we
proposed and will finalize 2008
measures in response to MIEA–TRHCA
statutory mandate, numerous
commenters expressed concerns that we
are proceeding with design and
implementation of PQRI 2008 before we
have been able to evaluate the 2007
PQRI. One such commenter specifically
declined to comment on the 2007 PQRI
in advance of public availability of 2007
PQRI evaluation information and
requested that we solicit comments on
the 2007 PQRI, and the 2007 PQRI
evaluation information, in the CY 2009
PFS proposed rule. Specific examples of
evaluation information that commenters
requested CMS consider and publish
include:
• Rates of participation by eligible
professionals;
• Cost or administrative burden of the
PQRI from the perspective of
participating professionals and the
Medicare program;
• The apparent impact of PQRI on
professionals’ clinical performance; and
• The impact on beneficiaries.
Some of these commenters, and
several other commenters who did not
specifically raise concerns about
program-level evaluation, requested that
we consider delaying the start of the
2008 reporting period until mid-2008 to
give 2007 participants a chance to assess
their 2008 results to identify process
PO 00000
Frm 00117
Fmt 4701
Sfmt 4700
66337
changes to improve their 2008 reporting
rate and clinical performance results.
Response: We are in the process of
operationalizing, in a phased manner
appropriate to data availability and
analytic infrastructure implementation,
a comprehensive ongoing program
monitoring strategy that will provide
interim indications, at the program
level, of some of the same aspects of the
program we will ultimately examine in
our evaluation(s) of the impact of the
2007 program after the conclusion of the
2007 reporting period. To the extent
feasible within the limits of available
resources including, but not limited to,
funding and sufficiently complete data,
we anticipate conducting an evaluation
of the 2007 PQRI. The aspects of PQRI
impact we would expect to assess
include participation rates by specialty/
profession, associated trends in clinical
performance and beneficiary outcomes,
and other observable impacts on
participants, the Medicare program, and
beneficiaries. Although we have not yet
finalized the operational details of our
evaluation strategy, we do anticipate
making the results of the evaluation, at
the national level, available to the
public. We may also make publicly
available the results of such analyses
aggregated at other meaningful levels
(for example, State, specialty, or
profession). We do not at this time plan
to make results publicly available in a
format or with content that would
enable identification of individual
professionals or specific practices’
specific reporting or performance
results. We have not made a
determination as to the most
appropriate venue(s) for making PQRI
evaluation information available to the
public.
This section of the final rule with
comment period is specific to the
establishment of measures appropriate
for use by professionals to submit
quality-of-care data in 2008, as we are
directed to do by section 101(b) of the
MIEA–TRHCA. The incentive bonus
requirements and reporting period for
PQRI in 2008 are addressed in section
101(d) of the MIEA–TRHCA, Physician
Assistance and Quality Improvement
(PAQI), section (II.S.5.) of this final rule
with comment period. Such details of
the 2008 bonus-incentive program are
beyond the scope of this MIEA–TRHCA
Section 101(b), PQRI section of this final
rule with comment period.
Comment: A number of comments
requested or recommended that we
make readily available on an ongoing
basis more detailed information on the
measure development process and
measures in development. Numerous
commenters also requested final
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66338
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
measure specifications be published as
far in advance of the beginning of the
reporting period as possible, and that
more detailed information about
measures proposed or finalized for use
in PQRI be published in, at the same
time as, or in advance of future
rulemaking.
Response: We agree that it could be
useful to our stakeholder partners in
health care quality measurement and
improvement, including but not limited
to potential measure developers, to
make available in a prominent place
(such as the CMS PQRI Web site)
additional information on measure
development in context of PQRI,
potentially including guidance to other
publicly available sources of general
information on health care quality
measurement and development of
specific metrics. We will consider our
options to accomplish this in a practical
and sustainable way and use various
appropriate communications channels
to notify stakeholder organizations and
the community at large of our strategy
once we have developed it.
We agree with the commenters that it
is desirable to provide final measure
specifications sufficiently in advance of
the reporting period to allow reasonable
time for professionals to analyze new or
revised measures and implement any
needed changes in their office
workflows to accurately capture and
successfully submit data on a selection
of measures applicable to their practice
on which they can act to improve the
quality of the services they furnish. We
are aware that such ‘‘lead time’’ should
also help the eligible professionals’
specialty or professional societies be
better prepared to support the
professionals’ selection of relevant,
actionable measures. Having detailed
information on measures available in
advance of the reporting period also
enhances the ability of vendors (such as
practice-management software, billing
services, and electronic health records
vendors) to support professionals’
successful implementation of revised
data-capture processes for the measures.
The MIEA–TRHCA requires that we
publish the final list of 2008 PQRI
measures no later than November 15,
2007. We would expect to publish
detailed specifications shortly after that
date. Detailed measure specifications for
measures new or revised for 2008 PQRI
will be published on the Measures/
Codes page of the CMS PQRI Web site
at https://www.cms.hhs.gov/pqri. These
detailed specifications will include
instructions for reporting and identify
the circumstances in which each
measure is applicable. The detailed
technical specifications for measures in
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the final listing for the 2008 PQRI
remain potentially subject to corrections
until the start of the 2008 reporting
period, as we stated in the proposed
rule.
Comment: Many commenters
expressed concerns that recent legal
rulings raise concerns about whether the
individual participating professionals’
reporting and clinical performance
results may constitute administrative
data potentially subject to disclosure
requirements of the Freedom of
Information Act (FOIA). Commenters
urged that any clinician performance
program or system should remain
voluntary and its results confidential.
Response: Commenting on or
otherwise addressing the legal standing
of PQRI participants’ reporting and
performance results in context of FOIA,
other applicable statutes, or case law is
outside the scope of this rule. At this
time, we have no plans to publish
without participants’ voluntary consent
either 2007 or 2008 PQRI participants’
reporting or performance results in a
way that would be specifically
identified or readily identifiable at the
individual-professional, group practicesite, or billing unit (Taxpayer
Identification Number) levels. As
mentioned in response to comments
urging us to share information resulting
from its 2007 PQRI program-evaluation
analyses, we do plan to make available
information at various meaningful levels
of aggregation other than the individual
professional, practice, or billing unit.
Comment: Several commenters
recommended specific enhancements to
PQRI participant feedback reporting
including displays of additional
analyses (beyond the measure
calculation as specified) for specific
measure(s) and/or provision of interim
reporting and performance results
during the 2008 reporting period. Some
commenters recommended we conduct
additional analyses of measure data but
did not specifically tie that
recommendation to the participant
feedback report content.
Response: Detailed design of the
participant feedback reports and
specific analyses of PQRI data for
purposes other than calculating bonus
payment eligibility or amount (for
example, for future measure
development or refinement) are outside
the scope of this section of this final
rule with comment period. However, we
will consider these recommendations as
part of the ongoing dialogue with the
stakeholder and participant community
in order to collaboratively identify ways
to enhance the measures’ and/or
program’s value to its participants and
the Medicare program. We are currently
PO 00000
Frm 00118
Fmt 4701
Sfmt 4700
assessing the feasible options and
timeframe within which we may be able
to provide meaningful interim feedback
reports to 2008 PQRI participants. As a
matter of practical, operational reality, it
is highly probable that we will not be
able to make any 2008 interim feedback
reports available until after we make
available the 2007 final feedback
reports. The 2007 PQRI was unable to
offer during the reporting period any
interim feedback reports of participants’
reporting and performance rates to date
because the aggressive statutory
timeframe for implementing the
program did not allow for the necessary
data infrastructure (including analytic
programming and report access
mechanisms) to be implemented in time
to provide accurate, meaningful results
feedback for 2007 in an appropriately
secure/confidential report access
environment prior to mid 2008.
Comment: Some commenters
requested specific or general
clarifications or additional guidance on
the PQRI program, and how to code its
measures, in the implementation
support tools (for example, a handbook,
or worksheets) provided on the CMS
PQRI Web site.
Response: Although not directly
applicable to the proposed rule content
on which we sought comment, these
comments are appreciated and will be
taken into consideration along with
other input that these materials’ users
have provided via less formal avenues
of communication.
Comment: Many commenters
expressed concern that the burden of
data collection and submission may be
an obstacle to program participation for
some practices. Some commenters
further noted that the claims-based
submission process may be particularly
burdensome for those practices that are
simultaneously implementing electronic
health records or whose PQRI-eligible
members already participate in a
medical data registry.
Response: To implement a data
submission mechanism that was
technically feasible for CMS and
providers, and that is broadly available
to and already used by the vast majority
of PQRI-eligible professionals, we
determined that claims-based data
submission is the only possible
mechanism for 2007 and the only viable
mechanism for full operationalization in
2008. Thus, measures appropriate for
use by professionals to submit qualityof-care data to CMS in 2008 must be
specified for claims-based submission
and analysis. We are, however,
committed to exploring and supporting
practical, effective mechanisms for
quality-of-care data submission that
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
promote efficiency by streamlining
participants’ and our data collection and
handling. As discussed below in this
section, in the registry- and EHR-based
submission topics of this section of this
final rule with comment period, we plan
to test in 2008 registry- and EHR-based
mechanisms for data submission, in
order to develop the potential ability to
fully implement such mechanisms in
the future. Those professionals whose
practices that have implemented the
referenced HIT will have available EHR
and e-prescribing structural measures
for reporting in 2008, which would, if
reported, count toward professionals’
eligibility for the incentive payment
discussed below in section II.S.5. of this
final rule with comment period.
Comment: Several comments
recommended or urged us to consider
using the group practice as the unit of
analysis, and to consider developing
and implementing sampling
methodologies at the group level as a
means of reducing reporting burden in
the future.
Response: The 2007 unit of analysis is
established at the individualprofessional level by MIEA–TRHCA,
and we have not proposed to change
that for 2008. As the 2007 PQRI
evaluation results become available and
further legislative action provides
additional guidance, such alternatives
may indeed prove important to explore
or develop.
b. MIEA–TRHCA Requirements for
Measures Included in the 2008 PQRI
cprice-sewell on PROD1PC72 with RULES
(i) MIEA–TRHCA Requirements for
2008 Quality Measures
(A) Overview and Summary
As noted in the CY 2008 PFS
proposed rule (72 FR 38196 through
38197), section 1848(k)(2)(B)(i) of the
Act requires, ‘‘for purposes of reporting
data on quality measures for covered
professional services furnished during
2008, the quality measures specified
under this paragraph for covered
professional services shall be measures
that have been adopted or endorsed by
a consensus organization (such as the
National Quality Forum or AQA), that
include measures that have been
submitted by a physician specialty, and
that the Secretary identifies as having
used a consensus-based process for
developing such measures. Such
measures shall include structural
measures, such as the use of electronic
health records and electronic
prescribing technology.’’
Section 1848(k)(2)(B)(ii) of the Act
requires that ‘‘[n]ot later than August 15,
2007, the Secretary shall publish in the
Federal Register a proposed set of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
quality measures that the Secretary
determines are described in clause (i)
and would be appropriate for eligible
professionals to use to submit data to
the Secretary in 2008. The Secretary
shall provide for a period of public
comment on such set of measures.’’
In the CY 2008 PFS proposed rule (72
FR 38197), we explained our
interpretation of these statutory
requirements and the policies used in
selecting measures to propose as
appropriate for professionals to use to
submit data on the quality of covered
professional services furnished to
Medicare beneficiaries in 2008.
In examining the statutory
requirements of section 1848(k)(2)(B)(i)
of the Act, we believe that the
requirement that measures be endorsed
or adopted by a consensus organization
applies to each measure that would be
included in the measures set for
submitting quality data on covered
professional services furnished during
2008. Likewise, the requirement for
measures to have been developed using
a consensus based process applies to
each measure. By contrast, we do not
interpret the provision requiring
inclusion of measures submitted by a
specialty to apply to each measure.
Rather, we believe this requirement
means that in endorsing or adopting
measures, a consensus organization
must include in its consideration
process at least some measures
submitted by a physician or an
organization representing a particular
specialty. Similarly, we interpret the
requirement that 2008 measures include
structural measures, such as the use of
EHRs and electronic prescribing
technology, to mean that the 2008
measure set must include at least 2
structural measures.
In examining sections 1848(k)(2)(B) of
the Act, we believe that the Secretary is
given broad discretion to determine
which quality measures meet the
statutory requirements and are
appropriate for inclusion in the final set
of measures for 2008. We do not
interpret the Act to require that all
measures that meet the basic
requirements of section 1848(k)(2)(B)(i)
of the Act must be included in the 2008
set of quality measures. We next discuss
the statutory requirements for consensus
organizations and the use of a
consensus-based process for developing
quality measures as they relate to the
requirements for the set of measures for
2008 in the context of other applicable
Federal law and policy.
The MIEA–TRHCA requires that
measures used for 2008 be identified by
the Secretary as having been endorsed
or adopted by a consensus organization
PO 00000
Frm 00119
Fmt 4701
Sfmt 4700
66339
and have been developed through the
use of a consensus-based process. As
stated in the proposed rule (72 FR 38197
through 38199), we believe that these
requirements should be interpreted in
the context of the National Institute of
Standards and Technology Act (NISTA)
(15 U.S.C. 271 et seq.) as amended by
the National Technology Transfer and
Advancement Act of 1995 (Pub. L. 104–
113) (NTTAA) and implemented by
Revised OMB Circular No. A–119 (OMB
A–119) dated February 10, 1998.
Per the NTTAA, except when it is
inconsistent with applicable law or
otherwise impractical, all Federal
agencies and departments shall use
standards that are developed or
approved by voluntary consensus
standards bodies. OMB A–119 provides
specific policy guidance to agencies on
the appropriate interpretation of agency
responsibilities under the NTTAA. As
we discussed in the proposed rule (72
FR 38197 through 38199), OMB A–119
establishes as government-wide policy
that agencies ‘‘must use voluntary
consensus standards, both domestic and
international, in its regulatory and
procurement activities in lieu of
government unique standards, unless
use of such standards would be
inconsistent with applicable law or
otherwise impractical.’’ OMB A–119
further explains that in determining
whether use of existing voluntary
consensus standards in its regulatory
and procurement activities is otherwise
impractical, ‘‘ ‘Impractical’ includes
circumstances in which such use would
fail to serve the agency’s program needs;
would be infeasible; would be
inadequate, ineffectual, inefficient, or
inconsistent with agency mission; or
would impose more burdens, or be less
useful, than the use of another
standard.’’ OMB A–119 also provides
that ‘‘voluntary consensus standards’’
are standards developed or adopted by
voluntary consensus standards bodies,
and defines ‘‘voluntary consensus
standards body’’ as an organization
maintaining the following attributes: (1)
Openness; (2) Balance of interest; (3)
Due process; (4) An appeals process; (5)
Consensus; which is defined as general
agreement, but not necessarily
unanimity, and also includes a process
for attempting to resolve objections by
interested parties. The process requires
that, as long as all comments have been
fairly considered, each objector is
advised of the disposition of his or her
objection(s) and the reasons for the
disposition, and the consensus body
members are given an opportunity to
change their votes after reviewing the
comments. Voluntary consensus
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66340
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
standards must include provisions
requiring that owners of relevant
intellectual property have agreed to
make that intellectual property available
to all interested parties on a
nondiscriminatory, royalty-free, or
reasonable royalty basis.
Other types of standards that are
distinct from voluntary consensus
standards but that may be used by
federal agencies when voluntary
consensus standards are not available
and practical to address the
government’s programmatic needs,
include government-unique standards,
industry standards, company standards,
nonconsensus standards, or de facto
standards which are developed in the
private sector but not in the full
consensus process of a voluntary
consensus standards body. For further
discussion of the NTTAA, OMB A–119,
and their relevance to quality measures
for use of professionals to submit
quality-of-care data to the Secretary,
please review the 2008 MPFS Proposed
Rule PQRI section at 72 FR 38197–
38199.
Two consensus organizations are
referenced in section 1848(k)(2)(B): the
National Quality Forum (NQF) and the
AQA Alliance. The NQF has a formal
organizational structure and established
processes that are intentionally
designed to comply with the NTTAA
and OMB A–119. Membership is open
and includes a broad cross-section of
stakeholder perspectives. In
determining whether or not to endorse
a standard, the NQF uses a formal
process that consists of five principal
steps that follow a project’s
conceptualization, prioritization, and
planning. The steps are: (1) Consensus
Standard Development; (2) Widespread
Review; (3) Member Voting and Member
Council Approval; (4) Board of Directors
Action; and (5) Evaluation that includes
an appeals process. The NQF meets the
NTTAA requirements for a voluntary
consensus standards body within the
meaning of the NTTAA and its endorsed
healthcare quality measures constitute
voluntary consensus standards within
the meaning of NTTAA.
The AQA is also referenced in section
1848(k)(2)(B) of the Act as a consensus
organization for the purpose of
identifying measures that have
successfully completed review by a
consensus organization, though it does
not feature all of the structural
characteristics or processes of a
voluntary consensus standards body per
NTTAA and the OMB A–119. By citing
AQA as an example of an acceptable
consensus organization, section
1848(k)(2)(B) of the Act establishes that
AQA adoption satisfies the requirement
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
of section 1848(k)(2)(B) of the Act that
PQRI quality measures be adopted or
endorsed by a consensus organization.
We believe it follows that the Congress
did not intend to require all 2008
quality measures under section
1848(k)(2)(B) of the Act to meet the
requirements to be considered voluntary
consensus standards under the NTTAA.
However, by giving NQF and AQA as
examples of consensus organizations,
we believe the Congress intended that
consensus organizations should, in the
context of section 1848(k)(2)(B) of the
Act, have a breadth of stakeholder
involvement and voting participation
substantially comparable to that of the
NQF or AQA.
Given the potential for apparent
overlap of NQF and AQA as consensus
organizations under the MIEA–TRHCA,
it is important to distinguish their roles.
As currently established, the principal
purpose of AQA for physician quality
measures is to select among NQF
endorsed measures for coordinated
implementation. However, during a
time of rapid physician quality
measures development and
implementation, it is impractical to
delay implementation of physician
quality measures until the formal
processes of NQF are completed.
Therefore, AQA has been able to enable
CMS to incorporate new measures into
the quality reporting system by
providing consensus review acceptable
under MIEA–TRHCA for
implementation of a measure prior to
actual NQF endorsement. In the event of
a determination by NQF to decline
endorsement of a particular measure
after it had been adopted by AQA, we
anticipate that AQA would withdraw its
adoption of such a measure.
Turning to the requirement of a
consensus-based process for developing
quality measures, we interpret this
requirement in light of the NTTAA and
the importance of broad consensus for
health care quality measures used for
regulatory purposes. In this context we
have outlined in the proposed rule, and
rather than cite the proposed rule, we
will for readers’ convenience reiterate
below the process of health care quality
measurement development and
distinguish basic development steps
from the completion of a consensusbased development process as required
under MIEA–TRHCA.
Many organizations are involved in
the development of health care quality
measures. These organizations include
physician organizations, health care
providers, Federal agencies,
accreditation organizations, diseasefocused not-for-profit organizations,
research organizations, and health
PO 00000
Frm 00120
Fmt 4701
Sfmt 4700
plans. The basic development processes
of leading health care quality measure
developers generally use standardized
methods that include identification of a
quality goal or gap, literature and
evidence review, expert and technical
evaluation, specification development,
testing, organizational review, and that
may include public comment.
In the framework of the NTTAA, upon
completion of the basic development
work, healthcare quality measures do
not constitute voluntary consensus
standards, even though they may have
utilized consensus as a mechanism of
achieving agreement among the
developer’s participants or within the
developer’s organizational structure.
Rather, to achieve the status as a
voluntary consensus standard under
NTTAA, the measure must go through
the additional development that occurs
through the broader consensus process
of consensus endorsement. During this
process, based on the need to achieve
agreement, quality measures are often
modified in order to achieve the
necessary broad consensus.
Consistent with this concept, we
interpret ‘‘consensus-based process for
developing measures’’ as used in MIEA–
TRHCA to encompass not only the basic
development work of the formal
measure developer, but also to include
the achievement of consensus among
stakeholders in the health care system
based on at least a level of openness,
balance of interest, and consensus
reflected in the structures and processes
of the NQF or the AQA as of the date
of enactment of MIEA–TRHCA.
Based on the considerations
previously discussed, we apply the
following policies in identifying
measures that meet the MIEA–TRHCA
requirements for having used a
consensus-based process for
development and the requirement for
having been endorsed or adopted by a
consensus organization such as the NQF
or AQA, and that are appropriate for
inclusion as 2008 measures:
(1) We interpret ‘‘a consensus-based
development process’’ as meaning that
in addition to the measure development,
the measure has achieved adoption or
endorsement by a consensus
organization having at least the basic
characteristics of the AQA as a
consensus organization as of December
2006, when the MIEA–TRHCA
incorporating reference to AQA was
passed and signed into law. Those basic
characteristics include a comparable
level of openness, balance of interest,
and consensus-based on voting
participation. As discussed above in this
section and further clarified in points
(3) and (5) of this section, we do not
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
interpret ‘‘consensus-based
development process’’ per section
1848(k)(2)(B) of the Act to require that
the consensus organization or process
meet all of the criteria of the NTTAA
and OMB A–119 definition of a
voluntary consensus standards body.
(2) ‘‘Voluntary consensus standard’’ is
interpreted to mean a voluntary
consensus standard that has been
endorsed as such by a consensus
organization that meets the
requirements of the NTTAA, and the
provisions of OMB A–119, for a
voluntary consensus standards body.
(3) Where there are available quality
measures, and some of these measures
meet the definition of ‘‘voluntary
consensus standards’’ while others do
not, those measures that meet the
definition of ‘‘voluntary consensus
standards’’ are preferred to other
measures not meeting the requirements
of the NTTAA.
(4) In view of the preference for
voluntary consensus standards, if, as of
the earlier of November 15, 2007, or the
date of publication of this final rule, a
measure has been specifically
considered by NQF for possible
endorsement but NQF has declined to
endorse it, we proposed not to include
it in the final set of 2008 PQRI Quality
Measures, even if previously adopted by
AQA.
(5) Although the AQA does not meet
the requirements of the NTTAA for a
voluntary consensus standards body, it
is a consensus organization per section
1848(k)(2)(B) of the Act. In
circumstances where no voluntary
consensus standard (NQF-endorsed)
measure is available, and the measure
has not been specifically declined for
endorsement by NQF, a quality measure
that has been adopted by the AQA (or
another consensus organization with
comparable consensus-organization
characteristics), will meet the
requirements of MIEA–TRHCA if we
determine that it is appropriate for
eligible professionals to use to submit
data.
(6) We are unaware of other
consensus organizations that are
comparable to the NQF in terms of
meeting the formal requirements of the
NTTAA, or of organizations other than
AQA that do not strictly meet the
requirements of the NISTA, as amended
by the NTTAA, but that feature the
breadth of stakeholder involvement in
the consensus process necessary to meet
the intent of the MIEA–TRHCA.
However, the MIEA–TRHCA does not
limit consensus organizations to the
NQF or the AQA, nor restrict the field
of potential consensus organizations.
The MIEA–TRHCA, thereby, maintains
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
flexibility in potential sources of
measure consensus review, which is,
like having multiple sources of measure
development, key to maintaining a
robust marketplace for development and
review of quality measures.
(7) The basic steps for developing the
physician level measures may be carried
out by a variety of different
organizations. We do not interpret the
MIEA–TRHCA to place special
restrictions on the type or make up of
the organizations carrying out this basic
development of physician measures,
such as restricting the initial
development to physician-controlled
organizations. Any such restriction
would unduly limit the basic
development of physician quality
measures and the scope and utility of
measures that may be considered for
endorsement as voluntary consensus
standards.
(8) The policies we proposed were
based on the preference as articulated in
NTTAA and OMB A–119 for ‘‘voluntary
consensus standards’’ to governmentunique standards. However, the MIEA–
TRHCA does not require that quality
measures meet the NTTAA or OMB A–
119 definition of ‘‘voluntary consensus
standards’’ in order to be used for PQRI.
Thus, though we prefer to use quality
measures meeting the NTTAA and OMB
A–119 criteria for voluntary consensus
standards, neither this CMS preference
nor the NTTA or OMB A–119 preclude
CMS from exercising our discretion
under the MIEA–TRHCA to select
measures for PQRI meeting the less
stringent consensus requirements of the
MIEA–TRHCA, when necessary to meet
our program needs as determined by the
Secretary.
(B) Summary of Comments and CMS’s
Responses
Comment: Many commenters thanked
us for clarifying the requirements for
consensus-based development,
consensus endorsement or adoption,
and the basic, high level structure of the
measure-development process. As
discussed above in context of the PQRI
program/overview content and
comments topic, multiple commenters
requested additional and more detailed
information about measure development
and related processes and organizations.
In context of the consensus
requirements, several commenters
requested further explanation of the
detailed definition or distinction
between the stages of measure
development.
Response: We are pleased that many
commenters that found our description
of the measurement development
processes useful and were supportive of
PO 00000
Frm 00121
Fmt 4701
Sfmt 4700
66341
our interpretation of the statutory
requirements for consensus
endorsement and adoption and
consensus-based development process.
In terms of providing additional
clarification, the status for PQRI
implementation of measures that have
been approved by AQA but declined for
endorsement by NQF is clarified in the
final language. Measures approved by
AQA are sufficient for inclusion in 2008
PQRI in terms of the statutory
requirements for consensus-organization
adoption or endorsement and
consensus-based development
requirements of MIEA–TRHCA.
Measures, however, that have been
specifically declined for endorsement
by NQF, are not selected for use in 2008
PQRI, based on our preference for
Voluntary Consensus Standards (72 FR
38198).
Comment: Many commenters
requested or recommended that measure
development processes employ robust
mechanisms for incorporation of
broadly inclusive consensus and/or
public comment during the initial, as
well as final phase of development.
However, some commenters expressed
the counterbalancing concern that we
should more specifically clarify that
appropriate quality measures for PQRI
should in fact be based on evidence
interpreted in processes which include
consensus methods and organizations,
as opposed to measures that are based
primarily on stakeholder consensus
about measure need and design without
a firm foundation in scientifically sound
clinical evidence.
Response: As described in the
proposed rule (72 FR 38197 through
38198) the basic (initial) development
processes of measure developers
typically include various standardized
processes that include both an
evaluation of the evidence base for a
measure and a public comment
opportunity. We do not believe that we
should delineate these processes via
rulemaking, nor require a particular
evidence base for a measure. Rather, the
adequacy of measures from these and
many other standpoints is subject to
evaluation during the consensus
process.
Comment: Several commenters
suggested we consider establishing as
policy that quality measures to be used
by, and analyzed at the level of,
individual PQRI-eligible professionals,
must be developed by cliniciancontrolled organizations to assure
relevance and promote uptake by the
eligible professional community.
Multiple commenters suggested explicit
preference be given for measures
developed or endorsed by physician
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66342
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
specialty societies, in context of
consensus-organization review and CMS
measure selection processes. Some
commenters stated that the AMA–PCPI
should be the sole source for physicianlevel measures. One commenter
specifically presented an interpretation
of the MIEA–TRHCA requirement for
the 2008 PQRI measures to include
measures submitted by a physician
specialty as meaning that the 2008 PQRI
should include only measures
developed by physician organizations,
to assure physician control of available
measures applicable to assessing the
clinical performance of individual
physicians. Other commenters
expressed differing viewpoints,
commenting on the importance of an
open process for initial measure
development, and noting that no single
organization stands ready to lead in the
quality arena. Multiple commenters
pointed to concerns about existing
measure development and consensus
organizations particularly in terms of
structure and transparency, opposing
any single organization controlling
measurement development, opposing
requiring PQRI measurement
development to come solely from
physician controlled organizations, and
supporting alternatives to existing
organizations.
Response: Physician involvement and
leadership is standard in the work of
both measure developers and consensus
organizations. As a result, physicians
are actively involved at all levels of
measurement development and
consensus adoption and endorsement.
We are in agreement that physician
expertise is an important ingredient in
measurement development and in the
consensus process. We further recognize
the leadership of physician
organizations, as is reflected in the large
number of physician quality measures
included in PQRI which were
developed by the AMA–PCPI and its
participating specialty societies.
However, we do not agree that
physicians should be in complete
control of the process of measure
development, as would be the case if
measures were required to be developed
solely by physician-controlled
organizations. Any such restriction
would unduly limit the basic
development of physician quality
measures and the scope and utility of
measures that may be considered for
endorsement as voluntary consensus
standards. Rather, as we described in
the proposed rule, the basic steps for
developing the physician level measures
are appropriately carried out by a
variety of different organizations. We do
not interpret the MIEA–TRHCA to place
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
special restrictions on the type or make
up of the organizations carrying out this
basic development of physician
measures, such as restricting the initial
development to physician-controlled
organizations. Similarly, we do not
interpret MIEA–TRHCA to require that
each measure included in the 2008
PQRI have been developed by a
physician specialty.
Finally, we do not interpret MIEA–
TRHCA to limit the field of potential
consensus organizations to those it
named as examples of acceptable
organizations, so long as the
requirements for broad consensus we
articulated as required under MIEA–
TRHCA is achieved. The MIEA–TRHCA,
thereby, maintains flexibility in
potential sources of measure consensus
review, which is, like having multiple
sources of measure development, key to
maintaining a robust marketplace for
development and review of quality
measures.
Comment: Many commenters
suggested we establish a centralized
process or structure to prioritize
measure development in specific ways.
Some commenters recommended
priority be given to meaningful,
actionable gaps in care or specific highimpact disease conditions. Others
recommended that the first priority be
assuring measure availability for all
PQRI-eligible professions and
specialties. Commenters recommended
a centralized establishment of national
priorities for measure development and
suggested that such prioritization would
help to align clinician-focused quality
measures with measures used in other
governmental and private-sector
initiatives focused on other provider
types, and advance measurement and
close gaps in care for high-prevalence
and/or high-cost conditions.
Response: Health care quality
measures are currently developed by a
variety of organizations and used by a
variety of governmental,
nongovernmental, and public-private
partnership initiatives which have
various and at times differing
programmatic needs for quality
measures. Although a cooperative and
voluntarily coordinated approach to
agreeing upon quality goals which
would guide development and selection
of measures may be of value, the
Secretary retains the authority to select
from available measures meeting
applicable statutory requirements those
most appropriate for use in this
program.
Comment: Many commenters
illustrated, directly or indirectly, that
the proposed rule language (72 FR
38198 through 38199) reads to a
PO 00000
Frm 00122
Fmt 4701
Sfmt 4700
material proportion of reviewers as
meaning or implying that a measure
must be both adopted by the AQA
‘‘and’’ endorsed by the NQF to be
included in the PQRI for 2008. Several
of these comments also specifically
requested clarification of the status of
measures that will, as of the date CMS
finalizes the list of 2008 PQRI quality
measures, be AQA-adopted but not yet
reviewed by NQF.
Response: In general, the consensus
requirement under the MIEA-TRHCA is
met if a measure is either NQF-endorsed
or AQA-adopted. However, where an
AQA-adopted measure has been
specifically considered by NQF but
declined for endorsement, we have not
selected such measures for 2008. This
derives from our stated preference for
standards of a voluntary consensus
standards organization (such as NQF)
over an organization which does not
(such as AQA). Also, as stated in the
proposed rule (72 FR 38198), in the
event of a determination by NQF to
decline endorsement of a particular
measure after it had been adopted by
AQA, we anticipate that AQA would
withdraw its adoption of that measure.
Thus, a measure that has been AQA
adopted and then reviewed by NQF
with a decision to decline endorsement
we would expect would, soon after the
NQF decision, be neither NQF-endorsed
nor AQA-adopted and therefore it
would be undesirable to include a
measure imminently destined to not
retain approval of either consensus
organization simply because we may
have been identifying final 2008
measures during the brief period of lag
between the NQF’s decision to decline
endorsement and the AQA’s
opportunity to reconsider its adoption
of the measure.
To further clarify this point, of the
measures proposed for 2008 (72 FR
38199 through 38202), the only ones
that might be removed as a result of
having been AQA adopted but then
subsequently declined NQF
endorsement are certain measures that
were included in the 2007 PQRI on the
basis of AQA adoption and that have
since been declined for endorsement by
NQF after specifically being considered.
For newly-proposed measures (those
not part of the 2007 PQRI set), either
NQF or AQA consensus endorsement or
adoption is sufficient for PQRI. Most of
these measures will have been adopted
by the AQA but not yet reviewed by
NQF. Others may have been endorsed
by the NQF, but not yet adopted by the
AQA.
Comment: One commenter suggested
that the entirety of the PQRI section of
the proposed rule could potentially be
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
construed to imply that there may be,
based on which specific entities develop
or own a measure, different levels of
consensus-standard status required for
measures to qualify for our
consideration for inclusion in PQRI.
Response: The measure developer was
listed for identification purposes only.
This was necessary for measures that
when proposed were still under
development. The remaining measures
that had achieved consensus
endorsement or adoption were
sufficiently identified by consensus
organization, without listing the
developer. The statutory requirements
for consensus-organization adoption or
endorsement, consensus-based
development and statutory and policy
preferences for measures that have
achieved the status of voluntary
consensus standards apply equally to all
potential PQRI quality measures
regardless of the organization type or
specific identity of any given measure’s
developer or owner.
Comment: We received a large
number of comments on the
interpretation of the requirement of per
Section 1848(k)(2)(B)(i) of the Act, that
2008 PQRI measures ‘‘shall be measures
that have been adopted or endorsed by
a consensus organization (such as the
National Quality Forum or AQA)’’.
These comments reflected a diversity of
opinion amongst various stakeholders
on key conceptual points related to the
balance between rigor and flexibility in
measure review and approval, as well as
on the suitability of specific
organizations for their roles as we define
them in the PFS rule.
Many commenters encouraged us to
rely solely on highly structured,
scientifically rigorous processes for
measure approval to promote stability in
measures over time. Many other
comments advised against requiring a
degree of formality or scientific rigor in
the review process that would unduly
slow the availability and
implementation of new quality
measures to fill current gaps in
professionals or clinical foci for which
applicable measures exist.
Several commenters closely related to
the recommendation of reliance on more
rigorous review processes further
suggested we identify a single voluntary
consensus standards body to be
considered qualified to establish
measures as PQRI measures. The
rationales provided for this suggestion
include enhanced probability of a
cohesive or coordinated universe of
endorsed measures and prevention of
endorsement of duplicate or near
duplicate (‘‘competing’’ or
‘‘conflicting’’) measures.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
The value of having multiple
consensus organizations available to
approve measures was noted by many
comments that were closely related to,
or that were elaborating upon,
maintaining flexibility and adaptability
of the universe of available measures.
These commenters included
observations that setting requirements
that limit the total available capacity for
measure review will slow the
development not only of specific
additional quality measures but likely
also innovative advancement in the
science of health care quality
measurement. Some of these
commenters urged us to remain alert for
the development of additional
organizations into potential consensus
organizations on par with the NQF or
with the AQA as of the date MIEA–
TRHCA was signed into law, and two
commenters named two specific
potential candidates that might choose
to develop to that degree in the near
future.
Response: We believe the existence of
multiple consensus organizations
promotes availability of a broad array of
measures from which we can select
those most appropriate for use in PQRI
based on program policy goals. The
availability of the AQA as a consensus
organization meeting the requirements
of MIEA–TRHCA, though it does not
meet the full NTTAA and OMB A–119
criteria for a voluntary consensus
standards body (VCSB), has proven
important to the consensus
development of the 2008 PQRI
measures. Specifically, the AQA’s more
flexible and expeditious processes have
made measures available on a shorter
timeline than would be possible within
the more rigorous processes of a VCSB.
At present, we are able to identify only
the NQF and the AQA as satisfying the
consensus organization requirements of
MIEA–TRHCA. Should additional
organizations develop to feature
consensus characteristics at least
comparable to the level of openness,
balance of interest, and broadly
representative voting membership
demonstrated by the AQA as of the date
MIEA–TRHCA became law, we would
consider measures endorsed by those
organizations eligible for consideration
for inclusion in PQRI.
We concur with the commenters
identifying the desirability of alignment
or harmony of quality measures across
settings to more effectively promote
overall CMS quality goals. We strive to
achieve synergy between measures used
in various settings and quality related
initiatives to the extent practical.
Comment: Many commenters
concurred with our interpretation that
PO 00000
Frm 00123
Fmt 4701
Sfmt 4700
66343
NQF is a VCSB per NTTAA and OMB
A–119. Several commenters also
commended NQF for the scientific rigor
of its structure and review processes.
Some commenters in favor of
establishing a single consensus
organization entity whose approval
would qualify a measure for PQRI
inclusion went on to name NQF as the
leading or only named candidate for
such an organization. Simultaneously,
multiple concerns were raised about the
uneven (project-driven) NQF funding
stream and its resultant potentially long
or uncertain review timeframes, and the
potential for this to impede measure
development. Several comments also
raised concern that the NQF’s processes
for review of physician-applicable
measures are not yet as developed and
predictable as those measures
applicable to other types of providers. A
few commenters noted that the NQF
determinations on physician-applicable
measures apparently vary unpredictably
between workgroups and that the
appeals process is not clearly
identifiable.
Some comments recommended that
CMS or another agency should provide
steady core funding to the NQF on an
ongoing basis.
Response: The NQF is currently the
only organization we identified that
reviews health care quality measures
while simultaneously meeting the
NTTAA and OMB A–119 definition of
a VCSB. NQF processes for review and
endorsement of physician-applicable
measures are expected to develop and
stabilize as it gains more experience
with such measures. We will continue
to monitor the NQF and its processes
and work with NQF and its members to
promote the prompt achievement of that
growth.
The funding stream of the NQF is
outside the scope of this rulemaking.
The concerns raised over the current
NQF funding mechanism and internal
operational structures does, however,
highlight the desirability of having an
alternative source or multiple
alternative sources of consensusorganization review of quality measures
to assure that the measure has been
vetted in a process that offers at least a
reasonable degree of openness, balance
of interests, and broad voting
participation.
Comment: Multiple comments
expressed concerns about the AQA’s
structure and original intended purpose
not being ideally suited to its current
role in PQRI, and its role in the measure
endorsement process being confusing or
its role not clearly adding value to the
process. Multiple other comments
commended the AQA as currently
E:\FR\FM\27NOR2.SGM
27NOR2
66344
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
structured, including its responsiveness,
openness, breadth of participation, and
utility as a forum for building consensus
among stakeholders in quality
measurement. Several comments also
noted that the AQA is currently reevaluating its structure, and
recommended either that the AQA be
required to restructure itself to meet the
NTTAA and OMB A–119 criteria for a
VCSB or that we reassess the AQA after
any restructure to assure that it retains
at least the comparable level of
consensus-organization characteristics
that it featured at the time MIEA–
TRHCA became law.
Response: As noted above in this
section, we interpret that the AQA
currently meets the MIEA–TRHCA
intended definition of a consensus
organization for purposes of measure
approval, as its mention in MIEA–
TRHCA as an example of a consensus
organization confirms it did at the time
the statute was enacted. Further, we
have expressed what we understand its
value to be for the purpose of making
quality measures available for
consideration for inclusion in the PQRI.
We do not have direct control over the
AQA; requiring the AQA to take any
specific action or restructure in any
specific way would be outside the scope
of CMS authority. However, we are
observing the AQA’s re-evaluation of its
structure and will consider altering its
role in relation to approval of future
PQRI measures based on its resultant
structure.
Comment: Several commenters
requested we specifically define the
minimum criteria to be a non-VCSB
consensus organization meeting the
requirements of MIEA–TRHCA.
Response: We have defined the
requirement as being that an
organization must possess a level of
consensus-organization characteristics
at least comparable to those of the AQA
as of the date MIEA–TRHCA became
law. To attempt to quantify or score an
organization’s level of consensus
characteristics would be difficult to do
in a way that was not misleading or
arbitrary. The key features, as stated in
the proposed rule (at 72 FR 38198),
include openness, balance of interest,
and consensus based on voting
participation.
cprice-sewell on PROD1PC72 with RULES
c. The Final 2008 PQRI Quality
Measures
In the proposed rule (72 FR 38199),
we solicited comments on the
implications of including or excluding
148 specific quality measures in 7 broad
categories. We received numerous
comments both general and measure-
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
specific, which are summarized and
addressed as follows.
Comment: Many comments on
measure inclusion were general or
conceptual and, in fact, mirrored
comments on prioritization of measure
development or endorsement.
Specific to measure selection, some
commenters supported our including or
excluding measures based on a targeted
focus on specific gaps in care, while
other commenters supported maximum
inclusivity of conditions, services, and
professionals. Some of the comments
specific to measure selection stated two
main perspectives: (1) We should set the
priorities and/or prioritization process
in collaboration with a maximally
inclusive and representative cohort of
stakeholders (to specifically include
pharmaceutical, device, and information
technology manufacturers and trade
associations, as well as clinicians and
consumers); and (2) the prioritization or
selection of quality measures should be
accomplished by a VCSB in a formal
consensus process.
Response: In selecting measures, we
have sought to achieve a broad
opportunity for eligible professionals to
participate, and to promote the quality
goals forming the basis for the measures
themselves. The general quality goal
underlying the measures as developed is
a performance gap relating to important
processes or outcomes of care. While we
agree that prioritized themes for quality
improvement can be useful in certain
contexts, for PQRI the scope of practice
of the various eligible professionals
varies significantly. Therefore, it would
be difficult to limit measures selected to
a few specific prioritized quality goals
without also limiting the opportunity to
participate. With respect to the role of
a VCSB under MIEA–TRHCA, it is to
achieve consensus endorsement of
particular measures, rather than to
prioritize measures for PQRI. The
responsibility for selection of measures
for PQRI is directed to the Secretary,
based on proposing measures, soliciting
public comment, and then finalizing the
measures. Public comment could
include the views of a VCSB as to which
measures are most appropriate for PQRI
based on quality goals or other
considerations. These could then be
considered, in conjunction with the
other public comments and the program
needs as determined by the Secretary, in
finalizing the measures.
Comment: Several comments in
context of measure selection urged us to
select or prioritize for PQRI inclusion
measures aligned or harmonized with
those used in other governmental
initiatives that focus other provider
PO 00000
Frm 00124
Fmt 4701
Sfmt 4700
types in addition to or instead of
individual PQRI-eligible professionals.
Response: We concur with comments
identifying the desirability of alignment
or harmony of quality measures across
settings to more effectively promote
overall CMS quality goals. We strive to
achieve such synergy among settings
and initiatives to the extent practical.
Comment: We received several
comments specifically commending or
recommending inclusion of specific
quality measures, including, but not
limited to: Specific eyecare measures;
vaccination and preventive services
measures; diabetic foot and ankle
measures; and perioperative care
measures including venous
thromboembolism(VTE) prophylaxis.
Response: All of the proposed
measures strongly supported by
multiple comments are included in the
final 2008 measures listed below in this
section.
Comment: We received many
comments expressing concern that the
following 2007 PQRI measure that has
achieved NQF endorsement was not
included in measures proposed for
2008: ‘‘Age Related Macular
Degeneration: Dilated Macular
Examination’’.
Response: As noted in the proposed
rule’s correction notice (72 FR 43581),
the omission of this measure was a
technical/editorial error that was
corrected via that notice. The measure
titled ‘‘Age Related Macular
Degeneration: Dilated Macular
Examination’’ is included in the final
list in Table 7.
Comment: Several commenters
recommended changes to specific
quality measures’ titles, definitions, and
detailed specifications or coding. Many
of these recommendations were based
on alternative interpretations of clinical
evidence or concerns about the utility of
the measures. Some requests were
specifically concerned that measures be
expanded or constrained to include or
exclude specific professionals from
those to whom the measure may be
applicable.
Response: Quality measures that have
completed the consensus processes of
NQF or AQA have a designated party
(generally the developer/owner) who
has accepted responsibility for
maintaining the measure. In general, it
is the role of the measure owner,
developer or maintainer to make any
changes to the basic elements of a
measure. Examples of such basic
elements would be the particular
process of care covered by the measure,
professional services to which the
measure applies, or the diagnosis (or
diagnoses) defining the denominator
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
population. A request to modify any
basic elements of a measure should be
addressed to the measure’s maintainer.
In addition, NQF has for its endorsed
measures an established maintenance
process which may be accessed.
Measure maintenance and modification
activities are conducted by the
developers/owners and/or maintainers
of measures outside the CMS rulemaking process. In implementing the
measures for PQRI, CMS may, when
necessary, make certain technical
modifications to assure that reporting
and performance rates can be
calculated. These technical
modifications do not modify the basic
elements of the measure and are carried
out in collaboration with the measure
developer/owner or maintainer.
Comment: Many commenters
requested the inclusion for 2008 of
additional measures not proposed as
PQRI measures in the proposed rule.
Measures requested included additional
structural measures, additional
measures of medication use
appropriateness and compliance,
measures applicable to additional
clinical topics, and the measures
identified in the proposed rule as
mandatory for erythropoietin
stimulating agent reimbursement in
2008.
Response: The MIEA–TRHCA
requires that measures proposed for use
in the 2008 PQRI be published in the
Federal Register prior to August 15,
2007. We are also required by other
applicable statutes to provide
opportunity for public comment on
provisions of policy or regulation that
are established via notice and comment
rulemaking. Measures that were not
included in the proposed rule for
inclusion in the 2008 PQRI that were
recommended to CMS via comments on
the proposed rule have not been placed
before the public with opportunity for
the public to comment on them within
the rulemaking process. When measures
have been published in the Federal
Register, but in other contexts and not
specifically proposed as PQRI measures,
such publication does not provide true
opportunity for public comment on
those measures’ potential inclusion in
PQRI. Thus, such additional measures
recommended via comments on the
proposed rule cannot be included in the
2008 measures MIEA–TRHCA requires
be finalized via publication in the
Federal Register by November 15, 2007.
However, we have captured these
recommendations and will have them
available for consideration in
identifying measure sets for future
years’ PQRI and other initiatives to
which those measures may be pertinent.
The measures we identify for 2008 in
this final rule with comment period will
be final as of the effective date of this
final rule, and no changes (no additions
or deletions of measures) will be made
after that date. However, as was done for
2007, we may make modifications or
refinements, such as code additions,
corrections, or revisions, to the detailed
specifications for the 2008 measures
until the beginning of the reporting
period. Such specification modifications
may be made through the last day
preceding the beginning of the reporting
period. The 2008 measures
specifications will be available on the
PQRI section of the CMS Web site at
https://www.cms.hhs.gov/pqri when they
are sufficiently developed or finalized,
but in no event later than December 31,
2007. No further changes to the
specifications will be made after the
start of the 2008 reporting period. The
measures’ detailed specifications will
include instructions for reporting and
66345
identify the circumstances in which
each measure is applicable.
The final 2008 PQRI Quality Measures
are listed in Tables 7 through 13, and
fall into 7 broad categories. The final
measures for 2008 were selected based
upon the following:
• The achievement of NQF
endorsement or AQA adoption by the
earlier of November 15, 2007, or the
date of publication of this final rule
with comment period;
• Identification in the proposed rule
for use in 2008 with opportunity for
public comment via the rulemaking
process;
• Development completion in a
sufficiently timely manner that
implementation for 2008 would be
practical;
• Their importance in relation to
quality goals;
• Their meaningfulness as measures
of quality;
• Their utility in the PQRI program
such as through augmenting the scope
of services provided by eligible
professionals to which PQRI measures
apply;
• The degree to which they meet the
needs of the Medicare program and their
functionality in terms of ability to be
collected and calculated in the PQRI
program;
• Statutory requirement for inclusion
in quality measures for 2008.
(i) Measures Selected From the 2007
PQRI Quality Measures
We include in the final 2008 PQRI
measures the following 2007 PQRI
measures in Table 7, proposed as 2008
PQRI measures (72 FR 38199 through
38200). The measures in Table 7 include
measures submitted by specialties, in
compliance with section 1848(k)(2)(B)
of the Act.
cprice-sewell on PROD1PC72 with RULES
TABLE 7.—2007 PQRI MEASURES
Hemoglobin A1c Poor Control in Type 1 or 2 Diabetes Mellitus.
Low Density Lipoprotein Control in Type 1 or 2 Diabetes Mellitus.
High Blood Pressure Control in Type 1 or 2 Diabetes Mellitus.
Screening for Future Fall Risk.
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD).
Oral Antiplatelet Therapy Prescribed for Patients with Coronary Artery Disease.
Beta-blocker Therapy for Coronary Artery Disease Patients with Prior Myocardial Infarction (MI).
Heart Failure: Beta-blocker Therapy for Left Ventricular Systolic Dysfunction.
Antidepressant Medication During Acute Phase for Patients with New Episode of Major Depression.
Medication Reconciliation.
Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older.
Characterization of Urinary Incontinence in Women Aged 65 Years and Older.
Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older.
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation.
Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy.
Asthma: Pharmacologic Therapy.
Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports.
Stroke and Stroke Rehabilitation: Carotid Imaging Reports.
Primary Open Angle Glaucoma: Optic Nerve Evaluation.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00125
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66346
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 7.—2007 PQRI MEASURES—Continued
cprice-sewell on PROD1PC72 with RULES
Age-Related Macular Degeneration: Dilated Macular Examination.
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy.
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care.
Perioperative Care: Timing of Antibiotic Prophylaxis—Ordering Physician.
Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin.
Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures).
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (when indicated in All patients).
Osteoporosis: Management Following Fracture.
Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture.
Aspirin at Arrival for Acute Myocardial Infarction (AMI).
Electrocardiogram Performed for Non-Traumatic Chest Pain.
Electrocardiogram Performed for Syncope.
Vital Signs for Community-Acquired Bacterial Pneumonia.
Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia.
Assessment of Mental Status for Community-Acquired Bacterial Pneumonia.
Empiric Antibiotic for Community-Acquired Bacterial Pneumonia.
Asthma Assessment.
Perioperative Care: Timing of Prophylactic Antibiotics—Administering Physician.
Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage.
Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy.
Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge.
Stroke and Stroke Rehabilitation: Tissue Plasminogen Activator (t-PA) Considered.
Stroke and Stroke Rehabilitation: Screening for Dysphagia.
Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services.
Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older.
Osteoporosis: Pharmacologic Therapy.
Use of Internal Mammary Artery (IMA) in Coronary Artery Bypass Graft (CABG) Surgery.
Preoperative Beta-blocker in Patients with Isolated Coronary Artery Bypass Graft (CABG) Surgery.
Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures).
Appropriate Treatment for Children with Upper Respiratory Infection (URI).
Appropriate Testing for Children with Pharyngitis.
Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow.
Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy.
Multiple Myeloma: Treatment with Bisphosphonates.
Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry.
Hormonal Therapy for Stage IC–III ER/PR Positive Breast Cancer.
Chemotherapy for Stage III Colon Cancer Patients.
Plan for Chemotherapy Documented Before Chemotherapy Administered.
Radiation Therapy Recommended for Invasive Breast Cancer Patients Who Have Undergone Breast Conserving Surgery.
Advance Care Plan.
Please note that detailed
specifications for some 2007 PQRI
measures may have been updated or
modified during the NQF endorsement
process during 2007. The detailed 2008
PQRI measure specifications for any
given measure may, therefore, be
different from detailed specifications for
the same measure used for 2007. All
specifications for 2008 measures must
be obtained from the specifications
document for 2008 measures, which
will be available on the CMS PQRI Web
site on or before December 31, 2007.
The following measures proposed for
2008 (72 FR 38200) are not included in
the final 2008 PQRI measures listed in
Table 7 because they have been
considered by NQF and did not achieve
endorsement:
• Dialysis Dose in End Stage Renal
Disease (ESRD) Patients.
• Hematocrit Level in ESRD Patients.
Comment: We did not receive any
comments specifically suggesting that
any of the 2007 PQRI measures
proposed for 2008 be removed from the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
2008 PQRI measures. Some commenters
suggested alternative measures
apparently in addition to the measures
we had proposed.
Response: We have not included in
final 2008 PQRI measures any measures
that were not identified in the proposed
rule as proposed 2008 measures for the
reporting system as required by Section
1848(k)(1) and 1848(k)(2)(B) of the Act.
As discussed above in this rule, we were
obligated by MIEA–TRHCA and other
applicable statutes to publish and
provide opportunity for public comment
on proposed PQRI quality measures.
Measures recommended via comments
on the proposed rule that were not
included in the proposed rule have not
been placed before the public with
opportunity for the public to comment
on their potential use in PQRI. Thus,
such additional measures recommended
via comments on the proposed rule
cannot be included in the 2008
measures MIEA–TRHCA requires be
finalized via publication in the Federal
Register by November 15, 2007.
PO 00000
Frm 00126
Fmt 4701
Sfmt 4700
However, we have captured these
recommendations and will have them
available for consideration in
identifying measure sets for future
years’ PQRI and other initiatives to
which those measures may be pertinent.
(ii) AMA—PCPI Measures
The measures listed in Table 8, which
were developed via the American
Medical Association (AMA) Physicians
Consortium for Performance
Improvement (PCPI), are finalized as
2008 PQRI measures as of the date of
publication of this final rule with
comment period. All of these measures
were proposed as 2008 PQRI measures
(72 FR 38200 through 38201). The
measures listed in Table 8 achieved
AQA adoption or NQF endorsement on
or before October 31, 2007.
We will publish the detailed
specifications for all final PQRI
measures on the CMS PQRI Web site at
https://www.cms.hhs.gov/pqri on or
before December 31, 2007.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66347
TABLE 8.—AMA/PCPI MEASURES FINALIZED FOR 2008 WITH CONSENSUS-ORGANIZATION APPROVAL BY 10/31/2007
cprice-sewell on PROD1PC72 with RULES
Prevention of Ventilator-Associated Pneumonia—Head elevation.
Prevention of Catheter-Related Bloodstream Infections (CRBSI)—Central Venous Catheter Insertion Protocol.
ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in patients with CKD.
Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile).
Influenza Vaccination in patients with End Stage Renal Disease (ESRD).
Vascular Access for patients undergoing Hemodialysis.
Plan of Care for ESRD patients with Anemia.
Plan of Care for Inadequate Hemodialysis in ESRD patients.
Plan of Care for Inadequate Peritoneal Dialysis.
Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD.
Testing of patients with Chronic Hepatitis C (HCV) for Hepatitis C Viremia.
Initial Hepatitis C RNA Testing.
HCV Genotype Testing Prior to Therapy.
Consideration for Antiviral Therapy in HCV Patients.
HCV RNA Testing at Week 12 of Therapy.
Hepatitis A and B Vaccination in patients with HCV.
Counseling patients with HCV Regarding Use of Alcohol.
Counseling of patients Regarding Use of Contraception Prior to Starting Antiviral Therapy.
Patients who have Major Depression Disorder who meet DSM IV Criteria.
Patients who have Major Depression Disorder who are assessed for suicide risks.
Patients with Osteoarthritis who have an assessment of their pain and function.
Acute Otitis Externa (AOE): Topical Therapy.
Acute Otitis Externa (AOE): Pain Assessment.
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use.
Otitis Media with Effusion (OME): Diagnostic Evaluation—Assessment of Tympanic Membrane Mobility.
Otitis Media with Effusion (OME): Hearing Testing.
Otitis Media with Effusion (OME): Antihistamines or Decongestants—Avoidance of Inappropriate Use.
Otitis Media with Effusion (OME): Systemic Antimicrobials—Avoidance of Inappropriate Use.
Otitis Media with Effusion (OME): Systemic Corticosteroids—Avoidance of Inappropriate Use.
Breast cancer patients who have a pT and pN category and histologic grade for their cancer.
Colorectal cancer patients who have a pT and pN category and histologic grade for their cancer.
Appropriate initial evaluation of patients with Prostate Cancer.
Inappropriate use of Bone Scan for staging Low-Risk Prostate Cancer patients.
Review of treatment options in patients with clinically localized Prostate Cancer.
Adjuvant Hormonal therapy for High-risk Prostate Cancer patients.
Three-dimensional radiotherapy for patients with Prostate Cancer.
Chronic Kidney Disease (CKD): Blood Pressure Management.
Chronic Kidney Disease (CKD): Plan of Care: Elevated Hemoglobin for Patients Receiving Erythropoiesis—Stimulating Agents (ESA).
The AMA PCPI measures that were
proposed in Table 17 of the proposed
rule (72 FR 38200 through 38201) were
under development at the time the
proposed rule was published. Several of
these measures did not complete
development or did not complete
development in a sufficiently timely
manner to permit implementation in the
2008 PQRI program. We have not
included in the final PQRI measures
listed in Table 8 the following proposed
2008 measures (from Table 17 of the
proposed rule, 72 FR 38200 through
38201) for which development was not
completed or not completed in
sufficient time for implementation for
2008:
• Stress Ulcer Disease (SUD)
Prophylaxis in Ventilated Patients
• Perioperative Temperature
Management for Surgical Procedures
Under General Anesthesia
• Assessment of Thromboembolic Risk
Factors in patients with Atrial
Fibrillation
• Chronic Anticoagulation in patients
with Atrial Fibrillation
• Monthly INR Measurements in
patients with Atrial Fibrillation
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
• GFR Calculation in patients with
Chronic Kidney Disease (CKD)
• Permanent Catheter Vascular Access
for patients Receiving Hemodialysis
• Patients with Osteoarthritis who
receive Anti inflammatory or
Analgesia Medication
• Documentation of hydration status in
Pediatric Patients with Acute
Gastroenteritis (PAG)
• Weight measurement in patients with
PAG
• Recommendation of appropriate oral
rehydration solution in PAG patients
• Education parents of PAG patients
• Perioperative Cardiac risk assessment
(history)
• Perioperative Cardiac risk assessment
(current symptoms)
• Perioperative Cardiac risk assessment
(physical examination)
• Perioperative Cardiac risk assessment
(electrocardiogram)
• Perioperative Cardiac risk assessment
(continuation of Beta Blockers).
During completion of the measure
development process, the measure
developer eliminated the restriction to
ventilated patients of the proposed (72
FR 38201) measure titled, ‘‘Prevention
PO 00000
Frm 00127
Fmt 4701
Sfmt 4700
of Catheter-Related Bloodstream
Infections in Ventilated Patients—
Catheter Insertion Protocol’’. This
measure is, therefore, listed in the Final
2008 PQRI measures in Table 8 as
‘‘Prevention of Catheter-Related
Bloodstream Infections (CRBSI)—
Central Venous Catheter Insertion
Protocol’’.
During completion of the measure
development process, several of the
measures proposed for 2008 in Table 17
of the proposed rule (72 FR 38200
through 38201) were combined into one
measure by the measure developer. The
final, combined measures contain the
substantive components of each of the
measures. The following is reflected in
the Final 2008 PQRI Measures listed in
Table 8:
• Proposed measures (72 FR 38201)
titled ‘‘Blood Pressure Measurement in
patients with CKD’’ and ‘‘Plan of Care
for patients with CKD and Elevated
Blood Pressure’’ were combined into the
measure entitled ‘‘Chronic Kidney
Disease (CKD): Blood Pressure
Management.’’
• Proposed measures (72 FR 38201)
‘‘Calcium, Phosphorus and Intact
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66348
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Parathyroid Hormone Measurement in
patients with CKD’’ and ‘‘Lipid Profile
in patients with CKD’’ were combined
into the measure in Table 8 entitled
‘‘Chronic Kidney Disease (CKD):
Laboratory Testing (Calcium,
Phosphorus, Intact Parathyroid
Hormone (iPTH) and Lipid Profile).’’
• Proposed measures (72 FR 38201)
‘‘Hemoglobin Monitoring in patients
with CKD’’ and ‘‘Erythropoietin Overuse
in patients with CKD and normal
Hemoglobin’’ were combined into the
measure in Table 8 entitled ‘‘Chronic
Kidney Disease (CKD): Plan of Care:
Elevated Hemoglobin for Patients
Receiving Erythropoiesis-Stimulating
Agents (ESA).’’
During the measure development
process, several measures listed in the
proposed rule (72 FR 38201) as
pertaining to the medical conditions
Acute Otitis Externa (AOE) and Otitis
Media with Effusion (OME) were
narrowed to apply to only one or the
other. The measure developer made
these refinements as a result of more indepth consideration of the evidence for
the clinical relevance of each specific
measure to each or either condition.
Modifications to the measures’ titles
reflect these decisions. Otitis Media
with Effusion (OME) was eliminated
from the proposed 2008 measures
below. The revised measure titles are
listed in Table 8 for each proposed 2008
measures:
• Measure proposed (72 FR 38201) as
‘‘Patients with Acute Otitis Externa
(AOE) or Otitis Media with Effusion
(OME) who receive Topical Therapy’’ is
now entitled ‘‘Acute Otitis Externa
(AOE): Topical Therapy.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who have a
pain assessment’’ is now entitled
‘‘Acute Otitis Externa (AOE): Pain
Assessment.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who are
inappropriately prescribed
antimicrobials’’ is now entitled ‘‘Acute
Otitis Externa (AOE): Systemic
Antimicrobial Therapy—Avoidance of
Inappropriate Use’’. Acute Otitis
Externa (AOE) was eliminated from the
proposed (72 FR 38201) measures
below. The revised measure titles are
listed in Table J2 for each proposed
2008 measures.
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who have an
assessment of tympanic membrane
mobility’’ is now entitled ‘‘Otitis Media
with Effusion (OME): Diagnostic
Evaluation—Assessment of Tympanic
Membrane Mobility.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who undergo
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
hearing testing’’ is now entitled ‘‘Otitis
Media with Effusion (OME): Hearing
Testing.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who
inappropriately receive antihistamines/
decongestants’’ is now entitled ‘‘Otitis
Media with Effusion (OME):
Antihistamines or Decongestants—
Avoidance of Inappropriate Use.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who
inappropriately receive systemic
antimicrobials’’ is now entitled ‘‘Otitis
Media with Effusion (OME): Systemic
Antimicrobials—Avoidance of
Inappropriate Use.’’
• Measure proposed (72 FR 38201) as
‘‘Patients with AOE/OME who
inappropriately receive systemic
steroids’’ is now entitled ‘‘Otitis Media
with Effusion (OME): Systemic
Corticosteroids—Avoidance of
Inappropriate Use.’’
Comment: We received several
comments from organizations involved
in the measure development process
noting that the measure titles as
proposed in Table 17 of the proposed
rule (72 FR 38200 through 38201) were
incorrect or obsolete based on progress
in measure development between the
time the proposed rule went on display
(July 2, 2007) and the date the
commenters submitted their comment
letters (various specific dates at the end
of August, 2007).
Response: As stated above, the
measure titles in Table 8 reflect the
correct titles as of the conclusion of the
development process preparing these
measures for consensus-organization
review in the late summer and early fall
of 2007.
Comment: We received comments in
support of certain measures listed in
Table 8, such as the Chronic Kidney
Disease measures. Other commenters
suggested including additional
measures not proposed as 2008 PQRI
measures. No commenters opposed
inclusion of any of the measures listed
on Table 8.
Response: The measures from Table
16 of the proposed rule (72 FR 38200
through 38201) that were sufficiently
completed in time for use in the 2008
PQRI are included in Table 8. As
discussed above, several of the CKD
measures proposed in Table 16 of the
proposed rule (72 FR 38201) have been
combined into with one another as
listed in Table 8.
As iterated above in response to
comments on measures in Table 7, we
cannot include in the 2008 PQRI
measures that were not published as
proposed 2008 PQRI measures in the
Federal Register by August 15, 2007.
PO 00000
Frm 00128
Fmt 4701
Sfmt 4700
We have, however, made note of the
measures suggested and may consider
them for inclusion in future qualityreporting initiatives to which they may
be relevant.
(iii) Nonphysician Measures
We include measures in the final 2008
PQRI quality measures listed in Table 9
developed by Quality Insights of
Pennsylvania (under the Medicare
Quality Improvement Organization
(QIO) contract for the State of
Pennsylvania) that were proposed as
2008 PQRI measures in Table 18 of the
proposed rule (72 FR 38201 through
38202). These measures were developed
primarily to afford expanded reporting
opportunities for NPPs who had few or
no measures available in 2007. Some
may also be applicable to physicians.
The clinicians who could report each
measure are identified in the measure’s
detailed specifications, which will be
available on the Measures/Codes page of
the CMS PQRI Web site at https://
www.cms.hhs.gov/pqri as far in advance
of the 2008 reporting period as practical.
We have not included in the final PQRI
measures listed in Table 9 the following
measures proposed in Table 18 of the
proposed rule (72 FR 38201 through
38202) whose development was not
completed in a sufficiently timely
manner for implementation in the 2008
PQRI program:
• Universal Hypertension Screening.
• Universal Hypertension Screening
Follow-up.
During completion of the measure
development process, several of the
measures proposed for 2008 in Table 18
of the proposed rule (72 FR 38201
through 38202) were combined into one
measure by the measure developer. The
final, combined measures contain the
substantive components of each of the
measures. The following is reflected in
the Final 2008 PQRI Measures listed in
Table 8:
• Proposed (72 FR 38201) measures
titled ‘‘Universal Weight Screening
(BMI)’’ and ‘‘Universal Weight
Screening Follow-up (BMI)’’ were
combined into the measure entitled
‘‘Universal Weight Screening and
Follow-up.’’
• Proposed (72 FR 38201) measures
‘‘Patient Co-development of Treatment
Plan’’ and ‘‘Patient Co-development of
Plan of Care’’ were combined into the
measure in Table 8 entitled ‘‘Patient Codevelopment of Treatment Plan/Plan of
Care.’’
Comment: We received numerous
comments pertaining to the measures
proposed in Table 18 of the proposed
rule (72 FR 38201 through 38202), now
listed in Table 9 of this final rule with
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
comment period. Most of these
comments addressed the scope of
applicability of these measures to
particular non-physician specialties,
such as speech language pathologists
(SLPs) and occupational therapists.
Response: The applicability of the
final 2008 PQRI measures is dependent
on whether the given practitioner can
bill for the services identified by the
procedures or services represented by
the Current Procedural Terminology
(CPT) Category I codes in the measure’s
denominator per its detailed
specifications. The inclusion of specific
procedures or services in a measure’s
denominator is determined during the
measure development and consensus
process, based on the clinical relevance
of the measure to particular services/
procedures. The determination of
services/procedures to which a specific
measure is relevant and therefore
applicable is not subject to change via
the rulemaking process. The measures
in Table 9 achieved AQA consensus
adoption on or before October 19, 2007.
These measures have not yet been
reviewed by the NQF.
We will publish the detailed
specifications for all final PQRI
measures, including these QIP
nonphysician measures, on the CMS
PQRI Web site at https://
www.cms.hhs.gov/pqri on or before
December 31, 2007.
TABLE 9.—QUALITY INSIGHTS OF
PENNSYLVANIA
NONPHYSICIAN
MEASURES
Universal Weight Screening (BMI) and Follow-up.
Universal Influenza Vaccine Screening and
Counseling.
Universal Documentation and Verification of
Current Medications in the Medical Record.
Screening for Clinical Depression.
Screening for Cognitive Impairment.
Patient Co-development of Treatment Plan/
Plan of Care.
Pain Assessment Prior to Initiation of Patient
Treatment.
(iv) Structural Measures Currently
Under Development
We include structural measures in the
final 2008 PQRI measures listed in
Table 10 developed by Quality Insights
of Pennsylvania (under the Medicare
Quality Improvement Organization
(QIO) contract for the State of
Pennsylvania), that were proposed as
2008 measures in Table 19 of the
proposed rule (72 FR 38202). These
measures meet the requirement of
section 1848(k)(2)(B)(i) of the Act.
Comment: Numerous comments
expressed support of the measures listed
in Table 10. Other commenters stated a
belief that there is a lack of scientific
evidence to support the benefits of eprescribing.
Response: As required by MIEATRHCA, the final 2008 PQRI measures
shall include structural measures such
as the use of EHRs and electronic
prescribing technology. The
determination of the sufficiency of the
scientific basis for quality measures is
part of the review and evaluation during
the measure development and
consensus processes. The measures are
included in Table 10. These measures
were adopted by the AQA on or before
October 31, 2007.
TABLE 10.—QUALITY INSIGHTS OF
PENNSYLVANIA STRUCTURAL MEASURES
HIT—Adoption/Use of E-Prescribing.
HIT—Adoption/Use of Health Information
Technology (Electronic Health Records).
(v) Additional AQA Starter-Set
Measures
We include measures in the final 2008
PQRI measures from the AQA starter set
that were not included in the 2007 PQRI
quality measures but that are relevant to
Medicare beneficiaries and which we
proposed as 2008 measures in Table 20
of the proposed rule (72 FR 38202). We
have not included in the final 2008
measures listed in Table 11 the
66349
following measure that was listed in
Table 20 of the proposed rule (72 FR
38202), because its adaptation to the
claims-based provider-self-reported
format was not found to be feasible:
• Beta Blocker Therapy (persistent for
6 months or more) Post MI.
We received several comments in
support of the measures listed in Table
20 of the proposed rule (72 FR 38202)
and now listed in Table 11, as
preventive care measures and measures
related to smoking cessation.
TABLE 11.—ADDITIONAL AQA
STARTER-SET MEASURES
Dilated eye exam in diabetic patient.
Screening Mammography.
Colorectal Cancer Screening.
Inquiry regarding Tobacco Use.
Advising Smokers to Quit.
(vi) Other NQF-Endorsed Measures
We include in the final 2008 PQRI
measures other measures endorsed by
the NQF that were not included in the
2007 PQRI quality measures but that
were proposed as 2008 measures (72 FR
38202) and that are relevant to Medicare
beneficiaries, address overuse/misuse of
pharmacologic therapy, and/or that
expand the specialty applicability and
patient population. We have not
included in the final PQRI measures
listed in Table 12 the following
proposed measure (72 FR 38202),
because its adaptation to the PQRI
format was subsequently not found to be
feasible:
• Annual Therapeutic monitoring for
patients on the following persistent
medications: Angiotensin Converting
Enzyme Inhibitor (ACE)/Angiotensin
Receptor Blocker (ARB), Digoxin,
Diuretics, Anticonvulsants; and Statins.
We received several comments in
support of including the measures listed
in Table 12. We did not receive any
comments opposing the inclusion of any
of the measures listed in Table 12.
TABLE 12.—OTHER NQF-ENDORSED MEASURES
cprice-sewell on PROD1PC72 with RULES
Inappropriate antibiotic treatment for adults with acute bronchitis.
Disease Modifying Anti-rheumatic Drug Therapy in Rheumatoid Arthritis.
Angiotensin Converting Enzyme Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) Therapy for patients with coronary artery disease and
diabetes and/or left ventricular systolic dysfunction (LVSD).
Urine screening for microalbumin or medical attention for nephropathy in diabetic patients.
Influenza vaccination for patients ≥ 50 years old.
Pneumonia vaccination for patients 65 years and older.
(vii) Podiatric Measures
We include measures in the final 2008
PQRI quality measures listed in Table
13 developed by the American Podiatric
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Medical Association (APMA). These
two measures are finalized as 2008 PQRI
measures as of the date of publication of
this final rule with comment period.
PO 00000
Frm 00129
Fmt 4701
Sfmt 4700
These measures were proposed as 2008
PQRI measures in Table 21 of the
proposed rule (72 FR 38202), and were
E:\FR\FM\27NOR2.SGM
27NOR2
66350
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
adopted by the AQA on or before
October 31, 2007.
A third proposed measure (72 FR
38202), titled ‘‘Diabetic Foot and Ankle
Care, Peripheral Arterial Disease: Ankle
Brachial Index (ABI) Measurement’’ has
not achieved AQA adoption or NQF
endorsement in time to be included in
this final rule with comment period,
and is therefore not included in the final
2008 PQRI quality measures.
Comment: A number of comments
expressed support of these measures.
We received comments requesting
correction of the title of this topic and
the substantive title/heading for the
table from ‘‘Podiatric Measures’’ to
‘‘Diabetic Foot and Ankle Measures’’ to
reflect the potential applicability of
these measures beyond podiatrist. At
the same time, we received comments
that these measures are not applicable to
orthopedic surgeons.
Response: We have retained the
original measure-category title to reflect
the developer, and thus the origin of the
measures, rather than the scope of
applicability. This identification of
nomenclature is aligned with the
nomenclature used for other categories
of measures, such as those in Table 11,
which are identified as originating in
the AQA Starter Set rather than by the
type of services to which they pertain.
MIEA–TRHCA makes no presumption
as to applicability based solely on
measure title or specifications, let alone
the categorization that may be applied
to various groups of measures for
identification and ease of reference.
Rather, measures are presumed
applicable to a practitioner based on the
scope and pattern of practice of the
physician reporting the measure in
combination with its specifications.
TABLE 13.—PODIATRIC MEASURES
Diabetic Foot and Ankle Care, Peripheral
Neuropathy: Neurological Evaluation.
Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear.
cprice-sewell on PROD1PC72 with RULES
d. Addressing a Mechanism for
Submission of Data on Quality Measures
via a Medical Registry or Electronic
Health Record
(i) Addressing a Mechanism for
Submission of Data on Quality Measures
via a Medical Registry—Background and
Summary of Proposed Rule
As explained in the proposed rule (72
FR 38202), section 1848(k)(4) of the Act,
as amended by the MIEA–TRHCA,
requires that ‘‘as part of the publication
of proposed and final quality measures
for 2008 under clauses (i) and (iii) of
paragraph (2)(B), the Secretary shall
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
address a mechanism whereby an
eligible professional may provide data
on quality measures through an
appropriate medical registry’’.
In the proposed rule, we discussed
what constitutes a medical registry and
the general desirability of registries
serving as an alternative to claims based
reporting. We proposed to address
reporting from medical registries by
testing one or more of five mechanisms
for such reporting during 2008, and
requested comment on five options for
data submission by registries. These
options vary as to whether individual
beneficiary-level data is submitted by
the registry, as well as the number and
type of data elements needed from the
registry. The five options were
described in detail in the proposed rule
(72 FR 38203 through 38204).
The 2008 registry reporting is only a
test of the feasibility and accuracy for
the two selected submission options
(identified as Options 2 and 3 in the
proposed rule (72 FR 38203 through
38204)) and described again, in
summary, below in response to
comments. In order to qualify for the
incentive bonus for PQRI data
submission, practitioners will need to
continue their quality data codes
through the claims process.
(ii) Addressing a Mechanism for
Submission of Data on Quality Measures
via a Medical Registry—Summary of
Comments and CMS’s Responses
Comment: The majority of the
comments advocated the use of option
2, 3, or 5. There was not significant
support for option 1 or option 4; instead
the preponderance of comments on
options 1 and 4 were in opposition to
their implementation.
Response: We have decided to test
options 2 and 3 in 2008.
We agree that option 1 should not be
tested. Under this option only the
quality data codes for selected PQRI
measures would be reported by the
registry without submission of
associated diagnosis or service
rendered. Under this option, the
denominator information would have to
be obtained from the claims and linked
to the quality data codes submitted via
the registry. This option would create an
added administrative burden for the
CMS systems that would need to link
data from the two sources at the
beneficiary or episode/encounter/
procedure level.
We also agree that option 4 should not
be tested. Option 4 would place
significant burden upon practitioners,
by requiring practitioners not only to
submit claims to Medicare for the
services provided, but also enter data
PO 00000
Frm 00130
Fmt 4701
Sfmt 4700
obtained from the explanation of
benefits into the registry.
Option 5, which calls for a ‘‘data
dump’’ was supported by some
commenters as this option would
potentially provide the most complete
and robust set of data for purposes of
clinical improvement. It could also be
beneficial in evaluating a physician’s
practice, particularly since it would not
necessarily need to be limited to
Medicare Part B beneficiaries or soley
PQRI measures. Thus, while we agree
that data submission via registry-based
mechanisms in models such as Option
5 has significant potential over time
because of the comprehensiveness of the
data, we do not believe that this option
is currently practical for
implementation even on a test basis. We
intend to continue to explore ways to
enhance our ability to capture registry
data so that it may be suitable for future
use.
Under Option 2, the registry would
provide the quality data codes and
diagnosis codes and beneficiary
identification (HIC) numbers or other
limited beneficiary information for
identification. Using the beneficiary
information to match registry
information to a submitted claim for a
particular service, CMS would have the
data needed to calculate a practitioner’s
reporting and performance rates.
Under Option 3 the registry will
calculate and submit reporting and
performance rates for various measures
to CMS, rather than have CMS calculate
the rates. While this is compatible with
the role of a registry in providing
feedback to the physician, for future
PQRI implementation, a validation
process for the registry calculations
would need to be in place and provided
to CMS.
Comment: Many commenters
requested that registry-based
mechanisms for 2008 be made a fully
operational alternative through which
participants could achieve satisfactory
reporting and quality for a 2008 PQRI
incentive payment. Several commenters
suggested we find a way to let
participants in testing activities ‘‘get
credit’’ toward PQRI reporting for their
participation in the test.
Response: We proposed a test of
registry submission (72 FR 38203
through 38204). It is not feasible or
practical to implement registry
submission without such testing. Any
registries and any of their subscribers
participating in any testing activities in
2008 will be participating in this datasubmission testing on a strictly
voluntary basis. Any registry seeking to
participate in the testing should notify
their subscribers to continue submitting
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
quality data codes on their Part B
professional services claims in order to
pursue PQRI bonus payments.
Comment: We received several
comments requesting that a specific
organization’s registry be deemed or
‘‘certified’’ to satisfy PQRI reporting.
Additionally, it was suggested that we
implement a mechanism to make those
professionals submitting data to the
registry potentially able to qualify for a
2008 PQRI bonus payment on the basis
of participating in the registry. We
received several related comments
suggesting we consider deeming
specialty boards’ maintenance of
certification (MOC) programs so that
successful participation in a deemed
MOC would qualify a professional for a
2008 PQRI bonus payment.
Response: We believe that, in the long
run, registries having such deemed
status may be a very suitable and
desirable way for quality data
submission and measures calculation to
be conducted for physicians and other
practitioners. However, at the present
time we do not find it feasible or
practical to implement such a
suggestion.
Comment: Several commenters
encouraged us to maintain for the
foreseeable future multiple options for
PQRI participants to submit data,
including claims based, as well as
registry or EHR-based submission
mechanisms. Some of these comments
noted that the state of the art for medical
registries is embryonic to nascent.
Commenters also noted that the
percentage of eligible professionals who
use EHRs capable of successful data
extraction and transmission to a CMS
data warehouse is relatively low.
Related comments recommended we
develop a long term strategy that will be
sufficiently flexible to allow for
innovative developments in the registry
field as it begins to grow in
sophistication and market penetration.
Response: For 2008, claims-based
submission will remain the only
mechanism of PQRI quality measure
data submission. We hope in future
years to make alternative ECI-based
submission mechanisms available.
However, we recognize that for the near
future, claims-based submission is
likely to be the only mechanism that
will provide an avenue for virtually all
eligible practitioners to participate
within PQRI. As a result, we would
anticipate that claims based submission
would be maintained.
Comment: Several commenters
expressed concern that many registries
are proprietary and charge a fee for
using the registry. Commenters
expressed concern about using
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
proprietary registries, specifically that
such use raises potential antitrust
(barrier to competition) issues, as well
as barriers to participation by
professionals who would have to
subscribe to a proprietary registry.
Several commenters urged that any CMS
registry-based mechanism be in the
public domain and supported by a
public domain registry available to
individual professionals.
Response: In the proposed rule, we
discussed registry-based reporting as an
alternative, not a requirement. We agree
that physicians should not be required
to use any particular proprietary service.
Rather, the purpose in addressing
registries is to allow physicians who
find it desirable to submit data to
registries to be able to avoid duplicate
data submission to CMS through the
claims process.
Comment: A few commenters
expressed concern that creating new
registries or altering existing interfaces
would be burdensome and costly.
Response: We are not recommending
developing new registries and any
decision to do so should be made
independently of PQRI. Nevertheless,
there are currently various registries in
existence which may, ultimately, be
capable of interfacing with the CMS
data warehouse. As has been previously
discussed, for 2008, we will only be
testing registry-based data submission.
As envisioned for the future, registrybased submission of quality-measures
data would be an alternative, not a
requirement.
Comment: Some comments expressed
concerns about transmitting patient data
through registries or EHRs in context of
applicable statutes, regulations, and
policies protecting patient privacy.
Response: Preserving the
confidentiality of patients’ individually
identifiable and protected health
information is a high priority at CMS.
Generally, personally identifiable data
on individuals and/or their health are
protected by the Privacy Act of 1974
and/or the Health Insurance Portability
and Accountability Act of 1996 (Pub. L.
104–191) (HIPAA). HIPAA establishes
protections specific to certain
individually identifiable health
information, and the Privacy Act
establishes the protections specific to
certain information that the government
maintains which is individually
identifiable. HIPAA and its extensive
implementing regulations have
established privacy and security
standards for health care plans, health
care clearinghouses, and providers that
conduct electronic transactions covered
by HIPAA. These entities are termed
‘‘covered entities’’. All patient registries,
PO 00000
Frm 00131
Fmt 4701
Sfmt 4700
66351
EHRs, data transmission, and data
storage done by or on behalf of a
covered entity must be HIPAA
compliant. The claims-based method of
reporting currently uses patient
identifiers for submission of quality data
along with data required to process the
provider’s claim for payment. The use of
registries or EHRs would require, for
purposes of validation, the same
information as currently used by the
claims-based method of submitting
quality-measures data.
(iii) Addressing a Mechanism for
Submission of Data on Quality Measures
Via a Medical Registry—Final Plan
For 2008, we will test Options 2 and
3 on a voluntary basis, based on selfnomination by the registries. Each
registry participating in the testing of
each option must maintain compliance
with all applicable statutory and
regulatory requirements and any
contractual obligations to the
professionals/providers for processing,
storing, and transmitting the data
required by the option.
Functionally, the registry would act as
a data submission vendor for the eligible
professional. A ‘‘data submission
vendor’’ is defined for purposes of this
rule as an entity that has permission
from the eligible professional to provide
medical registry data to the Quality
Reporting System developed per the
MIEA–TRHCA. This definition parallels
the definition of ‘‘data submission
vendor’’ as used in other programs, such
as the Hospital Compare datasubmission process, where examples of
such vendors include Joint Commission
Oryx vendors.
In the testing process, again in
parallel to similar mechanisms already
implemented for other provider types by
CMS, we anticipate the registry, acting
as a data submission vendor, will
submit data to the CMS clinical data
warehouse, using a CMS-specified
record layout based on the quality
measures’ specifications as published by
CMS. For purposes of this rule, the term
‘‘CMS clinical data warehouse’’ is
defined as a clinical data warehouse
designated by CMS for use in this
testing. The exact warehouse
infrastructure may vary between the
testing activity in 2008 and any full
implementation of registry-based data
submission that may in the future
follow from that testing.
Options 1 and 4 as described in the
proposed rule will not be tested in 2008,
and we do not envision any future
consideration. Thus, they are not
described in this rule. Option 5, while
of potential interest for future
consideration, is also not described
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66352
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
below. As options 2 and 3 will be tested
in 2008, they are described below.
Option 2: Registries provide the
quality codes and diagnosis codes. In
testing this option, we will use claims
data extracted from the National Claims
History to capture the payment
information at the NPI/Tax ID level. All
PQRI reporting and performance
calculations will be performed using
registry data. The registries will,
therefore, be required to include specific
data elements in their databases in order
to include the codes needed to calculate
performance measures and to match
registry data to claims data. Although
not identified in the proposed rule, we
have upon further technical analysis
concluded that along with data elements
previously identified, patient identifiers
will also be needed from the registry
under this option. Patient identifier data
are needed specifically in order to allow
matching of registry data with Medicare
claims. It is our understanding that for
many, if not all, registries, inclusion of
at least the patient identifier data
elements will represent an addition to
their databases.
While developing and through the
implementation of the testing phase we
may discover additional data elements
are needed to support reliably valid
analyses. The following is a list of
examples of the minimum data elements
we believe will be needed from a
registry under Option 2:
• Beneficiary/procedure-level data (ICD
9 and CPT codes)
• HCPCS quality-data codes (G codes
and CPT category II codes and
modifiers)
• NPI and Tax ID
• Date of service
• Beneficiary Date of Birth
• HIC number
Option 3: Registries calculate the
reporting and performance rates for
Medicare beneficiaries only, and submit
these rates to CMS (that is, aggregate
information by NPI within a Tax ID). We
assume no beneficiary level information
will be shared. Registries will be
required to include data elements in
their databases to capture either qualitydata codes or the clinical data needed to
compute the quality-data codes.
Registries will be required to perform
the necessary calculations to be able to
submit completed numerator/
denominators for both reporting and
performance rates. Additionally, the
registries must have a validation
strategy in place.
For any option, the registry must
maintain compliance with all applicable
statutory or regulatory requirements and
any contractual obligations to the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
providers for processing, storing, and
transmitting the data required by the
option. To be considered an appropriate
registry from which we can accept and
process data for the purposes of
calculating PQRI measures, a registry
must also comply with the
interoperability standards recognized by
the Secretary, and therefore, applicable
to HHS initiatives. Examples of
standards recognized by the Secretary
include Consolidated Health Informatics
Initiative (CHI) standards and standards
subsequently recognized by the
Secretary under Executive Order 13410
in place of CHI standards. A description
of the specific health informatics
standards adopted by the Federal
government, as well as the specific
interoperability standards recognized by
the Secretary, is available on the HHS
Office of the National Coordinator for
Health Information Technology (ONC)
Web site at https://www.hhs.gov/
healthit/chiinitiative.html.
We will request that registries
interested in participating in the testing
of the registry based quality data
submission project self nominate. A
letter stating the registries interest
should be received by CMS by 6 PM,
Eastern time, on January 4, 2008. Selfnomination letters should be sent to:
‘‘PQRI IT Testing Nomination’’, Centers
for Medicare and Medicaid Services
Office of Clinical Standards and
Quality, Quality Measurement and
Health Assessment Group, 7500
Security Boulevard, Mail Stop S3–02–
01, Baltimore, MD 21244–8532.
We plan to select for testing, from the
self nominees, a group of registries that
comply with all applicable statutory
and/or regulatory requirements, and any
contractual obligations to the
professionals/providers for processing,
storing, and transmitting the data
required by the option(s) tested.
Registries selected must also comply
with applicable system interoperability
standards recognized by the Secretary
and be technically capable of interfacing
with the CMS clinical warehouse
electronic data exchange interface. The
number of registries selected for testing
may be limited to those that are
technically capable or those that already
contain key minimum data elements for
testing purposes. Additionally, the
actual level of complexity and effort
required for testing from the CMS data
infrastructure may also limit registry
participation in the testing phase.
(Experience with other initiatives has
suggested that some data submission
vendors and their software are more
easily interfaced and tested with the
CMS data warehouse electronic data
exchange interface than others.)
PO 00000
Frm 00132
Fmt 4701
Sfmt 4700
In addition to the requirements listed
above in this section, any registry that
self-nominates for 2008 testing must, at
a minimum, have the following
characteristics:
(1) Be able to separate and report
information for Medicare beneficiaries
only.
(2) Use at least 1 PQRI measure that
is selected for 2008 inclusion. We will
consider other measures recommended
by specialty registries for possible future
use in quality reporting and
performance.
(3) Provide the data as outlined in the
rule for the particular available option
under which they are submitting data
(that is, being able to report using option
2 and/or option 3).
(4) Have a validation process for their
data.
(5) Have or have applied for a
QualityNet Exchange account.
We expect that information on the
results of the testing in 2008 will be
posted on the CMS PQRI Web site at
https://www.cms.hhs.gov/pqri.
(iv) Electronic Health Records (EHRs)
The proposed rule noted (72 FR
38204) that we would explore the
operational feasibility of accepting
clinical quality data for a limited
number of PQRI measures from EHRs,
and solicited comments on this concept.
The summaries of, and our responses to,
the numerous comments we received on
this topic are presented at the end of
this PQRI-specific section.
Having conducted further technical
analyses and reviewed public comments
received on the proposed rule, we have
determined that we will, in 2008,
partner with several self nominated EHR
vendors/groups that we select to
develop and test EHR clinical quality
data submission. Since mechanisms for
submission of electronic clinical data
extracted from an EHR will only be for
testing purposes in 2008, vendors
should notify their clients that the
practitioners will need to submit their
quality data codes through the claims
process to be eligible for a 2008 bonus
payment.
EHR vendors/groups who wish to
participate in the development and
testing process may self-nominate by
sending a letter to CMS expressing their
interest. Self-nomination letters should
be sent to: ‘‘PQRI IT Testing
Nomination’’, Centers for Medicare and
Medicaid Services Office of Clinical
Standards and Quality, Quality
Measurement and Health Assessment
Group, 7500 Security Boulevard, Mail
Stop S3–02–01, Baltimore, MD 21244–
8532.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
The letter must be received by CMS
by 6 p.m., e.s.t., on January 4, 2008.
Vendors who are selected for this
process must:
(1) Be able to submit data according
to the HL7 technical specifications for
submission of data to the Outpatient
Clinical Warehouse, as defined for the
Doctor’s Office Quality—Information
Technology (DOQ–IT) Project; and
(2) Have or have applied for a
QualityNet Exchange account.
As with registry-based mechanisms,
vendors and their customers (eligible
professionals) who choose to participate
in the testing in 2008 will be doing so
on a strictly voluntary basis. We will
continue to express this, and will urge
EHR vendors to explain this to their
customers when seeking volunteers to
participate in the testing with them.
For more information on required
capability (1), above, please see the
QualityNet Exchange User’s Guide, and
the DOQ–IT measures’ technical
specifications (as implemented in the
DOQ–IT project), both available for
download free of charge from https://
qualitynet.org. Additionally, 5
overlapping DOQ–IT and PQRI quality
measures have been updated for
potential use in the 2008 testing. The
updated detailed technical
specifications for these five DOQ–IT/
PQRI overlapping measures are
available for download from the 2008
PQRI Information page of the CMS PQRI
Web site at https://www.cms.hhs.gov/
pqri.
Comment: Numerous comments were
received regarding accepting clinical
quality data from EHRs for use in PQRI.
While some commenters opposed the
idea of using EHR-derived data in PQRI,
the majority of responses were in favor
of accepting clinical quality data from
an EHR.
Response: Although we will be unable
to offer EHR-based data submission
mechanism on other than a test basis,
we are encouraged by the generally
positive response to the pursuit of this
option due to its substantial potential to
enhance data quality and reduce data
collection burden on providers.
Comment: Numerous comments
expressed concerns about data security,
especially as it pertains to patient
privacy, and patient privacy as it relates
to CMS use of the quality data, in the
context of EHR-based data submission
mechanisms.
Response: Preservation of patient
confidentiality is imperative. It is the
inescapable responsibility of every party
that collects, stores, handles, or uses
patients’ personally identifiable health
information for any purpose. In order to
participate in the 2008 testing, all
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
participating parties must be able to
ensure that uses and disclosures of
protected health information EHRs, data
transmission mechanisms, and data
receipt and storage systems will be in
compliance with all applicable statutes
and regulations and any contractual
obligations to the professionals/
providers for processing, storing, and
transmitting the data required by each
option tested. Moreover, although EHR
submission may involve identifiable
personal health information, that
information is limited to what is
minimally necessary to be able to audit
the data accuracy and completeness in
addition to the particular clinical
information (lab values, vital sign
values, documentation of a procedure or
test ordered or performed) necessary to
calculate the performance measure. It
does not involve submitting the entire
patient medical record, and it is
possible that the information as
transmitted can have the patient’s actual
identifying information (for example,
name, and HIC number) ‘‘masked’’ by
using a practice-internal chart ID # or
other method that still allows for
accurate audit.
Comment: Multiple comments urged
us to develop and implement EHRbased data submission mechanisms in a
way that minimizes the burden such
submission might impose.
Response: We agree that data
submission burden is an important
factor to consider in PQRI data
submission.
Comment: We received several
comments expressing concern over
professionals losing ‘‘control’’ of patient
records as a result of EHR-based PQRI
quality data submission. The comments
appeared to assume that our plan was
either to import and maintain within
our data warehouse entire patient
medical records or to implement an
interface that would allow our
warehouse to access and mine the data
from patients’ medical records.
Response: The patient’s health record
is populated and maintained in a
practitioner’s office, regardless of
whether its content is stored on paper
or electronic format or media. Nothing
in this rule affects the rights of patients
or practitioners with respect to the
information contained in a patient’s
health record.
We plan to accept clinical data that is
extracted from medical records and then
submitted to us by a professional (or a
data-submission vendor acting on a
professional’s behalf).
We would not attempt to upload
entire medical records into the data
warehouse, only the data elements
minimally necessary to accomplish the
PO 00000
Frm 00133
Fmt 4701
Sfmt 4700
66353
purposes of PQRI. We do not plan to
enable our system to directly mine data
from the practice’s medical records
database; that will need to be
accomplished by the professional or a
data vendor acting on the professional’s
behalf. The data submission requires an
affirmative action on the part of the
professional to submit the data or to
instruct his or her data submission
vendor to submit the data to our
warehouse.
2. Section 110—Reporting of
Hemoglobin or Hematocrit for Part B
Cancer Anti-Anemia Drugs
(§ 414.707(b))
Medicare Part B provides payment for
certain drugs used to treat anemia.
Anemia is common in cancer patients
and may be caused by either the cancer
itself or by various anti-cancer
treatments, including chemotherapy,
radiation therapy, and surgical therapy.
Anemia occurs when the number of red
blood cells is reduced by an anti-cancer
treatment. This happens due to the
effect of chemotherapy or radiation
therapy on the bone marrow, wherein
red blood cells are produced by dividing
precursor cells. This chemotherapy
effect is commonly referred to as ‘‘bone
marrow suppression.’’ Anemia may also
result from blood loss in association
with surgical therapy for the cancer.
Anemia adversely impacts the quality
of life for beneficiaries being treated for
cancer. Fatigue and reduced
performance capacity are the side effects
of anemia that cancer patients report as
the most disabling and contributing to
poor quality of life. The treatment of
anemia in cancer patients commonly
includes the use of drugs, specifically
erythropoiesis stimulating agents (ESAs)
such as recombinant erythropoietin and
darbepoietin. Although other
pharmacologic interventions are
available, ESAs are the most commonly
used drugs to treat anemia in this
setting. Notably, recent research has
prompted a Black Boxed warnings in
the labels for ESAs, noting significant
adverse effects including a higher risk of
mortality and tumor progression in
some populations.
In 2006, we implemented a revised
ESA claims monitoring policy based on
the last hemoglobin or hematocrit value
from the preceding month on Medicare
claims for payment of ESAs
administered to beneficiaries with
anemia due to end-stage renal disease
(ESRD) receiving dialysis treatments in
facilities. For many years prior, we have
required the reporting of these red blood
cell indicators on the Medicare claims
by ESRD facilities to ensure that the
beneficiaries’ anemia was addressed.
E:\FR\FM\27NOR2.SGM
27NOR2
66354
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
Section 110 of the MIEA-TRHCA
amends section 1842 of the Act by
adding a new subsection (u) that reads
as follows: ‘‘Each request for payment,
or bill submitted, for a drug furnished
to an individual for the treatment of
anemia in connection with the
treatment of cancer shall include (in a
form and manner specified by the
Secretary) information on the
hemoglobin or hematocrit levels for the
individual.’’ Section 110 of the MIEATRHCA requires such reporting for
drugs furnished on or after January 1,
2008. In addition, subsection (b) directs
the Secretary to use the rulemaking
process under section 1848 of the Act to
address the implementation of this
requirement.
By requiring the reporting of anemia
quality indicators for Medicare Part B
anti-anemia drugs that are used in the
context of cancer treatment, we will
facilitate assessment of the quality of
care for this condition. We will use the
information reported to help determine
the prevalence and severity of anemia
associated with cancer therapy, the
clinical and hematologic responses to
the institution of anti-anemia therapy,
and the outcomes associated with
various doses of anti-anemia therapy.
While not specifically addressing
other indications, the recent research on
the adverse effects of ESAs in patients
with cancer does raise concerns as to
whether patients receiving ESAs for
other conditions, such as in the
treatment of HIV-AIDS and for some
surgical patients, are also at higher risk.
We solicited public comment on the
potential of expanding this regulation to
include all uses of ESAs.
Comments and Responses
In general, commenters responded
favorably to requiring the reporting of
the most recent hemoglobin or
hematocrit level on claims seeking
payment for the administration of ESAs
for all uses. One commenter supported
broadening the requirement for
reporting hemoglobin and hematocrit
levels for all ESA claims and stated that
such requirements would provide
valuable data concerning reasonable
care. The commenter stated that any
new information on the use of ESAs for
other, non-cancer diseases gained by the
data collection would be helpful in
understanding the effects of ESA use in
different diseases. Another commenter
supported the broad goal of gathering
the information to improve the quality
of care. Thus, in light of the potential
adverse events from ESA use and in
accordance with our reading of
Congressional intent, we believe it is
appropriate to require reporting of the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
hemoglobin or hematocrit with respect
to all ESA claims, and therefore, we
have revised the regulations text to
reflect this policy in this final rule with
comment period.
Most commenters’ concerns were
limited to the implementation of the
requirement and possible subsequent
undue administrative burden placed on
providers. A few commenters addressed
a recently published National Coverage
Determination on the use of ESAs for
certain patients and others included
comments related to our ESAs claims
monitoring policy (EMP). We are not
addressing those comments in this final
rule with comment period as the issues
are outside the scope of this regulation.
Comment: A commenter
recommended that we exercise caution
in implementing the anemia quality
indicator secondary to a recent Food
and Drug Association (FDA) Black
Boxed Warning (BBW) on the use of
ESAs. The commenter noted that
anemia measures were removed from
the Physician Consortium for
Performance and Improvement ESRD
measurement set pending further
clarification by either the FDA or the
National Kidney Foundation.
Response: This final rule with
comment period does not establish new
or additional standards related to
anemia or the administration of ESAs. It
simply mandates the reporting of the
most recent hemoglobin or hematocrit
level on claims for payment of the
administration of ESAs to treat anemia.
Similar to claims for ESAs administered
in renal dialysis facilities, the
requirement to report a recent
hemoglobin or hematocrit on claims for
the administration of ESAs for any use
is not a development of a clinical
standard. Thus, we believe that
collecting this information will not
impact nor be impacted by any
consensus standard organizations’
development of practice standards,
quality measures or new scientific
evidence.
Comment: A commenter asked that
we clarify if the reporting requirement
applies to all anemia treatment, which
includes, but is not limited to, the use
of ESAs.
Response: The statutory requirement
does not limit the scope to ESAs. We
recognize that other drugs and vitamin
and mineral supplements such as
Vitamin B12, folic acid, and iron may
also be used in the treatment of anemia.
ESAs are only FDA approved for the
treatment of anemia while the other
agents are commonly used to treat a
variety of conditions other than anemia.
Vitamin and mineral supplements are
commonly self administered and we
PO 00000
Frm 00134
Fmt 4701
Sfmt 4700
expect that most uses of these agents
would not result in claims for Medicare
payment in the context of the treatment
of anemia related to anti cancer therapy.
However, if payment is requested for
these anti-anemia drugs furnished to an
individual for the treatment of anemia
in connection with the treatment of
cancer, we believe that they are within
the scope of the statute.
We believe that the reporting of
hemoglobin or hematocrit levels on
claims for ESAs is consistent with
Congressional intent that quality
indicator data be submitted for patients
receiving anti-anemia drugs and to
ensure that anemia is addressed.
Comment: Several commenters
recommended that we provide clear
instruction on the scope and reporting
of the hemoglobin or hematocrit levels.
Response: We will use the change
request process to issue implementing
instructions to Medicare contractors.
Instructions to Medicare contractors
include requirements for provider
education.
Comment: Several commenters
expressed concern that the requirement
will be burdensome for providers. One
commenter asked that we delay the
implementation of this requirement
until the administrative burden to
practitioners is understood.
Response: We do not have the
authority to delay the effective date of
the statutory requirement. In addition,
we believe that reporting the most
recent hemoglobin or hematocrit level
on a claim for ESA will not result in
undue administrative burdens on
providers. Many local Medicare
contractors already require such
reporting for claims submitting within
their jurisdictions. ESRD providers have
been reporting hemoglobin or
hematocrit levels on claims for ESAs for
several years.
Comment: A commenter
recommended that should we broaden
the reporting requirement to all ESA use
and that we should assess minimal data
sets for understanding how beneficiaries
with various underlying conditions
respond to a particular course of anemia
management.
Response: We appreciate the
recommendation and shall review
available data sets when assessing
responses to anemia management.
Comment: A commenter
recommended that we include anemia
quality indicators in the Physician
Quality Reporting Initiative (PQRI) data
reporting.
Response: This comment is addressed
above in the section of this final rule
specific to 2008 PQRI measures. The
identification or establishment of PQRI
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
measures is not within the scope of this
section of this final rule with comment
period.
Comment: A commenter asked that
retail pharmacies be exempt from this
requirement.
Response: The MIEA TRHCA does not
provide for any exemption for retail
pharmacies.
Comment: One commenter asked that
we clarify whether a provider may
report a hematocrit or hemoglobin level.
Response: A provider seeking
payment for ESAs may report the
patient’s most recent hematocrit or
hemoglobin level on the claim.
Comment: Several commenters asked
that we clarify the requirement to report
‘‘the most recent’’ hemoglobin or
hematocrit level. They expressed
concern that we may require a patient
to have a hemoglobin or hematocrit
level drawn each time an ESA is
administered.
Response: We are not determining in
this regulation when a hematocrit or
hemoglobin level should be drawn to
inform a provider’s decision to
administer ESA therapy. The
requirement is that ‘‘the most recent’’
hemoglobin or hematocrit level be
reported on the claim. Thus, the
provider should report the most recent
level preceding the ESA administration.
We recognize that in some instances the
same hemoglobin or hematocrit value
might be reported on more than one
claim.
Comment: Several commenters stated
that we should permit providers to
report hematocrit or hemoglobin levels
in either box 19 or 24A of the CMS 1500
form. The CMS 1500 form was recently
modified to allow reporting in box 24A;
however, many providers utilize billing
vendors that provide software and are
unable to modify their product in time
for the January 1, 2008 implementation.
Response: We will consider this
information when developing claims
processing systems instructions.
Comment: One commenter suggested
that we employ Q codes for reporting
the most recent hemoglobin or
hematocrit levels. The commenter stated
that permitting a provider to report the
level in box 19 would not allow an
automated extraction of the data
element (the hemoglobin or hematocrit
level) for data analysis.
Response: We are working with
claims processing systems to ensure
appropriate retrieval of data sets.
3. Section 104—Extension of Treatment
of Certain Physician Pathology Services
Under Medicare
The technical component (TC) of
physician pathology services refers to
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the preparation of the slide involving
tissue or cells that a pathologist will
interpret. (In contrast, the pathologist’s
interpretation of the slide is the
professional component (PC) service. If
this service is furnished by the hospital
pathologist for a hospital patient, it is
separately billable. If the independent
laboratory’s pathologist furnishes the PC
service, it is usually billed with the TC
service as a combined service.)
In the CY 2000 PFS final rule with
comment period (64 FR 59408 through
59409), we stated that we would
implement a policy to pay only the
hospital for the TC of physician
pathology services furnished to hospital
patients. Before that provision, any
independent laboratory could bill the
carrier under the PFS for the TC of
physician pathology services for
hospital patients. As stated in the CY
2000 PFS final rule with comment
period (64 FR 59408 through 59409),
this policy has contributed to the
Medicare program paying twice for the
TC service, first through the inpatient
prospective payment rate to the hospital
where the patient is an inpatient and
again to the independent laboratory that
bills the carrier, instead of the hospital,
for the TC service.
Therefore, in the CY 2000 PFS final
rule with comment period (64 FR 59408
through 59409), in § 415.130, we
specified that for services furnished on
or after January 1, 2001, the carriers
would no longer pay claims to the
independent laboratory under the PFS
for the TC of physician pathology
services for hospital patients.
Ordinarily, the provisions in the PFS
final rule with comment period are
implemented in the following year.
However, in this case, the change to
§ 415.130 was delayed 1 year (until
January 1, 2001), at the request of the
industry, to allow independent
laboratories and hospitals sufficient
time to negotiate arrangements.
Moreover, our full implementation of
§ 415.130 was further delayed by section
542 of the Medicare, Medicaid, and
SCHIP Benefits Improvement and
Protection Act of 2000 (Pub. L. 106–554)
(BIPA) and section 732 of the MMA,
which directed us to continue payment
to independent laboratories for the TC
of physician pathology services for
hospital patients through CY 2006.
In the CY 2007 PFS final rule with
comment period (71 FR 69700), we
announced that beginning January 1,
2007, we would no longer allow the
carriers to pay the independent
laboratory for the TC of physician
pathology services to hospital patients.
In effect, we would be: (1) Implementing
the provisions of the CY 2000 PFS final
PO 00000
Frm 00135
Fmt 4701
Sfmt 4700
66355
rule with comment period whose
implementation had been delayed by
section 542 of the BIPA and section 732
of the MMA; and (2) ensuring that the
Medicare program does not make
duplicate payments for the same
service.
Subsequent to publication of the CY
2007 PFS final rule with comment
period, the MIEA–TRHCA was enacted.
Section 104 of the MIEA–TRHCA
provided for an additional 1 year
extension to allow carriers to continue
to pay independent laboratories under
the PFS for the TC portion of physician
pathology services furnished to patients
of a covered hospital.
Consistent with this legislative
change, we are amending § 415.130(d) to
specify that for services furnished after
December 31, 2007, an independent
laboratory may not bill the carrier for
the TC of physician pathology services
furnished to a hospital inpatient or
outpatient.
Comment: Many commenters asked
us to implement the grandfather
provision on a permanent basis, and if
this cannot be accomplished
administratively, the commenter
requested that we implement this
provision no earlier than July 1, 2008.
The commenter indicated that this delay
would allow the grandfathered
independent laboratories the
opportunity to implement new billing
requirements and inform customers of
this change.
Response: We will delay
implementation of this provision only if
legislation is enacted requiring a further
delay. Otherwise, we will, as explained
in the CY 2008 PFS proposed rule,
implement this provision effective for
TC services furnished on or after
January 1, 2008.
Comment: A commenter indicated a
potential problem in the preamble
language of the CY 2008 PFS proposed
rule that explains the implementation of
the TC physician pathology provision
effective January 1, 2008. In the CY 2008
PFS proposed rule, the preamble reads,
‘‘Consistent with this legislative change,
we are amending § 415.130(d) to reflect
that for services furnished after
December 31, 2007, an independent
laboratory may not bill the carrier for
physician pathology services furnished
to a hospital inpatient or outpatient’’ (72
FR 38205). As currently written, this
language would mean that the
independent laboratory cannot bill the
carrier for the PC of physician pathology
services for hospital patients, an
unintended result.
Response: The preamble inadvertently
omitted the term ‘‘technical
component’’ and should read, ‘‘For
E:\FR\FM\27NOR2.SGM
27NOR2
66356
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
services furnished after December 31,
2007, an independent laboratory may
not bill the carrier for the technical
component of physician pathology
services furnished to a hospital
inpatient or outpatient.’’ We proposed
this language in the regulations text of
the proposed rule and are finalizing this
language in this final rule with
comment period.
4. Section 201—Extension of Therapy
Cap Exception Process
Section 1833(g)(1) of the Act applies
an annual per beneficiary combined cap
beginning January 1, 1999, on outpatient
physical therapy and speech-language
pathology services, and a similar
separate cap on outpatient occupational
therapy services. These caps apply to
expenses incurred for the respective
therapy services under Medicare Part B,
with the exception of services furnished
as outpatient hospital services. Section
1833(g)(2) of the Act provides that, for
CY 1999 through CY 2001, the caps
were $1500, and for the calendar years
after 2001, the caps are equal to the
preceding year’s cap increased by the
percentage increase in the Medicare
Economic Index (MEI) (except that if an
increase for a year is not a multiple of
$10, it is rounded to the nearest
multiple of $10).
The cap for CY 2008 will be $1810 per
beneficiary for PT and SLP services
combined, and $1810 for OT services.
Therapy caps apply to expenses
incurred for therapy services in all
outpatient settings except the outpatient
hospital department. As explained
below in this section, the statute
requires that we implement the therapy
caps without providing for an
exceptions process beginning on
January 1, 2008.
Section 5107(a) of the DRA required
the Secretary to develop an exceptions
process for the therapy caps effective for
expenses incurred during CY 2006.
Details of the CY 2006 exceptions
process were published in a manual
change on February 13, 2006 (CR4364,
which consists of Transmittal 855,
Transmittal 47, and Transmittal 140).
Section 201 of the MIEA–TRHCA
extended the exceptions process to
apply for expenses incurred through
December 31, 2007. Therapy cap
exception policies for 2007 were
specified in Change Request 5478 which
consists of three transmittals with
current numbers of—
• Transmittal 1145CP, Pub. 100–04;
• Transmittal 63BP, Pub. 100–02; and
• Transmittal 181PI, Pub. 100–08.
The transmittals are incorporated into
the Internet Only Manuals available at
https://www.cms.hhs.gov/Manuals and
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
are also available on our Web site at
https://www.cms.hhs.gov/Transmittals/.
In accordance with the statute as
amended by the MIEA–TRHCA, we will
continue to implement therapy caps, but
the exceptions process will no longer be
applicable for expenses incurred for
services furnished beginning on January
1, 2008. As noted previously in this
section, under current law, therapy caps
will continue to apply to expenses
incurred for therapy services after
December 31, 2007, with one exception.
That is, in accordance with section
1833(g) of the Act, the therapy caps will
remain inapplicable to expenses
incurred for therapy services furnished
in the outpatient hospital setting.
We received several comments on this
proposal.
Comment: Most commenters
understood that we have no authority to
change therapy caps, but still
commented in favor of repealing them.
Some commenters supported the
continuation of the exceptions process
as a well-conceived method of
eliminating unnecessary treatment.
Some commenters objected to the
inapplicability of the caps for therapy
expenses incurred in the outpatient
hospital setting. One commenter
supported the repeal of therapy caps
and stated it is not an effective cost
control when a steady source of
replacement patients is available.
Another commenter opposed the
policy underlying the statutory
provision to apply a financial cap on
therapy services. The commenter cited
other means of ensuring appropriate
utilization of therapy services including
CCI edits, edits required by the Deficit
Reduction Act, local coverage
determination policies, and Transmittal
63, which required greater
documentation. The commenter
indicated that we are effectively
achieving the objective to assure
appropriate utilization of therapy
services without the financial caps.
Response: We do not have the
authority to repeal therapy caps, to
change the exception to applicability of
the caps for services provided in the
outpatient hospital setting, or to extend
the therapy cap exceptions process
beyond the period for which was made
applicable by statute (CYs 2006 and
2007).
Comment: Several commenters urged
CMS to implement the
recommendations contained in the
Computer Science Corporation (CSC)
Outpatient Therapy Service Pilot Report
of 2006 to collect patient-specific data
using available measurement tools.
Although they acknowledged that we
may have concerns about the use of
PO 00000
Frm 00136
Fmt 4701
Sfmt 4700
proprietary tools, the commenter urged
the use of therapy-specific tools already
on the market that were recommended
by both CSC and MedPAC, including
the National Outcomes Measurement
System.
Response: In evaluating alternative
payment systems, we will consider all
methods of obtaining the required
patient-related information including
reports of past and future contract
deliverables.
Comment: Many commenters are
deeply concerned about the negative
impact the caps would have, in the
absence of the exceptions process, on an
estimated 14.5 percent of the physical
therapy (PT) users who would exceed
the cap. The commenters commended
CMS for progress made toward
alternatives to the financial caps in
recent years and urged a high priority in
resources and funding to continuing
research to identify alternatives that
would also ensure access to medically
necessary therapy services. The
commenters support the collection of
patient outcome data with patient
assessment tools and use of risk
adjustment to account for individual
differences. They support the ongoing
study for which CMS recently issued a
Request for Task Order (RTOP–CMS–
07–033) and look forward to
participating in the study.
Many commenters reported that they
will be collecting and reporting outcome
data before January 1, 2008. They urged
CMS to use clinical outcome data to
determine the amount of care needed by
individuals and offered assistance in
data collection.
Response: We recently issued a
request for proposals (RTOP–CMS–07–
033) to continue our study of therapy
services. The study will: (1) Identify,
collect and use therapy-related
information that is tied to beneficiary
needs and treatment effectiveness; and
(2) develop payment method
alternatives to the current cap on
outpatient therapy services.
We welcome any information
concerning clinical outcome data
studies from providers or suppliers. If
the information is applicable to our
deliberations on payment alternatives,
we will consider it along with the
results of past and future contract
deliverables.
Comment: One commenter
recommended that we continue to
collect outpatient therapy utilization
information for 2006 and 2007.
Response: We contracted with the
CSC (HHSM–500–2007–00322G) to
extract 2006 therapy utilization data and
provide a high level analysis. To the
extent possible, we intend to further
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
study the impact of therapy caps
including the 2006 exceptions process.
5. Section 101(d)—Physician Assistance
and Quality Initiative (PAQI) Fund
Section 1848(l) of the Act, as added
by section 101(d) of the MIEA–TRHCA
requires the Secretary to establish a
Physician Assistance and Quality
Initiative (PAQI) Fund (the Fund) which
shall be available for physician payment
and quality improvement initiatives,
and which may include application of
an adjustment to the update of the PFS
conversion factor (CF). The provision
makes available $1.35 billion to the
Fund for services furnished during CY
2008. Specifically, the provision directs
the Secretary to provide for
expenditures from the Fund in a manner
designed to provide (to the maximum
extent feasible) for the obligation of the
entire $1.35 billion for payment for
physicians’ services furnished during
CY 2008. The provision also requires
that if expenditures from the Fund are
applied to, or otherwise affect, a CF for
a year, the CF for a subsequent year
shall be computed as if the adjustment
to the CF had never occurred. We note
that the Transitional Medical
Assistance, Abstinence Education, and
Qualifying Individual Programs
Extension Act of 2007 (Pub. L. 110–90)
recently was signed into law and it
provides an additional $325 million to
be used as a part of the PAQI Fund for
payment with regard to services
furnished in 2009 and $60 million for
payment for physicians’ services
furnished on or after January 1, 2013.
The legislation does not make any other
changes to the program, and therefore,
remains as discussed in the proposed
rule.
As the MIEA–TRHCA legislation
indicates, this Fund can be used for
physician payment and quality
improvement, including application of
an adjustment to the update of the
conversion factor. In the CY 2007 PFS
proposed rule, we proposed to use the
$1.35 billion to fund bonus payments to
be made during CY 2009 for physician
reporting of measures during CY 2008.
Specifically, we proposed that the
physician quality initiative for CY 2008
be structured and implemented in the
same manner as the 2007 PQRI with
regard to the professionals eligible to
participate in the program, reporting
quality measures via claims submission,
and the standards for satisfactory
reporting.
The differences between CY 2007 and
CY 2008 that we currently anticipate are
noted below in this section. As we
monitor the implementation of the 2007
PQRI and possibly make refinements to
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the 2007 program, we anticipate that
such refinements would also apply
under the 2008 program. Such
refinements, should they be needed,
will be noted with guidance linked from
the CMS quality reporting Web site at
https://www.cms.hhs.gov/PQRI.
As with the 2007 PQRI, we proposed
that eligible professionals who
successfully report a designated set of
quality measures in 2008 may earn a
bonus payment of a percentage of total
allowed charges for covered Medicare
services, subject to a cap based on the
volume of quality reporting. In contrast
to 2007, we proposed that eligible
professionals could report applicable
measures for services furnished from
January 1, 2008 through December 31,
2008, and allowed charges during such
period would be the basis for
calculating the bonus payments. We
proposed that the CY 2008 measures
that we finalize in this final rule with
comment period would apply for CY
2008. We also proposed to estimate all
of the bonus payments that would be
payable to physicians using the same
method as the one used for reporting
during 2007 and to calculate the amount
of the bonus payment, after the close of
CY 2008 reporting period. Given that we
proposed to use the PAQI Fund for the
2008 PQRI program, we also proposed
that the bonus payments to individual
physicians be subject to an aggregate
cap of $1.35 billion. Because we
proposed to scale aggregate payments to
physicians in a manner such that
Medicare would pay $1.35 billion
during CY 2009 for measures reported
for services furnished during CY 2008,
we were unable to provide an exact
percentage for the bonus payment.
However, we anticipated that the bonus
payments would be approximately 1.5
percent of allowed charges for
participating professionals (and we did
not expect that the ultimate percentage
amount would exceed 2 percent).
Comment: Comments received on the
proposed rule were generally opposed
to using the PAQI Fund for CY 2008
PQRI bonus payments. Almost all
comments on this issue requested that
we use the entire $1.35 billion to help
offset the estimated negative 9.9 percent
physician update for CY 2008.
Response: In the CY 2007 PFS
proposed rule, we acknowledged this
alternative approach of using the $1.35
billion in some manner to reduce the
update to the PFS of negative 9.9
percent that is projected for CY 2008.
However, we noted that there are
fundamental operational problems with
this approach that make it not feasible.
The $1.35 billion is a fixed dollar
amount. Once the amount is reached,
PO 00000
Frm 00137
Fmt 4701
Sfmt 4700
66357
there is no authority to pay any more
than that amount. Medicare is an
entitlement program that covers
medically necessary services for eligible
beneficiaries, but such coverage is not
limited to a fixed dollar amount for a
year. While we estimate that the $1.35
billion would reduce the negative
update by approximately 2 percentage
points, actual spending could be above
or below the estimate. To insure that we
do not exceed the Fund amount, we
would have to estimate an amount to
reduce the update by that is low enough
to ensure the $1.35 billion funding cap
is not exceeded. While this approach
might reduce the CY 2008 negative
update, it could still leave money in the
Fund. We are concerned that there may
be potential oversight or other legal
consequences in the event that we
significantly exceed the Fund or do not
apply the entire Fund. Therefore, we
believe the best use of the Fund is to
apply it to extend PQRI into CY 2008.
Comment: Commenters asserted that
use of the PAQI Fund for anything other
than the physician update was
inconsistent with Congressional intent.
Commenters cited TRHCA language that
the Fund ‘‘may include application of
an adjustment to the update of the
conversion factor.’’ Commenters further
noted that this use must have been
Congressional intent, since the
legislation includes explicit language of
how to deal with the update in
subsequent years when the Fund is used
towards the update: ‘‘[I]n the case that
expenditures from the Fund are applied
to, or otherwise affect, a conversion
factor * * * the conversion factor under
such subsection shall be computed for
a subsequent year as if such application
or effect had never occurred.’’
Many commenters cited the
Congressional Budget Office’s cost
estimate for the TRHCA legislation,
which anticipated CMS developing a
plan to use approximately 90 percent of
the Fund in CY 2008 and the remaining
funds in CY 2009. These comments
cited section 101(d) of the MIEA–
TRHCA, where the Congress stated that
the Fund should be used ‘‘to the
maximum extent feasible’’ for
physicians’ services during CY 2008,
interpreting Congressional intent to be
that CMS do its best to distribute most
of the money in CY 2008, and any
remaining monies in CY 2009.
Commenters rejected the rationale
that there were serious legal and
operational barriers to applying the
PAQI Fund to the physician update;
they expressed confidence that we
could find some way to use the Fund to
offset the reduction.
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66358
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Further, commenters noted that it was
within our discretion to apply the PAQI
Fund to the physician update, and they
were highly critical of our
unwillingness to take administrative
steps to mitigate the negative 9.9
percent physician update.
Response: Section 101(d) of the
MIEA–TRHCA directs the Secretary to
establish a PAQI Fund to be available to
the Secretary for physician payment and
quality improvement initiatives, which
may include application of an
adjustment to the update of the CF
under that subsection. The legislation
clearly indicates that the Secretary has
the discretion to use the Fund for
physician payment and quality
improvement initiatives, including
application of an adjustment to the
update of the conversion factor.
However, we are not required to use the
funds for the update.
As noted above, there are
fundamental operational problems with
applying the PAQI Fund to the
conversion factor update. We are
concerned that there may be potential
oversight or other legal consequences in
the event the Agency significantly
exceeds the Fund or does not apply the
entire Fund. For the reasons previously
discussed, we believe it is in the best
interests of the program to apply this
Fund to the extension of PQRI.
Comment: Commenters rejected the
notion that use of the $1.35 billion to
fund the CY 2008 PQRI is the best way
to insure physicians get the greatest
benefit from the PAQI Fund’s resources.
Commenters stated that the PQRI does
not provide all physicians with an
opportunity to participate and that
many specialties treat patients with
conditions for which PQRI measures do
not apply. In contrast, using the Fund to
offset the negative update for CY 2008
would benefit all physicians.
Response: Medicare payment systems
need to encourage reliable, high quality
and efficient care, rather than making
payment simply based on the quantity
of services provided and resources
consumed. Applying the $1.35 billion to
PQRI bonuses allows CMS to further the
goal of improving quality and efficiency
by utilizing the infrastructure that both
physicians and Medicare have invested
in for the CY 2007 PQRI. We believe
implementing this Fund through an
extension of the PQRI program is the
best way to ensure that the Fund is
being used to increase quality and
efficiency of care for Medicare
beneficiaries.
Comment: Commenters rejected the
notion that using the PAQI Fund for
bonuses would improve quality. For
most physicians, the proposed
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
estimated 1.5 percent bonus payment is
insufficient to cover the costs to
institute such quality reporting
measures. Commenters noted that if
CMS truly wished to encourage more
providers to participate in the PQRI,
‘‘new money’’ must be found to fund the
initiative. Commenters suggested
bonuses between 5 and 10 percent of
allowed charges would more reasonably
cover the costs of improving their
infrastructure to appropriately report
quality measures.
Response: Funding the PQRI is
consistent with the goal of improving
quality and efficiency in Medicare.
Eligible professional can participate in
the PQRI by reporting the appropriate
quality measure data on claims
submitted to their Medicare claims
processing contractor. We provide
educational resources on the PQRI Web
site that allow eligible professionals to
integrate PQRI reporting into their care
delivery process without significant
changes in their infrastructures.
We appreciate the desire of eligible
professionals to improve their
infrastructure to better track quality of
care. For many eligible professionals,
such infrastructure is already in place
for PQRI and will not require additional
investment. However, we note that PQRI
bonuses are financial incentives to
participate in a voluntary quality
reporting program and were not
intended to cover the costs of
significantly improving the
infrastructure of eligible professionals.
Comment: Many commenters noted
that the PQRI has not been proven to
have any positive effect on patient care
or health outcomes. Rather than
utilizing the $1.35 billion to support an
unproven program, it would be better to
directly improve physician
reimbursement and better cover the
costs of the necessary care they are
currently providing to beneficiaries.
Response: The PAQI Fund was made
available to the Secretary for physician
payment and quality improvement
initiatives. We are actively engaged with
the physician community in identifying
ways to align Medicare’s physician
payment system with the goals of health
professionals for high-quality care.
Using the PAQI Fund to pay for the
PQRI aligns reimbursement with quality
and efficiency. We have worked
collaboratively with the physician
community to develop measures that
capture the quality of care being
provided to our Medicare beneficiaries.
The PQRI encourages physicians to
provide the type of care that is best
suited for our beneficiaries: Care
focused on prevention and treating
complications; and care focused on the
PO 00000
Frm 00138
Fmt 4701
Sfmt 4700
most effective, proven treatments
available.
We acknowledge the relative newness
of the PQRI. To that end, we are
committed to continue working with the
physician community in an open and
transparent way to insure that the PQRI
supports the best approaches to provide
high quality health care services.
Comment: Commenters noted that
Congressional intent was to provide
some relief and stability to the
physician payment system during CY
2008. However, under the terms of the
proposed rule, CMS cannot let
physicians know the amount of the
reporting bonus until well after the
close of the CY 2008 reporting period,
and physicians would not receive
bonuses until some time in CY 2009.
Response: Section 101(d) of the
MIEA–TRHCA charges the Secretary
with a timely obligation of all available
funds for services furnished during CY
2008, directing the Secretary to provide
for expenditures from the Fund in a
manner designed to provide (to the
maximum extent feasible) for the
obligation of the entire $1.35 billion for
physicians’ services furnished during
CY 2008. Although the legislation is
clear that payment of the Fund is based
on services furnished during CY 2008,
the legislation does not limit the
Secretary to paying from the PAQI Fund
during CY 2008.
Comment: One commenter stated that
quality payments should not be
geographically adjusted. The commenter
suggested that PQRI payments should be
based on RVUs, not allowed charges.
Response: Section 101(c) of MIEA–
TRHCA authorizes a financial incentive
for eligible professionals to participate
in a voluntary quality reporting
program. Eligible professionals, who
choose to participate and successfully
report on a designated set of quality
measures for services paid under the
Medicare Physician Fee Schedule and
provided between July 1 and December
31, 2007, may earn a bonus payment of
1.5 percent of their allowed charges
during that period, subject to a cap. In
the CY 2008 PFS proposed rule (72 FR
38206), we proposed that the physician
quality initiative for CY 2008 be
structured and implemented in the same
manner as the 2007 PQRI, as described
above. This includes calculating the
amounts of the 2008 bonus payments
based upon a percentage of allowed
charges, as was statutorily required for
2007 bonus payments. By definition,
allowed charges include the
geographical adjustments in payments,
as determined by the geographic
practice cost indices (GPCIs), which
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
reflect the variation in practice costs
from area to area.
2. Medicare Regulations for Ambulance
Services
III. Revisions to the Payment Policies of
Ambulance Services Under the Fee
Schedule for Ambulance Services;
Ambulatory Inflation Factor Update for
CY 2007
Our regulations relating to ambulance
services are set forth at 42 CFR part 410,
subpart B and 42 CFR part 414, subpart
H. Section 410.10(i) lists ambulance
services as one of the covered medical
and other health services under
Medicare Part B. Therefore, ambulance
services are subject to basic conditions
and limitations set forth at § 410.12 and
to specific conditions and limitations as
specified in § 410.40. Part 414, subpart
H, describes how payment is made for
ambulance services covered by
Medicare.
As discussed in the CY 2008 PFS
proposed rule (72 FR 38207), under the
ambulance fee schedule, the Medicare
program pays for transportation services
for Medicare beneficiaries when other
means of transportation are
contraindicated. Ambulance services are
classified into different levels of ground
(including water) and air ambulance
services based on the medically
necessary treatment provided during
transport. These services include the
following levels of service:
For Ground—
• Basic Life Support (BLS).
• Advanced Life Support, Level 1
(ALS1).
• Advanced Life Support, Level 2
(ALS2).
• Specialty Care Transport (SCT).
• Paramedic ALS Intercept (PI).
For Air—
• Fixed Wing Air Ambulance (FW).
• Rotary Wing Air Ambulance (RW).
cprice-sewell on PROD1PC72 with RULES
A. History of Medicare Ambulance
Services
1. Statutory Coverage of Ambulance
Services
Under sections 1834(l) and 1861(s)(7)
of the Act, Medicare Part B covers and
pays for ambulance services, to the
extent prescribed in regulations, when
the use of other methods of
transportation would be contraindicated
by the beneficiary’s medical condition.
The House Ways and Means Committee
and Senate Finance Committee Reports
that accompanied the 1965 Social
Security Amendments suggest that the
Congress intended that—
• The ambulance benefit cover
transportation services only if other
means of transportation are
contraindicated by the beneficiary’s
medical condition; and
• Only ambulance service to local
facilities be covered unless necessary
services are not available locally, in
which case, transportation to the nearest
facility furnishing those services is
covered (H.R. Rep. No. 213, 89th Cong.,
1st Sess. 37 and Rep. No. 404, 89th
Cong., 1st Sess. Pt 1, 43 (1965)).
The reports indicate that
transportation may also be provided
from one hospital to another, to the
beneficiary’s home, or to an extended
care facility.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
3. Transition to National Fee Schedule
The national fee schedule for
ambulance services was phased in over
a 5-year transitional period beginning
April 1, 2002, as specified in § 414.615.
As of January 1, 2006, the total payment
amount for air ambulance providers and
suppliers is based on 100 percent of the
national ambulance fee schedule. In
accordance with section 414 of the
MMA, we added § 414.617 which
specifies that for ambulance services
furnished during the period July 1,
2004, through December 31, 2009, the
ground ambulance base rate is subject to
a floor amount, which is determined by
establishing nine fee schedules based on
each of the nine census divisions, and
using the same methodology as was
used to establish the national fee
schedule. If the regional fee schedule
methodology for a given census division
results in an amount that is lower than
or equal to the national ground base
rate, then it is not used, and the national
fee schedule amount applies for all
providers and suppliers in the census
division. If the regional fee schedule
methodology for a given census division
results in an amount that is greater than
the national ground base rate, then the
fee schedule portion of the base rate for
that census division is equal to a blend
of the national rate and the regional rate
through CY 2009. Thus, as of January 1,
2007, the total payment amount for
ground ambulance providers and
suppliers is based on either 100 percent
of the national ambulance fee schedule
amount, or a combination of 80 percent
of the national ambulance fee schedule
and 20 percent of the regional
ambulance fee schedule.
B. Ambulance Inflation Factor (AIF)
During the Transition Period
As we noted in the previous section,
the national fee schedule for ambulance
services was phased in over a 5 year
transition period beginning April 1,
2002, as specified in § 414.615. During
PO 00000
Frm 00139
Fmt 4701
Sfmt 4700
66359
the transition period, the ambulance
inflation factor (AIF) was applied
separately to both the fee schedule
portion of the blended payment amount
(regardless of whether a national or
regional fee schedule applied) and to
the supplier’s reasonable charge or
provider’s reasonable cost portion of the
blended payment amount, respectively,
for each ambulance provider or
supplier. Then, the two amounts were
added together to determine the total
payment amount for each provider or
supplier.
C. Ambulance Inflation Factor (AIF) for
CY 2008
Section 1834(l)(3)(B) of the Act
provides the basis for updating payment
amounts for ambulance services.
Section 414.610(f) specifies that certain
components of the ambulance fee
schedule are updated by the AIF
annually, based on the consumer price
index for all urban consumers (CPI–U)
(U.S. city average) for the 12-month
period ending with June of the previous
year. In the CY 2008 PFS proposed rule,
we stated the AIF for CY 2008 would be
announced as part of this final rule with
comment period. For CY 2008, the
percentage is 2.7 percent. In addition, as
set forth in Section III.D., we also
proposed to announce the AIF for CY
2009 and subsequent years via CMS
instruction and on the CMS Web site.
D. Revisions to the Publication of the
Ambulance Fee Schedule (§ 414.620)
Currently, § 414.620 specifies that
changes in payment rates resulting from
incorporation of the AIF will be
announced by notice in the Federal
Register without opportunity for prior
comment. As explained in the CY 2008
PFS proposed rule, we believe it is
unnecessary to undertake notice and
comment rulemaking to update the AIF
because the statute and regulations
specify the methods of computation of
annual inflation updates, and we have
no discretion in that matter. Thus, the
annual AIF notice does not change or
establish policy, but merely applies the
update methods specified in the statute
and regulations.
As discussed in the proposed rule, by
mid-July of each year, we have the CPI–
U for the 12-month period ending with
June of such year. Therefore, we know
what the AIF for the upcoming calendar
year will be by mid-July of each year.
However, § 414.620 currently states that
the AIF will be announced in the
Federal Register. Each document
published in the Federal Register
requires scheduling and a thorough
review by CMS, HHS, and OMB prior to
publication. Therefore, even though we
E:\FR\FM\27NOR2.SGM
27NOR2
66360
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
know the AIF by mid-July of each year,
the final rule announcing the AIF is not
published until November. This
publication timeframe does not allow
Medicare contractors the optimal
amount of time to update their systems
to implement the proper payment for
Medicare ambulance claims by January
1 of the coming year. In addition, it does
not provide an optimal amount of time
for either the Medicare contractors or
the ambulance industry to take
advantage of testing systems to make
sure that the update is working properly
as implemented. We believe that
announcing the AIF via CMS
instructions and on the CMS Web site
would enable the AIF to be released
earlier in the calendar year, allowing the
Medicare contractors to test their data
systems, and to timely effectuate and
provide accurate payments on Medicare
ambulance claims.
Therefore, we proposed to revise
§ 414.620 to state that we will announce
the AIF via CMS instruction and on the
CMS Web site and to remove the
language that states that we will
announce the AIF by notice in the
Federal Register.
Comment: Comments received
regarding the issue of announcing the
AIF via CMS instruction and on the
CMS Web site were very supportive of
this proposal.
Response: As we proposed, we are
revising § 414.620 to state that CMS will
announce the AIF via CMS instruction
and on the CMS Web site, and to
remove the language that states that we
will announce the AIF by notice in the
Federal Register.
IV. Refinement of RVUs for CY 2008
and Response to Public Comments on
Interim RVUs for 2007
[If you choose to comment on issues
in this section, please include the
caption ‘‘Interim Relative Value Units’’
at the beginning of your comments.]
cprice-sewell on PROD1PC72 with RULES
A. Summary of Issues Discussed Related
to the Adjustment of Relative Value
Units
Section IV.B. and IV.C. of this final
rule with comment describes the
methodology used to review the
comments received on the RVUs for
physician work, including the
additional codes from the 5-Year
Review of work RVUs, and the process
used to establish RVUs for new and
revised CPT codes. Changes to the RVUs
and billing status codes reflected in
Addendum B are effective for services
furnished beginning January 1, 2008.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
B. Process for Establishing Work
Relative Value Units for the Physician
Fee Schedule
The CY 2007 PFS final rule with
comment period (71 FR 69624)
contained the work RVUs for Medicare
payment for existing procedure codes
under the PFS and interim RVUs for
new and revised codes beginning
January 1, 2007. We considered the
RVUs for the interim codes to be subject
to public comment under the annual
refinement process. In the CY 2008 PFS
proposed rule we also proposed work
RVUs for additional codes from the 5Year Review of work RVUs. In this
section, we address comments and
summarize the refinements to the
additional codes from the 5-Year
Review of work RVUs, the interim work
RVUs published in the CY 2007 PFS
final rule with comment period, and our
establishment of the work RVUs for new
and revised codes for the CY 2008 PFS.
C. 5-Year Review of Work RVUS
1. Additional Codes From the 5-Year
Review of Work RVUs
The CY 2008 PFS proposed rule (72
FR 38146) discussed the RUC
recommendations on work RVUs for a
number of codes from the 5-Year
Review that were deferred from the CY
2007 PFS rulemaking and listed the
specific codes in Table 10. We proposed
to accept all of the RUC
recommendations, with the exception of
CPT code 93325, Doppler
echocardiography color flow velocity
mapping (List separately in addition to
codes for echocardiography), which we
proposed to bundle. We also noted that
CPT codes 92557, 92567, 92568, 92569,
92579, 92601, 92602, 92603 and 92604
previously had no work RVUs assigned
to them.
Many commenters expressed support
for our proposed valuations of many of
the services. However, other
commenters expressed specific concern
or disagreement with the proposed
valuation of approximately 17 codes.
To evaluate these comments, we used
a process similar to the process used
since 1997. (See the CY 1998 PFS final
rule published in the October 31, 1997
Federal Register (62 FR 59084) for the
discussion of refinement of CPT codes
with interim work RVUs.) We convened
a multi specialty panel of physicians to
assist us in the review of the comments.
The comments that we did not submit
to panel review are discussed at the end
of this section, as well as those that
were reviewed by the panel, which are
contained in Table 14: Work RVU
Revisions for Additional 5-Year Review
Codes. We invited representatives from
PO 00000
Frm 00140
Fmt 4701
Sfmt 4700
the organizations from which we
received substantive comments to
attend a panel for discussion of the code
on which they had commented. The
panel was moderated by our medical
staff, and consisted of the following
voting members:
• Clinicians representing the
commenting specialty(ies), based on our
determination of those specialties which
are most identified with the services in
question. Although commenting
specialties were welcomed to observe
the entire refinement process, they were
only involved in the discussion of those
services for which they were invited to
participate.
• Primary care clinicians nominated
by the AAFP and the American College
of Physicians.
• Carrier Medical Directors.
• Clinicians who practice in related
specialties and have knowledge of the
services under review.
The panel discussed the work
involved in the procedure under review
in comparison to the work associated
with other services under the PFS. We
assembled a set of reference services
and asked the panel members to
compare the clinical aspects of the work
for the service a commenter believed
was incorrectly valued to one or more
of the reference services. In compiling
the reference set, we attempted to
include: (1) Services that are commonly
furnished for which work RVUs are not
controversial; (2) services that span the
entire spectrum of work intensity from
the easiest to the most difficult; and (3)
at least three services furnished by each
of the major specialties so that each
specialty would be represented. The
intent of the panel process was to
capture each participant’s independent
judgment based on the discussion and
his or her clinical experience. Following
the discussion for each service, each
participant rated the work for that
procedure. Ratings were individual and
confidential; there was no attempt to
achieve consensus among the panel
members.
We then analyzed the ratings based on
a presumption that the interim RVUs
were correct. To overcome that
presumption, the inaccuracy of the
interim RVUs had to be apparent to the
broad range of physicians participating
in each panel.
Ratings of work were analyzed for
consistency among the groups
represented on each panel. In general
terms, we used statistical tests to
determine whether there was enough
agreement among the groups on the
panel and, if so, whether the agreedupon work RVUs were significantly
different from the proposed work RVUs
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
in the CY 2008 PFS proposed rule to
demonstrate that the proposed work
RVUs should be modified. We did not
modify the work RVUs unless there was
a clear indication for a change. If there
was agreement across groups for change,
but the groups did not agree on what the
new work RVUs should be, we
eliminated the outlier group, and looked
for agreement among the remaining
groups as to the basis for new work
RVUs. We used the same methodology
in analyzing the ratings that we first
used in the refinement process for the
CY 1993 PFS final rule published in the
November 25, 1992 Federal Register
which described the statistical tests in
detail (57 FR 55938). Our decision to
convene a multi-specialty panel of
physicians and to apply the statistical
tests described above in this section was
based on our need to balance the
interests of those who commented on
the work RVUs against the redistributive
effects that would occur in other
specialties.
Table 14 lists the additional codes for
the 5-Year Review on which we
received comments. This table includes
the following information:
• CPT/HCPCS Code. This is the CPT
or alphanumeric HCPCS code for a
service.
• Modifier. A modifier 26 is shown if
the work RVUs represent the
professional component (PC) of the
service.
• Description. This is an abbreviated
version of the narrative description of
the code.
• Proposed Work RVUs. This column
includes the work RVUs proposed in the
66361
CY 2008 PFS proposed rule for each
reviewed code.
• Requested Work RVUs. This
column identifies the work RVUs
requested by the commenters. If the
commenters requested different RVUs,
the table lists the highest requested
RVUs.
• RUC Recommendation. This
column identifies the work RVUs
recommended by the RUC that appeared
in the CY 2008 PFS proposed rule.
• 2008 Work RVUs. This column
contains the work RVUs for the CY 2008
PFS.
• Basis for Decision. This column
indicates whether the CY 2008 work
RVUs resulted from comments received
or the refinement panel process.
TABLE 14.—WORK RVU REVISIONS FOR ADDITIONAL 5-YEAR REVIEW CODES
CPT/HCPCS
code 1
92557
92579
99326
99327
99328
99334
99335
99336
99337
99343
99344
99345
99347
99348
99349
99350
93325
1 All
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
Descriptor
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
Comprehensive hearing test
Visual audiometry (vra) ........
Domicil/r-home visit new pat
Domicil/r-home visit new pat
Domicil/r-home visit new pat
Domicil/r-home visit est pat ..
Domicil/r-home visit est pat ..
Domicil/r-home visit est pat ..
Domicil/r-home visit est pat ..
Home visit, new patient ........
Home visit, new patient ........
Home visit, new patient ........
Home visit, est patient ..........
Home visit, est patient ..........
Home visit, est patient ..........
Home visit, est patient ..........
Doppler color flow add-on ....
Work RVUs
requested by
commenters
0.60
0.70
2.27
3.03
3.78
0.76
1.26
2.02
3.03
2.27
3.03
3.78
0.76
1.26
2.02
3.03
0.07
RUC rec
1.40
1.70
2.85
3.75
4.26
1.25
2.00
2.75
4.05
2.65
3.60
4.26
1.10
1.70
2.50
3.45
0.30
0.60
0.70
2.27
3.03
3.78
0.76
1.26
2.02
3.03
2.27
3.03
3.78
0.76
1.26
2.02
3.03
CPT
2008 work
RVU
0.60
0.70
2.63
3.46
4.09
1.07
1.72
2.46
3.58
2.53
3.38
4.09
1.00
1.56
2.33
3.28
0.07
Basis for decision
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Refinement.
Comments.
CPT codes and descriptors copyright 2007 American Medical Association.
Discussion of Comments by Clinical
Area
cprice-sewell on PROD1PC72 with RULES
Proposed work
RVU
Mod
For CPT code 92557, Comprehensive
audiometry threshold evaluation and
speech recognition, and CPT code
92579, Visual reinforcement audiometry
(VRA), the RUC recommended 0.60
work RVUs for CPT 92557 and 0.70
work RVUs for CPT code 92579, which
we accepted.
Comment: Commenters disagreed
with the RUC-recommended work
values for these services, which we had
accepted. The commenters believed that
the recommended values were not
appropriate considering the time and
intensity involved in performing these
services. Based on these comments, we
referred these codes to the multispecialty validation panel for review.
Response: As a result of the statistical
analysis of the 2007 multi-specialty
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
validation panel ratings, we have
assigned 0.60 work RVUs to CPT code
92557 and 0.70 work RVUs to CPT code
92579.
For CPT code 99326, Domiciliary or
rest home visit for the evaluation and
management of a new patient, which
requires these three key components: A
detailed history; a detailed examination;
and medical decision making of
moderate complexity; CPT code 99327,
Domiciliary or rest home visit for the
evaluation and management of a new
patient, which requires these three key
components: A comprehensive history;
a comprehensive examination; and
medical decision making of moderate
complexity; CPT code 99328,
Domiciliary or rest home visit for the
evaluation and management of a new
patient, which requires these three key
components: A comprehensive history;
a comprehensive examination; and
PO 00000
Frm 00141
Fmt 4701
Sfmt 4700
medical decision making of high
complexity; CPT code 99334,
Domiciliary or rest home visit for the
evaluation and management of an
established patient, which requires at
least two of these three key components:
A problem focused interval history; a
problem focused examination;
straightforward medical decision
making; CPT code 99335, Domiciliary or
rest home visit for the evaluation and
management of an established patient,
which requires at least two of these
three key components: An expanded
problem focused interval history; an
expanded problem focused
examination; medical decision making
of low complexity; CPT code 99336,
Domiciliary or rest home visit for the
evaluation and management of an
established patient, which requires at
least two of these three key components:
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66362
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
A detailed interval history; a detailed
examination; medical decision making
of moderate complexity; CPT code
99337, Domiciliary or rest home visit for
the evaluation and management of an
established patient, which requires at
least two of these three key components:
A comprehensive interval history; a
comprehensive examination; and
medical decision making of moderate to
high complexity; CPT code 99343, Home
visit for the evaluation and management
of a new patient, which requires these
three key components: A detailed
history; a detailed examination; and
medical decision making of moderate
complexity; CPT code 99344, Home visit
for the evaluation and management of
a new patient, which requires these
three components: A comprehensive
history; a comprehensive examination;
and a medical decision making of
moderate complexity; CPT code 99345,
Home visit for the evaluation and
management of a new patient, which
requires these three key components: A
comprehensive history; a
comprehensive examination; and
medical decision making of high
complexity; CPT code 99347, Home visit
for the evaluation and management of
an established patient, which requires at
least two of these three key components:
A problem focused interval history; a
problem focused examination;
straightforward medical decision
making; CPT code 99348, Home visit for
the evaluation and management of an
established patient, which requires at
least two of these three key components:
A problem focused interval history; a
problem focused examination;
straightforward medical decision
making; CPT code 99349, Home visit for
the evaluation and management of an
established patient, which requires at
least two of these three key components:
A detailed interval history; a detailed
examination; medical decision making
of moderate complexity; and CPT code
99350, Home visit for the evaluation
and management of an established
patient, which requires at least tow of
these three key components: A
comprehensive interval history; a
comprehensive examination; medical
decision making of moderate to high
complexity, the RUC recommended that
the work RVUs for these codes be
maintained at their current values: 2.27
work RVUs for CPT code 99326; 3.03
work RVUs for CPT code 99327; 3.78
work RVUs for CPT code 99328; 0.76
work RVUs for CPT code 99334; 1.26
work RVUs for CPT code 99335; 2.02
work RVUs for CPT code 99336; 3.03
work RVUs for CPT code 99337; 2.27
work RVUs for CPT code 99343; 3.03 for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
CPT code 99344; 3.78 work RVUs for
CPT code 99345; 0.76 work RVUs for
CPT code 99347; 1.26 work RVUs for
CPT code 99348; 2.02 work RVUs for
CPT code 99349; and 3.03 work RVUs
for CPT code 99350, which we accepted.
Comment: Commenters disagreed
with the RUC-recommended work
values for these services, which we had
accepted. The commenters disagreed
with the RUC-recommended work RVUs
and believed the services were
undervalued. The commenters also
believed that the home visit work RVUs
should remain ‘‘relatively’’ the same
with respect to office visit codes as they
did prior to the five-year review and
requested that CMS reject the RUC
recommended work RVUs and follow
their survey values. Based on these
comments, we referred these codes to
the multi-specialty validation panel for
review.
Response: As a result of the statistical
analysis of the 2007 multi-specialty
validation panel ratings, we have
assigned 2.63 work RVUs to CPT code
99326; 3.46 work RVUs to CPT code
99327; 4.09 work RVUs to CPT code
99328; 1.07 work RVUs to CPT code
99334; 1.72 work RVUs to CPT code
99335; 2.46 work RVUs to CPT code
99336; 3.58 work RVUs to CPT code
99337; 2.53 work RVUs to CPT code
99343; 3.38 work RVUs to CPT code
99344; 4.09 work RVUs to CPT code
99345; 1.00 work RVUs to CPT code
99347; 1.56 work RVUs to CPT code
99348; 2.33 work RVUs to CPT code
99349; and 3.28 work RVUs to CPT code
99350.
For CPT code 93325, Doppler
echocardiography color flow velocity
mapping (List separately in addition to
codes for echocardiography), the RUC 5Year Review workgroup recommended
sending the code to the CPT Editorial
Panel so that it could bundle CPT code
93325 into doppler echo code 93307.
However, we believe that the technology
of doppler imaging has evolved over the
past 2 decades to enable color flow
velocity and spectral analysis, both
important components of doppler
imaging, to be furnished concurrently or
in concert to obtain more accurate
interpretation and documentation of the
anatomy and physiologic function of the
structure(s) and organ being evaluated.
Since the services described in 93325
have become intrinsic to the
performance of other echocardiography
services, we proposed to bundle 93325
into CPT codes 76825, 76826, 76827,
76828, 93303, 93304, 93307, 93308,
93312, 93314, 93315, 93317, 93320,
93321, 93350 and assign CPT code
93325 a status indicator of ‘‘B’’
(Bundled).
PO 00000
Frm 00142
Fmt 4701
Sfmt 4700
Comment: Commenters uniformly
opposed this proposal. They did not
support the bundling of CPT codes
93325 into all of the codes we proposed.
The commenters would prefer for CMS
to adopt the new CPT code and not
bundle CPT code 93325 with any other
codes with CPT code 93325. The
commenters believed we are
circumventing the existing process to
address bundling of these services and
we should follow that process.
Alternatively, the commenters believed
that if we must bundle the codes, then
we should increase the RVUs for the
codes in which CPT code 93325 is being
bundled to recognize the work, PE, and
malpractice components that are unique
to CPT code 93325.
Response: Based on comments
received, we have decided to accept the
RUC recommendation and allow the
RUC to value the new CPT code for CY
2009 for bundling CPT code 93325 with
CPT codes 93320 and 93307. As a result
of this decision, the work RVUs for CPT
code 93325 will be maintained for CY
2008 at the 2007 work value of 0.07. The
cardiology community has indicated to
the RUC and CMS that the newly
bundled CPT code represents the first of
a series of coding changes they intend
to propose over the course of the next
year. These changes would result in the
bundling of CPT code 93325 and other
echocardiography codes to reflect the
utilization of ultrasound services that
are routinely performed together when
providing care to a patient. We
appreciate the initiative the cardiology
community is taking on this issue, and
we will reassess the echocardiography
codes once this process is complete.
2. Anesthesia Coding (Part of 5-Year
Review)
Although anesthesia services are paid
under the PFS, under section
1848(b)(2)(B) of the Act, they are paid
on the basis of an anesthesia code
specific base unit and time units that
vary based on the actual anesthesia time
of the case. Since anesthesia services do
not have a work RVU per code as do
other medical and surgical services, a
work value must be imputed for each
anesthesia code. The imputed value is
determined by multiplying the national
average allowed charge for each
anesthesia service by its anesthesia
work share and dividing this amount by
the general PFS conversion factor (CF).
This places the work of the anesthesia
service on the same relative value scale
as all other physicians’ services.
As discussed in the CY 2008 PFS
proposed rule, in the second 5-Year
Review of anesthesia work implemented
in 2002, the AMA RUC and the
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
American Society of Anesthesiologists
(ASA) used a building block approach
to estimate the value of anesthesia work
and compared this value to the imputed
work value to determine whether the
work of anesthesia services is properly
valued. Under the building block
approach, each anesthesia code was
uniformly divided into five
components; pre anesthesia, equipment
and supply preparation, induction, post
induction anesthesia, and post
anesthesia. Work is determined for each
of the five components and summed to
calculate total anesthesia work for the
anesthesia code. The imputed value for
the anesthesia code is compared to the
building block estimate of work in order
to assess whether, and if so, to what
extent, the anesthesia code is not
properly valued.
The most significant component of
work for the anesthesia service is the
intensity for the post-induction
anesthesia time. The ASA thought that
the RUC significantly misvalued this
component in the second 5-Year
Review. In addition, the ASA was
dissatisfied that the RUC did not extend
the analysis from the 19 high volume
anesthesia codes reviewed by the RUC
to all anesthesia codes.
In the CY 2007 PFS final rule with
comment period, we addressed the issue
of the work of anesthesia services under
the third 5-Year Review of work. As
explained in that rule, we made very
modest adjustments to the work of the
19 anesthesia codes surveyed and
analyzed by the RUC in the second 5Year Review of work. These adjustments
were made recognizing that the work of
the pre- and post-anesthesia service
components was linked to certain E/M
services. Since we accepted the AMA
RUC’s recommendations for increased
work values for certain E/M codes for
the third 5-Year Review of work, we
recalculated the work of the 19
anesthesia services to incorporate these
higher work values. The adjustment in
work was reflected by increasing the
anesthesia CF by less than 1 percent.
However, on the more significant
issue of the valuation of work in the
post induction anesthesia period, we
took no action. Rather, in the CY 2007
PFS final rule with comment period, we
asked the RUC to review and consider
this issue as part of the third 5-Year
Review of work. We also asked the RUC
to consider how increases in the work
of pre- and post-anesthesia services
could cause adjustments to the
anesthesia services not specifically
reviewed by the ASA and the RUC.
In January 2007, the ASA requested
the AMA RUC to review the
undervaluation of the work of the post-
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
induction anesthesia period and to
consider also an analytic approach,
based on linear regression analysis,
which could be used to evaluate the
work of the entire anesthesia service.
The linear regression model relates the
work of the post-induction period time
and the work of the entire anesthesia
service to the base unit value for the
anesthesia code. Under this model, the
work of anesthesia services is
undervalued by approximately 34
percent.
The RUC established an anesthesia
workgroup to examine this proposal.
The workgroup discussed this proposal
extensively at its two teleconferences,
prior to the April RUC meeting, and at
the April RUC meeting itself. In May
2007, the AMA RUC, based on the
analyses and recommendations of its
workgroup, submitted a
recommendation to CMS for a 32
percent increase in the work of
anesthesia services.
The workgroup approved the ASA’s
use of the linear regression model to
value only the work of the postinduction period time. In contrast to the
ASA proposal, the workgroup
considered an analytic approach
different from the regression model
developed by the ASA. This approach is
based on a building block approach that
could be used to evaluate the work of
all anesthesia service components other
than the post induction period time. For
example, for pre-anesthesia time, the
methodology is as shown in Table 15.
TABLE 15.—PRE-ANESTHESIA TIME
All Anesthesia codes with 3 base units—
linked to the work of 99201.
All Anesthesia codes with 4 base units—
linked to the blend of work for 99201 and
99202.
All Anesthesia codes with 5 to 15 base
units—linked to the work of 99202.
All Anesthesia codes with 16 to 30 base
units—linked to the work of 99252.
Note: The source of the link for work is the
pre anesthesia valuation from the 19 surveyed
anesthesia codes whose base units varied
from 3 units to 25 units.
Similar approaches are used for each
anesthesia component: Preparation
time, induction period time, and postanesthesia time. Systematically, codes
with lower anesthesia base unit values
have lower work values for each
component of the building block
approach than do codes with higher
anesthesia base unit values. For the
given building block component, the
work value of that component is the
same for all anesthesia services that
have the same base unit value.
PO 00000
Frm 00143
Fmt 4701
Sfmt 4700
66363
According to the workgroup’s revised
methodology which is extended from
the 19 surveyed codes to all CPT
anesthesia codes, the work of anesthesia
services is undervalued by
approximately 32 percent. Thus, based
on the acceptance of the workgroup and
the RUC’s recommendation, an
adjustment of approximately 25 percent
would be applied to the anesthesia CF.
Increases in the work of anesthesia
services would have to be offset by
additional adjustments to the PFS BN
adjustor for work. We estimated that the
increase in the anesthesia CF would
result in an additional 1.0 percent
increase in the BN adjuster for work.
Other adjustments also affect the
anesthesia CF. For example, an increase
in anesthesia work may have
implications for PE because indirect PEs
are allocated based on the sum of work
and direct PEs. When we ran the PE
RVU program, there was a 1 percent
decrease in the aggregate anesthesia PEs
for CY 2008. Thus, an adjustment was
made to the PE share of the anesthesia
service of the CY 2008 anesthesia CF for
this component.
We proposed to accept the RUC’s
recommendation and increase the work
of anesthesia services by 32 percent.
Comment: Organizations and
individual commenters supported our
proposal and urged us to take action to
implement this proposal in CY 2008.
They commented that this proposal
improves the valuation of the work of
anesthesia services and will help ensure
that Medicare beneficiaries have access
to quality anesthesia care. One
commenter indicated that three
additional anesthesia codes, 00142,
00210 and 00562, have been identified
as misvalued during the AMA RUC’s
evaluation of the work of anesthesia
services. Both CMS and the AMA RUC
agreed that the RUC would review the
base units for 00142 at the September
2007 RUC meeting and that the other
codes, as agreed by the ASA, would be
referred to the CPT so that the codes
descriptors could be clarified. The RUC
reviewed and approved the ASA’s
request to support the current base unit
value of four units for anesthesia code
00142.
Response: We have decided to accept
the RUC’s recommendation and increase
the work of anesthesia services by 32
percent. We have also accepted the
RUC’s recommendation to maintain the
value of four base units for anesthesia
code 00142.
3. Budget Neutrality Adjustment
Due to the proposed work RVU
changes for the additional codes from
the 5-Year Review of Work RVUs and
E:\FR\FM\27NOR2.SGM
27NOR2
66364
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the proposed increases in the work of
anesthesia services, in the CY 2008 PFS
proposed rule, we proposed to revise
the work adjustor to maintain budget
neutrality. Based upon the increases, the
proposed revised work adjustor was
estimated to be 0.8816. Further
discussion of this work adjustor was
included in the impact section of the CY
2008 PFS proposed rule (72 FR 38211
through 38220).
Comment: Several commenters
recommended that we reconsider
applying the BN adjustment associated
with the 5-Year Review of work RVUs
to the CF rather than the work RVUs.
Response: We appreciate the
commenters’ interest in this topic.
However, this issue was fully addressed
in the CY 2007 PFS final rule with
comment period (71 FR 69735), and we
made no further proposals regarding
this issue in the CY 2008 PFS proposed
rule. We continue to believe that it is
most appropriate to apply the BN
adjustment to work RVUs and refer the
commenters to the CY 2007 PFS final
rule for an explanation of our decision.
We note that as a result of the changes
made in response to comments received
and the work of the refinement panel,
the separate work adjustor has changed
from the proposed 0.8816. The separate
work adjustor for CY 2008 will be
0.8806.
D. Work Relative Value Unit
Refinements of Interim Relative Value
Units
1. Interim 2007 Codes
Although the RVUs in the CY 2007
PFS final rule with comment period
were used to calculate 2007 payment
amounts, we considered the RVUs for
the new or revised codes to be interim.
We accepted comments for a period of
60 days. We received comments on the
following CPT codes.
cprice-sewell on PROD1PC72 with RULES
Anticoagulation Management Codes
The CPT Editorial Panel created two
anticoagulation management codes in
February 2006: CPT code 99363,
Anticoagulant management for an
outpatient taking warfarin, physician
review and interpretation of
International Normalized Ratio (INR)
testing, patient instructions, dosage
adjustment (as needed), and ordering of
additional tests; initial 90 days of
therapy (must include a minimum of 8
INR measurements), and CPT code
99364, Anticoagulant management for
an outpatient taking warfarin, physician
review and interpretation of
International Normalized Ratio (INR)
testing, patient instructions, dosage
adjustment (as needed), and ordering of
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
additional tests; each subsequent 90
days of therapy (must include a
minimum of 3 INR measurements). The
RUC reviewed the codes and
recommended 1.65 work RVUs for code
99363 and 0.63 work RVUs for 99364.
In the CY 2007 PFS final rule with
comment period, we decided not to
accept the RUC recommendation and
decided that the services provided by
99363 and 99364 are bundled into
existing E/M services. Hence, there is no
separate payment under the PFS.
Currently clinicians managing
anticoagulation therapy may bill, if
appropriate, the CPT code that best
represents the level of outpatient E/M
service provided on that day, including
CPT code 99211.
Comment: We received comments
from commenters who strongly disagree
with our decision to continue to
consider anticoagulation management
codes to be bundled into the work of E/
M codes and noted that these CPT codes
recognize the important work of
managing serious disease. The
commenters also requested that we not
finalize our decision to consider these
services bundled but instead change
their status to separately payable,
covered services.
Response: We generally do not pay
separately for disease-specific
management services. We believe the
services represented by CPT codes
99363 and 99364 are inherent in the
services captured by the existing E/M
codes. We will continue to recognize
codes 99363 and 99364 as bundled
services and continue to pay for E/M
services as appropriate.
Medical Genetics and Genetic
Counseling
CPT code 96040, Medical genetics
and genetic counseling services, each 30
minutes face-to-face with patient/
family, was reviewed in the CY 2007
PFS final rule with comment period and
assigned status B (bundled service).
Comment: Commenters disagree with
the assigned status indicator of B
(bundled service) for this service and
urge CMS to reconsider its decision to
make this a bundled service because
they believe it is a separate and distinct
procedure.
Response: The procedure does not
contain any physician work and is a
code that is designed to capture clinical
labor time and PE. To the extent that
this service is covered, we believe this
service like other counseling services, is
incorporated into existing E/M services,
and therefore, will maintain the status
assignment of B.
PO 00000
Frm 00144
Fmt 4701
Sfmt 4700
Home Ventilator Management
For CPT code 94005, Home ventilator
management care plan oversight of a
patient (patient not present) in home,
domiciliary or rest home (eg, assisted
living) requiring review of status, review
of laboratories and other studies and
revision of orders and respiratory care
plan (as appropriate), within a calendar
month, 30 minutes or more, the RUC
recommended 1.50 work RVUs. We
assigned a status indicator of B (bundled
service) to this service in the CY 2007
PFS final rule with comment period
because: (1) The patient is not present
when this service is rendered; and (2)
we believe this service is captured in E/
M services.
Comment: Commenters believe this
service should not be bundled and
recommend that this code be separately
payable.
Response: We continue to believe this
service should be assigned a status
indicator of B (Bundled) for the reasons
previously stated in the CY 2007 PFS
final rule with comment period: (1) The
patient is not present when the service
is rendered; and (2) we believe this
service is captured in the E/M services.
(Note: The RUC-recommended RVUs for
this code will be reflected in Addendum
B.)
In the CY 2007 PFS final rule with
comment period (70 FR 66370), we also
responded to the RUC recommendations
on the PE inputs for the new and
revised CPT codes for 2007. In addition
to PE comments discussed in section
II.A.2. of this final rule with comment
period, concerning PE inputs:
Comment: One commenter,
representing a network of providers,
requested that the PE inputs for CPT
codes 35475 and 35476 be reviewed.
These codes are used as the basis for the
PE inputs for HCPCS codes G0392 and
G0393 that were included in Addendum
C. The commenter believes that the PE
inputs have changed since the service
was reviewed in 2004. The commenters
also believed that items were missing
from the PE database and included a list
of these items.
Response: We suggest that the
commenter work with the specialty
group to determine if the PE inputs for
CPT codes 35475 and 35476 should be
reviewed by the RUC PE subcommittee.
We have also reviewed the PE database
regarding the missing PE items noted by
the commenter and have verified that all
PE inputs from CPT 35475 and 35476
have been crosswalked to G0392 and
G0393, respectively.
Comment: One commenter,
representing the specialty of
dermatology, requested that the Unna
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
boot be removed from the PE database
as a supply item and be assigned a
HCPCS Q code so that it could be billed
separately.
Response: This issue was specifically
addressed in the CY 2007 PFS final rule
with comment period (71 FR 69644
through 69645). We clarified that the
policy we finalized relating to splint
and cast supplies did not change the
HCPCS Q-code descriptors or their
pairing with certain CPT codes for
payment purposes.
Comment: One commenter,
representing the ophthalmology
association, disagreed with our
assessment that the specific topography
equipment priced at $44,000 is not
typically used with CPT code 92025,
Computerized corneal topography,
unilateral or bilateral, with
interpretation and report, and
questioned our substitution of the
topography equipment priced at
$13,495. The commenter pointed out
that the $44,000 topography equipment
is the only equipment that will provide
the services of this procedure.
Response: We have reviewed the
request from the commenter and agree
that the $13,495 topography unit we
assigned for CY 2007 should be replaced
with the $44,000 equipment that is
specifically designed for the procedure
inherent to CPT code 92025.
Comment: One commenter,
representing therapeutic radiology,
requested that for CPT code 77371,
Radiation treatment delivery,
stereotactic radiosurgery (SRS),
complete course of treatment of cerebral
lesion(s) consisting of 1 session; multisource Cobalt 60 based, we treat the
radiation source (Cobalt 60), as a direct
PE rather than an indirect one. Since
Cobalt 60 is: (1) Purchased by the
physician; (2) exceeds the $500
threshold (price is $15,000); and, (3) is
clearly attributable to the procedure; it
meets the established criteria for
treatment as a direct expense. The
commenter indicated that this radiation
source must be replaced monthly,
requiring a useful life assignment of
0.08 years.
Response: Based on this comment, we
have re-examined our assignment of the
Cobalt 60 radiation source used in CPT
code 77371 as indirect PE. While the
radiation source may meet some of the
criteria to be considered as a direct PE
input for equipment (for example, that
it is an expense to the physician and its
price is above the $500 threshold), the
commenter did not present information
that is needed to verify the 1-month
useful life that was requested. We lack
the required evidence needed to
determine the amount of viable
radiation contained in the $15,000
source that is consumed through the
provision of the radiation treatments
versus the amount that was not utilized
but could have been used, during the 1month time period. This unused amount
would be considered a wasted resource
and cannot be accounted for as a direct
PE input. Consequently, we will not
include the Cobalt-60 radiation source
as a direct PE input as the commenter
requested.
E. Establishment of Interim Work
Relative Value Units for New and
Revised Physician’s Current Procedural
Terminology (CPT) Codes and New
Healthcare Common Procedure Coding
System Codes (HCPCS) for 2008
(Includes Table titled ‘‘American
Medical Association Specialty Relative
Value Update Committee and Health
Care Professionals Advisory Committee
Recommendations and CMS’s Decisions
for New and Revised 2008 CPT Codes’’)
One aspect of establishing RVUs for
2008 was to assign interim work RVUs
for all new and revised CPT codes. As
described in our November 25, 1992
notice on the 1993 PFS (57 FR 55951)
and in section III.B. of the CY 1997 PFS
final rule (61 FR 59505), we established
a process, based on recommendations
received from the AMA’s RUC, for
establishing interim work RVUs for new
and revised codes.
This year we received work RVU
recommendations for 169 new and
revised CPT codes from the RUC. Our
staff and medical officers reviewed the
RUC recommendations by comparing
them to our reference set or to other
66365
comparable services for which work
RVUs had previously been established.
We also considered the relationships
among the new and revised codes for
which we received RUC
recommendations and agreed with the
majority of the relative relationships
reflected in the RUC values. In some
instances, although we agreed with the
relationships, we nonetheless revised
the work RVUs to achieve work
neutrality within families of codes. That
is, the work RVUs were adjusted so that
the sum of the new or revised work
RVUs (weighted by projected frequency
of use) for a family will be the same as
the sum of the current work RVUs
(weighted by projected frequency of use)
for the family of codes.
We received approximately 7
recommendations from the Health Care
Professional Advisory Committee
(HCPAC).
Table 16: AMA RUC and HCPAC
Recommendations and CMS Decisions
for New and Revised 2008 CPT Codes
lists the new or revised CPT codes, and
their associated work RVUs, that will be
interim in 2008. Table 16 includes the
following information:
• A ‘‘#’’ identifies a new code for CY
2008.
• CPT code. This is the CPT code for
a service.
• Modifier. A ‘‘26’’ in this column
indicates that the work RVUs are for the
PC of the code.
• Description. This is an abbreviated
version of the narrative description of
the code.
• RUC recommendations. This
column identifies the work RVUs
recommended by the RUC.
• HCPAC recommendations. This
column identifies the work RVUs
recommended by the HCPAC.
• CMS decision. This column
indicates whether we agreed or we
disagreed with the RUC
recommendation. Codes for which we
did not accept the RUC
recommendation are discussed in
greater detail following this table.
• 2008 Work RVUs. This column
establishes the interim 2008 work RVUs
for physician work.
TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS’ DECISIONS FOR NEW AND REVISED 2008 CPT
CODES
cprice-sewell on PROD1PC72 with RULES
CPT 1 code
Mod
Descriptor
RUC
recommendation
HCPAC
recommendation
# 20555 ....
20660 ........
20690 ........
20692 ........
# 20985 * ..
.............
.............
.............
.............
.............
PLACE NDL MUSC/TIS FOR RT .....................
APPLY, REM FIXATION DEVICE ....................
APPLY BONE FIXATION DEVICE ...................
APPLY BONE FIXATION DEVICE ...................
CPTR–ASST DIR MS PX .................................
6.00 ......................
4.00 ......................
8.65 ......................
16.00 ....................
2.50 ......................
......................
......................
......................
......................
......................
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00145
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
CMS
decision
Agree
Agree
Agree
Agree
Agree
27NOR2
............
............
............
............
............
2008 work RVU
6.00
4.00
8.65
16.00
2.50
66366
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS’ DECISIONS FOR NEW AND REVISED 2008 CPT
CODES—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1 code
Mod
Descriptor
RUC
recommendation
HCPAC
recommendation
CMS
decision
# 20986 * ..
# 20987 * ..
# 21073 ....
# 22206 ....
# 22207 ....
# 22208 ....
23515 ........
23585 ........
23615 ........
23616 ........
23630 ........
23670 ........
23680 ........
# 24357 ....
# 24358 ....
# 24359 ....
24545 ........
24546 ........
24575 ........
24579 ........
24635 ........
24665 ........
24666 ........
24685 ........
25515 ........
25525 ........
25526 ........
25545 ........
25574 ........
25575 ........
25628 ........
26615 ........
26650 ........
26665 ........
26685 ........
26715 ........
26735 ........
26746 ........
26765 ........
26785 ........
27248 ........
# 27267 ....
# 27268 ....
# 27269 ....
# 27416 ....
27511 ........
27513 ........
27514 ........
27519 ........
27535 ........
27540 ........
27556 ........
27557 ........
27558 ........
# 27726 ....
27766 ........
# 27767 ....
# 27768 ....
# 27769 ....
27784 ........
27792 ........
27814 ........
27822 ........
27823 ........
27826 ........
27827 ........
27828 ........
27829 ........
27832 ........
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
CPTR–ASST DIR MS PX IO IMG ....................
CPTR–ASST DIR MS PX PRE IMG ................
MNPJ OF TMJ W/ANESTH ..............................
CUT SPINE 3 COL, THOR ..............................
CUT SPINE 3 COL, LUMB ...............................
CUT SPINE 3 COL, ADDL SEG ......................
TREAT CLAVICLE FRACTURE .......................
TREAT SCAPULA FRACTURE .......................
TREAT HUMERUS FRACTURE ......................
TREAT HUMERUS FRACTURE ......................
TREAT HUMERUS FRACTURE ......................
TREAT DISLOCATION/FRACTURE ................
TREAT DISLOCATION/FRACTURE ................
REPAIR ELBOW, PERC ..................................
REPAIR ELBOW W/DEB, OPEN .....................
REPAIR ELBOW DEB/ATTCH OPEN .............
TREAT HUMERUS FRACTURE ......................
TREAT HUMERUS FRACTURE ......................
TREAT HUMERUS FRACTURE ......................
TREAT HUMERUS FRACTURE ......................
TREAT ELBOW FRACTURE ...........................
TREAT RADIUS FRACTURE ...........................
TREAT RADIUS FRACTURE ...........................
TREAT ULNAR FRACTURE ............................
TREAT FRACTURE OF RADIUS .....................
TREAT FRACTURE OF RADIUS .....................
TREAT FRACTURE OF RADIUS .....................
TREAT FRACTURE OF ULNA .........................
TREAT FRACTURE RADIUS & ULNA ............
TREAT FRACTURE RADIUS/ULNA ................
TREAT WRIST BONE FRACTURE .................
TREAT METACARPAL FRACTURE ................
TREAT THUMB FRACTURE ...........................
TREAT THUMB FRACTURE ...........................
TREAT HAND DISLOCATION .........................
TREAT KNUCKLE DISLOCATION ..................
TREAT FINGER FRACTURE, EACH ...............
TREAT FINGER FRACTURE, EACH ...............
TREAT FINGER FRACTURE, EACH ...............
TREAT FINGER DISLOCATION ......................
TREAT THIGH FRACTURE .............................
CLTX THIGH FX ...............................................
CLTX THIGH FX W/MNPJ ...............................
OPTX THIGH FX ..............................................
OSTEOCHONDRAL KNEE AUTOGRAFT .......
TREATMENT OF THIGH FRACTURE .............
TREATMENT OF THIGH FRACTURE .............
TREATMENT OF THIGH FRACTURE .............
TREAT THIGH FX GROWTH PLATE ..............
TREAT KNEE FRACTURE ..............................
TREAT KNEE FRACTURE ..............................
TREAT KNEE DISLOCATION ..........................
TREAT KNEE DISLOCATION ..........................
TREAT KNEE DISLOCATION ..........................
REPAIR FIBULA NONUNION ..........................
OPTX MEDIAL ANKLE FX ...............................
CLTX POST ANKLE FX ...................................
CLTX POST ANKLE FX W/MNPJ ....................
OPTX POST ANKLE FX ..................................
TREATMENT OF FIBULA FRACTURE ...........
TREATMENT OF ANKLE FRACTURE ............
TREATMENT OF ANKLE FRACTURE ............
TREATMENT OF ANKLE FRACTURE ............
TREATMENT OF ANKLE FRACTURE ............
TREAT LOWER LEG FRACTURE ...................
TREAT LOWER LEG FRACTURE ...................
TREAT LOWER LEG FRACTURE ...................
TREAT LOWER LEG JOINT ............................
TREAT LOWER LEG DISLOCATION ..............
Carrier Priced ......
Carrier Priced ......
3.33 ......................
37.00 ....................
36.50 ....................
9.66 ......................
11.00 ....................
16.25 ....................
14.00 ....................
21.00 ....................
12.00 ....................
14.00 ....................
15.00 ....................
5.32 ......................
6.54 ......................
8.86 ......................
15.00 ....................
17.01 ....................
11.00 ....................
13.00 ....................
10.00 ....................
Referred to CPT ..
Referred to CPT ..
9.50 ......................
10.00 ....................
12.00 ....................
15.00 ....................
9.00 ......................
10.00 ....................
14.00 ....................
11.00 ....................
8.00 ......................
6.00 ......................
9.00 ......................
8.00 ......................
7.95 ......................
8.40 ......................
11.10 ....................
6.60 ......................
7.45 ......................
12.83 ....................
5.38 ......................
7.00 ......................
18.75 ....................
14.00 ....................
18.05 ....................
23.04 ....................
17.43 ....................
15.80 ....................
16.00 ....................
13.45 ....................
15.50 ....................
19.00 ....................
22.00 ....................
14.20 ....................
8.50 ......................
2.50 ......................
5.00 ......................
10.00 ....................
10.45 ....................
10.50 ....................
11.50 ....................
12.12 ....................
14.26 ....................
12.00 ....................
16.00 ....................
20.00 ....................
9.50 ......................
11.00 ....................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Agree ............
Agree ............
Agree ............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
CPT ..............
CPT ..............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Agree ............
Agree ............
Agree ............
Agree ............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Agree ............
Disagree .......
Agree ............
Agree ............
Agree ............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00146
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
2008 work RVU
Carrier Priced.
Carrier Priced.
3.33
37.00
36.50
9.66
9.53
14.07
12.12
18.19
10.39
12.12
12.99
5.32
6.54
8.86
12.99
14.73
9.53
11.26
8.64
8.22
9.74
8.21
8.64
10.37
12.96
7.78
8.64
12.10
9.51
6.91
5.19
7.78
6.91
6.87
7.26
9.59
5.70
6.44
10.64
5.38
7.00
18.75
14.00
14.97
19.11
14.46
13.11
13.27
11.16
12.86
15.76
18.25
14.20
7.73
2.50
5.00
10.00
9.51
9.55
10.46
11.03
12.98
10.92
14.56
18.20
8.64
10.01
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66367
TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS’ DECISIONS FOR NEW AND REVISED 2008 CPT
CODES—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1 code
Mod
Descriptor
RUC
recommendation
HCPAC
recommendation
CMS
decision
28415 ........
28420 ........
28445 ........
# 28446 ....
28465 ........
28485 ........
28505 ........
28525 ........
28555 ........
28585 ........
28615 ........
28645 ........
28675 ........
# 29828 * ..
# 29904 ....
# 29905 ....
# 29906 ....
# 29907 ....
31500 ........
# 33257 * ..
# 33258 * ..
# 33259 * ..
# 33864 * ..
# 34806 * ..
# 35523 ....
36620 ........
# 41019 ....
43760 ........
# 49203 ....
# 49204 ....
# 49205 ....
# 49440 ....
# 49441 ....
# 49442 ....
# 49446 ....
# 49450 ....
# 49451 ....
# 49452 ....
# 49460 ....
# 49465 ....
# 50385 ....
# 50386 ....
# 50593 * ..
51797 ........
# 52649 ....
# 55920 ....
57284 ........
# 57285 ....
# 57423 * ..
# 58570 * ..
# 58571 * ..
# 58572 * ..
# 58573 * ..
# 67041 ....
# 67042 ....
# 67043 ....
# 67113 ....
# 67229 ....
# 68816 * ..
# 75557 * ..
# 75558 * ..
# 75559 * ..
# 75560 * ..
# 75561 * ..
# 75562 * ..
# 75563 * ..
# 75564 * ..
78811 * ......
78812 * ......
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
26 ........
26 ........
26 ........
26 ........
26 ........
26 ........
26 ........
26 ........
26 ........
26 ........
TREAT HEEL FRACTURE ...............................
TREAT/GRAFT HEEL FRACTURE ..................
TREAT ANKLE FRACTURE ............................
OSTEOCHONDRAL TALUS AUTOGRFT .......
TREAT MIDFOOT FRACTURE, EACH ............
TREAT METATARSAL FRACTURE ................
TREAT BIG TOE FRACTURE .........................
TREAT TOE FRACTURE .................................
REPAIR FOOT DISLOCATION ........................
REPAIR FOOT DISLOCATION ........................
REPAIR FOOT DISLOCATION ........................
REPAIR TOE DISLOCATION ..........................
REPAIR OF TOE DISLOCATION ....................
ARTHROSCOPY BICEPS TENODESIS ..........
SUBTALAR ARTHRO W/FB RMVL .................
SUBTALAR ARTHRO W/EXC ..........................
SUBTALAR ARTHRO W/DEB ..........................
SUBTALAR ARTHRO W/FUSION ...................
INSERT EMERGENCY AIRWAY .....................
ABLATE ATRIA, LMTD, ADD-ON ....................
ABLATE ATRIA, X10SV, ADD-ON ...................
ABLATE ATRIA W/BYPASS ADD-ON .............
ASCENDING AORTIC GRAFT ........................
ANEURYSM PRESS SENSOR ADD-ON .........
ARTERY BYPASS GRAFT ..............................
INSERTION CATHETER, ARTERY .................
PLACE NEEDLES H&N FOR RT .....................
CHANGE GASTROSTOMY TUBE ...................
EXC ABD TUM 5 CM OR LESS ......................
EXC ABD TUM OVER 5 CM ............................
EXC ABD TUM OVER 10 CM ..........................
PLACE GASTROSTOMY TUBE PERC ...........
PLACE DUOD/JEJ TUBE PERC .....................
PLACE CECOSTOMY TUBE PERC ................
CHANGE G–TUBE TO G–J PERC ..................
REPLACE G/C TUBE PERC ............................
REPLACE DUOD/JEJ TUBE PERC ................
REPLACE G–J TUBE PERC ...........................
FIX G/COLON TUBE W/DEVICE .....................
FLUORO EXAM OF G/COLON TUBE .............
CHANGE STENT VIA TRANSURETH .............
REMOVE STENT VIA TRANSURETH .............
PERC CRYO ABLATE RENAL TUM ...............
INTRAABDOMINAL PRESSURE TEST ...........
PROSTATE LASER ENUCLEATION ...............
PLACE NEEDLES PELVIC FOR RT ...............
REPAIR PARAVAG DEFECT, OPEN ..............
REPAIR PARAVAG DEFECT, VAG .................
REPAIR PARAVAG DEFECT, LAP .................
TLH, UTERUS 250 G OR LESS ......................
TLH W/T/O 250 G OR LESS ...........................
TLH, UTERUS OVER 250 G ............................
TLH W/T/O UTERUS OVER 250 G .................
VIT FOR MACULAR PUCKER .........................
VIT FOR MACULAR HOLE ..............................
VIT FOR MEMBRANE DISSECT .....................
REPAIR RETINAL DETACH, CPLX .................
TR RETINAL LES PRETERM INF ...................
PROBE NL DUCT W/BALLOON ......................
CARDIAC MRI FOR MORPH ...........................
CARDIAC MRI FLOW/VELOCITY ....................
CARDIAC MRI W/STRESS IMG ......................
CARDIAC MRI FLOW/VEL/STRESS ...............
CARDIAC MRI FOR MORPH W/DYE ..............
CARD MRI FLOW/VEL W/DYE ........................
CARD MRI W/STRESS IMG & DYE ................
HT MRI W/FLO/VEL/STRS & DYE ..................
PET IMAGE, LTD AREA ..................................
PET IMAGE, SKULL–THIGH ...........................
17.54 ....................
19.00 ....................
17.07 ....................
17.50 ....................
9.50 ......................
8.00 ......................
8.00 ......................
6.00 ......................
10.43 ....................
12.00 ....................
11.50 ....................
8.00 ......................
6.00 ......................
13.00 ....................
8.50 ......................
9.00 ......................
9.47 ......................
12.00 ....................
2.33 ......................
9.63 ......................
11.00 ....................
14.14 ....................
60.00 ....................
2.06 ......................
24.00 ....................
1.15 ......................
8.84 ......................
0.90 ......................
20.00 ....................
26.00 ....................
30.00 ....................
4.18 ......................
4.77 ......................
4.00 ......................
3.31 ......................
1.36 ......................
1.84 ......................
2.86 ......................
0.96 ......................
0.62 ......................
4.44 ......................
3.30 ......................
9.08 ......................
0.80 ......................
17.16 ....................
8.31 ......................
14.25 ....................
11.52 ....................
16.00 ....................
15.75 ....................
17.56 ....................
19.96 ....................
22.98 ....................
19.00 ....................
22.13 ....................
22.94 ....................
25.00 ....................
16.00 ....................
3.00 ......................
2.35 ......................
2.60 ......................
2.95 ......................
3.00 ......................
2.60 ......................
2.86 ......................
3.00 ......................
3.35 ......................
1.54 ......................
1.93 ......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
Disagree .......
Disagree .......
Disagree .......
Agree ............
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Disagree .......
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree (c) ......
Agree ............
Agree (c) ......
Agree ............
Agree (c) ......
Agree ............
Agree (c) ......
Agree ............
Agree ............
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00147
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
2008 work RVU
15.96
17.29
15.53
17.50
8.64
7.28
7.28
5.46
9.49
10.92
10.46
7.28
5.46
13.00
8.50
9.00
9.47
12.00
2.33
9.63
11.00
14.14
60.00
2.06
24.00
1.15
8.84
0.90
20.00
26.00
30.00
4.18
4.77
4.00
3.31
1.36
1.84
2.86
0.96
0.62
4.44
3.30
9.08
0.80
17.16
8.31
14.25
11.52
16.00
15.75
17.56
19.96
22.98
19.00
22.13
22.94
25.00
16.00
3.00
2.35
2.60
2.95
3.00
2.60
2.86
3.00
3.35
1.54
1.93
66368
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS’ DECISIONS FOR NEW AND REVISED 2008 CPT
CODES—Continued
CPT 1 code
Mod
Descriptor
RUC
recommendation
HCPAC
recommendation
CMS
decision
78813 * ......
78814 * ......
78815 * ......
78816 * ......
86486 ........
88380 * ......
# 88381 * ..
# 90769 * ..
# 90770 * ..
93503 ........
# 93982 * **
95004 ........
95024 ........
95027 ........
# 95980 * ..
# 95981 * ..
# 95982 * ..
# 96125 ....
# 98966 * ..
# 98967 * ..
# 98968 * ..
# 98969 ....
# 99174 ....
# 99366 ....
# 99367 ....
# 99368 ....
# 99406 ....
# 99407 ....
# 99408 ....
# 99409 ....
# 99441 * ..
# 99442 * ..
# 99443 * ..
# 99444 ....
# 99477 ....
26 ........
26 ........
26 ........
26 ........
.............
.............
.............
.............
.............
26 ........
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
.............
PET IMAGE, FULL BODY ................................
PET IMAGE W/CT, LMTD ................................
PET IMAGE W/CT, SKULL–THIGH .................
PET IMAGE W/CT, FULL BODY .....................
SKIN TEST, NOS ANTIGEN ............................
MICRODISSECTION, LASER ..........................
MICRODISSECTION, MANUAL .......................
SC THER INFUSION, UP TO 1 HR .................
SC THER INFUSION, ADDL HR .....................
INSERT/PLACE HEART CATHETER ..............
ANEURYSM PRESSURE SENS STUDY ........
PERCUT ALLERGY SKIN TESTS ...................
ID ALLERGY TEST, DRUG/BUG .....................
ID ALLERGY TITRATE–AIRBORNE ................
IO ANAL GAST N–STIM INIT ..........................
IO ANAL GAST N–STIM SUBSQ ....................
IO GA N–STIM SUBSQ W/REPROG ..............
COGNITIVE TEST BY HC PRO ......................
HC PRO PHONE CALL 5–10 MIN ...................
HC PRO PHONE CALL 11–20 MIN .................
HC PRO PHONE CALL 21–30 MIN .................
ONLINE SERVICE BY HC PRO ......................
OCULAR PHOTOSCREENING ........................
TEAM CONF W/PAT BY HC PRO ...................
TEAM CONF W/O PAT BY PHYS ...................
TEAM CONF W/O PAT BY HC PRO ...............
BEHAV CHNG SMOKING 3–10 MIN ...............
BEHAV CHNG SMOKING < 10 MIN ................
AUDIT/DAST, 15–30 MIN .................................
AUDIT/DAST, OVER 30 MIN ...........................
PHONE E/M BY PHYS 5–10 MIN ....................
PHONE E/M BY PHYS 11–20 MIN ..................
PHONE E/M BY PHYS 21–30 MIN ..................
ONLINE E/M BY PHYS ....................................
INIT DAY HOSP NEONATE CARE .................
2.00 ......................
2.20 ......................
2.44 ......................
2.50 ......................
(a) ........................
1.56 ......................
1.18 ......................
0.21 ......................
0.18 ......................
2.91 ......................
0.30 ......................
0.01 ......................
0.01 ......................
0.01 ......................
0.80 ......................
0.30 ......................
0.65 ......................
..............................
..............................
..............................
..............................
..............................
(a) ........................
..............................
1.10 ......................
..............................
0.24 ......................
0.50 ......................
0.65 ......................
1.30 ......................
0.25 ......................
0.50 ......................
0.75 ......................
Carrier Priced ......
7.00 ......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
......................
1.70 ..............
0.25 ..............
0.50 ..............
0.75 ..............
Carrier Priced
......................
0.82 ..............
......................
0.72 ..............
......................
......................
......................
......................
......................
......................
......................
......................
......................
Agree ............
Agree ............
Agree ............
Agree ............
(a)* ...............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree ............
Agree (c) ......
Agree (c) ......
Agree (c) ......
Agree (c) ......
(a)* ...............
Agree (b) ......
Agree (b) ......
Agree (b) ......
Agree ............
Agree ............
Agree (c) ......
Agree (c) ......
Agree (c) ......
Agree (c) ......
Agree (c) ......
Agree (c) ......
Agree ............
2008 work RVU
2.00
2.20
2.44
2.50
0.00
1.56
1.18
0.21
0.18
2.91
0.30
0.01
0.01
0.01
0.80
0.30
0.65
1.70
0.25
0.50
0.75
Carrier Priced.
0.00
0.82
1.10
0.72
0.24
0.50
0.65
1.30
0.25
0.50
0.75
Carrier Priced.
7.00
# New CPT code.
1 All CPT codes copyright 2007 AMA.
* New Code for Re-Examination at the next 5-Year Review.
** Denotes restricted coverage of code.
(a) No RUC work RVU recommendation.
(a) * See code discussion in Section F, Discussion of Codes and RUC/HCPAC Recommendations.
(b) RUC-recommended work RVU accepted but coverage status of code is Bundled.
(c) RUC-recommended work RVU accepted but coverage status of code is Noncovered.
Table 17: AMA RUC Anesthesia
Recommendations and CMS Decisions
for New and Revised 2008 CPT Codes
lists the new or revised CPT codes for
anesthesia and their base units that will
be interim in CY 2008. Table 17
includes the following information:
• CPT code. This is the CPT code for
a service.
• Description. This is an abbreviated
version of the narrative description of
the code.
• RUC recommendations. This
column identifies the base units
recommended by the RUC.
• CMS decision. This column
indicates whether we agreed or we
disagreed with the RUC
recommendation. Codes for which we
did not accept the RUC
recommendation are discussed in
greater detail following this table.
• 2008 Base Units. This column
establishes the CY 2007 base units for
these services.
TABLE 17.—AMA RUC ANESTHESIA RECOMMENDATIONS AND CMS DECISIONS FOR NEW AND REVISED/REVIEWED CPT
CODES
RUC
recommendation
cprice-sewell on PROD1PC72 with RULES
* CPT 1 code
Description
## 00142 .....
# 01935 .......
# 01936 .......
ANESTH, LENS SURGERY ............................................................................................
ANESTH, PERC IMG DX SP PROC ...............................................................................
ANESTH, PERC IMG TX SP PROC ...............................................................................
1 All
CPT codes copyright 2007 AMA.
VerDate Aug<31>2005
16:01 Nov 26, 2007
4.00
5.00
5.00
Jkt 214001
PO 00000
Frm 00148
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
CMS
decision
Agree .......
Agree .......
Agree .......
2008 base
units
4.00
5.00
5.00
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66369
cprice-sewell on PROD1PC72 with RULES
# New CPT code.
## Note: CPT code 00142 is neither a new nor revised code for 2008. However, the RUC reviewed the base unit values for this code for 2008
and recommended that the value be maintained.
F. Discussion of Codes and RUC/HCPAC
Recommendations
The following is a summary of our
rationale for not accepting particular
RUC work RVUs. It is arranged by type
of service in CPT order. This summary
refers only to work RVUs.
1. Internal Fixation Codes—Shoulder/
Elbow (CPT codes 23515, 23585, 23615,
23616, 23680, 23670, 23680, 24545,
24546, 24575 and 24579), Elbow/Hand
(CPT codes 24635, 24685, 25515, 25525,
25526, 25545, 25574, 25575, 25628,
26615, 26650, 26665, 26685, 26715,
26735, 26746, 26765, 26785), Hip and
Knee (CPT codes 27248, 27511, 27513,
27514, 27519, 27535, 27540, 27556,
27557 and 27558) and Foot and Ankle
(CPT codes 27766, 27784, 27792, 27814,
27822, 27823, 27826, 27827, 27828,
27829, 27832, 28415, 28420, 28445,
28465, 28485, 28505, 28525, 28555,
28585, 28615, 28645 and 28675)
These codes were originally part of
the 5-Year Review of work RVUs and
were referred to the CPT Editorial Panel
by the RUC for further clarification
because it was unclear whether the
previous valuation for these codes
included the situation when internal
and external fixation is applied to the
fracture site. The CPT Editorial Panel
agreed that these codes needed to be
clarified and removed reference to
external fixation from these codes. As a
result of this editorial change, the RUC
reexamined these families of codes and
recommended increased work RVUs.
The RUC recommended 11.00 work
RVUs for CPT code 23515; 16.25 work
RVUs for CPT code 25385; 14.00 work
RVUs for CPT code 23615; 21.00 work
RVUs for CPT code 23616; 12.00 work
RVUs for CPT code 23680; 14.00 work
RVUs for CPT code 23670; 15.00 work
RVUs for CPT code 23680; 15.00 work
RVUs for CPT code 24545; 17.01 work
RVUs for CPT code 24546; 11.00 work
RVUs for CPT code 24575; 13.00 work
RVUs for CPT code 24579; 10.00 work
RVUs for CPT code 24635; 9.50 work
RVUs for CPT code 24685; 10.00 work
RVUs for CPT code 25515; 12.00 work
RVUs for CPT code 25525; 15.00 work
RVUs for CPT code 25526; 9.00 work
RVUs for CPT code 25545; 10.00 work
RVUs for CPT code 25574; 14.00 work
RVUs for CPT code 25575; 11.00 work
RVUs for CPT code 25628; 8.00 work
RVUs for CPT code 26615; 6.00 work
RVUs for CPT code 26650; 9.00 work
RVUs for CPT code 26665; 8.00 work
RVUs for CPT code 26685; 7.95 work
RVUs for CPT code 26715; 8.40 work
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
RVUs for CPT code 26735; 11.10 work
RVUs for CPT code 26746; 6.60 work
RVUs for CPT code 26765; 7.45 work
RVUs for CPT code 26785; 12.83 work
RVUs for CPT code 27248; 18.05 work
RVUs for CPT code 27511; 23.04 work
RVUs for CPT code 27513; 17.43 work
RVUs for CPT code 27514; 15.80 work
RVUs for CPT code 27519; 16.00 work
RVUs for CPT code 27535; 13.45 work
RVUs for CPT code 27540; 15.50 work
RVUs for CPT code 27556; 19.00 work
RVUs for CPT code 27557; 22.00 work
RVUs for CPT code 27558; 8.50 work
RVUs for CPT code 27766; 10.45 work
RVUs for CPT code 27784; 10.50 work
RVUs for CPT code 27792; 11.50 work
RVUs for CPT code 27814; 12.12 work
RVUs for CPT code 27822; 14.26 work
RVUs for CPT code 27823; 12.00 work
RVUs for CPT code 27826; 16.00 work
RVUs for CPT code 27827; 20.00 work
RVUs for CPT code 27828; 9.50 work
RVUs for CPT code 27829; 11.00 work
RVUs for CPT code 27832; 17.54 work
RVUs for CPT code 28415; 19.00 work
RVUs for CPT code 28420; 17.07 work
RVUs for CPT code 28445; 9.50 work
RVUs for CPT code 28465; 8.00 work
RVUs for CPT code 28485; 8.00 work
RVUs for CPT code 28505; 6.00 work
RVUs for CPT code 28525; 10.43 work
RVUs for CPT code 28555; 12.00 work
RVUs for CPT code 28585; 11.50 work
RVUs for CPT code 28615; 8.00 work
RVUs for CPT code 28645; and 6.00
work RVUs for CPT code 28675.
Although we agree with the
relationships, the increases in work
RVUs reestablish the relativity of the
services in these families and in doing
so created BN issues. In order to retain
BN within these families of codes, the
work RVUs associated with each code
had to be adjusted. That is, the work
RVUs were adjusted so that the sum of
the new or revised work RVUs
(weighted by projected frequency of use)
for each family will be the same as the
sum of the current work RVUs
(weighted by projected frequency of use)
for each family of codes. The adjusted
work RVUs are as follows: 9.53 work
RVUs for CPT code 23515; 14.07 work
RVUs for CPT code 25385; 12.12 work
RVUs for CPT code 23615; 18.19 work
RVUs for CPT code 23616; 10.39 work
RVUs for CPT code 23680; 12.12 work
RVUs for CPT code 23670; 12.99 work
RVUs for CPT code 23680; 12.99 work
RVUs for CPT code 24545; 14.73 work
RVUs for CPT code 24546; 9.53 work
RVUs for CPT code 24575; 11.26 work
RVUs for CPT code 24579; 8.64 work
PO 00000
Frm 00149
Fmt 4701
Sfmt 4700
RVUs for CPT code 24635; 8.21 work
RVUs for CPT code 24685; 8.64 work
RVUs for CPT code 25515; 10.37 work
RVUs for CPT code 25525; 12.96 work
RVUs for CPT code 25526; 7.78 work
RVUs for CPT code 25545; 8.64 work
RVUs for CPT code 25574; 12.10 work
RVUs for CPT code 25575; 9.51 work
RVUs for CPT code 25628; 6.91 work
RVUs for CPT code 26615; 5.19 work
RVUs for CPT code 26650; 7.78 work
RVUs for CPT code 26665; 6.91 work
RVUs for CPT code 26685; 6.87 work
RVUs for CPT code 26715; 7.26 work
RVUs for CPT code 26735; 9.59 work
RVUs for CPT code 26746; 5.70 work
RVUs for CPT code 26765; 6.44 work
RVUs for CPT code 26785; 10.64 work
RVUs for CPT code 27248; 14.97 work
RVUs for CPT code 27511; 19.11 work
RVUs for CPT code 27513; 14.46 work
RVUs for CPT code 27514; 13.11 work
RVUs for CPT code 27519; 13.27 work
RVUs for CPT code 27535; 11.16 work
RVUs for CPT code 27540; 12.86 work
RVUs for CPT code 27556; 15.76 work
RVUs for CPT code 27557; 18.25 work
RVUs for CPT code 27558; 7.73 work
RVUs for CPT code 27766; 9.51 work
RVUs for CPT code 27784; 9.55 work
RVUs for CPT code 27792; 10.46 work
RVUs for CPT code 27814; 11.03 work
RVUs for CPT code 27822; 12.98 work
RVUs for CPT code 27823; 10.92 work
RVUs for CPT code 27826; 14.56 work
RVUs for CPT code 27827; 18.20 work
RVUs for CPT code 27828; 8.64 work
RVUs for CPT code 27829; 10.01 work
RVUs for CPT code 27832; 15.96 work
RVUs for CPT code 28415; 17.29 work
RVUs for CPT code 28420; 15.53 work
RVUs for CPT code 28445; 8.64 work
RVUs for CPT code 28465; 7.28 work
RVUs for CPT code 28485; 7.28 work
RVUs for CPT code 28505; 5.46 work
RVUs for CPT code 28525; 9.49 work
RVUs for CPT code 28555; 10.92 work
RVUs for CPT code 28585; 10.46 work
RVUs for CPT code 28615; 7.28 work
RVUs for CPT code 28645; and 5.46
work RVUs for CPT code 28675.
2. Cardiac MRI Codes
Cardiac MRI services have evolved
over the past decade from providing
primarily anatomic information to
providing both anatomic and
physiologic information. We have had a
national noncoverage determination in
place for Magnetic Resonance Imaging
(MRI) that provides blood flow
measurement since March 1994. This
NCD provides that CPT code 75556,
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66370
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Cardiac magnetic resonance imaging for
velocity flow, is not covered.
As a result of the technological
changes in MRI scanning, the CPT
Editorial Panel created eight new
Cardiac MRI codes and deleted five
existing Cardiac MRI codes. The new
codes are: CPT code 75557, Cardiac
magnetic resonance imaging for
morphology and function without
contrast material; CPT code 75558,
Cardiac magnetic resonance imaging for
morphology and function without
contrast material; with flow/velocity
quantification; CPT code 75559, Cardiac
magnetic resonance imaging for
morphology and function without
contrast material; with stress imaging;
CPT code 75560, Cardiac magnetic
resonance imaging for morphology and
function without contrast material; with
flow/velocity quantification and stress;
CPT code 75561, Cardiac magnetic
resonance imaging for morphology and
function without contrast material(s),
followed by contrast material(s) and
further sequences; CPT code 75562,
Cardiac magnetic resonance imaging for
morphology and function without
contrast material(s), followed by
contrast material(s) and further
sequences; with flow/velocity
quantification; CPT code 75563, Cardiac
magnetic resonance imaging for
morphology and function without
contrast material(s), followed by
contrast material(s) and further
sequences; with stress imaging; and CPT
code 75564, Cardiac magnetic
resonance imaging for morphology and
function without contrast material(s),
followed by contrast material(s) and
further sequences; with flow/velocity
quantification and stress. The RUC
recommended 2.35 work RVUs for CPT
code 75557; 2.60 work RVUs for CPT
code 75558; 2.95 work RVUs for CPT
code 75559; 3.00 work RVUs for CPT
code 75560; 2.60 work RVUs for CPT
code 75561; 2.86 work RVUs for CPT
code 75562; 3.00 work RVUs for CPT
code 75563; and 3.35 work RVUs for
CPT code 75564.
The deleted codes are: CPT code
75552, Cardiac magnetic resonance
imaging for function, without contrast
material; CPT code 75553, Cardiac
magnetic resonance imaging for
function, without contrast material with
contrast material; CPT code 75554,
Cardiac magnetic resonance imaging for
function, with or without morphology;
complete study; CPT code 75555,
Cardiac magnetic resonance imaging for
function, with or without morphology;
limited study; and CPT code 75556
Cardiac magnetic resonance imaging for
velocity flow mapping.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Upon review of the new cardiac MRI
codes, we recognize that four of the new
codes incorporate blood flow
measurement, which remains one of the
nationally noncovered indications for
MRI in the Medicare program. Due to a
national non-coverage determination for
MRI that provides blood flow
measurement, CPT codes 75558, 75560,
75562 and 75564 will not be recognized
by the Medicare program and have been
assigned a status indicator of ‘‘N’’
(Noncovered) on the Medicare
physician fee schedule. (Note: The RUCrecommended RVUs for these codes will
be reflected in Addendum B.)
The remaining codes in this family
(CPT codes 75557, 75559, 75561 and
75563) will be recognized as active on
the Medicare PFS.
3. Skin Test, Unlisted Antigen
For CPT code 86486, Skin test;
unlisted antigen, the RUC did not make
a work RVU recommendation. During
our 2007 public meeting for new
clinical laboratory tests held in
accordance with § 414.506, we received
approximately four comments. The
commenters indicated the code belongs
in the skin test code series included in
the PFS with a payment crosswalk to
CPT code 86490 Skin test;
coccidioidomycosis. We agree with the
recommendations. We are assigning the
code a status indicator of A (Active
code). The status indicator does not
mean that Medicare has made a national
coverage determination regarding this
service. Contractors may develop local
coverage determinations. CPT also
deleted predecessor CPT code 86586
effective January 1, 2008; thus, CPT
code 86586 will be deleted from the
2008 clinical laboratory fee schedule.
4. Wireless Pressure Sensor
Implantation and Study
For CPT code 93982, Noninvasive
physiologic study of implanted wireless
pressure sensor in aneursymal sac
following endovascular repair, complete
study including recording, analysis of
pressure and waveform tracings,
interpretation and report, the RUC
recommended 0.30 work RVUs. We
have assigned a status indicator of R
(Restricted) to this service because the
sensor used in this procedure is FDA
approved for pressure interpretation at
the time of an endovascular aneurysm
repair only and is currently not FDA
approved for the follow-up evaluation of
pressure analysis in the office or
outpatient setting once the patient is
discharged from the hospital.
PO 00000
Frm 00150
Fmt 4701
Sfmt 4700
5. Non-Face-to-Face Physician and
Qualified Healthcare Professional
Services
For CPT code 98966, Telephone
assessment and management service
provided by a qualified non-physician
health care professional to an
established patient, parent, or guardian
not originating from a related
assessment and management service
provided within the previous seven days
nor leading to an assessment and
management service or procedure
within the next 24 hours or soonest
available appointment; 5–10 minutes of
medical discussion; CPT code 98967,
Telephone assessment and management
service provided by a qualified nonphysician health care professional to an
established patient, parent, or guardian
not originating from a related
assessment and management service
provided within the previous seven days
nor leading to an assessment and
management service or procedure
within the next 24 hours or soonest
available appointment; 11–20 minutes
of medical discussion; CPT code 98968,
Telephone assessment and management
service provided by a qualified nonphysician health care professional to an
established patient, parent, or guardian
not originating from a related
assessment and management service
provided within the previous seven days
nor leading to an assessment and
management service or procedure
within the next 24 hours or soonest
available appointment; 21–30 minutes
of medical discussion; CPT code 98969,
Online evaluation and management
service provided by a qualified nonphysician health care professional to an
established patient, guardian or health
care provider not originating from a
related assessment and management
service provided within the previous 7
days, using the Internet or similar
electronic communications network;
CPT code 99441, Telephone evaluation
and management service provided by a
physician to an established patient,
parent, or guardian not originating from
a related E/M service provided within
the previous seven days nor leading to
an E/M service or procedure within the
next 24 hours or soonest available
appointment; 5–10 minutes of medical
discussion; CPT code 99442, Telephone
evaluation and management service
provided by a physician to an
established patient, parent, or guardian
not originating from a related E/M
service provided within the previous
seven days nor leading to an E/M
service or procedure within the next 24
hours or soonest available appointment;
11–20 minutes of medical discussion;
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
CPT code 99443, Telephone evaluation
and management service provided by a
physician to an established patient,
parent, or guardian not originating from
a related E/M service provided within
the previous seven days nor leading to
an E/M service or procedure within the
next 24 hours or soonest available
appointment; 21–30 minutes of medical
discussion; and CPT code 99444, Online
evaluation and management service
provided by a physician to an
established patient, guardian or health
care provider not originating from a
related E/M service provided within the
previous 7 days, using the Internet or
similar electronic communications
network, the HCPAC recommended 0.25
work RVUs for CPT code 98966; 0.50
work RVUs for CPT code 98967; 0.75
work RVUs for CPT code 98968; carrier
pricing for CPT code 98969; and the
RUC recommended 0.25 work RVUs for
CPT code 99441; 0.50 work RVUs for
CPT code 99442; 0.75 work RVUs for
CPT code 99443; and carrier pricing for
CPT code 99444. We are assigning a
status indicator of ‘‘N’’ (Non-covered
service) to these services because: (1)
These services are non-face-to-face; and
(2) the code descriptor includes
language that recognizes the provision
of services to parties other than the
beneficiary and for whom Medicare
does not provide coverage (for example,
guardian). (Note: The RUC or HCPAC
recommended RVUs for these codes will
be reflected in Addendum B.)
cprice-sewell on PROD1PC72 with RULES
6. Team Conference
For CPT code 99366, Medical team
conference with interdisciplinary team
of health care professionals, face-to-face
with patient and/or family, 30 minutes
or more; participation by non-physician
qualified health care professional; CPT
code 99367, Medical team conference
with interdisciplinary team of health
care professionals, patient and/or
family not present, 30 minutes or more;
participation by physician; and CPT
code 99368, Medical team conference
with interdisciplinary team of health
care professionals, patient and/or
family not present, 30 minutes or more;
participation by non-physician qualified
health care professional, the HCPAC
recommended 0.82 work RVUs for CPT
code 99366; the RUC recommended 1.10
work RVUs for CPT code 99367; and the
HCPAC recommended 0.72 work RVUs
for CPT code 99368. We are assigning a
status indicator of ‘‘B’’ (Bundled) to
these services because to the extent that
these services are covered, we believe
these services like other counseling
services are incorporated into existing
E/M services. (Note: The RUC or HCPAC
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
recommended RVUs for these codes will
be reflected in Addendum B.)
7. Reporting of Alcohol and/or
Substance Abuse Assessment and
Intervention Services
For CY 2008, the CPT Editorial Panel
has created two new Category I CPT
codes for reporting alcohol and/or
substance abuse screening. They are
CPT code 99408, Alcohol and/or
substance (other than tobacco) abuse
structured screening (e.g., AUDIT,
DAST), and brief intervention (SBI)
services; 15 to 30 minutes, and CPT
code 99409, Alcohol and/or substance
(other than tobacco) abuse structured
screening (e.g., AUDIT, DAST), and
brief intervention (SBI) services; greater
than 30 minutes.
The code descriptions for these CPT
codes suggest that these CPT codes may
describe services that include screening
services. In general, screening services
under Medicare are considered to be
those services provided to beneficiaries
in the absence of signs or symptoms of
illness or injury; therefore, to the extent
that the services described by these two
CPT codes have a screening element, the
screening component would not meet
the statutory requirements for coverage
under section 1862(a)(1)(A) of the Act.
Screening services are not covered by
Medicare without specific statutory
authority, such as has been provided for
mammography, diabetes, and colorectal
cancer screening. Accordingly, we will
not recognize these CPT codes that
incorporate screening for payment
under the PFS.
Instead, we have created two parallel
G-codes to allow for appropriate
Medicare reporting and payment for
alcohol and substance abuse assessment
and intervention services that are not
provided as screening services, but that
are performed in the context of the
diagnosis or treatment of illness or
injury. The codes are HCPCS code
G0396, Alcohol and/or substance (other
than tobacco) abuse structured
assessment (e.g., AUDIT, DAST) and
brief intervention, 15 to 30 minutes and
HCPCS code G0397, Alcohol and/or
substance (other than tobacco) abuse
structured assessment (e.g., AUDIT,
DAST) and intervention greater than 30
minutes. We will instruct Medicare
contractors to pay for these codes only
when considered reasonable and
necessary. We will also provide coding
and payment instructions for these
assessment and intervention services in
the program instructions implementing
the CY 2008 PFS.
We are assigning a status indicator of
‘‘N’’ (Noncovered) to CPT codes 99408
and 99409. However, the work RVUs
PO 00000
Frm 00151
Fmt 4701
Sfmt 4700
66371
and PE inputs for 99408 will be
crosswalked to G0396 and the work
RVUs and PE inputs for 99409 will be
crosswalked to G0397.
8. Ocular Photoscreening
For CPT code 99174, Ocular
photoscreening with interpretation and
report, bilateral, the RUC did not
provide a recommendation. We are
assigning a status indicator of ‘‘N’’
(Noncovered) to this service because it
is a screening service that is not covered
under the Medicare statute.
G. Additional Coding Issues
1. Modifier ¥51 Exempt List
The CPT Editorial Panel reviewed all
of the codes on the modifier ¥51
exempt list to identify which codes
should be exempt from the multiple
procedure payment reduction rules and
which codes should be removed from
the exemption list. We have reviewed
all codes recommended for removal
from the exemption list and agree with
the CPT Editorial Panel’s
recommendations. We have updated
payment modifiers where applicable.
2. New Codes for Re-Examination at the
Next 5-Year Review
As part of its annual
recommendations, the RUC includes a
list identifying new CPT codes for
reexamination at the next 5-Year Review
of Work RVUs. New CPT codes that
have been added to this list are
identified with an asterisk (*) on
Table 16: AMA RUC and HCPAC
Recommendations and CMS’ Decisions
for New and Revised 2008 CPT Codes.
H. Establishment of Interim PE RVUs for
New and Revised Physician’s Current
Procedural Terminology (CPT) Codes
and New Healthcare Common
Procedure Coding System (HCPCS)
Codes for 2008
We have developed a process for
establishing interim PE RVUs for new
and revised codes that is similar to that
used for work RVUs. Under this process,
the RUC recommends the PE direct
inputs (the staff time, supplies and
equipment) associated with each new
code. We then review the
recommendations in a manner similar to
our evaluation of the recommended
work RVUs. The RUC recommendations
on the PE inputs for the new and
revised CY 2008 codes were submitted
to us as interim recommendations. We
have accepted, in the interim, the PE
recommendations submitted by the RUC
for the codes listed in Table 16: AMA
RUC and HCPAC Recommendations and
CMS’ Decisions for New and Revised
E:\FR\FM\27NOR2.SGM
27NOR2
66372
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
2008 CPT Codes except as noted below
in this section.
CPT Code Series 49450 Through 49465
In this series of nine G-, J-, and G-J
Tubes CPT codes, 49440, 49441, 49442,
49446, 49450, 49451, 49452, 49460 and
49465, we made revisions to the clinical
labor time to conform to the RUCestablished standard under which the
time assigned to any one labor type for
the ‘‘intra’’ time, based on the
physician’s time to perform the
procedure, can not exceed 100 percent
of the physician time. These revisions
affected the service period times for the
angio-tech/RT for each code. For each
CPT code, the angio-tech/RT time to
assist the physician in performing the
procedure was allocated at 67 percent of
the physician time and the angio-tech/
RT time to assist the physician with
image acquisition during the procedure
was allocated the remaining 33 percent
of the physician time.
We also made minor revisions to the
supply list for this family of codes in
order to match the number of requested
needles with the number of syringes.
We allocated one needle for each saline
flush syringe and 1 additional needle to
administer the lidocaine. Each needle
was assigned the supply category
‘‘SC029, needle, 18–27g’’ to encompass
both the 18g and 25g needles requested.
In addition, we added a 10–12 ml
syringe that could be used to administer
the lidocaine.
CPT Code 50593
We disagreed with the RUC
recommended number of renal
cryoablation probes typically needed to
perform this procedure. Instead of 4
probes, we believe that an average of 2.5
probes is typical to this procedure based
on 2005 clinical data (collected at
Karmonos Cancer Institute) that was
included as an attachment to
information provided by the
manufacturer. Therefore, we have
assigned 2.5 probes for renal
cryoablation, at $1,175 each, for CPT
50593.
V. Physician Self-Referral Prohibition:
Annual Update to List of CPT/HCPCS
Codes
cprice-sewell on PROD1PC72 with RULES
A. General
Section 1877 of the Act prohibits a
physician from referring a Medicare
beneficiary for certain designated health
services (DHS) to a health care entity
with which the physician (or a member
of the physician’s immediate family) has
a financial relationship, unless an
exception applies. Section 1877 of the
Act also prohibits the DHS entity from
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
submitting claims to Medicare or billing
the beneficiary or any other entity for
Medicare DHS that are furnished as a
result of a prohibited referral.
As specified in our regulations at
§ 411.351, the following services are
DHS:
• Clinical laboratory services.
• Physical therapy, occupational
therapy, and speech-language pathology
services.
• Radiology and certain other imaging
services.
• Radiation therapy services and
supplies.
• Durable medical equipment and
supplies.
• Parenteral and enteral nutrients,
equipment, and supplies.
• Prosthetics, orthotics, and
prosthetic devices and supplies.
• Home health services.
• Outpatient prescription drugs.
• Inpatient and outpatient hospital
services.
B. Annual Update to the Code List
1. Background
In § 411.351, we specify that the
entire scope of four DHS categories is
defined in a list of CPT/HCPCS codes
(the Code List), which is updated
annually to account for changes in the
most recent CPT and HCPCS
publications. The DHS categories
defined and updated in this manner are:
• Clinical laboratory services.
• Physical therapy, occupational
therapy, and speech-language pathology
services.
• Radiology and certain other imaging
services.
• Radiation therapy services and
supplies.
The Code List also identifies those
items and services that may qualify for
either of the following two exceptions to
the physician self-referral prohibition:
• EPO and other dialysis-related
drugs furnished in or by an ESRD
facility (§ 411.355(g)).
• Preventive screening tests,
immunizations or vaccines
(§ 411.355(h)).
The Code List was last updated in the
CY 2007 PFS final rule with comment
period (71 FR 69624) and in a
subsequent correction notice (72 FR
18909).
2. Response to Comments
We received only one public
comment relating to the Code List that
became effective January 1, 2007. The
commenter was supportive of our
additions and deletions.
3. Revisions Effective for 2008
The updated, comprehensive Code
List effective January 1, 2008, appears as
PO 00000
Frm 00152
Fmt 4701
Sfmt 4700
Addendum x in this final rule with
comment period and is available on our
Web site at https://www.cms.hhs.gov/
PhysicianSelfReferral/
11_List_of_Codes.asp#TopOfPage.
Tables 19 and 20 identify the
additions and deletions, respectively, to
the comprehensive Code List that was
published in Addendum J of the CY
2007 PFS final rule (71 FR 70247
through 70251) and revised in a
subsequent correction notice (72 FR
18909). Tables 19 and 20 also identify
the additions and deletions to the lists
of codes used to identify the items and
services that may qualify for the
exceptions in § 411.355(g) (regarding
EPO and other dialysis-related
outpatient prescription drugs furnished
in or by an ESRD facility) and
§ 411.355(h) (regarding preventive
screening tests, immunizations and
vaccines).
The additions and deletions specified
in Tables 19 and 20 are necessary to
conform the Code List to the most recent
publications of CPT and HCPCS and to
changes in Medicare payment policies.
We will consider comments regarding
the codes listed in Tables 19 and 20.
Comments will be considered if we
receive them by the date specified in the
DATES section of this final rule with
comment period. We will not consider
any comment that advocates a
substantive change to any of the DHS
defined in § 411.351.
TABLE 19.—ADDITIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT 1
HCPCS CODES
CLINICAL LABORATORY SERVICES
[no additions]
PHYSICAL THERAPY, OCCUPATIONAL
THERAPY, AND SPEECH-LANGUAGE
PATHOLOGY SERVICES
96125 ...............
Cognitive test by HC pro.
RADIOLOGY AND CERTAIN OTHER
IMAGING SERVICES
75557
75558
75559
75560
75561
...............
...............
...............
...............
...............
75562 ...............
75563 ...............
75564 ...............
A9501 ...............
A9509 ...............
A9569 ...............
A9570 ...............
A9571 ...............
E:\FR\FM\27NOR2.SGM
27NOR2
Cardiac mri for morph.
Cardiac mri flow/velocity.
Cardiac mri w/stress img.
Cardiac mri flow/vel/stress.
Cardiac mri for morph w/
dye.
Card mri flow/vel w/dye.
Card mri w/stress img &
dye.
Ht mri w/flo/vel/strs & dye.
Technetium TC-99m
teboroxime.
Iodine I-123 sod iodide mil.
Technetium TC-99m auto
WBC.
Indium In-111 auto WBC.
Indium In-111 auto platelet.
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 19.—ADDITIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT 1
HCPCS CODES—Continued
A9572 ...............
A9576
A9577
A9578
A9579
...............
...............
...............
...............
Q9965 ...............
Q9966 ...............
Q9967 ...............
Indium In-111
pentetreotide.
Inj prohance multipack.
Inj multihance.
Inj multihance multipack.
Gad-base MR contrast
NOS, 1ml.
LOCM 100–199mg/ml iodine, 1ml.
LOCM 200–299mg/ml iodine, 1ml.
LOCM 300–399mg/ml iodine, 1ml.
RADIATION THERAPY SERVICES AND
SUPPLIES
0182T
20555
41019
55920
C1716
C1717
...............
...............
...............
...............
...............
...............
C1719 ...............
C2616 ...............
C2634 ...............
C2635 ...............
C2636 ...............
C2637 ...............
C2638 ...............
C2639 ...............
C2640 ...............
C2641 ...............
C2642 ...............
C2643 ...............
C2698 ...............
C2699 ...............
HDR elect brachytherapy.
Place ndl musc/tis for rt.
Place needles h&n for rt.
Place needles pelvic for rt.
Brachytx source, Gold 198.
Brachytx source, HDR Ir192.
Brachytx source, Non-HDR
Ir-192.
Brachytx source, Yttrium-9.
Brachytx source, HA, I125.
Brachytx source, HA, P-13.
Brachytx linear source, P13.
Brachytx, Ytterbium-169.
Brachytx, stranded, I-125.
Brachytx, non-stranded, I125.
Brachytx, stranded, P-13.
Brachytx, non-stranded, P13.
Brachytx, stranded, C-131.
Brachytx, non-stranded, C131.
Brachytx, stranded, NOS.
Brachytx, non-stranded,
NOS.
DRUGS USED BY PATIENTS UNDERGOING
DIALYSIS
TABLE 20.—DELETIONS TO THE PHYSI- MIEA–TRHCA had not subsequently
CIAN SELF-REFERRAL LIST OF CPT1/ been enacted, the CY 2007 update
would have been ¥5.0 percent
HCPCS CODES—Continued
PHYSICAL THERAPY, OCCUPATIONAL
THERAPY, AND SPEECH-LANGUAGE
PATHOLOGY SERVICES
[no deletions]
RADIOLOGY AND CERTAIN OTHER
IMAGING SERVICES
75552 ..........
75553 ..........
75554 ..........
75555 ..........
78609 ..........
78615 ..........
A9565 ..........
Q9945 .........
Q9946 .........
Q9947 .........
Q9948 .........
Q9949 .........
Q9950 .........
Q9952 .........
Heart mri for morph w/o dye.
Heart mri for morph w/dye.
Cardiac MRI/function.
Cardiac MRI/limited study.
Brain imaging (PET).
Cerebral vascular flow image.
In111 pentetreotide.
LOCM≤149mg/ml iodine, 1ml.
LOCM 150–199mg/ml iodine,
1ml.
LOCM 200–249mg/ml iodine,
1ml.
LOCM 250–299mg/ml iodine,
1ml.
LOCM 300–349mg/ml iodine,
1ml.
LOCM 350–399mg/ml iodine,
1ml.
Inj Gad-base MR contrast,
1ml.
RADIATION THERAPY SERVICES AND
SUPPLIES
[no deletions]
DRUGS USED BY PATIENTS UNDERGOING
DIALYSIS
[no deletions]
PREVENTIVE SCREENING TESTS,
IMMUNIZATIONS AND VACCINES
[no deletions]
1 CPT codes and descriptions only are copyright 2007 AMA. All rights are reserved and
applicable FARS/DFARS clauses apply.
VI. Physician Fee Schedule Update for
CY 2008
A. Physician Fee Schedule Update
The PFS update is set under a formula
specified in section 1848(d)(4) of the
PREVENTIVE SCREENING TESTS,
Act, as amended by the MIEA–TRHCA.
IMMUNIZATIONS AND VACCINES
Section 101 of the MIEA–TRHCA
90669 ............... Pneumococcal vacc, ped
provided a 1 year increase in the CY
<5.
2007 conversion factor and specified
that the conversion factor for CY 2008
1 CPT codes and descriptions only are copyright 2007 AMA. All rights are reserved and must be computed as if the 1-year
increase had never applied. Consistent
applicable FARS/DFARS clauses apply.
with this requirement, the update for CY
TABLE 20.—DELETIONS TO THE PHYSI- 2008 is equal to the product of 1 plus
CIAN SELF-REFERRAL LIST OF CPT1/ the CY 2007 update (as published in the
CY 2007 PFS final rule with comment
HCPCS CODES
period (71 FR 69751)), 1 plus the
percentage increase in the MEI (divided
CLINICAL LABORATORY SERVICES
by 100), and 1 plus the UAF. As stated
in the CY 2007 PFS final rule with
[no deletions]
comment period, if section 101 of the
cprice-sewell on PROD1PC72 with RULES
[no additions]
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
66373
PO 00000
Frm 00153
Fmt 4701
Sfmt 4700
(0.94953). For CY 2008, the MEI is equal
to 1.8 percent (1.018). The UAF is ¥7.0
percent (0.930). The product of the
published CY 2007 update (0.94953),
MEI (1.018), and the UAF (0.930) equals
the CY 2008 update of ¥10.1 percent
(0.89896).
Our calculations of these figures are
explained in this section.
B. The Percentage Change in the
Medicare Economic Index (MEI)
The Medicare Economic Index (MEI)
is authorized by section 1842(b)(3) of
the Act, which states that prevailing
charge levels beginning after June 30,
1973 may not exceed the level from the
previous year except to the extent that
the Secretary finds, on the basis of
appropriate economic index data, that
the higher level is justified by year-toyear economic changes.
The MEI measures the weightedaverage annual price change for various
inputs needed to produce physicians’
services. The MEI is a fixed-weight
input price index, with an adjustment
for the change in economy-wide
multifactor productivity. This index,
which has CY 2000 base year weights,
is comprised of two broad categories: (1)
Physician’s own time; and (2)
physician’s PE.
The physician’s own time component
represents the net income portion of
business receipts and primarily reflects
the input of the physician’s own time
into the production of physicians’
services in physicians’ offices. This
category consists of two
subcomponents: (1) Wages and salaries;
and (2) fringe benefits.
The physician’s PE category
represents nonphysician inputs used in
the production of services in physicians’
offices. This category consists of wages
and salaries and fringe benefits for
nonphysician staff and other nonlabor
inputs. The physician’s PE component
also includes the following categories of
nonlabor inputs: Office expense;
medical materials and supplies;
professional liability insurance; medical
equipment; prescription drugs; and
other expenses. The components are
adjusted to reflect productivity growth
in physicians’ offices by the 10-year
moving average of productivity in the
private nonfarm business sector.
In the CY 2008 PFS proposed rule (72
FR 38190), we presented a listing of the
cost categories with the associated cost
weights. We also explained that the
Bureau of Labor Statistics (BLS) has
discontinued production and
publication of the white collar
E:\FR\FM\27NOR2.SGM
27NOR2
66374
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
occupation employment cost index
(ECI) series which was used as the price
proxy for nonphysician benefits in the
MEI. There was no other comparable
published series that was a suitable
replacement for the white collar benefit
ECI. Therefore, a nationally recognized
economic and financial forecasting firm,
Global Insight, Inc. (GII), and CMS
jointly developed a composite series
which is composed of four published
ECI series and weighted by November
2004 National Industry Specific
Occupational Employment and Wage
Estimates for NAICS 6211, Office of
Physicians. We proposed to replace the
ECI white collar benefit series with this
composite benefit index effective for the
CY 2008 MEI update (See the CY 2008
PFS proposed rule (72 FR 38190) for a
more detailed explanation of the
specific proposal). In addition, we also
published a preliminary estimate of the
expected MEI update.
Table 21 presents a listing of the MEI
cost categories with associated weights
and percent changes for price proxies
for the 2008 update. For CY 2008, the
increase in the MEI is 1.8 percent,
which includes a 1.4 percent
productivity offset based on the 10-year
moving average of multifactor
productivity. This is the result of a 3.7
percent increase in physician’s own
time and a 2.7 percent increase in
physician’s PE. Within the physician’s
PE, the largest increase occurred in
prescription drugs, which increased 4.2
percent, and professional and technical
wages, which increased 4.0 percent.
TABLE 21.—INCREASE IN THE MEDICARE ECONOMIC INDEX UPDATE FOR CY 2008 1
CY 2000
weights 2
Cost categories and price measures
Medicare Economic Index Total, productivity adjusted 3 .........................................................................................
Productivity: 10-year moving average of multifactor productivity, private nonfarm business sector 3 4 ...........
Medicare Economic Index Total, without productivity adjustment 4 ........................................................................
1. Physician’s Own Time 5 ........................................................................................................................
a. Wages and Salaries: Average Hourly Earnings, private Nonfarm ................................................
b. Fringe Benefits: Employment Cost Index, benefits, private nonfarm ............................................
2. Physician’s Practice Expense 5 .............................................................................................................
a. Nonphysician Employee Compensation ........................................................................................
(1) Wages and Salaries: Employment Cost Index, wages and salaries, weighted by occupation ...........................................................................................................................................
(2) Fringe Benefits: Employment Cost Index, fringe benefits, weighted by occupation 7 ..........
b. Office Expense: Consumer Price Index for Urban Areas (CPI–U), housing ................................
c. Drugs and Medical Materials and Supplies ...................................................................................
(1) Medical Materials and Supplies: Producer Price Index (PPI), surgical appliances and supplies/CPI–U, medical equipment and supplies (equally weighted) .........................................
(2) Pharmaceuticals: Producer Price Index (PPI ethical prescription drugs) .............................
d. Professional Liability Insurance: Professional liability insurance Premiums 6 ...............................
e. Medical Equipment: PPI, medical instruments and equipment .....................................................
f. Other Expenses ..............................................................................................................................
CY 2008
percent
changes
N/A
N/A
100.000
52.466
42.730
9.735
47.534
18.653
1.8
1.4
3.2
3.7
4.0
2.7
2.7
3.6
13.808
4.845
12.209
4.319
3.6
3.7
3.5
2.9
2.011
2.308
3.865
2.055
6.433
1.0
4.2
¥0.8
¥0.4
2.6
cprice-sewell on PROD1PC72 with RULES
1 The rates of historical change are estimated for the 12-month period ending June 30, 2007, which is the period used for computing the CY
2008 update. The price proxy values are based upon the latest available Bureau of Labor Statistics data as of August 31, 2007.
2 The weights shown for the MEI components are the 2000 base year weights, which may not sum to subtotals or totals because of rounding.
The MEI is a fixed weight, Laspeyres-type input price index whose category weights indicate the distribution of expenditures among the inputs to
physicians’ services for CY 2000. To determine the MEI level for a given year, the price proxy level for each component is multiplied by its 2000
weight. The sum of these products (weights multiplied by the price index levels) over all cost categories yields the composite MEI level for a
given year. The annual percent change in the MEI levels is an estimate of price change over time for a fixed market basket of inputs to physicians’ services.
3 These numbers may not sum due to rounding and the multiplicative nature of their relationship.
4 On March 23, 2006, Bureau of Labor Statistics introduced a new Multi Factor Productivity (MFP) series based on the 1997 NAICS classification system to replace its SIC based series published until 2005 (the last historical value was for 2002). The new series differs historically from
the old MFP series and adds two new historical values through 2004. Therefore, we used the most recently available information (thru CY 2006)
to develop the productivity adjustment for the CY 2008 update.
5 The measures of productivity, average hourly earnings, Employment Cost Indexes, as well as the various Producer and CPIs can be found
on the BLS Web site at https://stats.bls.gov.
6 Derived from data collected from several major insurers (the latest available historical percent change data are for the period ending second
quarter of 2007).
7 In April 2007, with their March 2007 publication, Bureau of Labor Statistics (BLS) discontinued production and publication of the white collar
occupation employment cost index (ECI) series. CMS replaced this proxy with a composite benefit series. The historical percent changes for the
non physician employee benefits match the BLS white collar benefit series through 2006Q4, and from 2007Q1 forward, the percent changes reflect those of the composite benefit series. For more detail on the composite benefit series see the CY 2008 PFS proposed rule (72 FR 38190).
Comment: Many commenters
proposed that we should reduce the
productivity adjustment to the MEI to
0.65 percentage points from the
proposed productivity adjustment of 1.5
percentage points. They believe the MEI
should be subject to the same
productivity adjustment as the
recommended productivity adjustment
for hospital, hospice, and ambulance
care providers, which they state was
recommended in the President’s Budget
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
proposal. The commenters also note that
it is not logical for CMS to believe that
physician’s productivity is increasing at
twice the rate of other health care
providers.
Response: We disagree that the
productivity adjustment to the MEI
should be changed based on the
proposals made in the FY 2008
PO 00000
President’s Budget.4 The MEI has
contained a productivity adjustment
since its inception in 1973. The
rationale for, and technical
appropriateness of the current MEI
productivity adjustment has been well
documented in the Federal Register (for
example, 67 FR 80020 through 80023).
Moreover, we recently partnered with
4 https://www.whitehouse.gov/omb/budget/fy2008/
hhs.html.
Frm 00154
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the Assistant Secretary of Planning and
Evaluation of the Department of Health
and Human Services to sponsor an
analysis of physician-specific
productivity. The results of this effort
were presented at a conference of
stakeholders in October 2006. A highly
respected panel of experts concluded
that the use of the 10-year moving
average for private, nonfarm business
sector multifactor productivity was not
an unreasonable proxy for physicianspecific productivity. Papers from this
research effort are expected to be
published in the forthcoming Winter
2007/2008 edition of the Health Care
Financing Review. We will continue to
monitor, on an ongoing basis, the
appropriateness of the use of this
economy-wide measure of multifactor
productivity for purposes of adjusting
the MEI.
With respect to historical productivity
achievement in other health care
sectors, there is comparatively little on
this topic in the literature. We intend to
continue to research various healthrelated productivity measures and
would welcome the provision of data or
completed studies on this topic.
Comment: One commenter questioned
why other providers receive a 0.65
percent adjustment while physicians
face an adjustment of more than twice
that amount.
Response: To date, there are no laws
in place requiring productivity
adjustments for other PPS-reimbursed
providers such as hospitals, and skilled
nursing facilities. However, the MEI has
contained an explicit productivity
adjustment since its inception in 1973.
The rationale and technical
appropriateness of the current MEI
productivity adjustment was addressed
in the CY 2003 PFS final rule with
comment period (67 FR 80019).
Comment: Several commenters
requested that we address the broader
issue that the MEI only measures
changes in the specific types of practice
costs that existed in 1973. They note
that inputs to the MEI are vastly
different now than when the MEI was
first developed in the 1970s, and suggest
additional inputs may be needed to
ensure that the current MEI adequately
measures the costs of practicing
medicine.
Response: We disagree with the
commenters’ claim that the MEI only
measures changes in specific types of
practice costs that existed in 1973. The
current MEI is based on costs reported
by physicians for the year 2000. The
2000-based cost weights are derived
from the 2003 AMA Physician
Socioeconomic Characteristics
publication (2003 Patient Care
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Physician Survey data), which measures
physicians’ earnings and overall PEs for
2000. This is the latest available data on
the breakdown of physician expenses.
Although cost weights in the various
market baskets do not tend to change
dramatically over short periods of time,
we do recognize that they can change
over long periods of time. We are
presently researching alternative data
sources for a forthcoming rebasing of the
MEI, including the potential use of an
AMA-sponsored Physician Practice
Information Survey that was fielded in
2007. We have also considered data
from the Census Bureau’s Business
Expenditure Survey (BES). This survey
is the most comprehensive source of
periodic national industry statistics on
major economic inputs by type. Data are
published every 5 years for years ending
in ‘‘2’’ and ‘‘7’’. Currently the most
recent data is reported for 2002. We
compared the cost weights we derived
from the 2002 BES data for NAICS 6211,
Offices of Physicians and found that the
overall cost weights for compensation
and all other costs are quite similar to
the cost weights for the current MEI
market basket as shown in Table 22. We
are optimistic that the new data from
AMA or the Census Bureau will be
sufficiently robust for the purpose of
updating the MEI’s input cost weights.
66375
would reflect changes in the
distributions of the cost weights
associated with new governmentimposed regulatory requirements up to
that point. These cost weights are
derived from the 2003 AMA Physician
Socioeconomic Characteristics
publication (2003 Patient Care
Physician Survey data), which measures
physicians’ earnings and overall PEs for
CY 2000. While we understand that
more recent data would better measure
relative input costs, we presently lack a
viable alternative data source with
which to compute new cost weights.
The data used as the basis for the
current MEI market basket cost weights
represent the latest available data on
physician expenses. As stated
previously, we are awaiting the data
from the 2007 AMA Physician Practice
Information Survey and are hopeful that
this source will be sufficiently robust for
use in rebasing the cost weights found
in the MEI. We would expect that any
relative cost changes related to
regulatory changes would be reflected in
this new data.
Comment: One commenter suggested
we should discontinue use of the MEI
to measure physician input price
pressures and switch to the same market
basket update used by the hospital
outpatient prospective payment system
(OPPS).
Response: We disagree with the
TABLE 22.—A COMPARISON OF MAJOR
commenter that physicians and
COST CATEGORY MEI MARKET BAS- outpatient hospital departments face the
KET WEIGHTS USING AMA AND BES same input costs.
DATA
The MEI reflects the cost structure
and price changes associated with the
2002 BES
inputs used in furnishing physicians’
MB 2000
(excluding
services while the hospital market
weights
capital)
(percent)
basket reflects the cost structure and
(percent)
price changes associated with the inputs
Compensation ...
71.2
73.5 used in providing hospital services.
Other .................
28.8
26.5
Comment: One commenter noted that
input expenses for recruiting and
Comment: Several commenters
employing trained personnel and other
believe that the MEI does not adequately PEs in the physician’s office are
account for the costs related to the
identical to those in a hospital.
multitude of regulations and
Response: The expenses for trained
requirements that physicians must
personnel are captured in the PE portion
comply with in their practices. For
of the MEI. These PE cost weights are
example, they note that the physician
derived from the 2003 AMA Physician
quality reporting initiative (PQRI) has
Socioeconomic Characteristics
reduced productivity in physician’s
publication (2003 Patient Care
offices. Similarly, a commenter had
Physician Survey data), which measures
concerns that employee wages used in
physicians’ earnings and overall PEs for
the MEI formula do not capture the
CY 2000. As indicated above in this
wages of highly skilled professionals
section, while we understand that more
such as nurse practitioners, physician
recent data would better measure
assistants, certified nurse specialists,
relative input costs, we presently lack a
nurse midwives, therapists, computer
viable alternative data source with
professional, and other types of
which to compute new cost weights.
professional occupations.
The data used as the basis for the
Response: The current MEI cost
current MEI market basket cost weights
weights are based on input costs
represent the latest available data on
reported by physicians for 2000, which
physician expenses. We are awaiting the
PO 00000
Frm 00155
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66376
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
data from the 2007 AMA Physician
Practice Information Survey and are
hopeful that this source will be
sufficiently robust for use in rebasing
the cost weights found in the MEI. We
would expect that any relative cost
changes related to PE costs would be
reflected in this new data.
Comment: One commenter disagreed
with the price proxy used for office
expenses in the MEI noting that the
growth in office rents differ from
apartment rents. The commenter also
suggested that we get data from a
contractor comparing the cost of
building medical office space to that of
residential living space.
Response: We agree that the
construction costs of a physician’s office
differ from the construction costs of a
residential dwelling; however, the cost
category for office expenses is not
designed to measure the changes in
initial construction costs. Instead, we
attempt to measure the rate of price
changes related to a monthly office
expense payment. The majority of
monthly office expenses are related to
rent or mortgage for commercial space.
As we are not aware of a publiclyavailable proxy that measures the price
changes in rental costs of commercial
space, we use what we believe to be the
best, technically appropriate alternative;
the consumer price index (CPI) for
housing. Other major office expenses,
such as medical equipment, are broken
out in greater detail. Once data is
available for the next rebasing of the
MEI, we will explore the feasibility of
breaking office expenses into more
comprehensive cost categories.
Comment: One commenter has
concerns that the forecasts of the MEI
have been and continue to be declining
(from over 3 percent to below 2 percent)
for the foreseeable future. The
commenter would like for CMS to
examine in more detail the assumptions
of the price proxy forecasts produced by
Global Insight Inc. (GII).
Response: It is important to note that
the MEI update is based on historical
data rather than on forecasted data. For
example, the CY 2008 update is based
on the actual measured price inflation
through the second quarter of 2007.
Since the MEI update is based on
historical data, not on a forecast, the
concern that GII’s work does not involve
forecasting the price proxies for
compensation and PEs accurately is not
relevant. Table 23 shows the MEI
updates for the past 5 years and the
current CY 2008 update. While the MEI
update for CY 2003 through CY 2006
was closer to 3.0 percent, the MEI
update for CY 2007 and CY 2008 is
closer to 2.0 percent. These lower
updates are not, however, a function of
an incorrect forecast. The recent lower
overall MEI updates are a function of
both a deceleration in input price
pressures and relatively higher gains in
multifactor productivity.
TABLE 23.—MEI UPDATES FOR THE PAST 5 YEARS AND THE CURRENT CY 2008 UPDATE *
MEI final updates
CY
CY
CY
CY
CY
CY
2003
2004
2005
2006
2007
2008
Adjusted
.......................................................................................................................................
.......................................................................................................................................
.......................................................................................................................................
.......................................................................................................................................
.......................................................................................................................................
.......................................................................................................................................
Unadjusted
3.0
2.9
3.1
2.8
2.1
1.8
Productivity
3.8
3.8
4.0
3.8
3.5
3.2
0.8
0.9
0.9
1.0
1.3
1.4
* Prior to the update for CY 2003 the MEI was adjusted for Labor productivity rather than by private non-farm multifactor productivity.
Comment: One commenter stated that
the only solution the commenter would
support at this time would be a
nationwide legislative solution that
would provide additional funding for
fair and equitable payment to Medicare
participating physicians in every State.
Response: We do not have the
administrative authority to make such a
legislative change. More so, this
comment is beyond the scope of the MEI
proposals of the CY 2008 PFS proposed
rule.
cprice-sewell on PROD1PC72 with RULES
C. The Update Adjustment Factor (UAF)
Section 1848(d) of the Act provides
that the PFS update is equal to the
product of the MEI and the UAF. The
UAF is applied to make actual and
target expenditures (referred to in the
statute as ‘‘allowed expenditures’’)
equal. Allowed expenditures are equal
to actual expenditures in a base period
updated each year by the sustainable
growth rate (SGR). The SGR sets the
annual rate of growth in allowed
expenditures and is determined by a
formula specified in section 1848(f) of
the Act.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Section 101 of the MIEA TRHCA
provided a 1 year increase in the CY
2007 conversion factor. The provision
specified that the CF for CY 2008 must
be computed as if the 1 year increase for
CY 2007 had never applied.
1. Calculation Under Current Law
Under section 1848(d)(4)(B) of the
Act, the UAF for a year beginning with
CY 2001 is equal to the sum of the
following—
• Prior Year Adjustment Component.
An amount determined by—
+ Computing the difference (which
may be positive or negative) between
the amount of the allowed expenditures
for physicians’ services for the prior
year (the year prior to the year for which
the update is being determined) and the
amount of the actual expenditures for
those services for that year;
+ Dividing that difference by the
amount of the actual expenditures for
those services for that year; and
+ Multiplying that quotient by 0.75.
• Cumulative Adjustment
Component. An amount determined
by—
PO 00000
Frm 00156
Fmt 4701
Sfmt 4700
+ Computing the difference (which
may be positive or negative) between
the amount of the allowed expenditures
for physicians’ services from April 1,
1996, through the end of the prior year
and the amount of the actual
expenditures for those services during
that period;
+ Dividing that difference by actual
expenditures for those services for the
prior year as increased by the SGR for
the year for which the UAF is to be
determined; and
+ Multiplying that quotient by 0.33.
Section 1848(d)(4)(E) of the Act
requires the Secretary to recalculate
allowed expenditures consistent with
section 1848(f)(3) of the Act. Section
1848(f)(3) specifies that the SGR (and, in
turn, allowed expenditures) for the
upcoming CY (CY 2008 in this case), the
current CY (that is, CY 2007) and the
preceding CY (that is, CY 2006) are to
be determined on the basis of the best
data available as of September 1 of the
current year. Allowed expenditures for
a year are initially estimated and
subsequently revised twice. The second
revision occurs after the CY has ended
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(that is, we are making the final revision
to 2006 allowed expenditures in this
final rule with comment). Once the SGR
and allowed expenditures for a year
have been revised twice, they are final.
Table 24 shows annual and
cumulative allowed and actual
expenditures for physicians’ services
from April 1, 1996 through the end of
the current CY, including the short
66377
periods in 1999 when we transitioned to
a CY system. Also shown is the SGR
corresponding with each period. The
calculation of the SGR is discussed in
detail below in this section.
TABLE 24.—ANNUAL AND CUMULATIVE ALLOWED AND ACTUAL EXPENDITURES FOR PHYSICIANS’ SERVICES FROM APRIL 1,
1996 THROUGH THE END OF THE CURRENT CALENDAR YEAR
Annual
allowed
expenditures
($ in billions)
Period
Annual
actual
expenditures
($ in billions)
1 $48.9
4/1/96–3/31/97 ..................................................
4/1/97–3/31/98 ..................................................
4/1/98–3/31/99 ..................................................
1/1/99–3/31/99 ..................................................
4/1/99–12/31/99 ................................................
1/1/99–12/31/99 ................................................
1/1/00–12/31/00 ................................................
1/1/01–12/31/01 ................................................
1/1/02–12/31/02 ................................................
1/1/03–12/31/03 ................................................
1/1/04–12/31/04 ................................................
1/1/05–12/31/05 ................................................
1/1/06–12/31/06 ................................................
1/1/07–12/31/07 ................................................
1/1/08–12/31/08 ................................................
50.5
52.6
13.3
42.1
55.3
59.3
62.0
67.2
72.1
76.8
80.1
81.3
83.9
83.8
Cumulative
allowed
expenditures
($ in billions)
$48.9
49.4
50.5
13.1
39.5
52.6
58.1
66.3
70.9
78.2
87.1
91.8
93.4
94.6
NA
Cumulative
actual
expenditures
($ in billions)
$48.9
99.4
152.0
(2)
(3)
194.0
253.4
315.4
382.6
454.6
531.5
611.5
692.8
776.6
860.4
$48.9
98.4
148.9
148.9
188.4
188.4
246.5
312.8
383.7
461.9
549.0
640.8
734.2
828.8
NA
FY/CY SGR
N/A
FY 1998=3.2%
FY 1999=4.2%
FY 1999=4.2%
FY 2000=6.9%
FY 1999/2000
CY 2000=7.3%
CY 2001=4.5%
CY 2002=8.3%
CY 2003=7.3%
CY 2004=6.6%
CY 2005=4.2%
CY 2006=1.5%
CY 2007=3.2%
CY 2008= 0.1%
1 Allowed expenditures in the first year (April 1, 1996–March 31, 1997) are equal to actual expenditures. All subsequent figures are equal to
quarterly allowed expenditure figures increased by the applicable SGR. Cumulative allowed expenditures are equal to the sum of annual allowed
expenditures. We provide more detailed quarterly allowed and actual expenditure data on our Web site at the following address: https://
www.cms.hhs.gov/SustainableGRatesConFact/. We expect to update the Web site with the most current information later this month.
2 Allowed expenditures for the first quarter of 1999 are based on the FY 1999 SGR.
3 Allowed expenditures for the last three quarters of 1999 are based on the FY 2000 SGR.
Consistent with section 1848(d)(4)(E)
of the Act, Table 24 includes our final
revision of allowed expenditures for CY
2006, a recalculation of allowed
expenditures for CY 2007, and our
initial estimate of allowed expenditures
for CY 2008. To determine the UAF for
CY 2008, the statute requires that we
UAF08 =
use allowed and actual expenditures
from April 1, 1996 through December
31, 2007 and the CY 2008 SGR.
Consistent with section 1848(d)(4)(E) of
the Act, we will be making revisions to
the CY 2007 and CY 2008 SGRs and CY
2007 and CY 2008 allowed
expenditures. Because we have
incomplete actual expenditure data for
CY 2007, we are using an estimate for
this period. Any difference between
current estimates and final figures will
be taken into account in determining the
UAF for future years.
We are using figures from Table 24 in
the following statutory formula:
Target 07 − Actual07
Target 4/96 −12/07 − Actual4/96 −12/07
× .75 +
× .33
Actual07
Actual07 × SGR 08
UAF08 = Update Adjustment Factor for CY
2008 = ¥26.7 percent
Target07 = Allowed Expenditures for CY 2007
= $83.9 billion
Actual07 = Estimated Actual Expenditures for
CY 2007 = $94.6 billion
Target 4/96–12/07 = Allowed Expenditures from
4/1/1996–12/31/2007 = $776.6 billion
Actual 4/96–12/07 = Estimated Actual
Expenditures from 4/1/1996–12/31/2007
= $828.8 billion
SGR08 = ¥0.1 percent (0.999)
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
1848(d)(4)(B) of the Act. Thus, adding
1.0 to ¥0.070 makes the UAF equal to
0.930.
PO 00000
VII. Allowed Expenditures for
Physicians’ Services and the
Sustainable Growth Rate
A. Medicare Sustainable Growth Rate
The SGR is an annual growth rate that
applies to physicians’ services paid by
Medicare. The use of the SGR is
intended to control growth in aggregate
Medicare expenditures for physicians’
Frm 00157
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
ER27NO07.001
Section 1848(d)(4)(D) of the Act
indicates that the UAF determined
under section 1848(d)(4)(B) of the Act
for a year may not be less than ¥0.070
or greater than 0.03. Since ¥0.267 is
less than ¥0.070, the UAF for CY 2008
will be ¥0.070.
Section 1848(d)(4)(A)(ii) of the Act
indicates that 1.0 should be added to the
UAF determined under section
ER27NO07.000
cprice-sewell on PROD1PC72 with RULES
$83.9 − $94.6
$776.6 − $828.8
× .75 +
× .33 = − 0.267
$94.6
$94.6 × 0.999
66378
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
services. Payments for services are not
withheld if the percentage increase in
actual expenditures exceeds the SGR.
Rather, the PFS update, as specified in
section 1848(d)(4) of the Act, is adjusted
based on a comparison of allowed
expenditures (determined using the
SGR) and actual expenditures. If actual
expenditures exceed allowed
expenditures, the update is reduced. If
actual expenditures are less than
allowed expenditures, the update is
increased.
Section 1848(f)(2) of the Act specifies
that the SGR for a year (beginning with
CY 2001) is equal to the product of the
following four factors:
(1) The estimated change in fees for
physicians’ services;
(2) The estimated change in the
average number of Medicare fee-forservice beneficiaries;
(3) The estimated projected growth in
real GDP per capita; and
(4) The estimated change in
expenditures due to changes in statute
or regulations.
In general, section 1848(f)(3) of the
Act requires us to publish SGRs for 3
different time periods, no later than
November 1 of each year, using the best
data available as of September 1 of each
year. Under section 1848(f)(3)(C)(i) of
the Act, the SGR is estimated and
subsequently revised twice (beginning
with the FY and CY 2000 SGRs) based
on later data. (The Act also provides for
adjustments to be made to the SGRs for
FY 1998 and FY 1999. See the February
28, 2003 Federal Register (68 FR 9567)
for a discussion of these SGRs). Under
section 1848(f)(3)(C)(ii) of the Act, there
are no further revisions to the SGR once
it has been estimated and subsequently
revised in each of the 2 years following
the preliminary estimate. In this final
rule with comment, we are making our
preliminary estimate of the CY 2008
SGR, a revision to the CY 2007 SGR, and
our final revision to the CY 2006 SGR.
B. Physicians’ Services
Section 1848(f)(4)(A) of the Act
defines the scope of physicians’ services
covered by the SGR. The statute
indicates that ‘‘the term physicians’
services includes other items and
services (such as clinical diagnostic
laboratory tests and radiology services),
specified by the Secretary, that are
commonly performed or furnished by a
physician or in a physician’s office, but
does not include services furnished to a
Medicare+Choice plan enrollee.’’ We
published a definition of physicians’
services for use in the SGR in the
November 1, 2001 Federal Register (66
FR 55316). We defined physicians’
services to include many of the medical
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
and other health services listed in
section 1861(s) of the Act. For purposes
of determining allowed expenditures,
actual expenditures, and SGRs, we have
specified that physicians’ services
include the following medical and other
health services if bills for the items and
services are processed and paid by
Medicare carriers (and those paid
through intermediaries where
specified):
• Physicians’ services.
• Services and supplies furnished
incident to physicians’ services.
• Outpatient physical therapy
services and outpatient occupational
therapy services.
• Antigens prepared by, or under the
direct supervision of, a physician.
• Services of PAs, certified registered
nurse anesthetists, certified nurse
midwives, clinical psychologists,
clinical social workers, NPs, and
certified nurse specialists.
• Screening tests for prostate cancer,
colorectal cancer, and glaucoma.
• Screening mammography,
screening pap smears, and screening
pelvic exams.
• Diabetes outpatient selfmanagement training (DSMT) services.
• MNT services.
• Diagnostic x-ray tests, diagnostic
laboratory tests, and other diagnostic
tests (including outpatient diagnostic
laboratory tests paid through
intermediaries).
• X-ray, radium, and radioactive
isotope therapy.
• Surgical dressings, splints, casts,
and other devices used for the reduction
of fractures and dislocations.
• Bone mass measurements.
• An initial preventive physical
exam.
• Cardiovascular screening blood
tests.
• Diabetes screening tests.
• Telehealth services.
• Physician work and resources to
establish and document the need for a
power mobility device (70 FR 50940).
Telehealth services and the power
mobility device related services were
added because they meet the statutory
criteria for services to be included in the
SGR (that is, these services are
commonly performed or furnished by a
physician or in a physician’s office) (70
FR 70305).
Summary of Comments on the
Physician Update and the SGR
We appreciate the comments we
received expressing concern about the
negative update for CY 2008 and the
SGR formula. These comments and our
responses are summarized here.
Comment: The 2007 Medicare
Trustees Report projected an
PO 00000
Frm 00158
Fmt 4701
Sfmt 4700
approximate 10 percent reduction in
payment for physicians’ services in CY
2008 and about a 5 percent reduction in
each subsequent year through CY 2016.
The cumulative impact of the projected
reductions from CY 2008 to CY 2016 is
estimated to be about ¥40 percent. In
contrast, the MEI increase over this
same period is projected to be about 15
percent.
Commenters noted that Medicare
reimbursement does not reflect the
actual costs of delivering services to
Medicare beneficiaries. The commenters
stated the reimbursement system has
been unstable, and physicians cannot
plan for the future in an unpredictable
reimbursement environment that fails to
keep pace with the costs of labor and
supplies. Commenters also stated that
practitioners unable to absorb the
sustained losses will refuse or limit
Medicare patients, resulting in reduced
access to care. Commenters believe that
beneficiaries will be forced to seek care
in inpatient settings, which will be more
costly for Medicare, less efficient in
delivering care, and yield worse health
outcomes for beneficiaries.
Commenters recommended that the
SGR be replaced with a more equitable
and sustainable formula, such as an
appropriate inflation rate linked to
changes in the actual costs of medical
practice. Many commenters suggested
the MEI as an appropriate measure.
Commenters requested that we assume
the leadership in pushing the Congress
to enact legislation preventing a
negative update for CY 2008, and to
replace the SGR with a more sustainable
system.
Response: We understand the
potential implications of more than 9
years of negative physician updates. We
remain concerned regarding these
trends, and we are closely monitoring
physicians’ participation in the
Medicare program, as well as
beneficiaries’ access to care.
It is a top priority at CMS to transform
Medicare from a passive payor to an
active purchaser of high quality,
efficient health care services. We are
studying and implementing value based
purchasing initiatives for Medicare
payment systems, including physicians’
services. In addition, the FY 2008
President’s Budget supports budget
neutral physician payment reform and
states that ‘‘an important component of
improving quality is encouraging more
efficient and high-quality physician
services.’’ (For further discussion of the
President’s FY 2008 Budget initiatives
to improve the quality, efficiency and
transparency of health care, see https://
www.whitehouse.gov/omb/budget/
fy2008/hhs.html.)
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Ultimately, the formula for the SGR
and the physician update are dictated
by statute. We are required to follow
this methodology when calculating the
payment rates under the PFS. We look
forward to working with the Congress,
the physician community, and other
interested parties as we continue to
analyze appropriate alternatives to the
current system that could ensure
appropriate payments while promoting
high quality care, without increasing
Medicare costs.
Comment: Commenters noted that
only physicians and other practitioners
under the PFS face steep cuts under the
SGR formula. The commenters also
noted that other health care providers
have payment updates that reflect the
cost of inflation. Further, the
commenters stated the approximately 10
percent cut in payment rates is in stark
contrast to providers enrolled in
Medicare Advantage (MA) plans, who
are paid on average 112 percent above
the cost of traditional Medicare.
Response: As noted previously, the
formula for the SGR and the physician
update are dictated by statute. We are
required to follow this methodology
when calculating the payment rates
under the PFS. Other Medicare payment
systems have their own update
formulas.
Comment: Many commenters
requested that we use our
administrative authority to reduce the
negative physician update for CY 2008.
Many commenters stated that we are
authorized to remove the cost of
Medicare-covered physicianadministered drugs from the SGR on a
retrospective basis. They stated that we
must also adjust the SGR target to reflect
the impact of National and Local
Coverage Decisions on physician
spending. Commenters noted that the
current formula does not account for
costs and savings associated with new
technologies. The commenters stated
that if we make such administrative
changes now, then the cost of legislation
revising the payment methodology for
physicians’ services will drop, and the
likelihood of Congressional action to fix
the SGR permanently will increase.
Commenters expressed frustration that
these administrative adjustments have
been requested numerous times, yet we
have never implemented the changes.
Response: We indicated in the past
(most recently in the CY 2007 PFS final
rule with comment period (71 FR
69756)) that many of these
administrative changes are statutorily
difficult, and according to our current
estimates, making such changes would
not provide relief from the projected
negative updates for the next several
years. As indicated above in this
section, we are working with the
Congress and health professional
organizations on potential reforms that
would improve the effectiveness of the
payment methodology for physicians
without increasing overall Medicare
costs.
Comment: Commenters noted that
payment updates under the SGR are tied
to the gross domestic product (GDP),
which bears little relationship to
Medicare beneficiaries’ health care
needs or physician practice costs.
Commenters noted that medical needs
of individual patients are not related to
the growth of the overall economy, and
beneficiaries’ medical needs do not
decline during economic downturns.
Commenters stated that MEI is a better
reflection than GDP of the growth in
health care costs.
Response: As discussed in the CY
2007 PFS final rule with comment
period (71 FR 69756), the percentage
change in the MEI is one of the key
components used to update the PFS CF.
GDP is a general measure of economic
growth. It is not intended to reflect
factors specific to operating a medical
practice because these factors are
captured in the MEI. The statute
requires that GDP be used as a
component of the SGR, which is then
used to calculate the target level of
66379
expenditures. Although both MEI and
GDP are factors that affect the
calculation of the CF, the MEI has a
more direct and greater impact on the
physician update than GDP.
Comment: Commenters stated that
additional funds need to be added to the
SGR allowed expenditures for all the
ancillary costs associated with new
benefits. New benefits adjust the target,
but they generate other services whose
costs are not added to the targeted
allowed expenditures.
Response: As discussed in the CY
2007 PFS final rule with comment
period (71 FR 69756 through 69757),
our estimate of changes in expenditures
arising from changes in laws and
regulations includes induced spending
impacts, when applicable and material.
Our estimate of the additional
expenditures associated with any new
benefit, like all of the figures used to
determine a particular year’s SGR, is an
estimate that will be revised based on
subsequent data. A 2-year look back
window allows adjustments to the
estimates to reflect actual impacts. Any
differences between these estimates and
the actual measurement of these figures
will be included in future revisions of
the SGR and allowed expenditures and
incorporated into subsequent PFS
updates. (See below in this section for
a discussion of all the new benefits that
were considered in estimating the
change in expenditures due to changes
in law and regulation in 2006, 2007, and
2008.)
C. Preliminary Estimate of the SGR for
2008
Our preliminary estimate of the CY
2008 SGR is ¥0.1 percent. We first
estimated the CY 2008 SGR in March
2007, and made the estimate available to
the MedPAC and on our Web site. Table
25 shows the March 2007 estimate and
our current estimates of the factors
included in the CY 2008 SGR.
TABLE 25.—2008 SGR CALCULATION
March estimate
Fees ...............................................................
Enrollment ......................................................
Real Per Capita GDP .....................................
Law and Regulation .......................................
2.0 percent (1.020) ............................................................................
¥0.2 percent (0.998) .........................................................................
1.9 percent (1.019) ............................................................................
¥1.5 percent (0.985) .........................................................................
1.9 percent (1.019).
¥0.7 percent (0.993).
1.7 percent (1.017).
¥2.9 percent (0.971).
Total ........................................................
cprice-sewell on PROD1PC72 with RULES
Statutory factors
Current estimate
2.2 percent (1.022) ............................................................................
¥0.1 percent (0.999).
Note: Consistent with section 1848(f)(2) of the Act, the statutory factors are multiplied, not added, to produce the total (that is, 1.019 × 0.993 ×
1.017 × 0.971 = 0.999). A more detailed explanation of each figure is provided in section VII.F.1 of this preamble.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00159
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66380
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
D. Revised Sustainable Growth Rate for
2007
Our current estimate of the CY 2007
SGR is 3.2 percent. Table 26 shows our
preliminary estimate of the CY 2007
SGR that was published in the CY 2007
PFS final rule with comment period (71
FR 69757) and our current estimate.
TABLE 26.—2007 SGR CALCULATION
Statutory factors
Estimate from CY 2006
final rule
Fees ...............................................................................................................................
Enrollment ......................................................................................................................
Real Per Capita GDP ....................................................................................................
Law and Regulation .......................................................................................................
2.2 percent (1.022) .............
¥0.9 percent (0.991) .........
2.0 percent (1.020) .............
¥1.5 percent (0.985) .........
1.9 percent (1.019).
¥2.6 percent (0.974).
1.9 percent (1.019).
2.0 percent (1.020).
Total ........................................................................................................................
1.8 percent (1.018) .............
3.2 percent (1.032).
A more detailed explanation of each
figure is provided in section VIII.F.2 of
this preamble.
E. Final Sustainable Growth Rate for
2006
The SGR for 2006 is 1.5 percent. Table
27 shows our preliminary estimate of
the 2006 SGR from the CY 2006 PFS
Current estimate
final rule with comment period (70 FR
70309), our revised estimate from the
CY 2007 PFS final rule with comment
period (71 FR 69757) and the final
figures determined using the best
available data as of September 1, 2007.
TABLE 27.—2006 SGR CALCULATION
Statutory factors
Estimate from CY 2006
final rule
Estimate from CY 2007
final rule
Fees ..............................................................................
Enrollment .....................................................................
Real Per Capita GDP ...................................................
Law and Reg .................................................................
2.7 percent (1.027) .............
¥3.1 percent (0.969) .........
2.2 percent (1.022) .............
0.0 percent (1.000) .............
2.2 percent (1.022) .............
¥2.2 percent (0.978) .........
2.1 percent (1.021) .............
0.0 percent (1.000) .............
2.1 percent (1.021).
¥2.6 percent (0.974).
2.1 percent (1.021).
0.0 percent (1.000).
Total .......................................................................
1.7 percent (1.017) .............
2.1 percent (1.021) .............
1.5 percent (1.015).
A more detailed explanation of each
figure is provided in section VIII.F.3.
F. Calculation of CY 2008, CY 2007, and
CY 2006 Sustainable Growth Rates
cprice-sewell on PROD1PC72 with RULES
1. Detail on the CY 2008 SGR
All of the figures used to determine
the CY 2008 SGR are estimates that will
be revised based on subsequent data.
Any differences between these estimates
and the actual measurement of these
figures will be included in future
revisions of the SGR and allowed
expenditures and incorporated into
subsequent PFS updates.
• Factor 1—Changes in Fees for
Physicians’ Services (Before Applying
Legislative Adjustments) for CY 2008
This factor is calculated as a
weighted-average of the CY 2008
changes in fees for the different types of
services included in the definition of
physicians’ services for the SGR.
Medical and other health services paid
using the PFS are estimated to account
for approximately 80.4 percent of total
allowed charges included in the SGR in
CY 2008 and are updated using the MEI.
The MEI for CY 2008 is 1.8 percent.
Diagnostic laboratory tests are estimated
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
to represent approximately 7.6 percent
of Medicare allowed charges included
in the SGR for CY 2008. Medicare
payments for these tests are updated by
the Consumer Price Index for Urban
Areas (CPI–U). However, section 629 of
the MMA specifies that diagnostic
laboratory services will receive an
update of 0.0 percent from CY 2004
through CY 2008.
Drugs are estimated to represent 12.0
percent of Medicare allowed charges
included in the SGR in CY 2008. We
estimated a weighted average change in
fees for drugs included in the SGR
(using the ASP + 6 percent pricing
methodology) of 4.0 percent for CY
2008.
Table 28 shows the weighted average
of the MEI, laboratory, and drug price
changes for CY 2008.
Final
TABLE 28.—WEIGHTED AVERAGE OF
THE MEI, LABORATORY, AND DRUG
PRICE CHANGES FOR CY 2008—
Continued
Weight
Weighted-average ....
1.000
Update
1.9
We estimate that the weighted average
increase in fees for physicians’ services
in CY 2008 under the SGR (before
applying any legislative adjustments)
will be 1.9 percent.
• Factor 2—The Percentage Change in
the Average Number of Part B Enrollees
From CY 2007 to CY 2008
This factor is our estimate of the
percent change in the average number of
fee-for-service enrollees from CY 2007
to CY 2008. Services provided to
TABLE 28.—WEIGHTED AVERAGE OF Medicare Advantage (MA) plan
enrollees are outside the scope of the
THE MEI, LABORATORY, AND DRUG
SGR and are excluded from this
PRICE CHANGES FOR CY 2008
estimate. OACT estimates that the
average number of Medicare Part B feeWeight
Update
for-service enrollees will decrease by 0.7
Physician ..................
0.804
1.8 percent from CY 2007 to CY 2008. Table
Laboratory .................
0.076
0.0 29 illustrates how this figure was
Drugs ........................
0.120
4.0 determined.
PO 00000
Frm 00160
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66381
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 29.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES
[(Excluding beneficiaries enrolled in MA plans) from CY 2007 to CY 2008]
2007
Overall .....................................................................................................................................................
Medicare Advantage (MA) ......................................................................................................................
Net ...........................................................................................................................................................
Percent Increase .....................................................................................................................................
An important factor affecting fee-forservice enrollment is beneficiary
enrollment in Medicare Advantage (MA)
plans. Because it is difficult to estimate
the size of the MA enrollee population
before the start of a CY, at this time we
do not know how actual enrollment in
MA plans will compare to current
estimates. For this reason, the estimate
may change substantially as actual
Medicare fee-for-service enrollment for
CY 2008 becomes known.
• Factor 3—Estimated Real Gross
Domestic Product Per Capita Growth in
2008
We estimate that the growth in real
GDP per capita from CY 2007 to CY
2008 will be 1.7 percent (based on the
10-year average GDP over the 10-years
of 1999–2008). Our past experience
indicates that there have also been
changes in estimates of real per capita
GDP growth made before the year begins
and the actual change in GDP computed
after the year is complete. Thus, it is
possible that this figure will change as
actual information on economic
performance becomes available to us in
2008.
• Factor 4—Percentage Change in
Expenditures for Physicians’ Services
Resulting From Changes in Statute or
Regulations in CY 2008 Compared With
CY 2007
The statutory and regulatory
provisions that will affect expenditures
in CY 2008 relative to CY 2007 are
estimated to have an impact on
expenditures of ¥2.9 percent. These
provisions include the expiration of the
MMA provisions for the work GPCI
floor and HPSA bonuses, the DRA
provision reducing payments for
imaging services, and the MIEA–TRHCA
provisions regarding the conversion
factor and the 2007 PQRI reporting
bonuses payable in 2008. The details of
these provisions are discussed
elsewhere in this final rule with
comment.
2. Detail on the 2007 SGR
A more detailed discussion of our
revised estimates of the four elements of
the 2007 SGR follows.
• Factor 1—Changes in Fees for
Physicians’ Services (Before Applying
Legislative Adjustments) for 2007
This factor was calculated as a
weighted-average of the 2007 changes in
fees that apply for the different types of
services included in the definition of
physicians’ services for the SGR.
We estimate that services paid using
the PFS account for approximately 82.5
percent of total allowed charges
included in the SGR in CY 2007. These
services were updated using the CY
2007 MEI of 2.1 percent. We estimate
that diagnostic laboratory tests represent
approximately 7.3 percent of total
allowed charges included in the SGR in
CY 2007. Medicare payments for these
tests are updated by the CPI–U.
However, section 629 of the MMA
specifies that diagnostic laboratory
services will receive an update of 0.0
percent from CY 2004 through CY 2008.
We estimate that drugs represent 10.2
percent of Medicare-allowed charges
2008
40.726 million ........
7.890 million ...........
32.836 million ........
................................
41.480 million.
8.888 million.
32.592 million.
¥0.7 percent.
included in the SGR in CY 2007. We
estimate a weighted-average change in
fees for drugs included in the SGR of 1.3
percent for CY 2007.
Table 30 shows the weighted-average
of the MEI, laboratory, and drug price
changes for CY 2007.
TABLE 30.—WEIGHTED AVERAGE OF
THE MEI, LABORATORY, AND DRUG
PRICE CHANGES FOR CY 2007
Weight
Physician ..................
Laboratory .................
Drugs ........................
Weighted-average ....
0.825
0.073
0.102
1.000
Update
2.1
0.0
1.3
1.9
After taking into account the elements
described in Table 30, we estimate that
the weighted-average increase in fees for
physicians’ services in 2007 under the
SGR (before applying any legislative
adjustments) will be 1.9 percent. Our
estimate of this factor in the CY 2007
PFS final rule with comment period was
2.2 percent. The decrease in the
estimate is due to the availability of
some actual data.
• Factor 2—The Percentage Change in
the Average Number of Part B Enrollees
from CY 2006 to CY 2007
OACT estimates that the average
number of Medicare Part B fee-forservice enrollees (excluding
beneficiaries enrolled in Medicare
Advantage plans) decreased by 2.6
percent in CY 2007. Table 31 illustrates
how we determined this figure.
TABLE 31.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES
[(Excluding beneficiaries enrolled in MA plans) from CY 2006 to CY 2007]
2006
2007
cprice-sewell on PROD1PC72 with RULES
Overall ...............................................................
Medicare Advantage (MA) .................................
Net .....................................................................
Percent Increase ...............................................
40.271 million ...................................................
6.550 million .....................................................
33.721 million ...................................................
......................................................................
40.726 million.
7.890 million.
32.836 million.
¥2.6 percent.
OACT’s estimate of the ¥2.6
percentage change in the number of feefor-service enrollees, net of Medicare
Advantage enrollment for CY 2007
compared to CY 2006, is lower than our
original estimate of ¥0.9 percent in the
CY 2007 PFS final rule with comment
period (71 FR 69758). While our current
projection based on data from 8 months
of 2007 is lower than our original
estimate of ¥0.9 percent when we had
no actual data, it is still possible that
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00161
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66382
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
our final estimate of this figure will be
different once we have complete
information on CY 2007 fee-for-service
enrollment.
• Factor 3—Estimated Real Gross
Domestic Product Per Capita Growth in
CY 2007
We estimate that the growth in real
GDP per capita will be 1.9 percent for
CY 2007 (based on the 10-year average
GDP over the 10 years of CY 1998
through CY 2007). Our past experience
indicates that there have also been
differences between our estimates of
real per capita GDP growth made prior
to the year’s end and the actual change
in this factor. Thus, it is possible that
this figure will change further as
complete actual information on CY 2007
economic performance becomes
available to us in 2008.
• Factor 4—Percentage Change in
Expenditures for Physicians’ Services
Resulting From Changes in Statute or
regulations in CY 2007 Compared With
CY 2006
The statutory and regulatory
provisions that will affect expenditures
in CY 2007 relative to CY 2006 are
estimated to have an impact on
expenditures of 2.0 percent. These
provisions include the DRA provisions
adding the AAA ultrasound test to the
Welcome to Medicare visit as a
preventive benefit and reducing
payments for imaging services. Also
included is the MIEA–TRHCA 1-year
adjustment to the conversion factor. The
details of these provisions are discussed
elsewhere in this final rule with
comment.
3. Detail on the CY 2006 SGR
A more detailed discussion of our
final revised estimates of the four
elements of the CY 2006 SGR follows.
• Factor 1—Changes in Fees for
Physicians’ Services (Before Applying
Legislative Adjustments) for 2006
This factor was calculated as a
weighted average of the CY 2006
changes in fees that apply for the
different types of services included in
the definition of physicians’ services for
the SGR.
Services paid using the PFS
accounted for approximately 83.8
percent of total Medicare-allowed
charges included in the SGR for CY
2006 and are updated using the MEI.
The MEI for CY 2006 was 2.8 percent.
Diagnostic laboratory tests represented
approximately 7.2 percent of total CY
2006 Medicare allowed charges
included in the SGR and are updated by
the CPI–U. However, section 629 of the
MMA specifies that diagnostic
laboratory services will receive an
update of 0.0 percent from CY 2004
through CY 2008. Drugs represented
approximately 9.1 percent of total
Medicare-allowed charges included in
the SGR for CY 2006. We estimate a
weighted-average change in fees for
drugs included in the SGR of ¥2.8
percent for 2006. Table 32 shows the
weighted average of the MEI, laboratory,
and drug price changes for CY 2006.
TABLE 32.—WEIGHTED AVERAGE OF
THE MEI, LABORATORY, AND DRUG
PRICE CHANGES FOR CY 2006
Weight
Physician ..................
Laboratory .................
Drugs ........................
Weighted-average ....
0.838
0.072
0.091
1.000
Update
2.8
0.0
¥2.8
2.1
After taking into account the elements
described in Table 32, we estimate that
the weighted-average increase in fees for
physicians’ services in CY 2006 under
the SGR (before applying any legislative
adjustments) was 2.1 percent. This
figure is a final one based on complete
data for CY 2006.
• Factor 2—The Percentage Change in
the Average Number of Part B Enrollees
from CY 2005 to CY 2006
We estimate the decrease in the
number of fee-for-service enrollees
(excluding beneficiaries enrolled in MA
plans) from CY 2005 to CY 2006 was 2.6
percent. Our calculation of this factor is
based on complete data from CY 2006.
Table 33 illustrates the calculation of
this factor.
TABLE 33.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES
[(Excluding beneficiaries enrolled in MA plans) from CY 2005 to CY 2006]
2005
2006
39.698 million ...................................................
5.084 million .....................................................
34.615 million ...................................................
......................................................................
40.271 million.
6.550 million.
33.721 million.
¥2.6 percent.
• Factor 3—Estimated Real Gross
Domestic Product Per Capita Growth in
2006
We estimate that the growth in real
per capita GDP was 2.1 percent in 2006
(based on the 10-year average GDP over
the 10 years of CY 1997 through CY
2006). This figure is a final one based on
complete data for CY 2006.
cprice-sewell on PROD1PC72 with RULES
Overall ...............................................................
Medicare Advantage (MA) .................................
Net .....................................................................
Percent Increase ...............................................
2005 is less than 0.05 percent. These
provisions include the expiration of the
temporary higher payments to
physicians in Alaska, the new power
wheelchair code for physicians, and the
IVIG pre-administration fee.
A. Physician Fee Schedule Conversion
Factor
Under section 1848(d)(1)(A) of the
Act, the PFS CF is equal to the CF for
the previous year timesplied by the
update determined under section
1848(d)(4) of the Act, as amended by the
MIEA–TRHCA. Section 101 of the
MIEA–TRHCA provided a 1-year
increase in the CY 2007 CF and
specified that the CF for CY 2008 must
be computed as if the 1-year increase
had never applied.
The PFS update for CY 2008 is
determined by timesplying the CY 2007
conversion factor update that would
have occurred in the absence of the
MIEA–TRHCA (as published in 71 FR
69760), the estimated MEI, and the
• Factor 4—Percentage Change in
Expenditures for Physicians’ Services
Resulting From Changes in Statute or
Regulations in CY 2006 Compared With
CY 2005
Our final estimate for the net impact
on expenditures from the statutory and
regulatory provisions that affect
expenditures in CY 2006 relative to CY
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
VIII. Anesthesia and Physician Fee
Schedule Conversion Factors for CY
2008
The CY 2008 PFS CF will be
$34.0682. The CY 2008 national average
anesthesia CF is $16.3176. Both CFs will
be subject to a separate, independent BN
adjustor, as described below.
PO 00000
Frm 00162
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
estimated update adjustment factor, as
shown in Table 34 (0.89896 = 0.94953
× 1.018 × 0.930). To determine the
estimated CY 2008 CF, the Pre-MIEA–
TRHCA CY 2007 CF update is applied
to the CY 2006 CF of $37.8975 to
produce the Pre-MIEA–TRHCA CY 2007
CF of $35.9848. Then applying the
estimated MEI for CY 2008 and the
estimated UAF for CY 2008 to the Pre-
66383
MIEA–TRHCA CY 2007 a CF produces
an estimated CF for CY 2008 of
$34.0682. We illustrate the calculation
for the 2008 PFS CF in Table 34.
TABLE 34.—CALCULATION OF THE CY 2008 CONVERSION FACTOR
CY 2006 Conversion Factor ...........................................................................................................................................
Pre-MIEA–TRHCA CY 2007 CF Update ........................................................................................................................
CY 2007 Pre-MIEA–TRHCA Conversion Factor ............................................................................................................
2008 MEI ........................................................................................................................................................................
2008 Update adjustment factor ......................................................................................................................................
CY 2008 Update .............................................................................................................................................................
CY 2008 Conversion Factor Update ..............................................................................................................................
CY 2008 Conversion Factor ...........................................................................................................................................
Section 1848(c)(2)(B)(ii)(II) of the Act
requires that increases or decreases in
RVUs for a year may not cause the
amount of expenditures for the year to
differ by more than $20 million from
what expenditures would have been in
the absence of these changes. If this
threshold is exceeded, we must make
adjustments to preserve BN.
The 5-Year Review of work RVUs,
including the refinement to the work
RVU changes for the additional codes
and the increases in the work of
anesthesia services, would result in a
change in expenditures that would
exceed $20 million if we made no
offsetting adjustments to either the CF
or RVUs. As discussed in section IV.C.3
of this final rule with comment period,
we are applying the following BN
adjustor to the work RVUs in order to
calculate payment for a service:
2008 Work Adjustor: 11.94 percent
(0.8806)
Payment for services under the PFS
will be calculated as follows:
Payment = [(RVU work × BN adjustor
(round product to two decimal places)
× GPCI work) + (RVU PE × GPCI PE) +
(RVU malpractice × GPCI malpractice)]
× CF
B. Anesthesia Fee Schedule Conversion
Factor
We calculate the physician anesthesia
CF similar to the general PFS CF in
Table 34. As noted, section 101 of the
TRCHA provided for a 1-year increase
in the CY 2007 conversion factor and
specified the conversion factor for 2008
must be computed as if the 1-year
increase had never applied. The PFS
update for CY 2008 is determined by
timesplying the CY 2007 conversion
$37.8975.
¥5.0 percent (0.94953).
$35.9848.
1.8 percent (1.018).
¥7.0 percent (0.930).
¥5.3 percent (0.94674).
¥10.1 percent (0.89896).
$34.0682.
factor that would have occurred in the
absence of TRCHA by the estimated MEI
and the estimated update adjustment
factor for 2008.
Anesthesia services do not have RVUs
like other PFS services. Therefore, we
account for any necessary RVU
adjustments through an adjustment to
the anesthesia fee schedule CF to
simulate changes to RVUs. We modeled
the resource based PE methodology
using imputed anesthesia RVUs that
were made comparable to other PFS
services. The 2008 adjustment factor in
Table 35 includes the combined effect of
the PE adjustment, the increase in work
of anesthesia services under the recent
five year review and the BN adjustment.
We illustrate the calculation for the
2008 anesthesia CF in Table 35.
TABLE 35.—CALCULATION FOR THE 2008 ANESTHESIA CONVERSION FACTOR
CY 2006 Anesthesia Conversion Factor ........................................................................................................................
Pre-TRHCA CY 2007 CF Update ...................................................................................................................................
2007 Combined Adjustment for PE and BN ..................................................................................................................
CY 2007 Pre-TRHCA Anesthesia Conversion Factor ....................................................................................................
$17.7663.
¥5.0 percent (0.94953).
0.9089.
$15.3328.
2008 MEI ........................................................................................................................................................................
2008 Update adjustment factor ......................................................................................................................................
CY 2008 Anesthesia CF after MEI and 2008 Adjustment Factor ..................................................................................
2008 Combined Adjustment for PE and BN ..................................................................................................................
CY 2008 Anesthesia Conversion Factor ........................................................................................................................
1.8 percent (1.018).
¥7.0 percent (0.930).
$14.5162.
1.1250.
$16.3307.
IX. Telehealth Originating Site Facility
Fee Payment Amount Update
cprice-sewell on PROD1PC72 with RULES
Section 1834(m) of the Act establishes
the payment amount for the Medicare
telehealth originating site facility fee for
telehealth services provided from
October 1, 2001 through December 31
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
2002, at $20. For telehealth services
provided on or after January 1 of each
subsequent calendar year, the telehealth
originating site facility fee is increased
by the percentage increase in the MEI as
defined in section 1842(i)(3) of the Act.
The MEI increase for 2008 is 1.8
percent.
PO 00000
Frm 00163
Fmt 4701
Sfmt 4700
Therefore, for CY 2007, the payment
amount for HCPCS code Q3014,
Telehealth originating site facility fee, is
80 percent of the lesser of the actual
charge or $23.35. The Medicare
telehealth originating site facility fee
and MEI increase by the applicable time
period is shown in Table 36.
E:\FR\FM\27NOR2.SGM
27NOR2
66384
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 36.—THE MEDICARE TELEHEALTH ORIGINATING SITE FACILITY FEE AND MEI INCREASE BY THE APPLICABLE TIME
PERIOD
MEI increase
(percent)
Facility fee
$20.00
$20.60
$21.20
$21.86
$22.47
$22.94
$23.35
..............................................................................................................................................
..............................................................................................................................................
..............................................................................................................................................
..............................................................................................................................................
..............................................................................................................................................
..............................................................................................................................................
..............................................................................................................................................
cprice-sewell on PROD1PC72 with RULES
X. Provisions of the Final Rule
The provisions of this final rule with
comment restate the provisions of the
CY 2008 PFS proposed rule, except as
noted elsewhere in the preamble.
XI. Waiver of Proposed Rulemaking
and Delay in Effective Date
We ordinarily publish a notice of
proposed rulemaking in the Federal
Register and invite public comment on
the proposed rule. The notice of
proposed rulemaking includes a
reference to the legal authority under
which the rule is proposed, and the
terms and substances of the proposed
rule or a description of the subjects and
issues involved. This procedure can be
waived, however, if an agency finds
good cause that a notice-and-comment
procedure is impracticable,
unnecessary, or contrary to the public
interest and incorporates a statement of
the finding and its reasons in the rule
issued.
We utilize HCPCS codes for Medicare
payment purposes. The HCPCS is a
national drug coding system comprised
of Level I (CPT) codes and Level II
(HCPCS National Codes) that are
intended to provide uniformity to
coding procedures, services, and
supplies across all types of medical
providers and suppliers. Level I (CPT)
codes are copyrighted by the AMA and
consist of several categories, including
Category I codes which are 5-digit
numeric codes, and Category III codes
which are temporary codes to track
emerging technology, services and
procedures.
The AMA issues an annual update of
the CPT code set each Fall, with January
1 as the effective date for implementing
the updated CPT codes. The HCPCS,
including both Level I and Level II
codes, is similarly updated annually on
a CY basis. Annual coding changes are
not available to the public until the Fall
immediately preceding the annual
January update of the PFS. Because of
the timing of the release of these new
codes, it is impracticable for CMS to
provide prior notice and solicit
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
comment on these codes and the RVUs
assigned to them in advance of
publication of the final rule that
implements the PFS. Yet, it is
imperative that these coding changes be
accounted for and recognized timely
under the PFS for payment because
services represented by these codes will
be provided to Medicare beneficiaries
by physicians during the CY in which
they become effective. Moreover,
regulations implementing HIPAA (42
CFR parts 160 and 162) require that the
HCPCS be used to report health care
services, including services paid under
the PFS. We also assign interim RVUs
to any new codes based on a review of
the RUC recommendations for valuing
these services. By reviewing these RUC
recommendations for the new codes, we
are able to assign RVUs to services
based on input from the medical
community and to establish payment for
them, on an interim basis, that
corresponds to the relative resources
associated with providing the services.
If we did not assign RVUs to new codes
on an interim basis, the alternative
would be to either not pay for these
services during the initial CY or have
each carrier establish a payment rate for
these new codes. We believe both of
these alternatives are contrary to the
public interest, particularly since the
RUC process allows for an assessment of
the valuation of these services by the
medical community prior to our
establishing payment for these codes on
an interim basis. Therefore, we believe
it would be contrary to the public
interest to delay establishment of fee
schedule payment amounts for these
codes.
For the reasons outlined above in this
section, we find good cause to waive the
notice of proposed rulemaking for the
interim RVUs for selected procedure
codes identified in Addendum C and to
establish RVUs for these codes on an
interim final basis. We are providing a
60-day public comment period.
In addition, we ordinarily publish a
notice of proposed rulemaking in the
Federal Register and provide a period
PO 00000
Frm 00164
Fmt 4701
Sfmt 4700
N/A
3.0
2.9
3.1
2.8
2.1
1.8
Period
10/01/2001–12/31/2002
01/01/2003–12/31/2003
01/01/2004–12/31/2004
01/01/2005–12/31/2005
01/01/2006–12/31/2006
01/01/2007–12/31/2007
01/01/2008–12/31/2008
for public comment before we make
final the provisions of the notice. We
can waive this procedure, however, if
we find good cause that notice-andcomment procedure is impracticable,
unnecessary, or contrary to the public
interest and we incorporate a statement
of finding and its reasons in the notice
issued. We find it unnecessary to
undertake notice and comment
rulemaking in this instance for the
ambulance inflation factor because the
law specifies the method of
computation of annual updates, and we
have no discretion in this matter.
Further, we are merely applying the
update method specified in statute and
regulation. Therefore, under 5 U.S.C.
553(b)(B), for good cause, we waive
notice and comment procedures for this
ambulance inflation factor update.
XII. Collection of Information
Requirements
Under the Paperwork Reduction Act
of 1995, we are required to provide 60day notice in the Federal Register and
solicit public comment before a
collection of information requirement is
submitted to the Office of Management
and Budget (OMB) for review and
approval. In order to fairly evaluate
whether an information collection
should be approved by OMB, section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires that we
solicit comment on the following issues:
• The need for the information
collection and its usefulness in carrying
out the proper functions of our agency.
• The accuracy of our estimate of the
information collection burden.
• The quality, utility, and clarity of
the information to be collected.
• Recommendations to minimize the
information collection burden on the
affected public, including automated
collection techniques.
This final rule with comment period
does not contain any new information
collection requirements. However, we
are republishing the discussion of the
information collection requirements as
it appeared in the CY 2008 PFS
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
proposed rule (72 FR 38122). We are
soliciting public comment on each of
these issues for the following sections of
this document that contain information
collection requirements.
Independent Diagnostic Testing Facility
(§ 410.33)
Section 410.33(g)(2) states that an
independent diagnostic testing facility
(IDTF) should provide complete and
accurate information on its Medicare
enrollment application. In addition, an
IDTF is required to notify its designated
fee-for-service contractor within 30-days
of any changes in ownership, changes of
location, changes in general
supervision, and any adverse legal
actions. The notification must be made
on the Medicare enrollment application.
All of the changes to the enrollment
application must be reported within 90
days.
The aforementioned requirements are
not new. The burden associated with
completing the Medicare enrollment
application is currently approved under
OMB control number 0938–0685. The
collection has an expiration date of
April 30, 2009.
Section 410.33(g)(6) states the
comprehensive liability insurance
requirements for IDTFs. Specifically,
§ 410.33(g)(6)(1) states they must have a
comprehensive insurance policy to
notify the CMS designated contractor, in
writing, of any policy changes or
cancellations. The burden associated
with this requirement is the time and
effort necessary to draft and submit the
written notification to the CMS
designated contractor. While this
requirement is subject to the PRA, we
believe it is exempt from the PRA as
stipulated under 5 CFR 1320.3(h)(6).
This information will be collected on
case by case basis.
Section 410.33(g)(8) requires an IDTF
to answer, document, maintain
documentation of beneficiaries
questions and responses to beneficiary
complaints at the physical site of the
IDTF. Sections 410.33(g)(8) (i through
iii) list the minimum amount of
documentation needed to comply with
this requirement. The burden associated
with these requirements is the time and
effort associated with responding to
beneficiary questions and complaints,
documenting the actions taken in
response to the questions and
complaints, and maintaining the
documentation. While this requirement
is subject to the PRA, we believe the
associated burden is exempt under 5
CFR 1320.3(b)(2). The burden associated
with documenting and maintaining the
documentation of the corrective actions
is a usual and customary business
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
practice. The time, effort, and financial
resources necessary to comply this
information collection requirement
would be incurred by persons in the
normal course of their activities (for
example, in compiling and maintaining
business records) and is not subject to
the PRA.
Basis of Payment (§ 414.707)
Section 414.707(c) states that effective
January 1, 2008, each request for
payment for anti-anemia drugs
furnished to treat anemia resulting from
the treatment of cancer must report the
beneficiary’s most recent hemoglobin or
hematocrit level. The burden associated
with this requirement is the time and
effort associated with obtaining the most
recent hemoglobin or hematocrit levels
and documenting it on the request for
payment. The requirement and its
associated burden are not subject to the
PRA under 5 CFR 1320.3(h)(5). The
interpretation of biological analyses of
body fluids, tissues, or other specimens,
or the identification or classification of
such specimens is not subject to the
PRA.
Term of Contract (§ 414.914)
Section 414.914(h) states that the
approved CAP vendor must verify drug
administration prior to the collection of
any applicable cost sharing amount. As
part of the verification process,
§ 414.914(h)(1) through (2) states lists
the documentation that is required as
part of the verification process. Section
414.914(h)(3) states that the approved
CAP vendor must provide this
information to CMS or the beneficiary
upon request.
The burden associated with the
requirements in § 414.914(1) through (3)
is the time and effort needed to verify
the drug administration. When
obtaining written verification, the CAP
vendor must document the elements
listed in § 414.914(h)(1)(i) through (vi).
When obtaining verbal verification, the
CAP vendor must document the
elements listed in § 414.914(h)(2)(i)
through (ii). We believe the
requirements and their associated
burden are not subject to the PRA; they
are part of the CAP vendor’s usual and
customary business practices as
stipulated under 5 CFR 1320.3(h)(5).
In addition, § 414.914(h)(3) imposes
both recordkeeping and reporting
requirements. We believe that the
burden associated with the
recordkeeping requirement imposed by
§ 414.914(h)(3) is not subject to the PRA
under 5 CFR 1320.3(c)(4) because it
would affect less than 10 persons.
The reporting requirement places
burden on the CAP vendor to provide
PO 00000
Frm 00165
Fmt 4701
Sfmt 4700
66385
the information listed in § 414.914(h)
(1–2) to a beneficiary upon request. We
estimate that the CAP vendor will
receive 72 requests per year from
beneficiaries. We believe it will take 15
minutes per request for the vendor to
provide this information to the
beneficiary. The total annual burden
associated with this requirement is 1080
minutes or 18 burden hours. However,
we believe this information collection
requirement and the associated burden
is not subject to the PRA as defined in
5 CFR 1320.3(c)(4) because it would
affect less than 10 persons.
Compendia for Determination of
Medically-Accepted Indications for OffLabel Uses of Drugs and Biologicals in
an Anti-Cancer Chemotherapeutic
Regimen (§ 414.930)
Section 414.930(b) states the process
for listing compendia for determining
medically-accepted uses of drugs and
biologicals in anti-cancer treatment. We
will annually provide an annual
opportunity to request changes to the
list of compendia. As stated in
§ 414.930(c)(1), CMS will review a
complete written request that is
submitted in writing, electronically or
via hard copy. A complete written
request must contain the following
information as stated in
§ 414.930(c)(1)(i) through (vi): Full name
and contact information for the
requestor; full identification of the
compendium in question; a complete
written copy of the compendium in
question; the specific action requested
of CMS; supporting documentation for
the requested action; address a single
compendium per request.
The burden associated with the
requirements contained in § 414.930(b)
through (c) is the time and effort
required to draft and submit to CMS a
complete written request for changes to
the list of compendia. While these
requirements are subject to the PRA, we
believe the burden is exempt under 5
CFR 1320.3(c)(4) because it would affect
less than 10 persons or entities. There
are only 6 compendia that could
reasonably be expected to be the subject
of a request, so 6 requests is a likely
maximum.
Signature Requirements (§ 424.36)
Section 424.36(a) requires the
beneficiary’s signature on a claim for
payment of services unless the
beneficiary has died or the provisions of
§ 424.36(b), (c), or (d) apply. Section
424.36(b) states that if the beneficiary is
physically or mentally incapable of
signing the claim, the claim may be
signed by one of the parties specified in
§ 424.36(b)(1) through (5). Proposed
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66386
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
§ 424.36(b)(6) states that, for emergency
ambulance transport services, if certain
conditions and documentation
requirements are met, an ambulance
provider or supplier would be permitted
to sign the claim on behalf of the
beneficiary. Specifically,
§ 424.36(b)(6)(ii)(A) through (C) lists the
documentation that would be required,
all of which would have to be
maintained by the ambulance provider
or supplier in its files for a period of at
least 4 years from the date of service. An
ambulance provider or supplier would
be required to obtain a signed,
contemporaneous statement from an
ambulance employee present during
transport of the patient that, at the time
the service was provided, the
beneficiary was physically or mentally
incapable of signing the claim and that
none of the other qualified parties listed
in § 424.36(b)(1) through (5) were
available or willing to sign the claim on
behalf of the beneficiary.
The ambulance provider or supplier
would also be required to maintain
documentation of the date and time that
the beneficiary was transported and the
name and location of the facility that
received the beneficiary. In addition, the
ambulance provider or supplier would
be required to obtain and maintain a
signed contemporaneous statement from
a representative of the facility that
received the beneficiary. The statement
would have to contain the name of the
beneficiary and the date and time the
beneficiary was received at the facility.
The burden associated with the
recordkeeping requirements contained
in § 424.36(b)(6) is the time and effort
associated with drafting, obtaining, and
maintaining written statements from
both employees of the ambulance
provider or supplier transporting the
beneficiary and employees of the facility
receiving the beneficiary. We estimate
that 9,000 ambulance providers or
suppliers will comply with these
requirements. We estimate that it will
take no more than five minutes for each
provider or supplier to comply with the
recordkeeping requirements. Based on
the best available data at this time, we
estimate the total annual burden
associated with the requirements in
§ 424.36(b)(6) to be 541,667 hours
nationwide. The annual total number of
burden hours was arrived at by
multiplying five minutes by the total
estimated number of emergency
ambulance transports of 6,500,000. We
note that the total number of burden
hours may be overstated, because not
every beneficiary who receives
emergency ambulance transport services
is unable to sign the claim. However, we
also note that the 6.5 million figure for
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
emergency transports is the estimated
number of ALS1-emergency and BLSemergency ambulance claims processed
by Part B carriers, incurred in 2006 and
processed through April of 2007, and
thus does not include the number of
emergency ambulance transport services
billed to fiscal intermediaries by
ambulance providers (which number is
not available to us). In any event, we
believe our proposal will benefit
ambulance providers and suppliers by
allowing them an alternative procedure
for submitting claims to Medicare. In
the absence of the proposed procedure
for signing claims on behalf of
beneficiaries for emergency ambulance
transport services, ambulance suppliers
and providers would be required to
track down beneficiaries after the
emergency transport services have been
rendered, in an attempt to have the
beneficiary sign the claim. Moreover,
such attempts may prove fruitless,
thereby preventing the ambulance
suppliers and providers from submitting
the claim to Medicare.
Additional Information Collection
Requirements
This final rule with comment period
imposes collection of information
requirements as outlined in the
regulation text and specified above.
However, this final rule with comment
period also makes reference to several
associated information collections that
are not discussed in the regulation text.
The following is a discussion of these
collections, which have already
received OMB approval.
Part B Drug Payment
Section II.F.1 of the preamble
discusses payment for Medicare Part B
drugs and biologicals under the ASP
methodology. Drug manufacturers are
required to submit ASP data to us on a
quarterly basis. As stated in section
II.F.1.a of the preamble, the ASP
reporting requirements are set forth in
section 1927(b) of the Act.
The collection of ASP data imposes a
reporting requirement on the public.
The burden associated with this
requirement is the time and effort
required by manufacturers of Medicare
Part B drugs and biologicals to calculate,
record, and submit the required data to
CMS. While the burden associated with
this requirement is subject to the PRA,
it is currently approved under OMB
control number 0938–0921, with an
expiration date of May 31, 2009.
Competitive Acquisition Program (CAP)
In section II.F.2.d of the preamble, we
propose to revise the CAP physician
election agreement. In conjunction with
PO 00000
Frm 00166
Fmt 4701
Sfmt 4700
post-payment review process, we are
revising the CAP physician election
agreement to reflect the physician’s
obligation to provide medical records to
assist with claims review. The CAP
physician election agreement is
currently approved under 0938–0955
with an expiration date of August 31,
2009. Under a separate notice, we will
make the revised instrument available
for public comment prior to submitting
the revised information collection
request to OMB for approval.
Section II.F.2.f of the preamble
discusses details of the competitive
acquisition program. Each year,
physicians are given the option to elect
to obtain Medicare Part B drugs and
biologicals through the CAP. In
addition, physicians are also given an
opportunity to select an approved CAP
vendor. The burden associated with
these election requirements is the time
and effort necessary for a physician to
make an election and notify CMS. The
burden associated with election
requirements for participating in the
CAP and selecting an approved CAP
vendor is subject to the PRA. However,
it is currently approved under OMB
control numbers 0938–0955 and 0938–
0987 with expiration dates of August 31,
2009 and April 30, 2009, respectively.
Section II.F.2.g. of the preamble also
discusses the exigent circumstances
exception for leaving the CAP outside of
the annual election process. A physician
may request a release from the CAP
within the first 60 days of his or her
participation if he or she can show that
CAP participation imposes a burden on
the practice, or later if he or she can
show that a change in circumstances
that was not known to the practice
previously results in a burden to the
practice. Specifically, the physician
must submit a release request to the
CAP-designated carrier.
While this burden is subject to the
PRA, we believe it is exempt under 5
CFR 1320.3(h)(6). Facts or opinions
collected from a single person or entity
are not subject to the PRA. The
aforementioned information collection
request will be reviewed individually
on a case by cases basis.
If the designated carrier receives an
exigent circumstance removal request
related to the approved CAP vendor’s
service, it is required to refer the
physician to his or her approved CAP
vendor within 1 business day of its
receipt of the request. As part of the
grievance process, the CAP vendor will
try to work with the physician to
address their concerns with respect to
participation in the program. The
designated carrier can alternatively
continue to investigate, and within 2
E:\FR\FM\27NOR2.SGM
27NOR2
66387
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
business days of its receipt of the
request, can request a single 2-business
day extension (after which it must
submit findings and a recommendation
to CMS), submit findings and a
recommendation to CMS that the
physician be permitted to terminate his
or her CAP participation, or submit
findings and a recommendation to CMS
that the physician not be permitted to
terminate his or her CAP participation.
Requests from physicians will be
reviewed by CAP vendors on an
individual, case by case basis. We will
continue to monitor the process. If we
believe that we will receive 10 or more
requests, we will submit an information
collection request to OMB.
Physician Quality Reporting Initiative
(PQRI)
Section II.U.1.a of the preamble
discusses the background of the
reporting initiative and provides
information about the measures
available to eligible professionals who
choose to participate in PQRI. Section
1848(k)(1) of the Act requires the
Secretary to implement a system for
eligible professionals to submit data
pertaining to certain quality measures.
As stated in section II.U.1.a, eligible
professionals, for the purpose of the
quality reporting system, include
physicians, other practitioners as
described in section 1842(b)(18)(c) of
the Act, physical and occupational
therapists, and qualified speechlanguage pathologists. As also stated in
section II.U.1.a, this is a voluntary
initiative. Eligible professionals may
choose whether to participate and, to
the extent they satisfactorily submit data
on quality measures for covered
professional services, they can qualify to
receive a bonus incentive payment.
Specifically, to qualify to receive a
bonus incentive payment for satisfactory
reporting of quality data on covered
professional services furnished in 2007,
an eligible professional must submit
data on 1, 2, or 3 measures selected from
the 74 PQRI 2007 quality measures. The
minimum number of measures each
professional must report in order to
qualify for the bonus payment is
determined by how many available
measures are applicable to the services
that professional furnishes to Medicare
beneficiaries. For a majority of the
eligible professionals, the requirement,
per 1848(k) of the Act, will be that they
satisfactorily report on at least three
measures. An eligible professional could
meet the satisfactory reporting
requirement, and thus be eligible for the
bonus incentive payment, by reporting
fewer than three measures only if his or
her practice has fewer than three
applicable measures. The quality
measures are posted and available for
download on the CMS Web site at
https://www.cms.hhs.gov/pqri.
The burden associated with this
requirement is the time and effort
associated with eligible professionals
identifying applicable PQRI quality
measures for which they can report the
necessary information. In addition, they
must gather the required information,
select the appropriate quality data
codes, and include the appropriate
quality-data codes on the claims they
submit for payment.
In 2007, the PQRI will collect qualitydata codes exclusively as additional
(optional) line items on the existing
HIPAA transaction 837–P and/or CMS
Form 1500. There will be no new forms
and no modifications to the existing
transaction or form in support of 2007
PQRI. CMS also does not anticipate
changes to the 837–P or CMS Form 1500
for 2008.
Because this is a voluntary program,
it is impossible to estimate with any
degree of accuracy how many eligible
professionals will opt to participate in
the PQRI in 2008. Moreover, the time
needed for an eligible professional to
review the quality measures and other
information, select measures applicable
to his or her patients and the services he
or she furnishes to them, and
incorporate the use of quality data codes
into the office work flows is expected to
vary along with the number of measures
that are potentially applicable to a given
professional’s practice. We estimate that
the additional time required to put
quality data codes on each claim is not
a material increment to the time
required to code the claim for payment.
The total estimated annual burden for
this requirement will also vary along
with the volume of claims on which
quality data is reported.
TABLE 37.—ESTIMATED ANNUAL REPORTING AND RECORDKEEPING BURDEN
OMB control
No.
Regulation section(s)
Respondents
Responses
Total annual
burden
(hours)
0938–0921
0938–0955
0938–0685
0938–New
120
12
400,000
9,000
480
12
400,000
6,500,000
17,760
480
1,000,000
541,667
Total ..........................................................................................................
cprice-sewell on PROD1PC72 with RULES
Preamble section II.F.1 ....................................................................................
Preamble section II.F.2.f ..................................................................................
§ 410.33 ...........................................................................................................
§ 424.36 ...........................................................................................................
........................
........................
........................
1,579,907
If you comment on these information
collection and recordkeeping
requirements, please mail copies
directly to the following: Centers for
Medicare & Medicaid Services, Office of
Strategic Operations and Regulatory
Affairs, Regulations Development
Group, Attn: William N. Parham, III,
CMS–1385–FC, Room C4–26–05, 7500
Security Boulevard, Baltimore, MD
21244–1850; and Office of Information
and Regulatory Affairs, Office of
Management and Budget, Room 10235,
New Executive Office Building,
Washington, DC 20503, Attn: Carolyn
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Lovett, CMS Desk Officer, [CMS–1385–
P], carolyn_lovett@omb.eop.gov. Fax
(202) 395 6974.
XIII. Response to Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble, and, when we proceed
with a subsequent document, we will
PO 00000
Frm 00167
Fmt 4701
Sfmt 4700
respond to the comments in the
preamble to that document.
XIV. Regulatory Impact Analysis
We have examined the impact of this
rule as required by Executive Order
12866 (September 1993, Regulatory
Planning and Review), the Regulatory
Flexibility Act (RFA) (September 19,
1980 Pub. L. 96–354), section 1102(b) of
the Social Security Act, the Unfunded
Mandates Reform Act of 1995 (Pub. L.
104–4), and Executive Order 13132.
Executive Order 12866 (as amended
by Executive Order 13258, which
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66388
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
merely reassigns responsibilities of
duties) directs agencies to assess all
costs and benefits of available regulatory
alternatives and, when regulation is
necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety
effects, distributive impacts, and
equity). A regulatory impact analysis
must be prepared for final rules with
economically significant effects (that is,
a final rule that would have an annual
effect on the economy of $100 million
or more in any one year, or would
adversely affect in a material way the
economy, a sector of the economy,
productivity, competition, jobs, the
environment, public health or safety, or
State, local, or tribal governments or
communities). As indicated in more
detail below in this regulatory impact
analysis, we estimate that the PFS
provisions included in this final rule
with comment period rule will
redistribute more than $100 million in
1 year. We are considering this final rule
with comment period rule to be
economically significant because its
provisions are estimated to result in an
increase, decrease or aggregate
redistribution of Medicare spending that
will exceed $100 million. Therefore,
this final rule with comment period is
a major rule and we have prepared a
regulatory impact analysis.
The RFA requires agencies to analyze
options for regulatory relief of small
entities. For purposes of the RFA, small
entities include small businesses,
nonprofit organizations, and small
governmental jurisdictions. Most
hospitals and most other providers and
suppliers are small entities, either by
nonprofit status or by having revenues
of $6.5 million to $31.5 million in any
1 year (For further information, see the
Small Business Administration’s
regulation at 70 FR 72577, December 6,
2003.) Individuals and States are not
included in the definition of a small
entity. The RFA requires that we
analyze regulatory options for small
businesses and other entities. We
prepare a regulatory flexibility analysis
unless we certify that a rule would not
have a significant economic impact on
a substantial number of small entities.
The analysis must include a justification
concerning the reason action is being
taken, the kinds and number of small
entities the rule affects, and an
explanation of any meaningful options
that achieve the objectives with less
significant adverse economic impact on
the small entities.
For purposes of the RFA, physicians,
NPPs, and suppliers, including IDTFs,
are considered small businesses if they
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
generate revenues of $6.5 million or
less. Approximately 95 percent of
physicians are considered to be small
entities. There are about 980,000
physicians, other practitioners and
medical suppliers that receive Medicare
payment under the PFS.
The CAP provides alternatives to
physicians who do not wish to purchase
drugs directly or collect coinsurance.
The impact of the CAP provisions on an
individual physician is dependent on
whether the drugs they furnish to
Medicare beneficiaries are included in
the list of CAP drugs, whether the
physician chooses to obtain drugs
administered to Medicare beneficiaries
through the CAP. The CAP provisions in
this final rule with comment period will
also have a potential impact on entities
that are involved in the dispensing or
distribution of drugs, plan to become
approved CAP vendors, or are approved
CAP vendors.
For purposes of the RFA,
approximately 80 percent of clinical
diagnostic laboratories are considered
small businesses according to the Small
Business Administration’s size
standards. Ambulance providers and
suppliers for purposes of the RFA are
also considered to be small entities.
In addition, most ESRD facilities are
considered small entities, either based
on nonprofit status or by having
revenues of $31.5 million or less in any
year. We consider a substantial number
of entities to be affected if the rule is
estimated to impact more than 5 percent
of the total number of small entities.
Based on our analysis of the 915
nonprofit ESRD facilities considered
small entities in accordance with the
above definitions, we estimate that the
combined impact of the changes to
payment for renal dialysis services
included in this final rule with
comment period will have a 0.9 percent
increase in overall payments to
nonprofit ESRD facilities relative to
current overall payments. The analysis
and discussion provided in this section,
as well as elsewhere in this final rule
with comment period, complies with
the RFA requirements.
For the e-prescribing provisions,
physician practices and independent
pharmacies are considered small
entities.
Because we acknowledge that many of
the affected entities are small entities,
the analysis discussed throughout the
preamble of this final rule with
comment period constitutes our
regulatory flexibility analysis for the
remaining provisions.
Section 1102(b) of the Act requires us
to prepare a regulatory impact analysis
for any final rule with comment period
PO 00000
Frm 00168
Fmt 4701
Sfmt 4700
that may have a significant impact on
the operations of a substantial number
of small rural hospitals. This analysis
must conform to the provisions of
section 604 of the RFA. For purposes of
section 1102(b) of the Act, we define a
small rural hospital as a hospital that is
located outside a Metropolitan
Statistical Area and has fewer than 100
beds. We have determined that this final
rule with comment period would have
minimal impact on small hospitals
located in rural areas. Of the 202
hospital based ESRD facilities located in
rural areas, only 40 are affiliated with
hospitals with fewer than 100 beds.
Section 202 of the Unfunded
Mandates Reform Act of 1995 also
requires that agencies assess anticipated
costs and benefits before issuing any
rule that may result in expenditures in
any year by State, local, or tribal
governments, in the aggregate, or by the
private sector, of $127 million. This
final rule with comment period will not
mandate any requirements for State,
local, or tribal governments. Medicare
beneficiaries are considered to be part of
the private sector for this purpose. A
discussion concerning the impact of this
rule on beneficiaries is found later in
this section.
We have examined this final rule with
comment period in accordance with
Executive Order 13132 and have
determined that this regulation would
not have any significant impact on the
rights, roles, or responsibilities of State,
local, or tribal governments.
We have prepared the following
analysis, which, together with the
information provided in the rest of this
preamble, meets all assessment
requirements. The analysis explains the
rationale for and purposes of this final
rule with comment period rule; details
the costs and benefits of the rule;
analyzes alternatives; and presents the
measures we use to minimize the
burden on small entities. As indicated
elsewhere in this final rule with
comment period, we are making a
variety of changes to our regulations,
payments, or payment policies to ensure
that our payment systems reflect
changes in medical practice and the
relative value of services. We provide
information for each of the policy
changes in the relevant sections of this
final rule with comment period. We are
unaware of any relevant Federal rules
that duplicate, overlap or conflict with
this final rule with comment period.
The relevant sections of this final rule
with comment period contain a
description of significant alternatives if
applicable.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
A. RVU Impacts
1. Resource-Based Work and PE RVUs
Section 1848(c)(2)(B)(ii) of the Act
requires that increases or decreases in
RVUs may not cause the amount of
expenditures for the year to differ by
more than $20 million from what
expenditures would have been in the
absence of these changes. If this
threshold is exceeded, we make
adjustments to preserve BN. In the CY
2007 PFS final rule with comment
period, the $4 billion impact of changes
in work RVUs resulting from the 5-Year
Review required that a BN adjustment
be made.
As discussed in section IV.D.3 of the
CY 2007 PFS final rule with comment
period (71 FR 69735), we carefully
reviewed the comments received
concerning the BN adjustment needed
to offset the $4 billion impact of changes
in work RVUs resulting from the 5-Year
Review. To meet the requirements set
forth in section 1848(c)(2)(B)(ii)(II) of
the Act, we implemented a BN adjustor
of 0.8994 or 10.1 percent to be applied
to the work RVUs.
Subsequent to the publication of the
CY 2007 PFS final rule with comment
period and the announcement of the
0.8994 BN adjustment to the work
RVUs, the AMA RUC supplied work
RVU recommendations on additional
CPT codes from the 5-Year Review and
recommendations for an increase in the
work of anesthesia services. As stated in
the CY 2007 PFS final rule with
comment period, these additional codes
are still considered part of the 5-Year
Review. The impact of these additional
recommendations and increases in the
work of anesthesia services on the BN
adjustment must be accounted for by
revising the current work adjustor of
0.8994. The work adjustor for CY 2008,
based upon the final work RVUs for
these additional CPT codes and
increases in the work of anesthesia
services, is approximately 0.8806. Table
38 shows the specialty-level impact of
the work and PE RVU changes.
Our estimates of changes in Medicare
revenues for PFS services compare
payment rates for CY 2007 with
payment rates for CY 2008 using CY
2006 Medicare utilization for all years.
To the extent that there are year to year
changes in the volume and mix of
services provided by physicians, the
actual impact on total Medicare
revenues will be different than those
shown in Table 38. The payment
impacts reflect averages for each
specialty based on Medicare utilization.
The payment impact for an individual
physician would be different from the
average, based on the mix of services the
physician provides. The average change
in total revenues would be less than the
impact displayed here because
physicians furnish services to both
Medicare and non Medicare patients
66389
and specialties may receive substantial
Medicare revenues for services that are
not paid under the PFS. For instance,
independent laboratories receive
approximately 80 percent of their
Medicare revenues from clinical
laboratory services that are not paid
under the PFS.
Table 38 shows only the payment
impact on PFS services. The following
is an explanation of the information
represented in Table 38.
• Specialty: The physician specialty
or type of practitioner/supplier.
• Allowed charges: Allowed charges
are the Medicare Fee Schedule amounts
for covered services and include
copayments and deductibles (which are
the financial responsibility of the
beneficiary.) These amounts have been
summed across all services furnished by
physicians, practitioners, or suppliers
within a specialty to arrive at the total
allowed charges for the specialty.
• Impact of Work RVU Changes for
additional changes in work RVUs from
the 5-Year Review.
• Impact of PE RVU changes. The
impact is shown for both 2008 which is
the second year of the 4-year transition
using the new methodology and the
fully implemented 2010 PE RVUs.
• Combined impact of the finalized
work RVUs and PE RVUs for both 2008
and the fully implemented 2010 PE
RVUs.
TABLE 38.—COMBINED TOTAL ALLOWED CHARGE IMPACT FOR WORK AND PRACTICE EXPENSE RVU CHANGES
Allowed
charges
(mil)
cprice-sewell on PROD1PC72 with RULES
Specialty
TOTAL ..............................................................................
ALLERGY/IMMUNOLOGY ...............................................
ANESTHESIOLOGY ........................................................
CARDIAC SURGERY ......................................................
CARDIOLOGY .................................................................
COLON AND RECTAL SURGERY .................................
CRITICAL CARE ..............................................................
DERMATOLOGY .............................................................
EMERGENCY MEDICINE ...............................................
ENDOCRINOLOGY .........................................................
FAMILY PRACTICE .........................................................
GASTROENTEROLOGY .................................................
GENERAL PRACTICE .....................................................
GENERAL SURGERY .....................................................
GERIATRICS ...................................................................
HAND SURGERY ............................................................
HEMATOLOGY/ONCOLOGY ..........................................
INFECTIOUS DISEASE ...................................................
INTERNAL MEDICINE .....................................................
INTERVENTIONAL RADIOLOGY ...................................
NEPHROLOGY ................................................................
NEUROLOGY ..................................................................
NEUROSURGERY ..........................................................
NUCLEAR MEDICINE .....................................................
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00169
$76,551
173
1,579
396
7,519
122
199
2,248
2,203
350
5,060
1,750
974
2,309
147
80
1,917
504
9,981
244
1,664
1,398
576
78
Fmt 4701
Impact of
work RVU
changes
(percent)
0
1
15
¥1
¥1
¥1
¥1
¥1
¥2
¥1
0
¥1
0
¥1
3
¥1
¥1
¥1
1
¥1
¥1
¥1
¥1
¥1
Sfmt 4700
Impact of PE RVU
changes
(percent)
2008
(PE trans.
year 2)
(percent)
Combined impact of PE
and work changes*
2010
(PE full implement.)
(percent)
0
1
¥1
¥1
¥1
1
0
2
0
0
0
1
0
0
0
¥1
0
0
0
¥1
¥1
0
¥1
5
E:\FR\FM\27NOR2.SGM
0
3
¥3
¥2
¥3
2
0
7
¥1
0
1
4
0
0
1
¥3
0
1
0
¥3
¥4
¥1
¥2
14
27NOR2
2008
(PE trans.
year 2)
(percent)
0
2
14
¥2
¥2
0
¥1
2
¥2
¥1
0
0
0
¥1
3
¥2
¥1
¥1
0
¥2
¥3
¥1
¥2
4
2010
(PE full implement.)
(percent)
0
4
12
¥3
¥4
2
¥2
7
¥2
¥1
1
3
0
0
4
¥4
¥1
0
0
¥4
¥5
¥2
¥3
14
66390
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
TABLE 38.—COMBINED TOTAL ALLOWED CHARGE IMPACT FOR WORK AND PRACTICE EXPENSE RVU CHANGES—
Continued
Allowed
charges
(mil)
Specialty
OBSTETRICS/GYNECOLOGY ........................................
OPHTHALMOLOGY ........................................................
ORTHOPEDIC SURGERY ..............................................
OTOLARNGOLOGY ........................................................
PATHOLOGY ...................................................................
PEDIATRICS ....................................................................
PHYSICAL MEDICINE .....................................................
PLASTIC SURGERY .......................................................
PSYCHIATRY ..................................................................
PULMONARY DISEASE ..................................................
RADIATION ONCOLOGY ................................................
RADIOLOGY ....................................................................
RHEUMATOLOGY ...........................................................
THORACIC SURGERY ...................................................
UROLOGY .......................................................................
VASCULAR SURGERY ...................................................
AUDIOLOGIST .................................................................
CHIROPRACTOR ............................................................
CLINICAL PSYCHOLOGIST ...........................................
CLINICAL SOCIAL WORKER .........................................
NURSE ANESTHETIST ...................................................
NURSE PRACTITIONER .................................................
OPTOMETRY ..................................................................
ORAL/MAXILLOFACIAL SURGERY ...............................
PHYSICAL/OCCUPATIONAL THERAPY ........................
PHYSICIAN ASSISTANT .................................................
PODIATRY .......................................................................
DIAGNOSTIC TESTING FACILITY .................................
INDEPENDENT LABORATORY ......................................
PORTABLE X-RAY SUPPLIER .......................................
628
4,664
3,248
913
948
74
784
272
1,099
1,691
1,612
5,245
494
436
2,033
641
31
725
531
354
608
796
790
37
1,391
600
1,575
1,191
1,087
81
Impact of
work RVU
changes
(percent)
Impact of PE RVU
changes
(percent)
2008
(PE trans.
year 2)
(percent)
¥1
2
¥1
2
¥1
0
1
¥1
¥1
¥1
¥1
¥1
¥1
¥1
¥1
¥1
26
¥1
¥1
¥1
22
2
4
¥1
¥1
0
0
0
0
0
2010
(PE full implement.)
(percent)
0
¥1
0
¥1
¥1
0
¥1
0
1
0
1
1
0
¥1
0
0
¥14
¥1
¥2
¥2
0
0
0
1
1
0
2
0
3
2
¥1
¥3
¥1
¥3
¥3
0
¥2
1
2
1
2
2
¥1
¥2
0
0
¥43
¥2
¥6
¥5
0
1
¥1
3
4
1
5
1
10
7
Combined impact of PE
and work changes*
2008
(PE trans.
year 2)
(percent)
¥1
1
¥1
1
¥2
0
¥1
¥1
0
¥1
0
0
¥1
¥2
¥1
¥1
12
¥2
¥3
¥3
22
2
4
1
1
0
2
0
3
2
2010
(PE full implement.)
(percent)
¥1
¥1
¥2
¥1
¥4
0
¥2
0
1
0
1
1
¥2
¥3
¥1
¥1
¥17
¥3
¥7
¥6
21
3
3
3
4
0
5
1
10
7
* Components may not sum to total due to rounding.
2. Adjustments for Payments for
Imaging Services
cprice-sewell on PROD1PC72 with RULES
Section 1848(c)(2)(B)(iv)(II) of the Act
as added by section 5102 of the Deficit
Reduction Act of 2005 (Pub. L. 109–171)
(DRA) exempts the estimated savings
from the application of the OPPS based
payment limitation on PFS imaging
services from the PFS BN requirement.
We estimate that the combined impact
of the current BN exemptions instituted
by such section, the addition of 6 codes
to the list of services subject to the DRA
OPPS cap (discussed in section II.E.1.),
and the payment revisions to OPPS cap
amounts would result in no measurable
changes in the specialty specific
impacts of the DRA provisions with the
exception of vascular surgery in CY
2008.
3. Combined Impact
Table 39 shows the specialty-level
impact of the work and PE RVU
changes, section 5102 of the DRA
(including the additional 6 services that
were added to the list of services subject
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
to the DRA OPPS cap and the revision
to OPPS payment amounts), and our
most recent estimate (¥10.1 percent) of
the CY 2008 Medicare PFS update.
Additionally, the impacts in this final
rule with comment period rule reflect
the use of updated physician time data
from the AMA–RUC.
As indicated in Table 39, our
estimates of changes in Medicare
revenues for PFS services compare
payment rates for CY 2007 with
payment rates for CY 2008 using CY
2006 Medicare utilization crosswalked
to 2008 services. To the extent that there
are year-to-year changes in the volume
and mix of services furnished by
physicians, the actual impact on total
Medicare revenues will be different than
those shown in Table 39. The payment
impacts reflect averages for each
specialty based on Medicare utilization.
The payment impact for an individual
physician would be different from the
average, based on the mix of services the
physician furnishes.
PO 00000
Frm 00170
Fmt 4701
Sfmt 4700
Table 39 shows only the payment
impact on PFS services. The following
is an explanation of the information
represented in Table 39.
• Specialty: The physician specialty
or type of practitioner/supplier.
• Allowed Charges: Allowed charges
are the Medicare Fee Schedule amounts
for covered services and include
copayments and deductibles (which are
the financial responsibility of the
beneficiary.) These amounts have been
summed across all services furnished by
physicians, practitioners, or suppliers
within a specialty to arrive at the total
allowed charges for the specialty.
• Impact of the CY 2008 Work and PE
RVU changes using the methodology
finalized in the CY 2007 PFS final rule
with comment period and the revised
data sources discussed in this final rule
with comment period.
• Impact of section 5102 of the DRA:
The CY 2008 percentage decrease in
allowed charges attributed to section
5102 of the DRA with the addition of six
codes to the OPPS cap list and revisions
to the OPPS payment amounts.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
• Combined impact of the finalized
work and PE RVUs, section 5102 of the
DRA and the addition of six codes to the
OPPS cap list, and the revisions to
OPPS payment amounts.
• CY 2008 Update: The percentage
decrease in allowed charges attributed
to the estimated CY 2008 PFS
conversion factor update of ¥10.1
percent.
• Combined impact with CY 2008
update: The CY 2008 percentage
decrease in allowed charges attributed
to the impact of the work and PE RVU
66391
changes, section 5102 of the DRA (plus
six additions to OPPS cap list), revisions
to OPPS payment amounts, and the CY
2008 update.
TABLE 39.—COMBINED CY 2008 TOTAL ALLOWED CHARGE IMPACT FOR THE REMAINING 5-YEAR REVIEW OF WORK
RVUS AND PRACTICE EXPENSE CHANGES, OPPS IMAGING CAP, AND THE CY 2008 UPDATE
Allowed
charges
(mil)
cprice-sewell on PROD1PC72 with RULES
Specialty
TOTAL ..............................................................................
ALLERGY/IMMUNOLOGY ...............................................
ANESTHESIOLOGY ........................................................
CARDIAC SURGERY ......................................................
CARDIOLOGY .................................................................
COLON AND RECTAL SURGERY .................................
CRITICAL CARE ..............................................................
DERMATOLOGY .............................................................
EMERGENCY MEDICINE ...............................................
ENDOCRINOLOGY .........................................................
FAMILY PRACTICE .........................................................
GASTROENTEROLOGY .................................................
GENERAL PRACTICE .....................................................
GENERAL SURGERY .....................................................
GERIATRICS ...................................................................
HAND SURGERY ............................................................
HEMATOLOGY/ONCOLOGY ..........................................
INFECTIOUS DISEASE ...................................................
INTERNAL MEDICINE .....................................................
INTERVENTIONAL RADIOLOGY ...................................
NEPHROLOGY ................................................................
NEUROLOGY ..................................................................
NEUROSURGERY ..........................................................
NUCLEAR MEDICINE .....................................................
OBSTETRICS/GYNECOLOGY ........................................
OPHTHALMOLOGY ........................................................
ORTHOPEDIC SURGERY ..............................................
OTOLARNGOLOGY ........................................................
PATHOLOGY ...................................................................
PEDIATRICS ....................................................................
PHYSICAL MEDICINE .....................................................
PLASTIC SURGERY .......................................................
PSYCHIATRY ..................................................................
PULMONARY DISEASE ..................................................
RADIATION ONCOLOGY ................................................
RADIOLOGY ....................................................................
RHEUMATOLOGY ...........................................................
THORACIC SURGERY ...................................................
UROLOGY .......................................................................
VASCULAR SURGERY ...................................................
AUDIOLOGIST .................................................................
CHIROPRACTOR ............................................................
CLINICAL PSYCHOLOGIST ...........................................
CLINICAL SOCIAL WORKER .........................................
NURSE ANESTHETIST ...................................................
NURSE PRACTITIONER .................................................
OPTOMETRY ..................................................................
ORAL/MAXILLOFACIAL SURGERY ...............................
PHYSICAL/OCCUPATIONAL THERAPY ........................
PHYSICIAN ASSISTANT .................................................
PODIATRY .......................................................................
DIAGNOSTIC TESTING FACILITY .................................
INDEPENDENT LABORATORY ......................................
PORTABLE X-RAY SUPPLIER .......................................
$76,551
173
1,579
396
7,519
122
199
2,248
2,203
350
5,060
1,750
974
2,309
147
80
1,917
504
9,981
244
1,664
1,398
576
78
628
4,664
3,248
913
948
74
784
272
1,099
1,691
1,612
5,245
494
436
2,033
641
31
725
531
354
608
796
790
37
1,391
600
1,575
1,191
1,087
81
Impact of
work and
PE RVU
changes *
(percent)
0
2
14
¥2
¥2
0
¥1
2
¥2
¥1
0
0
0
¥1
3
¥2
¥1
¥1
0
¥2
¥3
¥1
¥2
4
¥1
1
¥1
1
¥2
0
¥1
¥1
0
¥1
0
0
¥1
¥2
¥1
¥1
12
¥2
¥3
¥3
22
2
4
1
1
0
2
0
3
2
Impact of
DRA 5102
(percent)
Combined
impact RVU
and DRA
5102 **
(percent)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
¥1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
14
¥2
¥2
0
¥1
2
¥2
¥1
0
0
0
¥1
3
¥2
¥1
¥1
0
¥2
¥3
¥1
¥2
5
¥1
1
¥1
1
¥2
0
¥1
¥1
0
¥1
0
0
¥1
¥2
¥1
¥1
12
¥2
¥3
¥3
22
2
4
1
1
0
2
0
3
2
* PE changes are CY 2008 second year transition changes. For fully implemented CY 2010 PE changes see Table 1.
** Components may not sum to total due to rounding.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00171
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
CY 2008
update
(percent)
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
¥10
Combined
impact with
CY 2008
update **
(percent)
¥10
¥8
4
¥12
¥12
¥10
¥11
¥8
¥12
¥11
¥10
¥10
¥10
¥11
¥7
¥12
¥11
¥11
¥10
¥12
¥13
¥11
¥12
¥5
¥11
¥9
¥11
¥9
¥12
¥10
¥11
¥11
¥10
¥11
¥10
¥10
¥11
¥12
¥11
¥11
2
¥12
¥13
¥13
12
¥8
¥6
¥9
¥9
¥10
¥8
¥10
¥7
¥8
66392
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Table 40 shows the estimated impact
on total payments for selected high
volume procedures of all of the changes
discussed previously. We selected these
procedures because they are the most
commonly furnished by a broad
spectrum of physician specialties. There
are separate columns that show the
change in the facility rates and the
nonfacility rates. For an explanation of
facility and nonfacility PE refer to
Addendum A of this final rule with
comment period rule.
TABLE 40.—IMPACT OF FINAL RULE WITH COMMENT PERIOD AND ESTIMATED PHYSICIAN UPDATE ON 2008 PAYMENT FOR
SELECTED PROCEDURES
Facility
CPT/HCPCS
MOD
Description
2007
cprice-sewell on PROD1PC72 with RULES
11721
17000
27130
27244
27447
33533
35301
43239
66821
66984
67210
71010
71010
77056
77056
77057
77057
77427
78465
88305
90801
90862
90935
92012
92014
92980
93000
93010
93015
93307
93510
98941
99203
99213
99214
99222
99223
99231
99232
99233
99236
99239
99243
99244
99253
99254
99283
99284
99291
99292
99348
99350
G0008
G0317
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
..........
VerDate Aug<31>2005
............
............
............
............
............
............
............
............
............
............
............
............
26
............
26
............
26
............
26
26
............
............
............
............
............
............
............
............
............
26
26
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Debride nail, 6 or more ..................................
Destruct premalg lesion .................................
Total hip arthroplasty .....................................
Treat thigh fracture .........................................
Total knee arthroplasty ..................................
CABG, arterial, single ....................................
Rechanneling of artery ...................................
Upper GI endoscopy, biopsy .........................
After cataract laser surgery ............................
Cataract surg w/iol, 1 stage ...........................
Treatment of retinal lesion .............................
Chest x-ray .....................................................
Chest x-ray .....................................................
Mammogram, both breasts ............................
Mammogram, both breasts ............................
Mammogram, screening ................................
Mammogram, screening ................................
Radiation tx management, x5 ........................
Heart image (3d), multiple .............................
Tissue exam by pathologist ...........................
Psy dx interview .............................................
Medication management ................................
Hemodialysis, one evaluation ........................
Eye exam established pat ..............................
Eye exam & treatment ...................................
Insert intracoronary stent ...............................
Electrocardiogram, complete .........................
Electrocardiogram report ................................
Cardiovascular stress test ..............................
Echo exam of heart ........................................
Left heart catheterization ...............................
Chiropractic manipulation ...............................
Office/outpatient visit, new .............................
Office/outpatient visit, est ...............................
Office/outpatient visit, est ...............................
Initial hospital care .........................................
Initial hospital care .........................................
Subsequent hospital care ..............................
Subsequent hospital care ..............................
Subsequent hospital care ..............................
Observ/hosp same date .................................
Hospital discharge day ...................................
Office consultation ..........................................
Office consultation ..........................................
Inpatient consultation .....................................
Inpatient consultation .....................................
Emergency dept visit ......................................
Emergency dept visit ......................................
Critical care, first hour ....................................
Critical care, addtl 30 min ..............................
Home visit, est patient ...................................
Home visit, est patient ...................................
Admin influenza virus vac ..............................
ESRD related svs 4+mo 20+yrs ....................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00172
Fmt 4701
2008
$28.80
44.72
1,360.52
1,100.92
1,464.74
1,908.52
1,071.74
155.00
253.53
641.98
556.34
na
8.72
na
41.31
na
33.35
176.22
73.14
37.90
129.99
44.72
67.46
34.11
55.71
795.85
24.63
8.34
104.22
46.99
242.92
28.80
67.08
42.07
66.32
119.00
173.57
35.62
63.67
90.95
205.40
94.74
93.23
145.91
108.77
156.52
60.64
110.28
208.82
104.60
na
na
na
283.09
$24.53
41.56
1,194.77
963.11
1,283.35
1,658.44
934.49
140.36
222.81
560.08
487.86
na
7.84
na
37.48
na
30.32
158.42
66.43
32.36
112.08
39.18
58.26
38.50
59.28
720.88
20.78
7.50
93.01
42.24
215.31
25.55
58.60
37.48
58.60
104.59
153.65
31.68
56.55
81.08
179.20
83.13
83.13
130.14
97.09
140.02
52.81
97.44
182.61
91.64
na
na
na
245.29
Sfmt 4700
Non-facility
Percent
change
2007
2008
$39.03
63.29
na
na
na
na
na
325.16
270.97
na
580.59
26.15
8.72
97.40
41.31
81.86
33.35
176.22
73.14
37.90
145.15
50.40
na
61.77
91.33
na
24.63
8.34
104.22
46.99
242.92
33.35
91.71
59.50
90.20
na
na
na
na
na
na
na
122.41
179.26
na
na
na
na
256.19
114.45
66.32
150.83
18.95
283.09
$35.43
60.30
na
na
na
na
na
294.01
237.80
na
507.96
22.83
7.84
93.35
37.48
73.93
30.32
158.42
66.43
32.36
131.50
46.67
na
62.69
90.96
na
20.78
7.50
93.01
42.24
215.31
29.64
81.42
53.15
80.40
na
na
na
na
na
na
na
109.36
160.12
na
na
na
na
224.17
100.16
68.14
139.34
18.40
245.29
¥15
¥7
¥12
¥13
¥12
¥13
¥13
¥9
¥12
¥13
¥12
na
¥10
na
¥9
na
¥9
¥10
¥9
¥15
¥14
¥12
¥14
13
6
¥9
¥16
¥10
¥11
¥10
¥11
¥11
¥13
¥11
¥12
¥12
¥11
¥11
¥11
¥11
¥13
¥12
¥11
¥11
¥11
¥11
¥13
¥12
¥13
¥12
na
na
na
¥13
E:\FR\FM\27NOR2.SGM
27NOR2
Percent
change
¥9
¥5
na
na
na
na
na
¥10
¥12
na
¥13
¥13
¥10
¥4
¥9
¥10
¥9
¥10
¥9
¥15
¥9
¥7
na
1
0
na
¥16
¥10
¥11
¥10
¥11
¥11
¥11
¥11
¥11
na
na
na
na
na
na
na
¥11
¥11
na
na
na
na
¥12
¥12
2
¥8
¥3
¥13
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
B. Geographic Practice Cost Index
Changes
Section 1848(e)(1)(A) of the Act
requires that payments under the
Medicare physician fee schedule vary
among payment areas only to the extent
that area costs vary as reflected by the
area GPCIs. The GPCIs measure area
cost differences in the three components
of the physician fee schedule: Physician
work, PEs (employee wages, rent,
medical supplies, and equipment), and
malpractice insurance. Section
1848(e)(1)(C) of the Act requires that the
GPCIs be reviewed and, if necessary,
revised at least every 3 years. The first
GPCI revision occurred in 1993. The
second revision was implemented in
1998, the next in 2001, and the last in
2005. We are implementing the next
GPCI update in this rule and the 2008
updated, budget neutralized values are
shown in Addendum E. These values
reflect the removal of the 1.000 floor on
physician work as mandated by the
MIEA-TRHCA law of December 2006.
As required by law, the GPCIs are
phased in over a two year period;
therefore the 2008 GPCI values are
calculated as one-half the difference
between the fully implemented 2007
GPCIs and the fully implemented 2009
(updated) GPCIs.
An estimate of the overall effects of
GPCI changes on fee schedule area
payments can be demonstrated by a
comparison of area geographic
adjustment factors (GAFs). The GAFs
are a weighted composite of each area’s
work, PE, and malpractice expense
GPCIs using the national GPCI cost
share weights. While we do not actually
use the GAFs in computing the fee
schedule payment for a specific service,
they are useful in comparing overall
area costs and payments. The actual
effect on payment for any actual service
will deviate from the GAF to the extent
that the services proportions of work,
PE, and malpractice expense RVUs
differ from those of the GAF. The GAFs
reflect the removal of the 1.000 floor on
physician work as mandated by the
MIEA-TRHCA law of December 2006.
The most significant positive changes
occur in seven payment localities where
the GAF moves up between 5.91 percent
(Rest of Maine) and 2.05 percent
(Ventura, Calif.). Nineteen payment
localities show an increase in GAF of
between 1.99 percent (Rest of Texas) to
1.05 percent (New Hampshire). Twentytwo payment localities have increases of
less than 1 percent.
The Detroit, Michigan payment
locality shows a drop in the GAF value
of 4.32 percent, the largest, and eight
other payment localities (including
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Santa Clara, California, Atlanta, Georgia,
Fort Worth, Texas, and Chicago, Illinois)
decrease between 3.8 percent and 2.16
percent in the GAF value. Fourteen
payment localities show decreases
between 1.10 percent (Rest of Michigan)
and 1.92 percent (Miami, Florida).
Twenty-two payment localities show
decreases between 0.01 percent
(Anaheim, California) and 0.90 percent
(Seattle, Washington).
Increases or decreases in GPCI values
do not necessarily reflect increases or
decreases in the actual costs associated
with a specific locality, but rather reflect
the relative costs compared to a national
average. As an example, when rents go
up in Wisconsin or Ohio, the index for
California or New York goes down, even
if actual costs for California or New
York stay the same or even increase.
Other factors also play a part in the
overall GPCI picture. We do not have
sufficient data to undertake a sensitivity
analysis of exact elements of the change
but we can make some generalized
assumptions. For example, the changes
in GAF values for several areas of
California reflect significant changes in
the malpractice GPCIs; and, a lowering
of the PE GPCI in many urban settings
is offset by increases in the PE GPCI of
more rural settings.
The 2008 GPCIs are budget
neutralized so the update does not
result in an increase in spending as a
result of the changes.
C. Telehealth
In section II.D of this rule, we are
adding neurobehavioral status exam as
represented by HCPCS code 96116 to
the list of telehealth services. To date,
Medicare expenditures for telehealth
services have been extremely low. For
instance, in CY 2006, the total Medicare
payment amount for telehealth services
(including the originating site facility
fee) was approximately $2 million.
Moreover, previous additions to the list
of Medicare telehealth services have not
resulted in a significant increase in
Medicare program expenditures. For
example, the psychiatric diagnostic
interview examination (as described by
CPT code 90801) was added to the list
of Medicare telehealth services in CY
2003. The addition of CPT code 90801
resulted in an increase in Medicare
payment amounts of approximately
$100,000 in CY 2006.
The neurobehavioral status exam
(CPT code 96116) includes an initial
assessment and evaluation of the mental
status for a psychiatric patient. In this
regard, the neurobehavioral status exam
is similar to the psychiatric diagnostic
interview examination (CPT code
90801). However, the utilization rate of
PO 00000
Frm 00173
Fmt 4701
Sfmt 4700
66393
psychiatric diagnostic interview
examination is much greater than the
neurobehavioral status exam. For
instance, in CY 2006, the total allowed
services for CPT code 90801 was
approximately 1.3 million while total
allowed services for neurobehavioral
status exam in CY 2006 was
approximately 105,000. Because
utilization of neurobehavioral status
exam is substantially less than the
psychiatric diagnostic interview
examination, we believe the budgetary
impact of adding neurobehavioral status
exam to the list of Medicare telehealth
services will be even less than the
previously added psychiatric diagnostic
interview examination.
While we believe that addition of this
service to the telehealth service list will
enable more beneficiaries to access to
these services, we do not anticipate that
this change will have a significant
budgetary impact on the Medicare
program.
D. Payment for Covered Outpatient
Drugs and Biologicals
1. ASP Issues
The issues discussed in section II.F.1.
with respect to payment for covered
outpatient drugs and biologicals, are
estimated to have no impact on
Medicare expenditures. However, we
believe the policies we are adopting will
assist in clarifying existing policy with
respect to ASP payment.
2. CAP issues
This final rule describes a significant
change in how CAP drug claims are
paid due to the implementation of
section 108(a)(2) of the MIEA–TRHCA.
This rule also addresses comments and
finalizes regulations on certain
approaches to refining the CAP that seek
to improve service by improving
compliance, increasing flexibility, and
increasing choices available to
participating CAP physicians. The
finalized CAP provisions will also have
a potential impact on entities that are
involved in the dispensing or
distribution of drugs, that plan to
become approved CAP vendors, or are
approved CAP vendors. Changes
associated with section 108(a)(2) of the
MIEA–TRHCA, especially the provision
for payment to vendors upon receipt of
a claim, will almost certainly be
perceived as a positive step. Other
finalized changes seek to improve
service by improving compliance and
increasing flexibility under the CAP. At
this time, we anticipate that these
changes will result in no significant
additional cost savings or increases
E:\FR\FM\27NOR2.SGM
27NOR2
66394
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
associated with the CAP, relative to the
ASP payment system.
E. Clinical Laboratory Fee Schedule
Issues
As discussed in section II.G of this
final rule, we are adopting § 414.509 for
establishing payment for a new clinical
diagnostic laboratory paid under the
Medicare Part B clinical laboratory fee
schedule. Also, we are clarifying dates
in § 414.502 and § 414.508. These
changes will not increase or decrease
payments for current clinical diagnostic
laboratory tests. For newly developed
tests, we will permit an opportunity for
the public to request a reconsideration
of a payment amount. Because any new
laboratory tests to undergo a
reconsideration request of a payment
amount are unknown to us at the
current time, we do not have any data
to estimate the impact. However, we
anticipate that the reconsideration
process will apply to fewer than five
new tests per year so that no significant
additional costs to the clinical
laboratory payment system will occur.
F. Provisions Related to Payment for
Renal Dialysis Services Furnished by
End State Renal Disease (ESRD)
Facilities
The ESRD-related provisions in this
final rule are discussed in section II.H.
To understand the impact of the
changes affecting payments to different
categories of ESRD facilities, it is
necessary to compare estimated
payments under the current year (CY
2007 payments) to estimated payments
under the revisions to the composite
rate payment system as discussed in
II.H. of this final rule with comment
period (2008 payments). To estimate the
impact among various classes of ESRD
facilities, it is imperative that the
estimates of current payments and
projected payments contain similar
inputs. Therefore, we simulated
payments only for those ESRD facilities
that we are able to calculate both
current 2007 payments and projected
2008 payments.
ESRD providers were grouped into the
categories based on characteristics
furnished in the Online Survey and
Certification and Reporting (OSCAR)
file and the most recent cost report data
from the Healthcare Cost Report
Information System (HCRIS). We also
used the June 2007 update of CY 2006
National Claims History file as a basis
for Medicare dialysis treatments and
separately billable drugs and
biologicals. Due to data limitations, we
are unable to estimate current 2007
payments and projected 2008 payments
for 153 of the 4,813 ESRD facilities that
billed for ESRD dialysis treatments in
CY 2006.
Table 41 shows the impact of this
year’s changes to CY 2008 payments to
hospital-based and independent ESRD
facilities. The first column of Table 41
identifies the type of ESRD provider, the
second column indicates the number of
ESRD facilities for each type, and the
third column indicates the number of
dialysis treatments.
The fourth column shows the effect of
the change to the wage index floor as it
affects the composite rate payments to
ESRD facilities for CY 2008. The fourth
column compares aggregate ESRD wage
adjusted composite rate payments in the
third year of the transition (CY 2008)
using the CY 2008 wage index with a
0.80 floor compared to aggregate ESRD
wage adjusted composite rate payments
in the third year of the transition (CY
2008) using the CY 2008 wage index
with a 0.75 floor. Note that the fourth
column only includes the effect of the
change to the wage index floor and does
not include the effects of other wage
index changes, such as, moving from the
second to third year of the transition
and updated wage index values from CY
2007 to CY 2008.
The fifth column shows the effect of
all changes to the ESRD wage index for
CY 2008 as it affects the composite rate
payments to ESRD facilities. It is
inclusive of the changes in the fourth
column. The fifth column compares
aggregate ESRD wage adjusted
composite rate payments in the third
year of the transition (CY 2008) to
aggregate ESRD wage adjusted
composite rate payments in the second
year of the transition (CY 2007). In the
third year of the transition (CY 2008),
ESRD facilities receive 75 percent of the
CBSA wage adjusted composite rate and
25 percent of the MSA wage adjusted
composite rate. In the second year of the
transition, ESRD facilities receive 50
percent of the CBSA wage adjusted
composite rate and 50 percent of the
MSA wage adjusted composite rate. The
overall effect to all ESRD providers in
aggregate is zero because the CY 2008
ESRD wage index has been multiplied
by a BN adjustment factor to comply
with the statutory requirement that any
wage index revisions be done in a
manner that results in the same
aggregate amount of expenditures as
would have been made without any
changes in the wage index. The
decreases shown among census regions
is primarily due to reducing the wage
index floor, as there were areas in these
areas with wage index values below the
reduced floor.
The sixth column shows the overall
effect of the changes in composite rate
payments to ESRD providers. The
overall effect is measured as the
difference between the projected CY
2008 payment with all changes in this
final rule and CY 2007 payment. This
payment amount is computed by
multiplying the wage adjusted
composite rate with the drug add-on for
each provider times the number of
dialysis treatments from the CY 2006
claims. The projected CY 2008 payment
is the transition year 3 wage-adjusted
composite rate for each provider (with
the 15.5 percent drug add-on) times
dialysis treatments from CY 2006
claims. The CY 2007 current payment is
the transition year 2 wage-adjusted
composite rate for each provider (with
the current 14.9 percent drug add-on)
times dialysis treatments from CY 2006
claims.
The overall impact to ESRD providers
in aggregate is 0.5 percent. This increase
corresponds to the 0.5 percent increase
to the drug add-on. The variation shown
in column 6 is due to variation in
changes in the wage index (column 5).
All provider types receive the same 0.5
percent increase to the drug add-on.
TABLE 41.—IMPACT OF CY 2008 CHANGES IN PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES
cprice-sewell on PROD1PC72 with RULES
[Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)]
Number of
dialysis
treatments
(in millions)
Effect of
changes in
floor only 1
Effect of
changes in
wage
index 2
4,660
4,101
559
35.5
31.8
3.7
0.0
0.0
0.0
0.0
¥0.1
0.5
0.5
0.5
1.0
1,650
4.7
¥0.1
¥0.3
0.3
Number of
facilities
All Providers .............................................................................................
Independent ......................................................................................
Hospital Based .................................................................................
By Facility Size
Less than 5000 treatments ...............................................................
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00174
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
Overall
effect 3
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66395
TABLE 41.—IMPACT OF CY 2008 CHANGES IN PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES—
Continued
[Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)]
Number of
dialysis
treatments
(in millions)
Effect of
changes in
floor only 1
Effect of
changes in
wage
index 2
1,800
1,210
13.0
17.7
0.0
0.0
0.0
0.1
0.5
0.6
3,745
915
28.9
6.5
0.0
0.0
¥0.1
0.3
0.4
0.9
1,261
3,399
7.3
28.1
¥0.4
0.1
¥0.6
0.1
0.0
0.7
141
553
727
358
1,063
365
646
254
523
30
1.1
4.5
5.7
1.9
8.1
2.6
5.0
1.6
4.4
0.4
0.1
0.1
0.1
0.1
0.0
¥0.5
¥0.1
0.1
0.1
¥2.1
1.4
0.5
¥0.6
¥0.3
0.0
¥1.4
¥0.7
0.3
1.4
¥3.0
2.0
1.0
¥0.1
0.3
0.6
¥0.8
¥0.2
0.8
2.0
¥2.5
Number of
facilities
5000 to 9999 treatments ..................................................................
Greater than 9999 treatments ..........................................................
Type of Ownership
Profit .................................................................................................
Nonprofit ...........................................................................................
By Geographic Location
Rural .................................................................................................
Urban ................................................................................................
By Region
New England ....................................................................................
Middle Atlantic ..................................................................................
East North Central ............................................................................
West North Central ...........................................................................
South Atlantic ...................................................................................
East South Central ...........................................................................
West South Central ..........................................................................
Mountain ...........................................................................................
Pacific ...............................................................................................
Puerto Rico .......................................................................................
Overall
effect 3
1 This column shows the effect of the wage index floor changes on ESRD providers. Composite rate payments computed using the CY 2008
wage index with a 0.80 floor are compared to composite rate payments using the CY 2008 wage index with a 0.75 floor.
2 This column shows the overall effect of wage index changes on ESRD providers. Composite rate payments computed using the current wage
index are compared to composite rate payments using the CY 2008 wage index changes.
3 This column shows the percent change between CY 2008 and CY 2007 composite rate payments to ESRD facilities. The CY 2008 payments
include the CY 2008 wage adjusted composite rate, and the 15.5% drug add-on times treatments The CY 2007 payments to ESRD facilities includes the CY 2007 wage adjusted composite rate and the 14.9% drug add-on times treatments.
G. IDTF Changes
We believe that our provisions
regarding IDTFs as discussed in section
II.I. of this final rule with comment
period would have no budgetary impact.
However, we believe that these changes
are necessary to ensure that only
legitimate IDTFs are enrolled into the
program. In addition, we believe that
the IDTF provisions contained in this
final rule will help ensure that
beneficiaries receive quality care.
Therefore, we expect to have an impact
on an unknown number of persons and
entities who will be denied enrollment
into the Medicare program.
H. CORF Issues
cprice-sewell on PROD1PC72 with RULES
The revisions to the CORF regulations
discussed in section II.K. update the
regulations for consistency with the PFS
payment rules. These revisions will
help to clarify payment for CORF
services and are expected to have
minimal impact on Medicare
expenditures.
I. Compendia for Determination of
Medically-Accepted Indications for OffLabel Use of Drugs and Biologicals in an
Anti-Cancer Chemotherapeutic
Regimen.
We anticipate that the changes related
to the compendia discussed in section
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
II.L. of this final rule with comment
period will have a negligible cost to the
Medicare program. The changes will
enable CMS to respond quickly should
changes in the number and quality of
the compendia indicate a need to amend
the list.
J. Physician Self-Referral Provisions
We anticipate that our provisions in
section II.M. of this final rule with
comment period for the reassignment
and anti-markup provisions, and the
physician self-referral provisions will
result in savings to the program by
reducing overutilization and anticompetitive business arrangements. We
cannot gauge with any certainty the
extent of these savings to the Medicare
program.
K. Beneficiary Signature for Ambulance
Transport Services
We believe that our provision in
section II.N. of this final rule with
comment period for allowing the
ambulance provider or supplier to sign
the claim on behalf of the beneficiary
with respect to emergency transport
services, provided that certain
conditions are satisfied, will have no
budget impact.
PO 00000
Frm 00175
Fmt 4701
Sfmt 4700
L. Update to Fee Schedules for Class III
DME for CYs 2007 and 2008
In section II.O. of this final rule with
comment period, we discuss the update
to the fee schedules for class III DME for
CYs 2007 and 2008. Total allowed
charges for class III devices in 2005
were $71 million. Accordingly, with a
zero percent increase for DME, other
than class III devices, for 2005 and 2006
and with the establishment of an update
for 2007 of zero percent for class III
devices, rather than 4.3 percent based
on the CPI–U, this results in a savings
to the Medicare program of
approximately $2 million in FY 2007,
$4 million in FY 2008, $4 million in FY
2009, $5 million in FY 2010, $5 million
in FY 2011, and $5 million in FY 2012.
M. Therapy Services
In section II.R.2., we are changing the
certification requirement for the plan of
care, for outpatient physical therapy,
occupational therapy and speechlanguage pathology services from every
30 days to an appropriate length, based
on the patient’s needs, limited to 90
days. As we stated in the proposed rule,
analysis of Medicare claims data shows
negative or no impact for this change
and this was also supported by
commenters. In most cases, the
appropriate length of treatment will be
E:\FR\FM\27NOR2.SGM
27NOR2
66396
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
less than 30 days. Certification of the
appropriate length of treatment will
discourage the practice of billing for reevaluations prior to recertification
regardless of need.
The 30-day recertification allows
treatment under a plan of care for 30
days after initial certification, regardless
of the appropriate length of treatment.
The initial certification cannot assure
that a physician reviews the plan or
follows the patient’s progress.
We will review the utilization of
therapy services after a 2-year trial to
assess any changes that might be related
to certification of a plan of care for an
appropriate length of treatment. At that
time, if we determine that this change
has caused an increase in inappropriate
utilization, we will reconsider the 30day certification requirement.
cprice-sewell on PROD1PC72 with RULES
N. TRHCA 101(b) Physician Quality
Reporting Initiative
As discussed section II.S.1. of this
rule, the final 2008 PQRI measures
satisfy the requirement of section
1848(k)(2)(B)(ii) of the Act that the
Secretary publish in the Federal
Register by August 15, 2007, measures
that the Secretary proposes as
appropriate for eligible professionals to
use to submit data to the Secretary in
2008. We also expect to address registryand EHR-based data submission on a
test basis in 2008, as discussed in
section II.T.1. of this rule. Although
there may be some cost incurred for
maintaining the measures and their
associated code sets, and for enhancing
an existing clinical data warehouse to
accommodate the registry- and EHRbased data submission, we do not
anticipate a significant cost impact on
the Medicare program.
O. TRHCA 101(d) Physician Assistance
and Quality Initiative Fund
As discussed in section II.S.5. of this
final rule with comment period, section
101(d) of the MIEA–TRHCA created the
Physician Assistance and Quality
Initiative Fund (PAQI) which provides
$1.35 billion for physician payment and
quality improvement initiatives. The
legislation directs the Secretary to
provide for expenditures from the Fund
in a manner designed to provide (to the
maximum extent feasible) for the
obligation of the entire $1.35 billion for
payment for physicians’ services
furnished during 2008. As discussed in
section II.S.5. of this final rule with
comment period, we will scale aggregate
payments to physicians in a manner
such that Medicare would pay $1.35
billion during CY 2009 for measures
reported for services furnished during
CY 2008. We are unable to provide an
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
exact percentage for the bonus payment,
but we anticipate that the bonus
payments will be approximately 1.5
percent of allowed charges for
participating professionals (and we do
not expect that the ultimate percentage
amount would exceed 2 percent). We
also note that the Transitional Medical
Assistance, Abstinence Education, and
Qualifying Individual Programs
Extension Act of 2007 (Pub. L. 110–90)
provided an additional $325 million to
be used as a part of the PAQI Fund for
payment with regard to services
furnished in 2009 and $60,000,000 for
payment with respect to physicians’
services furnished on or after January 1,
2013.
P. TRHCA 110 Reporting of Anemia
Quality Indicators
As discussed in section II.S.2. of this
final rule with comment period, there
are no program cost savings or increased
expenditures associated with this
change; however, we expect that the
regulation will have a positive impact
on patient care.
Q. Amendment of the Exemption From
NCPDP SCRIPT Standard for ComputerGenerated Facsimile Transmissions
Under Medicare Part D
The amendment of the exemption for
computer-generated fax transactions
under Medicare Part D is discussed in
section II.R.3. of this rule. E-prescribing
is voluntary for providers and
pharmacies. This amendment only
affects providers and pharmacies that
already conduct e-prescribing using
products that generate faxes rather than
SCRIPT transactions.
We believe that providers and
pharmacies that are now e-prescribing
using products that generate faxes
generally already possess the hardware
necessary to e-prescribe. Many would
need to obtain software upgrades to
send and receive the SCRIPT
transaction. This software will generally
be available to providers through
automatic version upgrades built into
annual software vendor maintenance
fees. However, providers currently using
software that cannot be upgraded to
generate SCRIPT transactions would
need to purchase and install new eprescribing software or revert to sending
paper fax transactions to pharmacies.
Dispensers that currently e-prescribe
but have not established the
connectivity necessary to receive and
send SCRIPT transactions would need
to connect to a network, and may need
to install software upgrades, which will
generally be covered under annual fees.
Because pharmacies customarily bear
the cost of transaction fees for the
PO 00000
Frm 00176
Fmt 4701
Sfmt 4700
SCRIPT transactions they receive and
send, these costs would increase as the
rate of e-prescribing increases.
The amendment of this exemption
will have indirect benefits in that it will
help to encourage e-prescribing using
electronic data interchange, which will
ultimately result in improved patient
safety. We also will continue to allow
computer-generated faxes as a fallback
in cases of temporary/transient
transmission failures and
communications problems.
Because of the voluntary nature of eprescribing for physicians and
pharmacies, the relatively small number
of entities currently e-prescribing, and
the minimal nature of the anticipated
costs, we believe this provision does not
constitute a major rule for purposes of
this analysis.
R. Revisions to Payment Policies Under
the Ambulance Fee Schedule and the
Ambulance Inflation Factor Update for
CY 2008
For the purposes of the RFA,
ambulance providers and suppliers are
considered to be small entities.
Removing the requirement that the AIF
be published annually via Federal
Register notice has no monetary impact
on small entities or small businesses. It
merely allows for the earlier
dissemination of necessary information
to the ambulance industry, the Medicare
contractors, and the general public.
We estimate that the total program
expenditure for CY 2007 for ambulance
services covered by the Medicare
program is approximately $5.2 billion.
Application of an AIF of 2.7 percent
will result in an additional total
program expenditure for CY 2008 of
approximately $140 million over CY
2007 expenditures.
S. Alternatives Considered
This final rule with comment period
contains a range of policies, including
some provisions related to specific
MMA provisions. The preamble
provides descriptions of the statutory
provisions that are addressed, identifies
those policies when discretion has been
exercised, presents rationale for our
decisions and, where relevant,
alternatives that were considered.
T. Impact on Beneficiaries
There are a number of changes made
in this final rule with comment period
that would have an effect on
beneficiaries. In general, we believe
these changes, particularly the
implementation of the PQRI with its
continuing focus on measuring,
submitting, and analyzing quality data,
will have a positive impact and improve
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
the quality and value of care furnished
to Medicare beneficiaries.
We do not believe that beneficiaries
will experience drug access issues as a
result of the changes with respect to Part
B drugs and CAP.
As explained in more detail
subsequently in this section, the
regulatory provisions may affect
beneficiary liability in some cases. Most
changes in aggregate beneficiary liability
from a particular provision would be a
function of the coinsurance (20 percent
if applicable for the particular provision
after the beneficiary has met the
deductible) and the effect of the
aggregate cost (savings) of the provision
on the calculation of the Medicare Part
B premium rate (generally 25 percent of
the provision’s cost or savings). In 2008,
total cost sharing (coinsurance and
deductible) per Part B enrollee
associated with physician fee schedule
services is estimated to be $590. In
addition, the portion of the 2008
standard monthly Part B premium
attributable to PFS services is estimated
to be $38.60.
To illustrate this point, as shown in
Table 40, the 2007 national payment
amount in the nonfacility setting for
CPT code 99203 (Office/outpatient visit,
new), is $91.71 which means that
currently a beneficiary is responsible for
20 percent of this amount, or $18.34.
Based on this final rule with comment
period, the 2008 national payment
amount in the nonfacility setting for
CPT code 99203, as shown in Table 40,
is $81.42 which means that, in 2008, the
beneficiary coinsurance for this service
would be $16.28.
Policies discussed in this rule that do
affect overall spending, such as the
66397
additions to the list of codes that are
subject to section 5102 of the DRA
imaging provisions, would similarly
impact beneficiaries’’ coinsurance.
U. Accounting Statement
As required by OMB Circular A–4
(available at https://www.white
house.gov/omb/circulars/a004/a-4.pdf),
in Table 42, we have prepared an
accounting statement showing the
classification of the expenditures
associated with this final rule with
comment period. This estimate includes
the incurred benefit impact associated
with the estimated CY 2008 PFS update,
shown in this final rule with comment
period, based on the 2007 Trustees
Report baseline. All estimated impacts
are classified as transfers.
TABLE 42.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES FOR CY 2008
[In billions]
Category
Annualized Monetized
Transfers.
From Whom To Whom? .....
Transfers
¥$6.0.
Federal Government to physicians, other practitioners and suppliers who receive payment under the Medicare
Physician Fee Schedule; ESRD Medicare Providers; ambulance suppliers, DME suppliers, and Medicare suppliers billing for Part B drugs.
In accordance with the provisions of
Executive Order 12866, this final rule
with comment period was reviewed by
the Office of Management and Budget.
42 CFR Part 415
List of Subjects
42 CFR Part 418
42 CFR Part 409
Health facilities, Hospice care,
Medicare, Reporting and recordkeeping
requirements.
Health facilities, Medicare.
Health facilities, Health professions,
Medicare, Reporting and recordkeeping
requirements.
42 CFR Part 410
42 CFR Part 423
Health facilities, Health professions,
Kidney diseases, Laboratories,
Medicare, Reporting and recordkeeping
requirements, Rural areas, X-rays.
Administrative practice and
procedure, Emergency medical services,
Health facilities, Health maintenance
organizations (HMO), Health
Professionals, Medicare, Penalties,
Privacy, Reporting and recordkeeping
requirements.
42 CFR Part 411
Kidney diseases, Medicare, Physician
Referral, Reporting and recordkeeping
requirements.
42 CFR Part 413
Health facilities, Kidney diseases,
Medicare, Reporting and recordkeeping
requirements.
cprice-sewell on PROD1PC72 with RULES
42 CFR Part 414
Administrative practice and
procedure, Health facilities, Health
professions, Kidney diseases, Medicare,
Reporting and recordkeeping.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
42 CFR Part 424
Emergency medical services, Health
facilities, Health professions, Medicare,
Reporting and recordkeeping
requirements.
42 CFR Part 482
Grant programs—health, Hospitals,
Medicaid, Medicare, Reporting and
recordkeeping requirements.
homes, Nutrition, Reporting and
recordkeeping requirements, Safety.
42 CFR Part 485
Grant programs—health, Health
facilities, Medicaid, Medicare,
Reporting and recordkeeping
requirements.
I For the reasons set forth in the
preamble, the Centers for Medicare &
Medicaid Services amends 42 CFR
chapter IV as set forth below:
PART 409—HOSPITAL INSURANCE
BENEFITS
1. The authority citation for part 409
continues to read as follows:
I
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
Subpart B—Inpatient Hospital Services
and Inpatient Critical Access Hospital
Services
2. Section 409.17 is added to read as
follows:
I
42 CFR Part 484
§ 409.17 Physical therapy, occupational
therapy, and speech-language pathology
services.
Grant programs—health, Health
facilities, Health professions, Health
records, Medicaid, Medicare, Nursing
(a) General rules. (1) Except as
specified in paragraph (a)(1)(ii) of this
section, physical therapy, occupational
PO 00000
Frm 00177
Fmt 4701
Sfmt 4700
E:\FR\FM\27NOR2.SGM
27NOR2
66398
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
therapy or speech-language pathology
services must be furnished by qualified
physical therapists, physical therapist
assistants, occupational therapists,
occupational therapy assistants or
speech-language pathologists who meet
the requirements specified part 484 of
this chapter.
(2) Physical therapy, occupational
therapy or speech-language pathology
services must be furnished under a plan
that meets the requirements of
paragraphs (b) through (d) of this
section, or plan requirements specific to
the payment policy under which the
services are rendered, if applicable.
(b) Establishment of the plan. The
plan must be established before
treatment begins by one of the
following:
(1) A physician.
(2) A nurse practitioner, a clinical
nurse specialist or a physician assistant.
(3) The physical therapist furnishing
the physical therapy services.
(4) A speech-language pathologist
furnishing the speech-language
pathology services.
(5) An occupational therapist
furnishing the occupational therapy
services.
(c) Content of the plan. The plan:
(1) Prescribes the type, amount,
frequency, and duration of the physical
therapy, occupational therapy, or
speech-language pathology services to
be furnished to the individual; and
(2) Indicates the diagnosis and
anticipated goals.
(d) Changes in the plan. Any changes
in the plan are implemented in
accordance with hospital policies and
procedures.
Subpart C—Posthospital SNF Care
3. Section 409.23 is amended by
adding paragraph (c) to read as follows:
I
§ 409.23 Physical, occupational, and
speech therapy.
cprice-sewell on PROD1PC72 with RULES
*
*
*
*
*
(c) Except as specified in paragraph
(c)(1)(ii) of this section, physical
therapy, occupational therapy or
speech-language pathology services
must be furnished—
(1) By qualified physical therapists,
physical therapist assistants,
occupational therapists, occupational
therapy assistants or speech-language
pathologists as defined in part 484 of
this chapter
(2) In accordance with a plan that
meets the requirements of § 409.17(b)
through (d) of this part.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PART 410—SUPPLEMENTARY
MEDICAL INSURANCE (SMI)
BENEFITS
4. The authority citation for part 410
continues to read as follows:
I
Authority: Secs. 1102, 1834, 1871, and
1893 of the Social Security Act (42 U.S.C.
1302, 1395m, 1395hh, and 1395ddd).
Subpart B—Medical and Other Health
Services
§ 410.32
[Amended]
5. Section 410.32 is amended by—
A. Removing paragraph (a)(1).
B. Redesignating paragraphs (a)(2) and
(a)(3) as paragraphs (a)(1) and (a)(2).
I 6. Section 410.33 is amended by—
I A. Revising paragraphs (b)(1), (g)(2),
(g)(3), (g)(6), and (g)(8).
I B. Adding paragraphs (g)(15) and (i).
The revisions and addition read as
follows:
I
I
I
§ 410.33
facility.
Independent diagnostic testing
*
*
*
*
*
(b) * * *
(1) Each supervising physician must
be limited to providing general
supervision to no more than three IDTF
sites. This applies to both fixed sites
and mobile units where three
concurrent operations are capable of
performing tests.
*
*
*
*
*
(g) * * *
(2) Provides complete and accurate
information on its enrollment
application. Changes in ownership,
changes of location, changes in general
supervision, and adverse legal actions
must be reported to the Medicare feefor-service contractor on the Medicare
enrollment application within 30
calendar days of the change. All other
changes to the enrollment application
must be reported within 90 days.
(3) Maintain a physical facility on an
appropriate site. For the purposes of this
standard, a post office box, commercial
mailbox, hotel, or motel is not
considered an appropriate site.
(i) The physical facility, including
mobile units, must contain space for
equipment appropriate to the services
designated on the enrollment
application, facilities for hand washing,
adequate patient privacy
accommodations, and the storage of
both business records and current
medical records within the office setting
of the IDTF, or IDTF home office, not
within the actual mobile unit.
(ii) IDTF suppliers that provide
services remotely and do not see
beneficiaries at their practice location
are exempt from providing hand
PO 00000
Frm 00178
Fmt 4701
Sfmt 4700
washing and adequate patient privacy
accommodations.
*
*
*
*
*
(6) Have a comprehensive liability
insurance policy of at least $300,000 per
location that covers both the place of
business and all customers and
employees of the IDTF. The policy must
be carried by a nonrelative-owned
company. Failure to maintain required
insurance at all times will result in
revocation of the IDTF’s billing
privileges retroactive to the date the
insurance lapsed. IDTF suppliers are
responsible for providing the contact
information for the issuing insurance
agent and the underwriter. In addition,
the IDTF must—
(i) Ensure that the insurance policy
must remain in force at all times and
provide coverage of at least $300,000
per incident; and
(ii) Notify the CMS designated
contractor in writing of any policy
changes or cancellations.
*
*
*
*
*
(8) Answer, document, and maintain
documentation of a beneficiary’s written
clinical complaint at the physical site of
the IDTF (For mobile IDTFs, this
documentation would be stored at their
home office.) This includes, but is not
limited to, the following:
(i) The name, address, telephone
number, and health insurance claim
number of the beneficiary.
(ii) The date the complaint was
received; the name of the person
receiving the complaint; and a summary
of actions taken to resolve the
complaint.
(iii) If an investigation was not
conducted, the name of the person
making the decision and the reason for
the decision.
*
*
*
*
*
(15) With the exception of hospitalbased and mobile IDTFs, a fixed-base
IDTF does not include the following:
(i) Sharing a practice location with
another Medicare-enrolled individual or
organization;
(ii) Leasing or subleasing its
operations or its practice location to
another Medicare-enrolled individual or
organization; or
(iii) Sharing diagnostic testing
equipment used in the initial diagnostic
test with another Medicare-enrolled
individual or organization.
*
*
*
*
*
(i) Effective date of billing privileges.
The filing date of the Medicare
enrollment application is the date that
the Medicare contractor receives a
signed provider enrollment application
that it is able to process to approval. The
effective date of billing privileges for a
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
§ 410.78
newly enrolled IDTF is the later of the
following:
(1) The filing date of the Medicare
enrollment application that was
subsequently approved by a Medicare
fee-for-service contractor; or
(2) The date the IDTF first started
furnishing services at its new practice
location.
I 7. Section 410.43 is amended by
revising paragraph (a)(3)(ii) to read as
follows:
§ 410.43 Partial hospitalization services:
Conditions and exclusions.
(a) * * *
(3) * * *
(ii) Occupational therapy requiring
the skills of a qualified occupational
therapist, provided by an occupational
therapist, or under appropriate
supervision of a qualified occupational
therapist by an occupational therapy
assistant as specified in part 484 of this
chapter.
I 8. Section 410.59 is amended by
revising the introductory text to
paragraph (a) to read as follows:
§ 410.59 Outpatient occupational therapy
services: Conditions.
(a) Basic rule. Except as specified in
paragraph (a)(3)(iii) of this section,
Medicare Part B pays for outpatient
occupational therapy services only if
they are furnished by an individual
meeting the qualifications in part 484 of
this chapter for an occupational
therapist or an appropriately supervised
occupational therapy assistant but only
under the following conditions:
*
*
*
*
*
I 9. Section 410.60 is amended by
revising the introductory text of
paragraph (a) to read as follows:
§ 410.60 Outpatient physical therapy
services: Conditions.
*
*
*
*
(a) Basic rule. Except as specified in
paragraph (a)(3)(iii) of this section,
Medicare Part B pays for outpatient
physical therapy services only if they
are furnished by an individual meeting
the qualifications in part 484 of this
chapter for a physical therapist or an
appropriately supervised physical
therapist assistant but only under the
following conditions:
*
*
*
*
*
cprice-sewell on PROD1PC72 with RULES
*
§ 410.61
[Amended]
10. Section 410.61 is amended by
removing paragraph (e).
I 11. Section 410.78 is amended by
revising the introductory text of
paragraph (b) to read as follows:
I
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Telehealth services.
*
*
*
*
*
(b) General rule. Medicare Part B pays
for office and other outpatient visits,
professional consultation, psychiatric
diagnostic interview examination,
individual psychotherapy,
pharmacologic management, end stage
renal disease related services included
in the monthly capitation payment
(except for one visit per month to
examine the access site), individual
medical nutrition therapy, and
neurobehavioral status exam furnished
by an interactive telecommunications
system if the following conditions are
met:
*
*
*
*
*
Subpart D—Comprehensive Outpatient
Rehabilitation Facility (CORF) Services
12. Section 410.100 is amended by—
A. Revising the introductory text and
paragraphs (a), (e), and (h).
I B. Removing paragraph (i).
I C. Redesignating paragraphs (j), (k),
(l), and (m) to (i), (j), (k), and (l)
respectively.
I D. Revising new paragraphs (i), (j), (k),
and (l).
The revisions read as follows:
I
I
§ 410.100
Included services.
Subject to the conditions and
limitations set forth in § 410.102 and
§ 410.105, CORF services means the
following services furnished to an
outpatient of the CORF by personnel
that meet the qualifications set forth in
§ 485.70 of this chapter. Payment for
CORF services are made in accordance
with § 414.1105.
(a) Physician’s services. CORF facility
physician services are administrative in
nature and include consultation with
and medical supervision of
nonphysician staff, participation in plan
of treatment reviews and patient care
review conferences, and other medical
and facility administration activities.
Diagnostic and therapeutic services
furnished to an individual CORF patient
by a physician in a CORF facility are not
CORF physician services. These
services, if covered, are physician
services under § 410.20 with payment
for these services made to the physician
in accordance with part 414 subpart B.
*
*
*
*
*
(e) Respiratory therapy services. (1)
Respiratory therapy services are for the
assessment, treatment, and monitoring
of patients with deficiencies or
abnormalities of cardiopulmonary
function.
(2) Respiratory therapy services
include the following:
PO 00000
Frm 00179
Fmt 4701
Sfmt 4700
66399
(i) Application of techniques for
support of oxygenation and ventilation
of the patient.
(ii) Therapeutic use and monitoring of
gases, mists, and aerosols and related
equipment.
(iii) Bronchial hygiene therapy.
(iv) Pulmonary rehabilitation
techniques to develop strength and
endurance of respiratory muscles and
other techniques to increase respiratory
function, such as graded activity
services; these services include
physiologic monitoring and patient
education.
*
*
*
*
*
(h) Social and psychological services.
Social and psychological services
include the assessment and treatment of
an individual’s mental and emotional
functioning and the response to and rate
of progress as it relates to the
individual’s rehabilitation plan of
treatment, including physical therapy
services, occupational therapy services,
speech-language pathology services and
respiratory therapy services.
(i) Nursing care services. Nursing care
services include nursing services
provided by a registered nurse that are
prescribed by a physician and are
specified in or directly related to the
rehabilitation treatment plan and
necessary for the attainment of the
rehabilitation goals of the physical
therapy, occupational therapy, speechlanguage pathology, or respiratory
therapy plan of treatment.
(j) Drugs and biologicals. These are
drugs and biologicals that are the
following:
(1) Prescribed by a physician and
administered by or under the
supervision of a physician or by a
registered professional nurse; and
(2) Not excluded from Medicare Part
B payment for reasons specified in
§ 410.29.
(k) Supplies and durable medical
equipment. Supplies and durable
medical equipment include the
following:
(1) Disposable supplies.
(2) Durable medical equipment of the
type specified in § 410.38 (except for
renal dialysis systems) for a patient’s
use outside the CORF, whether
purchased or rented.
(l) Home environment evaluation. A
home environment evaluation—
(1) Is a single home visit to evaluate
the potential impact of the home
situation on the patient’s rehabilitation
goals.
(2) Requires the presence of the
patient and the physical therapist,
occupational therapist, or speechlanguage pathologist, as appropriate.
E:\FR\FM\27NOR2.SGM
27NOR2
66400
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
13. Section 410.105 is amended by
revising paragraphs (b)(3)(i), (b)(3)(ii),
(c)(1) introductory text, and (c)(2) to
read as follows:
I
PART 411—EXCLUSIONS FROM
MEDICARE AND LIMITATIONS ON
MEDICARE PAYMENT
15. The authority citation for part 411
continues to read as follows:
I
§ 410.105 Requirements for coverage of
CORF services.
*
*
*
*
*
(b) * * *
(3) * * *
(i) Physical therapy, occupational
therapy, and speech-language pathology
services may be furnished away from
the premises of the CORF including the
individual’s home when payment is not
otherwise made under Title XVIII of the
Act.
(ii) The single home environment
evaluation visit specified in
§ 410.100(m) is also covered.
(c) * * *
(1) The service must be furnished
under a written plan of treatment that—
(i) * * *
(ii) Indicates the diagnosis and
rehabilitation goals, and prescribes the
type, amount, frequency, and duration
of the skilled rehabilitation services,
including physical therapy,
occupational therapy, speech-language
pathology and respiratory therapy
services, and indicates the other CORF
services to be furnished that relate
directly to such rehabilitation goals.
(2) The plan must be reviewed at least
every 60 days for respiratory therapy
services and every 90 days for physical
therapy, occupational therapy and
speech-language pathology services by a
facility physician or the referring
physician who, when appropriate,
consults with the professional personnel
providing the services.
*
*
*
*
*
Subpart G—Medical Nutrition Therapy
14. Section 410.132 is amended by
revising paragraph (a) to read as follows:
I
cprice-sewell on PROD1PC72 with RULES
§ 410.132
Medical nutrition therapy.
(a) Conditions for coverage of MNT
services. Medicare Part B pays for MNT
services provided by a registered
dietitian or nutrition professional as
defined in § 410.134 when the
beneficiary is referred for the service by
the treating physician. Except as
provided at § 410.78, services covered
consist of face-to-face nutritional
assessments and interventions in
accordance with nationally-accepted
dietary or nutritional protocols.
*
*
*
*
*
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Authority: Secs. 1102, 1860D–1 through
1860D–42, 1871, and 1877 of the Social
Security Act (42 U.S.C. 1302, 1395w–101
through 1395w–152, 1395hh, and 1395nn).
Subpart A—General Exclusions and
Exclusion of Particular Services
16. Section 411.15 is amended by—
A. Revising paragraph (a)(1).
B. Adding paragraphs (k)(13) and
(k)(14).
The revision and additions read as
follows:
I
I
I
(3) For purposes of this subpart,
‘‘entity’’ does not include a physician’s
practice when it bills Medicare for the
technical component or professional
component of a diagnostic test for
which the anti-markup provision is
applicable in accordance with § 414.50
of this chapter and section 30.2.9 of the
CMS Internet-only Manual, publication
100–04, Claims Processing Manual,
Chapter 1 (general billing requirements).
PART 413—PRINCIPLES OF
REASONABLE COST
REIMBURSEMENT; PAYMENT FOR
END-STAGE RENAL DISEASE
SERVICES; PROSPECTIVELY
DETERMINED PAYMENT RATES FOR
SKILLED NURSING FACILITIES
18. The authority citation for part 413
continues to read as follows:
§ 411.15 Particular services excluded from
coverage.
I
*
Authority: Secs. 1102, 1812(d), 1814(b),
1815, 1833(a), (i), and (n), 1861(v), 1871,
1881, 1883, and 1886 of the Social Security
Act (42 U.S.C. 1302, 1395d(d), 1395f(b),
1395g, 1395l(a), (i), and (n), 1395x(v),
1395hh, 1395rr, 1395tt, and 1395ww); and
sec. 124 of Pub. L. 106–133 (113 Stat. 1501A–
332).
*
*
*
*
(a) * * *
(1) Examinations performed for a
purpose other than treatment or
diagnosis of a specific illness,
symptoms, complaint, or injury, except
for screening mammography, colorectal
cancer screening tests, screening pelvic
exams, prostate cancer screening tests,
glaucoma screening exams, initial
preventive physical exams, ultrasound
screening for abdominal aortic
aneurysms (AAA), cardiovascular
disease screening tests, or diabetes
screening tests that meet the criteria
specified in paragraphs (k)(6) through
(k)(14) of this section.
*
*
*
*
*
(k) * * *
(13) In the case of cardiovascular
disease screening tests for the early
detection of cardiovascular disease or
abnormalities associated with an
elevated risk for that disease, subject to
the conditions specified in § 410.17 of
this chapter.
(14) In the case of diabetes screening
tests furnished to an individual at risk
for diabetes for the purpose of the early
detection of that disease, subject to the
conditions specified in § 410.18 of this
chapter.
*
*
*
*
*
Subpart J—Financial Relationships
Between Physicians and Entities
Furnishing Designated Health Services
17. Section 411.351 is amended by
revising the definition of ‘‘entity’’ to
read as follows:
I
§ 411.351
Definitions.
*
*
*
*
Entity means—
*
*
*
*
PO 00000
Frm 00180
Fmt 4701
*
Subpart A—Introduction and General
Rules
§ 413.1
[Amended]
19. Section 413.1 is amended by—
A. Removing paragraphs (a)(2)(iv) and
(vi).
I B. Redesignating paragraphs (a)(2)(v)
and (vii) as paragraphs (a)(2)(iv) and (v),
respectively.
I
I
Subpart H—Payment for End-Stage
Renal Disease (ESRD) Services and
Organ Procurement Costs
20. Section 413.184 is amended by
revising the section heading as set forth
below:
I
§ 413.184 Payment exception: Pediatric
patient mix.
*
*
*
Sfmt 4700
*
PART 414—PAYMENT FOR PART B
MEDICAL AND OTHER HEALTH
SERVICES
21. The authority citation for part 414
continues to read as follows:
I
Authority: Secs. 1102, 1871, and 1881(b)(l)
of the Social Security Act (42 U.S.C. 1302,
1395hh, and 1395rr(b)(l)).
Subpart B—Physicians and Other
Practitioners
22. Section 414.50 is revised to read
as follows:
I
*
*
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
cprice-sewell on PROD1PC72 with RULES
§ 414.50 Physician or other supplier billing
for diagnostic tests performed or
interpreted by an outside supplier or at a
site other than the office of the billing
physician or other supplier.
(a) General rules. (1) The services
covered under section 1861(s)(3) of the
Act and paid for under part 414 of this
chapter (other than clinical diagnostic
laboratory tests paid under section
1833(a)(2)(D) of the Act, which are
subject to the special billing rules set
forth in section 1833(h)(5)(A) of the
Act), if a physician or other supplier
bills for the technical component or
professional component of a diagnostic
test that was ordered by the physician
or other supplier (or ordered by a party
related to such physician or other
supplier through common ownership or
control as described in § 413.17 of this
chapter) and the diagnostic test is either
purchased from an outside supplier or
performed at a site other than the office
of the billing physician or other
supplier, the payment to the billing
physician or other supplier (less the
applicable deductibles and coinsurance
paid by the beneficiary or on behalf of
the beneficiary) for the technical
component or professional component
of the diagnostic test may not exceed the
lowest of the following amounts:
(i) The performing supplier’s net
charge to the billing physician or other
supplier.
(ii) The billing physician or other
supplier’s actual charge.
(iii) The fee schedule amount for the
test that would be allowed if the
performing supplier billed directly.
(2) The following requirements are
applicable for purposes of paragraph (a)
of this section:
(i) The net charge must be determined
without regard to any charge that is
intended to reflect the cost of equipment
or space leased to the performing
supplier by or through the billing
physician or other supplier.
(ii) An ‘‘outside supplier’’ is someone
who is not an employee of the billing
physician or other supplier and who
does not furnish the test or
interpretation to the billing physician or
other supplier under a reassignment that
meets the requirements of § 424.80.
(iii) The ‘‘office of the billing
physician or other supplier’’ is medical
office space where the physician or
other supplier regularly furnishes
patient care. With respect to a billing
physician or other supplier that is a
physician organization (as defined at
§ 411.351 of this chapter), the ‘‘office of
the billing physician or other supplier’’
is space in which the physician
organization provides substantially the
full range of patient care services that
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
the physician organization provides
generally.
(b) Restriction on payment. (1) The
billing physician or other supplier must
identify the performing supplier and
indicate the performing supplier’s net
charge for the test. If the billing
physician or other supplier fails to
provide this information, CMS makes no
payment to the billing physician or
other supplier and the billing physician
or other supplier may not bill the
beneficiary.
(2) Physicians and other suppliers
that accept Medicare assignment may
bill beneficiaries for only the applicable
deductibles and coinsurance.
(3) Physicians and other suppliers
that do not accept Medicare assignment
may not bill the beneficiary more than
the payment amount described in
paragraph (a) of this section.
23. Section 414.65 is amended by
revising paragraph (a)(1) to read as
follows:
I
§ 414.65
Payment for telehealth services.
(a) * * *
(1) The Medicare payment amount for
office or other outpatient visits,
consultation, individual psychotherapy,
psychiatric diagnostic interview
examination, pharmacologic
management, end stage renal disease
related services included in the monthly
capitation payment (except for one visit
per month to examine the access site),
individual medical nutrition therapy,
and neurobehavioral status exam
furnished via an interactive
telecommunications system is equal to
the current fee schedule amount
applicable for the service of the
physician or practitioner.
*
*
*
*
*
Subpart G—Payment for New Clinical
Diagnostic Laboratory Tests
24. Section § 414.502 is amended by
adding the definition, ‘‘New test’’ in
alphabetical order to read as follows:
I
§ 414.502
Definitions.
*
*
*
*
*
New test means any clinical
diagnostic laboratory test for which a
new or substantially revised Healthcare
Common Procedure Coding System
Code is assigned on or after January 1,
2005.
25. Section 414.506 is amended by
revising the introductory text to read as
follows:
I
PO 00000
Frm 00181
Fmt 4701
Sfmt 4700
66401
§ 414.506 Procedures for public
consultation for payment for a new clinical
diagnostic laboratory test.
For a new test, CMS determines the
basis for and amount of payment after
performance of the following:
*
*
*
*
*
I 26. Section 414.508 is amended by
revising paragraph (b)(3) to read as
follows:
§ 414.508 Payment for a new clinical
diagnostic laboratory test.
*
*
*
*
*
(b) * * *
(3) For a new test for which a new or
substantially revised HCPCS code was
assigned on or before December 31,
2007, after the first year of gapfilling,
CMS determines whether the carrierspecific amounts will pay for the test
appropriately. If CMS determines that
the carrier-specific amounts will not pay
for the test appropriately, CMS may
crosswalk the test.
I 27. Section 414.509 is added to read
as follows:
§ 414.509 Reconsideration of basis for and
amount of payment for a new clinical
diagnostic laboratory test.
For a new test for which a new or
substantially revised HCPCS code was
assigned on or after January 1, 2008, the
following reconsideration procedures
apply:
(a) Reconsideration of basis for
payment. (1) CMS will receive
reconsideration requests in written
format for 60 days after making a
determination of the basis for payment
under § 414.506(d)(2) regarding whether
CMS should reconsider the basis for
payment and why a different basis for
payment would be more appropriate. If
a requestor recommends that the basis
for payment should be changed from
gapfilling to crosswalking, the requestor
may also recommend the code or codes
to which to crosswalk the new test.
(2)(i) A requestor that submitted a
request under paragraph (a)(1) of this
section may also present its
reconsideration request at the public
meeting convened under § 414.506(c),
provided that the requestor requests an
opportunity to present at the public
meeting as part of its written submission
under paragraph (a)(1) of this section.
(ii) If the requestor presents its
reconsideration request at the public
meeting convened under § 414.506(c),
members of public may comment on the
reconsideration request verbally at the
public meeting and may submit written
comments after the public meeting
(within the timeframe for public
comments established by CMS).
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66402
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(3) Considering reconsideration
requests and other comments received,
CMS may reconsider its determination
of the basis for payment. As the result
of such a reconsideration, CMS may
change the basis for payment from
crosswalking to gapfilling or from
gapfilling to crosswalking.
(4) If the basis for payment is revised
as the result of a reconsideration, the
new basis for payment is final and is not
subject to further reconsideration.
(b) Reconsideration of amount of
payment—(1) Crosswalking. (i) For 60
days after making a determination under
§ 414.506(d)(2) of the code or codes to
which a new test will be crosswalked,
CMS receives reconsideration requests
in written format regarding whether
CMS should reconsider its
determination and the recommended
code or codes to which to crosswalk the
new test.
(ii)(A) A requestor that submitted a
request under paragraph (b)(1)(i) of this
section may also present its
reconsideration request at the public
meeting convened under § 414.506(c),
provided that the requestor requests an
opportunity to present at the public
meeting as part of its written submission
under paragraph (b)(1)(i) of this section.
(B) If a requestor presents its
reconsideration request at the public
meeting convened under § 414.506(c),
members of public may comment on the
reconsideration request verbally at the
public meeting and may submit written
comments after the public meeting
(within the timeframe for public
comments established by CMS).
(iii) Considering comments received,
CMS may reconsider its determination
of the amount of payment. As the result
of such a reconsideration, CMS may
change the code or codes to which the
new test is crosswalked.
(iv) If CMS changes the basis for
payment from gapfilling to crosswalking
as a result of a reconsideration, the
crosswalked amount of payment is not
subject to reconsideration.
(2) Gapfilling. (i) By April 30 of the
year after CMS makes a determination
under § 414.506(d)(2) or § 414.509(a)(3)
that the basis for payment for a new test
will be gapfilling, CMS posts interim
carrier-specific amounts on the CMS
Web site.
(ii) For 60 days after CMS posts
interim carrier-specific amounts on the
CMS Web site, CMS will receive public
comments in written format regarding
the interim carrier-specific amounts.
(iii) After considering the public
comments, CMS will post final carrierspecific amounts on the CMS Web site.
(iv) For 30 days after CMS posts final
carrier-specific amounts on the CMS
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
Web site, CMS will receive
reconsideration requests in written
format regarding whether CMS should
reconsider the final payment amounts
and the appropriate national limitation
amount for the new test.
(v) Considering reconsideration
requests received, CMS may reconsider
its determination of the amount of
payment. As the result of a
reconsideration, CMS may revise the
national limitation amount for the new
test.
(3) For both gapfilled and crosswalked
new tests, if CMS revises the amount of
payment as the result of a
reconsideration, the new amount of
payment is final and is not subject to
further reconsideration.
(c) Effective date. If CMS changes a
determination as the result of a
reconsideration, the new determination
regarding the basis for or amount of
payment is effective January 1 of the
year following reconsideration. Claims
for services with dates of service prior
to the effective date will not be
reopened or otherwise reprocessed.
(d) Jurisdiction for Reconsideration
Decisions. Jurisdiction for reconsidering
a determination rests exclusively with
the Secretary. A decision whether to
reconsider a determination is committed
to the discretion of the Secretary. A
decision not to reconsider an initial
determination is not subject to
administrative or judicial review.
I 28. Section 414.510 is amended by—
I A. Revising the section heading to
read as set forth below.
I B. Revising the introductory text.
The revisions read as follows:
§ 414.510 Laboratory date of service for
clinical laboratory and pathology
specimens.
The date of service for either a clinical
laboratory test or the technical
component of physician pathology
service is as follows:
*
*
*
*
*
Subpart H—Fee Schedule for
Ambulance Services
§ 414.620
[Amended]
29. In § 414.620, the phrase ‘‘notice in
the Federal Register without
opportunity for prior comment’’ is
removed and the phrase ‘‘CMS by
instruction and on the CMS Web site’’
is added in its place.
I
Subpart I—Payment for Drugs and
Biologicals
30. Section 414.707 is amended by
adding paragraph (c) to read as follows:
I
PO 00000
Frm 00182
Fmt 4701
Sfmt 4700
§ 414.707
Basis of payment
*
*
*
*
*
(c) Mandatory reporting of anemia
quality indicators. The following
provisions are effective January 1, 2008:
(1) Each request for payment for antianemia drugs furnished to treat anemia
resulting from the treatment of cancer
must report the beneficiary’s most
recent hemoglobin or hematocrit level;
(2) Each request for payment for use
of erythropoiesis stimulating agents
must report the beneficiary’s most
recent hemoglobin or hematocrit level.
Subpart K—Payment for Drugs and
Biologicals Under Part B
31. Section 414.904 is amended by
revising paragraph (d)(3) to read as
follows:
I
§ 414.904 Average sales price as the basis
for payment.
*
*
*
*
*
(d) * * *
(3) Widely available market price and
average manufacturer price. If the
Inspector General finds that the average
sales price exceeds the widely available
market price or the average
manufacturer price by 5 percent or more
in CY 2005, 2006, 2007 or 2008, the
payment limit in the quarter following
the transmittal of this information to the
Secretary is the lesser of the widely
available market price or 103 percent of
the average manufacturer price.
*
*
*
*
*
I 32. Section 414.908 is amended by—
I A. Revising paragraphs (a)(2)(iv),
(a)(3)(x), and (a)(3)(xi).
I B. Adding paragraph (a)(2)(v).
I C. Removing paragraph (a)(5).
The revisions and addition read as
follows:
§ 414.908
program.
Competitive acquisition
(a) * * *
(2) * * *
(iv) The approved CAP vendor refuses
to ship to the participating CAP
physician because the conditions of
§ 414.914(i) have been met (if this
subparagraph (a)(2)(iv) applies, the
physician can withdraw from the CAP
category for the remainder of the year
immediately upon notice to CMS and
the approved CAP vendor); or
(v) Other exigent circumstances
defined by CMS are present,
including—
(A) If, up to and including 60 days
after the effective date of the physician’s
CAP election agreement, the
participating CAP physician submits a
written request to the designated carrier
to terminate the CAP election agreement
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
because CAP participation imposes a
burden on the physician’s practice. The
written request must document the
burden. The designated carrier will
process the participating CAP
physician’s request and CMS will
approve or deny the request under the
dispute resolution process as specified
under § 414.917 of this subpart.
(B) If, more than 60 days after the
effective date of the physician’s CAP
election agreement, the participating
CAP physician submits a written
request to the designated carrier to
terminate the CAP election agreement
because, based on a change in
circumstances of which the
participating CAP physician was not
previously aware, CAP participation
imposes a burden on the physician’s
practice. The written request must
document the burden. The designated
carrier will process the participating
CAP physician’s request and CMS will
approve or deny the request under the
dispute resolution process as specified
under § 414.917 of this subpart.
(3) * * *
(x) Agrees to file the Medicare claim
within 30 calendar days of the date of
drug administration.
(xi) Agrees to submit documentation
such as medical records or certification,
as necessary, to support payment for a
CAP drug;
*
*
*
*
*
I 33. Section 414.914 is amended by—
I A. Redesignating paragraph (h) as (i)
I B. Adding new paragraph (h).
I C. Revising new paragraphs (i)(1) and
(2).
I D. Removing the reference
‘‘§ 414.914(h)’’ in paragraph (f)(12) and
adding in its place the reference
‘‘§ 414.914(i)’’.
I E. Revising new paragraph (i)(5).
The addition and revision read as
follows:
§ 414.914
Terms of contract.
cprice-sewell on PROD1PC72 with RULES
*
*
*
*
*
(h) The approved CAP vendor must
verify drug administration prior to
collection of any applicable cost sharing
amount.
(1) The approved CAP vendor
documents, in writing, the following
information necessary to verify drug
administration:
(i) Beneficiary name.
(ii) Health insurance number.
(iii) Expected date of administration.
(iv) Actual date of administration.
(v) Identity of the participating CAP
physician.
(vi) Prescription order number.
(vii) Identity of the individuals who
supply and receive the information.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
(viii) Dosage supplied.
(ix) Dosage administered.
*
*
*
*
*
(2) If the information is obtained
verbally, the approved CAP vendor
must also maintain the following
information:
(i) The identities of individuals who
exchanged the information.
(ii) The date and time that the
information was obtained.
(3) The approved CAP vendor must
provide this information to CMS or the
beneficiary upon request.
(i) * * *
(1) Subsequent to receipt of payment
by Medicare, or the verification of drug
administration by the participating CAP
physician, the approved CAP vendor
must bill any applicable supplemental
insurance policies.
(2) An approved CAP vendor that has
received payment from the designated
carrier for CAP drugs that have not been
administered must promptly refund
payment for such drugs to the
designated carrier and must refund any
coinsurance and deductible collected
from the beneficiary and his or her
supplemental insurer.
*
*
*
*
*
(5) For purposes of paragraph (i) of
this section delivery means postmark
date, or the date the coinsurance bill or
notice was presented to the beneficiary
by the participating CAP physician on
behalf of the approved CAP vendor.
(i) Except as specified in paragraph
(i)(5)(ii) of this section, if after 45 days
from delivery of the approved CAP
vendor’s bill to the beneficiary, the
beneficiary’s cost-sharing obligation
remains unpaid, the approved CAP
vendor may refuse further shipments to
the participating CAP physician for that
beneficiary.
(ii) If the beneficiary has requested
cost-sharing assistance within 45 days
of receiving delivery of the approved
CAP vendor’s bill, provisions of
paragraphs (i)(6), (i)(7), or (i)(8) of this
section, apply.
I 34. Section 414.916 is amended by
revising paragraph (c)(1) to read as
follows:
§ 414.916 Dispute resolution for vendors
and beneficiaries.
*
*
*
*
*
(c) * * *
(1) Right to a reconsideration. A
participating CAP physician dissatisfied
with a determination that his or her
CAP election agreement has been
suspended by CMS or a determination
under § 414.917(d) denying the
participating CAP physician’s request to
terminate participation in the CAP
PO 00000
Frm 00183
Fmt 4701
Sfmt 4700
66403
under § 414.908(a)(v) is entitled to a
reconsideration as provided in this
subpart.
*
*
*
*
*
I 35. Section 414.917 is amended by—
I A. Revising the section heading as set
forth below.
I B. Adding paragraph (d).
The revision and addition read as
follows:
§ 414.917 Dispute resolution and process
for suspension or termination of approved
CAP contract and termination of physician
participation under exigent circumstances.
*
*
*
*
*
(d) CAP participating physicians’
exigent circumstances provision. The
following process must be completed for
participating CAP physicians’ requests
to terminate their participation in the
program under exigent circumstances
provisions described in
§ 414.908(a)(2)(v):
(1) The designated carrier must—
(i) Determine whether a request to
terminate CAP participation was related
to approved CAP vendor service, and if
so, forward the issue to the approved
CAP vendor’s grievance process within
1 business day of the receipt of the
request; or
(ii) Continue to investigate, consistent
with § 414.916(b)(2) of this chapter, and
within 2 business days of receipt, do
any of the following:
(A) Request a single, 2-business day
extension. No later than the end of any
2-business day extension, the
designated carrier must make findings
and a recommendation as provided in
subparagraph (B) or (C).
(B) Submit a recommendation and
relevant findings to CMS that the
requesting participating CAP physician
be permitted to terminate his or her
participation in the CAP.
(C) Submit a recommendation and
relevant findings to CMS that the
requesting participating CAP physician
not be permitted to terminate his or her
participation in the CAP.
(ii) In the case of a request made
under § 414.908(a)(2)(v)(B), the
designated carrier also shall include in
its recommendation its finding with
respect to whether the request is based
on a change in circumstances of which
the participating CAP physician was
previously unaware.
(2) CMS will consider the carrier’s
findings and recommendation and may
also make its own findings. As a result,
CMS will—
(i) Approve or deny the request to
terminate participation in the CAP
within 2 business days of receipt of the
recommendation.
E:\FR\FM\27NOR2.SGM
27NOR2
66404
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(ii) Communicate the decision to the
appropriate Medicare contractors and
the participating CAP physician.
(3) A denial of the participating CAP
physician’s request to terminate
participation in the CAP must include
written notification of the right to
request reconsideration under
§ 414.916(c).
(4) Upon termination of participation
in the CAP a physician must—
(i) Continue to submit claims for
drugs supplied and administered under
the CAP prior to the effective date of the
physician’s termination from the CAP
consistent with § 414.908(a) until all
such claims are timely submitted.
(ii) Return any unused CAP drugs that
had not been administered to the
beneficiary prior to the effective date of
the physician’s termination from the
CAP to the approved CAP vendor
consistent with applicable law and
regulation and any agreement with the
approved CAP vendor.
(iii) Cooperate in any post-payment
review activities on claims submitted
under the CAP, as required under
section 1847B(a)(3) of the Act.
(5) An approved CAP vendor that has
billed and been paid for CAP drugs that
have not been administered must refund
any payments made by CMS or the
beneficiary and his or her supplemental
insurer in accordance with
§ 414.914(h)(3)(i)(2) of this chapter.
I 36. Section 414.930 is added to
subpart K to read as follows:
cprice-sewell on PROD1PC72 with RULES
§ 414.930 Compendia for determination of
medically-accepted indications for off-label
uses of drugs and biologicals in an anticancer chemotherapeutic regimen.
(a) Definition. For purposes of this
section, compendium means a
comprehensive listing of FDA-approved
drugs and biologicals or a
comprehensive listing of a specific
subset of drugs and biologicals in a
specialty compendium, for example a
compendium of anti-cancer treatment. A
compendium includes a summary of the
pharmacologic characteristics of each
drug or biological and may include
information on dosage, as well as
recommended or endorsed uses in
specific diseases. A compendium is
indexed by drug or biological.
(b) Process for listing compendia for
determining medically-accepted uses of
drugs and biologicals in anti-cancer
treatment. (1) The CMS process—
(i) Receives formal written requests
for changes to the list of compendia
during a 30 day window beginning
January 15 each year.
(ii) Publishes a listing of the timely,
complete requests by March 15th and
solicits public comment on the requests
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
for 30 days. The listing identifies the
requestor and the requested action.
(iii) Considers a compendium’s
attainment of the MedCAC (Medicare
Evidence Development and Coverage
Advisory Committee, previously known
as the MCAC—Medicare Coverage
Advisory Committee) recommended
desirable characteristics of compendia
(including explicit listing and
recommendations) in reviewing
requests. CMS may consider additional
reasonable factors.
(iv) Considers a compendium’s
grading of evidence used in making
recommendations regarding off-label
uses and the process by which the
compendium grades the evidence.
(v) Publishes its decision no later than
90 days after the close of the public
comment period.
(2) Exception. In addition to the
annual process outlined in paragraph
(b)(1) of this section, CMS may
internally generate a request for changes
to the list of compendia at any time.
(c) Written request for review. (1) CMS
will review a complete, written request
that is submitted in writing,
electronically or via hard copy (no
duplicate submissions) and includes the
following:
(i) The full name and contact
information of the requestor.
(ii) The full identification of the
compendium that is the subject of the
request, including name, publisher,
edition if applicable, date of
publication, and any other information
needed for the accurate and precise
identification of the specific
compendium.
(iii) A complete written copy of the
compendium that is the subject of the
request.
(iv) The specific action that is
requested of CMS.
(v) Materials that the requestor must
submit for CMS review in support of the
requested action.
(vi) A single compendium as its
subject.
(d) CMS may at its discretion combine
and consider multiple requests that refer
to the same compendium.
(e) For the purposes of this section,
publication by CMS may be
accomplished by posting on the CMS
Web site.
I 37. Subpart M is added to read as
follows:
Subpart M—Payment for
Comprehensive Outpatient
Rehabilitation Facility (CORF) Services
§ 414.1100
Basis and Scope.
This subpart implements sections
1834(k)(1) and (k)(3) of the Act by
PO 00000
Frm 00184
Fmt 4701
Sfmt 4700
specifying the payment methodology for
comprehensive outpatient rehabilitation
facility services covered under Part B of
Title XVIII of the Act that are described
at section 1861(cc)(1) of the Act.
§ 414.1105 Payment for Comprehensive
Outpatient Rehabilitation Facility (CORF)
Services.
(a) Payment under the physician fee
schedule. Except as otherwise specified
under paragraphs (b), (c), (d), and (e) of
this section payment for CORF services,
as defined under § 410.100 of this
chapter, is paid the lesser of 80 percent
of the following:
(1) The actual charge for the item or
service; or
(2) The nonfacility amount
determined under the physician fee
schedule established under section
1848(b) of the Act for the item or
service.
(b) Payment for physician services. No
separate payment for physician services
that are CORF services under
§ 410.100(a) of this chapter will be
made.
(c) Payment for supplies and durable
medical equipment, prosthetic and
orthotic devices, and drugs and
biologicals. Supplies and durable
medical equipment that are CORF
services under § 410.100(l) of this
chapter, prosthetic device services that
are CORF services under § 410.100(f),
orthotic devices that are CORF services
under § 410.100(g) of this chapter and
drugs and biologicals that are CORF
services under § 410.100(k) of this
chapter are paid the lesser of 80 percent
of the following:
(1) The actual charge for the service
provided that payment for such item is
not included in the payment amount for
other CORF services paid under
paragraphs (a) or (d); or
(2) The amount determined under the
DMEPOS fee schedule established
under part 414 subparts D and F for the
item or the single payment amount
established under the DMEPOS
competitive bidding program provided
that payment for such item is not
included in the payment amount for
other CORF services paid under
paragraphs (a) or (d).
(d) Payment for drugs and biologicals.
Drugs and biologicals that are CORF
services under § 410.100(j) of this
chapter, are paid the lesser of 80 percent
of the following:
(1) The actual charge for the service
provided that payment for such item is
not included in the payment amount for
other CORF services paid under
paragraphs (a) or (c); or
(2) The amount determined using the
same methodology for drugs (as defined
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
in § 414.704 of this chapter) described
in section 1842(o)(1) of the Act provided
that payment for such drug is not
included in the payment amount for
other CORF services paid under
paragraphs (a) or (c).
(e) Payment for CORF services when
no fee schedule amount for the service.
If there is no fee schedule amount
established for a CORF service, payment
for the item or service will be the lesser
of 80 percent of:
(i) The actual charge for the service
provided that payment for such item or
service is not included in the payment
amount for other CORF services paid
under paragraphs (a), (c), or (d) of this
section.
(ii) The amount determined under the
fee schedule established for a
comparable service as specified by the
Secretary provided that payment for
such item or service is not included in
the payment amount for other CORF
services paid under paragraphs (a), (c),
or (d) of this section.
PART 415—SERVICES FURNISHED BY
PHYSICIANS IN PROVIDERS,
SUPERVISING PHYSICIANS IN
TEACHING SETTINGS, AND
RESIDENTS IN CERTAIN SETTINGS
technical component of specimens for
physician pathology services.
PART 418—HOSPICE CARE
40. The authority citation for part 418
continues to read as follows:
I
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
Subpart E—Condition of Participation:
Other Services
Subpart B—Certification and Plan
Requirements
(a) Physical therapy, occupational
therapy, and speech-language pathology
services must be—
(1) Available, and when provided,
offered in a manner consistent with
accepted standards of practice; and
(2) Furnished by personnel who meet
the qualifications specified in part 484
of this chapter.
*
*
*
*
*
PART 423—VOLUNTARY MEDICARE
PRESCRIPTION DRUG BENEFIT
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
Authority: Secs 1102, 1860D–1 through
1860D–42, and 1871 of the Social Security
Act (42 U.S.C. 1302, 1395w–101 through
1395w–152, and 1395hh).
cprice-sewell on PROD1PC72 with RULES
*
*
*
*
*
(d) Physician pathology services
furnished by an independent laboratory.
The technical component of physician
pathology services furnished by an
independent laboratory to a hospital
inpatient or outpatient on or before
December 31, 2007, may be paid to the
laboratory by the carrier under the
physician fee schedule if the Medicare
beneficiary is a patient of a covered
hospital as defined in paragraph (a)(1) of
this section. For services furnished after
December 31, 2007, an independent
laboratory may not bill the carrier for
the technical component of physician
pathology services furnished to a
hospital inpatient or outpatient. For
services furnished on or after January 1,
2008, the date of service policy in
§ 414.510 of this chapter applies for the
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
42. The authority citation for part 423
continues to read as follows:
Subpart D—Cost Control and Quality
Improvement Requirements
43. Section 423.160 is amended by—
A. Revising paragraph (a)(3)(i).
B. Redesignating paragraphs (a)(3)(ii)
and (iii) to (a)(3)(iii) and (iv),
respectively.
I C. Adding new paragraph (a)(3)(ii).
The revision and addition reads as
follows:
I
I
I
§ 415.130 Conditions for payment:
Physician pathology services.
44. The authority citation for part 424
continues to read as follows:
I
§ 418.92 Condition of participation—
Physical therapy, occupational therapy, and
speech-language pathology.
41. Section 418.92 is amended by
revising paragraph (a) to read as follows:
I
39. Section 415.130 is amended by
revising paragraph (d) to read as
follows:
PART 424—CONDITIONS FOR
MEDICARE PAYMENT
I
38. The authority citation for part 415
continues to read as follows:
I
and communication problems that
would preclude the use of the NCPDP
SCRIPT Standard adopted by this
section.
*
*
*
*
*
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
I
Subpart C—Part B Carrier Payments
for Physician Services to Beneficiaries
in Providers
66405
§ 423.160 Standards for electronic
prescribing.
(a) * * *
(3) * * *
(i) Entities transmitting prescriptions
or prescription-related information by
means of computer-generated facsimile
are exempt from the requirement to use
the NCPDP SCRIPT Standard adopted
by this section in transmitting such
prescriptions or prescription-related
information until January 1, 2009;
(ii) After January 1, 2009, electronic
transmission of prescriptions or
prescription-related information by
means of computer-generated facsimile
is only permitted in instances of
temporary/transient transmission failure
PO 00000
Frm 00185
Fmt 4701
Sfmt 4700
45. The heading for subpart B is
revised to read as set forth below.
I
46. Section 424.24 is amended by
revising paragraphs (c)(2) and (c)(4) to
read as follows:
I
§ 424.24 Requirements for medical and
other health services furnished by
providers under Medicare Part B.
*
*
*
*
*
(c) * * *
(2) Timing. The initial certification
must be obtained as soon as possible
after the plan is established.
(4) Recertification. (i) Timing.
Recertification is required at least every
90 days.
(ii) Content. When it is recertified, the
plan or other documentation in the
patient’s record must indicate the
continuing need for physical therapy,
occupational therapy or speechlanguage pathology services.
(iii) Signature. The physician, nurse
practitioner, clinical nurse specialist, or
physician assistant who reviews the
plan must recertify the plan by signing
the medical record.
*
*
*
*
*
I 47. Section 424.27 is amended by
revising paragraph (b)(1) to read as
follows:
§ 424.27 Requirements for comprehensive
outpatient rehabilitation facility (CORF)
services
*
*
*
*
*
(b) * * *
(1) Timing. Recertification is required
at least every 60 days for respiratory
therapy services and every 90 days for
physical therapy, occupational therapy,
and speech-language pathology services
based on review by a facility physician
or the referring physician who, when
appropriate, consults with the
professional personnel who furnish the
services.
*
*
*
*
*
I 48. In § 424.32, paragraph (a)(3) is
revised to read as follows:
E:\FR\FM\27NOR2.SGM
27NOR2
66406
§ 424.32
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Basic requirements for all claims.
(a) * * *
(3) A claim must be signed by the
beneficiary or on behalf of the
beneficiary (in accordance with
§ 424.36).
*
*
*
*
*
Subpart C—Claims for Payment
49. Section 424.36 is amended by—
A. Revising paragraph (b)(5).
B. Adding paragraph (b)(6).
The revision and addition read as
follows:
I
I
I
§ 424.36
cprice-sewell on PROD1PC72 with RULES
Subpart F—Limitations on Assignment
and Reassignment of Claims
Signature requirements.
*
*
*
*
*
(b) * * *
(5) A representative of the provider or
of the nonparticipating hospital
claiming payment for services it has
furnished if the provider or
nonparticipating hospital is unable to
have the claim signed in accordance
with paragraph (b)(1), (2), (3), or (4) of
this section after making reasonable
efforts to locate and obtain the signature
of one of the individuals specified in
paragraph (b)(1), (2), (3), or (4) of this
section.
(6) An ambulance provider or
supplier with respect to emergency
ambulance transport services, if the
following conditions and
documentation requirements are met.
(i) None of the individuals listed in
paragraph (b)(1), (2), (3), or (4) of this
section was available or willing to sign
the claim on behalf of the beneficiary at
the time the service was provided;
(ii) The ambulance provider or
supplier maintains in its files the
following information and
documentation for a period of at least
four years from the date of service:
(A) A contemporaneous statement,
signed by an ambulance employee
present during the trip to the receiving
facility, that, at the time the service was
provided, the beneficiary was physically
or mentally incapable of signing the
claim and that none of the individuals
listed in paragraph (b)(1), (2), (3), or (4)
of this section were available or willing
to sign the claim on behalf of the
beneficiary, and
(B) Documentation with the date and
time the beneficiary was transported,
and the name and location of the facility
that received the beneficiary, and
(C) Either of the following:
(1) A signed contemporaneous
statement from a representative of the
facility that received the beneficiary,
which documents the name of the
beneficiary and the date and time the
beneficiary was received by that facility;
or
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
(2) The requested information from a
representative of the facility using a
secondary form of verification obtained
at a later date, but prior to submitting
the claim to Medicare for payment.
Secondary forms of verification include
a copy of any of the following—
(i) The signed patient care/trip report;
(ii) The hospital registration/
admissions sheet;
(iii) The patient medical record;
(iv) The hospital log; or
(v) Other internal hospital records.
*
*
*
*
*
50. Section 424.80 is amended by
adding paragraph (d)(3) to read as
follows:
I
§ 424.80 Prohibition of reassignment of
claims by suppliers.
*
*
*
*
*
(d) * * *
(3) Reassignment of the technical or
professional component of a diagnostic
test. If a physician or other supplier bills
for the technical or professional
component of a diagnostic test covered
under section 1861(s)(3) of the Act and
paid for under part 414 of this chapter
(other than clinical diagnostic
laboratory tests paid under section
1833(a)(2)(D) of the Act, which are
subject to the special rules set forth in
section 1833(h)(5)(A) of the Act)
following a reassignment from a
physician or other supplier who
performed the technical or professional
component, the amount payable to the
billing physician or other supplier may
be subject to the limits specified in
§ 414.50 of this chapter.
PART 482—CONDITIONS OF
PARTICIPATION FOR HOSPITALS
51. The authority citation for part 482
continues to read as follows:
I
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
52. Section 482.56 is amended by
revising paragraphs (a)(2) and (b) to read
as follows:
I
§ 482.56 Condition of participation:
Rehabilitation services.
(a) * * *
(2) Physical therapy, occupational
therapy, speech-language pathology or
audiology services, if provided, must be
provided by qualified physical
therapists, physical therapist assistants,
occupational therapists, occupational
therapy assistants, speech-language
pathologists, or audiologists as defined
in part 484 of this chapter.
PO 00000
Frm 00186
Fmt 4701
Sfmt 4700
(b) Standard: Delivery of services.
Services must be given in accordance
with orders of practitioners who are
authorized by the medical staff to order
the services, and the orders must be
incorporated in the patient’s record. The
provision of care and the personnel
qualifications must be in accordance
with national acceptable standards of
practice and must also meet the
requirements of § 409.17
PART 484—HOME HEALTH SERVICES
53. The authority citation for part 484
continues to read as follows:
I
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395(hh)) unless otherwise indicated.
Subpart A—General Provisions
54. Section 484.4 is amended by
revising the definitions of
‘‘Occupational therapist,’’
‘‘Occupational therapy assistant,’’
‘‘Physical therapist,’’ ‘‘Physical therapist
assistant’’ and ‘‘Speech language
pathologist’’ to read as follows:
I
§ 484.4
Personnel Qualifications.
*
*
*
*
*
Occupational therapist. A person
who—
(a)(1) Is licensed or otherwise
regulated, if applicable, as an
occupational therapist by the State in
which practicing, unless licensure does
not apply;
(2) Graduated after successful
completion of an occupational therapist
education program accredited by the
Accreditation Council for Occupational
Therapy Education (ACOTE) of the
American Occupational Therapy
Association, Inc. (AOTA), or successor
organizations of ACOTE; and
(3) Is eligible to take, or has
successfully completed the entry-level
certification examination for
occupational therapists developed and
administered by the National Board for
Certification in Occupational Therapy,
Inc. (NBCOT).
(b) On or before December 31, 2009—
(1) Is licensed or otherwise regulated,
if applicable, as an occupational
therapist by the State in which
practicing; or
(2) When licensure or other regulation
does not apply—
(i) Graduated after successful
completion of an occupational therapist
education program accredited by the
Accreditation Council for Occupational
Therapy Education (ACOTE) of the
American Occupational Therapy
Association, Inc. (AOTA) or successor
organizations of ACOTE; and
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(ii) Is eligible to take, or has
successfully completed the entry-level
certification examination for
occupational therapists developed and
administered by the National Board for
Certification in Occupational Therapy,
Inc., (NBCOT).
(c) On or before January 1, 2008—
(1) Graduated after successful
completion of an occupational therapy
program accredited jointly by the
committee on Allied Health Education
and Accreditation of the American
Medical Association and the American
Occupational Therapy Association; or
(2) Is eligible for the National
Registration Examination of the
American Occupational Therapy
Association or the National Board for
Certification in Occupational Therapy.
(d) On or before December 31, 1977—
(1) Had 2 years of appropriate
experience as an occupational therapist;
and
(2) Had achieved a satisfactory grade
on an occupational therapist proficiency
examination conducted, approved, or
sponsored by the U.S. Public Health
Service.
(e) If educated outside the United
States—
(1) Must meet both of the following:
(i) Graduated after successful
completion of an occupational therapist
education program accredited as
substantially equivalent to occupational
therapist assistant entry level education
in the United States by one of the
following:
(A) The Accreditation Council for
Occupational Therapy Education
(ACOTE).
(B) Successor organizations of
ACOTE.
(C) The World Federation of
Occupational Therapists.
(D) A credentialing body approved by
the American Occupational Therapy
Association.
(ii) Successfully completed the entrylevel certification examination for
occupational therapists developed and
administered by the National Board for
Certification in Occupational Therapy,
Inc. (NBCOT).
(2) On or before December 31, 2009,
is licensed or otherwise regulated, if
applicable, as an occupational therapist
by the State in which practicing.
Occupational therapy assistant. A
person who—
(a) Meets all of the following:
(1) Is licensed or otherwise regulated,
if applicable, as an occupational therapy
assistant by the State in which
practicing, unless licensure does apply.
(2) Graduated after successful
completion of an occupational therapy
assistant education program accredited
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
by the Accreditation Council for
Occupational Therapy Education,
(ACOTE) of the American Occupational
Therapy Association, Inc. (AOTA) or its
successor organizations.
(3) Is eligible to take or successfully
completed the entry-level certification
examination for occupational therapy
assistants developed and administered
by the National Board for Certification
in Occupational Therapy, Inc. (NBCOT).
(b) On or before December 31, 2009—
(1) Is licensed or otherwise regulated
as an occupational therapy assistant, if
applicable, by the State in which
practicing; or any qualifications defined
by the State in which practicing, unless
licensure does not apply; or
(2) Must meet both of the following:
(i) Completed certification
requirements to practice as an
occupational therapy assistant
established by a credentialing
organization approved by the American
Occupational Therapy Association.
(ii) After January 1, 2010, meets the
requirements in paragraph (a) of this
section.
(c) After December 31, 1977 and on or
before December 31, 2007—
(1) Completed certification
requirements to practice as an
occupational therapy assistant
established by a credentialing
organization approved by the American
Occupational Therapy Association; or
(2) Completed the requirements to
practice as an occupational therapy
assistant applicable in the State in
which practicing.
(d) On or before December 31, 1977—
(1) Had 2 years of appropriate
experience as an occupational therapy
assistant; and
(2) Had achieved a satisfactory grade
on an occupational therapy assistant
proficiency examination conducted,
approved, or sponsored by the U.S.
Public Health Service.
(e) If educated outside the United
States, on or after January 1, 2008—
(1) Graduated after successful
completion of an occupational therapy
assistant education program that is
accredited as substantially equivalent to
occupational therapist assistant entry
level education in the United States
by—
(i) The Accreditation Council for
Occupational Therapy Education
(ACOTE).
(ii) Its successor organizations.
(iii) The World Federation of
Occupational Therapists.
(iv) By a credentialing body approved
by the American Occupational Therapy
Association; and
(2) Successfully completed the entrylevel certification examination for
PO 00000
Frm 00187
Fmt 4701
Sfmt 4700
66407
occupational therapy assistants
developed and administered by the
National Board for Certification in
Occupational Therapy, Inc. (NBCOT).
Physical therapist. A person who is
licensed, if applicable, by the State in
which practicing, unless licensure does
not apply and meets one of the
following requirements:
(a)(1) Graduated after successful
completion of one of a physical
therapist eduction program approved by
one of the following:
(i) The Commission on Accreditation
in Physical Therapy Education
(CAPTE).
(ii) Successor organizations of CAPTE.
(iii) An education program outside the
United States determined to be
substantially equivalent to physical
therapist entry level education in the
United States by a credentials
evaluation organization approved by the
American Physical Therapy Association
or an organization identified in 8 CFR
212.15(e) as it relates to physical
therapists.
(2) Passed an examination for
physical therapists approved by the
State in which physical therapy services
are provided.
(b) On or before December 31, 2009—
(1) Graduated after successful
completion of a physical therapy
curriculum approved by the
Commission on Accreditation in
Physical Therapy Education (CAPTE);
or
(2) Meets both of the following:
(i) Graduated after successful
completion of an education program
determined to be substantially
equivalent to physical therapist entry
level education in the United States by
a credentials evaluation organization
approved by the American Physical
Therapy Association or identified in 8
CFR 212.15(e) as it relates to physical
therapists.
(ii) Passed an examination for
physical therapists approved by the
State in which physical therapy services
are provided.
(c) Before January 1, 2008—
(1) Graduated from a physical therapy
curriculum approved by one of the
following:
(i) The American Physical Therapy
Association.
(ii) The Committee on Allied Health
Education and Accreditation of the
American Medical Association.
(iii) The Council on Medical
Education of the American Medical
Association and the American Physical
Therapy Association.
(d) On or before December 31, 1977
was licensed or qualified as a physical
therapist and meets both of the
following:
E:\FR\FM\27NOR2.SGM
27NOR2
cprice-sewell on PROD1PC72 with RULES
66408
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
(1) Has 2 years of appropriate
experience as a physical therapist.
(2) Has achieved a satisfactory grade
on a proficiency examination
conducted, approved, or sponsored by
the U.S. Public Health Service.
(e) Before January 1, 1966—
(1) Was admitted to membership by
the American Physical Therapy
Association;
(2) Was admitted to registration by the
American Registry of Physical
Therapists; and
(3) Graduated from a physical therapy
curriculum in a 4-year college or
university approved by a State
department of education.
(f) Before January 1, 1966 was
licensed or registered, and before
January 1, 1970, had 15 years of fulltime experience in the treatment of
illness or injury through the practice of
physical therapy in which services were
rendered under the order and direction
of attending and referring doctors of
medicine or osteopathy.
(g) If trained outside the United States
before January 1, 2008, meets the
following requirements:
(1) Was graduated since 1928 from a
physical therapy curriculum approved
in the country in which the curriculum
was located and in which there is a
member organization of the World
Confederation for Physical Therapy.
(2) Meets the requirements for
membership in a member organization
of the World Confederation for Physical
Therapy.
Physical therapist assistant. A person
who is licensed, registered or certified
as a physical therapist assistant, if
applicable, by the State in which
practicing, unless licensure does not
apply and meets one of the following
requirements:
(a)(1)(i) Graduated from a physical
therapist assistant curriculum approved
by the Commission on Accreditation in
Physical Therapy Education of the
American Physical Therapy
Association; or if educated outside the
United States or trained in the United
States military, graduated from an
education program determined to be
substantially equivalent to physical
therapist assistant entry level education
in the United States by a credentials
evaluation organization approved by the
American Physical Therapy Association
or identified at 8 CFR 212.15(e); and
(ii) Passed a national examination for
physical therapist assistants.
(b) On or before December 31, 2009,
meets one of the following:
(1) Is licensed, or otherwise regulated
in the State in which practicing.
(2) In States where licensure or other
regulations do not apply, graduated
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
before December 31, 2009, from a 2-year
college-level program approved by the
American Physical Therapy Association
and after January 1, 2010, meets the
requirements of paragraph (a) of this
definition.
(c) Before January 1, 2008, where
licensure or other regulation does not
apply, graduated from a 2-year collegelevel program approved by the
American Physical Therapy
Association.
(d) On or before December 31, 1977,
was licensed or qualified as a physical
therapist assistant and has achieved a
satisfactory grade on a proficiency
examination conducted, approved, or
sponsored by the U.S. Public Health
Service.
*
*
*
*
*
Speech-language pathologist. A
person who meets either of the
following requirements:
(a) The education and experience
requirements for a Certificate of Clinical
Competence in speech-language
pathology granted by the American
Speech-Language-Hearing Association.
(b) The educational requirements for
certification and is in the process of
accumulating the supervised experience
required for certification.
PART 485—CONDITIONS OF
PARTICIPATION: SPECIALIZED
PROVIDERS
55. The authority citation for part 485
continues to read as follows:
I
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395(hh)).
Subpart B—Conditions of
Participation: Comprehensive
Outpatient Rehabilitation Facilities
56. Section 485.51 is amended by—
A. Revising paragraph (a).
B. Adding paragraph (c).
The revision and addition read as
follows:
I
I
I
§ 485.51
Definition.
*
*
*
*
*
(a) Is established and operated
exclusively for the purpose of providing
diagnostic, therapeutic, and restorative
services to outpatients for the
rehabilitation of injured, disabled, or
sick persons, at a single fixed location,
by or under the supervision of a
physician except as provided in
paragraph (c) of this section;
*
*
*
*
*
(c) Exception. May provide influenza,
pneumococcal and Hepatitis B vaccines
provided the applicable conditions of
coverage under § 410.58 and § 410.63 of
this chapter are met.
PO 00000
Frm 00188
Fmt 4701
Sfmt 4700
57. Section 485.70 is amended by
revising paragraphs (c), (e), and (m) to
read as follows:
I
§ 485.70
Personnel qualifications.
*
*
*
*
*
(c) An occupational therapist and an
occupational therapy assistant must
meet the qualifications in part 484 of
this chapter.
*
*
*
*
*
(e) A physical therapist and a physical
therapist assistant must meet the
qualifications in part 484 of this
chapter.
*
*
*
*
*
(m) A speech-language pathologist
must meet the qualifications set forth in
part 484 of this chapter.
Subpart F—Conditions of
Participation: Critical Access Hospitals
(CAHs)
58. Section 485.635 is amended by
adding paragraph (e) to read as follows:
I
§ 485.635 Condition of participation:
Provision of services.
*
*
*
*
*
(e) Standard: Rehabilitation Therapy
Services. Physical therapy, occupational
therapy, and speech-language pathology
services furnished at the CAH, if
provided, are provided as direct services
by staff qualified under State law, and
consistent with the requirements for
therapy services in 409.17.
(Catalog of Federal Domestic Assistance
Program No. 93.774, Medicare—
Supplementary Medical Insurance Program)
Dated: October 23, 2007.
Kerry Weems,
Acting Administrator, Centers for Medicare
& Medicaid Services.
Approved: October 31, 2007.
Michael O. Leavitt,
Secretary.
Addendum A:
Note: These addenda will not appear in the
Code of Federal Regulations. Addendum A:
Explanation and Use of Addendum B.
The addenda on the following pages
provide various data pertaining to the
Medicare fee schedule for physicians’
services furnished in 2008. Addendum B
contains the RVUs for work, non-facility PE,
facility PE, and malpractice expense, and
other information for all services included in
the PFS.
In previous years, we have listed many
services in Addendum B that are not paid
under the PFS. To avoid publishing as many
pages of codes for these services, we are not
including clinical laboratory codes or the
alphanumeric codes (Healthcare Common
Procedure Coding System (HCPCS) codes not
included in CPT) not paid under the PFS in
Addendum B.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
Addendum B—2008 Relative Value
Units and Related Information Used in
Determining Medicare Payments for
2008
cprice-sewell on PROD1PC72 with RULES
This addendum contains the following
information for each CPT code and
alphanumeric HCPCS code, except for:
Alphanumeric codes beginning with B
(enteral and parenteral therapy), E (durable
medical equipment), K (temporary codes for
nonphysicians’ services or items), or L
(orthotics); and codes for anesthesiology.
Please also note the following:
• An ‘‘NA’’ in the ‘‘Non-facility PE RVUs’’
column of Addendum B means that CMS has
not developed a PE RVU in the non-facility
setting for the service because it is typically
performed in the hospital (for example, an
open heart surgery is generally performed in
the hospital setting and not a physician’s
office). If there is an ‘‘NA’’ in the non-facility
PE RVU column, and the contractor
determines that this service can be performed
in the non-facility setting, the service will be
paid at the facility PE RVU rate.
• Services that have an ‘‘NA’’ in the
‘‘Facility PE RVUs’’ column of Addendum B
are typically not paid using the PFS when
provided in a facility setting. These services
(which include ‘‘incident to’’ services and
the technical portion of diagnostic tests) are
generally paid under either the outpatient
hospital prospective payment system or
bundled into the hospital inpatient
prospective payment system payment.
1. CPT/HCPCS code. This is the CPT or
alphanumeric HCPCS number for the service.
Alphanumeric HCPCS codes are included at
the end of this addendum.
2. Modifier. A modifier is shown if there
is a technical component (modifier TC) and
a professional component (PC) (modifier-26)
for the service. If there is a PC and a TC for
the service, Addendum B contains three
entries for the code. A code for: the global
values (both professional and technical);
modifier-26 (PC); and, modifier TC. The
global service is not designated by a modifier,
and physicians must bill using the code
without a modifier if the physician furnishes
both the PC and the TC of the service.
Modifier-53 is shown for a discontinued
procedure, for example, a colonoscopy that is
not completed. There will be RVUs for a code
with this modifier.
3. Status indicator. This indicator shows
whether the CPT/HCPCS code is in the PFS
and whether it is separately payable if the
service is covered.
A = Active code. These codes are
separately payable under the PFS if covered.
There will be RVUs for codes with this
status. The presence of an ‘‘A’’ indicator does
not mean that Medicare has made a national
coverage determination regarding the service.
Carriers remain responsible for coverage
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
decisions in the absence of a national
Medicare policy.
B = Bundled code. Payments for covered
services are always bundled into payment for
other services not specified. If RVUs are
shown, they are not used for Medicare
payment. If these services are covered,
payment for them is subsumed by the
payment for the services to which they are
incident (an example is a telephone call from
a hospital nurse regarding care of a patient).
C = Carriers price the code. Carriers will
establish RVUs and payment amounts for
these services, generally on an individual
case basis following review of
documentation, such as an operative report.
D* = Deleted/discontinued code.
E = Excluded from the PFS by regulation.
These codes are for items and services that
CMS chose to exclude from the fee schedule
payment by regulation. No RVUs are shown,
and no payment may be made under the PFS
for these codes. Payment for them, when
covered, continues under reasonable charge
procedures.
F = Deleted/discontinued codes. (Code not
subject to a 90-day grace period.) These codes
are deleted effective with the beginning of
the year and are never subject to a grace
period. This indicator is no longer effective
beginning with the 2005 fee schedule as of
January 1, 2005.
G = Code not valid for Medicare purposes.
Medicare uses another code for reporting of,
and payment for, these services. (Codes
subject to a 90-day grace period.) This
indicator is no longer effective with the 2005
PFS as of January 1, 2005.
H* = Deleted modifier. For 2000 and later
years, either the TC or PC component shown
for the code has been deleted and the deleted
component is shown in the database with the
H status indicator.
I = Not valid for Medicare purposes.
Medicare uses another code for the reporting
of, and the payment for these services. (Codes
not subject to a 90-day grace period.)
L = Local codes. Carriers will apply this
status to all local codes in effect on January
1, 1998 or subsequently approved by central
office for use. Carriers will complete the
RVUs and payment amounts for these codes.
M = Measurement codes, used for reporting
purposes only. There are no RVUs and no
payment amounts for these codes. Medicare
uses them to aid with performance
measurement. No separate payment is made.
These codes should be billed with a zero
(($0.00) charge and are denied) on the
MPFSDB.
N = Non-covered service. These codes are
noncovered services. Medicare payment may
not be made for these codes. If RVUs are
shown, they are not used for Medicare
payment.
R = Restricted coverage. Special coverage
instructions apply. If the service is covered
and no RVUs are shown, it is carrier-priced.
PO 00000
Frm 00189
Fmt 4701
Sfmt 4700
66409
T = There are RVUs for these services, but
they are only paid if there are no other
services payable under the PFS billed on the
same date by the same provider. If any other
services payable under the PFS are billed on
the same date by the same provider, these
services are bundled into the service(s) for
which payment is made.
X = Statutory exclusion. These codes
represent an item or service that is not within
the statutory definition of ‘‘physicians’’
services’’ for PFS payment purposes. No
RVUs are shown for these codes, and no
payment may be made under the PFS.
(Examples are ambulance services and
clinical diagnostic laboratory services.)
4. Description of code. This is an
abbreviated version of the narrative
description of the code.
5. Physician work RVUs. These are the
RVUs for the physician work for this service
in 2008.
Note: The separate budget neutrality
adjustor is not reflected in these physician
work RVUs.
6. Fully implemented non-facility practice
expense RVUs. These are the fully
implemented resource-based PE RVUs for
non-facility settings.
7. Year 2008 Transitional Non-facility
practice expense RVUs. These are the 2008
resource-based PE RVUs for non-facility
settings.
8. Fully implemented facility practice
expense RVUs. These are the fully
implemented resource-based PE RVUs for
facility settings.
9. Year 2008 Transitional facility practice
expense RVUs. These are the 2008 resourcebased PE RVUs for facility settings.
10. Malpractice expense RVUs. These are
the RVUs for the malpractice expense for the
service for 2008.
11. Global period. This indicator shows the
number of days in the global period for the
code (0, 10, or 90 days).
An explanation of the alpha codes follows:
MMM = Code describes a service furnished
in uncomplicated maternity cases including
antepartum care, delivery, and postpartum
care. The usual global surgical concept does
not apply. See the 1999 Physicians’ Current
Procedural Terminology for specific
definitions.
XXX = The global concept does not apply.
YYY = The global period is to be set by the
carrier (for example, unlisted surgery codes).
ZZZ = Code related to another service that
is always included in the global period of the
other service. (Note: Physician work and PE
are associated with intra service time and in
some instances in the post service time.
*Codes with these indicators had a 90 day
grace period before January 1, 2005.
E:\FR\FM\27NOR2.SGM
27NOR2
66410
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
0016T
0017T
0019T
0026T
0027T
0028T
0029T
0030T
0031T
0032T
0041T
0042T
0043T
0046T
0047T
0048T
0049T
0050T
0051T
0052T
0053T
0058T
0059T
0060T
0061T
0062T
0063T
0064T
0066T
0066T
0066T
0067T
0067T
0067T
0068T
0069T
0070T
0071T
0072T
0073T
0075T
0075T
0075T
0076T
0076T
0076T
0077T
0078T
0079T
0080T
0081T
0084T
0085T
0086T
0087T
0088T
0089T
0090T
0092T
0093T
0095T
0096T
0098T
0099T
0100T
0101T
0102T
0103T
0104T
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
N
N
N
C
C
C
C
C
C
C
C
A
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Thermotx choroid vasc lesion .............
Photocoagulat macular drusen ...........
Extracorp shock wv tx,ms nos ............
Measure remnant lipoproteins ............
Endoscopic epidural lysis ...................
Dexa body composition study .............
Magnetic tx for incontinence ...............
Antiprothrombin antibody ....................
Speculoscopy ......................................
Speculoscopy w/direct sample ...........
Detect ur infect agnt w/cpas ...............
Ct perfusion w/contrast, cbf ................
Co expired gas analysis .....................
Cath lavage, mammary duct(s) ..........
Cath lavage, mammary duct(s) ..........
Implant ventricular device ...................
External circulation assist ...................
Removal circulation assist ..................
Implant total heart system ..................
Replace component heart syst ...........
Replace component heart syst ...........
Cryopreservation, ovary tiss ...............
Cryopreservation, oocyte ....................
Electrical impedance scan ..................
Destruction of tumor, breast ...............
Rep intradisc annulus;1 lev ................
Rep intradisc annulus;>1lev ................
Spectroscop eval expired gas ............
Ct colonography;screen ......................
Ct colonography;screen ......................
Ct colonography;screen ......................
Ct colonography;dx .............................
Ct colonography;dx .............................
Ct colonography;dx .............................
Interp/rept heart sound .......................
Analysis only heart sound ...................
Interp only heart sound .......................
U/s leiomyomata ablate <200 .............
U/s leiomyomata ablate >200 .............
Delivery, comp imrt .............................
Perq stent/chest vert art .....................
Perq stent/chest vert art .....................
Perq stent/chest vert art .....................
S&i stent/chest vert art .......................
S&i stent/chest vert art .......................
S&i stent/chest vert art .......................
Cereb therm perfusion probe ..............
Endovasc aort repr w/device ..............
Endovasc visc extnsn repr ..................
Endovasc aort repr rad s&i .................
Endovasc visc extnsn s&i ...................
Temp prostate urethral stent ..............
Breath test heart reject .......................
L ventricle fill pressure ........................
Sperm eval hyaluronan .......................
Rf tongue base vol reduxn .................
Actigraphy testing, 3-day ....................
Cervical artific disc ..............................
Artific disc addl ....................................
Cervical artific diskectomy ..................
Artific diskectomy addl ........................
Rev cervical artific disc .......................
Rev artific disc addl ............................
Implant corneal ring ............................
Prosth retina receive&gen ..................
Extracorp shockwv tx,hi enrg ..............
Extracorp shockwv tx,anesth ..............
Holotranscobalamin ............................
At rest cardio gas rebreathe ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
13.15
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
15.58
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Malpractice
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00190
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66411
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
0105T
0106T
0107T
0108T
0109T
0110T
0111T
0123T
0124T
0126T
0130T
0137T
0140T
0141T
0142T
0143T
0144T
0144T
0144T
0145T
0145T
0145T
0146T
0146T
0146T
0147T
0147T
0147T
0148T
0148T
0148T
0149T
0149T
0149T
0150T
0150T
0150T
0151T
0151T
0151T
0155T
0156T
0157T
0158T
0159T
0159T
0159T
0160T
0161T
0162T
0163T
0164T
0165T
0166T
0167T
0168T
0169T
0170T
0171T
0172T
0173T
0174T
0175T
0176T
0177T
0178T
0179T
0180T
0181T
0182T
0183T
0184T
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
I ..........
I ..........
I ..........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
Exerc cardio gas rebreathe ................
Touch quant sensory test ...................
Vibrate quant sensory test ..................
Cool quant sensory test ......................
Heat quant sensory test ......................
Nos quant sensory test .......................
Rbc membranes fatty acids ................
Scleral fistulization ..............................
Conjunctival drug placement ..............
Chd risk imt study ...............................
Chron care drug investigatn ...............
Prostate saturation sampling ..............
Exhaled breath condensate ph ...........
Perq islet transplant ............................
Open islet transplant ...........................
Laparoscopic islet transplnt ................
CT heart wo dye; qual calc .................
CT heart wo dye; qual calc .................
CT heart wo dye; qual calc .................
CT heart w/wo dye funct .....................
CT heart w/wo dye funct .....................
CT heart w/wo dye funct .....................
CCTA w/wo dye ..................................
CCTA w/wo dye ..................................
CCTA w/wo dye ..................................
CCTA w/wo, quan calcium .................
CCTA w/wo, quan calcium .................
CCTA w/wo, quan calcium .................
CCTA w/wo, strxr ................................
CCTA w/wo, strxr ................................
CCTA w/wo, strxr ................................
CCTA w/wo, strxr quan calc ...............
CCTA w/wo, strxr quan calc ...............
CCTA w/wo, strxr quan calc ...............
CCTA w/wo, disease strxr ..................
CCTA w/wo, disease strxr ..................
CCTA w/wo, disease strxr ..................
CT heart funct add-on .........................
CT heart funct add-on .........................
CT heart funct add-on .........................
Lap impl gast curve electrd ................
Lap remv gast curve electrd ...............
Open impl gast curve electrd ..............
Open remv gast curve electrd ............
Cad breast mri ....................................
Cad breast mri ....................................
Cad breast mri ....................................
Tcranial magn stim tx plan .................
Tcranial magn stim tx deliv .................
Anal program gast neurostim .............
Lumb artif diskectomy addl .................
Remove lumb artif disc addl ...............
Revise lumb artif disc addl .................
Tcath vsd close w/o bypass ...............
Tcath vsd close w bypass ..................
Rhinophototx light app bilat ................
Place stereo cath brain .......................
Anorectal fistula plug rpr .....................
Lumbar spine proces distract .............
Lumbar spine process addl ................
Iop monit io pressure ..........................
Cad cxr with interp ..............................
Cad cxr remote ...................................
Aqu canal dilat w/o retent ...................
Aqu canal dilat w retent ......................
64 lead ecg w i&r ................................
64 lead ecg w tracing .........................
64 lead ecg w i&r only ........................
Corneal hysteresis ..............................
Hdr elect brachytherapy ......................
Wound ultrasound ...............................
Exc rectal tumor endoscopic ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Malpractice
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00191
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
YYY
YYY
YYY
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66412
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
0185T
0186T
0187T
10021
10022
10040
10060
10061
10080
10081
10120
10121
10140
10160
10180
11000
11001
11004
11005
11006
11008
11010
11011
11012
11040
11041
11042
11043
11044
11055
11056
11057
11100
11101
11200
11201
11300
11301
11302
11303
11305
11306
11307
11308
11310
11311
11312
11313
11400
11401
11402
11403
11404
11406
11420
11421
11422
11423
11424
11426
11440
11441
11442
11443
11444
11446
11450
11451
11462
11463
11470
11471
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Comptr probability analysis .................
Suprachoroidal drug delivery ..............
Ophthalmic dx image anterior .............
Fna w/o image ....................................
Fna w/image .......................................
Acne surgery .......................................
Drainage of skin abscess ...................
Drainage of skin abscess ...................
Drainage of pilonidal cyst ...................
Drainage of pilonidal cyst ...................
Remove foreign body ..........................
Remove foreign body ..........................
Drainage of hematoma/fluid ................
Puncture drainage of lesion ................
Complex drainage, wound ..................
Debride infected skin ..........................
Debride infected skin add-on ..............
Debride genitalia & perineum .............
Debride abdom wall ............................
Debride genit/per/abdom wall .............
Remove mesh from abd wall ..............
Debride skin, fx ...................................
Debride skin/muscle, fx .......................
Debride skin/muscle/bone, fx ..............
Debride skin, partial ............................
Debride skin, full .................................
Debride skin/tissue ..............................
Debride tissue/muscle .........................
Debride tissue/muscle/bone ................
Trim skin lesion ...................................
Trim skin lesions, 2 to 4 .....................
Trim skin lesions, over 4 .....................
Biopsy, skin lesion ..............................
Biopsy, skin add-on ............................
Removal of skin tags ..........................
Remove skin tags add-on ...................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Shave skin lesion ................................
Exc tr-ext b9+marg 0.5 < cm ..............
Exc tr-ext b9+marg 0.6–1 cm .............
Exc tr-ext b9+marg 1.1–2 cm .............
Exc tr-ext b9+marg 2.1–3 cm .............
Exc tr-ext b9+marg 3.1–4 cm .............
Exc tr-ext b9+marg > 4.0 cm ..............
Exc h-f-nk-sp b9+marg 0.5 < ..............
Exc h-f-nk-sp b9+marg 0.6–1 .............
Exc h-f-nk-sp b9+marg 1.1–2 .............
Exc h-f-nk-sp b9+marg 2.1–3 .............
Exc h-f-nk-sp b9+marg 3.1–4 .............
Exc h-f-nk-sp b9+marg > 4 cm ...........
Exc face-mm b9+marg 0.5 < cm ........
Exc face-mm b9+marg 0.6–1 cm .......
Exc face-mm b9+marg 1.1–2 cm .......
Exc face-mm b9+marg 2.1–3 cm .......
Exc face-mm b9+marg 3.1–4 cm .......
Exc face-mm b9+marg > 4 cm ...........
Removal, sweat gland lesion ..............
Removal, sweat gland lesion ..............
Removal, sweat gland lesion ..............
Removal, sweat gland lesion ..............
Removal, sweat gland lesion ..............
Removal, sweat gland lesion ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
1.27
1.27
1.19
1.19
2.42
1.19
2.47
1.23
2.71
1.55
1.22
2.27
0.60
0.30
10.80
14.24
13.10
5.00
4.19
4.94
6.87
0.50
0.60
0.80
3.04
4.11
0.43
0.61
0.79
0.81
0.41
0.79
0.29
0.51
0.85
1.05
1.24
0.67
0.99
1.14
1.41
0.73
1.05
1.20
1.62
0.87
1.25
1.42
1.81
2.08
3.47
1.00
1.44
1.65
2.03
2.45
4.04
1.02
1.50
1.74
2.31
3.16
4.75
3.14
4.35
2.92
4.35
3.66
4.81
0.00
0.00
0.00
2.18
2.15
1.33
1.50
2.06
2.68
3.48
1.95
3.51
2.26
1.85
3.25
0.72
0.23
NA
NA
NA
NA
6.80
7.03
9.00
0.68
0.72
0.95
3.50
4.84
0.81
0.88
0.99
1.88
0.41
1.23
0.16
1.19
1.51
1.76
2.03
1.06
1.42
1.70
1.70
1.38
1.64
1.92
2.18
1.88
2.19
2.40
2.55
2.85
3.53
1.83
2.21
2.43
2.67
2.97
3.59
2.00
2.38
2.64
2.88
3.31
4.09
5.12
6.37
5.32
6.52
5.47
6.50
0.00
0.00
0.00
2.17
2.35
1.17
1.35
1.94
2.89
3.77
2.06
3.51
2.01
1.72
3.11
0.65
0.23
NA
NA
NA
NA
6.83
7.59
10.55
0.60
0.69
0.96
3.44
4.64
0.68
0.76
0.86
1.56
0.37
1.13
0.16
1.09
1.31
1.53
1.80
0.96
1.26
1.49
1.57
1.24
1.43
1.67
1.99
1.94
2.12
2.31
2.47
2.78
3.30
1.79
2.14
2.34
2.62
2.89
3.53
2.10
2.35
2.59
2.90
3.39
4.06
5.07
6.49
5.21
6.67
5.26
6.60
0.00
0.00
0.00
0.37
0.41
0.98
1.08
1.51
1.10
1.45
0.94
1.65
1.29
1.07
1.80
0.16
0.08
3.20
3.78
3.95
1.29
2.34
2.01
3.10
0.16
0.19
0.24
2.60
3.58
0.11
0.16
0.20
0.38
0.20
0.90
0.11
0.21
0.38
0.48
0.55
0.20
0.38
0.47
0.49
0.31
0.48
0.56
0.73
0.93
1.15
1.21
1.56
1.63
2.10
0.93
1.16
1.53
1.66
1.77
2.31
1.31
1.55
1.66
1.84
2.10
2.68
2.41
2.91
2.47
2.94
2.62
3.01
0.00
0.00
0.00
0.46
0.41
0.88
1.01
1.50
1.10
1.47
0.95
1.72
1.29
1.08
1.89
0.19
0.10
3.55
4.67
4.40
1.66
2.48
2.18
3.47
0.18
0.26
0.34
2.59
3.66
0.14
0.19
0.25
0.38
0.19
0.83
0.12
0.21
0.38
0.47
0.53
0.24
0.40
0.48
0.54
0.32
0.48
0.55
0.72
0.91
1.08
1.14
1.44
1.51
1.87
0.93
1.13
1.43
1.55
1.68
2.20
1.31
1.52
1.61
1.83
2.14
2.73
2.22
2.73
2.24
2.81
2.44
2.88
Malpractice
RVUs 2
0.00
0.00
0.00
0.10
0.08
0.05
0.12
0.26
0.11
0.24
0.12
0.33
0.19
0.14
0.35
0.07
0.04
0.67
0.96
1.28
0.61
0.66
0.74
1.16
0.06
0.10
0.13
0.32
0.43
0.05
0.07
0.10
0.03
0.02
0.04
0.02
0.03
0.04
0.05
0.07
0.07
0.07
0.07
0.13
0.04
0.05
0.06
0.10
0.06
0.10
0.13
0.17
0.21
0.32
0.09
0.13
0.16
0.20
0.25
0.44
0.08
0.13
0.16
0.22
0.30
0.43
0.34
0.53
0.32
0.54
0.40
0.58
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00192
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
010
010
010
010
010
010
010
010
010
010
000
ZZZ
000
000
000
ZZZ
010
000
000
000
000
000
010
010
000
000
000
000
ZZZ
010
ZZZ
000
000
000
000
000
000
000
000
000
000
000
000
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66413
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
11600
11601
11602
11603
11604
11606
11620
11621
11622
11623
11624
11626
11640
11641
11642
11643
11644
11646
11719
11720
11721
11730
11732
11740
11750
11752
11755
11760
11762
11765
11770
11771
11772
11900
11901
11920
11921
11922
11950
11951
11952
11954
11960
11970
11971
11975
11976
11977
11980
11981
11982
11983
12001
12002
12004
12005
12006
12007
12011
12013
12014
12015
12016
12017
12018
12020
12021
12031
12032
12034
12035
12036
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
R
R
R
R
A
A
A
N
R
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Exc tr-ext mlg+marg 0.5 < cm ............
Exc tr-ext mlg+marg 0.6–1 cm ...........
Exc tr-ext mlg+marg 1.1–2 cm ...........
Exc tr-ext mlg+marg 2.1–3 cm ...........
Exc tr-ext mlg+marg 3.1–4 cm ...........
Exc tr-ext mlg+marg > 4 cm ...............
Exc h-f-nk-sp mlg+marg 0.5 < ............
Exc h-f-nk-sp mlg+marg 0.6–1 ...........
Exc h-f-nk-sp mlg+marg 1.1–2 ...........
Exc h-f-nk-sp mlg+marg 2.1–3 ...........
Exc h-f-nk-sp mlg+marg 3.1–4 ...........
Exc h-f-nk-sp mlg+mar > 4 cm ...........
Exc face-mm malig+marg 0.5 < .........
Exc face-mm malig+marg 0.6–1 .........
Exc face-mm malig+marg 1.1–2 .........
Exc face-mm malig+marg 2.1–3 .........
Exc face-mm malig+marg 3.1–4 .........
Exc face-mm mlg+marg > 4 cm .........
Trim nail(s) ..........................................
Debride nail, 1–5 .................................
Debride nail, 6 or more .......................
Removal of nail plate ..........................
Remove nail plate, add-on ..................
Drain blood from under nail ................
Removal of nail bed ............................
Remove nail bed/finger tip ..................
Biopsy, nail unit ...................................
Repair of nail bed ...............................
Reconstruction of nail bed ..................
Excision of nail fold, toe ......................
Removal of pilonidal lesion .................
Removal of pilonidal lesion .................
Removal of pilonidal lesion .................
Injection into skin lesions ....................
Added skin lesions injection ...............
Correct skin color defects ...................
Correct skin color defects ...................
Correct skin color defects ...................
Therapy for contour defects ................
Therapy for contour defects ................
Therapy for contour defects ................
Therapy for contour defects ................
Insert tissue expander(s) ....................
Replace tissue expander ....................
Remove tissue expander(s) ................
Insert contraceptive cap ......................
Removal of contraceptive cap ............
Removal/reinsert contra cap ...............
Implant hormone pellet(s) ...................
Insert drug implant device ..................
Remove drug implant device ..............
Remove/insert drug implant ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Repair superficial wound(s) ................
Closure of split wound ........................
Closure of split wound ........................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.58
2.02
2.22
2.77
3.12
4.97
1.59
2.03
2.36
3.06
3.57
4.56
1.62
2.12
2.57
3.37
4.29
6.21
0.17
0.32
0.54
1.10
0.57
0.37
2.40
3.48
1.31
1.60
2.91
0.71
2.63
5.98
7.23
0.52
0.80
1.61
1.93
0.49
0.84
1.19
1.69
1.85
11.01
7.86
3.21
1.48
1.78
3.30
1.48
1.48
1.78
3.30
1.72
1.88
2.26
2.88
3.68
4.13
1.78
2.01
2.48
3.21
3.94
4.72
5.54
2.64
1.86
2.17
2.49
2.94
3.44
4.06
2.74
3.44
3.84
4.05
4.33
5.49
2.85
3.50
3.90
4.11
4.43
4.96
3.05
3.63
4.04
4.28
5.07
5.90
0.38
0.47
0.55
1.33
0.54
0.80
2.95
4.06
2.02
3.40
3.70
2.67
3.45
6.63
8.03
0.92
1.01
2.34
2.66
0.92
0.88
0.90
1.63
1.79
NA
NA
7.39
1.53
1.72
1.98
1.07
1.89
2.02
2.63
1.73
1.80
2.08
2.52
3.06
3.35
1.91
2.06
2.29
2.79
3.17
NA
NA
3.69
1.85
3.89
5.21
4.61
5.29
5.40
2.69
3.07
3.33
3.56
3.85
4.77
2.72
3.10
3.43
3.72
4.08
4.79
2.85
3.33
3.72
4.04
4.87
5.83
0.31
0.40
0.49
1.18
0.49
0.67
2.56
3.52
1.79
3.01
3.29
2.23
3.47
6.14
7.76
0.78
0.83
3.02
3.31
1.03
1.01
1.19
1.74
2.11
NA
NA
8.25
1.47
1.72
2.13
1.07
1.79
1.98
2.46
1.86
1.92
2.20
2.67
3.22
3.58
2.02
2.17
2.43
2.96
3.36
NA
NA
3.75
1.83
3.09
4.52
3.90
5.24
5.48
1.14
1.51
1.69
1.87
1.93
2.46
1.19
1.54
1.75
1.95
2.08
2.32
1.29
1.61
1.84
2.11
2.46
3.13
0.04
0.08
0.14
0.28
0.15
0.43
1.88
2.77
0.76
1.43
1.68
1.01
1.52
3.69
5.55
0.25
0.39
1.09
1.25
0.22
0.36
0.36
0.77
0.77
10.56
6.16
4.01
0.34
0.47
0.76
0.49
0.58
0.70
1.32
0.73
0.84
0.92
1.06
1.30
1.46
0.76
0.89
0.98
1.12
1.28
1.52
1.92
1.75
1.33
1.77
2.28
1.99
2.11
2.23
1.05
1.36
1.47
1.60
1.66
2.10
1.07
1.39
1.57
1.76
1.93
2.36
1.20
1.57
1.77
2.04
2.46
3.30
0.06
0.10
0.17
0.36
0.18
0.39
1.82
2.88
0.76
1.61
2.01
0.88
1.51
3.50
5.31
0.23
0.37
1.09
1.26
0.24
0.37
0.43
0.72
0.83
10.47
6.15
3.90
0.45
0.58
1.01
0.51
0.63
0.76
1.39
0.75
0.87
0.96
1.13
1.40
1.64
0.77
0.91
1.02
1.18
1.40
1.71
2.09
1.84
1.37
1.36
2.04
1.72
2.13
2.39
Malpractice
RVUs 2
0.10
0.12
0.12
0.16
0.20
0.36
0.09
0.12
0.14
0.20
0.27
0.45
0.11
0.16
0.19
0.26
0.37
0.61
0.02
0.04
0.07
0.14
0.07
0.04
0.22
0.35
0.14
0.21
0.36
0.08
0.33
0.74
0.89
0.02
0.03
0.24
0.29
0.07
0.06
0.11
0.16
0.25
1.31
1.05
0.32
0.17
0.21
0.37
0.13
0.12
0.17
0.23
0.15
0.17
0.21
0.27
0.35
0.45
0.16
0.18
0.23
0.29
0.37
0.47
0.64
0.30
0.24
0.17
0.16
0.25
0.39
0.55
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00193
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
000
000
000
000
ZZZ
000
010
010
000
010
010
010
010
090
090
000
000
000
000
ZZZ
000
000
000
000
090
090
090
XXX
000
XXX
000
XXX
XXX
XXX
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
66414
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
12037
12041
12042
12044
12045
12046
12047
12051
12052
12053
12054
12055
12056
12057
13100
13101
13102
13120
13121
13122
13131
13132
13133
13150
13151
13152
13153
13160
14000
14001
14020
14021
14040
14041
14060
14061
14300
14350
15002
15003
15004
15005
15040
15050
15100
15101
15110
15111
15115
15116
15120
15121
15130
15131
15135
15136
15150
15151
15152
15155
15156
15157
15170
15171
15175
15176
15200
15201
15220
15221
15240
15241
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Layer closure of wound(s) ..................
Repair of wound or lesion ...................
Repair of wound or lesion ...................
Repair wound/lesion add-on ...............
Repair of wound or lesion ...................
Repair of wound or lesion ...................
Repair wound/lesion add-on ...............
Repair of wound or lesion ...................
Repair of wound or lesion ...................
Repair wound/lesion add-on ...............
Repair of wound or lesion ...................
Repair of wound or lesion ...................
Repair of wound or lesion ...................
Repair wound/lesion add-on ...............
Late closure of wound ........................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Skin tissue rearrangement ..................
Wnd prep, ch/inf, trk/arm/lg ................
Wnd prep, ch/inf addl 100 cm ............
Wnd prep ch/inf, f/n/hf/g .....................
Wnd prep, f/n/hf/g, addl cm ................
Harvest cultured skin graft ..................
Skin pinch graft ...................................
Skin splt grft, trnk/arm/leg ...................
Skin splt grft t/a/l, add-on ....................
Epidrm autogrft trnk/arm/leg ...............
Epidrm autogrft t/a/l add-on ................
Epidrm a-grft face/nck/hf/g ..................
Epidrm a-grft f/n/hf/g addl ...................
Skn splt a-grft fac/nck/hf/g ..................
Skn splt a-grft f/n/hf/g add ..................
Derm autograft, trnk/arm/leg ...............
Derm autograft t/a/l add-on .................
Derm autograft face/nck/hf/g ..............
Derm autograft, f/n/hf/g add ................
Cult epiderm grft t/arm/leg ..................
Cult epiderm grft t/a/l addl ..................
Cult epiderm graft t/a/l +% ..................
Cult epiderm graft, f/n/hf/g ..................
Cult epidrm grft f/n/hfg add .................
Cult epiderm grft f/n/hfg +% ................
Acell graft trunk/arms/legs ..................
Acell graft t/arm/leg add-on ................
Acellular graft, f/n/hf/g .........................
Acell graft, f/n/hf/g add-on ..................
Skin full graft, trunk .............................
Skin full graft trunk add-on .................
Skin full graft sclp/arm/leg ..................
Skin full graft add-on ...........................
Skin full grft face/genit/hf ....................
Skin full graft add-on ...........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
4.68
2.39
2.76
3.16
3.65
4.26
4.66
2.49
2.81
3.14
3.47
4.44
5.25
5.97
3.14
3.93
1.24
3.32
4.36
1.44
3.80
6.48
2.19
3.82
4.46
6.34
2.38
11.84
6.83
9.60
7.66
11.18
8.44
12.67
9.07
13.67
13.26
10.82
3.65
0.80
4.58
1.60
2.00
5.37
9.74
1.72
10.88
1.85
11.19
2.50
10.96
2.67
7.41
1.50
10.91
1.50
9.30
2.00
2.50
10.05
2.75
3.00
5.99
1.55
7.99
2.45
8.97
1.32
7.95
1.19
10.15
1.86
5.98
3.87
4.49
5.40
5.03
5.65
6.49
4.11
4.86
5.38
5.42
6.01
6.56
7.75
4.42
5.94
1.35
4.58
6.71
1.37
5.01
7.88
1.87
4.72
5.51
7.53
2.05
NA
8.94
11.01
10.02
12.45
10.19
13.56
9.68
14.82
13.51
NA
4.21
0.90
4.87
1.24
3.93
7.62
9.76
2.47
8.74
0.87
9.22
1.19
11.34
3.43
7.95
0.65
9.48
0.66
7.04
0.88
1.05
7.65
1.15
1.33
4.01
0.60
4.46
1.04
9.90
2.02
10.45
2.00
12.03
2.54
6.04
3.20
3.88
4.31
5.14
6.08
6.41
3.69
4.04
4.31
4.49
5.24
6.65
6.94
4.23
5.30
1.26
4.36
5.78
1.44
4.68
6.89
1.76
4.79
5.15
6.78
1.99
NA
8.39
10.21
9.31
11.21
9.49
12.07
9.23
13.21
12.32
NA
4.21
0.90
4.87
1.24
4.24
7.26
11.17
3.10
9.70
1.08
9.22
1.38
11.03
3.96
8.90
0.86
9.67
0.77
7.74
1.09
1.30
7.73
1.35
1.55
3.92
0.64
4.94
1.07
9.65
2.29
9.82
2.16
11.11
2.49
2.63
1.77
2.12
1.95
2.06
2.29
2.66
1.92
2.56
2.12
2.05
2.09
2.58
2.93
2.46
2.97
0.53
2.57
3.64
0.58
2.88
4.95
0.98
2.72
3.22
3.91
1.03
7.02
6.04
7.48
6.88
8.65
6.98
9.34
7.17
10.17
9.44
6.89
1.68
0.26
2.01
0.52
1.05
5.00
6.67
0.85
6.36
0.62
6.73
0.86
7.45
1.29
5.57
0.48
7.04
0.51
5.75
0.67
0.84
6.30
0.94
1.03
2.60
0.46
3.14
0.79
6.34
0.47
6.69
0.50
8.89
0.81
2.80
1.45
1.79
1.77
2.17
2.52
2.87
1.68
1.99
1.82
1.84
2.11
2.81
3.34
2.38
2.83
0.55
2.46
3.21
0.60
2.78
4.55
1.00
2.74
3.18
3.97
1.08
7.09
5.75
7.27
6.70
8.46
7.09
9.00
7.30
9.83
9.30
7.01
1.68
0.26
2.01
0.52
1.09
5.05
7.24
1.01
6.68
0.70
7.04
0.99
7.61
1.57
5.95
0.56
7.58
0.59
6.10
0.76
0.95
6.63
1.09
1.19
2.48
0.54
3.57
0.89
6.27
0.54
6.68
0.53
8.42
0.86
Malpractice
RVUs 2
0.66
0.19
0.17
0.27
0.41
0.54
0.58
0.20
0.17
0.23
0.30
0.45
0.59
0.56
0.26
0.26
0.13
0.26
0.25
0.15
0.26
0.32
0.18
0.34
0.31
0.40
0.24
1.54
0.59
0.82
0.64
0.81
0.62
0.73
0.68
0.76
1.16
1.34
0.49
0.11
0.62
0.22
0.24
0.57
1.28
0.24
1.31
0.26
1.15
0.33
1.16
0.36
0.97
0.21
1.23
0.20
1.14
0.28
0.35
1.05
0.36
0.39
0.55
0.19
0.82
0.29
0.98
0.19
0.84
0.16
0.92
0.23
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00194
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
ZZZ
010
010
ZZZ
010
010
ZZZ
010
010
010
ZZZ
090
090
090
090
090
090
090
090
090
090
090
000
ZZZ
000
ZZZ
000
090
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
ZZZ
090
ZZZ
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66415
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
15260
15261
15300
15301
15320
15321
15330
15331
15335
15336
15340
15341
15360
15361
15365
15366
15400
15401
15420
15421
15430
15431
15570
15572
15574
15576
15600
15610
15620
15630
15650
15731
15732
15734
15736
15738
15740
15750
15756
15757
15758
15760
15770
15775
15776
15780
15781
15782
15783
15786
15787
15788
15789
15792
15793
15819
15820
15821
15822
15823
15824
15825
15826
15828
15829
15830
15832
15833
15834
15835
15836
15837
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
A
A
A
A
A
A
R
R
R
A
A
A
A
A
A
R
R
R
R
R
R
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Skin full graft een & lips ......................
Skin full graft add-on ...........................
Apply skinallogrft, t/arm/lg ...................
Apply sknallogrft t/a/l addl ...................
Apply skin allogrft f/n/hf/g ...................
Aply sknallogrft f/n/hfg add .................
Aply acell alogrft t/arm/leg ..................
Aply acell grft t/a/l add-on ...................
Apply acell graft, f/n/hf/g .....................
Aply acell grft f/n/hf/g add ...................
Apply cult skin substitute ....................
Apply cult skin sub add-on .................
Apply cult derm sub, t/a/l ....................
Aply cult derm sub t/a/l add ................
Apply cult derm sub f/n/hf/g ................
Apply cult derm f/hf/g add ...................
Apply skin xenograft, t/a/l ...................
Apply skn xenogrft t/a/l add ................
Apply skin xgraft, f/n/hf/g ....................
Apply skn xgrft f/n/hf/g add .................
Apply acellular xenograft ....................
Apply acellular xgraft add ...................
Form skin pedicle flap .........................
Form skin pedicle flap .........................
Form skin pedicle flap .........................
Form skin pedicle flap .........................
Skin graft .............................................
Skin graft .............................................
Skin graft .............................................
Skin graft .............................................
Transfer skin pedicle flap ....................
Forehead flap w/vasc pedicle .............
Muscle-skin graft, head/neck ..............
Muscle-skin graft, trunk .......................
Muscle-skin graft, arm ........................
Muscle-skin graft, leg ..........................
Island pedicle flap graft .......................
Neurovascular pedicle graft ................
Free myo/skin flap microvasc .............
Free skin flap, microvasc ....................
Free fascial flap, microvasc ................
Composite skin graft ...........................
Derma-fat-fascia graft .........................
Hair transplant punch grafts ...............
Hair transplant punch grafts ...............
Abrasion treatment of skin ..................
Abrasion treatment of skin ..................
Abrasion treatment of skin ..................
Abrasion treatment of skin ..................
Abrasion, lesion, single .......................
Abrasion, lesions, add-on ...................
Chemical peel, face, epiderm .............
Chemical peel, face, dermal ...............
Chemical peel, nonfacial .....................
Chemical peel, nonfacial .....................
Plastic surgery, neck ...........................
Revision of lower eyelid ......................
Revision of lower eyelid ......................
Revision of upper eyelid .....................
Revision of upper eyelid .....................
Removal of forehead wrinkles ............
Removal of neck wrinkles ...................
Removal of brow wrinkles ...................
Removal of face wrinkles ....................
Removal of skin wrinkles ....................
Exc skin abd .......................................
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
11.39
2.23
4.65
1.00
5.36
1.50
3.99
1.00
4.50
1.43
3.76
0.50
3.93
1.15
4.21
1.45
4.38
1.00
4.89
1.50
5.93
0.00
10.00
9.94
10.52
9.24
1.95
2.46
3.62
3.95
4.64
14.12
19.70
19.62
16.92
18.92
11.57
12.73
36.74
36.95
36.70
9.68
8.73
3.95
5.53
8.50
4.91
4.36
4.33
2.05
0.33
2.09
4.91
1.86
3.82
10.45
6.09
6.66
4.51
8.12
0.00
0.00
0.00
0.00
0.00
16.90
12.65
11.70
11.97
12.79
10.41
9.37
13.00
2.97
3.44
0.46
3.78
0.69
3.49
0.49
3.32
0.74
3.68
0.64
4.85
0.50
4.21
0.67
4.99
1.01
5.43
1.16
6.60
0.00
10.08
9.78
10.54
9.66
5.31
5.56
6.47
7.07
7.27
11.89
14.64
15.68
13.39
13.76
13.56
NA
NA
NA
NA
10.41
NA
2.88
4.85
11.23
8.67
8.70
7.91
3.89
0.83
9.45
9.42
8.97
8.09
NA
6.39
6.56
5.23
7.38
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
8.67
11.60
2.83
3.32
0.46
3.70
0.69
3.34
0.47
3.39
0.71
3.84
0.62
4.66
0.54
4.38
0.68
4.50
1.45
5.10
1.24
6.75
0.00
10.69
9.63
10.61
9.70
6.45
5.12
7.12
7.05
7.20
11.89
16.34
16.89
15.80
15.86
11.84
NA
NA
NA
NA
10.21
NA
3.55
5.10
11.37
7.79
9.28
7.39
3.62
0.96
8.08
8.75
8.03
7.19
NA
6.68
6.95
5.53
7.61
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
8.61
9.33
1.15
2.15
0.32
2.35
0.51
2.14
0.36
2.01
0.51
2.64
0.13
3.53
0.32
3.09
0.47
3.76
0.33
4.17
0.48
6.05
0.00
6.27
6.66
7.03
6.51
2.75
3.04
3.90
4.31
4.38
9.33
11.09
11.84
9.59
10.18
9.41
8.85
18.55
17.85
17.56
7.05
6.63
1.23
2.14
6.52
5.64
4.96
4.96
1.24
0.08
4.12
5.83
4.58
4.90
6.68
5.19
5.28
4.09
6.10
0.00
0.00
0.00
0.00
0.00
9.81
8.27
7.50
8.15
7.85
6.82
5.78
8.95
1.28
2.19
0.36
2.44
0.55
2.18
0.38
2.22
0.54
2.69
0.17
3.31
0.39
3.14
0.53
3.88
0.39
3.98
0.55
6.33
0.00
6.51
6.55
7.41
6.70
2.90
3.23
3.89
4.23
4.29
9.33
11.65
12.10
10.40
10.95
8.83
8.94
19.55
19.71
19.56
7.15
6.66
1.26
2.47
7.38
5.50
5.75
4.57
1.28
0.12
3.60
5.31
4.51
4.64
6.93
5.38
5.49
4.29
6.27
0.00
0.00
0.00
0.00
0.00
9.81
8.30
7.85
7.92
7.69
6.80
6.57
Malpractice
RVUs 2
0.69
0.21
0.49
0.14
0.58
0.21
0.49
0.14
0.55
0.20
0.41
0.06
0.43
0.14
0.46
0.17
0.47
0.14
0.52
0.21
0.66
0.00
1.34
1.20
1.20
0.87
0.27
0.35
0.35
0.34
0.42
1.28
2.00
2.62
2.46
2.66
0.63
1.42
4.62
3.90
4.24
0.85
1.05
0.52
0.72
0.67
0.34
0.34
0.28
0.11
0.04
0.11
0.20
0.13
0.19
0.97
0.40
0.45
0.37
0.50
0.00
0.00
0.00
0.00
0.00
2.93
1.66
1.49
1.61
1.60
1.34
1.18
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00195
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
010
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
090
090
090
090
010
ZZZ
090
090
090
090
090
090
090
090
090
000
000
000
000
000
090
090
090
090
090
090
090
66416
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
15838
15839
15840
15841
15842
15845
15847
15850
15851
15852
15860
15876
15877
15878
15879
15920
15922
15931
15933
15934
15935
15936
15937
15940
15941
15944
15945
15946
15950
15951
15952
15953
15956
15958
15999
16000
16020
16025
16030
16035
16036
17000
17003
17004
17106
17107
17108
17110
17111
17250
17260
17261
17262
17263
17264
17266
17270
17271
17272
17273
17274
17276
17280
17281
17282
17283
17284
17286
17311
17312
17313
17314
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
C
B
A
A
A
R
R
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Excise excessive skin tissue ..............
Excise excessive skin tissue ..............
Graft for face nerve palsy ...................
Graft for face nerve palsy ...................
Flap for face nerve palsy ....................
Skin and muscle repair, face ..............
Exc skin abd add-on ...........................
Removal of sutures .............................
Removal of sutures .............................
Dressing change not for burn .............
Test for blood flow in graft ..................
Suction assisted lipectomy .................
Suction assisted lipectomy .................
Suction assisted lipectomy .................
Suction assisted lipectomy .................
Removal of tail bone ulcer ..................
Removal of tail bone ulcer ..................
Remove sacrum pressure sore ..........
Remove sacrum pressure sore ..........
Remove sacrum pressure sore ..........
Remove sacrum pressure sore ..........
Remove sacrum pressure sore ..........
Remove sacrum pressure sore ..........
Remove hip pressure sore .................
Remove hip pressure sore .................
Remove hip pressure sore .................
Remove hip pressure sore .................
Remove hip pressure sore .................
Remove thigh pressure sore ..............
Remove thigh pressure sore ..............
Remove thigh pressure sore ..............
Remove thigh pressure sore ..............
Remove thigh pressure sore ..............
Remove thigh pressure sore ..............
Removal of pressure sore ..................
Initial treatment of burn(s) ...................
Dress/debrid p-thick burn, s ................
Dress/debrid p-thick burn, m ..............
Dress/debrid p-thick burn, l .................
Incision of burn scab, initi ...................
Escharotomy; add’l incision ................
Destruct premalg lesion ......................
Destruct premalg les, 2–14 .................
Destroy premlg lesions 15+ ................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruct b9 lesion, 1–14 .....................
Destruct lesion, 15 or more ................
Chemical cautery, tissue .....................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Destruction of skin lesions ..................
Mohs, 1 stage, h/n/hf/g .......................
Mohs addl stage .................................
Mohs, 1 stage, t/a/l .............................
Mohs, addl stage, t/a/l ........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.07
10.32
14.76
25.69
40.68
14.04
0.00
0.78
0.86
0.86
1.95
0.00
0.00
0.00
0.00
8.15
10.23
9.96
11.60
13.54
15.58
13.04
15.00
10.11
12.24
12.27
13.57
23.80
7.91
11.41
12.14
13.39
16.59
16.55
0.00
0.89
0.80
1.85
2.08
3.74
1.50
0.62
0.07
1.82
4.62
9.19
13.22
0.67
0.94
0.50
0.93
1.19
1.60
1.81
1.96
2.36
1.34
1.51
1.79
2.07
2.61
3.22
1.19
1.74
2.06
2.66
3.23
4.45
6.20
3.30
5.56
3.06
NA
9.75
NA
NA
NA
NA
0.00
1.20
1.33
NA
NA
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.72
1.11
1.57
2.08
NA
NA
1.41
0.10
2.44
4.69
6.97
8.86
1.79
2.25
1.32
1.41
2.49
2.83
3.06
3.27
3.50
2.43
2.66
2.97
3.21
3.60
3.88
2.36
2.73
3.14
3.55
3.97
4.44
10.70
6.88
9.87
6.37
NA
9.29
NA
NA
NA
NA
0.00
1.38
1.50
NA
NA
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.79
1.20
1.67
2.13
NA
NA
1.19
0.11
2.37
4.64
7.08
9.06
1.70
1.96
1.27
1.34
2.05
2.36
2.56
2.74
3.00
2.06
2.22
2.48
2.71
3.08
3.41
1.98
2.32
2.64
3.05
3.44
4.06
10.70
6.88
9.87
6.37
5.44
6.46
8.91
13.52
20.86
8.35
0.00
0.18
0.24
0.25
0.64
0.00
0.00
0.00
0.00
5.34
7.16
5.56
7.30
7.72
9.17
7.41
8.93
5.80
8.42
8.13
8.80
13.69
5.40
7.33
7.45
8.22
9.54
10.42
0.00
0.23
0.56
0.86
1.02
1.22
0.46
0.74
0.03
1.38
3.28
4.94
6.38
0.88
1.11
0.38
0.71
1.07
1.27
1.37
1.43
1.59
1.10
1.22
1.36
1.49
1.74
1.97
1.03
1.33
1.49
1.76
2.02
2.49
3.05
1.62
2.73
1.50
5.75
6.42
9.44
14.25
21.88
8.83
0.00
0.24
0.27
0.29
0.71
0.00
0.00
0.00
0.00
5.45
7.18
5.62
7.57
7.87
9.74
7.81
9.37
5.99
8.93
8.36
9.22
14.03
5.40
7.59
7.60
8.61
10.15
10.72
0.00
0.25
0.57
0.91
1.07
1.40
0.53
0.64
0.05
1.48
3.30
5.20
7.02
0.79
0.96
0.36
0.69
0.95
1.14
1.23
1.28
1.40
0.98
1.10
1.24
1.35
1.59
1.82
0.92
1.21
1.36
1.62
1.89
2.46
3.05
1.62
2.73
1.50
Malpractice
RVUs 2
0.58
1.22
1.32
2.55
4.94
0.81
0.00
0.05
0.06
0.09
0.27
0.00
0.00
0.00
0.00
1.04
1.42
1.25
1.52
1.79
2.10
1.77
2.07
1.31
1.66
1.65
1.85
3.17
1.04
1.49
1.60
1.80
2.22
2.26
0.00
0.08
0.08
0.19
0.24
0.46
0.20
0.03
0.01
0.11
0.35
0.63
0.54
0.05
0.05
0.06
0.04
0.05
0.06
0.07
0.08
0.09
0.05
0.06
0.07
0.08
0.10
0.16
0.05
0.07
0.08
0.11
0.13
0.23
0.24
0.13
0.22
0.12
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00196
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
YYY
XXX
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
000
000
000
000
000
ZZZ
010
ZZZ
010
090
090
090
010
010
000
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
010
000
ZZZ
000
ZZZ
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66417
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
17315
17340
17360
17380
17999
19000
19001
19020
19030
19100
19101
19102
19103
19105
19110
19112
19120
19125
19126
19260
19271
19272
19290
19291
19295
19296
19297
19298
19300
19301
19302
19303
19304
19305
19306
19307
19316
19318
19324
19325
19328
19330
19340
19342
19350
19355
19357
19361
19364
19366
19367
19368
19369
19370
19371
19380
19396
19499
20000
20005
20100
20101
20102
20103
20150
20200
20205
20206
20220
20225
20240
20245
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
R
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Mohs surg, addl block .........................
Cryotherapy of skin .............................
Skin peel therapy ................................
Hair removal by electrolysis ................
Skin tissue procedure .........................
Drainage of breast lesion ....................
Drain breast lesion add-on .................
Incision of breast lesion ......................
Injection for breast x-ray .....................
Bx breast percut w/o image ................
Biopsy of breast, open ........................
Bx breast percut w/image ...................
Bx breast percut w/device ..................
Cryosurg ablate fa, each ....................
Nipple exploration ...............................
Excise breast duct fistula ....................
Removal of breast lesion ....................
Excision, breast lesion ........................
Excision, addl breast lesion ................
Removal of chest wall lesion ..............
Revision of chest wall .........................
Extensive chest wall surgery ..............
Place needle wire, breast ...................
Place needle wire, breast ...................
Place breast clip, percut .....................
Place po breast cath for rad ...............
Place breast cath for rad ....................
Place breast rad tube/caths ................
Removal of breast tissue ....................
Partical mastectomy ............................
P-mastectomy w/ln removal ................
Mast, simple, complete .......................
Mast, subq ..........................................
Mast, radical ........................................
Mast, rad, urban type ..........................
Mast, mod rad .....................................
Suspension of breast ..........................
Reduction of large breast ...................
Enlarge breast .....................................
Enlarge breast with implant ................
Removal of breast implant ..................
Removal of implant material ...............
Immediate breast prosthesis ...............
Delayed breast prosthesis ..................
Breast reconstruction ..........................
Correct inverted nipple(s) ...................
Breast reconstruction ..........................
Breast reconstr w/lat flap ....................
Breast reconstruction ..........................
Breast reconstruction ..........................
Breast reconstruction ..........................
Breast reconstruction ..........................
Breast reconstruction ..........................
Surgery of breast capsule ...................
Removal of breast capsule .................
Revise breast reconstruction ..............
Design custom breast implant ............
Breast surgery procedure ...................
Incision of abscess .............................
Incision of deep abscess ....................
Explore wound, neck ..........................
Explore wound, chest .........................
Explore wound, abdomen ...................
Explore wound, extremity ...................
Excise epiphyseal bar .........................
Muscle biopsy .....................................
Deep muscle biopsy ...........................
Needle biopsy, muscle ........................
Bone biopsy, trocar/needle .................
Bone biopsy, trocar/needle .................
Bone biopsy, excisional ......................
Bone biopsy, excisional ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.87
0.76
1.44
0.00
0.00
0.84
0.42
3.74
1.53
1.27
3.20
2.00
3.69
3.69
4.35
3.72
5.84
6.59
2.93
17.60
21.86
24.82
1.27
0.63
0.00
3.63
1.72
6.00
5.20
10.00
13.88
15.67
7.81
17.23
17.85
17.95
10.98
15.91
6.65
8.52
6.35
8.39
6.32
12.40
8.99
8.37
20.57
23.17
42.40
21.70
26.59
33.61
31.02
8.99
10.42
10.21
2.17
0.00
2.14
3.55
10.33
3.22
3.95
5.31
14.60
1.46
2.35
0.99
1.27
1.87
3.25
8.77
1.14
0.35
1.86
0.00
0.00
1.91
0.25
6.62
2.66
2.08
4.37
3.46
10.09
46.46
6.06
6.22
5.08
5.55
NA
NA
NA
NA
2.89
1.14
2.28
85.92
NA
21.99
8.05
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.88
7.40
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.53
0.00
2.78
3.66
NA
6.59
6.94
7.80
NA
3.09
3.82
5.22
2.71
11.99
NA
NA
1.14
0.36
1.65
0.00
0.00
1.95
0.25
6.48
2.76
2.08
4.43
3.64
10.79
46.46
5.93
6.14
4.81
5.16
NA
NA
NA
NA
2.87
1.17
2.48
105.62
NA
32.06
7.59
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
11.86
8.82
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.80
0.00
2.74
3.58
NA
6.26
7.20
8.19
NA
3.06
3.85
5.86
3.63
18.21
NA
NA
0.43
0.38
1.01
0.00
0.00
0.26
0.14
3.03
0.54
0.33
1.78
0.68
1.19
0.99
3.09
3.12
3.36
3.64
0.75
10.14
15.81
16.95
0.45
0.22
NA
1.19
0.44
2.10
3.85
4.62
6.14
6.99
4.93
8.11
8.71
8.76
6.94
9.90
4.46
6.40
4.99
5.95
2.81
8.92
6.58
4.67
15.37
16.78
22.15
9.90
15.17
18.01
16.31
6.78
7.68
7.60
1.28
0.00
1.52
2.01
3.58
1.53
1.84
2.78
7.64
0.69
1.10
0.57
0.68
1.02
2.02
5.74
0.43
0.37
0.94
0.00
0.00
0.29
0.14
2.85
0.52
0.37
1.85
0.67
1.21
0.99
2.98
2.90
3.21
3.46
0.87
10.64
16.87
17.93
0.43
0.21
NA
1.36
0.54
2.26
3.62
4.02
6.23
6.00
4.84
8.03
8.47
8.48
7.22
10.53
4.67
6.46
5.00
5.99
2.96
8.92
6.87
4.68
15.49
14.60
22.84
10.73
15.93
18.46
17.35
6.84
7.75
7.65
1.13
0.00
1.63
2.13
4.02
1.57
1.87
3.09
7.33
0.72
1.14
0.60
0.73
1.07
2.29
6.15
Malpractice
RVUs 2
0.03
0.05
0.06
0.00
0.00
0.08
0.04
0.45
0.09
0.16
0.39
0.14
0.30
0.30
0.57
0.48
0.73
0.80
0.38
2.14
2.63
3.00
0.07
0.04
0.01
0.36
0.17
0.43
0.69
0.79
1.80
1.18
1.04
1.93
2.08
2.13
1.64
2.93
0.84
1.33
0.91
1.26
1.06
1.84
1.41
0.92
2.94
2.93
6.24
3.25
4.04
5.54
4.51
1.29
1.62
1.44
0.30
0.00
0.25
0.46
1.21
0.44
0.49
0.75
2.04
0.23
0.33
0.07
0.08
0.22
0.44
1.31
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00197
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
010
010
000
YYY
000
ZZZ
090
000
000
010
000
000
000
090
090
090
090
ZZZ
090
090
090
000
ZZZ
ZZZ
000
ZZZ
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
000
YYY
010
010
010
010
010
010
090
000
000
000
000
000
010
010
66418
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
20250
20251
20500
20501
20520
20525
20526
20550
20551
20552
20553
20555
20600
20605
20610
20612
20615
20650
20660
20661
20662
20663
20664
20665
20670
20680
20690
20692
20693
20694
20802
20805
20808
20816
20822
20824
20827
20838
20900
20902
20910
20912
20920
20922
20924
20926
20930
20931
20936
20937
20938
20950
20955
20956
20957
20962
20969
20970
20972
20973
20974
20975
20979
20982
20985
20986
20987
20999
21010
21015
21025
21026
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
A
B
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Open bone biopsy ...............................
Open bone biopsy ...............................
Injection of sinus tract .........................
Inject sinus tract for x-ray ...................
Removal of foreign body .....................
Removal of foreign body .....................
Ther injection, carp tunnel ..................
Inj tendon sheath/ligament ..................
Inj tendon origin/insertion ....................
Inj trigger point, 1/2 muscl ..................
Inject trigger points, =/> 3 ...................
Place ndl musc/tis for rt ......................
Drain/inject, joint/bursa .......................
Drain/inject, joint/bursa .......................
Drain/inject, joint/bursa .......................
Aspirate/inj ganglion cyst ....................
Treatment of bone cyst .......................
Insert and remove bone pin ................
Apply, rem fixation device ...................
Application of head brace ...................
Application of pelvis brace ..................
Application of thigh brace ...................
Halo brace application ........................
Removal of fixation device ..................
Removal of support implant ................
Removal of support implant ................
Apply bone fixation device ..................
Apply bone fixation device ..................
Adjust bone fixation device .................
Remove bone fixation device .............
Replantation, arm, complete ...............
Replant forearm, complete .................
Replantation hand, complete ..............
Replantation digit, complete ...............
Replantation digit, complete ...............
Replantation thumb, complete ............
Replantation thumb, complete ............
Replantation foot, complete ................
Removal of bone for graft ...................
Removal of bone for graft ...................
Remove cartilage for graft ..................
Remove cartilage for graft ..................
Removal of fascia for graft .................
Removal of fascia for graft .................
Removal of tendon for graft ................
Removal of tissue for graft .................
Sp bone algrft morsel add-on .............
Sp bone algrft struct add-on ...............
Sp bone agrft local add-on .................
Sp bone agrft morsel add-on ..............
Sp bone agrft struct add-on ................
Fluid pressure, muscle ........................
Fibula bone graft, microvasc ..............
Iliac bone graft, microvasc ..................
Mt bone graft, microvasc ....................
Other bone graft, microvasc ...............
Bone/skin graft, microvasc ..................
Bone/skin graft, iliac crest ...................
Bone/skin graft, metatarsal .................
Bone/skin graft, great toe ...................
Electrical bone stimulation ..................
Electrical bone stimulation ..................
Us bone stimulation ............................
Ablate, bone tumor(s) perq .................
Cptr-asst dir ms px .............................
Cptr-asst dir ms px io img ..................
Cptr-asst dir ms px pre img ................
Musculoskeletal surgery .....................
Incision of jaw joint .............................
Resection of facial tumor ....................
Excision of bone, lower jaw ................
Excision of facial bone(s) ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.16
5.69
1.25
0.76
1.87
3.51
0.94
0.75
0.75
0.66
0.75
6.00
0.66
0.68
0.79
0.70
2.30
2.25
4.00
5.14
6.26
5.62
9.86
1.33
1.76
5.90
8.65
16.00
5.97
4.20
42.30
51.14
62.77
31.74
26.42
31.74
27.24
42.56
5.77
7.98
5.41
6.42
5.42
6.84
6.59
5.70
0.00
1.81
0.00
2.79
3.02
1.26
40.02
40.93
42.33
39.21
45.11
44.26
44.19
46.95
0.62
2.60
0.62
7.27
2.50
0.00
0.00
0.00
10.90
5.59
11.07
5.54
NA
NA
1.34
2.36
2.60
7.11
0.81
0.63
0.64
0.58
0.64
NA
0.66
0.74
1.06
0.70
2.71
2.46
1.50
NA
NA
NA
NA
1.37
6.62
8.13
NA
NA
NA
5.31
NA
NA
NA
NA
NA
NA
NA
NA
9.22
NA
NA
NA
NA
7.56
NA
NA
0.00
NA
0.00
NA
NA
4.23
NA
NA
NA
NA
NA
NA
NA
NA
0.98
NA
0.61
79.99
0.99
0.00
0.00
0.00
NA
NA
12.54
8.82
NA
NA
1.80
2.64
2.76
8.12
0.89
0.67
0.66
0.65
0.73
NA
0.66
0.75
1.01
0.70
3.11
2.41
2.27
NA
NA
NA
NA
1.76
9.07
8.46
NA
NA
NA
6.22
NA
NA
NA
NA
NA
NA
NA
NA
8.82
NA
NA
NA
NA
7.54
NA
NA
0.00
NA
0.00
NA
NA
5.53
NA
NA
NA
NA
NA
NA
NA
NA
0.83
NA
0.71
94.74
0.99
0.00
0.00
0.00
NA
NA
12.39
8.34
3.63
3.84
0.88
0.27
1.45
2.21
0.41
0.28
0.29
0.24
0.26
2.18
0.31
0.32
0.40
0.32
1.41
1.45
1.50
6.04
4.80
4.85
7.80
0.98
1.67
4.06
4.91
9.79
4.49
3.52
13.22
17.97
30.31
16.35
15.05
16.19
14.73
14.01
4.90
5.98
4.56
4.94
4.33
4.99
4.97
4.49
0.00
0.68
0.00
1.08
1.15
0.88
18.53
20.31
15.87
21.29
21.09
20.89
14.92
14.15
0.48
1.46
0.20
2.68
0.99
0.00
0.00
0.00
6.29
4.30
8.74
5.93
3.56
4.00
1.20
0.26
1.61
2.41
0.46
0.25
0.31
0.22
0.24
2.18
0.33
0.34
0.41
0.34
1.63
1.50
1.55
5.47
5.16
4.84
7.42
1.16
1.88
3.89
3.71
6.78
4.96
3.78
17.08
26.13
36.25
27.06
24.81
26.36
25.59
18.14
5.28
6.43
4.87
5.37
4.28
4.93
5.42
4.62
0.00
0.80
0.00
1.26
1.35
0.93
21.39
22.52
17.40
23.90
23.85
23.13
17.74
19.64
0.51
1.58
0.27
2.83
0.99
0.00
0.00
0.00
6.69
4.65
9.04
6.12
Malpractice
RVUs 2
1.02
1.15
0.12
0.04
0.21
0.51
0.13
0.09
0.08
0.05
0.04
0.43
0.08
0.08
0.11
0.10
0.20
0.31
0.59
1.14
0.56
0.94
1.75
0.19
0.28
0.56
0.59
1.05
0.98
0.71
3.82
4.85
6.88
4.53
4.19
4.62
3.67
1.12
0.94
1.30
0.71
0.69
0.66
0.70
1.04
0.87
0.00
0.43
0.00
0.54
0.64
0.20
4.90
7.03
7.07
6.57
4.80
6.62
5.32
5.56
0.11
0.51
0.09
0.69
0.48
0.00
0.00
0.00
1.11
0.70
1.32
0.60
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00198
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
010
010
000
010
010
000
000
000
000
000
000
000
000
000
000
010
010
000
090
090
090
090
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
XXX
ZZZ
XXX
ZZZ
ZZZ
000
090
090
090
090
090
090
090
090
000
000
000
000
ZZZ
ZZZ
ZZZ
YYY
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66419
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
21029
21030
21031
21032
21034
21040
21044
21045
21046
21047
21048
21049
21050
21060
21070
21073
21076
21077
21079
21080
21081
21082
21083
21084
21085
21086
21087
21088
21089
21100
21110
21116
21120
21121
21122
21123
21125
21127
21137
21138
21139
21141
21142
21143
21145
21146
21147
21150
21151
21154
21155
21159
21160
21172
21175
21179
21180
21181
21182
21183
21184
21188
21193
21194
21195
21196
21198
21199
21206
21208
21209
21210
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Contour of face bone lesion ...............
Excise max/zygoma b9 tumor ............
Remove exostosis, mandible ..............
Remove exostosis, maxilla .................
Excise max/zygoma mlg tumor ...........
Excise mandible lesion .......................
Removal of jaw bone lesion ...............
Extensive jaw surgery .........................
Remove mandible cyst complex .........
Excise lwr jaw cyst w/repair ................
Remove maxilla cyst complex ............
Excis uppr jaw cyst w/repair ...............
Removal of jaw joint ...........................
Remove jaw joint cartilage ..................
Remove coronoid process ..................
Mnpj of tmj w/anesth ...........................
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Prepare face/oral prosthesis ...............
Maxillofacial fixation ............................
Interdental fixation ...............................
Injection, jaw joint x-ray ......................
Reconstruction of chin ........................
Reconstruction of chin ........................
Reconstruction of chin ........................
Reconstruction of chin ........................
Augmentation, lower jaw bone ...........
Augmentation, lower jaw bone ...........
Reduction of forehead ........................
Reduction of forehead ........................
Reduction of forehead ........................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct midface, lefort .................
Reconstruct orbit/forehead ..................
Reconstruct orbit/forehead ..................
Reconstruct entire forehead ...............
Reconstruct entire forehead ...............
Contour cranial bone lesion ................
Reconstruct cranial bone ....................
Reconstruct cranial bone ....................
Reconstruct cranial bone ....................
Reconstruction of midface ..................
Reconst lwr jaw w/o graft ...................
Reconst lwr jaw w/graft .......................
Reconst lwr jaw w/o fixation ...............
Reconst lwr jaw w/fixation ..................
Reconstr lwr jaw segment ..................
Reconstr lwr jaw w/advance ...............
Reconstruct upper jaw bone ...............
Augmentation of facial bones .............
Reduction of facial bones ...................
Face bone graft ...................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.26
4.80
3.26
3.28
17.17
4.80
12.61
18.13
13.97
19.83
14.47
19.08
11.54
10.91
8.50
3.33
13.40
33.70
22.31
25.06
22.85
20.84
19.27
22.48
8.99
24.88
24.88
0.00
0.00
4.56
5.80
0.81
4.99
7.70
8.59
11.22
10.68
12.24
10.12
12.73
14.90
19.27
19.98
20.75
23.64
24.54
26.14
25.78
28.84
31.05
34.98
42.90
46.95
28.07
33.43
22.53
25.46
10.18
32.45
35.57
38.49
22.97
18.65
21.54
18.88
20.55
15.48
16.62
15.36
11.15
7.58
11.40
9.55
7.19
5.91
6.04
13.92
7.19
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.50
8.01
18.42
13.95
16.14
15.01
14.89
14.89
16.83
6.92
12.90
13.03
0.00
0.00
14.86
13.04
2.52
9.64
10.63
NA
NA
63.93
84.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
33.14
12.19
43.44
9.46
6.76
5.54
5.69
14.92
6.79
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.50
10.18
24.86
17.72
20.31
18.65
17.11
16.83
19.63
7.60
18.31
18.15
0.00
0.00
13.19
11.30
3.42
10.11
10.18
NA
NA
59.56
63.85
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
27.73
11.49
34.15
6.52
4.68
3.47
3.36
10.11
4.64
8.10
10.78
11.48
10.21
11.38
10.28
8.20
7.19
6.26
2.31
4.68
11.82
8.09
9.01
8.40
8.26
7.77
8.94
3.51
8.44
8.54
0.00
0.00
5.53
9.73
0.23
6.64
7.58
8.45
7.03
6.42
7.49
7.43
7.78
6.98
11.85
10.07
11.80
12.96
9.17
14.29
16.90
11.60
17.87
18.15
15.12
23.21
13.73
13.51
11.21
12.98
6.82
15.26
19.20
15.61
15.63
9.80
12.12
13.06
13.93
11.88
7.56
10.88
8.00
7.39
7.63
6.76
4.85
3.54
3.43
11.38
4.68
8.73
11.56
11.69
11.82
11.75
11.65
8.82
7.89
6.68
2.31
7.34
18.90
12.62
14.18
12.94
11.99
11.10
13.31
5.14
13.93
13.86
0.00
0.00
5.13
9.04
0.28
7.06
7.70
8.53
8.91
7.37
8.47
7.58
8.65
9.02
12.75
11.44
13.05
13.43
12.25
14.67
16.83
17.27
20.49
21.02
22.09
25.33
13.74
15.65
12.66
14.18
7.14
17.18
20.01
18.77
17.24
11.23
12.93
13.94
14.81
12.29
8.34
11.75
8.79
7.72
8.49
Malpractice
RVUs 2
0.94
0.54
0.48
0.47
1.72
0.54
1.12
1.52
1.86
2.13
1.77
1.59
1.47
1.38
1.27
0.43
2.00
4.56
3.16
3.75
3.21
3.12
2.89
2.19
1.27
3.72
3.45
0.00
0.00
0.34
0.72
0.06
0.60
0.90
1.07
1.40
0.79
1.52
1.32
1.75
1.18
2.36
2.39
1.66
2.85
3.10
1.85
2.56
2.31
2.49
6.66
8.20
4.14
3.56
4.84
2.81
3.49
1.32
2.81
4.48
5.72
1.70
2.24
2.03
1.64
2.08
1.44
1.39
1.33
1.09
0.90
1.30
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00199
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
010
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66420
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
21215
21230
21235
21240
21242
21243
21244
21245
21246
21247
21248
21249
21255
21256
21260
21261
21263
21267
21268
21270
21275
21280
21282
21295
21296
21299
21310
21315
21320
21325
21330
21335
21336
21337
21338
21339
21340
21343
21344
21345
21346
21347
21348
21355
21356
21360
21365
21366
21385
21386
21387
21390
21395
21400
21401
21406
21407
21408
21421
21422
21423
21431
21432
21433
21435
21436
21440
21445
21450
21451
21452
21453
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Lower jaw bone graft ..........................
Rib cartilage graft ................................
Ear cartilage graft ...............................
Reconstruction of jaw joint ..................
Reconstruction of jaw joint ..................
Reconstruction of jaw joint ..................
Reconstruction of lower jaw ................
Reconstruction of jaw .........................
Reconstruction of jaw .........................
Reconstruct lower jaw bone ...............
Reconstruction of jaw .........................
Reconstruction of jaw .........................
Reconstruct lower jaw bone ...............
Reconstruction of orbit ........................
Revise eye sockets .............................
Revise eye sockets .............................
Revise eye sockets .............................
Revise eye sockets .............................
Revise eye sockets .............................
Augmentation, cheek bone .................
Revision, orbitofacial bones ................
Revision of eyelid ................................
Revision of eyelid ................................
Revision of jaw muscle/bone ..............
Revision of jaw muscle/bone ..............
Cranio/maxillofacial surgery ................
Treatment of nose fracture .................
Treatment of nose fracture .................
Treatment of nose fracture .................
Treatment of nose fracture .................
Treatment of nose fracture .................
Treatment of nose fracture .................
Treat nasal septal fracture ..................
Treat nasal septal fracture ..................
Treat nasoethmoid fracture .................
Treat nasoethmoid fracture .................
Treatment of nose fracture .................
Treatment of sinus fracture .................
Treatment of sinus fracture .................
Treat nose/jaw fracture .......................
Treat nose/jaw fracture .......................
Treat nose/jaw fracture .......................
Treat nose/jaw fracture .......................
Treat cheek bone fracture ..................
Treat cheek bone fracture ..................
Treat cheek bone fracture ..................
Treat cheek bone fracture ..................
Treat cheek bone fracture ..................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat eye socket fracture ....................
Treat mouth roof fracture ....................
Treat mouth roof fracture ....................
Treat mouth roof fracture ....................
Treat craniofacial fracture ...................
Treat craniofacial fracture ...................
Treat craniofacial fracture ...................
Treat craniofacial fracture ...................
Treat craniofacial fracture ...................
Treat dental ridge fracture ..................
Treat dental ridge fracture ..................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
11.94
11.06
7.31
15.77
14.32
24.03
13.35
12.88
12.78
24.05
12.54
18.57
18.14
17.42
17.74
33.78
30.72
20.45
26.78
10.52
11.65
6.92
4.11
1.82
4.67
0.00
0.58
1.78
1.86
4.07
5.68
8.91
6.56
3.26
6.76
8.39
11.33
14.11
21.36
8.87
11.29
13.37
17.36
4.32
4.70
7.03
16.52
18.44
9.46
9.46
10.00
11.07
14.62
1.44
3.57
7.31
8.91
12.67
5.80
8.62
10.71
7.74
8.76
26.13
20.02
30.01
3.28
6.04
3.55
5.46
2.29
6.40
86.03
NA
10.10
NA
NA
NA
NA
14.20
NA
NA
12.60
15.72
NA
NA
NA
NA
NA
NA
NA
11.15
NA
NA
NA
NA
NA
0.00
1.99
4.71
4.29
NA
NA
NA
NA
6.14
NA
NA
NA
NA
NA
10.48
NA
NA
NA
5.90
6.97
NA
NA
NA
NA
NA
NA
NA
NA
2.70
7.03
NA
NA
NA
12.45
NA
NA
NA
NA
NA
NA
NA
10.06
12.27
10.50
12.97
12.02
14.80
63.95
NA
9.97
NA
NA
NA
NA
14.30
NA
NA
12.36
16.22
NA
NA
NA
NA
NA
NA
NA
11.39
NA
NA
NA
NA
NA
0.00
2.14
4.47
4.10
NA
NA
NA
NA
6.13
NA
NA
NA
NA
NA
10.16
NA
NA
NA
6.07
7.04
NA
NA
NA
NA
NA
NA
NA
NA
2.66
7.51
NA
NA
NA
10.89
NA
NA
NA
NA
NA
NA
NA
8.58
11.01
8.94
11.16
12.52
12.76
7.96
7.01
6.18
9.43
9.01
14.14
11.51
8.61
7.42
12.69
7.51
9.61
14.03
9.57
12.95
14.74
14.03
16.03
13.13
5.90
7.15
5.66
4.16
2.23
5.43
0.00
0.11
1.78
1.36
6.97
7.62
8.47
8.66
3.56
9.92
9.82
7.24
12.79
13.05
6.55
10.82
11.73
10.99
3.25
4.05
5.39
9.09
10.50
7.13
6.00
7.44
7.01
8.33
1.96
3.04
5.29
5.92
7.44
9.20
7.04
7.39
10.83
6.81
12.13
11.07
13.13
7.45
8.46
7.71
9.67
6.05
11.64
8.66
7.52
6.29
10.73
10.25
15.78
11.80
9.23
8.23
15.01
8.45
11.15
15.08
10.69
12.85
19.48
16.55
17.90
16.66
6.57
7.65
5.79
4.32
2.38
5.16
0.00
0.13
1.83
1.49
7.79
8.66
9.04
9.13
3.56
11.97
11.86
7.82
14.12
14.77
6.86
11.51
13.96
11.05
3.36
4.30
5.66
9.95
10.91
7.70
6.53
8.20
7.40
8.68
1.92
3.27
5.68
6.39
8.16
8.75
7.56
8.36
10.18
7.43
14.26
11.88
15.67
6.80
8.41
7.29
9.03
5.33
11.18
Malpractice
RVUs 2
1.53
1.29
0.61
2.25
1.79
3.26
1.25
1.19
1.35
2.84
1.55
2.49
2.39
1.50
0.97
3.43
2.63
1.71
3.66
0.72
1.29
0.42
0.26
0.16
0.34
0.00
0.05
0.14
0.18
0.31
0.56
0.74
0.55
0.28
0.82
0.96
1.15
1.47
2.44
0.92
1.21
1.47
2.49
0.34
0.46
0.74
1.70
2.50
0.97
0.97
1.08
0.90
1.44
0.15
0.38
0.73
0.94
1.44
0.73
0.99
1.27
0.70
0.81
2.79
1.99
3.10
0.38
0.78
0.33
0.63
0.27
0.74
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00200
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
000
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66421
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
21454
21461
21462
21465
21470
21480
21485
21490
21495
21497
21499
21501
21502
21510
21550
21555
21556
21557
21600
21610
21615
21616
21620
21627
21630
21632
21685
21700
21705
21720
21725
21740
21742
21743
21750
21800
21805
21810
21820
21825
21899
21920
21925
21930
21935
22010
22015
22100
22101
22102
22103
22110
22112
22114
22116
22206
22207
22208
22210
22212
22214
22216
22220
22222
22224
22226
22305
22310
22315
22318
22319
22325
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Treat lower jaw fracture ......................
Reset dislocated jaw ...........................
Reset dislocated jaw ...........................
Repair dislocated jaw ..........................
Treat hyoid bone fracture ...................
Interdental wiring .................................
Head surgery procedure .....................
Drain neck/chest lesion .......................
Drain chest lesion ...............................
Drainage of bone lesion ......................
Biopsy of neck/chest ...........................
Remove lesion, neck/chest .................
Remove lesion, neck/chest .................
Remove tumor, neck/chest .................
Partial removal of rib ...........................
Partial removal of rib ...........................
Removal of rib .....................................
Removal of rib and nerves .................
Partial removal of sternum ..................
Sternal debridement ............................
Extensive sternum surgery .................
Extensive sternum surgery .................
Hyoid myotomy & suspension ............
Revision of neck muscle .....................
Revision of neck muscle/rib ................
Revision of neck muscle .....................
Revision of neck muscle .....................
Reconstruction of sternum ..................
Repair stern/nuss w/o scope ..............
Repair sternum/nuss w/scope ............
Repair of sternum separation .............
Treatment of rib fracture .....................
Treatment of rib fracture .....................
Treatment of rib fracture(s) .................
Treat sternum fracture ........................
Treat sternum fracture ........................
Neck/chest surgery procedure ............
Biopsy soft tissue of back ...................
Biopsy soft tissue of back ...................
Remove lesion, back or flank .............
Remove tumor, back ...........................
I&d, p-spine, c/t/cerv-thor ....................
I&d, p-spine, l/s/ls ...............................
Remove part of neck vertebra ............
Remove part, thorax vertebra .............
Remove part, lumbar vertebra ............
Remove extra spine segment .............
Remove part of neck vertebra ............
Remove part, thorax vertebra .............
Remove part, lumbar vertebra ............
Remove extra spine segment .............
Cut spine 3 col, thor ...........................
Cut spine 3 col, lumb ..........................
Cut spine 3 col, addl seg ....................
Revision of neck spine ........................
Revision of thorax spine .....................
Revision of lumbar spine ....................
Revise, extra spine segment ..............
Revision of neck spine ........................
Revision of thorax spine .....................
Revision of lumbar spine ....................
Revise, extra spine segment ..............
Treat spine process fracture ...............
Treat spine fracture .............................
Treat spine fracture .............................
Treat odontoid fx w/o graft ..................
Treat odontoid fx w/graft .....................
Treat spine fracture .............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
7.17
9.07
10.77
12.88
17.24
0.61
4.58
12.71
6.55
4.45
0.00
3.87
7.43
6.06
2.08
4.40
5.63
8.91
7.14
15.76
10.31
12.54
7.16
7.18
19.01
19.51
14.89
6.23
9.83
5.72
7.10
17.47
0.00
0.00
11.35
0.98
2.80
6.92
1.31
7.65
0.00
2.08
4.54
5.06
18.38
12.57
12.46
10.80
10.88
10.88
2.34
13.80
13.87
13.87
2.32
37.00
36.50
9.66
25.13
20.74
20.77
6.03
22.69
22.84
22.84
6.03
2.08
3.69
9.91
22.54
25.15
19.62
NA
41.68
42.97
NA
NA
1.52
12.09
NA
NA
12.21
0.00
6.55
NA
NA
4.35
5.78
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
1.36
NA
NA
1.82
NA
0.00
4.43
5.34
6.04
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.72
NA
NA
NA
NA
NA
NA
NA
NA
2.15
2.98
9.88
NA
NA
NA
NA
33.06
35.28
NA
NA
1.64
10.15
NA
NA
10.33
0.00
6.49
NA
NA
3.97
5.65
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
1.35
NA
NA
1.82
NA
0.00
3.86
5.25
5.88
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.72
NA
NA
NA
NA
NA
NA
NA
NA
2.23
2.89
9.78
NA
NA
NA
5.72
12.80
13.40
8.11
10.17
0.18
9.10
8.12
10.47
9.34
0.00
3.52
4.56
4.80
1.78
3.43
4.14
4.51
5.96
8.89
5.16
6.51
4.76
5.54
10.34
9.42
8.76
4.39
4.35
4.10
5.14
8.20
0.00
0.00
5.31
1.43
3.27
5.37
1.89
5.37
0.00
1.88
3.36
3.77
8.44
8.35
8.33
8.19
8.11
7.92
0.90
9.11
9.02
9.00
0.89
17.71
17.59
3.72
14.54
12.44
12.53
2.32
13.35
10.46
12.89
2.28
1.80
2.50
7.43
13.25
13.45
12.13
5.99
12.73
13.05
8.96
11.09
0.18
8.38
8.90
9.44
8.49
0.00
3.67
5.09
5.23
1.75
3.31
4.12
4.93
5.85
8.88
5.92
7.26
5.36
5.92
11.09
10.26
9.36
4.41
4.97
3.28
5.29
8.35
0.00
0.00
5.71
1.38
3.23
5.17
1.83
5.88
0.00
1.67
3.30
3.58
9.03
8.61
8.58
7.86
7.93
8.01
1.05
9.14
9.15
9.13
1.03
17.71
17.59
3.72
14.97
12.85
13.17
2.73
13.48
10.79
13.55
2.68
1.86
2.42
7.38
13.31
14.07
12.10
Malpractice
RVUs 2
0.82
0.98
1.27
1.50
1.97
0.06
0.51
1.97
0.46
0.50
0.00
0.43
0.97
0.80
0.16
0.56
0.65
1.08
0.99
3.08
1.45
1.87
0.98
1.02
2.59
2.66
1.06
0.32
1.43
0.91
1.21
2.37
0.00
0.00
1.63
0.09
0.38
0.94
0.16
1.11
0.00
0.14
0.60
0.66
2.48
1.74
1.72
2.14
1.91
1.88
0.44
2.77
2.53
2.64
0.50
6.23
6.07
2.07
5.46
3.91
3.92
1.29
5.08
4.13
4.19
1.29
0.39
0.50
1.86
5.30
6.05
3.88
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00201
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
000
090
090
090
090
YYY
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
010
090
090
090
090
090
090
090
090
ZZZ
090
090
090
ZZZ
090
090
ZZZ
090
090
090
ZZZ
090
090
090
ZZZ
090
090
090
090
090
090
66422
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
22326
22327
22328
22505
22520
22521
22522
22523
22524
22525
22526
22527
22532
22533
22534
22548
22554
22556
22558
22585
22590
22595
22600
22610
22612
22614
22630
22632
22800
22802
22804
22808
22810
22812
22818
22819
22830
22840
22841
22842
22843
22844
22845
22846
22847
22848
22849
22850
22851
22852
22855
22857
22862
22865
22899
22900
22999
23000
23020
23030
23031
23035
23040
23044
23065
23066
23075
23076
23077
23100
23101
23105
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
C
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treat neck spine fracture ....................
Treat thorax spine fracture .................
Treat each add spine fx ......................
Manipulation of spine ..........................
Percut vertebroplasty thor ...................
Percut vertebroplasty lumb .................
Percut vertebroplasty add’l .................
Percut kyphoplasty, thor .....................
Percut kyphoplasty, lumbar ................
Percut kyphoplasty, add-on ................
Idet, single level ..................................
Idet, 1 or more levels ..........................
Lat thorax spine fusion .......................
Lat lumbar spine fusion ......................
Lat thor/lumb, add’l seg ......................
Neck spine fusion ...............................
Neck spine fusion ...............................
Thorax spine fusion ............................
Lumbar spine fusion ...........................
Additional spinal fusion .......................
Spine & skull spinal fusion ..................
Neck spinal fusion ...............................
Neck spine fusion ...............................
Thorax spine fusion ............................
Lumbar spine fusion ...........................
Spine fusion, extra segment ...............
Lumbar spine fusion ...........................
Spine fusion, extra segment ...............
Fusion of spine ...................................
Fusion of spine ...................................
Fusion of spine ...................................
Fusion of spine ...................................
Fusion of spine ...................................
Fusion of spine ...................................
Kyphectomy, 1–2 segments ...............
Kyphectomy, 3 or more ......................
Exploration of spinal fusion .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert spine fixation device .................
Insert pelv fixation device ...................
Reinsert spinal fixation ........................
Remove spine fixation device .............
Apply spine prosth device ...................
Remove spine fixation device .............
Remove spine fixation device .............
Lumbar artif diskectomy ......................
Revise lumbar artif disc ......................
Remove lumb artif disc .......................
Spine surgery procedure ....................
Remove abdominal wall lesion ...........
Abdomen surgery procedure ..............
Removal of calcium deposits ..............
Release shoulder joint ........................
Drain shoulder lesion ..........................
Drain shoulder bursa ..........................
Drain shoulder bone lesion .................
Exploratory shoulder surgery ..............
Exploratory shoulder surgery ..............
Biopsy shoulder tissues ......................
Biopsy shoulder tissues ......................
Removal of shoulder lesion ................
Removal of shoulder lesion ................
Remove tumor of shoulder .................
Biopsy of shoulder joint ......................
Shoulder joint surgery .........................
Remove shoulder joint lining ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
20.64
20.52
4.60
1.87
9.17
8.60
4.30
9.21
8.81
4.47
6.07
3.03
25.81
24.61
5.99
26.86
17.54
24.50
23.33
5.52
21.56
20.44
17.20
17.08
23.38
6.43
21.89
5.22
19.30
31.91
37.30
27.31
31.30
34.00
34.18
39.18
11.13
12.52
0.00
12.56
13.44
16.42
11.94
12.40
13.78
5.99
19.08
9.74
6.70
9.29
15.77
26.93
32.43
31.55
0.00
6.14
0.00
4.40
9.24
3.44
2.76
9.04
9.63
7.48
2.28
4.21
2.41
7.77
18.08
6.09
5.63
8.36
NA
NA
NA
NA
43.78
44.96
NA
NA
NA
NA
46.67
40.35
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
0.00
7.88
NA
6.28
6.51
NA
NA
NA
2.95
7.75
3.70
NA
NA
NA
NA
NA
NA
NA
NA
NA
52.71
50.45
NA
NA
NA
NA
46.67
40.35
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
0.00
8.20
NA
6.83
7.18
NA
NA
NA
2.72
7.71
3.68
NA
NA
NA
NA
NA
12.02
12.32
1.76
1.10
4.58
4.36
1.51
4.67
4.52
1.69
2.04
0.70
13.77
13.56
2.28
14.92
10.64
12.95
11.42
2.05
13.07
12.63
11.19
10.81
12.49
2.45
12.53
1.99
11.15
15.98
18.11
14.05
14.90
17.37
16.61
18.86
7.05
4.77
0.00
4.79
5.15
6.40
4.48
4.66
5.19
2.33
10.16
6.40
2.54
6.17
9.17
14.80
10.06
9.86
0.00
3.53
0.00
3.73
6.48
2.40
2.21
6.45
6.74
5.51
1.74
3.61
1.72
5.32
9.60
4.99
4.53
6.09
12.36
12.34
2.01
1.02
4.84
4.65
1.59
5.28
5.11
1.98
2.04
0.70
14.29
13.57
2.65
15.36
11.49
13.83
12.35
2.42
13.19
12.73
11.19
11.11
13.34
2.90
13.06
2.32
11.96
17.78
20.40
15.17
16.62
18.71
17.73
19.45
7.50
5.63
0.00
5.64
5.88
7.57
5.27
5.49
6.10
2.76
10.94
6.69
2.95
6.48
9.41
14.80
10.06
9.86
0.00
3.38
0.00
4.07
7.02
2.65
2.47
7.35
7.30
5.97
1.68
3.79
1.75
5.43
9.90
5.32
4.93
6.60
Malpractice
RVUs 2
4.43
3.99
0.94
0.36
1.72
1.60
0.82
1.72
1.60
0.82
1.16
0.58
4.35
3.16
1.25
5.61
4.46
4.35
3.16
1.25
4.79
4.41
3.73
3.53
4.47
1.38
4.73
1.16
3.76
6.17
7.00
4.93
5.15
5.30
6.47
7.67
2.30
2.79
0.00
2.75
2.86
3.19
2.86
2.96
3.00
1.15
3.90
2.05
1.49
1.90
3.52
3.56
5.36
5.18
0.00
0.76
0.00
0.68
1.54
0.57
0.46
1.47
1.60
1.24
0.20
0.63
0.34
1.13
2.34
1.04
0.96
1.42
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00202
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
ZZZ
010
010
010
ZZZ
010
010
ZZZ
010
ZZZ
090
090
ZZZ
090
090
090
090
ZZZ
090
090
090
090
090
ZZZ
090
ZZZ
090
090
090
090
090
090
090
090
090
ZZZ
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
090
090
ZZZ
090
090
090
090
090
YYY
090
YYY
090
090
010
010
090
090
090
010
090
010
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66423
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
23106
23107
23120
23125
23130
23140
23145
23146
23150
23155
23156
23170
23172
23174
23180
23182
23184
23190
23195
23200
23210
23220
23221
23222
23330
23331
23332
23350
23395
23397
23400
23405
23406
23410
23412
23415
23420
23430
23440
23450
23455
23460
23462
23465
23466
23470
23472
23480
23485
23490
23491
23500
23505
23515
23520
23525
23530
23532
23540
23545
23550
23552
23570
23575
23585
23600
23605
23615
23616
23620
23625
23630
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Incision of collarbone joint ..................
Explore treat shoulder joint .................
Partial removal, collar bone ................
Removal of collar bone .......................
Remove shoulder bone, part ..............
Removal of bone lesion ......................
Removal of bone lesion ......................
Removal of bone lesion ......................
Removal of humerus lesion ................
Removal of humerus lesion ................
Removal of humerus lesion ................
Remove collar bone lesion .................
Remove shoulder blade lesion ...........
Remove humerus lesion .....................
Remove collar bone lesion .................
Remove shoulder blade lesion ...........
Remove humerus lesion .....................
Partial removal of scapula ..................
Removal of head of humerus .............
Removal of collar bone .......................
Removal of shoulder blade .................
Partial removal of humerus .................
Partial removal of humerus .................
Partial removal of humerus .................
Remove shoulder foreign body ...........
Remove shoulder foreign body ...........
Remove shoulder foreign body ...........
Injection for shoulder x-ray .................
Muscle transfer,shoulder/arm .............
Muscle transfers ..................................
Fixation of shoulder blade ..................
Incision of tendon & muscle ...............
Incise tendon(s) & muscle(s) ..............
Repair rotator cuff, acute ....................
Repair rotator cuff, chronic .................
Release of shoulder ligament .............
Repair of shoulder ..............................
Repair biceps tendon ..........................
Remove/transplant tendon ..................
Repair shoulder capsule .....................
Repair shoulder capsule .....................
Repair shoulder capsule .....................
Repair shoulder capsule .....................
Repair shoulder capsule .....................
Repair shoulder capsule .....................
Reconstruct shoulder joint ..................
Reconstruct shoulder joint ..................
Revision of collar bone .......................
Revision of collar bone .......................
Reinforce clavicle ................................
Reinforce shoulder bones ...................
Treat clavicle fracture .........................
Treat clavicle fracture .........................
Treat clavicle fracture .........................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat clavicle dislocation .....................
Treat shoulder blade fx .......................
Treat shoulder blade fx .......................
Treat scapula fracture .........................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.02
8.75
7.23
9.52
7.63
7.01
9.28
7.96
8.79
10.72
8.99
7.10
7.20
9.90
8.85
8.47
9.76
7.36
10.24
12.69
13.16
15.36
18.41
25.44
1.87
7.51
12.23
1.00
18.29
16.62
13.73
8.43
10.90
12.63
13.55
10.09
14.75
10.05
10.53
13.58
14.55
15.68
15.60
16.16
15.55
17.75
22.47
11.42
13.79
12.04
14.40
2.13
3.74
9.53
2.21
3.67
7.37
8.08
2.28
3.32
7.48
8.70
2.28
4.12
14.07
3.00
4.94
12.12
18.19
2.46
3.99
10.39
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.35
NA
NA
2.73
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.64
4.01
NA
2.77
4.16
NA
NA
2.66
3.74
NA
NA
2.78
4.59
NA
4.07
5.38
NA
NA
3.41
4.44
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.52
NA
NA
3.09
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.76
4.21
NA
2.81
4.35
NA
NA
2.76
3.96
NA
NA
2.89
4.73
NA
4.31
5.76
NA
NA
3.51
4.69
NA
4.78
6.25
5.47
6.39
6.07
4.90
6.49
5.91
6.25
7.25
6.28
5.00
5.51
7.17
6.41
6.42
6.92
5.31
6.91
7.11
7.80
9.14
10.61
13.33
1.51
5.83
7.96
0.35
11.20
9.54
8.54
5.92
6.90
7.77
8.15
6.58
9.70
6.77
6.77
8.17
8.55
9.36
9.07
9.49
9.99
10.11
12.14
7.29
8.20
6.74
8.71
2.71
3.61
7.00
2.84
3.64
5.30
6.01
2.73
3.26
5.54
6.25
2.92
4.08
8.50
3.65
4.59
8.05
10.45
3.14
3.91
7.36
5.24
6.82
5.96
6.97
6.60
5.06
6.96
6.51
6.58
7.78
6.83
5.51
5.90
7.76
7.70
7.48
8.12
5.74
7.32
7.92
8.40
9.98
11.16
14.55
1.70
6.31
8.64
0.34
12.03
10.45
9.30
6.42
7.62
8.59
9.02
7.28
10.27
7.43
7.51
9.00
9.49
10.36
9.91
10.33
10.67
11.18
13.27
8.03
9.04
7.72
9.71
2.62
3.73
6.77
2.79
3.79
5.62
6.49
2.55
3.31
5.95
6.78
2.91
4.19
8.07
3.60
4.85
8.44
12.29
3.06
4.09
7.00
Malpractice
RVUs 2
0.99
1.49
1.23
1.62
1.30
1.08
1.49
1.35
1.32
1.81
1.50
1.12
1.01
1.65
1.47
1.37
1.63
1.17
1.71
1.94
2.03
2.49
3.06
3.95
0.24
1.27
2.03
0.06
2.94
2.74
2.30
1.45
1.88
2.17
2.32
1.74
2.32
1.74
1.83
2.33
2.50
2.67
2.60
2.77
2.47
2.99
3.67
1.95
2.34
1.47
2.47
0.30
0.61
1.28
0.34
0.46
1.20
1.38
0.29
0.35
1.25
1.46
0.36
0.59
1.54
0.48
0.84
1.62
3.70
0.40
0.67
1.27
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00203
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66424
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
23650
23655
23660
23665
23670
23675
23680
23700
23800
23802
23900
23920
23921
23929
23930
23931
23935
24000
24006
24065
24066
24075
24076
24077
24100
24101
24102
24105
24110
24115
24116
24120
24125
24126
24130
24134
24136
24138
24140
24145
24147
24149
24150
24151
24152
24153
24155
24160
24164
24200
24201
24220
24300
24301
24305
24310
24320
24330
24331
24332
24340
24341
24342
24343
24344
24345
24346
24357
24358
24359
24360
24361
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treat shoulder dislocation ...................
Treat shoulder dislocation ...................
Treat shoulder dislocation ...................
Treat dislocation/fracture ....................
Treat dislocation/fracture ....................
Treat dislocation/fracture ....................
Treat dislocation/fracture ....................
Fixation of shoulder ............................
Fusion of shoulder joint ......................
Fusion of shoulder joint ......................
Amputation of arm & girdle .................
Amputation at shoulder joint ...............
Amputation follow-up surgery .............
Shoulder surgery procedure ...............
Drainage of arm lesion .......................
Drainage of arm bursa ........................
Drain arm/elbow bone lesion ..............
Exploratory elbow surgery ..................
Release elbow joint .............................
Biopsy arm/elbow soft tissue ..............
Biopsy arm/elbow soft tissue ..............
Remove arm/elbow lesion ..................
Remove arm/elbow lesion ..................
Remove tumor of arm/elbow ..............
Biopsy elbow joint lining .....................
Explore/treat elbow joint .....................
Remove elbow joint lining ...................
Removal of elbow bursa .....................
Remove humerus lesion .....................
Remove/graft bone lesion ...................
Remove/graft bone lesion ...................
Remove elbow lesion ..........................
Remove/graft bone lesion ...................
Remove/graft bone lesion ...................
Removal of head of radius .................
Removal of arm bone lesion ...............
Remove radius bone lesion ................
Remove elbow bone lesion ................
Partial removal of arm bone ...............
Partial removal of radius .....................
Partial removal of elbow .....................
Radical resection of elbow ..................
Extensive humerus surgery ................
Extensive humerus surgery ................
Extensive radius surgery ....................
Extensive radius surgery ....................
Removal of elbow joint .......................
Remove elbow joint implant ................
Remove radius head implant ..............
Removal of arm foreign body .............
Removal of arm foreign body .............
Injection for elbow x-ray ......................
Manipulate elbow w/anesth ................
Muscle/tendon transfer .......................
Arm tendon lengthening ......................
Revision of arm tendon .......................
Repair of arm tendon ..........................
Revision of arm muscles ....................
Revision of arm muscles ....................
Tenolysis, triceps ................................
Repair of biceps tendon ......................
Repair arm tendon/muscle ..................
Repair of ruptured tendon ...................
Repr elbow lat ligmnt w/tiss ................
Reconstruct elbow lat ligmnt ...............
Repr elbw med ligmnt w/tissu .............
Reconstruct elbow med ligmnt ...........
Repair elbow, perc ..............................
Repair elbow w/deb, open ..................
Repair elbow deb/attch open ..............
Reconstruct elbow joint .......................
Reconstruct elbow joint .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
3.44
4.64
7.55
4.54
12.12
6.13
12.99
2.54
14.59
18.17
20.57
16.03
5.61
0.00
2.96
1.81
6.27
5.99
9.62
2.10
5.26
3.96
6.36
11.95
4.98
6.19
8.15
3.67
7.46
10.00
12.11
6.71
8.02
8.50
6.31
10.10
8.29
8.33
9.43
7.70
7.69
15.92
13.70
16.08
10.24
11.73
11.97
7.89
6.34
1.78
4.61
1.31
3.86
10.26
7.51
6.03
10.74
9.67
10.83
7.77
7.96
9.24
10.74
8.99
14.97
8.99
14.97
5.32
6.54
8.86
12.53
14.27
3.29
NA
NA
4.85
NA
6.12
NA
NA
NA
NA
NA
NA
NA
0.00
4.98
4.35
NA
NA
NA
4.15
8.26
7.18
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.74
7.79
2.66
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.53
NA
NA
5.09
NA
6.47
NA
NA
NA
NA
NA
NA
NA
0.00
5.65
5.13
NA
NA
NA
3.68
8.60
7.26
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.07
8.80
3.14
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.82
4.15
5.68
4.26
7.92
5.13
8.23
1.90
8.86
11.20
10.41
9.21
4.85
0.00
1.98
1.75
5.09
4.75
6.59
1.92
3.92
3.26
4.59
6.85
4.09
5.04
5.80
4.02
5.65
4.32
7.67
5.17
5.99
6.00
5.12
6.90
5.76
6.48
6.57
5.64
6.28
10.76
8.49
9.68
6.16
4.87
7.41
5.82
4.89
1.36
3.66
0.46
5.16
6.83
5.65
4.73
7.02
6.63
6.94
5.91
5.96
7.52
7.06
6.98
9.95
6.93
10.03
4.72
5.27
6.19
7.84
8.75
2.79
4.16
6.03
4.49
7.37
5.48
8.16
2.04
9.63
10.68
11.06
9.56
4.96
0.00
2.14
1.96
5.50
5.08
7.17
1.83
4.02
3.33
4.72
7.29
4.30
5.49
6.33
4.20
6.15
5.76
8.37
5.55
6.07
6.51
5.57
7.87
6.49
7.13
7.83
6.84
7.43
11.19
9.24
10.59
6.94
5.22
7.90
6.35
5.33
1.49
3.94
0.45
5.43
7.50
6.18
5.15
7.27
7.25
7.81
6.34
6.47
7.71
7.79
7.56
10.73
7.47
10.68
5.15
5.73
6.19
8.65
9.66
Malpractice
RVUs 2
0.30
0.69
1.29
0.71
1.36
1.01
1.76
0.44
2.36
2.71
3.19
2.47
0.78
0.00
0.43
0.28
1.05
0.97
1.50
0.17
0.80
0.56
0.95
1.73
0.85
1.03
1.33
0.61
1.28
1.68
2.06
1.10
1.06
1.16
1.04
1.64
1.38
1.34
1.51
1.25
1.30
2.35
2.33
2.60
1.48
0.74
1.93
1.30
1.03
0.20
0.72
0.08
0.65
1.66
1.15
0.96
1.74
1.60
1.78
1.23
1.36
1.36
1.86
1.43
2.37
1.44
2.34
0.87
1.07
1.41
2.06
2.19
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00204
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
010
090
090
090
090
090
YYY
010
010
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66425
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
24362
24363
24365
24366
24400
24410
24420
24430
24435
24470
24495
24498
24500
24505
24515
24516
24530
24535
24538
24545
24546
24560
24565
24566
24575
24576
24577
24579
24582
24586
24587
24600
24605
24615
24620
24635
24640
24650
24655
24665
24666
24670
24675
24685
24800
24802
24900
24920
24925
24930
24931
24935
24940
24999
25000
25001
25020
25023
25024
25025
25028
25031
25035
25040
25065
25066
25075
25076
25077
25085
25100
25101
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Reconstruct elbow joint .......................
Replace elbow joint .............................
Reconstruct head of radius .................
Reconstruct head of radius .................
Revision of humerus ...........................
Revision of humerus ...........................
Revision of humerus ...........................
Repair of humerus ..............................
Repair humerus with graft ..................
Revision of elbow joint ........................
Decompression of forearm .................
Reinforce humerus ..............................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat elbow fracture ............................
Treat elbow fracture ............................
Treat elbow dislocation .......................
Treat elbow dislocation .......................
Treat elbow dislocation .......................
Treat elbow fracture ............................
Treat elbow fracture ............................
Treat elbow dislocation .......................
Treat radius fracture ...........................
Treat radius fracture ...........................
Treat radius fracture ...........................
Treat radius fracture ...........................
Treat ulnar fracture .............................
Treat ulnar fracture .............................
Treat ulnar fracture .............................
Fusion of elbow joint ...........................
Fusion/graft of elbow joint ...................
Amputation of upper arm ....................
Amputation of upper arm ....................
Amputation follow-up surgery .............
Amputation follow-up surgery .............
Amputate upper arm & implant ...........
Revision of amputation .......................
Revision of upper arm ........................
Upper arm/elbow surgery ...................
Incision of tendon sheath ....................
Incise flexor carpi radialis ...................
Decompress forearm 1 space ............
Decompress forearm 1 space ............
Decompress forearm 2 spaces ...........
Decompress forearm 2 spaces ...........
Drainage of forearm lesion .................
Drainage of forearm bursa ..................
Treat forearm bone lesion ..................
Explore/treat wrist joint .......................
Biopsy forearm soft tissues ................
Biopsy forearm soft tissues ................
Removal forearm lesion subcu ...........
Removal forearm lesion deep .............
Remove tumor, forearm/wrist .............
Incision of wrist capsule ......................
Biopsy of wrist joint .............................
Explore/treat wrist joint .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
15.18
22.47
8.51
9.25
11.19
14.96
13.58
15.07
14.74
8.81
8.30
12.16
3.29
5.25
11.97
12.07
3.57
6.96
9.63
12.99
14.73
2.87
5.64
8.86
9.53
2.94
5.87
11.26
9.89
15.64
15.65
4.28
5.50
9.72
7.07
8.64
1.22
2.22
4.48
8.22
9.74
2.60
4.79
8.21
11.27
14.18
10.04
10.02
7.19
10.72
13.32
16.30
0.00
0.00
3.44
3.68
5.97
13.69
10.62
17.77
5.30
4.18
7.54
7.41
2.01
4.18
3.78
4.97
9.90
5.55
3.94
4.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.45
5.83
NA
NA
4.73
6.81
NA
NA
NA
4.11
5.93
NA
NA
4.41
6.03
NA
NA
NA
NA
3.86
NA
NA
NA
NA
1.52
3.42
5.18
NA
NA
3.72
5.37
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.33
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.64
6.21
NA
NA
4.97
7.32
NA
NA
NA
4.29
6.27
NA
NA
4.58
6.48
NA
NA
NA
NA
4.36
NA
NA
NA
NA
1.68
3.60
5.56
NA
NA
3.91
5.68
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.77
NA
NA
NA
NA
NA
NA
NA
5.73
12.16
5.96
6.30
7.49
9.24
8.50
9.22
9.80
5.65
6.41
7.66
3.80
4.87
8.03
7.64
4.00
5.86
7.18
8.27
9.10
3.43
5.04
6.79
6.96
3.71
5.08
7.74
8.17
9.31
9.31
3.28
4.91
6.55
5.48
6.55
0.83
2.99
4.40
6.51
6.95
3.15
4.57
6.51
6.88
8.02
6.41
6.03
4.94
6.19
5.07
10.46
0.00
0.00
3.98
3.94
6.94
11.32
7.08
9.69
6.19
3.49
5.62
5.39
1.98
3.83
3.31
4.11
6.17
4.61
3.77
4.35
7.88
12.93
6.58
6.92
8.17
9.77
9.52
9.48
10.34
6.68
7.57
8.46
3.74
5.13
8.71
8.37
4.02
6.24
7.94
8.36
10.20
3.31
5.28
7.47
7.68
3.71
5.46
8.28
8.64
10.27
10.16
3.39
5.13
7.18
5.87
10.29
0.81
2.87
4.59
7.01
7.50
3.11
4.77
7.01
7.81
9.20
6.73
6.48
5.51
6.71
5.40
9.24
0.00
0.00
5.42
4.08
8.25
13.12
7.27
9.83
7.17
5.70
9.60
6.34
1.94
5.45
4.60
6.82
9.13
5.86
4.52
5.12
Malpractice
RVUs 2
2.61
3.02
1.41
1.52
1.93
2.58
2.18
2.22
2.28
1.48
1.18
2.07
0.50
0.89
2.03
2.03
0.57
1.18
1.64
1.83
2.74
0.44
0.93
1.30
1.87
0.46
0.95
2.03
1.48
2.65
2.53
0.50
0.89
1.60
1.07
2.29
0.12
0.35
0.70
1.41
1.62
0.41
0.81
1.52
1.63
2.38
1.53
1.61
1.14
1.68
1.90
2.14
0.00
0.00
0.55
0.55
0.93
2.04
1.36
1.83
0.81
0.63
1.24
1.15
0.15
0.64
0.55
0.74
1.42
0.85
0.59
0.75
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00205
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
66426
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
25105
25107
25109
25110
25111
25112
25115
25116
25118
25119
25120
25125
25126
25130
25135
25136
25145
25150
25151
25170
25210
25215
25230
25240
25246
25248
25250
25251
25259
25260
25263
25265
25270
25272
25274
25275
25280
25290
25295
25300
25301
25310
25312
25315
25316
25320
25332
25335
25337
25350
25355
25360
25365
25370
25375
25390
25391
25392
25393
25394
25400
25405
25415
25420
25425
25426
25430
25431
25440
25441
25442
25443
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove wrist joint lining .....................
Remove wrist joint cartilage ................
Excise tendon forearm/wrist ...............
Remove wrist tendon lesion ...............
Remove wrist tendon lesion ...............
Reremove wrist tendon lesion ............
Remove wrist/forearm lesion ..............
Remove wrist/forearm lesion ..............
Excise wrist tendon sheath .................
Partial removal of ulna ........................
Removal of forearm lesion ..................
Remove/graft forearm lesion ..............
Remove/graft forearm lesion ..............
Removal of wrist lesion .......................
Remove & graft wrist lesion ................
Remove & graft wrist lesion ................
Remove forearm bone lesion .............
Partial removal of ulna ........................
Partial removal of radius .....................
Extensive forearm surgery ..................
Removal of wrist bone ........................
Removal of wrist bones ......................
Partial removal of radius .....................
Partial removal of ulna ........................
Injection for wrist x-ray ........................
Remove forearm foreign body ............
Removal of wrist prosthesis ................
Removal of wrist prosthesis ................
Manipulate wrist w/anesthes ...............
Repair forearm tendon/muscle ...........
Repair forearm tendon/muscle ...........
Repair forearm tendon/muscle ...........
Repair forearm tendon/muscle ...........
Repair forearm tendon/muscle ...........
Repair forearm tendon/muscle ...........
Repair forearm tendon sheath ............
Revise wrist/forearm tendon ...............
Incise wrist/forearm tendon .................
Release wrist/forearm tendon .............
Fusion of tendons at wrist ..................
Fusion of tendons at wrist ..................
Transplant forearm tendon .................
Transplant forearm tendon .................
Revise palsy hand tendon(s) ..............
Revise palsy hand tendon(s) ..............
Repair/revise wrist joint .......................
Revise wrist joint .................................
Realignment of hand ...........................
Reconstruct ulna/radioulnar ................
Revision of radius ...............................
Revision of radius ...............................
Revision of ulna ..................................
Revise radius & ulna ...........................
Revise radius or ulna ..........................
Revise radius & ulna ...........................
Shorten radius or ulna ........................
Lengthen radius or ulna ......................
Shorten radius & ulna .........................
Lengthen radius & ulna .......................
Repair carpal bone, shorten ...............
Repair radius or ulna ..........................
Repair/graft radius or ulna ..................
Repair radius & ulna ...........................
Repair/graft radius & ulna ...................
Repair/graft radius or ulna ..................
Repair/graft radius & ulna ...................
Vasc graft into carpal bone .................
Repair nonunion carpal bone .............
Repair/graft wrist bone ........................
Reconstruct wrist joint .........................
Reconstruct wrist joint .........................
Reconstruct wrist joint .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.91
7.50
6.81
3.96
3.44
4.58
9.89
7.38
4.42
6.10
6.16
7.55
7.62
5.32
6.96
6.03
6.43
7.27
7.57
11.34
6.01
8.02
5.28
5.22
1.45
5.20
6.66
9.70
3.86
7.89
7.90
9.96
6.06
7.10
8.82
8.82
7.28
5.34
6.61
8.88
8.47
8.26
9.70
10.56
12.76
12.38
11.60
13.25
11.44
8.97
10.41
8.62
12.77
13.93
13.41
10.58
14.14
14.44
16.42
10.71
11.16
14.87
13.66
16.89
13.58
16.31
9.57
10.75
10.56
13.15
10.98
10.52
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.73
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.08
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.97
6.24
5.23
3.62
3.61
4.07
7.33
6.18
4.14
5.06
5.09
5.68
5.86
4.72
5.62
5.09
5.21
5.53
5.64
7.36
5.04
6.02
4.49
4.46
0.53
4.04
5.27
6.74
5.15
6.37
6.09
7.10
4.97
5.48
6.37
6.48
5.55
4.50
5.29
6.65
6.18
5.93
6.70
7.10
7.81
9.86
7.60
8.30
8.62
6.34
6.74
6.23
8.17
9.00
8.36
7.06
8.66
8.90
9.55
6.94
7.26
8.92
8.79
9.92
8.48
9.19
7.03
7.15
6.89
8.10
7.50
7.21
6.13
7.28
5.23
5.33
4.15
4.66
10.68
9.66
4.94
6.33
8.58
9.26
9.43
5.57
6.56
5.84
8.63
6.86
9.18
11.25
5.91
7.39
5.32
5.70
0.50
6.28
5.68
7.33
5.43
9.84
9.67
10.70
8.49
9.13
9.99
7.02
9.09
9.74
8.72
7.55
7.12
9.48
10.32
10.74
12.01
10.62
8.39
9.94
9.85
10.15
10.67
10.05
11.90
12.53
12.39
10.82
12.60
12.43
13.56
7.50
11.22
13.09
12.64
14.09
14.93
12.86
7.18
7.77
8.14
9.05
8.19
7.99
Malpractice
RVUs 2
0.92
0.99
0.96
0.62
0.53
0.70
1.31
1.11
0.68
0.96
1.00
1.06
1.27
0.80
1.02
1.03
1.01
1.14
1.18
1.78
0.88
1.19
0.79
0.81
0.09
0.72
1.01
1.26
0.62
1.19
1.18
1.47
0.95
1.11
1.36
1.31
1.08
0.82
1.00
1.26
1.29
1.21
1.41
1.58
1.75
1.61
1.84
1.93
1.61
1.46
1.74
1.41
2.16
2.29
2.27
1.65
2.22
2.11
2.77
1.59
1.83
2.33
2.18
2.62
2.09
2.55
1.27
1.91
1.63
2.08
1.53
1.37
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00206
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66427
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
25444
25445
25446
25447
25449
25450
25455
25490
25491
25492
25500
25505
25515
25520
25525
25526
25530
25535
25545
25560
25565
25574
25575
25600
25605
25606
25607
25608
25609
25622
25624
25628
25630
25635
25645
25650
25651
25652
25660
25670
25671
25675
25676
25680
25685
25690
25695
25800
25805
25810
25820
25825
25830
25900
25905
25907
25909
25915
25920
25922
25924
25927
25929
25931
25999
26010
26011
26020
26025
26030
26034
26035
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Reconstruct wrist joint .........................
Reconstruct wrist joint .........................
Wrist replacement ...............................
Repair wrist joint(s) .............................
Remove wrist joint implant ..................
Revision of wrist joint ..........................
Revision of wrist joint ..........................
Reinforce radius ..................................
Reinforce ulna .....................................
Reinforce radius and ulna ...................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of ulna ..........................
Treat fracture of ulna ..........................
Treat fracture of ulna ..........................
Treat fracture radius & ulna ................
Treat fracture radius & ulna ................
Treat fracture radius & ulna ................
Treat fracture radius/ulna ....................
Treat fracture radius/ulna ....................
Treat fracture radius/ulna ....................
Treat fx distal radial ............................
Treat fx rad extra-articul .....................
Treat fx rad intra-articul ......................
Treat fx radial 3+ frag .........................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Treat wrist bone fracture .....................
Pin ulnar styloid fracture .....................
Treat fracture ulnar styloid ..................
Treat wrist dislocation .........................
Treat wrist dislocation .........................
Pin radioulnar dislocation ....................
Treat wrist dislocation .........................
Treat wrist dislocation .........................
Treat wrist fracture ..............................
Treat wrist fracture ..............................
Treat wrist dislocation .........................
Treat wrist dislocation .........................
Fusion of wrist joint .............................
Fusion/graft of wrist joint .....................
Fusion/graft of wrist joint .....................
Fusion of hand bones .........................
Fuse hand bones with graft ................
Fusion, radioulnar jnt/ulna ..................
Amputation of forearm ........................
Amputation of forearm ........................
Amputation follow-up surgery .............
Amputation follow-up surgery .............
Amputation of forearm ........................
Amputate hand at wrist .......................
Amputate hand at wrist .......................
Amputation follow-up surgery .............
Amputation of hand .............................
Amputation follow-up surgery .............
Amputation follow-up surgery .............
Forearm or wrist surgery ....................
Drainage of finger abscess .................
Drainage of finger abscess .................
Drain hand tendon sheath ..................
Drainage of palm bursa ......................
Drainage of palm bursa(s) ..................
Treat hand bone lesion .......................
Decompress fingers/hand ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
11.28
9.76
17.16
10.95
14.80
7.94
9.57
9.61
10.03
12.52
2.51
5.30
8.64
6.35
10.37
12.96
2.15
5.22
7.78
2.50
5.71
8.64
12.10
2.69
7.02
8.10
9.35
10.86
14.12
2.68
4.62
9.51
2.94
4.47
7.31
3.12
5.68
7.92
4.84
7.98
6.32
4.75
8.17
6.08
9.97
5.58
8.40
9.95
11.59
11.75
7.52
9.54
10.69
9.46
9.48
7.98
9.20
17.38
8.92
7.54
8.70
8.98
7.71
7.93
0.00
1.56
2.21
4.97
4.99
6.16
6.49
11.14
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.30
5.82
NA
5.69
NA
NA
3.48
5.57
NA
3.36
5.90
NA
NA
3.68
6.86
NA
NA
NA
NA
3.90
5.63
NA
3.75
5.11
NA
3.84
NA
NA
NA
NA
NA
4.71
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.06
6.24
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.44
6.18
NA
6.27
NA
NA
3.62
5.79
NA
3.53
6.30
NA
NA
3.88
7.04
NA
NA
NA
NA
4.08
5.96
NA
3.96
5.53
NA
4.07
NA
NA
NA
NA
NA
5.18
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.81
7.53
NA
NA
NA
NA
NA
7.43
6.69
9.98
7.86
8.95
3.84
6.84
6.57
6.78
8.33
2.86
4.98
6.46
5.14
7.41
8.68
2.97
4.83
6.23
2.85
4.92
6.55
8.36
3.17
6.13
6.69
7.19
7.79
9.65
3.35
4.77
6.84
3.25
4.34
5.55
3.44
5.15
6.16
4.32
5.81
5.53
3.99
6.13
4.38
6.62
4.85
6.00
6.79
7.67
8.03
6.41
7.65
10.57
6.73
6.06
5.77
6.32
5.97
6.59
6.27
6.12
8.65
5.66
8.32
0.00
1.52
1.96
4.74
4.46
5.00
5.57
8.12
8.23
7.34
10.94
8.26
9.81
7.01
8.85
10.15
10.62
11.81
2.79
5.20
6.96
5.60
8.70
11.09
2.92
5.06
6.94
2.73
5.17
6.87
8.93
3.07
6.17
7.82
7.19
7.79
9.65
3.23
4.92
7.33
3.09
4.12
6.09
3.31
5.31
6.58
4.51
6.40
5.84
4.32
6.71
4.56
7.21
5.17
6.54
7.94
8.96
8.97
7.12
8.44
12.49
9.64
9.17
8.76
9.30
12.42
7.21
6.66
7.10
10.16
5.77
9.89
0.00
1.57
2.14
5.05
4.78
5.36
5.96
7.99
Malpractice
RVUs 2
1.72
1.55
2.48
1.61
2.22
1.36
0.96
1.43
1.60
2.15
0.35
0.90
1.59
1.08
2.13
2.20
0.34
0.89
1.53
0.35
0.93
1.21
1.82
0.42
1.00
1.26
1.36
1.84
2.38
0.41
0.76
1.37
0.45
0.74
1.20
0.45
0.86
1.21
0.58
1.28
1.00
0.62
1.34
0.78
1.60
0.88
1.32
1.57
1.81
1.68
1.22
1.41
1.55
1.30
1.40
1.10
1.44
2.94
1.35
1.12
1.32
1.27
1.14
1.15
0.00
0.18
0.33
0.73
0.76
0.92
1.01
1.47
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00207
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
010
010
090
090
090
090
090
66428
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
26037
26040
26045
26055
26060
26070
26075
26080
26100
26105
26110
26115
26116
26117
26121
26123
26125
26130
26135
26140
26145
26160
26170
26180
26185
26200
26205
26210
26215
26230
26235
26236
26250
26255
26260
26261
26262
26320
26340
26350
26352
26356
26357
26358
26370
26372
26373
26390
26392
26410
26412
26415
26416
26418
26420
26426
26428
26432
26433
26434
26437
26440
26442
26445
26449
26450
26455
26460
26471
26474
26476
26477
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Decompress fingers/hand ...................
Release palm contracture ...................
Release palm contracture ...................
Incise finger tendon sheath ................
Incision of finger tendon .....................
Explore/treat hand joint .......................
Explore/treat finger joint ......................
Explore/treat finger joint ......................
Biopsy hand joint lining .......................
Biopsy finger joint lining ......................
Biopsy finger joint lining ......................
Removal hand lesion subcut ..............
Removal hand lesion, deep ................
Remove tumor, hand/finger ................
Release palm contracture ...................
Release palm contracture ...................
Release palm contracture ...................
Remove wrist joint lining .....................
Revise finger joint, each .....................
Revise finger joint, each .....................
Tendon excision, palm/finger ..............
Remove tendon sheath lesion ............
Removal of palm tendon, each ...........
Removal of finger tendon ...................
Remove finger bone ...........................
Remove hand bone lesion ..................
Remove/graft bone lesion ...................
Removal of finger lesion .....................
Remove/graft finger lesion ..................
Partial removal of hand bone .............
Partial removal, finger bone ................
Partial removal, finger bone ................
Extensive hand surgery ......................
Extensive hand surgery ......................
Extensive finger surgery .....................
Extensive finger surgery .....................
Partial removal of finger ......................
Removal of implant from hand ...........
Manipulate finger w/anesth .................
Repair finger/hand tendon ..................
Repair/graft hand tendon ....................
Repair finger/hand tendon ..................
Repair finger/hand tendon ..................
Repair/graft hand tendon ....................
Repair finger/hand tendon ..................
Repair/graft hand tendon ....................
Repair finger/hand tendon ..................
Revise hand/finger tendon ..................
Repair/graft hand tendon ....................
Repair hand tendon ............................
Repair/graft hand tendon ....................
Excision, hand/finger tendon ..............
Graft hand or finger tendon ................
Repair finger tendon ...........................
Repair/graft finger tendon ...................
Repair finger/hand tendon ..................
Repair/graft finger tendon ...................
Repair finger tendon ...........................
Repair finger tendon ...........................
Repair/graft finger tendon ...................
Realignment of tendons ......................
Release palm/finger tendon ................
Release palm & finger tendon ............
Release hand/finger tendon ................
Release forearm/hand tendon ............
Incision of palm tendon .......................
Incision of finger tendon .....................
Incise hand/finger tendon ...................
Fusion of finger tendons .....................
Fusion of finger tendons .....................
Tendon lengthening ............................
Tendon shortening ..............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
7.48
3.38
5.62
3.00
2.85
3.73
3.83
4.36
3.71
3.75
3.57
3.92
5.61
8.62
7.61
10.63
4.60
5.48
7.02
6.23
6.38
3.46
4.82
5.24
6.32
5.56
7.82
5.21
7.16
6.38
6.24
5.37
7.61
12.80
7.09
9.28
5.72
4.02
2.62
6.07
7.75
10.22
8.65
9.22
7.17
8.89
8.29
9.31
10.38
4.68
6.37
8.40
9.44
4.33
6.83
6.21
7.28
4.07
4.61
6.15
5.88
5.07
9.50
4.36
8.34
3.71
3.68
3.50
5.79
5.38
5.24
5.21
NA
NA
NA
9.04
NA
NA
NA
NA
NA
NA
NA
9.83
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.03
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
11.69
NA
NA
NA
NA
NA
NA
NA
11.46
NA
NA
NA
NA
NA
NA
NA
NA
NA
10.70
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.49
3.60
4.88
3.82
3.05
3.05
3.37
4.32
3.66
3.68
3.60
4.23
5.30
6.18
5.92
8.21
1.87
4.88
5.47
5.16
5.18
3.94
4.37
4.71
5.73
4.55
5.85
4.73
5.54
4.95
4.94
4.57
5.71
8.28
5.46
6.72
4.74
3.79
4.60
9.52
10.06
13.70
10.35
10.94
9.50
10.53
10.16
9.20
11.16
7.63
8.62
7.46
9.04
8.14
8.80
5.11
9.25
6.78
7.01
7.93
7.81
8.48
11.81
8.23
7.27
5.19
5.15
5.11
7.79
7.60
7.35
7.57
5.91
3.82
5.26
3.88
3.28
3.21
3.57
4.58
3.89
3.95
3.82
4.49
5.65
6.62
6.44
8.53
2.15
5.11
5.96
5.60
5.62
4.03
4.65
5.06
5.88
4.95
6.37
5.08
5.92
5.43
5.38
4.95
6.07
8.82
5.82
6.44
5.04
4.05
4.74
12.06
12.70
16.03
12.99
13.79
12.30
13.52
13.10
11.24
13.94
9.78
10.94
9.62
11.81
10.23
11.21
9.13
11.55
8.52
8.90
9.73
9.68
10.95
13.87
10.68
11.52
6.26
6.21
6.12
9.51
9.49
9.14
9.31
Malpractice
RVUs 2
1.13
0.53
0.93
0.43
0.45
0.48
0.53
0.66
0.54
0.59
0.53
0.59
0.84
1.26
1.17
1.43
0.70
0.94
1.07
0.92
0.97
0.49
0.69
0.78
0.81
0.88
1.20
0.79
0.98
1.01
0.95
0.81
1.07
1.69
1.01
1.14
0.88
0.59
0.39
0.93
1.13
1.21
1.33
1.38
1.12
1.40
1.23
1.40
1.57
0.73
0.97
0.98
0.79
0.67
1.07
0.95
1.09
0.64
0.72
0.93
0.89
0.75
1.20
0.65
1.06
0.59
0.58
0.55
0.88
0.76
0.79
0.81
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00208
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66429
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
26478
26479
26480
26483
26485
26489
26490
26492
26494
26496
26497
26498
26499
26500
26502
26508
26510
26516
26517
26518
26520
26525
26530
26531
26535
26536
26540
26541
26542
26545
26546
26548
26550
26551
26553
26554
26555
26556
26560
26561
26562
26565
26567
26568
26580
26587
26590
26591
26593
26596
26600
26605
26607
26608
26615
26641
26645
26650
26665
26670
26675
26676
26685
26686
26700
26705
26706
26715
26720
26725
26727
26735
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Lengthening of hand tendon ...............
Shortening of hand tendon .................
Transplant hand tendon ......................
Transplant/graft hand tendon ..............
Transplant palm tendon ......................
Transplant/graft palm tendon ..............
Revise thumb tendon ..........................
Tendon transfer with graft ...................
Hand tendon/muscle transfer ..............
Revise thumb tendon ..........................
Finger tendon transfer ........................
Finger tendon transfer ........................
Revision of finger ................................
Hand tendon reconstruction ................
Hand tendon reconstruction ................
Release thumb contracture .................
Thumb tendon transfer .......................
Fusion of knuckle joint ........................
Fusion of knuckle joints ......................
Fusion of knuckle joints ......................
Release knuckle contracture ..............
Release finger contracture ..................
Revise knuckle joint ............................
Revise knuckle with implant ...............
Revise finger joint ...............................
Revise/implant finger joint ...................
Repair hand joint .................................
Repair hand joint with graft .................
Repair hand joint with graft .................
Reconstruct finger joint .......................
Repair nonunion hand ........................
Reconstruct finger joint .......................
Construct thumb replacement .............
Great toe-hand transfer ......................
Single transfer, toe-hand ....................
Double transfer, toe-hand ...................
Positional change of finger .................
Toe joint transfer .................................
Repair of web finger ...........................
Repair of web finger ...........................
Repair of web finger ...........................
Correct metacarpal flaw ......................
Correct finger deformity ......................
Lengthen metacarpal/finger ................
Repair hand deformity ........................
Reconstruct extra finger ......................
Repair finger deformity .......................
Repair muscles of hand ......................
Release muscles of hand ...................
Excision constricting tissue .................
Treat metacarpal fracture ...................
Treat metacarpal fracture ...................
Treat metacarpal fracture ...................
Treat metacarpal fracture ...................
Treat metacarpal fracture ...................
Treat thumb dislocation ......................
Treat thumb fracture ...........................
Treat thumb fracture ...........................
Treat thumb fracture ...........................
Treat hand dislocation ........................
Treat hand dislocation ........................
Pin hand dislocation ............................
Treat hand dislocation ........................
Treat hand dislocation ........................
Treat knuckle dislocation ....................
Treat knuckle dislocation ....................
Pin knuckle dislocation .......................
Treat knuckle dislocation ....................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.86
5.80
6.76
8.36
7.77
9.74
8.48
9.70
8.54
9.66
9.64
14.07
9.05
6.02
7.20
6.07
5.49
7.21
8.96
9.15
5.36
5.39
6.76
7.99
5.30
6.44
6.49
8.69
6.84
6.99
10.53
8.10
21.54
48.23
47.92
56.73
16.94
49.43
5.43
10.98
16.40
6.80
6.88
9.15
19.50
14.36
18.51
3.30
5.38
9.02
2.48
2.92
5.40
5.43
6.91
4.01
4.47
5.19
7.78
3.74
4.71
5.60
6.91
8.06
3.74
4.26
5.19
6.87
1.70
3.39
5.30
7.26
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.83
4.08
NA
NA
NA
4.03
4.60
NA
NA
3.62
5.25
NA
NA
NA
3.30
4.74
NA
NA
2.58
4.08
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.72
4.32
NA
NA
NA
4.30
4.88
NA
NA
3.94
5.36
NA
NA
NA
3.53
5.04
NA
NA
2.68
4.42
NA
NA
7.78
7.73
9.65
10.22
10.07
10.82
8.87
9.82
9.23
9.57
9.52
11.65
8.84
7.74
8.32
7.80
7.63
8.30
8.99
8.96
8.86
8.88
5.41
6.16
4.09
9.24
8.05
9.11
8.19
8.45
11.42
8.80
14.53
17.15
27.34
35.78
13.99
18.03
6.65
9.50
8.76
8.15
8.11
10.69
9.73
8.01
12.41
6.21
7.79
7.48
3.49
3.50
4.88
5.22
6.01
3.40
3.92
4.88
6.31
3.03
4.51
5.56
5.97
6.07
2.93
4.04
4.70
5.99
2.30
3.41
5.18
6.12
9.80
9.64
12.34
12.85
12.71
11.43
10.84
11.71
11.10
11.40
11.54
13.90
10.94
9.59
10.17
9.73
9.48
10.26
11.24
11.17
11.37
11.42
5.77
6.64
3.91
9.44
9.96
11.25
10.11
10.29
13.22
10.82
16.05
24.79
25.01
36.65
16.08
25.67
8.22
10.92
12.95
10.07
10.03
13.05
11.68
8.61
13.17
7.91
9.46
8.15
3.07
3.58
5.58
5.74
5.66
3.46
4.05
5.78
6.46
2.99
4.49
6.12
6.05
6.48
2.89
4.17
4.89
5.75
2.18
3.45
5.70
5.84
Malpractice
RVUs 2
0.90
0.92
1.02
1.26
1.15
1.26
1.21
1.40
1.28
1.45
1.41
2.11
1.35
0.90
1.13
0.98
0.79
1.10
1.41
1.35
0.80
0.81
1.04
1.17
0.71
0.96
0.99
1.28
1.02
1.05
1.44
1.20
2.46
7.98
2.42
9.44
2.49
2.58
0.85
1.45
2.24
1.00
1.04
1.49
2.29
1.53
2.78
0.48
0.78
1.43
0.30
0.49
0.87
0.88
0.86
0.39
0.67
0.94
0.90
0.39
0.77
0.91
1.09
1.24
0.35
0.66
0.81
0.91
0.24
0.53
0.84
0.95
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00209
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66430
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
26740
26742
26746
26750
26755
26756
26765
26770
26775
26776
26785
26820
26841
26842
26843
26844
26850
26852
26860
26861
26862
26863
26910
26951
26952
26989
26990
26991
26992
27000
27001
27003
27005
27006
27025
27030
27033
27035
27036
27040
27041
27047
27048
27049
27050
27052
27054
27060
27062
27065
27066
27067
27070
27071
27075
27076
27077
27078
27079
27080
27086
27087
27090
27091
27093
27095
27096
27097
27098
27100
27105
27110
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Pin finger fracture, each .....................
Treat finger fracture, each ..................
Treat finger dislocation .......................
Treat finger dislocation .......................
Pin finger dislocation ...........................
Treat finger dislocation .......................
Thumb fusion with graft ......................
Fusion of thumb ..................................
Thumb fusion with graft ......................
Fusion of hand joint ............................
Fusion/graft of hand joint ....................
Fusion of knuckle ................................
Fusion of knuckle with graft ................
Fusion of finger joint ...........................
Fusion of finger jnt, add-on .................
Fusion/graft of finger joint ...................
Fuse/graft added joint .........................
Amputate metacarpal bone .................
Amputation of finger/thumb .................
Amputation of finger/thumb .................
Hand/finger surgery ............................
Drainage of pelvis lesion ....................
Drainage of pelvis bursa .....................
Drainage of bone lesion ......................
Incision of hip tendon ..........................
Incision of hip tendon ..........................
Incision of hip tendon ..........................
Incision of hip tendon ..........................
Incision of hip tendons ........................
Incision of hip/thigh fascia ..................
Drainage of hip joint ............................
Exploration of hip joint ........................
Denervation of hip joint .......................
Excision of hip joint/muscle ................
Biopsy of soft tissues ..........................
Biopsy of soft tissues ..........................
Remove hip/pelvis lesion ....................
Remove hip/pelvis lesion ....................
Remove tumor, hip/pelvis ...................
Biopsy of sacroiliac joint .....................
Biopsy of hip joint ...............................
Removal of hip joint lining ..................
Removal of ischial bursa ....................
Remove femur lesion/bursa ................
Removal of hip bone lesion ................
Removal of hip bone lesion ................
Remove/graft hip bone lesion .............
Partial removal of hip bone .................
Partial removal of hip bone .................
Extensive hip surgery .........................
Extensive hip surgery .........................
Extensive hip surgery .........................
Extensive hip surgery .........................
Extensive hip surgery .........................
Removal of tail bone ...........................
Remove hip foreign body ....................
Remove hip foreign body ....................
Removal of hip prosthesis ..................
Removal of hip prosthesis ..................
Injection for hip x-ray ..........................
Injection for hip x-ray ..........................
Inject sacroiliac joint ............................
Revision of hip tendon ........................
Transfer tendon to pelvis ....................
Transfer of abdominal muscle ............
Transfer of spinal muscle ...................
Transfer of iliopsoas muscle ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.99
3.90
9.59
1.74
3.15
4.46
5.70
3.07
3.78
4.87
6.44
8.33
7.21
8.37
7.67
8.86
7.03
8.59
4.76
1.74
7.44
3.89
7.67
5.85
6.37
0.00
7.84
6.97
13.37
5.66
7.05
7.70
9.96
9.99
12.66
13.54
13.99
17.23
14.18
2.89
10.07
7.51
6.44
15.20
4.65
7.27
9.09
5.78
5.66
6.44
11.06
14.57
11.44
12.25
36.77
24.25
42.54
14.54
14.91
6.80
1.89
8.72
11.57
24.15
1.30
1.50
1.40
9.16
9.20
11.21
11.90
13.63
3.01
4.26
NA
2.25
3.74
NA
NA
2.92
4.62
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
8.61
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.19
NA
7.02
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.66
NA
NA
NA
3.15
3.71
2.52
NA
NA
NA
NA
NA
3.07
4.62
NA
2.36
4.08
NA
NA
3.17
4.90
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
9.88
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.21
NA
7.06
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.10
NA
NA
NA
3.80
4.71
3.43
NA
NA
NA
NA
NA
2.71
3.56
7.19
2.26
2.94
4.86
5.47
2.54
3.88
4.98
5.77
8.96
8.76
9.01
8.56
9.15
8.26
9.13
7.53
0.70
8.66
1.58
8.27
8.39
7.90
0.00
6.20
4.88
8.41
4.51
5.22
5.72
6.48
6.75
8.20
8.03
8.39
8.52
8.91
1.87
5.73
4.49
4.60
8.16
3.01
5.64
6.49
4.36
4.60
4.99
7.43
8.83
8.02
8.47
16.13
12.82
19.92
8.81
8.00
4.58
1.48
5.65
7.40
12.90
0.47
0.51
0.33
6.33
4.91
7.39
7.35
8.27
2.71
3.72
6.38
2.14
2.97
5.29
4.93
2.48
3.84
5.49
5.15
11.10
10.99
11.19
10.45
11.25
10.23
11.01
9.35
0.81
10.50
1.85
9.74
9.27
9.78
0.00
6.70
5.15
9.39
4.90
5.66
6.10
7.15
7.36
8.37
8.83
9.15
9.87
9.45
1.94
6.18
4.63
4.70
8.28
3.71
5.76
6.91
4.37
4.89
5.21
7.93
9.74
8.58
9.29
17.66
13.66
21.29
9.37
8.77
4.70
1.65
6.15
8.09
13.44
0.48
0.51
0.33
6.37
5.96
8.03
8.25
8.69
Malpractice
RVUs 2
0.31
0.58
0.91
0.22
0.42
0.71
0.66
0.27
0.54
0.77
0.68
1.30
1.18
1.32
1.15
1.33
1.06
1.22
0.73
0.27
1.10
0.56
1.16
0.71
0.95
0.00
1.22
1.11
2.17
0.98
1.24
1.12
1.73
1.70
1.85
2.27
2.33
2.16
2.27
0.27
1.35
1.03
0.92
2.07
0.60
1.08
1.47
0.80
0.93
1.01
1.80
1.85
1.75
1.93
5.66
3.71
6.14
2.23
1.95
0.93
0.25
1.35
1.95
3.85
0.13
0.14
0.08
1.57
0.95
1.86
1.73
2.19
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00210
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
ZZZ
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
000
000
000
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66431
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27111
27120
27122
27125
27130
27132
27134
27137
27138
27140
27146
27147
27151
27156
27158
27161
27165
27170
27175
27176
27177
27178
27179
27181
27185
27187
27193
27194
27200
27202
27215
27216
27217
27218
27220
27222
27226
27227
27228
27230
27232
27235
27236
27238
27240
27244
27245
27246
27248
27250
27252
27253
27254
27256
27257
27258
27259
27265
27266
27267
27268
27269
27275
27280
27282
27284
27286
27290
27295
27299
27301
27303
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Transfer of iliopsoas muscle ...............
Reconstruction of hip socket ..............
Reconstruction of hip socket ..............
Partial hip replacement .......................
Total hip arthroplasty ..........................
Total hip arthroplasty ..........................
Revise hip joint replacement ..............
Revise hip joint replacement ..............
Revise hip joint replacement ..............
Transplant femur ridge ........................
Incision of hip bone .............................
Revision of hip bone ...........................
Incision of hip bones ...........................
Revision of hip bones .........................
Revision of pelvis ................................
Incision of neck of femur ....................
Incision/fixation of femur .....................
Repair/graft femur head/neck .............
Treat slipped epiphysis .......................
Treat slipped epiphysis .......................
Treat slipped epiphysis .......................
Treat slipped epiphysis .......................
Revise head/neck of femur .................
Treat slipped epiphysis .......................
Revision of femur epiphysis ................
Reinforce hip bones ............................
Treat pelvic ring fracture .....................
Treat pelvic ring fracture .....................
Treat tail bone fracture .......................
Treat tail bone fracture .......................
Treat pelvic fracture(s) ........................
Treat pelvic ring fracture .....................
Treat pelvic ring fracture .....................
Treat pelvic ring fracture .....................
Treat hip socket fracture .....................
Treat hip socket fracture .....................
Treat hip wall fracture .........................
Treat hip fracture(s) ............................
Treat hip fracture(s) ............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat thigh fracture .............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Treat hip dislocation ............................
Cltx thigh fx .........................................
Cltx thigh fx w/mnpj ............................
Optx thigh fx ........................................
Manipulation of hip joint ......................
Fusion of sacroiliac joint .....................
Fusion of pubic bones ........................
Fusion of hip joint ...............................
Fusion of hip joint ...............................
Amputation of leg at hip ......................
Amputation of leg at hip ......................
Pelvis/hip joint surgery ........................
Drain thigh/knee lesion .......................
Drainage of bone lesion ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
12.46
19.10
15.95
16.46
21.61
25.49
30.13
22.55
23.55
12.66
18.72
21.87
23.92
26.03
20.89
17.74
20.06
17.46
9.29
12.78
15.94
12.78
13.83
15.98
9.67
14.09
5.98
10.08
1.87
7.25
10.45
15.73
14.65
20.93
6.72
13.97
15.45
25.21
29.13
5.69
11.66
12.88
17.43
5.64
13.66
17.08
21.09
4.75
10.64
7.21
10.92
13.46
18.80
4.25
5.35
16.04
23.03
5.12
7.67
5.38
7.00
18.75
2.29
14.49
11.71
24.91
24.97
24.38
19.54
0.00
6.67
8.52
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.62
NA
2.07
NA
NA
NA
NA
NA
5.24
NA
NA
NA
NA
4.93
NA
NA
NA
NA
NA
NA
NA
3.91
NA
NA
NA
NA
NA
2.52
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
8.19
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.85
NA
2.15
NA
NA
NA
NA
NA
5.48
NA
NA
NA
NA
5.22
NA
NA
NA
NA
NA
NA
NA
4.18
NA
NA
NA
NA
NA
3.02
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
9.13
NA
8.06
10.81
9.43
9.59
11.76
13.42
14.67
11.72
12.10
7.87
10.68
12.00
12.87
13.71
11.51
10.35
11.56
9.75
5.16
8.17
9.63
7.97
8.56
9.73
6.64
8.68
4.75
6.60
2.22
4.90
6.54
9.13
8.62
11.32
5.14
8.51
8.92
13.37
14.83
4.86
6.09
7.97
10.13
4.65
8.20
9.61
11.33
3.94
6.37
4.29
6.48
8.16
10.53
1.41
2.54
9.47
12.77
3.94
5.50
4.39
5.02
9.88
1.85
8.87
7.77
12.00
12.60
12.10
9.57
0.00
4.64
5.99
8.60
11.32
10.23
10.10
12.53
14.52
16.23
12.82
13.24
8.64
11.40
12.62
10.41
14.88
11.23
11.22
12.23
10.52
5.91
8.59
10.26
8.19
9.27
9.96
7.08
9.50
4.92
7.12
2.19
10.88
6.81
9.36
9.38
11.35
5.39
9.24
8.36
14.38
16.22
4.98
6.63
8.71
10.58
4.89
8.83
10.45
12.53
4.18
7.29
4.45
6.95
8.97
11.27
1.74
2.67
10.17
13.44
4.36
5.92
4.39
5.02
9.88
1.97
9.56
7.88
13.37
14.19
13.07
10.44
0.00
4.89
6.48
Malpractice
RVUs 2
1.95
3.09
2.62
2.55
3.51
4.05
4.95
3.68
3.85
2.12
2.97
3.58
3.92
4.22
3.17
2.95
3.11
2.82
1.46
2.23
2.62
2.09
2.26
1.57
2.40
2.38
0.96
1.65
0.28
1.06
1.98
2.64
2.42
3.49
1.07
2.20
2.49
4.06
4.67
0.95
1.86
2.12
2.72
0.89
2.17
2.78
3.53
0.81
1.82
0.62
1.66
2.25
3.18
0.46
0.69
2.65
3.75
0.63
1.29
0.89
1.16
2.93
0.39
2.54
1.87
3.93
3.13
3.44
2.96
0.00
1.04
1.43
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00211
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
010
090
090
090
090
090
090
090
010
090
090
090
090
090
090
YYY
090
090
66432
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27305
27306
27307
27310
27323
27324
27325
27326
27327
27328
27329
27330
27331
27332
27333
27334
27335
27340
27345
27347
27350
27355
27356
27357
27358
27360
27365
27370
27372
27380
27381
27385
27386
27390
27391
27392
27393
27394
27395
27396
27397
27400
27403
27405
27407
27409
27412
27415
27416
27418
27420
27422
27424
27425
27427
27428
27429
27430
27435
27437
27438
27440
27441
27442
27443
27445
27446
27447
27448
27450
27454
27455
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Incise thigh tendon & fascia ...............
Incision of thigh tendon .......................
Incision of thigh tendons .....................
Exploration of knee joint .....................
Biopsy, thigh soft tissues ....................
Biopsy, thigh soft tissues ....................
Neurectomy, hamstring .......................
Neurectomy, popliteal .........................
Removal of thigh lesion ......................
Removal of thigh lesion ......................
Remove tumor, thigh/knee ..................
Biopsy, knee joint lining ......................
Explore/treat knee joint .......................
Removal of knee cartilage ..................
Removal of knee cartilage ..................
Remove knee joint lining ....................
Remove knee joint lining ....................
Removal of kneecap bursa .................
Removal of knee cyst .........................
Remove knee cyst ..............................
Removal of kneecap ...........................
Remove femur lesion ..........................
Remove femur lesion/graft ..................
Remove femur lesion/graft ..................
Remove femur lesion/fixation .............
Partial removal, leg bone(s) ................
Extensive leg surgery .........................
Injection for knee x-ray .......................
Removal of foreign body .....................
Repair of kneecap tendon ..................
Repair/graft kneecap tendon ..............
Repair of thigh muscle ........................
Repair/graft of thigh muscle ................
Incision of thigh tendon .......................
Incision of thigh tendons .....................
Incision of thigh tendons .....................
Lengthening of thigh tendon ...............
Lengthening of thigh tendons .............
Lengthening of thigh tendons .............
Transplant of thigh tendon ..................
Transplants of thigh tendons ..............
Revise thigh muscles/tendons ............
Repair of knee cartilage ......................
Repair of knee ligament ......................
Repair of knee ligament ......................
Repair of knee ligaments ....................
Autochondrocyte implant knee ...........
Osteochondral knee allograft ..............
Osteochondral knee autograft ............
Repair degenerated kneecap .............
Revision of unstable kneecap .............
Revision of unstable kneecap .............
Revision/removal of kneecap ..............
Lat retinacular release open ...............
Reconstruction, knee ..........................
Reconstruction, knee ..........................
Reconstruction, knee ..........................
Revision of thigh muscles ...................
Incision of knee joint ...........................
Revise kneecap ..................................
Revise kneecap with implant ..............
Revision of knee joint .........................
Revision of knee joint .........................
Revision of knee joint .........................
Revision of knee joint .........................
Revision of knee joint .........................
Revision of knee joint .........................
Total knee arthroplasty .......................
Incision of thigh ...................................
Incision of thigh ...................................
Realignment of thigh bone ..................
Realignment of knee ...........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.09
4.66
5.97
9.88
2.30
4.95
7.09
6.36
4.52
5.62
15.68
5.02
5.93
8.34
7.43
9.07
10.43
4.23
5.98
6.58
8.54
7.89
9.97
11.02
4.73
11.34
17.93
0.96
5.12
7.34
10.64
8.00
10.99
5.44
7.38
9.51
6.50
8.68
12.10
8.04
12.46
9.21
8.51
8.96
10.71
13.57
24.53
19.79
14.00
11.46
10.14
10.09
10.12
5.28
9.67
15.33
17.24
10.04
10.68
8.82
11.77
10.97
11.42
12.25
11.29
18.52
16.26
23.04
11.48
14.47
18.97
13.24
NA
NA
NA
NA
4.19
NA
NA
NA
6.03
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.99
8.30
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.85
NA
NA
NA
6.01
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.36
9.17
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.68
4.07
4.74
6.77
1.93
3.82
4.99
5.12
3.57
4.06
8.46
4.26
4.79
6.12
5.68
6.43
7.01
4.03
4.88
5.25
6.24
5.80
6.83
7.47
1.81
8.04
10.40
0.36
4.04
6.05
7.56
6.30
7.92
4.46
5.54
6.66
4.95
6.14
7.92
5.82
8.34
6.51
6.02
6.38
6.82
8.25
13.64
11.77
8.38
7.57
6.90
6.87
6.89
4.70
6.69
10.03
11.25
6.84
7.58
6.18
7.49
6.99
7.35
7.64
7.34
10.40
9.28
12.56
7.31
8.83
10.72
8.30
4.93
4.39
5.06
7.17
1.90
4.00
4.96
5.17
3.65
4.21
8.74
4.41
5.16
6.62
6.17
6.92
7.61
4.29
5.25
5.34
6.74
6.29
7.34
8.08
2.16
8.79
11.04
0.34
4.36
6.66
8.32
6.96
8.71
4.78
6.05
7.12
5.39
6.68
8.62
6.41
8.69
6.88
6.60
6.93
7.57
9.10
14.22
12.16
8.38
8.23
7.50
7.49
7.49
5.11
7.24
10.63
11.83
7.41
8.03
6.71
8.01
6.49
7.03
8.27
8.03
11.38
10.27
13.58
7.95
9.70
11.61
9.09
Malpractice
RVUs 2
1.01
0.85
1.04
1.61
0.24
0.75
1.09
1.06
0.64
0.84
2.15
0.86
1.02
1.43
1.26
1.51
1.75
0.72
1.00
0.98
1.41
1.32
1.65
1.96
0.82
1.84
2.80
0.08
0.84
1.24
1.80
1.36
1.86
0.92
1.23
1.57
1.10
1.47
2.05
1.34
1.83
1.31
1.44
1.51
1.79
2.25
4.36
4.36
2.32
1.89
1.72
1.71
1.71
0.90
1.63
2.43
2.71
1.70
1.70
1.49
1.96
1.82
1.89
2.10
1.91
3.09
2.81
3.80
1.95
2.43
3.13
2.25
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00212
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66433
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27457
27465
27466
27468
27470
27472
27475
27477
27479
27485
27486
27487
27488
27495
27496
27497
27498
27499
27500
27501
27502
27503
27506
27507
27508
27509
27510
27511
27513
27514
27516
27517
27519
27520
27524
27530
27532
27535
27536
27538
27540
27550
27552
27556
27557
27558
27560
27562
27566
27570
27580
27590
27591
27592
27594
27596
27598
27599
27600
27601
27602
27603
27604
27605
27606
27607
27610
27612
27613
27614
27615
27618
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Realignment of knee ...........................
Shortening of thigh bone ....................
Lengthening of thigh bone ..................
Shorten/lengthen thighs ......................
Repair of thigh ....................................
Repair/graft of thigh ............................
Surgery to stop leg growth .................
Surgery to stop leg growth .................
Surgery to stop leg growth .................
Surgery to stop leg growth .................
Revise/replace knee joint ....................
Revise/replace knee joint ....................
Removal of knee prosthesis ...............
Reinforce thigh ....................................
Decompression of thigh/knee .............
Decompression of thigh/knee .............
Decompression of thigh/knee .............
Decompression of thigh/knee .............
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treat thigh fx growth plate ..................
Treat thigh fx growth plate ..................
Treat thigh fx growth plate ..................
Treat kneecap fracture ........................
Treat kneecap fracture ........................
Treat knee fracture .............................
Treat knee fracture .............................
Treat knee fracture .............................
Treat knee fracture .............................
Treat knee fracture(s) .........................
Treat knee fracture .............................
Treat knee dislocation .........................
Treat knee dislocation .........................
Treat knee dislocation .........................
Treat knee dislocation .........................
Treat knee dislocation .........................
Treat kneecap dislocation ...................
Treat kneecap dislocation ...................
Treat kneecap dislocation ...................
Fixation of knee joint ...........................
Fusion of knee ....................................
Amputate leg at thigh ..........................
Amputate leg at thigh ..........................
Amputate leg at thigh ..........................
Amputation follow-up surgery .............
Amputation follow-up surgery .............
Amputate lower leg at knee ................
Leg surgery procedure ........................
Decompression of lower leg ...............
Decompression of lower leg ...............
Decompression of lower leg ...............
Drain lower leg lesion .........................
Drain lower leg bursa ..........................
Incision of achilles tendon ..................
Incision of achilles tendon ..................
Treat lower leg bone lesion ................
Explore/treat ankle joint ......................
Exploration of ankle joint ....................
Biopsy lower leg soft tissue ................
Biopsy lower leg soft tissue ................
Remove tumor, lower leg ....................
Remove lower leg lesion ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
13.92
18.44
17.13
19.82
16.97
18.57
8.82
10.03
13.04
9.02
20.92
26.91
17.40
16.40
6.66
7.70
8.54
9.31
6.21
6.34
11.24
11.13
19.42
14.39
6.08
8.02
9.68
14.97
19.11
14.46
5.45
8.98
13.11
2.93
10.25
3.97
7.43
13.27
17.19
4.95
11.16
5.84
8.04
12.86
15.76
18.25
3.88
5.86
12.59
1.76
20.90
13.35
13.82
10.86
7.17
11.15
11.08
0.00
5.94
5.94
7.71
5.12
4.51
2.89
4.15
8.51
9.01
8.01
2.19
5.71
12.93
5.14
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.36
5.00
NA
NA
NA
NA
5.68
NA
NA
NA
NA
NA
5.71
NA
NA
4.10
NA
4.82
6.39
NA
NA
5.51
NA
5.21
NA
NA
NA
NA
4.24
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
7.04
6.48
5.15
NA
NA
NA
NA
3.91
7.75
NA
6.43
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.74
5.40
NA
NA
NA
NA
6.07
NA
NA
NA
NA
NA
6.03
NA
NA
4.31
NA
5.06
6.87
NA
NA
5.82
NA
5.61
NA
NA
NA
NA
4.54
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
7.26
6.28
6.41
NA
NA
NA
NA
3.57
7.44
NA
6.22
8.22
10.28
10.05
11.16
10.15
10.63
6.19
6.59
8.84
6.21
11.62
13.97
10.24
9.59
4.97
4.98
5.18
5.98
4.58
4.91
6.85
7.21
11.35
8.12
5.05
6.53
6.26
8.10
9.74
7.88
5.07
6.41
7.38
3.52
6.93
4.26
5.62
7.44
10.19
4.89
7.38
4.50
6.08
7.25
8.44
9.28
3.71
4.61
7.88
1.61
12.17
6.01
7.34
5.45
4.72
5.97
6.19
0.00
3.79
4.17
4.29
3.90
3.42
1.74
2.62
5.70
6.10
5.17
1.77
3.93
7.27
3.80
9.07
10.25
10.94
11.75
10.96
11.65
6.70
7.16
9.24
6.80
12.55
15.25
10.96
10.49
5.29
5.21
5.57
6.40
4.78
5.15
7.48
7.74
12.07
8.98
5.26
7.24
6.79
9.65
11.81
10.61
5.29
6.93
9.48
3.48
7.58
4.34
6.03
8.77
10.89
5.04
8.44
4.71
6.51
9.45
10.78
11.16
3.45
4.69
8.60
1.69
13.48
6.34
7.99
5.81
4.94
6.39
6.60
0.00
4.16
4.51
4.71
4.03
3.69
2.03
2.99
5.93
6.55
5.63
1.79
4.18
8.33
3.89
Malpractice
RVUs 2
2.35
2.48
2.78
3.31
2.80
3.08
1.36
1.74
2.79
1.53
3.37
4.40
2.75
2.72
0.99
1.15
1.24
1.47
1.02
1.03
1.79
1.85
3.04
2.43
0.97
1.34
1.53
2.38
3.13
3.01
0.81
1.22
2.56
0.47
1.75
0.65
1.26
2.01
2.74
0.84
2.28
0.76
1.36
2.51
2.98
3.09
0.40
0.94
2.13
0.30
3.38
1.75
2.03
1.45
1.02
1.57
1.65
0.00
0.86
0.80
1.10
0.74
0.69
0.41
0.69
1.31
1.40
1.13
0.20
0.78
1.84
0.72
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00213
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
YYY
090
090
090
090
090
010
010
090
090
090
010
090
090
090
66434
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27619
27620
27625
27626
27630
27635
27637
27638
27640
27641
27645
27646
27647
27648
27650
27652
27654
27656
27658
27659
27664
27665
27675
27676
27680
27681
27685
27686
27687
27690
27691
27692
27695
27696
27698
27700
27702
27703
27704
27705
27707
27709
27712
27715
27720
27722
27724
27725
27726
27727
27730
27732
27734
27740
27742
27745
27750
27752
27756
27758
27759
27760
27762
27766
27767
27768
27769
27780
27781
27784
27786
27788
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove lower leg lesion ....................
Explore/treat ankle joint ......................
Remove ankle joint lining ....................
Remove ankle joint lining ....................
Removal of tendon lesion ...................
Remove lower leg bone lesion ...........
Remove/graft leg bone lesion .............
Remove/graft leg bone lesion .............
Partial removal of tibia ........................
Partial removal of fibula ......................
Extensive lower leg surgery ................
Extensive lower leg surgery ................
Extensive ankle/heel surgery ..............
Injection for ankle x-ray ......................
Repair achilles tendon ........................
Repair/graft achilles tendon ................
Repair of achilles tendon ....................
Repair leg fascia defect ......................
Repair of leg tendon, each .................
Repair of leg tendon, each .................
Repair of leg tendon, each .................
Repair of leg tendon, each .................
Repair lower leg tendons ....................
Repair lower leg tendons ....................
Release of lower leg tendon ...............
Release of lower leg tendons .............
Revision of lower leg tendon ..............
Revise lower leg tendons ...................
Revision of calf tendon .......................
Revise lower leg tendon .....................
Revise lower leg tendon .....................
Revise additional leg tendon ..............
Repair of ankle ligament .....................
Repair of ankle ligaments ...................
Repair of ankle ligament .....................
Revision of ankle joint .........................
Reconstruct ankle joint .......................
Reconstruction, ankle joint ..................
Removal of ankle implant ...................
Incision of tibia ....................................
Incision of fibula ..................................
Incision of tibia & fibula .......................
Realignment of lower leg ....................
Revision of lower leg ..........................
Repair of tibia ......................................
Repair/graft of tibia .............................
Repair/graft of tibia .............................
Repair of lower leg ..............................
Repair fibula nonunion ........................
Repair of lower leg ..............................
Repair of tibia epiphysis .....................
Repair of fibula epiphysis ...................
Repair lower leg epiphyses ................
Repair of leg epiphyses ......................
Repair of leg epiphyses ......................
Reinforce tibia .....................................
Treatment of tibia fracture ..................
Treatment of tibia fracture ..................
Treatment of tibia fracture ..................
Treatment of tibia fracture ..................
Treatment of tibia fracture ..................
Cltx medial ankle fx ............................
Cltx med ankle fx w/mnpj ...................
Optx medial ankle fx ...........................
Cltx post ankle fx ................................
Cltx post ankle fx w/mnpj ....................
Optx post ankle fx ...............................
Treatment of fibula fracture ................
Treatment of fibula fracture ................
Treatment of fibula fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.47
6.04
8.37
8.98
4.85
7.91
10.17
10.87
12.10
9.73
14.78
13.21
12.85
0.96
9.94
10.64
10.32
4.62
5.03
6.99
4.64
5.46
7.24
8.61
5.79
6.94
6.57
7.64
6.30
8.96
10.28
1.87
6.58
8.46
9.49
9.54
14.28
16.79
7.69
10.74
4.67
17.32
15.67
15.36
12.22
12.31
19.18
17.15
14.20
14.69
7.59
5.37
8.72
9.49
10.49
10.37
3.26
6.15
7.33
12.40
14.31
3.09
5.33
7.73
2.50
5.00
10.00
2.72
4.47
9.51
2.91
4.52
9.99
NA
NA
NA
7.98
NA
NA
NA
NA
NA
NA
NA
NA
2.88
NA
NA
NA
7.95
NA
NA
NA
NA
NA
NA
NA
NA
8.77
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.32
5.94
NA
NA
NA
4.28
5.47
NA
3.62
NA
NA
3.86
4.87
NA
4.05
4.96
9.75
NA
NA
NA
7.76
NA
NA
NA
NA
NA
NA
NA
NA
3.20
NA
NA
NA
8.24
NA
NA
NA
NA
NA
NA
NA
NA
8.03
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.54
6.29
NA
NA
NA
4.47
5.90
NA
3.62
NA
NA
4.02
5.18
NA
4.25
5.30
5.27
4.56
5.49
5.77
3.80
5.63
6.90
7.04
7.46
6.09
8.73
7.64
6.54
0.34
6.15
6.44
5.98
3.58
3.88
4.67
3.88
4.32
4.67
5.72
4.16
5.09
4.57
5.28
4.47
5.37
6.65
0.71
4.87
5.25
5.87
5.20
8.64
9.77
5.61
6.95
4.48
9.95
9.44
9.03
7.92
7.88
10.28
10.58
7.67
9.06
5.30
4.16
6.16
6.60
4.60
6.99
3.73
5.10
5.75
8.02
8.66
3.67
4.65
6.12
3.65
4.29
6.07
3.31
4.26
6.84
3.43
4.23
5.61
5.01
5.98
6.34
4.09
6.18
7.59
7.66
8.88
7.21
10.38
9.33
7.07
0.34
6.83
7.23
6.56
3.67
4.22
5.16
4.21
4.64
5.20
6.23
4.63
5.50
5.02
5.89
4.89
5.86
7.20
0.82
5.37
5.84
6.40
5.44
9.55
10.50
5.60
7.56
4.71
9.04
10.09
9.89
8.66
8.50
11.32
11.24
7.67
9.70
5.86
4.54
6.22
7.29
5.08
7.58
3.79
5.39
6.10
8.60
9.48
3.63
4.96
6.67
3.65
4.29
6.07
3.26
4.45
6.65
3.38
4.44
Malpractice
RVUs 2
1.25
0.97
1.28
1.48
0.74
1.31
1.66
1.85
1.89
1.46
2.42
2.06
1.76
0.08
1.59
1.72
1.58
0.69
0.79
1.09
0.76
0.89
1.11
1.37
0.93
1.15
0.97
1.24
1.00
1.33
1.64
0.32
1.05
1.28
1.47
1.30
2.38
2.77
1.27
1.81
0.76
1.74
2.48
2.50
2.05
2.06
3.17
2.72
1.43
2.44
1.73
0.77
1.35
1.62
1.80
1.76
0.55
1.01
1.17
2.04
2.39
0.48
0.85
1.44
0.30
0.79
1.45
0.41
0.73
1.23
0.46
0.74
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00214
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66435
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27792
27808
27810
27814
27816
27818
27822
27823
27824
27825
27826
27827
27828
27829
27830
27831
27832
27840
27842
27846
27848
27860
27870
27871
27880
27881
27882
27884
27886
27888
27889
27892
27893
27894
27899
28001
28002
28003
28005
28008
28010
28011
28020
28022
28024
28035
28043
28045
28046
28050
28052
28054
28055
28060
28062
28070
28072
28080
28086
28088
28090
28092
28100
28102
28103
28104
28106
28107
28108
28110
28111
28112
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treat lower leg fracture .......................
Treat lower leg fracture .......................
Treat lower leg fracture .......................
Treat lower leg fracture .......................
Treat lower leg fracture .......................
Treat lower leg joint ............................
Treat lower leg dislocation ..................
Treat lower leg dislocation ..................
Treat lower leg dislocation ..................
Treat ankle dislocation ........................
Treat ankle dislocation ........................
Treat ankle dislocation ........................
Treat ankle dislocation ........................
Fixation of ankle joint ..........................
Fusion of ankle joint, open .................
Fusion of tibiofibular joint ....................
Amputation of lower leg ......................
Amputation of lower leg ......................
Amputation of lower leg ......................
Amputation follow-up surgery .............
Amputation follow-up surgery .............
Amputation of foot at ankle .................
Amputation of foot at ankle .................
Decompression of leg .........................
Decompression of leg .........................
Decompression of leg .........................
Leg/ankle surgery procedure ..............
Drainage of bursa of foot ....................
Treatment of foot infection ..................
Treatment of foot infection ..................
Treat foot bone lesion .........................
Incision of foot fascia ..........................
Incision of toe tendon .........................
Incision of toe tendons ........................
Exploration of foot joint .......................
Exploration of foot joint .......................
Exploration of toe joint ........................
Decompression of tibia nerve .............
Excision of foot lesion .........................
Excision of foot lesion .........................
Resection of tumor, foot .....................
Biopsy of foot joint lining .....................
Biopsy of foot joint lining .....................
Biopsy of toe joint lining ......................
Neurectomy, foot .................................
Partial removal, foot fascia .................
Removal of foot fascia ........................
Removal of foot joint lining .................
Removal of foot joint lining .................
Removal of foot lesion ........................
Excise foot tendon sheath ..................
Excise foot tendon sheath ..................
Removal of foot lesion ........................
Removal of toe lesions .......................
Removal of ankle/heel lesion ..............
Remove/graft foot lesion .....................
Remove/graft foot lesion .....................
Removal of foot lesion ........................
Remove/graft foot lesion .....................
Remove/graft foot lesion .....................
Removal of toe lesions .......................
Part removal of metatarsal .................
Part removal of metatarsal .................
Part removal of metatarsal .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
9.55
2.91
5.20
10.46
2.96
5.57
11.03
12.98
3.20
6.60
10.92
14.56
18.20
8.64
3.85
4.62
10.01
4.65
6.34
10.16
11.56
2.36
15.21
9.42
15.24
13.32
9.67
8.64
9.88
10.23
10.72
7.82
7.78
12.42
0.00
2.75
5.78
8.95
9.30
4.50
2.89
4.19
5.06
4.72
4.43
5.14
3.58
4.77
10.55
4.30
3.98
3.49
6.20
5.29
6.58
5.15
4.63
4.65
4.83
3.90
4.46
3.69
5.72
7.80
6.56
5.17
7.23
5.62
4.21
4.13
5.06
4.54
NA
4.39
5.40
NA
3.99
5.41
NA
NA
3.65
5.78
NA
NA
NA
NA
4.09
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.00
6.67
7.77
NA
6.17
2.86
3.79
7.36
6.92
6.55
7.27
4.78
7.02
10.36
6.94
6.30
6.25
NA
7.07
7.82
7.36
7.56
7.66
7.86
7.00
6.77
6.46
8.09
NA
NA
7.23
NA
7.69
6.35
6.92
7.09
7.18
NA
4.59
5.82
NA
4.18
5.89
NA
NA
3.85
6.19
NA
NA
NA
NA
4.24
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
3.49
5.83
7.00
NA
5.36
2.62
3.55
6.68
6.06
5.88
6.56
4.29
6.20
9.56
5.91
5.60
5.48
NA
6.27
7.17
6.29
6.54
6.38
7.92
6.37
5.95
5.84
8.02
NA
NA
6.35
NA
7.11
5.46
6.07
6.68
6.49
6.80
3.70
4.55
7.23
3.33
4.44
8.20
8.93
3.47
4.75
8.20
10.17
11.56
6.97
3.56
4.05
6.83
3.65
4.85
6.76
7.31
1.68
9.07
6.53
6.64
7.37
4.90
5.10
5.65
6.00
5.43
5.09
5.12
7.33
0.00
1.61
3.57
4.55
5.52
3.00
2.35
3.03
3.58
3.33
3.11
3.54
2.73
3.24
5.76
3.29
2.87
2.79
3.44
3.54
3.82
3.54
3.60
4.19
3.81
3.19
3.18
2.98
3.99
4.84
4.02
3.46
4.22
3.66
2.98
3.06
3.20
3.24
6.88
3.70
4.85
7.89
3.37
4.80
9.42
10.19
3.51
5.07
8.51
11.47
12.74
6.87
3.70
4.25
6.50
3.70
4.98
7.34
8.51
1.83
9.79
7.05
6.88
8.11
5.69
5.43
6.08
6.75
5.95
5.34
5.29
7.55
0.00
1.78
3.67
4.89
5.78
3.10
2.36
3.16
3.85
3.59
3.52
3.81
2.95
3.42
6.11
3.44
3.15
3.01
3.54
3.70
3.91
3.67
3.95
3.93
4.24
3.54
3.31
3.25
4.34
5.39
4.31
3.69
4.32
3.93
3.12
3.14
3.42
3.40
Malpractice
RVUs 2
1.32
0.46
0.82
1.86
0.43
0.82
1.92
2.26
0.45
1.02
1.47
2.44
2.82
0.95
0.54
0.73
1.03
0.46
1.00
1.71
1.95
0.39
2.37
1.59
1.76
1.99
1.29
1.22
1.40
1.51
1.46
1.10
1.10
1.65
0.00
0.33
0.61
1.12
1.16
0.57
0.36
0.59
0.72
0.62
0.58
0.70
0.46
0.63
1.36
0.60
0.53
0.46
0.74
0.70
0.83
0.73
0.68
0.47
0.76
0.61
0.59
0.49
0.82
1.14
0.91
0.70
0.97
0.74
0.53
0.54
0.67
0.61
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00215
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
YYY
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66436
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
28113
28114
28116
28118
28119
28120
28122
28124
28126
28130
28140
28150
28153
28160
28171
28173
28175
28190
28192
28193
28200
28202
28208
28210
28220
28222
28225
28226
28230
28232
28234
28238
28240
28250
28260
28261
28262
28264
28270
28272
28280
28285
28286
28288
28289
28290
28292
28293
28294
28296
28297
28298
28299
28300
28302
28304
28305
28306
28307
28308
28309
28310
28312
28313
28315
28320
28322
28340
28341
28344
28345
28360
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Part removal of metatarsal .................
Removal of metatarsal heads .............
Revision of foot ...................................
Removal of heel bone .........................
Removal of heel spur ..........................
Part removal of ankle/heel ..................
Partial removal of foot bone ...............
Partial removal of toe ..........................
Partial removal of toe ..........................
Removal of ankle bone .......................
Removal of metatarsal ........................
Removal of toe ....................................
Partial removal of toe ..........................
Partial removal of toe ..........................
Extensive foot surgery ........................
Extensive foot surgery ........................
Extensive foot surgery ........................
Removal of foot foreign body .............
Removal of foot foreign body .............
Removal of foot foreign body .............
Repair of foot tendon ..........................
Repair/graft of foot tendon ..................
Repair of foot tendon ..........................
Repair/graft of foot tendon ..................
Release of foot tendon .......................
Release of foot tendons ......................
Release of foot tendon .......................
Release of foot tendons ......................
Incision of foot tendon(s) ....................
Incision of toe tendon .........................
Incision of foot tendon ........................
Revision of foot tendon .......................
Release of big toe ...............................
Revision of foot fascia ........................
Release of midfoot joint ......................
Revision of foot tendon .......................
Revision of foot and ankle ..................
Release of midfoot joint ......................
Release of foot contracture ................
Release of toe joint, each ...................
Fusion of toes .....................................
Repair of hammertoe ..........................
Repair of hammertoe ..........................
Partial removal of foot bone ...............
Repair hallux rigidus ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Correction of bunion ...........................
Incision of heel bone ...........................
Incision of ankle bone .........................
Incision of midfoot bones ....................
Incise/graft midfoot bones ...................
Incision of metatarsal ..........................
Incision of metatarsal ..........................
Incision of metatarsal ..........................
Incision of metatarsals ........................
Revision of big toe ..............................
Revision of toe ....................................
Repair deformity of toe .......................
Removal of sesamoid bone ................
Repair of foot bones ...........................
Repair of metatarsals ..........................
Resect enlarged toe tissue .................
Resect enlarged toe ............................
Repair extra toe(s) ..............................
Repair webbed toe(s) .........................
Reconstruct cleft foot ..........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.88
11.61
8.94
6.02
5.45
5.64
7.56
4.88
3.56
9.30
7.03
4.14
3.71
3.79
9.85
9.05
6.17
1.98
4.69
5.79
4.65
6.96
4.42
6.41
4.58
5.67
3.70
4.58
4.28
3.43
3.43
7.85
4.40
5.97
8.08
12.91
17.01
10.53
4.82
3.84
5.24
4.65
4.61
5.81
8.11
5.72
8.72
11.10
8.63
9.31
9.31
8.01
11.39
9.61
9.62
9.29
10.63
5.91
6.39
5.36
13.96
5.48
4.60
5.06
4.91
9.25
8.41
7.04
8.60
4.31
5.98
14.67
8.36
13.38
9.44
7.92
7.21
8.08
8.46
6.77
5.96
NA
7.81
6.35
6.21
6.31
NA
8.72
7.14
4.01
6.71
7.33
6.87
7.76
6.69
7.62
6.41
6.92
6.01
6.88
6.26
5.93
6.29
8.38
6.35
7.55
8.44
10.66
15.52
10.31
6.91
5.83
7.28
6.70
6.52
8.59
9.42
8.18
10.33
14.46
9.45
9.57
10.46
9.29
10.54
NA
NA
9.55
NA
8.41
9.27
7.91
NA
7.54
7.37
7.26
6.67
NA
9.74
8.09
8.59
6.41
7.61
NA
7.20
12.49
8.11
7.08
6.31
7.68
7.64
5.88
5.08
NA
7.51
5.59
5.26
5.43
NA
8.15
6.42
3.70
6.09
6.47
5.98
7.48
5.75
6.91
5.54
6.08
5.14
5.83
5.46
5.22
5.48
7.81
5.49
6.58
7.38
9.63
14.53
9.02
5.90
5.00
6.76
5.78
5.65
7.26
8.70
7.21
8.89
12.60
8.44
8.86
9.70
8.25
9.65
NA
NA
8.74
NA
7.62
10.14
6.83
NA
6.64
6.40
6.27
5.78
NA
9.45
7.26
7.76
6.07
6.90
NA
4.61
8.29
5.34
4.02
3.57
3.96
4.77
3.46
2.66
6.15
4.11
2.97
2.89
2.92
5.25
4.61
3.62
1.34
3.19
3.63
3.23
3.93
3.18
3.93
3.07
3.34
2.71
3.25
2.87
2.67
3.05
4.37
2.95
3.82
4.61
6.33
9.72
5.95
3.44
2.65
3.54
3.34
3.06
4.69
5.33
3.96
6.15
6.91
4.77
4.79
5.33
4.59
5.72
6.03
6.21
5.08
5.78
3.89
4.33
3.82
7.68
3.42
3.23
3.60
3.22
5.68
5.31
4.07
4.42
2.93
3.78
6.34
4.46
8.33
5.25
4.18
3.65
4.18
5.02
3.55
2.82
6.43
4.43
3.13
2.78
3.13
5.34
4.90
3.66
1.41
3.41
3.77
3.39
4.21
3.24
3.97
3.25
3.73
2.81
3.49
3.27
2.99
3.20
4.64
3.21
3.97
4.80
6.81
10.31
6.61
3.58
2.75
4.01
3.38
3.15
4.78
5.55
4.34
5.84
6.50
4.74
5.10
5.79
4.79
5.89
6.53
6.54
5.40
6.25
4.03
4.81
3.75
7.81
3.48
3.43
4.21
3.27
6.19
5.82
4.15
4.61
3.28
4.23
8.41
Malpractice
RVUs 2
0.63
1.42
1.03
0.84
0.70
0.77
0.98
0.60
0.45
1.26
0.92
0.53
0.47
0.49
1.33
1.12
0.73
0.22
0.61
0.73
0.61
0.91
0.58
0.81
0.57
0.69
0.46
0.58
0.55
0.44
0.44
1.06
0.58
0.82
1.14
1.57
2.60
1.54
0.62
0.46
0.73
0.59
0.57
0.65
1.02
0.82
0.91
1.13
1.09
1.19
1.32
1.05
1.37
1.54
1.42
1.27
1.27
0.84
0.90
0.70
2.05
0.70
0.63
0.73
0.63
1.43
1.27
0.84
1.01
0.51
0.80
2.29
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00216
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66437
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
28400
28405
28406
28415
28420
28430
28435
28436
28445
28446
28450
28455
28456
28465
28470
28475
28476
28485
28490
28495
28496
28505
28510
28515
28525
28530
28531
28540
28545
28546
28555
28570
28575
28576
28585
28600
28605
28606
28615
28630
28635
28636
28645
28660
28665
28666
28675
28705
28715
28725
28730
28735
28737
28740
28750
28755
28760
28800
28805
28810
28820
28825
28890
28899
29000
29010
29015
29020
29025
29035
29040
29044
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Treatment of heel fracture ..................
Treatment of heel fracture ..................
Treatment of heel fracture ..................
Treat heel fracture ..............................
Treat/graft heel fracture ......................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treat ankle fracture .............................
Osteochondral talus autogrft ...............
Treat midfoot fracture, each ...............
Treat midfoot fracture, each ...............
Treat midfoot fracture .........................
Treat midfoot fracture, each ...............
Treat metatarsal fracture ....................
Treat metatarsal fracture ....................
Treat metatarsal fracture ....................
Treat metatarsal fracture ....................
Treat big toe fracture ..........................
Treat big toe fracture ..........................
Treat big toe fracture ..........................
Treat big toe fracture ..........................
Treatment of toe fracture ....................
Treatment of toe fracture ....................
Treat toe fracture ................................
Treat sesamoid bone fracture .............
Treat sesamoid bone fracture .............
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Repair foot dislocation ........................
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Repair foot dislocation ........................
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Treat foot dislocation ..........................
Repair foot dislocation ........................
Treat toe dislocation ...........................
Treat toe dislocation ...........................
Treat toe dislocation ...........................
Repair toe dislocation .........................
Treat toe dislocation ...........................
Treat toe dislocation ...........................
Treat toe dislocation ...........................
Repair of toe dislocation .....................
Fusion of foot bones ...........................
Fusion of foot bones ...........................
Fusion of foot bones ...........................
Fusion of foot bones ...........................
Fusion of foot bones ...........................
Revision of foot bones ........................
Fusion of foot bones ...........................
Fusion of big toe joint .........................
Fusion of big toe joint .........................
Fusion of big toe joint .........................
Amputation of midfoot .........................
Amputation thru metatarsal .................
Amputation toe & metatarsal ..............
Amputation of toe ................................
Partial amputation of toe .....................
High energy eswt, plantar f .................
Foot/toes surgery procedure ...............
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Application of body cast ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.22
4.63
6.44
15.96
17.29
2.14
3.45
4.78
15.53
17.50
1.95
3.15
2.75
8.64
1.99
2.97
3.46
7.28
1.12
1.62
2.39
7.28
1.12
1.50
5.46
1.08
2.51
2.10
2.51
3.28
9.49
1.70
3.38
4.48
10.92
1.94
2.78
4.97
10.46
1.72
1.93
2.77
7.28
1.25
1.94
2.66
5.46
20.12
14.40
11.97
12.21
12.03
10.83
9.09
8.37
4.79
8.94
8.65
12.55
6.52
4.89
3.71
3.36
0.00
2.25
2.06
2.41
2.11
2.40
1.77
2.22
2.12
3.36
4.42
NA
NA
NA
3.12
3.98
NA
NA
NA
2.91
3.74
NA
NA
2.80
3.13
NA
NA
2.09
2.46
7.41
8.45
1.68
2.22
8.11
1.62
6.54
2.74
3.43
8.05
10.80
2.49
4.41
NA
11.56
3.02
3.89
NA
NA
1.84
2.27
4.38
8.33
1.30
1.82
NA
8.23
NA
NA
NA
NA
NA
NA
10.86
10.76
7.25
9.86
NA
NA
NA
7.64
7.13
4.56
0.00
4.00
4.38
3.61
3.81
4.04
3.70
3.28
3.57
3.49
4.62
NA
NA
NA
3.25
3.93
NA
NA
NA
3.01
3.58
NA
NA
2.96
3.23
NA
NA
2.05
2.32
7.83
8.27
1.60
2.06
7.81
1.53
6.90
2.57
2.88
7.48
10.35
2.45
4.06
NA
9.44
2.92
3.50
NA
NA
1.70
2.15
4.12
6.64
1.28
1.62
NA
7.68
NA
NA
NA
NA
NA
NA
10.86
11.33
6.67
8.91
NA
NA
NA
7.59
7.06
5.14
0.00
3.48
3.83
3.29
3.49
3.59
3.65
2.87
3.77
2.91
3.67
5.55
10.23
10.27
2.57
3.26
4.74
9.48
10.34
2.41
3.10
3.72
6.06
2.36
2.51
4.32
5.56
1.67
1.86
2.99
4.81
1.61
1.82
4.31
1.34
2.42
2.30
2.81
3.64
6.29
1.91
3.71
4.06
6.96
2.37
3.27
4.11
8.13
0.91
1.33
2.05
4.61
0.78
1.32
1.82
4.44
10.64
8.48
6.82
7.75
6.96
6.06
5.98
5.88
3.35
5.26
5.00
5.89
4.06
3.55
3.12
2.20
0.00
1.64
1.62
1.56
1.41
1.76
1.48
1.34
1.47
2.98
4.14
6.17
11.75
11.59
2.57
3.50
5.32
10.25
10.34
2.44
3.26
3.94
6.18
2.40
2.86
4.65
5.50
1.65
1.96
3.09
4.36
1.57
1.86
3.87
1.39
2.24
2.35
2.57
4.01
5.98
2.12
3.71
4.11
6.40
2.53
3.19
4.40
8.08
0.95
1.43
2.34
3.94
0.78
1.37
2.20
3.90
11.54
9.11
7.52
8.11
7.39
6.43
6.22
6.27
3.55
5.39
5.40
5.77
4.26
3.66
3.30
2.14
0.00
1.69
1.70
1.58
1.41
1.81
1.53
1.42
1.69
Malpractice
RVUs 2
0.35
0.73
1.11
2.67
2.81
0.31
0.55
0.81
2.59
2.45
0.28
0.44
0.44
1.10
0.30
0.44
0.54
0.83
0.14
0.20
0.36
0.56
0.14
0.18
0.49
0.14
0.34
0.26
0.37
0.52
1.04
0.23
0.56
0.69
1.25
0.27
0.40
0.82
1.30
0.20
0.26
0.43
0.57
0.13
0.26
0.43
0.45
3.09
2.17
1.87
1.71
1.69
1.47
1.22
1.13
0.65
1.05
1.15
1.18
0.86
0.61
0.50
0.41
0.00
0.41
0.45
0.28
0.28
0.44
0.28
0.36
0.35
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00217
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
010
010
090
010
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
000
000
000
000
000
000
000
000
66438
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
29046
29049
29055
29058
29065
29075
29085
29086
29105
29125
29126
29130
29131
29200
29220
29240
29260
29280
29305
29325
29345
29355
29358
29365
29405
29425
29435
29440
29445
29450
29505
29515
29520
29530
29540
29550
29580
29590
29700
29705
29710
29715
29720
29730
29740
29750
29799
29800
29804
29805
29806
29807
29819
29820
29821
29822
29823
29824
29825
29826
29827
29828
29830
29834
29835
29836
29837
29838
29840
29843
29844
29845
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Application of body cast ......................
Application of figure eight ...................
Application of shoulder cast ................
Application of shoulder cast ................
Application of long arm cast ...............
Application of forearm cast .................
Apply hand/wrist cast ..........................
Apply finger cast .................................
Apply long arm splint ..........................
Apply forearm splint ............................
Apply forearm splint ............................
Application of finger splint ...................
Application of finger splint ...................
Strapping of chest ...............................
Strapping of low back .........................
Strapping of shoulder ..........................
Strapping of elbow or wrist .................
Strapping of hand or finger .................
Application of hip cast .........................
Application of hip casts .......................
Application of long leg cast .................
Application of long leg cast .................
Apply long leg cast brace ...................
Application of long leg cast .................
Apply short leg cast ............................
Apply short leg cast ............................
Apply short leg cast ............................
Addition of walker to cast ...................
Apply rigid leg cast .............................
Application of leg cast .........................
Application, long leg splint ..................
Application lower leg splint .................
Strapping of hip ...................................
Strapping of knee ................................
Strapping of ankle and/or ft ................
Strapping of toes .................................
Application of paste boot ....................
Application of foot splint ......................
Removal/revision of cast .....................
Removal/revision of cast .....................
Removal/revision of cast .....................
Removal/revision of cast .....................
Repair of body cast .............................
Windowing of cast ...............................
Wedging of cast ..................................
Wedging of clubfoot cast ....................
Casting/strapping procedure ...............
Jaw arthroscopy/surgery .....................
Jaw arthroscopy/surgery .....................
Shoulder arthroscopy, dx ....................
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Shoulder arthroscopy/surgery .............
Arthroscop rotator cuff repr .................
Arthroscopy biceps tenodesis .............
Elbow arthroscopy ..............................
Elbow arthroscopy/surgery .................
Elbow arthroscopy/surgery .................
Elbow arthroscopy/surgery .................
Elbow arthroscopy/surgery .................
Elbow arthroscopy/surgery .................
Wrist arthroscopy ................................
Wrist arthroscopy/surgery ...................
Wrist arthroscopy/surgery ...................
Wrist arthroscopy/surgery ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.41
0.89
1.78
1.31
0.87
0.77
0.87
0.62
0.87
0.59
0.77
0.50
0.55
0.65
0.64
0.71
0.55
0.51
2.03
2.32
1.40
1.53
1.43
1.18
0.86
1.01
1.18
0.57
1.78
2.08
0.69
0.73
0.54
0.57
0.51
0.47
0.55
0.76
0.57
0.76
1.34
0.94
0.68
0.75
1.12
1.26
0.00
6.73
8.71
5.94
14.95
14.48
7.68
7.12
7.78
7.49
8.24
8.82
7.68
9.05
15.44
13.00
5.80
6.33
6.53
7.61
6.92
7.77
5.59
6.06
6.42
7.58
4.49
1.11
2.82
1.26
1.28
1.23
1.26
1.07
1.09
0.97
1.01
0.43
0.59
0.60
0.65
0.68
0.67
0.67
3.28
3.33
1.66
1.62
2.01
1.58
1.19
1.22
1.52
0.64
1.56
1.59
1.07
0.96
0.66
0.65
0.55
0.56
0.71
0.59
0.95
0.76
1.32
1.20
1.17
0.74
1.03
1.06
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.86
1.21
2.90
1.41
1.30
1.24
1.27
1.02
1.16
0.99
1.11
0.45
0.66
0.66
0.68
0.76
0.70
0.73
3.31
3.43
1.71
1.66
2.03
1.62
1.20
1.22
1.54
0.67
1.68
1.53
1.12
0.91
0.75
0.72
0.48
0.49
0.68
0.55
0.92
0.79
1.42
1.18
1.16
0.77
1.09
1.06
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.91
0.59
1.23
0.67
0.70
0.66
0.68
0.55
0.53
0.42
0.48
0.18
0.24
0.34
0.38
0.40
0.37
0.37
1.56
1.58
0.94
0.93
0.91
0.85
0.65
0.65
0.81
0.26
0.89
0.90
0.45
0.46
0.37
0.36
0.31
0.30
0.33
0.26
0.25
0.36
0.55
0.43
0.35
0.34
0.47
0.52
0.00
4.62
5.69
4.71
9.35
9.19
5.62
5.17
5.65
5.57
6.04
6.53
5.63
6.18
9.31
8.17
4.48
4.85
4.96
5.54
5.06
5.65
4.62
4.80
4.87
5.59
2.00
0.56
1.35
0.70
0.73
0.67
0.66
0.52
0.52
0.41
0.47
0.18
0.24
0.34
0.38
0.38
0.35
0.35
1.66
1.77
1.00
1.03
1.00
0.90
0.68
0.70
0.87
0.26
0.92
0.99
0.45
0.46
0.42
0.35
0.31
0.29
0.34
0.27
0.26
0.37
0.62
0.42
0.37
0.34
0.48
0.55
0.00
5.79
6.65
5.19
10.25
10.09
6.20
5.70
6.22
6.13
6.63
7.03
6.19
6.85
10.41
8.17
4.91
5.34
5.42
6.16
5.59
6.27
4.97
5.21
5.35
6.03
Malpractice
RVUs 2
0.42
0.13
0.30
0.17
0.15
0.13
0.14
0.07
0.12
0.07
0.07
0.06
0.03
0.04
0.04
0.06
0.05
0.03
0.35
0.40
0.24
0.26
0.25
0.20
0.14
0.15
0.20
0.08
0.27
0.27
0.08
0.09
0.03
0.05
0.06
0.06
0.07
0.09
0.08
0.13
0.20
0.09
0.12
0.12
0.18
0.21
0.00
0.99
1.38
1.02
2.50
2.42
1.32
1.22
1.33
1.28
1.41
1.42
1.32
1.55
2.67
2.17
0.99
1.08
1.13
1.22
1.19
1.30
0.84
0.92
1.04
0.99
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00218
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
YYY
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66439
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
29846
29847
29848
29850
29851
29855
29856
29860
29861
29862
29863
29866
29867
29868
29870
29871
29873
29874
29875
29876
29877
29879
29880
29881
29882
29883
29884
29885
29886
29887
29888
29889
29891
29892
29893
29894
29895
29897
29898
29899
29900
29901
29902
29904
29905
29906
29907
29999
30000
30020
30100
30110
30115
30117
30118
30120
30124
30125
30130
30140
30150
30160
30200
30210
30220
30300
30310
30320
30400
30410
30420
30430
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
R
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Wrist arthroscopy/surgery ...................
Wrist arthroscopy/surgery ...................
Wrist endoscopy/surgery ....................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Tibial arthroscopy/surgery ...................
Tibial arthroscopy/surgery ...................
Hip arthroscopy, dx .............................
Hip arthroscopy/surgery ......................
Hip arthroscopy/surgery ......................
Hip arthroscopy/surgery ......................
Autgrft implnt, knee w/scope ..............
Allgrft implnt, knee w/scope ................
Meniscal trnspl, knee w/scpe ..............
Knee arthroscopy, dx ..........................
Knee arthroscopy/drainage .................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Knee arthroscopy/surgery ...................
Ankle arthroscopy/surgery ..................
Ankle arthroscopy/surgery ..................
Scope, plantar fasciotomy ..................
Ankle arthroscopy/surgery ..................
Ankle arthroscopy/surgery ..................
Ankle arthroscopy/surgery ..................
Ankle arthroscopy/surgery ..................
Ankle arthroscopy/surgery ..................
Mcp joint arthroscopy, dx ....................
Mcp joint arthroscopy, surg ................
Mcp joint arthroscopy, surg ................
Subtalar arthro w/fb rmvl ....................
Subtalar arthro w/exc ..........................
Subtalar arthro w/deb .........................
Subtalar arthro w/fusion ......................
Arthroscopy of joint .............................
Drainage of nose lesion ......................
Drainage of nose lesion ......................
Intranasal biopsy .................................
Removal of nose polyp(s) ...................
Removal of nose polyp(s) ...................
Removal of intranasal lesion ..............
Removal of intranasal lesion ..............
Revision of nose .................................
Removal of nose lesion ......................
Removal of nose lesion ......................
Excise inferior turbinate ......................
Resect inferior turbinate ......................
Partial removal of nose .......................
Removal of nose .................................
Injection treatment of nose .................
Nasal sinus therapy ............................
Insert nasal septal button ...................
Remove nasal foreign body ................
Remove nasal foreign body ................
Remove nasal foreign body ................
Reconstruction of nose .......................
Reconstruction of nose .......................
Reconstruction of nose .......................
Revision of nose .................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.80
7.13
6.24
8.18
13.08
10.60
14.12
8.85
9.95
10.97
10.97
14.48
18.18
24.89
5.11
6.60
6.09
7.10
6.36
8.72
8.15
8.84
9.30
8.56
9.45
11.61
8.13
10.03
8.34
9.98
14.14
17.15
9.47
10.07
6.08
7.26
7.04
7.23
8.38
15.21
5.74
6.45
7.02
8.50
9.00
9.47
12.00
0.00
1.45
1.45
0.94
1.65
4.38
3.20
9.81
5.31
3.14
7.21
3.41
3.48
9.44
9.88
0.78
1.10
1.56
1.06
1.98
4.56
10.58
13.72
16.62
7.96
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
8.83
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.01
4.16
2.58
3.90
NA
18.15
NA
7.07
NA
NA
NA
NA
NA
NA
2.02
2.51
5.81
4.29
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
7.56
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.04
3.72
2.28
3.57
NA
15.64
NA
6.78
NA
NA
NA
NA
NA
NA
1.82
2.30
5.02
4.46
NA
NA
NA
NA
NA
NA
5.11
5.27
5.27
4.72
8.21
7.27
8.69
6.24
6.39
7.57
7.48
9.46
11.03
13.79
4.18
5.05
5.59
5.08
4.88
6.18
5.97
6.23
6.42
6.13
6.45
7.58
5.96
7.03
6.03
6.96
8.26
10.61
6.64
6.38
4.66
4.72
4.51
4.81
5.24
9.20
4.66
5.09
4.70
5.89
6.51
6.87
7.86
0.00
1.34
1.39
0.75
1.45
5.99
4.91
8.55
5.09
3.68
7.40
5.63
7.10
9.02
8.87
0.67
1.27
1.42
1.87
2.91
6.35
13.90
15.32
15.82
13.24
5.58
5.73
5.44
4.88
9.00
8.02
9.67
6.60
6.86
8.06
7.99
10.40
12.12
15.29
4.53
5.46
6.08
5.58
5.37
6.60
6.36
6.67
6.89
6.55
6.84
8.32
6.33
7.49
6.44
7.44
9.23
11.52
7.07
7.06
4.32
5.09
4.99
5.35
5.71
9.87
5.26
5.68
5.62
5.89
6.51
6.87
7.86
0.00
1.36
1.43
0.78
1.51
5.87
4.77
8.87
5.54
3.64
7.86
5.61
6.64
10.01
9.54
0.70
1.29
1.47
1.89
3.00
6.69
14.69
16.84
16.86
14.62
Malpractice
RVUs 2
1.07
1.08
0.86
1.25
2.35
1.85
2.40
1.36
1.59
1.62
1.42
2.40
2.79
4.36
0.85
1.14
1.04
1.11
1.09
1.37
1.28
1.39
1.47
1.34
1.50
1.93
1.27
1.58
1.30
1.57
2.42
2.79
1.39
1.41
0.63
1.15
1.11
1.17
1.28
2.41
0.94
1.06
1.12
1.25
1.32
1.39
1.90
0.00
0.12
0.12
0.07
0.14
0.41
0.26
0.78
0.52
0.25
0.63
0.31
0.35
0.93
0.88
0.06
0.09
0.12
0.08
0.16
0.39
1.04
1.42
1.46
0.77
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00219
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
010
010
000
010
090
090
090
090
090
090
090
090
090
090
000
010
010
010
010
090
090
090
090
090
66440
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
30435
30450
30460
30462
30465
30520
30540
30545
30560
30580
30600
30620
30630
30801
30802
30901
30903
30905
30906
30915
30920
30930
30999
31000
31002
31020
31030
31032
31040
31050
31051
31070
31075
31080
31081
31084
31085
31086
31087
31090
31200
31201
31205
31225
31230
31231
31233
31235
31237
31238
31239
31240
31254
31255
31256
31267
31276
31287
31288
31290
31291
31292
31293
31294
31299
31300
31320
31360
31365
31367
31368
31370
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Revision of nose .................................
Revision of nose .................................
Revision of nose .................................
Revision of nose .................................
Repair nasal stenosis .........................
Repair of nasal septum .......................
Repair nasal defect .............................
Repair nasal defect .............................
Release of nasal adhesions ...............
Repair upper jaw fistula ......................
Repair mouth/nose fistula ...................
Intranasal reconstruction .....................
Repair nasal septum defect ................
Ablate inf turbinate, superf ..................
Cauterization, inner nose ....................
Control of nosebleed ...........................
Control of nosebleed ...........................
Control of nosebleed ...........................
Repeat control of nosebleed ...............
Ligation, nasal sinus artery .................
Ligation, upper jaw artery ...................
Ther fx, nasal inf turbinate ..................
Nasal surgery procedure ....................
Irrigation, maxillary sinus ....................
Irrigation, sphenoid sinus ....................
Exploration, maxillary sinus ................
Exploration, maxillary sinus ................
Explore sinus, remove polyps .............
Exploration behind upper jaw .............
Exploration, sphenoid sinus ................
Sphenoid sinus surgery ......................
Exploration of frontal sinus .................
Exploration of frontal sinus .................
Removal of frontal sinus .....................
Removal of frontal sinus .....................
Removal of frontal sinus .....................
Removal of frontal sinus .....................
Removal of frontal sinus .....................
Removal of frontal sinus .....................
Exploration of sinuses .........................
Removal of ethmoid sinus ..................
Removal of ethmoid sinus ..................
Removal of ethmoid sinus ..................
Removal of upper jaw .........................
Removal of upper jaw .........................
Nasal endoscopy, dx ..........................
Nasal/sinus endoscopy, dx .................
Nasal/sinus endoscopy, dx .................
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Revision of ethmoid sinus ...................
Removal of ethmoid sinus ..................
Exploration maxillary sinus .................
Endoscopy, maxillary sinus ................
Sinus endoscopy, surgical ..................
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Nasal/sinus endoscopy, surg ..............
Sinus surgery procedure .....................
Removal of larynx lesion ....................
Diagnostic incision, larynx ..................
Removal of larynx ...............................
Removal of larynx ...............................
Partial removal of larynx .....................
Partial removal of larynx .....................
Partial removal of larynx .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
12.45
19.38
10.24
20.12
12.20
6.85
7.81
11.50
1.28
6.76
6.07
6.04
7.18
1.11
2.05
1.21
1.54
1.97
2.45
7.36
11.03
1.28
0.00
1.17
1.93
2.99
5.95
6.61
9.66
5.31
7.16
4.32
9.40
12.54
13.99
14.75
15.44
14.16
14.39
10.88
5.03
8.49
10.47
26.44
30.56
1.10
2.18
2.64
2.98
3.26
9.23
2.61
4.64
6.95
3.29
5.45
8.84
3.91
4.57
18.50
19.45
15.79
17.36
20.20
0.00
15.71
5.62
29.57
38.47
30.23
33.85
27.23
NA
NA
NA
NA
NA
NA
NA
NA
5.28
8.13
7.67
NA
NA
4.30
4.97
1.27
3.27
3.93
4.28
NA
NA
NA
0.00
3.22
NA
8.60
10.40
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.59
4.26
4.64
4.90
4.82
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.02
7.95
7.59
NA
NA
4.21
4.79
1.31
2.99
3.72
4.08
NA
NA
NA
0.00
3.03
NA
8.56
10.94
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.49
4.28
4.77
5.05
5.03
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
15.42
16.88
7.48
14.64
11.07
8.04
8.54
11.08
2.02
4.69
4.18
8.66
7.73
2.12
2.51
0.30
0.43
0.51
0.76
6.46
8.96
1.64
0.00
1.34
2.69
5.54
6.44
7.00
7.37
6.50
8.36
6.18
9.32
10.61
15.36
12.87
14.42
12.77
11.64
13.40
7.43
8.99
9.51
17.88
19.48
0.77
1.12
1.26
1.39
1.48
6.42
1.27
1.93
2.69
1.49
2.20
3.31
1.69
1.91
9.04
9.53
8.05
8.68
9.66
0.00
14.57
10.14
20.06
22.97
22.50
24.58
22.13
17.38
19.38
8.71
17.44
11.52
7.35
8.91
11.48
2.08
5.24
4.60
8.75
7.83
2.02
2.44
0.31
0.46
0.63
0.98
6.57
8.96
1.63
0.00
1.37
2.96
5.36
6.55
7.11
8.59
6.43
8.30
6.06
9.52
12.07
14.67
13.18
14.19
13.02
12.08
12.97
8.32
9.08
10.69
17.85
19.41
0.82
1.30
1.49
1.63
1.79
7.21
1.50
2.39
3.40
1.80
2.74
4.21
2.07
2.36
10.54
11.00
9.33
10.02
11.26
0.00
14.77
10.22
18.39
21.66
22.19
25.03
22.19
Malpractice
RVUs 2
1.22
1.97
1.03
2.54
1.06
0.46
0.67
1.71
0.10
0.89
0.70
0.57
0.61
0.09
0.16
0.11
0.13
0.17
0.20
0.58
0.80
0.12
0.00
0.09
0.15
0.29
0.60
0.59
0.87
0.49
0.62
0.38
0.75
1.23
2.47
1.19
1.73
1.07
1.44
0.94
0.29
0.82
0.67
1.59
1.78
0.09
0.20
0.26
0.28
0.27
0.62
0.24
0.45
0.73
0.33
0.55
0.92
0.39
0.46
1.40
1.69
1.21
1.28
1.53
0.00
1.17
0.46
1.38
1.98
1.79
2.21
1.75
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00220
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
010
090
090
090
090
010
010
000
000
000
000
090
090
010
YYY
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
010
000
000
000
000
000
000
000
000
010
010
010
010
010
YYY
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66441
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
31375
31380
31382
31390
31395
31400
31420
31500
31502
31505
31510
31511
31512
31513
31515
31520
31525
31526
31527
31528
31529
31530
31531
31535
31536
31540
31541
31545
31546
31560
31561
31570
31571
31575
31576
31577
31578
31579
31580
31582
31584
31587
31588
31590
31595
31599
31600
31601
31603
31605
31610
31611
31612
31613
31614
31615
31620
31622
31623
31624
31625
31628
31629
31630
31631
31632
31633
31635
31636
31637
31638
31640
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Partial removal of larynx .....................
Partial removal of larynx .....................
Partial removal of larynx .....................
Removal of larynx & pharynx .............
Reconstruct larynx & pharynx .............
Revision of larynx ...............................
Removal of epiglottis ..........................
Insert emergency airway .....................
Change of windpipe airway ................
Diagnostic laryngoscopy .....................
Laryngoscopy with biopsy ...................
Remove foreign body, larynx ..............
Removal of larynx lesion ....................
Injection into vocal cord ......................
Laryngoscopy for aspiration ................
Dx laryngoscopy, newborn .................
Dx laryngoscopy excl nb .....................
Dx laryngoscopy w/oper scope ...........
Laryngoscopy for treatment ................
Laryngoscopy and dilation ..................
Laryngoscopy and dilation ..................
Laryngoscopy w/fb removal ................
Laryngoscopy w/fb & op scope ..........
Laryngoscopy w/biopsy .......................
Laryngoscopy w/bx & op scope ..........
Laryngoscopy w/exc of tumor .............
Larynscop w/tumr exc + scope ...........
Remove vc lesion w/scope .................
Remove vc lesion scope/graft ............
Laryngoscop w/arytenoidectom ..........
Larynscop, remve cart + scop ............
Laryngoscope w/vc inj ........................
Laryngoscop w/vc inj + scope ............
Diagnostic laryngoscopy .....................
Laryngoscopy with biopsy ...................
Remove foreign body, larynx ..............
Removal of larynx lesion ....................
Diagnostic laryngoscopy .....................
Revision of larynx ...............................
Revision of larynx ...............................
Treat larynx fracture ............................
Revision of larynx ...............................
Revision of larynx ...............................
Reinnervate larynx ..............................
Larynx nerve surgery ..........................
Larynx surgery procedure ...................
Incision of windpipe ............................
Incision of windpipe ............................
Incision of windpipe ............................
Incision of windpipe ............................
Incision of windpipe ............................
Surgery/speech prosthesis .................
Puncture/clear windpipe ......................
Repair windpipe opening ....................
Repair windpipe opening ....................
Visualization of windpipe ....................
Endobronchial us add-on ....................
Dx bronchoscope/wash .......................
Dx bronchoscope/brush ......................
Dx bronchoscope/lavage ....................
Bronchoscopy w/biopsy(s) ..................
Bronchoscopy/lung bx, each ...............
Bronchoscopy/needle bx, each ...........
Bronchoscopy dilate/fx repr ................
Bronchoscopy, dilate w/stent ..............
Bronchoscopy/lung bx, add’l ...............
Bronchoscopy/needle bx add’l ............
Bronchoscopy w/fb removal ................
Bronchoscopy, bronch stents .............
Bronchoscopy, stent add-on ...............
Bronchoscopy, revise stent .................
Bronchoscopy w/tumor excise ............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
25.73
25.23
28.23
42.17
43.46
11.48
11.32
2.33
0.65
0.61
1.92
2.16
2.07
2.10
1.80
2.56
2.63
2.57
3.27
2.37
2.68
3.38
3.58
3.16
3.55
4.12
4.52
6.30
9.73
5.45
5.99
3.86
4.26
1.10
1.97
2.47
2.84
2.26
14.46
22.87
20.35
15.12
14.62
7.63
8.75
0.00
7.17
4.44
4.14
3.57
9.29
5.92
0.91
4.63
8.47
2.09
1.40
2.78
2.88
2.88
3.36
3.80
4.09
3.81
4.36
1.03
1.32
3.67
4.30
1.58
4.88
4.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.42
3.22
2.94
2.97
NA
3.19
NA
3.45
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.26
NA
1.69
3.52
3.37
3.99
2.86
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
1.09
NA
NA
2.37
6.01
5.23
5.97
5.33
5.48
6.95
12.00
NA
NA
0.85
0.99
5.19
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.43
3.26
3.03
3.08
NA
3.37
NA
3.54
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.96
NA
1.80
3.59
3.56
4.13
3.32
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
1.09
NA
NA
2.48
5.83
5.44
6.20
5.55
5.64
6.98
13.12
NA
NA
0.83
0.95
5.65
NA
NA
NA
NA
21.14
20.78
22.68
25.96
28.50
12.49
8.58
0.42
0.21
0.59
1.00
1.03
1.06
1.08
0.88
1.21
1.23
1.25
1.40
1.09
1.25
1.45
1.58
1.44
1.57
1.76
1.89
2.51
3.43
2.15
2.32
1.64
1.81
0.76
1.04
1.17
1.34
1.15
13.82
22.55
15.26
8.63
12.50
12.78
9.64
0.00
2.28
1.74
1.19
0.82
7.72
7.07
0.26
6.13
9.57
1.04
0.33
0.90
0.89
0.89
1.01
1.10
1.17
1.27
1.42
0.24
0.31
1.13
1.34
0.41
1.54
1.53
20.75
20.69
22.14
25.16
28.39
13.12
9.06
0.48
0.25
0.60
1.12
1.04
1.21
1.27
0.97
1.38
1.44
1.48
1.63
1.27
1.48
1.70
1.93
1.72
1.91
2.15
2.34
2.99
4.20
2.65
2.84
2.01
2.20
0.82
1.16
1.35
1.43
1.31
14.86
24.16
16.70
8.95
13.05
14.15
10.09
0.00
2.73
2.07
1.45
1.00
7.99
7.06
0.30
6.06
9.14
1.12
0.44
0.98
0.97
0.97
1.11
1.20
1.28
1.49
1.59
0.27
0.35
1.28
1.55
0.48
1.76
1.80
Malpractice
RVUs 2
1.63
1.71
1.68
2.24
2.49
0.83
0.83
0.17
0.05
0.05
0.16
0.19
0.18
0.17
0.14
0.20
0.21
0.21
0.26
0.19
0.22
0.29
0.29
0.26
0.29
0.33
0.37
0.37
0.78
0.43
0.49
0.31
0.35
0.09
0.14
0.21
0.23
0.18
1.00
1.76
1.72
0.97
1.06
0.84
0.68
0.00
0.80
0.40
0.44
0.40
0.79
0.46
0.08
0.42
0.58
0.16
0.11
0.18
0.13
0.13
0.18
0.18
0.16
0.32
0.34
0.18
0.16
0.24
0.31
0.13
0.22
0.46
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00221
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
YYY
000
000
000
000
090
090
000
090
090
000
ZZZ
000
000
000
000
000
000
000
000
ZZZ
ZZZ
000
000
ZZZ
000
000
66442
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
31641
31643
31645
31646
31656
31715
31717
31720
31725
31730
31750
31755
31760
31766
31770
31775
31780
31781
31785
31786
31800
31805
31820
31825
31830
31899
32035
32036
32095
32100
32110
32120
32124
32140
32141
32150
32151
32160
32200
32201
32215
32220
32225
32310
32320
32400
32402
32405
32420
32421
32422
32440
32442
32445
32480
32482
32484
32486
32488
32491
32500
32501
32503
32504
32540
32550
32551
32560
32601
32602
32603
32604
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Bronchoscopy, treat blockage ............
Diag bronchoscope/catheter ...............
Bronchoscopy, clear airways ..............
Bronchoscopy, reclear airway .............
Bronchoscopy, inj for x-ray .................
Injection for bronchus x-ray ................
Bronchial brush biopsy .......................
Clearance of airways ..........................
Clearance of airways ..........................
Intro, windpipe wire/tube .....................
Repair of windpipe ..............................
Repair of windpipe ..............................
Repair of windpipe ..............................
Reconstruction of windpipe .................
Repair/graft of bronchus .....................
Reconstruct bronchus .........................
Reconstruct windpipe ..........................
Reconstruct windpipe ..........................
Remove windpipe lesion .....................
Remove windpipe lesion .....................
Repair of windpipe injury ....................
Repair of windpipe injury ....................
Closure of windpipe lesion ..................
Repair of windpipe defect ...................
Revise windpipe scar ..........................
Airways surgical procedure .................
Exploration of chest ............................
Exploration of chest ............................
Biopsy through chest wall ...................
Exploration/biopsy of chest .................
Explore/repair chest ............................
Re-exploration of chest .......................
Explore chest free adhesions .............
Removal of lung lesion(s) ...................
Remove/treat lung lesions ..................
Removal of lung lesion(s) ...................
Remove lung foreign body ..................
Open chest heart massage ................
Drain, open, lung lesion ......................
Drain, percut, lung lesion ....................
Treat chest lining ................................
Release of lung ...................................
Partial release of lung .........................
Removal of chest lining ......................
Free/remove chest lining ....................
Needle biopsy chest lining ..................
Open biopsy chest lining ....................
Biopsy, lung or mediastinum ..............
Puncture/clear lung .............................
Thoracentesis for aspiration ...............
Thoracentesis w/tube insert ................
Removal of lung ..................................
Sleeve pneumonectomy .....................
Removal of lung ..................................
Partial removal of lung ........................
Bilobectomy .........................................
Segmentectomy ..................................
Sleeve lobectomy ................................
Completion pneumonectomy ..............
Lung volume reduction .......................
Partial removal of lung ........................
Repair bronchus add-on .....................
Resect apical lung tumor ....................
Resect apical lung tum/chest ..............
Removal of lung lesion .......................
Insert pleural cath ...............................
Insertion of chest tube ........................
Treat lung lining chemically ................
Thoracoscopy, diagnostic ...................
Thoracoscopy, diagnostic ...................
Thoracoscopy, diagnostic ...................
Thoracoscopy, diagnostic ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.02
3.49
3.16
2.72
2.17
1.11
2.12
1.06
1.96
2.85
15.19
17.19
23.36
31.58
23.48
24.51
19.70
24.77
18.29
25.34
8.10
13.34
4.58
6.98
4.54
0.00
11.20
12.21
10.06
16.08
25.15
14.27
15.33
16.54
27.10
16.70
16.82
13.02
18.48
3.99
12.93
26.41
16.63
15.16
27.04
1.76
8.89
1.93
2.18
1.54
2.19
27.17
56.37
63.60
25.71
27.28
25.30
42.80
42.83
25.09
24.48
4.68
31.61
36.41
30.22
4.17
3.29
2.19
5.45
5.95
7.80
8.77
NA
NA
4.72
4.41
5.68
NA
5.84
NA
NA
25.71
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.85
7.44
5.93
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
19.84
NA
NA
NA
NA
NA
2.15
NA
0.69
NA
2.40
2.87
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
14.95
NA
5.05
NA
NA
NA
NA
NA
NA
4.93
4.63
6.48
NA
7.04
NA
NA
13.95
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.76
7.55
5.84
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
20.27
NA
NA
NA
NA
NA
2.14
NA
0.68
NA
2.73
3.04
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
17.45
NA
5.75
NA
NA
NA
NA
1.49
1.04
0.96
0.85
0.68
0.25
0.72
0.27
0.41
0.74
17.44
23.97
9.77
11.68
8.53
9.50
8.79
9.66
7.67
9.61
8.67
6.21
3.26
4.47
3.56
0.00
6.08
6.29
5.10
7.00
9.87
6.78
6.95
7.39
10.17
7.50
7.91
5.84
8.76
1.42
6.23
11.90
7.45
6.92
11.44
0.57
4.68
0.69
0.71
0.47
1.03
10.91
18.71
22.77
10.18
11.08
9.56
14.60
15.56
10.42
10.26
1.33
12.08
13.46
11.48
1.51
0.97
0.58
2.06
2.22
2.74
3.05
1.68
1.13
1.04
0.92
0.76
0.29
0.75
0.30
0.49
0.87
17.49
24.24
10.24
12.66
9.38
10.64
9.92
10.89
8.92
11.35
8.95
6.71
3.45
4.92
3.77
0.00
5.96
6.36
5.23
7.41
10.29
6.92
7.08
7.53
8.86
7.55
7.95
5.55
8.68
1.36
6.56
12.42
7.55
7.15
11.79
0.56
4.89
0.66
0.69
0.47
1.04
11.90
16.73
18.41
11.12
11.99
10.47
13.92
14.67
11.52
11.30
1.43
13.57
15.06
10.55
1.58
1.16
0.64
2.21
2.37
2.88
3.25
Malpractice
RVUs 2
0.35
0.20
0.16
0.14
0.15
0.07
0.14
0.07
0.14
0.21
1.05
1.29
2.95
4.53
2.84
3.02
1.65
2.25
1.59
3.30
0.79
1.83
0.38
0.53
0.44
0.00
1.26
1.43
1.22
2.24
3.22
1.63
1.90
1.97
2.01
2.01
2.04
1.31
2.14
0.24
1.69
3.57
2.07
2.00
3.52
0.10
1.07
0.11
0.12
0.08
0.12
3.69
3.85
3.72
3.50
3.67
3.04
3.52
3.81
2.99
3.26
0.65
4.38
5.09
2.08
0.42
0.43
0.23
0.80
0.87
1.14
1.25
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00222
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
090
090
090
090
000
090
000
000
000
000
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
000
000
000
000
000
000
000
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66443
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
32605
32606
32650
32651
32652
32653
32654
32655
32656
32657
32658
32659
32660
32661
32662
32663
32664
32665
32800
32810
32815
32820
32850
32851
32852
32853
32854
32855
32856
32900
32905
32906
32940
32960
32997
32998
32999
33010
33011
33015
33020
33025
33030
33031
33050
33120
33130
33140
33141
33202
33203
33206
33207
33208
33210
33211
33212
33213
33214
33215
33216
33217
33218
33220
33222
33223
33224
33225
33226
33233
33234
33235
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
X
A
A
A
A
C
C
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Thoracoscopy, diagnostic ...................
Thoracoscopy, diagnostic ...................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Thoracoscopy, surgical .......................
Repair lung hernia ..............................
Close chest after drainage ..................
Close bronchial fistula .........................
Reconstruct injured chest ...................
Donor pneumonectomy .......................
Lung transplant, single ........................
Lung transplant with bypass ...............
Lung transplant, double ......................
Lung transplant with bypass ...............
Prepare donor lung, single .................
Prepare donor lung, double ................
Removal of rib(s) ................................
Revise & repair chest wall ..................
Revise & repair chest wall ..................
Revision of lung ..................................
Therapeutic pneumothorax .................
Total lung lavage ................................
Perq rf ablate tx, pul tumor .................
Chest surgery procedure ....................
Drainage of heart sac .........................
Repeat drainage of heart sac .............
Incision of heart sac ............................
Incision of heart sac ............................
Incision of heart sac ............................
Partial removal of heart sac ................
Partial removal of heart sac ................
Removal of heart sac lesion ...............
Removal of heart lesion ......................
Removal of heart lesion ......................
Heart revascularize (tmr) ....................
Heart tmr w/other procedure ...............
Insert epicard eltrd, open ....................
Insert epicard eltrd, endo ....................
Insertion of heart pacemaker ..............
Insertion of heart pacemaker ..............
Insertion of heart pacemaker ..............
Insertion of heart electrode .................
Insertion of heart electrode .................
Insertion of pulse generator ................
Insertion of pulse generator ................
Upgrade of pacemaker system ...........
Reposition pacing-defib lead ..............
Insert lead pace-defib, one .................
Insert lead pace-defib, dual ................
Repair lead pace-defib, one ...............
Repair lead pace-defib, dual ...............
Revise pocket, pacemaker .................
Revise pocket, pacing-defib ................
Insert pacing lead & connect ..............
L ventric pacing lead add-on ..............
Reposition l ventric lead .....................
Removal of pacemaker system ..........
Removal of pacemaker system ..........
Removal pacemaker electrode ...........
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.92
8.39
10.77
18.70
29.00
18.09
20.44
16.09
13.18
12.85
11.65
11.86
17.69
13.27
14.91
24.56
14.22
21.45
15.59
14.83
49.79
22.33
0.00
40.94
44.65
50.11
53.88
0.00
0.00
23.69
23.17
29.18
21.22
1.84
7.31
5.68
0.00
2.24
2.24
8.44
14.87
13.65
22.27
25.30
16.85
27.33
24.05
28.26
2.54
13.15
13.92
7.31
8.00
8.72
3.30
3.39
5.51
6.36
7.78
4.89
5.81
5.78
5.97
6.05
5.01
6.49
9.04
8.33
8.68
3.33
7.85
9.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
1.61
NA
70.18
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
1.67
NA
70.18
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.57
2.97
5.24
7.69
11.13
7.45
7.95
6.88
5.95
5.97
5.50
5.79
7.58
6.05
6.63
9.39
5.61
8.56
6.92
6.97
18.57
10.56
0.00
20.17
22.56
22.77
25.76
0.00
0.00
9.56
9.52
11.03
8.48
0.68
1.83
1.98
0.00
1.04
1.12
5.15
6.37
5.84
9.11
9.57
7.36
10.55
9.36
10.29
0.78
6.07
6.13
5.12
5.22
5.65
1.66
1.59
3.70
4.21
5.36
3.48
4.54
4.43
4.82
4.78
4.30
4.87
4.90
4.35
4.73
3.26
5.48
7.23
2.74
3.15
6.00
7.46
10.63
7.21
7.74
7.06
6.94
6.82
6.42
6.62
8.53
6.91
7.73
10.07
6.62
8.34
7.16
7.24
14.77
11.36
0.00
23.91
27.85
27.25
30.24
0.00
0.00
9.72
9.82
11.54
8.98
0.62
1.87
1.98
0.00
0.91
0.97
5.05
6.57
6.09
9.31
9.80
7.60
11.06
9.73
10.58
1.18
6.07
6.13
4.79
4.94
5.21
1.45
1.45
3.53
3.96
5.12
3.33
4.37
4.33
4.56
4.52
4.29
4.73
4.45
3.80
4.28
3.27
5.19
7.02
Malpractice
RVUs 2
1.00
1.22
1.58
1.87
2.73
1.89
1.63
1.90
1.90
2.00
1.70
1.62
2.09
1.93
2.18
2.73
2.33
2.16
1.99
1.94
3.28
2.53
0.00
5.58
6.02
7.07
7.22
0.00
0.00
2.94
3.16
3.98
2.89
0.16
0.55
0.36
0.00
0.14
0.15
0.65
1.80
1.81
2.84
3.14
2.15
3.70
3.01
2.86
0.69
1.71
1.39
0.52
0.59
0.56
0.18
0.21
0.43
0.45
0.58
0.37
0.36
0.39
0.37
0.37
0.42
0.45
0.54
0.45
0.59
0.22
0.56
0.73
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00223
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
XXX
090
090
090
090
XXX
XXX
090
090
090
090
000
000
000
YYY
000
000
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
000
000
090
090
090
090
090
090
090
090
090
090
000
ZZZ
000
090
090
090
66444
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
33236
33237
33238
33240
33241
33243
33244
33249
33250
33251
33254
33255
33256
33257
33258
33259
33261
33265
33266
33282
33284
33300
33305
33310
33315
33320
33321
33322
33330
33332
33335
33400
33401
33403
33404
33405
33406
33410
33411
33412
33413
33414
33415
33416
33417
33420
33422
33425
33426
33427
33430
33460
33463
33463
33464
33465
33468
33470
33471
33472
33474
33475
33476
33478
33496
33500
33501
33502
33503
33504
33505
33506
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove electrode/thoracotomy ..........
Remove electrode/thoracotomy ..........
Remove electrode/thoracotomy ..........
Insert pulse generator .........................
Remove pulse generator ....................
Remove eltrd/thoracotomy ..................
Remove eltrd, transven .......................
Eltrd/insert pace-defib .........................
Ablate heart dysrhythm focus .............
Ablate heart dysrhythm focus .............
Ablate atria, lmtd .................................
Ablate atria w/o bypass, ext ...............
Ablate atria w/bypass, exten ...............
Ablate atria, lmtd, add-on ...................
Ablate atria, x10sv, add-on .................
Ablate atria w/bypass add-on .............
Ablate heart dysrhythm focus .............
Ablate atria, lmtd, endo .......................
Ablate atria, x10sv, endo ....................
Implant pat-active ht record ................
Remove pat-active ht record ..............
Repair of heart wound ........................
Repair of heart wound ........................
Exploratory heart surgery ...................
Exploratory heart surgery ...................
Repair major blood vessel(s) ..............
Repair major vessel ............................
Repair major blood vessel(s) ..............
Insert major vessel graft .....................
Insert major vessel graft .....................
Insert major vessel graft .....................
Repair of aortic valve ..........................
Valvuloplasty, open .............................
Valvuloplasty, w/cp bypass .................
Prepare heart-aorta conduit ................
Replacement of aortic valve ...............
Replacement of aortic valve ...............
Replacement of aortic valve ...............
Replacement of aortic valve ...............
Replacement of aortic valve ...............
Replacement of aortic valve ...............
Repair of aortic valve ..........................
Revision, subvalvular tissue ...............
Revise ventricle muscle ......................
Repair of aortic valve ..........................
Revision of mitral valve .......................
Revision of mitral valve .......................
Repair of mitral valve ..........................
Repair of mitral valve ..........................
Repair of mitral valve ..........................
Replacement of mitral valve ...............
Revision of tricuspid valve ..................
Valvuloplasty, tricuspid .......................
Valvuloplasty, tricuspid .......................
Valvuloplasty, tricuspid .......................
Replace tricuspid valve .......................
Revision of tricuspid valve ..................
Revision of pulmonary valve ...............
Valvotomy, pulmonary valve ...............
Revision of pulmonary valve ...............
Revision of pulmonary valve ...............
Replacement, pulmonary valve ..........
Revision of heart chamber ..................
Revision of heart chamber ..................
Repair, prosth valve clot .....................
Repair heart vessel fistula ..................
Repair heart vessel fistula ..................
Coronary artery correction ..................
Coronary artery graft ...........................
Coronary artery graft ...........................
Repair artery w/tunnel .........................
Repair artery, translocation .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
12.64
13.75
15.28
7.61
3.26
23.42
13.84
15.02
25.78
28.80
23.58
28.91
34.77
9.63
11.00
14.14
28.80
23.58
32.91
4.70
3.04
44.89
76.85
20.22
26.05
18.46
20.71
24.30
25.17
24.46
33.79
41.37
24.41
25.39
31.25
41.19
52.55
46.28
61.94
43.77
59.74
39.29
37.19
36.43
29.17
25.67
29.61
49.83
43.15
44.70
50.75
44.62
56.95
56.95
44.49
50.59
32.82
21.32
22.83
22.90
39.27
42.27
26.41
27.38
29.71
27.82
19.43
21.69
22.29
25.30
38.35
37.80
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.37
8.01
8.04
5.25
3.00
10.93
9.43
10.15
10.88
10.95
9.76
11.36
13.11
5.46
5.98
7.79
11.68
9.76
12.55
4.23
3.37
15.05
25.11
8.35
10.34
8.00
8.37
9.54
9.49
9.45
12.48
14.56
10.27
12.52
12.00
15.10
18.36
16.51
21.08
16.20
23.52
14.27
13.14
13.23
11.69
9.49
11.35
17.59
15.74
15.69
18.55
14.70
19.71
19.71
15.83
17.63
15.23
7.92
11.58
8.78
12.93
15.05
10.36
11.01
11.08
11.02
7.99
9.33
12.31
10.58
15.12
12.69
6.90
7.89
8.12
4.91
2.98
11.19
9.16
9.25
10.94
11.30
9.76
11.36
13.11
5.46
5.98
7.79
11.72
9.76
12.55
4.12
3.45
12.14
17.85
8.96
10.61
8.11
9.07
9.95
9.87
9.98
12.90
15.11
11.88
13.41
13.27
16.69
18.74
16.54
19.90
18.30
22.16
14.20
12.57
13.36
12.65
9.52
12.50
15.32
16.43
17.52
17.91
13.00
16.31
16.31
14.67
15.29
14.44
9.30
10.67
10.31
11.90
15.21
11.15
12.03
11.91
11.24
8.13
10.19
11.02
11.19
14.01
13.62
Malpractice
RVUs 2
1.69
1.59
2.03
0.41
0.18
2.10
0.99
0.77
3.19
3.60
3.35
3.94
4.95
0.89
1.09
1.78
3.46
3.35
4.80
0.23
0.14
2.66
3.13
2.59
3.28
2.08
2.91
2.86
2.82
3.03
4.28
4.11
3.57
3.55
4.33
5.33
5.45
4.69
5.48
6.39
6.53
4.57
4.14
4.57
4.10
1.82
3.94
4.07
5.03
6.09
5.10
3.45
3.87
3.87
4.15
4.39
4.07
1.03
3.39
3.55
3.22
4.93
2.42
3.89
4.13
3.87
1.91
3.00
1.78
3.36
2.19
4.66
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00224
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66445
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
33507
33508
33510
33511
33512
33513
33514
33516
33517
33518
33519
33521
33522
33523
33530
33533
33534
33535
33536
33542
33545
33548
33572
33600
33602
33606
33608
33610
33611
33612
33615
33617
33619
33641
33645
33647
33660
33665
33670
33675
33676
33677
33681
33684
33688
33690
33692
33694
33697
33702
33710
33720
33722
33724
33726
33730
33732
33735
33736
33737
33750
33755
33762
33764
33766
33767
33768
33770
33771
33774
33775
33776
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Repair art, intramural ..........................
Endoscopic vein harvest .....................
CABG, vein, single ..............................
CABG, vein, two .................................
CABG, vein, three ...............................
CABG, vein, four .................................
CABG, vein, five .................................
Cabg, vein, six or more ......................
CABG, artery-vein, single ...................
CABG, artery-vein, two .......................
CABG, artery-vein, three ....................
CABG, artery-vein, four ......................
CABG, artery-vein, five .......................
Cabg, art-vein, six or more .................
Coronary artery, bypass/reop .............
CABG, arterial, single .........................
CABG, arterial, two .............................
CABG, arterial, three ..........................
Cabg, arterial, four or more ................
Removal of heart lesion ......................
Repair of heart damage ......................
Restore/remodel, ventricle ..................
Open coronary endarterectomy ..........
Closure of valve ..................................
Closure of valve ..................................
Anastomosis/artery-aorta ....................
Repair anomaly w/conduit ..................
Repair by enlargement .......................
Repair double ventricle .......................
Repair double ventricle .......................
Repair, modified fontan .......................
Repair single ventricle ........................
Repair single ventricle ........................
Repair heart septum defect ................
Revision of heart veins .......................
Repair heart septum defects ..............
Repair of heart defects .......................
Repair of heart defects .......................
Repair of heart chambers ...................
Close mult vsd ....................................
Close mult vsd w/resection .................
Cl mult vsd w/rem pul band ................
Repair heart septum defect ................
Repair heart septum defect ................
Repair heart septum defect ................
Reinforce pulmonary artery ................
Repair of heart defects .......................
Repair of heart defects .......................
Repair of heart defects .......................
Repair of heart defects .......................
Repair of heart defects .......................
Repair of heart defect .........................
Repair of heart defect .........................
Repair venous anomaly ......................
Repair pul venous stenosis ................
Repair heart-vein defect(s) .................
Repair heart-vein defect .....................
Revision of heart chamber ..................
Revision of heart chamber ..................
Revision of heart chamber ..................
Major vessel shunt ..............................
Major vessel shunt ..............................
Major vessel shunt ..............................
Major vessel shunt & graft ..................
Major vessel shunt ..............................
Major vessel shunt ..............................
Cavopulmonary shunting ....................
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
31.35
0.31
34.87
38.34
43.87
45.26
47.97
49.65
3.61
7.93
10.49
12.59
14.14
16.08
10.13
33.64
39.77
44.64
48.32
48.08
56.93
53.96
4.44
30.15
29.18
31.37
31.72
31.24
35.49
36.49
35.76
38.96
48.60
29.50
27.98
29.37
31.75
34.77
36.58
35.87
36.87
38.37
32.16
34.29
34.67
20.20
31.38
35.49
37.49
27.11
30.28
27.13
29.05
27.55
37.04
36.01
28.80
22.04
24.16
22.34
22.06
22.44
22.44
22.44
23.41
25.14
8.00
39.02
40.58
31.54
32.83
34.53
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
11.08
0.09
12.90
14.15
15.93
16.36
17.33
17.95
1.08
2.36
3.14
3.77
4.23
4.78
2.95
12.55
14.73
16.29
17.31
16.88
20.13
19.32
1.31
12.14
11.16
11.90
12.85
13.54
12.36
14.30
13.78
13.94
17.97
10.88
10.66
12.70
11.82
12.16
15.62
15.74
16.04
16.61
12.87
13.28
11.61
8.63
19.57
10.04
16.93
10.52
11.25
10.68
10.60
10.37
13.21
12.85
12.65
11.03
12.06
9.12
9.42
7.79
8.68
8.94
8.47
8.50
1.84
11.91
13.07
12.19
10.09
10.24
12.36
0.10
14.61
15.60
16.76
17.07
17.69
18.37
0.96
1.97
2.73
3.42
4.02
4.65
2.43
14.50
16.22
17.20
17.80
14.93
17.87
19.30
1.38
12.32
11.80
12.78
13.47
13.57
13.24
14.72
13.46
14.96
19.38
10.22
11.21
13.23
12.65
12.99
14.39
15.74
16.04
16.61
13.77
13.45
11.04
9.39
16.74
12.12
15.90
11.54
12.60
11.48
12.22
10.37
13.21
13.48
13.01
9.99
11.95
10.02
9.81
8.29
9.41
9.58
10.06
10.11
2.25
13.29
12.73
13.42
12.54
13.02
Malpractice
RVUs 2
4.06
0.04
4.41
4.56
4.67
4.88
4.77
5.13
0.39
0.73
1.04
1.37
1.78
2.13
0.88
4.56
4.70
5.03
5.44
4.38
5.21
5.53
0.65
4.42
3.82
4.41
4.74
4.56
4.37
5.30
4.32
5.66
6.46
3.23
3.79
3.32
4.49
4.00
4.65
4.95
5.44
5.68
4.45
3.39
4.73
1.97
4.58
5.28
4.09
3.68
4.43
3.84
1.30
4.00
5.03
5.03
3.68
1.92
3.09
3.25
1.16
3.26
3.14
3.01
3.70
3.82
1.19
5.74
5.68
4.81
4.99
5.09
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00225
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
ZZZ
090
090
090
090
090
090
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
66446
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
33777
33778
33779
33780
33781
33786
33788
33800
33802
33803
33813
33814
33820
33822
33824
33840
33845
33851
33852
33853
33860
33861
33863
33864
33870
33875
33877
33880
33881
33883
33884
33886
33889
33891
33910
33915
33916
33917
33920
33922
33924
33925
33926
33930
33933
33935
33940
33944
33945
33960
33961
33967
33968
33970
33971
33973
33974
33975
33976
33977
33978
33979
33980
33999
34001
34051
34101
34111
34151
34201
34203
34401
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
X
C
R
X
C
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Repair great vessels defect ................
Repair arterial trunk ............................
Revision of pulmonary artery ..............
Aortic suspension ................................
Repair vessel defect ...........................
Repair vessel defect ...........................
Repair septal defect ............................
Repair septal defect ............................
Revise major vessel ............................
Revise major vessel ............................
Revise major vessel ............................
Remove aorta constriction ..................
Remove aorta constriction ..................
Remove aorta constriction ..................
Repair septal defect ............................
Repair septal defect ............................
Ascending aortic graft .........................
Ascending aortic graft .........................
Ascending aortic graft .........................
Ascending aortic graft .........................
Transverse aortic arch graft ................
Thoracic aortic graft ............................
Thoracoabdominal graft ......................
Endovasc taa repr incl subcl ..............
Endovasc taa repr w/o subcl ..............
Insert endovasc prosth, taa ................
Endovasc prosth, taa, add-on .............
Endovasc prosth, delayed ..................
Artery transpose/endovas taa .............
Car-car bp grft/endovas taa ................
Remove lung artery emboli .................
Remove lung artery emboli .................
Surgery of great vessel .......................
Repair pulmonary artery .....................
Repair pulmonary atresia ....................
Transect pulmonary artery ..................
Remove pulmonary shunt ...................
Rpr pul art unifocal w/o cpb ................
Repr pul art, unifocal w/cpb ................
Removal of donor heart/lung ..............
Prepare donor heart/lung ....................
Transplantation, heart/lung .................
Removal of donor heart ......................
Prepare donor heart ............................
Transplantation of heart ......................
External circulation assist ...................
External circulation assist ...................
Insert ia percut device ........................
Remove aortic assist device ...............
Aortic circulation assist .......................
Aortic circulation assist .......................
Insert balloon device ...........................
Remove intra-aortic balloon ................
Implant ventricular device ...................
Implant ventricular device ...................
Remove ventricular device .................
Remove ventricular device .................
Insert intracorporeal device ................
Remove intracorporeal device ............
Cardiac surgery procedure .................
Removal of artery clot .........................
Removal of artery clot .........................
Removal of artery clot .........................
Removal of arm artery clot .................
Removal of artery clot .........................
Removal of artery clot .........................
Removal of leg artery clot ...................
Removal of vein clot ...........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
33.95
42.62
43.15
43.85
43.16
41.74
27.26
17.23
18.24
20.18
21.23
26.41
16.61
17.63
20.10
21.21
22.77
21.85
24.28
32.35
59.33
43.94
58.71
60.00
45.93
35.68
68.85
34.48
29.48
20.99
8.20
17.99
15.92
20.00
29.59
24.83
28.30
25.14
32.58
24.09
5.49
31.25
44.68
0.00
0.00
61.68
0.00
0.00
89.08
19.33
10.91
4.84
0.64
6.74
11.91
9.75
14.93
20.97
22.97
20.07
22.51
45.93
64.86
0.00
17.78
16.91
10.85
10.85
26.41
19.38
17.73
26.41
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
9.91
14.91
12.44
13.13
11.11
14.09
8.24
6.82
7.94
6.38
8.80
10.39
6.95
5.93
8.45
9.33
9.37
8.87
14.75
12.24
20.20
15.69
19.58
20.09
16.27
12.90
21.00
10.91
9.66
7.23
2.08
6.33
3.98
5.81
11.34
9.11
10.82
10.02
9.46
10.24
1.59
16.42
14.79
0.00
0.00
22.94
0.00
0.00
30.37
5.25
2.98
2.40
0.26
2.53
6.00
3.94
7.73
6.29
7.66
9.41
10.42
13.28
23.06
0.00
6.36
7.43
4.30
4.28
8.65
6.54
6.38
9.26
12.76
15.90
13.90
16.10
12.22
15.40
10.09
7.46
8.58
8.07
9.85
11.52
7.65
7.44
9.21
9.81
10.36
9.77
13.05
13.53
18.32
16.69
19.13
20.09
17.32
13.49
18.65
12.19
10.80
8.20
2.33
7.28
4.58
6.38
11.38
9.37
11.07
11.10
11.64
10.57
1.72
15.54
16.23
0.00
0.00
25.84
0.00
0.00
25.87
5.08
3.30
2.12
0.24
2.41
6.00
3.62
7.80
6.29
7.60
10.23
11.08
14.09
24.14
0.00
6.53
7.60
4.82
4.82
9.52
5.98
7.21
9.96
Malpractice
RVUs 2
5.49
6.20
2.92
3.68
5.97
5.71
4.03
2.46
2.27
3.20
3.13
3.85
2.35
2.68
2.89
2.16
3.22
3.18
2.16
4.48
5.76
6.37
6.59
6.73
6.62
4.89
5.94
2.75
2.33
2.11
0.86
1.80
2.18
2.73
3.70
1.44
3.67
3.70
4.38
3.10
0.82
4.61
6.22
0.00
0.00
9.06
0.00
0.00
6.26
2.67
0.88
0.35
0.07
0.82
1.25
1.26
1.74
3.07
3.26
2.81
3.31
6.97
8.59
0.00
1.85
2.21
1.41
1.40
3.56
1.45
2.36
3.10
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00226
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
000
000
090
090
090
090
090
090
ZZZ
090
090
XXX
XXX
090
XXX
XXX
090
000
ZZZ
000
000
000
090
000
090
XXX
XXX
090
090
XXX
090
YYY
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66447
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
34421
34451
34471
34490
34501
34502
34510
34520
34530
34800
34802
34803
34804
34805
34806
34808
34812
34813
34820
34825
34826
34830
34831
34832
34833
34834
34900
35001
35002
35005
35011
35013
35021
35022
35045
35081
35082
35091
35092
35102
35103
35111
35112
35121
35122
35131
35132
35141
35142
35151
35152
35180
35182
35184
35188
35189
35190
35201
35206
35207
35211
35216
35221
35226
35231
35236
35241
35246
35251
35256
35261
35266
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of vein clot ...........................
Removal of vein clot ...........................
Removal of vein clot ...........................
Removal of vein clot ...........................
Repair valve, femoral vein ..................
Reconstruct vena cava .......................
Transposition of vein valve .................
Cross-over vein graft ..........................
Leg vein fusion ....................................
Endovas aaa repr w/sm tube ..............
Endovas aaa repr w/2-p part ..............
Endovas aaa repr w/3-p part ..............
Endovas aaa repr w/1-p part ..............
Endovas aaa repr w/long tube ............
Aneurysm press sensor add-on ..........
Endovas iliac a device addon .............
Xpose for endoprosth, femorl .............
Femoral endovas graft add-on ...........
Xpose for endoprosth, iliac .................
Endovasc extend prosth, init ..............
Endovasc exten prosth, add’l .............
Open aortic tube prosth repr ..............
Open aortoiliac prosth repr .................
Open aortofemor prosth repr ..............
Xpose for endoprosth, iliac .................
Xpose, endoprosth, brachial ...............
Endovasc iliac repr w/graft .................
Repair defect of artery ........................
Repair artery rupture, neck .................
Repair defect of artery ........................
Repair defect of artery ........................
Repair artery rupture, arm ..................
Repair defect of artery ........................
Repair artery rupture, chest ................
Repair defect of arm artery .................
Repair defect of artery ........................
Repair artery rupture, aorta ................
Repair defect of artery ........................
Repair artery rupture, aorta ................
Repair defect of artery ........................
Repair artery rupture, groin ................
Repair defect of artery ........................
Repair artery rupture,spleen ...............
Repair defect of artery ........................
Repair artery rupture, belly .................
Repair defect of artery ........................
Repair artery rupture, groin ................
Repair defect of artery ........................
Repair artery rupture, thigh .................
Repair defect of artery ........................
Repair artery rupture, knee .................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
13.29
28.41
21.00
10.83
16.74
27.86
19.80
19.05
17.77
21.46
23.71
24.74
23.71
22.59
2.06
4.12
6.74
4.79
9.74
12.72
4.12
35.10
37.85
37.85
11.98
5.34
16.77
20.70
22.12
19.18
18.50
23.10
22.09
25.62
17.94
33.37
41.93
35.35
50.81
36.37
43.49
26.17
32.44
31.41
37.76
26.29
32.44
20.83
25.03
23.61
27.53
15.01
31.58
18.72
15.05
29.85
13.33
16.84
13.76
10.85
24.50
36.47
26.54
15.22
21.08
17.94
25.50
28.15
31.83
18.98
18.88
15.75
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.51
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.51
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.19
9.38
7.86
4.34
6.42
10.47
7.52
7.01
6.76
7.25
8.17
8.01
8.06
7.26
0.51
1.05
1.66
1.16
2.45
5.14
1.14
10.33
11.27
11.80
3.29
1.57
6.05
7.70
7.51
8.52
6.29
7.76
8.46
10.57
6.27
10.70
12.76
9.99
14.50
11.28
12.63
8.50
10.07
9.96
11.51
8.63
10.28
6.93
8.24
7.64
9.11
6.25
10.82
6.50
6.28
10.67
5.23
6.31
5.30
6.63
9.70
13.56
8.33
5.79
7.72
6.29
10.02
10.10
9.45
6.37
6.97
5.47
5.74
10.40
6.58
4.88
7.45
11.38
8.46
7.73
7.68
8.20
8.97
9.11
8.93
8.45
0.51
1.21
1.95
1.36
2.84
5.64
1.25
12.01
11.49
13.21
3.86
1.88
6.81
8.62
8.60
8.68
7.13
8.71
8.93
10.21
6.88
11.08
14.02
11.77
16.06
11.82
14.23
9.48
11.01
11.16
12.65
9.68
11.32
7.92
9.30
8.81
10.24
6.60
11.81
7.39
6.95
11.30
5.85
7.15
5.92
6.99
10.15
11.26
9.13
6.61
8.74
7.08
10.56
10.76
10.61
7.35
7.49
6.23
Malpractice
RVUs 2
1.55
3.84
1.18
1.41
2.35
3.63
2.33
2.29
1.74
2.46
2.33
2.01
2.30
2.01
0.30
0.59
1.18
0.67
1.50
1.28
0.44
4.55
4.89
4.85
1.70
0.76
2.00
2.81
3.00
1.77
2.55
3.10
2.87
3.17
2.45
4.01
5.44
5.14
6.40
4.48
5.76
3.47
4.08
4.30
4.75
3.80
4.30
2.90
3.36
3.24
3.61
1.00
4.36
2.53
2.16
4.01
1.80
2.34
1.87
1.48
3.20
2.65
3.37
2.02
2.89
2.43
3.53
3.86
4.13
2.63
2.61
2.10
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00227
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
000
ZZZ
000
090
ZZZ
090
090
090
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66448
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
35271
35276
35281
35286
35301
35302
35303
35304
35305
35306
35311
35321
35331
35341
35351
35355
35361
35363
35371
35372
35390
35400
35450
35452
35454
35456
35458
35459
35460
35470
35471
35472
35473
35474
35475
35476
35480
35481
35482
35483
35484
35485
35490
35491
35492
35493
35494
35495
35500
35501
35506
35508
35509
35510
35511
35512
35515
35516
35518
35521
35522
35523
35525
35526
35531
35533
35536
35537
35538
35539
35540
35548
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Repair blood vessel lesion ..................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Rechanneling of artery ........................
Reoperation, carotid add-on ...............
Angioscopy ..........................................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair venous blockage .....................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair venous blockage .....................
Atherectomy, open ..............................
Atherectomy, open ..............................
Atherectomy, open ..............................
Atherectomy, open ..............................
Atherectomy, open ..............................
Atherectomy, open ..............................
Atherectomy, percutaneous ................
Atherectomy, percutaneous ................
Atherectomy, percutaneous ................
Atherectomy, percutaneous ................
Atherectomy, percutaneous ................
Atherectomy, percutaneous ................
Harvest vein for bypass ......................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
24.50
25.72
29.93
17.06
19.53
21.27
23.52
24.52
23.52
9.25
28.52
16.51
27.61
26.10
24.53
19.78
30.11
32.22
15.23
18.50
3.19
3.00
10.05
6.90
6.03
7.34
9.48
8.62
6.03
8.62
10.05
6.90
6.03
7.35
9.48
6.03
11.06
7.60
6.64
8.09
10.42
9.48
11.06
7.60
6.64
8.09
10.42
9.48
6.44
28.99
25.23
25.99
27.99
24.29
22.12
23.79
25.99
24.11
22.57
24.00
23.05
24.00
21.59
31.47
38.98
29.79
33.60
41.75
46.82
43.98
49.20
22.57
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
61.12
65.97
47.48
46.50
60.37
48.63
37.11
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
74.97
83.09
55.90
53.15
74.03
52.35
40.91
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.68
9.78
9.28
6.31
6.68
6.90
7.45
7.70
7.45
2.28
9.63
5.77
8.81
8.24
7.64
6.35
9.59
10.43
5.33
6.12
0.82
0.72
2.97
2.06
1.76
2.12
2.80
2.65
1.74
3.44
4.68
2.81
2.49
2.98
3.38
2.23
4.04
2.57
2.01
2.56
2.90
2.87
5.17
3.85
3.48
3.96
5.15
4.45
1.59
11.06
8.31
8.76
10.77
7.69
7.65
7.47
9.08
7.45
7.32
7.94
7.39
9.20
7.03
14.03
11.46
9.49
9.50
13.08
14.43
13.46
14.80
7.73
10.09
10.48
10.48
7.17
7.55
6.90
7.45
7.70
7.45
2.28
10.68
6.57
10.01
9.55
8.61
7.21
10.64
11.50
6.14
7.08
0.94
0.91
3.26
2.33
2.04
2.44
3.13
2.91
2.01
3.39
4.31
2.78
2.46
2.93
3.47
2.29
4.04
2.72
2.28
2.79
3.33
3.20
4.93
3.57
3.34
3.88
4.80
4.42
1.81
9.75
8.88
9.10
9.77
8.93
8.50
8.73
9.18
7.12
8.14
8.88
8.57
9.20
8.20
13.26
12.96
10.60
11.22
13.08
14.43
13.46
14.80
8.57
Malpractice
RVUs 2
3.16
3.49
3.97
2.35
2.68
2.98
3.26
3.41
3.26
1.34
3.42
2.25
3.83
3.78
3.35
2.67
4.15
4.33
2.14
2.63
0.46
0.43
1.25
0.94
0.87
1.04
1.26
1.21
0.83
0.69
0.67
0.58
0.51
0.57
0.62
0.34
1.28
1.13
0.89
1.15
1.27
1.35
0.71
0.74
0.43
0.56
0.59
0.69
0.93
4.10
2.87
2.78
3.92
2.12
2.91
2.12
2.78
2.34
3.03
3.13
2.12
2.14
2.12
3.63
5.18
3.85
4.62
5.72
6.39
6.02
6.76
2.98
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00228
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66449
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
35549
35551
35556
35558
35560
35563
35565
35566
35571
35572
35583
35585
35587
35600
35601
35606
35612
35616
35621
35623
35626
35631
35636
35637
35638
35642
35645
35646
35647
35650
35651
35654
35656
35661
35663
35665
35666
35671
35681
35682
35683
35685
35686
35691
35693
35694
35695
35697
35700
35701
35721
35741
35761
35800
35820
35840
35860
35870
35875
35876
35879
35881
35883
35884
35901
35903
35905
35907
36000
36002
36005
36010
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Harvest femoropopliteal vein ..............
Vein bypass graft ................................
Vein bypass graft ................................
Vein bypass graft ................................
Harvest art for cabg add-on ................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Bypass graft, not vein .........................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Artery bypass graft ..............................
Composite bypass graft ......................
Composite bypass graft ......................
Composite bypass graft ......................
Bypass graft patency/patch ................
Bypass graft/av fist patency ................
Arterial transposition ...........................
Arterial transposition ...........................
Arterial transposition ...........................
Arterial transposition ...........................
Reimplant artery each .........................
Reoperation, bypass graft ...................
Exploration, carotid artery ...................
Exploration, femoral artery ..................
Exploration popliteal artery .................
Exploration of artery/vein ....................
Explore neck vessels ..........................
Explore chest vessels .........................
Explore abdominal vessels .................
Explore limb vessels ...........................
Repair vessel graft defect ...................
Removal of clot in graft .......................
Removal of clot in graft .......................
Revise graft w/vein .............................
Revise graft w/vein .............................
Revise graft w/nonauto graft ...............
Revise graft w/vein .............................
Excision, graft, neck ............................
Excision, graft, extremity .....................
Excision, graft, thorax .........................
Excision, graft, abdomen ....................
Place needle in vein ...........................
Pseudoaneurysm injection trt .............
Injection ext venography .....................
Place catheter in vein .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
24.34
27.72
26.62
23.00
33.90
25.99
25.00
32.22
25.39
6.81
27.62
32.22
26.08
4.94
26.99
22.36
16.71
21.74
20.95
25.79
29.06
35.90
31.62
32.92
33.47
18.85
18.34
32.84
29.62
20.08
25.97
26.17
20.39
20.22
23.80
22.22
23.53
20.64
1.60
7.19
8.49
4.04
3.34
18.32
15.64
19.19
19.97
3.00
3.08
9.11
7.66
8.61
5.84
7.99
36.81
10.87
6.72
24.39
10.64
17.74
17.28
19.22
23.07
24.57
8.26
9.44
33.39
37.14
0.18
1.96
0.95
2.43
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.46
2.24
8.46
11.09
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.51
2.55
8.05
15.19
8.73
9.37
8.63
7.86
10.61
8.87
8.16
9.84
8.08
1.92
8.63
10.10
8.50
1.52
10.42
7.30
6.31
7.12
6.77
8.43
10.27
10.55
9.71
10.64
10.78
6.21
7.97
10.44
9.65
6.92
8.70
8.35
6.83
7.04
7.89
7.35
8.50
7.62
0.40
1.69
1.96
0.96
0.85
5.94
6.11
6.31
6.70
0.74
0.76
4.31
3.83
3.86
3.43
3.95
12.90
4.81
3.38
7.91
4.28
5.94
5.97
6.46
8.49
8.93
4.24
4.60
10.65
10.87
0.06
0.85
0.39
0.78
9.55
10.42
9.17
8.70
11.96
9.69
9.14
10.61
9.46
2.08
9.39
11.15
9.97
1.57
9.52
8.15
7.09
7.61
7.72
9.46
11.12
12.18
11.00
10.64
10.78
7.45
8.12
11.77
10.70
7.64
9.71
9.50
7.71
7.98
8.93
8.40
9.56
8.49
0.47
2.04
2.39
1.15
0.99
7.17
6.91
7.45
7.62
0.88
0.89
4.73
4.13
4.26
3.72
4.30
10.05
5.04
3.70
8.84
4.73
6.72
6.83
7.56
8.49
8.93
4.77
5.37
11.91
12.51
0.06
0.91
0.35
0.79
Malpractice
RVUs 2
3.30
3.75
3.10
3.00
4.75
3.52
3.30
3.83
3.43
0.99
3.17
4.02
3.52
0.73
3.72
2.70
2.09
2.20
2.92
3.46
4.08
4.96
4.10
4.44
4.52
2.28
2.50
4.44
3.99
2.72
3.36
3.53
2.80
2.72
3.11
3.01
3.16
2.78
0.23
1.03
1.20
0.58
0.47
2.59
2.22
2.70
2.74
0.41
0.44
1.12
1.03
1.12
0.75
0.95
1.95
1.34
0.78
3.01
1.41
2.40
2.28
2.56
3.19
3.41
1.15
1.30
4.44
4.92
0.01
0.17
0.05
0.20
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00229
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
090
090
090
090
ZZZ
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
XXX
000
000
XXX
66450
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
36011
36012
36013
36014
36015
36100
36120
36140
36145
36160
36200
36215
36216
36217
36218
36245
36246
36247
36248
36260
36261
36262
36299
36400
36405
36406
36410
36415
36416
36420
36425
36430
36440
36450
36455
36460
36468
36469
36470
36471
36475
36476
36478
36479
36481
36500
36510
36511
36512
36513
36514
36515
36516
36522
36555
36556
36557
36558
36560
36561
36563
36565
36566
36568
36569
36570
36571
36575
36576
36578
36580
36581
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
X
B
A
A
A
A
A
A
A
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Place catheter in vein .........................
Place catheter in vein .........................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Establish access to artery ...................
Establish access to artery ...................
Establish access to artery ...................
Artery to vein shunt .............................
Establish access to aorta ....................
Place catheter in aorta ........................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Place catheter in artery .......................
Insertion of infusion pump ..................
Revision of infusion pump ..................
Removal of infusion pump ..................
Vessel injection procedure ..................
Bl draw < 3 yrs fem/jugular .................
Bl draw < 3 yrs scalp vein ..................
Bl draw < 3 yrs other vein ..................
Non-routine bl draw > 3 yrs ................
Routine venipuncture ..........................
Capillary blood draw ...........................
Vein access cutdown < 1 yr ...............
Vein access cutdown > 1 yr ...............
Blood transfusion service ....................
Bl push transfuse, 2 yr or < ................
Bl exchange/transfuse, nb ..................
Bl exchange/transfuse non-nb ............
Transfusion service, fetal ....................
Injection(s), spider veins .....................
Injection(s), spider veins .....................
Injection therapy of vein ......................
Injection therapy of veins ....................
Endovenous rf, 1st vein ......................
Endovenous rf, vein add-on ................
Endovenous laser, 1st vein ................
Endovenous laser vein addon ............
Insertion of catheter, vein ...................
Insertion of catheter, vein ...................
Insertion of catheter, vein ...................
Apheresis wbc .....................................
Apheresis rbc ......................................
Apheresis platelets ..............................
Apheresis plasma ...............................
Apheresis, adsorp/reinfuse .................
Apheresis, selective ............................
Photopheresis .....................................
Insert non-tunnel cv cath ....................
Insert non-tunnel cv cath ....................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert tunneled cv cath .......................
Insert picc cath ....................................
Insert picc cath ....................................
Insert picvad cath ................................
Insert picvad cath ................................
Repair tunneled cv cath ......................
Repair tunneled cv cath ......................
Replace tunneled cv cath ...................
Replace cvad cath ..............................
Replace tunneled cv cath ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
3.14
3.51
2.52
3.02
3.51
3.02
2.01
2.01
2.01
2.52
3.02
4.67
5.27
6.29
1.01
4.67
5.27
6.29
1.01
9.82
5.55
4.05
0.00
0.38
0.31
0.18
0.18
0.00
0.00
1.01
0.76
0.00
1.03
2.23
2.43
6.58
0.00
0.00
1.09
1.60
6.72
3.38
6.72
3.38
6.98
3.51
1.09
1.74
1.74
1.74
1.74
1.74
1.22
1.67
2.68
2.50
5.11
4.81
6.26
6.01
6.21
6.01
6.51
1.92
1.82
5.33
5.31
0.67
3.21
3.51
1.31
3.45
19.61
20.23
18.76
18.94
18.54
11.23
9.20
10.47
10.28
11.54
13.65
25.94
28.03
45.85
3.76
28.77
27.41
45.15
3.17
NA
NA
NA
0.00
0.28
0.27
0.25
0.32
0.00
0.00
NA
NA
0.93
NA
NA
NA
NA
0.00
0.00
2.41
2.56
35.74
6.14
26.95
6.35
NA
NA
1.08
NA
NA
NA
10.49
45.46
49.53
37.40
3.81
2.85
15.09
14.84
21.31
22.24
23.09
17.51
111.82
5.87
4.47
21.23
24.50
3.30
5.90
9.16
3.96
15.49
23.71
19.58
20.06
19.52
21.09
11.65
9.95
11.62
11.41
12.51
15.08
26.48
28.54
50.63
4.42
30.42
28.68
47.31
3.61
NA
NA
NA
0.00
0.28
0.27
0.26
0.30
0.00
0.00
NA
NA
0.97
NA
NA
NA
NA
0.00
0.00
2.54
2.82
43.55
7.00
36.85
7.17
NA
NA
2.48
NA
NA
NA
13.73
55.86
66.77
34.87
4.78
4.24
18.11
17.93
25.48
25.90
24.91
21.10
68.65
6.70
5.90
27.19
28.86
3.67
6.42
10.14
5.45
17.49
1.01
1.28
0.93
1.11
1.05
1.21
0.59
0.71
0.66
1.05
1.02
1.89
2.09
2.43
0.39
2.11
1.99
2.36
0.38
4.64
3.06
2.71
0.00
0.09
0.08
0.04
0.05
0.00
0.00
0.21
0.21
NA
0.25
0.77
0.66
1.81
0.00
0.00
0.64
0.79
1.88
0.83
2.04
0.95
2.35
1.25
0.30
0.57
0.60
0.55
0.53
0.48
0.39
0.94
0.59
0.55
2.29
2.35
2.72
2.64
2.60
2.47
2.60
0.59
0.67
2.10
2.44
0.23
1.56
2.00
0.43
1.73
1.03
1.23
0.81
1.07
1.12
1.16
0.62
0.67
0.66
0.94
1.01
1.75
1.94
2.30
0.36
1.89
1.91
2.25
0.36
4.76
3.36
2.73
0.00
0.09
0.08
0.05
0.05
0.00
0.00
0.24
0.21
NA
0.27
0.74
0.84
2.03
0.00
0.00
0.68
0.87
2.20
0.98
2.29
1.04
2.47
1.31
0.45
0.65
0.67
0.64
0.62
0.57
0.43
0.95
0.69
0.65
2.47
2.45
2.87
2.79
2.79
2.71
2.85
0.59
0.62
2.41
2.58
0.25
1.70
2.15
0.42
1.83
Malpractice
RVUs 2
0.27
0.23
0.25
0.19
0.21
0.26
0.14
0.16
0.11
0.26
0.24
0.27
0.31
0.44
0.07
0.31
0.38
0.47
0.07
1.29
0.70
0.54
0.00
0.03
0.03
0.01
0.01
0.00
0.00
0.07
0.06
0.06
0.10
0.21
0.15
0.79
0.00
0.00
0.12
0.19
0.37
0.18
0.37
0.18
0.55
0.20
0.10
0.08
0.08
0.17
0.08
0.08
0.08
0.13
0.11
0.19
0.57
0.57
0.57
0.57
0.84
0.57
0.57
0.11
0.19
0.57
0.57
0.20
0.19
0.19
0.19
0.19
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00230
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
ZZZ
090
090
090
YYY
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
010
010
000
ZZZ
000
ZZZ
000
000
000
000
000
000
000
000
000
000
000
000
010
010
010
010
010
010
010
000
000
010
010
000
010
010
000
010
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66451
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
36582
36583
36584
36585
36589
36590
36591
36592
36593
36595
36596
36597
36598
36600
36620
36625
36640
36660
36680
36800
36810
36815
36818
36819
36820
36821
36822
36823
36825
36830
36831
36832
36833
36834
36835
36838
36860
36861
36870
37140
37145
37160
37180
37181
37182
37183
37184
37185
37186
37187
37188
37195
37200
37201
37202
37203
37204
37205
37206
37207
37208
37209
37210
37215
37216
37250
37251
37500
37501
37565
37600
37605
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
A ........
A ........
A ........
A ........
A ........
T .........
T .........
A ........
A ........
A ........
A ........
T .........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
R ........
N ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
Replace tunneled cv cath ...................
Replace tunneled cv cath ...................
Replace picc cath ...............................
Replace picvad cath ...........................
Removal tunneled cv cath ..................
Removal tunneled cv cath ..................
Draw blood off venous device ............
Collect blood from picc .......................
Declot vascular device ........................
Mech remov tunneled cv cath ............
Mech remov tunneled cv cath ............
Reposition venous catheter ................
Inj w/fluor, eval cv device ...................
Withdrawal of arterial blood ................
Insertion catheter, artery .....................
Insertion catheter, artery .....................
Insertion catheter, artery .....................
Insertion catheter, artery .....................
Insert needle, bone cavity ...................
Insertion of cannula ............................
Insertion of cannula ............................
Insertion of cannula ............................
Av fuse, uppr arm, cephalic ................
Av fuse, uppr arm, basilic ...................
Av fusion/forearm vein ........................
Av fusion direct any site .....................
Insertion of cannula(s) ........................
Insertion of cannula(s) ........................
Artery-vein autograft ...........................
Artery-vein nonautograft .....................
Open thrombect av fistula ...................
Av fistula revision, open ......................
Av fistula revision ................................
Repair A-V aneurysm .........................
Artery to vein shunt .............................
Dist revas ligation, hemo ....................
External cannula declotting .................
Cannula declotting ..............................
Percut thrombect av fistula .................
Revision of circulation .........................
Revision of circulation .........................
Revision of circulation .........................
Revision of circulation .........................
Splice spleen/kidney veins ..................
Insert hepatic shunt (tips) ...................
Remove hepatic shunt (tips) ...............
Prim art mech thrombectomy .............
Prim art m-thrombect add-on ..............
Sec art m-thrombect add-on ...............
Venous mech thrombectomy ..............
Venous m-thrombectomy add-on .......
Thrombolytic therapy, stroke ..............
Transcatheter biopsy ..........................
Transcatheter therapy infuse ..............
Transcatheter therapy infuse ..............
Transcatheter retrieval ........................
Transcatheter occlusion ......................
Transcath iv stent, percut ...................
Transcath iv stent/perc addl ...............
Transcath iv stent, open .....................
Transcath iv stent/open addl ..............
Change iv cath at thromb tx ...............
Embolization uterine fibroid ................
Transcath stent, cca w/eps .................
Transcath stent, cca w/o eps ..............
Iv us first vessel add-on ......................
Iv us each add vessel add-on ............
Endoscopy ligate perf veins ................
Vascular endoscopy procedure ..........
Ligation of neck vein ...........................
Ligation of neck artery ........................
Ligation of neck artery ........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.21
5.26
1.20
4.81
2.27
3.32
0.00
0.00
0.00
3.59
0.75
1.21
0.74
0.32
1.15
2.11
2.10
1.40
1.20
2.43
3.96
2.62
11.81
14.39
14.39
9.15
5.51
22.82
10.00
12.00
8.01
10.50
11.95
11.11
7.43
21.59
2.01
2.52
5.17
25.12
26.13
23.13
26.13
28.26
16.97
7.99
8.66
3.28
4.92
8.03
5.71
0.00
4.55
4.99
5.67
5.02
18.11
8.27
4.12
8.27
4.12
2.27
10.60
19.58
18.85
2.10
1.60
11.54
0.00
11.97
12.34
14.20
21.53
21.57
3.96
22.54
1.86
3.62
0.54
0.67
0.82
10.83
2.57
2.04
2.22
0.50
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.36
NA
40.78
NA
NA
NA
NA
NA
NA
NA
49.91
16.38
34.90
48.21
42.22
0.00
NA
NA
NA
30.10
NA
108.64
66.45
NA
NA
NA
83.21
NA
NA
NA
NA
NA
0.00
NA
NA
NA
23.76
23.80
5.47
25.17
2.05
3.49
0.54
0.67
0.60
14.04
3.13
2.22
2.43
0.49
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.57
NA
46.89
NA
NA
NA
NA
NA
NA
NA
60.78
19.62
42.13
59.18
52.08
0.00
NA
NA
NA
31.48
NA
56.20
33.94
NA
NA
NA
83.21
NA
NA
NA
NA
NA
0.00
NA
NA
NA
2.45
2.48
0.61
2.42
1.23
1.59
NA
NA
NA
1.38
0.43
0.46
0.27
0.07
0.15
0.50
0.91
0.41
0.28
1.53
1.32
1.04
4.49
5.11
5.24
3.94
3.74
8.63
4.22
4.13
3.18
3.74
4.12
4.21
3.74
7.04
0.63
1.22
2.76
8.92
10.45
7.92
9.27
8.83
6.33
3.09
3.23
1.12
1.79
2.99
2.18
0.00
1.65
2.33
3.34
2.07
6.23
3.25
1.58
2.37
1.01
0.77
3.68
9.93
5.75
0.77
0.50
5.35
0.00
5.13
4.91
5.44
2.66
2.68
0.58
2.58
1.31
1.65
NA
NA
NA
1.41
0.47
0.45
1.45
0.08
0.19
0.52
0.97
0.42
0.38
1.67
1.50
1.10
5.26
5.74
5.81
4.29
4.06
9.00
4.63
4.68
3.56
4.23
4.66
4.50
4.03
8.21
0.65
1.35
2.95
9.70
10.65
8.59
9.78
9.91
6.19
3.05
3.29
1.11
1.72
3.06
2.27
0.00
1.57
2.44
3.18
2.05
6.07
3.50
1.50
2.77
1.19
0.75
3.68
9.51
7.28
0.76
0.52
6.10
0.00
5.38
5.77
6.17
Malpractice
RVUs 2
0.19
0.19
0.19
0.19
0.24
0.44
0.01
0.01
0.37
0.21
0.05
0.07
0.05
0.02
0.07
0.26
0.21
0.14
0.11
0.25
0.45
0.35
1.90
1.96
1.95
1.23
0.79
2.89
1.35
1.66
1.09
1.44
1.65
1.37
0.98
3.02
0.11
0.27
0.29
2.02
3.26
2.82
3.35
3.41
1.00
0.47
0.55
0.21
0.32
0.51
0.37
0.00
0.27
0.33
0.43
0.29
1.48
0.60
0.31
1.17
0.59
0.15
0.60
1.09
1.04
0.21
0.19
1.54
0.00
1.33
1.41
1.99
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00231
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
010
000
010
010
010
XXX
XXX
XXX
000
000
000
000
XXX
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
090
090
090
090
090
090
000
000
000
ZZZ
ZZZ
000
000
XXX
000
000
000
000
000
000
ZZZ
000
ZZZ
000
000
090
090
ZZZ
ZZZ
090
YYY
090
090
090
66452
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
37606
37607
37609
37615
37616
37617
37618
37620
37650
37660
37700
37718
37722
37735
37760
37765
37766
37780
37785
37788
37790
37799
38100
38101
38102
38115
38120
38129
38200
38204
38205
38206
38207
38208
38209
38210
38211
38212
38213
38214
38215
38220
38221
38230
38240
38241
38242
38300
38305
38308
38380
38381
38382
38500
38505
38510
38520
38525
38530
38542
38550
38555
38562
38564
38570
38571
38572
38589
38700
38720
38724
38740
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
B ........
R ........
R ........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
A ........
A ........
R ........
R ........
R ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
Ligation of neck artery ........................
Ligation of a-v fistula ...........................
Temporal artery procedure .................
Ligation of neck artery ........................
Ligation of chest artery .......................
Ligation of abdomen artery .................
Ligation of extremity artery .................
Revision of major vein ........................
Revision of major vein ........................
Revision of major vein ........................
Revise leg vein ...................................
Ligate/strip short leg vein ....................
Ligate/strip long leg vein .....................
Removal of leg veins/lesion ................
Ligation, leg veins, open .....................
Phleb veins extrem 10–20 ..................
Phleb veins extrem 20+ ......................
Revision of leg vein ............................
Ligate/divide/excise vein .....................
Revascularization, penis .....................
Penile venous occlusion .....................
Vascular surgery procedure ................
Removal of spleen, total .....................
Removal of spleen, partial ..................
Removal of spleen, total .....................
Repair of ruptured spleen ...................
Laparoscopy, splenectomy .................
Laparoscope proc, spleen ..................
Injection for spleen x-ray ....................
Bl donor search management ............
Harvest allogenic stem cells ...............
Harvest auto stem cells ......................
Cryopreserve stem cells .....................
Thaw preserved stem cells .................
Wash harvest stem cells .....................
T-cell depletion of harvest ..................
Tumor cell deplete of harvst ...............
Rbc depletion of harvest .....................
Platelet deplete of harvest ..................
Volume deplete of harvest ..................
Harvest stem cell concentrte ..............
Bone marrow aspiration ......................
Bone marrow biopsy ...........................
Bone marrow collection ......................
Bone marrow/stem transplant .............
Bone marrow/stem transplant .............
Lymphocyte infuse transplant .............
Drainage, lymph node lesion ..............
Drainage, lymph node lesion ..............
Incision of lymph channels .................
Thoracic duct procedure .....................
Thoracic duct procedure .....................
Thoracic duct procedure .....................
Biopsy/removal, lymph nodes .............
Needle biopsy, lymph nodes ..............
Biopsy/removal, lymph nodes .............
Biopsy/removal, lymph nodes .............
Biopsy/removal, lymph nodes .............
Biopsy/removal, lymph nodes .............
Explore deep node(s), neck ................
Removal, neck/armpit lesion ...............
Removal, neck/armpit lesion ...............
Removal, pelvic lymph nodes .............
Removal, abdomen lymph nodes .......
Laparoscopy, lymph node biop ...........
Laparoscopy, lymphadenectomy ........
Laparoscopy, lymphadenectomy ........
Laparoscope proc, lymphatic ..............
Removal of lymph nodes, neck ..........
Removal of lymph nodes, neck ..........
Removal of lymph nodes, neck ..........
Remove armpit lymph nodes ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.72
6.19
3.02
7.72
18.89
23.71
5.95
11.49
8.41
22.20
3.76
7.05
8.08
10.81
10.69
7.63
9.58
3.87
3.87
23.21
8.37
0.00
19.47
19.47
4.79
21.80
16.97
0.00
2.64
2.00
1.50
1.50
0.89
0.56
0.24
1.57
1.42
0.94
0.24
0.81
0.94
1.08
1.37
4.80
2.24
2.24
1.71
2.28
6.55
6.73
8.34
13.32
10.51
3.76
1.14
6.69
6.95
6.35
8.26
6.08
6.99
15.42
10.92
11.29
9.28
14.70
16.86
0.00
12.68
21.72
23.72
10.57
NA
NA
4.19
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.91
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
0.46
NA
NA
0.40
0.25
0.11
0.71
0.64
0.42
0.11
0.36
0.42
2.67
2.78
NA
NA
NA
NA
4.22
NA
NA
NA
NA
NA
3.75
2.11
5.38
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
4.34
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.05
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
0.46
NA
NA
0.40
0.25
0.11
0.71
0.64
0.42
0.11
0.36
0.42
3.20
3.36
NA
NA
NA
NA
4.26
NA
NA
NA
NA
NA
3.72
2.08
5.46
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
4.86
3.02
1.82
4.09
7.92
7.88
3.36
5.45
4.23
7.58
2.38
3.47
3.68
4.68
4.48
3.57
4.13
2.39
2.57
12.03
5.15
0.00
6.84
6.91
1.23
7.43
6.92
0.00
1.09
0.46
0.53
0.55
0.40
0.25
0.11
0.71
0.64
0.42
0.11
0.36
0.42
0.45
0.57
3.13
0.93
0.94
0.67
2.03
4.20
3.54
5.05
6.07
5.43
2.02
0.73
3.08
3.75
3.47
4.12
3.96
4.28
7.45
5.76
5.20
4.03
6.79
5.93
0.00
6.51
10.16
10.92
5.00
4.71
3.29
1.89
4.10
8.00
8.52
3.48
5.58
4.45
8.32
2.59
3.76
4.04
5.09
4.91
4.09
4.72
2.62
2.65
10.56
4.76
0.00
6.50
6.71
1.43
7.04
7.15
0.00
0.99
0.46
0.60
0.61
0.40
0.25
0.11
0.71
0.64
0.42
0.11
0.36
0.42
0.48
0.61
3.17
0.98
0.99
0.72
2.04
4.32
3.64
5.37
6.47
5.59
2.05
0.76
3.28
3.90
3.38
4.25
4.22
4.09
7.98
5.76
5.22
4.00
6.22
6.50
0.00
6.37
9.76
10.37
4.96
Malpractice
RVUs 2
1.23
0.85
0.36
0.68
2.33
2.98
0.67
0.91
1.01
2.49
0.53
0.14
0.86
1.48
1.44
0.48
0.48
0.53
0.54
2.26
0.59
0.00
1.92
2.05
0.63
2.09
2.25
0.00
0.14
0.06
0.07
0.07
0.01
0.02
0.01
0.03
0.02
0.02
0.01
0.01
0.02
0.05
0.07
0.48
0.11
0.11
0.08
0.25
0.88
0.85
0.74
1.85
1.37
0.49
0.09
0.72
0.84
0.80
1.12
0.60
0.88
1.76
1.20
1.32
1.13
1.15
1.91
0.00
0.72
1.20
1.28
1.32
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00232
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
090
090
ZZZ
090
090
YYY
000
XXX
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
010
XXX
XXX
000
010
090
090
090
090
090
010
000
010
090
090
090
090
090
090
090
090
010
010
010
YYY
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66453
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
38745
38746
38747
38760
38765
38770
38780
38790
38792
38794
38999
39000
39010
39200
39220
39400
39499
39501
39502
39503
39520
39530
39531
39540
39541
39545
39560
39561
39599
40490
40500
40510
40520
40525
40527
40530
40650
40652
40654
40700
40701
40702
40720
40761
40799
40800
40801
40804
40805
40806
40808
40810
40812
40814
40816
40818
40819
40820
40830
40831
40840
40842
40843
40844
40845
40899
41000
41005
41006
41007
41008
41009
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
R
R
C
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove armpit lymph nodes ..............
Remove thoracic lymph nodes ...........
Remove abdominal lymph nodes .......
Remove groin lymph nodes ................
Remove groin lymph nodes ................
Remove pelvis lymph nodes ...............
Remove abdomen lymph nodes .........
Inject for lymphatic x-ray .....................
Identify sentinel node ..........................
Access thoracic lymph duct ................
Blood/lymph system procedure ..........
Exploration of chest ............................
Exploration of chest ............................
Removal chest lesion ..........................
Removal chest lesion ..........................
Visualization of chest ..........................
Chest procedure .................................
Repair diaphragm laceration ...............
Repair paraesophageal hernia ...........
Repair of diaphragm hernia ................
Repair of diaphragm hernia ................
Repair of diaphragm hernia ................
Repair of diaphragm hernia ................
Repair of diaphragm hernia ................
Repair of diaphragm hernia ................
Revision of diaphragm ........................
Resect diaphragm, simple ..................
Resect diaphragm, complex ...............
Diaphragm surgery procedure ............
Biopsy of lip ........................................
Partial excision of lip ...........................
Partial excision of lip ...........................
Partial excision of lip ...........................
Reconstruct lip with flap ......................
Reconstruct lip with flap ......................
Partial removal of lip ...........................
Repair lip .............................................
Repair lip .............................................
Repair lip .............................................
Repair cleft lip/nasal ...........................
Repair cleft lip/nasal ...........................
Repair cleft lip/nasal ...........................
Repair cleft lip/nasal ...........................
Repair cleft lip/nasal ...........................
Lip surgery procedure .........................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Removal, foreign body, mouth ............
Removal, foreign body, mouth ............
Incision of lip fold ................................
Biopsy of mouth lesion .......................
Excision of mouth lesion .....................
Excise/repair mouth lesion ..................
Excise/repair mouth lesion ..................
Excision of mouth lesion .....................
Excise oral mucosa for graft ...............
Excise lip or cheek fold .......................
Treatment of mouth lesion ..................
Repair mouth laceration ......................
Repair mouth laceration ......................
Reconstruction of mouth .....................
Reconstruction of mouth .....................
Reconstruction of mouth .....................
Reconstruction of mouth .....................
Reconstruction of mouth .....................
Mouth surgery procedure ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
13.71
4.88
4.88
13.49
21.78
13.98
17.56
1.29
0.52
4.51
0.00
7.49
13.11
15.04
19.47
8.00
0.00
13.89
17.09
108.67
16.63
16.22
17.23
14.51
15.67
14.58
12.97
19.75
0.00
1.22
4.35
4.74
4.71
7.61
9.20
5.45
3.69
4.32
5.37
13.97
17.03
14.09
14.54
15.69
0.00
1.19
2.57
1.26
2.73
0.31
0.98
1.33
2.33
3.45
3.70
2.72
2.45
1.30
1.78
2.50
9.03
9.03
12.62
16.57
19.13
0.00
1.32
1.28
3.28
3.14
3.40
3.63
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
2.08
7.90
6.73
6.99
NA
NA
7.58
5.98
7.25
8.08
NA
NA
NA
NA
NA
0.00
3.84
4.88
3.78
5.13
2.43
3.60
3.68
4.54
5.69
5.90
5.82
4.93
5.30
4.04
5.24
10.01
10.20
11.33
15.21
16.02
0.00
2.55
4.32
5.43
5.34
5.51
5.83
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
1.85
7.40
6.67
7.26
NA
NA
7.69
6.38
7.49
8.34
NA
NA
NA
NA
NA
0.00
3.40
4.45
3.59
4.80
2.13
3.13
3.28
4.13
5.31
5.53
5.49
4.50
4.61
3.88
4.94
9.90
10.13
11.63
15.48
16.54
0.00
2.43
3.83
5.11
5.24
5.09
5.40
6.04
1.42
1.26
5.91
8.34
6.71
7.98
0.75
0.49
3.17
0.00
4.27
6.33
6.19
7.99
4.15
0.00
5.81
6.58
27.38
6.79
6.23
6.58
5.70
6.06
6.92
5.52
9.31
0.00
0.57
4.36
3.62
3.81
5.33
6.13
4.26
3.16
4.11
4.68
8.65
7.81
5.81
9.52
9.28
0.00
1.88
2.58
1.83
2.65
0.51
1.62
1.72
2.28
3.69
3.77
3.74
3.10
2.94
2.00
2.70
5.58
5.72
5.74
9.11
10.21
0.00
1.33
1.77
2.82
2.72
2.84
3.14
6.06
1.51
1.46
6.02
8.57
6.22
8.08
0.75
0.46
3.31
0.00
4.46
6.93
6.86
8.67
4.50
0.00
6.13
6.86
30.37
7.41
6.68
6.98
5.96
6.32
7.23
5.90
9.32
0.00
0.59
4.34
3.81
3.96
5.81
6.74
4.42
3.23
4.18
4.80
8.86
9.56
7.03
9.70
9.77
0.00
1.83
2.66
1.84
2.73
0.50
1.55
1.69
2.34
3.79
3.88
3.85
3.10
2.69
2.05
2.87
6.27
6.25
6.77
10.33
11.71
0.00
1.37
1.74
2.99
2.87
3.02
3.35
Malpractice
RVUs 2
1.74
0.72
0.64
1.72
2.48
1.40
1.89
0.13
0.06
0.32
0.00
0.89
1.76
2.03
2.46
0.82
0.00
1.78
2.17
10.98
2.24
2.11
2.22
1.80
1.93
1.84
1.59
2.45
0.00
0.05
0.38
0.49
0.52
0.85
0.97
0.55
0.38
0.52
0.60
0.95
1.65
1.23
1.80
1.94
0.00
0.13
0.31
0.11
0.32
0.04
0.10
0.13
0.28
0.41
0.40
0.21
0.29
0.11
0.19
0.30
1.08
1.08
1.39
2.00
2.01
0.00
0.12
0.12
0.35
0.31
0.42
0.47
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00233
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
ZZZ
ZZZ
090
090
090
090
000
000
090
YYY
090
090
090
090
010
YYY
090
090
090
090
090
090
090
090
090
090
090
YYY
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
010
010
010
010
000
010
010
010
090
090
090
090
010
010
010
090
090
090
090
090
YYY
010
010
090
090
090
090
66454
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
41010
41015
41016
41017
41018
41019
41100
41105
41108
41110
41112
41113
41114
41115
41116
41120
41130
41135
41140
41145
41150
41153
41155
41250
41251
41252
41500
41510
41520
41599
41800
41805
41806
41820
41821
41822
41823
41825
41826
41827
41828
41830
41850
41870
41872
41874
41899
42000
42100
42104
42106
42107
42120
42140
42145
42160
42180
42182
42200
42205
42210
42215
42220
42225
42226
42227
42235
42260
42280
42281
42299
42300
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
R
R
R
R
A
A
A
R
R
R
R
R
R
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Incision of tongue fold .........................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Drainage of mouth lesion ....................
Place needles h&n for rt .....................
Biopsy of tongue .................................
Biopsy of tongue .................................
Biopsy of floor of mouth ......................
Excision of tongue lesion ....................
Excision of tongue lesion ....................
Excision of tongue lesion ....................
Excision of tongue lesion ....................
Excision of tongue fold .......................
Excision of mouth lesion .....................
Partial removal of tongue ....................
Partial removal of tongue ....................
Tongue and neck surgery ...................
Removal of tongue ..............................
Tongue removal, neck surgery ...........
Tongue, mouth, jaw surgery ...............
Tongue, mouth, neck surgery .............
Tongue, jaw, & neck surgery ..............
Repair tongue laceration .....................
Repair tongue laceration .....................
Repair tongue laceration .....................
Fixation of tongue ...............................
Tongue to lip surgery ..........................
Reconstruction, tongue fold ................
Tongue and mouth surgery ................
Drainage of gum lesion .......................
Removal foreign body, gum ................
Removal foreign body,jawbone ..........
Excision, gum, each quadrant ............
Excision of gum flap ...........................
Excision of gum lesion ........................
Excision of gum lesion ........................
Excision of gum lesion ........................
Excision of gum lesion ........................
Excision of gum lesion ........................
Excision of gum lesion ........................
Removal of gum tissue .......................
Treatment of gum lesion .....................
Gum graft ............................................
Repair gum .........................................
Repair tooth socket .............................
Dental surgery procedure ...................
Drainage mouth roof lesion ................
Biopsy roof of mouth ...........................
Excision lesion, mouth roof .................
Excision lesion, mouth roof .................
Excision lesion, mouth roof .................
Remove palate/lesion .........................
Excision of uvula .................................
Repair palate, pharynx/uvula ..............
Treatment mouth roof lesion ...............
Repair palate .......................................
Repair palate .......................................
Reconstruct cleft palate ......................
Reconstruct cleft palate ......................
Reconstruct cleft palate ......................
Reconstruct cleft palate ......................
Reconstruct cleft palate ......................
Reconstruct cleft palate ......................
Lengthening of palate .........................
Lengthening of palate .........................
Repair palate .......................................
Repair nose to lip fistula .....................
Preparation, palate mold .....................
Insertion, palate prosthesis .................
Palate/uvula surgery ...........................
Drainage of salivary gland ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.08
4.00
4.11
4.11
5.14
8.84
1.39
1.44
1.07
1.53
2.77
3.23
8.71
1.76
2.47
10.91
15.51
29.83
28.81
37.59
29.52
33.28
43.96
1.93
2.29
2.99
3.74
3.45
2.77
0.00
1.21
1.28
2.73
0.00
0.00
2.35
3.63
1.35
2.35
3.72
3.11
3.38
0.00
0.00
2.90
3.13
0.00
1.25
1.33
1.66
2.12
4.48
11.70
1.65
9.63
1.82
2.52
3.84
12.41
13.57
14.91
8.88
7.07
9.66
10.24
9.81
7.92
10.10
1.56
1.95
0.00
1.95
3.90
6.29
6.22
6.37
6.75
NA
2.68
2.67
2.52
3.65
5.26
5.51
NA
4.18
5.56
NA
NA
NA
NA
NA
NA
NA
NA
3.86
3.48
4.59
NA
NA
5.80
0.00
4.80
4.64
5.82
0.00
0.00
4.80
6.45
3.69
5.09
6.64
4.09
5.98
0.00
0.00
6.04
5.66
0.00
2.48
2.27
3.57
4.45
6.53
NA
4.58
NA
3.77
3.37
3.99
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.73
2.23
3.03
0.00
3.13
3.66
5.84
5.92
6.00
6.44
NA
2.55
2.49
2.30
3.32
4.86
5.12
NA
3.74
4.95
NA
NA
NA
NA
NA
NA
NA
NA
3.30
3.38
4.24
NA
NA
5.21
0.00
3.69
3.65
4.70
0.00
0.00
4.34
6.01
3.37
3.76
6.08
3.94
5.47
0.00
0.00
5.53
5.25
0.00
2.52
2.18
3.06
3.83
6.12
NA
4.15
NA
4.01
3.22
3.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.96
2.10
2.83
0.00
2.98
1.56
3.98
4.07
4.12
4.48
3.28
1.17
1.20
1.08
1.64
3.24
3.39
6.30
1.72
2.80
14.32
15.88
21.84
23.56
28.79
23.02
23.92
27.59
1.61
1.78
2.12
7.52
6.47
3.26
0.00
2.12
2.70
3.34
0.00
0.00
1.85
3.73
1.46
2.57
3.38
1.64
3.11
0.00
0.00
3.30
2.72
0.00
1.20
1.26
1.67
2.07
3.69
12.28
2.11
7.48
1.69
1.86
2.39
8.62
7.36
10.24
7.41
7.21
12.23
11.89
11.20
10.34
6.02
0.83
1.69
0.00
1.74
1.58
4.06
4.14
4.21
4.52
3.28
1.29
1.26
1.10
1.64
3.23
3.43
6.74
1.79
2.80
14.81
16.03
22.53
25.11
29.66
23.86
24.46
27.19
1.39
1.66
2.19
7.48
7.20
3.44
0.00
1.70
2.46
3.19
0.00
0.00
1.86
3.87
1.85
2.34
3.52
2.30
3.37
0.00
0.00
3.38
2.94
0.00
1.22
1.31
1.60
2.25
3.82
12.02
2.10
7.48
1.99
1.98
2.71
9.41
8.71
10.84
8.24
6.99
14.64
13.29
13.37
11.09
6.54
0.98
1.78
0.00
1.77
Malpractice
RVUs 2
0.07
0.46
0.53
0.53
0.68
0.59
0.15
0.13
0.10
0.13
0.28
0.34
0.83
0.18
0.23
0.79
0.93
1.89
2.27
2.55
1.95
2.01
2.34
0.18
0.22
0.29
0.30
0.20
0.27
0.00
0.12
0.13
0.37
0.00
0.00
0.31
0.47
0.15
0.30
0.35
0.44
0.44
0.00
0.00
0.30
0.45
0.00
0.12
0.13
0.16
0.25
0.44
0.52
0.13
0.65
0.17
0.21
0.40
1.27
1.58
2.17
1.31
0.73
0.86
1.01
0.98
0.72
1.26
0.19
0.17
0.00
0.16
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00234
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
090
090
090
090
000
010
010
010
010
090
090
090
010
090
090
090
090
090
090
090
090
090
010
010
010
090
090
090
YYY
010
010
010
000
000
010
090
010
010
090
010
010
000
000
090
090
YYY
010
010
010
010
090
090
090
090
010
010
010
090
090
090
090
090
090
090
090
090
090
010
010
YYY
010
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66455
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
42305
42310
42320
42330
42335
42340
42400
42405
42408
42409
42410
42415
42420
42425
42426
42440
42450
42500
42505
42507
42508
42509
42510
42550
42600
42650
42660
42665
42699
42700
42720
42725
42800
42802
42804
42806
42808
42809
42810
42815
42820
42821
42825
42826
42830
42831
42835
42836
42842
42844
42845
42860
42870
42890
42892
42894
42900
42950
42953
42955
42960
42961
42962
42970
42971
42972
42999
43020
43030
43045
43100
43101
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Drainage of salivary gland ..................
Drainage of salivary gland ..................
Drainage of salivary gland ..................
Removal of salivary stone ..................
Removal of salivary stone ..................
Removal of salivary stone ..................
Biopsy of salivary gland ......................
Biopsy of salivary gland ......................
Excision of salivary cyst ......................
Drainage of salivary cyst ....................
Excise parotid gland/lesion .................
Excise parotid gland/lesion .................
Excise parotid gland/lesion .................
Excise parotid gland/lesion .................
Excise parotid gland/lesion .................
Excise submaxillary gland ..................
Excise sublingual gland ......................
Repair salivary duct ............................
Repair salivary duct ............................
Parotid duct diversion .........................
Parotid duct diversion .........................
Parotid duct diversion .........................
Parotid duct diversion .........................
Injection for salivary x-ray ...................
Closure of salivary fistula ....................
Dilation of salivary duct .......................
Dilation of salivary duct .......................
Ligation of salivary duct ......................
Salivary surgery procedure .................
Drainage of tonsil abscess .................
Drainage of throat abscess .................
Drainage of throat abscess .................
Biopsy of throat ...................................
Biopsy of throat ...................................
Biopsy of upper nose/throat ................
Biopsy of upper nose/throat ................
Excise pharynx lesion .........................
Remove pharynx foreign body ............
Excision of neck cyst ..........................
Excision of neck cyst ..........................
Remove tonsils and adenoids ............
Remove tonsils and adenoids ............
Removal of tonsils ..............................
Removal of tonsils ..............................
Removal of adenoids ..........................
Removal of adenoids ..........................
Removal of adenoids ..........................
Removal of adenoids ..........................
Extensive surgery of throat .................
Extensive surgery of throat .................
Extensive surgery of throat .................
Excision of tonsil tags .........................
Excision of lingual tonsil .....................
Partial removal of pharynx ..................
Revision of pharyngeal walls ..............
Revision of pharyngeal walls ..............
Repair throat wound ...........................
Reconstruction of throat ......................
Repair throat, esophagus ...................
Surgical opening of throat ...................
Control throat bleeding .......................
Control throat bleeding .......................
Control throat bleeding .......................
Control nose/throat bleeding ...............
Control nose/throat bleeding ...............
Control nose/throat bleeding ...............
Throat surgery procedure ...................
Incision of esophagus .........................
Throat muscle surgery ........................
Incision of esophagus .........................
Excision of esophagus lesion .............
Excision of esophagus lesion .............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.23
1.58
2.37
2.23
3.35
4.64
0.78
3.31
4.58
2.85
9.46
17.99
20.87
13.31
22.54
7.05
4.66
4.34
6.23
6.16
9.22
11.65
8.26
1.25
4.86
0.77
1.13
2.57
0.00
1.64
6.31
12.28
1.41
1.56
1.26
1.60
2.32
1.83
3.30
7.23
4.17
4.31
3.45
3.40
2.60
2.75
2.33
3.21
12.02
17.57
32.35
2.25
5.44
18.92
25.77
33.61
5.26
8.16
9.33
7.92
2.35
5.69
7.31
5.76
6.54
7.53
0.00
8.14
7.91
21.70
9.55
16.99
NA
2.29
3.74
3.41
5.77
6.70
2.00
3.96
6.41
5.31
NA
NA
NA
NA
NA
NA
6.38
6.11
7.27
NA
NA
NA
NA
2.28
6.57
1.28
1.46
5.00
0.00
2.97
4.69
NA
2.46
4.13
3.58
3.83
3.22
2.23
6.22
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
2.28
3.50
3.27
5.33
6.37
1.82
3.98
6.16
4.91
NA
NA
NA
NA
NA
NA
6.14
5.90
7.19
NA
NA
NA
NA
2.74
6.57
1.19
1.40
4.58
0.00
2.81
4.76
NA
2.32
4.44
3.66
3.95
3.15
2.28
5.96
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
3.99
1.39
1.88
1.73
2.85
3.48
0.65
2.15
3.27
2.53
5.36
8.62
9.56
6.83
10.00
3.86
4.02
3.86
4.71
6.33
8.07
8.91
6.89
0.44
3.42
0.66
0.75
2.40
0.00
1.65
3.17
7.08
1.30
1.67
1.50
1.61
1.60
1.32
3.73
6.25
2.85
2.99
2.90
2.68
2.43
2.66
1.78
2.64
12.03
15.46
21.14
2.30
8.70
15.24
19.20
23.53
2.95
11.06
13.77
10.10
1.71
4.48
5.18
3.58
4.50
4.98
0.00
4.57
4.51
9.30
5.20
7.16
4.35
1.46
1.99
1.79
2.99
3.70
0.68
2.30
3.44
2.65
5.79
9.74
10.97
7.72
11.50
4.32
4.14
4.02
5.04
6.43
8.20
9.55
7.34
0.43
3.77
0.68
0.80
2.49
0.00
1.67
3.48
7.65
1.35
1.87
1.62
1.77
1.77
1.32
3.63
6.33
3.07
3.24
3.03
2.86
2.49
2.75
2.12
2.80
11.51
15.84
22.16
2.35
8.63
14.69
18.18
22.77
3.30
11.46
15.54
10.38
1.84
4.72
5.54
3.88
4.81
5.34
0.00
4.99
5.00
9.99
5.71
7.52
Malpractice
RVUs 2
0.51
0.13
0.21
0.19
0.29
0.42
0.06
0.28
0.45
0.27
0.91
1.43
1.65
1.05
1.81
0.59
0.42
0.41
0.55
0.49
1.04
0.93
0.66
0.07
0.43
0.07
0.09
0.23
0.00
0.13
0.44
0.91
0.11
0.12
0.10
0.13
0.19
0.16
0.29
0.61
0.31
0.35
0.25
0.27
0.20
0.22
0.21
0.26
0.71
1.16
1.99
0.18
0.44
1.05
1.28
1.87
0.50
0.72
0.88
0.80
0.19
0.45
0.58
0.39
0.51
0.62
0.00
0.87
0.70
2.59
0.93
2.32
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00235
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
010
010
010
090
090
000
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
000
000
090
YYY
010
010
090
010
010
010
010
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
010
090
090
090
090
090
YYY
090
090
090
090
090
66456
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
43107
43108
43112
43113
43116
43117
43118
43121
43122
43123
43124
43130
43135
43200
43201
43202
43204
43205
43215
43216
43217
43219
43220
43226
43227
43228
43231
43232
43234
43235
43236
43237
43238
43239
43240
43241
43242
43243
43244
43245
43246
43247
43248
43249
43250
43251
43255
43256
43257
43258
43259
43260
43261
43262
43263
43264
43265
43267
43268
43269
43271
43272
43280
43289
43300
43305
43310
43312
43313
43314
43320
43324
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of esophagus .......................
Removal of esophagus .......................
Removal of esophagus .......................
Removal of esophagus .......................
Partial removal of esophagus .............
Partial removal of esophagus .............
Partial removal of esophagus .............
Partial removal of esophagus .............
Partial removal of esophagus .............
Partial removal of esophagus .............
Removal of esophagus .......................
Removal of esophagus pouch ............
Removal of esophagus pouch ............
Esophagus endoscopy ........................
Esoph scope w/submucous inj ...........
Esophagus endoscopy, biopsy ...........
Esoph scope w/sclerosis inj ................
Esophagus endoscopy/ligation ...........
Esophagus endoscopy ........................
Esophagus endoscopy/lesion .............
Esophagus endoscopy ........................
Esophagus endoscopy ........................
Esoph endoscopy, dilation ..................
Esoph endoscopy, dilation ..................
Esoph endoscopy, repair ....................
Esoph endoscopy, ablation .................
Esoph endoscopy w/us exam .............
Esoph endoscopy w/us fn bx ..............
Upper GI endoscopy, exam ................
Uppr gi endoscopy, diagnosis ............
Uppr gi scope w/submuc inj ...............
Endoscopic us exam, esoph ...............
Uppr gi endoscopy w/us fn bx ............
Upper GI endoscopy, biopsy ..............
Esoph endoscope w/drain cyst ...........
Upper GI endoscopy with tube ...........
Uppr gi endoscopy w/us fn bx ............
Upper gi endoscopy & inject ...............
Upper GI endoscopy/ligation ..............
Uppr gi scope dilate strictr ..................
Place gastrostomy tube ......................
Operative upper GI endoscopy ...........
Uppr gi endoscopy/guide wire ............
Esoph endoscopy, dilation ..................
Upper GI endoscopy/tumor .................
Operative upper GI endoscopy ...........
Operative upper GI endoscopy ...........
Uppr gi endoscopy w/stent .................
Uppr gi scope w/thrml txmnt ...............
Operative upper GI endoscopy ...........
Endoscopic ultrasound exam ..............
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Endo cholangiopancreatograph ..........
Laparoscopy, fundoplasty ...................
Laparoscope proc, esoph ...................
Repair of esophagus ...........................
Repair esophagus and fistula .............
Repair of esophagus ...........................
Repair esophagus and fistula .............
Esophagoplasty congenital .................
Tracheo-esophagoplasty cong ............
Fuse esophagus & stomach ...............
Revise esophagus & stomach ............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
43.97
82.66
47.27
79.85
92.78
43.52
66.86
51.22
43.97
82.91
68.83
12.41
26.09
1.59
2.09
1.89
3.76
3.78
2.60
2.40
2.90
2.80
2.10
2.34
3.59
3.76
3.19
4.47
2.01
2.39
2.92
3.98
5.02
2.87
6.85
2.59
7.30
4.56
5.04
3.18
4.32
3.38
3.15
2.90
3.20
3.69
4.81
4.34
5.50
4.54
5.19
5.95
6.26
7.38
7.28
8.89
10.00
7.38
7.38
8.20
7.38
7.38
18.00
0.00
9.21
17.98
26.18
29.23
48.17
53.15
23.18
22.86
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.72
5.62
5.16
NA
NA
NA
3.08
6.57
NA
NA
NA
NA
NA
NA
NA
4.98
5.29
6.71
NA
NA
6.05
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.92
5.12
5.35
NA
NA
NA
2.07
6.76
NA
NA
NA
NA
NA
NA
NA
5.15
5.22
6.55
NA
NA
5.88
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
16.25
24.46
17.00
25.34
30.30
15.14
21.50
18.26
15.60
25.75
24.34
6.37
9.92
0.98
1.19
0.98
2.01
2.06
1.29
1.26
1.38
1.55
1.13
1.29
1.77
1.89
1.76
2.39
1.02
1.35
1.65
2.16
2.56
1.56
3.28
1.40
3.67
2.35
2.64
1.63
2.11
1.78
1.77
1.62
1.61
1.92
2.52
2.25
2.14
2.37
2.69
3.06
3.20
3.73
3.63
4.44
4.98
3.39
3.88
4.10
3.70
3.77
6.65
0.00
5.41
8.33
9.81
10.27
17.46
15.09
8.60
8.34
17.25
19.33
18.18
20.22
23.49
16.20
17.64
15.96
16.49
19.92
18.71
6.96
9.00
1.02
1.14
0.96
1.76
1.79
1.24
1.16
1.28
1.45
1.05
1.16
1.61
1.72
1.53
2.10
0.94
1.18
1.43
1.87
2.26
1.37
2.94
1.25
3.20
2.07
2.30
1.46
1.90
1.57
1.54
1.41
1.46
1.70
2.20
1.98
2.17
2.07
2.34
2.67
2.80
3.25
3.20
3.87
4.34
3.09
3.38
3.58
3.24
3.28
6.96
0.00
5.89
9.51
10.43
11.07
18.13
17.13
8.90
8.55
Malpractice
RVUs 2
5.24
4.08
5.81
4.43
3.06
5.19
4.11
3.91
5.42
4.16
3.74
1.16
2.34
0.13
0.15
0.15
0.30
0.28
0.22
0.20
0.26
0.24
0.17
0.19
0.28
0.34
0.23
0.34
0.17
0.19
0.21
0.43
0.43
0.22
0.56
0.21
0.53
0.33
0.37
0.26
0.34
0.27
0.23
0.22
0.26
0.29
0.35
0.32
0.36
0.33
0.35
0.43
0.46
0.54
0.54
0.65
0.73
0.54
0.54
0.60
0.54
0.54
2.28
0.00
1.12
1.54
3.61
4.01
5.47
6.65
2.74
2.76
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00236
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
YYY
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66457
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
43325
43326
43330
43331
43340
43341
43350
43351
43352
43360
43361
43400
43401
43405
43410
43415
43420
43425
43450
43453
43456
43458
43460
43496
43499
43500
43501
43502
43510
43520
43600
43605
43610
43611
43620
43621
43622
43631
43632
43633
43634
43635
43640
43641
43644
43645
43647
43648
43651
43652
43653
43659
43752
43760
43761
43770
43771
43772
43773
43774
43800
43810
43820
43825
43830
43831
43832
43840
43842
43843
43845
43846
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Revise esophagus & stomach ............
Revise esophagus & stomach ............
Repair of esophagus ...........................
Repair of esophagus ...........................
Fuse esophagus & intestine ...............
Fuse esophagus & intestine ...............
Surgical opening, esophagus .............
Surgical opening, esophagus .............
Surgical opening, esophagus .............
Gastrointestinal repair .........................
Gastrointestinal repair .........................
Ligate esophagus veins ......................
Esophagus surgery for veins ..............
Ligate/staple esophagus .....................
Repair esophagus wound ...................
Repair esophagus wound ...................
Repair esophagus opening .................
Repair esophagus opening .................
Dilate esophagus ................................
Dilate esophagus ................................
Dilate esophagus ................................
Dilate esophagus ................................
Pressure treatment esophagus ...........
Free jejunum flap, microvasc ..............
Esophagus surgery procedure ............
Surgical opening of stomach ..............
Surgical repair of stomach ..................
Surgical repair of stomach ..................
Surgical opening of stomach ..............
Incision of pyloric muscle ....................
Biopsy of stomach ..............................
Biopsy of stomach ..............................
Excision of stomach lesion .................
Excision of stomach lesion .................
Removal of stomach ...........................
Removal of stomach ...........................
Removal of stomach ...........................
Removal of stomach, partial ...............
Removal of stomach, partial ...............
Removal of stomach, partial ...............
Removal of stomach, partial ...............
Removal of stomach, partial ...............
Vagotomy & pylorus repair .................
Vagotomy & pylorus repair .................
Lap gastric bypass/roux-en-y ..............
Lap gastr bypass incl smll i ................
Lap impl electrode, antrum .................
Lap revise/remv eltrd antrum ..............
Laparoscopy, vagus nerve ..................
Laparoscopy, vagus nerve ..................
Laparoscopy, gastrostomy ..................
Laparoscope proc, stom .....................
Nasal/orogastric w/stent ......................
Change gastrostomy tube ...................
Reposition gastrostomy tube ..............
Lap place gastr adj device ..................
Lap revise gastr adj device .................
Lap rmvl gastr adj device ...................
Lap replace gastr adj device ..............
Lap rmvl gastr adj all parts .................
Reconstruction of pylorus ...................
Fusion of stomach and bowel .............
Fusion of stomach and bowel .............
Fusion of stomach and bowel .............
Place gastrostomy tube ......................
Place gastrostomy tube ......................
Place gastrostomy tube ......................
Repair of stomach lesion ....................
V-band gastroplasty ............................
Gastroplasty w/o v-band .....................
Gastroplasty duodenal switch .............
Gastric bypass for obesity ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
22.47
22.15
22.06
22.93
22.86
24.10
19.31
21.87
17.68
39.90
45.50
25.47
26.36
24.55
16.28
28.70
16.65
24.91
1.38
1.51
2.57
3.06
3.79
0.00
0.00
12.71
22.47
25.56
15.01
11.21
1.91
13.64
16.26
20.25
33.91
39.40
39.90
24.38
35.01
33.01
36.51
2.06
19.43
19.68
29.24
31.37
0.00
0.00
10.13
12.13
8.38
0.00
0.81
0.90
2.01
17.85
20.64
15.62
20.64
15.66
15.35
16.80
22.40
21.63
10.75
8.38
17.26
22.70
20.90
21.08
33.12
27.23
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.67
6.31
13.01
6.92
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
5.98
1.04
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.65
6.18
13.37
6.78
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
4.03
1.10
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
8.38
9.20
8.09
9.82
9.27
9.65
8.75
10.86
7.94
14.88
18.13
13.58
9.54
10.66
7.66
11.83
7.47
10.45
0.93
1.01
1.45
1.59
1.76
0.00
0.00
5.29
8.09
8.96
9.13
4.81
0.77
5.36
6.03
7.48
11.09
12.39
12.49
8.58
11.26
10.75
11.78
0.52
7.34
7.62
10.10
10.48
0.00
0.00
4.61
5.22
4.46
0.00
0.26
0.33
0.70
7.40
8.12
5.99
8.10
6.18
5.81
6.13
8.07
7.89
5.17
4.92
7.06
8.14
6.75
7.84
12.88
9.97
8.58
9.24
8.31
9.80
9.12
9.83
8.59
10.32
8.16
14.97
17.50
11.51
9.51
10.12
7.64
11.78
7.43
10.21
0.81
0.87
1.27
1.43
1.62
0.00
0.00
5.12
8.19
9.21
7.85
5.03
0.71
5.32
6.08
7.52
11.44
12.17
12.53
8.87
10.21
10.03
10.93
0.61
7.29
7.49
10.65
11.24
0.00
0.00
4.68
5.49
4.32
0.00
0.26
0.39
0.68
7.55
8.35
6.21
8.34
6.37
5.85
6.15
7.23
7.95
5.00
4.71
6.95
7.45
7.26
7.79
11.82
9.99
Malpractice
RVUs 2
2.60
2.85
2.63
2.94
2.46
2.92
1.42
2.47
2.06
4.97
4.50
1.96
3.05
2.84
1.72
3.53
1.43
3.03
0.11
0.11
0.20
0.24
0.31
0.00
0.00
1.45
2.65
3.10
1.48
1.36
0.14
1.58
1.94
2.36
3.96
4.04
4.30
2.99
2.99
3.06
3.33
0.27
2.26
2.25
3.16
3.54
0.00
0.00
1.33
1.55
1.01
0.00
0.02
0.09
0.13
2.19
2.55
1.93
2.56
1.85
1.82
1.94
2.04
2.54
1.25
1.03
1.98
2.06
2.45
2.46
4.06
3.19
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00237
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
090
YYY
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
YYY
YYY
090
090
090
YYY
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66458
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
43847
43848
43850
43855
43860
43865
43870
43880
43881
43882
43886
43887
43888
43999
44005
44010
44015
44020
44021
44025
44050
44055
44100
44110
44111
44120
44121
44125
44126
44127
44128
44130
44132
44133
44135
44136
44137
44139
44140
44141
44143
44144
44145
44146
44147
44150
44151
44155
44156
44157
44158
44160
44180
44186
44187
44188
44202
44203
44204
44205
44206
44207
44208
44210
44211
44212
44213
44227
44238
44300
44310
44312
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
C
C
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
R
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Gastric bypass incl small i ..................
Revision gastroplasty ..........................
Revise stomach-bowel fusion .............
Revise stomach-bowel fusion .............
Revise stomach-bowel fusion .............
Revise stomach-bowel fusion .............
Repair stomach opening .....................
Repair stomach-bowel fistula ..............
Impl/redo electrd, antrum ....................
Revise/remove electrd antrum ............
Revise gastric port, open ....................
Remove gastric port, open .................
Change gastric port, open ..................
Stomach surgery procedure ...............
Freeing of bowel adhesion .................
Incision of small bowel ........................
Insert needle cath bowel .....................
Explore small intestine ........................
Decompress small bowel ....................
Incision of large bowel ........................
Reduce bowel obstruction ..................
Correct malrotation of bowel ...............
Biopsy of bowel ...................................
Excise intestine lesion(s) ....................
Excision of bowel lesion(s) .................
Removal of small intestine ..................
Removal of small intestine ..................
Removal of small intestine ..................
Enterectomy w/o taper, cong ..............
Enterectomy w/taper, cong .................
Enterectomy cong, add-on ..................
Bowel to bowel fusion .........................
Enterectomy, cadaver donor ...............
Enterectomy, live donor ......................
Intestine transplnt, cadaver .................
Intestine transplant, live ......................
Remove intestinal allograft .................
Mobilization of colon ...........................
Partial removal of colon ......................
Partial removal of colon ......................
Partial removal of colon ......................
Partial removal of colon ......................
Partial removal of colon ......................
Partial removal of colon ......................
Partial removal of colon ......................
Removal of colon ................................
Removal of colon/ileostomy ................
Removal of colon/ileostomy ................
Removal of colon/ileostomy ................
Colectomy w/ileoanal anast ................
Colectomy w/neo-rectum pouch .........
Removal of colon ................................
Lap, enterolysis ...................................
Lap, jejunostomy .................................
Lap, ileo/jejuno-stomy .........................
Lap, colostomy ....................................
Lap, enterectomy ................................
Lap resect s/intestine, addl .................
Laparo partial colectomy .....................
Lap colectomy part w/ileum ................
Lap part colectomy w/stoma ...............
L colectomy/coloproctostomy ..............
L colectomy/coloproctostomy ..............
Laparo total proctocolectomy ..............
Lap colectomy w/proctectomy ............
Laparo total proctocolectomy ..............
Lap, mobil splenic fl add-on ................
Lap, close enterostomy .......................
Laparoscope proc, intestine ................
Open bowel to skin .............................
Ileostomy/jejunostomy .........................
Revision of ileostomy ..........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
30.10
32.57
27.45
28.56
27.76
28.92
11.36
27.05
0.00
0.00
4.54
4.24
6.34
0.00
18.38
14.18
2.62
16.14
16.23
16.43
15.44
25.53
2.01
13.96
16.44
20.74
4.44
19.93
42.02
49.09
4.44
21.98
0.00
0.00
0.00
0.00
0.00
2.23
22.46
29.75
27.63
29.75
28.45
35.14
33.56
29.99
34.73
34.23
37.23
35.49
36.49
20.78
15.19
10.30
17.27
19.20
23.26
4.44
26.29
22.86
29.63
31.79
33.86
29.88
36.87
34.37
3.50
28.49
0.00
13.65
17.49
9.33
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
10.51
11.29
9.49
9.70
9.47
9.73
4.95
9.27
0.00
0.00
3.44
3.05
4.01
0.00
6.58
5.53
0.68
6.00
6.15
6.05
5.82
8.48
0.91
5.50
6.09
7.14
1.12
7.03
13.59
15.63
1.21
7.97
0.00
0.00
0.00
0.00
0.00
0.56
8.06
11.83
10.28
10.62
9.48
13.36
10.77
12.60
13.91
13.44
14.48
17.08
17.42
7.51
5.80
4.58
8.12
8.67
8.31
1.12
8.88
7.80
10.46
10.10
12.01
11.17
13.58
13.03
0.86
9.48
0.00
5.55
6.40
4.65
10.70
11.55
9.65
10.01
9.71
10.11
4.73
9.58
0.00
0.00
3.29
2.91
3.88
0.00
6.64
5.48
0.78
5.96
6.05
6.03
5.88
8.60
0.81
5.36
6.10
7.11
1.32
7.14
13.85
15.67
1.37
7.09
0.00
0.00
0.00
0.00
0.00
0.66
8.35
10.93
10.48
10.11
10.13
13.10
9.73
12.30
13.65
13.37
14.75
17.08
17.42
7.62
6.01
4.68
8.19
8.75
8.61
1.31
9.41
8.32
10.85
10.78
12.57
11.52
14.12
13.35
1.04
10.05
0.00
5.52
6.54
4.32
Malpractice
RVUs 2
3.56
3.88
3.28
3.47
3.31
3.51
1.27
3.27
0.00
0.00
0.25
0.51
0.70
0.00
2.15
1.64
0.35
1.86
1.87
1.90
1.86
2.91
0.17
1.55
1.87
2.25
0.58
2.27
4.69
5.77
0.61
1.88
0.00
0.00
0.00
0.00
0.00
0.28
2.71
2.53
3.05
2.86
3.29
3.41
2.56
3.04
3.49
3.28
3.95
3.93
4.06
2.37
1.86
1.27
1.96
2.24
2.85
0.57
3.11
2.75
3.46
3.67
3.88
3.42
4.17
3.78
0.44
3.38
0.00
1.60
1.99
0.92
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00238
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
YYY
YYY
090
090
090
YYY
090
090
ZZZ
090
090
090
090
090
000
090
090
090
ZZZ
090
090
090
ZZZ
090
XXX
XXX
XXX
XXX
XXX
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
ZZZ
090
YYY
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66459
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
44314
44316
44320
44322
44340
44345
44346
44360
44361
44363
44364
44365
44366
44369
44370
44372
44373
44376
44377
44378
44379
44380
44382
44383
44385
44386
44388
44389
44390
44391
44392
44393
44394
44397
44500
44602
44603
44604
44605
44615
44620
44625
44626
44640
44650
44660
44661
44680
44700
44701
44715
44720
44721
44799
44800
44820
44850
44899
44900
44901
44950
44955
44960
44970
44979
45000
45005
45020
45100
45108
45110
45111
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
C
A
A
A
C
A
A
A
A
A
A
C
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Revision of ileostomy ..........................
Devise bowel pouch ............................
Colostomy ...........................................
Colostomy with biopsies .....................
Revision of colostomy .........................
Revision of colostomy .........................
Revision of colostomy .........................
Small bowel endoscopy ......................
Small bowel endoscopy/biopsy ...........
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy/stent .............
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Small bowel endoscopy/biopsy ...........
Small bowel endoscopy ......................
S bowel endoscope w/stent ................
Small bowel endoscopy ......................
Small bowel endoscopy ......................
Ileoscopy w/stent ................................
Endoscopy of bowel pouch .................
Endoscopy, bowel pouch/biop ............
Colonoscopy .......................................
Colonoscopy with biopsy ....................
Colonoscopy for foreign body .............
Colonoscopy for bleeding ...................
Colonoscopy & polypectomy ..............
Colonoscopy, lesion removal ..............
Colonoscopy w/snare ..........................
Colonoscopy w/stent ...........................
Intro, gastrointestinal tube ..................
Suture, small intestine ........................
Suture, small intestine ........................
Suture, large intestine .........................
Repair of bowel lesion ........................
Intestinal stricturoplasty ......................
Repair bowel opening .........................
Repair bowel opening .........................
Repair bowel opening .........................
Repair bowel-skin fistula .....................
Repair bowel fistula ............................
Repair bowel-bladder fistula ...............
Repair bowel-bladder fistula ...............
Surgical revision, intestine ..................
Suspend bowel w/prosthesis ..............
Intraop colon lavage add-on ...............
Prepare donor intestine ......................
Prep donor intestine/venous ...............
Prep donor intestine/artery .................
Unlisted procedure intestine ...............
Excision of bowel pouch .....................
Excision of mesentery lesion ..............
Repair of mesentery ...........................
Bowel surgery procedure ....................
Drain app abscess, open ....................
Drain app abscess, percut ..................
Appendectomy ....................................
Appendectomy add-on ........................
Appendectomy ....................................
Laparoscopy, appendectomy ..............
Laparoscope proc, app .......................
Drainage of pelvic abscess .................
Drainage of rectal abscess .................
Drainage of rectal abscess .................
Biopsy of rectum .................................
Removal of anorectal lesion ...............
Removal of rectum ..............................
Partial removal of rectum ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
16.61
23.46
19.75
13.15
9.12
17.06
19.47
2.59
2.87
3.49
3.73
3.31
4.40
4.51
4.79
4.40
3.49
5.25
5.52
7.12
7.46
1.05
1.27
2.94
1.82
2.12
2.82
3.13
3.82
4.31
3.81
4.83
4.42
4.70
0.49
24.64
28.03
18.06
22.00
18.08
14.35
17.20
27.82
24.12
25.04
23.83
27.27
17.88
17.40
3.10
0.00
5.00
7.00
0.00
11.94
13.63
12.03
0.00
12.44
3.37
10.52
1.53
14.39
9.35
0.00
6.20
2.00
8.43
3.96
5.04
30.57
17.89
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.90
6.65
6.12
7.11
8.33
8.93
7.36
8.03
8.50
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
0.00
NA
NA
NA
0.00
NA
19.79
NA
NA
NA
NA
0.00
NA
3.98
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.12
6.64
5.60
6.86
7.72
8.83
6.97
7.46
8.15
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
0.00
NA
NA
NA
0.00
NA
23.83
NA
NA
NA
NA
0.00
NA
4.01
NA
NA
NA
NA
NA
6.77
8.87
7.59
9.10
4.93
6.92
7.52
1.50
1.63
1.85
1.97
1.74
2.37
2.36
2.56
2.12
1.76
2.47
2.76
3.57
3.92
0.74
0.84
1.61
0.89
1.02
1.35
1.57
1.92
2.21
1.72
2.13
2.07
2.16
0.17
7.61
8.96
6.06
7.82
6.53
5.50
6.14
8.88
8.01
8.30
9.75
9.39
6.68
6.15
0.76
0.00
1.27
1.78
0.00
5.49
5.56
5.01
0.00
5.02
1.20
4.04
0.40
5.40
4.19
0.00
3.57
1.59
4.54
2.81
3.09
11.84
6.99
6.66
8.70
7.62
8.83
4.60
6.90
7.45
1.30
1.41
1.61
1.73
1.55
2.05
2.05
2.26
1.93
1.59
2.25
2.45
3.13
3.42
0.65
0.73
1.44
0.82
0.95
1.25
1.42
1.70
1.95
1.60
2.00
1.89
1.97
0.17
7.00
8.11
6.25
8.10
6.60
5.41
6.22
9.34
8.29
8.59
9.04
9.47
6.56
6.40
0.91
0.00
1.48
2.08
0.00
5.43
5.52
5.00
0.00
4.85
1.15
4.17
0.47
5.37
4.13
0.00
3.26
1.58
3.91
2.59
2.93
12.12
7.07
Malpractice
RVUs 2
1.75
2.38
2.26
1.54
0.99
1.97
2.13
0.19
0.21
0.27
0.27
0.24
0.32
0.33
0.37
0.35
0.27
0.42
0.40
0.52
0.62
0.08
0.12
0.21
0.15
0.20
0.26
0.27
0.32
0.34
0.34
0.42
0.38
0.39
0.03
2.12
2.42
2.12
2.52
2.07
1.51
1.86
3.27
2.78
2.93
2.14
2.81
2.00
1.84
0.37
0.00
0.37
0.97
0.00
1.47
1.59
1.39
0.00
1.33
0.22
1.31
0.20
1.63
1.14
0.00
0.52
0.25
0.55
0.44
0.59
3.36
2.07
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00239
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
XXX
XXX
XXX
YYY
090
090
090
YYY
090
000
090
ZZZ
090
090
YYY
090
010
090
090
090
090
090
66460
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
45112
45113
45114
45116
45119
45120
45121
45123
45126
45130
45135
45136
45150
45160
45170
45190
45300
45303
45305
45307
45308
45309
45315
45317
45320
45321
45327
45330
45331
45332
45333
45334
45335
45337
45338
45339
45340
45341
45342
45345
45355
45378
45378
45379
45380
45381
45382
45383
45384
45385
45386
45387
45391
45392
45395
45397
45400
45402
45499
45500
45505
45520
45540
45541
45550
45560
45562
45563
45800
45805
45820
45825
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
53 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of rectum ..............................
Partial proctectomy .............................
Partial removal of rectum ....................
Partial removal of rectum ....................
Remove rectum w/reservoir ................
Removal of rectum ..............................
Removal of rectum and colon .............
Partial proctectomy .............................
Pelvic exenteration ..............................
Excision of rectal prolapse ..................
Excision of rectal prolapse ..................
Excise ileoanal reservior .....................
Excision of rectal stricture ...................
Excision of rectal lesion ......................
Excision of rectal lesion ......................
Destruction, rectal tumor .....................
Proctosigmoidoscopy dx .....................
Proctosigmoidoscopy dilate ................
Proctosigmoidoscopy w/bx .................
Proctosigmoidoscopy fb ......................
Proctosigmoidoscopy removal ............
Proctosigmoidoscopy removal ............
Proctosigmoidoscopy removal ............
Proctosigmoidoscopy bleed ................
Proctosigmoidoscopy ablate ...............
Proctosigmoidoscopy volvul ................
Proctosigmoidoscopy w/stent .............
Diagnostic sigmoidoscopy ..................
Sigmoidoscopy and biopsy .................
Sigmoidoscopy w/fb removal ..............
Sigmoidoscopy & polypectomy ...........
Sigmoidoscopy for bleeding ................
Sigmoidoscopy w/submuc inj ..............
Sigmoidoscopy & decompress ...........
Sigmoidoscopy w/tumr remove ...........
Sigmoidoscopy w/ablate tumr .............
Sig w/balloon dilation ..........................
Sigmoidoscopy w/ultrasound ..............
Sigmoidoscopy w/us guide bx ............
Sigmoidoscopy w/stent .......................
Surgical colonoscopy ..........................
Diagnostic colonoscopy ......................
Diagnostic colonoscopy ......................
Colonoscopy w/fb removal ..................
Colonoscopy and biopsy .....................
Colonoscopy, submucous inj ..............
Colonoscopy/control bleeding .............
Lesion removal colonoscopy ..............
Lesion remove colonoscopy ...............
Lesion removal colonoscopy ..............
Colonoscopy dilate stricture ................
Colonoscopy w/stent ...........................
Colonoscopy w/endoscope us ............
Colonoscopy w/endoscopic fnb ..........
Lap, removal of rectum .......................
Lap, remove rectum w/pouch .............
Laparoscopic proc ...............................
Lap proctopexy w/sig resect ...............
Laparoscope proc, rectum ..................
Repair of rectum .................................
Repair of rectum .................................
Treatment of rectal prolapse ...............
Correct rectal prolapse .......................
Correct rectal prolapse .......................
Repair rectum/remove sigmoid ...........
Repair of rectocele ..............................
Exploration/repair of rectum ................
Exploration/repair of rectum ................
Repair rect/bladder fistula ...................
Repair fistula w/colostomy ..................
Repair rectourethral fistula ..................
Repair fistula w/colostomy ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
33.05
33.09
30.63
27.56
33.35
26.25
28.93
18.70
48.89
18.37
22.15
30.63
5.77
16.17
12.48
10.29
0.80
1.50
1.25
1.70
1.40
1.50
1.80
2.00
1.78
1.75
2.00
0.96
1.15
1.79
1.79
2.73
1.46
2.36
2.34
3.14
1.89
2.60
4.05
2.92
3.51
3.69
0.96
4.68
4.43
4.19
5.68
5.86
4.69
5.30
4.57
5.90
5.09
6.54
32.79
36.29
19.31
26.38
0.00
7.64
8.20
0.55
18.02
14.72
24.67
11.42
17.82
26.22
20.18
23.19
20.24
24.01
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.96
19.91
3.19
3.25
3.40
3.53
3.82
3.36
3.40
NA
NA
2.52
3.28
5.53
5.66
NA
5.34
NA
5.90
5.73
10.25
NA
NA
NA
NA
6.38
2.52
8.07
7.75
7.72
10.35
8.55
7.19
8.37
12.35
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
2.86
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.74
19.29
2.91
3.14
2.70
3.17
3.34
2.90
3.15
NA
NA
2.40
3.17
5.26
5.26
NA
4.27
NA
5.56
4.59
8.21
NA
NA
NA
NA
6.26
2.40
7.86
7.47
7.41
10.14
8.23
6.99
8.08
12.38
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
2.25
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
10.30
11.57
10.28
9.64
11.53
9.26
10.03
6.94
17.87
6.66
8.60
11.94
3.34
6.43
5.36
5.52
0.45
0.66
0.59
0.70
0.63
0.67
0.87
0.76
0.80
0.86
0.91
0.62
0.79
0.99
0.99
1.53
0.90
1.25
1.28
1.66
1.03
1.47
2.17
1.50
1.58
1.82
0.62
2.17
2.23
2.16
2.88
2.63
2.18
2.59
2.17
2.80
2.60
3.21
12.94
13.38
7.07
8.73
0.00
4.46
5.04
0.38
5.83
6.59
8.95
5.52
8.10
10.75
9.14
9.92
9.09
9.46
11.02
12.08
10.57
9.83
11.99
9.69
10.56
6.89
18.53
6.71
8.50
12.23
3.15
6.54
5.29
5.07
0.37
0.49
0.55
0.59
0.53
0.75
0.75
0.71
0.75
0.71
0.80
0.56
0.69
0.90
0.89
1.34
0.79
1.12
1.14
1.47
0.93
1.27
1.85
1.33
1.48
1.64
0.56
1.99
1.98
1.90
2.53
2.43
2.00
2.31
1.98
2.57
2.29
2.85
13.30
13.82
7.45
9.35
0.00
3.99
4.44
0.38
6.31
6.26
9.08
5.28
7.54
10.62
8.28
9.71
8.35
9.63
Malpractice
RVUs 2
3.43
3.49
3.36
2.88
3.36
2.90
3.25
1.86
4.33
1.80
2.36
2.82
0.61
1.68
1.35
1.13
0.04
0.05
0.11
0.11
0.09
0.22
0.15
0.15
0.16
0.13
0.16
0.08
0.09
0.16
0.15
0.20
0.11
0.21
0.19
0.26
0.15
0.19
0.30
0.23
0.36
0.30
0.08
0.39
0.35
0.30
0.41
0.48
0.38
0.42
0.39
0.48
0.42
0.42
3.63
3.67
2.03
2.82
0.00
0.75
0.86
0.05
1.85
1.55
2.62
1.13
1.84
3.11
1.86
2.03
1.58
2.32
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00240
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
090
090
090
YYY
090
090
000
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66461
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
45900
45905
45910
45915
45990
45999
46020
46030
46040
46045
46050
46060
46070
46080
46083
46200
46210
46211
46220
46221
46230
46250
46255
46257
46258
46260
46261
46262
46270
46275
46280
46285
46288
46320
46500
46505
46600
46604
46606
46608
46610
46611
46612
46614
46615
46700
46705
46706
46710
46712
46715
46716
46730
46735
46740
46742
46744
46746
46748
46750
46751
46753
46754
46760
46761
46762
46900
46910
46916
46917
46922
46924
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Reduction of rectal prolapse ...............
Dilation of anal sphincter ....................
Dilation of rectal narrowing .................
Remove rectal obstruction ..................
Surg dx exam, anorectal .....................
Rectum surgery procedure .................
Placement of seton .............................
Removal of rectal marker ...................
Incision of rectal abscess ...................
Incision of rectal abscess ...................
Incision of anal abscess .....................
Incision of rectal abscess ...................
Incision of anal septum .......................
Incision of anal sphincter ....................
Incise external hemorrhoid .................
Removal of anal fissure ......................
Removal of anal crypt .........................
Removal of anal crypts .......................
Removal of anal tag ............................
Ligation of hemorrhoid(s) ....................
Removal of anal tags ..........................
Hemorrhoidectomy ..............................
Hemorrhoidectomy ..............................
Remove hemorrhoids & fissure ..........
Remove hemorrhoids & fistula ...........
Hemorrhoidectomy ..............................
Remove hemorrhoids & fissure ..........
Remove hemorrhoids & fistula ...........
Removal of anal fistula .......................
Removal of anal fistula .......................
Removal of anal fistula .......................
Removal of anal fistula .......................
Repair anal fistula ...............................
Removal of hemorrhoid clot ................
Injection into hemorrhoid(s) ................
Chemodenervation anal musc ............
Diagnostic anoscopy ...........................
Anoscopy and dilation .........................
Anoscopy and biopsy ..........................
Anoscopy, remove for body ................
Anoscopy, remove lesion ....................
Anoscopy ............................................
Anoscopy, remove lesions ..................
Anoscopy, control bleeding .................
Anoscopy ............................................
Repair of anal stricture .......................
Repair of anal stricture .......................
Repr of anal fistula w/glue ..................
Repr per/vag pouch sngl proc ............
Repr per/vag pouch dbl proc ..............
Rep perf anoper fistu ..........................
Rep perf anoper/vestib fistu ................
Construction of absent anus ...............
Construction of absent anus ...............
Construction of absent anus ...............
Repair of imperforated anus ...............
Repair of cloacal anomaly ..................
Repair of cloacal anomaly ..................
Repair of cloacal anomaly ..................
Repair of anal sphincter ......................
Repair of anal sphincter ......................
Reconstruction of anus .......................
Removal of suture from anus .............
Repair of anal sphincter ......................
Repair of anal sphincter ......................
Implant artificial sphincter ...................
Destruction, anal lesion(s) ..................
Destruction, anal lesion(s) ..................
Cryosurgery, anal lesion(s) .................
Laser surgery, anal lesions .................
Excision of anal lesion(s) ....................
Destruction, anal lesion(s) ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.96
2.32
2.82
3.16
1.80
0.00
2.94
1.24
5.26
5.79
1.21
6.24
2.74
2.50
1.42
3.48
2.73
4.31
1.58
2.31
2.59
4.17
4.88
5.68
6.28
6.65
7.63
7.80
4.81
5.31
6.28
5.31
7.68
1.62
1.64
3.13
0.55
1.03
1.20
1.30
1.28
1.30
1.50
1.00
1.50
9.68
7.32
2.41
17.01
36.32
7.54
17.14
30.17
35.66
33.42
39.66
58.46
64.93
70.91
12.02
9.19
8.81
2.88
17.21
15.16
14.66
1.91
1.88
1.88
1.88
1.88
2.78
NA
NA
NA
4.20
NA
0.00
3.26
1.88
6.53
NA
3.19
NA
NA
3.06
2.36
6.29
5.82
7.84
3.02
3.73
3.50
5.95
6.34
NA
NA
NA
NA
NA
6.38
6.62
NA
6.53
NA
2.41
3.60
3.28
1.37
12.51
3.87
3.76
3.79
2.53
4.70
1.93
1.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.63
NA
NA
NA
3.65
3.88
3.77
8.78
4.14
9.57
NA
NA
NA
4.26
NA
0.00
2.80
1.61
6.01
NA
2.87
NA
NA
2.71
2.44
5.07
5.46
6.62
2.66
3.19
3.29
5.63
6.08
NA
NA
NA
NA
NA
5.68
5.62
NA
5.14
NA
2.26
2.86
3.16
1.46
10.81
3.82
4.08
3.91
2.93
4.94
2.13
2.11
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.61
NA
NA
NA
3.12
3.39
3.46
8.95
3.70
9.13
1.65
1.60
1.84
2.01
0.72
0.00
2.35
0.81
3.98
3.94
0.98
4.41
2.35
1.12
0.96
3.73
3.30
4.66
1.10
2.00
1.33
2.83
3.06
3.84
3.95
4.06
4.29
4.65
3.91
3.97
4.27
3.95
4.67
0.88
1.25
2.28
0.38
0.51
0.58
0.58
0.59
0.57
0.72
0.52
0.64
5.15
4.06
1.49
7.54
14.00
3.75
9.59
12.49
15.00
15.28
13.75
18.13
19.66
21.04
5.76
5.02
4.59
2.21
8.05
6.47
7.07
1.31
1.20
1.58
1.22
1.20
1.51
1.57
1.51
1.75
2.05
0.76
0.00
2.10
0.76
3.78
3.41
0.91
3.83
2.09
1.12
0.94
3.29
2.96
4.08
1.02
1.87
1.31
2.72
2.95
3.36
3.61
3.62
3.94
4.19
3.37
3.47
3.76
3.35
4.17
0.86
1.20
2.12
0.36
0.56
0.50
0.61
0.60
0.67
0.85
0.68
0.85
4.67
3.87
1.37
7.64
14.52
3.66
8.77
12.25
14.27
14.25
15.56
19.61
22.39
22.33
5.40
5.22
4.21
1.94
7.56
6.23
6.29
1.29
1.13
1.48
1.17
1.13
1.43
Malpractice
RVUs 2
0.30
0.27
0.30
0.30
0.17
0.00
0.31
0.14
0.62
0.54
0.14
0.67
0.36
0.30
0.15
0.39
0.31
0.48
0.17
0.23
0.30
0.48
0.58
0.64
0.68
0.76
0.79
0.83
0.46
0.52
0.66
0.44
0.79
0.18
0.16
0.14
0.05
0.12
0.09
0.16
0.15
0.19
0.28
0.20
0.33
0.94
0.91
0.28
1.38
3.67
0.92
1.58
2.47
3.21
2.42
3.20
6.40
7.70
3.37
1.10
0.94
0.94
0.19
1.59
1.43
1.24
0.17
0.19
0.11
0.21
0.22
0.26
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00241
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
010
010
010
000
YYY
010
010
090
090
010
090
090
010
010
090
090
090
010
010
010
090
090
090
090
090
090
090
090
090
090
090
090
010
010
010
000
000
000
000
000
000
000
000
000
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
090
090
010
010
010
010
010
010
66462
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
46934
46935
46936
46937
46938
46940
46942
46945
46946
46947
46999
47000
47001
47010
47011
47015
47100
47120
47122
47125
47130
47133
47135
47136
47140
47141
47142
47143
47144
47145
47146
47147
47300
47350
47360
47361
47362
47370
47371
47379
47380
47381
47382
47399
47400
47420
47425
47460
47480
47490
47500
47505
47510
47511
47525
47530
47550
47552
47553
47554
47555
47556
47560
47561
47562
47563
47564
47570
47579
47600
47605
47610
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
X
R
R
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
C
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Destruction of hemorrhoids .................
Destruction of hemorrhoids .................
Destruction of hemorrhoids .................
Cryotherapy of rectal lesion ................
Cryotherapy of rectal lesion ................
Treatment of anal fissure ....................
Treatment of anal fissure ....................
Ligation of hemorrhoids ......................
Ligation of hemorrhoids ......................
Hemorrhoidopexy by stapling .............
Anus surgery procedure .....................
Needle biopsy of liver .........................
Needle biopsy, liver add-on ................
Open drainage, liver lesion .................
Percut drain, liver lesion .....................
Inject/aspirate liver cyst ......................
Wedge biopsy of liver .........................
Partial removal of liver ........................
Extensive removal of liver ...................
Partial removal of liver ........................
Partial removal of liver ........................
Removal of donor liver ........................
Transplantation of liver .......................
Transplantation of liver .......................
Partial removal, donor liver .................
Partial removal, donor liver .................
Partial removal, donor liver .................
Prep donor liver, whole .......................
Prep donor liver, 3-segment ...............
Prep donor liver, lobe split ..................
Prep donor liver/venous ......................
Prep donor liver/arterial ......................
Surgery for liver lesion ........................
Repair liver wound ..............................
Repair liver wound ..............................
Repair liver wound ..............................
Repair liver wound ..............................
Laparo ablate liver tumor rf ................
Laparo ablate liver cryosurg ...............
Laparoscope procedure, liver .............
Open ablate liver tumor rf ...................
Open ablate liver tumor cryo ..............
Percut ablate liver rf ............................
Liver surgery procedure ......................
Incision of liver duct ............................
Incision of bile duct .............................
Incision of bile duct .............................
Incise bile duct sphincter ....................
Incision of gallbladder .........................
Incision of gallbladder .........................
Injection for liver x-rays .......................
Injection for liver x-rays .......................
Insert catheter, bile duct .....................
Insert bile duct drain ...........................
Change bile duct catheter ...................
Revise/reinsert bile tube .....................
Bile duct endoscopy add-on ...............
Biliary endoscopy thru skin .................
Biliary endoscopy thru skin .................
Biliary endoscopy thru skin .................
Biliary endoscopy thru skin .................
Biliary endoscopy thru skin .................
Laparoscopy w/cholangio ...................
Laparo w/cholangio/biopsy .................
Laparoscopic cholecystectomy ...........
Laparo cholecystectomy/graph ...........
Laparo cholecystectomy/explr ............
Laparo cholecystoenterostomy ...........
Laparoscope proc, biliary ....................
Removal of gallbladder .......................
Removal of gallbladder .......................
Removal of gallbladder .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
3.79
2.44
3.70
2.70
4.70
2.33
2.05
2.13
2.60
5.49
0.00
1.90
1.90
19.27
3.69
18.37
12.78
38.82
59.35
52.91
57.06
0.00
83.29
70.39
59.22
71.27
79.21
0.00
0.00
0.00
6.00
7.00
18.01
22.36
31.18
52.47
23.41
20.67
20.67
0.00
24.43
24.72
15.19
0.00
36.23
21.92
22.20
20.41
13.12
8.05
1.96
0.76
7.94
10.74
5.55
5.96
3.02
6.03
6.34
9.05
7.55
8.55
4.88
5.17
11.63
12.03
14.21
12.56
0.00
17.35
15.90
20.84
5.56
3.86
6.23
3.40
5.62
2.84
2.80
4.79
4.63
NA
0.00
7.66
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
14.85
30.56
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
5.31
3.66
5.55
3.09
4.80
2.42
2.32
4.03
4.17
NA
0.00
5.36
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
14.96
32.16
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
2.87
1.11
2.65
1.43
3.55
1.04
0.96
2.98
2.64
3.10
0.00
0.70
0.48
8.31
1.32
8.16
6.31
14.07
18.74
17.16
18.10
0.00
27.72
24.53
21.60
25.33
27.34
0.00
0.00
0.00
1.52
1.77
7.74
8.77
11.24
17.38
9.30
7.69
7.89
0.00
8.60
9.31
6.20
0.00
13.01
8.54
8.64
9.13
6.64
5.29
0.71
0.27
4.63
5.04
2.69
3.44
0.78
2.48
2.25
3.29
2.74
3.09
1.24
1.58
5.26
5.06
5.41
4.96
0.00
7.22
6.38
7.65
2.91
1.16
2.57
1.32
3.30
1.06
0.99
2.72
2.52
2.91
0.00
0.66
0.57
8.35
1.26
7.82
6.17
14.60
20.08
18.33
19.53
0.00
29.60
25.76
21.93
26.11
28.39
0.00
0.00
0.00
1.78
2.08
7.48
8.81
11.40
17.94
9.00
7.90
8.01
0.00
8.97
9.44
6.14
0.00
13.21
8.65
8.72
8.74
6.27
5.43
0.67
0.26
4.82
5.06
2.74
3.58
0.90
2.43
2.16
3.32
2.60
2.93
1.45
1.75
5.12
5.18
5.68
5.16
0.00
6.67
6.43
7.78
Malpractice
RVUs 2
0.32
0.23
0.34
0.14
0.58
0.23
0.19
0.19
0.27
0.75
0.00
0.12
0.25
1.81
0.22
1.84
1.53
4.66
7.21
6.47
6.96
0.00
9.96
8.44
5.19
5.19
5.19
0.00
0.00
0.00
0.83
0.97
1.99
2.59
3.38
5.87
2.51
2.56
2.61
0.00
2.87
2.85
0.96
0.00
3.08
2.63
2.62
2.21
1.42
0.43
0.12
0.04
0.46
0.62
0.33
0.37
0.40
0.42
0.37
0.96
0.45
0.50
0.65
0.66
1.46
1.58
1.89
1.65
0.00
1.80
1.95
2.49
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00242
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
010
090
010
090
010
010
090
090
090
YYY
000
ZZZ
090
000
090
090
090
090
090
090
XXX
090
090
090
090
090
XXX
090
XXX
XXX
XXX
090
090
090
090
090
090
090
YYY
090
090
010
YYY
090
090
090
090
090
090
000
000
090
090
010
090
ZZZ
000
000
000
000
000
000
000
090
090
090
090
YYY
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66463
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
47612
47620
47630
47700
47701
47711
47712
47715
47720
47721
47740
47741
47760
47765
47780
47785
47800
47801
47802
47900
47999
48000
48001
48020
48100
48102
48105
48120
48140
48145
48146
48148
48150
48152
48153
48154
48155
48160
48400
48500
48510
48511
48520
48540
48545
48547
48548
48550
48551
48552
48554
48556
48999
49000
49002
49010
49020
49021
49040
49041
49060
49061
49062
49080
49081
49180
49203
49204
49205
49215
49220
49250
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
A
A
A
A
A
A
X
C
A
R
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of gallbladder .......................
Removal of gallbladder .......................
Remove bile duct stone ......................
Exploration of bile ducts .....................
Bile duct revision .................................
Excision of bile duct tumor .................
Excision of bile duct tumor .................
Excision of bile duct cyst ....................
Fuse gallbladder & bowel ...................
Fuse upper gi structures .....................
Fuse gallbladder & bowel ...................
Fuse gallbladder & bowel ...................
Fuse bile ducts and bowel ..................
Fuse liver ducts & bowel ....................
Fuse bile ducts and bowel ..................
Fuse bile ducts and bowel ..................
Reconstruction of bile ducts ...............
Placement, bile duct support ..............
Fuse liver duct & intestine ..................
Suture bile duct injury .........................
Bile tract surgery procedure ...............
Drainage of abdomen .........................
Placement of drain, pancreas .............
Removal of pancreatic stone ..............
Biopsy of pancreas, open ...................
Needle biopsy, pancreas ....................
Resect/debride pancreas ....................
Removal of pancreas lesion ...............
Partial removal of pancreas ................
Partial removal of pancreas ................
Pancreatectomy ..................................
Removal of pancreatic duct ................
Partial removal of pancreas ................
Pancreatectomy ..................................
Pancreatectomy ..................................
Pancreatectomy ..................................
Removal of pancreas ..........................
Pancreas removal/transplant ..............
Injection, intraop add-on .....................
Surgery of pancreatic cyst ..................
Drain pancreatic pseudocyst ..............
Drain pancreatic pseudocyst ..............
Fuse pancreas cyst and bowel ...........
Fuse pancreas cyst and bowel ...........
Pancreatorrhaphy ................................
Duodenal exclusion .............................
Fuse pancreas and bowel ..................
Donor pancreatectomy ........................
Prep donor pancreas ..........................
Prep donor pancreas/venous ..............
Transpl allograft pancreas ..................
Removal, allograft pancreas ...............
Pancreas surgery procedure ..............
Exploration of abdomen ......................
Reopening of abdomen ......................
Exploration behind abdomen ..............
Drain abdominal abscess ...................
Drain abdominal abscess ...................
Drain, open, abdom abscess ..............
Drain, percut, abdom abscess ............
Drain, open, retrop abscess ...............
Drain, percut, retroper absc ................
Drain to peritoneal cavity ....................
Puncture, peritoneal cavity .................
Removal of abdominal fluid ................
Biopsy, abdominal mass .....................
Exc abd tum 5 cm or less ...................
Exc abd tum over 5 cm ......................
Exc abd tum over 10 cm ....................
Excise sacral spine tumor ...................
Multiple surgery, abdomen .................
Excision of umbilicus ..........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
21.13
22.99
9.57
16.39
28.62
25.77
33.59
21.42
18.21
21.86
21.10
24.08
38.14
52.01
42.14
56.01
26.04
17.47
24.80
22.31
0.00
31.82
39.56
18.96
14.38
4.68
49.05
18.33
26.19
27.26
30.42
20.26
52.63
48.47
52.61
48.70
29.27
0.00
1.95
18.03
17.06
3.99
18.07
21.86
22.10
30.25
27.96
0.00
0.00
4.30
37.03
19.24
0.00
12.44
17.55
15.98
26.46
3.37
16.41
3.99
18.42
3.69
12.12
1.35
1.26
1.73
20.00
26.00
30.00
37.66
15.70
8.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
9.60
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
20.17
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
19.63
NA
19.91
NA
19.74
NA
2.73
2.93
2.47
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
8.77
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
20.53
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
0.00
NA
NA
NA
NA
20.33
NA
19.71
NA
19.68
NA
3.35
2.76
2.79
NA
NA
NA
NA
NA
NA
7.67
8.15
4.73
7.30
10.64
9.64
11.65
8.60
7.70
8.54
8.33
9.24
13.03
16.94
14.11
17.84
9.77
8.43
9.68
8.85
0.00
10.86
12.76
7.59
5.95
1.91
15.76
6.85
9.37
9.55
11.93
8.20
18.01
16.82
17.89
17.05
11.96
0.00
0.66
7.66
7.60
1.43
6.82
7.80
8.41
10.28
9.88
0.00
0.00
1.14
20.51
9.22
0.00
5.20
6.38
6.19
9.88
1.21
6.51
1.43
7.24
1.33
5.11
0.48
0.47
0.62
7.65
9.26
10.34
12.67
6.45
4.34
7.77
8.33
4.80
7.35
11.05
9.77
12.02
8.51
7.58
8.54
8.34
9.26
11.93
13.86
12.65
15.36
9.90
8.28
9.66
8.85
0.00
11.17
13.30
7.44
5.77
1.93
16.15
6.84
9.45
9.68
11.94
7.89
18.74
17.50
18.70
17.62
11.80
0.00
0.65
7.49
7.51
1.37
6.76
7.94
8.19
10.37
10.01
0.00
0.00
1.30
19.37
8.64
0.00
5.29
5.69
6.04
10.03
1.16
6.46
1.37
7.33
1.27
5.27
0.47
0.45
0.59
7.65
9.26
10.34
13.35
6.54
4.30
Malpractice
RVUs 2
2.48
2.74
0.65
2.07
3.68
3.05
3.93
2.49
2.11
2.53
2.42
2.83
3.42
3.30
3.50
4.10
3.08
1.16
2.86
2.65
0.00
3.48
4.69
2.13
1.62
0.28
5.56
2.10
3.03
3.18
3.50
2.30
6.32
5.80
6.31
5.84
3.27
0.00
0.15
2.03
1.83
0.24
2.06
2.61
2.38
3.42
3.28
0.00
0.00
0.31
4.19
2.08
0.00
1.52
1.37
1.51
2.85
0.20
1.70
0.24
1.75
0.22
1.39
0.08
0.09
0.10
2.27
2.94
3.40
4.38
1.89
1.08
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00243
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
XXX
ZZZ
090
090
000
090
090
090
090
090
XXX
XXX
XXX
090
090
YYY
090
090
090
090
000
090
000
090
000
090
000
000
000
090
090
090
090
090
090
66464
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
49255
49320
49321
49322
49323
49324
49325
49326
49329
49400
49402
49419
49420
49421
49422
49423
49424
49425
49426
49427
49428
49429
49435
49436
49440
49441
49442
49446
49450
49451
49452
49460
49465
49491
49492
49495
49496
49500
49501
49505
49507
49520
49521
49525
49540
49550
49553
49555
49557
49560
49561
49565
49566
49568
49570
49572
49580
49582
49585
49587
49590
49600
49605
49606
49610
49611
49650
49651
49659
49900
49904
49905
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of omentum ..........................
Diag laparo separate proc ..................
Laparoscopy, biopsy ...........................
Laparoscopy, aspiration ......................
Laparo drain lymphocele ....................
Lap insertion perm ip cath ..................
Lap revision perm ip cath ...................
Lap w/omentopexy add-on .................
Laparo proc, abdm/per/oment ............
Air injection into abdomen ..................
Remove foreign body, adbomen ........
Insrt abdom cath for chemotx .............
Insert abdom drain, temp ....................
Insert abdom drain, perm ...................
Remove perm cannula/catheter ..........
Exchange drainage catheter ...............
Assess cyst, contrast inject ................
Insert abdomen-venous drain .............
Revise abdomen-venous shunt ..........
Injection, abdominal shunt ..................
Ligation of shunt .................................
Removal of shunt ................................
Insert subq exten to ip cath ................
Embedded ip cath exit-site .................
Place gastrostomy tube perc ..............
Place duod/jej tube perc .....................
Place cecostomy tube perc ................
Change g-tube to g-j perc ...................
Replace g/c tube perc .........................
Replace duod/jej tube perc .................
Replace g-j tube perc .........................
Fix g/colon tube w/device ...................
Fluoro exam of g/colon tube ...............
Rpr hern preemie reduc ......................
Rpr ing hern premie, blocked .............
Rpr ing hernia baby, reduc .................
Rpr ing hernia baby, blocked ..............
Rpr ing hernia, init, reduce .................
Rpr ing hernia, init blocked .................
Prp i/hern init reduc >5 yr ...................
Prp i/hern init block >5 yr ....................
Rerepair ing hernia, reduce ................
Rerepair ing hernia, blocked ...............
Repair ing hernia, sliding ....................
Repair lumbar hernia ..........................
Rpr rem hernia, init, reduce ................
Rpr fem hernia, init blocked ................
Rerepair fem hernia, reduce ...............
Rerepair fem hernia, blocked .............
Rpr ventral hern init, reduc .................
Rpr ventral hern init, block ..................
Rerepair ventrl hern, reduce ...............
Rerepair ventrl hern, block .................
Hernia repair w/mesh ..........................
Rpr epigastric hern, reduce ................
Rpr epigastric hern, blocked ...............
Rpr umbil hern, reduc < 5 yr ..............
Rpr umbil hern, block < 5 yr ...............
Rpr umbil hern, reduc > 5 yr ..............
Rpr umbil hern, block > 5 yr ...............
Repair spigelian hernia .......................
Repair umbilical lesion ........................
Repair umbilical lesion ........................
Repair umbilical lesion ........................
Repair umbilical lesion ........................
Repair umbilical lesion ........................
Laparo hernia repair initial ..................
Laparo hernia repair recur ..................
Laparo proc, hernia repair ..................
Repair of abdominal wall ....................
Omental flap, extra-abdom .................
Omental flap, intra-abdom ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
12.41
5.09
5.39
5.96
10.13
6.27
6.77
3.50
0.00
1.88
14.01
7.03
2.22
5.87
6.26
1.46
0.76
12.13
10.33
0.89
6.79
7.41
2.25
2.69
4.18
4.77
4.00
3.31
1.36
1.84
2.86
0.96
0.62
12.42
15.32
6.15
9.32
5.76
9.28
7.88
9.97
9.91
12.36
8.85
10.66
8.91
9.84
9.31
11.54
11.84
15.30
12.29
15.45
4.88
5.97
7.79
4.39
7.05
6.51
7.96
8.82
11.47
86.85
18.92
10.83
9.26
6.30
8.29
0.00
12.26
22.16
6.54
NA
NA
NA
NA
NA
NA
NA
NA
0.00
2.47
NA
NA
NA
NA
NA
13.08
3.08
NA
NA
NA
NA
NA
NA
NA
25.03
30.10
24.43
25.74
18.94
19.69
23.48
20.56
3.88
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
2.77
NA
NA
NA
NA
NA
13.57
3.39
NA
NA
NA
NA
NA
NA
NA
25.03
30.10
24.43
25.74
18.94
19.69
23.48
20.56
3.88
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
5.62
2.44
2.56
2.63
4.68
2.78
2.91
0.92
0.00
0.62
5.51
3.43
1.18
3.12
2.61
0.56
0.30
5.29
4.56
0.32
2.99
2.99
0.61
1.66
1.81
2.00
1.63
1.15
0.44
0.64
1.00
0.31
0.22
4.61
6.22
3.06
4.44
3.64
4.26
3.88
4.45
4.37
4.98
4.12
4.57
4.11
4.41
4.20
4.83
4.87
5.79
5.08
5.85
1.24
3.38
3.82
2.94
3.69
3.51
3.86
4.08
5.38
27.56
6.77
5.28
4.21
3.34
4.22
0.00
6.28
11.88
1.69
5.61
2.53
2.60
2.81
4.58
2.78
2.91
0.92
0.00
0.62
5.50
3.49
1.13
3.13
2.75
0.54
0.30
5.44
4.66
0.31
3.45
3.20
0.61
1.66
1.81
2.00
1.63
1.15
0.44
0.64
1.00
0.31
0.22
4.83
6.16
3.01
4.35
3.38
4.23
3.81
4.45
4.40
5.11
4.09
4.65
4.11
4.41
4.23
4.90
5.00
5.92
5.15
5.98
1.45
3.27
3.64
2.77
3.57
3.40
3.79
4.08
5.35
28.02
7.22
5.24
5.59
3.27
4.13
0.00
6.25
13.54
1.99
Malpractice
RVUs 2
1.43
0.65
0.70
0.71
1.20
0.73
0.86
0.44
0.00
0.15
1.62
0.81
0.21
0.74
0.83
0.09
0.04
1.54
1.28
0.07
0.80
1.02
0.28
0.28
0.49
0.29
0.24
0.18
0.08
0.11
0.18
0.05
0.03
1.40
1.81
0.74
1.07
0.71
1.12
1.03
1.27
1.28
1.59
1.13
1.37
1.14
1.24
1.20
1.47
1.52
1.89
1.52
1.91
0.64
0.75
0.88
0.54
0.88
0.82
0.99
1.13
1.32
9.39
2.46
1.07
0.78
0.93
1.14
0.00
1.62
2.70
0.75
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00244
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
010
010
010
090
010
010
ZZZ
YYY
000
090
090
000
090
010
000
000
090
090
000
010
010
ZZZ
010
010
010
010
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
090
090
ZZZ
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66465
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
49906
49999
50010
50020
50021
50040
50045
50060
50065
50070
50075
50080
50081
50100
50120
50125
50130
50135
50200
50205
50220
50225
50230
50234
50236
50240
50250
50280
50290
50300
50320
50323
50325
50327
50328
50329
50340
50360
50365
50370
50380
50382
50384
50385
50386
50387
50389
50390
50391
50392
50393
50394
50395
50396
50398
50400
50405
50500
50520
50525
50526
50540
50541
50542
50543
50544
50545
50546
50547
50548
50549
50551
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
X
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Free omental flap, microvasc .............
Abdomen surgery procedure ..............
Exploration of kidney ..........................
Renal abscess, open drain .................
Renal abscess, percut drain ...............
Drainage of kidney ..............................
Exploration of kidney ..........................
Removal of kidney stone ....................
Incision of kidney ................................
Incision of kidney ................................
Removal of kidney stone ....................
Removal of kidney stone ....................
Removal of kidney stone ....................
Revise kidney blood vessels ..............
Exploration of kidney ..........................
Explore and drain kidney ....................
Removal of kidney stone ....................
Exploration of kidney ..........................
Biopsy of kidney ..................................
Biopsy of kidney ..................................
Remove kidney, open .........................
Removal kidney open, complex ..........
Removal kidney open, radical ............
Removal of kidney & ureter ................
Removal of kidney & ureter ................
Partial removal of kidney ....................
Cryoablate renal mass open ...............
Removal of kidney lesion ....................
Removal of kidney lesion ....................
Remove cadaver donor kidney ...........
Remove kidney, living donor ..............
Prep cadaver renal allograft ...............
Prep donor renal graft .........................
Prep renal graft/venous ......................
Prep renal graft/arterial .......................
Prep renal graft/ureteral ......................
Removal of kidney ..............................
Transplantation of kidney ....................
Transplantation of kidney ....................
Remove transplanted kidney ..............
Reimplantation of kidney ....................
Change ureter stent, percut ................
Remove ureter stent, percut ...............
Change stent via transureth ...............
Remove stent via transureth ...............
Change ext/int ureter stent .................
Remove renal tube w/fluoro ................
Drainage of kidney lesion ...................
Instll rx agnt into rnal tub ....................
Insert kidney drain ..............................
Insert ureteral tube ..............................
Injection for kidney x-ray .....................
Create passage to kidney ...................
Measure kidney pressure ...................
Change kidney tube ............................
Revision of kidney/ureter ....................
Revision of kidney/ureter ....................
Repair of kidney wound ......................
Close kidney-skin fistula .....................
Repair renal-abdomen fistula ..............
Repair renal-abdomen fistula ..............
Revision of horseshoe kidney .............
Laparo ablate renal cyst .....................
Laparo ablate renal mass ...................
Laparo partial nephrectomy ................
Laparoscopy, pyeloplasty ...................
Laparo radical nephrectomy ...............
Laparoscopic nephrectomy .................
Laparo removal donor kidney .............
Laparo remove w/ureter ......................
Laparoscope proc, renal .....................
Kidney endoscopy ...............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
12.13
17.88
3.37
16.48
16.67
20.80
22.17
21.70
26.91
15.61
23.32
17.30
17.06
17.67
18.67
20.44
2.63
12.19
18.53
21.73
23.68
23.90
26.74
24.01
22.06
16.94
16.00
0.00
22.28
0.00
0.00
4.00
3.50
3.34
13.86
40.45
45.68
18.68
29.66
5.50
5.00
4.44
3.30
2.00
1.10
1.96
1.96
3.37
4.15
0.76
3.37
2.09
1.46
21.12
25.68
21.07
18.73
24.21
26.13
20.95
16.76
21.18
27.18
23.27
24.93
21.69
26.24
25.26
0.00
5.59
0.00
0.00
NA
NA
21.09
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
26.34
20.66
30.61
19.36
12.60
6.67
NA
1.38
NA
NA
1.87
NA
NA
11.83
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.59
0.00
0.00
NA
NA
21.36
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
31.22
27.93
30.61
19.36
15.40
9.71
NA
1.48
NA
NA
2.28
NA
NA
14.07
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.36
0.00
0.00
6.73
8.48
1.22
8.82
8.14
10.81
11.51
11.32
13.49
8.55
12.17
6.51
9.11
9.71
10.05
10.69
1.19
5.51
9.51
11.01
11.64
12.03
13.90
12.60
11.48
9.06
7.73
0.00
12.30
0.00
0.00
1.09
0.98
1.05
7.80
18.66
19.40
9.18
16.19
2.05
1.86
2.05
1.60
0.73
0.40
0.71
0.72
1.52
1.80
0.58
1.56
1.08
0.56
10.94
12.90
8.69
9.24
11.79
8.15
10.61
8.69
11.17
14.08
11.43
12.14
11.28
12.47
12.10
0.00
2.64
0.00
0.00
5.97
8.11
1.16
7.81
7.36
9.31
8.79
9.76
11.69
7.41
10.46
7.14
7.93
8.33
8.60
9.23
1.24
5.25
8.37
9.57
10.10
10.42
12.07
10.80
10.31
7.87
7.09
0.00
11.47
0.00
0.00
1.22
1.08
1.09
7.14
17.06
18.79
8.16
14.10
1.96
1.78
2.05
1.60
0.70
0.38
0.67
0.67
1.52
1.79
0.62
1.53
1.08
0.54
9.40
10.96
8.53
8.33
10.39
9.00
9.46
7.58
9.65
12.13
9.97
10.66
9.81
11.78
10.64
0.00
2.31
Malpractice
RVUs 2
0.00
0.00
0.93
1.34
0.20
1.03
1.24
1.36
1.59
1.44
1.81
1.04
1.54
2.07
1.21
1.43
1.22
1.33
0.16
1.30
1.35
1.50
1.55
1.59
1.77
1.55
1.39
1.19
1.41
0.00
2.36
0.00
0.00
0.29
0.26
0.25
1.65
3.82
4.43
1.68
2.51
0.34
0.31
0.27
0.20
0.12
0.07
0.12
0.14
0.20
0.25
0.05
0.21
0.13
0.09
1.38
1.79
2.02
1.49
1.84
1.97
1.36
1.13
1.39
1.81
1.58
1.71
1.57
2.77
1.73
0.00
0.40
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00245
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
YYY
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
XXX
090
XXX
XXX
XXX
XXX
XXX
090
090
090
090
090
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
000
66466
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
50553
50555
50557
50561
50562
50570
50572
50574
50575
50576
50580
50590
50592
50593
50600
50605
50610
50620
50630
50650
50660
50684
50686
50688
50690
50700
50715
50722
50725
50727
50728
50740
50750
50760
50770
50780
50782
50783
50785
50800
50810
50815
50820
50825
50830
50840
50845
50860
50900
50920
50930
50940
50945
50947
50948
50949
50951
50953
50955
50957
50961
50970
50972
50974
50976
50980
51020
51030
51040
51045
51050
51060
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Kidney endoscopy ...............................
Kidney endoscopy & biopsy ...............
Kidney endoscopy & treatment ...........
Kidney endoscopy & treatment ...........
Renal scope w/tumor resect ...............
Kidney endoscopy ...............................
Kidney endoscopy ...............................
Kidney endoscopy & biopsy ...............
Kidney endoscopy ...............................
Kidney endoscopy & treatment ...........
Kidney endoscopy & treatment ...........
Fragmenting of kidney stone ..............
Perc rf ablate renal tumor ...................
Perc cryo ablate renal tum .................
Exploration of ureter ...........................
Insert ureteral support .........................
Removal of ureter stone .....................
Removal of ureter stone .....................
Removal of ureter stone .....................
Removal of ureter ...............................
Removal of ureter ...............................
Injection for ureter x-ray ......................
Measure ureter pressure ....................
Change of ureter tube/stent ................
Injection for ureter x-ray ......................
Revision of ureter ................................
Release of ureter ................................
Release of ureter ................................
Release/revise ureter ..........................
Revise ureter .......................................
Revise ureter .......................................
Fusion of ureter & kidney ...................
Fusion of ureter & kidney ...................
Fusion of ureters .................................
Splicing of ureters ...............................
Reimplant ureter in bladder ................
Reimplant ureter in bladder ................
Reimplant ureter in bladder ................
Reimplant ureter in bladder ................
Implant ureter in bowel .......................
Fusion of ureter & bowel ....................
Urine shunt to intestine .......................
Construct bowel bladder .....................
Construct bowel bladder .....................
Revise urine flow ................................
Replace ureter by bowel .....................
Appendico-vesicostomy ......................
Transplant ureter to skin .....................
Repair of ureter ...................................
Closure ureter/skin fistula ...................
Closure ureter/bowel fistula ................
Release of ureter ................................
Laparoscopy ureterolithotomy .............
Laparo new ureter/bladder ..................
Laparo new ureter/bladder ..................
Laparoscope proc, ureter ....................
Endoscopy of ureter ............................
Endoscopy of ureter ............................
Ureter endoscopy & biopsy ................
Ureter endoscopy & treatment ............
Ureter endoscopy & treatment ............
Ureter endoscopy ................................
Ureter endoscopy & catheter ..............
Ureter endoscopy & biopsy ................
Ureter endoscopy & treatment ............
Ureter endoscopy & treatment ............
Incise & treat bladder ..........................
Incise & treat bladder ..........................
Incise & drain bladder .........................
Incise bladder/drain ureter ..................
Removal of bladder stone ...................
Removal of ureter stone .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.98
6.52
6.61
7.58
10.90
9.53
10.33
11.00
13.96
10.97
11.84
9.64
6.77
9.08
17.04
16.66
17.12
16.30
16.08
18.67
20.87
0.76
1.51
1.18
1.16
16.54
20.49
17.80
20.05
8.17
12.00
19.92
21.07
19.92
21.07
19.80
19.51
20.52
22.08
16.23
22.38
22.06
23.89
30.48
33.57
22.19
22.21
16.93
14.89
15.66
20.04
15.78
17.87
25.63
23.69
0.00
5.83
6.23
6.74
6.78
6.04
7.13
6.88
9.16
9.03
6.84
7.56
7.68
4.43
7.68
7.87
9.82
4.49
5.09
5.26
5.80
NA
NA
NA
NA
NA
NA
NA
17.08
75.40
114.48
NA
NA
NA
NA
NA
NA
NA
3.96
2.29
NA
1.45
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.82
4.92
5.14
5.37
4.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.42
4.95
4.92
5.44
NA
NA
NA
NA
NA
NA
NA
14.73
112.17
114.48
NA
NA
NA
NA
NA
NA
NA
4.46
2.87
NA
1.64
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
4.55
4.66
5.77
4.96
4.55
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.63
3.02
3.07
3.40
5.36
4.14
4.31
4.79
5.95
4.77
5.09
6.12
3.00
3.44
8.50
7.88
8.97
8.87
8.19
9.95
10.72
0.63
0.81
0.95
0.75
8.75
8.53
7.26
8.81
5.72
6.74
8.96
11.07
9.88
10.87
10.10
9.88
10.11
11.18
9.16
10.56
11.45
11.84
14.89
15.60
11.92
12.05
9.21
7.98
8.51
9.48
7.78
9.28
12.28
11.17
0.00
2.76
3.21
3.45
3.14
2.79
3.24
3.05
3.76
3.85
3.12
5.38
4.89
3.68
5.14
5.32
6.42
2.40
2.68
2.68
3.02
4.83
3.68
3.90
4.26
5.29
4.22
4.52
5.11
2.99
3.44
7.58
7.31
7.96
7.60
7.23
8.58
9.33
0.55
0.82
1.00
0.73
7.93
8.63
7.53
8.42
5.00
6.15
8.34
9.52
8.77
9.41
8.84
9.32
9.15
9.73
7.81
9.82
9.94
10.24
13.00
13.88
10.16
10.47
7.91
7.06
7.54
8.72
7.08
8.15
10.98
9.93
0.00
2.40
2.79
3.06
2.75
2.48
2.85
2.76
3.43
3.45
2.75
4.62
4.43
3.22
4.53
4.48
5.45
Malpractice
RVUs 2
0.39
0.45
0.47
0.54
0.73
0.68
0.85
0.77
0.99
0.78
0.83
0.65
0.43
0.58
1.13
1.45
1.43
1.07
1.09
1.23
1.38
0.05
0.11
0.07
0.07
1.27
2.14
1.91
1.52
0.61
1.00
1.97
1.38
1.55
1.45
1.51
1.61
1.99
1.45
1.19
2.32
1.54
1.90
2.08
2.38
1.47
1.57
1.29
1.14
1.01
1.28
1.26
1.36
2.17
1.71
0.00
0.41
0.43
0.48
0.48
0.41
0.52
0.49
0.64
0.66
0.48
0.47
0.58
0.31
0.52
0.49
0.62
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00246
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
000
090
000
000
000
000
000
000
090
010
010
090
090
090
090
090
090
090
000
000
010
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
YYY
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66467
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
51065
51080
51100
51101
51102
51500
51520
51525
51530
51535
51550
51555
51565
51570
51575
51580
51585
51590
51595
51596
51597
51600
51605
51610
51700
51701
51702
51703
51705
51710
51715
51720
51725
51725
51725
51726
51726
51726
51736
51736
51736
51741
51741
51741
51772
51772
51772
51784
51784
51784
51785
51785
51785
51792
51792
51792
51795
51795
51795
51797
51797
51797
51798
51800
51820
51840
51841
51845
51860
51865
51880
51900
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove ureter calculus ......................
Drainage of bladder abscess ..............
Drain bladder by needle .....................
Drain bladder by trocar/cath ...............
Drain bl w/cath insertion .....................
Removal of bladder cyst .....................
Removal of bladder lesion ..................
Removal of bladder lesion ..................
Removal of bladder lesion ..................
Repair of ureter lesion ........................
Partial removal of bladder ...................
Partial removal of bladder ...................
Revise bladder & ureter(s) ..................
Removal of bladder .............................
Removal of bladder & nodes ..............
Remove bladder/revise tract ...............
Removal of bladder & nodes ..............
Remove bladder/revise tract ...............
Remove bladder/revise tract ...............
Remove bladder/create pouch ............
Removal of pelvic structures ..............
Injection for bladder x-ray ...................
Preparation for bladder xray ...............
Injection for bladder x-ray ...................
Irrigation of bladder .............................
Insert bladder catheter ........................
Insert temp bladder cath .....................
Insert bladder cath, complex ..............
Change of bladder tube ......................
Change of bladder tube ......................
Endoscopic injection/implant ...............
Treatment of bladder lesion ................
Simple cystometrogram ......................
Simple cystometrogram ......................
Simple cystometrogram ......................
Complex cystometrogram ...................
Complex cystometrogram ...................
Complex cystometrogram ...................
Urine flow measurement .....................
Urine flow measurement .....................
Urine flow measurement .....................
Electro-uroflowmetry, first ...................
Electro-uroflowmetry, first ...................
Electro-uroflowmetry, first ...................
Urethra pressure profile ......................
Urethra pressure profile ......................
Urethra pressure profile ......................
Anal/urinary muscle study ...................
Anal/urinary muscle study ...................
Anal/urinary muscle study ...................
Anal/urinary muscle study ...................
Anal/urinary muscle study ...................
Anal/urinary muscle study ...................
Urinary reflex study .............................
Urinary reflex study .............................
Urinary reflex study .............................
Urine voiding pressure study ..............
Urine voiding pressure study ..............
Urine voiding pressure study ..............
Intraabdominal pressure test ..............
Intraabdominal pressure test ..............
Intraabdominal pressure test ..............
Us urine capacity measure .................
Revision of bladder/urethra .................
Revision of urinary tract ......................
Attach bladder/urethra ........................
Attach bladder/urethra ........................
Repair bladder neck ............................
Repair of bladder wound ....................
Repair of bladder wound ....................
Repair of bladder opening ..................
Repair bladder/vagina lesion ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
9.82
6.61
0.78
1.02
4.27
10.92
10.08
15.29
13.58
13.77
17.10
23.03
23.50
27.31
34.00
35.14
39.41
36.15
41.12
44.01
42.61
0.88
0.64
1.05
0.88
0.50
0.50
1.47
1.03
1.50
3.73
1.50
1.51
0.00
1.51
1.71
0.00
1.71
0.61
0.00
0.61
1.14
0.00
1.14
1.61
0.00
1.61
1.53
0.00
1.53
1.53
0.00
1.53
1.10
0.00
1.10
1.53
0.00
1.53
0.80
0.00
0.80
0.00
18.74
19.41
11.28
13.60
10.07
12.49
15.69
7.81
14.48
NA
NA
0.92
2.40
4.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.23
NA
1.91
1.50
1.04
1.53
2.26
2.02
2.72
4.41
1.61
4.22
3.67
0.55
7.11
6.47
0.64
0.94
0.70
0.24
1.27
0.83
0.44
5.06
4.51
0.55
4.12
3.56
0.56
4.55
3.99
0.56
5.05
4.66
0.39
6.72
6.15
0.57
2.43
2.14
0.29
0.59
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.92
2.40
4.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.64
NA
2.10
1.55
1.31
1.80
2.49
2.15
3.03
4.15
1.68
4.90
4.38
0.52
7.30
6.70
0.60
0.76
0.54
0.22
1.02
0.62
0.40
5.31
4.76
0.55
4.05
3.52
0.53
4.49
3.96
0.53
5.52
5.12
0.40
7.00
6.47
0.53
4.11
3.70
0.41
0.47
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.24
4.60
0.27
0.34
2.36
5.75
6.31
8.46
7.38
7.37
8.70
11.34
12.11
13.48
16.43
17.57
19.24
17.22
19.56
21.18
20.17
0.32
0.43
0.70
0.34
0.24
0.33
0.80
0.84
1.17
1.72
0.74
NA
NA
0.55
NA
NA
0.64
NA
NA
0.24
NA
NA
0.44
NA
NA
0.55
NA
NA
0.56
NA
NA
0.56
NA
NA
0.39
NA
NA
0.57
NA
NA
0.29
NA
9.71
9.74
5.75
6.85
5.88
6.73
8.32
4.72
7.97
5.29
4.07
0.27
0.34
2.36
5.37
5.48
7.29
6.56
6.74
7.71
10.00
10.53
11.60
14.22
15.02
16.46
14.91
16.83
18.19
17.49
0.31
0.39
0.65
0.31
0.22
0.29
0.68
0.73
0.97
1.54
0.71
NA
NA
0.52
NA
NA
0.60
NA
NA
0.22
NA
NA
0.40
NA
NA
0.55
NA
NA
0.53
NA
NA
0.53
NA
NA
0.40
NA
NA
0.53
NA
NA
0.41
NA
8.63
9.01
5.66
6.61
5.31
6.24
7.49
4.34
7.01
Malpractice
RVUs 2
0.63
0.43
0.05
0.10
0.28
1.03
0.69
0.99
1.05
1.23
1.31
1.70
1.63
1.72
2.17
2.25
2.49
2.28
2.60
2.78
2.82
0.06
0.04
0.07
0.06
0.04
0.04
0.10
0.07
0.11
0.29
0.14
0.16
0.04
0.12
0.18
0.05
0.13
0.06
0.01
0.05
0.11
0.02
0.09
0.20
0.05
0.15
0.16
0.04
0.12
0.15
0.04
0.11
0.20
0.13
0.07
0.22
0.10
0.12
0.17
0.05
0.12
0.08
1.32
1.75
1.06
1.24
0.79
1.16
1.23
0.72
1.21
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00247
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
000
000
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
000
000
010
010
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
ZZZ
ZZZ
ZZZ
XXX
090
090
090
090
090
090
090
090
090
66468
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
51920
51925
51940
51960
51980
51990
51992
51999
52000
52001
52005
52007
52010
52204
52214
52224
52234
52235
52240
52250
52260
52265
52270
52275
52276
52277
52281
52282
52283
52285
52290
52300
52301
52305
52310
52315
52317
52318
52320
52325
52327
52330
52332
52334
52341
52342
52343
52344
52345
52346
52351
52352
52353
52354
52355
52400
52402
52450
52500
52601
52606
52612
52614
52620
52630
52640
52647
52648
52649
52700
53000
53010
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Close bladder-uterus fistula ................
Hysterectomy/bladder repair ...............
Correction of bladder defect ...............
Revision of bladder & bowel ...............
Construct bladder opening ..................
Laparo urethral suspension ................
Laparo sling operation ........................
Laparoscope proc, bla ........................
Cystoscopy ..........................................
Cystoscopy, removal of clots ..............
Cystoscopy & ureter catheter .............
Cystoscopy and biopsy .......................
Cystoscopy & duct catheter ................
Cystoscopy w/biopsy(s) ......................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and radiotracer ................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy & revise urethra ...............
Cystoscopy & revise urethra ...............
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy, implant stent ...................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Remove bladder stone ........................
Remove bladder stone ........................
Cystoscopy and treatment ..................
Cystoscopy, stone removal .................
Cystoscopy, inject material .................
Cystoscopy and treatment ..................
Cystoscopy and treatment ..................
Create passage to kidney ...................
Cysto w/ureter stricture tx ...................
Cysto w/up stricture tx ........................
Cysto w/renal stricture tx ....................
Cysto/uretero, stricture tx ....................
Cysto/uretero w/up stricture ................
Cystouretero w/renal strict ..................
Cystouretero & or pyeloscope ............
Cystouretero w/stone remove .............
Cystouretero w/lithotripsy ....................
Cystouretero w/biopsy ........................
Cystouretero w/excise tumor ..............
Cystouretero w/congen repr ...............
Cystourethro cut ejacul duct ...............
Incision of prostate ..............................
Revision of bladder neck ....................
Prostatectomy (TURP) ........................
Control postop bleeding ......................
Prostatectomy, first stage ...................
Prostatectomy, second stage .............
Remove residual prostate ...................
Remove prostate regrowth .................
Relieve bladder contracture ................
Laser surgery of prostate ....................
Laser surgery of prostate ....................
2Prostate laser enucleation ................
Drainage of prostate abscess .............
Incision of urethra ...............................
Incision of urethra ...............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
13.26
17.35
30.48
25.20
12.44
13.26
14.77
0.00
2.23
5.44
2.37
3.02
3.02
2.59
3.70
3.14
4.62
5.44
9.71
4.49
3.91
2.94
3.36
4.69
4.99
6.16
2.80
6.39
3.73
3.60
4.58
5.30
5.50
5.30
2.81
5.20
6.71
9.18
4.69
6.15
5.18
5.03
2.83
4.82
6.11
6.61
7.31
7.81
8.31
9.34
5.85
6.87
7.96
7.33
8.81
10.06
5.27
7.63
9.39
15.13
8.84
9.07
7.81
7.19
7.65
6.89
11.15
12.00
17.16
7.39
2.30
4.35
NA
NA
NA
NA
NA
NA
NA
0.00
3.66
5.04
5.73
10.70
8.07
8.30
19.87
19.05
NA
NA
NA
NA
NA
7.48
7.02
9.29
NA
NA
5.28
NA
4.06
4.32
NA
NA
NA
NA
4.00
6.62
17.04
NA
NA
NA
2.04
20.39
12.41
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
41.90
42.44
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
3.48
5.05
5.64
13.57
9.41
11.40
28.97
27.74
NA
NA
NA
NA
NA
10.41
9.02
12.42
NA
NA
6.18
NA
4.00
4.16
NA
NA
NA
NA
4.34
7.64
22.98
NA
NA
NA
16.92
29.59
9.07
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
57.90
58.17
NA
NA
NA
NA
8.03
12.40
11.72
12.88
7.06
5.92
6.51
0.00
1.31
2.56
1.37
1.61
1.62
1.37
1.83
1.60
2.27
2.63
4.34
2.29
1.93
1.46
1.74
2.27
2.44
2.90
1.54
2.95
1.86
1.83
2.26
2.55
2.68
2.48
1.42
2.47
2.99
4.03
2.20
2.78
2.04
2.34
1.55
2.33
3.03
3.25
3.48
3.90
4.10
4.50
2.95
3.46
3.90
3.64
4.24
5.39
2.15
5.47
6.17
8.42
5.47
5.87
5.37
4.61
4.79
4.41
6.88
7.21
9.31
4.89
1.78
3.83
6.83
10.50
11.89
11.25
6.21
6.03
6.35
0.00
1.03
2.21
1.13
1.38
1.38
1.14
1.58
1.37
1.96
2.28
3.82
1.97
1.67
1.28
1.49
1.96
2.11
2.56
1.31
2.59
1.62
1.58
1.95
2.23
2.33
2.17
1.23
2.15
2.63
3.56
1.91
2.44
1.93
2.05
1.30
2.03
2.62
2.80
3.03
3.34
3.53
3.89
2.55
2.98
3.37
3.15
3.69
4.56
1.92
4.57
5.04
6.75
4.51
4.80
4.35
3.79
3.99
3.68
5.70
6.00
9.31
4.04
1.66
3.37
Malpractice
RVUs 2
1.18
2.04
2.15
1.63
0.86
1.39
1.41
0.00
0.14
0.39
0.17
0.22
0.21
0.17
0.26
0.22
0.33
0.39
0.69
0.32
0.28
0.22
0.24
0.33
0.35
0.44
0.20
0.45
0.26
0.26
0.32
0.38
0.46
0.38
0.20
0.37
0.48
0.65
0.33
0.44
0.37
0.36
0.21
0.35
0.43
0.46
0.51
0.55
0.58
0.65
0.41
0.49
0.57
0.52
0.63
0.68
0.40
0.54
0.60
0.87
0.57
0.56
0.48
0.47
0.51
0.47
0.73
0.79
1.11
0.48
0.16
0.24
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00248
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
YYY
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66469
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
53020
53025
53040
53060
53080
53085
53200
53210
53215
53220
53230
53235
53240
53250
53260
53265
53270
53275
53400
53405
53410
53415
53420
53425
53430
53431
53440
53442
53444
53445
53446
53447
53448
53449
53450
53460
53500
53502
53505
53510
53515
53520
53600
53601
53605
53620
53621
53660
53661
53665
53850
53852
53853
53899
54000
54001
54015
54050
54055
54056
54057
54060
54065
54100
54105
54110
54111
54112
54115
54120
54125
54130
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Incision of urethra ...............................
Incision of urethra ...............................
Drainage of urethra abscess ..............
Drainage of urethra abscess ..............
Drainage of urinary leakage ...............
Drainage of urinary leakage ...............
Biopsy of urethra .................................
Removal of urethra .............................
Removal of urethra .............................
Treatment of urethra lesion ................
Removal of urethra lesion ...................
Removal of urethra lesion ...................
Surgery for urethra pouch ...................
Removal of urethra gland ...................
Treatment of urethra lesion ................
Treatment of urethra lesion ................
Removal of urethra gland ...................
Repair of urethra defect ......................
Revise urethra, stage 1 ......................
Revise urethra, stage 2 ......................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruct urethra, stage 1 ..............
Reconstruct urethra, stage 2 ..............
Reconstruction of urethra ...................
Reconstruct urethra/bladder ...............
Male sling procedure ..........................
Remove/revise male sling ...................
Insert tandem cuff ...............................
Insert uro/ves nck sphincter ................
Remove uro sphincter .........................
Remove/replace ur sphincter ..............
Remov/replc ur sphinctr comp ............
Repair uro sphincter ...........................
Revision of urethra ..............................
Revision of urethra ..............................
Urethrlys, transvag w/ scope ..............
Repair of urethra injury .......................
Repair of urethra injury .......................
Repair of urethra injury .......................
Repair of urethra injury .......................
Repair of urethra defect ......................
Dilate urethra stricture ........................
Dilate urethra stricture ........................
Dilate urethra stricture ........................
Dilate urethra stricture ........................
Dilate urethra stricture ........................
Dilation of urethra ...............................
Dilation of urethra ...............................
Dilation of urethra ...............................
Prostatic microwave thermotx .............
Prostatic rf thermotx ............................
Prostatic water thermother ..................
Urology surgery procedure .................
Slitting of prepuce ...............................
Slitting of prepuce ...............................
Drain penis lesion ...............................
Destruction, penis lesion(s) ................
Destruction, penis lesion(s) ................
Cryosurgery, penis lesion(s) ...............
Laser surg, penis lesion(s) .................
Excision of penis lesion(s) ..................
Destruction, penis lesion(s) ................
Biopsy of penis ...................................
Biopsy of penis ...................................
Treatment of penis lesion ...................
Treat penis lesion, graft ......................
Treat penis lesion, graft ......................
Treatment of penis lesion ...................
Partial removal of penis ......................
Removal of penis ................................
Remove penis & nodes ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.77
1.13
6.49
2.65
6.82
11.05
2.59
13.59
16.72
7.53
10.31
10.86
6.98
6.42
3.00
3.14
3.11
4.54
13.98
15.51
17.53
20.55
15.04
16.94
17.30
21.03
15.34
13.29
14.06
15.21
10.89
14.15
23.26
10.43
6.67
7.65
12.87
8.16
8.16
10.83
14.09
9.35
1.21
0.98
1.28
1.62
1.35
0.71
0.72
0.76
9.98
10.68
5.54
0.00
1.56
2.21
5.33
1.26
1.23
1.26
1.26
1.95
2.44
1.90
3.51
10.79
14.29
16.83
6.82
10.88
14.43
21.66
NA
NA
NA
2.09
NA
NA
1.70
NA
NA
NA
NA
NA
NA
NA
2.45
2.93
2.46
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.15
1.36
NA
1.70
1.81
1.32
1.29
NA
49.19
46.31
29.06
0.00
2.69
3.05
NA
2.10
1.97
2.37
2.63
3.08
3.29
3.34
3.97
NA
NA
NA
5.75
NA
NA
NA
NA
NA
NA
2.09
NA
NA
1.51
NA
NA
NA
NA
NA
NA
NA
2.35
2.82
2.33
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.14
1.31
NA
1.84
1.94
1.31
1.29
NA
71.60
67.52
42.19
0.00
2.80
3.12
NA
1.87
1.77
2.03
2.42
3.09
2.96
3.07
4.12
NA
NA
NA
5.06
NA
NA
NA
0.95
0.82
4.40
1.54
4.96
4.41
1.29
7.75
9.11
4.97
6.36
6.92
4.86
4.38
1.83
1.98
1.84
2.76
8.16
8.68
9.66
10.68
7.11
8.99
8.80
10.97
9.18
8.35
8.01
8.74
6.99
8.37
12.31
6.60
4.75
5.04
7.40
5.10
5.37
6.82
7.95
6.20
0.57
0.52
0.51
0.83
0.67
0.45
0.41
0.27
5.86
6.65
4.34
0.00
1.48
1.67
3.21
1.39
1.23
1.53
1.36
1.63
1.99
1.36
2.43
6.71
8.02
9.30
4.94
6.72
8.06
11.56
0.81
0.66
3.91
1.45
5.46
5.90
1.13
6.79
7.87
4.34
5.53
5.90
4.19
3.83
1.62
1.70
1.69
2.51
7.09
7.49
8.35
9.00
6.69
7.93
7.89
9.50
7.57
6.89
6.94
7.91
6.10
7.39
10.67
5.66
4.02
4.36
6.80
4.54
4.62
5.99
6.94
5.33
0.50
0.44
0.46
0.71
0.58
0.38
0.35
0.26
4.90
5.51
3.60
0.00
1.20
1.39
2.88
1.21
1.01
1.33
1.10
1.34
1.61
1.09
2.18
5.73
6.89
8.04
4.19
5.69
6.94
9.86
Malpractice
RVUs 2
0.13
0.08
0.45
0.28
0.52
0.92
0.20
0.89
1.10
0.49
0.73
0.72
0.52
0.49
0.25
0.24
0.30
0.32
0.98
1.10
1.16
1.37
0.96
1.13
1.15
1.41
0.96
0.82
0.94
0.99
0.72
0.95
1.50
0.68
0.43
0.50
0.90
0.62
0.54
0.74
1.05
0.61
0.09
0.07
0.09
0.11
0.10
0.05
0.05
0.06
0.67
0.70
0.37
0.00
0.11
0.15
0.38
0.08
0.08
0.06
0.09
0.13
0.13
0.10
0.25
0.72
0.96
1.11
0.43
0.68
0.95
1.52
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00249
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
090
010
090
090
000
090
090
090
090
090
090
090
010
010
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
000
000
000
000
090
090
090
YYY
010
010
010
010
010
010
010
010
010
000
010
090
090
090
090
090
090
090
66470
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
54135
54150
54160
54161
54162
54163
54164
54200
54205
54220
54230
54231
54235
54240
54240
54240
54250
54250
54250
54300
54304
54308
54312
54316
54318
54322
54324
54326
54328
54332
54336
54340
54344
54348
54352
54360
54380
54385
54390
54400
54401
54405
54406
54408
54410
54411
54415
54416
54417
54420
54430
54435
54440
54450
54500
54505
54512
54520
54522
54530
54535
54550
54560
54600
54620
54640
54650
54660
54670
54680
54690
54692
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove penis & nodes ......................
Circumcision w/regionl block ..............
Circumcision, neonate ........................
Circum 28 days or older .....................
Lysis penil circumic lesion ..................
Repair of circumcision ........................
Frenulotomy of penis ..........................
Treatment of penis lesion ...................
Treatment of penis lesion ...................
Treatment of penis lesion ...................
Prepare penis study ............................
Dynamic cavernosometry ...................
Penile injection ....................................
Penis study .........................................
Penis study .........................................
Penis study .........................................
Penis study .........................................
Penis study .........................................
Penis study .........................................
Revision of penis ................................
Revision of penis ................................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Reconstruction of urethra ...................
Revise penis/urethra ...........................
Revise penis/urethra ...........................
Revise penis/urethra ...........................
Secondary urethral surgery ................
Secondary urethral surgery ................
Secondary urethral surgery ................
Reconstruct urethra/penis ...................
Penis plastic surgery ...........................
Repair penis ........................................
Repair penis ........................................
Repair penis and bladder ...................
Insert semi-rigid prosthesis .................
Insert self-contd prosthesis .................
Insert multi-comp penis pros ..............
Remove muti-comp penis pros ...........
Repair multi-comp penis pros .............
Remove/replace penis prosth .............
Remov/replc penis pros, comp ...........
Remove self-contd penis pros ............
Remv/repl penis contain pros .............
Remv/replc penis pros, compl ............
Revision of penis ................................
Revision of penis ................................
Revision of penis ................................
Repair of penis ....................................
Preputial stretching .............................
Biopsy of testis ....................................
Biopsy of testis ....................................
Excise lesion testis .............................
Removal of testis ................................
Orchiectomy, partial ............................
Removal of testis ................................
Extensive testis surgery ......................
Exploration for testis ...........................
Exploration for testis ...........................
Reduce testis torsion ..........................
Suspension of testis ............................
Suspension of testis ............................
Orchiopexy (Fowler-Stephens) ...........
Revision of testis .................................
Repair testis injury ..............................
Relocation of testis(es) .......................
Laparoscopy, orchiectomy ..................
Laparoscopy, orchiopexy ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
27.99
1.90
2.50
3.29
3.27
3.27
2.77
1.08
8.84
2.42
1.34
2.04
1.19
1.31
0.00
1.31
2.22
0.00
2.22
11.07
13.15
12.49
14.36
17.90
12.28
13.85
17.40
16.87
16.74
18.22
21.44
9.58
16.91
18.17
25.95
12.65
14.03
16.38
22.59
9.09
10.26
14.39
12.76
13.73
16.48
18.14
8.75
11.87
15.94
12.26
10.93
6.71
0.00
1.12
1.31
3.47
9.23
5.25
10.15
9.31
13.06
8.31
11.97
7.54
5.16
7.57
12.24
5.64
6.57
13.91
11.60
13.64
NA
2.39
3.80
NA
4.00
NA
NA
2.01
NA
3.31
1.40
1.97
1.39
1.51
1.03
0.48
1.22
0.37
0.85
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.85
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.13
3.97
NA
4.32
NA
NA
1.90
NA
3.58
1.24
1.67
1.17
1.26
0.81
0.45
1.06
0.28
0.78
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.90
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
14.10
0.73
1.48
2.20
2.26
2.85
2.65
1.30
6.05
1.35
0.90
1.24
0.89
NA
NA
0.48
NA
NA
0.85
6.70
7.79
4.75
8.86
9.93
4.83
7.93
9.74
9.15
9.47
10.06
7.31
6.35
9.53
10.12
13.98
7.44
8.03
11.29
7.41
5.74
8.14
8.11
7.59
8.24
9.34
10.39
6.00
7.89
9.09
7.38
6.96
4.99
0.00
0.48
0.76
2.44
5.66
3.71
5.58
6.05
6.90
5.20
6.87
5.11
3.22
5.34
5.65
4.34
4.79
7.69
5.58
7.55
12.13
0.72
1.28
1.88
1.85
2.43
2.24
1.13
5.36
1.15
0.77
1.06
0.73
NA
NA
0.45
NA
NA
0.78
6.13
7.05
5.35
7.92
8.93
5.30
7.19
8.84
8.46
8.35
8.88
8.79
5.69
8.63
9.22
12.57
6.73
7.32
9.77
8.41
5.04
6.93
7.01
6.50
6.98
7.97
8.71
5.09
6.63
7.63
6.47
6.03
4.30
0.00
0.46
0.66
2.18
4.89
3.25
5.22
5.14
6.22
4.50
6.00
4.32
2.82
4.53
5.52
3.67
4.16
6.92
5.25
6.49
Malpractice
RVUs 2
1.88
0.16
0.19
0.23
0.21
0.21
0.18
0.08
0.56
0.17
0.09
0.16
0.08
0.17
0.06
0.11
0.18
0.02
0.16
0.76
0.88
0.84
1.24
1.21
1.39
0.92
1.14
1.11
0.98
1.21
2.21
0.63
1.54
1.23
2.25
0.84
0.93
0.86
1.54
0.64
0.73
0.95
0.86
0.90
1.10
1.13
0.58
0.77
1.00
0.81
0.72
0.43
0.00
0.08
0.10
0.27
0.67
0.50
0.89
0.66
0.95
0.59
0.90
0.51
0.37
0.62
1.16
0.44
0.47
1.16
1.02
1.30
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00250
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
000
010
010
010
010
010
010
090
000
000
000
000
000
000
000
000
000
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
010
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66471
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
54699
54700
54800
54830
54840
54860
54861
54865
54900
54901
55000
55040
55041
55060
55100
55110
55120
55150
55175
55180
55200
55250
55300
55400
55450
55500
55520
55530
55535
55540
55550
55559
55600
55605
55650
55680
55700
55705
55720
55725
55801
55810
55812
55815
55821
55831
55840
55842
55845
55860
55862
55865
55866
55870
55873
55875
55876
55899
55920
55970
55980
56405
56420
56440
56441
56442
56501
56515
56605
56606
56620
56625
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
N
N
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Laparoscope proc, testis .....................
Drainage of scrotum ...........................
Biopsy of epididymis ...........................
Remove epididymis lesion ..................
Remove epididymis lesion ..................
Removal of epididymis ........................
Removal of epididymis ........................
Explore epididymis ..............................
Fusion of spermatic ducts ...................
Fusion of spermatic ducts ...................
Drainage of hydrocele .........................
Removal of hydrocele .........................
Removal of hydroceles .......................
Repair of hydrocele .............................
Drainage of scrotum abscess .............
Explore scrotum ..................................
Removal of scrotum lesion .................
Removal of scrotum ............................
Revision of scrotum ............................
Revision of scrotum ............................
Incision of sperm duct .........................
Removal of sperm duct(s) ..................
Prepare, sperm duct x-ray ..................
Repair of sperm duct ..........................
Ligation of sperm duct ........................
Removal of hydrocele .........................
Removal of sperm cord lesion ............
Revise spermatic cord veins ...............
Revise spermatic cord veins ...............
Revise hernia & sperm veins ..............
Laparo ligate spermatic vein ...............
Laparo proc, spermatic cord ...............
Incise sperm duct pouch .....................
Incise sperm duct pouch .....................
Remove sperm duct pouch .................
Remove sperm pouch lesion ..............
Biopsy of prostate ...............................
Biopsy of prostate ...............................
Drainage of prostate abscess .............
Drainage of prostate abscess .............
Removal of prostate ............................
Extensive prostate surgery .................
Extensive prostate surgery .................
Extensive prostate surgery .................
Removal of prostate ............................
Removal of prostate ............................
Extensive prostate surgery .................
Extensive prostate surgery .................
Extensive prostate surgery .................
Surgical exposure, prostate ................
Extensive prostate surgery .................
Extensive prostate surgery .................
Laparo radical prostatectomy .............
Electroejaculation ................................
Cryoablate prostate .............................
Transperi needle place, pros ..............
Place rt device/marker, pros ...............
Genital surgery procedure ..................
Place needles pelvic for rt ..................
Sex transformation, M to F .................
Sex transformation, F to M .................
I & D of vulva/perineum ......................
Drainage of gland abscess .................
Surgery for vulva lesion ......................
Lysis of labial lesion(s) .......................
Hymenotomy .......................................
Destroy, vulva lesions, sim .................
Destroy vulva lesion/s compl ..............
Biopsy of vulva/perineum ....................
Biopsy of vulva/perineum ....................
Partial removal of vulva ......................
Complete removal of vulva .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
3.44
2.33
5.91
5.22
6.85
9.57
5.67
14.05
18.92
1.43
5.39
8.41
6.05
2.40
6.23
5.62
8.01
5.77
11.63
4.50
3.32
3.50
8.53
4.38
6.12
6.56
5.69
7.09
8.20
7.10
0.00
6.91
8.63
12.52
5.59
2.58
4.58
7.67
9.90
19.62
24.14
29.69
32.75
15.63
17.06
24.45
26.31
30.52
15.71
19.89
24.39
32.25
2.58
20.25
13.31
1.73
0.00
8.31
0.00
0.00
1.46
1.41
2.86
1.99
0.68
1.55
3.03
1.10
0.55
8.44
9.55
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.85
NA
NA
NA
3.49
NA
NA
NA
NA
NA
8.00
7.82
NA
NA
5.46
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
3.71
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.49
NA
NA
2.07
0.00
NA
0.00
0.00
1.18
1.52
NA
1.71
NA
1.63
2.39
0.92
0.36
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.96
NA
NA
NA
3.58
NA
NA
NA
NA
NA
10.15
9.64
NA
NA
6.22
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
3.95
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.01
NA
NA
2.07
0.00
NA
0.00
0.00
1.25
1.90
NA
1.76
NA
1.71
2.47
1.00
0.42
NA
NA
0.00
2.37
1.22
4.43
3.79
4.86
6.24
4.26
5.24
10.50
0.91
3.95
5.68
4.45
2.10
4.48
4.20
5.44
4.33
7.26
3.30
3.06
1.75
5.40
2.56
4.19
3.81
4.08
4.83
4.24
4.54
0.00
4.90
4.62
7.39
3.92
1.32
2.85
4.88
6.27
10.33
12.33
14.19
16.18
8.66
9.23
12.67
13.46
14.85
8.53
10.69
12.40
15.94
1.45
11.27
7.83
1.05
0.00
3.13
0.00
0.00
1.16
0.78
1.56
1.56
0.52
1.21
1.74
0.34
0.15
4.39
4.81
0.00
2.15
1.06
3.72
3.28
4.08
5.27
3.59
5.51
9.00
0.78
3.42
4.82
3.76
1.83
3.80
3.57
4.63
3.66
6.31
2.84
2.64
1.53
4.73
2.21
3.64
3.53
3.54
4.11
4.02
3.92
0.00
4.11
4.45
6.33
3.44
0.98
2.57
4.34
5.37
8.96
10.62
12.57
14.02
7.43
7.93
10.97
11.64
12.87
7.46
9.26
10.82
13.82
1.26
10.10
6.83
1.05
0.00
3.13
0.00
0.00
1.15
0.91
1.63
1.48
0.51
1.22
1.78
0.40
0.19
4.59
5.06
Malpractice
RVUs 2
0.00
0.28
0.23
0.41
0.37
0.45
0.63
0.40
0.93
1.83
0.11
0.43
0.60
0.46
0.17
0.43
0.39
0.56
0.37
0.90
0.33
0.25
0.25
0.64
0.29
0.55
0.75
0.45
0.47
0.94
0.57
0.00
0.62
0.64
0.92
0.47
0.11
0.32
0.95
0.70
1.34
1.60
2.05
2.17
1.01
1.10
1.61
1.73
2.03
1.02
1.49
1.63
2.17
0.16
1.38
0.89
0.28
0.00
0.58
0.00
0.00
0.17
0.16
0.34
0.20
0.08
0.18
0.33
0.13
0.07
0.90
1.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00251
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
YYY
010
000
090
090
090
090
090
090
090
000
090
090
090
010
090
090
090
090
090
090
090
000
090
010
090
090
090
090
090
090
YYY
090
090
090
090
000
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
090
090
000
YYY
000
XXX
XXX
010
010
010
010
000
010
010
000
ZZZ
090
090
66472
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
56630
56631
56632
56633
56634
56637
56640
56700
56740
56800
56805
56810
56820
56821
57000
57010
57020
57022
57023
57061
57065
57100
57105
57106
57107
57109
57110
57111
57112
57120
57130
57135
57150
57155
57160
57170
57180
57200
57210
57220
57230
57240
57250
57260
57265
57267
57268
57270
57280
57282
57283
57284
57285
57287
57288
57289
57291
57292
57295
57296
57300
57305
57307
57308
57310
57311
57320
57330
57335
57400
57410
57415
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Extensive vulva surgery ......................
Partial removal of hymen ....................
Remove vagina gland lesion ..............
Repair of vagina ..................................
Repair clitoris ......................................
Repair of perineum .............................
Exam of vulva w/scope .......................
Exam/biopsy of vulva w/scope ...........
Exploration of vagina ..........................
Drainage of pelvic abscess .................
Drainage of pelvic fluid .......................
I & d vaginal hematoma, pp ...............
I & d vag hematoma, non-ob ..............
Destroy vag lesions, simple ................
Destroy vag lesions, complex .............
Biopsy of vagina .................................
Biopsy of vagina .................................
Remove vagina wall, partial ................
Remove vagina tissue, part ................
Vaginectomy partial w/nodes ..............
Remove vagina wall, complete ...........
Remove vagina tissue, compl .............
Vaginectomy w/nodes, compl .............
Closure of vagina ................................
Remove vagina lesion ........................
Remove vagina lesion ........................
Treat vagina infection .........................
Insert uteri tandems/ovoids .................
Insert pessary/other device .................
Fitting of diaphragm/cap .....................
Treat vaginal bleeding ........................
Repair of vagina ..................................
Repair vagina/perineum ......................
Revision of urethra ..............................
Repair of urethral lesion .....................
Repair bladder & vagina .....................
Repair rectum & vagina ......................
Repair of vagina ..................................
Extensive repair of vagina ..................
Insert mesh/pelvic flr addon ................
Repair of bowel bulge .........................
Repair of bowel pouch ........................
Suspension of vagina .........................
Colpopexy, extraperitoneal .................
Colpopexy, intraperitoneal ..................
Repair paravag defect, open ..............
Repair paravag defect, vag ................
Revise/remove sling repair .................
Repair bladder defect .........................
Repair bladder & vagina .....................
Construction of vagina ........................
Construct vagina with graft .................
Revise vag graft via vagina ................
Revise vag graft, open abd ................
Repair rectum-vagina fistula ...............
Repair rectum-vagina fistula ...............
Fistula repair & colostomy ..................
Fistula repair, transperine ...................
Repair urethrovaginal lesion ...............
Repair urethrovaginal lesion ...............
Repair bladder-vagina lesion ..............
Repair bladder-vagina lesion ..............
Repair vagina ......................................
Dilation of vagina ................................
Pelvic examination ..............................
Remove vaginal foreign body .............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
14.67
18.81
21.61
19.47
20.48
24.57
24.65
2.79
4.83
3.90
19.75
4.26
1.50
2.05
2.99
6.74
1.50
2.70
5.13
1.27
2.63
1.20
1.71
7.35
24.43
28.25
15.38
28.25
30.37
8.18
2.44
2.68
0.55
6.79
0.89
0.91
1.60
4.34
5.63
4.77
6.22
11.42
11.42
14.36
15.86
4.88
7.47
13.57
16.62
7.84
11.58
14.25
11.52
11.49
14.01
12.69
8.54
13.91
7.74
16.46
8.58
15.24
17.02
10.48
7.55
8.81
8.78
13.11
19.87
2.27
1.75
2.44
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.19
1.53
NA
NA
0.77
NA
NA
1.52
2.02
0.95
1.59
NA
NA
NA
NA
NA
NA
NA
1.96
2.03
0.58
NA
1.04
0.57
1.86
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.25
1.64
NA
NA
0.85
NA
NA
1.58
2.16
1.01
1.69
NA
NA
NA
NA
NA
NA
NA
2.06
2.15
0.84
NA
1.03
1.02
2.01
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.28
7.78
9.29
7.80
8.18
9.30
8.83
1.77
2.33
1.96
7.68
2.04
0.53
0.68
1.75
3.80
0.45
1.42
2.37
1.11
1.49
0.37
1.33
4.27
9.05
10.25
6.19
10.42
10.61
4.19
1.47
1.53
0.15
3.49
0.25
0.25
0.93
2.99
3.27
3.00
3.64
5.48
5.03
5.85
6.32
1.49
4.33
5.83
6.96
4.49
5.11
5.98
5.16
6.35
7.01
6.70
4.89
5.90
4.08
6.66
4.43
6.19
6.90
4.96
5.01
5.51
5.28
7.20
7.82
1.00
0.91
1.49
6.55
8.29
9.40
8.19
8.80
10.18
9.72
1.80
2.45
2.08
8.54
2.16
0.59
0.79
1.73
3.80
0.52
1.45
2.47
1.12
1.58
0.42
1.37
4.22
9.75
10.74
6.73
11.51
11.35
4.39
1.50
1.59
0.18
4.02
0.30
0.29
1.09
2.94
3.35
3.05
3.52
4.65
4.30
5.34
6.17
1.73
4.26
6.04
7.16
4.49
5.51
6.56
5.16
5.91
6.46
6.37
4.90
6.41
4.25
6.66
4.35
6.23
6.95
5.02
4.42
4.81
4.82
6.45
8.42
1.05
0.90
1.45
Malpractice
RVUs 2
1.49
1.96
2.39
1.98
2.17
2.61
2.89
0.30
0.56
0.44
2.15
0.49
0.18
0.25
0.31
0.71
0.18
0.26
0.58
0.15
0.31
0.14
0.20
0.73
2.72
3.22
1.74
3.18
3.08
0.89
0.29
0.31
0.07
0.43
0.10
0.11
0.19
0.46
0.62
0.51
0.54
0.62
0.65
0.97
1.32
0.64
0.79
1.42
1.68
1.02
1.02
1.41
0.63
0.90
1.12
1.21
0.93
1.58
0.91
1.68
0.87
1.73
2.02
1.14
0.54
0.65
0.69
1.06
1.92
0.26
0.18
0.24
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00252
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
010
010
010
090
010
000
000
010
090
000
010
010
010
010
000
010
090
090
090
090
090
090
090
010
010
000
090
000
000
010
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
010
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66473
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
57420
57421
57423
57425
57452
57454
57455
57456
57460
57461
57500
57505
57510
57511
57513
57520
57522
57530
57531
57540
57545
57550
57555
57556
57558
57700
57720
57800
58100
58110
58120
58140
58145
58146
58150
58152
58180
58200
58210
58240
58260
58262
58263
58267
58270
58275
58280
58285
58290
58291
58292
58293
58294
58300
58301
58321
58322
58323
58340
58345
58346
58350
58353
58356
58400
58410
58520
58540
58541
58542
58543
58544
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Exam of vagina w/scope .....................
Exam/biopsy of vag w/scope ..............
Repair paravag defect, lap .................
Laparoscopy, surg, colpopexy ............
Exam of cervix w/scope ......................
Bx/curett of cervix w/scope .................
Biopsy of cervix w/scope ....................
Endocerv curettage w/scope ..............
Bx of cervix w/scope, leep ..................
Conz of cervix w/scope, leep ..............
Biopsy of cervix ...................................
Endocervical curettage .......................
Cauterization of cervix ........................
Cryocautery of cervix ..........................
Laser surgery of cervix .......................
Conization of cervix ............................
Conization of cervix ............................
Removal of cervix ...............................
Removal of cervix, radical ..................
Removal of residual cervix .................
Remove cervix/repair pelvis ................
Removal of residual cervix .................
Remove cervix/repair vagina ..............
Remove cervix, repair bowel ..............
D&c of cervical stump .........................
Revision of cervix ................................
Revision of cervix ................................
Dilation of cervical canal .....................
Biopsy of uterus lining ........................
Bx done w/colposcopy add-on ............
Dilation and curettage .........................
Myomectomy abdom method .............
Myomectomy vag method ...................
Myomectomy abdom complex ............
Total hysterectomy ..............................
Total hysterectomy ..............................
Partial hysterectomy ...........................
Extensive hysterectomy ......................
Extensive hysterectomy ......................
Removal of pelvis contents .................
Vaginal hysterectomy ..........................
Vag hyst including t/o .........................
Vag hyst w/t/o & vag repair ................
Vag hyst w/urinary repair ....................
Vag hyst w/enterocele repair ..............
Hysterectomy/revise vagina ................
Hysterectomy/revise vagina ................
Extensive hysterectomy ......................
Vag hyst complex ...............................
Vag hyst incl t/o, complex ...................
Vag hyst t/o & repair, compl ...............
Vag hyst w/uro repair, compl ..............
Vag hyst w/enterocele, compl .............
Insert intrauterine device ....................
Remove intrauterine device ................
Artificial insemination ..........................
Artificial insemination ..........................
Sperm washing ...................................
Catheter for hysterography .................
Reopen fallopian tube .........................
Insert heyman uteri capsule ...............
Reopen fallopian tube .........................
Endometr ablate, thermal ...................
Endometrial cryoablation ....................
Suspension of uterus ..........................
Suspension of uterus ..........................
Repair of ruptured uterus ....................
Revision of uterus ...............................
Lsh, uterus 250 g or less ....................
Lsh w/t/o ut 250 g or less ...................
Lsh uterus above 250 g ......................
Lsh w/t/o uterus above 250 g .............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.60
2.20
16.00
16.93
1.50
2.33
1.99
1.85
2.83
3.43
1.20
1.16
1.90
1.92
1.92
4.06
3.62
5.19
29.77
13.19
14.00
6.24
9.84
9.26
1.69
4.22
4.53
0.77
1.53
0.77
3.54
15.69
8.81
20.24
17.21
21.73
16.50
23.00
30.76
49.02
14.02
15.81
17.10
18.23
15.20
16.90
18.20
23.30
20.17
21.96
23.25
24.23
21.45
1.01
1.27
0.92
1.10
0.23
0.88
4.67
7.48
1.03
3.57
6.36
7.06
13.70
13.38
15.61
14.57
16.43
16.74
18.24
1.23
1.59
NA
NA
1.18
1.39
1.50
1.45
4.28
4.56
2.01
1.32
1.30
1.60
1.57
3.38
2.77
NA
NA
NA
NA
NA
NA
NA
1.34
NA
NA
0.72
1.14
0.39
2.70
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.63
1.04
0.94
1.03
0.16
2.15
NA
NA
1.35
22.81
43.33
NA
NA
NA
NA
NA
NA
NA
NA
1.29
1.72
NA
NA
1.23
1.51
1.61
1.55
5.06
5.33
2.28
1.39
1.43
1.71
1.64
3.65
2.96
NA
NA
NA
NA
NA
NA
NA
1.40
NA
NA
0.74
1.23
0.47
2.50
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.02
1.18
1.04
1.11
0.34
2.66
NA
NA
1.42
29.23
52.36
NA
NA
NA
NA
NA
NA
NA
NA
0.56
0.72
6.51
6.90
0.74
0.95
0.66
0.62
1.09
1.05
0.64
1.07
0.89
1.26
1.28
2.51
2.25
3.10
10.85
5.44
5.72
3.61
4.75
4.60
1.05
3.28
2.93
0.41
0.58
0.21
1.65
6.17
4.23
7.34
6.55
8.02
6.33
8.14
10.71
17.62
5.78
6.23
6.63
6.96
5.93
6.60
6.95
7.93
7.34
7.81
8.20
8.50
7.50
0.23
0.34
0.23
0.31
0.07
0.56
2.11
3.73
0.88
1.71
1.85
3.86
5.55
5.48
6.14
6.12
6.63
6.71
7.11
0.61
0.84
6.51
6.77
0.75
1.05
0.76
0.72
1.23
1.26
0.64
1.08
0.97
1.31
1.34
2.69
2.35
3.24
12.00
5.83
6.19
3.71
4.91
4.72
1.09
3.19
3.02
0.44
0.65
0.26
1.76
6.64
4.50
8.17
7.01
8.93
6.89
9.06
11.95
17.61
6.23
6.80
7.25
7.66
6.49
7.18
7.60
8.93
8.23
8.84
9.28
9.57
8.52
0.31
0.41
0.30
0.36
0.08
0.61
2.27
3.83
0.90
1.88
2.27
3.89
5.99
5.76
6.54
6.12
6.63
6.71
7.11
Malpractice
RVUs 2
0.19
0.27
1.65
1.76
0.18
0.28
0.24
0.22
0.34
0.41
0.12
0.14
0.23
0.23
0.23
0.49
0.41
0.58
3.35
1.49
1.52
0.67
1.09
0.92
0.20
0.41
0.49
0.09
0.18
0.09
0.39
1.82
0.97
2.33
1.85
2.48
1.64
2.55
3.38
4.23
1.57
1.80
1.95
2.07
1.74
1.92
2.07
2.71
2.30
2.53
2.68
2.79
2.40
0.12
0.15
0.10
0.13
0.03
0.09
0.41
0.56
0.12
0.43
0.82
0.75
1.45
1.47
1.79
1.68
1.69
1.73
1.89
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00253
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
090
090
000
000
000
000
000
000
000
010
010
010
010
090
090
090
090
090
090
090
090
090
010
090
090
000
000
ZZZ
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
XXX
000
000
000
000
000
010
090
010
010
010
090
090
090
090
090
090
090
090
66474
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
58545
58546
58548
58550
58552
58553
58554
58555
58558
58559
58560
58561
58562
58563
58565
58570
58571
58572
58573
58578
58579
58600
58605
58611
58615
58660
58661
58662
58670
58671
58672
58673
58679
58700
58720
58740
58750
58752
58760
58770
58800
58805
58820
58822
58823
58825
58900
58920
58925
58940
58943
58950
58951
58952
58953
58954
58956
58957
58958
58960
58970
58974
58976
58999
59000
59001
59012
59015
59020
59020
59020
59025
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
C
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Laparoscopic myomectomy ................
Laparo-myomectomy, complex ...........
Lap radical hyst ...................................
Laparo-asst vag hysterectomy ............
Laparo-vag hyst incl t/o ......................
Laparo-vag hyst, complex ...................
Laparo-vag hyst w/t/o, compl ..............
Hysteroscopy, dx, sep proc ................
Hysteroscopy, biopsy ..........................
Hysteroscopy, lysis .............................
Hysteroscopy, resect septum .............
Hysteroscopy, remove myoma ...........
Hysteroscopy, remove fb ....................
Hysteroscopy, ablation ........................
Hysteroscopy, sterilization ..................
Tlh, uterus 250 g or less .....................
Tlh w/t/o 250 g or less ........................
Tlh, uterus over 250 g ........................
Tlh w/t/o uterus over 250 g .................
Laparo proc, uterus .............................
Hysteroscope procedure .....................
Division of fallopian tube .....................
Division of fallopian tube .....................
Ligate oviduct(s) add-on .....................
Occlude fallopian tube(s) ....................
Laparoscopy, lysis ..............................
Laparoscopy, remove adnexa ............
Laparoscopy, excise lesions ...............
Laparoscopy, tubal cautery .................
Laparoscopy, tubal block ....................
Laparoscopy, fimbrioplasty .................
Laparoscopy, salpingostomy ..............
Laparo proc, oviduct-ovary .................
Removal of fallopian tube ...................
Removal of ovary/tube(s) ....................
Revise fallopian tube(s) ......................
Repair oviduct .....................................
Revise ovarian tube(s) ........................
Remove tubal obstruction ...................
Create new tubal opening ...................
Drainage of ovarian cyst(s) .................
Drainage of ovarian cyst(s) .................
Drain ovary abscess, open .................
Drain ovary abscess, percut ...............
Drain pelvic abscess, percut ...............
Transposition, ovary(s) .......................
Biopsy of ovary(s) ...............................
Partial removal of ovary(s) ..................
Removal of ovarian cyst(s) .................
Removal of ovary(s) ............................
Removal of ovary(s) ............................
Resect ovarian malignancy .................
Resect ovarian malignancy .................
Resect ovarian malignancy .................
Tah, rad dissect for debulk .................
Tah rad debulk/lymph remove ............
Bso, omentectomy w/tah ....................
Resect recurrent gyn mal ...................
Resect recur gyn mal w/lym ...............
Exploration of abdomen ......................
Retrieval of oocyte ..............................
Transfer of embryo .............................
Transfer of embryo .............................
Genital surgery procedure ..................
Amniocentesis, diagnostic ..................
Amniocentesis, therapeutic .................
Fetal cord puncture,prenatal ...............
Chorion biopsy ....................................
Fetal contract stress test ....................
Fetal contract stress test ....................
Fetal contract stress test ....................
Fetal non-stress test ...........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
15.45
19.84
31.45
14.97
16.78
19.96
22.98
3.33
4.74
6.16
6.99
9.99
5.20
6.16
7.06
15.75
17.56
19.96
22.98
0.00
0.00
5.86
5.25
1.45
3.91
11.54
11.30
12.08
5.86
5.86
12.88
13.99
0.00
12.84
12.08
14.79
15.56
15.56
13.85
14.69
4.54
6.34
4.62
11.71
3.37
11.70
6.51
11.87
12.33
8.12
19.42
18.24
24.15
27.15
33.97
36.97
22.65
26.06
29.06
15.68
3.52
0.00
3.82
0.00
1.30
3.00
3.44
2.20
0.66
0.00
0.66
0.53
NA
NA
NA
NA
NA
NA
NA
2.75
3.62
NA
NA
NA
3.52
37.22
41.94
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
3.21
NA
NA
NA
19.98
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.85
0.00
1.94
0.00
1.75
NA
NA
1.42
1.07
0.89
0.18
0.63
NA
NA
NA
NA
NA
NA
NA
2.47
2.90
NA
NA
NA
2.94
46.69
45.74
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
3.42
NA
NA
NA
20.64
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.08
0.00
2.31
0.00
1.91
NA
NA
1.48
0.92
0.70
0.22
0.54
5.86
7.04
12.45
6.12
6.55
7.08
8.23
1.23
1.65
2.04
2.31
3.11
1.75
2.04
3.37
6.45
6.94
7.59
8.41
0.00
0.00
2.92
2.71
0.40
2.03
4.49
3.98
4.75
2.94
2.93
4.77
5.12
0.00
5.48
5.08
6.05
6.04
5.98
5.58
5.74
2.69
3.50
2.90
5.15
1.16
4.83
3.55
5.05
5.24
4.03
7.17
7.24
8.59
9.81
11.62
12.51
8.58
9.55
10.35
6.24
1.28
0.00
1.20
0.00
0.55
1.07
1.13
0.79
NA
NA
0.18
NA
6.52
7.98
12.45
6.70
7.28
8.00
9.31
1.39
1.91
2.38
2.70
3.69
2.05
2.40
3.63
6.45
6.94
7.59
8.41
0.00
0.00
3.12
2.91
0.48
2.37
4.87
4.55
5.27
3.11
3.10
5.47
5.84
0.00
5.73
5.43
6.59
6.70
6.46
6.14
6.32
2.79
3.50
3.09
5.18
1.14
5.31
3.56
5.31
5.46
4.06
7.90
7.82
9.51
10.77
13.08
14.10
9.44
9.55
10.35
6.79
1.38
0.00
1.51
0.00
0.61
1.24
1.33
0.91
NA
NA
0.22
NA
Malpractice
RVUs 2
1.78
2.31
3.52
1.73
1.73
2.31
2.28
0.40
0.57
0.74
0.84
1.21
0.63
0.74
1.19
1.82
1.81
2.31
2.28
0.00
0.00
0.66
0.59
0.18
0.47
1.40
1.34
1.43
0.67
0.68
1.60
1.70
0.00
1.51
1.39
1.72
1.85
1.81
1.80
1.74
0.43
0.69
0.52
1.16
0.24
1.32
0.69
1.43
1.41
0.91
2.23
2.05
2.64
3.03
3.84
4.18
4.01
2.95
3.29
1.80
0.43
0.00
0.47
0.00
0.31
0.71
0.82
0.52
0.26
0.10
0.16
0.15
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00254
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
000
000
000
000
000
000
000
090
090
090
090
090
YYY
YYY
090
090
ZZZ
010
090
010
090
090
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
YYY
000
000
000
000
000
000
000
000
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66475
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
59025
59025
59030
59050
59051
59070
59072
59074
59076
59100
59120
59121
59130
59135
59136
59140
59150
59151
59160
59200
59300
59320
59325
59350
59400
59409
59410
59412
59414
59425
59426
59430
59510
59514
59515
59525
59610
59612
59614
59618
59620
59622
59812
59820
59821
59830
59840
59841
59850
59851
59852
59855
59856
59857
59866
59870
59871
59897
59898
59899
60000
60100
60200
60210
60212
60220
60225
60240
60252
60254
60260
60270
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
R
R
R
R
R
R
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Fetal non-stress test ...........................
Fetal non-stress test ...........................
Fetal scalp blood sample ....................
Fetal monitor w/report .........................
Fetal monitor/interpret only .................
Transabdom amnioinfus w/us .............
Umbilical cord occlud w/us .................
Fetal fluid drainage w/us .....................
Fetal shunt placement, w/us ...............
Remove uterus lesion .........................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
Treat ectopic pregnancy .....................
D & c after delivery .............................
Insert cervical dilator ...........................
Episiotomy or vaginal repair ...............
Revision of cervix ................................
Revision of cervix ................................
Repair of uterus ..................................
Obstetrical care ...................................
Obstetrical care ...................................
Obstetrical care ...................................
Antepartum manipulation ....................
Deliver placenta ..................................
Antepartum care only ..........................
Antepartum care only ..........................
Care after delivery ..............................
Cesarean delivery ...............................
Cesarean delivery only .......................
Cesarean delivery ...............................
Remove uterus after cesarean ...........
Vbac delivery ......................................
Vbac delivery only ...............................
Vbac care after delivery ......................
Attempted vbac delivery .....................
Attempted vbac delivery only ..............
Attempted vbac after care ..................
Treatment of miscarriage ....................
Care of miscarriage ............................
Treatment of miscarriage ....................
Treat uterus infection ..........................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion ...............................................
Abortion (mpr) .....................................
Evacuate mole of uterus .....................
Remove cerclage suture .....................
Fetal invas px w/us .............................
Laparo proc, ob care/deliver ...............
Maternity care procedure ....................
Drain thyroid/tongue cyst ....................
Biopsy of thyroid .................................
Remove thyroid lesion ........................
Partial thyroid excision ........................
Partial thyroid excision ........................
Partial removal of thyroid ....................
Partial removal of thyroid ....................
Removal of thyroid ..............................
Removal of thyroid ..............................
Extensive thyroid surgery ...................
Repeat thyroid surgery .......................
Removal of thyroid ..............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.53
1.99
0.89
0.74
5.24
8.99
5.24
8.99
13.26
12.56
12.64
14.98
14.82
14.15
5.86
12.19
12.01
2.73
0.79
2.41
2.48
4.06
4.94
26.80
13.48
15.29
1.71
1.61
6.22
11.04
2.13
30.34
15.95
18.26
8.53
28.21
15.04
16.59
31.78
17.50
19.70
4.39
4.68
4.97
6.51
3.01
5.57
5.90
5.92
8.23
6.38
7.74
9.30
3.99
6.40
2.13
0.00
0.00
0.00
1.78
1.56
9.91
11.15
16.32
12.29
14.67
16.18
21.88
28.29
18.18
23.07
0.48
0.15
NA
NA
NA
4.39
NA
3.60
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.98
0.94
2.19
NA
NA
NA
NA
NA
NA
NA
NA
4.24
7.78
1.08
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.10
4.07
3.91
NA
2.00
3.11
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.00
2.08
1.31
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.36
0.18
NA
NA
NA
4.77
NA
4.08
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.64
1.06
2.18
NA
NA
NA
NA
NA
NA
NA
NA
4.22
7.66
1.15
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.82
4.24
4.09
NA
2.06
3.30
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.00
2.00
1.35
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.15
0.46
0.27
0.20
1.76
2.39
1.53
2.39
5.55
5.39
5.34
6.73
5.08
4.93
3.30
5.23
4.86
1.17
0.22
1.00
1.00
1.44
1.21
14.08
3.70
4.91
0.64
0.44
1.68
2.99
0.71
15.96
4.42
6.13
2.25
14.93
4.19
5.11
16.35
4.66
6.70
2.35
3.46
3.23
3.44
1.77
2.54
2.45
3.28
3.82
3.07
3.31
3.64
1.36
4.38
0.90
0.00
0.00
0.00
1.70
0.52
5.50
5.22
6.94
5.66
6.91
6.40
8.82
11.21
7.40
9.31
NA
0.18
0.61
0.31
0.25
2.04
2.75
1.92
2.75
6.00
5.82
5.83
5.76
6.15
5.76
2.76
5.61
5.45
1.65
0.26
0.98
1.12
1.66
1.54
14.69
4.50
5.60
0.72
0.54
1.77
3.10
0.82
16.61
5.32
6.98
2.77
15.39
5.12
6.02
17.28
5.71
7.66
2.45
3.51
3.32
3.71
1.95
2.76
2.85
3.51
4.43
3.31
3.68
4.17
1.63
4.43
1.02
0.00
0.00
0.00
1.70
0.52
5.74
5.43
7.30
5.90
7.15
6.99
9.45
12.67
8.02
9.88
Malpractice
RVUs 2
0.02
0.13
0.47
0.21
0.17
0.28
0.16
0.28
0.16
2.95
2.73
2.79
3.39
3.31
3.14
1.29
2.79
2.74
0.64
0.19
0.57
0.59
0.88
1.17
5.50
3.22
3.52
0.40
0.38
1.14
1.98
0.50
6.25
3.80
4.13
1.95
5.87
3.59
3.89
6.61
4.17
4.50
0.95
0.95
1.06
1.44
0.71
1.24
1.28
1.28
1.81
1.45
1.79
2.02
0.87
1.42
0.50
0.00
0.00
0.00
0.15
0.10
1.01
1.23
1.95
1.32
1.64
1.86
2.30
2.61
1.94
2.33
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00255
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
XXX
XXX
000
000
000
000
090
090
090
090
090
090
090
090
090
010
000
000
000
000
000
MMM
MMM
MMM
MMM
MMM
MMM
MMM
MMM
MMM
MMM
MMM
ZZZ
MMM
MMM
MMM
MMM
MMM
MMM
090
090
090
090
010
010
090
090
090
090
090
090
000
090
000
YYY
YYY
YYY
010
000
090
090
090
090
090
090
090
090
090
090
66476
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
60271
60280
60281
60300
60500
60502
60505
60512
60520
60521
60522
60540
60545
60600
60605
60650
60659
60699
61000
61001
61020
61026
61050
61055
61070
61105
61107
61108
61120
61140
61150
61151
61154
61156
61210
61215
61250
61253
61304
61305
61312
61313
61314
61315
61316
61320
61321
61322
61323
61330
61332
61333
61334
61340
61343
61345
61440
61450
61458
61460
61470
61480
61490
61500
61501
61510
61512
61514
61516
61517
61518
61519
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of thyroid ..............................
Remove thyroid duct lesion ................
Remove thyroid duct lesion ................
Aspir/inj thyroid cyst ............................
Explore parathyroid glands .................
Re-explore parathyroids ......................
Explore parathyroid glands .................
Autotransplant parathyroid ..................
Removal of thymus gland ...................
Removal of thymus gland ...................
Removal of thymus gland ...................
Explore adrenal gland .........................
Explore adrenal gland .........................
Remove carotid body lesion ...............
Remove carotid body lesion ...............
Laparoscopy adrenalectomy ...............
Laparo proc, endocrine .......................
Endocrine surgery procedure .............
Remove cranial cavity fluid .................
Remove cranial cavity fluid .................
Remove brain cavity fluid ...................
Injection into brain canal .....................
Remove brain canal fluid ....................
Injection into brain canal .....................
Brain canal shunt procedure ...............
Twist drill hole .....................................
Drill skull for implantation ....................
Drill skull for drainage .........................
Burr hole for puncture .........................
Pierce skull for biopsy .........................
Pierce skull for drainage .....................
Pierce skull for drainage .....................
Pierce skull & remove clot ..................
Pierce skull for drainage .....................
Pierce skull, implant device ................
Insert brain-fluid device .......................
Pierce skull & explore .........................
Pierce skull & explore .........................
Open skull for exploration ...................
Open skull for exploration ...................
Open skull for drainage ......................
Open skull for drainage ......................
Open skull for drainage ......................
Open skull for drainage ......................
Implt cran bone flap to abdo ...............
Open skull for drainage ......................
Open skull for drainage ......................
Decompressive craniotomy .................
Decompressive lobectomy ..................
Decompress eye socket .....................
Explore/biopsy eye socket ..................
Explore orbit/remove lesion ................
Explore orbit/remove object ................
Subtemporal decompression ..............
Incise skull (press relief) .....................
Relieve cranial pressure .....................
Incise skull for surgery ........................
Incise skull for surgery ........................
Incise skull for brain wound ................
Incise skull for surgery ........................
Incise skull for surgery ........................
Incise skull for surgery ........................
Incise skull for surgery ........................
Removal of skull lesion .......................
Remove infected skull bone ...............
Removal of brain lesion ......................
Remove brain lining lesion .................
Removal of brain abscess ..................
Removal of brain lesion ......................
Implt brain chemotx add-on ................
Removal of brain lesion ......................
Remove brain lining lesion .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
17.54
6.05
8.71
0.97
16.69
21.01
22.91
4.44
17.07
19.11
23.37
17.91
20.82
24.99
31.86
20.63
0.00
0.00
1.58
1.49
1.51
1.69
1.51
2.10
0.89
5.40
4.99
11.51
9.52
17.10
18.80
13.41
16.92
17.37
5.83
5.77
11.41
13.41
23.31
28.51
30.07
27.94
25.77
29.52
1.39
27.32
30.40
34.08
34.93
25.17
28.50
29.17
19.50
20.01
31.73
29.10
28.53
27.59
28.71
30.11
27.52
27.95
27.12
19.05
16.22
30.63
36.99
27.10
26.45
1.38
39.69
43.28
NA
NA
NA
1.94
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.67
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
7.14
4.47
5.31
0.30
6.85
8.60
9.38
1.21
7.01
8.12
9.60
8.24
8.94
8.82
12.13
8.08
0.00
0.00
1.24
1.08
1.63
1.30
1.15
1.33
1.16
4.90
1.83
8.34
6.77
10.40
10.67
8.43
10.82
9.71
2.15
5.44
7.37
7.48
12.53
14.95
15.22
15.35
14.14
15.49
0.51
14.23
16.05
17.46
17.29
11.52
12.95
12.87
9.01
11.67
15.92
14.84
15.22
14.05
14.87
14.56
14.04
8.13
14.21
10.68
9.44
16.93
18.44
14.40
14.04
0.51
20.29
20.63
7.86
4.56
5.57
0.31
7.12
8.97
10.15
1.41
7.64
8.83
10.43
7.91
8.73
9.89
12.19
8.03
0.00
0.00
1.09
1.07
1.48
1.34
1.21
1.37
1.08
4.41
2.18
7.74
6.38
10.14
10.52
8.12
10.15
9.77
2.53
4.72
7.11
7.60
12.68
15.13
15.12
15.07
13.58
15.75
0.55
14.48
16.08
16.56
16.68
12.62
14.27
14.22
9.81
11.39
16.36
15.11
14.70
14.16
15.18
15.48
13.94
11.70
14.26
10.74
9.32
16.81
19.05
14.41
14.15
0.57
20.68
21.63
Malpractice
RVUs 2
1.75
0.54
0.73
0.07
2.01
2.54
2.65
0.53
2.20
2.82
3.27
1.75
2.08
2.20
2.50
2.29
0.00
0.00
0.13
0.16
0.34
0.33
0.11
0.17
0.17
1.32
1.29
2.64
2.10
4.12
4.32
3.01
4.21
4.23
1.50
1.26
2.77
2.62
5.63
6.09
6.36
6.45
6.28
7.16
0.35
6.62
7.14
7.63
8.03
2.32
4.83
3.92
1.75
4.84
7.64
7.04
6.90
5.79
7.03
6.04
5.90
6.73
6.92
4.11
3.22
7.35
9.08
6.54
6.35
0.35
9.65
10.63
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00256
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
000
090
090
090
ZZZ
090
090
090
090
090
090
090
090
YYY
YYY
000
000
000
000
000
000
000
090
000
090
090
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66477
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
61520
61521
61522
61524
61526
61530
61531
61533
61534
61535
61536
61537
61538
61539
61540
61541
61542
61543
61544
61545
61546
61548
61550
61552
61556
61557
61558
61559
61563
61564
61566
61567
61570
61571
61575
61576
61580
61581
61582
61583
61584
61585
61586
61590
61591
61592
61595
61596
61597
61598
61600
61601
61605
61606
61607
61608
61609
61610
61611
61612
61613
61615
61616
61618
61619
61623
61624
61626
61630
61635
61640
61641
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
N
N
N
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of brain lesion ......................
Removal of brain lesion ......................
Removal of brain abscess ..................
Removal of brain lesion ......................
Removal of brain lesion ......................
Removal of brain lesion ......................
Implant brain electrodes .....................
Implant brain electrodes .....................
Removal of brain lesion ......................
Remove brain electrodes ....................
Removal of brain lesion ......................
Removal of brain tissue ......................
Removal of brain tissue ......................
Removal of brain tissue ......................
Removal of brain tissue ......................
Incision of brain tissue ........................
Removal of brain tissue ......................
Removal of brain tissue ......................
Remove & treat brain lesion ...............
Excision of brain tumor .......................
Removal of pituitary gland ..................
Removal of pituitary gland ..................
Release of skull seams .......................
Release of skull seams .......................
Incise skull/sutures ..............................
Incise skull/sutures ..............................
Excision of skull/sutures .....................
Excision of skull/sutures .....................
Excision of skull tumor ........................
Excision of skull tumor ........................
Removal of brain tissue ......................
Incision of brain tissue ........................
Remove foreign body, brain ...............
Incise skull for brain wound ................
Skull base/brainstem surgery .............
Skull base/brainstem surgery .............
Craniofacial approach, skull ................
Craniofacial approach, skull ................
Craniofacial approach, skull ................
Craniofacial approach, skull ................
Orbitocranial approach/skull ...............
Orbitocranial approach/skull ...............
Resect nasopharynx, skull ..................
Infratemporal approach/skull ...............
Infratemporal approach/skull ...............
Orbitocranial approach/skull ...............
Transtemporal approach/skull .............
Transcochlear approach/skull .............
Transcondylar approach/skull .............
Transpetrosal approach/skull ..............
Resect/excise cranial lesion ...............
Resect/excise cranial lesion ...............
Resect/excise cranial lesion ...............
Resect/excise cranial lesion ...............
Resect/excise cranial lesion ...............
Resect/excise cranial lesion ...............
Transect artery, sinus .........................
Transect artery, sinus .........................
Transect artery, sinus .........................
Transect artery, sinus .........................
Remove aneurysm, sinus ...................
Resect/excise lesion, skull ..................
Resect/excise lesion, skull ..................
Repair dura .........................................
Repair dura .........................................
Endovasc tempory vessel occl ...........
Transcath occlusion, cns ....................
Transcath occlusion, non-cns .............
Intracranial angioplasty .......................
Intracran angioplsty w/stent ................
Dilate ic vasospasm, init .....................
Dilate ic vasospasm add-on ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
56.89
46.84
31.41
29.76
53.90
45.43
16.28
21.36
22.88
13.05
37.59
36.35
39.35
34.15
31.30
30.81
33.03
31.18
27.26
46.23
33.31
23.27
15.44
20.27
24.00
23.16
26.35
33.82
28.35
34.59
32.32
36.84
26.38
28.29
36.43
55.11
34.34
38.88
34.93
38.41
37.61
42.46
27.28
46.87
46.87
42.98
33.57
39.31
40.73
36.41
29.84
31.04
32.40
41.94
40.82
45.45
9.88
29.63
7.41
27.84
44.94
35.63
46.60
18.58
22.01
9.95
20.12
16.60
22.07
24.28
12.32
4.33
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
25.93
22.14
15.75
15.68
22.50
19.47
10.45
11.78
13.11
8.83
18.51
17.02
18.35
16.81
16.28
16.07
16.76
13.84
14.26
22.80
16.72
11.60
5.65
12.14
13.27
13.62
14.68
18.36
13.07
17.89
16.63
19.05
14.00
14.62
16.08
28.06
22.82
27.80
30.44
25.86
26.01
25.10
22.61
24.78
24.57
26.77
21.12
20.92
23.25
22.13
19.74
22.35
19.44
23.74
20.98
26.29
3.25
11.05
1.70
6.40
27.32
21.27
27.21
10.42
11.66
3.72
7.29
5.97
6.43
6.94
2.83
0.99
28.12
23.17
16.08
15.67
25.98
22.25
9.79
11.65
12.59
8.12
19.14
15.87
16.82
17.28
16.76
16.13
17.29
15.11
14.04
23.50
17.10
12.19
6.29
10.62
12.31
13.62
14.43
18.83
14.15
18.08
17.19
19.85
13.95
14.88
17.85
31.39
24.19
25.62
28.86
25.48
25.26
25.79
22.59
26.69
27.04
26.63
21.73
22.67
23.11
22.68
19.75
21.42
20.69
24.44
22.37
26.43
4.05
12.09
2.76
9.85
26.78
21.99
27.92
10.43
11.95
3.90
7.09
5.74
9.46
10.24
2.83
0.99
Malpractice
RVUs 2
11.21
11.39
7.62
7.16
7.07
6.15
3.79
5.12
5.44
3.02
9.21
6.94
6.94
8.32
8.32
6.60
8.03
7.56
5.97
10.63
7.67
3.43
0.98
1.06
4.65
5.80
1.36
8.51
5.17
8.78
6.94
6.54
5.88
6.79
5.34
5.58
3.37
3.92
7.21
9.21
8.18
7.03
4.37
5.31
5.66
10.07
3.98
3.40
8.84
5.70
3.79
6.63
2.86
8.97
6.90
10.75
2.56
7.68
1.89
4.31
8.45
4.73
8.26
3.72
3.95
1.05
1.96
1.24
2.02
2.21
0.71
0.25
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00257
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
ZZZ
ZZZ
090
090
090
090
090
000
000
000
090
090
000
ZZZ
66478
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
61642
61680
61682
61684
61686
61690
61692
61697
61698
61700
61702
61703
61705
61708
61710
61711
61720
61735
61750
61751
61760
61770
61790
61791
61793
61795
61850
61860
61863
61864
61867
61868
61870
61875
61880
61885
61886
61888
62000
62005
62010
62100
62115
62116
62117
62120
62121
62140
62141
62142
62143
62145
62146
62147
62148
62160
62161
62162
62163
62164
62165
62180
62190
62192
62194
62200
62201
62220
62223
62225
62230
62252
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Dilate ic vasospasm add-on ...............
Intracranial vessel surgery ..................
Intracranial vessel surgery ..................
Intracranial vessel surgery ..................
Intracranial vessel surgery ..................
Intracranial vessel surgery ..................
Intracranial vessel surgery ..................
Brain aneurysm repr, complx ..............
Brain aneurysm repr, complx ..............
Brain aneurysm repr, simple ...............
Inner skull vessel surgery ...................
Clamp neck artery ...............................
Revise circulation to head ..................
Revise circulation to head ..................
Revise circulation to head ..................
Fusion of skull arteries ........................
Incise skull/brain surgery ....................
Incise skull/brain surgery ....................
Incise skull/brain biopsy ......................
Brain biopsy w/ct/mr guide .................
Implant brain electrodes .....................
Incise skull for treatment .....................
Treat trigeminal nerve .........................
Treat trigeminal tract ...........................
Focus radiation beam .........................
Brain surgery using computer .............
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrode .......................
Implant neuroelectrde, addl ................
Implant neuroelectrode .......................
Implant neuroelectrde, add’l ...............
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Revise/remove neuroelectrode ...........
Insrt/redo neurostim 1 array ...............
Implant neurostim arrays ....................
Revise/remove neuroreceiver .............
Treat skull fracture ..............................
Treat skull fracture ..............................
Treatment of head injury .....................
Repair brain fluid leakage ...................
Reduction of skull defect ....................
Reduction of skull defect ....................
Reduction of skull defect ....................
Repair skull cavity lesion ....................
Incise skull repair ................................
Repair of skull defect ..........................
Repair of skull defect ..........................
Remove skull plate/flap .......................
Replace skull plate/flap .......................
Repair of skull & brain ........................
Repair of skull with graft .....................
Repair of skull with graft .....................
Retr bone flap to fix skull ....................
Neuroendoscopy add-on .....................
Dissect brain w/scope .........................
Remove colloid cyst w/scope .............
Neuroendoscopy w/fb removal ...........
Remove brain tumor w/scope .............
Remove pituit tumor w/scope .............
Establish brain cavity shunt ................
Establish brain cavity shunt ................
Establish brain cavity shunt ................
Replace/irrigate catheter .....................
Establish brain cavity shunt ................
Brain cavity shunt w/scope .................
Establish brain cavity shunt ................
Establish brain cavity shunt ................
Replace/irrigate catheter .....................
Replace/revise brain shunt .................
Csf shunt reprogram ...........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.66
32.40
63.31
41.49
67.32
31.18
54.43
63.22
69.45
50.44
59.86
18.70
37.97
37.07
31.19
38.10
17.52
22.22
19.73
18.64
22.24
23.09
11.50
15.31
17.75
4.03
13.26
22.16
20.56
4.49
32.88
7.91
16.24
16.36
6.87
7.37
9.73
5.20
13.83
17.53
21.30
23.40
22.71
24.90
28.26
24.39
22.93
14.45
15.97
11.73
14.05
19.99
17.18
20.57
2.00
3.00
21.10
26.67
16.40
29.27
23.10
22.45
12.07
13.25
5.68
19.19
15.89
14.00
13.90
6.11
11.35
0.74
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.77
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.62
1.99
16.73
27.51
20.35
30.44
16.50
24.32
28.60
30.55
24.00
27.47
10.05
18.30
14.86
13.77
18.59
7.88
9.16
10.94
11.35
12.05
9.88
7.69
8.20
9.54
1.43
7.88
11.59
12.40
1.67
16.35
2.94
9.68
5.33
5.17
7.05
8.51
3.46
7.61
9.58
11.80
12.08
13.87
13.33
12.73
17.31
14.23
8.63
9.33
7.78
8.72
10.25
9.51
10.98
0.74
1.11
12.14
14.63
9.24
15.91
11.76
12.36
7.36
8.01
3.14
10.69
10.34
8.61
9.35
5.48
7.20
NA
1.99
17.07
29.85
21.17
32.57
16.61
25.89
28.30
28.62
25.89
26.74
10.25
18.77
15.00
13.70
19.19
8.92
10.66
10.77
11.08
10.38
11.06
6.80
8.56
9.83
1.73
7.77
11.82
12.08
1.98
17.18
3.47
9.69
6.94
4.87
6.18
7.43
3.57
6.56
9.19
11.75
12.43
12.75
13.34
14.04
17.89
14.83
8.47
9.18
7.38
8.38
10.56
9.57
11.14
0.80
1.32
12.11
14.73
9.58
15.42
12.57
12.32
7.22
7.81
2.79
10.76
9.89
8.29
8.79
4.78
6.84
NA
Malpractice
RVUs 2
0.50
7.95
15.90
10.31
16.71
6.94
13.43
12.85
12.54
13.02
10.79
4.06
8.87
2.51
4.52
9.42
2.79
2.73
4.72
4.56
5.42
3.55
2.82
3.40
4.46
0.79
3.22
4.95
5.43
5.43
5.43
5.43
3.87
2.95
1.66
1.59
1.97
1.33
1.06
3.87
5.14
4.84
5.51
6.11
4.53
3.00
4.17
3.47
3.76
2.73
3.37
4.50
3.62
4.32
0.48
0.77
5.19
5.91
4.01
5.38
3.01
4.98
2.80
3.02
0.92
4.65
3.68
3.35
3.14
1.39
2.71
0.21
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00258
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
ZZZ
090
ZZZ
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
ZZZ
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66479
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
62252
62252
62256
62258
62263
62264
62268
62269
62270
62272
62273
62280
62281
62282
62284
62287
62290
62291
62292
62294
62310
62311
62318
62319
62350
62351
62355
62360
62361
62362
62365
62367
62368
63001
63003
63005
63011
63012
63015
63016
63017
63020
63030
63035
63040
63042
63043
63044
63045
63046
63047
63048
63050
63051
63055
63056
63057
63064
63066
63075
63076
63077
63078
63081
63082
63085
63086
63087
63088
63090
63091
63101
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Csf shunt reprogram ...........................
Csf shunt reprogram ...........................
Remove brain cavity shunt .................
Replace brain cavity shunt .................
Epidural lysis mult sessions ................
Epidural lysis on single day ................
Drain spinal cord cyst .........................
Needle biopsy, spinal cord .................
Spinal fluid tap, diagnostic ..................
Drain cerebro spinal fluid ....................
Inject epidural patch ............................
Treat spinal cord lesion ......................
Treat spinal cord lesion ......................
Treat spinal canal lesion .....................
Injection for myelogram ......................
Percutaneous diskectomy ...................
Inject for spine disk x-ray ....................
Inject for spine disk x-ray ....................
Injection into disk lesion ......................
Injection into spinal artery ...................
Inject spine c/t .....................................
Inject spine l/s (cd) ..............................
Inject spine w/cath, c/t ........................
Inject spine w/cath l/s (cd) ..................
Implant spinal canal cath ....................
Implant spinal canal cath ....................
Remove spinal canal catheter ............
Insert spine infusion device ................
Implant spine infusion pump ...............
Implant spine infusion pump ...............
Remove spine infusion device ............
Analyze spine infusion pump ..............
Analyze spine infusion pump ..............
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Neck spine disk surgery .....................
Low back disk surgery ........................
Spinal disk surgery add-on .................
Laminotomy, single cervical ................
Laminotomy, single lumbar .................
Laminotomy, add’l cervical .................
Laminotomy, add’l lumbar ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Removal of spinal lamina ...................
Remove spinal lamina add-on ............
Cervical laminoplasty ..........................
C-laminoplasty w/graft/plate ................
Decompress spinal cord .....................
Decompress spinal cord .....................
Decompress spine cord add-on ..........
Decompress spinal cord .....................
Decompress spine cord add-on ..........
Neck spine disk surgery .....................
Neck spine disk surgery .....................
Spine disk surgery, thorax ..................
Spine disk surgery, thorax ..................
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Removal of vertebral body ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.74
7.30
15.54
6.41
4.42
4.73
5.01
1.37
1.35
2.15
2.63
2.66
2.33
1.54
8.88
3.00
2.91
9.14
12.77
1.91
1.54
2.04
1.87
8.04
11.54
6.60
3.68
6.59
8.58
6.57
0.48
0.75
17.51
17.64
16.28
15.78
16.72
20.70
21.90
17.18
16.05
13.03
3.15
20.18
18.61
0.00
0.00
17.82
17.12
15.22
3.47
21.88
25.38
23.42
21.73
5.25
26.09
3.26
19.47
4.04
22.75
3.28
25.97
4.36
29.34
3.19
37.38
4.32
30.78
3.03
33.92
1.50
0.27
NA
NA
9.45
5.62
6.69
6.25
2.39
3.13
1.67
4.62
4.07
4.08
3.79
NA
4.50
4.23
NA
NA
3.00
2.66
3.09
2.79
NA
NA
NA
NA
NA
NA
NA
0.42
0.58
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.30
0.32
NA
NA
11.07
6.67
9.11
10.46
2.69
3.37
2.19
5.77
4.86
6.22
4.37
NA
5.81
5.08
NA
NA
3.90
3.79
4.40
3.88
NA
NA
NA
NA
NA
NA
NA
0.52
0.63
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.27
5.90
9.29
2.97
1.24
1.80
1.48
0.57
0.62
0.57
1.15
1.02
1.11
0.71
4.30
1.15
1.08
2.87
6.49
0.56
0.52
0.43
0.44
3.98
7.64
3.52
3.17
4.06
4.65
3.71
0.11
0.17
9.76
9.72
9.73
9.00
9.75
11.83
11.64
10.34
9.87
8.59
1.19
11.01
10.57
0.00
0.00
10.33
9.78
9.32
1.32
11.81
13.07
12.44
11.37
1.98
13.20
1.21
11.00
1.51
11.06
1.21
13.48
1.64
13.52
1.17
16.63
1.59
14.38
1.14
17.02
NA
0.32
5.29
9.00
3.08
1.33
1.97
1.73
0.57
0.66
0.64
1.08
0.96
1.01
0.70
4.92
1.26
1.15
3.67
6.03
0.60
0.56
0.54
0.52
3.96
7.38
3.34
2.92
3.99
4.50
3.64
0.11
0.17
9.63
9.79
9.85
8.63
9.93
11.85
11.71
10.36
9.77
8.50
1.39
11.25
10.95
0.00
0.00
10.34
9.98
9.61
1.49
11.82
13.26
12.78
11.96
2.30
13.81
1.43
11.54
1.78
11.92
1.42
13.89
1.93
14.49
1.38
18.03
1.88
15.20
1.30
18.14
Malpractice
RVUs 2
0.02
0.19
1.72
3.74
0.41
0.27
0.43
0.37
0.08
0.18
0.13
0.30
0.19
0.17
0.13
0.58
0.23
0.26
0.82
1.24
0.12
0.09
0.12
0.11
1.02
2.25
0.71
0.34
0.80
1.18
0.86
0.03
0.06
3.77
3.73
3.35
3.38
3.49
4.76
4.59
3.64
3.72
3.01
0.79
4.68
4.26
0.00
0.00
3.99
3.56
3.24
0.72
4.67
4.67
5.29
4.76
1.22
5.71
0.69
4.63
0.96
3.99
0.66
5.56
1.02
4.49
0.59
6.22
0.82
4.22
0.48
5.71
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00259
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
090
090
010
010
000
000
000
000
000
010
010
010
000
090
000
000
090
090
000
000
000
000
090
090
090
090
090
090
090
XXX
XXX
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
ZZZ
ZZZ
090
090
090
ZZZ
090
090
090
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
ZZZ
090
66480
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
63102
63103
63170
63172
63173
63180
63182
63185
63190
63191
63194
63195
63196
63197
63198
63199
63200
63250
63251
63252
63265
63266
63267
63268
63270
63271
63272
63273
63275
63276
63277
63278
63280
63281
63282
63283
63285
63286
63287
63290
63295
63300
63301
63302
63303
63304
63305
63306
63307
63308
63600
63610
63615
63650
63655
63660
63685
63688
63700
63702
63704
63706
63707
63709
63710
63740
63741
63744
63746
64400
64402
64405
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Incise spinal cord tract(s) ....................
Drainage of spinal cyst .......................
Drainage of spinal cyst .......................
Revise spinal cord ligaments ..............
Revise spinal cord ligaments ..............
Incise spinal column/nerves ................
Incise spinal column/nerves ................
Incise spinal column/nerves ................
Incise spinal column & cord ................
Incise spinal column & cord ................
Incise spinal column & cord ................
Incise spinal column & cord ................
Incise spinal column & cord ................
Incise spinal column & cord ................
Release of spinal cord ........................
Revise spinal cord vessels .................
Revise spinal cord vessels .................
Revise spinal cord vessels .................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Excise intraspinal lesion .....................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Biopsy/excise spinal tumor .................
Repair of laminectomy defect .............
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Removal of vertebral body ..................
Remove vertebral body add-on ..........
Remove spinal cord lesion .................
Stimulation of spinal cord ...................
Remove lesion of spinal cord .............
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Revise/remove neuroelectrode ...........
Insrt/redo spine n generator ...............
Revise/remove neuroreceiver .............
Repair of spinal herniation ..................
Repair of spinal herniation ..................
Repair of spinal herniation ..................
Repair of spinal herniation ..................
Repair spinal fluid leakage .................
Repair spinal fluid leakage .................
Graft repair of spine defect .................
Install spinal shunt ..............................
Install spinal shunt ..............................
Revision of spinal shunt ......................
Removal of spinal shunt .....................
N block inj, trigeminal .........................
N block inj, facial .................................
N block inj, occipital ............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
33.92
4.82
22.08
19.66
24.18
20.40
22.69
16.36
18.76
18.79
21.97
21.54
25.14
23.95
29.75
31.32
21.31
43.73
44.49
44.48
23.69
24.55
19.32
19.89
29.67
29.79
27.37
26.34
25.73
25.56
22.26
21.99
30.14
29.84
28.00
26.61
37.90
37.47
39.93
40.67
5.25
26.67
31.42
31.00
33.42
33.70
36.09
35.40
34.81
5.24
15.02
8.72
17.22
7.57
11.43
6.87
7.87
6.10
17.32
19.26
22.23
25.15
12.52
15.52
15.27
12.50
9.02
8.86
7.25
1.11
1.25
1.32
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
13.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.41
1.41
1.16
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
36.79
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.65
1.51
1.31
16.81
1.74
10.43
11.06
13.55
10.93
7.17
9.79
9.59
4.10
11.18
12.09
13.77
7.46
8.92
9.28
12.09
20.89
21.51
20.85
12.98
13.16
11.12
11.24
15.34
15.30
14.28
14.06
13.73
13.50
12.11
11.91
15.86
15.85
14.99
14.67
18.07
18.69
19.59
19.26
1.95
13.78
14.19
13.77
14.98
17.56
16.97
16.63
14.81
1.95
4.03
1.49
8.51
2.92
7.62
3.42
3.65
3.53
9.94
9.97
11.65
14.29
7.82
8.96
9.18
8.27
4.93
5.75
5.68
0.44
0.49
0.49
18.04
2.12
11.14
10.85
13.17
10.95
9.06
8.94
9.86
7.28
11.44
11.56
13.57
9.83
8.67
12.15
11.68
20.40
22.04
21.53
12.87
13.16
11.09
10.80
15.39
15.43
14.47
14.19
13.74
13.58
12.31
12.14
16.08
16.00
15.15
14.65
19.00
19.28
20.00
19.92
2.05
14.03
14.87
14.80
15.94
17.40
17.50
17.20
15.80
2.27
4.71
1.87
8.89
3.04
7.25
3.51
3.89
3.54
10.12
10.49
12.28
13.93
7.76
9.17
9.10
7.80
4.84
5.50
4.72
0.44
0.55
0.48
Malpractice
RVUs 2
5.71
0.69
4.87
4.49
5.70
3.96
5.32
2.80
3.25
6.36
3.27
4.88
5.78
5.38
6.45
1.40
4.97
9.04
10.44
10.67
5.45
5.56
4.38
3.70
6.84
6.92
6.20
5.76
5.82
5.85
5.03
4.56
7.29
7.19
6.78
6.28
9.21
9.24
9.42
9.05
1.03
5.99
5.41
5.55
4.69
6.43
5.73
8.35
4.47
1.29
1.52
0.86
2.85
0.53
2.44
0.78
1.05
0.89
3.53
4.13
4.58
6.25
2.52
3.10
3.41
2.94
1.66
1.90
1.53
0.07
0.09
0.08
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00260
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
ZZZ
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66481
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
64408
64410
64412
64413
64415
64416
64417
64418
64420
64421
64425
64430
64435
64445
64446
64447
64448
64449
64450
64470
64472
64475
64476
64479
64480
64483
64484
64505
64508
64510
64517
64520
64530
64550
64553
64555
64560
64561
64565
64573
64575
64577
64580
64581
64585
64590
64595
64600
64605
64610
64612
64613
64614
64620
64622
64623
64626
64627
64630
64640
64650
64653
64680
64681
64702
64704
64708
64712
64713
64714
64716
64718
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
N block inj, vagus ...............................
N block inj, phrenic .............................
N block inj, spinal accessor ................
N block inj, cervical plexus .................
N block inj, brachial plexus .................
N block cont infuse, b plex .................
N block inj, axillary ..............................
N block inj, suprascapular ..................
N block inj, intercost, sng ...................
N block inj, intercost, mlt ....................
N block inj, ilio-ing/hypogi ...................
N block inj, pudendal ..........................
N block inj, paracervical ......................
N block inj, sciatic, sng .......................
N blk inj, sciatic, cont inf .....................
N block inj fem, single ........................
N block inj fem, cont inf ......................
N block inj, lumbar plexus ..................
N block, other peripheral ....................
Inj paravertebral c/t .............................
Inj paravertebral c/t add-on .................
Inj paravertebral l/s .............................
Inj paravertebral l/s add-on .................
Inj foramen epidural c/t .......................
Inj foramen epidural add-on ................
Inj foramen epidural l/s .......................
Inj foramen epidural add-on ................
N block, spenopalatine gangl .............
N block, carotid sinus s/p ...................
N block, stellate ganglion ....................
N block inj, hypogas plxs ....................
N block, lumbar/thoracic .....................
N block inj, celiac pelus ......................
Apply neurostimulator .........................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Implant neuroelectrodes .....................
Revise/remove neuroelectrode ...........
Insrt/redo pn/gastr stimul ....................
Revise/rmv pn/gastr stimul .................
Injection treatment of nerve ................
Injection treatment of nerve ................
Injection treatment of nerve ................
Destroy nerve, face muscle ................
Destroy nerve, neck muscle ...............
Destroy nerve, extrem musc ...............
Injection treatment of nerve ................
Destr paravertebrl nerve l/s ................
Destr paravertebral n add-on ..............
Destr paravertebrl nerve c/t ................
Destr paravertebral n add-on ..............
Injection treatment of nerve ................
Injection treatment of nerve ................
Chemodenerv eccrine glands .............
Chemodenerv eccrine glands .............
Injection treatment of nerve ................
Injection treatment of nerve ................
Revise finger/toe nerve .......................
Revise hand/foot nerve .......................
Revise arm/leg nerve ..........................
Revision of sciatic nerve .....................
Revision of arm nerve(s) ....................
Revise low back nerve(s) ...................
Revision of cranial nerve ....................
Revise ulnar nerve at elbow ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.41
1.43
1.18
1.40
1.48
3.85
1.44
1.32
1.18
1.68
1.75
1.46
1.45
1.48
3.61
1.50
3.36
3.24
1.27
1.85
1.29
1.41
0.98
2.20
1.54
1.90
1.33
1.36
1.12
1.22
2.20
1.35
1.58
0.18
2.33
2.29
2.38
7.07
1.78
8.15
4.37
4.64
4.14
14.15
2.08
2.42
1.75
3.46
5.62
7.17
1.98
1.98
2.20
2.86
3.02
0.99
3.82
1.16
3.02
2.78
0.70
0.88
2.64
3.78
6.10
4.61
6.22
7.98
11.29
10.44
6.86
7.06
1.45
1.92
2.13
1.31
1.41
NA
1.43
1.89
2.40
3.55
1.29
2.39
1.99
1.62
NA
NA
NA
NA
1.27
3.82
1.22
3.64
1.10
3.75
1.55
3.81
1.62
1.13
2.03
1.90
1.72
2.57
2.79
0.20
2.64
2.78
2.41
19.59
2.47
NA
NA
NA
NA
NA
5.91
6.40
6.44
5.42
7.21
9.17
1.58
1.37
1.61
3.30
4.05
1.68
4.74
2.37
2.76
2.42
0.72
0.75
4.25
4.81
NA
NA
NA
NA
NA
NA
NA
NA
1.51
2.21
2.39
1.57
2.11
NA
2.23
2.26
3.14
4.81
1.47
2.45
2.26
2.15
NA
NA
NA
NA
1.25
5.52
1.78
5.26
1.61
5.62
2.19
5.85
2.45
1.18
2.68
2.67
2.22
3.85
3.62
0.24
2.74
2.94
2.52
24.81
2.87
NA
NA
NA
NA
NA
8.59
6.77
8.41
7.38
8.38
9.01
2.03
2.15
2.42
4.18
5.90
2.32
6.25
3.45
2.75
3.30
0.79
0.83
5.48
7.05
NA
NA
NA
NA
NA
NA
NA
NA
0.71
0.56
0.58
0.48
0.30
0.46
0.32
0.52
0.44
0.53
0.53
0.77
0.55
0.50
0.48
0.17
0.39
0.42
0.49
0.70
0.33
0.58
0.22
0.81
0.39
0.75
0.32
0.74
0.56
0.43
0.68
0.51
0.65
0.05
1.44
1.49
1.26
3.76
1.29
5.16
2.05
4.78
2.70
6.60
2.28
2.45
2.17
1.63
2.26
3.43
1.33
1.14
1.30
1.11
1.25
0.22
1.87
0.25
1.84
1.42
0.16
0.19
1.20
1.27
5.19
3.28
4.20
4.37
6.04
4.36
5.45
6.20
0.78
0.51
0.51
0.49
0.38
0.63
0.40
0.48
0.43
0.52
0.53
0.66
0.62
0.50
0.74
0.30
0.60
0.69
0.48
0.70
0.33
0.60
0.23
0.85
0.43
0.79
0.35
0.70
0.65
0.47
0.77
0.53
0.65
0.05
1.65
1.34
1.27
3.26
1.27
5.20
2.36
4.03
3.13
5.98
2.21
2.37
2.05
1.64
2.22
3.57
1.32
1.18
1.31
1.22
1.31
0.22
1.92
0.26
1.62
1.63
0.23
0.28
1.31
1.67
4.52
3.29
4.53
4.66
5.96
4.28
5.71
6.09
Malpractice
RVUs 2
0.10
0.09
0.08
0.08
0.09
0.31
0.11
0.07
0.08
0.11
0.13
0.10
0.16
0.10
0.20
0.09
0.18
0.15
0.13
0.11
0.08
0.10
0.07
0.12
0.10
0.11
0.08
0.10
0.07
0.07
0.11
0.08
0.10
0.01
0.18
0.19
0.22
0.51
0.13
1.60
0.61
1.04
0.36
1.05
0.20
0.19
0.19
0.34
0.79
1.58
0.11
0.11
0.10
0.20
0.18
0.06
0.20
0.07
0.22
0.29
0.06
0.08
0.18
0.28
0.61
0.61
0.96
0.95
1.83
1.19
0.63
1.05
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00261
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
000
000
010
000
000
000
000
000
000
000
000
010
000
010
010
000
000
ZZZ
000
ZZZ
000
ZZZ
000
ZZZ
000
000
000
000
000
000
000
010
010
010
010
010
090
090
090
090
090
010
010
010
010
010
010
010
010
010
010
010
ZZZ
010
ZZZ
010
010
000
000
010
010
090
090
090
090
090
090
090
090
66482
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
64719
64721
64722
64726
64727
64732
64734
64736
64738
64740
64742
64744
64746
64752
64755
64760
64761
64763
64766
64771
64772
64774
64776
64778
64782
64783
64784
64786
64787
64788
64790
64792
64795
64802
64804
64809
64818
64820
64821
64822
64823
64831
64832
64834
64835
64836
64837
64840
64856
64857
64858
64859
64861
64862
64864
64865
64866
64868
64870
64872
64874
64876
64885
64886
64890
64891
64892
64893
64895
64896
64897
64898
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Revise ulnar nerve at wrist .................
Carpal tunnel surgery .........................
Relieve pressure on nerve(s) .............
Release foot/toe nerve ........................
Internal nerve revision ........................
Incision of brow nerve .........................
Incision of cheek nerve .......................
Incision of chin nerve ..........................
Incision of jaw nerve ...........................
Incision of tongue nerve .....................
Incision of facial nerve ........................
Incise nerve, back of head .................
Incise diaphragm nerve ......................
Incision of vagus nerve .......................
Incision of stomach nerves .................
Incision of vagus nerve .......................
Incision of pelvis nerve .......................
Incise hip/thigh nerve ..........................
Incise hip/thigh nerve ..........................
Sever cranial nerve .............................
Incision of spinal nerve .......................
Remove skin nerve lesion ..................
Remove digit nerve lesion ..................
Digit nerve surgery add-on .................
Remove limb nerve lesion ..................
Limb nerve surgery add-on .................
Remove nerve lesion ..........................
Remove sciatic nerve lesion ...............
Implant nerve end ...............................
Remove skin nerve lesion ..................
Removal of nerve lesion .....................
Removal of nerve lesion .....................
Biopsy of nerve ...................................
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Remove sympathetic nerves ..............
Repair of digit nerve ...........................
Repair nerve add-on ...........................
Repair of hand or foot nerve ..............
Repair of hand or foot nerve ..............
Repair of hand or foot nerve ..............
Repair nerve add-on ...........................
Repair of leg nerve .............................
Repair/transpose nerve .......................
Repair arm/leg nerve ..........................
Repair sciatic nerve ............................
Nerve surgery .....................................
Repair of arm nerves ..........................
Repair of low back nerves ..................
Repair of facial nerve ..........................
Repair of facial nerve ..........................
Fusion of facial/other nerve ................
Fusion of facial/other nerve ................
Fusion of facial/other nerve ................
Subsequent repair of nerve ................
Repair & revise nerve add-on .............
Repair nerve/shorten bone .................
Nerve graft, head or neck ...................
Nerve graft, head or neck ...................
Nerve graft, hand or foot ....................
Nerve graft, hand or foot ....................
Nerve graft, arm or leg .......................
Nerve graft, arm or leg .......................
Nerve graft, hand or foot ....................
Nerve graft, hand or foot ....................
Nerve graft, arm or leg .......................
Nerve graft, arm or leg .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
4.89
4.84
4.74
4.21
3.10
4.81
5.45
5.13
6.26
6.12
6.75
5.64
6.46
7.59
14.97
7.49
6.94
7.46
9.34
8.02
7.74
5.70
5.52
3.11
6.76
3.71
10.49
16.12
4.29
5.14
11.97
15.71
3.01
10.24
15.78
14.61
11.24
10.64
9.19
9.19
10.80
10.23
5.65
10.71
11.60
11.60
6.25
13.87
14.94
15.69
17.69
4.25
20.74
20.94
13.31
15.96
16.70
14.80
16.95
1.99
2.98
3.37
17.50
20.72
16.11
17.22
15.61
16.74
20.26
21.81
19.25
20.82
NA
4.70
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.03
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.14
4.65
2.99
2.80
1.19
3.66
4.43
3.72
4.64
4.98
4.28
4.04
3.86
3.79
5.50
3.78
4.32
3.91
4.73
5.63
5.12
4.03
3.72
1.21
4.22
1.36
6.40
8.43
1.64
4.05
6.97
8.29
1.43
3.50
5.96
7.03
4.32
6.93
6.53
6.42
6.46
6.61
2.31
6.44
6.90
7.06
2.57
7.51
8.47
8.75
9.55
1.75
10.00
10.12
7.46
11.52
11.09
9.78
8.05
0.78
1.26
1.42
8.94
10.36
8.97
9.65
9.12
9.62
11.03
11.65
10.49
11.45
4.33
5.00
3.02
2.79
1.34
3.58
4.24
3.87
4.62
5.05
4.49
3.90
4.18
4.03
5.56
3.61
3.92
4.55
4.99
5.59
5.01
3.93
3.70
1.35
3.99
1.60
6.49
9.13
1.88
3.76
7.08
8.56
1.49
4.31
6.56
6.39
4.80
7.02
6.93
6.82
7.29
6.84
2.62
6.76
7.29
7.36
2.90
7.88
8.83
9.19
10.16
1.97
10.88
11.02
8.11
12.52
12.13
10.60
8.39
0.93
1.39
1.58
10.26
11.95
9.48
8.61
8.99
9.74
10.34
11.31
10.58
11.61
Malpractice
RVUs 2
0.77
0.73
0.48
0.54
0.48
0.98
0.89
0.52
1.08
0.69
0.73
1.16
0.82
0.93
1.84
0.81
0.53
0.94
1.06
1.23
1.40
0.74
0.76
0.46
0.86
0.51
1.38
2.61
0.58
0.73
2.11
2.49
0.52
1.29
2.15
1.50
1.33
1.49
1.24
1.30
1.57
1.41
0.85
1.54
1.74
1.68
0.97
1.37
2.13
2.22
3.34
0.67
4.09
4.32
1.26
1.50
2.05
1.43
1.30
0.29
0.42
0.47
1.63
2.09
2.30
1.63
2.48
2.62
2.58
3.17
2.55
2.78
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00262
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
090
ZZZ
090
090
ZZZ
090
090
090
000
090
090
090
090
090
090
090
090
090
ZZZ
090
090
090
ZZZ
090
090
090
090
ZZZ
090
090
090
090
090
090
090
ZZZ
ZZZ
ZZZ
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66483
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
64901
64902
64905
64907
64910
64911
64999
65091
65093
65101
65103
65105
65110
65112
65114
65125
65130
65135
65140
65150
65155
65175
65205
65210
65220
65222
65235
65260
65265
65270
65272
65273
65275
65280
65285
65286
65290
65400
65410
65420
65426
65430
65435
65436
65450
65600
65710
65730
65750
65755
65760
65765
65767
65770
65771
65772
65775
65780
65781
65782
65800
65805
65810
65815
65820
65850
65855
65860
65865
65870
65875
65880
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
N
N
A
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Nerve graft add-on ..............................
Nerve graft add-on ..............................
Nerve pedicle transfer .........................
Nerve pedicle transfer .........................
Nerve repair w/allograft .......................
Neurorraphy w/vein autograft .............
Nervous system surgery .....................
Revise eye ..........................................
Revise eye with implant ......................
Removal of eye ...................................
Remove eye/insert implant .................
Remove eye/attach implant ................
Removal of eye ...................................
Remove eye/revise socket ..................
Remove eye/revise socket ..................
Revise ocular implant .........................
Insert ocular implant ...........................
Insert ocular implant ...........................
Attach ocular implant ..........................
Revise ocular implant .........................
Reinsert ocular implant .......................
Removal of ocular implant ..................
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Remove foreign body from eye ..........
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye wound ...........................
Repair of eye socket wound ...............
Removal of eye lesion ........................
Biopsy of cornea .................................
Removal of eye lesion ........................
Removal of eye lesion ........................
Corneal smear ....................................
Curette/treat cornea ............................
Curette/treat cornea ............................
Treatment of corneal lesion ................
Revision of cornea ..............................
Corneal transplant ...............................
Corneal transplant ...............................
Corneal transplant ...............................
Corneal transplant ...............................
Revision of cornea ..............................
Revision of cornea ..............................
Corneal tissue transplant ....................
Revise cornea with implant .................
Radial keratotomy ...............................
Correction of astigmatism ...................
Correction of astigmatism ...................
Ocular reconst, transplant ...................
Ocular reconst, transplant ...................
Ocular reconst, transplant ...................
Drainage of eye ..................................
Drainage of eye ..................................
Drainage of eye ..................................
Drainage of eye ..................................
Relieve inner eye pressure .................
Incision of eye .....................................
Laser surgery of eye ...........................
Incise inner eye adhesions .................
Incise inner eye adhesions .................
Incise inner eye adhesions .................
Incise inner eye adhesions .................
Incise inner eye adhesions .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
10.20
11.81
14.98
19.90
11.21
14.21
0.00
7.13
6.93
8.10
8.64
9.70
15.42
18.18
19.32
3.18
8.22
8.40
9.23
6.32
9.87
7.22
0.71
0.84
0.71
0.93
8.78
12.29
14.06
1.92
4.49
5.03
6.14
8.87
14.43
6.45
6.35
7.27
1.47
4.24
5.93
1.47
0.92
4.72
3.35
4.07
14.09
15.99
16.60
16.49
0.00
0.00
0.00
19.41
0.00
4.96
6.73
10.43
17.84
15.16
1.91
1.91
5.67
5.85
8.72
11.24
3.90
3.56
5.66
7.21
7.61
8.16
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
6.70
NA
NA
NA
NA
NA
NA
0.57
0.71
0.59
0.78
NA
NA
NA
3.82
6.29
NA
6.29
NA
NA
8.69
NA
7.43
1.66
6.84
8.08
1.08
0.85
3.75
3.67
4.42
NA
NA
NA
NA
0.00
0.00
0.00
NA
0.00
4.84
NA
NA
NA
NA
1.39
1.69
NA
7.90
NA
NA
3.48
3.25
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
7.75
NA
NA
NA
NA
NA
NA
0.60
0.76
0.62
0.83
NA
NA
NA
4.52
7.00
NA
6.30
NA
NA
9.91
NA
7.88
1.89
7.85
9.12
1.18
0.93
3.92
3.87
4.71
NA
NA
NA
NA
0.00
0.00
0.00
NA
0.00
5.18
NA
NA
NA
NA
1.59
1.93
NA
8.95
NA
NA
3.89
3.64
NA
NA
NA
NA
3.62
4.65
6.99
6.35
4.66
5.31
0.00
6.72
6.78
7.95
8.11
8.76
11.41
13.29
13.55
3.16
7.67
7.73
8.37
6.29
8.76
7.04
0.32
0.39
0.28
0.41
6.77
8.73
9.58
1.20
3.15
3.36
3.89
5.83
8.38
4.38
4.43
5.83
0.86
3.95
4.49
0.86
0.64
3.43
3.59
3.38
10.13
10.94
10.60
10.56
0.00
0.00
0.00
11.64
0.00
3.91
5.29
8.91
11.56
10.17
1.02
1.02
4.66
4.57
7.49
7.31
2.62
2.07
4.68
5.69
6.12
6.29
4.44
5.31
7.74
9.43
4.66
5.31
0.00
7.53
7.75
8.74
8.92
9.61
12.54
14.71
14.94
3.38
8.41
8.52
9.12
7.12
9.62
7.75
0.30
0.38
0.28
0.39
6.76
9.19
10.10
1.29
3.22
3.47
3.92
6.03
8.79
4.49
4.58
5.98
0.91
4.19
4.70
0.92
0.68
3.55
3.76
3.36
10.66
11.48
11.28
11.22
0.00
0.00
0.00
12.42
0.00
4.02
5.62
9.60
12.61
11.08
1.10
1.10
4.68
4.69
8.27
7.87
2.86
2.29
5.15
6.05
6.45
6.66
Malpractice
RVUs 2
1.37
1.55
2.01
3.17
1.74
1.91
0.00
0.32
0.34
0.35
0.37
0.42
0.81
1.30
1.02
0.19
0.35
0.36
0.40
0.31
0.50
0.31
0.03
0.04
0.05
0.04
0.37
0.57
0.62
0.09
0.19
0.22
0.26
0.38
0.64
0.27
0.31
0.30
0.07
0.21
0.25
0.07
0.04
0.21
0.16
0.17
0.61
0.70
0.74
0.73
0.00
0.00
0.00
0.87
0.00
0.21
0.28
0.44
0.44
0.44
0.09
0.09
0.24
0.25
0.40
0.52
0.19
0.18
0.28
0.31
0.32
0.35
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00263
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
ZZZ
090
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
000
000
000
090
090
090
010
090
090
090
090
090
090
090
090
000
090
090
000
000
090
090
090
090
090
090
090
XXX
XXX
XXX
090
XXX
090
090
090
090
090
000
000
090
090
090
090
010
090
090
090
090
090
66484
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
65900
65920
65930
66020
66030
66130
66150
66155
66160
66165
66170
66172
66180
66185
66220
66225
66250
66500
66505
66600
66605
66625
66630
66635
66680
66682
66700
66710
66711
66720
66740
66761
66762
66770
66820
66821
66825
66830
66840
66850
66852
66920
66930
66940
66982
66983
66984
66985
66986
66990
66999
67005
67010
67015
67025
67027
67028
67030
67031
67036
67039
67040
67041
67042
67043
67101
67105
67107
67108
67110
67112
67113
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Remove eye lesion .............................
Remove implant of eye .......................
Remove blood clot from eye ...............
Injection treatment of eye ...................
Injection treatment of eye ...................
Remove eye lesion .............................
Glaucoma surgery ...............................
Glaucoma surgery ...............................
Glaucoma surgery ...............................
Glaucoma surgery ...............................
Glaucoma surgery ...............................
Incision of eye .....................................
Implant eye shunt ...............................
Revise eye shunt ................................
Repair eye lesion ................................
Repair/graft eye lesion ........................
Follow-up surgery of eye ....................
Incision of iris ......................................
Incision of iris ......................................
Remove iris and lesion .......................
Removal of iris ....................................
Removal of iris ....................................
Removal of iris ....................................
Removal of iris ....................................
Repair iris & ciliary body .....................
Repair iris & ciliary body .....................
Destruction, ciliary body ......................
Ciliary transsleral therapy ...................
Ciliary endoscopic ablation .................
Destruction, ciliary body ......................
Destruction, ciliary body ......................
Revision of iris ....................................
Revision of iris ....................................
Removal of inner eye lesion ...............
Incision, secondary cataract ...............
After cataract laser surgery ................
Reposition intraocular lens .................
Removal of lens lesion .......................
Removal of lens material ....................
Removal of lens material ....................
Removal of lens material ....................
Extraction of lens ................................
Extraction of lens ................................
Extraction of lens ................................
Cataract surgery, complex ..................
Cataract surg w/iol, 1 stage ................
Cataract surg w/iol, 1 stage ................
Insert lens prosthesis ..........................
Exchange lens prosthesis ...................
Ophthalmic endoscope add-on ...........
Eye surgery procedure .......................
Partial removal of eye fluid .................
Partial removal of eye fluid .................
Release of eye fluid ............................
Replace eye fluid ................................
Implant eye drug system ....................
Injection eye drug ...............................
Incise inner eye strands ......................
Laser surgery, eye strands .................
Removal of inner eye fluid ..................
Laser treatment of retina ....................
Laser treatment of retina ....................
Vit for macular pucker .........................
Vit for macular hole .............................
Vit for membrane dissect ....................
Repair detached retina .......................
Repair detached retina .......................
Repair detached retina .......................
Repair detached retina .......................
Repair detached retina .......................
Rerepair detached retina ....................
Repair retinal detach, cplx ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
12.26
9.74
8.24
1.61
1.27
7.74
10.18
10.17
12.04
9.89
14.57
18.26
16.02
9.35
8.98
12.38
6.92
3.75
4.13
9.89
13.99
5.19
7.10
7.19
6.24
7.15
5.06
5.06
7.70
4.86
5.06
4.87
5.25
5.98
3.93
3.32
8.82
9.27
8.98
10.32
11.18
9.93
11.38
10.14
14.83
10.20
10.36
9.73
12.26
1.51
0.00
5.77
6.94
7.00
7.91
11.43
2.52
5.91
4.34
13.09
16.39
19.23
19.00
22.13
22.94
8.60
8.35
16.35
22.49
10.02
18.45
22.49
NA
NA
NA
2.42
2.29
7.50
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
9.22
NA
NA
NA
NA
NA
NA
NA
NA
NA
4.77
4.59
NA
5.36
4.52
5.01
5.09
5.52
NA
3.82
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
7.85
NA
2.15
NA
4.09
NA
NA
NA
NA
NA
NA
8.48
7.40
NA
NA
8.91
NA
NA
NA
NA
NA
2.77
2.63
8.56
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
10.45
NA
NA
NA
NA
NA
NA
NA
NA
NA
5.01
4.88
NA
5.58
4.80
5.30
5.37
5.80
NA
3.95
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
8.53
NA
2.42
NA
4.34
NA
NA
NA
NA
NA
NA
8.80
7.74
NA
NA
9.57
NA
NA
8.88
7.45
5.76
1.27
1.15
4.86
8.80
8.80
9.46
8.76
11.52
14.61
9.68
7.03
7.16
8.10
5.24
3.94
4.30
8.24
9.44
4.20
5.33
5.36
5.05
6.70
3.58
3.59
6.28
4.31
3.60
4.18
4.06
4.58
4.61
3.41
7.76
6.36
6.28
7.06
7.38
6.63
7.44
6.99
8.94
6.50
6.44
7.12
8.04
0.54
0.00
4.57
4.99
5.69
5.91
7.36
1.24
5.59
3.42
8.05
10.68
11.98
10.36
11.48
12.34
6.16
5.78
10.33
12.92
6.95
10.84
12.75
9.56
7.81
6.30
1.35
1.21
5.23
9.10
9.07
9.82
9.00
11.87
14.90
10.21
7.20
7.13
8.42
5.36
4.29
4.64
8.23
9.73
4.46
5.52
5.55
5.16
6.65
3.76
3.72
6.37
4.51
3.78
4.24
4.17
4.69
5.21
3.51
8.41
6.65
6.57
7.35
7.73
6.96
7.79
7.29
9.40
6.31
6.93
7.28
8.61
0.61
0.00
4.71
5.20
6.07
6.06
7.67
1.35
5.72
3.53
8.58
11.43
12.83
10.36
11.48
12.34
6.34
5.96
10.81
13.66
7.17
11.32
12.75
Malpractice
RVUs 2
0.54
0.41
0.37
0.08
0.06
0.38
0.46
0.41
0.50
0.40
0.60
0.74
0.71
0.40
0.40
0.55
0.30
0.18
0.20
0.43
0.77
0.26
0.31
0.31
0.27
0.31
0.24
0.23
0.30
0.26
0.23
0.20
0.23
0.26
0.19
0.11
0.40
0.36
0.39
0.45
0.49
0.44
0.49
0.43
0.63
0.14
0.39
0.36
0.60
0.07
0.00
0.28
0.34
0.34
0.34
0.54
0.12
0.24
0.18
0.58
0.71
0.85
0.86
1.00
1.04
0.37
0.37
0.73
1.02
0.44
0.83
1.13
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00264
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
010
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
ZZZ
YYY
090
090
090
090
090
000
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66485
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
67115
67120
67121
67141
67145
67208
67210
67218
67220
67221
67225
67227
67228
67229
67250
67255
67299
67311
67312
67314
67316
67318
67320
67331
67332
67334
67335
67340
67343
67345
67346
67399
67400
67405
67412
67413
67414
67415
67420
67430
67440
67445
67450
67500
67505
67515
67550
67560
67570
67599
67700
67710
67715
67800
67801
67805
67808
67810
67820
67825
67830
67835
67840
67850
67875
67880
67882
67900
67901
67902
67903
67904
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
R
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Release encircling material .................
Remove eye implant material .............
Remove eye implant material .............
Treatment of retina .............................
Treatment of retina .............................
Treatment of retinal lesion ..................
Treatment of retinal lesion ..................
Treatment of retinal lesion ..................
Treatment of choroid lesion ................
Ocular photodynamic ther ...................
Eye photodynamic ther add-on ...........
Treatment of retinal lesion ..................
Treatment of retinal lesion ..................
Tr retinal les preterm inf .....................
Reinforce eye wall ..............................
Reinforce/graft eye wall ......................
Eye surgery procedure .......................
Revise eye muscle ..............................
Revise two eye muscles .....................
Revise eye muscle ..............................
Revise two eye muscles .....................
Revise eye muscle(s) .........................
Revise eye muscle(s) add-on .............
Eye surgery follow-up add-on .............
Rerevise eye muscles add-on ............
Revise eye muscle w/suture ...............
Eye suture during surgery ..................
Revise eye muscle add-on .................
Release eye tissue .............................
Destroy nerve of eye muscle ..............
Biopsy, eye muscle .............................
Eye muscle surgery procedure ...........
Explore/biopsy eye socket ..................
Explore/drain eye socket ....................
Explore/treat eye socket .....................
Explore/treat eye socket .....................
Explr/decompress eye socket .............
Aspiration, orbital contents .................
Explore/treat eye socket .....................
Explore/treat eye socket .....................
Explore/drain eye socket ....................
Explr/decompress eye socket .............
Explore/biopsy eye socket ..................
Inject/treat eye socket .........................
Inject/treat eye socket .........................
Inject/treat eye socket .........................
Insert eye socket implant ....................
Revise eye socket implant ..................
Decompress optic nerve .....................
Orbit surgery procedure ......................
Drainage of eyelid abscess ................
Incision of eyelid .................................
Incision of eyelid fold ..........................
Remove eyelid lesion ..........................
Remove eyelid lesions ........................
Remove eyelid lesions ........................
Remove eyelid lesion(s) .....................
Biopsy of eyelid ...................................
Revise eyelashes ................................
Revise eyelashes ................................
Revise eyelashes ................................
Revise eyelashes ................................
Remove eyelid lesion ..........................
Treat eyelid lesion ...............................
Closure of eyelid by suture .................
Revision of eyelid ................................
Revision of eyelid ................................
Repair brow defect ..............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
5.93
6.92
12.00
6.00
6.17
7.50
9.35
20.22
14.19
3.45
0.47
7.38
13.67
16.00
9.46
9.97
0.00
7.59
9.48
8.59
10.73
8.92
5.40
5.13
5.56
5.05
2.49
6.00
8.29
2.98
2.87
0.00
10.97
9.00
10.17
10.09
17.78
1.76
21.62
14.99
14.56
18.96
15.11
1.44
1.27
1.40
11.52
11.93
14.21
0.00
1.37
1.04
1.24
1.39
1.89
2.24
4.47
1.48
0.71
1.40
1.72
5.61
2.06
1.71
1.35
4.47
5.87
6.69
7.47
9.68
6.42
7.83
NA
7.34
NA
5.40
5.33
5.64
5.91
NA
9.20
2.91
0.22
5.99
13.58
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.17
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.57
0.65
0.77
NA
NA
NA
0.00
4.30
3.70
3.83
1.39
1.67
2.18
NA
3.93
0.43
1.40
3.99
NA
3.90
3.28
2.38
5.43
6.35
7.36
8.98
NA
6.62
8.16
NA
7.96
NA
5.63
5.53
5.88
6.24
NA
9.81
3.62
0.24
6.28
12.52
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.38
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.62
0.67
0.68
NA
NA
NA
0.00
5.16
4.53
4.60
1.50
1.82
2.35
NA
3.63
0.52
1.57
4.76
NA
4.69
3.33
2.84
6.02
6.99
8.21
7.19
NA
8.09
8.89
4.92
5.27
7.94
4.65
4.70
5.19
5.43
10.60
8.15
1.38
0.17
5.15
10.18
9.51
7.66
8.42
0.00
5.49
6.19
6.15
6.91
6.50
1.92
1.81
1.97
1.80
0.88
2.13
6.06
1.69
1.62
0.00
9.41
8.33
8.52
8.69
11.62
0.62
14.22
11.86
11.86
12.13
12.29
0.44
0.50
0.61
9.81
9.77
11.00
0.00
1.17
1.07
1.15
0.90
1.07
1.40
3.60
0.68
0.50
1.26
1.32
4.12
1.45
1.44
0.83
3.56
4.45
4.60
5.28
6.33
4.33
5.37
5.00
5.40
8.23
4.75
4.81
5.35
5.65
11.37
8.58
1.59
0.19
5.34
9.36
9.51
8.41
9.15
0.00
5.76
6.47
6.35
7.20
6.71
1.94
1.82
2.00
1.80
1.00
2.17
6.28
1.85
1.75
0.00
10.33
9.05
9.72
9.73
11.83
0.69
15.80
13.37
13.06
13.02
13.48
0.37
0.41
0.49
10.55
10.57
12.28
0.00
1.22
1.14
1.22
0.97
1.17
1.52
3.69
0.68
0.53
1.33
1.41
4.37
1.55
1.45
0.88
3.68
4.63
4.93
5.34
5.90
4.92
5.30
Malpractice
RVUs 2
0.25
0.29
0.53
0.26
0.27
0.33
0.44
0.92
0.65
0.20
0.02
0.33
0.63
0.71
0.47
0.44
0.00
0.37
0.43
0.39
0.49
0.41
0.22
0.21
0.23
0.20
0.13
0.25
0.37
0.17
0.15
0.00
0.56
0.44
0.48
0.50
0.65
0.09
1.15
0.86
0.70
0.90
0.68
0.05
0.05
0.03
0.72
0.60
0.68
0.00
0.07
0.05
0.06
0.07
0.09
0.11
0.19
0.06
0.04
0.07
0.08
0.28
0.10
0.07
0.07
0.19
0.25
0.38
0.54
0.60
0.47
0.41
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00265
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
000
ZZZ
090
090
090
090
090
YYY
090
090
090
090
090
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
090
010
000
YYY
090
090
090
090
090
000
090
090
090
090
090
000
000
000
090
090
090
YYY
010
010
010
010
010
010
090
000
000
010
010
090
010
010
000
090
090
090
090
090
090
090
66486
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
67906
67908
67909
67911
67912
67914
67915
67916
67917
67921
67922
67923
67924
67930
67935
67938
67950
67961
67966
67971
67973
67974
67975
67999
68020
68040
68100
68110
68115
68130
68135
68200
68320
68325
68326
68328
68330
68335
68340
68360
68362
68371
68399
68400
68420
68440
68500
68505
68510
68520
68525
68530
68540
68550
68700
68705
68720
68745
68750
68760
68761
68770
68801
68810
68811
68815
68816
68840
68850
68899
69000
69005
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Repair eyelid defect ............................
Repair eyelid defect ............................
Revise eyelid defect ............................
Revise eyelid defect ............................
Correction eyelid w/implant .................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid defect ............................
Repair eyelid wound ...........................
Repair eyelid wound ...........................
Remove eyelid foreign body ...............
Revision of eyelid ................................
Revision of eyelid ................................
Revision of eyelid ................................
Reconstruction of eyelid .....................
Reconstruction of eyelid .....................
Reconstruction of eyelid .....................
Reconstruction of eyelid .....................
Revision of eyelid ................................
Incise/drain eyelid lining ......................
Treatment of eyelid lesions .................
Biopsy of eyelid lining .........................
Remove eyelid lining lesion ................
Remove eyelid lining lesion ................
Remove eyelid lining lesion ................
Remove eyelid lining lesion ................
Treat eyelid by injection ......................
Revise/graft eyelid lining .....................
Revise/graft eyelid lining .....................
Revise/graft eyelid lining .....................
Revise/graft eyelid lining .....................
Revise eyelid lining .............................
Revise/graft eyelid lining .....................
Separate eyelid adhesions .................
Revise eyelid lining .............................
Revise eyelid lining .............................
Harvest eye tissue, alograft ................
Eyelid lining surgery ............................
Incise/drain tear gland ........................
Incise/drain tear sac ............................
Incise tear duct opening .....................
Removal of tear gland ........................
Partial removal, tear gland ..................
Biopsy of tear gland ............................
Removal of tear sac ............................
Biopsy of tear sac ...............................
Clearance of tear duct ........................
Remove tear gland lesion ...................
Remove tear gland lesion ...................
Repair tear ducts ................................
Revise tear duct opening ....................
Create tear sac drain ..........................
Create tear duct drain .........................
Create tear duct drain .........................
Close tear duct opening ......................
Close tear duct opening ......................
Close tear system fistula ....................
Dilate tear duct opening ......................
Probe nasolacrimal duct .....................
Probe nasolacrimal duct .....................
Probe nasolacrimal duct .....................
Probe nl duct w/balloon ......................
Explore/irrigate tear ducts ...................
Injection for tear sac x-ray ..................
Tear duct system surgery ...................
Drain external ear lesion .....................
Drain external ear lesion .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
6.84
5.19
5.46
7.38
6.23
3.70
3.21
5.37
6.08
3.42
3.09
5.94
5.84
3.62
6.27
1.35
5.88
5.75
8.83
9.87
12.96
12.93
9.21
0.00
1.39
0.85
1.35
1.79
2.38
4.99
1.86
0.49
6.44
8.43
8.22
9.25
5.63
8.26
4.84
5.04
8.41
4.97
0.00
1.71
2.32
0.96
12.49
12.41
4.60
8.58
4.42
3.67
11.93
14.86
7.67
2.08
9.78
9.70
9.87
1.75
1.38
8.09
0.96
2.63
2.39
3.24
3.00
1.27
0.80
0.00
1.47
2.13
NA
5.55
6.17
NA
13.12
4.74
4.31
6.36
6.72
4.61
4.15
6.43
6.90
4.36
6.76
3.83
6.65
6.81
8.04
NA
NA
NA
NA
0.00
1.23
0.60
2.36
3.07
4.32
6.63
1.58
0.45
9.15
NA
NA
NA
7.40
NA
6.87
6.43
NA
NA
0.00
4.42
4.58
1.25
NA
NA
5.21
NA
NA
5.59
NA
NA
NA
3.03
NA
NA
NA
2.58
1.83
NA
1.77
3.39
NA
6.41
12.73
1.51
0.72
0.00
2.88
2.99
NA
6.09
7.10
NA
16.02
5.54
5.15
7.20
7.58
5.40
5.03
7.27
7.91
5.04
7.63
4.60
7.64
7.74
8.58
NA
NA
NA
NA
0.00
1.32
0.65
2.80
3.58
5.14
7.67
1.70
0.49
10.21
NA
NA
NA
8.41
NA
7.87
7.23
NA
NA
0.00
5.16
5.39
1.67
NA
NA
6.27
NA
NA
6.88
NA
NA
NA
3.60
NA
NA
NA
3.06
2.05
NA
1.86
3.52
NA
7.32
12.73
1.55
0.80
0.00
2.88
2.96
4.46
4.12
4.16
5.04
4.73
2.67
2.43
4.14
4.40
2.55
2.33
4.32
4.05
1.78
3.58
1.22
4.37
4.30
5.74
6.17
7.70
7.68
5.94
0.00
1.05
0.35
0.86
1.48
1.69
4.02
1.47
0.29
5.30
6.09
5.91
6.37
4.44
5.91
3.86
3.95
5.97
4.05
0.00
1.21
1.41
1.18
9.51
8.90
2.02
6.49
1.56
2.07
8.48
9.66
5.55
1.58
6.87
6.97
7.42
1.45
1.25
5.74
1.41
2.68
2.12
2.43
2.51
1.28
0.60
0.00
1.34
1.61
4.74
4.73
4.55
4.91
5.13
2.86
2.61
4.45
4.73
2.72
2.54
4.64
4.36
1.97
3.99
1.24
4.79
4.66
5.65
6.72
8.51
8.45
6.44
0.00
1.13
0.39
0.90
1.56
1.80
4.31
1.56
0.31
5.41
6.32
6.16
6.83
4.58
6.14
3.98
4.06
6.18
4.39
0.00
1.52
1.76
1.22
9.62
9.77
2.06
6.95
1.79
2.36
8.93
10.50
5.77
1.69
7.36
7.41
7.84
1.54
1.28
4.46
1.44
2.67
2.27
2.62
2.51
1.20
0.64
0.00
1.35
1.72
Malpractice
RVUs 2
0.46
0.28
0.31
0.31
0.28
0.19
0.16
0.28
0.36
0.17
0.15
0.30
0.30
0.19
0.39
0.06
0.36
0.33
0.37
0.53
0.75
0.75
0.50
0.00
0.06
0.04
0.07
0.09
0.12
0.24
0.09
0.02
0.27
0.44
0.35
0.54
0.24
0.36
0.21
0.22
0.36
0.44
0.00
0.08
0.11
0.05
0.55
0.55
0.23
0.37
0.22
0.18
0.52
0.80
0.32
0.10
0.44
0.52
0.43
0.09
0.06
0.35
0.05
0.10
0.13
0.17
0.16
0.06
0.04
0.00
0.12
0.17
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00266
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
010
090
010
090
090
090
090
090
090
090
YYY
010
000
000
010
010
090
010
000
090
090
090
090
090
090
090
090
090
010
YYY
010
010
010
090
090
000
090
000
010
090
090
090
010
090
090
090
010
010
090
010
010
010
010
010
010
000
YYY
010
010
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66487
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
69020
69090
69100
69105
69110
69120
69140
69145
69150
69155
69200
69205
69210
69220
69222
69300
69310
69320
69399
69400
69401
69405
69420
69421
69424
69433
69436
69440
69450
69501
69502
69505
69511
69530
69535
69540
69550
69552
69554
69601
69602
69603
69604
69605
69610
69620
69631
69632
69633
69635
69636
69637
69641
69642
69643
69644
69645
69646
69650
69660
69661
69662
69666
69667
69670
69676
69700
69710
69711
69714
69715
69717
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
N
A
A
A
A
A
A
A
A
A
A
A
A
A
R
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Drain outer ear canal lesion ...............
Pierce earlobes ...................................
Biopsy of external ear .........................
Biopsy of external ear canal ...............
Remove external ear, partial ..............
Removal of external ear .....................
Remove ear canal lesion(s) ................
Remove ear canal lesion(s) ................
Extensive ear canal surgery ...............
Extensive ear/neck surgery ................
Clear outer ear canal ..........................
Clear outer ear canal ..........................
Remove impacted ear wax .................
Clean out mastoid cavity ....................
Clean out mastoid cavity ....................
Revise external ear .............................
Rebuild outer ear canal ......................
Rebuild outer ear canal ......................
Outer ear surgery procedure ..............
Inflate middle ear canal ......................
Inflate middle ear canal ......................
Catheterize middle ear canal ..............
Incision of eardrum .............................
Incision of eardrum .............................
Remove ventilating tube .....................
Create eardrum opening .....................
Create eardrum opening .....................
Exploration of middle ear ....................
Eardrum revision .................................
Mastoidectomy ....................................
Mastoidectomy ....................................
Remove mastoid structures ................
Extensive mastoid surgery ..................
Extensive mastoid surgery ..................
Remove part of temporal bone ...........
Remove ear lesion ..............................
Remove ear lesion ..............................
Remove ear lesion ..............................
Remove ear lesion ..............................
Mastoid surgery revision .....................
Mastoid surgery revision .....................
Mastoid surgery revision .....................
Mastoid surgery revision .....................
Mastoid surgery revision .....................
Repair of eardrum ...............................
Repair of eardrum ...............................
Repair eardrum structures ..................
Rebuild eardrum structures ................
Rebuild eardrum structures ................
Repair eardrum structures ..................
Rebuild eardrum structures ................
Rebuild eardrum structures ................
Revise middle ear & mastoid ..............
Revise middle ear & mastoid ..............
Revise middle ear & mastoid ..............
Revise middle ear & mastoid ..............
Revise middle ear & mastoid ..............
Revise middle ear & mastoid ..............
Release middle ear bone ....................
Revise middle ear bone ......................
Revise middle ear bone ......................
Revise middle ear bone ......................
Repair middle ear structures ..............
Repair middle ear structures ..............
Remove mastoid air cells ...................
Remove middle ear nerve ..................
Close mastoid fistula ...........................
Implant/replace hearing aid ................
Remove/repair hearing aid .................
Implant temple bone w/stimul .............
Temple bne implnt w/stimulat .............
Temple bone implant revision .............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.50
0.00
0.81
0.85
3.47
4.08
8.03
2.65
13.49
23.06
0.77
1.20
0.61
0.83
1.42
6.69
10.85
17.03
0.00
0.83
0.63
2.65
1.35
1.75
0.85
1.54
1.98
7.62
5.61
9.12
12.44
13.05
13.58
20.24
37.27
1.22
11.04
19.69
35.71
13.31
13.64
14.08
14.08
18.55
4.44
5.94
9.93
12.82
12.17
13.39
15.29
15.18
12.77
16.91
15.45
17.09
16.57
18.23
9.71
11.94
15.80
15.49
9.80
9.81
11.62
9.58
8.28
0.00
10.50
14.31
18.80
15.29
4.09
0.00
1.85
2.64
7.83
NA
NA
7.03
NA
NA
2.15
NA
0.58
2.56
3.97
10.71
NA
NA
0.00
2.81
1.53
3.65
3.32
NA
2.34
3.32
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.90
NA
NA
NA
NA
NA
NA
NA
NA
4.91
10.90
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
4.04
0.00
1.78
2.49
7.29
NA
NA
6.40
NA
NA
2.27
NA
0.60
2.46
3.91
7.46
NA
NA
0.00
2.49
1.38
3.58
3.23
NA
2.26
3.20
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.82
NA
NA
NA
NA
NA
NA
NA
NA
5.23
11.01
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
1.90
0.00
0.39
0.71
4.44
5.36
13.21
3.37
11.45
16.98
0.61
1.24
0.17
0.68
1.90
5.18
15.48
20.05
0.00
0.68
0.59
1.96
1.56
1.85
0.68
1.59
1.90
9.11
7.61
8.65
11.04
16.14
16.32
19.65
26.75
1.85
14.27
18.18
23.98
11.91
12.80
16.43
12.77
19.28
2.58
5.83
11.52
13.30
13.08
16.28
18.19
18.10
12.47
15.52
14.15
18.72
18.58
19.10
9.53
10.49
13.46
12.50
9.80
9.83
11.24
10.60
8.67
0.00
10.40
11.78
13.32
11.95
1.98
0.00
0.39
0.74
4.45
5.77
13.24
3.33
12.42
18.25
0.58
1.30
0.20
0.70
1.98
4.70
15.88
20.94
0.00
0.67
0.62
2.14
1.57
2.01
0.68
1.61
2.09
8.94
7.32
8.82
11.31
16.66
16.89
20.63
29.34
1.91
14.56
19.42
27.15
12.29
13.01
17.39
13.23
20.11
2.93
6.06
11.36
13.38
13.06
16.51
18.74
18.66
12.62
15.90
14.48
19.56
19.30
19.92
9.72
10.83
14.07
13.12
9.88
9.90
11.47
10.67
8.96
0.00
10.59
12.22
14.17
13.21
Malpractice
RVUs 2
0.12
0.00
0.03
0.07
0.30
0.38
0.65
0.21
1.22
1.93
0.06
0.10
0.05
0.07
0.12
0.72
0.85
1.37
0.00
0.07
0.05
0.21
0.11
0.15
0.07
0.13
0.19
0.61
0.45
0.73
1.00
1.05
1.09
1.54
2.93
0.10
0.89
1.59
2.92
1.07
1.10
1.14
1.14
1.50
0.36
0.48
0.80
1.03
0.98
1.08
1.23
1.22
1.03
1.36
1.24
1.37
1.33
1.46
0.78
0.96
1.27
1.25
0.79
0.79
0.93
0.81
0.67
0.00
0.83
1.13
1.48
0.90
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00267
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
010
XXX
000
000
090
090
090
090
090
090
000
010
000
000
010
YYY
090
090
YYY
000
000
010
010
010
000
010
010
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
010
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
XXX
090
090
090
090
66488
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
69718
69720
69725
69740
69745
69799
69801
69802
69805
69806
69820
69840
69905
69910
69915
69930
69949
69950
69955
69960
69970
69979
69990
70010
70010
70010
70015
70015
70015
70030
70030
70030
70100
70100
70100
70110
70110
70110
70120
70120
70120
70130
70130
70130
70134
70134
70134
70140
70140
70140
70150
70150
70150
70160
70160
70160
70170
70170
70170
70190
70190
70190
70200
70200
70200
70210
70210
70210
70220
70220
70220
70240
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
C
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Revise temple bone implant ...............
Release facial nerve ...........................
Release facial nerve ...........................
Repair facial nerve ..............................
Repair facial nerve ..............................
Middle ear surgery procedure .............
Incise inner ear ...................................
Incise inner ear ...................................
Explore inner ear ................................
Explore inner ear ................................
Establish inner ear window .................
Revise inner ear window ....................
Remove inner ear ...............................
Remove inner ear & mastoid ..............
Incise inner ear nerve .........................
Implant cochlear device ......................
Inner ear surgery procedure ...............
Incise inner ear nerve .........................
Release facial nerve ...........................
Release inner ear canal ......................
Remove inner ear lesion .....................
Temporal bone surgery .......................
Microsurgery add-on ...........................
Contrast x-ray of brain ........................
Contrast x-ray of brain ........................
Contrast x-ray of brain ........................
Contrast x-ray of brain ........................
Contrast x-ray of brain ........................
Contrast x-ray of brain ........................
X-ray eye for foreign body ..................
X-ray eye for foreign body ..................
X-ray eye for foreign body ..................
X-ray exam of jaw ...............................
X-ray exam of jaw ...............................
X-ray exam of jaw ...............................
X-ray exam of jaw ...............................
X-ray exam of jaw ...............................
X-ray exam of jaw ...............................
X-ray exam of mastoids ......................
X-ray exam of mastoids ......................
X-ray exam of mastoids ......................
X-ray exam of mastoids ......................
X-ray exam of mastoids ......................
X-ray exam of mastoids ......................
X-ray exam of middle ear ...................
X-ray exam of middle ear ...................
X-ray exam of middle ear ...................
X-ray exam of facial bones .................
X-ray exam of facial bones .................
X-ray exam of facial bones .................
X-ray exam of facial bones .................
X-ray exam of facial bones .................
X-ray exam of facial bones .................
X-ray exam of nasal bones .................
X-ray exam of nasal bones .................
X-ray exam of nasal bones .................
X-ray exam of tear duct ......................
X-ray exam of tear duct ......................
X-ray exam of tear duct ......................
X-ray exam of eye sockets .................
X-ray exam of eye sockets .................
X-ray exam of eye sockets .................
X-ray exam of eye sockets .................
X-ray exam of eye sockets .................
X-ray exam of eye sockets .................
X-ray exam of sinuses ........................
X-ray exam of sinuses ........................
X-ray exam of sinuses ........................
X-ray exam of sinuses ........................
X-ray exam of sinuses ........................
X-ray exam of sinuses ........................
X-ray exam, pituitary saddle ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
19.05
14.57
27.44
16.18
16.91
0.00
8.61
13.39
14.55
12.52
10.40
10.32
11.15
13.80
22.65
17.60
0.00
27.44
29.22
29.22
32.21
0.00
3.46
1.19
0.00
1.19
1.19
0.00
1.19
0.17
0.00
0.17
0.18
0.00
0.18
0.25
0.00
0.25
0.18
0.00
0.18
0.34
0.00
0.34
0.34
0.00
0.34
0.19
0.00
0.19
0.26
0.00
0.26
0.17
0.00
0.17
0.00
0.00
0.30
0.21
0.00
0.21
0.28
0.00
0.28
0.17
0.00
0.17
0.25
0.00
0.25
0.19
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
0.00
NA
2.82
2.40
0.42
2.92
2.49
0.43
0.61
0.55
0.06
0.63
0.58
0.05
0.81
0.72
0.09
0.69
0.64
0.05
1.15
1.04
0.11
0.92
0.80
0.12
0.54
0.49
0.05
0.85
0.77
0.08
0.71
0.65
0.06
0.00
0.00
0.10
0.72
0.65
0.07
0.87
0.78
0.09
0.58
0.53
0.05
0.73
0.65
0.08
0.61
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
0.00
NA
3.76
3.36
0.40
2.33
1.92
0.41
0.54
0.48
0.06
0.61
0.55
0.06
0.75
0.67
0.08
0.69
0.63
0.06
1.02
0.91
0.11
0.87
0.76
0.11
0.62
0.56
0.06
0.85
0.77
0.08
0.64
0.58
0.06
0.00
0.00
0.10
0.70
0.63
0.07
0.87
0.78
0.09
0.62
0.57
0.05
0.80
0.72
0.08
0.54
13.40
14.01
18.01
11.58
9.93
0.00
9.61
11.86
10.89
10.39
10.24
11.37
11.03
10.88
14.81
13.10
0.00
16.84
19.38
17.90
19.51
0.00
1.27
NA
NA
0.42
NA
NA
0.43
NA
NA
0.06
NA
NA
0.05
NA
NA
0.09
NA
NA
0.05
NA
NA
0.11
NA
NA
0.12
NA
NA
0.05
NA
NA
0.08
NA
NA
0.06
NA
NA
0.10
NA
NA
0.07
NA
NA
0.09
NA
NA
0.05
NA
NA
0.08
NA
14.35
14.26
19.07
12.49
12.44
0.00
9.54
12.09
11.38
10.71
10.73
12.27
11.19
11.39
15.63
13.92
0.00
17.86
20.37
18.97
21.39
0.00
1.53
NA
NA
0.40
NA
NA
0.41
NA
NA
0.06
NA
NA
0.06
NA
NA
0.08
NA
NA
0.06
NA
NA
0.11
NA
NA
0.11
NA
NA
0.06
NA
NA
0.08
NA
NA
0.06
NA
NA
0.10
NA
NA
0.07
NA
NA
0.09
NA
NA
0.05
NA
NA
0.08
NA
Malpractice
RVUs 2
3.22
1.16
2.45
1.27
1.14
0.00
0.69
1.06
1.12
1.00
0.90
0.79
0.90
1.07
1.70
1.36
0.00
2.29
2.49
2.18
2.42
0.00
0.89
0.27
0.22
0.05
0.16
0.08
0.08
0.03
0.02
0.01
0.03
0.02
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.07
0.05
0.02
0.07
0.05
0.02
0.05
0.04
0.01
0.06
0.05
0.01
0.03
0.02
0.01
0.00
0.00
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00268
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
YYY
090
090
090
090
090
090
090
090
090
090
YYY
090
090
090
090
YYY
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66489
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
70240
70240
70250
70250
70250
70260
70260
70260
70300
70300
70300
70310
70310
70310
70320
70320
70320
70328
70328
70328
70330
70330
70330
70332
70332
70332
70336
70336
70336
70350
70350
70350
70355
70355
70355
70360
70360
70360
70370
70370
70370
70371
70371
70371
70373
70373
70373
70380
70380
70380
70390
70390
70390
70450
70450
70450
70460
70460
70460
70470
70470
70470
70480
70480
70480
70481
70481
70481
70482
70482
70482
70486
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
X-ray exam, pituitary saddle ...............
X-ray exam, pituitary saddle ...............
X-ray exam of skull .............................
X-ray exam of skull .............................
X-ray exam of skull .............................
X-ray exam of skull .............................
X-ray exam of skull .............................
X-ray exam of skull .............................
X-ray exam of teeth ............................
X-ray exam of teeth ............................
X-ray exam of teeth ............................
X-ray exam of teeth ............................
X-ray exam of teeth ............................
X-ray exam of teeth ............................
Full mouth x-ray of teeth .....................
Full mouth x-ray of teeth .....................
Full mouth x-ray of teeth .....................
X-ray exam of jaw joint .......................
X-ray exam of jaw joint .......................
X-ray exam of jaw joint .......................
X-ray exam of jaw joints .....................
X-ray exam of jaw joints .....................
X-ray exam of jaw joints .....................
X-ray exam of jaw joint .......................
X-ray exam of jaw joint .......................
X-ray exam of jaw joint .......................
Magnetic image, jaw joint ...................
Magnetic image, jaw joint ...................
Magnetic image, jaw joint ...................
X-ray head for orthodontia ..................
X-ray head for orthodontia ..................
X-ray head for orthodontia ..................
Panoramic x-ray of jaws .....................
Panoramic x-ray of jaws .....................
Panoramic x-ray of jaws .....................
X-ray exam of neck .............................
X-ray exam of neck .............................
X-ray exam of neck .............................
Throat x-ray & fluoroscopy .................
Throat x-ray & fluoroscopy .................
Throat x-ray & fluoroscopy .................
Speech evaluation, complex ...............
Speech evaluation, complex ...............
Speech evaluation, complex ...............
Contrast x-ray of larynx ......................
Contrast x-ray of larynx ......................
Contrast x-ray of larynx ......................
X-ray exam of salivary gland ..............
X-ray exam of salivary gland ..............
X-ray exam of salivary gland ..............
X-ray exam of salivary duct ................
X-ray exam of salivary duct ................
X-ray exam of salivary duct ................
Ct head/brain w/o dye .........................
Ct head/brain w/o dye .........................
Ct head/brain w/o dye .........................
Ct head/brain w/dye ............................
Ct head/brain w/dye ............................
Ct head/brain w/dye ............................
Ct head/brain w/o & w/dye .................
Ct head/brain w/o & w/dye .................
Ct head/brain w/o & w/dye .................
Ct orbit/ear/fossa w/o dye ...................
Ct orbit/ear/fossa w/o dye ...................
Ct orbit/ear/fossa w/o dye ...................
Ct orbit/ear/fossa w/dye ......................
Ct orbit/ear/fossa w/dye ......................
Ct orbit/ear/fossa w/dye ......................
Ct orbit/ear/fossa w/o&w/dye ..............
Ct orbit/ear/fossa w/o&w/dye ..............
Ct orbit/ear/fossa w/o&w/dye ..............
Ct maxillofacial w/o dye ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.19
0.24
0.00
0.24
0.34
0.00
0.34
0.10
0.00
0.10
0.16
0.00
0.16
0.22
0.00
0.22
0.18
0.00
0.18
0.24
0.00
0.24
0.54
0.00
0.54
1.48
0.00
1.48
0.17
0.00
0.17
0.20
0.00
0.20
0.17
0.00
0.17
0.32
0.00
0.32
0.84
0.00
0.84
0.44
0.00
0.44
0.17
0.00
0.17
0.38
0.00
0.38
0.85
0.00
0.85
1.13
0.00
1.13
1.27
0.00
1.27
1.28
0.00
1.28
1.38
0.00
1.38
1.45
0.00
1.45
1.14
0.55
0.06
0.70
0.63
0.07
0.88
0.78
0.10
0.24
0.21
0.03
0.82
0.77
0.05
1.06
0.99
0.07
0.63
0.57
0.06
1.01
0.93
0.08
1.45
1.29
0.16
12.15
11.65
0.50
0.32
0.27
0.05
0.30
0.23
0.07
0.56
0.51
0.05
1.65
1.55
0.10
1.47
1.21
0.26
1.58
1.47
0.11
0.82
0.76
0.06
2.33
2.20
0.13
4.91
4.61
0.30
6.51
6.11
0.40
7.93
7.48
0.45
8.48
8.03
0.45
9.97
9.48
0.49
11.40
10.89
0.51
6.78
0.48
0.06
0.69
0.62
0.07
0.94
0.83
0.11
0.27
0.23
0.04
0.65
0.59
0.06
0.96
0.89
0.07
0.59
0.53
0.06
0.96
0.88
0.08
1.88
1.70
0.18
11.91
11.42
0.49
0.39
0.33
0.06
0.47
0.40
0.07
0.52
0.46
0.06
1.53
1.43
0.10
1.93
1.66
0.27
1.75
1.62
0.13
0.78
0.72
0.06
2.12
1.99
0.13
4.95
4.66
0.29
6.27
5.88
0.39
7.70
7.27
0.43
6.80
6.37
0.43
8.04
7.57
0.47
9.47
8.98
0.49
5.93
NA
0.06
NA
NA
0.07
NA
NA
0.10
NA
NA
0.03
NA
NA
0.05
NA
NA
0.07
NA
NA
0.06
NA
NA
0.08
NA
NA
0.16
NA
NA
0.50
NA
NA
0.05
NA
NA
0.07
NA
NA
0.05
NA
NA
0.10
NA
NA
0.26
NA
NA
0.11
NA
NA
0.06
NA
NA
0.13
NA
NA
0.30
NA
NA
0.40
NA
NA
0.45
NA
NA
0.45
NA
NA
0.49
NA
NA
0.51
NA
NA
0.06
NA
NA
0.07
NA
NA
0.11
NA
NA
0.04
NA
NA
0.06
NA
NA
0.07
NA
NA
0.06
NA
NA
0.08
NA
NA
0.18
NA
NA
0.49
NA
NA
0.06
NA
NA
0.07
NA
NA
0.06
NA
NA
0.10
NA
NA
0.27
NA
NA
0.13
NA
NA
0.06
NA
NA
0.13
NA
NA
0.29
NA
NA
0.39
NA
NA
0.43
NA
NA
0.43
NA
NA
0.47
NA
NA
0.49
NA
Malpractice
RVUs 2
0.02
0.01
0.05
0.04
0.01
0.08
0.06
0.02
0.03
0.02
0.01
0.03
0.02
0.01
0.06
0.05
0.01
0.03
0.02
0.01
0.06
0.05
0.01
0.14
0.12
0.02
0.66
0.59
0.07
0.03
0.02
0.01
0.05
0.04
0.01
0.03
0.02
0.01
0.08
0.07
0.01
0.16
0.12
0.04
0.13
0.11
0.02
0.05
0.04
0.01
0.13
0.11
0.02
0.29
0.25
0.04
0.35
0.30
0.05
0.43
0.37
0.06
0.31
0.25
0.06
0.36
0.30
0.06
0.43
0.37
0.06
0.30
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00269
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66490
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
70486
70486
70487
70487
70487
70488
70488
70488
70490
70490
70490
70491
70491
70491
70492
70492
70492
70496
70496
70496
70498
70498
70498
70540
70540
70540
70542
70542
70542
70543
70543
70543
70544
70544
70544
70545
70545
70545
70546
70546
70546
70547
70547
70547
70548
70548
70548
70549
70549
70549
70551
70551
70551
70552
70552
70552
70553
70553
70553
70554
70554
70554
70555
70555
70555
70557
70557
70557
70558
70558
70558
70559
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Ct maxillofacial w/o dye ......................
Ct maxillofacial w/o dye ......................
Ct maxillofacial w/dye .........................
Ct maxillofacial w/dye .........................
Ct maxillofacial w/dye .........................
Ct maxillofacial w/o & w/dye ...............
Ct maxillofacial w/o & w/dye ...............
Ct maxillofacial w/o & w/dye ...............
Ct soft tissue neck w/o dye ................
Ct soft tissue neck w/o dye ................
Ct soft tissue neck w/o dye ................
Ct soft tissue neck w/dye ....................
Ct soft tissue neck w/dye ....................
Ct soft tissue neck w/dye ....................
Ct sft tsue nck w/o & w/dye ................
Ct sft tsue nck w/o & w/dye ................
Ct sft tsue nck w/o & w/dye ................
Ct angiography, head .........................
Ct angiography, head .........................
Ct angiography, head .........................
Ct angiography, neck ..........................
Ct angiography, neck ..........................
Ct angiography, neck ..........................
Mri orbit/face/neck w/o dye .................
Mri orbit/face/neck w/o dye .................
Mri orbit/face/neck w/o dye .................
Mri orbit/face/neck w/dye ....................
Mri orbit/face/neck w/dye ....................
Mri orbit/face/neck w/dye ....................
Mri orbt/fac/nck w/o & w/dye ..............
Mri orbt/fac/nck w/o & w/dye ..............
Mri orbt/fac/nck w/o & w/dye ..............
Mr angiography head w/o dye ............
Mr angiography head w/o dye ............
Mr angiography head w/o dye ............
Mr angiography head w/dye ...............
Mr angiography head w/dye ...............
Mr angiography head w/dye ...............
Mr angiograph head w/o&w/dye .........
Mr angiograph head w/o&w/dye .........
Mr angiograph head w/o&w/dye .........
Mr angiography neck w/o dye ............
Mr angiography neck w/o dye ............
Mr angiography neck w/o dye ............
Mr angiography neck w/dye ................
Mr angiography neck w/dye ................
Mr angiography neck w/dye ................
Mr angiograph neck w/o&w/dye .........
Mr angiograph neck w/o&w/dye .........
Mr angiograph neck w/o&w/dye .........
Mri brain w/o dye ................................
Mri brain w/o dye ................................
Mri brain w/o dye ................................
Mri brain w/dye ...................................
Mri brain w/dye ...................................
Mri brain w/dye ...................................
Mri brain w/o & w/dye .........................
Mri brain w/o & w/dye .........................
Mri brain w/o & w/dye .........................
Fmri brain by tech ...............................
Fmri brain by tech ...............................
Fmri brain by tech ...............................
Fmri brain by phys/psych ....................
Fmri brain by phys/psych ....................
Fmri brain by phys/psych ....................
Mri brain w/o dye ................................
Mri brain w/o dye ................................
Mri brain w/o dye ................................
Mri brain w/dye ...................................
Mri brain w/dye ...................................
Mri brain w/dye ...................................
Mri brain w/o & w/dye .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.14
1.30
0.00
1.30
1.42
0.00
1.42
1.28
0.00
1.28
1.38
0.00
1.38
1.45
0.00
1.45
1.75
0.00
1.75
1.75
0.00
1.75
1.35
0.00
1.35
1.62
0.00
1.62
2.15
0.00
2.15
1.20
0.00
1.20
1.20
0.00
1.20
1.80
0.00
1.80
1.20
0.00
1.20
1.20
0.00
1.20
1.80
0.00
1.80
1.48
0.00
1.48
1.78
0.00
1.78
2.36
0.00
2.36
2.11
0.00
2.11
0.00
0.00
2.54
0.00
0.00
2.90
0.00
0.00
3.20
0.00
6.39
0.39
8.34
7.88
0.46
10.39
9.90
0.49
6.48
6.03
0.45
8.03
7.54
0.49
10.03
9.52
0.51
17.08
16.45
0.63
17.22
16.57
0.65
14.16
13.70
0.46
15.28
14.72
0.56
18.75
18.01
0.74
15.84
15.42
0.42
15.73
15.31
0.42
24.00
23.38
0.62
15.77
15.36
0.41
16.63
16.21
0.42
24.02
23.39
0.63
14.42
13.91
0.51
15.58
14.96
0.62
18.06
17.24
0.82
15.40
14.71
0.69
0.00
0.00
0.90
0.00
0.00
1.03
0.00
0.00
1.09
0.00
5.55
0.38
7.21
6.77
0.44
8.96
8.48
0.48
5.81
5.37
0.44
7.07
6.60
0.47
8.78
8.29
0.49
14.12
13.52
0.60
14.19
13.58
0.61
12.90
12.45
0.45
14.61
14.07
0.54
22.16
21.44
0.72
13.72
13.31
0.41
13.65
13.25
0.40
23.50
22.89
0.61
13.68
13.28
0.40
14.11
13.70
0.41
23.50
22.89
0.61
13.05
12.55
0.50
14.79
14.19
0.60
21.86
21.06
0.80
15.40
14.71
0.69
0.00
0.00
0.90
0.00
0.00
1.08
0.00
0.00
1.16
0.00
NA
0.39
NA
NA
0.46
NA
NA
0.49
NA
NA
0.45
NA
NA
0.49
NA
NA
0.51
NA
NA
0.63
NA
NA
0.65
NA
NA
0.46
NA
NA
0.56
NA
NA
0.74
NA
NA
0.42
NA
NA
0.42
NA
NA
0.62
NA
NA
0.41
NA
NA
0.42
NA
NA
0.63
NA
NA
0.51
NA
NA
0.62
NA
NA
0.82
NA
NA
0.69
NA
NA
0.90
NA
NA
1.03
NA
NA
1.09
NA
NA
0.38
NA
NA
0.44
NA
NA
0.48
NA
NA
0.44
NA
NA
0.47
NA
NA
0.49
NA
NA
0.60
NA
NA
0.61
NA
NA
0.45
NA
NA
0.54
NA
NA
0.72
NA
NA
0.41
NA
NA
0.40
NA
NA
0.61
NA
NA
0.40
NA
NA
0.41
NA
NA
0.61
NA
NA
0.50
NA
NA
0.60
NA
NA
0.80
NA
NA
0.69
NA
NA
0.90
NA
NA
1.08
NA
NA
1.16
NA
Malpractice
RVUs 2
0.25
0.05
0.36
0.30
0.06
0.43
0.37
0.06
0.31
0.25
0.06
0.36
0.30
0.06
0.43
0.37
0.06
0.66
0.58
0.08
0.66
0.58
0.08
0.45
0.39
0.06
0.54
0.47
0.07
0.94
0.84
0.10
0.64
0.59
0.05
0.64
0.59
0.05
0.67
0.59
0.08
0.64
0.59
0.05
0.64
0.59
0.05
0.67
0.59
0.08
0.66
0.59
0.07
0.78
0.70
0.08
1.41
1.31
0.10
0.92
0.82
0.10
0.00
0.00
0.11
0.00
0.00
0.08
0.00
0.00
0.10
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00270
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66491
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
70559
70559
71010
71010
71010
71015
71015
71015
71020
71020
71020
71021
71021
71021
71022
71022
71022
71023
71023
71023
71030
71030
71030
71034
71034
71034
71035
71035
71035
71040
71040
71040
71060
71060
71060
71090
71090
71090
71100
71100
71100
71101
71101
71101
71110
71110
71110
71111
71111
71111
71120
71120
71120
71130
71130
71130
71250
71250
71250
71260
71260
71260
71270
71270
71270
71275
71275
71275
71550
71550
71550
71551
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Mri brain w/o & w/dye .........................
Mri brain w/o & w/dye .........................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray and fluoroscopy ...............
Chest x-ray and fluoroscopy ...............
Chest x-ray and fluoroscopy ...............
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray and fluoroscopy ...............
Chest x-ray and fluoroscopy ...............
Chest x-ray and fluoroscopy ...............
Chest x-ray ..........................................
Chest x-ray ..........................................
Chest x-ray ..........................................
Contrast x-ray of bronchi ....................
Contrast x-ray of bronchi ....................
Contrast x-ray of bronchi ....................
Contrast x-ray of bronchi ....................
Contrast x-ray of bronchi ....................
Contrast x-ray of bronchi ....................
X-ray & pacemaker insertion ..............
X-ray & pacemaker insertion ..............
X-ray & pacemaker insertion ..............
X-ray exam of ribs ..............................
X-ray exam of ribs ..............................
X-ray exam of ribs ..............................
X-ray exam of ribs/chest .....................
X-ray exam of ribs/chest .....................
X-ray exam of ribs/chest .....................
X-ray exam of ribs ..............................
X-ray exam of ribs ..............................
X-ray exam of ribs ..............................
X-ray exam of ribs/chest .....................
X-ray exam of ribs/chest .....................
X-ray exam of ribs/chest .....................
X-ray exam of breastbone ..................
X-ray exam of breastbone ..................
X-ray exam of breastbone ..................
X-ray exam of breastbone ..................
X-ray exam of breastbone ..................
X-ray exam of breastbone ..................
Ct thorax w/o dye ................................
Ct thorax w/o dye ................................
Ct thorax w/o dye ................................
Ct thorax w/dye ...................................
Ct thorax w/dye ...................................
Ct thorax w/dye ...................................
Ct thorax w/o & w/dye ........................
Ct thorax w/o & w/dye ........................
Ct thorax w/o & w/dye ........................
Ct angiography, chest .........................
Ct angiography, chest .........................
Ct angiography, chest .........................
Mri chest w/o dye ................................
Mri chest w/o dye ................................
Mri chest w/o dye ................................
Mri chest w/dye ...................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
3.20
0.18
0.00
0.18
0.21
0.00
0.21
0.22
0.00
0.22
0.27
0.00
0.27
0.31
0.00
0.31
0.38
0.00
0.38
0.31
0.00
0.31
0.46
0.00
0.46
0.18
0.00
0.18
0.58
0.00
0.58
0.74
0.00
0.74
0.00
0.00
0.54
0.22
0.00
0.22
0.27
0.00
0.27
0.27
0.00
0.27
0.32
0.00
0.32
0.20
0.00
0.20
0.22
0.00
0.22
1.16
0.00
1.16
1.24
0.00
1.24
1.38
0.00
1.38
1.92
0.00
1.92
1.46
0.00
1.46
1.73
0.00
1.14
0.43
0.37
0.06
0.58
0.51
0.07
0.57
0.50
0.07
0.71
0.62
0.09
0.90
0.80
0.10
1.54
1.40
0.14
0.92
0.82
0.10
2.11
1.90
0.21
0.78
0.72
0.06
2.06
1.88
0.18
3.11
2.85
0.26
0.00
0.00
0.28
0.62
0.55
0.07
0.77
0.68
0.09
0.77
0.69
0.08
1.06
0.96
0.10
0.63
0.56
0.07
0.76
0.68
0.08
6.45
6.04
0.41
7.99
7.55
0.44
10.03
9.55
0.48
11.75
11.06
0.69
16.35
15.85
0.50
17.92
0.00
1.19
0.48
0.42
0.06
0.58
0.51
0.07
0.63
0.56
0.07
0.76
0.67
0.09
0.86
0.76
0.10
1.23
1.09
0.14
0.90
0.80
0.10
1.85
1.67
0.18
0.68
0.62
0.06
1.85
1.67
0.18
2.77
2.52
0.25
0.00
0.00
0.24
0.63
0.56
0.07
0.76
0.67
0.09
0.82
0.73
0.09
1.02
0.92
0.10
0.67
0.60
0.07
0.76
0.69
0.07
6.36
5.97
0.39
7.73
7.31
0.42
9.67
9.20
0.47
12.38
11.72
0.66
14.01
13.52
0.49
15.96
NA
1.14
NA
NA
0.06
NA
NA
0.07
NA
NA
0.07
NA
NA
0.09
NA
NA
0.10
NA
NA
0.14
NA
NA
0.10
NA
NA
0.21
NA
NA
0.06
NA
NA
0.18
NA
NA
0.26
NA
NA
0.28
NA
NA
0.07
NA
NA
0.09
NA
NA
0.08
NA
NA
0.10
NA
NA
0.07
NA
NA
0.08
NA
NA
0.41
NA
NA
0.44
NA
NA
0.48
NA
NA
0.69
NA
NA
0.50
NA
NA
1.19
NA
NA
0.06
NA
NA
0.07
NA
NA
0.07
NA
NA
0.09
NA
NA
0.10
NA
NA
0.14
NA
NA
0.10
NA
NA
0.18
NA
NA
0.06
NA
NA
0.18
NA
NA
0.25
NA
NA
0.24
NA
NA
0.07
NA
NA
0.09
NA
NA
0.09
NA
NA
0.10
NA
NA
0.07
NA
NA
0.07
NA
NA
0.39
NA
NA
0.42
NA
NA
0.47
NA
NA
0.66
NA
NA
0.49
NA
Malpractice
RVUs 2
0.00
0.12
0.03
0.02
0.01
0.03
0.02
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.06
0.05
0.01
0.06
0.05
0.01
0.06
0.05
0.01
0.10
0.08
0.02
0.03
0.02
0.01
0.11
0.08
0.03
0.16
0.13
0.03
0.00
0.00
0.02
0.05
0.04
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.07
0.06
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.36
0.31
0.05
0.42
0.37
0.05
0.52
0.46
0.06
0.48
0.39
0.09
0.51
0.45
0.06
0.60
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00271
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66492
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
71551
71551
71552
71552
71552
71555
71555
71555
72010
72010
72010
72020
72020
72020
72040
72040
72040
72050
72050
72050
72052
72052
72052
72069
72069
72069
72070
72070
72070
72072
72072
72072
72074
72074
72074
72080
72080
72080
72090
72090
72090
72100
72100
72100
72110
72110
72110
72114
72114
72114
72120
72120
72120
72125
72125
72125
72126
72126
72126
72127
72127
72127
72128
72128
72128
72129
72129
72129
72130
72130
72130
72131
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
R
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Mri chest w/dye ...................................
Mri chest w/dye ...................................
Mri chest w/o & w/dye ........................
Mri chest w/o & w/dye ........................
Mri chest w/o & w/dye ........................
Mri angio chest w or w/o dye .............
Mri angio chest w or w/o dye .............
Mri angio chest w or w/o dye .............
X-ray exam of spine ............................
X-ray exam of spine ............................
X-ray exam of spine ............................
X-ray exam of spine ............................
X-ray exam of spine ............................
X-ray exam of spine ............................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of neck spine ...................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of thoracic spine ..............
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of trunk spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
X-ray exam of lower spine ..................
Ct neck spine w/o dye ........................
Ct neck spine w/o dye ........................
Ct neck spine w/o dye ........................
Ct neck spine w/dye ...........................
Ct neck spine w/dye ...........................
Ct neck spine w/dye ...........................
Ct neck spine w/o & w/dye .................
Ct neck spine w/o & w/dye .................
Ct neck spine w/o & w/dye .................
Ct chest spine w/o dye .......................
Ct chest spine w/o dye .......................
Ct chest spine w/o dye .......................
Ct chest spine w/dye ..........................
Ct chest spine w/dye ..........................
Ct chest spine w/dye ..........................
Ct chest spine w/o & w/dye ................
Ct chest spine w/o & w/dye ................
Ct chest spine w/o & w/dye ................
Ct lumbar spine w/o dye .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.73
2.26
0.00
2.26
1.81
0.00
1.81
0.45
0.00
0.45
0.15
0.00
0.15
0.22
0.00
0.22
0.31
0.00
0.31
0.36
0.00
0.36
0.22
0.00
0.22
0.22
0.00
0.22
0.22
0.00
0.22
0.22
0.00
0.22
0.22
0.00
0.22
0.28
0.00
0.28
0.22
0.00
0.22
0.31
0.00
0.31
0.36
0.00
0.36
0.22
0.00
0.22
1.16
0.00
1.16
1.22
0.00
1.22
1.27
0.00
1.27
1.16
0.00
1.16
1.22
0.00
1.22
1.27
0.00
1.27
1.16
17.32
0.60
22.55
21.75
0.80
15.30
14.64
0.66
1.43
1.30
0.13
0.47
0.42
0.05
0.76
0.69
0.07
1.08
0.97
0.11
1.39
1.27
0.12
0.76
0.68
0.08
0.64
0.57
0.07
0.77
0.70
0.07
0.94
0.87
0.07
0.70
0.62
0.08
1.00
0.90
0.10
0.81
0.74
0.07
1.15
1.04
0.11
1.57
1.44
0.13
1.08
1.00
0.08
6.46
6.05
0.41
7.99
7.56
0.43
10.03
9.59
0.44
6.45
6.04
0.41
7.99
7.56
0.43
9.97
9.53
0.44
6.42
15.38
0.58
24.08
23.31
0.77
13.54
12.91
0.63
1.30
1.16
0.14
0.47
0.42
0.05
0.72
0.65
0.07
1.03
0.93
0.10
1.32
1.20
0.12
0.66
0.58
0.08
0.68
0.61
0.07
0.78
0.71
0.07
0.96
0.89
0.07
0.71
0.64
0.07
0.88
0.78
0.10
0.77
0.70
0.07
1.07
0.97
0.10
1.43
1.31
0.12
1.01
0.94
0.07
6.37
5.98
0.39
7.72
7.31
0.41
9.65
9.22
0.43
6.36
5.97
0.39
7.72
7.31
0.41
9.62
9.19
0.43
6.36
NA
0.60
NA
NA
0.80
NA
NA
0.66
NA
NA
0.13
NA
NA
0.05
NA
NA
0.07
NA
NA
0.11
NA
NA
0.12
NA
NA
0.08
NA
NA
0.07
NA
NA
0.07
NA
NA
0.07
NA
NA
0.08
NA
NA
0.10
NA
NA
0.07
NA
NA
0.11
NA
NA
0.13
NA
NA
0.08
NA
NA
0.41
NA
NA
0.43
NA
NA
0.44
NA
NA
0.41
NA
NA
0.43
NA
NA
0.44
NA
NA
0.58
NA
NA
0.77
NA
NA
0.63
NA
NA
0.14
NA
NA
0.05
NA
NA
0.07
NA
NA
0.10
NA
NA
0.12
NA
NA
0.08
NA
NA
0.07
NA
NA
0.07
NA
NA
0.07
NA
NA
0.07
NA
NA
0.10
NA
NA
0.07
NA
NA
0.10
NA
NA
0.12
NA
NA
0.07
NA
NA
0.39
NA
NA
0.41
NA
NA
0.43
NA
NA
0.39
NA
NA
0.41
NA
NA
0.43
NA
Malpractice
RVUs 2
0.52
0.08
0.78
0.68
0.10
0.67
0.59
0.08
0.08
0.06
0.02
0.03
0.02
0.01
0.05
0.04
0.01
0.07
0.06
0.01
0.08
0.06
0.02
0.03
0.02
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.07
0.06
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.07
0.06
0.01
0.08
0.06
0.02
0.07
0.06
0.01
0.36
0.31
0.05
0.42
0.37
0.05
0.52
0.46
0.06
0.36
0.31
0.05
0.42
0.37
0.05
0.52
0.46
0.06
0.36
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00272
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66493
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
72131
72131
72132
72132
72132
72133
72133
72133
72141
72141
72141
72142
72142
72142
72146
72146
72146
72147
72147
72147
72148
72148
72148
72149
72149
72149
72156
72156
72156
72157
72157
72157
72158
72158
72158
72159
72159
72159
72170
72170
72170
72190
72190
72190
72191
72191
72191
72192
72192
72192
72193
72193
72193
72194
72194
72194
72195
72195
72195
72196
72196
72196
72197
72197
72197
72198
72198
72198
72200
72200
72200
72202
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
N
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Ct lumbar spine w/o dye .....................
Ct lumbar spine w/o dye .....................
Ct lumbar spine w/dye ........................
Ct lumbar spine w/dye ........................
Ct lumbar spine w/dye ........................
Ct lumbar spine w/o & w/dye ..............
Ct lumbar spine w/o & w/dye ..............
Ct lumbar spine w/o & w/dye ..............
Mri neck spine w/o dye .......................
Mri neck spine w/o dye .......................
Mri neck spine w/o dye .......................
Mri neck spine w/dye ..........................
Mri neck spine w/dye ..........................
Mri neck spine w/dye ..........................
Mri chest spine w/o dye ......................
Mri chest spine w/o dye ......................
Mri chest spine w/o dye ......................
Mri chest spine w/dye .........................
Mri chest spine w/dye .........................
Mri chest spine w/dye .........................
Mri lumbar spine w/o dye ...................
Mri lumbar spine w/o dye ...................
Mri lumbar spine w/o dye ...................
Mri lumbar spine w/dye .......................
Mri lumbar spine w/dye .......................
Mri lumbar spine w/dye .......................
Mri neck spine w/o & w/dye ................
Mri neck spine w/o & w/dye ................
Mri neck spine w/o & w/dye ................
Mri chest spine w/o & w/dye ...............
Mri chest spine w/o & w/dye ...............
Mri chest spine w/o & w/dye ...............
Mri lumbar spine w/o & w/dye ............
Mri lumbar spine w/o & w/dye ............
Mri lumbar spine w/o & w/dye ............
Mr angio spine w/o&w/dye ..................
Mr angio spine w/o&w/dye ..................
Mr angio spine w/o&w/dye ..................
X-ray exam of pelvis ...........................
X-ray exam of pelvis ...........................
X-ray exam of pelvis ...........................
X-ray exam of pelvis ...........................
X-ray exam of pelvis ...........................
X-ray exam of pelvis ...........................
Ct angiograph pelv w/o&w/dye ...........
Ct angiograph pelv w/o&w/dye ...........
Ct angiograph pelv w/o&w/dye ...........
Ct pelvis w/o dye ................................
Ct pelvis w/o dye ................................
Ct pelvis w/o dye ................................
Ct pelvis w/dye ....................................
Ct pelvis w/dye ....................................
Ct pelvis w/dye ....................................
Ct pelvis w/o & w/dye .........................
Ct pelvis w/o & w/dye .........................
Ct pelvis w/o & w/dye .........................
Mri pelvis w/o dye ...............................
Mri pelvis w/o dye ...............................
Mri pelvis w/o dye ...............................
Mri pelvis w/dye ..................................
Mri pelvis w/dye ..................................
Mri pelvis w/dye ..................................
Mri pelvis w/o & w/dye ........................
Mri pelvis w/o & w/dye ........................
Mri pelvis w/o & w/dye ........................
Mr angio pelvis w/o & w/dye ...............
Mr angio pelvis w/o & w/dye ...............
Mr angio pelvis w/o & w/dye ...............
X-ray exam sacroiliac joints ................
X-ray exam sacroiliac joints ................
X-ray exam sacroiliac joints ................
X-ray exam sacroiliac joints ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.16
1.22
0.00
1.22
1.27
0.00
1.27
1.60
0.00
1.60
1.92
0.00
1.92
1.60
0.00
1.60
1.92
0.00
1.92
1.48
0.00
1.48
1.78
0.00
1.78
2.57
0.00
2.57
2.57
0.00
2.57
2.36
0.00
2.36
1.80
0.00
1.80
0.17
0.00
0.17
0.21
0.00
0.21
1.81
0.00
1.81
1.09
0.00
1.09
1.16
0.00
1.16
1.22
0.00
1.22
1.46
0.00
1.46
1.73
0.00
1.73
2.26
0.00
2.26
1.80
0.00
1.80
0.17
0.00
0.17
0.19
6.02
0.40
7.97
7.54
0.43
10.01
9.57
0.44
12.45
11.90
0.55
15.60
14.94
0.66
12.47
11.92
0.55
13.56
12.89
0.67
12.41
11.90
0.51
15.51
14.89
0.62
17.76
16.88
0.88
16.20
15.30
0.90
17.68
16.86
0.82
14.65
14.24
0.41
0.50
0.44
0.06
0.84
0.77
0.07
11.32
10.67
0.65
6.03
5.64
0.39
7.54
7.13
0.41
10.12
9.69
0.43
14.43
13.92
0.51
15.52
14.91
0.61
18.95
18.16
0.79
15.08
14.44
0.64
0.59
0.54
0.05
0.74
5.97
0.39
7.71
7.30
0.41
9.64
9.21
0.43
12.09
11.55
0.54
14.84
14.19
0.65
12.72
12.18
0.54
13.81
13.16
0.65
12.67
12.17
0.50
14.77
14.16
0.61
21.74
20.87
0.87
20.95
20.08
0.87
21.66
20.86
0.80
13.78
13.23
0.55
0.54
0.48
0.06
0.79
0.72
0.07
11.97
11.35
0.62
6.15
5.78
0.37
7.37
6.98
0.39
9.49
9.08
0.41
13.04
12.55
0.49
14.76
14.17
0.59
22.27
21.51
0.76
13.42
12.81
0.61
0.59
0.53
0.06
0.71
NA
0.40
NA
NA
0.43
NA
NA
0.44
NA
NA
0.55
NA
NA
0.66
NA
NA
0.55
NA
NA
0.67
NA
NA
0.51
NA
NA
0.62
NA
NA
0.88
NA
NA
0.90
NA
NA
0.82
NA
NA
0.41
NA
NA
0.06
NA
NA
0.07
NA
NA
0.65
NA
NA
0.39
NA
NA
0.41
NA
NA
0.43
NA
NA
0.51
NA
NA
0.61
NA
NA
0.79
NA
NA
0.64
NA
NA
0.05
NA
NA
0.39
NA
NA
0.41
NA
NA
0.43
NA
NA
0.54
NA
NA
0.65
NA
NA
0.54
NA
NA
0.65
NA
NA
0.50
NA
NA
0.61
NA
NA
0.87
NA
NA
0.87
NA
NA
0.80
NA
NA
0.55
NA
NA
0.06
NA
NA
0.07
NA
NA
0.62
NA
NA
0.37
NA
NA
0.39
NA
NA
0.41
NA
NA
0.49
NA
NA
0.59
NA
NA
0.76
NA
NA
0.61
NA
NA
0.06
NA
Malpractice
RVUs 2
0.31
0.05
0.42
0.37
0.05
0.52
0.46
0.06
0.66
0.59
0.07
0.79
0.70
0.09
0.71
0.64
0.07
0.79
0.70
0.09
0.71
0.64
0.07
0.78
0.70
0.08
1.42
1.31
0.11
1.42
1.31
0.11
1.41
1.31
0.10
0.74
0.64
0.10
0.03
0.02
0.01
0.05
0.04
0.01
0.47
0.39
0.08
0.36
0.31
0.05
0.41
0.36
0.05
0.48
0.43
0.05
0.51
0.45
0.06
0.60
0.52
0.08
1.02
0.92
0.10
0.67
0.59
0.08
0.03
0.02
0.01
0.05
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00273
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66494
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
72202
72202
72220
72220
72220
72240
72240
72240
72255
72255
72255
72265
72265
72265
72270
72270
72270
72275
72275
72275
72285
72285
72285
72291
72291
72291
72292
72292
72292
72295
72295
72295
73000
73000
73000
73010
73010
73010
73020
73020
73020
73030
73030
73030
73040
73040
73040
73050
73050
73050
73060
73060
73060
73070
73070
73070
73080
73080
73080
73085
73085
73085
73090
73090
73090
73092
73092
73092
73100
73100
73100
73110
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
X-ray exam sacroiliac joints ................
X-ray exam sacroiliac joints ................
X-ray exam of tailbone ........................
X-ray exam of tailbone ........................
X-ray exam of tailbone ........................
Contrast x-ray of neck spine ...............
Contrast x-ray of neck spine ...............
Contrast x-ray of neck spine ...............
Contrast x-ray, thorax spine ...............
Contrast x-ray, thorax spine ...............
Contrast x-ray, thorax spine ...............
Contrast x-ray, lower spine .................
Contrast x-ray, lower spine .................
Contrast x-ray, lower spine .................
Contrast x-ray, spine ...........................
Contrast x-ray, spine ...........................
Contrast x-ray, spine ...........................
Epidurography .....................................
Epidurography .....................................
Epidurography .....................................
X-ray c/t spine disk .............................
X-ray c/t spine disk .............................
X-ray c/t spine disk .............................
Perq vertebroplasty, fluor ....................
Perq vertebroplasty, fluor ....................
Perq vertebroplasty, fluor ....................
Perq vertebroplasty, ct ........................
Perq vertebroplasty, ct ........................
Perq vertebroplasty, ct ........................
X-ray of lower spine disk ....................
X-ray of lower spine disk ....................
X-ray of lower spine disk ....................
X-ray exam of collar bone ..................
X-ray exam of collar bone ..................
X-ray exam of collar bone ..................
X-ray exam of shoulder blade ............
X-ray exam of shoulder blade ............
X-ray exam of shoulder blade ............
X-ray exam of shoulder ......................
X-ray exam of shoulder ......................
X-ray exam of shoulder ......................
X-ray exam of shoulder ......................
X-ray exam of shoulder ......................
X-ray exam of shoulder ......................
Contrast x-ray of shoulder ..................
Contrast x-ray of shoulder ..................
Contrast x-ray of shoulder ..................
X-ray exam of shoulders .....................
X-ray exam of shoulders .....................
X-ray exam of shoulders .....................
X-ray exam of humerus ......................
X-ray exam of humerus ......................
X-ray exam of humerus ......................
X-ray exam of elbow ...........................
X-ray exam of elbow ...........................
X-ray exam of elbow ...........................
X-ray exam of elbow ...........................
X-ray exam of elbow ...........................
X-ray exam of elbow ...........................
Contrast x-ray of elbow .......................
Contrast x-ray of elbow .......................
Contrast x-ray of elbow .......................
X-ray exam of forearm ........................
X-ray exam of forearm ........................
X-ray exam of forearm ........................
X-ray exam of arm, infant ...................
X-ray exam of arm, infant ...................
X-ray exam of arm, infant ...................
X-ray exam of wrist .............................
X-ray exam of wrist .............................
X-ray exam of wrist .............................
X-ray exam of wrist .............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.19
0.17
0.00
0.17
0.91
0.00
0.91
0.91
0.00
0.91
0.83
0.00
0.83
1.33
0.00
1.33
0.76
0.00
0.76
1.16
0.00
1.16
0.00
0.00
1.31
0.00
0.00
1.38
0.83
0.00
0.83
0.16
0.00
0.16
0.17
0.00
0.17
0.15
0.00
0.15
0.18
0.00
0.18
0.54
0.00
0.54
0.20
0.00
0.20
0.17
0.00
0.17
0.15
0.00
0.15
0.17
0.00
0.17
0.54
0.00
0.54
0.16
0.00
0.16
0.16
0.00
0.16
0.16
0.00
0.16
0.17
0.67
0.07
0.57
0.52
0.05
2.58
2.26
0.32
2.24
1.96
0.28
2.53
2.24
0.29
3.99
3.52
0.47
1.73
1.53
0.20
1.44
1.14
0.30
0.00
0.00
0.47
0.00
0.00
0.50
1.45
1.21
0.24
0.55
0.50
0.05
0.58
0.52
0.06
0.44
0.39
0.05
0.57
0.51
0.06
2.24
2.05
0.19
0.74
0.66
0.08
0.58
0.52
0.06
0.55
0.50
0.05
0.76
0.70
0.06
1.83
1.65
0.18
0.55
0.50
0.05
0.58
0.53
0.05
0.61
0.55
0.06
0.78
0.65
0.06
0.61
0.55
0.06
3.80
3.50
0.30
3.42
3.14
0.28
3.43
3.16
0.27
5.26
4.81
0.45
2.02
1.82
0.20
5.08
4.75
0.33
0.00
0.00
0.47
0.00
0.00
0.49
4.79
4.53
0.26
0.56
0.51
0.05
0.58
0.52
0.06
0.48
0.43
0.05
0.60
0.54
0.06
2.26
2.08
0.18
0.73
0.66
0.07
0.60
0.54
0.06
0.56
0.51
0.05
0.69
0.63
0.06
2.07
1.88
0.19
0.56
0.51
0.05
0.56
0.51
0.05
0.57
0.52
0.05
0.68
NA
0.07
NA
NA
0.05
NA
NA
0.32
NA
NA
0.28
NA
NA
0.29
NA
NA
0.47
NA
NA
0.20
NA
NA
0.30
NA
NA
0.47
NA
NA
0.50
NA
NA
0.24
NA
NA
0.05
NA
NA
0.06
NA
NA
0.05
NA
NA
0.06
NA
NA
0.19
NA
NA
0.08
NA
NA
0.06
NA
NA
0.05
NA
NA
0.06
NA
NA
0.18
NA
NA
0.05
NA
NA
0.05
NA
NA
0.06
NA
NA
0.06
NA
NA
0.06
NA
NA
0.30
NA
NA
0.28
NA
NA
0.27
NA
NA
0.45
NA
NA
0.20
NA
NA
0.33
NA
NA
0.47
NA
NA
0.49
NA
NA
0.26
NA
NA
0.05
NA
NA
0.06
NA
NA
0.05
NA
NA
0.06
NA
NA
0.18
NA
NA
0.07
NA
NA
0.06
NA
NA
0.05
NA
NA
0.06
NA
NA
0.19
NA
NA
0.05
NA
NA
0.05
NA
NA
0.05
NA
Malpractice
RVUs 2
0.04
0.01
0.05
0.04
0.01
0.29
0.25
0.04
0.26
0.22
0.04
0.26
0.22
0.04
0.39
0.33
0.06
0.26
0.22
0.04
0.50
0.43
0.07
0.00
0.00
0.10
0.00
0.00
0.07
0.46
0.40
0.06
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.05
0.04
0.01
0.14
0.12
0.02
0.05
0.04
0.01
0.05
0.04
0.01
0.03
0.02
0.01
0.05
0.04
0.01
0.14
0.12
0.02
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00274
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66495
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
73110
73110
73115
73115
73115
73120
73120
73120
73130
73130
73130
73140
73140
73140
73200
73200
73200
73201
73201
73201
73202
73202
73202
73206
73206
73206
73218
73218
73218
73219
73219
73219
73220
73220
73220
73221
73221
73221
73222
73222
73222
73223
73223
73223
73225
73225
73225
73500
73500
73500
73510
73510
73510
73520
73520
73520
73525
73525
73525
73530
73530
73530
73540
73540
73540
73542
73542
73542
73550
73550
73550
73560
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
N
N
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
X-ray exam of wrist .............................
X-ray exam of wrist .............................
Contrast x-ray of wrist .........................
Contrast x-ray of wrist .........................
Contrast x-ray of wrist .........................
X-ray exam of hand ............................
X-ray exam of hand ............................
X-ray exam of hand ............................
X-ray exam of hand ............................
X-ray exam of hand ............................
X-ray exam of hand ............................
X-ray exam of finger(s) .......................
X-ray exam of finger(s) .......................
X-ray exam of finger(s) .......................
Ct upper extremity w/o dye .................
Ct upper extremity w/o dye .................
Ct upper extremity w/o dye .................
Ct upper extremity w/dye ....................
Ct upper extremity w/dye ....................
Ct upper extremity w/dye ....................
Ct uppr extremity w/o&w/dye ..............
Ct uppr extremity w/o&w/dye ..............
Ct uppr extremity w/o&w/dye ..............
Ct angio upr extrm w/o&w/dye ...........
Ct angio upr extrm w/o&w/dye ...........
Ct angio upr extrm w/o&w/dye ...........
Mri upper extremity w/o dye ...............
Mri upper extremity w/o dye ...............
Mri upper extremity w/o dye ...............
Mri upper extremity w/dye ..................
Mri upper extremity w/dye ..................
Mri upper extremity w/dye ..................
Mri uppr extremity w/o&w/dye ............
Mri uppr extremity w/o&w/dye ............
Mri uppr extremity w/o&w/dye ............
Mri joint upr extrem w/o dye ...............
Mri joint upr extrem w/o dye ...............
Mri joint upr extrem w/o dye ...............
Mri joint upr extrem w/dye ..................
Mri joint upr extrem w/dye ..................
Mri joint upr extrem w/dye ..................
Mri joint upr extr w/o&w/dye ...............
Mri joint upr extr w/o&w/dye ...............
Mri joint upr extr w/o&w/dye ...............
Mr angio upr extr w/o&w/dye ..............
Mr angio upr extr w/o&w/dye ..............
Mr angio upr extr w/o&w/dye ..............
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hips ..............................
X-ray exam of hips ..............................
X-ray exam of hips ..............................
Contrast x-ray of hip ...........................
Contrast x-ray of hip ...........................
Contrast x-ray of hip ...........................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of hip ...............................
X-ray exam of pelvis & hips ................
X-ray exam of pelvis & hips ................
X-ray exam of pelvis & hips ................
X-ray exam, sacroiliac joint .................
X-ray exam, sacroiliac joint .................
X-ray exam, sacroiliac joint .................
X-ray exam of thigh ............................
X-ray exam of thigh ............................
X-ray exam of thigh ............................
X-ray exam of knee, 1 or 2 .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.17
0.54
0.00
0.54
0.16
0.00
0.16
0.17
0.00
0.17
0.13
0.00
0.13
1.09
0.00
1.09
1.16
0.00
1.16
1.22
0.00
1.22
1.81
0.00
1.81
1.35
0.00
1.35
1.62
0.00
1.62
2.15
0.00
2.15
1.35
0.00
1.35
1.62
0.00
1.62
2.15
0.00
2.15
1.73
0.00
1.73
0.17
0.00
0.17
0.21
0.00
0.21
0.26
0.00
0.26
0.54
0.00
0.54
0.00
0.00
0.29
0.20
0.00
0.20
0.59
0.00
0.59
0.17
0.00
0.17
0.17
0.72
0.06
2.33
2.14
0.19
0.56
0.51
0.05
0.66
0.60
0.06
0.67
0.63
0.04
6.39
6.01
0.38
7.91
7.50
0.41
10.54
10.12
0.42
10.91
10.24
0.67
14.63
14.17
0.46
15.39
14.83
0.56
19.03
18.29
0.74
13.55
13.08
0.47
14.29
13.73
0.56
17.56
16.82
0.74
14.64
14.24
0.40
0.49
0.43
0.06
0.77
0.70
0.07
0.79
0.70
0.09
1.82
1.64
0.18
0.00
0.00
0.11
0.81
0.74
0.07
1.12
0.98
0.14
0.55
0.49
0.06
0.58
0.62
0.06
2.04
1.86
0.18
0.55
0.50
0.05
0.62
0.56
0.06
0.57
0.53
0.04
5.85
5.48
0.37
7.09
6.70
0.39
9.18
8.77
0.41
11.23
10.60
0.63
13.13
12.68
0.45
14.68
14.13
0.55
22.31
21.58
0.73
12.59
12.14
0.45
14.12
13.58
0.54
21.56
20.84
0.72
13.15
12.62
0.53
0.51
0.45
0.06
0.71
0.64
0.07
0.77
0.68
0.09
2.05
1.87
0.18
0.00
0.00
0.10
0.72
0.65
0.07
1.69
1.54
0.15
0.59
0.53
0.06
0.58
NA
0.06
NA
NA
0.19
NA
NA
0.05
NA
NA
0.06
NA
NA
0.04
NA
NA
0.38
NA
NA
0.41
NA
NA
0.42
NA
NA
0.67
NA
NA
0.46
NA
NA
0.56
NA
NA
0.74
NA
NA
0.47
NA
NA
0.56
NA
NA
0.74
NA
NA
0.40
NA
NA
0.06
NA
NA
0.07
NA
NA
0.09
NA
NA
0.18
NA
NA
0.11
NA
NA
0.07
NA
NA
0.14
NA
NA
0.06
NA
NA
0.06
NA
NA
0.18
NA
NA
0.05
NA
NA
0.06
NA
NA
0.04
NA
NA
0.37
NA
NA
0.39
NA
NA
0.41
NA
NA
0.63
NA
NA
0.45
NA
NA
0.55
NA
NA
0.73
NA
NA
0.45
NA
NA
0.54
NA
NA
0.72
NA
NA
0.53
NA
NA
0.06
NA
NA
0.07
NA
NA
0.09
NA
NA
0.18
NA
NA
0.10
NA
NA
0.07
NA
NA
0.15
NA
NA
0.06
NA
Malpractice
RVUs 2
0.02
0.01
0.12
0.10
0.02
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.30
0.25
0.05
0.36
0.31
0.05
0.44
0.39
0.05
0.47
0.39
0.08
0.45
0.39
0.06
0.54
0.47
0.07
0.94
0.84
0.10
0.45
0.39
0.06
0.54
0.47
0.07
0.94
0.84
0.10
0.69
0.59
0.10
0.03
0.02
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.15
0.12
0.03
0.00
0.00
0.01
0.05
0.04
0.01
0.15
0.12
0.03
0.05
0.04
0.01
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00275
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66496
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
73560
73560
73562
73562
73562
73564
73564
73564
73565
73565
73565
73580
73580
73580
73590
73590
73590
73592
73592
73592
73600
73600
73600
73610
73610
73610
73615
73615
73615
73620
73620
73620
73630
73630
73630
73650
73650
73650
73660
73660
73660
73700
73700
73700
73701
73701
73701
73702
73702
73702
73706
73706
73706
73718
73718
73718
73719
73719
73719
73720
73720
73720
73721
73721
73721
73722
73722
73722
73723
73723
73723
73725
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
X-ray exam of knee, 1 or 2 .................
X-ray exam of knee, 1 or 2 .................
X-ray exam of knee, 3 ........................
X-ray exam of knee, 3 ........................
X-ray exam of knee, 3 ........................
X-ray exam, knee, 4 or more ..............
X-ray exam, knee, 4 or more ..............
X-ray exam, knee, 4 or more ..............
X-ray exam of knees ...........................
X-ray exam of knees ...........................
X-ray exam of knees ...........................
Contrast x-ray of knee joint ................
Contrast x-ray of knee joint ................
Contrast x-ray of knee joint ................
X-ray exam of lower leg ......................
X-ray exam of lower leg ......................
X-ray exam of lower leg ......................
X-ray exam of leg, infant ....................
X-ray exam of leg, infant ....................
X-ray exam of leg, infant ....................
X-ray exam of ankle ............................
X-ray exam of ankle ............................
X-ray exam of ankle ............................
X-ray exam of ankle ............................
X-ray exam of ankle ............................
X-ray exam of ankle ............................
Contrast x-ray of ankle .......................
Contrast x-ray of ankle .......................
Contrast x-ray of ankle .......................
X-ray exam of foot ..............................
X-ray exam of foot ..............................
X-ray exam of foot ..............................
X-ray exam of foot ..............................
X-ray exam of foot ..............................
X-ray exam of foot ..............................
X-ray exam of heel .............................
X-ray exam of heel .............................
X-ray exam of heel .............................
X-ray exam of toe(s) ...........................
X-ray exam of toe(s) ...........................
X-ray exam of toe(s) ...........................
Ct lower extremity w/o dye .................
Ct lower extremity w/o dye .................
Ct lower extremity w/o dye .................
Ct lower extremity w/dye ....................
Ct lower extremity w/dye ....................
Ct lower extremity w/dye ....................
Ct lwr extremity w/o&w/dye ................
Ct lwr extremity w/o&w/dye ................
Ct lwr extremity w/o&w/dye ................
Ct angio lwr extr w/o&w/dye ...............
Ct angio lwr extr w/o&w/dye ...............
Ct angio lwr extr w/o&w/dye ...............
Mri lower extremity w/o dye ................
Mri lower extremity w/o dye ................
Mri lower extremity w/o dye ................
Mri lower extremity w/dye ...................
Mri lower extremity w/dye ...................
Mri lower extremity w/dye ...................
Mri lwr extremity w/o&w/dye ...............
Mri lwr extremity w/o&w/dye ...............
Mri lwr extremity w/o&w/dye ...............
Mri jnt of lwr extre w/o dye .................
Mri jnt of lwr extre w/o dye .................
Mri jnt of lwr extre w/o dye .................
Mri joint of lwr extr w/dye ....................
Mri joint of lwr extr w/dye ....................
Mri joint of lwr extr w/dye ....................
Mri joint lwr extr w/o&w/dye ................
Mri joint lwr extr w/o&w/dye ................
Mri joint lwr extr w/o&w/dye ................
Mr ang lwr ext w or w/o dye ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.17
0.18
0.00
0.18
0.22
0.00
0.22
0.17
0.00
0.17
0.54
0.00
0.54
0.17
0.00
0.17
0.16
0.00
0.16
0.16
0.00
0.16
0.17
0.00
0.17
0.54
0.00
0.54
0.16
0.00
0.16
0.17
0.00
0.17
0.16
0.00
0.16
0.13
0.00
0.13
1.09
0.00
1.09
1.16
0.00
1.16
1.22
0.00
1.22
1.90
0.00
1.90
1.35
0.00
1.35
1.62
0.00
1.62
2.15
0.00
2.15
1.35
0.00
1.35
1.62
0.00
1.62
2.15
0.00
2.15
1.82
0.52
0.06
0.73
0.66
0.07
0.86
0.78
0.08
0.65
0.59
0.06
2.55
2.36
0.19
0.54
0.48
0.06
0.58
0.53
0.05
0.56
0.51
0.05
0.68
0.62
0.06
2.00
1.82
0.18
0.52
0.48
0.04
0.65
0.60
0.05
0.55
0.50
0.05
0.64
0.60
0.04
6.40
6.02
0.38
7.97
7.56
0.41
10.72
10.28
0.44
12.34
11.62
0.72
14.25
13.79
0.46
15.39
14.82
0.57
18.98
18.23
0.75
13.86
13.39
0.47
14.48
13.91
0.57
17.54
16.80
0.74
15.11
0.52
0.06
0.68
0.62
0.06
0.77
0.70
0.07
0.60
0.54
0.06
2.67
2.49
0.18
0.56
0.50
0.06
0.56
0.51
0.05
0.55
0.50
0.05
0.63
0.57
0.06
2.14
1.96
0.18
0.54
0.49
0.05
0.62
0.56
0.06
0.53
0.48
0.05
0.55
0.51
0.04
5.86
5.49
0.37
7.13
6.73
0.40
9.27
8.85
0.42
11.96
11.29
0.67
12.94
12.49
0.45
14.68
14.13
0.55
22.27
21.55
0.72
12.74
12.29
0.45
14.22
13.67
0.55
21.55
20.83
0.72
13.45
NA
0.06
NA
NA
0.07
NA
NA
0.08
NA
NA
0.06
NA
NA
0.19
NA
NA
0.06
NA
NA
0.05
NA
NA
0.05
NA
NA
0.06
NA
NA
0.18
NA
NA
0.04
NA
NA
0.05
NA
NA
0.05
NA
NA
0.04
NA
NA
0.38
NA
NA
0.41
NA
NA
0.44
NA
NA
0.72
NA
NA
0.46
NA
NA
0.57
NA
NA
0.75
NA
NA
0.47
NA
NA
0.57
NA
NA
0.74
NA
NA
0.06
NA
NA
0.06
NA
NA
0.07
NA
NA
0.06
NA
NA
0.18
NA
NA
0.06
NA
NA
0.05
NA
NA
0.05
NA
NA
0.06
NA
NA
0.18
NA
NA
0.05
NA
NA
0.06
NA
NA
0.05
NA
NA
0.04
NA
NA
0.37
NA
NA
0.40
NA
NA
0.42
NA
NA
0.67
NA
NA
0.45
NA
NA
0.55
NA
NA
0.72
NA
NA
0.45
NA
NA
0.55
NA
NA
0.72
NA
Malpractice
RVUs 2
0.02
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.03
0.02
0.01
0.17
0.14
0.03
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.15
0.12
0.03
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.30
0.25
0.05
0.36
0.31
0.05
0.44
0.39
0.05
0.47
0.39
0.08
0.45
0.39
0.06
0.54
0.47
0.07
0.94
0.84
0.10
0.45
0.39
0.06
0.54
0.47
0.07
0.94
0.84
0.10
0.67
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00276
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66497
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
73725
73725
74000
74000
74000
74010
74010
74010
74020
74020
74020
74022
74022
74022
74150
74150
74150
74160
74160
74160
74170
74170
74170
74175
74175
74175
74181
74181
74181
74182
74182
74182
74183
74183
74183
74185
74185
74185
74190
74190
74190
74210
74210
74210
74220
74220
74220
74230
74230
74230
74235
74235
74235
74240
74240
74240
74241
74241
74241
74245
74245
74245
74246
74246
74246
74247
74247
74247
74249
74249
74249
74250
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
R
R
C
C
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Mr ang lwr ext w or w/o dye ...............
Mr ang lwr ext w or w/o dye ...............
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam of abdomen .....................
X-ray exam series, abdomen ..............
X-ray exam series, abdomen ..............
X-ray exam series, abdomen ..............
Ct abdomen w/o dye ...........................
Ct abdomen w/o dye ...........................
Ct abdomen w/o dye ...........................
Ct abdomen w/dye ..............................
Ct abdomen w/dye ..............................
Ct abdomen w/dye ..............................
Ct abdomen w/o & w/dye ...................
Ct abdomen w/o & w/dye ...................
Ct abdomen w/o & w/dye ...................
Ct angio abdom w/o & w/dye .............
Ct angio abdom w/o & w/dye .............
Ct angio abdom w/o & w/dye .............
Mri abdomen w/o dye .........................
Mri abdomen w/o dye .........................
Mri abdomen w/o dye .........................
Mri abdomen w/dye ............................
Mri abdomen w/dye ............................
Mri abdomen w/dye ............................
Mri abdomen w/o & w/dye ..................
Mri abdomen w/o & w/dye ..................
Mri abdomen w/o & w/dye ..................
Mri angio, abdom w orw/o dye ...........
Mri angio, abdom w orw/o dye ...........
Mri angio, abdom w orw/o dye ...........
X-ray exam of peritoneum ..................
X-ray exam of peritoneum ..................
X-ray exam of peritoneum ..................
Contrst x-ray exam of throat ...............
Contrst x-ray exam of throat ...............
Contrst x-ray exam of throat ...............
Contrast x-ray, esophagus ..................
Contrast x-ray, esophagus ..................
Contrast x-ray, esophagus ..................
Cine/vid x-ray, throat/esoph ................
Cine/vid x-ray, throat/esoph ................
Cine/vid x-ray, throat/esoph ................
Remove esophagus obstruction .........
Remove esophagus obstruction .........
Remove esophagus obstruction .........
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
X-ray exam, upper gi tract ..................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
Contrst x-ray uppr gi tract ...................
X-ray exam of small bowel .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.82
0.18
0.00
0.18
0.23
0.00
0.23
0.27
0.00
0.27
0.32
0.00
0.32
1.19
0.00
1.19
1.27
0.00
1.27
1.40
0.00
1.40
1.90
0.00
1.90
1.46
0.00
1.46
1.73
0.00
1.73
2.26
0.00
2.26
1.80
0.00
1.80
0.00
0.00
0.48
0.36
0.00
0.36
0.46
0.00
0.46
0.53
0.00
0.53
0.00
0.00
1.19
0.69
0.00
0.69
0.69
0.00
0.69
0.91
0.00
0.91
0.69
0.00
0.69
0.69
0.00
0.69
0.91
0.00
0.91
0.47
14.47
0.64
0.46
0.40
0.06
0.79
0.71
0.08
0.81
0.72
0.09
0.98
0.87
0.11
6.06
5.64
0.42
8.81
8.36
0.45
12.17
11.68
0.49
12.27
11.58
0.69
12.44
11.93
0.51
17.42
16.82
0.60
18.98
18.19
0.79
15.07
14.43
0.64
0.00
0.00
0.17
1.77
1.64
0.13
2.01
1.85
0.16
1.95
1.76
0.19
0.00
0.00
0.47
2.30
2.06
0.24
2.56
2.32
0.24
3.96
3.64
0.32
2.80
2.55
0.25
3.21
2.97
0.24
4.35
4.03
0.32
2.48
12.83
0.62
0.52
0.46
0.06
0.72
0.64
0.08
0.76
0.67
0.09
0.91
0.80
0.11
6.06
5.65
0.41
8.03
7.60
0.43
10.56
10.08
0.48
12.45
11.80
0.65
12.06
11.56
0.50
15.72
15.13
0.59
22.29
21.53
0.76
13.42
12.81
0.61
0.00
0.00
0.16
1.53
1.41
0.12
1.68
1.52
0.16
1.71
1.53
0.18
0.00
0.00
0.43
2.00
1.76
0.24
2.13
1.90
0.23
3.32
3.01
0.31
2.33
2.09
0.24
2.56
2.32
0.24
3.61
3.30
0.31
1.97
NA
0.64
NA
NA
0.06
NA
NA
0.08
NA
NA
0.09
NA
NA
0.11
NA
NA
0.42
NA
NA
0.45
NA
NA
0.49
NA
NA
0.69
NA
NA
0.51
NA
NA
0.60
NA
NA
0.79
NA
NA
0.64
NA
NA
0.17
NA
NA
0.13
NA
NA
0.16
NA
NA
0.19
NA
NA
0.47
NA
NA
0.24
NA
NA
0.24
NA
NA
0.32
NA
NA
0.25
NA
NA
0.24
NA
NA
0.32
NA
NA
0.62
NA
NA
0.06
NA
NA
0.08
NA
NA
0.09
NA
NA
0.11
NA
NA
0.41
NA
NA
0.43
NA
NA
0.48
NA
NA
0.65
NA
NA
0.50
NA
NA
0.59
NA
NA
0.76
NA
NA
0.61
NA
NA
0.16
NA
NA
0.12
NA
NA
0.16
NA
NA
0.18
NA
NA
0.43
NA
NA
0.24
NA
NA
0.23
NA
NA
0.31
NA
NA
0.24
NA
NA
0.24
NA
NA
0.31
NA
Malpractice
RVUs 2
0.59
0.08
0.03
0.02
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.06
0.05
0.01
0.35
0.30
0.05
0.42
0.36
0.06
0.49
0.43
0.06
0.47
0.39
0.08
0.51
0.45
0.06
0.60
0.52
0.08
1.02
0.92
0.10
0.67
0.59
0.08
0.00
0.00
0.02
0.08
0.06
0.02
0.08
0.06
0.02
0.09
0.07
0.02
0.00
0.00
0.05
0.11
0.08
0.03
0.11
0.08
0.03
0.17
0.13
0.04
0.13
0.10
0.03
0.14
0.11
0.03
0.18
0.14
0.04
0.09
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00277
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66498
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
74250
74250
74251
74251
74251
74260
74260
74260
74270
74270
74270
74280
74280
74280
74283
74283
74283
74290
74290
74290
74291
74291
74291
74300
74300
74300
74301
74301
74301
74305
74305
74305
74320
74320
74320
74327
74327
74327
74328
74328
74328
74329
74329
74329
74330
74330
74330
74340
74340
74340
74355
74355
74355
74360
74360
74360
74363
74363
74363
74400
74400
74400
74410
74410
74410
74415
74415
74415
74420
74420
74420
74425
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
A
A
A
C
C
A
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
X-ray exam of small bowel .................
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray exam of colon .............
Contrast x-ray, gallbladder ..................
Contrast x-ray, gallbladder ..................
Contrast x-ray, gallbladder ..................
Contrast x-rays, gallbladder ................
Contrast x-rays, gallbladder ................
Contrast x-rays, gallbladder ................
X-ray bile ducts/pancreas ...................
X-ray bile ducts/pancreas ...................
X-ray bile ducts/pancreas ...................
X-rays at surgery add-on ....................
X-rays at surgery add-on ....................
X-rays at surgery add-on ....................
X-ray bile ducts/pancreas ...................
X-ray bile ducts/pancreas ...................
X-ray bile ducts/pancreas ...................
Contrast x-ray of bile ducts .................
Contrast x-ray of bile ducts .................
Contrast x-ray of bile ducts .................
X-ray bile stone removal .....................
X-ray bile stone removal .....................
X-ray bile stone removal .....................
X-ray bile duct endoscopy ..................
X-ray bile duct endoscopy ..................
X-ray bile duct endoscopy ..................
X-ray for pancreas endoscopy ............
X-ray for pancreas endoscopy ............
X-ray for pancreas endoscopy ............
X-ray bile/panc endoscopy .................
X-ray bile/panc endoscopy .................
X-ray bile/panc endoscopy .................
X-ray guide for GI tube .......................
X-ray guide for GI tube .......................
X-ray guide for GI tube .......................
X-ray guide, intestinal tube .................
X-ray guide, intestinal tube .................
X-ray guide, intestinal tube .................
X-ray guide, GI dilation .......................
X-ray guide, GI dilation .......................
X-ray guide, GI dilation .......................
X-ray, bile duct dilation .......................
X-ray, bile duct dilation .......................
X-ray, bile duct dilation .......................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.47
0.69
0.00
0.69
0.50
0.00
0.50
0.69
0.00
0.69
0.99
0.00
0.99
2.02
0.00
2.02
0.32
0.00
0.32
0.20
0.00
0.20
0.00
0.00
0.36
0.00
0.00
0.21
0.00
0.00
0.42
0.54
0.00
0.54
0.70
0.00
0.70
0.00
0.00
0.70
0.00
0.00
0.70
0.00
0.00
0.90
0.00
0.00
0.54
0.00
0.00
0.76
0.00
0.00
0.54
0.00
0.00
0.88
0.49
0.00
0.49
0.49
0.00
0.49
0.49
0.00
0.49
0.00
0.00
0.36
0.00
2.32
0.16
10.01
9.76
0.25
8.30
8.12
0.18
3.59
3.34
0.25
4.94
4.59
0.35
3.49
2.80
0.69
1.58
1.47
0.11
1.55
1.48
0.07
0.00
0.00
0.13
0.00
0.00
0.07
0.00
0.00
0.15
2.13
1.93
0.20
2.97
2.72
0.25
0.00
0.00
0.26
0.00
0.00
0.27
0.00
0.00
0.33
0.00
0.00
0.19
0.00
0.00
0.28
0.00
0.00
0.24
0.00
0.00
0.32
2.60
2.43
0.17
2.69
2.51
0.18
3.27
3.10
0.17
0.00
0.00
0.14
0.00
1.81
0.16
5.77
5.53
0.24
4.97
4.80
0.17
2.76
2.52
0.24
3.74
3.41
0.33
3.35
2.68
0.67
1.21
1.10
0.11
1.02
0.95
0.07
0.00
0.00
0.12
0.00
0.00
0.07
0.00
0.00
0.15
2.73
2.54
0.19
2.48
2.24
0.24
0.00
0.00
0.25
0.00
0.00
0.25
0.00
0.00
0.31
0.00
0.00
0.19
0.00
0.00
0.26
0.00
0.00
0.21
0.00
0.00
0.30
2.22
2.05
0.17
2.40
2.23
0.17
2.78
2.61
0.17
0.00
0.00
0.13
0.00
NA
0.16
NA
NA
0.25
NA
NA
0.18
NA
NA
0.25
NA
NA
0.35
NA
NA
0.69
NA
NA
0.11
NA
NA
0.07
NA
NA
0.13
NA
NA
0.07
NA
NA
0.15
NA
NA
0.20
NA
NA
0.25
NA
NA
0.26
NA
NA
0.27
NA
NA
0.33
NA
NA
0.19
NA
NA
0.28
NA
NA
0.24
NA
NA
0.32
NA
NA
0.17
NA
NA
0.18
NA
NA
0.17
NA
NA
0.14
NA
NA
0.16
NA
NA
0.24
NA
NA
0.17
NA
NA
0.24
NA
NA
0.33
NA
NA
0.67
NA
NA
0.11
NA
NA
0.07
NA
NA
0.12
NA
NA
0.07
NA
NA
0.15
NA
NA
0.19
NA
NA
0.24
NA
NA
0.25
NA
NA
0.25
NA
NA
0.31
NA
NA
0.19
NA
NA
0.26
NA
NA
0.21
NA
NA
0.30
NA
NA
0.17
NA
NA
0.17
NA
NA
0.17
NA
NA
0.13
NA
Malpractice
RVUs 2
0.07
0.02
0.10
0.07
0.03
0.10
0.08
0.02
0.14
0.11
0.03
0.17
0.13
0.04
0.23
0.14
0.09
0.06
0.05
0.01
0.03
0.02
0.01
0.00
0.00
0.02
0.00
0.00
0.01
0.00
0.00
0.02
0.19
0.17
0.02
0.14
0.11
0.03
0.00
0.00
0.03
0.00
0.00
0.03
0.00
0.00
0.04
0.00
0.00
0.02
0.00
0.00
0.03
0.00
0.00
0.02
0.00
0.00
0.04
0.13
0.11
0.02
0.13
0.11
0.02
0.14
0.12
0.02
0.00
0.00
0.02
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00278
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66499
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
74425
74425
74430
74430
74430
74440
74440
74440
74445
74445
74445
74450
74450
74450
74455
74455
74455
74470
74470
74470
74475
74475
74475
74480
74480
74480
74485
74485
74485
74710
74710
74710
74740
74740
74740
74742
74742
74742
74775
74775
74775
75557
75557
75557
75558
75558
75558
75559
75559
75559
75560
75560
75560
75561
75561
75561
75562
75562
75562
75563
75563
75563
75564
75564
75564
75600
75600
75600
75605
75605
75605
75625
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
C
A
A
A
A
A
A
A
C
C
A
C
C
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
A
A
A
N
N
N
A
A
A
N
N
N
A
A
A
N
N
N
A
A
A
N
N
N
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Contrst x-ray, urinary tract ..................
Contrst x-ray, urinary tract ..................
Contrast x-ray, bladder .......................
Contrast x-ray, bladder .......................
Contrast x-ray, bladder .......................
X-ray, male genital tract ......................
X-ray, male genital tract ......................
X-ray, male genital tract ......................
X-ray exam of penis ............................
X-ray exam of penis ............................
X-ray exam of penis ............................
X-ray, urethra/bladder .........................
X-ray, urethra/bladder .........................
X-ray, urethra/bladder .........................
X-ray, urethra/bladder .........................
X-ray, urethra/bladder .........................
X-ray, urethra/bladder .........................
X-ray exam of kidney lesion ...............
X-ray exam of kidney lesion ...............
X-ray exam of kidney lesion ...............
X-ray control, cath insert .....................
X-ray control, cath insert .....................
X-ray control, cath insert .....................
X-ray control, cath insert .....................
X-ray control, cath insert .....................
X-ray control, cath insert .....................
X-ray guide, GU dilation .....................
X-ray guide, GU dilation .....................
X-ray guide, GU dilation .....................
X-ray measurement of pelvis ..............
X-ray measurement of pelvis ..............
X-ray measurement of pelvis ..............
X-ray, female genital tract ...................
X-ray, female genital tract ...................
X-ray, female genital tract ...................
X-ray, fallopian tube ............................
X-ray, fallopian tube ............................
X-ray, fallopian tube ............................
X-ray exam of perineum .....................
X-ray exam of perineum .....................
X-ray exam of perineum .....................
Cardiac mri for morph .........................
Cardiac mri for morph .........................
Cardiac mri for morph .........................
Cardiac mri flow/velocity .....................
Cardiac mri flow/velocity .....................
Cardiac mri flow/velocity .....................
Cardiac mri w/stress img ....................
Cardiac mri w/stress img ....................
Cardiac mri w/stress img ....................
Cardiac mri flow/vel/stress ..................
Cardiac mri flow/vel/stress ..................
Cardiac mri flow/vel/stress ..................
Cardiac mri for morph w/dye ..............
Cardiac mri for morph w/dye ..............
Cardiac mri for morph w/dye ..............
Card mri flow/vel w/dye ......................
Card mri flow/vel w/dye ......................
Card mri flow/vel w/dye ......................
Card mri w/stress img & dye ..............
Card mri w/stress img & dye ..............
Card mri w/stress img & dye ..............
Ht mri w/flo/vel/strs & dye ...................
Ht mri w/flo/vel/strs & dye ...................
Ht mri w/flo/vel/strs & dye ...................
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.36
0.32
0.00
0.32
0.38
0.00
0.38
0.00
0.00
1.14
0.00
0.00
0.33
0.33
0.00
0.33
0.00
0.00
0.54
0.54
0.00
0.54
0.54
0.00
0.54
0.54
0.00
0.54
0.34
0.00
0.34
0.38
0.00
0.38
0.00
0.00
0.61
0.00
0.00
0.62
2.35
0.00
2.35
2.60
0.00
2.60
2.95
0.00
2.95
3.00
0.00
3.00
2.60
0.00
2.60
2.86
0.00
2.86
3.00
0.00
3.00
3.35
0.00
3.35
0.49
0.00
0.49
1.14
0.00
1.14
1.14
0.00
0.13
1.96
1.84
0.12
2.11
1.97
0.14
0.00
0.00
0.45
0.00
0.00
0.12
2.18
2.06
0.12
0.00
0.00
0.17
2.12
1.92
0.20
2.13
1.93
0.20
2.27
2.07
0.20
0.64
0.53
0.11
1.76
1.63
0.13
0.00
0.00
0.19
0.00
0.00
0.22
11.25
10.31
0.94
12.38
11.78
0.60
17.24
15.97
1.27
16.82
16.13
0.69
15.95
14.92
1.03
16.75
16.09
0.66
20.20
18.82
1.38
19.71
18.94
0.77
6.42
6.18
0.24
3.55
3.06
0.49
3.35
0.00
0.13
1.55
1.44
0.11
1.68
1.55
0.13
0.00
0.00
0.41
0.00
0.00
0.12
1.94
1.82
0.12
0.00
0.00
0.18
3.18
2.99
0.19
3.19
3.00
0.19
2.80
2.61
0.19
0.90
0.79
0.11
1.60
1.47
0.13
0.00
0.00
0.20
0.00
0.00
0.21
11.25
10.31
0.94
12.38
11.78
0.60
17.24
15.97
1.27
16.82
16.13
0.69
15.95
14.92
1.03
16.75
16.09
0.66
20.20
18.82
1.38
19.71
18.94
0.77
9.61
9.39
0.22
8.27
7.83
0.44
8.16
NA
0.13
NA
NA
0.12
NA
NA
0.14
NA
NA
0.45
NA
NA
0.12
NA
NA
0.12
NA
NA
0.17
NA
NA
0.20
NA
NA
0.20
NA
NA
0.20
NA
NA
0.11
NA
NA
0.13
NA
NA
0.19
NA
NA
0.22
NA
NA
0.94
NA
NA
0.60
NA
NA
1.27
NA
NA
0.69
NA
NA
1.03
NA
NA
0.66
NA
NA
1.38
NA
NA
0.77
NA
NA
0.24
NA
NA
0.49
NA
NA
0.13
NA
NA
0.11
NA
NA
0.13
NA
NA
0.41
NA
NA
0.12
NA
NA
0.12
NA
NA
0.18
NA
NA
0.19
NA
NA
0.19
NA
NA
0.19
NA
NA
0.11
NA
NA
0.13
NA
NA
0.20
NA
NA
0.21
NA
NA
0.94
NA
NA
0.60
NA
NA
1.27
NA
NA
0.69
NA
NA
1.03
NA
NA
0.66
NA
NA
1.38
NA
NA
0.77
NA
NA
0.22
NA
NA
0.44
NA
Malpractice
RVUs 2
0.00
0.02
0.08
0.06
0.02
0.08
0.06
0.02
0.00
0.00
0.07
0.00
0.00
0.02
0.12
0.10
0.02
0.00
0.00
0.02
0.24
0.22
0.02
0.24
0.22
0.02
0.20
0.17
0.03
0.08
0.06
0.02
0.09
0.07
0.02
0.00
0.00
0.03
0.00
0.00
0.03
0.97
0.87
0.10
1.07
0.96
0.11
0.97
0.87
0.10
1.00
0.89
0.11
1.07
0.96
0.11
1.03
0.92
0.11
1.08
0.97
0.11
1.21
1.08
0.13
0.67
0.65
0.02
0.70
0.65
0.05
0.71
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00279
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66500
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
75625
75625
75630
75630
75630
75635
75635
75635
75650
75650
75650
75658
75658
75658
75660
75660
75660
75662
75662
75662
75665
75665
75665
75671
75671
75671
75676
75676
75676
75680
75680
75680
75685
75685
75685
75705
75705
75705
75710
75710
75710
75716
75716
75716
75722
75722
75722
75724
75724
75724
75726
75726
75726
75731
75731
75731
75733
75733
75733
75736
75736
75736
75741
75741
75741
75743
75743
75743
75746
75746
75746
75756
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Contrast x-ray exam of aorta ..............
Contrast x-ray exam of aorta ..............
X-ray aorta, leg arteries ......................
X-ray aorta, leg arteries ......................
X-ray aorta, leg arteries ......................
Ct angio abdominal arteries ................
Ct angio abdominal arteries ................
Ct angio abdominal arteries ................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, arm ...............................
Artery x-rays, arm ...............................
Artery x-rays, arm ...............................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, head & neck .................
Artery x-rays, neck ..............................
Artery x-rays, neck ..............................
Artery x-rays, neck ..............................
Artery x-rays, neck ..............................
Artery x-rays, neck ..............................
Artery x-rays, neck ..............................
Artery x-rays, spine .............................
Artery x-rays, spine .............................
Artery x-rays, spine .............................
Artery x-rays, spine .............................
Artery x-rays, spine .............................
Artery x-rays, spine .............................
Artery x-rays, arm/leg .........................
Artery x-rays, arm/leg .........................
Artery x-rays, arm/leg .........................
Artery x-rays, arms/legs ......................
Artery x-rays, arms/legs ......................
Artery x-rays, arms/legs ......................
Artery x-rays, kidney ...........................
Artery x-rays, kidney ...........................
Artery x-rays, kidney ...........................
Artery x-rays, kidneys .........................
Artery x-rays, kidneys .........................
Artery x-rays, kidneys .........................
Artery x-rays, abdomen ......................
Artery x-rays, abdomen ......................
Artery x-rays, abdomen ......................
Artery x-rays, adrenal gland ...............
Artery x-rays, adrenal gland ...............
Artery x-rays, adrenal gland ...............
Artery x-rays, adrenals ........................
Artery x-rays, adrenals ........................
Artery x-rays, adrenals ........................
Artery x-rays, pelvis ............................
Artery x-rays, pelvis ............................
Artery x-rays, pelvis ............................
Artery x-rays, lung ...............................
Artery x-rays, lung ...............................
Artery x-rays, lung ...............................
Artery x-rays, lungs .............................
Artery x-rays, lungs .............................
Artery x-rays, lungs .............................
Artery x-rays, lung ...............................
Artery x-rays, lung ...............................
Artery x-rays, lung ...............................
Artery x-rays, chest .............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.14
1.79
0.00
1.79
2.40
0.00
2.40
1.49
0.00
1.49
1.31
0.00
1.31
1.31
0.00
1.31
1.66
0.00
1.66
1.31
0.00
1.31
1.66
0.00
1.66
1.31
0.00
1.31
1.66
0.00
1.66
1.31
0.00
1.31
2.18
0.00
2.18
1.14
0.00
1.14
1.31
0.00
1.31
1.14
0.00
1.14
1.49
0.00
1.49
1.14
0.00
1.14
1.14
0.00
1.14
1.31
0.00
1.31
1.14
0.00
1.14
1.31
0.00
1.31
1.66
0.00
1.66
1.14
0.00
1.14
1.14
2.93
0.42
3.76
3.05
0.71
12.92
12.00
0.92
3.52
2.95
0.57
3.72
3.28
0.44
3.88
3.39
0.49
5.01
4.31
0.70
4.09
3.61
0.48
5.10
4.46
0.64
3.86
3.38
0.48
4.61
3.95
0.66
3.88
3.38
0.50
4.17
3.37
0.80
3.94
3.52
0.42
4.92
4.42
0.50
3.84
3.37
0.47
5.12
4.38
0.74
3.76
3.34
0.42
4.09
3.59
0.50
5.45
4.80
0.65
3.87
3.44
0.43
3.18
2.69
0.49
3.56
2.94
0.62
3.52
3.12
0.40
4.34
7.76
0.40
8.75
8.09
0.66
14.80
13.95
0.85
8.30
7.77
0.53
8.40
7.94
0.46
8.46
7.99
0.47
9.09
8.45
0.64
8.57
8.11
0.46
9.12
8.53
0.59
8.45
7.99
0.46
8.87
8.27
0.60
8.46
7.99
0.47
8.74
7.98
0.76
8.47
8.06
0.41
8.97
8.51
0.46
8.42
7.98
0.44
9.14
8.49
0.65
8.36
7.97
0.39
8.54
8.10
0.44
9.25
8.70
0.55
8.42
8.02
0.40
8.10
7.64
0.46
8.35
7.77
0.58
8.25
7.86
0.39
8.69
NA
0.42
NA
NA
0.71
NA
NA
0.92
NA
NA
0.57
NA
NA
0.44
NA
NA
0.49
NA
NA
0.70
NA
NA
0.48
NA
NA
0.64
NA
NA
0.48
NA
NA
0.66
NA
NA
0.50
NA
NA
0.80
NA
NA
0.42
NA
NA
0.50
NA
NA
0.47
NA
NA
0.74
NA
NA
0.42
NA
NA
0.50
NA
NA
0.65
NA
NA
0.43
NA
NA
0.49
NA
NA
0.62
NA
NA
0.40
NA
NA
0.40
NA
NA
0.66
NA
NA
0.85
NA
NA
0.53
NA
NA
0.46
NA
NA
0.47
NA
NA
0.64
NA
NA
0.46
NA
NA
0.59
NA
NA
0.46
NA
NA
0.60
NA
NA
0.47
NA
NA
0.76
NA
NA
0.41
NA
NA
0.46
NA
NA
0.44
NA
NA
0.65
NA
NA
0.39
NA
NA
0.44
NA
NA
0.55
NA
NA
0.40
NA
NA
0.46
NA
NA
0.58
NA
NA
0.39
NA
Malpractice
RVUs 2
0.65
0.06
0.80
0.69
0.11
0.50
0.39
0.11
0.72
0.65
0.07
0.72
0.65
0.07
0.71
0.65
0.06
0.71
0.65
0.06
0.74
0.65
0.09
0.72
0.65
0.07
0.72
0.65
0.07
0.72
0.65
0.07
0.71
0.65
0.06
0.78
0.65
0.13
0.72
0.65
0.07
0.72
0.65
0.07
0.70
0.65
0.05
0.70
0.65
0.05
0.70
0.65
0.05
0.71
0.65
0.06
0.71
0.65
0.06
0.71
0.65
0.06
0.71
0.65
0.06
0.72
0.65
0.07
0.70
0.65
0.05
0.69
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00280
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66501
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
75756
75756
75774
75774
75774
75790
75790
75790
75801
75801
75801
75803
75803
75803
75805
75805
75805
75807
75807
75807
75809
75809
75809
75810
75810
75810
75820
75820
75820
75822
75822
75822
75825
75825
75825
75827
75827
75827
75831
75831
75831
75833
75833
75833
75840
75840
75840
75842
75842
75842
75860
75860
75860
75870
75870
75870
75872
75872
75872
75880
75880
75880
75885
75885
75885
75887
75887
75887
75889
75889
75889
75891
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Artery x-rays, chest .............................
Artery x-rays, chest .............................
Artery x-ray, each vessel ....................
Artery x-ray, each vessel ....................
Artery x-ray, each vessel ....................
Visualize A-V shunt .............................
Visualize A-V shunt .............................
Visualize A-V shunt .............................
Lymph vessel x-ray, arm/leg ...............
Lymph vessel x-ray, arm/leg ...............
Lymph vessel x-ray, arm/leg ...............
Lymph vessel x-ray,arms/legs ............
Lymph vessel x-ray,arms/legs ............
Lymph vessel x-ray,arms/legs ............
Lymph vessel x-ray, trunk ...................
Lymph vessel x-ray, trunk ...................
Lymph vessel x-ray, trunk ...................
Lymph vessel x-ray, trunk ...................
Lymph vessel x-ray, trunk ...................
Lymph vessel x-ray, trunk ...................
Nonvascular shunt, x-ray ....................
Nonvascular shunt, x-ray ....................
Nonvascular shunt, x-ray ....................
Vein x-ray, spleen/liver .......................
Vein x-ray, spleen/liver .......................
Vein x-ray, spleen/liver .......................
Vein x-ray, arm/leg ..............................
Vein x-ray, arm/leg ..............................
Vein x-ray, arm/leg ..............................
Vein x-ray, arms/legs ..........................
Vein x-ray, arms/legs ..........................
Vein x-ray, arms/legs ..........................
Vein x-ray, trunk ..................................
Vein x-ray, trunk ..................................
Vein x-ray, trunk ..................................
Vein x-ray, chest .................................
Vein x-ray, chest .................................
Vein x-ray, chest .................................
Vein x-ray, kidney ...............................
Vein x-ray, kidney ...............................
Vein x-ray, kidney ...............................
Vein x-ray, kidneys .............................
Vein x-ray, kidneys .............................
Vein x-ray, kidneys .............................
Vein x-ray, adrenal gland ....................
Vein x-ray, adrenal gland ....................
Vein x-ray, adrenal gland ....................
Vein x-ray, adrenal glands ..................
Vein x-ray, adrenal glands ..................
Vein x-ray, adrenal glands ..................
Vein x-ray, neck ..................................
Vein x-ray, neck ..................................
Vein x-ray, neck ..................................
Vein x-ray, skull ..................................
Vein x-ray, skull ..................................
Vein x-ray, skull ..................................
Vein x-ray, skull ..................................
Vein x-ray, skull ..................................
Vein x-ray, skull ..................................
Vein x-ray, eye socket ........................
Vein x-ray, eye socket ........................
Vein x-ray, eye socket ........................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.14
0.36
0.00
0.36
1.84
0.00
1.84
0.00
0.00
0.81
0.00
0.00
1.17
0.00
0.00
0.81
0.00
0.00
1.17
0.47
0.00
0.47
0.00
0.00
1.14
0.70
0.00
0.70
1.06
0.00
1.06
1.14
0.00
1.14
1.14
0.00
1.14
1.14
0.00
1.14
1.49
0.00
1.49
1.14
0.00
1.14
1.49
0.00
1.49
1.14
0.00
1.14
1.14
0.00
1.14
1.14
0.00
1.14
0.70
0.00
0.70
1.44
0.00
1.44
1.44
0.00
1.44
1.14
0.00
1.14
1.14
3.76
0.58
2.50
2.36
0.14
3.12
2.52
0.60
0.00
0.00
0.22
0.00
0.00
0.40
0.00
0.00
0.27
0.00
0.00
0.39
2.17
2.01
0.16
0.00
0.00
0.39
3.01
2.72
0.29
3.17
2.80
0.37
2.92
2.54
0.38
2.95
2.58
0.37
3.05
2.67
0.38
3.67
3.17
0.50
2.96
2.60
0.36
3.75
3.20
0.55
3.39
2.90
0.49
3.29
2.89
0.40
4.04
3.60
0.44
3.21
2.94
0.27
3.18
2.66
0.52
3.42
2.85
0.57
3.07
2.66
0.41
3.06
8.18
0.51
7.61
7.48
0.13
2.53
1.93
0.60
0.00
0.00
0.25
0.00
0.00
0.39
0.00
0.00
0.27
0.00
0.00
0.39
1.54
1.39
0.15
0.00
0.00
0.38
2.09
1.83
0.26
2.50
2.14
0.36
7.95
7.57
0.38
7.96
7.59
0.37
8.00
7.63
0.37
8.38
7.88
0.50
7.97
7.60
0.37
8.41
7.90
0.51
8.19
7.75
0.44
8.14
7.74
0.40
8.51
8.10
0.41
2.19
1.94
0.25
8.12
7.63
0.49
8.24
7.72
0.52
8.02
7.63
0.39
8.01
NA
0.58
NA
NA
0.14
NA
NA
0.60
NA
NA
0.22
NA
NA
0.40
NA
NA
0.27
NA
NA
0.39
NA
NA
0.16
NA
NA
0.39
NA
NA
0.29
NA
NA
0.37
NA
NA
0.38
NA
NA
0.37
NA
NA
0.38
NA
NA
0.50
NA
NA
0.36
NA
NA
0.55
NA
NA
0.49
NA
NA
0.40
NA
NA
0.44
NA
NA
0.27
NA
NA
0.52
NA
NA
0.57
NA
NA
0.41
NA
NA
0.51
NA
NA
0.13
NA
NA
0.60
NA
NA
0.25
NA
NA
0.39
NA
NA
0.27
NA
NA
0.39
NA
NA
0.15
NA
NA
0.38
NA
NA
0.26
NA
NA
0.36
NA
NA
0.38
NA
NA
0.37
NA
NA
0.37
NA
NA
0.50
NA
NA
0.37
NA
NA
0.51
NA
NA
0.44
NA
NA
0.40
NA
NA
0.41
NA
NA
0.25
NA
NA
0.49
NA
NA
0.52
NA
NA
0.39
NA
Malpractice
RVUs 2
0.65
0.04
0.67
0.65
0.02
0.17
0.08
0.09
0.00
0.00
0.08
0.00
0.00
0.05
0.00
0.00
0.05
0.00
0.00
0.05
0.07
0.05
0.02
0.00
0.00
0.05
0.09
0.06
0.03
0.13
0.08
0.05
0.72
0.65
0.07
0.70
0.65
0.05
0.71
0.65
0.06
0.74
0.65
0.09
0.72
0.65
0.07
0.72
0.65
0.07
0.69
0.65
0.04
0.70
0.65
0.05
0.79
0.65
0.14
0.09
0.06
0.03
0.71
0.65
0.06
0.71
0.65
0.06
0.70
0.65
0.05
0.70
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00281
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66502
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
75891
75891
75893
75893
75893
75894
75894
75894
75896
75896
75896
75898
75898
75898
75900
75900
75900
75901
75901
75901
75902
75902
75902
75940
75940
75940
75945
75945
75945
75946
75946
75946
75952
75952
75952
75953
75953
75953
75954
75954
75954
75956
75956
75956
75957
75957
75957
75958
75958
75958
75959
75959
75959
75960
75960
75960
75961
75961
75961
75962
75962
75962
75964
75964
75964
75966
75966
75966
75968
75968
75968
75970
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Vein x-ray, liver ...................................
Vein x-ray, liver ...................................
Venous sampling by catheter .............
Venous sampling by catheter .............
Venous sampling by catheter .............
X-rays, transcath therapy ....................
X-rays, transcath therapy ....................
X-rays, transcath therapy ....................
X-rays, transcath therapy ....................
X-rays, transcath therapy ....................
X-rays, transcath therapy ....................
Follow-up angiography ........................
Follow-up angiography ........................
Follow-up angiography ........................
Intravascular cath exchange ...............
Intravascular cath exchange ...............
Intravascular cath exchange ...............
Remove cva device obstruct ..............
Remove cva device obstruct ..............
Remove cva device obstruct ..............
Remove cva lumen obstruct ...............
Remove cva lumen obstruct ...............
Remove cva lumen obstruct ...............
X-ray placement, vein filter .................
X-ray placement, vein filter .................
X-ray placement, vein filter .................
Intravascular us ...................................
Intravascular us ...................................
Intravascular us ...................................
Intravascular us add-on ......................
Intravascular us add-on ......................
Intravascular us add-on ......................
Endovasc repair abdom aorta ............
Endovasc repair abdom aorta ............
Endovasc repair abdom aorta ............
Abdom aneurysm endovas rpr ...........
Abdom aneurysm endovas rpr ...........
Abdom aneurysm endovas rpr ...........
Iliac aneurysm endovas rpr ................
Iliac aneurysm endovas rpr ................
Iliac aneurysm endovas rpr ................
Xray, endovasc thor ao repr ...............
Xray, endovasc thor ao repr ...............
Xray, endovasc thor ao repr ...............
Xray, endovasc thor ao repr ...............
Xray, endovasc thor ao repr ...............
Xray, endovasc thor ao repr ...............
Xray, place prox ext thor ao ...............
Xray, place prox ext thor ao ...............
Xray, place prox ext thor ao ...............
Xray, place dist ext thor ao .................
Xray, place dist ext thor ao .................
Xray, place dist ext thor ao .................
Transcath iv stent rs&i ........................
Transcath iv stent rs&i ........................
Transcath iv stent rs&i ........................
Retrieval, broken catheter ...................
Retrieval, broken catheter ...................
Retrieval, broken catheter ...................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair artery blockage, each ..............
Repair artery blockage, each ..............
Repair artery blockage, each ..............
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair arterial blockage ......................
Repair artery blockage, each ..............
Repair artery blockage, each ..............
Repair artery blockage, each ..............
Vascular biopsy ...................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.14
0.54
0.00
0.54
0.00
0.00
1.31
0.00
0.00
1.31
0.00
0.00
1.65
0.00
0.00
0.49
0.49
0.00
0.49
0.39
0.00
0.39
0.00
0.00
0.54
0.00
0.00
0.40
0.00
0.00
0.40
0.00
0.00
4.49
0.00
0.00
1.36
0.00
0.00
2.25
0.00
0.00
7.00
0.00
0.00
6.00
0.00
0.00
4.00
0.00
0.00
3.50
0.82
0.00
0.82
4.24
0.00
4.24
0.54
0.00
0.54
0.36
0.00
0.36
1.31
0.00
1.31
0.36
0.00
0.36
0.00
2.65
0.41
2.86
2.66
0.20
0.00
0.00
0.46
0.00
0.00
0.52
0.00
0.00
0.63
0.00
0.00
0.17
4.15
3.98
0.17
1.63
1.50
0.13
0.00
0.00
0.18
0.00
0.00
0.14
0.00
0.00
0.12
0.00
0.00
1.30
0.00
0.00
0.40
0.00
0.00
0.63
0.00
0.00
1.88
0.00
0.00
1.63
0.00
0.00
1.04
0.00
0.00
0.92
2.71
2.39
0.32
4.66
3.18
1.48
3.50
3.30
0.20
2.35
2.22
0.13
4.16
3.59
0.57
2.41
2.25
0.16
0.00
7.62
0.39
7.82
7.63
0.19
0.00
0.00
0.44
0.00
0.00
0.48
0.00
0.00
0.59
0.00
0.00
0.16
2.80
2.64
0.16
1.53
1.40
0.13
0.00
0.00
0.18
0.00
0.00
0.14
0.00
0.00
0.13
0.00
0.00
1.39
0.00
0.00
0.42
0.00
0.00
0.70
0.00
0.00
2.29
0.00
0.00
1.97
0.00
0.00
1.29
0.00
0.00
1.14
8.94
8.64
0.30
8.28
6.84
1.44
9.71
9.52
0.19
5.42
5.30
0.12
10.17
9.66
0.51
5.46
5.32
0.14
0.00
NA
0.41
NA
NA
0.20
NA
NA
0.46
NA
NA
0.52
NA
NA
0.63
NA
NA
0.17
NA
NA
0.17
NA
NA
0.13
NA
NA
0.18
NA
NA
0.14
NA
NA
0.12
NA
NA
1.30
NA
NA
0.40
NA
NA
0.63
NA
NA
1.88
NA
NA
1.63
NA
NA
1.04
NA
NA
0.92
NA
NA
0.32
NA
NA
1.48
NA
NA
0.20
NA
NA
0.13
NA
NA
0.57
NA
NA
0.16
NA
NA
0.39
NA
NA
0.19
NA
NA
0.44
NA
NA
0.48
NA
NA
0.59
NA
NA
0.16
NA
NA
0.16
NA
NA
0.13
NA
NA
0.18
NA
NA
0.14
NA
NA
0.13
NA
NA
1.39
NA
NA
0.42
NA
NA
0.70
NA
NA
2.29
NA
NA
1.97
NA
NA
1.29
NA
NA
1.14
NA
NA
0.30
NA
NA
1.44
NA
NA
0.19
NA
NA
0.12
NA
NA
0.51
NA
NA
0.14
NA
Malpractice
RVUs 2
0.65
0.05
0.67
0.65
0.02
0.00
0.00
0.08
0.00
0.00
0.05
0.00
0.00
0.07
0.00
0.00
0.03
0.85
0.83
0.02
0.85
0.83
0.02
0.00
0.00
0.04
0.00
0.00
0.04
0.00
0.00
0.05
0.00
0.00
0.43
0.00
0.00
0.13
0.00
0.00
0.15
0.00
0.00
0.69
0.00
0.00
0.59
0.00
0.00
0.39
0.00
0.00
0.34
0.82
0.77
0.05
0.73
0.55
0.18
0.86
0.83
0.03
0.46
0.43
0.03
0.89
0.83
0.06
0.45
0.43
0.02
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00282
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66503
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
75970
75970
75978
75978
75978
75980
75980
75980
75982
75982
75982
75984
75984
75984
75989
75989
75989
75992
75992
75992
75993
75993
75993
75994
75994
75994
75995
75995
75995
75996
75996
75996
76000
76000
76000
76001
76001
76001
76010
76010
76010
76080
76080
76080
76098
76098
76098
76100
76100
76100
76101
76101
76101
76102
76102
76102
76120
76120
76120
76125
76125
76125
76140
76150
76350
76376
76376
76376
76377
76377
76377
76380
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
C ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
I ..........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
Vascular biopsy ...................................
Vascular biopsy ...................................
Repair venous blockage .....................
Repair venous blockage .....................
Repair venous blockage .....................
Contrast xray exam bile duct ..............
Contrast xray exam bile duct ..............
Contrast xray exam bile duct ..............
Contrast xray exam bile duct ..............
Contrast xray exam bile duct ..............
Contrast xray exam bile duct ..............
Xray control catheter change ..............
Xray control catheter change ..............
Xray control catheter change ..............
Abscess drainage under x-ray ............
Abscess drainage under x-ray ............
Abscess drainage under x-ray ............
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Atherectomy, x-ray exam ....................
Fluoroscope examination ....................
Fluoroscope examination ....................
Fluoroscope examination ....................
Fluoroscope exam, extensive .............
Fluoroscope exam, extensive .............
Fluoroscope exam, extensive .............
X-ray, nose to rectum .........................
X-ray, nose to rectum .........................
X-ray, nose to rectum .........................
X-ray exam of fistula ...........................
X-ray exam of fistula ...........................
X-ray exam of fistula ...........................
X-ray exam, breast specimen .............
X-ray exam, breast specimen .............
X-ray exam, breast specimen .............
X-ray exam of body section ................
X-ray exam of body section ................
X-ray exam of body section ................
Complex body section x-ray ...............
Complex body section x-ray ...............
Complex body section x-ray ...............
Complex body section x-rays .............
Complex body section x-rays .............
Complex body section x-rays .............
Cine/video x-rays ................................
Cine/video x-rays ................................
Cine/video x-rays ................................
Cine/video x-rays add-on ....................
Cine/video x-rays add-on ....................
Cine/video x-rays add-on ....................
X-ray consultation ...............................
X-ray exam, dry process .....................
Special x-ray contrast study ...............
3d render w/o postprocess .................
3d render w/o postprocess .................
3d render w/o postprocess .................
3d rendering w/postprocess ................
3d rendering w/postprocess ................
3d rendering w/postprocess ................
CAT scan follow-up study ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.83
0.54
0.00
0.54
0.00
0.00
1.44
0.00
0.00
1.44
0.72
0.00
0.72
1.19
0.00
1.19
0.00
0.00
0.54
0.00
0.00
0.36
0.00
0.00
1.31
0.00
0.00
1.31
0.00
0.00
0.36
0.17
0.00
0.17
0.00
0.00
0.67
0.18
0.00
0.18
0.54
0.00
0.54
0.16
0.00
0.16
0.58
0.00
0.58
0.58
0.00
0.58
0.58
0.00
0.58
0.38
0.00
0.38
0.00
0.00
0.27
0.00
0.00
0.00
0.20
0.00
0.20
0.79
0.00
0.79
0.98
0.00
0.31
3.26
3.08
0.18
0.00
0.00
0.52
0.00
0.00
0.52
2.31
2.05
0.26
2.24
1.82
0.42
0.00
0.00
0.22
0.00
0.00
0.14
0.00
0.00
0.54
0.00
0.00
0.48
0.00
0.00
0.12
2.77
2.71
0.06
0.00
0.00
0.24
0.54
0.48
0.06
1.10
0.90
0.20
0.32
0.27
0.05
3.55
3.35
0.20
5.45
5.27
0.18
7.64
7.46
0.18
1.87
1.74
0.13
0.00
0.00
0.12
0.00
0.68
0.00
1.40
1.33
0.07
1.40
1.12
0.28
4.71
0.00
0.29
9.59
9.41
0.18
0.00
0.00
0.49
0.00
0.00
0.50
2.24
2.00
0.24
2.89
2.48
0.41
0.00
0.00
0.21
0.00
0.00
0.13
0.00
0.00
0.50
0.00
0.00
0.47
0.00
0.00
0.12
2.06
2.01
0.05
0.00
0.00
0.23
0.56
0.50
0.06
1.16
0.97
0.19
0.39
0.34
0.05
2.50
2.30
0.20
3.53
3.34
0.19
4.78
4.60
0.18
1.52
1.39
0.13
0.00
0.00
0.11
0.00
0.55
0.00
2.45
2.38
0.07
2.54
2.27
0.27
4.26
NA
0.31
NA
NA
0.18
NA
NA
0.52
NA
NA
0.52
NA
NA
0.26
NA
NA
0.42
NA
NA
0.22
NA
NA
0.14
NA
NA
0.54
NA
NA
0.48
NA
NA
0.12
NA
NA
0.06
NA
NA
0.24
NA
NA
0.06
NA
NA
0.20
NA
NA
0.05
NA
NA
0.20
NA
NA
0.18
NA
NA
0.18
NA
NA
0.13
NA
NA
0.12
0.00
NA
0.00
NA
NA
0.07
NA
NA
0.28
NA
NA
0.29
NA
NA
0.18
NA
NA
0.49
NA
NA
0.50
NA
NA
0.24
NA
NA
0.41
NA
NA
0.21
NA
NA
0.13
NA
NA
0.50
NA
NA
0.47
NA
NA
0.12
NA
NA
0.05
NA
NA
0.23
NA
NA
0.06
NA
NA
0.19
NA
NA
0.05
NA
NA
0.20
NA
NA
0.19
NA
NA
0.18
NA
NA
0.13
NA
NA
0.11
0.00
NA
0.00
NA
NA
0.07
NA
NA
0.27
NA
Malpractice
RVUs 2
0.00
0.04
0.85
0.83
0.02
0.00
0.00
0.06
0.00
0.00
0.06
0.14
0.11
0.03
0.22
0.17
0.05
0.00
0.00
0.03
0.00
0.00
0.02
0.00
0.00
0.07
0.00
0.00
0.05
0.00
0.00
0.02
0.08
0.07
0.01
0.00
0.00
0.05
0.03
0.02
0.01
0.08
0.06
0.02
0.03
0.02
0.01
0.10
0.07
0.03
0.11
0.08
0.03
0.14
0.11
0.03
0.08
0.06
0.02
0.00
0.00
0.01
0.00
0.02
0.00
0.10
0.08
0.02
0.39
0.31
0.08
0.22
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00283
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66504
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
76380
76380
76390
76390
76390
76496
76496
76496
76497
76497
76497
76498
76498
76498
76499
76499
76499
76506
76506
76506
76510
76510
76510
76511
76511
76511
76512
76512
76512
76513
76513
76513
76514
76514
76514
76516
76516
76516
76519
76519
76519
76529
76529
76529
76536
76536
76536
76604
76604
76604
76645
76645
76645
76700
76700
76700
76705
76705
76705
76770
76770
76770
76775
76775
76775
76776
76776
76776
76800
76800
76800
76801
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
N
N
N
C
C
C
C
C
C
C
C
C
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
CAT scan follow-up study ...................
CAT scan follow-up study ...................
Mr spectroscopy ..................................
Mr spectroscopy ..................................
Mr spectroscopy ..................................
Fluoroscopic procedure ......................
Fluoroscopic procedure ......................
Fluoroscopic procedure ......................
Ct procedure .......................................
Ct procedure .......................................
Ct procedure .......................................
Mri procedure ......................................
Mri procedure ......................................
Mri procedure ......................................
Radiographic procedure ......................
Radiographic procedure ......................
Radiographic procedure ......................
Echo exam of head .............................
Echo exam of head .............................
Echo exam of head .............................
Ophth us, b & quant a ........................
Ophth us, b & quant a ........................
Ophth us, b & quant a ........................
Ophth us, quant a only .......................
Ophth us, quant a only .......................
Ophth us, quant a only .......................
Ophth us, b w/non-quant a .................
Ophth us, b w/non-quant a .................
Ophth us, b w/non-quant a .................
Echo exam of eye, water bath ............
Echo exam of eye, water bath ............
Echo exam of eye, water bath ............
Echo exam of eye, thickness ..............
Echo exam of eye, thickness ..............
Echo exam of eye, thickness ..............
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Echo exam of eye ...............................
Us exam of head and neck ................
Us exam of head and neck ................
Us exam of head and neck ................
Us exam, chest ...................................
Us exam, chest ...................................
Us exam, chest ...................................
Us exam, breast(s) .............................
Us exam, breast(s) .............................
Us exam, breast(s) .............................
Us exam, abdom, complete ................
Us exam, abdom, complete ................
Us exam, abdom, complete ................
Echo exam of abdomen ......................
Echo exam of abdomen ......................
Echo exam of abdomen ......................
Us exam abdo back wall, comp .........
Us exam abdo back wall, comp .........
Us exam abdo back wall, comp .........
Us exam abdo back wall, lim ..............
Us exam abdo back wall, lim ..............
Us exam abdo back wall, lim ..............
Us exam k transpl w/doppler ..............
Us exam k transpl w/doppler ..............
Us exam k transpl w/doppler ..............
Us exam, spinal canal ........................
Us exam, spinal canal ........................
Us exam, spinal canal ........................
Ob us < 14 wks, single fetus ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.98
1.40
0.00
1.40
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.63
0.00
0.63
1.55
0.00
1.55
0.94
0.00
0.94
0.94
0.00
0.94
0.66
0.00
0.66
0.17
0.00
0.17
0.54
0.00
0.54
0.54
0.00
0.54
0.57
0.00
0.57
0.56
0.00
0.56
0.55
0.00
0.55
0.54
0.00
0.54
0.81
0.00
0.81
0.59
0.00
0.59
0.74
0.00
0.74
0.58
0.00
0.58
0.76
0.00
0.76
1.13
0.00
1.13
0.99
4.37
0.34
9.42
9.10
0.32
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2.76
2.56
0.20
2.25
1.70
0.55
1.35
1.02
0.33
1.16
0.83
0.33
1.52
1.29
0.23
0.16
0.10
0.06
1.15
0.97
0.18
1.28
1.09
0.19
1.15
0.95
0.20
2.67
2.49
0.18
1.83
1.64
0.19
2.12
1.93
0.19
3.02
2.75
0.27
2.35
2.14
0.21
2.93
2.67
0.26
2.42
2.21
0.21
3.43
3.16
0.27
2.31
2.03
0.28
2.46
3.93
0.33
10.44
10.05
0.39
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2.21
1.99
0.22
2.55
1.94
0.61
1.88
1.52
0.36
1.69
1.32
0.37
1.66
1.40
0.26
0.15
0.08
0.07
1.30
1.09
0.21
1.42
1.20
0.22
1.26
1.04
0.22
2.13
1.95
0.18
1.66
1.47
0.19
1.67
1.49
0.18
2.63
2.36
0.27
1.98
1.78
0.20
2.57
2.32
0.25
2.01
1.81
0.20
2.82
2.57
0.25
2.03
1.72
0.31
2.45
NA
0.34
NA
NA
0.32
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.20
NA
NA
0.55
NA
NA
0.33
NA
NA
0.33
NA
NA
0.23
NA
NA
0.06
NA
NA
0.18
NA
NA
0.19
NA
NA
0.20
NA
NA
0.18
NA
NA
0.19
NA
NA
0.19
NA
NA
0.27
NA
NA
0.21
NA
NA
0.26
NA
NA
0.21
NA
NA
0.27
NA
NA
0.28
NA
NA
0.33
NA
NA
0.39
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
NA
NA
0.22
NA
NA
0.61
NA
NA
0.36
NA
NA
0.37
NA
NA
0.26
NA
NA
0.07
NA
NA
0.21
NA
NA
0.22
NA
NA
0.22
NA
NA
0.18
NA
NA
0.19
NA
NA
0.18
NA
NA
0.27
NA
NA
0.20
NA
NA
0.25
NA
NA
0.20
NA
NA
0.25
NA
NA
0.31
NA
Malpractice
RVUs 2
0.18
0.04
0.66
0.59
0.07
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.14
0.08
0.06
0.10
0.07
0.03
0.10
0.07
0.03
0.12
0.10
0.02
0.12
0.10
0.02
0.02
0.01
0.01
0.08
0.07
0.01
0.08
0.07
0.01
0.10
0.08
0.02
0.10
0.08
0.02
0.09
0.07
0.02
0.08
0.06
0.02
0.15
0.11
0.04
0.11
0.08
0.03
0.14
0.11
0.03
0.11
0.08
0.03
0.14
0.11
0.03
0.13
0.08
0.05
0.16
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00284
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66505
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
76801
76801
76802
76802
76802
76805
76805
76805
76810
76810
76810
76811
76811
76811
76812
76812
76812
76813
76813
76813
76814
76814
76814
76815
76815
76815
76816
76816
76816
76817
76817
76817
76818
76818
76818
76819
76819
76819
76820
76820
76820
76821
76821
76821
76825
76825
76825
76826
76826
76826
76827
76827
76827
76828
76828
76828
76830
76830
76830
76831
76831
76831
76856
76856
76856
76857
76857
76857
76870
76870
76870
76872
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Ob us < 14 wks, single fetus ..............
Ob us < 14 wks, single fetus ..............
Ob us < 14 wks, add’l fetus ................
Ob us < 14 wks, add’l fetus ................
Ob us < 14 wks, add’l fetus ................
Ob us >/= 14 wks, sngl fetus ..............
Ob us >/= 14 wks, sngl fetus ..............
Ob us >/= 14 wks, sngl fetus ..............
Ob us >/= 14 wks, addl fetus .............
Ob us >/= 14 wks, addl fetus .............
Ob us >/= 14 wks, addl fetus .............
Ob us, detailed, sngl fetus ..................
Ob us, detailed, sngl fetus ..................
Ob us, detailed, sngl fetus ..................
Ob us, detailed, addl fetus ..................
Ob us, detailed, addl fetus ..................
Ob us, detailed, addl fetus ..................
Ob us nuchal meas, 1 gest ................
Ob us nuchal meas, 1 gest ................
Ob us nuchal meas, 1 gest ................
Ob us nuchal meas, add-on ...............
Ob us nuchal meas, add-on ...............
Ob us nuchal meas, add-on ...............
Ob us, limited, fetus(s) ........................
Ob us, limited, fetus(s) ........................
Ob us, limited, fetus(s) ........................
Ob us, follow-up, per fetus .................
Ob us, follow-up, per fetus .................
Ob us, follow-up, per fetus .................
Transvaginal us, obstetric ...................
Transvaginal us, obstetric ...................
Transvaginal us, obstetric ...................
Fetal biophys profile w/nst ..................
Fetal biophys profile w/nst ..................
Fetal biophys profile w/nst ..................
Fetal biophys profil w/o nst .................
Fetal biophys profil w/o nst .................
Fetal biophys profil w/o nst .................
Umbilical artery echo ..........................
Umbilical artery echo ..........................
Umbilical artery echo ..........................
Middle cerebral artery echo ................
Middle cerebral artery echo ................
Middle cerebral artery echo ................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Echo exam of fetal heart ....................
Transvaginal us, non-ob .....................
Transvaginal us, non-ob .....................
Transvaginal us, non-ob .....................
Echo exam, uterus ..............................
Echo exam, uterus ..............................
Echo exam, uterus ..............................
Us exam, pelvic, complete ..................
Us exam, pelvic, complete ..................
Us exam, pelvic, complete ..................
Us exam, pelvic, limited ......................
Us exam, pelvic, limited ......................
Us exam, pelvic, limited ......................
Us exam, scrotum ...............................
Us exam, scrotum ...............................
Us exam, scrotum ...............................
Us, transrectal .....................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.99
0.83
0.00
0.83
0.99
0.00
0.99
0.98
0.00
0.98
1.90
0.00
1.90
1.78
0.00
1.78
1.18
0.00
1.18
0.99
0.00
0.99
0.65
0.00
0.65
0.85
0.00
0.85
0.75
0.00
0.75
1.05
0.00
1.05
0.77
0.00
0.77
0.50
0.00
0.50
0.70
0.00
0.70
1.67
0.00
1.67
0.83
0.00
0.83
0.58
0.00
0.58
0.56
0.00
0.56
0.69
0.00
0.69
0.72
0.00
0.72
0.69
0.00
0.69
0.38
0.00
0.38
0.64
0.00
0.64
0.69
2.16
0.30
0.97
0.71
0.26
3.04
2.73
0.31
1.65
1.35
0.30
3.05
2.51
0.54
3.98
3.48
0.50
2.21
1.81
0.40
1.15
0.86
0.29
1.80
1.60
0.20
2.38
2.13
0.25
2.02
1.79
0.23
2.21
1.91
0.30
1.63
1.40
0.23
0.56
0.42
0.14
1.86
1.66
0.20
4.37
3.87
0.50
2.76
2.52
0.24
1.07
0.90
0.17
0.63
0.48
0.15
2.76
2.54
0.22
2.73
2.52
0.21
2.79
2.55
0.24
2.48
2.34
0.14
2.83
2.60
0.23
3.40
2.13
0.32
1.16
0.88
0.28
2.74
2.42
0.32
1.52
1.20
0.32
3.64
3.02
0.62
2.84
2.26
0.58
2.21
1.81
0.40
1.15
0.86
0.29
1.72
1.51
0.21
1.90
1.62
0.28
1.89
1.65
0.24
2.11
1.76
0.35
1.75
1.50
0.25
1.18
1.01
0.17
1.87
1.63
0.24
3.47
2.92
0.55
1.88
1.61
0.27
1.50
1.31
0.19
0.98
0.79
0.19
2.26
2.03
0.23
2.25
2.02
0.23
2.26
2.03
0.23
2.15
2.02
0.13
2.28
2.06
0.22
2.82
NA
0.30
NA
NA
0.26
NA
NA
0.31
NA
NA
0.30
NA
NA
0.54
NA
NA
0.50
NA
NA
0.40
NA
NA
0.29
NA
NA
0.20
NA
NA
0.25
NA
NA
0.23
NA
NA
0.30
NA
NA
0.23
NA
NA
0.14
NA
NA
0.20
NA
NA
0.50
NA
NA
0.24
NA
NA
0.17
NA
NA
0.15
NA
NA
0.22
NA
NA
0.21
NA
NA
0.24
NA
NA
0.14
NA
NA
0.23
NA
NA
0.32
NA
NA
0.28
NA
NA
0.32
NA
NA
0.32
NA
NA
0.62
NA
NA
0.58
NA
NA
0.40
NA
NA
0.29
NA
NA
0.21
NA
NA
0.28
NA
NA
0.24
NA
NA
0.35
NA
NA
0.25
NA
NA
0.17
NA
NA
0.24
NA
NA
0.55
NA
NA
0.27
NA
NA
0.19
NA
NA
0.19
NA
NA
0.23
NA
NA
0.23
NA
NA
0.23
NA
NA
0.13
NA
NA
0.22
NA
Malpractice
RVUs 2
0.12
0.04
0.16
0.12
0.04
0.16
0.12
0.04
0.26
0.22
0.04
0.52
0.43
0.09
0.49
0.41
0.08
0.19
0.14
0.05
0.19
0.14
0.05
0.11
0.08
0.03
0.10
0.06
0.04
0.09
0.06
0.03
0.15
0.10
0.05
0.13
0.10
0.03
0.15
0.12
0.03
0.15
0.12
0.03
0.18
0.11
0.07
0.08
0.05
0.03
0.14
0.12
0.02
0.11
0.08
0.03
0.13
0.10
0.03
0.13
0.10
0.03
0.13
0.10
0.03
0.08
0.06
0.02
0.13
0.10
0.03
0.14
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00285
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66506
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
76872
76872
76873
76873
76873
76880
76880
76880
76885
76885
76885
76886
76886
76886
76930
76930
76930
76932
76932
76932
76936
76936
76936
76937
76937
76937
76940
76940
76940
76941
76941
76941
76942
76942
76942
76945
76945
76945
76946
76946
76946
76948
76948
76948
76950
76950
76950
76965
76965
76965
76970
76970
76970
76975
76975
76975
76977
76977
76977
76998
76998
76998
76999
76999
76999
77001
77001
77001
77002
77002
77002
77003
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
C
C
A
C
C
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
C
C
A
C
C
C
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Us, transrectal .....................................
Us, transrectal .....................................
Echograp trans r, pros study ..............
Echograp trans r, pros study ..............
Echograp trans r, pros study ..............
Us exam, extremity .............................
Us exam, extremity .............................
Us exam, extremity .............................
Us exam infant hips, dynamic ............
Us exam infant hips, dynamic ............
Us exam infant hips, dynamic ............
Us exam infant hips, static .................
Us exam infant hips, static .................
Us exam infant hips, static .................
Echo guide, cardiocentesis .................
Echo guide, cardiocentesis .................
Echo guide, cardiocentesis .................
Echo guide for heart biopsy ................
Echo guide for heart biopsy ................
Echo guide for heart biopsy ................
Echo guide for artery repair ................
Echo guide for artery repair ................
Echo guide for artery repair ................
Us guide, vascular access ..................
Us guide, vascular access ..................
Us guide, vascular access ..................
Us guide, tissue ablation ....................
Us guide, tissue ablation ....................
Us guide, tissue ablation ....................
Echo guide for transfusion ..................
Echo guide for transfusion ..................
Echo guide for transfusion ..................
Echo guide for biopsy .........................
Echo guide for biopsy .........................
Echo guide for biopsy .........................
Echo guide, villus sampling ................
Echo guide, villus sampling ................
Echo guide, villus sampling ................
Echo guide for amniocentesis ............
Echo guide for amniocentesis ............
Echo guide for amniocentesis ............
Echo guide, ova aspiration .................
Echo guide, ova aspiration .................
Echo guide, ova aspiration .................
Echo guidance radiotherapy ...............
Echo guidance radiotherapy ...............
Echo guidance radiotherapy ...............
Echo guidance radiotherapy ...............
Echo guidance radiotherapy ...............
Echo guidance radiotherapy ...............
Ultrasound exam follow-up .................
Ultrasound exam follow-up .................
Ultrasound exam follow-up .................
GI endoscopic ultrasound ...................
GI endoscopic ultrasound ...................
GI endoscopic ultrasound ...................
Us bone density measure ...................
Us bone density measure ...................
Us bone density measure ...................
Us guide, intraop .................................
Us guide, intraop .................................
Us guide, intraop .................................
Echo examination procedure ..............
Echo examination procedure ..............
Echo examination procedure ..............
Fluoroguide for vein device ................
Fluoroguide for vein device ................
Fluoroguide for vein device ................
Needle localization by xray .................
Needle localization by xray .................
Needle localization by xray .................
Fluoroguide for spine inject ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.69
1.55
0.00
1.55
0.59
0.00
0.59
0.74
0.00
0.74
0.62
0.00
0.62
0.67
0.00
0.67
0.00
0.00
0.67
1.99
0.00
1.99
0.30
0.00
0.30
0.00
0.00
2.00
0.00
0.00
1.34
0.67
0.00
0.67
0.00
0.00
0.67
0.38
0.00
0.38
0.38
0.00
0.38
0.58
0.00
0.58
1.34
0.00
1.34
0.40
0.00
0.40
0.00
0.00
0.81
0.05
0.00
0.05
0.00
0.00
1.20
0.00
0.00
0.00
0.38
0.00
0.38
0.54
0.00
0.54
0.60
3.13
0.27
3.40
2.85
0.55
3.18
3.00
0.18
3.26
3.01
0.25
2.27
2.05
0.22
2.08
1.74
0.34
0.00
0.00
0.35
6.12
5.41
0.71
0.62
0.52
0.10
0.00
0.00
0.65
0.00
0.00
0.38
4.79
4.55
0.24
0.00
0.00
0.21
0.45
0.34
0.11
0.45
0.35
0.10
1.21
1.02
0.19
1.20
0.70
0.50
1.98
1.87
0.11
0.00
0.00
0.30
0.10
0.09
0.01
0.00
0.00
0.35
0.00
0.00
0.00
2.72
2.59
0.13
1.23
1.07
0.16
0.76
2.58
0.24
2.99
2.47
0.52
2.40
2.21
0.19
2.50
2.26
0.24
1.94
1.73
0.21
1.92
1.63
0.29
0.00
0.00
0.30
6.54
5.85
0.69
0.55
0.45
0.10
0.00
0.00
0.65
0.00
0.00
0.42
3.91
3.68
0.23
0.00
0.00
0.21
1.05
0.93
0.12
1.04
0.93
0.11
1.35
1.16
0.19
3.60
3.14
0.46
1.58
1.46
0.12
0.00
0.00
0.29
0.48
0.46
0.02
0.00
0.00
0.37
0.00
0.00
0.00
2.08
1.95
0.13
1.35
1.19
0.16
1.11
NA
0.27
NA
NA
0.55
NA
NA
0.18
NA
NA
0.25
NA
NA
0.22
NA
NA
0.34
NA
NA
0.35
NA
NA
0.71
NA
NA
0.10
NA
NA
0.65
NA
NA
0.38
NA
NA
0.24
NA
NA
0.21
NA
NA
0.11
NA
NA
0.10
NA
NA
0.19
NA
NA
0.50
NA
NA
0.11
NA
NA
0.30
NA
NA
0.01
NA
NA
0.35
NA
NA
0.00
NA
NA
0.13
NA
NA
0.16
NA
NA
0.24
NA
NA
0.52
NA
NA
0.19
NA
NA
0.24
NA
NA
0.21
NA
NA
0.29
NA
NA
0.30
NA
NA
0.69
NA
NA
0.10
NA
NA
0.65
NA
NA
0.42
NA
NA
0.23
NA
NA
0.21
NA
NA
0.12
NA
NA
0.11
NA
NA
0.19
NA
NA
0.46
NA
NA
0.12
NA
NA
0.29
NA
NA
0.02
NA
NA
0.37
NA
NA
0.00
NA
NA
0.13
NA
NA
0.16
NA
Malpractice
RVUs 2
0.10
0.04
0.25
0.16
0.09
0.11
0.08
0.03
0.13
0.10
0.03
0.11
0.08
0.03
0.12
0.10
0.02
0.00
0.00
0.02
0.47
0.34
0.13
0.13
0.10
0.03
0.00
0.00
0.31
0.00
0.00
0.07
0.13
0.10
0.03
0.00
0.00
0.03
0.12
0.10
0.02
0.12
0.10
0.02
0.10
0.07
0.03
0.37
0.29
0.08
0.08
0.06
0.02
0.00
0.00
0.04
0.06
0.05
0.01
0.00
0.00
0.13
0.00
0.00
0.00
0.11
0.10
0.01
0.09
0.07
0.02
0.10
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00286
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66507
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
77003
77003
77011
77011
77011
77012
77012
77012
77013
77013
77013
77014
77014
77014
77021
77021
77021
77022
77022
77022
77031
77031
77031
77032
77032
77032
77051
77051
77051
77052
77052
77052
77053
77053
77053
77054
77054
77054
77055
77055
77055
77056
77056
77056
77057
77057
77057
77058
77058
77058
77059
77059
77059
77071
77072
77072
77072
77073
77073
77073
77074
77074
77074
77075
77075
77075
77076
77076
77076
77077
77077
77077
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Fluoroguide for spine inject ................
Fluoroguide for spine inject ................
Ct scan for localization .......................
Ct scan for localization .......................
Ct scan for localization .......................
Ct scan for needle biopsy ...................
Ct scan for needle biopsy ...................
Ct scan for needle biopsy ...................
Ct guide for tissue ablation .................
Ct guide for tissue ablation .................
Ct guide for tissue ablation .................
Ct scan for therapy guide ...................
Ct scan for therapy guide ...................
Ct scan for therapy guide ...................
Mr guidance for needle place .............
Mr guidance for needle place .............
Mr guidance for needle place .............
Mri for tissue ablation .........................
Mri for tissue ablation .........................
Mri for tissue ablation .........................
Stereotact guide for brst bx ................
Stereotact guide for brst bx ................
Stereotact guide for brst bx ................
Guidance for needle, breast ...............
Guidance for needle, breast ...............
Guidance for needle, breast ...............
Computer dx mammogram add-on .....
Computer dx mammogram add-on .....
Computer dx mammogram add-on .....
Comp screen mammogram add-on ....
Comp screen mammogram add-on ....
Comp screen mammogram add-on ....
X-ray of mammary duct ......................
X-ray of mammary duct ......................
X-ray of mammary duct ......................
X-ray of mammary ducts ....................
X-ray of mammary ducts ....................
X-ray of mammary ducts ....................
Mammogram, one breast ....................
Mammogram, one breast ....................
Mammogram, one breast ....................
Mammogram, both breasts .................
Mammogram, both breasts .................
Mammogram, both breasts .................
Mammogram, screening .....................
Mammogram, screening .....................
Mammogram, screening .....................
Mri, one breast ....................................
Mri, one breast ....................................
Mri, one breast ....................................
Mri, both breasts .................................
Mri, both breasts .................................
Mri, both breasts .................................
X-ray stress view ................................
X-rays for bone age ............................
X-rays for bone age ............................
X-rays for bone age ............................
X-rays, bone length studies ................
X-rays, bone length studies ................
X-rays, bone length studies ................
X-rays, bone survey, limited ...............
X-rays, bone survey, limited ...............
X-rays, bone survey, limited ...............
X-rays, bone survey complete ............
X-rays, bone survey complete ............
X-rays, bone survey complete ............
X-rays, bone survey, infant .................
X-rays, bone survey, infant .................
X-rays, bone survey, infant .................
Joint survey, single view .....................
Joint survey, single view .....................
Joint survey, single view .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.60
1.21
0.00
1.21
1.16
0.00
1.16
0.00
0.00
3.99
0.85
0.00
0.85
1.50
0.00
1.50
0.00
0.00
4.24
1.59
0.00
1.59
0.56
0.00
0.56
0.06
0.00
0.06
0.06
0.00
0.06
0.36
0.00
0.36
0.45
0.00
0.45
0.70
0.00
0.70
0.87
0.00
0.87
0.70
0.00
0.70
1.63
0.00
1.63
1.63
0.00
1.63
0.41
0.19
0.00
0.19
0.27
0.00
0.27
0.45
0.00
0.45
0.54
0.00
0.54
0.70
0.00
0.70
0.31
0.00
0.31
0.62
0.14
20.26
19.86
0.40
2.33
1.92
0.41
0.00
0.00
1.43
4.47
4.19
0.28
9.70
9.18
0.52
0.00
0.00
1.52
1.87
1.34
0.53
0.84
0.64
0.20
0.20
0.18
0.02
0.20
0.18
0.02
1.24
1.11
0.13
1.68
1.52
0.16
1.65
1.40
0.25
2.15
1.84
0.31
1.44
1.20
0.24
21.62
21.06
0.56
21.56
20.99
0.57
0.77
0.42
0.36
0.06
0.67
0.57
0.10
1.44
1.28
0.16
2.29
2.10
0.19
2.13
1.90
0.23
0.66
0.55
0.11
0.96
0.15
14.45
14.05
0.40
5.47
5.08
0.39
0.00
0.00
1.36
3.85
3.57
0.28
10.70
10.19
0.51
0.00
0.00
1.45
4.77
4.25
0.52
1.16
0.97
0.19
0.32
0.30
0.02
0.32
0.30
0.02
1.98
1.86
0.12
2.74
2.59
0.15
1.46
1.22
0.24
1.86
1.57
0.29
1.45
1.21
0.24
19.89
19.34
0.55
22.99
22.44
0.55
0.47
0.42
0.36
0.06
0.77
0.67
0.10
1.30
1.14
0.16
1.96
1.77
0.19
1.54
1.31
0.23
0.93
0.83
0.10
NA
0.14
NA
NA
0.40
NA
NA
0.41
NA
NA
1.43
NA
NA
0.28
NA
NA
0.52
NA
NA
1.52
NA
NA
0.53
NA
NA
0.20
NA
NA
0.02
NA
NA
0.02
NA
NA
0.13
NA
NA
0.16
NA
NA
0.25
NA
NA
0.31
NA
NA
0.24
NA
NA
0.56
NA
NA
0.57
0.77
NA
NA
0.06
NA
NA
0.10
NA
NA
0.16
NA
NA
0.19
NA
NA
0.23
NA
NA
0.11
NA
0.15
NA
NA
0.40
NA
NA
0.39
NA
NA
1.36
NA
NA
0.28
NA
NA
0.51
NA
NA
1.45
NA
NA
0.52
NA
NA
0.19
NA
NA
0.02
NA
NA
0.02
NA
NA
0.12
NA
NA
0.15
NA
NA
0.24
NA
NA
0.29
NA
NA
0.24
NA
NA
0.55
NA
NA
0.55
0.47
NA
NA
0.06
NA
NA
0.10
NA
NA
0.16
NA
NA
0.19
NA
NA
0.23
NA
NA
0.10
Malpractice
RVUs 2
0.07
0.03
0.47
0.42
0.05
0.47
0.42
0.05
0.00
0.00
0.18
0.20
0.16
0.04
0.64
0.55
0.09
0.00
0.00
0.24
0.46
0.37
0.09
0.09
0.07
0.02
0.02
0.01
0.01
0.02
0.01
0.01
0.16
0.14
0.02
0.21
0.19
0.02
0.09
0.06
0.03
0.11
0.07
0.04
0.10
0.07
0.03
0.99
0.92
0.07
1.31
1.24
0.07
0.06
0.03
0.02
0.01
0.06
0.05
0.01
0.08
0.06
0.02
0.10
0.08
0.02
0.08
0.05
0.03
0.08
0.06
0.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00287
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66508
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
77078
77078
77078
77079
77079
77079
77080
77080
77080
77081
77081
77081
77082
77082
77082
77083
77083
77083
77084
77084
77084
77261
77262
77263
77280
77280
77280
77285
77285
77285
77290
77290
77290
77295
77295
77295
77299
77299
77299
77300
77300
77300
77301
77301
77301
77305
77305
77305
77310
77310
77310
77315
77315
77315
77321
77321
77321
77326
77326
77326
77327
77327
77327
77328
77328
77328
77331
77331
77331
77332
77332
77332
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Ct bone density, axial .........................
Ct bone density, axial .........................
Ct bone density, axial .........................
Ct bone density, peripheral .................
Ct bone density, peripheral .................
Ct bone density, peripheral .................
Dxa bone density, axial ......................
Dxa bone density, axial ......................
Dxa bone density, axial ......................
Dxa bone density/peripheral ...............
Dxa bone density/peripheral ...............
Dxa bone density/peripheral ...............
Dxa bone density, vert fx ....................
Dxa bone density, vert fx ....................
Dxa bone density, vert fx ....................
Radiographic absorptiometry ..............
Radiographic absorptiometry ..............
Radiographic absorptiometry ..............
Magnetic image, bone marrow ...........
Magnetic image, bone marrow ...........
Magnetic image, bone marrow ...........
Radiation therapy planning .................
Radiation therapy planning .................
Radiation therapy planning .................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Set radiation therapy field ...................
Radiation therapy planning .................
Radiation therapy planning .................
Radiation therapy planning .................
Radiation therapy dose plan ...............
Radiation therapy dose plan ...............
Radiation therapy dose plan ...............
Radiotherapy dose plan, imrt ..............
Radiotherapy dose plan, imrt ..............
Radiotherapy dose plan, imrt ..............
Teletx isodose plan simple .................
Teletx isodose plan simple .................
Teletx isodose plan simple .................
Teletx isodose plan intermed ..............
Teletx isodose plan intermed ..............
Teletx isodose plan intermed ..............
Teletx isodose plan complex ..............
Teletx isodose plan complex ..............
Teletx isodose plan complex ..............
Special teletx port plan .......................
Special teletx port plan .......................
Special teletx port plan .......................
Brachytx isodose calc simp ................
Brachytx isodose calc simp ................
Brachytx isodose calc simp ................
Brachytx isodose calc interm ..............
Brachytx isodose calc interm ..............
Brachytx isodose calc interm ..............
Brachytx isodose plan compl ..............
Brachytx isodose plan compl ..............
Brachytx isodose plan compl ..............
Special radiation dosimetry .................
Special radiation dosimetry .................
Special radiation dosimetry .................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.25
0.00
0.25
0.22
0.00
0.22
0.20
0.00
0.20
0.22
0.00
0.22
0.17
0.00
0.17
0.20
0.00
0.20
1.60
0.00
1.60
1.39
2.11
3.14
0.70
0.00
0.70
1.05
0.00
1.05
1.56
0.00
1.56
4.56
0.00
4.56
0.00
0.00
0.00
0.62
0.00
0.62
7.99
0.00
7.99
0.70
0.00
0.70
1.05
0.00
1.05
1.56
0.00
1.56
0.95
0.00
0.95
0.93
0.00
0.93
1.39
0.00
1.39
2.09
0.00
2.09
0.87
0.00
0.87
0.54
0.00
0.54
4.74
4.65
0.09
0.83
0.75
0.08
1.10
1.04
0.06
0.47
0.41
0.06
0.53
0.48
0.05
0.37
0.32
0.05
13.55
13.03
0.52
0.48
0.69
1.03
4.43
4.20
0.23
8.01
7.67
0.34
13.41
12.90
0.51
7.45
5.95
1.50
0.00
0.00
0.00
1.18
0.98
0.20
57.41
54.79
2.62
0.90
0.67
0.23
1.24
0.90
0.34
2.08
1.57
0.51
1.51
1.20
0.31
2.98
2.68
0.30
4.09
3.64
0.45
5.25
4.56
0.69
0.81
0.52
0.29
1.55
1.37
0.18
3.88
3.80
0.08
1.92
1.85
0.07
2.15
2.07
0.08
0.65
0.58
0.07
0.66
0.61
0.05
0.59
0.53
0.06
12.63
12.11
0.52
0.49
0.72
1.07
4.05
3.83
0.22
6.96
6.62
0.34
10.21
9.71
0.50
18.41
16.93
1.48
0.00
0.00
0.00
1.36
1.16
0.20
43.94
41.35
2.59
1.50
1.27
0.23
1.96
1.62
0.34
2.62
2.12
0.50
2.93
2.62
0.31
2.82
2.52
0.30
4.00
3.55
0.45
5.44
4.76
0.68
0.79
0.51
0.28
1.52
1.35
0.17
NA
NA
0.09
NA
NA
0.08
NA
NA
0.06
NA
NA
0.06
NA
NA
0.05
NA
NA
0.05
NA
NA
0.52
0.48
0.69
1.03
NA
NA
0.23
NA
NA
0.34
NA
NA
0.51
NA
NA
1.50
NA
NA
0.00
NA
NA
0.20
NA
NA
2.62
NA
NA
0.23
NA
NA
0.34
NA
NA
0.51
NA
NA
0.31
NA
NA
0.30
NA
NA
0.45
NA
NA
0.69
NA
NA
0.29
NA
NA
0.18
NA
NA
0.08
NA
NA
0.07
NA
NA
0.08
NA
NA
0.07
NA
NA
0.05
NA
NA
0.06
NA
NA
0.52
0.49
0.72
1.07
NA
NA
0.22
NA
NA
0.34
NA
NA
0.50
NA
NA
1.48
NA
NA
0.00
NA
NA
0.20
NA
NA
2.59
NA
NA
0.23
NA
NA
0.34
NA
NA
0.50
NA
NA
0.31
NA
NA
0.30
NA
NA
0.45
NA
NA
0.68
NA
NA
0.28
NA
NA
0.17
Malpractice
RVUs 2
0.17
0.16
0.01
0.06
0.05
0.01
0.18
0.17
0.01
0.06
0.05
0.01
0.06
0.05
0.01
0.06
0.05
0.01
0.66
0.59
0.07
0.07
0.11
0.16
0.22
0.18
0.04
0.35
0.30
0.05
0.43
0.35
0.08
1.71
1.48
0.23
0.00
0.00
0.00
0.10
0.07
0.03
1.88
1.48
0.40
0.15
0.11
0.04
0.18
0.13
0.05
0.22
0.14
0.08
0.26
0.21
0.05
0.18
0.13
0.05
0.25
0.18
0.07
0.36
0.25
0.11
0.06
0.02
0.04
0.10
0.07
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00288
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66509
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
77333
77333
77333
77334
77334
77334
77336
77370
77371
77372
77373
77399
77399
77399
77401
77402
77403
77404
77406
77407
77408
77409
77411
77412
77413
77414
77416
77417
77418
77421
77421
77421
77422
77423
77427
77431
77432
77435
77470
77470
77470
77499
77499
77499
77520
77522
77523
77525
77600
77600
77600
77605
77605
77605
77610
77610
77610
77615
77615
77615
77620
77620
77620
77750
77750
77750
77761
77761
77761
77762
77762
77762
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
C
C
C
C
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation treatment aid(s) ..................
Radiation physics consult ...................
Radiation physics consult ...................
Srs, multisource ..................................
Srs, linear based .................................
Sbrt delivery ........................................
External radiation dosimetry ...............
External radiation dosimetry ...............
External radiation dosimetry ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiation treatment delivery ...............
Radiology port film(s) ..........................
Radiation tx delivery, imrt ...................
Stereoscopic x-ray guidance ..............
Stereoscopic x-ray guidance ..............
Stereoscopic x-ray guidance ..............
Neutron beam tx, simple .....................
Neutron beam tx, complex ..................
Radiation tx management, x5 .............
Radiation therapy management ..........
Stereotactic radiation trmt ...................
Sbrt management ...............................
Special radiation treatment .................
Special radiation treatment .................
Special radiation treatment .................
Radiation therapy management ..........
Radiation therapy management ..........
Radiation therapy management ..........
Proton trmt, simple w/o comp .............
Proton trmt, simple w/comp ................
Proton trmt, intermediate ....................
Proton treatment, complex ..................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Hyperthermia treatment ......................
Infuse radioactive materials ................
Infuse radioactive materials ................
Infuse radioactive materials ................
Apply intrcav radiat simple ..................
Apply intrcav radiat simple ..................
Apply intrcav radiat simple ..................
Apply intrcav radiat interm ..................
Apply intrcav radiat interm ..................
Apply intrcav radiat interm ..................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.84
0.00
0.84
1.24
0.00
1.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.39
0.00
0.39
0.00
0.00
3.70
1.81
7.92
13.00
2.09
0.00
2.09
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.56
0.00
1.56
2.09
0.00
2.09
1.56
0.00
1.56
2.09
0.00
2.09
1.56
0.00
1.56
4.94
0.00
4.94
3.82
0.00
3.82
5.73
0.00
5.73
0.52
0.24
0.28
2.71
2.31
0.40
1.14
3.04
30.07
22.80
42.62
0.00
0.00
0.00
0.47
4.34
3.75
4.20
4.23
5.78
5.19
5.76
5.73
6.78
6.85
7.71
7.72
0.36
13.15
2.38
2.25
0.13
5.35
7.46
1.39
0.77
2.59
4.75
1.92
1.24
0.68
0.00
0.00
0.00
0.00
0.00
0.00
0.00
10.23
9.73
0.50
18.46
17.91
0.55
17.92
17.56
0.36
25.90
25.26
0.64
10.49
10.09
0.40
4.55
2.93
1.62
6.34
5.10
1.24
7.62
5.75
1.87
1.34
1.07
0.27
3.18
2.78
0.40
2.06
3.27
30.07
22.80
42.62
0.00
0.00
0.00
1.12
3.06
2.76
2.99
3.00
3.93
3.64
3.93
3.91
4.56
4.59
5.02
5.02
0.48
15.58
2.93
2.80
0.13
3.53
4.86
1.22
0.73
2.75
4.75
6.87
6.19
0.68
0.00
0.00
0.00
0.00
0.00
0.00
0.00
6.89
6.39
0.50
11.58
10.98
0.60
10.74
10.31
0.43
15.31
14.66
0.65
7.03
6.57
0.46
3.73
2.13
1.60
4.96
3.80
1.16
6.53
4.68
1.85
NA
NA
0.28
NA
NA
0.40
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.13
NA
NA
1.39
0.77
2.59
NA
NA
NA
0.68
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.50
NA
NA
0.55
NA
NA
0.36
NA
NA
0.64
NA
NA
0.40
NA
NA
1.62
NA
NA
1.24
NA
NA
1.87
NA
NA
0.27
NA
NA
0.40
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.13
NA
NA
1.22
0.73
2.75
NA
NA
NA
0.68
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.50
NA
NA
0.60
NA
NA
0.43
NA
NA
0.65
NA
NA
0.46
NA
NA
1.60
NA
NA
1.16
NA
NA
1.85
Malpractice
RVUs 2
0.15
0.11
0.04
0.23
0.17
0.06
0.16
0.18
0.13
0.13
0.13
0.00
0.00
0.00
0.11
0.11
0.11
0.11
0.11
0.12
0.12
0.12
0.12
0.13
0.13
0.13
0.13
0.04
0.13
0.12
0.10
0.02
0.13
0.13
0.17
0.09
0.41
0.67
0.70
0.59
0.11
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.24
0.16
0.08
0.38
0.22
0.16
0.24
0.16
0.08
0.33
0.22
0.11
0.36
0.16
0.20
0.32
0.07
0.25
0.33
0.14
0.19
0.48
0.19
0.29
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00289
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
090
090
090
090
090
090
090
090
090
66510
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
77763
77763
77763
77776
77776
77776
77777
77777
77777
77778
77778
77778
77781
77781
77781
77782
77782
77782
77783
77783
77783
77784
77784
77784
77789
77789
77789
77790
77790
77790
77799
77799
77799
78000
78000
78000
78001
78001
78001
78003
78003
78003
78006
78006
78006
78007
78007
78007
78010
78010
78010
78011
78011
78011
78015
78015
78015
78016
78016
78016
78018
78018
78018
78020
78020
78020
78070
78070
78070
78075
78075
78075
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Apply intrcav radiat compl ..................
Apply intrcav radiat compl ..................
Apply intrcav radiat compl ..................
Apply interstit radiat simpl ...................
Apply interstit radiat simpl ...................
Apply interstit radiat simpl ...................
Apply interstit radiat inter ....................
Apply interstit radiat inter ....................
Apply interstit radiat inter ....................
Apply interstit radiat compl .................
Apply interstit radiat compl .................
Apply interstit radiat compl .................
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
High intensity brachytherapy ..............
Apply surface radiation .......................
Apply surface radiation .......................
Apply surface radiation .......................
Radiation handling ..............................
Radiation handling ..............................
Radiation handling ..............................
Radium/radioisotope therapy ..............
Radium/radioisotope therapy ..............
Radium/radioisotope therapy ..............
Thyroid, single uptake .........................
Thyroid, single uptake .........................
Thyroid, single uptake .........................
Thyroid, multiple uptakes ....................
Thyroid, multiple uptakes ....................
Thyroid, multiple uptakes ....................
Thyroid suppress/stimul ......................
Thyroid suppress/stimul ......................
Thyroid suppress/stimul ......................
Thyroid imaging with uptake ...............
Thyroid imaging with uptake ...............
Thyroid imaging with uptake ...............
Thyroid image, mult uptakes ..............
Thyroid image, mult uptakes ..............
Thyroid image, mult uptakes ..............
Thyroid imaging ..................................
Thyroid imaging ..................................
Thyroid imaging ..................................
Thyroid imaging with flow ...................
Thyroid imaging with flow ...................
Thyroid imaging with flow ...................
Thyroid met imaging ...........................
Thyroid met imaging ...........................
Thyroid met imaging ...........................
Thyroid met imaging/studies ...............
Thyroid met imaging/studies ...............
Thyroid met imaging/studies ...............
Thyroid met imaging, body .................
Thyroid met imaging, body .................
Thyroid met imaging, body .................
Thyroid met uptake .............................
Thyroid met uptake .............................
Thyroid met uptake .............................
Parathyroid nuclear imaging ...............
Parathyroid nuclear imaging ...............
Parathyroid nuclear imaging ...............
Adrenal nuclear imaging .....................
Adrenal nuclear imaging .....................
Adrenal nuclear imaging .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
8.60
0.00
8.60
4.67
0.00
4.67
7.49
0.00
7.49
11.23
0.00
11.23
1.21
0.00
1.21
2.04
0.00
2.04
3.27
0.00
3.27
5.15
0.00
5.15
1.14
0.00
1.14
1.05
0.00
1.05
0.00
0.00
0.00
0.19
0.00
0.19
0.26
0.00
0.26
0.33
0.00
0.33
0.49
0.00
0.49
0.50
0.00
0.50
0.39
0.00
0.39
0.45
0.00
0.45
0.67
0.00
0.67
0.82
0.00
0.82
0.86
0.00
0.86
0.60
0.00
0.60
0.82
0.00
0.82
0.74
0.00
0.74
10.33
7.52
2.81
7.46
5.79
1.67
7.92
5.47
2.45
11.31
7.62
3.69
4.41
4.01
0.40
12.41
11.74
0.67
24.19
23.12
1.07
45.65
43.97
1.68
2.02
1.64
0.38
1.46
1.12
0.34
0.00
0.00
0.00
1.85
1.79
0.06
2.30
2.21
0.09
1.94
1.82
0.12
6.22
6.05
0.17
3.05
2.88
0.17
4.18
4.05
0.13
4.54
4.38
0.16
5.34
5.12
0.22
8.52
8.25
0.27
7.93
7.63
0.30
1.80
1.60
0.20
3.48
3.20
0.28
11.61
11.36
0.25
8.78
6.00
2.78
5.29
3.98
1.31
7.26
4.85
2.41
10.00
6.37
3.63
12.61
12.15
0.46
16.74
16.01
0.73
22.83
21.70
1.13
33.87
32.13
1.74
1.42
1.04
0.38
1.15
0.81
0.34
0.00
0.00
0.00
1.44
1.38
0.06
1.85
1.76
0.09
1.50
1.39
0.11
4.38
4.22
0.16
2.90
2.73
0.17
3.07
2.94
0.13
3.55
3.40
0.15
4.07
3.84
0.23
6.14
5.86
0.28
6.82
6.52
0.30
1.66
1.45
0.21
4.01
3.73
0.28
8.64
8.39
0.25
NA
NA
2.81
NA
NA
1.67
NA
NA
2.45
NA
NA
3.69
NA
NA
0.40
NA
NA
0.67
NA
NA
1.07
NA
NA
1.68
NA
NA
0.38
NA
NA
0.34
NA
NA
0.00
NA
NA
0.06
NA
NA
0.09
NA
NA
0.12
NA
NA
0.17
NA
NA
0.17
NA
NA
0.13
NA
NA
0.16
NA
NA
0.22
NA
NA
0.27
NA
NA
0.30
NA
NA
0.20
NA
NA
0.28
NA
NA
0.25
NA
NA
2.78
NA
NA
1.31
NA
NA
2.41
NA
NA
3.63
NA
NA
0.46
NA
NA
0.73
NA
NA
1.13
NA
NA
1.74
NA
NA
0.38
NA
NA
0.34
NA
NA
0.00
NA
NA
0.06
NA
NA
0.09
NA
NA
0.11
NA
NA
0.16
NA
NA
0.17
NA
NA
0.13
NA
NA
0.15
NA
NA
0.23
NA
NA
0.28
NA
NA
0.30
NA
NA
0.21
NA
NA
0.28
NA
NA
0.25
Malpractice
RVUs 2
0.66
0.23
0.43
0.57
0.13
0.44
0.61
0.22
0.39
0.84
0.27
0.57
1.14
1.06
0.08
1.19
1.06
0.13
1.25
1.06
0.19
1.35
1.06
0.29
0.08
0.02
0.06
0.07
0.02
0.05
0.00
0.00
0.00
0.07
0.06
0.01
0.08
0.07
0.01
0.07
0.06
0.01
0.15
0.13
0.02
0.16
0.14
0.02
0.13
0.11
0.02
0.15
0.13
0.02
0.17
0.14
0.03
0.21
0.18
0.03
0.33
0.29
0.04
0.16
0.14
0.02
0.15
0.11
0.04
0.32
0.29
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00290
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
090
090
090
090
090
090
090
090
090
090
090
090
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66511
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78099
78099
78099
78102
78102
78102
78103
78103
78103
78104
78104
78104
78110
78110
78110
78111
78111
78111
78120
78120
78120
78121
78121
78121
78122
78122
78122
78130
78130
78130
78135
78135
78135
78140
78140
78140
78185
78185
78185
78190
78190
78190
78191
78191
78191
78195
78195
78195
78199
78199
78199
78201
78201
78201
78202
78202
78202
78205
78205
78205
78206
78206
78206
78215
78215
78215
78216
78216
78216
78220
78220
78220
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Endocrine nuclear procedure ..............
Endocrine nuclear procedure ..............
Endocrine nuclear procedure ..............
Bone marrow imaging, ltd ...................
Bone marrow imaging, ltd ...................
Bone marrow imaging, ltd ...................
Bone marrow imaging, mult ................
Bone marrow imaging, mult ................
Bone marrow imaging, mult ................
Bone marrow imaging, body ...............
Bone marrow imaging, body ...............
Bone marrow imaging, body ...............
Plasma volume, single ........................
Plasma volume, single ........................
Plasma volume, single ........................
Plasma volume, multiple .....................
Plasma volume, multiple .....................
Plasma volume, multiple .....................
Red cell mass, single ..........................
Red cell mass, single ..........................
Red cell mass, single ..........................
Red cell mass, multiple .......................
Red cell mass, multiple .......................
Red cell mass, multiple .......................
Blood volume ......................................
Blood volume ......................................
Blood volume ......................................
Red cell survival study ........................
Red cell survival study ........................
Red cell survival study ........................
Red cell survival kinetics ....................
Red cell survival kinetics ....................
Red cell survival kinetics ....................
Red cell sequestration ........................
Red cell sequestration ........................
Red cell sequestration ........................
Spleen imaging ...................................
Spleen imaging ...................................
Spleen imaging ...................................
Platelet survival, kinetics .....................
Platelet survival, kinetics .....................
Platelet survival, kinetics .....................
Platelet survival ...................................
Platelet survival ...................................
Platelet survival ...................................
Lymph system imaging .......................
Lymph system imaging .......................
Lymph system imaging .......................
Blood/lymph nuclear exam .................
Blood/lymph nuclear exam .................
Blood/lymph nuclear exam .................
Liver imaging .......................................
Liver imaging .......................................
Liver imaging .......................................
Liver imaging with flow .......................
Liver imaging with flow .......................
Liver imaging with flow .......................
Liver imaging (3D) ..............................
Liver imaging (3D) ..............................
Liver imaging (3D) ..............................
Liver image (3d) with flow ...................
Liver image (3d) with flow ...................
Liver image (3d) with flow ...................
Liver and spleen imaging ....................
Liver and spleen imaging ....................
Liver and spleen imaging ....................
Liver & spleen image/flow ...................
Liver & spleen image/flow ...................
Liver & spleen image/flow ...................
Liver function study .............................
Liver function study .............................
Liver function study .............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.55
0.00
0.55
0.75
0.00
0.75
0.80
0.00
0.80
0.19
0.00
0.19
0.22
0.00
0.22
0.23
0.00
0.23
0.32
0.00
0.32
0.45
0.00
0.45
0.61
0.00
0.61
0.64
0.00
0.64
0.61
0.00
0.61
0.40
0.00
0.40
1.09
0.00
1.09
0.61
0.00
0.61
1.20
0.00
1.20
0.00
0.00
0.00
0.44
0.00
0.44
0.51
0.00
0.51
0.71
0.00
0.71
0.96
0.00
0.96
0.49
0.00
0.49
0.57
0.00
0.57
0.49
0.00
0.49
0.00
0.00
0.00
4.18
3.99
0.19
5.43
5.17
0.26
6.23
5.94
0.29
2.13
2.06
0.07
2.14
2.07
0.07
2.10
2.02
0.08
2.20
2.10
0.10
2.25
2.10
0.15
3.50
3.29
0.21
8.67
8.45
0.22
2.94
2.72
0.22
5.19
5.05
0.14
8.37
8.12
0.25
3.51
3.30
0.21
8.68
8.27
0.41
0.00
0.00
0.00
4.59
4.46
0.13
5.34
5.17
0.17
5.27
5.02
0.25
8.60
8.26
0.34
4.82
4.65
0.17
2.84
2.65
0.19
3.08
2.91
0.17
0.00
0.00
0.00
3.20
3.01
0.19
4.43
4.17
0.26
5.28
5.00
0.28
1.57
1.50
0.07
2.40
2.32
0.08
1.96
1.88
0.08
2.61
2.50
0.11
3.51
3.35
0.16
3.28
3.07
0.21
6.88
6.66
0.22
3.53
3.32
0.21
3.85
3.71
0.14
7.24
6.92
0.32
5.53
5.32
0.21
6.58
6.17
0.41
0.00
0.00
0.00
3.55
3.41
0.14
4.20
4.03
0.17
5.70
5.46
0.24
7.41
7.08
0.33
3.96
3.79
0.17
3.26
3.07
0.19
3.47
3.31
0.16
NA
NA
0.00
NA
NA
0.19
NA
NA
0.26
NA
NA
0.29
NA
NA
0.07
NA
NA
0.07
NA
NA
0.08
NA
NA
0.10
NA
NA
0.15
NA
NA
0.21
NA
NA
0.22
NA
NA
0.22
NA
NA
0.14
NA
NA
0.25
NA
NA
0.21
NA
NA
0.41
NA
NA
0.00
NA
NA
0.13
NA
NA
0.17
NA
NA
0.25
NA
NA
0.34
NA
NA
0.17
NA
NA
0.19
NA
NA
0.17
NA
NA
0.00
NA
NA
0.19
NA
NA
0.26
NA
NA
0.28
NA
NA
0.07
NA
NA
0.08
NA
NA
0.08
NA
NA
0.11
NA
NA
0.16
NA
NA
0.21
NA
NA
0.22
NA
NA
0.21
NA
NA
0.14
NA
NA
0.32
NA
NA
0.21
NA
NA
0.41
NA
NA
0.00
NA
NA
0.14
NA
NA
0.17
NA
NA
0.24
NA
NA
0.33
NA
NA
0.17
NA
NA
0.19
NA
NA
0.16
Malpractice
RVUs 2
0.00
0.00
0.00
0.14
0.12
0.02
0.20
0.17
0.03
0.25
0.22
0.03
0.07
0.06
0.01
0.15
0.14
0.01
0.12
0.11
0.01
0.15
0.14
0.01
0.26
0.24
0.02
0.17
0.14
0.03
0.28
0.25
0.03
0.24
0.21
0.03
0.15
0.13
0.02
0.38
0.30
0.08
0.40
0.37
0.03
0.28
0.22
0.06
0.00
0.00
0.00
0.15
0.13
0.02
0.16
0.14
0.02
0.34
0.31
0.03
0.15
0.11
0.04
0.16
0.14
0.02
0.20
0.18
0.02
0.21
0.19
0.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00291
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66512
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78223
78223
78223
78230
78230
78230
78231
78231
78231
78232
78232
78232
78258
78258
78258
78261
78261
78261
78262
78262
78262
78264
78264
78264
78267
78268
78270
78270
78270
78271
78271
78271
78272
78272
78272
78278
78278
78278
78282
78282
78282
78290
78290
78290
78291
78291
78291
78299
78299
78299
78300
78300
78300
78305
78305
78305
78306
78306
78306
78315
78315
78315
78320
78320
78320
78350
78350
78350
78351
78399
78399
78399
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
X
X
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
N
N
N
C
C
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Hepatobiliary imaging .........................
Hepatobiliary imaging .........................
Hepatobiliary imaging .........................
Salivary gland imaging ........................
Salivary gland imaging ........................
Salivary gland imaging ........................
Serial salivary imaging ........................
Serial salivary imaging ........................
Serial salivary imaging ........................
Salivary gland function exam ..............
Salivary gland function exam ..............
Salivary gland function exam ..............
Esophageal motility study ...................
Esophageal motility study ...................
Esophageal motility study ...................
Gastric mucosa imaging .....................
Gastric mucosa imaging .....................
Gastric mucosa imaging .....................
Gastroesophageal reflux exam ...........
Gastroesophageal reflux exam ...........
Gastroesophageal reflux exam ...........
Gastric emptying study .......................
Gastric emptying study .......................
Gastric emptying study .......................
Breath tst attain/anal c-14 ...................
Breath test analysis, c-14 ...................
Vit B-12 absorption exam ...................
Vit B-12 absorption exam ...................
Vit B-12 absorption exam ...................
Vit b-12 absrp exam, int fac ...............
Vit b-12 absrp exam, int fac ...............
Vit b-12 absrp exam, int fac ...............
Vit B-12 absorp, combined .................
Vit B-12 absorp, combined .................
Vit B-12 absorp, combined .................
Acute GI blood loss imaging ...............
Acute GI blood loss imaging ...............
Acute GI blood loss imaging ...............
GI protein loss exam ...........................
GI protein loss exam ...........................
GI protein loss exam ...........................
Meckel’s divert exam ..........................
Meckel’s divert exam ..........................
Meckel’s divert exam ..........................
Leveen/shunt patency exam ...............
Leveen/shunt patency exam ...............
Leveen/shunt patency exam ...............
GI nuclear procedure ..........................
GI nuclear procedure ..........................
GI nuclear procedure ..........................
Bone imaging, limited area .................
Bone imaging, limited area .................
Bone imaging, limited area .................
Bone imaging, multiple areas .............
Bone imaging, multiple areas .............
Bone imaging, multiple areas .............
Bone imaging, whole body .................
Bone imaging, whole body .................
Bone imaging, whole body .................
Bone imaging, 3 phase .......................
Bone imaging, 3 phase .......................
Bone imaging, 3 phase .......................
Bone imaging (3D) ..............................
Bone imaging (3D) ..............................
Bone imaging (3D) ..............................
Bone mineral, single photon ...............
Bone mineral, single photon ...............
Bone mineral, single photon ...............
Bone mineral, dual photon ..................
Musculoskeletal nuclear exam ............
Musculoskeletal nuclear exam ............
Musculoskeletal nuclear exam ............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.84
0.00
0.84
0.45
0.00
0.45
0.52
0.00
0.52
0.47
0.00
0.47
0.74
0.00
0.74
0.69
0.00
0.69
0.68
0.00
0.68
0.78
0.00
0.78
0.00
0.00
0.20
0.00
0.20
0.20
0.00
0.20
0.27
0.00
0.27
0.99
0.00
0.99
0.00
0.00
0.38
0.68
0.00
0.68
0.88
0.00
0.88
0.00
0.00
0.00
0.62
0.00
0.62
0.83
0.00
0.83
0.86
0.00
0.86
1.02
0.00
1.02
1.04
0.00
1.04
0.22
0.00
0.22
0.30
0.00
0.00
0.00
8.50
8.21
0.29
4.17
4.01
0.16
2.80
2.63
0.17
2.77
2.62
0.15
5.52
5.25
0.27
6.00
5.76
0.24
5.95
5.73
0.22
7.16
6.89
0.27
0.00
0.00
1.95
1.88
0.07
1.88
1.83
0.05
2.06
1.99
0.07
8.60
8.25
0.35
0.00
0.00
0.13
8.51
8.27
0.24
6.14
5.84
0.30
0.00
0.00
0.00
4.23
4.01
0.22
5.47
5.19
0.28
6.06
5.76
0.30
8.59
8.23
0.36
5.35
4.99
0.36
0.51
0.46
0.05
NA
0.00
0.00
0.00
6.22
5.93
0.29
3.25
3.10
0.15
3.07
2.90
0.17
3.24
3.08
0.16
4.32
4.06
0.26
5.17
4.93
0.24
5.21
4.99
0.22
5.78
5.51
0.27
0.00
0.00
1.78
1.71
0.07
1.79
1.73
0.06
2.23
2.15
0.08
6.90
6.56
0.34
0.00
0.00
0.13
5.89
5.66
0.23
4.75
4.45
0.30
0.00
0.00
0.00
3.46
3.25
0.21
4.70
4.42
0.28
5.31
5.01
0.30
6.85
6.50
0.35
5.81
5.45
0.36
0.67
0.61
0.06
NA
0.00
0.00
0.00
NA
NA
0.29
NA
NA
0.16
NA
NA
0.17
NA
NA
0.15
NA
NA
0.27
NA
NA
0.24
NA
NA
0.22
NA
NA
0.27
0.00
0.00
NA
NA
0.07
NA
NA
0.05
NA
NA
0.07
NA
NA
0.35
NA
NA
0.13
NA
NA
0.24
NA
NA
0.30
NA
NA
0.00
NA
NA
0.22
NA
NA
0.28
NA
NA
0.30
NA
NA
0.36
NA
NA
0.36
NA
NA
0.05
0.07
NA
NA
0.00
NA
NA
0.29
NA
NA
0.15
NA
NA
0.17
NA
NA
0.16
NA
NA
0.26
NA
NA
0.24
NA
NA
0.22
NA
NA
0.27
0.00
0.00
NA
NA
0.07
NA
NA
0.06
NA
NA
0.08
NA
NA
0.34
NA
NA
0.13
NA
NA
0.23
NA
NA
0.30
NA
NA
0.00
NA
NA
0.21
NA
NA
0.28
NA
NA
0.30
NA
NA
0.35
NA
NA
0.36
NA
NA
0.06
0.09
NA
NA
0.00
Malpractice
RVUs 2
0.23
0.19
0.04
0.15
0.13
0.02
0.19
0.17
0.02
0.20
0.18
0.02
0.17
0.14
0.03
0.25
0.22
0.03
0.25
0.22
0.03
0.25
0.22
0.03
0.00
0.00
0.11
0.10
0.01
0.11
0.10
0.01
0.14
0.13
0.01
0.29
0.25
0.04
0.00
0.00
0.02
0.19
0.16
0.03
0.20
0.16
0.04
0.00
0.00
0.00
0.17
0.14
0.03
0.23
0.19
0.04
0.26
0.22
0.04
0.29
0.25
0.04
0.35
0.31
0.04
0.06
0.05
0.01
0.01
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00292
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66513
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78414
78414
78414
78428
78428
78428
78445
78445
78445
78456
78456
78456
78457
78457
78457
78458
78458
78458
78459
78459
78459
78460
78460
78460
78461
78461
78461
78464
78464
78464
78465
78465
78465
78466
78466
78466
78468
78468
78468
78469
78469
78469
78472
78472
78472
78473
78473
78473
78478
78478
78478
78480
78480
78480
78481
78481
78481
78483
78483
78483
78491
78491
78491
78492
78492
78492
78494
78494
78494
78496
78496
78496
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Non-imaging heart function .................
Non-imaging heart function .................
Non-imaging heart function .................
Cardiac shunt imaging ........................
Cardiac shunt imaging ........................
Cardiac shunt imaging ........................
Vascular flow imaging .........................
Vascular flow imaging .........................
Vascular flow imaging .........................
Acute venous thrombus image ...........
Acute venous thrombus image ...........
Acute venous thrombus image ...........
Venous thrombosis imaging ...............
Venous thrombosis imaging ...............
Venous thrombosis imaging ...............
Ven thrombosis images, bilat .............
Ven thrombosis images, bilat .............
Ven thrombosis images, bilat .............
Heart muscle imaging (PET) ..............
Heart muscle imaging (PET) ..............
Heart muscle imaging (PET) ..............
Heart muscle blood, single .................
Heart muscle blood, single .................
Heart muscle blood, single .................
Heart muscle blood, multiple ..............
Heart muscle blood, multiple ..............
Heart muscle blood, multiple ..............
Heart image (3d), single .....................
Heart image (3d), single .....................
Heart image (3d), single .....................
Heart image (3d), multiple ..................
Heart image (3d), multiple ..................
Heart image (3d), multiple ..................
Heart infarct image .............................
Heart infarct image .............................
Heart infarct image .............................
Heart infarct image (ef) .......................
Heart infarct image (ef) .......................
Heart infarct image (ef) .......................
Heart infarct image (3D) .....................
Heart infarct image (3D) .....................
Heart infarct image (3D) .....................
Gated heart, planar, single .................
Gated heart, planar, single .................
Gated heart, planar, single .................
Gated heart, multiple ..........................
Gated heart, multiple ..........................
Gated heart, multiple ..........................
Heart wall motion add-on ....................
Heart wall motion add-on ....................
Heart wall motion add-on ....................
Heart function add-on .........................
Heart function add-on .........................
Heart function add-on .........................
Heart first pass, single ........................
Heart first pass, single ........................
Heart first pass, single ........................
Heart first pass, multiple .....................
Heart first pass, multiple .....................
Heart first pass, multiple .....................
Heart image (pet), single ....................
Heart image (pet), single ....................
Heart image (pet), single ....................
Heart image (pet), multiple .................
Heart image (pet), multiple .................
Heart image (pet), multiple .................
Heart image, spect ..............................
Heart image, spect ..............................
Heart image, spect ..............................
Heart first pass add-on .......................
Heart first pass add-on .......................
Heart first pass add-on .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.45
0.78
0.00
0.78
0.49
0.00
0.49
1.00
0.00
1.00
0.77
0.00
0.77
0.90
0.00
0.90
0.00
0.00
1.50
0.86
0.00
0.86
1.23
0.00
1.23
1.09
0.00
1.09
1.46
0.00
1.46
0.69
0.00
0.69
0.80
0.00
0.80
0.92
0.00
0.92
0.98
0.00
0.98
1.47
0.00
1.47
0.50
0.00
0.50
0.30
0.00
0.30
0.98
0.00
0.98
1.47
0.00
1.47
0.00
0.00
1.50
0.00
0.00
1.87
1.19
0.00
1.19
0.50
0.00
0.50
0.00
0.00
0.17
5.26
4.90
0.36
4.48
4.31
0.17
8.80
8.43
0.37
4.65
4.41
0.24
4.51
4.22
0.29
0.00
0.00
0.60
4.66
4.34
0.32
4.07
3.61
0.46
5.86
5.36
0.50
11.44
10.73
0.71
4.57
4.28
0.29
5.86
5.47
0.39
6.28
5.84
0.44
6.03
5.62
0.41
7.76
7.12
0.64
0.80
0.56
0.24
0.70
0.56
0.14
5.07
4.58
0.49
6.87
6.09
0.78
0.00
0.00
0.63
0.00
0.00
0.91
6.22
5.68
0.54
0.88
0.65
0.23
0.00
0.00
0.17
3.90
3.58
0.32
3.26
3.09
0.17
6.56
6.20
0.36
3.78
3.53
0.25
4.43
4.12
0.31
0.00
0.00
0.59
3.65
3.35
0.30
4.60
4.16
0.44
6.65
6.21
0.44
11.87
11.26
0.61
3.71
3.45
0.26
4.89
4.56
0.33
5.90
5.53
0.37
5.93
5.56
0.37
8.25
7.68
0.57
1.30
1.06
0.24
1.24
1.06
0.18
5.33
4.90
0.43
7.63
6.97
0.66
0.00
0.00
0.61
0.00
0.00
0.82
6.85
6.37
0.48
4.06
3.86
0.20
NA
NA
0.17
NA
NA
0.36
NA
NA
0.17
NA
NA
0.37
NA
NA
0.24
NA
NA
0.29
NA
NA
0.60
NA
NA
0.32
NA
NA
0.46
NA
NA
0.50
NA
NA
0.71
NA
NA
0.29
NA
NA
0.39
NA
NA
0.44
NA
NA
0.41
NA
NA
0.64
NA
NA
0.24
NA
NA
0.14
NA
NA
0.49
NA
NA
0.78
NA
NA
0.63
NA
NA
0.91
NA
NA
0.54
NA
NA
0.23
NA
NA
0.17
NA
NA
0.32
NA
NA
0.17
NA
NA
0.36
NA
NA
0.25
NA
NA
0.31
NA
NA
0.59
NA
NA
0.30
NA
NA
0.44
NA
NA
0.44
NA
NA
0.61
NA
NA
0.26
NA
NA
0.33
NA
NA
0.37
NA
NA
0.37
NA
NA
0.57
NA
NA
0.24
NA
NA
0.18
NA
NA
0.43
NA
NA
0.66
NA
NA
0.61
NA
NA
0.82
NA
NA
0.48
NA
NA
0.20
Malpractice
RVUs 2
0.00
0.00
0.02
0.16
0.13
0.03
0.13
0.11
0.02
0.33
0.29
0.04
0.17
0.14
0.03
0.25
0.21
0.04
0.00
0.00
0.05
0.17
0.13
0.04
0.30
0.25
0.05
0.41
0.37
0.04
0.67
0.62
0.05
0.17
0.14
0.03
0.22
0.19
0.03
0.31
0.28
0.03
0.34
0.30
0.04
0.48
0.42
0.06
0.12
0.10
0.02
0.12
0.10
0.02
0.31
0.28
0.03
0.46
0.41
0.05
0.00
0.00
0.06
0.00
0.00
0.07
0.35
0.30
0.05
0.32
0.30
0.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00293
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
66514
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78499
78499
78499
78580
78580
78580
78584
78584
78584
78585
78585
78585
78586
78586
78586
78587
78587
78587
78588
78588
78588
78591
78591
78591
78593
78593
78593
78594
78594
78594
78596
78596
78596
78599
78599
78599
78600
78600
78600
78601
78601
78601
78605
78605
78605
78606
78606
78606
78607
78607
78607
78608
78608
78608
78609
78609
78609
78610
78610
78610
78630
78630
78630
78635
78635
78635
78645
78645
78645
78647
78647
78647
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
N
N
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Cardiovascular nuclear exam .............
Cardiovascular nuclear exam .............
Cardiovascular nuclear exam .............
Lung perfusion imaging ......................
Lung perfusion imaging ......................
Lung perfusion imaging ......................
Lung V/Q image single breath ............
Lung V/Q image single breath ............
Lung V/Q image single breath ............
Lung V/Q imaging ...............................
Lung V/Q imaging ...............................
Lung V/Q imaging ...............................
Aerosol lung image, single .................
Aerosol lung image, single .................
Aerosol lung image, single .................
Aerosol lung image, multiple ..............
Aerosol lung image, multiple ..............
Aerosol lung image, multiple ..............
Perfusion lung image ..........................
Perfusion lung image ..........................
Perfusion lung image ..........................
Vent image, 1 breath, 1 proj ...............
Vent image, 1 breath, 1 proj ...............
Vent image, 1 breath, 1 proj ...............
Vent image, 1 proj, gas ......................
Vent image, 1 proj, gas ......................
Vent image, 1 proj, gas ......................
Vent image, mult proj, gas ..................
Vent image, mult proj, gas ..................
Vent image, mult proj, gas ..................
Lung differential function .....................
Lung differential function .....................
Lung differential function .....................
Respiratory nuclear exam ...................
Respiratory nuclear exam ...................
Respiratory nuclear exam ...................
Brain image < 4 views ........................
Brain image < 4 views ........................
Brain image < 4 views ........................
Brain image w/flow < 4 views .............
Brain image w/flow < 4 views .............
Brain image w/flow < 4 views .............
Brain image 4+ views .........................
Brain image 4+ views .........................
Brain image 4+ views .........................
Brain image w/flow 4 + views .............
Brain image w/flow 4 + views .............
Brain image w/flow 4 + views .............
Brain imaging (3D) ..............................
Brain imaging (3D) ..............................
Brain imaging (3D) ..............................
Brain imaging (PET) ...........................
Brain imaging (PET) ...........................
Brain imaging (PET) ...........................
Brain imaging (PET) ...........................
Brain imaging (PET) ...........................
Brain imaging (PET) ...........................
Brain flow imaging only .......................
Brain flow imaging only .......................
Brain flow imaging only .......................
Cerebrospinal fluid scan .....................
Cerebrospinal fluid scan .....................
Cerebrospinal fluid scan .....................
CSF ventriculography .........................
CSF ventriculography .........................
CSF ventriculography .........................
CSF shunt evaluation .........................
CSF shunt evaluation .........................
CSF shunt evaluation .........................
Cerebrospinal fluid scan .....................
Cerebrospinal fluid scan .....................
Cerebrospinal fluid scan .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.74
0.00
0.74
0.99
0.00
0.99
1.09
0.00
1.09
0.40
0.00
0.40
0.49
0.00
0.49
1.09
0.00
1.09
0.40
0.00
0.40
0.49
0.00
0.49
0.53
0.00
0.53
1.27
0.00
1.27
0.00
0.00
0.00
0.44
0.00
0.44
0.51
0.00
0.51
0.53
0.00
0.53
0.64
0.00
0.64
1.23
0.00
1.23
0.00
0.00
1.50
1.50
0.00
1.50
0.30
0.00
0.30
0.68
0.00
0.68
0.61
0.00
0.61
0.57
0.00
0.57
0.90
0.00
0.90
0.00
0.00
0.00
5.13
4.87
0.26
3.02
2.67
0.35
8.62
8.24
0.38
4.17
4.03
0.14
5.43
5.26
0.17
8.65
8.27
0.38
4.17
4.03
0.14
4.82
4.65
0.17
5.29
5.11
0.18
8.67
8.28
0.39
0.00
0.00
0.00
4.39
4.24
0.15
5.38
5.20
0.18
4.84
4.65
0.19
8.53
8.31
0.22
8.63
8.22
0.41
0.00
0.00
0.49
0.00
0.00
0.00
4.45
4.35
0.10
8.65
8.41
0.24
8.79
8.58
0.21
8.48
8.28
0.20
8.52
8.23
0.29
0.00
0.00
0.00
4.41
4.15
0.26
3.27
2.93
0.34
7.31
6.94
0.37
3.44
3.31
0.13
4.20
4.03
0.17
6.11
5.74
0.37
3.57
3.44
0.13
4.21
4.05
0.16
5.22
5.04
0.18
8.08
7.67
0.41
0.00
0.00
0.00
3.71
3.56
0.15
4.47
4.30
0.17
4.22
4.03
0.19
6.30
6.09
0.21
7.80
7.38
0.42
0.00
0.00
0.50
0.49
0.00
0.49
4.23
4.10
0.13
6.95
6.72
0.23
5.78
5.56
0.22
6.04
5.85
0.19
7.37
7.07
0.30
NA
NA
0.00
NA
NA
0.26
NA
NA
0.35
NA
NA
0.38
NA
NA
0.14
NA
NA
0.17
NA
NA
0.38
NA
NA
0.14
NA
NA
0.17
NA
NA
0.18
NA
NA
0.39
NA
NA
0.00
NA
NA
0.15
NA
NA
0.18
NA
NA
0.19
NA
NA
0.22
NA
NA
0.41
NA
NA
0.49
NA
NA
0.00
NA
NA
0.10
NA
NA
0.24
NA
NA
0.21
NA
NA
0.20
NA
NA
0.29
NA
NA
0.00
NA
NA
0.26
NA
NA
0.34
NA
NA
0.37
NA
NA
0.13
NA
NA
0.17
NA
NA
0.37
NA
NA
0.13
NA
NA
0.16
NA
NA
0.18
NA
NA
0.41
NA
NA
0.00
NA
NA
0.15
NA
NA
0.17
NA
NA
0.19
NA
NA
0.21
NA
NA
0.42
NA
NA
0.50
NA
NA
0.49
NA
NA
0.13
NA
NA
0.23
NA
NA
0.22
NA
NA
0.19
NA
NA
0.30
Malpractice
RVUs 2
0.00
0.00
0.00
0.21
0.18
0.03
0.21
0.17
0.04
0.35
0.30
0.05
0.16
0.14
0.02
0.16
0.14
0.02
0.23
0.18
0.05
0.16
0.14
0.02
0.20
0.18
0.02
0.27
0.25
0.02
0.42
0.37
0.05
0.00
0.00
0.00
0.16
0.14
0.02
0.20
0.18
0.02
0.20
0.18
0.02
0.24
0.21
0.03
0.40
0.35
0.05
0.00
0.00
0.06
0.06
0.00
0.06
0.11
0.10
0.01
0.30
0.27
0.03
0.16
0.14
0.02
0.20
0.18
0.02
0.35
0.31
0.04
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00294
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66515
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78650
78650
78650
78660
78660
78660
78699
78699
78699
78700
78700
78700
78701
78701
78701
78707
78707
78707
78708
78708
78708
78709
78709
78709
78710
78710
78710
78725
78725
78725
78730
78730
78730
78740
78740
78740
78761
78761
78761
78799
78799
78799
78800
78800
78800
78801
78801
78801
78802
78802
78802
78803
78803
78803
78804
78804
78804
78805
78805
78805
78806
78806
78806
78807
78807
78807
78811
78811
78811
78812
78812
78812
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
Status
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
CSF leakage imaging .........................
CSF leakage imaging .........................
CSF leakage imaging .........................
Nuclear exam of tear flow ...................
Nuclear exam of tear flow ...................
Nuclear exam of tear flow ...................
Nervous system nuclear exam ...........
Nervous system nuclear exam ...........
Nervous system nuclear exam ...........
Kidney imaging, morphol ....................
Kidney imaging, morphol ....................
Kidney imaging, morphol ....................
Kidney imaging with flow ....................
Kidney imaging with flow ....................
Kidney imaging with flow ....................
K flow/funct image w/o drug ...............
K flow/funct image w/o drug ...............
K flow/funct image w/o drug ...............
K flow/funct image w/drug ..................
K flow/funct image w/drug ..................
K flow/funct image w/drug ..................
K flow/funct image, multiple ................
K flow/funct image, multiple ................
K flow/funct image, multiple ................
Kidney imaging (3D) ...........................
Kidney imaging (3D) ...........................
Kidney imaging (3D) ...........................
Kidney function study ..........................
Kidney function study ..........................
Kidney function study ..........................
Urinary bladder retention ....................
Urinary bladder retention ....................
Urinary bladder retention ....................
Ureteral reflux study ............................
Ureteral reflux study ............................
Ureteral reflux study ............................
Testicular imaging w/flow ....................
Testicular imaging w/flow ....................
Testicular imaging w/flow ....................
Genitourinary nuclear exam ................
Genitourinary nuclear exam ................
Genitourinary nuclear exam ................
Tumor imaging, limited area ...............
Tumor imaging, limited area ...............
Tumor imaging, limited area ...............
Tumor imaging, mult areas .................
Tumor imaging, mult areas .................
Tumor imaging, mult areas .................
Tumor imaging, whole body ...............
Tumor imaging, whole body ...............
Tumor imaging, whole body ...............
Tumor imaging (3D) ............................
Tumor imaging (3D) ............................
Tumor imaging (3D) ............................
Tumor imaging, whole body ...............
Tumor imaging, whole body ...............
Tumor imaging, whole body ...............
Abscess imaging, ltd area ..................
Abscess imaging, ltd area ..................
Abscess imaging, ltd area ..................
Abscess imaging, whole body ............
Abscess imaging, whole body ............
Abscess imaging, whole body ............
Nuclear localization/abscess ...............
Nuclear localization/abscess ...............
Nuclear localization/abscess ...............
Pet image, ltd area .............................
Pet image, ltd area .............................
Pet image, ltd area .............................
Pet image, skull-thigh .........................
Pet image, skull-thigh .........................
Pet image, skull-thigh .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.61
0.00
0.61
0.53
0.00
0.53
0.00
0.00
0.00
0.45
0.00
0.45
0.49
0.00
0.49
0.96
0.00
0.96
1.21
0.00
1.21
1.41
0.00
1.41
0.66
0.00
0.66
0.38
0.00
0.38
0.15
0.00
0.15
0.57
0.00
0.57
0.71
0.00
0.71
0.00
0.00
0.00
0.66
0.00
0.66
0.79
0.00
0.79
0.86
0.00
0.86
1.09
0.00
1.09
1.07
0.00
1.07
0.73
0.00
0.73
0.86
0.00
0.86
1.09
0.00
1.09
0.00
0.00
1.54
0.00
0.00
1.93
8.56
8.35
0.21
4.26
4.07
0.19
0.00
0.00
0.00
4.38
4.22
0.16
5.38
5.21
0.17
5.49
5.15
0.34
3.48
3.05
0.43
8.88
8.39
0.49
5.28
5.06
0.22
2.35
2.23
0.12
1.98
1.92
0.06
5.65
5.46
0.19
5.05
4.80
0.25
0.00
0.00
0.00
4.33
4.12
0.21
6.04
5.78
0.26
8.14
7.84
0.30
8.53
8.16
0.37
14.83
14.46
0.37
4.22
3.97
0.25
8.35
8.05
0.30
8.51
8.14
0.37
0.00
0.00
0.54
0.00
0.00
0.67
6.70
6.49
0.21
3.28
3.10
0.18
0.00
0.00
0.00
3.80
3.64
0.16
4.55
4.38
0.17
5.14
4.81
0.33
4.18
3.76
0.42
6.91
6.43
0.48
5.70
5.48
0.22
2.14
2.01
0.13
1.78
1.69
0.09
3.98
3.79
0.19
4.24
4.00
0.24
0.00
0.00
0.00
3.98
3.76
0.22
5.27
5.00
0.27
6.98
6.69
0.29
7.74
7.36
0.38
13.13
12.76
0.37
3.94
3.69
0.25
7.53
7.24
0.29
7.73
7.35
0.38
0.00
0.00
0.53
0.00
0.00
0.66
NA
NA
0.21
NA
NA
0.19
NA
NA
0.00
NA
NA
0.16
NA
NA
0.17
NA
NA
0.34
NA
NA
0.43
NA
NA
0.49
NA
NA
0.22
NA
NA
0.12
NA
NA
0.06
NA
NA
0.19
NA
NA
0.25
NA
NA
0.00
NA
NA
0.21
NA
NA
0.26
NA
NA
0.30
NA
NA
0.37
NA
NA
0.37
NA
NA
0.25
NA
NA
0.30
NA
NA
0.37
NA
NA
0.54
NA
NA
0.67
NA
NA
0.21
NA
NA
0.18
NA
NA
0.00
NA
NA
0.16
NA
NA
0.17
NA
NA
0.33
NA
NA
0.42
NA
NA
0.48
NA
NA
0.22
NA
NA
0.13
NA
NA
0.09
NA
NA
0.19
NA
NA
0.24
NA
NA
0.00
NA
NA
0.22
NA
NA
0.27
NA
NA
0.29
NA
NA
0.38
NA
NA
0.37
NA
NA
0.25
NA
NA
0.29
NA
NA
0.38
NA
NA
0.53
NA
NA
0.66
Malpractice
RVUs 2
0.27
0.24
0.03
0.14
0.12
0.02
0.00
0.00
0.00
0.18
0.16
0.02
0.20
0.18
0.02
0.27
0.23
0.04
0.28
0.23
0.05
0.29
0.23
0.06
0.34
0.31
0.03
0.13
0.11
0.02
0.10
0.08
0.02
0.15
0.12
0.03
0.20
0.17
0.03
0.00
0.00
0.00
0.22
0.18
0.04
0.27
0.22
0.05
0.34
0.30
0.04
0.40
0.35
0.05
0.34
0.30
0.04
0.21
0.18
0.03
0.39
0.35
0.04
0.39
0.35
0.04
0.00
0.00
0.11
0.00
0.00
0.11
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00295
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66516
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
78813
78813
78813
78814
78814
78814
78815
78815
78815
78816
78816
78816
78890
78890
78890
78891
78891
78891
78999
78999
78999
79005
79005
79005
79101
79101
79101
79200
79200
79200
79300
79300
79300
79403
79403
79403
79440
79440
79440
79445
79445
79445
79999
79999
79999
80500
80502
83020
83912
84165
84166
84181
84182
85060
85097
85390
85396
85576
86077
86078
86079
86255
86256
86320
86325
86327
86334
86335
86485
86486
86490
86510
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
26 .......
26 .......
26 .......
26 .......
26 .......
26 .......
............
............
26 .......
............
26 .......
............
............
............
26 .......
26 .......
26 .......
26 .......
26 .......
26 .......
26 .......
............
............
............
............
Status
C
C
A
C
C
A
C
C
A
C
C
A
B
B
B
B
B
B
C
C
C
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
C
C
A
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Pet image, full body ............................
Pet image, full body ............................
Pet image, full body ............................
Pet image w/ct, lmtd ...........................
Pet image w/ct, lmtd ...........................
Pet image w/ct, lmtd ...........................
Pet image w/ct, skull-thigh ..................
Pet image w/ct, skull-thigh ..................
Pet image w/ct, skull-thigh ..................
Pet image w/ct, full body ....................
Pet image w/ct, full body ....................
Pet image w/ct, full body ....................
Nuclear medicine data proc ................
Nuclear medicine data proc ................
Nuclear medicine data proc ................
Nuclear med data proc .......................
Nuclear med data proc .......................
Nuclear med data proc .......................
Nuclear diagnostic exam ....................
Nuclear diagnostic exam ....................
Nuclear diagnostic exam ....................
Nuclear rx, oral admin ........................
Nuclear rx, oral admin ........................
Nuclear rx, oral admin ........................
Nuclear rx, iv admin ............................
Nuclear rx, iv admin ............................
Nuclear rx, iv admin ............................
Nuclear rx, intracav admin ..................
Nuclear rx, intracav admin ..................
Nuclear rx, intracav admin ..................
Nuclr rx, interstit colloid ......................
Nuclr rx, interstit colloid ......................
Nuclr rx, interstit colloid ......................
Hematopoietic nuclear tx ....................
Hematopoietic nuclear tx ....................
Hematopoietic nuclear tx ....................
Nuclear rx, intra-articular ....................
Nuclear rx, intra-articular ....................
Nuclear rx, intra-articular ....................
Nuclear rx, intra-arterial ......................
Nuclear rx, intra-arterial ......................
Nuclear rx, intra-arterial ......................
Nuclear medicine therapy ...................
Nuclear medicine therapy ...................
Nuclear medicine therapy ...................
Lab pathology consultation .................
Lab pathology consultation .................
Hemoglobin electrophoresis ...............
Genetic examination ...........................
Protein e-phoresis, serum ...................
Protein e-phoresis/urine/csf ................
Western blot test .................................
Protein, western blot test ....................
Blood smear interpretation ..................
Bone marrow interpretation ................
Fibrinolysins screen ............................
Clotting assay, whole blood ................
Blood platelet aggregation ..................
Physician blood bank service .............
Physician blood bank service .............
Physician blood bank service .............
Fluorescent antibody, screen ..............
Fluorescent antibody, titer ..................
Serum immunoelectrophoresis ...........
Other immunoelectrophoresis .............
Immunoelectrophoresis assay ............
Immunofix e-phoresis, serum .............
Immunfix e-phorsis/urine/csf ...............
Skin test, candida ...............................
Skin test, nos antigen .........................
Coccidioidomycosis skin test ..............
Histoplasmosis skin test .....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
2.00
0.00
0.00
2.20
0.00
0.00
2.44
0.00
0.00
2.50
0.05
0.00
0.05
0.10
0.00
0.10
0.00
0.00
0.00
1.80
0.00
1.80
1.96
0.00
1.96
1.99
0.00
1.99
0.00
0.00
1.60
2.25
0.00
2.25
1.99
0.00
1.99
0.00
0.00
2.40
0.00
0.00
0.00
0.37
1.33
0.37
0.37
0.37
0.37
0.37
0.37
0.45
0.94
0.37
0.37
0.37
0.94
0.94
0.94
0.37
0.37
0.37
0.37
0.42
0.37
0.37
0.00
0.00
0.00
0.00
0.00
0.00
0.68
0.00
0.00
0.74
0.00
0.00
0.84
0.00
0.00
0.85
0.39
0.38
0.01
0.88
0.86
0.02
0.00
0.00
0.00
1.85
1.27
0.58
2.17
1.43
0.74
2.22
1.57
0.65
0.00
0.00
0.54
2.92
2.17
0.75
1.84
1.16
0.68
0.00
0.00
0.85
0.00
0.00
0.00
0.20
0.31
0.12
0.11
0.12
0.12
0.12
0.12
0.14
1.25
0.13
NA
0.12
0.38
0.38
0.39
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.00
0.13
0.13
0.13
0.00
0.00
0.68
0.00
0.00
0.75
0.00
0.00
0.84
0.00
0.00
0.85
0.86
0.84
0.02
1.77
1.74
0.03
0.00
0.00
0.00
2.53
1.94
0.59
2.72
2.02
0.70
2.77
2.10
0.67
0.00
0.00
0.55
4.04
3.22
0.82
2.59
1.89
0.70
0.00
0.00
0.83
0.00
0.00
0.00
0.20
0.43
0.13
0.12
0.13
0.13
0.13
0.14
0.16
1.58
0.13
NA
0.14
0.39
0.42
0.42
0.13
0.13
0.14
0.13
0.15
0.13
0.13
0.00
0.13
0.21
0.22
NA
NA
0.68
NA
NA
0.74
NA
NA
0.84
NA
NA
0.85
NA
NA
0.01
NA
NA
0.02
NA
NA
0.00
NA
NA
0.58
NA
NA
0.74
NA
NA
0.65
NA
NA
0.54
NA
NA
0.75
NA
NA
0.68
NA
NA
0.85
NA
NA
0.00
0.11
0.25
0.12
0.11
0.12
0.12
0.12
0.12
0.14
0.27
0.13
0.10
0.12
0.30
0.30
0.30
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.00
NA
NA
NA
NA
NA
0.68
NA
NA
0.75
NA
NA
0.84
NA
NA
0.85
NA
NA
0.02
NA
NA
0.03
NA
NA
0.00
NA
NA
0.59
NA
NA
0.70
NA
NA
0.67
NA
NA
0.55
NA
NA
0.82
NA
NA
0.70
NA
NA
0.83
NA
NA
0.00
0.14
0.40
0.13
0.12
0.13
0.13
0.13
0.14
0.16
0.34
0.13
0.13
0.14
0.34
0.35
0.36
0.13
0.13
0.14
0.13
0.15
0.13
0.13
0.00
NA
NA
NA
Malpractice
RVUs 2
0.00
0.00
0.11
0.00
0.00
0.11
0.00
0.00
0.11
0.00
0.00
0.11
0.07
0.06
0.01
0.14
0.13
0.01
0.00
0.00
0.00
0.22
0.14
0.08
0.22
0.14
0.08
0.23
0.14
0.09
0.00
0.00
0.13
0.24
0.14
0.10
0.22
0.14
0.08
0.00
0.00
0.12
0.00
0.00
0.00
0.01
0.04
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.04
0.01
0.04
0.01
0.03
0.03
0.03
0.01
0.01
0.01
0.01
0.02
0.01
0.01
0.00
0.02
0.02
0.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00296
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66517
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
86580
87164
87207
88104
88104
88104
88106
88106
88106
88107
88107
88107
88108
88108
88108
88112
88112
88112
88125
88125
88125
88141
88160
88160
88160
88161
88161
88161
88162
88162
88162
88172
88172
88172
88173
88173
88173
88182
88182
88182
88184
88185
88187
88188
88189
88199
88199
88199
88291
88299
88300
88300
88300
88302
88302
88302
88304
88304
88304
88305
88305
88305
88307
88307
88307
88309
88309
88309
88311
88311
88311
88312
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
26 .......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
TB intradermal test .............................
Dark field examination ........................
Smear, special stain ...........................
Cytopath fl nongyn, smears ................
Cytopath fl nongyn, smears ................
Cytopath fl nongyn, smears ................
Cytopath fl nongyn, filter .....................
Cytopath fl nongyn, filter .....................
Cytopath fl nongyn, filter .....................
Cytopath fl nongyn, sm/fltr ..................
Cytopath fl nongyn, sm/fltr ..................
Cytopath fl nongyn, sm/fltr ..................
Cytopath, concentrate tech .................
Cytopath, concentrate tech .................
Cytopath, concentrate tech .................
Cytopath, cell enhance tech ...............
Cytopath, cell enhance tech ...............
Cytopath, cell enhance tech ...............
Forensic cytopathology .......................
Forensic cytopathology .......................
Forensic cytopathology .......................
Cytopath, c/v, interpret ........................
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopath smear, other source ............
Cytopathology eval of fna ...................
Cytopathology eval of fna ...................
Cytopathology eval of fna ...................
Cytopath eval, fna, report ...................
Cytopath eval, fna, report ...................
Cytopath eval, fna, report ...................
Cell marker study ................................
Cell marker study ................................
Cell marker study ................................
Flowcytometry/ tc, 1 marker ...............
Flowcytometry/tc, add-on ....................
Flowcytometry/read, 2–8 .....................
Flowcytometry/read, 9–15 ...................
Flowcytometry/read, 16 & > ................
Cytopathology procedure ....................
Cytopathology procedure ....................
Cytopathology procedure ....................
Cyto/molecular report ..........................
Cytogenetic study ...............................
Surgical path, gross ............................
Surgical path, gross ............................
Surgical path, gross ............................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Tissue exam by pathologist ................
Decalcify tissue ...................................
Decalcify tissue ...................................
Decalcify tissue ...................................
Special stains ......................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.37
0.37
0.56
0.00
0.56
0.56
0.00
0.56
0.76
0.00
0.76
0.56
0.00
0.56
1.18
0.00
1.18
0.26
0.00
0.26
0.42
0.50
0.00
0.50
0.50
0.00
0.50
0.76
0.00
0.76
0.60
0.00
0.60
1.39
0.00
1.39
0.77
0.00
0.77
0.00
0.00
1.36
1.69
2.23
0.00
0.00
0.00
0.52
0.00
0.08
0.00
0.08
0.13
0.00
0.13
0.22
0.00
0.22
0.75
0.00
0.75
1.59
0.00
1.59
2.80
0.00
2.80
0.24
0.00
0.24
0.54
0.16
0.12
0.12
1.19
1.03
0.16
1.52
1.37
0.15
2.00
1.77
0.23
1.47
1.32
0.15
1.47
1.18
0.29
0.21
0.16
0.05
0.38
0.91
0.78
0.13
1.06
0.92
0.14
1.58
1.35
0.23
0.81
0.64
0.17
2.20
1.82
0.38
2.02
1.88
0.14
2.46
1.50
0.39
0.44
0.47
0.00
0.00
0.00
0.27
0.00
0.56
0.54
0.02
1.29
1.25
0.04
1.47
1.41
0.06
2.04
1.84
0.20
4.41
3.94
0.47
6.16
5.34
0.82
0.24
0.17
0.07
2.29
0.20
0.12
0.14
1.02
0.82
0.20
1.44
1.24
0.20
1.77
1.49
0.28
1.34
1.14
0.20
1.72
1.32
0.40
0.24
0.16
0.08
0.26
0.87
0.70
0.17
1.00
0.82
0.18
1.30
1.02
0.28
0.77
0.55
0.22
2.16
1.68
0.48
1.99
1.76
0.23
1.89
1.07
0.42
0.50
0.61
0.00
0.00
0.00
0.22
0.00
0.51
0.48
0.03
1.16
1.11
0.05
1.39
1.32
0.07
1.97
1.71
0.26
3.78
3.20
0.58
5.28
4.38
0.90
0.23
0.15
0.08
1.90
NA
0.12
0.12
NA
NA
0.16
NA
NA
0.15
NA
NA
0.23
NA
NA
0.15
NA
NA
0.29
NA
NA
0.05
0.38
NA
NA
0.13
NA
NA
0.14
NA
NA
0.23
NA
NA
0.17
NA
NA
0.38
NA
NA
0.14
NA
NA
0.39
0.44
0.47
NA
NA
0.00
0.27
0.00
NA
NA
0.02
NA
NA
0.04
NA
NA
0.06
NA
NA
0.20
NA
NA
0.47
NA
NA
0.82
NA
NA
0.07
NA
NA
0.12
0.14
NA
NA
0.20
NA
NA
0.20
NA
NA
0.28
NA
NA
0.20
NA
NA
0.40
NA
NA
0.08
0.26
NA
NA
0.17
NA
NA
0.18
NA
NA
0.28
NA
NA
0.22
NA
NA
0.48
NA
NA
0.23
NA
NA
0.42
0.50
0.61
NA
NA
0.00
0.22
0.00
NA
NA
0.03
NA
NA
0.05
NA
NA
0.07
NA
NA
0.26
NA
NA
0.58
NA
NA
0.90
NA
NA
0.08
NA
Malpractice
RVUs 2
0.02
0.01
0.01
0.04
0.02
0.02
0.04
0.02
0.02
0.05
0.02
0.03
0.04
0.02
0.02
0.04
0.02
0.02
0.02
0.01
0.01
0.02
0.04
0.02
0.02
0.04
0.02
0.02
0.05
0.02
0.03
0.04
0.02
0.02
0.07
0.02
0.05
0.07
0.04
0.03
0.02
0.02
0.01
0.01
0.01
0.00
0.00
0.00
0.02
0.00
0.02
0.01
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.07
0.04
0.03
0.12
0.06
0.06
0.14
0.06
0.08
0.02
0.01
0.01
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00297
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66518
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
88312
88312
88313
88313
88313
88314
88314
88314
88318
88318
88318
88319
88319
88319
88321
88323
88323
88323
88325
88329
88331
88331
88331
88332
88332
88332
88333
88333
88333
88334
88334
88334
88342
88342
88342
88346
88346
88346
88347
88347
88347
88348
88348
88348
88349
88349
88349
88355
88355
88355
88356
88356
88356
88358
88358
88358
88360
88360
88360
88361
88361
88361
88362
88362
88362
88365
88365
88365
88367
88367
88367
88368
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Special stains ......................................
Special stains ......................................
Special stains ......................................
Special stains ......................................
Special stains ......................................
Histochemical stain .............................
Histochemical stain .............................
Histochemical stain .............................
Chemical histochemistry .....................
Chemical histochemistry .....................
Chemical histochemistry .....................
Enzyme histochemistry .......................
Enzyme histochemistry .......................
Enzyme histochemistry .......................
Microslide consultation ........................
Microslide consultation ........................
Microslide consultation ........................
Microslide consultation ........................
Comprehensive review of data ...........
Path consult introp ..............................
Path consult intraop, 1 bloc ................
Path consult intraop, 1 bloc ................
Path consult intraop, 1 bloc ................
Path consult intraop, add’l ..................
Path consult intraop, add’l ..................
Path consult intraop, add’l ..................
Intraop cyto path consult, 1 ................
Intraop cyto path consult, 1 ................
Intraop cyto path consult, 1 ................
Intraop cyto path consult, 2 ................
Intraop cyto path consult, 2 ................
Intraop cyto path consult, 2 ................
Immunohistochemistry ........................
Immunohistochemistry ........................
Immunohistochemistry ........................
Immunofluorescent study ....................
Immunofluorescent study ....................
Immunofluorescent study ....................
Immunofluorescent study ....................
Immunofluorescent study ....................
Immunofluorescent study ....................
Electron microscopy ............................
Electron microscopy ............................
Electron microscopy ............................
Scanning electron microscopy ............
Scanning electron microscopy ............
Scanning electron microscopy ............
Analysis, skeletal muscle ....................
Analysis, skeletal muscle ....................
Analysis, skeletal muscle ....................
Analysis, nerve ....................................
Analysis, nerve ....................................
Analysis, nerve ....................................
Analysis, tumor ...................................
Analysis, tumor ...................................
Analysis, tumor ...................................
Tumor immunohistochem/manual .......
Tumor immunohistochem/manual .......
Tumor immunohistochem/manual .......
Tumor immunohistochem/comput .......
Tumor immunohistochem/comput .......
Tumor immunohistochem/comput .......
Nerve teasing preparations .................
Nerve teasing preparations .................
Nerve teasing preparations .................
Insitu hybridization (fish) .....................
Insitu hybridization (fish) .....................
Insitu hybridization (fish) .....................
Insitu hybridization, auto .....................
Insitu hybridization, auto .....................
Insitu hybridization, auto .....................
Insitu hybridization, manual ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.54
0.24
0.00
0.24
0.45
0.00
0.45
0.42
0.00
0.42
0.53
0.00
0.53
1.63
1.83
0.00
1.83
2.50
0.67
1.19
0.00
1.19
0.59
0.00
0.59
1.20
0.00
1.20
0.73
0.00
0.73
0.85
0.00
0.85
0.86
0.00
0.86
0.86
0.00
0.86
1.51
0.00
1.51
0.76
0.00
0.76
1.85
0.00
1.85
3.02
0.00
3.02
0.95
0.00
0.95
1.10
0.00
1.10
1.18
0.00
1.18
2.17
0.00
2.17
1.20
0.00
1.20
1.30
0.00
1.30
1.40
2.15
0.14
1.94
1.88
0.06
1.96
1.82
0.14
2.94
2.82
0.12
3.22
3.07
0.15
0.71
2.21
1.75
0.46
2.40
0.66
1.21
0.84
0.37
0.48
0.30
0.18
1.32
0.95
0.37
0.78
0.56
0.22
1.99
1.77
0.22
1.91
1.68
0.23
1.31
1.13
0.18
18.24
17.82
0.42
9.39
9.16
0.23
3.22
2.85
0.37
5.35
4.77
0.58
1.10
0.94
0.16
2.22
1.95
0.27
2.79
2.52
0.27
4.99
4.42
0.57
3.34
3.04
0.30
5.15
4.93
0.22
4.97
1.72
0.18
1.59
1.51
0.08
2.00
1.84
0.16
2.29
2.14
0.15
3.32
3.13
0.19
0.75
1.99
1.48
0.51
2.66
0.66
1.15
0.71
0.44
0.46
0.25
0.21
1.20
0.75
0.45
0.69
0.45
0.24
1.72
1.43
0.29
1.73
1.44
0.29
1.29
1.02
0.27
13.79
13.26
0.53
6.47
6.19
0.28
5.99
5.41
0.58
4.77
3.85
0.92
0.97
0.69
0.28
1.97
1.60
0.37
2.91
2.53
0.38
4.84
4.09
0.75
2.73
2.33
0.40
4.59
4.21
0.38
3.69
NA
0.14
NA
NA
0.06
NA
NA
0.14
NA
NA
0.12
NA
NA
0.15
0.46
NA
NA
0.46
0.69
0.20
NA
NA
0.37
NA
NA
0.18
NA
NA
0.37
NA
NA
0.22
NA
NA
0.22
NA
NA
0.23
NA
NA
0.18
NA
NA
0.42
NA
NA
0.23
NA
NA
0.37
NA
NA
0.58
NA
NA
0.16
NA
NA
0.27
NA
NA
0.27
NA
NA
0.57
NA
NA
0.30
NA
NA
0.22
NA
NA
0.18
NA
NA
0.08
NA
NA
0.16
NA
NA
0.15
NA
NA
0.19
0.51
NA
NA
0.51
0.82
0.24
NA
NA
0.44
NA
NA
0.21
NA
NA
0.45
NA
NA
0.24
NA
NA
0.29
NA
NA
0.29
NA
NA
0.27
NA
NA
0.53
NA
NA
0.28
NA
NA
0.58
NA
NA
0.92
NA
NA
0.28
NA
NA
0.37
NA
NA
0.38
NA
NA
0.75
NA
NA
0.40
NA
NA
0.38
NA
Malpractice
RVUs 2
0.01
0.02
0.02
0.01
0.01
0.04
0.02
0.02
0.03
0.01
0.02
0.04
0.02
0.02
0.05
0.07
0.02
0.05
0.07
0.02
0.08
0.04
0.04
0.04
0.02
0.02
0.08
0.04
0.04
0.04
0.02
0.02
0.05
0.02
0.03
0.05
0.02
0.03
0.05
0.02
0.03
0.13
0.07
0.06
0.09
0.06
0.03
0.13
0.06
0.07
0.19
0.07
0.12
0.17
0.07
0.10
0.08
0.02
0.06
0.17
0.07
0.10
0.15
0.06
0.09
0.05
0.02
0.03
0.12
0.06
0.06
0.12
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00298
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66519
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
88368
88368
88371
88372
88380
88380
88380
88381
88381
88381
88384
88384
88384
88385
88385
88385
88386
88386
88386
88399
88399
88399
89049
89060
89100
89105
89130
89132
89135
89136
89140
89141
89220
89230
89240
90281
90283
90284
90287
90288
90291
90296
90371
90375
90376
90378
90379
90384
90385
90386
90389
90393
90396
90399
90465
90466
90467
90468
90471
90472
90473
90474
90476
90477
90581
90585
90586
90632
90633
90634
90636
90645
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
TC ......
26 .......
26 .......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
I ..........
I ..........
X ........
I ..........
I ..........
I ..........
E ........
E ........
E ........
E ........
X ........
I ..........
I ..........
E ........
I ..........
I ..........
E ........
E ........
I ..........
A ........
A ........
R ........
R ........
A ........
A ........
R ........
R ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
Insitu hybridization, manual ................
Insitu hybridization, manual ................
Protein, western blot tissue ................
Protein analysis w/probe .....................
Microdissection, laser .........................
Microdissection, laser .........................
Microdissection, laser .........................
Microdissection, manual .....................
Microdissection, manual .....................
Microdissection, manual .....................
Eval molecular probes, 11–50 ............
Eval molecular probes, 11–50 ............
Eval molecular probes, 11–50 ............
Eval molecul probes, 51–250 .............
Eval molecul probes, 51–250 .............
Eval molecul probes, 51–250 .............
Eval molecul probes, 251–500 ...........
Eval molecul probes, 251–500 ...........
Eval molecul probes, 251–500 ...........
Surgical pathology procedure .............
Surgical pathology procedure .............
Surgical pathology procedure .............
Chct for mal hyperthermia ..................
Exam,synovial fluid crystals ................
Sample intestinal contents ..................
Sample intestinal contents ..................
Sample stomach contents ..................
Sample stomach contents ..................
Sample stomach contents ..................
Sample stomach contents ..................
Sample stomach contents ..................
Sample stomach contents ..................
Sputum specimen collection ...............
Collect sweat for test ..........................
Pathology lab procedure .....................
Human ig, im .......................................
Human ig, iv ........................................
Human ig, sc .......................................
Botulinum antitoxin ..............................
Botulism ig, iv ......................................
Cmv ig, iv ............................................
Diphtheria antitoxin .............................
Hep b ig, im ........................................
Rabies ig, im/sc ..................................
Rabies ig, heat treated .......................
Rsv ig, im, 50mg .................................
Rsv ig, iv .............................................
Rh ig, full-dose, im ..............................
Rh ig, minidose, im .............................
Rh ig, iv ...............................................
Tetanus ig, im .....................................
Vaccina ig, im .....................................
Varicella-zoster ig, im .........................
Immune globulin ..................................
Immune admin 1 inj, < 8 yrs ...............
Immune admin addl inj, < 8 y .............
Immune admin o or n, < 8 yrs ............
Immune admin o/n, addl < 8 y ............
Immunization admin ............................
Immunization admin, each add ...........
Immune admin oral/nasal ...................
Immune admin oral/nasal addl ...........
Adenovirus vaccine, type 4 .................
Adenovirus vaccine, type 7 .................
Anthrax vaccine, sc .............................
Bcg vaccine, percut ............................
Bcg vaccine, intravesical ....................
Hep a vaccine, adult im ......................
Hep a vacc, ped/adol, 2 dose .............
Hep a vacc, ped/adol, 3 dose .............
Hep a/hep b vacc, adult im .................
Hib vaccine, hboc, im .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.40
0.37
0.37
1.56
0.00
1.56
1.18
0.00
1.18
0.00
0.00
0.00
1.50
0.00
1.50
1.88
0.00
1.88
0.00
0.00
0.00
1.40
0.37
0.60
0.50
0.45
0.19
0.79
0.21
0.94
0.85
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.17
0.15
0.17
0.15
0.17
0.15
0.17
0.15
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
4.72
0.25
0.10
0.12
2.65
2.22
0.43
4.47
4.15
0.32
0.00
0.00
0.00
15.53
15.26
0.27
15.44
15.10
0.34
0.00
0.00
0.00
3.56
0.12
7.89
7.84
6.54
8.38
8.82
5.94
6.22
6.36
0.37
0.07
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.44
0.12
0.17
0.11
0.44
0.12
0.17
0.08
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
3.26
0.43
0.12
0.14
2.65
2.22
0.43
4.47
4.15
0.32
0.00
0.00
0.00
11.31
10.85
0.46
11.24
10.66
0.58
0.00
0.00
0.00
3.55
0.14
4.86
5.03
4.14
4.96
5.36
3.84
4.15
4.57
0.40
0.09
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.38
0.12
0.17
0.11
0.38
0.13
0.18
0.09
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.25
0.10
0.12
NA
NA
0.43
NA
NA
0.32
NA
NA
0.00
NA
NA
0.27
NA
NA
0.34
NA
NA
0.00
0.19
0.12
0.54
0.46
0.38
0.39
0.67
0.26
0.43
0.49
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.04
0.07
0.04
NA
0.04
0.04
0.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.43
0.12
0.14
NA
NA
0.43
NA
NA
0.32
NA
NA
0.00
NA
NA
0.46
NA
NA
0.58
NA
NA
0.00
0.23
0.14
0.37
0.31
0.25
0.22
0.46
0.18
0.35
0.41
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.08
0.08
0.05
NA
0.08
0.06
0.05
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Malpractice
RVUs 2
0.06
0.06
0.01
0.01
0.14
0.07
0.07
0.08
0.02
0.06
0.00
0.00
0.00
0.12
0.06
0.06
0.16
0.08
0.08
0.00
0.00
0.00
0.06
0.01
0.03
0.02
0.02
0.01
0.04
0.01
0.04
0.03
0.02
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00299
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
ZZZ
XXX
ZZZ
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66520
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
90646
90647
90648
90649
90655
90656
90657
90658
90660
90661
90662
90663
90665
90669
90675
90676
90680
90690
90691
90692
90693
90698
90700
90701
90702
90703
90704
90705
90706
90707
90708
90710
90712
90713
90714
90715
90716
90717
90718
90719
90720
90721
90723
90725
90727
90732
90733
90734
90735
90736
90740
90743
90744
90746
90747
90748
90749
90760
90761
90765
90766
90767
90768
90769
90770
90771
90772
90773
90774
90775
90776
90779
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
E ........
E ........
E ........
E ........
X ........
X ........
X ........
X ........
X ........
X ........
X ........
X ........
E ........
X ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
E ........
I ..........
E ........
E ........
X ........
E ........
E ........
E ........
E ........
X ........
X ........
X ........
X ........
X ........
I ..........
E ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
X ........
C ........
Hib vaccine, prp-d, im .........................
Hib vaccine, prp-omp, im ....................
Hib vaccine, prp-t, im ..........................
H papilloma vacc 3 dose im ...............
Flu vaccine no preserv 6–35m ...........
Flu vaccine no preserv 3 & > .............
Flu vaccine, 3 yrs, im ..........................
Flu vaccine, 3 yrs & >, im ...................
Flu vaccine, nasal ...............................
Flu vacc cell cult prsv free ..................
Flu vacc prsv free inc antig ................
Flu vacc pandemic ..............................
Lyme disease vaccine, im ..................
Pneumococcal vacc, ped <5 ...............
Rabies vaccine, im ..............................
Rabies vaccine, id ...............................
Rotovirus vacc 3 dose, oral ................
Typhoid vaccine, oral ..........................
Typhoid vaccine, im ............................
Typhoid vaccine, h-p, sc/id .................
Typhoid vaccine, akd, sc ....................
Dtap-hib-ip vaccine, im .......................
Dtap vaccine, < 7 yrs, im ....................
Dtp vaccine, im ...................................
Dt vaccine < 7, im ...............................
Tetanus vaccine, im ............................
Mumps vaccine, sc .............................
Measles vaccine, sc ............................
Rubella vaccine, sc .............................
Mmr vaccine, sc ..................................
Measles-rubella vaccine, sc ................
Mmrv vaccine, sc ................................
Oral poliovirus vaccine ........................
Poliovirus, ipv, sc/im ...........................
Td vaccine no prsrv >/= 7 im ..............
Tdap vaccine >7 im ............................
Chicken pox vaccine, sc .....................
Yellow fever vaccine, sc .....................
Td vaccine > 7, im ..............................
Diphtheria vaccine, im ........................
Dtp/hib vaccine, im .............................
Dtap/hib vaccine, im ...........................
Dtap-hep b-ipv vaccine, im .................
Cholera vaccine, injectable .................
Plague vaccine, im ..............................
Pneumococcal vaccine .......................
Meningococcal vaccine, sc .................
Meningococcal vaccine, im .................
Encephalitis vaccine, sc ......................
Zoster vacc, sc ....................................
Hepb vacc, ill pat 3 dose im ...............
Hep b vacc, adol, 2 dose, im ..............
Hepb vacc ped/adol 3 dose im ...........
Hep b vaccine, adult, im .....................
Hepb vacc, ill pat 4 dose im ...............
Hep b/hib vaccine, im .........................
Vaccine toxoid .....................................
Hydration iv infusion, init .....................
Hydrate iv infusion, add-on .................
Ther/proph/diag iv inf, init ...................
Ther/proph/dg iv inf, add-on ...............
Tx/proph/dg addl seq iv inf .................
Ther/diag concurrent inf ......................
Sc ther infusion, up to 1 hr .................
Sc ther infusion, addl hr ......................
Sc ther infusion, reset pump ...............
Ther/proph/diag inj, sc/im ...................
Ther/proph/diag inj, ia .........................
Ther/proph/diag inj, iv push ................
Tx/pro/dx inj new drug addon .............
Tx/pro/dx inj same drug adon .............
Ther/prop/diag inj/inf proc ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.17
0.09
0.21
0.18
0.19
0.17
0.21
0.18
0.00
0.17
0.17
0.18
0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.32
0.32
1.62
0.37
0.69
0.33
3.92
0.22
1.86
0.44
0.30
1.33
0.51
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.37
0.36
1.69
0.42
0.79
0.39
3.92
0.22
1.86
0.38
0.31
1.31
0.54
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
Malpractice
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.07
0.04
0.07
0.04
0.04
0.04
0.06
0.04
0.01
0.01
0.02
0.04
0.04
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00300
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
ZZZ
ZZZ
ZZZ
XXX
ZZZ
ZZZ
XXX
XXX
XXX
ZZZ
ZZZ
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66521
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
90801
90802
90804
90805
90806
90807
90808
90809
90810
90811
90812
90813
90814
90815
90816
90817
90818
90819
90821
90822
90823
90824
90826
90827
90828
90829
90845
90846
90847
90849
90853
90857
90862
90865
90870
90875
90876
90880
90882
90885
90887
90889
90899
90901
90911
90918
90919
90920
90921
90922
90923
90924
90925
90935
90937
90940
90945
90947
90989
90993
90997
90999
91000
91000
91000
91010
91010
91010
91011
91011
91011
91012
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
R ........
R ........
R ........
A ........
A ........
A ........
A ........
A ........
N ........
N ........
A ........
N ........
B ........
B ........
B ........
C ........
A ........
A ........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
A ........
A ........
X ........
A ........
A ........
X ........
X ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
Psy dx interview ..................................
Intac psy dx interview .........................
Psytx, office, 20–30 min .....................
Psytx, off, 20–30 min w/e&m ..............
Psytx, off, 45–50 min ..........................
Psytx, off, 45–50 min w/e&m ..............
Psytx, office, 75–80 min .....................
Psytx, off, 75–80, w/e&m ....................
Intac psytx, off, 20–30 min .................
Intac psytx, 20–30, w/e&m .................
Intac psytx, off, 45–50 min .................
Intac psytx, 45–50 min w/e&m ...........
Intac psytx, off, 75–80 min .................
Intac psytx, 75–80 w/e&m ..................
Psytx, hosp, 20–30 min ......................
Psytx, hosp, 20–30 min w/e&m ..........
Psytx, hosp, 45–50 min ......................
Psytx, hosp, 45–50 min w/e&m ..........
Psytx, hosp, 75–80 min ......................
Psytx, hosp, 75–80 min w/e&m ..........
Intac psytx, hosp, 20–30 min ..............
Intac psytx, hsp 20–30 w/e&m ...........
Intac psytx, hosp, 45–50 min ..............
Intac psytx, hsp 45–50 w/e&m ...........
Intac psytx, hosp, 75–80 min ..............
Intac psytx, hsp 75–80 w/e&m ...........
Psychoanalysis ...................................
Family psytx w/o patient .....................
Family psytx w/patient ........................
Multiple family group psytx .................
Group psychotherapy ..........................
Intac group psytx ................................
Medication management .....................
Narcosynthesis ....................................
Electroconvulsive therapy ...................
Psychophysiological therapy ...............
Psychophysiological therapy ...............
Hypnotherapy ......................................
Environmental manipulation ................
Psy evaluation of records ...................
Consultation with family ......................
Preparation of report ...........................
Psychiatric service/therapy .................
Biofeedback train, any meth ...............
Biofeedback peri/uro/rectal .................
ESRD related services, month ...........
ESRD related services, month ...........
ESRD related services, month ...........
ESRD related services, month ...........
ESRD related services, day ................
Esrd related services, day ..................
Esrd related services, day ..................
Esrd related services, day ..................
Hemodialysis, one evaluation .............
Hemodialysis, repeated eval ...............
Hemodialysis access study .................
Dialysis, one evaluation ......................
Dialysis, repeated eval ........................
Dialysis training, complete ..................
Dialysis training, incompl ....................
Hemoperfusion ....................................
Dialysis procedure ..............................
Esophageal intubation ........................
Esophageal intubation ........................
Esophageal intubation ........................
Esophagus motility study ....................
Esophagus motility study ....................
Esophagus motility study ....................
Esophagus motility study ....................
Esophagus motility study ....................
Esophagus motility study ....................
Esophagus motility study ....................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.80
3.01
1.21
1.37
1.86
2.02
2.79
2.95
1.32
1.48
1.97
2.13
2.90
3.06
1.25
1.41
1.89
2.05
2.83
2.99
1.36
1.52
2.01
2.16
2.94
3.10
1.79
1.83
2.21
0.59
0.59
0.63
0.95
2.84
1.88
1.20
1.90
2.19
0.00
0.97
1.48
0.00
0.00
0.41
0.89
11.16
8.53
7.26
4.46
0.37
0.28
0.24
0.15
1.22
2.11
0.00
1.28
2.16
0.00
0.00
1.84
0.00
0.73
0.00
0.73
1.25
0.00
1.25
1.50
0.00
1.50
1.46
1.49
1.54
0.56
0.60
0.53
0.70
0.69
0.86
0.54
0.72
0.65
0.83
0.81
0.99
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.39
0.51
0.74
0.33
0.26
0.38
0.62
1.16
1.92
0.53
0.67
0.57
0.00
0.22
0.61
0.00
0.00
0.46
1.37
4.70
3.03
2.73
1.71
0.16
0.10
0.09
0.05
NA
NA
0.00
NA
NA
0.00
0.00
NA
0.00
2.13
1.91
0.22
3.67
3.12
0.55
5.37
4.65
0.72
5.44
1.33
1.37
0.52
0.55
0.61
0.70
0.86
0.93
0.52
0.64
0.72
0.80
0.95
1.02
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.48
0.58
0.78
0.30
0.26
0.33
0.51
1.26
1.93
0.71
0.91
0.81
0.00
0.30
0.71
0.00
0.00
0.56
1.46
5.40
3.51
3.24
2.07
0.18
0.11
0.10
0.07
NA
NA
0.00
NA
NA
0.00
0.00
NA
0.00
1.23
0.99
0.24
4.03
3.54
0.49
5.29
4.67
0.62
5.60
0.60
0.68
0.21
0.24
0.33
0.35
0.49
0.52
0.23
0.26
0.34
0.37
0.53
0.53
0.32
0.35
0.44
0.46
0.60
0.62
0.35
0.37
0.46
0.48
0.62
0.64
0.32
0.42
0.49
0.21
0.20
0.21
0.27
0.63
0.38
0.28
0.44
0.39
0.00
0.22
0.34
0.00
0.00
0.10
0.30
3.74
2.55
2.26
1.61
0.13
0.08
0.07
0.05
0.53
0.77
0.00
0.55
0.79
0.00
0.00
0.50
0.00
NA
NA
0.22
NA
NA
0.55
NA
NA
0.72
NA
0.76
0.83
0.30
0.33
0.46
0.49
0.69
0.72
0.33
0.36
0.49
0.52
0.75
0.74
0.39
0.40
0.56
0.55
0.80
0.79
0.41
0.43
0.59
0.58
0.84
0.81
0.43
0.54
0.63
0.22
0.21
0.23
0.29
0.77
0.48
0.37
0.58
0.54
0.00
0.30
0.45
0.00
0.00
0.12
0.30
4.92
3.27
3.01
2.03
0.17
0.11
0.10
0.07
0.60
0.87
0.00
0.62
0.89
0.00
0.00
0.58
0.00
NA
NA
0.24
NA
NA
0.49
NA
NA
0.62
NA
Malpractice
RVUs 2
0.06
0.07
0.03
0.03
0.04
0.05
0.06
0.07
0.04
0.04
0.04
0.05
0.06
0.07
0.03
0.03
0.04
0.05
0.06
0.08
0.03
0.04
0.05
0.05
0.06
0.07
0.04
0.04
0.05
0.02
0.01
0.01
0.02
0.12
0.04
0.04
0.05
0.05
0.00
0.02
0.04
0.00
0.00
0.02
0.06
0.36
0.29
0.23
0.14
0.01
0.01
0.01
0.01
0.04
0.07
0.00
0.04
0.07
0.00
0.00
0.06
0.00
0.04
0.01
0.03
0.12
0.06
0.06
0.13
0.06
0.07
0.13
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00301
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
XXX
000
000
XXX
XXX
000
XXX
000
000
000
000
000
000
000
000
000
000
66522
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
91012
91012
91020
91020
91020
91022
91022
91022
91030
91030
91030
91034
91034
91034
91035
91035
91035
91037
91037
91037
91038
91038
91038
91040
91040
91040
91052
91052
91052
91055
91055
91055
91065
91065
91065
91100
91105
91110
91110
91110
91111
91111
91111
91120
91120
91120
91122
91122
91122
91123
91132
91132
91132
91133
91133
91133
91299
91299
91299
92002
92004
92012
92014
92015
92018
92019
92020
92025
92025
92025
92060
92060
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
C
C
A
C
C
A
C
C
C
A
A
A
A
N
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Esophagus motility study ....................
Esophagus motility study ....................
Gastric motility studies ........................
Gastric motility studies ........................
Gastric motility studies ........................
Duodenal motility study .......................
Duodenal motility study .......................
Duodenal motility study .......................
Acid perfusion of esophagus ..............
Acid perfusion of esophagus ..............
Acid perfusion of esophagus ..............
Gastroesophageal reflux test ..............
Gastroesophageal reflux test ..............
Gastroesophageal reflux test ..............
G-esoph reflx tst w/electrod ................
G-esoph reflx tst w/electrod ................
G-esoph reflx tst w/electrod ................
Esoph imped function test ..................
Esoph imped function test ..................
Esoph imped function test ..................
Esoph imped funct test > 1h ...............
Esoph imped funct test > 1h ...............
Esoph imped funct test > 1h ...............
Esoph balloon distension tst ...............
Esoph balloon distension tst ...............
Esoph balloon distension tst ...............
Gastric analysis test ............................
Gastric analysis test ............................
Gastric analysis test ............................
Gastric intubation for smear ...............
Gastric intubation for smear ...............
Gastric intubation for smear ...............
Breath hydrogen test ..........................
Breath hydrogen test ..........................
Breath hydrogen test ..........................
Pass intestine bleeding tube ...............
Gastric intubation treatment ................
Gi tract capsule endoscopy ................
Gi tract capsule endoscopy ................
Gi tract capsule endoscopy ................
Esophageal capsule endoscopy .........
Esophageal capsule endoscopy .........
Esophageal capsule endoscopy .........
Rectal sensation test ..........................
Rectal sensation test ..........................
Rectal sensation test ..........................
Anal pressure record ..........................
Anal pressure record ..........................
Anal pressure record ..........................
Irrigate fecal impaction ........................
Electrogastrography ............................
Electrogastrography ............................
Electrogastrography ............................
Electrogastrography w/test .................
Electrogastrography w/test .................
Electrogastrography w/test .................
Gastroenterology procedure ...............
Gastroenterology procedure ...............
Gastroenterology procedure ...............
Eye exam, new patient .......................
Eye exam, new patient .......................
Eye exam established pat ..................
Eye exam & treatment ........................
Refraction ............................................
New eye exam & treatment ................
Eye exam & treatment ........................
Special eye evaluation ........................
Corneal topography ............................
Corneal topography ............................
Corneal topography ............................
Special eye evaluation ........................
Special eye evaluation ........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
1.46
1.44
0.00
1.44
1.44
0.00
1.44
0.91
0.00
0.91
0.97
0.00
0.97
1.59
0.00
1.59
0.97
0.00
0.97
1.10
0.00
1.10
0.97
0.00
0.97
0.79
0.00
0.79
0.94
0.00
0.94
0.20
0.00
0.20
1.08
0.37
3.64
0.00
3.64
1.00
0.00
1.00
0.97
0.00
0.97
1.77
0.00
1.77
0.00
0.00
0.00
0.52
0.00
0.00
0.66
0.00
0.00
0.00
0.88
1.82
0.92
1.42
0.38
2.50
1.31
0.37
0.35
0.00
0.35
0.69
0.00
4.76
0.68
4.81
4.20
0.61
3.13
2.51
0.62
2.90
2.48
0.42
4.15
3.73
0.42
11.37
10.67
0.70
3.47
3.03
0.44
2.80
2.30
0.50
7.72
7.44
0.28
2.92
2.55
0.37
2.57
2.28
0.29
1.33
1.27
0.06
2.14
1.67
20.63
18.97
1.66
18.82
18.37
0.45
8.88
8.61
0.27
4.30
3.68
0.62
0.00
0.00
0.00
0.25
0.00
0.00
0.32
0.00
0.00
0.00
0.93
1.57
0.99
1.37
0.10
NA
NA
0.25
0.49
0.37
0.12
0.76
0.54
5.00
0.60
4.66
4.11
0.55
3.76
3.20
0.56
2.66
2.29
0.37
4.69
4.31
0.38
11.08
10.45
0.63
3.20
2.81
0.39
2.52
2.07
0.45
9.42
9.11
0.31
2.68
2.36
0.32
2.76
2.48
0.28
1.40
1.33
0.07
2.46
1.89
21.40
19.93
1.47
18.82
18.37
0.45
9.92
9.62
0.30
4.70
4.09
0.61
0.00
0.00
0.00
0.22
0.00
0.00
0.28
0.00
0.00
0.00
0.95
1.63
1.01
1.39
0.79
NA
NA
0.29
0.49
0.37
0.12
0.75
0.49
NA
0.68
NA
NA
0.61
NA
NA
0.62
NA
NA
0.42
NA
NA
0.42
NA
NA
0.70
NA
NA
0.44
NA
NA
0.50
NA
NA
0.28
NA
NA
0.37
NA
NA
0.29
NA
NA
0.06
0.32
0.07
NA
NA
1.66
NA
NA
0.45
NA
NA
0.27
NA
NA
0.62
0.00
NA
NA
0.25
NA
NA
0.32
NA
NA
0.00
0.25
0.55
0.31
0.46
0.09
0.86
0.35
0.13
NA
NA
0.12
NA
NA
NA
0.60
NA
NA
0.55
NA
NA
0.56
NA
NA
0.37
NA
NA
0.38
NA
NA
0.63
NA
NA
0.39
NA
NA
0.45
NA
NA
0.31
NA
NA
0.32
NA
NA
0.28
NA
NA
0.07
0.30
0.08
NA
NA
1.47
NA
NA
0.45
NA
NA
0.30
NA
NA
0.61
0.00
NA
NA
0.22
NA
NA
0.28
NA
NA
0.00
0.30
0.62
0.30
0.46
0.12
0.96
0.46
0.14
NA
NA
0.12
NA
NA
Malpractice
RVUs 2
0.07
0.06
0.13
0.06
0.07
0.13
0.06
0.07
0.06
0.02
0.04
0.12
0.06
0.06
0.12
0.06
0.06
0.12
0.06
0.06
0.12
0.06
0.06
0.12
0.06
0.06
0.05
0.02
0.03
0.07
0.02
0.05
0.03
0.02
0.01
0.07
0.03
0.16
0.07
0.09
0.05
0.02
0.03
0.11
0.04
0.07
0.21
0.08
0.13
0.00
0.00
0.00
0.02
0.00
0.00
0.03
0.00
0.00
0.00
0.02
0.04
0.02
0.03
0.01
0.07
0.03
0.01
0.02
0.01
0.01
0.03
0.01
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00302
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66523
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
92060
92065
92065
92065
92070
92081
92081
92081
92082
92082
92082
92083
92083
92083
92100
92120
92130
92135
92135
92135
92136
92136
92136
92140
92225
92226
92230
92235
92235
92235
92240
92240
92240
92250
92250
92250
92260
92265
92265
92265
92270
92270
92270
92275
92275
92275
92283
92283
92283
92284
92284
92284
92285
92285
92285
92286
92286
92286
92287
92310
92311
92312
92313
92314
92315
92316
92317
92325
92326
92340
92341
92342
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
N
A
A
A
A
A
N
N
N
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Special eye evaluation ........................
Orthoptic/pleoptic training ...................
Orthoptic/pleoptic training ...................
Orthoptic/pleoptic training ...................
Fitting of contact lens ..........................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Visual field examination(s) ..................
Serial tonometry exam(s) ....................
Tonography & eye evaluation .............
Water provocation tonography ............
Ophth dx imaging post seg .................
Ophth dx imaging post seg .................
Ophth dx imaging post seg .................
Ophthalmic biometry ...........................
Ophthalmic biometry ...........................
Ophthalmic biometry ...........................
Glaucoma provocative tests ...............
Special eye exam, initial .....................
Special eye exam, subsequent ...........
Eye exam with photos ........................
Eye exam with photos ........................
Eye exam with photos ........................
Eye exam with photos ........................
Icg angiography ..................................
Icg angiography ..................................
Icg angiography ..................................
Eye exam with photos ........................
Eye exam with photos ........................
Eye exam with photos ........................
Ophthalmoscopy/dynamometry ..........
Eye muscle evaluation ........................
Eye muscle evaluation ........................
Eye muscle evaluation ........................
Electro-oculography ............................
Electro-oculography ............................
Electro-oculography ............................
Electroretinography .............................
Electroretinography .............................
Electroretinography .............................
Color vision examination .....................
Color vision examination .....................
Color vision examination .....................
Dark adaptation eye exam ..................
Dark adaptation eye exam ..................
Dark adaptation eye exam ..................
Eye photography .................................
Eye photography .................................
Eye photography .................................
Internal eye photography ....................
Internal eye photography ....................
Internal eye photography ....................
Internal eye photography ....................
Contact lens fitting ..............................
Contact lens fitting ..............................
Contact lens fitting ..............................
Contact lens fitting ..............................
Prescription of contact lens ................
Prescription of contact lens ................
Prescription of contact lens ................
Prescription of contact lens ................
Modification of contact lens ................
Replacement of contact lens ..............
Fitting of spectacles ............................
Fitting of spectacles ............................
Fitting of spectacles ............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.69
0.37
0.00
0.37
0.70
0.36
0.00
0.36
0.44
0.00
0.44
0.50
0.00
0.50
0.92
0.81
0.81
0.35
0.00
0.35
0.54
0.00
0.54
0.50
0.38
0.33
0.60
0.81
0.00
0.81
1.10
0.00
1.10
0.44
0.00
0.44
0.20
0.81
0.00
0.81
0.81
0.00
0.81
1.01
0.00
1.01
0.17
0.00
0.17
0.24
0.00
0.24
0.20
0.00
0.20
0.66
0.00
0.66
0.81
1.17
1.08
1.26
0.92
0.69
0.45
0.68
0.45
0.00
0.00
0.37
0.47
0.53
0.22
0.86
0.77
0.09
0.90
0.95
0.84
0.11
1.32
1.18
0.14
1.51
1.35
0.16
1.24
0.97
1.18
0.79
0.67
0.12
1.42
1.23
0.19
0.89
0.24
0.23
0.68
2.26
1.97
0.29
4.38
3.99
0.39
1.30
1.16
0.14
0.23
1.00
0.76
0.24
1.32
1.09
0.23
2.42
2.07
0.35
0.99
0.94
0.05
1.13
1.06
0.07
0.80
0.73
0.07
2.08
1.86
0.22
1.90
1.06
1.27
1.45
1.42
1.14
1.31
1.63
1.31
0.83
0.73
0.44
0.46
0.48
0.26
0.69
0.57
0.12
0.98
0.94
0.81
0.13
1.27
1.11
0.16
1.47
1.28
0.19
1.29
1.02
1.23
0.78
0.65
0.13
1.54
1.32
0.22
0.94
0.23
0.22
1.10
2.44
2.11
0.33
5.23
4.79
0.44
1.41
1.25
0.16
0.24
1.24
0.98
0.26
1.42
1.14
0.28
2.18
1.79
0.39
0.91
0.85
0.06
1.50
1.43
0.07
0.89
0.81
0.08
2.56
2.31
0.25
2.14
1.09
1.18
1.26
1.24
1.04
1.08
1.27
1.12
0.62
1.18
0.57
0.60
0.62
0.22
NA
NA
0.09
0.22
NA
NA
0.11
NA
NA
0.14
NA
NA
0.16
0.27
0.25
0.27
NA
NA
0.12
NA
NA
0.19
0.14
0.12
0.11
0.19
NA
NA
0.29
NA
NA
0.39
NA
NA
0.14
0.07
NA
NA
0.24
NA
NA
0.23
NA
NA
0.35
NA
NA
0.05
NA
NA
0.07
NA
NA
0.07
NA
NA
0.22
0.27
0.27
0.30
0.33
0.31
0.16
0.13
0.22
0.11
NA
NA
0.09
0.11
0.12
0.26
NA
NA
0.12
0.27
NA
NA
0.13
NA
NA
0.16
NA
NA
0.19
0.32
0.28
0.32
NA
NA
0.13
NA
NA
0.22
0.18
0.14
0.13
0.19
NA
NA
0.33
NA
NA
0.44
NA
NA
0.16
0.08
NA
NA
0.26
NA
NA
0.28
NA
NA
0.39
NA
NA
0.06
NA
NA
0.07
NA
NA
0.08
NA
NA
0.25
0.29
0.36
0.33
0.41
0.30
0.21
0.14
0.26
0.13
NA
NA
0.11
0.14
0.17
Malpractice
RVUs 2
0.02
0.02
0.01
0.01
0.02
0.02
0.01
0.01
0.02
0.01
0.01
0.02
0.01
0.01
0.02
0.02
0.02
0.02
0.01
0.01
0.08
0.07
0.01
0.01
0.01
0.01
0.02
0.08
0.06
0.02
0.09
0.06
0.03
0.02
0.01
0.01
0.01
0.06
0.02
0.04
0.05
0.02
0.03
0.05
0.02
0.03
0.02
0.01
0.01
0.02
0.01
0.01
0.02
0.01
0.01
0.04
0.02
0.02
0.02
0.04
0.03
0.03
0.02
0.01
0.01
0.02
0.01
0.01
0.06
0.01
0.01
0.01
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00303
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66524
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
92352
92353
92354
92355
92358
92370
92371
92499
92499
92499
92502
92504
92506
92507
92508
92511
92512
92516
92520
92526
92531
92532
92533
92534
92541
92541
92541
92542
92542
92542
92543
92543
92543
92544
92544
92544
92545
92545
92545
92546
92546
92546
92547
92548
92548
92548
92551
92552
92553
92555
92556
92557
92559
92560
92561
92562
92563
92564
92565
92567
92568
92569
92571
92572
92575
92576
92577
92579
92582
92583
92584
92585
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
B
B
B
B
B
N
B
C
C
C
A
A
A
A
A
A
A
A
A
A
B
B
B
B
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
A
A
N
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Special spectacles fitting ....................
Special spectacles fitting ....................
Special spectacles fitting ....................
Special spectacles fitting ....................
Eye prosthesis service ........................
Repair & adjust spectacles .................
Repair & adjust spectacles .................
Eye service or procedure ....................
Eye service or procedure ....................
Eye service or procedure ....................
Ear and throat examination ................
Ear microscopy examination ...............
Speech/hearing evaluation .................
Speech/hearing therapy ......................
Speech/hearing therapy ......................
Nasopharyngoscopy ...........................
Nasal function studies .........................
Facial nerve function test ....................
Laryngeal function studies ..................
Oral function therapy ..........................
Spontaneous nystagmus study ...........
Positional nystagmus test ...................
Caloric vestibular test .........................
Optokinetic nystagmus test .................
Spontaneous nystagmus test .............
Spontaneous nystagmus test .............
Spontaneous nystagmus test .............
Positional nystagmus test ...................
Positional nystagmus test ...................
Positional nystagmus test ...................
Caloric vestibular test .........................
Caloric vestibular test .........................
Caloric vestibular test .........................
Optokinetic nystagmus test .................
Optokinetic nystagmus test .................
Optokinetic nystagmus test .................
Oscillating tracking test .......................
Oscillating tracking test .......................
Oscillating tracking test .......................
Sinusoidal rotational test .....................
Sinusoidal rotational test .....................
Sinusoidal rotational test .....................
Supplemental electrical test ................
Posturography .....................................
Posturography .....................................
Posturography .....................................
Pure tone hearing test, air ..................
Pure tone audiometry, air ...................
Audiometry, air & bone .......................
Speech threshold audiometry .............
Speech audiometry, complete ............
Comprehensive hearing test ...............
Group audiometric testing ...................
Bekesy audiometry, screen ................
Bekesy audiometry, diagnosis ............
Loudness balance test ........................
Tone decay hearing test .....................
Sisi hearing test ..................................
Stenger test, pure tone .......................
Tympanometry ....................................
Acoustic refl threshold tst ...................
Acoustic reflex decay test ...................
Filtered speech hearing test ...............
Staggered spondaic word test ............
Sensorineural acuity test ....................
Synthetic sentence test .......................
Stenger test, speech ...........................
Visual audiometry (vra) .......................
Conditioning play audiometry .............
Select picture audiometry ...................
Electrocochleography ..........................
Auditor evoke potent, compre .............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.37
0.50
0.00
0.00
0.00
0.32
0.00
0.00
0.00
0.00
1.51
0.18
0.86
0.52
0.26
0.84
0.55
0.43
0.75
0.55
0.00
0.00
0.00
0.00
0.40
0.00
0.40
0.33
0.00
0.33
0.10
0.00
0.10
0.26
0.00
0.26
0.23
0.00
0.23
0.29
0.00
0.29
0.00
0.50
0.00
0.50
0.00
0.00
0.00
0.00
0.00
0.60
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
0.29
0.20
0.00
0.00
0.00
0.00
0.00
0.70
0.00
0.00
0.00
0.50
0.56
0.59
0.28
0.44
0.24
0.39
0.24
0.00
0.00
0.00
NA
0.60
3.49
1.23
0.55
3.12
1.00
1.23
0.93
1.70
0.00
0.00
0.00
0.00
1.14
1.03
0.11
1.29
1.20
0.09
0.65
0.62
0.03
1.03
0.96
0.07
1.00
0.94
0.06
1.81
1.73
0.08
0.11
1.70
1.56
0.14
0.25
0.61
0.77
0.41
0.51
0.29
0.00
0.00
0.70
0.62
0.55
0.48
0.25
0.13
0.10
0.07
0.44
0.59
1.15
0.58
0.26
0.35
1.17
0.73
1.36
2.10
0.62
0.66
4.57
2.38
0.60
0.47
0.43
0.00
0.00
0.00
NA
0.55
3.04
1.17
0.53
3.21
1.07
1.21
0.72
1.67
0.00
0.00
0.00
0.00
1.09
0.94
0.15
1.22
1.09
0.13
0.61
0.57
0.04
0.97
0.87
0.10
0.90
0.81
0.09
1.89
1.79
0.10
0.09
1.98
1.78
0.20
0.25
0.52
0.71
0.40
0.54
0.74
0.00
0.00
0.71
0.51
0.46
0.47
0.33
0.33
0.24
0.24
0.41
0.34
0.72
0.51
0.49
0.54
0.95
0.81
1.91
2.08
0.09
0.11
NA
NA
NA
0.07
NA
NA
NA
0.00
0.90
0.06
0.28
0.16
0.09
0.67
0.17
0.14
0.24
0.16
0.00
0.00
0.00
0.00
NA
NA
0.11
NA
NA
0.09
NA
NA
0.03
NA
NA
0.07
NA
NA
0.06
NA
NA
0.08
0.11
NA
NA
0.14
NA
NA
NA
NA
NA
0.20
0.00
0.00
NA
NA
NA
NA
NA
0.07
0.09
0.07
NA
NA
NA
NA
NA
0.23
NA
NA
NA
NA
0.11
0.15
NA
NA
NA
0.10
NA
NA
NA
0.00
1.00
0.07
0.34
0.19
0.11
0.72
0.18
0.18
0.31
0.18
0.00
0.00
0.00
0.00
NA
NA
0.15
NA
NA
0.13
NA
NA
0.04
NA
NA
0.10
NA
NA
0.09
NA
NA
0.10
0.09
NA
NA
0.20
NA
NA
NA
NA
NA
0.69
0.00
0.00
NA
NA
NA
NA
NA
0.29
0.24
0.24
NA
NA
NA
NA
NA
0.48
NA
NA
NA
NA
Malpractice
RVUs 2
0.01
0.02
0.10
0.01
0.05
0.02
0.02
0.00
0.00
0.00
0.05
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.00
0.00
0.00
0.00
0.04
0.02
0.02
0.03
0.02
0.01
0.02
0.01
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.06
0.15
0.13
0.02
0.01
0.04
0.06
0.04
0.06
0.12
0.00
0.00
0.06
0.04
0.04
0.05
0.04
0.06
0.04
0.04
0.04
0.01
0.02
0.05
0.07
0.06
0.06
0.08
0.21
0.17
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00304
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66525
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
92585
92585
92586
92587
92587
92587
92588
92588
92588
92590
92591
92592
92593
92594
92595
92596
92597
92601
92602
92603
92604
92605
92606
92607
92608
92609
92610
92611
92612
92613
92614
92615
92616
92617
92620
92621
92625
92626
92627
92630
92633
92640
92700
92950
92953
92960
92961
92970
92971
92973
92974
92975
92977
92978
92978
92978
92979
92979
92979
92980
92981
92982
92984
92986
92987
92990
92992
92993
92995
92996
92997
92998
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
N ........
N ........
N ........
N ........
N ........
N ........
A ........
A ........
A ........
A ........
A ........
A ........
B ........
B ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
I ..........
I ..........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
C ........
A ........
A ........
A ........
A ........
Auditor evoke potent, compre .............
Auditor evoke potent, compre .............
Auditor evoke potent, limit ..................
Evoked auditory test ...........................
Evoked auditory test ...........................
Evoked auditory test ...........................
Evoked auditory test ...........................
Evoked auditory test ...........................
Evoked auditory test ...........................
Hearing aid exam, one ear .................
Hearing aid exam, both ears ..............
Hearing aid check, one ear ................
Hearing aid check, both ears ..............
Electro hearng aid test, one ...............
Electro hearng aid tst, both ................
Ear protector evaluation ......................
Oral speech device eval .....................
Cochlear implt f/up exam < 7 .............
Reprogram cochlear implt < 7 ............
Cochlear implt f/up exam 7 > .............
Reprogram cochlear implt 7 > ............
Eval for nonspeech device rx .............
Non-speech device service .................
Ex for speech device rx, 1hr ...............
Ex for speech device rx addl ..............
Use of speech device service .............
Evaluate swallowing function ..............
Motion fluoroscopy/swallow ................
Endoscopy swallow tst (fees) .............
Endoscopy swallow tst (fees) .............
Laryngoscopic sensory test ................
Eval laryngoscopy sense tst ...............
Fees w/laryngeal sense test ...............
Interprt fees/laryngeal test ..................
Auditory function, 60 min ....................
Auditory function, + 15 min .................
Tinnitus assessment ...........................
Eval aud rehab status .........................
Eval aud status rehab add-on ............
Aud rehab pre-ling hear loss ..............
Aud rehab postling hear loss ..............
Aud brainstem implt programg ...........
Ent procedure/service .........................
Heart/lung resuscitation cpr ................
Temporary external pacing .................
Cardioversion electric, ext ..................
Cardioversion, electric, int ..................
Cardioassist, internal ..........................
Cardioassist, external .........................
Percut coronary thrombectomy ...........
Cath place, cardio brachytx ................
Dissolve clot, heart vessel ..................
Dissolve clot, heart vessel ..................
Intravasc us, heart add-on ..................
Intravasc us, heart add-on ..................
Intravasc us, heart add-on ..................
Intravasc us, heart add-on ..................
Intravasc us, heart add-on ..................
Intravasc us, heart add-on ..................
Insert intracoronary stent ....................
Insert intracoronary stent ....................
Coronary artery dilation ......................
Coronary artery dilation ......................
Revision of aortic valve .......................
Revision of mitral valve .......................
Revision of pulmonary valve ...............
Revision of heart chamber ..................
Revision of heart chamber ..................
Coronary atherectomy ........................
Coronary atherectomy add-on ............
Pul art balloon repr, percut .................
Pul art balloon repr, percut .................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.50
0.00
0.13
0.00
0.13
0.36
0.00
0.36
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.86
2.30
1.30
2.25
1.25
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.27
0.71
1.27
0.63
1.88
0.79
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
3.79
0.23
2.25
4.59
3.51
1.77
3.28
3.00
7.24
0.00
0.00
0.00
1.80
0.00
0.00
1.44
14.82
4.16
10.96
2.97
22.70
23.48
18.12
0.00
0.00
12.07
3.26
11.98
5.99
1.95
0.15
1.41
0.65
0.61
0.04
1.11
1.00
0.11
0.00
0.00
0.00
0.00
0.00
0.00
1.02
1.99
1.08
0.84
1.19
0.78
0.00
0.00
4.63
0.88
2.45
1.70
1.95
2.97
0.24
2.42
0.21
3.16
0.26
1.93
0.44
1.94
2.00
0.46
0.00
0.00
1.34
0.00
3.24
NA
4.37
NA
NA
NA
NA
NA
NA
1.73
0.00
0.00
0.96
0.00
0.00
0.77
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
1.90
0.18
1.63
1.01
0.96
0.05
1.37
1.23
0.14
0.00
0.00
0.00
0.00
0.00
0.00
0.80
1.84
2.29
1.61
1.66
1.06
0.00
0.00
3.85
0.72
2.02
2.56
2.69
2.85
0.32
2.46
0.28
3.27
0.35
1.53
0.34
1.53
2.10
0.50
0.00
0.00
1.34
0.00
3.72
NA
5.34
NA
NA
NA
NA
NA
NA
4.88
0.00
0.00
0.83
0.00
0.00
0.67
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
0.15
NA
NA
NA
0.04
NA
NA
0.11
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.28
0.64
0.40
0.73
0.41
0.00
0.00
NA
NA
NA
NA
NA
0.42
0.23
0.42
0.20
0.60
0.26
NA
NA
1.94
NA
0.46
0.00
0.00
1.34
0.00
0.77
0.07
1.45
2.43
1.46
1.09
1.76
1.62
3.83
NA
NA
NA
0.96
NA
NA
0.77
8.12
2.22
6.05
1.58
15.32
15.94
11.33
0.00
0.00
6.64
1.76
5.61
3.00
NA
0.18
NA
NA
NA
0.05
NA
NA
0.14
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.37
2.07
1.39
1.44
0.88
0.00
0.00
NA
NA
NA
NA
NA
0.54
0.31
0.54
0.28
0.80
0.35
NA
NA
1.53
NA
0.50
0.00
0.00
1.34
0.00
0.87
0.07
1.31
2.26
1.26
0.97
1.52
1.40
3.32
NA
NA
NA
0.83
NA
NA
0.67
7.08
1.92
5.29
1.37
13.57
14.07
10.56
0.00
0.00
5.80
1.51
5.21
2.60
Malpractice
RVUs 2
0.14
0.03
0.14
0.12
0.11
0.01
0.14
0.13
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.06
0.03
0.07
0.07
0.07
0.07
0.00
0.00
0.05
0.05
0.04
0.08
0.08
0.04
0.05
0.04
0.05
0.06
0.05
0.06
0.06
0.06
0.06
0.02
0.00
0.00
0.01
0.00
0.28
0.02
0.07
0.29
0.16
0.06
0.23
0.21
0.50
0.46
0.00
0.00
0.06
0.00
0.00
0.06
1.03
0.29
0.76
0.21
1.51
1.59
1.20
0.00
0.00
0.84
0.10
0.40
0.28
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00305
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
ZZZ
XXX
XXX
XXX
XXX
000
000
000
000
000
000
ZZZ
ZZZ
000
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
000
ZZZ
000
ZZZ
090
090
090
090
090
000
ZZZ
000
ZZZ
66526
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
93000
93005
93010
93012
93014
93015
93016
93017
93018
93024
93024
93024
93025
93025
93025
93040
93041
93042
93224
93225
93226
93227
93230
93231
93232
93233
93235
93236
93237
93268
93270
93271
93272
93278
93278
93278
93303
93303
93303
93304
93304
93304
93307
93307
93307
93308
93308
93308
93312
93312
93312
93313
93314
93314
93314
93315
93315
93315
93316
93317
93317
93317
93318
93318
93318
93320
93320
93320
93321
93321
93321
93325
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
C
C
A
C
C
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Electrocardiogram, complete ..............
Electrocardiogram, tracing ..................
Electrocardiogram report ....................
Transmission of ecg ............................
Report on transmitted ecg ..................
Cardiovascular stress test ..................
Cardiovascular stress test ..................
Cardiovascular stress test ..................
Cardiovascular stress test ..................
Cardiac drug stress test ......................
Cardiac drug stress test ......................
Cardiac drug stress test ......................
Microvolt t-wave assess ......................
Microvolt t-wave assess ......................
Microvolt t-wave assess ......................
Rhythm ECG with report .....................
Rhythm ECG, tracing ..........................
Rhythm ECG, report ...........................
ECG monitor/report, 24 hrs ................
ECG monitor/record, 24 hrs ................
ECG monitor/report, 24 hrs ................
ECG monitor/review, 24 hrs ...............
ECG monitor/report, 24 hrs ................
Ecg monitor/record, 24 hrs .................
ECG monitor/report, 24 hrs ................
ECG monitor/review, 24 hrs ...............
ECG monitor/report, 24 hrs ................
ECG monitor/report, 24 hrs ................
ECG monitor/review, 24 hrs ...............
ECG record/review ..............................
ECG recording ....................................
Ecg/monitoring and analysis ...............
Ecg/review, interpret only ...................
ECG/signal-averaged ..........................
ECG/signal-averaged ..........................
ECG/signal-averaged ..........................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo exam of heart ............................
Echo exam of heart ............................
Echo exam of heart ............................
Echo exam of heart ............................
Echo exam of heart ............................
Echo exam of heart ............................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal ........................
Echo transesophageal intraop ............
Echo transesophageal intraop ............
Echo transesophageal intraop ............
Doppler echo exam, heart ..................
Doppler echo exam, heart ..................
Doppler echo exam, heart ..................
Doppler echo exam, heart ..................
Doppler echo exam, heart ..................
Doppler echo exam, heart ..................
Doppler color flow add-on ...................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.17
0.00
0.17
0.00
0.52
0.75
0.45
0.00
0.30
1.17
0.00
1.17
0.75
0.00
0.75
0.16
0.00
0.16
0.52
0.00
0.00
0.52
0.52
0.00
0.00
0.52
0.00
0.00
0.45
0.52
0.00
0.00
0.52
0.25
0.00
0.25
1.30
0.00
1.30
0.75
0.00
0.75
0.92
0.00
0.92
0.53
0.00
0.53
2.20
0.00
2.20
0.95
1.25
0.00
1.25
0.00
0.00
2.78
0.95
0.00
0.00
1.83
0.00
0.00
2.20
0.38
0.00
0.38
0.15
0.00
0.15
0.07
0.35
0.28
0.07
4.16
0.22
1.90
0.22
1.53
0.15
2.40
1.82
0.58
3.93
3.55
0.38
0.19
0.14
0.05
2.31
0.85
1.19
0.27
2.30
0.72
1.35
0.23
0.00
0.00
0.22
5.78
0.29
5.27
0.22
0.62
0.52
0.10
4.49
3.96
0.53
3.10
2.80
0.30
3.73
3.28
0.45
2.62
2.35
0.27
7.39
6.42
0.97
NA
7.21
6.65
0.56
0.00
0.00
1.30
NA
0.00
0.00
0.55
0.00
0.00
0.85
1.67
1.49
0.18
0.61
0.54
0.07
0.66
0.42
0.36
0.06
5.09
0.21
1.93
0.20
1.60
0.13
1.98
1.47
0.51
5.76
5.42
0.34
0.20
0.15
0.05
2.96
1.04
1.69
0.23
3.09
1.12
1.76
0.21
0.00
0.00
0.19
6.60
0.76
5.64
0.20
0.93
0.83
0.10
4.41
3.91
0.50
2.66
2.37
0.29
3.97
3.57
0.40
2.38
2.15
0.23
5.98
5.10
0.88
NA
5.73
5.22
0.51
0.00
0.00
1.16
NA
0.00
0.00
0.61
0.00
0.00
0.67
1.77
1.60
0.17
0.89
0.82
0.07
1.80
NA
NA
0.07
NA
0.22
NA
0.22
NA
0.15
NA
NA
0.58
NA
NA
0.38
NA
NA
0.05
NA
NA
NA
0.27
NA
NA
NA
0.23
0.00
0.00
0.22
NA
NA
NA
0.22
NA
NA
0.10
NA
NA
0.53
NA
NA
0.30
NA
NA
0.45
NA
NA
0.27
NA
NA
0.97
0.12
NA
NA
0.56
NA
NA
1.30
0.26
NA
NA
0.55
NA
NA
0.85
NA
NA
0.18
NA
NA
0.07
NA
NA
NA
0.06
NA
0.21
NA
0.20
NA
0.13
NA
NA
0.51
NA
NA
0.34
NA
NA
0.05
NA
NA
NA
0.23
NA
NA
NA
0.21
0.00
0.00
0.19
NA
NA
NA
0.20
NA
NA
0.10
NA
NA
0.50
NA
NA
0.29
NA
NA
0.40
NA
NA
0.23
NA
NA
0.88
0.17
NA
NA
0.51
NA
NA
1.16
0.25
NA
NA
0.61
NA
NA
0.67
NA
NA
0.17
NA
NA
0.07
NA
Malpractice
RVUs 2
0.03
0.02
0.01
0.18
0.02
0.14
0.02
0.11
0.01
0.12
0.08
0.04
0.14
0.11
0.03
0.02
0.01
0.01
0.24
0.08
0.14
0.02
0.26
0.11
0.13
0.02
0.00
0.00
0.02
0.28
0.08
0.18
0.02
0.12
0.11
0.01
0.27
0.23
0.04
0.15
0.13
0.02
0.26
0.23
0.03
0.15
0.13
0.02
0.37
0.29
0.08
0.06
0.33
0.29
0.04
0.00
0.00
0.09
0.05
0.00
0.00
0.08
0.00
0.00
0.14
0.13
0.12
0.01
0.09
0.08
0.01
0.22
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00306
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66527
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
93325
93325
93350
93350
93350
93501
93501
93501
93503
93505
93505
93505
93508
93508
93508
93510
93510
93510
93511
93511
93511
93514
93514
93514
93524
93524
93524
93526
93526
93526
93527
93527
93527
93528
93528
93528
93529
93529
93529
93530
93530
93530
93531
93531
93531
93532
93532
93532
93533
93533
93533
93539
93540
93541
93542
93543
93544
93545
93555
93555
93555
93556
93556
93556
93561
93561
93561
93562
93562
93562
93571
93571
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
Status
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Doppler color flow add-on ...................
Doppler color flow add-on ...................
Echo transthoracic ..............................
Echo transthoracic ..............................
Echo transthoracic ..............................
Right heart catheterization ..................
Right heart catheterization ..................
Right heart catheterization ..................
Insert/place heart catheter ..................
Biopsy of heart lining ..........................
Biopsy of heart lining ..........................
Biopsy of heart lining ..........................
Cath placement, angiography .............
Cath placement, angiography .............
Cath placement, angiography .............
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Left heart catheterization ....................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt & Lt heart catheters .......................
Rt, lt heart catheterization ...................
Rt, lt heart catheterization ...................
Rt, lt heart catheterization ...................
Rt heart cath, congenital .....................
Rt heart cath, congenital .....................
Rt heart cath, congenital .....................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
R & l heart cath, congenital ................
Injection, cardiac cath .........................
Injection, cardiac cath .........................
Injection for lung angiogram ...............
Injection for heart x-rays .....................
Injection for heart x-rays .....................
Injection for aortography .....................
Inject for coronary x-rays ....................
Imaging, cardiac cath ..........................
Imaging, cardiac cath ..........................
Imaging, cardiac cath ..........................
Imaging, cardiac cath ..........................
Imaging, cardiac cath ..........................
Imaging, cardiac cath ..........................
Cardiac output measurement .............
Cardiac output measurement .............
Cardiac output measurement .............
Cardiac output measurement .............
Cardiac output measurement .............
Cardiac output measurement .............
Heart flow reserve measure ...............
Heart flow reserve measure ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.07
1.48
0.00
1.48
3.02
0.00
3.02
0.00
4.37
0.00
4.37
4.09
0.00
4.09
4.32
0.00
4.32
0.00
0.00
5.02
0.00
0.00
7.04
0.00
0.00
6.94
5.98
0.00
5.98
0.00
0.00
7.27
0.00
0.00
8.99
0.00
0.00
4.79
0.00
0.00
4.22
0.00
0.00
8.34
0.00
0.00
9.99
0.00
0.00
6.69
0.40
0.43
0.29
0.29
0.29
0.25
0.40
0.81
0.00
0.81
0.83
0.00
0.83
0.00
0.00
0.50
0.00
0.00
0.16
0.00
0.00
0.63
0.03
5.09
4.33
0.76
18.69
17.12
1.57
NA
20.90
18.62
2.28
28.82
26.65
2.17
28.12
25.84
2.28
NA
NA
2.65
NA
NA
2.95
NA
NA
3.77
35.09
31.93
3.16
NA
NA
3.85
NA
NA
4.43
NA
NA
2.58
NA
NA
1.84
NA
NA
3.57
NA
NA
3.65
NA
NA
3.15
2.46
8.61
0.15
5.18
2.62
1.84
5.86
0.59
0.17
0.42
0.88
0.44
0.44
NA
NA
0.14
NA
NA
0.03
NA
NA
1.77
0.03
3.71
3.05
0.66
18.37
17.01
1.36
NA
12.28
10.30
1.98
21.75
19.62
2.13
33.61
31.39
2.22
NA
NA
2.54
NA
NA
3.03
NA
NA
3.47
42.99
40.00
2.99
NA
NA
3.58
NA
NA
4.23
NA
NA
2.43
NA
NA
1.89
NA
NA
3.57
NA
NA
3.95
NA
NA
2.97
11.72
15.53
7.60
10.07
8.86
7.41
13.42
3.59
3.22
0.37
5.54
5.16
0.38
NA
NA
0.15
NA
NA
0.04
NA
NA
NA
0.03
NA
NA
0.76
NA
NA
1.57
NA
NA
NA
2.28
NA
NA
2.17
NA
NA
2.28
NA
NA
2.65
NA
NA
2.95
NA
NA
3.77
NA
NA
3.16
NA
NA
3.85
NA
NA
4.43
NA
NA
2.58
NA
NA
1.84
NA
NA
3.57
NA
NA
3.65
NA
NA
3.15
0.21
0.23
0.15
0.15
0.16
0.13
0.21
NA
NA
0.42
NA
NA
0.44
NA
NA
0.14
NA
NA
0.03
NA
NA
NA
0.03
NA
NA
0.66
NA
NA
1.36
NA
NA
NA
1.98
NA
NA
2.13
NA
NA
2.22
NA
NA
2.54
NA
NA
3.03
NA
NA
3.47
NA
NA
2.99
NA
NA
3.58
NA
NA
4.23
NA
NA
2.43
NA
NA
1.89
NA
NA
3.57
NA
NA
3.95
NA
NA
2.97
0.19
0.20
0.13
0.13
0.13
0.12
0.19
NA
NA
0.37
NA
NA
0.38
NA
NA
0.15
NA
NA
0.04
NA
NA
Malpractice
RVUs 2
0.21
0.01
0.18
0.13
0.05
1.27
1.06
0.21
0.00
0.46
0.16
0.30
0.93
0.65
0.28
2.61
2.31
0.30
0.00
0.00
0.35
0.00
0.00
0.49
0.00
0.00
0.48
3.46
3.04
0.42
0.00
0.00
0.51
0.00
0.00
0.62
0.00
0.00
0.33
0.00
0.00
0.29
0.00
0.00
0.58
0.00
0.00
0.69
0.00
0.00
0.47
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.37
0.34
0.03
0.54
0.51
0.03
0.00
0.00
0.02
0.00
0.00
0.01
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00307
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
ZZZ
XXX
XXX
XXX
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
000
000
000
ZZZ
ZZZ
66528
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
93571
93572
93572
93572
93580
93581
93600
93600
93600
93602
93602
93602
93603
93603
93603
93609
93609
93609
93610
93610
93610
93612
93612
93612
93613
93615
93615
93615
93616
93616
93616
93618
93618
93618
93619
93619
93619
93620
93620
93620
93621
93621
93621
93622
93622
93622
93623
93623
93623
93624
93624
93624
93631
93631
93631
93640
93640
93640
93641
93641
93641
93642
93642
93642
93650
93651
93652
93660
93660
93660
93662
93662
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
26 .......
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
Status
A
C
C
A
A
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
C
A
C
A
A
A
A
A
A
A
A
C
C
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Heart flow reserve measure ...............
Heart flow reserve measure ...............
Heart flow reserve measure ...............
Heart flow reserve measure ...............
Transcath closure of asd ....................
Transcath closure of vsd ....................
Bundle of His recording ......................
Bundle of His recording ......................
Bundle of His recording ......................
Intra-atrial recording ............................
Intra-atrial recording ............................
Intra-atrial recording ............................
Right ventricular recording ..................
Right ventricular recording ..................
Right ventricular recording ..................
Map tachycardia, add-on ....................
Map tachycardia, add-on ....................
Map tachycardia, add-on ....................
Intra-atrial pacing ................................
Intra-atrial pacing ................................
Intra-atrial pacing ................................
Intraventricular pacing .........................
Intraventricular pacing .........................
Intraventricular pacing .........................
Electrophys map 3d, add-on ...............
Esophageal recording .........................
Esophageal recording .........................
Esophageal recording .........................
Esophageal recording .........................
Esophageal recording .........................
Esophageal recording .........................
Heart rhythm pacing ...........................
Heart rhythm pacing ...........................
Heart rhythm pacing ...........................
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Stimulation, pacing heart ....................
Stimulation, pacing heart ....................
Stimulation, pacing heart ....................
Electrophysiologic study .....................
Electrophysiologic study .....................
Electrophysiologic study .....................
Heart pacing, mapping ........................
Heart pacing, mapping ........................
Heart pacing, mapping ........................
Evaluation heart device ......................
Evaluation heart device ......................
Evaluation heart device ......................
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Electrophysiology evaluation ..............
Ablate heart dysrhythm focus .............
Ablate heart dysrhythm focus .............
Ablate heart dysrhythm focus .............
Tilt table evaluation .............................
Tilt table evaluation .............................
Tilt table evaluation .............................
Intracardiac ecg (ice) ..........................
Intracardiac ecg (ice) ..........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
1.80
0.00
0.00
1.44
17.97
24.39
0.00
0.00
2.12
0.00
0.00
2.12
0.00
0.00
2.12
0.00
0.00
4.99
0.00
0.00
3.02
0.00
0.00
3.02
6.99
0.00
0.00
0.99
0.00
0.00
1.49
0.00
0.00
4.25
0.00
0.00
7.31
0.00
0.00
11.57
0.00
0.00
2.10
0.00
0.00
3.10
0.00
0.00
2.85
0.00
0.00
4.80
0.00
0.00
7.59
0.00
0.00
3.51
0.00
0.00
5.92
0.00
0.00
4.88
10.49
16.23
17.65
1.89
0.00
1.89
0.00
0.00
0.95
NA
NA
0.74
NA
NA
0.00
0.00
1.09
0.00
0.00
1.04
0.00
0.00
1.04
0.00
0.00
2.61
0.00
0.00
1.47
0.00
0.00
1.42
NA
0.00
0.00
0.54
0.00
0.00
0.26
0.00
0.00
2.28
0.00
0.00
3.87
0.00
0.00
6.08
0.00
0.00
1.10
0.00
0.00
1.56
0.00
0.00
1.49
0.00
0.00
2.60
0.00
0.00
2.75
0.00
0.00
1.81
0.00
0.00
3.10
0.00
4.76
2.60
NA
NA
NA
3.01
2.04
0.97
0.00
0.00
0.82
NA
NA
0.62
NA
NA
0.00
0.00
0.96
0.00
0.00
0.93
0.00
0.00
0.92
0.00
0.00
2.28
0.00
0.00
1.31
0.00
0.00
1.29
NA
0.00
0.00
0.40
0.00
0.00
0.35
0.00
0.00
1.97
0.00
0.00
3.52
0.00
0.00
5.46
0.00
0.00
0.96
0.00
0.00
1.39
0.00
0.00
1.30
0.00
0.00
2.39
0.00
0.00
2.76
0.00
0.00
1.58
0.00
0.00
2.71
0.00
5.97
2.40
NA
NA
NA
2.71
1.86
0.85
0.00
0.00
0.95
NA
NA
0.74
9.40
11.55
NA
NA
1.09
NA
NA
1.04
NA
NA
1.04
NA
NA
2.61
NA
NA
1.47
NA
NA
1.42
3.69
NA
NA
0.54
NA
NA
0.26
NA
NA
2.28
NA
NA
3.87
NA
NA
6.08
NA
NA
1.10
NA
NA
1.56
NA
NA
1.49
NA
NA
2.60
NA
NA
2.75
NA
NA
1.81
NA
NA
3.10
NA
NA
2.60
5.80
8.52
9.34
NA
NA
0.97
NA
NA
0.82
NA
NA
0.62
8.39
10.47
NA
NA
0.96
NA
NA
0.93
NA
NA
0.92
NA
NA
2.28
NA
NA
1.31
NA
NA
1.29
3.22
NA
NA
0.40
NA
NA
0.35
NA
NA
1.97
NA
NA
3.52
NA
NA
5.46
NA
NA
0.96
NA
NA
1.39
NA
NA
1.30
NA
NA
2.39
NA
NA
2.76
NA
NA
1.58
NA
NA
2.71
NA
NA
2.40
5.11
7.42
8.11
NA
NA
0.85
NA
NA
Malpractice
RVUs 2
0.06
0.00
0.00
0.04
1.25
1.72
0.00
0.00
0.16
0.00
0.00
0.17
0.00
0.00
0.18
0.00
0.00
0.35
0.00
0.00
0.24
0.00
0.00
0.25
0.49
0.00
0.00
0.03
0.00
0.00
0.09
0.00
0.00
0.30
0.00
0.00
0.51
0.00
0.00
0.80
0.00
0.00
0.15
0.00
0.00
0.22
0.00
0.00
0.20
0.00
0.00
0.33
0.00
0.00
0.97
0.00
0.00
0.24
0.00
0.00
0.41
0.00
0.42
0.15
0.73
1.13
1.23
0.08
0.02
0.06
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00308
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
ZZZ
ZZZ
ZZZ
000
000
000
000
000
000
000
000
000
000
000
ZZZ
ZZZ
ZZZ
000
000
000
000
000
000
ZZZ
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
000
ZZZ
ZZZ
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66529
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
93662
93668
93701
93701
93701
93720
93721
93722
93724
93724
93724
93727
93731
93731
93731
93732
93732
93732
93733
93733
93733
93734
93734
93734
93735
93735
93735
93736
93736
93736
93740
93740
93740
93741
93741
93741
93742
93742
93742
93743
93743
93743
93744
93744
93744
93745
93745
93745
93760
93762
93770
93770
93770
93784
93786
93788
93790
93797
93798
93799
93799
93799
93875
93875
93875
93880
93880
93880
93882
93882
93882
93886
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
26 .......
............
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
N
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
B
B
A
A
A
A
A
A
A
A
A
A
A
A
C
C
C
N
N
B
B
B
A
A
A
A
A
A
C
C
C
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Intracardiac ecg (ice) ..........................
Peripheral vascular rehab ...................
Bioimpedance, thoracic .......................
Bioimpedance, thoracic .......................
Bioimpedance, thoracic .......................
Total body plethysmography ...............
Plethysmography tracing ....................
Plethysmography report ......................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze ilr system ...............................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Telephone analy, pacemaker .............
Telephone analy, pacemaker .............
Telephone analy, pacemaker .............
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Analyze pacemaker system ................
Telephonic analy, pacemaker .............
Telephonic analy, pacemaker .............
Telephonic analy, pacemaker .............
Temperature gradient studies .............
Temperature gradient studies .............
Temperature gradient studies .............
Analyze ht pace device sngl ...............
Analyze ht pace device sngl ...............
Analyze ht pace device sngl ...............
Analyze ht pace device sngl ...............
Analyze ht pace device sngl ...............
Analyze ht pace device sngl ...............
Analyze ht pace device dual ...............
Analyze ht pace device dual ...............
Analyze ht pace device dual ...............
Analyze ht pace device dual ...............
Analyze ht pace device dual ...............
Analyze ht pace device dual ...............
Set-up cardiovert-defibrill ....................
Set-up cardiovert-defibrill ....................
Set-up cardiovert-defibrill ....................
Cephalic thermogram ..........................
Peripheral thermogram .......................
Measure venous pressure ..................
Measure venous pressure ..................
Measure venous pressure ..................
Ambulatory BP monitoring ..................
Ambulatory BP recording ....................
Ambulatory BP analysis ......................
Review/report BP recording ................
Cardiac rehab .....................................
Cardiac rehab/monitor ........................
Cardiovascular procedure ...................
Cardiovascular procedure ...................
Cardiovascular procedure ...................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Extracranial study ...............................
Intracranial study .................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.80
0.00
0.17
0.00
0.17
0.17
0.00
0.17
4.88
0.00
4.88
0.52
0.45
0.00
0.45
0.92
0.00
0.92
0.17
0.00
0.17
0.38
0.00
0.38
0.74
0.00
0.74
0.15
0.00
0.15
0.16
0.00
0.16
0.80
0.00
0.80
0.91
0.00
0.91
1.03
0.00
1.03
1.18
0.00
1.18
0.00
0.00
0.00
0.00
0.00
0.16
0.00
0.16
0.38
0.00
0.00
0.38
0.18
0.28
0.00
0.00
0.00
0.22
0.00
0.22
0.60
0.00
0.60
0.40
0.00
0.40
0.94
1.47
0.41
0.70
0.64
0.06
1.17
1.13
0.04
3.22
0.87
2.35
0.63
0.79
0.55
0.24
1.15
0.67
0.48
0.93
0.85
0.08
0.69
0.50
0.19
0.96
0.57
0.39
0.91
0.84
0.07
0.04
0.00
0.04
1.01
0.59
0.42
1.15
0.67
0.48
1.19
0.64
0.55
1.35
0.72
0.63
0.00
0.00
0.00
0.00
0.00
0.04
0.00
0.04
1.39
0.81
0.45
0.13
0.32
0.44
0.00
0.00
0.00
2.54
2.47
0.07
6.15
5.94
0.21
4.11
4.00
0.11
7.02
1.29
0.41
0.84
0.77
0.07
0.97
0.92
0.05
4.55
2.42
2.13
0.42
0.72
0.52
0.20
1.00
0.59
0.41
0.86
0.79
0.07
0.59
0.42
0.17
0.84
0.51
0.33
0.79
0.73
0.06
0.11
0.07
0.04
0.99
0.63
0.36
1.09
0.67
0.42
1.16
0.69
0.47
1.23
0.69
0.54
0.00
0.00
0.00
0.00
0.00
0.05
0.01
0.04
1.47
0.86
0.48
0.13
0.31
0.45
0.00
0.00
0.00
2.43
2.36
0.07
5.85
5.65
0.20
3.81
3.68
0.13
6.87
1.47
NA
NA
NA
0.06
NA
NA
0.04
NA
NA
2.35
0.63
NA
NA
0.24
NA
NA
0.48
NA
NA
0.08
NA
NA
0.19
NA
NA
0.39
NA
NA
0.07
NA
NA
0.04
NA
NA
0.42
NA
NA
0.48
NA
NA
0.55
NA
NA
0.63
NA
NA
0.00
0.00
0.00
NA
NA
0.04
NA
NA
NA
0.13
0.09
0.13
NA
NA
0.00
NA
NA
0.07
NA
NA
0.21
NA
NA
0.11
NA
1.29
NA
NA
NA
0.07
NA
NA
0.05
NA
NA
2.13
0.42
NA
NA
0.20
NA
NA
0.41
NA
NA
0.07
NA
NA
0.17
NA
NA
0.33
NA
NA
0.06
NA
NA
0.04
NA
NA
0.36
NA
NA
0.42
NA
NA
0.47
NA
NA
0.54
NA
NA
0.00
0.00
0.00
NA
NA
0.04
NA
NA
NA
0.13
0.08
0.12
NA
NA
0.00
NA
NA
0.07
NA
NA
0.20
NA
NA
0.13
NA
Malpractice
RVUs 2
0.09
0.01
0.02
0.01
0.01
0.07
0.06
0.01
0.39
0.24
0.15
0.02
0.05
0.04
0.01
0.07
0.04
0.03
0.07
0.06
0.01
0.03
0.02
0.01
0.06
0.04
0.02
0.07
0.06
0.01
0.02
0.01
0.01
0.07
0.04
0.03
0.07
0.04
0.03
0.07
0.04
0.03
0.08
0.04
0.04
0.00
0.00
0.00
0.00
0.00
0.02
0.01
0.01
0.03
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.12
0.11
0.01
0.39
0.35
0.04
0.26
0.22
0.04
0.45
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00309
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66530
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
93886
93886
93888
93888
93888
93890
93890
93890
93892
93892
93892
93893
93893
93893
93922
93922
93922
93923
93923
93923
93924
93924
93924
93925
93925
93925
93926
93926
93926
93930
93930
93930
93931
93931
93931
93965
93965
93965
93970
93970
93970
93971
93971
93971
93975
93975
93975
93976
93976
93976
93978
93978
93978
93979
93979
93979
93980
93980
93980
93981
93981
93981
93982
93990
93990
93990
94002
94003
94004
94005
94010
94010
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
............
............
............
............
TC ......
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
R
A
A
A
A
A
A
B
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Intracranial study .................................
Intracranial study .................................
Intracranial study .................................
Intracranial study .................................
Intracranial study .................................
Tcd, vasoreactivity study ....................
Tcd, vasoreactivity study ....................
Tcd, vasoreactivity study ....................
Tcd, emboli detect w/o inj ...................
Tcd, emboli detect w/o inj ...................
Tcd, emboli detect w/o inj ...................
Tcd, emboli detect w/inj ......................
Tcd, emboli detect w/inj ......................
Tcd, emboli detect w/inj ......................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Lower extremity study .........................
Lower extremity study .........................
Lower extremity study .........................
Lower extremity study .........................
Lower extremity study .........................
Lower extremity study .........................
Upper extremity study .........................
Upper extremity study .........................
Upper extremity study .........................
Upper extremity study .........................
Upper extremity study .........................
Upper extremity study .........................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Extremity study ...................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Vascular study ....................................
Penile vascular study ..........................
Penile vascular study ..........................
Penile vascular study ..........................
Penile vascular study ..........................
Penile vascular study ..........................
Penile vascular study ..........................
Aneurysm pressure sens study ..........
Doppler flow testing ............................
Doppler flow testing ............................
Doppler flow testing ............................
Vent mgmt inpat, init day ....................
Vent mgmt inpat, subq day .................
Vent mgmt nf per day .........................
Home vent mgmt supervision .............
Breathing capacity test .......................
Breathing capacity test .......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.94
0.62
0.00
0.62
1.00
0.00
1.00
1.15
0.00
1.15
1.15
0.00
1.15
0.25
0.00
0.25
0.45
0.00
0.45
0.50
0.00
0.50
0.58
0.00
0.58
0.39
0.00
0.39
0.46
0.00
0.46
0.31
0.00
0.31
0.35
0.00
0.35
0.68
0.00
0.68
0.45
0.00
0.45
1.80
0.00
1.80
1.21
0.00
1.21
0.65
0.00
0.65
0.44
0.00
0.44
1.25
0.00
1.25
0.44
0.00
0.44
0.30
0.25
0.00
0.25
1.99
1.37
1.00
1.50
0.17
0.00
6.74
0.28
4.91
4.71
0.20
6.44
6.13
0.31
6.84
6.52
0.32
6.99
6.66
0.33
3.10
3.02
0.08
4.68
4.54
0.14
5.93
5.76
0.17
8.01
7.82
0.19
5.14
5.03
0.11
6.24
6.09
0.15
4.18
4.08
0.10
3.00
2.89
0.11
6.20
5.99
0.21
4.07
3.92
0.15
8.45
7.82
0.63
4.57
4.15
0.42
6.02
5.81
0.21
4.16
4.02
0.14
3.48
3.02
0.46
2.84
2.68
0.16
0.80
5.21
5.15
0.06
NA
NA
NA
0.70
0.74
0.70
6.55
0.32
4.57
4.36
0.21
5.67
5.31
0.36
6.00
5.61
0.39
6.00
5.61
0.39
2.89
2.81
0.08
4.35
4.21
0.14
5.36
5.19
0.17
7.39
7.20
0.19
4.59
4.47
0.12
5.79
5.64
0.15
3.83
3.73
0.10
2.89
2.78
0.11
5.72
5.50
0.22
3.83
3.68
0.15
8.03
7.42
0.61
4.45
4.04
0.41
5.27
5.05
0.22
3.69
3.54
0.15
3.16
2.73
0.43
2.85
2.70
0.15
0.80
4.61
4.53
0.08
NA
NA
NA
0.70
0.71
0.66
NA
0.28
NA
NA
0.20
NA
NA
0.31
NA
NA
0.32
NA
NA
0.33
NA
NA
0.08
NA
NA
0.14
NA
NA
0.17
NA
NA
0.19
NA
NA
0.11
NA
NA
0.15
NA
NA
0.10
NA
NA
0.11
NA
NA
0.21
NA
NA
0.15
NA
NA
0.63
NA
NA
0.42
NA
NA
0.21
NA
NA
0.14
NA
NA
0.46
NA
NA
0.16
NA
NA
NA
0.06
0.35
0.32
0.23
NA
NA
NA
NA
0.32
NA
NA
0.21
NA
NA
0.36
NA
NA
0.39
NA
NA
0.39
NA
NA
0.08
NA
NA
0.14
NA
NA
0.17
NA
NA
0.19
NA
NA
0.12
NA
NA
0.15
NA
NA
0.10
NA
NA
0.11
NA
NA
0.22
NA
NA
0.15
NA
NA
0.61
NA
NA
0.41
NA
NA
0.22
NA
NA
0.15
NA
NA
0.43
NA
NA
0.15
NA
NA
NA
0.08
0.34
0.32
0.23
NA
NA
NA
Malpractice
RVUs 2
0.39
0.06
0.32
0.27
0.05
0.45
0.39
0.06
0.45
0.39
0.06
0.45
0.39
0.06
0.15
0.13
0.02
0.26
0.22
0.04
0.30
0.25
0.05
0.39
0.35
0.04
0.27
0.23
0.04
0.41
0.37
0.04
0.27
0.24
0.03
0.14
0.12
0.02
0.46
0.40
0.06
0.30
0.27
0.03
0.56
0.43
0.13
0.35
0.30
0.05
0.43
0.37
0.06
0.27
0.24
0.03
0.42
0.34
0.08
0.33
0.31
0.02
0.01
0.26
0.23
0.03
0.09
0.06
0.04
0.06
0.03
0.02
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00310
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66531
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
94010
94014
94015
94016
94060
94060
94060
94070
94070
94070
94150
94150
94150
94200
94200
94200
94240
94240
94240
94250
94250
94250
94260
94260
94260
94350
94350
94350
94360
94360
94360
94370
94370
94370
94375
94375
94375
94400
94400
94400
94450
94450
94450
94452
94452
94452
94453
94453
94453
94610
94620
94620
94620
94621
94621
94621
94640
94642
94644
94645
94660
94662
94664
94667
94668
94680
94680
94680
94681
94681
94681
94690
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
B
B
B
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Breathing capacity test .......................
Patient recorded spirometry ................
Patient recorded spirometry ................
Review patient spirometry ..................
Evaluation of wheezing .......................
Evaluation of wheezing .......................
Evaluation of wheezing .......................
Evaluation of wheezing .......................
Evaluation of wheezing .......................
Evaluation of wheezing .......................
Vital capacity test ................................
Vital capacity test ................................
Vital capacity test ................................
Lung function test (MBC/MVV) ...........
Lung function test (MBC/MVV) ...........
Lung function test (MBC/MVV) ...........
Residual lung capacity ........................
Residual lung capacity ........................
Residual lung capacity ........................
Expired gas collection .........................
Expired gas collection .........................
Expired gas collection .........................
Thoracic gas volume ...........................
Thoracic gas volume ...........................
Thoracic gas volume ...........................
Lung nitrogen washout curve .............
Lung nitrogen washout curve .............
Lung nitrogen washout curve .............
Measure airflow resistance .................
Measure airflow resistance .................
Measure airflow resistance .................
Breath airway closing volume .............
Breath airway closing volume .............
Breath airway closing volume .............
Respiratory flow volume loop .............
Respiratory flow volume loop .............
Respiratory flow volume loop .............
CO2 breathing response curve ...........
CO2 breathing response curve ...........
CO2 breathing response curve ...........
Hypoxia response curve .....................
Hypoxia response curve .....................
Hypoxia response curve .....................
Hast w/report .......................................
Hast w/report .......................................
Hast w/report .......................................
Hast w/oxygen titrate ..........................
Hast w/oxygen titrate ..........................
Hast w/oxygen titrate ..........................
Surfactant admin thru tube .................
Pulmonary stress test/simple ..............
Pulmonary stress test/simple ..............
Pulmonary stress test/simple ..............
Pulm stress test/complex ....................
Pulm stress test/complex ....................
Pulm stress test/complex ....................
Airway inhalation treatment ................
Aerosol inhalation treatment ...............
Cbt, 1st hour .......................................
Cbt, each addl hour ............................
Pos airway pressure, CPAP ...............
Neg press ventilation, cnp ..................
Evaluate pt use of inhaler ...................
Chest wall manipulation ......................
Chest wall manipulation ......................
Exhaled air analysis, o2 ......................
Exhaled air analysis, o2 ......................
Exhaled air analysis, o2 ......................
Exhaled air analysis, o2/co2 ...............
Exhaled air analysis, o2/co2 ...............
Exhaled air analysis, o2/co2 ...............
Exhaled air analysis ............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.17
0.52
0.00
0.52
0.31
0.00
0.31
0.60
0.00
0.60
0.07
0.00
0.07
0.11
0.00
0.11
0.26
0.00
0.26
0.11
0.00
0.11
0.13
0.00
0.13
0.26
0.00
0.26
0.26
0.00
0.26
0.26
0.00
0.26
0.31
0.00
0.31
0.40
0.00
0.40
0.40
0.00
0.40
0.31
0.00
0.31
0.40
0.00
0.40
1.16
0.64
0.00
0.64
1.42
0.00
1.42
0.00
0.00
0.00
0.00
0.76
0.76
0.00
0.00
0.00
0.26
0.00
0.26
0.20
0.00
0.20
0.07
0.04
0.81
0.67
0.14
1.32
1.24
0.08
1.00
0.85
0.15
0.48
0.46
0.02
0.50
0.47
0.03
0.81
0.75
0.06
0.51
0.48
0.03
0.75
0.72
0.03
0.61
0.55
0.06
0.95
0.89
0.06
0.60
0.53
0.07
0.73
0.65
0.08
1.03
0.93
0.10
1.01
0.92
0.09
1.27
1.20
0.07
1.69
1.59
0.10
0.34
0.79
0.63
0.16
3.18
2.73
0.45
0.38
0.00
0.96
0.35
0.81
NA
0.40
0.53
0.50
1.06
1.00
0.06
1.07
1.02
0.05
1.04
0.05
0.78
0.63
0.15
1.19
1.11
0.08
0.90
0.74
0.16
0.47
0.45
0.02
0.47
0.44
0.03
0.74
0.67
0.07
0.58
0.55
0.03
0.66
0.63
0.03
0.69
0.62
0.07
0.82
0.75
0.07
0.66
0.59
0.07
0.66
0.58
0.08
0.93
0.82
0.11
0.92
0.82
0.10
1.14
1.06
0.08
1.60
1.49
0.11
0.34
1.64
1.46
0.18
2.69
2.25
0.44
0.34
0.00
0.96
0.35
0.73
NA
0.35
0.53
0.48
1.46
1.39
0.07
1.79
1.74
0.05
1.52
0.04
NA
NA
0.14
NA
NA
0.08
NA
NA
0.15
NA
NA
0.02
NA
NA
0.03
NA
NA
0.06
NA
NA
0.03
NA
NA
0.03
NA
NA
0.06
NA
NA
0.06
NA
NA
0.07
NA
NA
0.08
NA
NA
0.10
NA
NA
0.09
NA
NA
0.07
NA
NA
0.10
0.34
NA
NA
0.16
NA
NA
0.45
NA
0.00
NA
NA
0.19
0.20
NA
NA
NA
NA
NA
0.06
NA
NA
0.05
NA
0.05
NA
NA
0.15
NA
NA
0.08
NA
NA
0.16
NA
NA
0.02
NA
NA
0.03
NA
NA
0.07
NA
NA
0.03
NA
NA
0.03
NA
NA
0.07
NA
NA
0.07
NA
NA
0.07
NA
NA
0.08
NA
NA
0.11
NA
NA
0.10
NA
NA
0.08
NA
NA
0.11
0.34
NA
NA
0.18
NA
NA
0.44
NA
0.00
NA
NA
0.21
0.21
NA
NA
NA
NA
NA
0.07
NA
NA
0.05
NA
Malpractice
RVUs 2
0.01
0.03
0.01
0.02
0.07
0.06
0.01
0.13
0.10
0.03
0.02
0.01
0.01
0.03
0.02
0.01
0.06
0.05
0.01
0.02
0.01
0.01
0.05
0.04
0.01
0.05
0.04
0.01
0.07
0.06
0.01
0.03
0.02
0.01
0.03
0.02
0.01
0.09
0.06
0.03
0.04
0.02
0.02
0.04
0.02
0.02
0.04
0.02
0.02
0.26
0.13
0.10
0.03
0.16
0.10
0.06
0.02
0.00
0.02
0.02
0.04
0.03
0.04
0.05
0.02
0.07
0.06
0.01
0.13
0.12
0.01
0.05
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00311
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66532
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
94690
94690
94720
94720
94720
94725
94725
94725
94750
94750
94750
94760
94761
94762
94770
94770
94770
94772
94772
94772
94774
94775
94776
94777
94799
94799
94799
95004
95010
95012
95015
95024
95027
95028
95044
95052
95056
95060
95065
95070
95071
95075
95115
95117
95120
95125
95130
95131
95132
95133
95134
95144
95145
95146
95147
95148
95149
95165
95170
95180
95199
95250
95251
95805
95805
95805
95806
95806
95806
95807
95807
95807
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
T .........
T .........
A ........
A ........
A ........
A ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
Exhaled air analysis ............................
Exhaled air analysis ............................
Monoxide diffusing capacity ................
Monoxide diffusing capacity ................
Monoxide diffusing capacity ................
Membrane diffusion capacity ..............
Membrane diffusion capacity ..............
Membrane diffusion capacity ..............
Pulmonary compliance study ..............
Pulmonary compliance study ..............
Pulmonary compliance study ..............
Measure blood oxygen level ...............
Measure blood oxygen level ...............
Measure blood oxygen level ...............
Exhaled carbon dioxide test ...............
Exhaled carbon dioxide test ...............
Exhaled carbon dioxide test ...............
Breath recording, infant ......................
Breath recording, infant ......................
Breath recording, infant ......................
Ped home apnea rec, compl ..............
Ped home apnea rec, hk-up ...............
Ped home apnea rec, downld .............
Ped home apnea rec, report ...............
Pulmonary service/procedure .............
Pulmonary service/procedure .............
Pulmonary service/procedure .............
Percut allergy skin tests ......................
Percut allergy titrate test .....................
Exhaled nitric oxide meas ...................
Id allergy titrate-drug/bug ....................
Id allergy test, drug/bug ......................
Id allergy titrate-airborne .....................
Id allergy test-delayed type .................
Allergy patch tests ..............................
Photo patch test ..................................
Photosensitivity tests ..........................
Eye allergy tests .................................
Nose allergy test .................................
Bronchial allergy tests .........................
Bronchial allergy tests .........................
Ingestion challenge test ......................
Immunotherapy, one injection .............
Immunotherapy injections ...................
Immunotherapy, one injection .............
Immunotherapy, many antigens .........
Immunotherapy, insect venom ............
Immunotherapy, insect venoms ..........
Immunotherapy, insect venoms ..........
Immunotherapy, insect venoms ..........
Immunotherapy, insect venoms ..........
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Antigen therapy services ....................
Rapid desensitization ..........................
Allergy immunology services ..............
Glucose monitoring, cont ....................
Gluc monitor, cont, phys i&r ...............
Multiple sleep latency test ..................
Multiple sleep latency test ..................
Multiple sleep latency test ..................
Sleep study, unattended .....................
Sleep study, unattended .....................
Sleep study, unattended .....................
Sleep study, attended .........................
Sleep study, attended .........................
Sleep study, attended .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.07
0.26
0.00
0.26
0.26
0.00
0.26
0.23
0.00
0.23
0.00
0.00
0.00
0.15
0.00
0.15
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.15
0.00
0.15
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.95
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
2.01
0.00
0.00
0.85
1.88
0.00
1.88
1.66
0.00
1.66
1.66
0.00
1.66
1.02
0.02
1.15
1.09
0.06
0.98
0.91
0.07
1.77
1.71
0.06
0.06
0.11
0.84
0.81
0.77
0.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.15
0.31
0.49
0.21
0.17
0.10
0.31
0.15
0.16
1.25
0.73
0.70
0.81
0.98
0.68
0.23
0.28
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.27
0.36
0.68
0.66
0.98
1.30
0.26
0.20
1.66
0.00
3.49
0.26
7.01
6.50
0.51
3.92
3.45
0.47
12.29
11.88
0.41
1.50
0.02
1.08
1.01
0.07
1.94
1.87
0.07
1.55
1.49
0.06
0.05
0.09
0.66
0.78
0.74
0.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.13
0.31
0.49
0.18
0.16
0.12
0.27
0.18
0.20
0.71
0.54
0.45
1.55
1.95
0.75
0.31
0.39
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.23
0.34
0.56
0.54
0.78
1.05
0.23
0.17
1.85
0.00
3.80
0.22
12.13
11.55
0.58
3.62
3.12
0.50
12.07
11.60
0.47
NA
0.02
NA
NA
0.06
NA
NA
0.07
NA
NA
0.06
NA
NA
NA
NA
NA
0.04
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.73
0.70
NA
NA
0.26
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.77
0.00
NA
0.26
NA
NA
0.51
NA
NA
0.47
NA
NA
0.41
NA
0.02
NA
NA
0.07
NA
NA
0.07
NA
NA
0.06
NA
NA
NA
NA
NA
0.04
NA
NA
0.00
0.00
0.00
0.00
0.00
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.54
0.45
NA
NA
0.32
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.85
0.00
NA
0.22
NA
NA
0.58
NA
NA
0.50
NA
NA
0.47
Malpractice
RVUs 2
0.04
0.01
0.07
0.06
0.01
0.13
0.12
0.01
0.05
0.04
0.01
0.02
0.06
0.10
0.08
0.07
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.01
0.02
0.02
0.03
0.02
0.02
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.04
0.00
0.01
0.02
0.43
0.34
0.09
0.39
0.31
0.08
0.50
0.42
0.08
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00312
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
YYY
YYY
YYY
YYY
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66533
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
95808
95808
95808
95810
95810
95810
95811
95811
95811
95812
95812
95812
95813
95813
95813
95816
95816
95816
95819
95819
95819
95822
95822
95822
95824
95824
95824
95827
95827
95827
95829
95829
95829
95830
95831
95832
95833
95834
95851
95852
95857
95860
95860
95860
95861
95861
95861
95863
95863
95863
95864
95864
95864
95865
95865
95865
95866
95866
95866
95867
95867
95867
95868
95868
95868
95869
95869
95869
95870
95870
95870
95872
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Polysomnography, 1–3 .......................
Polysomnography, 1–3 .......................
Polysomnography, 1–3 .......................
Polysomnography, 4 or more .............
Polysomnography, 4 or more .............
Polysomnography, 4 or more .............
Polysomnography w/cpap ...................
Polysomnography w/cpap ...................
Polysomnography w/cpap ...................
Eeg, 41–60 minutes ............................
Eeg, 41–60 minutes ............................
Eeg, 41–60 minutes ............................
Eeg, over 1 hour .................................
Eeg, over 1 hour .................................
Eeg, over 1 hour .................................
Eeg, awake and drowsy .....................
Eeg, awake and drowsy .....................
Eeg, awake and drowsy .....................
Eeg, awake and asleep ......................
Eeg, awake and asleep ......................
Eeg, awake and asleep ......................
Eeg, coma or sleep only .....................
Eeg, coma or sleep only .....................
Eeg, coma or sleep only .....................
Eeg, cerebral death only .....................
Eeg, cerebral death only .....................
Eeg, cerebral death only .....................
Eeg, all night recording .......................
Eeg, all night recording .......................
Eeg, all night recording .......................
Surgery electrocorticogram .................
Surgery electrocorticogram .................
Surgery electrocorticogram .................
Insert electrodes for EEG ...................
Limb muscle testing, manual ..............
Hand muscle testing, manual .............
Body muscle testing, manual ..............
Body muscle testing, manual ..............
Range of motion measurements ........
Range of motion measurements ........
Tensilon test ........................................
Muscle test, one limb ..........................
Muscle test, one limb ..........................
Muscle test, one limb ..........................
Muscle test, 2 limbs ............................
Muscle test, 2 limbs ............................
Muscle test, 2 limbs ............................
Muscle test, 3 limbs ............................
Muscle test, 3 limbs ............................
Muscle test, 3 limbs ............................
Muscle test, 4 limbs ............................
Muscle test, 4 limbs ............................
Muscle test, 4 limbs ............................
Muscle test, larynx ..............................
Muscle test, larynx ..............................
Muscle test, larynx ..............................
Muscle test, hemidiaphragm ...............
Muscle test, hemidiaphragm ...............
Muscle test, hemidiaphragm ...............
Muscle test cran nerv unilat ................
Muscle test cran nerv unilat ................
Muscle test cran nerv unilat ................
Muscle test cran nerve bilat ................
Muscle test cran nerve bilat ................
Muscle test cran nerve bilat ................
Muscle test, thor paraspinal ................
Muscle test, thor paraspinal ................
Muscle test, thor paraspinal ................
Muscle test, nonparaspinal .................
Muscle test, nonparaspinal .................
Muscle test, nonparaspinal .................
Muscle test, one fiber .........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
2.65
0.00
2.65
3.52
0.00
3.52
3.79
0.00
3.79
1.08
0.00
1.08
1.73
0.00
1.73
1.08
0.00
1.08
1.08
0.00
1.08
1.08
0.00
1.08
0.00
0.00
0.74
1.08
0.00
1.08
6.20
0.00
6.20
1.70
0.28
0.29
0.47
0.60
0.16
0.11
0.53
0.96
0.00
0.96
1.54
0.00
1.54
1.87
0.00
1.87
1.99
0.00
1.99
1.57
0.00
1.57
1.25
0.00
1.25
0.79
0.00
0.79
1.18
0.00
1.18
0.37
0.00
0.37
0.37
0.00
0.37
2.88
15.74
15.04
0.70
17.68
16.78
0.90
19.68
18.72
0.96
5.89
5.59
0.30
6.51
6.03
0.48
5.27
4.97
0.30
6.13
5.83
0.30
5.51
5.21
0.30
0.00
0.00
0.21
11.52
11.22
0.30
24.75
22.99
1.76
2.96
0.40
0.37
0.49
0.54
0.26
0.24
0.58
1.16
0.84
0.32
1.66
1.15
0.51
1.92
1.35
0.57
2.14
1.53
0.61
1.39
0.90
0.49
1.32
0.93
0.39
1.15
0.91
0.24
1.47
1.11
0.36
1.03
0.91
0.12
0.99
0.87
0.12
1.63
14.46
13.65
0.81
17.58
16.54
1.04
19.42
18.31
1.11
4.96
4.58
0.38
5.76
5.17
0.59
4.49
4.11
0.38
4.55
4.17
0.38
5.05
4.67
0.38
0.00
0.00
0.26
7.11
6.76
0.35
27.87
25.83
2.04
3.13
0.43
0.35
0.54
0.58
0.31
0.25
0.59
1.29
0.92
0.37
1.53
0.94
0.59
1.82
1.14
0.68
2.40
1.66
0.74
1.42
0.79
0.63
1.03
0.56
0.47
1.03
0.74
0.29
1.34
0.90
0.44
0.70
0.56
0.14
0.68
0.54
0.14
1.43
NA
NA
0.70
NA
NA
0.90
NA
NA
0.96
NA
NA
0.30
NA
NA
0.48
NA
NA
0.30
NA
NA
0.30
NA
NA
0.30
NA
NA
0.21
NA
NA
0.30
NA
NA
1.76
0.41
0.09
0.10
0.14
0.17
0.04
0.04
0.16
NA
NA
0.32
NA
NA
0.51
NA
NA
0.57
NA
NA
0.61
NA
NA
0.49
NA
NA
0.39
NA
NA
0.24
NA
NA
0.36
NA
NA
0.12
NA
NA
0.12
NA
NA
NA
0.81
NA
NA
1.04
NA
NA
1.11
NA
NA
0.38
NA
NA
0.59
NA
NA
0.38
NA
NA
0.38
NA
NA
0.38
NA
NA
0.26
NA
NA
0.35
NA
NA
2.04
0.57
0.11
0.11
0.18
0.23
0.06
0.04
0.19
NA
NA
0.37
NA
NA
0.59
NA
NA
0.68
NA
NA
0.74
NA
NA
0.63
NA
NA
0.47
NA
NA
0.29
NA
NA
0.44
NA
NA
0.14
NA
NA
0.14
NA
Malpractice
RVUs 2
0.55
0.42
0.13
0.59
0.42
0.17
0.61
0.43
0.18
0.17
0.11
0.06
0.20
0.11
0.09
0.16
0.10
0.06
0.16
0.10
0.06
0.19
0.13
0.06
0.00
0.00
0.04
0.19
0.14
0.05
0.50
0.02
0.48
0.11
0.01
0.02
0.02
0.03
0.01
0.01
0.02
0.07
0.02
0.05
0.13
0.06
0.07
0.15
0.06
0.09
0.21
0.12
0.09
0.11
0.03
0.08
0.10
0.03
0.07
0.07
0.04
0.03
0.10
0.05
0.05
0.04
0.02
0.02
0.04
0.02
0.02
0.13
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00313
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66534
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
95872
95872
95873
95873
95873
95874
95874
95874
95875
95875
95875
95900
95900
95900
95903
95903
95903
95904
95904
95904
95920
95920
95920
95921
95921
95921
95922
95922
95922
95923
95923
95923
95925
95925
95925
95926
95926
95926
95927
95927
95927
95928
95928
95928
95929
95929
95929
95930
95930
95930
95933
95933
95933
95934
95934
95934
95936
95936
95936
95937
95937
95937
95950
95950
95950
95951
95951
95951
95953
95953
95953
95954
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Muscle test, one fiber .........................
Muscle test, one fiber .........................
Guide nerv destr, elec stim .................
Guide nerv destr, elec stim .................
Guide nerv destr, elec stim .................
Guide nerv destr, needle emg ............
Guide nerv destr, needle emg ............
Guide nerv destr, needle emg ............
Limb exercise test ...............................
Limb exercise test ...............................
Limb exercise test ...............................
Motor nerve conduction test ...............
Motor nerve conduction test ...............
Motor nerve conduction test ...............
Motor nerve conduction test ...............
Motor nerve conduction test ...............
Motor nerve conduction test ...............
Sense nerve conduction test ..............
Sense nerve conduction test ..............
Sense nerve conduction test ..............
Intraop nerve test add-on ...................
Intraop nerve test add-on ...................
Intraop nerve test add-on ...................
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Autonomic nerv function test ..............
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
Somatosensory testing .......................
C motor evoked, uppr limbs ...............
C motor evoked, uppr limbs ...............
C motor evoked, uppr limbs ...............
C motor evoked, lwr limbs ..................
C motor evoked, lwr limbs ..................
C motor evoked, lwr limbs ..................
Visual evoked potential test ................
Visual evoked potential test ................
Visual evoked potential test ................
Blink reflex test ...................................
Blink reflex test ...................................
Blink reflex test ...................................
H-reflex test .........................................
H-reflex test .........................................
H-reflex test .........................................
H-reflex test .........................................
H-reflex test .........................................
H-reflex test .........................................
Neuromuscular junction test ...............
Neuromuscular junction test ...............
Neuromuscular junction test ...............
Ambulatory eeg monitoring .................
Ambulatory eeg monitoring .................
Ambulatory eeg monitoring .................
EEG monitoring/videorecord ...............
EEG monitoring/videorecord ...............
EEG monitoring/videorecord ...............
EEG monitoring/computer ...................
EEG monitoring/computer ...................
EEG monitoring/computer ...................
EEG monitoring/giving drugs ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
2.88
0.37
0.00
0.37
0.37
0.00
0.37
1.10
0.00
1.10
0.42
0.00
0.42
0.60
0.00
0.60
0.34
0.00
0.34
2.11
0.00
2.11
0.90
0.00
0.90
0.96
0.00
0.96
0.90
0.00
0.90
0.54
0.00
0.54
0.54
0.00
0.54
0.54
0.00
0.54
1.50
0.00
1.50
1.50
0.00
1.50
0.35
0.00
0.35
0.59
0.00
0.59
0.51
0.00
0.51
0.55
0.00
0.55
0.65
0.00
0.65
1.51
0.00
1.51
0.00
0.00
5.99
3.30
0.00
3.30
2.45
0.76
0.87
1.02
0.88
0.14
0.95
0.83
0.12
1.46
1.08
0.38
0.92
0.78
0.14
0.99
0.82
0.17
0.84
0.74
0.10
1.72
1.10
0.62
1.16
0.91
0.25
1.61
1.35
0.26
2.33
2.08
0.25
3.07
2.92
0.15
3.00
2.85
0.15
3.12
2.96
0.16
3.94
3.50
0.44
4.25
3.81
0.44
2.63
2.53
0.10
1.11
0.94
0.17
0.85
0.70
0.15
0.59
0.43
0.16
0.92
0.72
0.20
4.92
4.50
0.42
0.00
0.00
1.68
7.21
6.29
0.92
4.37
0.68
0.75
0.69
0.54
0.15
0.67
0.52
0.15
1.46
1.03
0.43
1.09
0.93
0.16
1.09
0.88
0.21
0.97
0.84
0.13
1.97
1.20
0.77
0.93
0.64
0.29
1.19
0.86
0.33
2.14
1.82
0.32
2.10
1.91
0.19
2.07
1.88
0.19
2.14
1.93
0.21
3.47
2.93
0.54
3.74
3.19
0.55
2.44
2.31
0.13
1.07
0.86
0.21
0.64
0.45
0.19
0.52
0.32
0.20
0.76
0.53
0.23
4.42
3.89
0.53
0.00
0.00
2.12
7.42
6.31
1.11
4.30
NA
0.87
NA
NA
0.14
NA
NA
0.12
NA
NA
0.38
NA
NA
0.14
NA
NA
0.17
NA
NA
0.10
NA
NA
0.62
NA
NA
0.25
NA
NA
0.26
NA
NA
0.25
NA
NA
0.15
NA
NA
0.15
NA
NA
0.16
NA
NA
0.44
NA
NA
0.44
NA
NA
0.10
NA
NA
0.17
NA
NA
0.15
NA
NA
0.16
NA
NA
0.20
NA
NA
0.42
NA
NA
1.68
NA
NA
0.92
NA
NA
0.75
NA
NA
0.15
NA
NA
0.15
NA
NA
0.43
NA
NA
0.16
NA
NA
0.21
NA
NA
0.13
NA
NA
0.77
NA
NA
0.29
NA
NA
0.33
NA
NA
0.32
NA
NA
0.19
NA
NA
0.19
NA
NA
0.21
NA
NA
0.54
NA
NA
0.55
NA
NA
0.13
NA
NA
0.21
NA
NA
0.19
NA
NA
0.20
NA
NA
0.23
NA
NA
0.53
NA
NA
2.12
NA
NA
1.11
NA
Malpractice
RVUs 2
0.05
0.08
0.04
0.02
0.02
0.04
0.02
0.02
0.11
0.06
0.05
0.04
0.02
0.02
0.05
0.02
0.03
0.04
0.02
0.02
0.23
0.07
0.16
0.06
0.02
0.04
0.07
0.02
0.05
0.07
0.02
0.05
0.10
0.06
0.04
0.09
0.06
0.03
0.10
0.06
0.04
0.09
0.03
0.06
0.09
0.03
0.06
0.03
0.01
0.02
0.10
0.06
0.04
0.04
0.02
0.02
0.05
0.02
0.03
0.10
0.02
0.08
0.51
0.43
0.08
0.00
0.00
0.32
0.60
0.43
0.17
0.19
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00314
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66535
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
95954
95954
95955
95955
95955
95956
95956
95956
95957
95957
95957
95958
95958
95958
95961
95961
95961
95962
95962
95962
95965
95965
95965
95966
95966
95966
95967
95967
95967
95970
95971
95972
95973
95974
95975
95978
95979
95980
95981
95982
95990
95991
95999
96000
96001
96002
96003
96004
96020
96020
96020
96040
96101
96102
96103
96105
96110
96111
96116
96118
96119
96120
96125
96150
96151
96152
96153
96154
96155
96401
96402
96405
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
C
A
C
C
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
C
A
A
A
A
A
C
C
A
B
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
N
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
EEG monitoring/giving drugs ..............
EEG monitoring/giving drugs ..............
EEG during surgery ............................
EEG during surgery ............................
EEG during surgery ............................
Eeg monitoring, cable/radio ................
Eeg monitoring, cable/radio ................
Eeg monitoring, cable/radio ................
EEG digital analysis ............................
EEG digital analysis ............................
EEG digital analysis ............................
EEG monitoring/function test ..............
EEG monitoring/function test ..............
EEG monitoring/function test ..............
Electrode stimulation, brain ................
Electrode stimulation, brain ................
Electrode stimulation, brain ................
Electrode stim, brain add-on ...............
Electrode stim, brain add-on ...............
Electrode stim, brain add-on ...............
Meg, spontaneous ..............................
Meg, spontaneous ..............................
Meg, spontaneous ..............................
Meg, evoked, single ............................
Meg, evoked, single ............................
Meg, evoked, single ............................
Meg, evoked, each add’l .....................
Meg, evoked, each add’l .....................
Meg, evoked, each add’l .....................
Analyze neurostim, no prog ................
Analyze neurostim, simple ..................
Analyze neurostim, complex ...............
Analyze neurostim, complex ...............
Cranial neurostim, complex ................
Cranial neurostim, complex ................
Analyze neurostim brain/1h ................
Analyz neurostim brain addon ............
Io anal gast n-stim init ........................
Io anal gast n-stim subsq ...................
Io ga n-stim subsq w/reprog ...............
Spin/brain pump refil & main ..............
Spin/brain pump refil & main ..............
Neurological procedure .......................
Motion analysis, video/3d ...................
Motion test w/ft press meas ................
Dynamic surface emg .........................
Dynamic fine wire emg .......................
Phys review of motion tests ................
Functional brain mapping ...................
Functional brain mapping ...................
Functional brain mapping ...................
Genetic counseling, 30 min ................
Psycho testing by psych/phys ............
Psycho testing by technician ..............
Psycho testing admin by comp ...........
Assessment of aphasia .......................
Developmental test, lim ......................
Developmental test, extend ................
Neurobehavioral status exam .............
Neuropsych tst by psych/phys ............
Neuropsych testing by tec ..................
Neuropsych tst admin w/comp ...........
Cognitive test by hc pro ......................
Assess hlth/behave, init ......................
Assess hlth/behave, subseq ...............
Intervene hlth/behave, indiv ................
Intervene hlth/behave, group ..............
Interv hlth/behav, fam w/pt .................
Interv hlth/behav fam no pt .................
Chemo, anti-neopl, sq/im ....................
Chemo hormon antineopl sq/im ..........
Chemo intralesional, up to 7 ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
2.45
1.01
0.00
1.01
3.08
0.00
3.08
1.98
0.00
1.98
4.24
0.00
4.24
2.97
0.00
2.97
3.21
0.00
3.21
0.00
0.00
7.99
0.00
0.00
3.99
0.00
0.00
3.49
0.45
0.78
1.50
0.92
3.00
1.70
3.50
1.64
0.80
0.30
0.65
0.00
0.77
0.00
1.80
2.15
0.41
0.37
2.14
0.00
0.00
3.43
0.00
1.86
0.50
0.51
0.00
0.00
2.60
1.86
1.86
0.55
0.51
1.70
0.50
0.48
0.46
0.10
0.45
0.44
0.21
0.19
0.52
3.95
0.42
2.75
2.47
0.28
16.28
15.42
0.86
5.84
5.29
0.55
6.70
5.47
1.23
3.05
2.18
0.87
2.21
1.30
0.91
0.00
0.00
2.39
0.00
0.00
1.19
0.00
0.00
1.01
0.90
0.58
1.14
0.49
1.44
0.73
1.85
0.72
NA
0.44
0.47
1.62
1.61
0.00
NA
NA
NA
NA
0.65
0.00
0.00
1.07
0.98
0.35
1.10
0.92
1.66
0.19
0.69
0.52
0.84
1.53
1.69
0.76
0.10
0.10
0.09
0.02
0.09
0.10
1.86
0.77
3.69
3.57
0.73
2.54
2.22
0.32
15.84
14.76
1.08
4.19
3.49
0.70
5.09
3.60
1.49
2.83
1.74
1.09
2.45
1.30
1.15
0.00
0.00
2.90
0.00
0.00
1.45
0.00
0.00
1.09
0.87
0.63
1.18
0.55
1.57
0.81
1.89
0.79
NA
0.44
0.47
1.56
1.55
0.00
NA
NA
NA
NA
0.79
0.00
0.00
1.07
0.98
0.50
0.88
0.56
1.71
0.18
0.87
0.68
1.11
1.27
1.21
0.76
0.14
0.14
0.13
0.03
0.13
0.14
1.51
0.89
3.06
NA
0.42
NA
NA
0.28
NA
NA
0.86
NA
NA
0.55
NA
NA
1.23
NA
NA
0.87
NA
NA
0.91
NA
NA
2.39
NA
NA
1.19
NA
NA
1.01
0.13
0.18
0.44
0.21
0.78
0.47
1.02
0.46
0.25
0.12
0.18
NA
0.17
0.00
0.44
0.56
0.10
0.09
0.65
NA
NA
1.07
NA
0.33
0.09
0.10
NA
NA
0.58
0.40
0.33
0.10
0.10
0.37
0.09
0.09
0.08
0.02
0.08
0.10
NA
NA
0.24
NA
0.73
NA
NA
0.32
NA
NA
1.08
NA
NA
0.70
NA
NA
1.49
NA
NA
1.09
NA
NA
1.15
NA
NA
2.90
NA
NA
1.45
NA
NA
1.09
0.13
0.20
0.46
0.28
1.04
0.60
1.16
0.57
0.25
0.12
0.18
NA
0.17
0.00
0.48
0.61
0.13
0.10
0.79
NA
NA
1.07
NA
0.48
0.13
0.14
NA
NA
0.81
0.52
0.48
0.14
0.13
0.37
0.13
0.13
0.12
0.02
0.12
0.14
NA
NA
0.24
Malpractice
RVUs 2
0.06
0.13
0.22
0.17
0.05
0.59
0.43
0.16
0.23
0.12
0.11
0.34
0.13
0.21
0.55
0.07
0.48
0.39
0.07
0.32
0.00
0.00
0.46
0.00
0.00
0.19
0.00
0.00
0.16
0.03
0.07
0.14
0.07
0.16
0.12
0.18
0.08
0.07
0.02
0.05
0.06
0.06
0.00
0.11
0.10
0.02
0.02
0.11
0.00
0.00
0.17
0.01
0.05
0.01
0.02
0.18
0.18
0.18
0.18
0.18
0.18
0.02
0.16
0.01
0.01
0.01
0.01
0.01
0.02
0.01
0.01
0.03
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00315
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
ZZZ
XXX
ZZZ
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
66536
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
96406
96409
96411
96413
96415
96416
96417
96420
96422
96423
96425
96440
96445
96450
96521
96522
96523
96542
96549
96567
96570
96571
96900
96902
96904
96910
96912
96913
96920
96921
96922
96999
97001
97002
97003
97004
97005
97006
97010
97012
97014
97016
97018
97022
97024
97026
97028
97032
97033
97034
97035
97036
97039
97110
97112
97113
97116
97124
97139
97140
97150
97530
97532
97533
97535
97537
97542
97545
97546
97597
97598
97602
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
T .........
A ........
C ........
A ........
A ........
A ........
A ........
B ........
R ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
I ..........
I ..........
B ........
A ........
I ..........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
R ........
R ........
A ........
A ........
B ........
Chemo intralesional over 7 .................
Chemo, iv push, sngl drug ..................
Chemo, iv push, addl drug .................
Chemo, iv infusion, 1 hr ......................
Chemo, iv infusion, addl hr .................
Chemo prolong infuse w/pump ...........
Chemo iv infus each addl seq ............
Chemo, ia, push tecnique ...................
Chemo ia infusion up to 1 hr ..............
Chemo ia infuse each addl hr ............
Chemotherapy,infusion method ..........
Chemotherapy, intracavitary ...............
Chemotherapy, intracavitary ...............
Chemotherapy, into CNS ....................
Refill/maint, portable pump .................
Refill/maint pump/resvr syst ................
Irrig drug delivery device ....................
Chemotherapy injection ......................
Chemotherapy, unspecified ................
Photodynamic tx, skin .........................
Photodynamic tx, 30 min ....................
Photodynamic tx, addl 15 min ............
Ultraviolet light therapy .......................
Trichogram ..........................................
Whole body photography ....................
Photochemotherapy with UV-B ...........
Photochemotherapy with UV-A ...........
Photochemotherapy, UV-A or B .........
Laser tx, skin < 250 sq cm .................
Laser tx, skin 250–500 sq cm ............
Laser tx, skin > 500 sq cm .................
Dermatological procedure ...................
Pt evaluation .......................................
Pt re-evaluation ...................................
Ot evaluation .......................................
Ot re-evaluation ..................................
Athletic train eval ................................
Athletic train reeval .............................
Hot or cold packs therapy ...................
Mechanical traction therapy ................
Electric stimulation therapy .................
Vasopneumatic device therapy ...........
Paraffin bath therapy ..........................
Whirlpool therapy ................................
Diathermy eg, microwave ...................
Infrared therapy ...................................
Ultraviolet therapy ...............................
Electrical stimulation ...........................
Electric current therapy .......................
Contrast bath therapy .........................
Ultrasound therapy ..............................
Hydrotherapy .......................................
Physical therapy treatment .................
Therapeutic exercises .........................
Neuromuscular reeducation ................
Aquatic therapy/exercises ...................
Gait training therapy ...........................
Massage therapy ................................
Physical medicine procedure ..............
Manual therapy ...................................
Group therapeutic procedures ............
Therapeutic activities ..........................
Cognitive skills development ..............
Sensory integration .............................
Self care mngment training .................
Community/work reintegration ............
Wheelchair mngment training .............
Work hardening ...................................
Work hardening add-on ......................
Active wound care/20 cm or < ............
Active wound care > 20 cm ................
Wound(s) care non-selective ..............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.80
0.24
0.20
0.28
0.19
0.21
0.21
0.17
0.17
0.17
0.17
2.37
2.20
1.53
0.21
0.21
0.04
0.75
0.00
0.00
1.10
0.55
0.00
0.41
0.00
0.00
0.00
0.00
1.15
1.17
2.10
0.00
1.20
0.60
1.20
0.60
0.00
0.00
0.06
0.25
0.18
0.18
0.06
0.17
0.06
0.06
0.08
0.25
0.26
0.21
0.21
0.28
0.00
0.45
0.45
0.44
0.40
0.35
0.00
0.43
0.27
0.44
0.44
0.44
0.45
0.45
0.45
0.00
0.00
0.58
0.80
0.00
3.61
2.79
1.50
3.63
0.66
4.08
1.73
2.78
4.49
1.99
4.67
5.55
5.41
4.99
3.15
2.78
0.64
3.55
0.00
3.74
0.40
0.19
0.57
0.11
1.90
2.01
2.58
3.47
3.58
3.32
4.63
0.00
0.65
0.41
0.76
0.54
0.00
0.00
0.07
0.14
0.18
0.24
0.17
0.33
0.08
0.07
0.08
0.20
0.44
0.20
0.10
0.44
0.00
0.32
0.34
0.53
0.27
0.27
0.00
0.29
0.22
0.38
0.22
0.27
0.37
0.28
0.29
0.00
0.00
1.09
1.27
0.00
3.31
2.86
1.55
3.91
0.71
4.34
1.83
2.72
4.66
1.94
4.57
6.84
6.72
5.97
3.45
2.71
0.66
3.90
0.00
2.84
0.38
0.19
0.50
0.15
1.90
1.50
1.92
2.57
3.05
2.96
4.06
0.00
0.70
0.42
0.82
0.60
0.00
0.00
0.06
0.13
0.18
0.21
0.13
0.27
0.07
0.06
0.08
0.18
0.36
0.17
0.10
0.38
0.00
0.29
0.33
0.46
0.26
0.25
0.00
0.27
0.20
0.35
0.21
0.25
0.35
0.27
0.28
0.00
0.00
0.88
1.03
0.00
0.32
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.98
0.96
0.83
NA
NA
NA
0.32
0.00
NA
0.40
0.19
NA
0.09
NA
NA
NA
NA
0.56
0.51
1.04
0.00
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.12
0.17
0.00
0.31
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.10
1.07
1.06
NA
NA
NA
0.49
0.00
NA
0.38
0.19
NA
0.13
NA
NA
NA
NA
0.56
0.54
0.83
0.00
NA
NA
NA
NA
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
0.00
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.00
0.39
0.48
0.00
Malpractice
RVUs 2
0.03
0.06
0.06
0.08
0.07
0.08
0.07
0.08
0.08
0.02
0.08
0.17
0.14
0.09
0.06
0.06
0.01
0.07
0.00
0.04
0.11
0.03
0.02
0.01
0.01
0.04
0.05
0.10
0.02
0.03
0.04
0.00
0.05
0.02
0.06
0.02
0.00
0.00
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.02
0.01
0.01
0.01
0.01
0.00
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.05
0.05
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00316
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
000
XXX
ZZZ
XXX
ZZZ
XXX
ZZZ
XXX
XXX
ZZZ
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66537
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
97605
97606
97750
97755
97760
97761
97762
97799
97802
97803
97804
97810
97811
97813
97814
98925
98926
98927
98928
98929
98940
98941
98942
98943
98960
98961
98962
98966
98967
98968
98969
99000
99001
99002
99024
99026
99027
99050
99051
99053
99056
99058
99060
99070
99071
99075
99078
99080
99082
99090
99091
99100
99116
99135
99140
99143
99144
99145
99148
99149
99150
99170
99172
99173
99174
99175
99183
99185
99186
99190
99191
99192
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
A
A
A
C
A
A
A
N
N
N
N
A
A
A
A
A
A
A
A
N
B
B
B
N
N
N
N
B
B
B
B
N
N
B
B
B
B
B
B
B
B
N
B
B
C
B
B
B
B
B
B
C
C
C
C
C
C
A
N
N
N
A
A
A
A
X
X
X
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Neg press wound tx, < 50 cm ............
Neg press wound tx, > 50 cm ............
Physical performance test ..................
Assistive technology assess ...............
Orthotic mgmt and training .................
Prosthetic training ...............................
C/o for orthotic/prosth use ..................
Physical medicine procedure ..............
Medical nutrition, indiv, in ...................
Med nutrition, indiv, subseq ................
Medical nutrition, group ......................
Acupunct w/o stimul 15 min ................
Acupunct w/o stimul addl 15m ............
Acupunct w/stimul 15 min ...................
Acupunct w/stimul addl 15m ...............
Osteopathic manipulation ...................
Osteopathic manipulation ...................
Osteopathic manipulation ...................
Osteopathic manipulation ...................
Osteopathic manipulation ...................
Chiropractic manipulation ...................
Chiropractic manipulation ...................
Chiropractic manipulation ...................
Chiropractic manipulation ...................
Self-mgmt educ & train, 1 pt ...............
Self-mgmt educ/train, 2–4 pt ..............
Self-mgmt educ/train, 5–8 pt ..............
Hc pro phone call 5–10 min ...............
Hc pro phone call 11–20 min .............
Hc pro phone call 21–30 min .............
Online service by hc pro .....................
Specimen handling .............................
Specimen handling .............................
Device handling ..................................
Postop follow-up visit ..........................
In-hospital on call service ...................
Out-of-hosp on call service .................
Medical services after hrs ...................
Med serv, eve/wkend/holiday .............
Med serv 10pm-8am, 24 hr fac ..........
Med service out of office ....................
Office emergency care ........................
Out of office emerg med serv .............
Special supplies ..................................
Patient education materials ................
Medical testimony ...............................
Group health education ......................
Special reports or forms .....................
Unusual physician travel .....................
Computer data analysis ......................
Collect/review data from pt .................
Special anesthesia service .................
Anesthesia with hypothermia ..............
Special anesthesia procedure ............
Emergency anesthesia .......................
Mod cs by same phys, < 5 yrs ...........
Mod cs by same phys, 5 yrs + ...........
Mod cs by same phys add-on ............
Mod cs diff phys < 5 yrs .....................
Mod cs diff phys 5 yrs + .....................
Mod cs diff phys add-on .....................
Anogenital exam, child ........................
Ocular function screen ........................
Visual acuity screen ............................
Ocular photoscreening ........................
Induction of vomiting ...........................
Hyperbaric oxygen therapy .................
Regional hypothermia .........................
Total body hypothermia ......................
Special pump services ........................
Special pump services ........................
Special pump services ........................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.55
0.60
0.45
0.62
0.45
0.45
0.25
0.00
0.45
0.37
0.25
0.60
0.50
0.65
0.55
0.45
0.65
0.87
1.03
1.19
0.45
0.65
0.87
0.40
0.00
0.00
0.00
0.25
0.50
0.75
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.75
0.00
0.00
0.00
0.00
2.34
0.00
0.00
0.00
0.00
0.00
0.40
0.41
0.33
0.27
0.42
0.33
0.73
0.00
0.14
0.12
0.08
0.26
0.15
0.27
0.19
0.29
0.37
0.45
0.51
0.57
0.21
0.27
0.33
0.17
0.58
0.28
0.20
0.09
0.14
0.20
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.83
0.00
0.06
0.00
0.36
2.60
1.67
1.63
0.00
0.00
0.00
0.37
0.38
0.32
0.28
0.38
0.30
0.57
0.00
0.30
0.29
0.13
0.32
0.20
0.33
0.24
0.30
0.39
0.47
0.55
0.62
0.22
0.29
0.35
0.21
0.58
0.28
0.20
0.09
0.14
0.20
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.80
0.00
0.06
0.00
0.87
2.92
1.15
1.70
0.00
0.00
0.00
0.11
0.13
NA
NA
NA
NA
NA
0.00
0.11
0.09
0.07
0.14
0.11
0.15
0.13
0.12
0.17
0.22
0.26
0.30
0.12
0.17
0.24
0.09
NA
NA
NA
0.06
0.11
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.61
0.00
NA
0.00
NA
0.57
NA
NA
0.00
0.00
0.00
0.17
0.18
NA
NA
NA
NA
NA
0.00
0.29
0.28
0.12
0.18
0.15
0.20
0.17
0.13
0.21
0.26
0.30
0.33
0.12
0.17
0.23
0.13
NA
NA
NA
0.06
0.11
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.58
0.00
NA
0.00
NA
0.65
NA
NA
0.00
0.00
0.00
Malpractice
RVUs 2
0.02
0.03
0.02
0.02
0.03
0.02
0.02
0.00
0.01
0.01
0.01
0.03
0.03
0.03
0.03
0.02
0.03
0.03
0.04
0.05
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.02
0.03
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.08
0.00
0.01
0.00
0.10
0.16
0.04
0.45
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00317
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
ZZZ
000
000
000
000
000
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
ZZZ
XXX
XXX
ZZZ
XXX
XXX
ZZZ
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66538
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
99195
99199
99201
99202
99203
99204
99205
99211
99212
99213
99214
99215
99217
99218
99219
99220
99221
99222
99223
99231
99232
99233
99234
99235
99236
99238
99239
99241
99242
99243
99244
99245
99251
99252
99253
99254
99255
99281
99282
99283
99284
99285
99288
99289
99290
99291
99292
99293
99294
99295
99296
99298
99299
99300
99304
99305
99306
99307
99308
99309
99310
99315
99316
99318
99324
99325
99326
99327
99328
99334
99335
99336
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Phlebotomy .........................................
Special service/proc/report .................
Office/outpatient visit, new ..................
Office/outpatient visit, new ..................
Office/outpatient visit, new ..................
Office/outpatient visit, new ..................
Office/outpatient visit, new ..................
Office/outpatient visit, est ....................
Office/outpatient visit, est ....................
Office/outpatient visit, est ....................
Office/outpatient visit, est ....................
Office/outpatient visit, est ....................
Observation care discharge ................
Observation care .................................
Observation care .................................
Observation care .................................
Initial hospital care ..............................
Initial hospital care ..............................
Initial hospital care ..............................
Subsequent hospital care ...................
Subsequent hospital care ...................
Subsequent hospital care ...................
Observ/hosp same date ......................
Observ/hosp same date ......................
Observ/hosp same date ......................
Hospital discharge day .......................
Hospital discharge day .......................
Office consultation ..............................
Office consultation ..............................
Office consultation ..............................
Office consultation ..............................
Office consultation ..............................
Inpatient consultation ..........................
Inpatient consultation ..........................
Inpatient consultation ..........................
Inpatient consultation ..........................
Inpatient consultation ..........................
Emergency dept visit ..........................
Emergency dept visit ..........................
Emergency dept visit ..........................
Emergency dept visit ..........................
Emergency dept visit ..........................
Direct advanced life support ...............
Ped crit care transport ........................
Ped crit care transport addl ................
Critical care, first hour .........................
Critical care, add’l 30 min ...................
Ped critical care, initial ........................
Ped critical care, subseq ....................
Neonate crit care, initial ......................
Neonate critical care subseq ..............
Ic for lbw infant < 1500 gm .................
Ic, lbw infant 1500–2500 gm ..............
Ic, infant pbw 2501–5000 gm .............
Nursing facility care, init ......................
Nursing facility care, init ......................
Nursing facility care, init ......................
Nursing fac care, subseq ....................
Nursing fac care, subseq ....................
Nursing fac care, subseq ....................
Nursing fac care, subseq ....................
Nursing fac discharge day ..................
Nursing fac discharge day ..................
Annual nursing fac assessmnt ............
Domicil/r-home visit new pat ...............
Domicil/r-home visit new pat ...............
Domicil/r-home visit new pat ...............
Domicil/r-home visit new pat ...............
Domicil/r-home visit new pat ...............
Domicil/r-home visit est pat ................
Domicil/r-home visit est pat ................
Domicil/r-home visit est pat ................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.45
0.88
1.34
2.30
3.00
0.17
0.45
0.92
1.42
2.00
1.28
1.28
2.14
2.99
1.88
2.56
3.78
0.76
1.39
2.00
2.56
3.41
4.26
1.28
1.90
0.64
1.34
1.88
3.02
3.77
1.00
1.50
2.27
3.29
4.00
0.45
0.88
1.34
2.56
3.80
0.00
4.79
2.40
4.50
2.25
15.98
7.99
18.46
7.99
2.75
2.50
2.40
1.61
2.30
3.00
0.76
1.16
1.55
2.35
1.13
1.50
1.71
1.01
1.52
2.63
3.46
4.09
1.07
1.72
2.46
2.56
0.00
0.55
0.84
1.11
1.49
1.78
0.32
0.55
0.76
1.10
1.38
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.66
1.08
1.45
1.93
2.26
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
2.26
0.80
NA
NA
NA
NA
NA
NA
NA
0.57
0.74
0.90
0.31
0.47
0.61
0.87
0.41
0.50
0.56
0.43
0.55
0.82
1.02
1.16
0.43
0.59
0.77
1.50
0.00
0.52
0.81
1.12
1.49
1.78
0.36
0.55
0.72
1.06
1.35
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.65
1.06
1.42
1.88
2.27
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
NA
NA
2.41
0.85
NA
NA
NA
NA
NA
NA
NA
0.53
0.68
0.83
0.29
0.46
0.61
0.82
0.43
0.55
0.53
0.46
0.62
0.87
1.09
1.29
0.41
0.58
0.79
NA
0.00
0.16
0.29
0.43
0.71
0.91
0.06
0.15
0.28
0.44
0.61
0.50
0.38
0.59
0.84
0.54
0.71
1.07
0.24
0.42
0.59
0.78
0.98
1.21
0.49
0.67
0.22
0.48
0.67
1.08
1.31
0.31
0.49
0.80
1.18
1.38
0.09
0.17
0.25
0.46
0.67
0.00
1.08
0.89
1.10
0.56
3.78
1.65
4.56
2.06
0.68
0.58
0.71
0.57
0.74
0.90
0.31
0.47
0.61
0.87
0.41
0.50
0.56
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.00
0.15
0.30
0.45
0.71
0.93
0.06
0.15
0.26
0.42
0.63
0.51
0.41
0.65
0.93
0.50
0.72
1.05
0.23
0.40
0.56
0.83
1.06
1.32
0.52
0.70
0.22
0.47
0.65
1.00
1.27
0.27
0.49
0.74
1.08
1.36
0.09
0.15
0.28
0.47
0.69
0.00
1.26
0.85
1.19
0.60
4.26
2.03
4.97
2.30
0.80
0.72
0.77
0.53
0.68
0.83
0.29
0.46
0.61
0.82
0.43
0.55
0.53
NA
NA
NA
NA
NA
NA
NA
NA
Malpractice
RVUs 2
0.02
0.00
0.03
0.05
0.09
0.12
0.15
0.01
0.03
0.03
0.05
0.08
0.06
0.06
0.10
0.14
0.07
0.10
0.13
0.03
0.04
0.06
0.13
0.16
0.19
0.05
0.07
0.05
0.10
0.13
0.16
0.21
0.05
0.09
0.11
0.13
0.18
0.02
0.04
0.09
0.14
0.23
0.00
0.24
0.12
0.21
0.11
1.12
0.45
1.16
0.32
0.17
0.16
0.15
0.05
0.07
0.09
0.03
0.04
0.06
0.08
0.05
0.06
0.05
0.05
0.07
0.10
0.13
0.16
0.04
0.06
0.09
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00318
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66539
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
99337
99339
99340
99341
99342
99343
99344
99345
99347
99348
99349
99350
99354
99355
99356
99357
99358
99359
99360
99363
99364
99366
99367
99368
99374
99375
99377
99378
99379
99380
99381
99382
99383
99384
99385
99386
99387
99391
99392
99393
99394
99395
99396
99397
99401
99402
99403
99404
99406
99407
99408
99409
99411
99412
99420
99429
99431
99432
99433
99435
99436
99440
99441
99442
99443
99444
99450
99455
99456
99477
99499
99500
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A ........
B ........
B ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
B ........
B ........
X ........
B ........
B ........
B ........
B ........
B ........
B ........
I ..........
B ........
I ..........
B ........
B ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
N ........
A ........
A ........
N ........
N ........
N ........
N ........
N ........
N ........
A ........
A ........
A ........
A ........
A ........
A ........
N ........
N ........
N ........
N ........
N ........
R ........
R ........
A ........
C ........
I ..........
Domicil/r-home visit est pat ................
Domicil/r-home care supervis .............
Domicil/r-home care supervis .............
Home visit, new patient ......................
Home visit, new patient ......................
Home visit, new patient ......................
Home visit, new patient ......................
Home visit, new patient ......................
Home visit, est patient ........................
Home visit, est patient ........................
Home visit, est patient ........................
Home visit, est patient ........................
Prolonged service, office ....................
Prolonged service, office ....................
Prolonged service, inpatient ...............
Prolonged service, inpatient ...............
Prolonged serv, w/o contact ...............
Prolonged serv, w/o contact ...............
Physician standby services .................
Anticoag mgmt, init .............................
Anticoag mgmt, subseq ......................
Team conf w/pat by hc pro .................
Team conf w/o pat by phys ................
Team conf w/o pat by hc pro ..............
Home health care supervision ............
Home health care supervision ............
Hospice care supervision ....................
Hospice care supervision ....................
Nursing fac care supervision ..............
Nursing fac care supervision ..............
Init pm e/m, new pat, inf .....................
Init pm e/m, new pat 1–4 yrs ..............
Prev visit, new, age 5–11 ...................
Prev visit, new, age 12–17 .................
Prev visit, new, age 18–39 .................
Prev visit, new, age 40–64 .................
Init pm e/m, new pat 65+ yrs ..............
Per pm reeval, est pat, inf ..................
Prev visit, est, age 1–4 .......................
Prev visit, est, age 5–11 .....................
Prev visit, est, age 12–17 ...................
Prev visit, est, age 18–39 ...................
Prev visit, est, age 40–64 ...................
Per pm reeval est pat 65+ yr ..............
Preventive counseling, indiv ...............
Preventive counseling, indiv ...............
Preventive counseling, indiv ...............
Preventive counseling, indiv ...............
Behav chng smoking 3–10 min ..........
Behav chng smoking < 10 min ...........
Audit/dast, 15–30 min .........................
Audit/dast, over 30 min .......................
Preventive counseling, group .............
Preventive counseling, group .............
Health risk assessment test ................
Unlisted preventive service .................
Initial care, normal newborn ...............
Newborn care, not in hosp .................
Normal newborn care/hospital ............
Newborn discharge day hosp .............
Attendance, birth .................................
Newborn resuscitation ........................
Phone e/m by phys 5–10 min .............
Phone e/m by phys 11–20 min ...........
Phone e/m by phys 21–30 min ...........
Online e/m by phys .............................
Basic life disability exam .....................
Work related disability exam ...............
Disability examination .........................
Init day hosp neonate care .................
Unlisted e&m service ..........................
Home visit, prenatal ............................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
3.58
1.25
1.80
1.01
1.52
2.53
3.38
4.09
1.00
1.56
2.33
3.28
1.77
1.77
1.71
1.71
2.10
1.00
1.20
1.65
0.63
0.82
1.10
0.72
1.10
1.73
1.10
1.73
1.10
1.73
1.19
1.36
1.36
1.53
1.53
1.88
2.06
1.02
1.19
1.19
1.36
1.36
1.53
1.71
0.48
0.98
1.46
1.95
0.24
0.50
0.65
1.30
0.15
0.25
0.00
0.00
1.17
1.26
0.62
1.50
1.50
2.93
0.25
0.50
0.75
0.00
0.00
0.00
0.00
7.00
0.00
0.00
1.03
0.58
0.77
0.43
0.56
0.82
1.00
1.15
0.42
0.56
0.73
0.96
0.65
0.62
NA
NA
0.51
0.26
0.28
1.30
0.38
0.20
0.25
0.16
0.55
0.75
0.55
0.75
0.55
0.75
1.00
1.04
1.03
1.07
1.07
1.15
1.28
0.86
0.90
0.89
0.93
0.94
0.98
1.12
0.36
0.48
0.59
0.70
0.11
0.18
0.19
0.34
0.22
0.24
0.22
0.00
NA
1.01
NA
NA
NA
NA
0.09
0.14
0.20
0.00
0.00
0.00
0.00
1.98
0.00
0.00
1.09
0.58
0.77
0.45
0.62
0.88
1.09
1.29
0.41
0.57
0.78
1.07
0.71
0.68
NA
NA
0.51
0.26
0.28
1.30
0.38
0.20
0.25
0.16
0.62
1.15
0.62
1.35
0.62
0.87
1.25
1.29
1.25
1.31
1.31
1.45
1.58
0.94
0.99
0.98
1.03
1.05
1.11
1.24
0.49
0.67
0.84
1.01
0.10
0.18
0.19
0.34
0.20
0.25
0.22
0.00
NA
0.97
NA
NA
NA
NA
0.09
0.14
0.20
0.00
0.00
0.00
0.00
1.98
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.50
0.47
0.50
0.50
0.51
0.26
0.28
0.38
0.14
0.19
0.25
0.16
0.25
0.40
0.25
0.40
0.25
0.40
0.27
0.31
0.31
0.35
0.35
0.43
0.47
0.23
0.27
0.27
0.31
0.31
0.35
0.39
0.11
0.22
0.34
0.45
0.07
0.13
0.15
0.30
0.03
0.06
NA
0.00
0.27
0.29
0.17
0.50
0.33
0.67
0.06
0.11
0.17
0.00
0.00
0.00
0.00
1.98
0.00
0.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.58
0.54
0.56
0.56
0.51
0.26
0.28
0.38
0.14
0.19
0.25
0.16
0.34
0.97
0.34
1.17
0.34
0.53
0.36
0.42
0.42
0.47
0.47
0.58
0.63
0.31
0.36
0.36
0.42
0.42
0.47
0.53
0.15
0.30
0.45
0.60
0.08
0.15
0.15
0.30
0.05
0.08
NA
0.00
0.32
0.34
0.19
0.54
0.40
0.80
0.06
0.11
0.17
0.00
0.00
0.00
0.00
1.98
0.00
0.00
Malpractice
RVUs 2
0.13
0.06
0.07
0.05
0.07
0.10
0.13
0.16
0.04
0.06
0.09
0.13
0.08
0.07
0.07
0.08
0.09
0.04
0.05
0.07
0.04
0.06
0.05
0.03
0.05
0.07
0.05
0.07
0.04
0.06
0.05
0.05
0.05
0.06
0.06
0.07
0.07
0.04
0.05
0.05
0.05
0.05
0.06
0.06
0.01
0.02
0.04
0.05
0.01
0.01
0.01
0.03
0.01
0.01
0.01
0.00
0.05
0.07
0.02
0.06
0.06
0.12
0.02
0.02
0.03
0.00
0.00
0.00
0.00
0.32
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00319
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66540
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
Physician
work
RVUs 2
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
Mod
Status
Description
99501 ....
99502 ....
99503 ....
99504 ....
99505 ....
99506 ....
99507 ....
99509 ....
99510 ....
99511 ....
99512 ....
99600 ....
99601 ....
99602 ....
99605 ....
99606 ....
99607 ....
A4890 ....
G0008 ...
G0009 ...
G0010 ...
G0027 ...
G0101 ...
G0102 ...
G0103 ...
G0104 ...
G0105 ...
G0105 ...
G0106 ...
G0106 ...
G0106 ...
G0108 ...
G0109 ...
G0117 ...
G0118 ...
G0120 ...
G0120 ...
G0120 ...
G0121 ...
G0121 ...
G0122 ...
G0122 ...
G0122 ...
G0123 ...
G0124 ...
G0127 ...
G0128 ...
G0130 ...
G0130 ...
G0130 ...
G0141 ...
G0143 ...
G0144 ...
G0145 ...
G0147 ...
G0148 ...
G0166 ...
G0168 ...
G0173 ...
G0175 ...
G0176 ...
G0177 ...
G0179 ...
G0180 ...
G0181 ...
G0182 ...
G0186 ...
G0202 ...
G0202 ...
G0202 ...
G0204 ...
G0204 ...
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
53 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
53 .......
............
TC ......
26 .......
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
I ..........
X ........
X ........
X ........
R ........
X ........
X ........
X ........
X ........
A ........
A ........
X ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
T .........
T .........
A ........
A ........
A ........
A ........
A ........
N ........
N ........
N ........
X ........
A ........
R ........
R ........
A ........
A ........
A ........
A ........
X ........
X ........
X ........
X ........
X ........
A ........
A ........
X ........
X ........
X ........
X ........
A ........
A ........
A ........
A ........
C ........
A ........
A ........
A ........
A ........
A ........
Home visit, postnatal ..........................
Home visit, nb care .............................
Home visit, resp therapy .....................
Home visit mech ventilator .................
Home visit, stoma care .......................
Home visit, im injection .......................
Home visit, cath maintain ...................
Home visit day life activity ..................
Home visit, sing/m/fam couns .............
Home visit, fecal/enema mgmt ...........
Home visit for hemodialysis ................
Home visit nos ....................................
Home infusion/visit, 2 hrs ...................
Home infusion, each addtl hr ..............
Mtms by pharm, np, 15 min ................
Mtms by pharm, est, 15 min ...............
Mtms by pharm, addl 15 min ..............
Repair/maint cont hemo equip ............
Admin influenza virus vac ...................
Admin pneumococcal vaccine ............
Admin hepatitis b vaccine ...................
Semen analysis ...................................
CA screen;pelvic/breast exam ............
Prostate ca screening; dre ..................
PSA screening ....................................
CA screen;flexi sigmoidscope .............
Colorectal scrn; hi risk ind ..................
Colorectal scrn; hi risk ind ..................
Colon CA screen;barium enema ........
Colon CA screen;barium enema ........
Colon CA screen;barium enema ........
Diab manage trn per indiv ..................
Diab manage trn ind/group .................
Glaucoma scrn hgh risk direc .............
Glaucoma scrn hgh risk direc .............
Colon ca scrn; barium enema ............
Colon ca scrn; barium enema ............
Colon ca scrn; barium enema ............
Colon ca scrn not hi rsk ind ................
Colon ca scrn not hi rsk ind ................
Colon ca scrn; barium enema ............
Colon ca scrn; barium enema ............
Colon ca scrn; barium enema ............
Screen cerv/vag thin layer ..................
Screen c/v thin layer by MD ...............
Trim nail(s) ..........................................
CORF skilled nursing service .............
Single energy x-ray study ...................
Single energy x-ray study ...................
Single energy x-ray study ...................
Scr c/v cyto,autosys and md ..............
Scr c/v cyto,thinlayer,rescr ..................
Scr c/v cyto,thinlayer,rescr ..................
Scr c/v cyto,thinlayer,rescr ..................
Scr c/v cyto, automated sys ...............
Scr c/v cyto, autosys, rescr ................
Extrnl counterpulse, per tx ..................
Wound closure by adhesive ...............
Linear acc stereo radsur com .............
OPPS Service,sched team conf .........
OPPS/PHP;activity therapy .................
OPPS/PHP; train & educ serv ............
MD recertification HHA PT .................
MD certification HHA patient ..............
Home health care supervision ............
Hospice care supervision ....................
Dstry eye lesn,fdr vssl tech ................
Screeningmammographydigital ...........
Screeningmammographydigital ...........
Screeningmammographydigital ...........
Diagnosticmammographydigital ..........
Diagnosticmammographydigital ..........
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.45
0.17
0.00
0.96
3.69
0.96
0.99
0.00
0.99
0.00
0.00
0.45
0.17
0.99
0.00
0.99
3.69
0.96
0.99
0.00
0.99
0.00
0.42
0.17
0.08
0.22
0.00
0.22
0.42
0.00
0.00
0.00
0.00
0.00
0.07
0.45
0.00
0.00
0.00
0.00
0.45
0.67
1.73
1.73
0.00
0.70
0.00
0.70
0.87
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.48
0.32
0.00
2.52
6.38
2.52
4.94
4.59
0.35
0.59
0.31
0.76
0.71
4.94
4.59
0.35
6.38
2.52
5.64
5.41
0.23
0.00
0.38
0.38
0.02
0.55
0.49
0.06
0.38
0.00
0.00
0.00
0.00
0.00
4.50
1.58
0.00
0.00
0.00
0.00
0.48
0.56
0.80
0.82
0.00
2.80
2.56
0.24
3.40
3.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.50
0.36
0.00
2.40
6.26
2.40
3.74
3.41
0.33
0.71
0.40
0.74
0.62
3.74
3.41
0.33
6.26
2.40
4.10
3.80
0.30
0.00
0.26
0.32
0.02
0.71
0.64
0.07
0.26
0.00
0.00
0.00
0.00
0.00
4.03
1.76
0.00
0.00
0.00
0.00
0.75
0.91
1.14
1.24
0.00
2.78
2.55
0.23
3.09
2.80
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.06
0.00
0.62
1.82
0.62
NA
NA
0.35
NA
NA
NA
NA
NA
NA
0.35
1.82
0.62
NA
NA
0.23
0.00
0.38
0.04
0.02
NA
NA
0.06
0.38
0.00
0.00
0.00
0.00
0.00
NA
0.21
0.00
0.00
0.00
0.00
NA
NA
NA
NA
0.00
NA
NA
0.24
NA
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
NA
0.06
0.00
0.56
1.64
0.56
NA
NA
0.33
NA
NA
NA
NA
NA
NA
0.33
1.64
0.56
NA
NA
0.30
0.00
0.26
0.06
0.02
NA
NA
0.07
0.26
0.00
0.00
0.00
0.00
0.00
NA
0.21
0.00
0.00
0.00
0.00
NA
NA
NA
NA
0.00
NA
NA
0.23
NA
NA
Malpractice
RVUs 2
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.01
0.00
0.08
0.30
0.08
0.17
0.13
0.04
0.01
0.01
0.01
0.01
0.17
0.13
0.04
0.30
0.08
0.18
0.13
0.05
0.00
0.02
0.01
0.01
0.06
0.05
0.01
0.02
0.00
0.00
0.00
0.00
0.00
0.01
0.03
0.00
0.00
0.00
0.00
0.02
0.03
0.07
0.07
0.00
0.10
0.07
0.03
0.11
0.07
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00320
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
XXX
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
YYY
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66541
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
G0204
G0206
G0206
G0206
G0219
G0219
G0219
G0235
G0235
G0235
G0237
G0238
G0239
G0245
G0246
G0247
G0248
G0249
G0250
G0251
G0252
G0252
G0252
G0255
G0255
G0255
G0257
G0259
G0260
G0268
G0269
G0270
G0271
G0275
G0278
G0281
G0282
G0283
G0288
G0289
G0290
G0291
G0293
G0294
G0295
G0297
G0300
G0302
G0303
G0304
G0305
G0306
G0307
G0308
G0309
G0310
G0311
G0312
G0313
G0314
G0315
G0316
G0317
G0318
G0319
G0320
G0321
G0322
G0323
G0324
G0325
G0326
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
Mod
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Status
A
A
A
A
N
N
N
N
N
N
A
A
A
R
R
R
R
R
R
E
N
N
N
N
N
N
E
E
E
A
B
A
A
A
A
A
N
A
A
A
E
E
E
E
N
X
X
X
X
X
X
X
X
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Diagnosticmammographydigital ..........
Diagnosticmammographydigital ..........
Diagnosticmammographydigital ..........
Diagnosticmammographydigital ..........
PET img wholbod melano nonco ........
PET img wholbod melano nonco ........
PET img wholbod melano nonco ........
PET not otherwise specified ...............
PET not otherwise specified ...............
PET not otherwise specified ...............
Therapeutic procd strg endur .............
Oth resp proc, indiv ............................
Oth resp proc, group ...........................
Initial foot exam pt lops .......................
Followup eval of foot pt lop ................
Routine footcare pt w lops ..................
Demonstrate use home inr mon .........
Provide test material,equipm ..............
MD review interpret of test .................
Linear acc based stero radio ..............
PET imaging initial dx .........................
PET imaging initial dx .........................
PET imaging initial dx .........................
Current percep threshold tst ...............
Current percep threshold tst ...............
Current percep threshold tst ...............
Unsched dialysis ESRD pt hos ...........
Inject for sacroiliac joint ......................
Inj for sacroiliac jt anesth ....................
Removal of impacted wax md ............
Occlusive device in vein art ................
MNT subs tx for change dx ................
Group MNT 2 or more 30 mins ..........
Renal angio, cardiac cath ...................
Iliac art angio,cardiac cath ..................
Elec stim unattend for press ...............
Elect stim wound care not pd .............
Elec stim other than wound ................
Recon, CTA for surg plan ...................
Arthro, loose body + chondro .............
Drug-eluting stents, single ..................
Drug-eluting stents,each add ..............
Non-cov surg proc,clin trial .................
Non-cov proc, clinical trial ...................
Electromagnetic therapy onc ..............
Insert single chamber/cd .....................
Insert reposit lead dual+gen ...............
Pre-op service LVRS complete ..........
Pre-op service LVRS 10–15dos .........
Pre-op service LVRS 1–9 dos ............
Post op service LVRS min 6 ..............
CBC/diffwbc w/o platelet .....................
CBC without platelet ...........................
ESRD related svc 4+mo < 2yrs ..........
ESRD related svc 2–3mo <2yrs .........
ESRD related svc 1 vst <2yrs ............
ESRD related svs 4+mo 2–11yr .........
ESRD relate svs 2–3 mo 2–11y .........
ESRD related svs 1 mon 2–11y .........
ESRD related svs 4+ mo 12–19 .........
ESRD related svs 2–3mo/12–19 ........
ESRD related svs 1vis/12–19y ...........
ESRD related svs 4+mo 20+yrs .........
ESRD related svs 2–3 mo 20+y .........
ESRD related svs 1visit 20+y .............
ESD related svs home undr 2 ............
ESRDrelatedsvs home mo 2–11y ......
ESRD related svs hom mo12–19 .......
ESRD related svs home mo 20+ ........
ESRD relate svs home/dy <2yr ..........
ESRD relate home/day/ 2–11yr ..........
ESRD relate home/dy 12–19yr ...........
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.87
0.70
0.00
0.70
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.88
0.45
0.50
0.00
0.00
0.18
0.00
0.00
0.00
1.50
0.00
0.00
0.00
0.00
0.00
0.00
0.61
0.00
0.37
0.25
0.25
0.25
0.18
0.00
0.18
0.00
1.48
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
12.74
10.61
8.49
9.73
8.11
6.49
8.28
6.90
5.52
5.09
4.24
3.39
10.61
8.11
6.90
4.24
0.35
0.23
0.27
0.30
2.66
2.42
0.24
0.00
0.00
0.00
0.00
0.00
0.00
0.21
0.23
0.31
0.84
0.55
0.68
3.40
3.40
0.08
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.66
0.00
0.12
0.08
NA
NA
0.14
0.00
0.14
1.03
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
5.57
4.16
2.78
3.54
2.70
1.83
3.39
2.56
1.66
2.25
1.69
1.13
2.68
1.99
1.71
1.14
0.16
0.09
0.10
0.29
2.45
2.22
0.23
0.00
0.00
0.00
0.00
0.00
0.00
0.34
0.36
0.32
0.81
0.55
0.60
5.00
3.68
0.07
0.00
0.00
0.00
0.60
0.00
0.00
0.00
0.00
0.00
0.00
0.65
0.00
0.29
0.13
NA
NA
0.12
0.00
0.12
5.82
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
7.05
5.63
4.23
4.13
3.31
2.49
3.90
3.11
2.30
2.55
2.04
1.52
4.89
2.95
2.69
1.76
0.20
0.10
0.11
0.30
NA
NA
0.24
NA
NA
0.00
NA
NA
0.00
NA
NA
NA
0.29
0.15
0.16
NA
NA
NA
0.00
NA
NA
0.00
NA
NA
0.00
0.00
0.00
0.00
0.20
0.00
0.09
0.07
0.13
0.13
NA
0.00
NA
NA
0.58
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
5.57
4.16
2.78
3.54
2.70
1.83
3.39
2.56
1.66
2.25
1.69
1.13
2.68
1.99
1.71
1.14
0.16
0.09
0.10
0.29
NA
NA
0.23
NA
NA
0.00
NA
NA
0.00
NA
NA
NA
0.30
0.15
0.18
NA
NA
NA
0.00
NA
NA
0.60
NA
NA
0.00
0.00
0.00
0.00
0.22
0.00
0.28
0.12
0.12
0.12
NA
0.00
NA
NA
0.69
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
7.05
5.63
4.23
4.13
3.31
2.49
3.90
3.11
2.30
2.55
2.04
1.52
4.89
2.95
2.69
1.76
0.20
0.10
0.11
Malpractice
RVUs 2
0.04
0.09
0.06
0.03
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.02
0.04
0.02
0.02
0.01
0.01
0.01
0.00
0.00
0.00
0.04
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.00
0.01
0.01
0.01
0.01
0.01
0.00
0.01
0.18
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.42
0.36
0.28
0.34
0.29
0.22
0.27
0.23
0.17
0.17
0.14
0.11
0.36
0.29
0.23
0.14
0.01
0.01
0.01
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00321
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
XXX
XXX
XXX
ZZZ
ZZZ
XXX
XXX
XXX
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
66542
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
Mod
G0327 ...
G0328 ...
G0329 ...
G0332 ...
G0333 ...
G0337 ...
G0339 ...
G0340 ...
G0341 ...
G0342 ...
G0343 ...
G0344 ...
G0364 ...
G0365 ...
G0365 ...
G0365 ...
G0366 ...
G0367 ...
G0368 ...
G0372 ...
G0377 ...
G0378 ...
G0379 ...
G0389 ...
G0389 ...
G0389 ...
G0392 ...
G0393 ...
G0394 ...
G0396 ...
G0397 ...
G3001 ...
G9001 ...
G9002 ...
G9003 ...
G9004 ...
G9005 ...
G9006 ...
G9007 ...
G9008 ...
G9009 ...
G9010 ...
G9011 ...
G9012 ...
G9013 ...
G9014 ...
G9016 ...
G9017 ...
G9018 ...
G9019 ...
G9020 ...
G9033 ...
G9034 ...
G9035 ...
G9036 ...
G9041 ...
G9042 ...
G9043 ...
G9044 ...
G9140 ...
M0064 ...
P3001 ....
Q0035 ...
Q0035 ...
Q0035 ...
Q0091 ...
Q0092 ...
Q3001 ...
Q3014 ...
R0070 ...
R0075 ...
R0076 ...
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
TC ......
26 .......
............
............
............
............
............
............
............
Status
A
X
A
A
X
X
C
C
A
A
A
A
A
A
A
A
A
A
A
A
X
X
X
A
A
A
A
A
X
A
A
X
X
X
X
X
X
X
X
X
X
X
X
X
N
N
N
X
X
X
X
X
X
X
X
A
A
A
A
X
A
A
A
A
A
A
A
C
X
C
C
B
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
ESRD relate home/dy 20+yrs .............
Fecal blood scrn immunoassay ..........
Electromagntic tx for ulcers ................
Preadmin IV immunoglobulin ..............
Dispense fee initial 30 day .................
Hospice evaluation preelecti ...............
Robot lin-radsurg com, first ................
Robt lin-radsurg fractx 2–5 .................
Percutaneous islet celltrans ................
Laparoscopy islet cell trans ................
Laparotomy islet cell transp ................
Initial preventive exam ........................
Bone marrow aspirate &biopsy ...........
Vessel mapping hemo access ............
Vessel mapping hemo access ............
Vessel mapping hemo access ............
EKG for initial prevent exam ...............
EKG tracing for initial prev ..................
EKG interpret & report preve ..............
MD service required for PMD .............
Administra Part D vaccine ..................
Hospital observation per hr .................
Direct admit hospital observ ...............
Ultrasound exam AAA screen ............
Ultrasound exam AAA screen ............
Ultrasound exam AAA screen ............
AV fistula or graft arterial ....................
AV fistula or graft venous ...................
Blood occult test,colorectal .................
Alcohol/subs interv 15–30mn ..............
Alcohol/subs interv >30 min ................
Admin + supply, tositumomab ............
MCCD, initial rate ................................
MCCD,maintenance rate ....................
MCCD, risk adj hi, initial .....................
MCCD, risk adj lo, initial .....................
MCCD, risk adj, maintenance .............
MCCD, Home monitoring ....................
MCCD, sch team conf ........................
Mccd,phys coor-care ovrsght ..............
MCCD, risk adj, level 3 .......................
MCCD, risk adj, level 4 .......................
MCCD, risk adj, level 5 .......................
Other Specified Case Mgmt ...............
ESRD demo bundle level I .................
ESRD demo bundle-level II ................
Demo-smoking cessation coun ...........
Amantadine HCL 100mg oral .............
Zanamivir,inhalation pwd 10m ............
Oseltamivir phosphate 75mg ..............
Rimantadine HCL 100mg oral ............
Amantadine HCL oral brand ...............
Zanamivir, inh pwdr, brand .................
Oseltamivir phosp, brand ....................
Rimantadine HCL, brand ....................
Low vision rehab occupationa ............
Low vision rehab orient/mobi ..............
Low vision lowvision therapi ...............
Low vision rehabilate teache ..............
Frontier extended stay demo ..............
Visit for drug monitoring ......................
Screening pap smear by phys ............
Cardiokymography ..............................
Cardiokymography ..............................
Cardiokymography ..............................
Obtaining screen pap smear ..............
Set up port xray equipment ................
Brachytherapy Radioelements ............
Telehealth facility fee ..........................
Transport portable x-ray .....................
Transport port x-ray multipl .................
Transport portable EKG ......................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.14
0.00
0.06
0.00
0.00
1.34
0.00
0.00
6.98
11.92
19.85
1.34
0.16
0.25
0.00
0.25
0.17
0.00
0.17
0.17
0.00
0.00
0.00
0.58
0.00
0.58
9.48
6.03
0.00
0.65
1.30
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.44
0.10
0.10
0.10
0.00
0.37
0.42
0.17
0.00
0.17
0.37
0.00
0.00
0.00
0.00
0.00
0.00
0.06
0.00
0.15
0.00
0.00
0.31
0.00
0.00
NA
NA
NA
1.11
0.16
5.21
5.15
0.06
0.35
0.28
0.07
0.04
0.00
0.00
0.00
2.41
2.21
0.20
48.63
37.11
0.00
0.19
0.34
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.10
0.02
0.02
0.02
0.00
0.91
0.38
0.30
0.25
0.05
0.75
0.47
0.00
0.00
0.00
0.00
0.00
0.07
0.00
0.14
1.97
0.00
0.41
0.00
0.00
NA
NA
NA
1.12
0.15
4.61
4.53
0.08
0.42
0.36
0.06
0.22
0.00
0.00
0.00
2.41
2.21
0.20
48.63
37.11
0.00
0.19
0.34
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
0.16
0.16
0.13
0.00
0.62
0.26
0.37
0.32
0.05
0.71
0.40
0.00
0.00
0.00
0.00
0.00
0.06
0.00
NA
NA
0.00
0.31
0.00
0.00
2.35
5.06
8.54
0.43
0.07
NA
NA
0.06
NA
NA
0.07
0.04
0.00
0.00
0.00
NA
NA
0.20
NA
NA
0.00
0.15
0.29
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.10
0.02
0.02
0.02
0.00
0.07
0.38
NA
NA
0.05
0.10
0.47
0.00
0.00
0.00
0.00
0.00
0.07
0.00
NA
NA
0.00
0.41
0.00
0.00
2.47
5.18
8.65
0.45
0.06
NA
NA
0.08
NA
NA
0.06
0.05
0.00
0.00
0.00
NA
NA
0.20
NA
NA
0.00
0.15
0.29
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
0.16
0.16
0.13
0.00
0.09
0.26
NA
NA
0.05
0.12
0.40
0.00
0.00
0.00
0.00
0.00
Malpractice
RVUs 2
0.01
0.00
0.01
0.00
0.00
0.09
0.00
0.00
0.48
1.46
2.07
0.10
0.04
0.25
0.23
0.02
0.03
0.02
0.01
0.01
0.00
0.00
0.00
0.11
0.08
0.03
0.62
0.34
0.00
0.01
0.03
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.00
0.01
0.02
0.03
0.02
0.01
0.02
0.01
0.00
0.00
0.00
0.00
0.00
——————————
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare
payment.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00322
Fmt 4742
Sfmt 4742
E:\FR\FM\27NOR2.SGM
27NOR2
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
090
090
XXX
ZZZ
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
000
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66543
ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR
2008—Continued
Physician
work
RVUs 2
CPT 1/
HCPCS
Mod
Status
Description
V5299 ....
............
R ........
Hearing service ...................................
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented facility PE
RVUs 2
Year 2008
transitional facility PE
RVUs 2
0.00
0.00
0.00
0.00
0.00
Malpractice
RVUs 2
Global
0.00
XXX
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courteesy to the general public and are not
used for Medicare payment.
ADDENDUM C.—CODES WITH INTERIM RVUS
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
20555
20660
20690
20692
20985
20986
20987
21073
22206
22207
22208
23515
23585
23615
23616
23630
23670
23680
24357
24358
24359
24545
24546
24575
24579
24635
24685
25515
25525
25526
25545
25574
25575
25628
26615
26650
26665
26685
26715
26735
26746
26765
26785
27248
27267
27268
27269
27416
27511
27513
27514
27519
27535
27540
27556
27557
27558
27726
27766
27767
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
VerDate Aug<31>2005
Status
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Place ndl musc/tis for rt ......................
Apply, rem fixation device ..................
Apply bone fixation device .................
Apply bone fixation device .................
Cptr-asst dir ms px .............................
Cptr-asst dir ms px io img ..................
Cptr-asst dir ms px pre img ................
Mnpj of tmj w/anesth ..........................
Cut spine 3 col, thor ...........................
Cut spine 3 col, lumb .........................
Cut spine 3 col, addl seg ...................
Treat clavicle fracture .........................
Treat scapula fracture ........................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat dislocation/fracture ....................
Treat dislocation/fracture ....................
Repair elbow, perc .............................
Repair elbow w/deb, open ..................
Repair elbow deb/attch open .............
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat humerus fracture .......................
Treat elbow fracture ...........................
Treat ulnar fracture .............................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of radius .......................
Treat fracture of ulna ..........................
Treat fracture radius & ulna ...............
Treat fracture radius/ulna ...................
Treat wrist bone fracture ....................
Treat metacarpal fracture ...................
Treat thumb fracture ...........................
Treat thumb fracture ...........................
Treat hand dislocation ........................
Treat knuckle dislocation ....................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger fracture, each ..................
Treat finger dislocation .......................
Treat thigh fracture .............................
Cltx thigh fx .........................................
Cltx thigh fx w/mnpj ............................
Optx thigh fx .......................................
Osteochondral knee autograft ............
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treatment of thigh fracture .................
Treat thigh fx growth plate .................
Treat knee fracture .............................
Treat knee fracture .............................
Treat knee dislocation ........................
Treat knee dislocation ........................
Treat knee dislocation ........................
Repair fibula nonunion .......................
Optx medial ankle fx ...........................
Cltx post ankle fx ................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00323
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented
facility PE
RVUs 2
Year 2008
transitional
facility PE
RVUs 2
6.00
4.00
8.65
16.00
2.50
0.00
0.00
3.33
37.00
36.50
9.66
9.53
14.07
12.12
18.19
10.39
12.12
12.99
5.32
6.54
8.86
12.99
14.73
9.53
11.26
8.64
8.21
8.64
10.37
12.96
7.78
8.64
12.10
9.51
6.91
5.19
7.78
6.91
6.87
7.26
9.59
5.70
6.44
10.64
5.38
7.00
18.75
14.00
14.97
19.11
14.46
13.11
13.27
11.16
12.86
15.76
18.25
14.20
7.73
2.50
NA
2.27
NA
NA
0.99
0.00
0.00
5.50
NA
NA
3.72
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.62
NA
2.27
NA
NA
0.99
0.00
0.00
5.50
NA
NA
3.72
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.62
2.18
1.55
3.71
6.78
0.99
0.00
0.00
2.31
17.71
17.59
3.72
6.77
8.07
8.44
12.29
7.00
7.37
8.16
5.15
5.73
6.19
8.36
10.20
7.68
8.28
10.29
7.01
6.96
8.70
11.09
6.94
6.87
8.93
7.33
5.66
5.78
6.46
6.05
5.75
5.84
6.38
4.93
5.15
7.29
4.39
5.02
9.88
8.38
9.65
11.81
10.61
9.48
8.77
8.44
9.45
10.78
11.16
7.67
6.67
3.65
2.18
1.55
3.71
6.78
0.99
0.00
0.00
2.31
17.71
17.59
3.72
6.77
8.07
8.44
12.29
7.00
7.37
8.16
5.15
5.73
6.19
8.36
10.20
7.68
8.28
10.29
7.01
6.96
8.70
11.09
6.94
6.87
8.93
7.33
5.66
5.78
6.46
6.05
5.75
5.84
6.38
4.93
5.15
7.29
4.39
5.02
9.88
8.38
9.65
11.81
10.61
9.48
8.77
8.44
9.45
10.78
11.16
7.67
6.67
3.65
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
Malpractice
RVUs 2
0.43
0.59
0.59
1.05
0.48
0.00
0.00
0.43
6.23
6.07
2.07
1.28
1.54
1.62
3.70
1.27
1.36
1.76
0.87
1.07
1.41
1.83
2.74
1.87
2.03
2.29
1.52
1.59
2.13
2.20
1.53
1.21
1.82
1.37
0.86
0.94
0.90
1.09
0.91
0.95
0.91
0.66
0.68
1.82
0.89
1.16
2.93
2.32
2.38
3.13
3.01
2.56
2.01
2.28
2.51
2.98
3.09
1.43
1.44
0.30
Global
000
000
090
090
ZZZ
ZZZ
ZZZ
090
090
090
ZZZ
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
66544
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM C.—CODES WITH INTERIM RVUS—Continued
cprice-sewell on PROD1PC72 with RULES
CPT 1/
HCPCS
27768
27769
27784
27792
27814
27822
27823
27826
27827
27828
27829
27832
28415
28420
28445
28446
28465
28485
28505
28525
28555
28585
28615
28645
28675
29828
29904
29905
29906
29907
31500
33257
33258
33259
33864
34806
35523
36591
36592
36593
36620
41019
43760
49203
49204
49205
49440
49441
49442
49446
49450
49451
49452
49460
49465
50385
50386
50593
51797
52649
55920
57284
57285
57423
58570
58571
58572
58573
67041
67042
67043
67113
67229
68816
75557
75558
75559
75560
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Physician
work
RVUs 2
Mod
Status
Description
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
26
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
26
26
26
26
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
T .........
T .........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
A ........
N ........
A ........
N ........
Cltx post ankle fx w/mnpj ...................
Optx post ankle fx ..............................
Treatment of fibula fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treatment of ankle fracture ................
Treat lower leg fracture ......................
Treat lower leg fracture ......................
Treat lower leg fracture ......................
Treat lower leg joint ............................
Treat lower leg dislocation .................
Treat heel fracture ..............................
Treat/graft heel fracture ......................
Treat ankle fracture ............................
Osteochondral talus autogrft ..............
Treat midfoot fracture, each ...............
Treat metatarsal fracture ....................
Treat big toe fracture ..........................
Treat toe fracture ................................
Repair foot dislocation ........................
Repair foot dislocation ........................
Repair foot dislocation ........................
Repair toe dislocation .........................
Repair of toe dislocation .....................
Arthroscopy biceps tenodesis ............
Subtalar arthro w/fb rmvl ....................
Subtalar arthro w/exc .........................
Subtalar arthro w/deb .........................
Subtalar arthro w/fusion .....................
Insert emergency airway ....................
Ablate atria, lmtd, add-on ...................
Ablate atria, x10sv, add-on ................
Ablate atria w/bypass add-on .............
Ascending aortic graft .........................
Aneurysm press sensor add-on .........
Artery bypass graft .............................
Draw blood off venous device ............
Collect blood from picc .......................
Declot vascular device .......................
Insertion catheter, artery ....................
Place needles h&n for rt .....................
Change gastrostomy tube ..................
Exc abd tum 5 cm or less ..................
Exc abd tum over 5 cm ......................
Exc abd tum over 10 cm ....................
Place gastrostomy tube perc ..............
Place duod/jej tube perc .....................
Place cecostomy tube perc ................
Change g-tube to g-j perc ..................
Replace g/c tube perc ........................
Replace duod/jej tube perc ................
Replace g-j tube perc .........................
Fix g/colon tube w/device ...................
Fluoro exam of g/colon tube ..............
Change stent via transureth ...............
Remove stent via transureth ..............
Perc cryo ablate renal tum .................
Intraabdominal pressure test ..............
2Prostate laser enucleation ................
Place needles pelvic for rt ..................
Repair paravag defect, open ..............
Repair paravag defect, vag ................
Repair paravag defect, lap .................
Tlh, uterus 250 g or less ....................
Tlh w/t/o 250 g or less ........................
Tlh, uterus over 250 g ........................
Tlh w/t/o uterus over 250 g ................
Vit for macular pucker ........................
Vit for macular hole ............................
Vit for membrane dissect ...................
Repair retinal detach, cplx ..................
Tr retinal les preterm inf .....................
Probe nl duct w/balloon ......................
Cardiac mri for morph ........................
Cardiac mri flow/velocity .....................
Cardiac mri w/stress img ....................
Cardiac mri flow/vel/stress .................
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00324
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented
facility PE
RVUs 2
Year 2008
transitional
facility PE
RVUs 2
5.00
10.00
9.51
9.55
10.46
11.03
12.98
10.92
14.56
18.20
8.64
10.01
15.96
17.29
15.53
17.50
8.64
7.28
7.28
5.46
9.49
10.92
10.46
7.28
5.46
13.00
8.50
9.00
9.47
12.00
2.33
9.63
11.00
14.14
60.00
2.06
24.00
0.00
0.00
0.00
1.15
8.84
0.90
20.00
26.00
30.00
4.18
4.77
4.00
3.31
1.36
1.84
2.86
0.96
0.62
4.44
3.30
9.08
0.80
17.16
8.31
14.25
11.52
16.00
15.75
17.56
19.96
22.98
19.00
22.13
22.94
22.49
16.00
3.00
2.35
2.60
2.95
3.00
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
8.27
7.81
10.35
9.44
NA
6.64
7.68
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.51
NA
0.54
0.67
0.60
NA
NA
4.03
NA
NA
NA
25.03
30.10
24.43
25.74
18.94
19.69
23.48
20.56
3.88
30.61
19.36
114.48
0.41
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
12.73
0.94
0.60
1.27
0.69
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
8.27
7.81
10.35
9.44
NA
6.64
7.68
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0.51
NA
0.54
0.67
0.60
NA
NA
4.03
NA
NA
NA
25.03
30.10
24.43
25.74
18.94
19.69
23.48
20.56
3.88
30.61
19.36
114.48
0.41
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
12.73
0.94
0.60
1.27
0.69
4.29
6.07
6.65
6.88
7.89
9.42
10.19
8.51
11.47
12.74
6.87
6.50
11.75
11.59
10.25
10.34
6.18
5.50
4.36
3.87
5.98
6.40
8.08
3.94
3.90
8.17
5.89
6.51
6.87
7.86
0.48
5.46
5.98
7.79
20.09
0.51
9.20
NA
NA
NA
0.19
3.28
0.39
7.65
9.26
10.34
1.81
2.00
1.63
1.15
0.44
0.64
1.00
0.31
0.22
2.05
1.60
3.44
0.41
9.31
3.13
6.56
5.16
6.51
6.45
6.94
7.59
8.41
10.36
11.48
12.34
12.75
9.51
2.51
0.94
0.60
1.27
0.69
4.29
6.07
6.65
6.88
7.89
9.42
10.19
8.51
11.47
12.74
6.87
6.50
11.75
11.59
10.25
10.34
6.18
5.50
4.36
3.87
5.98
6.40
8.08
3.94
3.90
8.17
5.89
6.51
6.87
7.86
0.48
5.46
5.98
7.79
20.09
0.51
9.20
NA
NA
NA
0.19
3.28
0.39
7.65
9.26
10.34
1.81
2.00
1.63
1.15
0.44
0.64
1.00
0.31
0.22
2.05
1.60
3.44
0.41
9.31
3.13
6.56
5.16
6.51
6.45
6.94
7.59
8.41
10.36
11.48
12.34
12.75
9.51
2.51
0.94
0.60
1.27
0.69
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
Malpractice
RVUs 2
0.79
1.45
1.23
1.32
1.86
1.92
2.26
1.47
2.44
2.82
0.95
1.03
2.67
2.81
2.59
2.45
1.10
0.83
0.56
0.49
1.04
1.25
1.30
0.57
0.45
2.17
1.25
1.32
1.39
1.90
0.17
0.89
1.09
1.78
6.73
0.30
2.14
0.01
0.01
0.37
0.07
0.59
0.09
2.27
2.94
3.40
0.49
0.29
0.24
0.18
0.08
0.11
0.18
0.05
0.03
0.27
0.20
0.58
0.12
1.11
0.58
1.41
0.63
1.65
1.82
1.81
2.31
2.28
0.86
1.00
1.04
1.13
0.71
0.16
0.10
0.11
0.10
0.11
Global
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
090
000
ZZZ
ZZZ
ZZZ
090
ZZZ
090
XXX
XXX
XXX
000
000
000
090
090
090
010
010
010
000
000
000
000
000
000
000
000
010
ZZZ
090
000
090
090
090
090
090
090
090
090
090
090
090
090
010
XXX
XXX
XXX
XXX
66545
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM C.—CODES WITH INTERIM RVUS—Continued
CPT 1/
HCPCS
75561
75562
75563
75564
78811
78812
78813
78814
78815
78816
86486
88380
88381
90769
90770
90771
93503
93982
95004
95024
95027
95980
95981
95982
96125
98966
98967
98968
98969
99174
99366
99367
99368
99406
99407
99408
99409
99441
99442
99443
99444
99477
G0396
G0397
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
....
Mod
Status
26
26
26
26
26
26
26
26
26
26
............
26
26
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
A
N
A
N
A
A
A
A
A
A
A
A
A
A
A
A
C
R
A
A
A
A
A
A
A
N
N
N
N
N
B
B
B
A
A
N
N
N
N
N
N
A
A
A
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Physician
work
RVUs 2
Description
Cardiac mri for morph w/dye ..............
Card mri flow/vel w/dye ......................
Card mri w/stress img & dye ..............
Ht mri w/flo/vel/strs & dye ..................
Pet image, ltd area .............................
Pet image, skull-thigh .........................
Pet image, full body ............................
Pet image w/ct, lmtd ...........................
Pet image w/ct, skull-thigh .................
Pet image w/ct, full body ....................
Skin test, nos antigen .........................
Microdissection, laser .........................
Microdissection, manual .....................
Sc ther infusion, up to 1 hr .................
Sc ther infusion, addl hr .....................
Sc ther infusion, reset pump ..............
Insert/place heart catheter ..................
Aneurysm pressure sens study ..........
Percut allergy skin tests .....................
Id allergy test, drug/bug ......................
Id allergy titrate-airborne ....................
Io anal gast n-stim init ........................
Io anal gast n-stim subsq ...................
Io ga n-stim subsq w/reprog ...............
Cognitive test by hc pro .....................
Hc pro phone call 5–10 min ...............
Hc pro phone call 11–20 min .............
Hc pro phone call 21–30 min .............
Online service by hc pro ....................
Ocular photoscreening .......................
Team conf w/pat by hc pro ................
Team conf w/o pat by phys ................
Team conf w/o pat by hc pro .............
Behav chng smoking 3–10 min ..........
Behav chng smoking < 10 min ..........
Audit/dast, 15–30 min .........................
Audit/dast, over 30 min ......................
Phone e/m by phys 5–10 min ............
Phone e/m by phys 11–20 min ..........
Phone e/m by phys 21–30 min ..........
Online e/m by phys ............................
Init day hosp neonate care .................
Alcohol/subs interv 15–30 min ...........
Alcohol/subs interv >30 min ...............
Fully
implemented
non-facility
PE RVUs 2
Year 2008
transitional nonfacility PE
RVUs 2
Fully
implemented
facility PE
RVUs 2
Year 2008
transitional
facility PE
RVUs 2
2.60
2.86
3.00
3.35
1.54
1.93
2.00
2.20
2.44
2.50
0.00
1.56
1.18
0.21
0.18
0.00
0.00
0.30
0.01
0.01
0.01
0.80
0.30
0.65
1.70
0.25
0.50
0.75
0.00
0.00
0.82
1.10
0.72
0.24
0.50
0.65
1.30
0.25
0.50
0.75
0.00
7.00
0.65
1.30
1.03
0.66
1.38
0.77
0.53
0.66
0.68
0.75
0.84
0.85
0.13
0.43
0.32
3.92
0.22
1.86
NA
0.80
0.13
0.16
0.12
NA
0.44
0.47
0.76
0.09
0.14
0.20
0.00
0.00
0.20
0.25
0.16
0.10
0.18
0.19
0.34
0.09
0.14
0.20
0.00
1.98
0.19
0.34
1.03
0.66
1.38
0.77
0.53
0.66
0.68
0.75
0.84
0.85
0.13
0.43
0.32
3.92
0.22
1.86
NA
0.80
0.13
0.16
0.12
NA
0.44
0.47
0.76
0.09
0.14
0.20
0.00
0.00
0.20
0.25
0.16
0.10
0.18
0.19
0.34
0.09
0.14
0.20
0.00
1.98
0.19
0.34
1.03
0.66
1.38
0.77
0.53
0.66
0.68
0.75
0.84
0.85
NA
0.43
0.32
NA
NA
NA
NA
NA
NA
NA
NA
0.25
0.12
0.18
0.37
0.06
0.11
0.17
0.00
0.00
0.19
0.25
0.16
0.08
0.15
0.15
0.30
0.06
0.11
0.17
0.00
1.98
0.15
0.29
1.03
0.66
1.38
0.77
0.53
0.66
0.68
0.75
0.84
0.85
NA
0.43
0.32
NA
NA
NA
NA
NA
NA
NA
NA
0.25
0.12
0.18
0.37
0.06
0.11
0.17
0.00
0.00
0.19
0.25
0.16
0.08
0.15
0.15
0.30
0.06
0.11
0.17
0.00
1.98
0.15
0.29
Malpractice
RVUs 2
0.11
0.11
0.11
0.13
0.11
0.11
0.11
0.11
0.11
0.11
0.02
0.07
0.06
0.06
0.04
0.01
0.00
0.01
0.01
0.01
0.01
0.07
0.02
0.05
0.16
0.01
0.02
0.03
0.00
0.00
0.06
0.05
0.03
0.01
0.01
0.01
0.03
0.02
0.02
0.03
0.00
0.32
0.01
0.03
Global
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
ZZZ
ZZZ
000
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
1 CPT
codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
2 If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not
used for Medicare payment.
ADDENDUM D.—2008 GEOGRAPHIC ADJUSTMENT FACTORS (GAFS)
cprice-sewell on PROD1PC72 with RULES
Carrier
31140
31140
31140
00803
00803
31140
31143
14330
31140
00805
00903
31146
31146
31146
00591
00952
00590
00953
00805
00952
00865
00836
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
VerDate Aug<31>2005
Locality
06
05
09
01
02
07
01
04
03
01
01
26
17
18
00
16
04
01
99
15
01
02
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
Locality name
GAF
San Mateo, CA ........................................................................................................................................................
San Francisco, CA ..................................................................................................................................................
Santa Clara, CA ......................................................................................................................................................
Manhattan, NY ........................................................................................................................................................
NYC Suburbs/Long I., NY .......................................................................................................................................
Oakland/Berkley, CA ...............................................................................................................................................
Metropolitan Boston ................................................................................................................................................
Queens, NY .............................................................................................................................................................
Marin/Napa/Solano, CA ...........................................................................................................................................
Northern NJ .............................................................................................................................................................
DC + MD/VA Suburbs .............................................................................................................................................
Anaheim/Santa Ana, CA .........................................................................................................................................
Ventura, CA .............................................................................................................................................................
Los Angeles, CA .....................................................................................................................................................
Connecticut ..............................................................................................................................................................
Chicago, IL ..............................................................................................................................................................
Miami, FL .................................................................................................................................................................
Detroit, MI ................................................................................................................................................................
Rest of New Jersey .................................................................................................................................................
Suburban Chicago, IL .............................................................................................................................................
Metropolitan Philadelphia, PA .................................................................................................................................
Seattle (King Cnty), WA ..........................................................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00325
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.232
1.229
1.207
1.174
1.171
1.154
1.143
1.137
1.133
1.130
1.127
1.124
1.102
1.100
1.096
1.093
1.092
1.091
1.078
1.074
1.072
1.046
66546
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM D.—2008 GEOGRAPHIC ADJUSTMENT FACTORS (GAFS)—Continued
cprice-sewell on PROD1PC72 with RULES
Carrier
00831
00833
31143
00803
00901
00590
00524
00511
00900
00900
00834
31140
31146
00902
00900
00835
00900
00528
31144
00952
00900
00973
00900
00824
00901
31142
03102
00523
00590
00953
00836
00740
00883
00954
00865
31145
00904
03502
00900
00801
00951
00952
05535
00521
00630
00511
00900
00835
00884
00528
05440
00880
00650
00740
31142
00660
00510
05130
03602
00826
00512
00655
03202
00522
00740
03402
00523
03302
00520
00973
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
VerDate Aug<31>2005
Locality
01
01
99
03
01
03
01
01
11
18
00
99
99
01
31
01
09
01
40
15
28
50
15
01
99
03
00
01
99
99
99
02
00
00
99
50
00
09
20
99
00
99
00
05
00
99
99
99
16
99
35
01
00
04
99
00
00
00
21
00
00
00
01
00
99
02
99
01
13
20
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
Locality name
GAF
Alaska ......................................................................................................................................................................
Hawaii/Guam ...........................................................................................................................................................
Rest of Massachusetts ............................................................................................................................................
Poughkpsie/N NYC Suburbs, NY ............................................................................................................................
Baltimore/Surr. Cntys, MD ......................................................................................................................................
Fort Lauderdale, FL .................................................................................................................................................
Rhode Island ...........................................................................................................................................................
Atlanta, GA ..............................................................................................................................................................
Dallas, TX ................................................................................................................................................................
Houston, TX ............................................................................................................................................................
Nevada ....................................................................................................................................................................
Rest of California * ...................................................................................................................................................
Rest of California * ...................................................................................................................................................
Delaware .................................................................................................................................................................
Austin, TX ................................................................................................................................................................
Portland, OR ............................................................................................................................................................
Brazoria, TX ............................................................................................................................................................
New Orleans, LA .....................................................................................................................................................
New Hampshire .......................................................................................................................................................
East St. Louis, IL .....................................................................................................................................................
Fort Worth, TX .........................................................................................................................................................
Virgin Islands ...........................................................................................................................................................
Galveston, TX ..........................................................................................................................................................
Colorado ..................................................................................................................................................................
Rest of Maryland .....................................................................................................................................................
Southern Maine .......................................................................................................................................................
Arizona ....................................................................................................................................................................
Metropolitan Kansas City, MO ................................................................................................................................
Rest of Florida .........................................................................................................................................................
Rest of Michigan .....................................................................................................................................................
Rest of Washington .................................................................................................................................................
Metropolitan St. Louis, MO .....................................................................................................................................
Ohio .........................................................................................................................................................................
Minnesota ................................................................................................................................................................
Rest of Pennsylvania ..............................................................................................................................................
Vermont ...................................................................................................................................................................
Virginia .....................................................................................................................................................................
Utah .........................................................................................................................................................................
Beaumont, TX .........................................................................................................................................................
Rest of New York ....................................................................................................................................................
Wisconsin ................................................................................................................................................................
Rest of Illinois ..........................................................................................................................................................
North Carolina .........................................................................................................................................................
New Mexico .............................................................................................................................................................
Indiana .....................................................................................................................................................................
Rest of Georgia .......................................................................................................................................................
Rest of Texas ..........................................................................................................................................................
Rest of Oregon ........................................................................................................................................................
West Virginia ...........................................................................................................................................................
Rest of Louisiana ....................................................................................................................................................
Tennessee ...............................................................................................................................................................
South Carolina .........................................................................................................................................................
Kansas * ...................................................................................................................................................................
Kansas * ...................................................................................................................................................................
Rest of Maine ..........................................................................................................................................................
Kentucky ..................................................................................................................................................................
Alabama ..................................................................................................................................................................
Idaho ........................................................................................................................................................................
Wyoming ..................................................................................................................................................................
Iowa .........................................................................................................................................................................
Mississippi ...............................................................................................................................................................
Nebraska .................................................................................................................................................................
Montana ...................................................................................................................................................................
Oklahoma ................................................................................................................................................................
Rest of Missouri * ....................................................................................................................................................
South Dakota ...........................................................................................................................................................
Rest of Missouri * ....................................................................................................................................................
North Dakota ...........................................................................................................................................................
Arkansas ..................................................................................................................................................................
Puerto Rico ..............................................................................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00326
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.045
1.044
1.042
1.040
1.037
1.033
1.030
1.024
1.022
1.021
1.019
1.015
1.015
1.012
1.001
0.997
0.995
0.993
0.993
0.992
0.990
0.989
0.985
0.983
0.981
0.981
0.980
0.980
0.977
0.976
0.973
0.971
0.969
0.967
0.956
0.953
0.950
0.948
0.946
0.946
0.942
0.940
0.937
0.936
0.935
0.932
0.931
0.930
0.926
0.923
0.923
0.921
0.917
0.917
0.915
0.912
0.910
0.909
0.907
0.906
0.903
0.902
0.898
0.898
0.890
0.890
0.889
0.888
0.888
0.789
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66547
ADDENDUM E.—2008 *** GEOGRAPHIC PRACTICE COST INDICES BY STATE AND MEDICARE LOCALITY
Carrier
Locality
2008 budget neutral
GPCIs
Locality name
cprice-sewell on PROD1PC72 with RULES
Work
00510
00831
03102
00520
31146
31146
31140
31140
31140
31140
31140
31146
31140
31146
00824
00591
00903
00902
00590
00590
00590
00511
00511
00833
05130
00952
00952
00952
00952
00630
00826
00650
00740
00660
00528
00528
31142
31142
00901
00901
31143
31143
00953
00953
00954
00512
00523
00740
00523
00740
03202
00655
00834
31144
00805
00805
00521
00803
00803
00803
14330
00801
05535
03302
00883
00522
00835
00835
00865
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
VerDate Aug<31>2005
00
01
00
13
26
18
03
07
05
06
09
17
99
99
01
00
01
01
03
04
99
01
99
01
00
16
12
15
99
00
00
00
04
00
01
99
03
99
01
99
01
99
01
99
00
00
01
02
99
99
01
00
00
40
01
99
05
01
02
03
04
99
00
01
00
00
01
99
01
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
Alabama ..................................................................................................................................
Alaska .....................................................................................................................................
Arizona ....................................................................................................................................
Arkansas .................................................................................................................................
Anaheim/Santa Ana, CA .........................................................................................................
Los Angeles, CA .....................................................................................................................
Marin/Napa/Solano, CA ..........................................................................................................
Oakland/Berkley, CA ...............................................................................................................
San Francisco, CA ..................................................................................................................
San Mateo, CA .......................................................................................................................
Santa Clara, CA ......................................................................................................................
Ventura, CA ............................................................................................................................
Rest of California * ..................................................................................................................
Rest of California * ..................................................................................................................
Colorado ..................................................................................................................................
Connecticut .............................................................................................................................
DC + MD/VA Suburbs .............................................................................................................
Delaware .................................................................................................................................
Fort Lauderdale, FL ................................................................................................................
Miami, FL ................................................................................................................................
Rest of Florida ........................................................................................................................
Atlanta, GA ..............................................................................................................................
Rest of Georgia .......................................................................................................................
Hawaii/Guam ...........................................................................................................................
Idaho .......................................................................................................................................
Chicago, IL ..............................................................................................................................
East St. Louis, IL ....................................................................................................................
Suburban Chicago, IL .............................................................................................................
Rest of Illinois .........................................................................................................................
Indiana ....................................................................................................................................
Iowa .........................................................................................................................................
Kansas * ..................................................................................................................................
Kansas * ..................................................................................................................................
Kentucky .................................................................................................................................
New Orleans, LA .....................................................................................................................
Rest of Louisiana ....................................................................................................................
Southern Maine .......................................................................................................................
Rest of Maine ..........................................................................................................................
Baltimore/Surr. Cntys, MD ......................................................................................................
Rest of Maryland .....................................................................................................................
Metropolitan Boston ................................................................................................................
Rest of Massachusetts ...........................................................................................................
Detroit, MI ...............................................................................................................................
Rest of Michigan .....................................................................................................................
Minnesota ................................................................................................................................
Mississippi ...............................................................................................................................
Metropolitan Kansas City, MO ................................................................................................
Metropolitan St. Louis, MO .....................................................................................................
Rest of Missouri * ....................................................................................................................
Rest of Missouri * ....................................................................................................................
Montana ..................................................................................................................................
Nebraska .................................................................................................................................
Nevada ....................................................................................................................................
New Hampshire ......................................................................................................................
Northern NJ .............................................................................................................................
Rest of New Jersey ................................................................................................................
New Mexico ............................................................................................................................
Manhattan, NY ........................................................................................................................
NYC Suburbs/Long I., NY .......................................................................................................
Poughkpsie/N NYC Suburbs, NY ...........................................................................................
Queens, NY ............................................................................................................................
Rest of New York ....................................................................................................................
North Carolina .........................................................................................................................
North Dakota ...........................................................................................................................
Ohio .........................................................................................................................................
Oklahoma ................................................................................................................................
Portland, OR ...........................................................................................................................
Rest of Oregon .......................................................................................................................
Metropolitan Philadelphia, PA .................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00327
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
PE
MP
0.982
1.018
0.987
0.961
1.034
1.041
1.035
1.054
1.060
1.073
1.083
1.028
1.008
.008
0.986
1.038
1.048
1.012
0.988
1.001
0.973
1.010
0.979
0.990
0.967
1.025
0.988
1.018
0.974
0.985
0.966
0.968
0.968
0.969
0.986
0.970
0.980
0.962
1.013
0.993
1.030
1.008
1.037
0.998
0.991
0.959
0.989
0.992
0.950
0.951
0.950
0.959
1.003
0.981
1.058
1.043
0.972
1.065
1.052
1.015
1.032
0.997
0.971
0.946
0.992
0.964
1.003
0.968
1.017
0.850
1.097
0.975
0.839
1.254
1.192
1.304
1.330
1.494
1.486
1.419
1.223
1.056
1.056
1.003
1.179
1.235
1.033
1.004
1.058
0.937
1.052
0.879
1.137
0.876
1.104
0.929
1.092
0.877
0.913
0.870
0.881
0.881
0.858
0.995
0.863
1.019
0.890
1.068
0.981
1.311
1.105
1.048
0.922
0.994
0.848
0.961
0.943
0.812
0.812
0.846
0.883
1.035
1.034
1.225
1.124
0.889
1.299
1.286
1.076
1.235
0.920
0.923
0.853
0.930
0.853
1.037
0.927
1.101
0.617
0.828
0.936
0.439
0.875
0.871
0.535
0.532
0.526
0.511
0.485
0.749
0.634
0.634
0.715
0.934
0.972
0.777
1.965
2.705
1.490
0.893
0.889
0.726
0.499
1.889
1.758
1.628
1.197
0.515
0.506
0.633
0.633
0.755
1.066
0.966
0.558
0.558
1.010
0.812
0.787
0.787
2.300
1.287
0.324
0.760
1.061
1.001
0.938
0.938
0.781
0.345
1.067
0.693
1.038
1.038
0.989
1.243
1.494
0.984
1.450
0.544
0.632
0.489
1.097
0.503
0.453
0.453
1.492
66548
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM E.—2008 *** GEOGRAPHIC PRACTICE COST INDICES BY STATE AND MEDICARE LOCALITY—Continued
Carrier
Locality
2008 budget neutral
GPCIs
Locality name
Work
00865
00973
00524
00880
03402
05440
00900
00900
00900
00900
00900
00900
00900
00900
03502
31145
00904
00973
00836
00836
00884
00951
03602
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
99
20
01
01
02
35
31
20
09
11
28
15
18
99
09
50
00
50
02
99
16
00
21
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
Rest of Pennsylvania ..............................................................................................................
Puerto Rico .............................................................................................................................
Rhode Island ...........................................................................................................................
South Carolina ........................................................................................................................
South Dakota ..........................................................................................................................
Tennessee ..............................................................................................................................
Austin, TX ...............................................................................................................................
Beaumont, TX .........................................................................................................................
Brazoria, TX ............................................................................................................................
Dallas, TX ...............................................................................................................................
Fort Worth, TX ........................................................................................................................
Galveston, TX .........................................................................................................................
Houston, TX ............................................................................................................................
Rest of Texas ..........................................................................................................................
Utah .........................................................................................................................................
Vermont ...................................................................................................................................
Virginia ....................................................................................................................................
Virgin Islands ..........................................................................................................................
Seattle (King Cnty), WA ..........................................................................................................
Rest of Washington ................................................................................................................
West Virginia ...........................................................................................................................
Wisconsin ................................................................................................................................
Wyoming .................................................................................................................................
PE
MP
0.992
0.905
1.029
0.975
0.942
0.977
0.991
0.983
1.020
1.010
0.998
0.990
1,017
0.968
0.977
0.968
0.981
0.982
1.015
0.987
0.973
0.987
0.956
0.914
0.697
1.039
0.900
0.871
0.885
1.015
0.869
0.942
1.032
0.972
0.956
1.000
0.873
0.922
0.976
0.942
0.996
1.109
0.977
0.824
0.920
0.849
0.938
0.253
0.946
0.418
0.390
0.614
0.970
1.312
1.250
1.078
1.078
1.250
1.311
1.092
0.841
0.497
0.613
0.998
0.755
0.749
1.437
0.592
0.905
* Indicates multiple carriers.
** Transition value for work GPCI does not reflect the 2007 1.000 floor.
*** 2008 GPCIs are the first year of the update transition.
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)
cprice-sewell on PROD1PC72 with RULES
HCPCS/
CPT *
31620
37250
37251
51798
70010
70015
70030
70100
70110
70120
70130
70134
70140
70150
70160
70170
70190
70200
70210
70220
70240
70250
70260
70300
70310
70320
70328
70330
70332
70336
70350
70355
70360
70370
70371
70373
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
VerDate Aug<31>2005
Short descriptor
Endobronchial us add-on.
Iv us first vessel add-on.
Iv us each add vessel add-on.
Us urine capacity measure.
Contrast x-ray of brain.
Contrast x-ray of brain.
X-ray eye for foreign body.
X-ray exam of jaw.
X-ray exam of jaw.
X-ray exam of mastoids.
X-ray exam of mastoids.
X-ray exam of middle ear.
X-ray exam of facial bones.
X-ray exam of facial bones.
X-ray exam of nasal bones.
X-ray exam of tear duct.
X-ray exam of eye sockets.
X-ray exam of eye sockets.
X-ray exam of sinuses.
X-ray exam of sinuses.
X-ray exam, pituitary saddle.
X-ray exam of skull.
X-ray exam of skull.
X-ray exam of teeth.
X-ray exam of teeth.
Full mouth x-ray of teeth.
X-ray exam of jaw joint.
X-ray exam of jaw joints.
X-ray exam of jaw joint.
Magnetic image, jaw joint.
X-ray head for orthodontia.
Panoramic x-ray of jaws.
X-ray exam of neck.
Throat x-ray & fluoroscopy.
Speech evaluation, complex.
Contrast x-ray of larynx.
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
70380
70390
70450
70460
70470
70480
70481
70482
70486
70487
70488
70490
70491
70492
70496
70498
70540
70542
70543
70544
70545
70546
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
70547 ........
70548 ........
70549 ........
70551
70552
70553
70557
70558
70559
71010
PO 00000
........
........
........
........
........
........
........
Frm 00328
Short descriptor
X-ray exam of salivary gland.
X-ray exam of salivary duct.
Ct head/brain w/o dye.
Ct head/brain w/dye.
Ct head/brain w/o & w/dye.
Ct orbit/ear/fossa w/o dye.
Ct orbit/ear/fossa w/dye.
Ct orbit/ear/fossa w/o & w/dye.
Ct maxillofacial w/o dye.
Ct maxillofacial w/dye.
Ct maxillofacial w/o & w/dye.
Ct soft tissue neck w/o dye.
Ct soft tissue neck w/dye.
Ct sft tsue nck w/o & w/dye.
Ct angiography, head.
Ct angiography, neck.
Mri orbit/face/neck w/o dye.
Mri orbit/face/neck w/dye.
Mri orbt/fac/nck w/o & w/dye.
Mr angiography head w/o dye.
Mr angiography head w/dye.
Mr angiograph head w/o & w/
dye.
Mr angiography neck w/o dye.
Mr angiography neck w/dye.
Mr angiograph neck w/o & w/
dye.
Mri brain w/o dye.
Mri brain w/dye.
Mri brain w/o & w/dye.
Mri brain w/o dye.
Mri brain w/dye.
Mri brain w/o & w/dye.
Chest x-ray.
Fmt 4701
Sfmt 4701
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
71015
71020
71021
71022
71023
71030
71034
71035
71040
71060
71090
71100
71101
71110
71111
71120
71130
71250
71260
71270
71275
71550
71551
71552
71555
72010
72020
72040
72050
72052
72069
72070
72072
72074
E:\FR\FM\27NOR2.SGM
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
27NOR2
Short descriptor
Chest x-ray.
Chest x-ray.
Chest x-ray.
Chest x-ray.
Chest x-ray and fluoroscopy.
Chest x-ray.
Chest x-ray and fluoroscopy.
Chest x-ray.
Contrast x-ray of bronchi.
Contrast x-ray of bronchi.
X-ray & pacemaker insertion.
X-ray exam of ribs.
X-ray exam of ribs/chest.
X-ray exam of ribs.
X-ray exam of ribs/chest.
X-ray exam of breastbone.
X-ray exam of breastbone.
Ct thorax w/o dye.
Ct thorax w/dye.
Ct thorax w/o & w/dye.
Ct angiography, chest.
Mri chest w/o dye.
Mri chest w/dye.
Mri chest w/o & w/dye.
Mri angio chest w/ or w/o dye.
X-ray exam of spine.
X-ray exam of spine.
X-ray exam of neck spine.
X-ray exam of neck spine.
X-ray exam of neck spine.
X-ray exam of trunk spine.
X-ray exam of thoracic spine.
X-ray exam of thoracic spine.
X-ray exam of thoracic spine.
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
cprice-sewell on PROD1PC72 with RULES
72080
72090
72100
72110
72114
72120
72125
72126
72127
72128
72129
72130
72131
72132
72133
72141
72142
72146
72147
72148
72149
72156
72157
72158
72159
72170
72190
72191
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
72192
72193
72194
72195
72196
72197
72198
72200
72202
72220
72240
72255
72265
72270
72275
72285
72291
72293
72295
73000
73010
73020
73030
73040
73050
73060
73070
73080
73085
73090
73092
73100
73110
73115
73120
73130
73140
73200
73201
73202
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
VerDate Aug<31>2005
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
Short descriptor
HCPCS/
CPT *
Short descriptor
X-ray exam of trunk spine.
X-ray exam of trunk spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
Ct neck spine w/o dye.
Ct neck spine w/dye.
Ct neck spine w/o & w/dye.
Ct chest spine w/o dye.
Ct chest spine w/dye.
Ct chest spine w/o & w/dye.
Ct lumbar spine w/o dye.
Ct lumbar spine w/dye.
Ct lumbar spine w/o & w/dye.
Mri neck spine w/o dye.
Mri neck spine w/dye.
Mri chest spine w/o dye.
Mri chest spine w/dye.
Mri lumbar spine w/o dye.
Mri lumbar spine w/dye.
Mri neck spine w/o & w/dye.
Mri chest spine w/o & w/dye.
Mri lumbar spine w/o & w/dye.
Mr angio spine w/o & w/dye.
X-ray exam of pelvis.
X-ray exam of pelvis.
Ct angiograph pelv w/o & w/
dye.
Ct pelvis w/o dye.
Ct pelvis w/dye.
Ct pelvis w/o & w/dye.
Mri pelvis w/o dye.
Mri pelvis w/dye.
Mri pelvis w/o & w/dye.
Mr angio pelvis w/o & w/dye.
X-ray exam sacroiliac joints.
X-ray exam sacroiliac joints.
X-ray exam of tailbone.
Contrast x-ray of neck spine.
Contrast x-ray, thorax spine.
Contrast x-ray, lower spine.
Contrast x-ray, spine.
Epidurography.
X-ray c/t spine disk.
Percut vertebroplasty fluor.
Percut vertebroplasty, ct.
X-ray of lower spine disk.
X-ray exam of collar bone.
X-ray exam of shoulder blade.
X-ray exam of shoulder.
X-ray exam of shoulder.
Contrast x-ray of shoulder.
X-ray exam of shoulders.
X-ray exam of humerus.
X-ray exam of elbow.
X-ray exam of elbow.
Contrast x-ray of elbow.
X-ray exam of forearm.
X-ray exam of arm, infant.
X-ray exam of wrist.
X-ray exam of wrist.
Contrast x-ray of wrist.
X-ray exam of hand.
X-ray exam of hand.
X-ray exam of finger(s).
Ct upper extremity w/o dye.
Ct upper extremity w/dye.
Ct uppr extremity w/o & w/dye.
73206 ........
Ct angio upr extrm w/o &
w/dye.
Mri upper extremity w/o dye.
Mri upper extremity w/dye.
Mri uppr extremity w/o & w/dye.
Mri joint upr extrem w/o dye.
Mri joint upr extrem w/dye.
Mri joint upr extr w/o & w/dye.
Mr angio upr extr w/o & w/dye.
X-ray exam of hip.
X-ray exam of hip.
X-ray exam of hips.
Contrast x-ray of hip.
X-ray exam of hip.
X-ray exam of pelvis & hips.
X-ray exam, sacroiliac joint.
X-ray exam of thigh.
X-ray exam of knee, 1 or 2.
X-ray exam of knee, 3.
X-ray exam, knee, 4 or more.
X-ray exam of knees.
Contrast x-ray of knee joint.
X-ray exam of lower leg.
X-ray exam of leg, infant.
X-ray exam of ankle.
X-ray exam of ankle.
Contrast x-ray of ankle.
X-ray exam of foot.
X-ray exam of foot.
X-ray exam of heel.
X-ray exam of toe(s).
Ct lower extremity w/o dye.
Ct lower extremity w/dye.
Ct lwr extremity w/o & w/dye.
Ct angio lwr extr w/o & w/dye.
Mri lower extremity w/o dye.
Mri lower extremity w/dye.
Mri lwr extremity w/o & w/dye.
Mri jnt of lwr extre w/o dye.
Mri joint of lwr extr w/dye.
Mri joint lwr extr w/o & w/dye.
Mr ang lwr ext w or w/o dye.
X-ray exam of abdomen.
X-ray exam of abdomen.
X-ray exam of abdomen.
X-ray exam series, abdomen.
Ct abdomen w/o dye.
Ct abdomen w/dye.
Ct abdomen w/o & w/dye.
Ct angio abdom w/o & w/dye.
Mri abdomen w/o dye.
Mri abdomen w/dye.
Mri abdomen w/o & w/dye.
Mri angio, abdom w/ or w/o
dye.
X-ray exam of peritoneum.
Contrast x-ray exam of throat.
Contrast x-ray, esophagus.
Cine/vid x-ray, throat/esoph.
Remove esophagus obstruction.
X-ray exam, upper gi tract.
X-ray exam, upper gi tract.
X-ray exam, upper gi tract.
Contrast x-ray uppr gi tract.
Contrast x-ray uppr gi tract.
Contrast x-ray uppr gi tract.
X-ray exam of small bowel.
X-ray exam of small bowel.
16:01 Nov 26, 2007
Jkt 214001
73218
73219
73220
73221
73222
73223
73225
73500
73510
73520
73525
73530
73540
73542
73550
73560
73562
73564
73565
73580
73590
73592
73600
73610
73615
73620
73630
73650
73660
73700
73701
73702
73706
73718
73719
73720
73721
73722
73723
73725
74000
74010
74020
74022
74150
74160
74170
74175
74181
74182
74183
74185
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
74190
74210
74220
74230
74235
........
........
........
........
........
74240
74241
74245
74246
74247
74249
74250
74251
........
........
........
........
........
........
........
........
PO 00000
Frm 00329
Fmt 4701
Sfmt 4701
66549
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
74260
74270
74280
74283
74290
74291
74300
74301
74305
74320
74327
74328
74329
74330
74340
74355
74360
74363
74400
74410
74415
74420
74425
74430
74440
74445
74450
74455
74470
74475
74480
74485
74710
74740
74742
74775
75557
75558
75559
75560
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
75561
75562
75563
75564
........
........
........
........
75600
75605
75625
75630
75635
75650
75658
75660
75662
75665
75671
75676
75680
75685
75705
75710
75716
75722
75724
75726
75731
75733
75736
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
E:\FR\FM\27NOR2.SGM
27NOR2
Short descriptor
X-ray exam of small bowel.
Contrast x-ray exam of colon.
Contrast x-ray exam of colon.
Contrast x-ray exam of colon.
Contrast x-ray, gallbladder.
Contrast x-rays, gallbladder.
X-ray bile ducts/pancreas.
X-rays at surgery add-on.
X-ray bile ducts/pancreas.
Contrast x-ray of bile ducts.
X-ray bile stone removal.
X-ray bile duct endoscopy.
X-ray for pancreas endoscopy.
X-ray bile/panc endoscopy.
X-ray guide for GI tube.
X-ray guide, intestinal tube.
X-ray guide, GI dilation.
X-ray, bile duct dilation.
Contrast x-ray, urinary tract.
Contrast x-ray, urinary tract.
Contrast x-ray, urinary tract.
Contrast x-ray, urinary tract.
Contrast x-ray, urinary tract.
Contrast x-ray, bladder.
X-ray, male genital tract.
X-ray exam of penis.
X-ray, urethra/bladder.
X-ray, urethra/bladder.
X-ray exam of kidney lesion.
X-ray control, cath insert.
X-ray control, cath insert.
X-ray guide, GU dilation.
X-ray measurement of pelvis.
X-ray, female genital tract.
X-ray, fallopian tube.
X-ray exam of perineum.
Cardiac MRI w/o contrast.
Cardiac MRI w/flow/velocity.
Cardiac MRI w/stress imaging.
Cardiac MRI w/flow/velocity/
stress.
Cardiac MRI w/ & w/o contrast.
Cardiac MRI w/flow velocity.
Cardiac MRI w/stress imaging.
Cardiac MRI w/flow/velocity/
stress.
Contrast x-ray exam of aorta.
Contrast x-ray exam of aorta.
Contrast x-ray exam of aorta.
X-ray aorta, leg arteries.
Ct angio abdominal arteries.
Artery x-rays, head & neck.
Artery x-rays, arm.
Artery x-rays, head & neck.
Artery x-rays, head & neck.
Artery x-rays, head & neck.
Artery x-rays, head & neck.
Artery x-rays, neck.
Artery x-rays, neck.
Artery x-rays, spine.
Artery x-rays, spine.
Artery x-rays, arm/leg.
Artery x-rays, arms/legs.
Artery x-rays, kidney.
Artery x-rays, kidneys.
Artery x-rays, abdomen.
Artery x-rays, adrenal gland.
Artery x-rays, adrenals.
Artery x-rays, pelvis.
66550
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
cprice-sewell on PROD1PC72 with RULES
HCPCS/
CPT *
75741
75743
75746
75756
75774
75790
75801
75803
75805
75807
75809
75810
75820
75822
75825
75827
75831
75833
75840
75842
75860
75870
75872
75880
75885
75887
75889
75891
75893
75894
75896
75898
75900
75901
75902
75940
75945
75946
75953
75956
75957
75958
75959
75960
75961
75962
75964
75966
75968
75970
75978
75980
75982
75984
75989
75992
76000
76001
76010
76080
76098
76100
76101
76102
76120
76125
76140
76150
76350
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
VerDate Aug<31>2005
HCPCS/
CPT *
Short descriptor
Artery x-rays, lung.
Artery x-rays, lungs.
Artery x-rays, lung.
Artery x-rays, chest.
Artery x-ray, each vessel.
Visualize A–V shunt.
Lymph vessel x-ray, arm/leg.
Lymph vessel x-ray, arms/legs.
Lymph vessel x-ray, trunk.
Lymph vessel x-ray, trunk.
Nonvascular shunt, x-ray.
Vein x-ray, spleen/liver.
Vein x-ray, arm/leg.
Vein x-ray, arms/legs.
Vein x-ray, trunk.
Vein x-ray, chest.
Vein x-ray, kidney.
Vein x-ray, kidneys.
Vein x-ray, adrenal gland.
Vein x-ray, adrenal glands.
Vein x-ray, neck.
Vein x-ray, skull.
Vein x-ray, skull.
Vein x-ray, eye socket.
Vein x-ray, liver.
Vein x-ray, liver.
Vein x-ray, liver.
Vein x-ray, liver.
Venous sampling by catheter.
X-rays, transcath therapy.
X-rays, transcath therapy.
Follow-up angiography.
Intravascular cath exchange.
Remove cva device obstruct.
Remove cva lumen obstruct.
X-ray placement, vein filter.
Intravascular us.
Intravascular us add-on.
Abdom aneurysm endovas rpr.
X-ray, endovasc thor ao repr.
X-ray, endovasc thor ao repr.
X-ray, place prox ext thor ao.
X-ray, place dist ext thor ao.
Transcath iv stent rs&i.
Retrieval, broken catheter.
Repair arterial blockage.
Repair artery blockage, each.
Repair arterial blockage.
Repair artery blockage, each.
Vascular biopsy.
Repair venous blockage.
Contrast x-ray exam bile duct.
Contrast x-ray exam bile duct.
X-ray control catheter change.
Abscess drainage under x-ray.
Atherectomy, x-ray exam.
Fluoroscope examination.
Fluoroscope exam, extensive.
X-ray, nose to rectum.
X-ray exam of fistula.
X-ray exam, breast specimen.
X-ray exam of body section.
Complex body section x-ray.
Complex body section x-rays.
Cine/video x-rays.
Cine/video x-rays add-on.
X-ray consultation.
X-ray exam, dry process.
Special x-ray contrast study.
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
76376
76377
76380
76390
76496
76497
76498
76506
76510
76511
76512
76513
76514
76516
76519
76529
76536
76604
76645
76700
76705
76770
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
76775
76778
76800
76801
76802
76805
76810
76811
76812
76815
76816
76817
76818
76819
76820
76821
76825
76826
76827
76828
76830
76831
76856
76857
76870
76872
76873
76880
76885
76886
76930
76932
76936
76937
76940
76941
76942
76945
76946
76948
76950
76965
76970
76975
76977
76998
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
PO 00000
Frm 00330
Short descriptor
3d render w/o postprocess.
3d rendering w/postprocess.
CAT scan follow-up study.
Mr spectroscopy.
Fluoroscopic procedure.
Ct procedure.
Mri procedure.
Echo exam of head.
Ophth us, b & quant a.
Ophth us, quant a only.
Ophth us, b w/non-quant a.
Echo exam of eye, water bath.
Echo exam of eye, thickness.
Echo exam of eye.
Echo exam of eye.
Echo exam of eye.
Us exam of head and neck.
Us exam, chest, b-scan.
Us exam, breast(s).
Us exam, abdom, complete.
Echo exam of abdomen.
Us exam abdo back wall,
comp.
Us exam abdo back wall, lim.
Us exam kidney transplant.
Us exam, spinal canal.
Ob us < 14 wks, single fetus.
Ob us < 14 wks, addl fetus.
Ob us > 14 wks, sngl fetus.
Ob us > 14 wks, addl fetus.
Ob us, detailed, sngl fetus.
Ob us, detailed, addl fetus.
Ob us, limited, fetus(s).
Ob us, follow-up, per fetus.
Transvaginal us, obstetric.
Fetal biophys profile w/nst.
Fetal biophys profil w/o nst.
Umbilical artery echo.
Middle cerebral artery echo.
Echo exam of fetal heart.
Echo exam of fetal heart.
Echo exam of fetal heart.
Echo exam of fetal heart.
Transvaginal us, non-ob.
Echo exam, uterus.
Us exam, pelvic, complete.
Us exam, pelvic, limited.
Us exam, scrotum.
Us, transrectal.
Echograp trans r, pros study.
Us exam, extremity.
Us exam infant hips, dynamic.
Us exam infant hips, static.
Echo guide, cardiocentesis.
Echo guide for heart biopsy.
Echo guide for artery repair.
Us guide, vascular access.
Us guide, tissue ablation.
Echo guide for transfusion.
Echo guide for biopsy.
Echo guide, villus sampling.
Echo guide for amniocentesis.
Echo guide, ova aspiration.
Echo guidance radiotherapy.
Echo guidance radiotherapy.
Ultrasound exam follow-up.
GI endoscopic ultrasound.
Us bone density measure.
Ultrasound guide intraoper.
Fmt 4701
Sfmt 4701
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
77001
77002
77003
77011
77012
77013
77014
77021
77022
77031
77032
77053
77054
77058
77059
77071
77072
77073
77074
77075
77076
77077
77078
77079
77080
77081
77082
77083
77084
77417
77421
78006
78007
78010
78011
78015
78016
78018
78020
78070
78075
78102
78103
78104
78135
78140
78185
78190
78195
78201
78202
78205
78206
78215
78216
78220
78223
78230
78231
78232
78258
78261
78262
78264
78278
78282
78290
78291
78300
E:\FR\FM\27NOR2.SGM
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
27NOR2
Short descriptor
Fluoroguide for vein device.
Needle localization by x-ray.
Fluoroguide for spine inject.
Ct scan for localization.
Ct scan for needle biopsy.
Ct guide for tissue ablation.
Ct scan for therapy guide.
Mr guidance for needle place.
Mri for tissue ablation.
Stereotactic breast biopsy.
X-ray of needle wire, breast.
X-ray of mammary duct.
X-ray of mammary ducts.
Magnetic image, breast.
Magnetic image, both breasts.
X-ray stress view.
X-rays for bone age.
X-rays, bone evaluation.
X-rays, bone survey.
X-rays, bone survey.
X-rays, bone evaluation.
Joint survey, single view.
Ct bone density, axial.
Ct bone density, peripheral.
Dxa bone density, axial.
Dxa bone density/peripheral.
Dxa bone density/v-fracture.
Radiographic absorptiometry.
Magnetic image, bone marrow.
Radiology port film(s).
Stereoscopic x-ray guidance.
Thyroid imaging with uptake.
Thyroid image, mult uptakes.
Thyroid imaging.
Thyroid imaging with flow.
Thyroid met imaging.
Thyroid met imaging/studies.
Thyroid met imaging, body.
Thyroid met uptake.
Parathyroid nuclear imaging.
Adrenal nuclear imaging.
Bone marrow imaging, ltd.
Bone marrow imaging, mult.
Bone marrow imaging, body.
Red cell survival kinetics.
Red cell sequestration.
Spleen imaging.
Platelet survival, kinetics.
Lymph system imaging.
Liver imaging.
Liver imaging with flow.
Liver imaging (3D).
Liver image (3d) with flow.
Liver and spleen imaging.
Liver & spleen image/flow.
Liver function study.
Hepatobiliary imaging.
Salivary gland imaging.
Serial salivary imaging.
Salivary gland function exam.
Esophageal motility study.
Gastric mucosa imaging.
Gastroesophageal reflux exam.
Gastric emptying study.
Acute GI blood loss imaging.
GI protein loss exam.
Meckels divert exam.
Leveen/shunt patency exam.
Bone imaging, limited area.
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
cprice-sewell on PROD1PC72 with RULES
78305
78306
78315
78320
78350
78351
78428
78445
78456
78457
78458
78459
78460
78461
78464
78465
78466
78468
78469
78472
78473
78478
78480
78481
78483
78491
78492
78494
78496
78580
78584
78585
78586
78587
78588
78591
78593
78594
78596
78600
78601
78605
78606
78607
78608
78609
78610
78630
78635
78645
78647
78650
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
VerDate Aug<31>2005
HCPCS/
CPT *
Short descriptor
Bone imaging, multiple areas.
Bone imaging, whole body.
Bone imaging, 3 phase.
Bone imaging (3D).
Bone mineral, single photon.
Bone mineral, dual photon.
Cardiac shunt imaging.
Vascular flow imaging.
Acute venous thrombus image.
Venous thrombosis imaging.
Ven thrombosis images, bilat.
Heart muscle imaging (PET).
Heart muscle blood, single.
Heart muscle blood, multiple.
Heart image (3d), single.
Heart image (3d), multiple.
Heart infarct image.
Heart infarct image (ef).
Heart infarct image (3D).
Gated heart, planar, single.
Gated heart, multiple.
Heart wall motion add-on.
Heart function add-on.
Heart first pass, single.
Heart first pass, multiple.
Heart image (pet), single.
Heart image (pet), multiple.
Heart image, spect.
Heart first pass add-on.
Lung perfusion imaging.
Lung V/Q image single breath.
Lung V/Q imaging.
Aerosol lung image, single.
Aerosol lung image, multiple.
Perfusion lung image.
Vent image, 1 breath, 1 proj.
Vent image, 1 proj, gas.
Vent image, mult proj, gas.
Lung differential function.
Brain imaging, ltd static.
Brain imaging, ltd w/flow.
Brain imaging, complete.
Brain imaging, compl w/flow.
Brain imaging (3D).
Brain imaging (PET).
Brain imaging (PET).
Brain flow imaging only.
Cerebrospinal fluid scan.
CSF ventriculography.
CSF shunt evaluation.
Cerebrospinal fluid scan.
CSF leakage imaging.
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
78660
78700
78701
78704
78707
78708
78709
78710
78715
78730
78740
78760
78761
78800
78801
78802
78803
78804
78805
78806
78807
78811
78812
78813
78814
78815
78816
78890
78891
92135
92235
92240
92250
92285
92286
93303
93304
93307
93308
93312
93313
93314
93315
93316
93317
93318
93320
93321
93325
93350
93555
93556
PO 00000
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
Frm 00331
Short descriptor
Nuclear exam of tear flow.
Kidney imaging, static.
Kidney imaging with flow.
Imaging renogram.
Kidney flow/function image.
Kidney flow/function image.
Kidney flow/function image.
Kidney imaging (3D).
Renal vascular flow exam.
Urinary bladder retention.
Ureteral reflux study.
Testicular imaging.
Testicular imaging/flow.
Tumor imaging, limited area.
Tumor imaging, mult areas.
Tumor imaging, whole body.
Tumor imaging (3D).
Tumor imaging, whole body.
Abscess imaging, ltd area.
Abscess imaging, whole body.
Nuclear localization/abscess.
Tumor imaging (pet), limited.
Tumor image (pet)/skul-thigh.
Tumor image (pet) full body.
Tumor image pet/ct, limited.
Tumorimage pet/ct skul-thigh.
Tumor image pet/ct full body.
Nuclear medicine data proc.
Nuclear med data proc.
Scanning computer ophthalmic.
Fluorscein angioscopy.
IDC green angiography.
Fundus photography.
External ocular photography.
Anterior segment photography.
Echo transthoracic.
Echo transthoracic.
Echo exam of heart.
Echo exam of heart.
Echo transesophageal.
Echo transesophageal.
Echo transesophageal.
Echo transesophageal.
Echo transesophageal.
Echo transesophageal.
Echo transesophageal intraop.
Doppler echo exam, heart.
Doppler echo exam, heart.
Doppler color flow add-on.
Echo transthoracic.
Imaging, cardiac cath.
Imaging, cardiac cath.
Fmt 4701
Sfmt 4701
66551
ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued
HCPCS/
CPT *
93571
93572
93880
93882
93886
93888
93890
93892
93893
93925
93926
93930
93931
93970
93971
93975
93976
93978
93979
93980
93981
93990
0028T
0042T
0066T
0067T
0080T
0081T
0144T
0145T
0146T
0147T
0148T
0149T
0150T
0151T
0152T
G0120
G0122
G0130
G0219
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
........
G0235
G0275
G0278
G0288
G0365
........
........
........
........
........
Short descriptor
Heart flow reserve measure.
Heart flow reserve measure.
Extracranial study.
Extracranial study.
Intracranial study.
Intracranial study.
Tcd, vasoreactivity study.
Tcd, emboli detect w/o inj.
Tcd, emboli detect w/inj.
Lower extremity study.
Lower extremity study.
Upper extremity study.
Upper extremity study.
Extremity study.
Extremity study.
Vascular study.
Vascular study.
Vascular study.
Vascular study.
Penile vascular study.
Penile vascular study.
Doppler flow testing.
Dexa body composition study.
Ct perfusion w/contrast, cbf.
Ct colonography; screen.
Ct colonography; dx.
Endovasc aort repr rad s&i.
Endovasc visc extnsn s&i.
CT heart wo dye; qual calc.
CT heart w/wo dye funct.
CCTA w/wo dye.
CCTA w/wo, quan calcium.
CCTA w/wo, strxr.
CCTA w/wo, strxr quan calc.
CCTA w/wo, disease strxr.
CT heart funct add-on.
Computer chest add-on.
Colon ca scrn; barium enema.
Colon ca scrn; barium enema.
Single energy x-ray study.
PET img wholbod melano
nonco.
PET not otherwise specified.
Renal angio, cardiac cath.
Iliac art angio, cardiac cath.
Recon, CTA for surg plan.
Vessel mapping hemo access.
* CPT codes are descriptors only are copyright 2007 American Medical Association.
All rights reserved.
Applicable FARS/DFARS apply.
E:\FR\FM\27NOR2.SGM
27NOR2
66552
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS
CBSA
code
Urban area
(constituent counties)
Wage
index
10180 .......
Abilene, TX ................................................................................................................................................................................
Callahan County, TX.
Jones County, TX.
Taylor County, TX.
´
Aguadilla-Isabela-San Sebastian, PR .......................................................................................................................................
Aguada Municipio, PR.
Aguadilla Municipio, PR.
˜
Anasco Municipio, PR.
Isabela Municipio, PR.
Lares Municipio, PR.
Moca Municipio, PR.
´
Rincon Municipio, PR.
´
San Sebastian Municipio, PR.
Akron, OH ..................................................................................................................................................................................
Portage County, OH.
Summit County, OH.
Albany, GA ................................................................................................................................................................................
Baker County, GA.
Dougherty County, GA.
Lee County, GA.
Terrell County, GA.
Worth County, GA.
Albany-Schenectady-Troy, NY ..................................................................................................................................................
Albany County, NY.
Rensselaer County, NY.
Saratoga County, NY.
Schenectady County, NY.
Schoharie County, NY.
Albuquerque, NM ......................................................................................................................................................................
Bernalillo County, NM.
Sandoval County, NM.
Torrance County, NM.
Valencia County, NM.
Alexandria, LA ...........................................................................................................................................................................
Grant Parish, LA.
Rapides Parish, LA.
Allentown-Bethlehem-Easton, PA–NJ .......................................................................................................................................
Warren County, NJ.
Carbon County, PA.
Lehigh County, PA.
Northampton County, PA.
Altoona, PA ...............................................................................................................................................................................
Blair County, PA.
Amarillo, TX ...............................................................................................................................................................................
Armstrong County, TX.
Carson County, TX.
Potter County, TX.
Randall County, TX.
Ames, IA ....................................................................................................................................................................................
Story County, IA.
Anchorage, AK ..........................................................................................................................................................................
Anchorage Municipality, AK.
Matanuska-Susitna Borough, AK.
Anderson, IN .............................................................................................................................................................................
Madison County, IN.
Anderson, SC ............................................................................................................................................................................
Anderson County, SC.
Ann Arbor, MI ............................................................................................................................................................................
Washtenaw County, MI.
Anniston-Oxford, AL ..................................................................................................................................................................
Calhoun County, AL.
Appleton, WI ..............................................................................................................................................................................
Calumet County, WI.
Outagamie County, WI.
Asheville, NC .............................................................................................................................................................................
Buncombe County, NC.
Haywood County, NC.
Henderson County, NC.
Madison County, NC.
Athens-Clarke County, GA ........................................................................................................................................................
Clarke County, GA.
0.8398
10380 .......
10420 .......
10500 .......
10580 .......
10740 .......
10780 .......
10900 .......
11020 .......
11100 .......
11180 .......
11260 .......
11300 .......
11340 .......
11460 .......
11500 .......
cprice-sewell on PROD1PC72 with RULES
11540 .......
11700 .......
12020 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00332
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.7916
0.9282
0.8986
0.9064
1.0084
0.8422
1.0412
0.9096
0.9622
1.0603
1.2574
0.9317
0.9590
1.1124
0.8366
1.0130
0.9695
1.1100
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66553
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
12060 .......
12100 .......
12220 .......
12260 .......
12420 .......
12540 .......
12580 .......
12620 .......
12700 .......
cprice-sewell on PROD1PC72 with RULES
12940 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Madison County, GA.
Oconee County, GA.
Oglethorpe County, GA.
Atlanta-Sandy Springs-Marietta, GA .........................................................................................................................................
Barrow County, GA.
Bartow County, GA.
Butts County, GA.
Carroll County, GA.
Cherokee County, GA.
Clayton County, GA.
Cobb County, GA.
Coweta County, GA.
Dawson County, GA.
DeKalb County, GA.
Douglas County, GA.
Fayette County, GA.
Forsyth County, GA.
Fulton County, GA.
Gwinnett County, GA.
Haralson County, GA.
Heard County, GA.
Henry County, GA.
Jasper County, GA.
Lamar County, GA.
Meriwether County, GA.
Newton County, GA.
Paulding County, GA.
Pickens County, GA.
Pike County, GA.
Rockdale County, GA.
Spalding County, GA.
Walton County, GA.
Atlantic City, NJ .........................................................................................................................................................................
Atlantic County, NJ.
Auburn-Opelika, AL ...................................................................................................................................................................
Lee County, AL.
Augusta-Richmond County, GA–SC .........................................................................................................................................
Burke County, GA.
Columbia County, GA.
McDuffie County, GA.
Richmond County, GA.
Aiken County, SC.
Edgefield County, SC.
Austin-Round Rock, TX .............................................................................................................................................................
Bastrop County, TX.
Caldwell County, TX.
Hays County, TX.
Travis County, TX.
Williamson County, TX.
Bakersfield, CA ..........................................................................................................................................................................
Kern County, CA.
Baltimore-Towson, MD ..............................................................................................................................................................
Anne Arundel County, MD.
Baltimore County, MD.
Carroll County, MD.
Harford County, MD.
Howard County, MD.
Queen Anne’s County, MD.
Baltimore City, MD.
Bangor, ME ...............................................................................................................................................................................
Penobscot County, ME.
Barnstable Town, MA ................................................................................................................................................................
Barnstable County, MA.
Baton Rouge, LA .......................................................................................................................................................................
Ascension Parish, LA.
East Baton Rouge Parish, LA.
East Feliciana Parish, LA.
Iberville Parish, LA.
Livingston Parish, LA.
Pointe Coupee Parish, LA.
St. Helena Parish, LA.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00333
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0373
1.2875
0.8539
1.0180
1.0073
1.1664
1.0696
1.0532
1.3302
0.8480
66554
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
12980 .......
13020 .......
13140 .......
13380 .......
13460 .......
13644 .......
13740 .......
13780 .......
13820 .......
13900 .......
13980 .......
14020 .......
14060 .......
14260 .......
14484 .......
14500 .......
14540 .......
14740 .......
cprice-sewell on PROD1PC72 with RULES
14860 .......
15180 .......
15260 .......
15380 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
West Baton Rouge Parish, LA.
West Feliciana Parish, LA.
Battle Creek, MI ........................................................................................................................................................................
Calhoun County, MI.
Bay City, MI ...............................................................................................................................................................................
Bay County, MI.
Beaumont-Port Arthur, TX .........................................................................................................................................................
Hardin County, TX.
Jefferson County, TX.
Orange County, TX.
Bellingham, WA .........................................................................................................................................................................
Whatcom County, WA.
Bend, OR ...................................................................................................................................................................................
Deschutes County, OR.
Bethesda-Frederick-Gaithersburg, MD .....................................................................................................................................
Frederick County, MD.
Montgomery County, MD.
Billings, MT ................................................................................................................................................................................
Carbon County, MT.
Yellowstone County, MT.
Binghamton, NY ........................................................................................................................................................................
Broome County, NY.
Tioga County, NY.
Birmingham-Hoover, AL ............................................................................................................................................................
Bibb County, AL.
Blount County, AL.
Chilton County, AL.
Jefferson County, AL.
St. Clair County, AL.
Shelby County, AL.
Walker County, AL.
Bismarck, ND ............................................................................................................................................................................
Burleigh County, ND.
Morton County, ND.
Blacksburg-Christiansburg-Radford, VA ...................................................................................................................................
Giles County, VA.
Montgomery County, VA.
Pulaski County, VA.
Radford City, VA.
Bloomington, IN .........................................................................................................................................................................
Greene County, IN.
Monroe County, IN.
Owen County, IN.
Bloomington-Normal, IL .............................................................................................................................................................
McLean County, IL.
Boise City-Nampa, ID ................................................................................................................................................................
Ada County, ID.
Boise County, ID.
Canyon County, ID.
Gem County, ID.
Owyhee County, ID.
Boston-Quincy, MA ...................................................................................................................................................................
Norfolk County, MA.
Plymouth County, MA.
Suffolk County, MA.
Boulder, CO ...............................................................................................................................................................................
Boulder County, CO.
Bowling Green, KY ....................................................................................................................................................................
Edmonson County, KY.
Warren County, KY.
Bremerton-Silverdale, WA .........................................................................................................................................................
Kitsap County, WA.
Bridgeport-Stamford-Norwalk, CT .............................................................................................................................................
Fairfield County, CT.
Brownsville-Harlingen, TX .........................................................................................................................................................
Cameron County, TX.
Brunswick, GA ...........................................................................................................................................................................
Brantley County, GA.
Glynn County, GA.
McIntosh County, GA.
Buffalo-Niagara Falls, NY ..........................................................................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00334
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0744
0.9391
0.9004
1.2110
1.1549
1.1094
0.9147
0.9445
0.9392
0.7916
0.8646
0.9410
0.9842
0.9990
1.2285
1.1004
0.8612
1.1509
1.3441
0.9408
1.0001
1.0099
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66555
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
15500 .......
15540 .......
15764 .......
15804 .......
15940 .......
15980 .......
16180 .......
16220 .......
16300 .......
16580 .......
16620 .......
16700 .......
16740 .......
16820 .......
16860 .......
16940 .......
cprice-sewell on PROD1PC72 with RULES
16974 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Erie County, NY.
Niagara County, NY.
Burlington, NC ...........................................................................................................................................................................
Alamance County, NC.
Burlington-South Burlington, VT ................................................................................................................................................
Chittenden County, VT.
Franklin County, VT.
Grand Isle County, VT.
Cambridge-Newton-Framingham, MA .......................................................................................................................................
Middlesex County, MA.
Camden, NJ ..............................................................................................................................................................................
Burlington County, NJ.
Camden County, NJ.
Gloucester County, NJ.
Canton-Massillon, OH ...............................................................................................................................................................
Carroll County, OH.
Stark County, OH.
Cape Coral-Fort Myers, FL .......................................................................................................................................................
Lee County, FL.
Carson City, NV ........................................................................................................................................................................
Carson City, NV.
Casper, WY ...............................................................................................................................................................................
Natrona County, WY.
Cedar Rapids, IA .......................................................................................................................................................................
Benton County, IA.
Jones County, IA.
Linn County, IA.
Champaign-Urbana, IL ..............................................................................................................................................................
Champaign County, IL.
Ford County, IL.
Piatt County, IL.
Charleston, WV .........................................................................................................................................................................
Boone County, WV.
Clay County, WV.
Kanawha County, WV.
Lincoln County, WV.
Putnam County, WV.
Charleston-North Charleston, SC .............................................................................................................................................
Berkeley County, SC.
Charleston County, SC.
Dorchester County, SC.
Charlotte-Gastonia-Concord, NC SC ........................................................................................................................................
Anson County, NC.
Cabarrus County, NC.
Gaston County, NC.
Mecklenburg County, NC.
Union County, NC.
York County, SC.
Charlottesville, VA .....................................................................................................................................................................
Albemarle County, VA.
Fluvanna County, VA.
Greene County, VA.
Nelson County, VA.
Charlottesville City, VA.
Chattanooga, TN–GA ................................................................................................................................................................
Catoosa County, GA.
Dade County, GA.
Walker County, GA.
Hamilton County, TN.
Marion County, TN.
Sequatchie County, TN.
Cheyenne, WY ..........................................................................................................................................................................
Laramie County, WY.
Chicago-Naperville-Joliet, IL .....................................................................................................................................................
Cook County, IL.
DeKalb County, IL.
DuPage County, IL.
Grundy County, IL.
Kane County, IL.
Kendall County, IL.
McHenry County, IL.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00335
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.9232
1.0196
1.1837
1.0989
0.9431
0.9917
1.0558
0.9906
0.9343
0.9913
0.8749
0.9630
1.0048
0.9792
0.9493
0.9824
1.1331
66556
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
17020 .......
17140 .......
17300 .......
17420 .......
17460 .......
17660 .......
17780 .......
17820 .......
17860 .......
17900 .......
17980 .......
18020 .......
cprice-sewell on PROD1PC72 with RULES
18140 .......
18580 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Will County, IL.
Chico, CA ..................................................................................................................................................................................
Butte County, CA.
Cincinnati-Middletown, OH–KY–IN ...........................................................................................................................................
Dearborn County, IN.
Franklin County, IN.
Ohio County, IN.
Boone County, KY.
Bracken County, KY.
Campbell County, KY.
Gallatin County, KY.
Grant County, KY.
Kenton County, KY.
Pendleton County, KY.
Brown County, OH.
Butler County, OH.
Clermont County, OH.
Hamilton County, OH.
Warren County, OH.
Clarksville, TN–KY ....................................................................................................................................................................
Christian County, KY.
Trigg County, KY.
Montgomery County, TN.
Stewart County, TN.
Cleveland, TN ............................................................................................................................................................................
Bradley County, TN.
Polk County, TN.
Cleveland-Elyria-Mentor, OH ....................................................................................................................................................
Cuyahoga County, OH.
Geauga County, OH.
Lake County, OH.
Lorain County, OH.
Medina County, OH.
Coeur d’Alene, ID ......................................................................................................................................................................
Kootenai County, ID.
College Station-Bryan, TX .........................................................................................................................................................
Brazos County, TX.
Burleson County, TX.
Robertson County, TX.
Colorado Springs, CO ...............................................................................................................................................................
El Paso County, CO.
Teller County, CO.
Columbia, MO ...........................................................................................................................................................................
Boone County, MO.
Howard County, MO.
Columbia, SC ............................................................................................................................................................................
Calhoun County, SC.
Fairfield County, SC.
Kershaw County, SC.
Lexington County, SC.
Richland County, SC.
Saluda County, SC.
Columbus, GA–AL .....................................................................................................................................................................
Russell County, AL.
Chattahoochee County, GA.
Harris County, GA.
Marion County, GA.
Muscogee County, GA.
Columbus, IN .............................................................................................................................................................................
Bartholomew County, IN.
Columbus, OH ...........................................................................................................................................................................
Delaware County, OH.
Fairfield County, OH.
Franklin County, OH.
Licking County, OH.
Madison County, OH.
Morrow County, OH.
Pickaway County, OH.
Union County, OH.
Corpus Christi, TX .....................................................................................................................................................................
Aransas County, TX.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00336
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.1916
1.0327
0.8709
0.8499
0.9857
1.0061
0.9877
1.0258
0.9138
0.9288
0.9213
1.0066
1.0644
0.9064
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66557
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
18700 .......
19060 .......
19124 .......
19140 .......
19180 .......
19260 .......
19340 .......
19380 .......
19460 .......
19500 .......
19660 .......
19740 .......
19780 .......
19804 .......
cprice-sewell on PROD1PC72 with RULES
20020 .......
20100 .......
20220 .......
20260 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Nueces County, TX.
San Patricio County, TX.
Corvallis, OR .............................................................................................................................................................................
Benton County, OR.
Cumberland, MD–WV ...............................................................................................................................................................
Allegany County, MD.
Mineral County, WV.
Dallas-Plano-Irving, TX .............................................................................................................................................................
Collin County, TX.
Dallas County, TX.
Delta County, TX.
Denton County, TX.
Ellis County, TX.
Hunt County, TX.
Kaufman County, TX.
Rockwall County, TX.
Dalton, GA .................................................................................................................................................................................
Murray County, GA.
Whitfield County, GA.
Danville, IL .................................................................................................................................................................................
Vermilion County, IL.
Danville, VA ...............................................................................................................................................................................
Pittsylvania County, VA.
Danville City, VA.
Davenport-Moline-Rock Island, IA–IL .......................................................................................................................................
Henry County, IL.
Mercer County, IL.
Rock Island County, IL.
Scott County, IA.
Dayton, OH ................................................................................................................................................................................
Greene County, OH.
Miami County, OH.
Montgomery County, OH.
Preble County, OH.
Decatur, AL ...............................................................................................................................................................................
Lawrence County, AL.
Morgan County, AL.
Decatur, IL .................................................................................................................................................................................
Macon County, IL.
Deltona-Daytona Beach-Ormond Beach, FL ............................................................................................................................
Volusia County, FL.
Denver-Aurora, CO ...................................................................................................................................................................
Adams County, CO.
Arapahoe County, CO.
Broomfield County, CO.
Clear Creek County, CO.
Denver County, CO.
Douglas County, CO.
Elbert County, CO.
Gilpin County, CO.
Jefferson County, CO.
Park County, CO.
Des Moines-West Des Moines, IA ............................................................................................................................................
Dallas County, IA.
Guthrie County, IA.
Madison County, IA.
Polk County, IA.
Warren County, IA.
Detroit-Livonia-Dearborn, MI .....................................................................................................................................................
Wayne County, MI.
Dothan, AL ................................................................................................................................................................................
Geneva County, AL.
Henry County, AL.
Houston County, AL.
Dover, DE ..................................................................................................................................................................................
Kent County, DE.
Dubuque, IA ..............................................................................................................................................................................
Dubuque County, IA.
Duluth, MN–WI ..........................................................................................................................................................................
Carlton County, MN.
St. Louis County, MN.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00337
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.1567
0.8754
1.0465
0.9246
0.9454
0.8697
0.9320
0.9700
0.8322
0.8522
0.9532
1.1313
0.9738
1.0554
0.7916
1.0659
0.9560
1.0528
66558
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
20500 .......
20740 .......
20764 .......
20940 .......
21060 .......
21140 .......
21300 .......
21340 .......
21500 .......
21660 .......
21780 .......
21820 .......
21940 .......
22020 .......
22140 .......
22180 .......
22220 .......
22380 .......
22420 .......
22500 .......
cprice-sewell on PROD1PC72 with RULES
22520 .......
22540 .......
22660 .......
22744 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Douglas County, WI.
Durham, NC ..............................................................................................................................................................................
Chatham County, NC.
Durham County, NC.
Orange County, NC.
Person County, NC.
Eau Claire, WI ...........................................................................................................................................................................
Chippewa County, WI.
Eau Claire County, WI.
Edison, NJ .................................................................................................................................................................................
Middlesex County, NJ.
Monmouth County, NJ.
Ocean County, NJ.
Somerset County, NJ.
El Centro, CA ............................................................................................................................................................................
Imperial County, CA.
Elizabethtown, KY .....................................................................................................................................................................
Hardin County, KY.
Larue County, KY.
Elkhart-Goshen, IN ....................................................................................................................................................................
Elkhart County, IN.
Elmira, NY .................................................................................................................................................................................
Chemung County, NY.
El Paso, TX ...............................................................................................................................................................................
El Paso County, TX.
Erie, PA .....................................................................................................................................................................................
Erie County, PA.
Eugene-Springfield, OR ............................................................................................................................................................
Lane County, OR.
Evansville, IN–KY ......................................................................................................................................................................
Gibson County, IN.
Posey County, IN.
Vanderburgh County, IN.
Warrick County, IN.
Henderson County, KY.
Webster County, KY.
Fairbanks, AK ............................................................................................................................................................................
Fairbanks North Star Borough, AK.
Fajardo, PR ...............................................................................................................................................................................
Ceiba Municipio, PR.
Fajardo Municipio, PR.
Luquillo Municipio, PR.
Fargo, ND–MN ..........................................................................................................................................................................
Cass County, ND.
Clay County, MN.
Farmington, NM .........................................................................................................................................................................
San Juan County, NM.
Fayetteville, NC .........................................................................................................................................................................
Cumberland County, NC.
Hoke County, NC.
Fayetteville-Springdale-Rogers, AR–MO ..................................................................................................................................
Benton County, AR.
Madison County, AR.
Washington County, AR.
McDonald County, MO.
Flagstaff, AZ ..............................................................................................................................................................................
Coconino County, AZ.
Flint, MI ......................................................................................................................................................................................
Genesee County, MI.
Florence, SC .............................................................................................................................................................................
Darlington County, SC.
Florence County, SC.
Florence-Muscle Shoals, AL .....................................................................................................................................................
Colbert County, AL.
Lauderdale County, AL.
Fond du Lac, WI ........................................................................................................................................................................
Fond du Lac County, WI.
Fort Collins-Loveland, CO .........................................................................................................................................................
Larimer County, CO.
Fort Lauderdale-Pompano Beach-Deerfield Beach, FL ............................................................................................................
Broward County, FL.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00338
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0361
1.0001
1.1801
0.9408
0.9194
1.0144
0.8722
0.9488
0.8966
1.1538
0.9143
1.1663
0.7916
0.8488
1.0119
0.9888
0.9227
1.2335
1.1842
0.8707
0.8106
1.0203
1.0446
1.0796
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66559
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
22900 .......
Fort Smith, AR–OK ...................................................................................................................................................................
Crawford County, AR.
Franklin County, AR.
Sebastian County, AR.
Le Flore County, OK.
Sequoyah County, OK.
Fort Walton Beach-Crestview-Destin, FL ..................................................................................................................................
Okaloosa County, FL.
Fort Wayne, IN ..........................................................................................................................................................................
Allen County, IN.
Wells County, IN.
Whitley County, IN.
Fort Worth-Arlington, TX ...........................................................................................................................................................
Johnson County, TX.
Parker County, TX.
Tarrant County, TX.
Wise County, TX.
Fresno, CA ................................................................................................................................................................................
Fresno County, CA.
Gadsden, AL .............................................................................................................................................................................
Etowah County, AL.
Gainesville, FL ...........................................................................................................................................................................
Alachua County, FL.
Gilchrist County, FL.
Gainesville, GA ..........................................................................................................................................................................
Hall County, GA.
Gary, IN .....................................................................................................................................................................................
Jasper County, IN.
Lake County, IN.
Newton County, IN.
Porter County, IN.
Glens Falls, NY .........................................................................................................................................................................
Warren County, NY.
Washington County, NY.
Goldsboro, NC ...........................................................................................................................................................................
Wayne County, NC.
Grand Forks, ND–MN ...............................................................................................................................................................
Polk County, MN.
Grand Forks County, ND.
Grand Junction, CO ..................................................................................................................................................................
Mesa County, CO.
Grand Rapids-Wyoming, MI ......................................................................................................................................................
Barry County, MI.
Ionia County, MI.
Kent County, MI.
Newaygo County, MI.
Great Falls, MT .........................................................................................................................................................................
Cascade County, MT.
Greeley, CO ..............................................................................................................................................................................
Weld County, CO.
Green Bay, WI ...........................................................................................................................................................................
Brown County, WI.
Kewaunee County, WI.
Oconto County, WI.
Greensboro-High Point, NC ......................................................................................................................................................
Guilford County, NC.
Randolph County, NC.
Rockingham County, NC.
Greenville, NC ...........................................................................................................................................................................
Greene County, NC.
Pitt County, NC.
Greenville-Maudlin-Easley, SC .................................................................................................................................................
Greenville County, SC.
Laurens County, SC.
Pickens County, SC.
Guayama, PR ............................................................................................................................................................................
Arroyo Municipio, PR.
Guayama Municipio, PR.
Patillas Municipio, PR.
Gulfport-Biloxi, MS ....................................................................................................................................................................
Hancock County, MS.
0.8373
23020 .......
23060 .......
23104 .......
23420 .......
23460 .......
23540 .......
23580 .......
23844 .......
24020 .......
24140 .......
24220 .......
24300 .......
24340 .......
24500 .......
24540 .......
24580 .......
24660 .......
24780 .......
cprice-sewell on PROD1PC72 with RULES
24860 .......
25020 .......
25060 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00339
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.9228
0.9799
1.0231
1.1603
0.8612
0.9706
0.9727
0.9736
0.8714
0.9803
0.8318
1.0411
0.9832
0.9156
1.0194
1.0267
0.9510
0.9924
1.0407
0.7916
0.9260
66560
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
25180 .......
25260 .......
25420 .......
25500 .......
25540 .......
25620 .......
25860 .......
25980 .......
26100 .......
26180 .......
26300 .......
26380 .......
26420 .......
26580 .......
26620 .......
cprice-sewell on PROD1PC72 with RULES
26820 .......
26900 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Harrison County, MS.
Stone County, MS.
Hagerstown-Martinsburg, MD–WV ............................................................................................................................................
Washington County, MD.
Berkeley County, WV.
Morgan County, WV.
Hanford-Corcoran, CA ...............................................................................................................................................................
Kings County, CA.
Harrisburg-Carlisle, PA ..............................................................................................................................................................
Cumberland County, PA.
Dauphin County, PA.
Perry County, PA.
Harrisonburg, VA .......................................................................................................................................................................
Rockingham County, VA.
Harrisonburg City, VA.
Hartford-West Hartford-East Hartford, CT ................................................................................................................................
Hartford County, CT.
Litchfield County, CT.
Middlesex County, CT.
Tolland County, CT.
Hattiesburg, MS .........................................................................................................................................................................
Forrest County, MS.
Lamar County, MS.
Perry County, MS.
Hickory-Lenoir-Morganton, NC ..................................................................................................................................................
Alexander County, NC.
Burke County, NC.
Caldwell County, NC.
Catawba County, NC.
Hinesville-Fort Stewart, GA 3 .....................................................................................................................................................
Liberty County, GA.
Long County, GA.
Holland-Grand Haven, MI .........................................................................................................................................................
Ottawa County, MI.
Honolulu, HI ...............................................................................................................................................................................
Honolulu County, HI.
Hot Springs, AR ........................................................................................................................................................................
Garland County, AR.
Houma-Bayou Cane-Thibodaux, LA .........................................................................................................................................
Lafourche Parish, LA.
Terrebonne Parish, LA.
Houston-Sugar Land-Baytown, TX ...........................................................................................................................................
Austin County, TX.
Brazoria County, TX.
Chambers County, TX.
Fort Bend County, TX.
Galveston County, TX.
Harris County, TX.
Liberty County, TX.
Montgomery County, TX.
San Jacinto County, TX.
Waller County, TX.
Huntington-Ashland, WV–KY–OH .............................................................................................................................................
Boyd County, KY.
Greenup County, KY.
Lawrence County, OH.
Cabell County, WV.
Wayne County, WV.
Huntsville, AL ............................................................................................................................................................................
Limestone County, AL.
Madison County, AL.
Idaho Falls, ID ...........................................................................................................................................................................
Bonneville County, ID.
Jefferson County, ID.
Indianapolis-Carmel, IN .............................................................................................................................................................
Boone County, IN.
Brown County, IN.
Hamilton County, IN.
Hancock County, IN.
Hendricks County, IN.
Johnson County, IN.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00340
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.9513
1.1081
0.9795
0.9359
1.1536
0.7916
0.9529
0.9697
0.9506
1.2197
0.9614
0.8330
1.0490
0.9543
0.9653
0.9778
1.0390
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66561
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
26980 .......
27060 .......
27100 .......
27140 .......
27180 .......
27260 .......
27340 .......
27500 .......
27620 .......
27740 .......
27780 .......
27860 .......
27900 .......
28020 .......
28100 .......
cprice-sewell on PROD1PC72 with RULES
28140 .......
28420 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Marion County, IN.
Morgan County, IN.
Putnam County, IN.
Shelby County, IN.
Iowa City, IA ..............................................................................................................................................................................
Johnson County, IA.
Washington County, IA.
Ithaca, NY ..................................................................................................................................................................................
Tompkins County, NY.
Jackson, MI ...............................................................................................................................................................................
Jackson County, MI.
Jackson, MS ..............................................................................................................................................................................
Copiah County, MS.
Hinds County, MS.
Madison County, MS.
Rankin County, MS.
Simpson County, MS.
Jackson, TN ..............................................................................................................................................................................
Chester County, TN.
Madison County, TN.
Jacksonville, FL .........................................................................................................................................................................
Baker County, FL.
Clay County, FL.
Duval County, FL.
Nassau County, FL.
St. Johns County, FL.
Jacksonville, NC ........................................................................................................................................................................
Onslow County, NC.
Janesville, WI ............................................................................................................................................................................
Rock County, WI.
Jefferson City, MO ....................................................................................................................................................................
Callaway County, MO.
Cole County, MO.
Moniteau County, MO.
Osage County, MO.
Johnson City, TN .......................................................................................................................................................................
Carter County, TN.
Unicoi County, TN.
Washington County, TN.
Johnstown, PA ..........................................................................................................................................................................
Cambria County, PA.
Jonesboro, AR ...........................................................................................................................................................................
Craighead County, AR.
Poinsett County, AR.
Joplin, MO .................................................................................................................................................................................
Jasper County, MO.
Newton County, MO.
Kalamazoo-Portage, MI .............................................................................................................................................................
Kalamazoo County, MI.
Van Buren County, MI.
Kankakee-Bradley, IL ................................................................................................................................................................
Kankakee County, IL.
Kansas City, MO–KS ................................................................................................................................................................
Franklin County, KS.
Johnson County, KS.
Leavenworth County, KS.
Linn County, KS.
Miami County, KS.
Wyandotte County, KS.
Bates County, MO.
Caldwell County, MO.
Cass County, MO.
Clay County, MO.
Clinton County, MO.
Jackson County, MO.
Lafayette County, MO.
Platte County, MO.
Ray County, MO.
Kennewick-Richland-Pasco, WA ...............................................................................................................................................
Benton County, WA.
Franklin County, WA.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00341
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0099
1.0164
0.9847
0.8455
0.9157
0.9521
0.8527
1.0240
0.8948
0.8103
0.7961
0.8222
0.9448
1.1012
1.0806
1.0031
1.0634
66562
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
28660 .......
Killeen-Temple-Fort Hood, TX ..................................................................................................................................................
Bell County, TX.
Coryell County, TX.
Lampasas County, TX.
Kingsport-Bristol-Bristol, TN–VA ...............................................................................................................................................
Hawkins County, TN.
Sullivan County, TN.
Bristol City, VA.
Scott County, VA.
Washington County, VA.
Kingston, NY .............................................................................................................................................................................
Ulster County, NY.
Knoxville, TN .............................................................................................................................................................................
Anderson County, TN.
Blount County, TN.
Knox County, TN.
Loudon County, TN.
Union County, TN.
Kokomo, IN ................................................................................................................................................................................
Howard County, IN.
Tipton County, IN.
La Crosse, WI–MN ....................................................................................................................................................................
Houston County, MN.
La Crosse County, WI.
Lafayette, IN ..............................................................................................................................................................................
Benton County, IN.
Carroll County, IN.
Tippecanoe County, IN.
Lafayette, LA .............................................................................................................................................................................
Lafayette Parish, LA.
St. Martin Parish, LA.
Lake Charles, LA .......................................................................................................................................................................
Calcasieu Parish, LA.
Cameron Parish, LA.
Lake County-Kenosha County, IL–WI .......................................................................................................................................
Lake County, IL.
Kenosha County, WI.
Lake Havasu City—Kingman, AZ .............................................................................................................................................
Mohave, County, AZ.
Lakeland, FL ..............................................................................................................................................................................
Polk County, FL.
Lancaster, PA ............................................................................................................................................................................
Lancaster County, PA.
Lansing-East Lansing, MI ..........................................................................................................................................................
Clinton County, MI.
Eaton County, MI.
Ingham County, MI.
Laredo, TX .................................................................................................................................................................................
Webb County, TX.
Las Cruces, NM ........................................................................................................................................................................
Dona Ana County, NM.
Las Vegas-Paradise, NV ...........................................................................................................................................................
Clark County, NV.
Lawrence, KS ............................................................................................................................................................................
Douglas County, KS.
Lawton, OK ................................................................................................................................................................................
Comanche County, OK.
Lebanon, PA ..............................................................................................................................................................................
Lebanon County, PA.
Lewiston, ID–WA .......................................................................................................................................................................
Nez Perce County, ID.
Asotin County, WA.
Lewiston-Auburn, ME ................................................................................................................................................................
Androscoggin County, ME.
Lexington-Fayette, KY ...............................................................................................................................................................
Bourbon County, KY.
Clark County, KY.
Fayette County, KY.
Jessamine County, KY.
Scott County, KY.
Woodford County, KY.
0.8707
28700 .......
28740 .......
28940 .......
29020 .......
29100 .......
29140 .......
29180 .......
29340 .......
29404 .......
29420 .......
29460 .......
29540 .......
29620 .......
29700 .......
29740 .......
29820 .......
29940 .......
30020 .......
30140 .......
30300 .......
cprice-sewell on PROD1PC72 with RULES
30340 .......
30460 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00342
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.8083
1.0086
0.8482
1.0123
1.0222
0.9361
0.8704
0.8208
1.0887
0.9851
0.9141
0.9765
1.0680
0.8542
0.9157
1.2454
0.8683
0.8470
0.8646
0.9978
0.9703
0.9701
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66563
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
30620 .......
Lima, OH ...................................................................................................................................................................................
Allen County, OH.
Lincoln, NE ................................................................................................................................................................................
Lancaster County, NE.
Seward County, NE.
Little Rock-North Little Rock-Conway, AR ................................................................................................................................
Faulkner County, AR.
Grant County, AR.
Lonoke County, AR.
Perry County, AR.
Pulaski County, AR.
Saline County, AR.
Logan, UT–ID ............................................................................................................................................................................
Franklin County, ID.
Cache County, UT.
Longview, TX .............................................................................................................................................................................
Gregg County, TX.
Rusk County, TX.
Upshur County, TX.
Longview, WA ...........................................................................................................................................................................
Cowlitz County, WA.
Los Angeles-Long Beach-Glendale, CA ...................................................................................................................................
Los Angeles County, CA.
Louisville-Jefferson County, KY–IN ...........................................................................................................................................
Clark County, IN.
Floyd County, IN.
Harrison County, IN.
Washington County, IN.
Bullitt County, KY.
Henry County, KY.
Jefferson County, KY.
Meade County, KY.
Nelson County, KY.
Oldham County, KY.
Shelby County, KY.
Spencer County, KY.
Trimble County, KY.
Lubbock, TX ..............................................................................................................................................................................
Crosby County, TX.
Lubbock County, TX.
Lynchburg, VA ...........................................................................................................................................................................
Amherst County, VA.
Appomattox County, VA.
Bedford County, VA.
Campbell County, VA.
Bedford City, VA.
Lynchburg City, VA.
Macon, GA ................................................................................................................................................................................
Bibb County, GA.
Crawford County, GA.
Jones County, GA.
Monroe County, GA.
Twiggs County, GA.
Madera, CA ...............................................................................................................................................................................
Madera County, CA.
Madison, WI ..............................................................................................................................................................................
Columbia County, WI.
Dane County, WI.
Iowa County, WI.
Manchester-Nashua, NH ...........................................................................................................................................................
Hillsborough County, NH.
Merrimack County, NH.
Mansfield, OH 1 .........................................................................................................................................................................
Richland County, OH.
¨
Mayaguez, PR ...........................................................................................................................................................................
Hormigueros Municipio, PR.
¨
Mayaguez Municipio, PR.
McAllen-Edinburg-Mission, TX ..................................................................................................................................................
Hidalgo County, TX.
Medford, OR ..............................................................................................................................................................................
Jackson County, OR.
0.9947
30700 .......
30780 .......
30860 .......
30980 .......
31020 .......
31084 .......
31140 .......
31180 .......
31340 .......
31420 .......
31460 .......
31540 .......
31700 .......
cprice-sewell on PROD1PC72 with RULES
31900 .......
32420 .......
32580 .......
32780 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00343
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0609
0.9355
0.9692
0.9201
1.1428
1.2424
0.9568
0.9162
0.9216
1.0070
0.8517
1.1542
1.0621
0.9785
0.7916
0.9629
1.0890
66564
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
32820 .......
Memphis, TN–MS–AR ...............................................................................................................................................................
Crittenden County, AR.
DeSoto County, MS.
Marshall County, MS.
Tate County, MS.
Tunica County, MS.
Fayette County, TN.
Shelby County, TN.
Tipton County, TN.
Merced, CA ...............................................................................................................................................................................
Merced County, CA.
Miami-Miami Beach-Kendall, FL ...............................................................................................................................................
Miami-Dade County, FL.
Michigan City-La Porte, IN ........................................................................................................................................................
LaPorte County, IN.
Midland, TX ...............................................................................................................................................................................
Midland County, TX.
Milwaukee-Waukesha-West Allis, WI ........................................................................................................................................
Milwaukee County, WI.
Ozaukee County, WI.
Washington County, WI.
Waukesha County, WI.
Minneapolis-St. Paul-Bloomington, MN–WI ..............................................................................................................................
Anoka County, MN.
Carver County, MN.
Chisago County, MN.
Dakota County, MN.
Hennepin County, MN.
Isanti County, MN.
Ramsey County, MN.
Scott County, MN.
Sherburne County, MN.
Washington County, MN.
Wright County, MN.
Pierce County, WI.
St. Croix County, WI.
Missoula, MT .............................................................................................................................................................................
Missoula County, MT.
Mobile, AL .................................................................................................................................................................................
Mobile County, AL.
Modesto, CA ..............................................................................................................................................................................
Stanislaus County, CA.
Monroe, LA ................................................................................................................................................................................
Ouachita Parish, LA.
Union Parish, LA.
Monroe, MI ................................................................................................................................................................................
Monroe County, MI.
Montgomery, AL ........................................................................................................................................................................
Autauga County, AL.
Elmore County, AL.
Lowndes County, AL.
Montgomery County, AL.
Morgantown, WV .......................................................................................................................................................................
Monongalia County, WV.
Preston County, WV.
Morristown, TN ..........................................................................................................................................................................
Grainger County, TN.
Hamblen County, TN.
Jefferson County, TN.
Mount Vernon-Anacortes, WA ..................................................................................................................................................
Skagit County, WA.
Muncie, IN .................................................................................................................................................................................
Delaware County, IN.
Muskegon-Norton Shores, MI ...................................................................................................................................................
Muskegon County, MI.
Myrtle Beach-Conway-North Myrtle Beach, SC ........................................................................................................................
Horry County, SC.
Napa, CA ...................................................................................................................................................................................
Napa County, CA.
Naples-Marco Island, FL ...........................................................................................................................................................
Collier County, FL.
0.9763
32900 .......
33124 .......
33140 .......
33260 .......
33340 .......
33460 .......
33540 .......
33660 .......
33700 .......
33740 .......
33780 .......
33860 .......
34060 .......
34100 .......
34580 .......
34620 .......
cprice-sewell on PROD1PC72 with RULES
34740 .......
34820 .......
34900 .......
34940 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00344
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.2792
1.0557
0.9408
1.0573
1.0781
1.1708
0.9450
0.8479
1.2626
0.8266
0.9936
0.8537
0.8783
0.7916
1.1113
0.8670
1.0382
0.9113
1.5279
1.0013
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66565
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
34980 .......
Nashville-Davidson-Murfreesboro, TN ......................................................................................................................................
Cannon County, TN.
Cheatham County, TN.
Davidson County, TN.
Dickson County, TN.
Hickman County, TN.
Macon County, TN.
Robertson County, TN.
Rutherford County, TN.
Smith County, TN.
Sumner County, TN.
Trousdale County, TN.
Williamson County, TN.
Wilson County, TN.
Nassau-Suffolk, NY ...................................................................................................................................................................
Nassau County, NY.
Suffolk County, NY.
Newark-Union, NJ–PA ..............................................................................................................................................................
Essex County, NJ.
Hunterdon County, NJ.
Morris County, NJ.
Sussex County, NJ.
Union County, NJ.
Pike County, PA.
New Haven-Milford, CT .............................................................................................................................................................
New Haven County, CT.
New Orleans-Metairie-Kenner, LA ............................................................................................................................................
Jefferson Parish, LA.
Orleans Parish, LA.
Plaquemines Parish, LA.
St. Bernard Parish, LA.
St. Charles Parish, LA.
St. John the Baptist Parish, LA.
St. Tammany Parish, LA.
New York-Wayne-White Plains, NY–NJ ...................................................................................................................................
Bergen County, NJ.
Hudson County, NJ.
Passaic County, NJ.
Bronx County, NY.
Kings County, NY.
New York County, NY.
Putnam County, NY.
Queens County, NY.
Richmond County, NY.
Rockland County, NY.
Westchester County, NY.
Niles-Benton Harbor, MI ............................................................................................................................................................
Berrien County, MI.
Norwich-New London, CT .........................................................................................................................................................
New London County, CT.
Oakland-Fremont-Hayward, CA ................................................................................................................................................
Alameda County, CA.
Contra Costa County, CA.
Ocala, FL ...................................................................................................................................................................................
Marion County, FL.
Ocean City, NJ ..........................................................................................................................................................................
Cape May County, NJ.
Odessa, TX ...............................................................................................................................................................................
Ector County, TX.
Ogden-Clearfield, UT ................................................................................................................................................................
Davis County, UT.
Morgan County, UT.
Weber County, UT.
Oklahoma City, OK ...................................................................................................................................................................
Canadian County, OK.
Cleveland County, OK.
Grady County, OK.
Lincoln County, OK.
Logan County, OK.
McClain County, OK.
Oklahoma County, OK.
1.0226
35004 .......
35084 .......
35300 .......
35380 .......
35644 .......
35660 .......
35980 .......
36084 .......
36100 .......
36140 .......
36220 .......
36260 .......
cprice-sewell on PROD1PC72 with RULES
36420 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00345
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.3341
1.2520
1.2530
0.9391
1.3843
0.9648
1.2066
1.6555
0.9106
1.1598
1.0599
0.9499
0.9304
66566
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
36500 .......
Olympia, WA .............................................................................................................................................................................
Thurston County, WA.
Omaha-Council Bluffs, NE–IA ...................................................................................................................................................
Harrison County, IA.
Mills County, IA.
Pottawattamie County, IA.
Cass County, NE.
Douglas County, NE.
Sarpy County, NE.
Saunders County, NE.
Washington County, NE.
Orlando-Kissimmee, FL .............................................................................................................................................................
Lake County, FL.
Orange County, FL.
Osceola County, FL.
Seminole County, FL.
Oshkosh-Neenah, WI ................................................................................................................................................................
Winnebago County, WI.
Owensboro, KY .........................................................................................................................................................................
Daviess County, KY.
Hancock County, KY.
McLean County, KY.
Oxnard-Thousand Oaks-Ventura, CA .......................................................................................................................................
Ventura County, CA.
Palm Bay-Melbourne-Titusville, FL ...........................................................................................................................................
Brevard County, FL.
Palm Coast, FL .........................................................................................................................................................................
Flagler County, FL.
Panama City-Lynn Haven, FL ...................................................................................................................................................
Bay County, FL.
Parkersburg-Marietta-Vienna, WV–OH .....................................................................................................................................
Washington County, OH.
Pleasants County, WV.
Wirt County, WV.
Wood County, WV.
Pascagoula, MS ........................................................................................................................................................................
George County, MS.
Jackson County, MS.
Peabody, MA .............................................................................................................................................................................
Essex County, MA.
Pensacola-Ferry Pass-Brent, FL ...............................................................................................................................................
Escambia County, FL.
Santa Rosa County, FL.
Peoria, IL ...................................................................................................................................................................................
Marshall County, IL.
Peoria County, IL.
Stark County, IL.
Tazewell County, IL.
Woodford County, IL.
Philadelphia, PA ........................................................................................................................................................................
Bucks County, PA.
Chester County, PA.
Delaware County, PA.
Montgomery County, PA.
Philadelphia County, PA.
Phoenix-Mesa-Scottsdale, AZ ...................................................................................................................................................
Maricopa County, AZ.
Pinal County, AZ.
Pine Bluff, AR ............................................................................................................................................................................
Cleveland County, AR.
Jefferson County, AR.
Lincoln County, AR.
Pittsburgh, PA ...........................................................................................................................................................................
Allegheny County, PA.
Armstrong County, PA.
Beaver County, PA.
Butler County, PA.
Fayette County, PA.
Washington County, PA.
Westmoreland County, PA.
Pittsfield, MA .............................................................................................................................................................................
1.2151
36540 .......
36740 .......
36780 .......
36980 .......
37100 .......
37340 .......
37380 .......
37460 .......
37620 .......
37700 .......
37764 .......
37860 .......
37900 .......
37964 .......
38060 .......
38220 .......
cprice-sewell on PROD1PC72 with RULES
38300 .......
38340 .......
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00346
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.0091
0.9738
1.0081
0.9132
1.2509
0.9842
0.9441
0.8774
0.8555
0.9127
1.1241
0.8740
0.9815
1.1531
1.0833
0.8274
0.8998
1.0651
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66567
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
38540 .......
38660 .......
38860 .......
38900 .......
38940 .......
39100 .......
39140 .......
39300 .......
39340 .......
39380 .......
39460 .......
39540 .......
39580 .......
39660 .......
39740 .......
39820 .......
39900 .......
cprice-sewell on PROD1PC72 with RULES
40060 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Berkshire County, MA.
Pocatello, ID ..............................................................................................................................................................................
Bannock County, ID.
Power County, ID.
Ponce, PR .................................................................................................................................................................................
´
Juana Dıaz Municipio, PR.
Ponce Municipio, PR.
Villalba Municipio, PR.
Portland-South Portland-Biddeford, ME ....................................................................................................................................
Cumberland County, ME.
Sagadahoc County, ME.
York County, ME.
Portland-Vancouver-Beaverton, OR–WA ..................................................................................................................................
Clackamas County, OR.
Columbia County, OR.
Multnomah County, OR.
Washington County, OR.
Yamhill County, OR.
Clark County, WA.
Skamania County, WA.
Port St. Lucie, FL ......................................................................................................................................................................
Martin County, FL.
St. Lucie County, FL.
Poughkeepsie-Newburgh-Middletown, NY ................................................................................................................................
Dutchess County, NY.
Orange County, NY.
Prescott, AZ ...............................................................................................................................................................................
Yavapai County, AZ.
Providence-New Bedford-Fall River, RI–MA .............................................................................................................................
Bristol County, MA.
Bristol County, RI.
Kent County, RI.
Newport County, RI.
Providence County, RI.
Washington County, RI.
Provo-Orem, UT ........................................................................................................................................................................
Juab County, UT.
Utah County, UT.
Pueblo, CO ................................................................................................................................................................................
Pueblo County, CO.
Punta Gorda, FL ........................................................................................................................................................................
Charlotte County, FL.
Racine, WI .................................................................................................................................................................................
Racine County, WI.
Raleigh-Cary, NC ......................................................................................................................................................................
Franklin County, NC.
Johnston County, NC.
Wake County, NC.
Rapid City, SD ...........................................................................................................................................................................
Meade County, SD.
Pennington County, SD.
Reading, PA ..............................................................................................................................................................................
Berks County, PA.
Redding, CA ..............................................................................................................................................................................
Shasta County, CA.
Reno-Sparks, NV ......................................................................................................................................................................
Storey County, NV.
Washoe County, NV.
Richmond, VA ...........................................................................................................................................................................
Amelia County, VA.
Caroline County, VA.
Charles City County, VA.
Chesterfield County, VA.
Cumberland County, VA.
Dinwiddie County, VA.
Goochland County, VA.
Hanover County, VA.
Henrico County, VA.
King and Queen County, VA.
King William County, VA.
Louisa County, VA.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00347
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.9990
0.7916
1.0599
1.2136
1.0572
1.1591
1.0576
1.1278
1.0087
0.9342
0.9767
1.0025
1.0385
0.9300
0.9875
1.4292
1.1309
0.9948
66568
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
40140 .......
40220 .......
40340 .......
40380 .......
40420 .......
40484 .......
40580 .......
40660 .......
40900 .......
40980 .......
41060 .......
41100 .......
41140 .......
cprice-sewell on PROD1PC72 with RULES
41180 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
New Kent County, VA.
Powhatan County, VA.
Prince George County, VA.
Sussex County, VA.
Colonial Heights City, VA.
Hopewell City, VA.
Petersburg City, VA.
Richmond City, VA.
Riverside-San Bernardino-Ontario, CA .....................................................................................................................................
Riverside County, CA.
San Bernardino County, CA.
Roanoke, VA .............................................................................................................................................................................
Botetourt County, VA.
Craig County, VA.
Franklin County, VA.
Roanoke County, VA.
Roanoke City, VA.
Salem City, VA.
Rochester, MN ..........................................................................................................................................................................
Dodge County, MN.
Olmsted County, MN.
Wabasha County, MN.
Rochester, NY ...........................................................................................................................................................................
Livingston County, NY.
Monroe County, NY.
Ontario County, NY.
Orleans County, NY.
Wayne County, NY.
Rockford, IL ...............................................................................................................................................................................
Boone County, IL.
Winnebago County, IL.
Rockingham County-Strafford County, NH ...............................................................................................................................
Rockingham County, NH.
Strafford County, NH.
Rocky Mount, NC ......................................................................................................................................................................
Edgecombe County, NC.
Nash County, NC.
Rome, GA ..................................................................................................................................................................................
Floyd County, GA.
Sacramento-Arden-Arcade-Roseville, CA .................................................................................................................................
El Dorado County, CA.
Placer County, CA.
Sacramento County, CA.
Yolo County, CA.
Saginaw-Saginaw Township North, MI .....................................................................................................................................
Saginaw County, MI.
St. Cloud, MN ............................................................................................................................................................................
Benton County, MN.
Stearns County, MN.
St. George, UT ..........................................................................................................................................................................
Washington County, UT.
St. Joseph, MO–KS ...................................................................................................................................................................
Doniphan County, KS.
Andrew County, MO.
Buchanan County, MO.
DeKalb County, MO.
St. Louis, MO–IL .......................................................................................................................................................................
Bond County, IL.
Calhoun County, IL.
Clinton County, IL.
Jersey County, IL.
Macoupin County, IL.
Madison County, IL.
Monroe County, IL.
St. Clair County, IL.
Crawford County, MO.
Franklin County, MO.
Jefferson County, MO.
Lincoln County, MO.
St. Charles County, MO.
St. Louis County, MO.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00348
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.1716
0.9173
1.1352
0.9349
1.0358
1.0672
0.9500
0.9544
1.4254
0.9301
1.1134
0.9877
0.9248
0.9525
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66569
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
41420 .......
41500 .......
41540 .......
41620 .......
41660 .......
41700 .......
41740 .......
41780 .......
41884 .......
41900 .......
41940 .......
cprice-sewell on PROD1PC72 with RULES
41980 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Warren County, MO.
Washington County, MO.
St. Louis City, MO.
Salem, OR .................................................................................................................................................................................
Marion County, OR.
Polk County, OR.
Salinas, CA ................................................................................................................................................................................
Monterey County, CA.
Salisbury, MD ............................................................................................................................................................................
Somerset County, MD.
Wicomico County, MD.
Salt Lake City, UT .....................................................................................................................................................................
Salt Lake County, UT.
Summit County, UT.
Tooele County, UT.
San Angelo, TX .........................................................................................................................................................................
Irion County, TX.
Tom Green County, TX.
San Antonio, TX ........................................................................................................................................................................
Atascosa County, TX.
Bandera County, TX.
Bexar County, TX.
Comal County, TX.
Guadalupe County, TX.
Kendall County, TX.
Medina County, TX.
Wilson County, TX.
San Diego-Carlsbad-San Marcos, CA ......................................................................................................................................
San Diego County, CA.
Sandusky, OH ...........................................................................................................................................................................
Erie County, OH.
San Francisco-San Mateo-Redwood City, CA ..........................................................................................................................
Marin County, CA.
San Francisco County, CA.
San Mateo County, CA.
´
San German-Cabo Rojo, PR ....................................................................................................................................................
Cabo Rojo Municipio, PR.
Lajas Municipio, PR.
Sabana Grande Municipio, PR.
´
San German Municipio, PR.
San Jose-Sunnyvale-Santa Clara, CA ......................................................................................................................................
San Benito County, CA.
Santa Clara County, CA.
San Juan-Caguas-Guaynabo, PR .............................................................................................................................................
Aguas Buenas Municipio, PR.
Aibonito Municipio, PR.
Arecibo Municipio, PR.
Barceloneta Municipio, PR.
Barranquitas Municipio, PR.
´
Bayamon Municipio, PR.
Caguas Municipio, PR.
Camuy Municipio, PR.
´
Canovanas Municipio, PR.
Carolina Municipio, PR.
˜
Catano Municipio, PR.
Cayey Municipio, PR.
Ciales Municipio, PR.
Cidra Municipio, PR.
´
Comerıo Municipio, PR.
Corozal Municipio, PR.
Dorado Municipio, PR.
Florida Municipio, PR.
Guaynabo Municipio, PR.
Gurabo Municipio, PR.
Hatillo Municipio, PR.
Humacao Municipio, PR.
Juncos Municipio, PR.
Las Piedras Municipio, PR.
´
Loıza Municipio, PR.
´
Manatı Municipio, PR.
Maunabo Municipio, PR.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00349
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.1158
1.5595
0.9493
0.9920
0.9055
0.9324
1.2129
0.9311
1.6038
0.7916
1.6608
0.7916
66570
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
42020 .......
42044 .......
42060 .......
42100 .......
42140 .......
42220 .......
42260 .......
42340 .......
42540 .......
42644 .......
42680 .......
43100 .......
43300 .......
43340 .......
43580 .......
43620 .......
43780 .......
cprice-sewell on PROD1PC72 with RULES
43900 .......
44060 .......
44100 .......
44140 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Morovis Municipio, PR.
Naguabo Municipio, PR.
Naranjito Municipio, PR.
Orocovis Municipio, PR.
Quebradillas Municipio, PR.
´
Rıo Grande Municipio, PR.
San Juan Municipio, PR.
San Lorenzo Municipio, PR.
Toa Alta Municipio, PR.
Toa Baja Municipio, PR.
Trujillo Alto Municipio, PR.
Vega Alta Municipio, PR.
Vega Baja Municipio, PR.
Yabucoa Municipio, PR.
San Luis Obispo-Paso Robles, CA ...........................................................................................................................................
San Luis Obispo County, CA.
Santa Ana-Anaheim-Irvine, CA .................................................................................................................................................
Orange County, CA.
Santa Barbara-Santa Maria-Goleta, CA ...................................................................................................................................
Santa Barbara County, CA.
Santa Cruz-Watsonville, CA ......................................................................................................................................................
Santa Cruz County, CA.
Santa Fe, NM ............................................................................................................................................................................
Santa Fe County, NM.
Santa Rosa-Petaluma, CA ........................................................................................................................................................
Sonoma County, CA.
Sarasota-Bradenton-Venice, FL ................................................................................................................................................
Manatee County, FL.
Sarasota County, FL.
Savannah, GA ...........................................................................................................................................................................
Bryan County, GA.
Chatham County, GA.
Effingham County, GA.
Scranton-Wilkes-Barre, PA .......................................................................................................................................................
Lackawanna County, PA.
Luzerne County, PA.
Wyoming County, PA.
Seattle-Bellevue-Everett, WA ....................................................................................................................................................
King County, WA.
Snohomish County, WA.
Sebastian-Vero Beach, FL ........................................................................................................................................................
Indian River County, FL.
Sheboygan, WI ..........................................................................................................................................................................
Sheboygan County, WI.
Sherman-Denison, TX ...............................................................................................................................................................
Grayson County, TX.
Shreveport-Bossier City, LA ......................................................................................................................................................
Bossier Parish, LA.
Caddo Parish, LA.
De Soto Parish, LA.
Sioux City, IA–NE–SD ...............................................................................................................................................................
Woodbury County, IA.
Dakota County, NE.
Dixon County, NE.
Union County, SD.
Sioux Falls, SD ..........................................................................................................................................................................
Lincoln County, SD.
McCook County, SD.
Minnehaha County, SD.
Turner County, SD.
South Bend-Mishawaka, IN–MI .................................................................................................................................................
St. Joseph County, IN.
Cass County, MI.
Spartanburg, SC ........................................................................................................................................................................
Spartanburg County, SC.
Spokane, WA ............................................................................................................................................................................
Spokane County, WA.
Springfield, IL ............................................................................................................................................................................
Menard County, IL.
Sangamon County, IL.
Springfield, MA ..........................................................................................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00350
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.3181
1.2419
1.2364
1.7016
1.1329
1.5511
1.0484
0.9638
0.8926
1.2214
0.9934
0.9473
0.8782
0.8946
0.9764
1.0093
1.0150
0.9945
1.1035
0.9440
1.0941
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66571
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
44180 .......
44220 .......
44300 .......
44700 .......
44940 .......
45060 .......
45104 .......
45220 .......
45300 .......
45460 .......
45500 .......
45780 .......
45820 .......
45940 .......
46060 .......
cprice-sewell on PROD1PC72 with RULES
46140 .......
46220 .......
46340 .......
46540 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Franklin County, MA.
Hampden County, MA.
Hampshire County, MA.
Springfield, MO ..........................................................................................................................................................................
Christian County, MO.
Dallas County, MO.
Greene County, MO.
Polk County, MO.
Webster County, MO.
Springfield, OH ..........................................................................................................................................................................
Clark County, OH.
State College, PA ......................................................................................................................................................................
Centre County, PA.
Stockton, CA .............................................................................................................................................................................
San Joaquin County, CA.
Sumter, SC ................................................................................................................................................................................
Sumter County, SC.
Syracuse, NY ............................................................................................................................................................................
Madison County, NY.
Onondaga County, NY.
Oswego County, NY.
Tacoma, WA ..............................................................................................................................................................................
Pierce County, WA.
Tallahassee, FL .........................................................................................................................................................................
Gadsden County, FL.
Jefferson County, FL.
Leon County, FL.
Wakulla County, FL.
Tampa-St. Petersburg-Clearwater, FL ......................................................................................................................................
Hernando County, FL.
Hillsborough County, FL.
Pasco County, FL.
Pinellas County, FL.
Terre Haute, IN .........................................................................................................................................................................
Clay County, IN.
Sullivan County, IN.
Vermillion County, IN.
Vigo County, IN.
Texarkana, TX-Texarkana, AR .................................................................................................................................................
Miller County, AR.
Bowie County, TX.
Toledo, OH ................................................................................................................................................................................
Fulton County, OH.
Lucas County, OH.
Ottawa County, OH.
Wood County, OH.
Topeka, KS ................................................................................................................................................................................
Jackson County, KS.
Jefferson County, KS.
Osage County, KS.
Shawnee County, KS.
Wabaunsee County, KS.
Trenton-Ewing, NJ .....................................................................................................................................................................
Mercer County, NJ.
Tucson, AZ ................................................................................................................................................................................
Pima County, AZ.
Tulsa, OK ..................................................................................................................................................................................
Creek County, OK.
Okmulgee County, OK.
Osage County, OK.
Pawnee County, OK.
Rogers County, OK.
Tulsa County, OK.
Wagoner County, OK.
Tuscaloosa, AL ..........................................................................................................................................................................
Greene County, AL.
Hale County, AL.
Tuscaloosa County, AL.
Tyler, TX ....................................................................................................................................................................................
Smith County, TX.
Utica-Rome, NY ........................................................................................................................................................................
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00351
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.9177
0.9176
0.9254
1.2513
0.9076
1.0460
1.1668
0.9526
0.9520
0.9293
0.8201
0.9954
0.9012
1.1293
0.9758
0.8803
0.8764
0.9620
0.8957
66572
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
46660 .......
46700 .......
47020 .......
47220 .......
47260 .......
47300 .......
47380 .......
47580 .......
47644 .......
cprice-sewell on PROD1PC72 with RULES
47894 .......
47940 .......
48140 .......
VerDate Aug<31>2005
Urban area
(constituent counties)
Wage
index
Herkimer County, NY.
Oneida County, NY.
Valdosta, GA .............................................................................................................................................................................
Brooks County, GA.
Echols County, GA.
Lanier County, GA.
Lowndes County, GA.
Vallejo-Fairfield, CA ...................................................................................................................................................................
Solano County, CA.
Victoria, TX ................................................................................................................................................................................
Calhoun County, TX.
Goliad County, TX.
Victoria County, TX.
Vineland-Millville-Bridgeton, NJ .................................................................................................................................................
Cumberland County, NJ.
Virginia Beach-Norfolk-Newport News, VA–NC ........................................................................................................................
Currituck County, NC.
Gloucester County, VA.
Isle of Wight County, VA.
James City County, VA.
Mathews County, VA.
Surry County, VA.
York County, VA.
Chesapeake City, VA.
Hampton City, VA.
Newport News City, VA.
Norfolk City, VA.
Poquoson City, VA.
Portsmouth City, VA.
Suffolk City, VA.
Virginia Beach City, VA.
Williamsburg City, VA.
Visalia-Porterville, CA ................................................................................................................................................................
Tulare County, CA.
Waco, TX ...................................................................................................................................................................................
McLennan County, TX.
Warner Robins, GA ...................................................................................................................................................................
Houston County, GA.
Warren-Troy-Farmington Hills, MI .............................................................................................................................................
Lapeer County, MI.
Livingston County, MI.
Macomb County, MI.
Oakland County, MI.
St. Clair County, MI.
Washington-Arlington-Alexandria, DC–VA–MD–WV ................................................................................................................
District of Columbia, DC.
Calvert County, MD.
Charles County, MD.
Prince George’s County, MD.
Arlington County, VA.
Clarke County, VA.
Fairfax County, VA.
Fauquier County, VA.
Loudoun County, VA.
Prince William County, VA.
Spotsylvania County, VA.
Stafford County, VA.
Warren County, VA.
Alexandria City, VA.
Fairfax City, VA.
Falls Church City, VA.
Fredericksburg City, VA.
Manassas City, VA.
Manassas Park City, VA.
Jefferson County, WV.
Waterloo-Cedar Falls, IA ...........................................................................................................................................................
Black Hawk County, IA.
Bremer County, IA.
Grundy County, IA.
Wausau, WI ...............................................................................................................................................................................
Marathon County, WI.
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00352
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
0.8547
1.5480
0.8763
1.0695
0.9307
1.0651
0.8991
0.9634
1.0556
1.1457
0.8992
1.0216
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
66573
ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued
CBSA
code
Urban area
(constituent counties)
Wage
index
48260 .......
Weirton-Steubenville, WV–OH ..................................................................................................................................................
Jefferson County, OH.
Brooke County, WV.
Hancock County, WV.
Wenatchee, WA ........................................................................................................................................................................
Chelan County, WA.
Douglas County, WA.
West Palm Beach-Boca Raton-Boynton Beach, FL .................................................................................................................
Palm Beach County, FL.
Wheeling, WV–OH ....................................................................................................................................................................
Belmont County, OH.
Marshall County, WV.
Ohio County, WV.
Wichita, KS ................................................................................................................................................................................
Butler County, KS.
Harvey County, KS.
Sedgwick County, KS.
Sumner County, KS.
Wichita Falls, TX .......................................................................................................................................................................
Archer County, TX.
Clay County, TX.
Wichita County, TX.
Williamsport, PA ........................................................................................................................................................................
Lycoming County, PA.
Wilmington, DE–MD–NJ ............................................................................................................................................................
New Castle County, DE.
Cecil County, MD.
Salem County, NJ.
Wilmington, NC .........................................................................................................................................................................
Brunswick County, NC.
New Hanover County, NC.
Pender County, NC.
Winchester, VA–WV ..................................................................................................................................................................
Frederick County, VA.
Winchester City, VA.
Hampshire County, WV.
Winston-Salem, NC ...................................................................................................................................................................
Davie County, NC.
Forsyth County, NC.
Stokes County, NC.
Yadkin County, NC.
Worcester, MA ...........................................................................................................................................................................
Worcester County, MA.
Yakima, WA ...............................................................................................................................................................................
Yakima County, WA.
Yauco, PR .................................................................................................................................................................................
´
Guanica Municipio, PR.
Guayanilla Municipio, PR.
˜
Penuelas Municipio, PR.
Yauco Municipio, PR.
York-Hanover, PA .....................................................................................................................................................................
York County, PA.
Youngstown-Warren-Boardman, OH–PA ..................................................................................................................................
Mahoning County, OH.
Trumbull County, OH.
Mercer County, PA.
Yuba City, CA ............................................................................................................................................................................
Sutter County, CA.
Yuba County, CA.
Yuma, AZ ..................................................................................................................................................................................
Yuma County, AZ.
0.8364
48300 .......
48424 .......
48540 .......
48620 .......
48660 .......
48700 .......
48864 .......
48900 .......
49020 .......
49180 .......
49340 .......
49420 .......
49500 .......
49620 .......
49660 .......
49700 .......
49740 .......
cprice-sewell on PROD1PC72 with RULES
1 At
this time, there are no hospitals located in this urban area on which to base a wage index.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
PO 00000
Frm 00353
Fmt 4701
Sfmt 4701
E:\FR\FM\27NOR2.SGM
27NOR2
1.2105
1.0268
0.7916
0.9565
0.8359
0.8489
1.1424
0.9932
1.0463
0.9624
1.1913
1.0837
0.7916
0.9878
0.9501
1.1353
1.0014
66574
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM H.—CY 2008 ESRD
WAGE INDEX BASED ON CBSA
LABOR MARKET AREAS FOR RURAL
AREAS
Nonurban area
Wage
index
1 .........
2 .........
3 .........
4 .........
5 .........
6 .........
7 .........
8 .........
10 .......
11 .......
12 .......
13 .......
14 .......
15 .......
16 .......
17 .......
18 .......
19 .......
20 .......
21 .......
22 .......
23 .......
24 .......
25 .......
26 .......
27 .......
28 .......
29 .......
30 .......
31 .......
32 .......
33 .......
34 .......
35 .......
36 .......
37 .......
38 .......
39 .......
40 .......
41 .......
42 .......
43 .......
44 .......
45 .......
46 .......
47 .......
48 .......
49 .......
50 .......
51 .......
52 .......
53 .......
cprice-sewell on PROD1PC72 with RULES
CBSA
code
Alabama .......................
Alaska ..........................
Arizona .........................
Arkansas ......................
California ......................
Colorado ......................
Connecticut ..................
Delaware ......................
Florida ..........................
Georgia ........................
Hawaii ..........................
Idaho ............................
Illinois ...........................
Indiana .........................
Iowa .............................
Kansas .........................
Kentucky ......................
Louisiana ......................
Maine ...........................
Maryland ......................
Massachusetts 1 ...........
Michigan .......................
Minnesota ....................
Mississippi ....................
Missouri ........................
Montana .......................
Nebraska ......................
Nevada .........................
New Hampshire ...........
New Jersey 1 ................
New Mexico .................
New York .....................
North Carolina ..............
North Dakota ................
Ohio .............................
Oklahoma .....................
Oregon .........................
Pennsylvania ................
Puerto Rico 1 ................
Rhode Island 1 .............
South Carolina .............
South Dakota ...............
Tennessee ...................
Texas ...........................
Utah .............................
Vermont .......................
Virgin Islands ...............
Virginia .........................
Washington ..................
West Virginia ................
Wisconsin .....................
Wyoming ......................
0.7951
1.2781
0.8949
0.7916
1.2690
1.0242
1.2361
1.0267
0.8935
0.8084
1.1201
0.8359
0.8797
0.9052
0.9041
0.8424
0.8225
0.7916
0.8946
0.9535
1.2290
0.9450
0.9583
0.8127
0.8370
0.8844
0.9340
0.9786
1.1466
................
0.9436
0.8727
0.9080
0.7916
0.9197
0.7916
1.0456
0.8850
0.7916
................
0.9136
0.9023
0.8151
0.8410
0.8566
1.0469
0.7916
0.8334
1.0828
0.7916
1.0203
0.9802
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY ACT
1 All counties within the State are classified
as urban, with the exception of Massachusetts
and Puerto Rico. Massachusetts and Puerto
Rico have areas designated as rural; however,
no short-term, acute care hospitals are located
in the area(s) for FY 2008.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
[Effective Date: January 1, 2008]
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
CLINICAL LABORATORY SERVICES
INCLUDE CPT codes for all clinical laboratory services in the 80000 series, except EXCLUDE CPT
codes for the following blood component collection services:
86890 ................... Autologous blood process.
86891 ................... Autologous blood, op salvage.
86927 ................... Plasma, fresh frozen.
86930 ................... Frozen blood prep.
86931 ................... Frozen blood thaw.
86932 ................... Frozen blood freeze/thaw.
86945 ................... Blood product/irradiation.
86950 ................... Leukacyte transfusion.
86960 ................... Vol reduction of blood/prod.
86965 ................... Pooling blood platelets.
86985 ................... Split blood or products.
INCLUDE the following CPT and HCPCS level 2
codes for other clinical laboratory services:
0026T ................... Measure remnant lipoproteins.
0030T ................... Antiprothrombin antibody.
0041T ................... Detect ur infect agnt w/cpas.
0043T ................... Co expired gas analysis.
0058T ................... Cryopreservation, ovary tiss.
0059T ................... Cryopreservation, oocyte.
0064T ................... Spectroscop eval expired gas.
0085T ................... Breath test heart reject.
0087T ................... Sperm eval hyaluronan.
0103T ................... Holotranscobalamin.
0104T ................... At rest cardio gas rebreathe.
0111T ................... RBC membranes fatty acids.
0140T ................... Exhaled breath condensate ph.
36415 ................... Routine venipuncture.
78110 ................... Plasma volume, single.
78111 ................... Plasma volume, multiple.
78120 ................... Red cell mass, single.
78121 ................... Red cell mass, multiple.
78122 ................... Blood volume.
78130 ................... Red cell survival study.
78191 ................... Platelet survival.
78267 ................... Breath tst attain/anal c–14.
78268 ................... Breath test analysis c–14.
78270 ................... Vit B–12 absorption exam.
78271 ................... Vit B–12 absrp exam, int fac.
78272 ................... Vit B–12 absorp, combined.
78725 ................... Kidney function study.
G0027 .................. Semen analysis.
G0103 .................. Psa, total screening.
G0123 .................. Screen cerv/vag thin layer.
G0124 .................. Screen c/v thin layer by MD.
G0141 .................. Scr c/v cyto,autosys and md.
G0143 .................. Scr c/v cyto,thinlayer,rescr.
G0144 .................. Scr c/v cyto,thinlayer,rescr.
G0145 .................. Scr c/v cyto,thinlayer,rescr.
G0147 .................. Scr c/v cyto, automated sys.
G0148 .................. Scr c/v cyto, autosys, rescr.
G0306 .................. CBC/diffwbc w/o platelet.
G0307 .................. CBC without platelet.
G0328 .................. Fecal blood scrn immunoassay.
G0394 .................. Blood occult test colorectal.
P2028 ................... Cephalin floculation test.
P2029 ................... Congo red blood test.
P2033 ................... Blood thymol turbidity.
P2038 ................... Blood mucoprotein.
P3000 ................... Screen pap by tech w md supv.
P3001 ................... Screening pap smear by phys.
P9612 ................... Catheterize for urine spec.
P9615 ................... Urine specimen collect mult.
Q0111 .................. Wet mounts/w preparations.
Q0112 .................. Potassium hydroxide preps.
Q0113 .................. Pinworm examinations.
Q0114 .................. Fern test.
Q0115 .................. Post-coital mucous exam.
PO 00000
Frm 00354
Fmt 4701
Sfmt 4701
PHYSICAL THERAPY, OCCUPATIONAL THERAPY, AND SPEECH-LANGUAGE PATHOLOGY
SERVICES
INCLUDE the following CPT and HCPCS codes for
physical therapy/occupational therapy/speech-language pathology services:
0019T ................... Extracorp shock wv tx, ms nos.
0029T ................... Magnetic tx for incontinence.
64550 ................... Apply neurostimulator.
90901 ................... Biofeedback train, any meth.
90911 ................... Biofeedback peri/uro/rectal.
92506 ................... Speech/hearing evaluation.
92507 ................... Speech/hearing therapy.
92508 ................... Speech/hearing therapy.
92526 ................... Oral function therapy.
92597 ................... Oral speech device eval.
92607 ................... Ex for speech device rx, 1hr.
92608 ................... Ex for speech device rx addl.
92609 ................... Use of speech device service.
92610 ................... Evaluate swallowing function.
92611 ................... Motion fluoroscopy/swallow.
92612 ................... Endoscopy swallow tst (fees).
92614 ................... Laryngoscopic sensory test.
92616 ................... Fees w/laryngeal sense test.
93797 ................... Cardiac rehab.
93798 ................... Cardiac rehab/monitor.
94667 ................... Chest wall manipulation.
94668 ................... Chest wall manipulation.
95831 ................... Limb muscle testing, manual.
95832 ................... Hand muscle testing, manual.
95833 ................... Body muscle testing, manual.
95834 ................... Body muscle testing, manual.
95851 ................... Range of motion measurements.
95852 ................... Range of motion measurements.
96000 ................... Motion analysis, video/3d.
96001 ................... Motion test w/ft press meas.
96002 ................... Dynamic surface emg.
96003 ................... Dynamic fine wire emg.
96105 ................... Assessment of aphasia.
96110 ................... Developmental test, lim.
96111 ................... Developmental test, extend.
96125 ................... Cognitive test by HC pro.
97001 ................... Pt evaluation.
97002 ................... Pt re-evaluation.
97003 ................... Ot evaluation.
97004 ................... Ot re-evaluation.
97010 ................... Hot or cold packs therapy.
97012 ................... Mechanical traction therapy.
97016 ................... Vasopneumatic device therapy.
97018 ................... Paraffin bath therapy.
97022 ................... Whirlpool therapy.
97024 ................... Diathermy eg, microwave.
97026 ................... Infrared therapy.
97028 ................... Ultraviolet therapy.
97032 ................... Electrical stimulation.
97033 ................... Electric current therapy.
97034 ................... Contrast bath therapy.
97035 ................... Ultrasound therapy.
97036 ................... Hydrotherapy.
97039 ................... Physical therapy treatment.
97110 ................... Therapeutic exercises.
97112 ................... Neuromuscular reeducation.
97113 ................... Aquatic therapy/exercises.
97116 ................... Gait training therapy.
97124 ................... Massage therapy.
97139 ................... Physical medicine procedure.
97140 ................... Manual therapy.
97150 ................... Group therapeutic procedures.
97530 ................... Therapeutic activities.
97532 ................... Cognitive skills development.
97533 ................... Sensory integration.
97535 ................... Self care mngment training.
97537 ................... Community/work reintegration.
E:\FR\FM\27NOR2.SGM
27NOR2
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
cprice-sewell on PROD1PC72 with RULES
INCLUDE the following CPT and HCPCS codes:
0028T ................... Dexa body composition study.
0042T ................... Ct perfusion w/contrast, cbf.
0067T ................... Ct colonography; dx.
0144T ................... Ct heart wo dye; qual calc.
0145T ................... Ct heart w/wo dye funct.
0146T ................... Ccta w/wo dye 0147T Ccta w/
wo, quan calcium.
0148T ................... Ccta w/wo, strxr.
0149T ................... Ccta w/wo, strxr quan calc.
0150T ................... Ccta w/wo, disease strxr.
0151T ................... Ct heart funct add-on.
0159T ................... Cad breast mri.
0174T ................... Cad cxr with interp.
0175T ................... Cad cxr remote.
51798 ................... Us urine capacity measure.
70100 ................... X-ray exam of jaw.
70110 ................... X-ray exam of jaw.
70120 ................... X-ray exam of mastoids.
70130 ................... X-ray exam of mastoids.
70134 ................... X-ray exam of middle ear.
70140 ................... X-ray exam of facial bones.
70150 ................... X-ray exam of facial bones.
70160 ................... X-ray exam of nasal bones.
70190 ................... X-ray exam of eye sockets.
70200 ................... X-ray exam of eye sockets.
70210 ................... X-ray exam of sinuses.
70220 ................... X-ray exam of sinuses.
70240 ................... X-ray exam, pituitary saddle.
70250 ................... X-ray exam of skull.
70260 ................... X-ray exam of skull.
70300 ................... X-ray exam of teeth.
70310 ................... X-ray exam of teeth.
70320 ................... Full mouth x-ray of teeth.
70328 ................... X-ray exam of jaw joint.
70330 ................... X-ray exam of jaw joints.
70336 ................... Magnetic image, jaw joint.
70350 ................... X-ray head for orthodontia.
70355 ................... Panoramic x-ray of jaws.
70360 ................... X-ray exam of neck.
70370 ................... Throat x-ray & fluoroscopy.
70371 ................... Speech evaluation, complex.
70380 ................... X-ray exam of salivary gland.
70450 ................... Ct head/brain w/o dye.
70460 ................... Ct head/brain w/dye.
70470 ................... Ct head/brain w/o & w/dye.
70480 ................... Ct orbit/ear/fossa w/o dye.
70481 ................... Ct orbit/ear/fossa w/dye.
70482 ................... Ct orbit/ear/fossa w/ o& w/dye.
70486 ................... Ct maxillofacial w/o dye.
70487 ................... Ct maxillofacial w/dye.
70488 ................... Ct maxillofacial w/o & w/dye.
70490 ................... Ct soft tissue neck w/o dye.
70491 ................... Ct soft tissue neck w/dye.
70492 ................... Ct sft tsue nck w/o & w/dye.
70496 ................... Ct angiography, head.
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
97542 ................... Wheelchair mngment training.
97545 ................... Work hardening.
97546 ................... Work hardening add-on.
97597 ................... Active wound care/20cm or <.
97598 ................... Active wound care > 20cm.
97602 ................... Wound(s) care nonselective.
97605 ................... Neg press wound tx, < 50 cm.
97606 ................... Neg press wound tx, > 50 cm.
97750 ................... Physical performance test.
97755 ................... Assistive technology assess.
97760 ................... Orthotic mgmt and training.
97761 ................... Prosthetic training.
97762 ................... C/O for orthotic/prosth use.
97799 ................... Physical medicine procedure.
G0281 .................. Elec stim unattend for press.
G0283 .................. Elec stim other than wound.
G0329 .................. Electromagntic tx for ulcers.
RADIOLOGY AND CERTAIN OTHER IMAGING
SERVICES
70498
70540
70542
70543
70544
70545
70546
...................
...................
...................
...................
...................
...................
...................
70547 ...................
70548 ...................
70549 ...................
70551
70552
70553
70554
70555
71010
71020
71021
71022
71023
71030
71034
71035
71100
71101
71110
71111
71120
71130
71250
71260
71270
71275
71550
71551
71552
71555
72010
72020
72040
72050
72052
72069
72070
72072
72074
72080
72090
72100
72110
72114
72120
72125
72126
72127
72128
72129
72130
72131
72132
72133
72141
72142
72146
72147
72148
72149
72156
72157
72158
72170
72190
72191
PO 00000
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
Frm 00355
Ct angiography, neck.
Mri orbit/face/neck w/o dye.
Mri orbit/face/neck w/dye.
Mri orbt/fac/nck w/o & w/dye.
Mr angiography head w/o dye.
Mr angiography head w/dye.
Mr angiograph head w/o&w/
dye.
Mr angiography neck w/o dye.
Mr angiography neck w/dye.
Mr angiograph neck w/o&w/
dye.
Mri brain w/o dye.
Mri brain w/dye.
Mri brain w/o & w/dye.
Fmri brain by tech.
Fmri brain by phys/psych.
Chest x-ray 71015 Chest x-ray.
Chest x-ray.
Chest x-ray.
Chest x-ray.
Chest x-ray and fluoroscopy.
Chest x-ray.
Chest x-ray and fluoroscopy.
Chest x-ray.
X-ray exam of ribs.
X-ray exam of ribs/chest.
X-ray exam of ribs.
X-ray exam of ribs/chest.
X-ray exam of breastbone.
X-ray exam of breastbone.
Ct thorax w/o dye.
Ct thorax w/dye.
Ct thorax w/o & w/dye.
Ct angiography, chest.
Mri chest w/o dye.
Mri chest w/dye.
Mri chest w/o & w/dye.
Mri angio chest w or w/o dye.
X-ray exam of spine.
X-ray exam of spine.
X-ray exam of neck spine.
X-ray exam of neck spine.
X-ray exam of neck spine.
X-ray exam of trunk spine.
X-ray exam of thoracic spine.
X-ray exam of thoracic spine.
X-ray exam of thoracic spine.
X-ray exam of trunk spine.
X-ray exam of trunk spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
X-ray exam of lower spine.
Ct neck spine w/o dye.
Ct neck spine w/dye.
Ct neck spine w/o & w/dye.
Ct chest spine w/o dye.
Ct chest spine w/dye.
Ct chest spine w/o & w/dye.
Ct lumbar spine w/o dye.
Ct lumbar spine w/dye.
Ct lumbar spine w/o & w/dye.
Mri neck spine w/o dye.
Mri neck spine w/dye.
Mri chest spine w/o dye.
Mri chest spine w/dye.
Mri lumbar spine w/o dye.
Mri lumbar spine w/dye.
Mri neck spine w/o & w/dye.
Mri chest spine w/o & w/dye.
Mri lumbar spine w/o & w/dye.
X-ray exam of pelvis.
X-ray exam of pelvis.
Ct angiograph pelv w/o & w/
dye.
Fmt 4701
Sfmt 4701
66575
[Effective Date: January 1, 2008]
72192
72193
72194
72195
72196
72197
72198
72200
72202
72220
73000
73010
73020
73030
73050
73060
73070
73080
73090
73092
73100
73110
73120
73130
73140
73200
73201
73202
73206
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
73218
73219
73220
73221
73222
73223
73500
73510
73520
73540
73550
73560
73562
73564
73565
73590
73592
73600
73610
73620
73630
73650
73660
73700
73701
73702
73706
73718
73719
73720
73721
73722
73723
73725
74000
74010
74020
74022
74150
74160
74170
74175
74181
74182
74183
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
E:\FR\FM\27NOR2.SGM
27NOR2
Ct pelvis w/o dye.
Ct pelvis w/dye.
Ct pelvis w/o & w/dye.
Mri pelvis w/o dye.
Mri pelvis w/dye.
Mri pelvis w/o & w/dye.
Mr angio pelvis w/o & w/dye.
X-ray exam sacroiliac joints.
X-ray exam sacroiliac joints.
X-ray exam of tailbone.
X-ray exam of collar bone.
X-ray exam of shoulder blade.
X-ray exam of shoulder.
X-ray exam of shoulder.
X-ray exam of shoulders.
X-ray exam of humerus.
X-ray exam of elbow.
X-ray exam of elbow.
X-ray exam of forearm.
X-ray exam of arm, infant.
X-ray exam of wrist.
X-ray exam of wrist.
X-ray exam of hand.
X-ray exam of hand.
X-ray exam of finger(s).
Ct upper extremity w/o dye.
Ct upper extremity w/dye.
Ct uppr extremity w/o & w/dye.
Ct angio upr extrm w/o & w/
dye.
Mri upper extremity w/o dye.
Mri upper extremity w/dye.
Mri uppr extremity w/o & w/dye.
Mri joint upr extrem w/o dye.
Mri joint upr extrem w/dye.
Mri joint upr extr w/o & w/dye.
X-ray exam of hip.
X-ray exam of hip.
X-ray exam of hips.
X-ray exam of pelvis & hips.
X-ray exam of thigh.
X-ray exam of knee, 1 or 2.
X-ray exam of knee, 3.
X-ray exam, knee, 4 or more.
X-ray exam of knees.
X-ray exam of lower leg.
X-ray exam of leg, infant.
X-ray exam of ankle.
X-ray exam of ankle.
X-ray exam of foot.
X-ray exam of foot.
X-ray exam of heel.
X-ray exam of toe(s).
Ct lower extremity w/o dye.
Ct lower extremity w/dye.
Ct lwr extremity w/o & w/dye.
Ct angio lwr extr w/o & w/dye.
Mri lower extremity w/o dye.
Mri lower extremity w/dye.
Mri lwr extremity w/o & w/dye.
Mri jnt of lwr extre w/o dye.
Mri joint of lwr extr w/dye.
Mri joint lwr extr w/o & w/dye.
Mr ang lwr ext w or w/o dye.
X-ray exam of abdomen.
X-ray exam of abdomen.
X-ray exam of abdomen.
X-ray exam series, abdomen.
Ct abdomen w/o dye.
Ct abdomen w/dye.
Ct abdomen w/o & w/dye.
Ct angio abdom w/o & w/dye.
Mri abdomen w/o dye.
Mri abdomen w/dye.
Mri abdomen w/o & w/dye.
66576
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
cprice-sewell on PROD1PC72 with RULES
74185
74210
74220
74230
74240
74241
74245
74246
74247
74249
74250
74290
74291
74710
75557
75558
75559
75560
75561
75562
75563
75564
75635
76000
76010
76100
76101
76102
76120
76125
76150
76376
76377
76380
76499
76506
76510
76511
76512
76513
76514
76516
76519
76536
76604
76645
76700
76705
76770
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
76775
76776
76800
76802
76805
76810
76811
76812
76815
76816
76818
76819
76820
76821
76825
76826
76827
76828
76856
76857
76870
76880
76885
76886
76970
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
VerDate Aug<31>2005
[Effective Date: January 1, 2008]
Mri angio, abdom w orw/o dye.
Contrst x-ray exam of throat.
Contrast x-ray, esophagus.
Cine/vid x-ray, throat/esoph.
X-ray exam, upper gi tract.
X-ray exam, upper gi tract.
X-ray exam, upper gi tract.
Contrst x-ray uppr gi tract.
Contrst x-ray uppr gi tract.
Contrst x-ray uppr gi tract.
X-ray exam of small bowel.
Contrast x-ray, gallbladder.
Contrast x-rays, gallbladder.
X-ray measurement of pelvis.
Cardiac MRI for morph.
Cardiac MRI flow/velocity.
Cardiac MRI w/stress img.
Cardiac MRI flo/vel/stress.
Cardiac MRI for morph w/dye.
Card MRI flow/vel w/dye.
Card MRI w/stress img & dye.
Ht MRI w/flo/vel/strs & dye.
Ct angio abdominal arteries.
Fluoroscope examination.
X-ray, nose to rectum.
X-ray exam of body section.
Complex body section x-ray.
Complex body section x-rays.
Cine/video x-rays.
Cine/video x-rays add-on.
X-ray exam, dry process.
3d render w/o postprocess.
3d rendering w/postprocess.
CAT scan follow-up study.
Radiographic procedure.
Echo exam of head.
Ophth us, b & quant a.
Ophth us, quant a only.
Ophth us, b w/non-quant a.
Echo exam of eye, water bath.
Echo exam of eye, thickness.
Echo exam of eye.
Echo exam of eye.
Us exam of head and neck.
Us exam, chest.
Us exam, breast(s).
Us exam, abdom, complete.
Echo exam of abdomen
Us exam abdo back wall,
comp.
Us exam abdo back wall, lim.
Us exam k transpl w/Doppler.
Us exam, spinal canal.
Ob us < 14 wks, add’l fetus.
Ob us >/= 14 wks, sngl fetus.
Ob us >/= 14 wks, addl fetus.
Ob us, detailed, sngl fetus.
Ob us, detailed, addl fetus.
Ob us, limited, fetus(s).
Ob us, follow-up, per fetus.
Fetal biophys profile w/nst.
Fetal biophys profil w/o nst.
Umbilical artery echo.
Middle cerebral artery echo.
Echo exam of fetal heart.
Echo exam of fetal heart.
Echo exam of fetal heart.
Echo exam of fetal heart.
Us exam, pelvic, complete.
Us exam, pelvic, limited.
Us exam, scrotum.
Us exam, extremity.
Us exam infant hips, dynamic.
Us exam infant hips, static.
Ultrasound exam follow-up.
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
76977
76999
77014
77051
...................
...................
...................
...................
77052 ...................
77055
77056
77057
77058
77059
77071
77072
77073
77074
77075
77076
77077
77078
77079
77080
77081
77082
77083
77084
78000
78001
78003
78006
78007
78010
78011
78015
78016
78018
78020
78070
78075
78099
78102
78103
78104
78135
78140
78185
78190
78195
78199
78201
78202
78205
78206
78215
78216
78220
78223
78230
78231
78232
78258
78261
78262
78264
78278
78282
78290
78291
78299
78300
78305
78306
78315
78320
78399
PO 00000
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
Frm 00356
Us bone density measure.
Echo examination procedure.
Ct scan for therapy guide.
Computer dx mammogram
add-on.
Comp screen mammogram
add-on.
Mammogram, one breast.
Mammogram, both breasts.
Mammogram, screening.
Mri, one breast.
Mri, both breasts.
X-ray stress view.
X-rays for bone age.
X-rays, bone length studies.
X-rays, bone survey, limited.
X-rays, bone survey complete.
X-rays, bone survey, infant.
Joint survey, single view.
Ct bone density, axial.
Ct bone density, peripheral.
Dxa bone density, axial.
Dxa bone density/peripheral.
Dxa bone density, vert fx.
Radiographic absorptiometry.
Magnetic image, bone marrow.
Thyroid, single uptake.
Thyroid, multiple uptakes.
Thyroid suppress/stimul.
Thyroid imaging with uptake.
Thyroid image, mult uptakes.
Thyroid imaging.
Thyroid imaging with flow.
Thyroid met imaging.
Thyroid met imaging/studies.
Thyroid met imaging, body.
Thyroid met uptake.
Parathyroid nuclear imaging.
Adrenal nuclear imaging.
Endocrine nuclear procedure.
Bone marrow imaging, ltd.
Bone marrow imaging, mult.
Bone marrow imaging, body.
Red cell survival kinetics.
Red cell sequestration.
Spleen imaging.
Platelet survival, kinetics.
Lymph system imaging.
Blood/lymph nuclear exam.
Liver imaging.
Liver imaging with flow.
Liver imaging (3D).
Liver image (3d) with flow.
Liver and spleen imaging.
Liver & spleen image/flow.
Liver function study.
Hepatobiliary imaging.
Salivary gland imaging.
Serial salivary imaging.
Salivary gland function exam.
Esophageal motility study.
Gastric mucosa imaging.
Gastroesophageal reflux exam.
Gastric emptying study.
Acute GI blood loss imaging.
GI protein loss exam.
Meckel’s divert exam.
Leveen/shunt patency exam.
GI nuclear procedure.
Bone imaging, limited area.
Bone imaging, multiple areas.
Bone imaging, whole body.
Bone imaging, 3 phase.
Bone imaging (3D).
Musculoskeletal nuclear exam.
Fmt 4701
Sfmt 4701
[Effective Date: January 1, 2008]
78414
78428
78445
78456
78457
78458
78459
78460
78461
78464
78465
78466
78468
78469
78472
78473
78478
78480
78481
78483
78491
78492
78494
78496
78499
78580
78584
78585
78586
78587
78588
78591
78593
78594
78596
78599
78600
78601
78605
78606
78607
78608
78610
78630
78635
78645
78647
78650
78660
78699
78700
78701
78707
78708
78709
78710
78730
78740
78761
78799
78800
78801
78802
78803
78804
78805
78806
78807
78811
78812
78813
78814
78815
78816
78890
E:\FR\FM\27NOR2.SGM
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
27NOR2
Non-imaging heart function.
Cardiac shunt imaging.
Vascular flow imaging.
Acute venous thrombus image.
Venous thrombosis imaging.
Ven thrombosis images, bilat.
Heart muscle imaging (PET).
Heart muscle blood, single.
Heart muscle blood, multiple.
Heart image (3d), single.
Heart image (3d), multiple.
Heart infarct image.
Heart infarct image (ef).
Heart infarct image (3D).
Gated heart, planar, single.
Gated heart, multiple.
Heart wall motion add-on.
Heart function add-on.
Heart first pass, single.
Heart first pass, multiple.
Heart image (pet), single.
Heart image (pet), multiple.
Heart image, spect.
Heart first pass add-on.
Cardiovascular nuclear exam.
Lung perfusion imaging.
Lung V/Q image single breath.
Lung V/Q imaging.
Aerosol lung image, single.
Aerosol lung image, multiple.
Perfusion lung image.
Vent image, 1 breath, 1 proj.
Vent image, 1 proj, gas.
Vent image, mult proj, gas.
Lung differential function.
Respiratory nuclear exam.
Brain image < 4 views.
Brain image w/flow < 4 views.
Brain image 4+ views.
Brain image w/flow 4 + views.
Brain imaging (3D).
Brain imaging (PET).
Brain flow imaging only.
Cerebrospinal fluid scan.
CSF ventriculography.
CSF shunt evaluation.
Cerebrospinal fluid scan.
CSF leakage imaging.
Nuclear exam of tear flow.
Nervous system nuclear exam.
Kidney imaging, morphol.
Kidney imaging with flow.
K flow/funct image w/o drug.
K flow/funct image w/drug.
K flow/funct image, multiple.
Kidney imaging (3D).
Urinary bladder retention.
Ureteral reflux study.
Testicular imaging w/flow.
Genitourinary nuclear exam.
Tumor imaging, limited area.
Tumor imaging, mult areas.
Tumor imaging, whole body.
Tumor imaging (3D).
Tumor imaging, whole body.
Abscess imaging, ltd area.
Abscess imaging, whole body.
Nuclear localization/abscess.
PET image, ltd area.
PET image, skull-thigh.
PET image, full body.
PET image w/ct, lmtd.
PET image w/ct, skull-thigh.
PET image w/ct, full body.
Nuclear medicine data proc.
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
78891
78999
91110
91111
...................
...................
...................
...................
93303
93304
93307
93308
93320
...................
...................
...................
...................
...................
93321 ...................
93325 ...................
cprice-sewell on PROD1PC72 with RULES
93875
93880
93882
93886
93888
93890
93892
93922
93923
93924
93925
93926
93930
93931
93965
93970
93971
93975
93976
93978
93979
93980
93981
93990
A4641
A4642
A9500
A9501
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
A9502
A9503
A9504
A9505
A9507
A9508
A9509
A9510
A9512
A9516
A9521
A9524
A9526
A9528
A9529
A9531
A9532
A9536
A9537
A9538
A9539
A9540
A9541
A9542
A9544
A9546
A9547
A9548
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
VerDate Aug<31>2005
Nuclear med data proc.
Nuclear diagnostic exam.
Gi tract capsule endoscopy.
Esophageal capsule endoscopy.
Echo transthoracic.
Echo transthoracic.
Echo exam of heart.
Echo exam of heart.
Doppler echo exam, heart [if
used in conjunction with
93303–93308].
Doppler echo exam, heart [if
used in conjunction with
93303–93308].
Doppler color flow add-on [if
used in conjunction with
93303–93308].
Extracranial study.
Extracranial study.
Extracranial study.
Intracranial study.
Intracranial study.
Tcd, vasoreactivity study.
Tcd, emboli detect w/o inj.
Extremity study.
Extremity study.
Extremity study.
Lower extremity study.
Lower extremity study.
Upper extremity study.
Upper extremity study.
Extremity study.
Extremity study.
Extremity study.
Vascular study.
Vascular study.
Vascular study.
Vascular study.
Penile vascular study.
Penile vascular study.
Doppler flow testing.
Radiopharm dx agent noc.
In111 satumomab.
Tc99m sestamibi.
Technitium TC–99m
teboroxime.
Tc99m tetrofosmin.
Tc99m medronate.
Tc99m apcitide.
TL201 thallium.
In111 capromab.
I131 iodobenguate, dx.
Iodine I–123 sod iodide mil.
Tc99m disofenin.
Tc99m pertechnetate.
Iodine I–123 sod iodide mic.
Tc99m exametazime.
I131 serum albumin, dx.
Nitrogen N–13 ammonia.
Iodine I–131 iodide cap, dx.
I131 iodide sol, dx.
I131 max 100uCi.
I125 serum albumin, dx.
TC99m depreotide.
Tc99m mebrofenin.
Tc99m pyrophosphate.
Tc99m pentetate.
Tc99m MAA.
Tc99m sulfur colloid.
In111 ibritumomab, dx.
I131 tositumomab, dx.
CO57/58.
In111 oxyquinoline.
In111 pentetate.
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
A9550
A9551
A9552
A9553
A9554
A9555
A9556
A9557
A9558
A9559
A9560
A9561
A9562
A9566
A9567
A9568
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
Tc99m gluceptate.
Tc99m succimer.
F18 fdg.
Cr51 chromate.
I125 iothalamate, dx.
Rb82 rubidium.
Ga67 gallium.
Tc99m bicisate.
Xe133 xenon 10mci.
Co57 cyano.
Tc99m labeled rbc.
Tc99m oxidronate.
Tc99m mertiatide.
Tc99m fanolesomab.
Technetium TC–99m aerosol.
Technetium tc99m
arcitumomab.
A9569 ................... Technetium TC–99m auto
WBC.
A9570 ................... Indium In-111 auto WBC.
A9571 ................... Indium In-111 auto platelet.
A9572 ................... Indium In-111 pentetreotide.
A9576 ................... Inj prohance multipack.
A9577 ................... Inj multihance.
A9578 ................... Inj multihance multipack.
A9579 ................... Gad-base MR contrast
NOS,1ml.
A9700 ................... Echocardiography contrast.
G0130 .................. Single energy x-ray study.
G0202 .................. Screeningmammographydigital.
G0204 .................. Diagnosticmammographydigital.
G0206 .................. Diagnosticmammographydigital.
G0288 .................. Recon, CTA for surg plan.
G0389 .................. Ultrasound exam AAA screen.
Q0092 .................. Set up port xray equipment.
Q9951 .................. LOCM>=400 mg/ml iodine,1ml.
Q9953 .................. Inj Fe-base MR contrast,1ml.
Q9954 .................. Oral MR contrast, 100ml.
Q9955 .................. Inj perflexane lip micros,ml.
Q9956 .................. Inj octafluoropropane mic,ml.
Q9957 .................. Inj perflutren lip micros,ml.
Q9958 .................. HOCM <=149 mg/ml iodine,
1ml.
Q9959 .................. HOCM 150–199mg/ml iodine,1ml.
Q9960 .................. HOCM 200–249mg/ml iodine,1ml.
Q9961 .................. HOCM 250–299mg/ml iodine,1ml.
Q9962 .................. HOCM 300–349mg/ml iodine,1ml.
Q9963 .................. HOCM 350–399mg/ml iodine,1ml.
Q9964 .................. HOCM>= 400mg/ml iodine,
1ml.
Q9965 .................. LOCM 100–199mg/ml iodine,1ml.
Q9966 .................. LOCM 200–299mg/ml iodine,1ml.
Q9967 .................. LOCM 300–399mg/ml iodine,1ml.
R0070 ................... Transport portable x-ray.
R0075 ................... Transport port x-ray multipl.
RADIATION THERAPY SERVICES AND SUPPLIES
INCLUDE the following CPT and HCPCS codes:
0073T ................... Delivery, comp imrt.
0182T ................... HDR elect brachytherapy.
19296 ................... Place po breast cath for rad.
19297 ................... Place breast cath for rad.
19298 ................... Place breast rad tube/caths.
20555 ................... Place ndl musc/tis for rt.
31643 ................... Diag bronchoscope/catheter.
41019 ................... Place needles h&n for rt.
55875 ................... Transperi needle place, pros.
PO 00000
Frm 00357
Fmt 4701
Sfmt 4701
66577
[Effective Date: January 1, 2008]
55876
55920
57155
58346
61770
61793
77261
77262
77263
77280
77285
77290
77295
77299
77300
77301
77305
77310
77315
77321
77326
77327
77328
77331
77332
77333
77334
77336
77370
77371
77372
77373
77399
77401
77402
77403
77404
77406
77407
77408
77409
77411
77412
77413
77414
77416
77417
77418
77421
77422
77423
77427
77431
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
77432
77435
77470
77499
...................
...................
...................
...................
77520
77522
77523
77525
77600
77605
77610
77615
77620
77750
77761
77762
77763
77776
77777
77778
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
E:\FR\FM\27NOR2.SGM
27NOR2
Place rt device/marker, pros.
Place needles pelvic for rt.
Insert uteri tandems/ovoids.
Insert heyman uteri capsule.
Incise skull for treatment.
Focus radiation beam.
Radiation therapy planning.
Radiation therapy planning.
Radiation therapy planning.
Set radiation therapy field.
Set radiation therapy field.
Set radiation therapy field.
Set radiation therapy field.
Radiation therapy planning.
Radiation therapy dose plan.
Radiotherapy dose plan, imrt.
Teletx isodose plan simple.
Teletx isodose plan intermed.
Teletx isodose plan complex.
Special teletx port plan.
Brachytx isodose calc simp.
Brachytx isodose calc interm.
Brachytx isodose plan compl.
Special radiation dosimetry.
Radiation treatment aid(s).
Radiation treatment aid(s).
Radiation treatment aid(s).
Radiation physics consult.
Radiation physics consult.
Srs, multisource.
Srs, linear based.
Sbrt delivery.
External radiation dosimetry.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiation treatment delivery.
Radiology port film(s).
Radiation tx delivery, imrt.
Stereoscopic x-ray guidance.
Neutron beam tx, simple.
Neutron beam tx, complex.
Radiation tx management, x5.
Radiation therapy management.
Stereotactic radiation trmt.
Sbrt management.
Special radiation treatment.
Radiation therapy management.
Proton trmt, simple w/o comp.
Proton trmt, simple w/comp.
Proton trmt, intermediate.
Proton treatment, complex.
Hyperthermia treatment.
Hyperthermia treatment.
Hyperthermia treatment.
Hyperthermia treatment.
Hyperthermia treatment.
Infuse radioactive materials.
Apply intrcav radiat simple.
Apply intrcav radiat interm.
Apply intrcav radiat compl.
Apply interstit radiat simpl.
Apply interstit radiat inter.
Apply interstit radiat compl.
66578
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 / Rules and Regulations
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
[Effective Date: January 1, 2008]
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
[Effective Date: January 1, 2008]
High intensity brachytherapy.
High intensity brachytherapy.
High intensity brachytherapy.
High intensity brachytherapy.
Apply surface radiation.
Radiation handling.
Radium/radioisotope therapy.
Nuclear rx, oral admin.
Nuclear rx, iv admin.
Nuclear rx, intracav admin.
Nuclr rx, interstit colloid.
Hematopoietic nuclear tx.
Nuclear rx, intra-articular.
Nuclear rx, intra-arterial.
Nuclear medicine therapy.
Cath place, cardio brachytx.
I131 iodide cap, rx.
Iodine I–125 sodium iodide.
I131 iodide sol, rx.
Y90 ibritumomab, rx.
I131 tositumomab, rx.
P32 Na phosphate.
P32 chromic phosphate.
Sr89 strontium.
Sm 153 lexidronm.
Radiopharm rx agent noc.
Brachytx source, Gold 198.
Brachytx source, HDR Ir-192.
Brachytx sour, Non-HDR Ir192.
C2616 ................... Brachytx source, Yttrium-9.
C2634 ................... Brachytx source, HA, I–125.
C2635 ................... Brachytx source, HA, P–13.
C2636 ................... Brachytx linear source, P–13.
C2637 ................... Brachytx, Ytterbium-169.
C2638 ................... Brachytx, stranded, I–125.
C2639 ................... Brachytx,non-stranded, I–125.
C2640 ................... Brachytx, stranded, P–13.
C2641 ................... Brachytx, non-stranded, P–13.
C2642 ................... Brachytx, stranded, C–131.
C2643 ................... Brachytx, non-stranded, C–131.
C2698 ................... Brachytx, stranded, NOS.
C2699 ................... Brachytx, non-stranded, NOS.
G0173 .................. Linear acc stereo radsur com.
G0251 .................. Linear acc based stero radio.
G0339 .................. Robot lin-radsurg com, first.
G0340 .................. Robt lin-radsurg fractx 2–5.
Q3001 .................. Brachytherapy Radioelements.
EPO AND OTHER DIALYSIS-RELATED DRUGS
The physician self-referral prohibition does not
apply to the following codes for EPO and other
dialysis-related drugs furnished in or by an ESRD
facility if the conditions in § 411.355(g) are satisfied:
cprice-sewell on PROD1PC72 with RULES
77781
77782
77783
77784
77789
77790
77799
79005
79101
79200
79300
79403
79440
79445
79999
92974
A9517
A9527
A9530
A9543
A9545
A9563
A9564
A9600
A9605
A9699
C1716
C1717
C1719
VerDate Aug<31>2005
16:01 Nov 26, 2007
Jkt 214001
ADDENDUM I.—LIST OF CPT 1/HCPCS
CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE
UNDER
SECTION
CATEGORIES 2
1877 OF THE SOCIAL SECURITY
ACT—Continued
J0630
J0636
J0882
J0895
J1270
J1751
J1752
J1756
J1955
J2501
J2916
J2993
J2995
J2997
J3364
P9041
P9045
P9046
P9047
Q4081
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
..................
Calcitonin salmon injection.
Inj calcitriol per 0.1 mcg.
Darbepoetin alfa, esrd use.
Deferoxamine mesylate inj.
Injection, doxercalciferol.
Iron dextran 165 injection.
Iron dextran 267 injection.
Iron sucrose injection.
Inj levocarnitine per 1 gm.
Paricalcitol.
Na ferric gluconate complex.
Reteplase injection.
Inj streptokinase/250000 IU.
Alteplase recombinant.
Urokinase 5000 IU injection.
Albumin (human),5%, 50ml.
Albumin (human), 5%, 250ml.
Albumin (human), 25%, 20ml.
Albumin (human), 25%, 50ml.
Epoetin alfa, 100 units ESRD.
PREVENTIVE SCREENING TESTS,
IMMUNIZATIONS AND VACCINES
The physician self-referral prohibition does not
apply to the following tests if they are performed
for screening purposes and satisfy the conditions
in § 411.355(h):
77052 ................... Comp screen mammogram
add-on.
77057 ................... Mammogram, screening.
80061 ................... Lipid panel [only when billed
with one of the following
ICD–9–CM codes: V81.0,
V81.1, or V.81.2].
82270 ................... Occult blood, feces.
82465 ................... Assay, bld/serum cholesterol
[only when billed with one of
the following ICD–9–CM
codes: V81.0, V81.1, or
V.81.2].
82947 ................... Assay, glucose, blood quant
[only when billed with ICD–
9–CM code V77.1].
82950 ................... Glucose test [only when billed
with ICD–9–CM code V77.1].
82951 ................... Glucose tolerance test (GTT)
[only when billed with ICD–
9–CM code V77.1].
83718 ................... Assay of lipoprotein [only when
billed with one of the following ICD–9–CM codes:
V81.0, V81.1, or V.81.2].
PO 00000
Frm 00358
Fmt 4701
Sfmt 4701
[Effective Date: January 1, 2008]
84478 ...................
Assay of triglycerides [only
when billed with one of the
following ICD–9–CM codes:
V81.0, V81.1, or V.81.2].
G0103 .................. Psa, total screening.
G0123 .................. Screen cerv/vag thin layer.
G0124 .................. Screen c/v thin layer by MD.
G0141 .................. Scr c/v cyto,autosys and md.
G0143 .................. Scr c/v cyto,thinlayer,rescr.
G0144 .................. Scr c/v cyto,thinlayer,rescr.
G0145 .................. Scr c/v cyto,thinlayer,rescr.
G0147 .................. Scr c/v cyto, automated sys.
G0148 .................. Scr c/v cyto, autosys, rescr.
G0202 .................. Screeningmammographydigital.
G0328 .................. Fecal blood scrn immunoassay.
G0389 .................. Ultrasound exam AAA screen.
P3000 ................... Screen pap by tech w md supv.
P3001 ................... Screening pap smear by phys.
The physician self-referral prohibition does not
apply to the following immunization and vaccine
codes if they satisfy the conditions in
§ 411.355(h):
90655 ................... Flu vaccine no preserv 6–35m.
90656 ................... Flu vaccine no preserv 3 & >.
90657 ................... Flu vaccine, 3 yrs, im.
90658 ................... Flu vaccine 3 yrs & >, im.
90660 ................... Flu vaccine, nasal.
90669 ................... Pneumococcal vacc, ped <5.
90732 ................... Pneumococcal vaccine.
90740 ................... Hepb vacc, ill pat 3 dose im.
90743 ................... Hep b vacc, adol, 2 dose, im.
90744 ................... Hepb vacc ped/adol 3 dose im.
90746 ................... Hep b vaccine, adult, im.
90747 ................... Hepb vacc, ill pat 4 dose im.
1 CPT codes and descriptions only are copyright 2007 American Medical Association. All
rights are reserved and applicable FARS/
DFARS clauses apply.
2 This list does not include codes for the following designated health service (DHS) categories: durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics, and
prosthetic devices and supplies; home health
services; outpatient prescription drugs; and inpatient and outpatient hospital services. For
the definitions of these DHS categories, refer
to § 411.351. For more information, refer to the
CMS Web site at https://www.cms.hhs.gov/
PhysicianSelfReferral/.
[FR Doc. 07–5506 Filed 11–1–07; 4:00 pm]
BILLING CODE 4120–01–P
E:\FR\FM\27NOR2.SGM
27NOR2
Agencies
[Federal Register Volume 72, Number 227 (Tuesday, November 27, 2007)]
[Rules and Regulations]
[Pages 66222-66578]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-5506]
[[Page 66221]]
-----------------------------------------------------------------------
Part II
Department of Health and Human Services
-----------------------------------------------------------------------
Centers for Medicare & Medicaid Services
-----------------------------------------------------------------------
42 CFR Parts 409, 410, et al.
Medicare Program; Revisions to Payment Policies Under the Physician Fee
Schedule, and Other Part B Payment Policies for CY 2008; Revisions to
the Payment Policies of Ambulance Services Under the Ambulance Fee
Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption
for Computer Generated Facsimile Transmissions; Final Rule
Federal Register / Vol. 72, No. 227 / Tuesday, November 27, 2007 /
Rules and Regulations
[[Page 66222]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 409, 410, 411, 413, 414, 415, 418, 423, 424, 482, 484,
and 485
[CMS-1385-FC]
RIN 0938-AO65
Medicare Program; Revisions to Payment Policies Under the
Physician Fee Schedule, and Other Part B Payment Policies for CY 2008;
Revisions to the Payment Policies of Ambulance Services Under the
Ambulance Fee Schedule for CY 2008; and the Amendment of the E-
Prescribing Exemption for Computer Generated Facsimile Transmissions
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Final rule with comment period.
-----------------------------------------------------------------------
SUMMARY: This final rule with comment period addresses certain
provisions of the Tax Relief and Health Care Act of 2006, as well as
making other proposed changes to Medicare Part B payment policy. We are
making these changes to ensure that our payment systems are updated to
reflect changes in medical practice and the relative value of services.
This final rule with comment period also discusses refinements to
resource-based practice expense (PE) relative value units (RVUs);
geographic practice cost indices (GPCI) changes; malpractice RVUs;
requests for additions to the list of telehealth services; several
coding issues including additional codes from the 5-Year Review;
payment for covered outpatient drugs and biologicals; the competitive
acquisition program (CAP); clinical lab fee schedule issues; payment
for renal dialysis services; performance standards for independent
diagnostic testing facilities; expiration of the physician scarcity
area (PSA) bonus payment; conforming and clarifying changes for
comprehensive outpatient rehabilitation facilities (CORFs); a process
for updating the drug compendia; physician self referral issues;
beneficiary signature for ambulance transport services; durable medical
equipment (DME) update; the chiropractic services demonstration; a
Medicare economic index (MEI) data change; technical corrections;
standards and requirements related to therapy services under Medicare
Parts A and B; revisions to the ambulance fee schedule; the ambulance
inflation factor for CY 2008; and amending the e-prescribing exemption
for computer-generated facsimile transmissions. We are also finalizing
the calendar year (CY) 2007 interim RVUs and are issuing interim RVUs
for new and revised procedure codes for CY 2008.
As required by the statute, we are announcing that the physician
fee schedule update for CY 2008 is -10.1 percent, the initial estimate
for the sustainable growth rate for CY 2008 is -0.1 percent, and the
conversion factor (CF) for CY 2008 is $34.0682.
DATES: Effective Date: The provisions of this final rule with comment
period are effective January 1, 2008, except for the amendments to
Sec. 409.17 and Sec. 409.23 which are effective July 1, 2008, and the
amendments to Sec. 423.160 which is effective January 1, 2009.
Comment Date: Comments will be considered if we receive them at one
of the addresses provided below, no later than 5 p.m. e.s.t. on
December 31, 2007.
ADDRESSES: In commenting, please refer to file code CMS-1385-FC.
Because of staff and resource limitations, we cannot accept comments by
facsimile (FAX) transmission.
You may submit comments in one of three ways (no duplicates,
please):
1. Electronically. You may submit electronic comments on specific
issues in this regulation to https://www.cms.hhs.gov/eRulemaking. Click
on the link ``Submit electronic comments on CMS regulations with an
open comment period.'' (Attachments should be in Microsoft Word,
WordPerfect, or Excel; however, we prefer Microsoft Word.)
2. By mail. You may mail written comments (one original and two
copies) to the following address ONLY: Centers for Medicare & Medicaid
Services, Department of Health and Human Services, Attention: CMS-1385-
FC, P.O. Box 8020, Baltimore, MD 21244-8020.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments (one
original and two copies) to the following address ONLY: Centers for
Medicare & Medicaid Services, Department of Health and Human Services,
Attention: CMS-1385-FC, Mail Stop C4-26-05, 7500 Security Boulevard,
Baltimore, MD 21244-1850.
4. By hand or courier. If you prefer, you may deliver (by hand or
courier) your written comments (one original and two copies) before the
close of the comment period to one of the following addresses. If you
intend to deliver your comments to the Baltimore address, please call
telephone number (410) 786-7197 in advance to schedule your arrival
with one of our staff members.
Room 445-G, Hubert H. Humphrey (HHH) Building, 200 Independence
Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard,
Baltimore, MD 21244-1850.
(Because access to the interior of the HHH Building is not readily
available to persons without Federal Government identification,
commenters are encouraged to leave their comments in the CMS drop slots
located in the main lobby of the building. A stamp-in clock is
available for persons wishing to retain a proof of filing by stamping
in and retaining an extra copy of the comments being filed.)
Comments mailed to the addresses indicated as appropriate for hand
or courier delivery may be delayed and received after the comment
period.
Submission of comments on paperwork requirements. You may submit
comments on this document's paperwork requirements by mailing your
comments to the addresses provided at the end of the ``Collection of
Information Requirements'' section in this document.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Pam West, (410) 786-2302 for issues
related to practice expense and comprehensive outpatient rehabilitation
facilities.
Rick Ensor, (410) 786-5617 for issues related to practice expense
methodology.
Stephanie Monroe, (410) 786-6864 for issues related to the
geographic practice cost index and malpractice RVUs.
Craig Dobyski, (410) 786-4584 for issues related to list of
telehealth services.
Ken Marsalek, (410) 786-4502 for issues related to the DRA imaging
cap.
Catherine Jansto, (410) 786-7762 for issues related to payment for
covered outpatient drugs and biologicals.
Edmund Kasaitis (410) 786-0477 for issues related to the
Competitive Acquisition Program (CAP) for part B drugs.
Anita Greenberg (410) 786-4601 for issues related to the clinical
laboratory fee schedule.
Henry Richter, (410) 786-4562 for issues related to payments for
end-stage renal disease facilities.
August Nemec (410) 786-0612 for issues related to independent
diagnostic testing facilities.
Kate Tillman (410) 786-9252 or Brijit Burton (410) 786-7364 for
issues related to the drug compendia.
[[Page 66223]]
David Walczak (410) 786-4475 for issues related to reassignment and
physician self-referral rules for diagnostic tests and beneficiary
signature for ambulance transport.
Lisa Ohrin (410) 786-4565 or Joanne Sinsheimer (410) 786-4620 for
issues related to physician self-referral rules.
Bob Kuhl (410) 786-4597 for issues related to the DME update.
Rachel Nelson (410) 786-1175 for issues related to the physician
quality reporting system for CY 2008.
Maria Ciccanti (410) 786-3107 for issues related to the reporting
of anemia quality indicators.
James Menas (410) 786-4507 for issues related to payment for
physician pathology services.
Dorothy Shannon, (410) 786-3396 for issues related to the
outpatient therapy caps.
Drew Morgan, (410) 786-2543 for issues related to the E-Prescribing
Exemption for Computer Generated Facsimile Transmissions.
Roechel Kujawa (410) 786-9111 or Anne Tayloe (410) 786-4546 for
issues related to the ambulance fee schedule.
Diane Milstead, (410) 786-3355 or Gaysha Brooks (410) 786-9649 for
all other issues.
SUPPLEMENTARY INFORMATION:
Submitting Comments: We welcome comments from the public on the
following issues: Interim Relative Value Units (RVUs) for selected
codes identified in Addendum C and the physician self-referral
designated health services (DHS) procedures listed in Addendum I. You
can assist us by referencing the file code [CMS-1385-FC] and the
specific ``issue identifier'' that precedes the section on which you
choose to comment.
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following Web
site as soon as possible after they have been received: https://
www.cms.hhs.gov/eRulemaking. Click on the link ``Electronic Comments on
CMS Regulations'' on that Web site to view public comments.
Comments received timely will also be available for public
inspection as they are received, generally beginning approximately 3
weeks after publication of a document, at the headquarters of the
Centers for Medicare & Medicaid Services, 7500 Security Boulevard,
Baltimore, Maryland 21244, Monday through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an appointment to view public comments,
phone 1-800-743-3951.
This Federal Register document is also available from the Federal
Register online database through Government Printing Office Access a
service of the U.S. Government Printing Office. The Web site address
is: https://www.access.gpo.gov/nara/.
Information on the physician fee schedule can also be found on the
CMS homepage. You can access this data by using the following
directions:
1. Go to the following Web site: https://www.cms.hhs.gov/
PhysicianFeeSched/.
2. Select ``PFS Federal Regulation Notices.''
To assist readers in referencing sections contained in this
preamble, we are providing the following table of contents. Some of the
issues discussed in this preamble affect the payment policies, but do
not require changes to the regulations in the Code of Federal
Regulations. Information on the regulation's impact appears throughout
the preamble and is not exclusively in section VI.
Table of Contents
I. Background
A. Development of the Relative Value System
B. Components of the Fee Schedule Payment Amounts
C. Most Recent Changes to Fee Schedule
II. Provisions of the Final Rule Related to the Physician Fee
Schedule
A. Resource Based Practice Expense (PE) Relative Value Units
(RVUs)
1. Current Methodology
2. PE Proposals for CY 2008
B. Geographic Practice Cost Indices (GPCIs)
1. GPCI Update
2. Payment Localities
C. Malpractice (MP) RVUs (TC/PC issue)
D. Medicare Telehealth Services
E. Specific Coding Issues Related to PFS
1. Reduction in the Technical Component (TC) Payment for Imaging
Services Under the PFS to the Outpatient Department (OPD) Payment
Amount
2. Application of Multiple Procedure Payment Reduction for Mohs
Micrographic Surgery (CPT Codes 17311 Through 17315)
3. Payment for Intravenous Immune Globulin (IVIG) Add On Code
for Preadmission Related Services
4. Reporting of Cardiac Rehabilitation Services
F. Part B Drug Payment
1. Average Sales Price (ASP) Issues
2. Competitive Acquisition Program (CAP) Issues
G. Issues Related to the Clinical Lab Fee Schedule
1. Date of Service for the Technical Component (TC) of Physician
Pathology Services (Sec. 414.510)
2. New Clinical Diagnostic Laboratory Test (Sec. 414.508)
H. Revisions Related to Payment for Renal Dialysis Services
Furnished by End-Stage Renal Disease (ESRD) Facilities
1. Growth Update to the Drug Add-On Adjustment to the Composite
Rates
2. Update to the Geographic Adjustment to the Composite Rates
I. Independent Diagnostic Testing Facility (IDTF) Issues
1. Revisions of Existing IDTF Performance Standards
2. New IDTF Standards
J. Expiration of MMA Section 413 Provisions for Physician
Scarcity Area (PSA)
K. Comprehensive Outpatient Rehabilitation Facility (CORF)
Issues
1. Requirements for Coverage of CORF Services Plan of Treatment
(Sec. 410.105(c))
2. Included Services (Sec. 410.100)
3. Physician Services (Sec. 410.100(a))
4. Clarifications of CORF Respiratory Therapy Services
5. Social and Psychological Services
6. Nursing Care Services
7. Drugs and Biologicals
8. Supplies and DME
9. Clarifications and Payment Updates for Other CORF Services
10. Cost Based Payment (Sec. 413.1)
11. Payment for Comprehensive Outpatient Rehabilitation Facility
(CORF) Services
12. Vaccines
L. Compendia for Determination of Medically Accepted Indications
for Off Label Uses of Drugs and Biologicals in an Anti-Cancer
Chemotherapeutic Regimen (Sec. 414.930)
1. Background
2. Process for Determining Changes to the Compendia List
M. Physician Self Referral Issues
1. General
2. Changes to Reassignment and Physician Self Referral Rules
Relating to Diagnostic Tests (Anti Markup Provision)
N. Beneficiary Signature for Ambulance Transport Services
O. Update to Fee Schedules for Class III DME for CYs 2007 and
2008
1. Background
2. Update to Fee Schedule
P. Discussion of Chiropractic Services Demonstration
Q. Technical Corrections
1. Particular Services Excluded From Coverage (Sec. 411.15(a))
2. Medical Nutrition Therapy (Sec. 410.132(a))
3. Payment Exception: Pediatric Patient Mix (Sec. 413.184)
4. Diagnostic X ray Tests, Diagnostic Laboratory Tests, and
Other Diagnostic Tests: Conditions (Sec. 410.32(a)(1))
R. Other Issues
1. Recalls and Replacement Devices
2. Therapy Standards and Requirements
3. Amendment to the Exemption for Computer Generated Facsimile
Transmission from the National Council for Prescription Drug
Programs (NCPDP) SCRIPT Standard for Transmitting Prescription and
Certain Prescription Related Information for Part D Eligible
Individuals
[[Page 66224]]
S. Division B of the Tax Relief and Health Care Act of 2006--
Medicare Improvements and Extension Act of 2006 (Pub. L. 109-432)
(MIEA-TRHCA)
1. Section 101(b)--Physician Quality Reporting Initiative (PQRI)
2. Section 110--Reporting of Hemoglobin or Hematocrit for Part B
Cancer Anti-Anemia Drugs (Sec. 414.707(b))
3. Section 104--Extension of Treatment of Certain Physician
Pathology Services Under Medicare
4. Section 201--Extension of Therapy Cap Exception Process
5. Section 101(d)--Physician Assistance and Quality Initiative
(PAQI) Fund
III. Revisions to the Payment Policies of Ambulance Services Under
the Fee Schedule for Ambulance Services; Ambulatory Inflation Factor
Update for CY 2007
A. History of Medicare Ambulance Services
1. Statutory Coverage of Ambulance Services
2. Medicare Regulations for Ambulance Services
3. Transition to National Fee Schedule
B. Ambulance Inflation Factor (AIF) During the Transition Period
C. Ambulance Inflation Factor (AIF) for CY 2008
D. Revisions to the Publication of the Ambulance Fee Schedule
(Sec. 414.620)
IV. Refinement of Relative Value Units for Calendar Year 2008 and
Response to Public Comments on Interim Relative Value Units for 2007
A. Summary of Issues Discussed Related to the Adjustment of
Relative Value Units
B. Process for Establishing Work Relative Value Units for the
Physician Fee Schedule
C. 5 Year Review of Work RVUs
1. Additional Codes from the 5-Year Review of Work RVUs
2. Anesthesia Coding (Part of 5-Year Review)
3. Budget Neutrality Adjustment
D. Work Relative Value Unit Refinements of Interim Relative
Value Units (Interim 2007 Codes)
E. Establishment of Interim Work Relative Value Units for New
and Revised Physician's Current Procedural Terminology (CPT) Codes
and New Healthcare Common Procedure Coding System Codes (HCPCS) for
2008 (Includes Table Titled ``American Medical Association Specialty
Relative Value Update Committee and Health Care Professionals
Advisory Committee Recommendations and CMS's Decisions for New and
Revised 2008 CPT Codes'')
F. Discussion of Codes and RUC/HCPAC Recommendations
G. Additional Coding Issues
H. Establishment of Interim PE RVUs for New and Revised
Physician's Current Procedural Terminology (CPT) Codes and New
Healthcare Common Procedure Coding System (HCPCS) Codes for 2008
V. Physician Self-Referral Prohibition: Annual Update to the List of
CPT/HCPCS Codes
VI. Physician Fee Schedule Update for CY 2008
A. Physician Fee Schedule Update
B. The Percentage Change in the Medicare Economic Index (MEI)
C. The Update Adjustment Factor (UAF)
VII. Allowed Expenditures for Physicians' Services and the
Sustainable Growth Rate
A. Medicare Sustainable Growth Rate
B. Physicians' Services
C. Preliminary Estimate of the SGR for 2008
D. Revised Sustainable Growth Rate for 2007
E. Final Sustainable Growth Rate for 2006
F. Calculation of 2008, 2007, and 2006 Sustainable Growth Rates
VIII. Anesthesia and Physician Fee Schedule Conversion Factors for
CY 2008
A. Physician Fee Schedule Conversion Factor
B. Anesthesia Fee Schedule Conversion Factor
IX. Telehealth Originating Site Facility Fee Payment Amount Update
X. Provisions of the Final Rule
XI. Waiver of Proposed Rulemaking and Delay in Effective Date
XII. Collection of Information Requirements
XIII. Response to Comments
XIV. Regulatory Impact Analysis
Regulation Text
Addendum A--Explanation and Use of Addendum B
Addendum B--2008 Relative Value Units and Related Information Used
in Determining Medicare Payments for 2007
Addendum C--Codes With Interim RVUS
Addendum D--2008 Geographic Adjustment Factors (GAFs)
Addendum E--2008 Geographic Practice Cost Indices (GPCIs) by State
and Medicare Locality
Addendum F--CPT/HCPCS Imaging Codes Defined by Section 5102(b) of
the DRA
Addendum G--FY 2008 Wage Index for Urban Areas Based on CBSA Labor
Market Areas
Addendum H--FY 2008 Wage Index Based on CBSA Labor Market Areas for
Rural Areas
Addendum I--Updated List of CPT/HCPCS Codes Used To Describe Certain
Designated Health Services Under the Physician Self-Referral
Provision
Acronyms
In addition, because of the many organizations and terms to which
we refer by acronym in this final rule with comment period, we are
listing these acronyms and their corresponding terms in alphabetical
order below:
AAA Abdominal aortic aneurysm
AAP Average acquisition price
ACOTE Accreditation Council for Occupational Therapy Education
ACR American College of Radiology
AFROC Association of Freestanding Radiation Oncology Centers
AHFS-DI American Hospital Formulary Service--Drug Information
AHRQ Agency for Healthcare Research and Quality (HHS)
AIF Ambulance inflation factor
AMA American Medical Association
AMA-DE American Medical Association Drug Evaluations
AMP Average manufacturer price
AOTA American Occupational Therapy Association
APC Ambulatory payment classification
APTA American Physical Therapy Association
ASA American Society of Anesthesiologists
ASC Ambulatory surgical center
ASP Average sales price
ASTRO American Society for Therapeutic Radiology and Oncology
ATA American Telemedicine Association
AWP Average wholesale price
BBA Balanced Budget Act of 1997 (Pub. L. 105-33)
BBRA [Medicare, Medicaid and State Child Health Insurance Program]
Balanced Budget Refinement Act of 1999 (Pub. L. 106-113)
BIPA Medicare, Medicaid, and SCHIP Benefits Improvement Protection
Act of 2000
BLS Bureau of Labor Statistics
BMD Bone mineral density
BMI Body mass index
BMM Bone mass measurement
BN Budget neutrality
BSA Body surface area
CAD Computer aided detection
CAH Critical access hospital
CAP Competitive acquisition program
CBSA Core-Based Statistical Area
CEM Cardiac event monitoring
CF Conversion factor
CFR Code of Federal Regulations
CMA California Medical Association
CMS Centers for Medicare & Medicaid Services
CNS Clinical nurse specialist
CORF Comprehensive Outpatient Rehabilitation Facility
COTA Certified Occupational Therapy Assistant
CPEP Clinical Practice Expert Panel
CPI Consumer Price Index
CPI-U Consumer price index for urban customers
CPT (Physicians') Current Procedural Terminology (4th Edition, 2002,
copyrighted by the American Medical Association)
CRT-D Cardiac resynchronization therapy defibrillator
CT Computed tomography
CTA Computed tomographic angiography
CY Calendar year
DEXA Dual energy x-ray absorptiometry
DHS Designated health services
DME Durable medical equipment
DMEPOS Durable medical equipment, prosthetics, orthotics, and
supplies
DO Doctor of Osteopathy
DRA Deficit Reduction Act of 2005 (Pub. L. 109-432)
E/M Evaluation and management
ECI Employment cost index
EHR Electronic health record
EPC [Duke] Evidence-based Practice Centers
EPO Erythopoeitin
ESRD End stage renal disease
F&C Facts and Comparisons
FAW Furnish as written
[[Page 66225]]
FAX Facsimile
FDA Food and Drug Administration (HHS)
FMR Fair market rents
FQHC Federally qualified health center
FR Federal Register
GAF Geographic adjustment factor
GAO General Accounting Office
GII Global Insight, Inc.
GPO Group purchasing organization
GPCI Geographic practice cost index
HCPAC Health Care Professional Advisory Committee
HCPCS Healthcare Common Procedure Coding System
HCRIS Healthcare Cost Report Information System
HIPAA Health Insurance Portability and Accountability Act of 1996
(Pub. L. 104-191)
HHA Home health agency
HHS [Department of] Health and Human Services
HIT Health information technology
HMO Health maintenance organization
HPSA Health Professional Shortage Area
HRSA Health Resources Services Administration (HHS)
HUD [Department of] Housing and Urban Development
ICD Implantable cardioverter-defibrillator
ICF Intermediate care facilities
IDTF Independent diagnostic testing facility
IFC Interim final rule with comment period
IOTED International Occupational Therapy Eligibility Determination
IPPE Initial preventive physical examination
IPPS Inpatient prospective payment system
IV Intravenous
IVIG Intravenous immune globulin
IWPUT Intra-service work per unit of time
JCAAI Joint Council of Allergy, Asthma, and Immunology
LPN Licensed practical nurse
MA Medicare Advantage
MA-PD Medicare Advantage Prescription Drug Plans
MD Medical doctor
MedCAC Medicare Evidence Development and Coverage Advisory Committee
(formerly the Medicare Coverage Advisory Committee (MCAC))
MedPAC Medicare Payment Advisory Commission
MEI Medicare Economic Index
MIEA-TRHCA Medicare Improvements and Extension Act of 2006 (That is,
Division B of the Tax Relief and Health Care Act of 2006 (TRHCA)
MMA Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 (Pub. L. 108-173)
MNT Medical nutrition therapy
MP Malpractice
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
MSP Medicare Secondary Payer
MSVP Multi-specialty visit package
NBCOT National Board for Certification in Occupational Therapy, Inc.
NCCN National Comprehensive Cancer Network
NCPDP National Council for Prescription Drug Programs
NCQDIS National Coalition of Quality Diagnostic Imaging Services
NDC National drug code
NEMC New England Medical Center
NISTA National Institute of Standards and Technology Act
NLA National limitation amount
NP Nurse practitioner
NPP Nonphysician practitioners
NQF National Quality Forum
NTTAA National Technology Transfer and Advancement Act of 1995 (Pub.
L. 104-113)
OACT [CMS'] Office of the Actuary
OBRA Omnibus Budget Reconciliation Act
OIG Office of Inspector General
OMB Office of Management and Budget
OPD Outpatient Department
OPPS Outpatient prospective payment system
OPT Outpatient physical therapy
OSCAR Online Survey and Certification and Reporting
PA Physician assistant
PC Professional component
PCF Patient compensation fund
PDP Prescription Drug Plan
PE Practice Expense
PE/HR Practice expense per hour
PEAC Practice Expense Advisory Committee
PECOS Provider Enrollment, Chain, and Ownership System
PERC Practice Expense Review Committee
PET Positron emission tomography
PFS Physician Fee Schedule
PLI Professional liability insurance
PPI Producer price index
PPS Prospective payment system
PQRI Physician Quality Reporting Initiative
PRA Paperwork Reduction Act
PSA Physician scarcity areas
PT Physical therapy
PT/INR Prothrombin time, international normalized ratio
RFA Regulatory Flexibility Act
RHC Rural health clinic
RIA Regulatory impact analysis
RN Registered nurse
RT Respiratory therapist
RUC [AMA's Specialty Society] Relative (Value) Update Committee
RVU Relative value unit
SBA Small Business Administration
SGR Sustainable growth rate
SLP Speech--language pathology
SLPs Speech--language pathologists
SMS [AMA's] Socioeconomic Monitoring System
SNF Skilled nursing facility
STS Society of Thoracic Surgeons
TA Technology Assessment
TC Technical Component
TENS Transcutaneous electric nerve stimulator
TRHCA Tax Relief and Health Care Act of 2006 (Pub. L. 109-432)
USP-DI United States Pharmacopoeia-Drug Information
WAC Wholesale acquisition cost
WAMP Widely available market price
Wet AMD Exudative age-related macular degeneration
WFOT World Federation of Occupational Therapists
I. Background
Since January 1, 1992, Medicare has paid for physicians' services
under section 1848 of the Social Security Act (the Act), ``Payment for
Physicians' Services.'' The Act requires that payments under the
physician fee schedule (PFS) be based on national uniform relative
value units (RVUs) based on the resources used in furnishing a service.
Section 1848(c) of the Act requires that national RVUs be established
for physician work, practice expense (PE), and malpractice expense.
Before the establishment of the resource-based relative value system,
Medicare payment for physicians' services was based on reasonable
charges.
A. Development of the Relative Value System
1. Work RVUs
The concepts and methodology underlying the PFS were enacted as
part of the Omnibus Budget Reconciliation Act (OBRA) of 1989, Pub. L.
101-239, and OBRA 1990, (Pub. L. 101-508). The final rule, published
November 25, 1991 (56 FR 59502), set forth the fee schedule for payment
for physicians' services beginning January 1, 1992. Initially, only the
physician work RVUs were resource-based, and the PE and malpractice
RVUs were based on average allowable charges.
The physician work RVUs established for the implementation of the
fee schedule in January 1992 were developed with extensive input from
the physician community. A research team at the Harvard School of
Public Health developed the original physician work RVUs for most codes
in a cooperative agreement with the Department of Health and Human
Services (HHS). In constructing the code-specific vignettes for the
original physician work RVUs, Harvard worked with panels of experts,
both inside and outside the Federal government, and obtained input from
numerous physician specialty groups.
Section 1848(b)(2)(B) of the Act specifies that the RVUs for
anesthesia services are based on RVUs from a uniform relative value
guide. We established a separate conversion factor (CF) for anesthesia
services, and we continue to utilize time units as a factor in
determining payment for these services. As a result, there is a
separate formula used to calculate payment for anesthesia services.
We establish physician work RVUs for new and revised codes based on
recommendations received from the American Medical Association's (AMA)
Specialty Society Relative Value Update Committee (RUC).
[[Page 66226]]
2. Practice Expense Relative Value Units (PE RVUs)
Section 121 of the Social Security Act Amendments of 1994 (Pub. L.
103-32), enacted on October 31, 1994, amended section 1848(c)(2)(C)(ii)
of the Act and required us to develop resource-based PE RVUs for each
physician's service beginning in 1998. We were to consider general
categories of expenses (such as office rent and wages of personnel, but
excluding malpractice expenses) comprising PEs.
Section 4505(a) of the Balanced Budget Act of 1997 (BBA) (Pub. L.
105 33), amended section 1848(c)(2)(C)(ii) of the Act to delay
implementation of the resource based PE RVU system until January 1,
1999. In addition, section 4505(b) of the BBA provided for a 4-year
transition period from charge based PE RVUs to resource-based RVUs.
We established the resource based PE RVUs for each physician's
service in a final rule, published November 2, 1998 (63 FR 58814),
effective for services furnished in 1999. Based on the requirement to
transition to a resource based system for PE over a 4-year period,
resource-based PE RVUs did not become fully effective until 2002.
This resource-based system was based on two significant sources of
actual PE data: The Clinical Practice Expert Panel (CPEP) data and the
AMA's Socioeconomic Monitoring System (SMS) data. The CPEP data were
collected from panels of physicians, practice administrators, and
nonphysicians (for example, registered nurses (RNs)) nominated by
physician specialty societies and other groups. The CPEP panels
identified the direct inputs required for each physician's service in
both the office setting and out-of-office setting. We have since
refined and revised these inputs based on recommendations from the RUC.
The AMA's SMS data provided aggregate specialty-specific information on
hours worked and PEs.
Separate PE RVUs are established for procedures that can be
performed in both a nonfacility setting, such as a physician's office,
and a facility setting, such as a hospital outpatient department. The
difference between the facility and nonfacility RVUs reflects the fact
that a facility typically receives separate payment from Medicare for
its costs of providing the service, apart from payment under the PFS.
The nonfacility RVUs reflect all of the direct and indirect PEs of
providing a particular service.
Section 212 of the Balanced Budget Refinement Act of 1999 (BBRA)
(Pub. L. 106-113) directed the Secretary of Health and Human Services
(the Secretary) to establish a process under which we accept and use,
to the maximum extent practicable and consistent with sound data
practices, data collected or developed by entities and organizations to
supplement the data we normally collect in determining the PE
component. On May 3, 2000, we published the interim final rule (65 FR
25664) that set forth the criteria for the submission of these
supplemental PE survey data. The criteria were modified in response to
comments received, and published in the Federal Register (65 FR 65376)
as part of a November 1, 2000 final rule. The PFS final rules published
in 2001 and 2003, respectively, (66 FR 55246 and 68 FR 63196) extended
the period during which we would accept these supplemental data through
March 1, 2005.
In the CY 2007 PFS final rule with comment period (71 FR 69624), we
revised the methodology for calculating PE RVUs beginning in CY 2007
and provided for a 4-year transition for the new PE RVUs under this new
methodology. We will continue to reexamine this policy and proposed
necessary revisions through future rulemaking.
3. Resource-Based Malpractice (MP) RVUs
Section 4505(f) of the BBA amended section 1848(c) of the Act to
require us to implement resource-based malpractice (MP) RVUs for
services furnished on or after 2000. The resource-based MP RVUs were
implemented in the PFS final rule published November 2, 1999 (64 FR
59380). The MP RVUs were based on malpractice insurance premium data
collected from commercial and physician-owned insurers from all the
States, the District of Columbia, and Puerto Rico.
4. Refinements to the RVUs
Section 1848(c)(2)(B)(i) of the Act requires that we review RVUs no
less often than every 5 years. The first 5-Year Review of the physician
work RVUs was effective in 1997, published on November 22, 1996 (61 FR
59489). The second 5-Year Review went into effect in 2002, published in
the CY 2002 PFS final rule (66 FR 55246). The third 5-Year Review of
physician work RVUs went into effect on January 1, 2007 and was
published in the CY 2007 PFS final rule with comment period (71 FR
69624) (although we note that certain additional proposals relating to
the third 5-Year Review are addressed in the CY 2008 PFS proposed rule
and in this final rule with comment period).
In 1999, the AMA's RUC established the Practice Expense Advisory
Committee (PEAC) for the purpose of refining the direct PE inputs.
Through March 2004, the PEAC provided recommendations to CMS for over
7,600 codes (all but a few hundred of the codes currently listed in the
AMA's Current Procedural Terminology (CPT) codes). As part of the CY
2007 PFS final rule with comment period (71 FR 69624), we implemented a
new methodology for determining resource-based PE RVUs and are
transitioning this over a 4-year period.
In the CY 2005 PFS final rule with comment period (69 FR 66236), we
implemented the first 5-Year Review of the malpractice RVUs (69 FR
66263).
5. Adjustments to RVUs are Budget Neutral
Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments
in RVUs for a year may not cause total PFS payments to differ by more
than $20 million from what they would have been if the adjustments were
not made. In accordance with section 1848(c)(2)(B)(ii)(II) of the Act,
if adjustments to RVUs cause expenditures to change by more than $20
million, we make adjustments to ensure that expenditures do not
increase or decrease by more than $20 million.
As explained in the CY 2007 PFS final rule with comment period (71
FR 69624), due to the increase in work RVUs resulting from the third 5-
Year Review of physician work RVUs, we are applying a separate budget
neutrality (BN) adjustor to the work RVUs for services furnished during
2007. This approach is consistent with the method we use to make BN
adjustments to the PE RVUs to reflect the changes in these PE RVUs.
B. Components of the Fee Schedule Payment Amounts
To calculate the payment for every physician service, the
components of the fee schedule (physician work, PE, and MP RVUs) are
adjusted by a geographic practice cost index (GPCI). The GPCIs reflect
the relative costs of physician work, PE, and malpractice insurance in
an area compared to the national average costs for each component.
Payments are converted to dollar amounts through the application of
a CF, which is calculated by the Office of the Actuary (OACT) and is
updated annually for inflation.
The formula for calculating the Medicare fee schedule amount for a
given service and fee schedule area can be expressed as:
[[Page 66227]]
Payment = [(RVU work x budget neutrality adjuster x work GPCI) +
(RVU PE x PE GPCI) + (MP RVU x MP GPCI)] x CF.
C. Most Recent Changes to the Fee Schedule
The CY 2007 PFS final rule with comment period (71 FR 69624)
addressed certain provisions of the Deficit Reduction Act of 2005 (Pub.
L. 109-432) (DRA) and made other changes to Medicare Part B payment
policy to ensure that our payment systems are updated to reflect
changes in medical practice and the relative value of services. This
final rule with comment period also discussed GPCI changes; requests
for additions to the list of telehealth services; payment for covered
outpatient drugs and biologicals; payment for renal dialysis services;
policies related to private contracts and opt-out; policies related to
bone mass measurement (BMM) services, independent diagnostic testing
facilities (IDTFs), the physician self-referral prohibition; laboratory
billing for the technical component (TC) of physician pathology
services; the clinical laboratory fee schedule; certification of
advanced practice nurses; health information technology, the health
care information transparency initiative; updated the list of certain
services subject to the physician self-referral prohibitions, finalized
ASP reporting requirements, and codified Medicare's longstanding policy
that payment of bad debts associated with services paid under a fee
schedule/charge-based system is not allowable.
We also finalized the CY 2006 interim RVUs and issued interim RVUs
for new and revised procedure codes for CY 2007.
In addition, the CY 2007 PFS final rule with comment period
included revisions to payment policies under the fee schedule for
ambulance services and announced the ambulance inflation factor (AIF)
update for CY 2007.
In accordance with section 1848(d)(1)(E)(i) of the Act, we also
announced that the PFS update for CY 2007 is -5.0 percent, the initial
estimate for the sustainable growth rate (SGR) for CY 2007 is 1.8
percent and the CF for CY 2007 is $35.9848. However, subsequent to
publication of the CY 2007 PFS final rule with comment period, section
101(a) of Division B, Title I of the Tax Relief and Health Care Act of
2006 (Pub. L. 109-432) (MIEA-TRHCA), which was enacted on December 20,
2006, amended section 1848(d) of the Act. [Division B of the Tax Relief
and Health Care Act of 2006 is entitled Medicare and Other Health
Provisions and its short title is the Medicare Improvements and
Extension Act of 2006. Therefore, the law is hereinafter referred to as
``MIEA-TRHCA''.] As a result of this statutory change, the CF of
$37.8975 was maintained for CY 2007.
II. Provisions of the Final Rule Related to the Physician Fee Schedule
In response to the CY 2008 PFS proposed rule (72 FR 38122), we
received approximately 27,000 comments. We received comments from
individual physicians, health care workers, professional associations
and societies, and beneficiaries. The majority of the comments
addressed the proposals related to anesthesia coding and the 5-Year
Review, the physician self-referral provisions and the technical
correction to Sec. 410.32(a)(1) concerning an exception to the
requirement that diagnostic services (including x-rays) must be ordered
by the treating physician. To the extent that comments were outside the
scope of the proposed rule, they are not addressed in this final rule
with comment period.
RVU changes implemented through this final rule with comment are
subject to the $20 million limitation on annual adjustments contained
in section 1848(c)(2)(B)(ii)(II) of the Act. After reviewing the
comments and determining the policies we would implement, we have
estimated the costs and savings of these policies and discuss in detail
the effects of these changes in the Regulatory Impact Analysis in
section XIV. For the convenience of the reader, the headings for the
policy issues correspond to the headings used in the CY 2008 PFS
proposed rule (72 FR 38122). More detailed background information for
each issue can be found in the CY 2008 PFS proposed rule.
A. Resource Based Practice Expense (PE) Relative Value Units (RVUs)
Practice expense (PE) is the portion of the resources used in
furnishing the service that reflects the general categories of
physician and practitioner expenses, such as office rent and personnel
wages but excluding malpractice expenses, as specified in section
1848(c)(1)(B) of the Act.
Section 121 of the Social Security Amendments of 1994 (Pub. L. 103-
432), enacted on October 31, 1994, required CMS to develop a
methodology for a resource-based system for determining PE RVUs for
each physician's service. Until that time, PE RVUs were based on
historical allowed charges. This legislation required that the revised
PE methodology must consider the staff, equipment, and supplies used in
the provision of various medical and surgical services in various
settings beginning in 1998. The Secretary has interpreted this to mean
that Medicare payments for each service would be based on the relative
PE resources typically involved with furnishing the service.
The initial implementation of resource-based PE RVUs was delayed
from January 1, 1998, until January 1, 1999, by section 4505(a) of the
BBA. In addition, section 4505(b) of the BBA required that the new
payment methodology be phased in over 4 years, effective for services
furnished in CY 1999, and fully effective in CY 2002. The first step
toward implementation of the statute was to adjust the PE values for
certain services for CY 1998. Section 4505(d) of the BBA required that,
in developing the resource-based PE RVUs, the Secretary must:
Use, to the maximum extent possible, generally-accepted
cost accounting principles that recognize all staff, equipment,
supplies, and expenses, not solely those that can be linked to specific
procedures and actual data on equipment utilization.
Develop a refinement method to be used during the
transition.
Consider, in the course of notice and comment rulemaking,
impact projections that compare new proposed payment amounts to data on
actual physician PE.
In CY 1999, we began the 4-year transition to resource-based PE
RVUs utilizing a ``top-down'' methodology whereby we allocated
aggregate specialty-specific practice costs to individual procedures.
The specialty-specific PEs were derived from the American Medical
Association's (AMA's) Socioeconomic Monitoring Survey (SMS). In
addition, under section 212 of the BBRA, we established a process
extending through March 2005 to supplement the SMS data with data
submitted by a specialty. The aggregate PEs for a given specialty were
then allocated to the services furnished by that specialty on the basis
of the direct input data (that is, the staff time, equipment, and
supplies) and work RVUs assigned to each CPT code.
For CY 2007, we implemented a new methodology for calculating PE
RVUs. Under this new methodology, we use the same data sources for
calculating PE, but instead of using the ``top-down'' approach to
calculate the direct PE RVUs, under which the aggregate direct and
indirect costs for each specialty are allocated to each individual
service, we now utilize a ``bottom-up'' approach to
[[Page 66228]]
calculate the direct costs. Under the ``bottom-up'' approach, we
determine the direct PE by adding the costs of the resources (that is,
the clinical staff, equipment, and supplies) typically required to
furnish each service. The costs of the resources are calculated using
the refined direct PE inputs assigned to each CPT code in our PE
database, which are based on our review of recommendations received
from the AMA's Relative Value Update Committee (RUC). For a more
detailed explanation of the PE methodology see the Five-Year Review of
Work RVUs Under the PFS and Proposed Changes to the PE Methodology
proposed notice (71 FR 37242) and the CY 2007 PFS final rule with
comment period (71 FR 69629).
1. Current Methodology
a. Data Sources for Calculating Practice Expense
The AMA's SMS survey data and supplemental survey data from the
specialties of cardio-thoracic surgery, vascular surgery, physical and
occupational therapy, independent laboratories, allergy/immunology,
cardiology, dermatology, gastroenterology, radiology, independent
diagnostic testing facilities (IDTFs), radiation oncology, and urology
are used to develop the PE per hour (PE/HR) for each specialty. For
those specialties for which we do not have PE/HR, the appropriate PE/HR
is obtained from a crosswalk to a similar specialty.
The AMA developed the SMS survey in 1981 and discontinued it in
1999. Beginning in 2002, we incorporated the 1999 SMS survey data into
our calculation of the PE RVUs, using a 5-year average of SMS survey
data. (See the Revisions to Payment Policies and Five-Year Review of
and Adjustments to the Relative Value Units Under the Physician Fee
Schedule for CY 2002 final rule (66 FR 55246, November 1, 2002)
(hereinafter referred to as CY 2002 PFS final rule).) The SMS PE survey
data are adjusted to a common year, 2005. The SMS data provide the
following six categories of PE costs:
Clinical payroll expenses, which are payroll expenses
(including fringe benefits) for nonphysician clinical personnel.
Administrative payroll expenses, which are payroll
expenses (including fringe benefits) for nonphysician personnel
involved in administrative, secretarial or clerical activities.
Office expenses, which include expenses for rent, mortgage
interest, depreciation on medical buildings, utilities and telephones.
Medical material and supply expenses, which include
expenses for drugs, x-ray films, and disposable medical products.
Medical equipment expenses, which include expenses
depreciation, leases, and rent of medical equipment used in the
diagnosis or treatment of patients.
All other expenses, which include expenses for legal
services, accounting, office management, professional association
memberships, and any professional expenses not previously mentioned in
this section.
In accordance with section 212 of the BBRA, we established a
process to supplement the SMS data for a specialty with data collected
by entities and organizations other than the AMA (that is, the
specialty itself). (See the Criteria for Submitting Supplemental
Practice Expense Survey Data interim final rule with comment period,
(65 FR 25664, May 3, 2000).) Originally, the deadline to submit
supplementary survey data was through August 1, 2001. In the CY 2002
PFS final rule (66 FR 55246), the deadline was extended through August
1, 2003. To ensure maximum opportunity for specialties to submit
supplementary survey data, we extended the deadline to submit surveys
until March 1, 2005 in the Revisions to Payment Policies Under the
Physician Fee Schedule for CY 2004 final rule, (November 7, 2003; 68 FR
63196) (hereinafter referred to as CY 2004 PFS final rule).
The direct cost data for individual services were originally
developed by the Clinical Practice Expert Panels (CPEP). The CPEP data
include the supplies, equipment, and staff times specific to each
procedure. The CPEPs consisted of panels of physicians, practice
administrators, and nonphysicians (for example, RNs) who were nominated
by physician specialty societies and other groups. There were 15 CPEPs
consisting of 180 members from more than 61 specialties and
subspecialties. Approximately 50 percent of the panelists were
physicians.
The CPEPs identified specific inputs involved in each physician's
service provided in an office or facility setting. The inputs
identified were the quantity and type of nonphysician labor, medical
supplies, and medical equipment.
In 1999, the AMA's RUC established the Practice Expense Advisory
Committee (PEAC). From 1999 to March 2004, the PEAC, a multi-specialty
committee, reviewed the original CPEP inputs and provided us with
recommendations for refining these direct PE inputs for existing CPT
codes. Through its last meeting in March 2004, the PEAC provided
recommendations for over 7,600 codes which we have reviewed and
accepted. As a result, the current PE inputs differ markedly from those
originally recommended by the CPEPs. The PEAC has now been replaced by
the Practice Expense Review Committee (PERC), which acts to assist the
RUC in recommending PE inputs.
b. Allocation of PE to Services
The aggregate level specialty-specific PEs are derived from the
AMA's SMS survey and supplementary survey data. To establish PE RVUs
for specific services, it is necessary to establish the direct and
indirect PE associated with each service.
(i) Direct costs. The direct costs are determined by adding the
costs of the resources (that is, the clinical staff, equipment, and
supplies) typically required to provide the service. The costs of these
resources are calculated from the refined direct PE inputs in our PE
database. These direct inputs are then scaled to the current aggregate
pool of direct PE RVUs. The aggregate pool of direct PE RVUs can be
derived using the following formula: (PE RVUs * physician CF) *
(average direct percentage from SMS/(Supplemental PE/HR data)).
(ii) Indirect costs. The SMS and supplementary survey data are the
source for the specialty-specific aggregate indirect costs used in our
PE calculations. We then allocate the indirect costs to the code level
on the basis of the direct costs specifically associated with a code
and the maximum of either the clinical labor costs or the physician
work RVUs. For calculation of the 2008 PE RVUs, we are using the 2006
procedure-specific utilization data crosswalked to 2007 services. To
arrive at the indirect PE costs:
We apply a specialty-specific indirect percentage factor
to the direct expenses to recognize the varying proportion that
indirect costs represent of total costs by specialty. For a given
service, the specific indirect percentage factor to apply to the direct
costs for the purpose of the indirect allocation is calculated as the
weighted average of the ratio of the indirect to direct costs (based on
the survey data) for the specialties that furnish the service. For
example, if a service is furnished by a single specialty with indirect
PEs that were 75 percent of total PEs, the indirect percentage factor
to apply to the direct costs for the purposes of the indirect
[[Page 66229]]
allocation would be (0.75/0.25) = 3.0. The indirect percentage factor
is then applied to the service level adjusted indirect PE allocators.
We use the specialty-specific PE/HR from the SMS survey
data, as well as the supplemental surveys for cardio-thoracic surgery,
vascular surgery, physical and occupational therapy, independent
laboratories, allergy/immunology, cardiology, dermatology, radiology,
gastroenterology, IDTFs, radiation oncology and urology. (Note: For
radiation oncology, the data represent the combined survey data from
the American Society for Therapeutic Radiology and Oncology (ASTRO) and
the Association of Freestanding Radiation Oncology Centers (AFROC).) We
incorporate this PE/HR into the calculation of indirect costs using an
index which reflects the relationship between each specialty's indirect
scaling factor and the overall indirect scaling factor for the entire
PFS. For example, if a specialty had an indirect practice cost index of
2.00, this specialty would have an indirect scaling factor that was
twice the overall average indirect scaling factor. If a specialty had
an indirect practice cost index of 0.50, this specialty would have an
indirect scaling factor that was half the overall average indirect
scaling factor.
When the clinical labor portion of the direct PE RVU is
greater than the physician work RVU for a particular service, the
indirect costs are allocated based upon the direct costs and the
clinical labor costs. For example, if a service has no physician work
and 1.10 direct PE RVUs, and the clinical labor portion of the direct
PE RVUs is 0.65 RVUs, we would use the 1.10 direct PE RVUs and the 0.65
clinical labor portions of the direct PE RVUs to allocate the indirect
PE for that service.
c. Facility/Nonfacility Costs
Procedures that can be furnished in a physician's office, as well
as in a hospital or facility setting, have two PE RVUs: facility and
nonfacility. The nonfacility setting includes physicians' offices,
patients' homes, freestanding imaging centers, and independent
pathology labs. Facility settings include hospitals, ambulatory
surgical centers (ASCs), and skilled nursing facilities (SNFs). The
methodology for calculating PE RVUs is the same for both, facility and
nonfacility RVUs, but is applied independently to yield two separate PE
RVUs. Because the PEs for services provided in a facility setting are
generally included in the payment to the facility (rather than the
payment to the physician under the PFS), the PE RVUs are generally
lower for services provided in the facility setting.
d. Services With Technical Components (TCs) and Professional Components
(PCs)
Diagnostic services are generally comprised of two components; a
professional component (PC) and a technical component (TC), which may
be furnished independently or by different providers. When services
have TC, PC, and global components that can be billed separately, the
payment for the global component equals the sum of the payment for the
TC and PCs. This is a result of using a weighted average of the ratio
of indirect to direct costs across all the specialties that furnish the
global components, TCs, and PCs; that is, we apply the same weighted
average indirect percentage factor to allocate indirect expenses to the
global components, PC, and TCs for a service. (The direct PE RVUs for
the TC and PCs sum to the global under the bottom-up methodology.)
e. Transition Period
As discussed in the CY 2007 PFS final rule with comment period (71
FR 69674), we are implementing the change in the methodology for
calculating PE RVUs over a 4-year period. During this transition
period, the PE RVUs will be calculated on the basis of a blend of RVUs
calculated using our methodology described previously in this section
(weighted by 25 percent during CY 2007, 50 percent during CY 2008, 75
percent during CY 2009, and 100 percent thereinafter), and the CY 2006
PE RVUs for each existing code. PE RVUs for codes that are new during
this period will be calculated using only the current PE methodology,
and will be paid at the fully transitioned rate.
f. PE RVU Methodology
The following is a description of the PE RVU methodology.
(i) Setup File
First, we create a setup file for the PE methodology. The setup
file contains the direct cost inputs, the utilization for each
procedure code at the specialty and facility/nonfacility place of
service level, and the specialty-specific survey PE per physician hour
data.
(ii) Calculate the Direct Cost PE RVUs
Sum the Costs of Each Direct Input
Step 1: Sum the direct costs of the inputs for each service. The
direct costs consist of the costs of the direct inputs for clinical
labor, medical supplies, and medical equipment. The clinical labor cost
is the sum of the cost of all the staff types associated with the
service; it is the product of the time for each staff type and the wage
rate for that staff type. The medical supplies cost is the sum of the
supplies associated with the service; it is the product of the quantity
of each supply and the cost of the supply. The medical equipment cost
is the sum of the cost of the equipment associated with the service; it
is the product of the number of minutes each piece of equipment is used
in the service and the equipment cost per minute. The equipment cost
per minute is calculated as described at the end of this section.
Apply a BN Adjustment to the Direct Inputs
Step 2: Calculate the current aggregate pool of direct PE costs. To
do this, multiply the current aggregate pool of total direct and
indirect PE costs (that is, the current aggregate PE RVUs multiplied by
the CF) by the average direct PE percentage from the SMS and
supplementary specialty survey data.
Step 3: Calculate the aggregate pool of direct costs. To do this,
for all PFS services, sum the product of the direct costs for each
service from Step 1 and the utilization data for that service.
Step 4: Using the results of Step 2 and Step 3 calculate a direct
PE BN adjustment so that the proposed aggregate direct cost pool does
not exceed the current aggregate direct cost pool and apply it to the
direct costs from Step 1 for each service.
Step 5: Convert the results of Step 4 to an RVU scale for each
service. To do this, divide the results of Step 4 by the Medicare PFS
CF.
(iii) Create the Indirect PE RVUs
Create Indirect Allocators
Step 6: Based on the SMS and supplementary specialty survey data,
calculate direct and indirect PE percentages for each physician
specialty.
Step 7: Calculate direct and indirect PE percentages at the service
level by taking a weighted average of the results of Step 6 for the
specialties that furnish the service. Note that for services with a TC
and PCs we are calculating the direct and indirect percentages across
the global components, PCs and TCs. That is, the direct and indirect
percentages for a given service (for example, echocardiogram) do not
vary by the PC, TC and global component.
Step 8: Calculate the service level allocators for the indirect PEs
based on the percentages calculated in Step 7. The indirect PEs are
allocated based on the three components: the direct PE
[[Page 66230]]
RVU, the clinical PE RVU and the work RVU.
For most services the indirect allocator is: indirect percentage *
(direct PE RVU/direct percentage) + work RVU.
There are two situations where this formula is modified:
If the service is a global service (that is, a service
with global, professional and technical components), then the indirect
allocator is: indirect percentage * (direct PERVU/direct percentage) +
clinical PE RVU + work RVU.
If the clinical labor PE RVU exceeds the work RVU (and the
service is not a global service), then the indirect allocator is:
indirect percentage * (direct PERVU/direct percentage) + clinical PE
RVU.
(Note that for global services the indirect allocator is based on
both the work RVU and the clinical labor PE RVU. We do this to
recognize that, for the professional service, indirect PEs will be
allocated using the work RVUs, and for the TC service, indirect PEs
will be allocated using the direct PE RVU and the clinical labor PE
RVU. This also allows the global component RVUs to equal the sum of the
PC and TC RVUs.)
For presentation purposes in the examples in Table 1, the formulas
were divided into two parts for each service. The first part does not
vary by service and is the indirect percentage * (direct PE RVU/direct
percentage). The second part is either the work RVU, clinical PE RVU,
or both depending on whether the service is a global service and
whether the clinical PE RVU exceeds the work RVU (as described earlier
in this step.)
Apply a BN Adjustment to the Indirect Allocators
Step 9: Calculate the current aggregate pool of indirect PE RVUs by
multiplying the current aggregate pool of PE RVUs by the average
indirect PE percentage from the physician specialty survey data. This
is similar to the Step 2 calculation for the direct PE RVUs.
Step 10: Calculate an aggregate pool of proposed indirect PE RVUs
for all PFS services by adding the product of the indirect PE
allocators for a service from Step 8 and the utilization data for that
service. This is similar to the Step 3 calculation for the direct PE
RVUs.
Step 11: Using the results of Step 9 and Step 10, calculate an
indirect PE adjustment so that the aggregate indirect allocation does
not exceed the available aggregate indirect PE RVUs and apply it to
indirect allocators calculated in Step 8. This is similar to the Step 4
calculation for the direct PE RVUs.
Calculate the Indirect Practice Cost Index
Step 12: Using the results of Step 11, calculate aggregate pools of
specialty-specific adjusted indirect PE allocators for all PFS services
for a specialty by adding the product of the adjusted indirect PE
allocator for each service and the utilization data for that service.
Step 13: Using the specialty-specific indirect PE/HR data,
calculate specialty-specific aggregate pools of indirect PE for all PFS
services for that specialty by adding the product of the indirect PE/HR
for the specialty, the physician time for the service, and the
specialty's utilization for the service.
Step 14: Using the results of Step 12 and Step 13, calculate the
specialty-specific indirect PE scaling factors as under the current
methodology.
Step 15: Using the results of Step 14, calculate an indirect
practice cost index at the specialty level by dividing each specialty-
specific indirect scaling factor by the average indirect scaling factor
for the entire PFS.
Step 16: Calculate the indirect practice cost index at the service
level to ensure the capture of all indirect costs. Calculate a weighted
average of the practice cost index values for the specialties that
furnish the service. Note: For services with TC and PCs, we calculate
the indirect practice cost index across the global components, PCs and
TCs. Under this method, the indirect practice cost index for a given
service (for example, echocardiogram) does not vary by the PC, TC and
global components.
Step 17: Apply the service level indirect practice cost index
calculated in Step 16 to the service level adjusted indirect allocators
calculated in Step 11 to get the indirect PE RVU.
(iv) Calculate the Final PE RVUs
Step 18: Add the direct PE RVUs from Step 6 to the indirect PE RVUs
from Step 17.
Step 19: Calculate and apply the final PE BN adjustment by
comparing the results of Step 18 to the current pool of PE RVUs. This
final BN adjustment is required primarily because certain specialties
are excluded from the PE RVU calculation for rate-setting purposes, but
all specialties are included for purposes of calculating the final BN
adjustment. (See ``Specialties excluded from rate-setting calculation''
below in this section.)
(v) Setup File Information
Specialties excluded from rate-setting calculation: For
the purposes of calculating the PE RVUs, we exclude certain specialties
such as midlevel practitioners paid at a percentage of the PFS,
audiology, and low volume specialties from the calculation. These
specialties are included for the purposes of calculating the BN
adjustment.
Crosswalk certain low volume physician specialties:
Crosswalk the utilization of certain specialties with relatively low
PFS utilization to the associated specialties.
Physical therapy utilization: Crosswalk the utilization
associated with all physical therapy services to the specialty of
physical therapy.
Identify professional and technical services not
identified under the usual TC and 26 modifier: Flag the services that
are PC and TC services, but do not use TC and 26 modifiers (for
example, electrocardiograms). This flag associates the PC and TC with
the associated global code for use in creating the indirect PE RVU. For
example, the professional service code 93010 is associated with the
global code 93000.
Payment modifiers: Payment modifiers are accounted for in
the creation of the file. For example, services billed with the
assistant at surgery modifier are paid 16 percent of the PFS amount for
that service; therefore, the utilization file is modified to only
account for 16 percent of any service that contains the assistant at
surgery modifier.
Work RVUs: The setup file contains the work RVUs from this
final rule with comment period.
(vi) Equipment Cost Per Minute =
The equipment cost per minute is calculated as:
(1/(minutes per year * usage)) * price * ((interest rate/(1-(1/((1
+ interest rate) * life of equipment)))) + maintenance)
Where:
minutes per year = maximum minutes per year if usage were continuous
(that is, usage = 1); 150,000 minutes.
usage = equipment utili